PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Chen, J; Lee, BH; Williams, IR; Kutok, JL; Mitsiades, CS; Duclos, N; Cohen, S; Adelsperger, J; Okabe, R; Coburn, A; Moore, S; Huntly, BJP; Fabbro, D; Anderson, KC; Griffin, JD; Gilliland, DG				Chen, J; Lee, BH; Williams, IR; Kutok, JL; Mitsiades, CS; Duclos, N; Cohen, S; Adelsperger, J; Okabe, R; Coburn, A; Moore, S; Huntly, BJP; Fabbro, D; Anderson, KC; Griffin, JD; Gilliland, DG			FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies	ONCOGENE			English	Article						fibroblast growth factor receptor 3 (FGFR3); multiple myeloma; small molecule tyrosine inhibitor; murine bone marrow transplant (BMT) assay	GROWTH-FACTOR RECEPTOR-3; MULTIPLE-MYELOMA; KINASE INHIBITOR; TYROSINE KINASE; ACTIVATING MUTATIONS; SIGNAL-TRANSDUCTION; IMATINIB MESYLATE; CELL-LINES; TRANSLOCATION; EXPRESSION	Reccurent chromosomal translocation t(4;14) (p16.3;q32.3) occurs in patients with multiple myeloma (MM) and is associated with ectopic overexpression of fibroblast growth factor receptor 3 (FGFR3) that sometimes may contain the activation mutations such as K650E thanatophoric dysplasia type II (TDII). Although there have been significant advances in therapy for MM including the use of proteasome inhibitors, t(4;14) MM has a particularly poor prognosis and most patients still die from complications related to their disease or therapy. One potential therapeutic strategy is to inhibit FGFR3 in those myeloma patients that overexpress the receptor tyrosine kinase due to chromosomal translocation. Here we evaluated PKC412, a small molecule tyrosine kinase inhibitor, for treatment of FGFR3-induced hematopoietic malignancies. PKC412 inhibited kinase activation and proliferation of hematopoietic Ba/F3 cells transformed by FGFR3 TDII or a TEL-FGFR3 fusion. Similar results were obtained in PKC412 inhibition of several different t(4;14)-positive human MM cell lines. Further more, treatment with PKC412 resulted in a statistically significant prolongation of survival in murine bone marrow transplant models of FGFR3 TDII-induced pre-B cell lymphoma, or a peripheral T-cell lymphoma associated TEL-FGFR3 fusion-induced myeloproliferative disease. These data indicate that PKC412 may be a useful molecularly targeted therapy for MM associated with overexpression of FGFR3, and perhaps other diseases associated with dysregulation of FGFR3 or related mutants.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Emory Univ, Dept Pathol, Atlanta, GA 30322 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Novartis Pharma AG, Basel, Switzerland	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital; Emory University; Harvard University; Dana-Farber Cancer Institute; Novartis	Gilliland, DG (corresponding author), Brigham & Womens Hosp, Div Hematol, Childrens Hosp Res Bldg,1 Blackfan Circle,5th Flo, Boston, MA 02115 USA.	ggilliland@rics.bwh.harvard.edu	huntly, brian JP/E-6725-2014; Williams, Ifor R/D-3648-2011	huntly, brian JP/0000-0003-0312-161X; Williams, Ifor R/0000-0002-8810-2911	NATIONAL CANCER INSTITUTE [P01CA066996] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050654] Funding Source: NIH RePORTER; NCI NIH HHS [CA66996] Funding Source: Medline; NIDDK NIH HHS [DK50654] Funding Source: Medline; PHS HHS [P0-1 78378, R01 50947] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDREJAUSKASBUCHDUNGER E, 1992, CANCER RES, V52, P5353; Apperley JF, 2002, NEW ENGL J MED, V347, P481, DOI 10.1056/NEJMoa020150; Bastuji-Garin S, 2002, J INVEST DERMATOL, V119, P1020, DOI 10.1046/j.1523-1747.2002.19502.x; Bergsagel PL, 1996, P NATL ACAD SCI USA, V93, P13931, DOI 10.1073/pnas.93.24.13931; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; Cavo M, 2000, BLOOD, V96, P355, DOI 10.1182/blood.V96.1.355.013k02_355_357; Chen J, 2004, P NATL ACAD SCI USA, V101, P14479, DOI 10.1073/pnas.0404438101; Chen J, 2005, BLOOD, V106, P328, DOI 10.1182/blood-2004-09-3686; Chen J, 2004, BLOOD, V104, P535, DOI 10.1182/blood-2004-01-0169; Chesi M, 1996, BLOOD, V88, P674, DOI 10.1182/blood.V88.2.674.bloodjournal882674; Chesi M, 1998, BLOOD, V92, P3025, DOI 10.1182/blood.V92.9.3025.421k53_3025_3034; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Chesi M, 2001, BLOOD, V97, P729, DOI 10.1182/blood.V97.3.729; Chesi M, 1998, BLOOD, V91, P4457, DOI 10.1182/blood.V91.12.4457.412k48_4457_4463; Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496-390; Cools J, 2003, CANCER CELL, V3, P459, DOI 10.1016/S1535-6108(03)00108-9; De Angelo DJ, 2003, BLOOD, V102, p65A; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Druker BJ, 2003, SEMIN HEMATOL, V40, P50, DOI 10.1053/shem.2003.50000; Estey EH, 2003, BLOOD, V102, p614A; Fabbro D, 2000, ANTI-CANCER DRUG DES, V15, P17; Golla A, 1997, J MED GENET, V34, P683, DOI 10.1136/jmg.34.8.683; GOLUB T, 1996, BIOCHIM BIOPHYS ACTA, V1288, P7; Grand EK, 2004, LEUKEMIA, V18, P962, DOI 10.1038/sj.leu.2403347; Heffner LT, 2003, DRUGS, V63, P1621, DOI 10.2165/00003495-200363160-00001; Keats JJ, 2005, BLOOD, V105, P4060, DOI 10.1182/blood-2004-09-3704; Kelly LM, 2002, CANCER CELL, V1, P421, DOI 10.1016/S1535-6108(02)00070-3; Lemoli RM, 2000, BLOOD, V95, P2234, DOI 10.1182/blood.V95.7.2234.007k25_2234_2239; Li ZH, 2001, BLOOD, V97, P2413, DOI 10.1182/blood.V97.8.2413; Liu Q, 2000, EMBO J, V19, P1827, DOI 10.1093/emboj/19.8.1827; Martinelli G, 2000, J CLIN ONCOL, V18, P2273, DOI 10.1200/JCO.2000.18.11.2273; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; Paramore A, 2003, NAT REV DRUG DISCOV, V2, P611, DOI 10.1038/nrd1159; Paterson JL, 2004, BRIT J HAEMATOL, V124, P595, DOI 10.1111/j.1365-2141.2004.04814.x; Persons DA, 1997, BLOOD, V90, P1777, DOI 10.1182/blood.V90.5.1777; Plowright EE, 2000, BLOOD, V95, P992, DOI 10.1182/blood.V95.3.992.003k29_992_998; Richardson P, 2002, BIOMED PHARMACOTHER, V56, P115, DOI 10.1016/S0753-3322(02)00168-3; Ronchetti D, 2001, ONCOGENE, V20, P3553, DOI 10.1038/sj.onc.1204465; San Miguel JF, 1999, HAEMATOLOGICA, V84, P36; Santra M, 2003, BLOOD, V101, P2374, DOI 10.1182/blood-2002-09-2801; Schwaller J, 1998, EMBO J, V17, P5321, DOI 10.1093/emboj/17.18.5321; Sternberg DW, 2001, BLOOD, V98, P3390, DOI 10.1182/blood.V98.12.3390; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; Trudel S, 2004, BLOOD, V103, P3521, DOI 10.1182/blood-2003-10-3650; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; Weisberg E, 2002, CANCER CELL, V1, P433, DOI 10.1016/S1535-6108(02)00069-7; Yagasaki F, 2001, CANCER RES, V61, P8371	47	73	119	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2005	24	56					8259	8267		10.1038/sj.onc.1208989	http://dx.doi.org/10.1038/sj.onc.1208989			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	993LV	16091734				2022-12-25	WOS:000233956500005
J	Miyamoto, S; Howes, AL; Adams, JW; Dorn, GW; Brown, JH				Miyamoto, S; Howes, AL; Adams, JW; Dorn, GW; Brown, JH			Ca2+ dysregulation induces mitochondrial depolarization and apoptosis - Role of Na+/Ca2+ exchanger and Akt	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM SIGNAL TRANSMISSION; CARDIAC MYOCYTE APOPTOSIS; CARDIOMYOCYTES IN-VITRO; HEART-FAILURE; PERMEABILITY TRANSITION; RYANODINE RECEPTORS; NA+-CA2+ EXCHANGE; SURVIVAL PATHWAY; DEATH PATHWAY; CELL-DEATH	We previously reported that constitutively activated G alpha(q) (Q209L) expression in cardiomyocytes induces apoptosis through opening of the mitochondrial permeability transition pore. We assessed the hypothesis that disturbances in Ca2+ handling linked G alpha(q) activity to apoptosis because resting Ca2+ levels were significantly increased prior to development of apoptosis. Treating cells with EGTA lowered Ca2+ and blocked both loss of mitochondrial membrane potential ( an indicator of permeability transition pore opening) and apoptosis ( assessed by DNA fragmentation). When cytosolic Ca2+ and mitochondrial membrane potential were simultaneously measured by confocal microscopy, sarcoplasmic reticulum (SR)-driven slow Ca2+ oscillations (time-to-peak similar to 4 s) were observed in Q209L-expressing cells. These oscillations were seen to transition into sustained increases in cytosolic Ca2+, directly paralleled by loss of mitochondrial membrane potential. Ca2+ transients generated by caffeine-induced release of SR Ca2+ were greatly prolonged in Q209L-expressing cells, suggesting a decreased ability to extrude Ca2+. Indeed, the Na+/Ca2+ exchanger (NCX), which removes Ca2+ from the cell, was markedly down-regulated at the mRNA and protein levels. Adenoviral NCX expression normalized cytosolic Ca2+ levels and prevented DNA fragmentation in cells expressing Q209L. Interestingly, constitutively activated Akt, which rescues cells from Q209L-induced apoptosis, prevented the decrease in NCX expression, normalized cytosolic Ca2+ levels and spontaneous Ca2+ oscillations, shortened caffeine-induced Ca2+ transients, and prevented loss of the mitochondrial membrane potential. Our findings demonstrate that NCX down-regulation and consequent increases in cytosolic and SR Ca2+ can lead to Ca2+ overloading-induced loss of mitochondrial membrane potential and suggest that recovery of Ca2+ dysregulation is a target of Akt-mediated protection.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA; Arena Pharmaceut, San Diego, CA 92121 USA; Univ Cincinnati, Dept Med, Cincinnati, OH 45267 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University System of Ohio; University of Cincinnati	Brown, JH (corresponding author), Univ Calif San Diego, Dept Pharmacol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	jhbrown@ucsd.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL028143, R01HL028143] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL28143] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams JW, 2001, ONCOGENE, V20, P1626, DOI 10.1038/sj.onc.1204275; Adams JW, 2000, CIRC RES, V87, P1180, DOI 10.1161/01.RES.87.12.1180; Adams JW, 1998, P NATL ACAD SCI USA, V95, P10140, DOI 10.1073/pnas.95.17.10140; Akao M, 2003, CIRC RES, V92, P186, DOI 10.1161/01.RES.0000051861.21316.E9; Bano D, 2005, CELL, V120, P275, DOI 10.1016/j.cell.2004.11.049; Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; Borutaite V, 2003, FEBS LETT, V541, P1, DOI 10.1016/S0014-5793(03)00278-3; Brookes PS, 2004, AM J PHYSIOL-CELL PH, V287, pC817, DOI 10.1152/ajpcell.00139.2004; Csordas G, 2001, TRENDS CARDIOVAS MED, V11, P269, DOI 10.1016/S1050-1738(01)00123-2; Di Lisa F, 1998, MOL CELL BIOCHEM, V184, P379, DOI 10.1023/A:1006810523586; Di Lisa F, 2001, J BIOL CHEM, V276, P2571, DOI 10.1074/jbc.M006825200; FABIATO A, 1981, J GEN PHYSIOL, V78, P457, DOI 10.1085/jgp.78.5.457; Fujio Y, 2000, CIRCULATION, V101, P660, DOI 10.1161/01.CIR.101.6.660; Golfman L, 1998, MOL CELL BIOCHEM, V188, P91, DOI 10.1023/A:1006824623496; Hattori Y, 2000, J PHYSIOL-LONDON, V527, P85, DOI 10.1111/j.1469-7793.2000.00085.x; Hayakawa Y, 2003, CIRCULATION, V108, P3036, DOI 10.1161/01.CIR.0000101920.72665.58; Henderson SA, 2004, CIRC RES, V95, P604, DOI 10.1161/01.RES.0000142316.08250.68; Hirota H, 1999, CELL, V97, P189, DOI 10.1016/S0092-8674(00)80729-1; Howes AL, 2003, J BIOL CHEM, V278, P40343, DOI 10.1074/jbc.M305964200; Jaconi M, 2000, MOL BIOL CELL, V11, P1845, DOI 10.1091/mbc.11.5.1845; Ju HS, 1998, CIRCULATION, V97, P892, DOI 10.1161/01.CIR.97.9.892; Kang PM, 2003, TRENDS MOL MED, V9, P177, DOI 10.1016/S1471-4914(03)00025-X; Korge P, 2002, P NATL ACAD SCI USA, V99, P3312, DOI 10.1073/pnas.052713199; Lai HC, 2003, MOL CELL ENDOCRINOL, V205, P99, DOI 10.1016/S0303-7207(03)00200-4; Matsui T, 2001, CIRCULATION, V104, P330; Matsui T, 1999, CIRCULATION, V100, P2373, DOI 10.1161/01.CIR.100.23.2373; Mattson MP, 2003, TRENDS MOL MED, V9, P196, DOI 10.1016/S1471-4914(03)00046-7; Mende U, 1998, P NATL ACAD SCI USA, V95, P13893, DOI 10.1073/pnas.95.23.13893; Metivier D, 1998, IMMUNOL LETT, V61, P157, DOI 10.1016/S0165-2478(98)00013-3; Mitarai S, 2000, AM J PHYSIOL-HEART C, V279, pH139, DOI 10.1152/ajpheart.2000.279.1.H139; Murata M, 2001, CIRC RES, V89, P891, DOI 10.1161/hh2201.100205; Pacher P, 2001, EMBO J, V20, P4107, DOI 10.1093/emboj/20.15.4107; Petronilli V, 2001, J BIOL CHEM, V276, P12030, DOI 10.1074/jbc.M010604200; Pogwizd SM, 1999, CIRC RES, V85, P1009; Sakata Y, 1998, CIRCULATION, V97, P1488; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Shiraishi I, 2004, CIRC RES, V94, P884, DOI 10.1161/01.RES.0000124394.01180.BE; Singh K, 2000, CARDIOVASC RES, V45, P713, DOI 10.1016/S0008-6363(99)00370-3; Sipido KR, 2002, CARDIOVASC RES, V53, P782, DOI 10.1016/S0008-6363(01)00470-9; Song QJ, 2003, J CLIN INVEST, V111, P859, DOI 10.1172/JCI200316738; SWEDBERG K, 1984, AM J CARDIOL, V54, P783, DOI 10.1016/S0002-9149(84)80208-8; Szalai G, 2000, J BIOL CHEM, V275, P15305, DOI 10.1074/jbc.275.20.15305; Uchiyama T, 2004, CIRCULATION, V109, P3042, DOI 10.1161/01.CIR.0000130647.29030.90; Weiss JN, 2003, CIRC RES, V93, P292, DOI 10.1161/01.RES.0000087542.26971.D4; Wencker D, 2003, J CLIN INVEST, V111, P1497, DOI 10.1172/JCI200317664; Yussman MG, 2002, NAT MED, V8, P725, DOI 10.1038/nm719	46	59	60	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38505	38512		10.1074/jbc.M505223200	http://dx.doi.org/10.1074/jbc.M505223200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16061478	hybrid			2022-12-25	WOS:000233239800048
J	Fischer, M; Schwieger, M; Horn, S; Niebuhr, B; Ford, A; Roscher, S; Bergholz, U; Greaves, M; Lohler, J; Stocking, C				Fischer, M; Schwieger, M; Horn, S; Niebuhr, B; Ford, A; Roscher, S; Bergholz, U; Greaves, M; Lohler, J; Stocking, C			Defining the oncogenic function of the TEL/AML1 (ETV6/RUNX1) fusion protein in a mouse model	ONCOGENE			English	Article						acute lymphoblastic leukemia (ALL); RUNX1; ETV6/TEL; translocation(12;21)	HEMATOPOIETIC STEM-CELLS; ACUTE MYELOID-LEUKEMIA; PUTATIVE TUMOR-SUPPRESSOR; TRANSCRIPTIONAL REPRESSION; MURINE MODEL; TEL; GENE; AML1; TEL-AML1; TRANSLOCATION	The t(12;21) translocation, generating the TEL/AML1 fusion protein, is the most common genetic lesion in childhood cancer. Using a bone marrow transplantation model, we demonstrate that TEL/AML1 expression impinges on normal hematopoietic differentiation, leading to the in vivo accumulation and persistence of an early progenitor compartment with a Sca1(+)/Kit(hi)/CD11b(+) phenotype and an increased self- renewal capacity, as documented by replating assays in vitro. Differ entiation of these cells is not blocked, but the frequency of mature blood cells arising from TEL/AML1- transduced progenitors is low. Impa ired differentiation is prominently observed in the pro- B- cell compartment, resulting in an proportional increase in early progenitors in vivo, consistent with the t(12;21) ALL phenotype. Desp ite the accumulation of both multipotent and B- cell progenitors in vivo, no leukemia induction was observed during an observation period of over 1 year. These results are consistent with. ndings in twins with concordant ALL, showing that TEL/AML1 generates a preleukemic clone in utero that persists for several years in a clinically covert fashion. Fur thermore, our studies showed that the pointed domain of TEL/AML1, which recruits transcriptional repressors and directs oligomerization with either TEL/AML1 or wild-type TEL, was essential for the observed differentiation impairment and could not be replaced with another oligomerization domain.	Heinrich Pette Inst Expt Virol & Immunol, Mol Pathol Grp, D-20251 Hamburg, Germany; Inst Canc Res, Leukaemia Res Fund Ctr, London SW3 6JB, England; Inst Canc Res, Chester Beatty Labs, London SW3 6JB, England	Heinrich Pette Institute; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Stocking, C (corresponding author), Heinrich Pette Inst Expt Virol & Immunol, POB 201652, D-20206 Hamburg, Germany.	stocking@hpi.uni-hamburg.de						Akashi K, 2003, BLOOD, V101, P383, DOI 10.1182/blood-2002-06-1780; Bernardi R, 2002, ONCOGENE, V21, P3445, DOI 10.1038/sj.onc.1205313; Bernardin F, 2002, CANCER RES, V62, P3904; Borkhardt A, 1997, BLOOD, V90, P571, DOI 10.1182/blood.V90.2.571.571_571_577; Christensen JL, 2001, P NATL ACAD SCI USA, V98, P14541, DOI 10.1073/pnas.261562798; de Guzman CG, 2002, MOL CELL BIOL, V22, P5506, DOI 10.1128/MCB.22.15.5506-5517.2002; ELEFANTY AG, 1992, MOL CELL BIOL, V12, P1755, DOI 10.1128/MCB.12.4.1755; ERICKSON P, 1992, BLOOD, V80, P1825; Fenrick R, 2000, MOL CELL BIOL, V20, P5828, DOI 10.1128/MCB.20.16.5828-5839.2000; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; GONG JK, 1978, SCIENCE, V199, P1443, DOI 10.1126/science.75570; Greaves MF, 2003, BLOOD, V102, P2321, DOI 10.1182/blood-2002-12-3817; Growney JD, 2005, BLOOD, V106, P494, DOI 10.1182/blood-2004-08-3280; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; Hayashi K, 2000, J IMMUNOL, V165, P6816, DOI 10.4049/jimmunol.165.12.6816; Hiebert SW, 2001, CANCER CHEMOTH PHARM, V48, pS31, DOI 10.1007/s002800100302; Higuchi M, 2002, CANCER CELL, V1, P63, DOI 10.1016/S1535-6108(02)00016-8; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Ichikawa M, 2004, NAT MED, V10, P299, DOI 10.1038/nm997; Irvin BJ, 2003, J BIOL CHEM, V278, P46378, DOI 10.1074/jbc.M305189200; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Lagasse E, 2001, IMMUNITY, V14, P425, DOI 10.1016/S1074-7613(01)00123-6; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Li ZX, 2003, EXP HEMATOL, V31, P1206, DOI 10.1016/j.exphem.2003.08.008; Licht JD, 2001, ONCOGENE, V20, P5660, DOI 10.1038/sj.onc.1204593; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; McLean TW, 1996, BLOOD, V88, P4252; Meyer J, 1998, BLOOD, V91, P1901, DOI 10.1182/blood.V91.6.1901.1901_1901_1908; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Mori H, 2002, P NATL ACAD SCI USA, V99, P8242, DOI 10.1073/pnas.112218799; Morrison SJ, 1997, DEVELOPMENT, V124, P1929; Morrow M, 2004, BLOOD, V103, P3890, DOI 10.1182/blood-2003-10-3695; Muller-Tidow C, 2004, MOL CELL BIOL, V24, P2890, DOI 10.1128/MCB.24.7.2890-2904.2004; Okada H, 1998, ONCOGENE, V17, P2287, DOI 10.1038/sj.onc.1202151; Osato M, 2004, ONCOGENE, V23, P4284, DOI 10.1038/sj.onc.1207779; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; PUTZ G, 2005, UNPUB ONCOGENE; Randall TD, 1997, BLOOD, V89, P3596, DOI 10.1182/blood.V89.10.3596.3596_3596_3606; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Schebesta M, 2002, CURR OPIN IMMUNOL, V14, P216, DOI 10.1016/S0952-7915(02)00324-2; Schwieger M, 2002, J EXP MED, V196, P1227, DOI 10.1084/jem.20020824; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; Smith KS, 2003, MOL CELL, V12, P393, DOI 10.1016/S1097-2765(03)00277-6; Speck NA, 2002, NAT REV CANCER, V2, P502, DOI 10.1038/nrc840; Sun W, 2004, BLOOD, V104, P3565, DOI 10.1182/blood-2003-12-4349; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Terskikh AV, 2003, BLOOD, V102, P94, DOI 10.1182/blood-2002-08-2509; Tsuzuki S, 2004, P NATL ACAD SCI USA, V101, P8443, DOI 10.1073/pnas.0402063101; Van Rompaey L, 2000, ONCOGENE, V19, P5244, DOI 10.1038/sj.onc.1203899; Wang LL, 2001, ONCOGENE, V20, P3716, DOI 10.1038/sj.onc.1204479; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Yuan YZ, 2001, P NATL ACAD SCI USA, V98, P10398, DOI 10.1073/pnas.171321298; Zelent A, 2004, ONCOGENE, V23, P4275, DOI 10.1038/sj.onc.1207672; Zhang SL, 2001, MOL CELL BIOL, V21, P310, DOI 10.1128/MCB.21.1.310-318.2001	59	68	69	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2005	24	51					7579	7591		10.1038/sj.onc.1208931	http://dx.doi.org/10.1038/sj.onc.1208931			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	984VQ	16044150				2022-12-25	WOS:000233333800007
J	Rishavy, MA; Hallgren, KW; Yakubenko, AV; Zuerner, RL; Runge, KW; Berkner, KL				Rishavy, MA; Hallgren, KW; Yakubenko, AV; Zuerner, RL; Runge, KW; Berkner, KL			The vitamin K-dependent carboxylase has been acquired by Leptospira pathogens and shows altered activity that suggests a role other than protein carboxylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYL CARBOXYLASE; POSTTRANSLATIONAL MODIFICATION; CONUS-TEXTILE; IDENTIFICATION; EXPRESSION; HYDROQUINONE; COAGULATION; PHYSIOLOGY; DROSOPHILA; MECHANISM	Leptospirosis is an emerging infectious disease whose pathology includes a hemorrhagic response, and sequencing of the Leptospira interrogans genome revealed an ortholog of the vitamin K-dependent (VKD) carboxylase as one of several hemostatic proteins present in the bacterium. Until now, the VKD carboxylase was known to be present only in the animal kingdom (i.e. metazoans that include mammals, fish, snails, and insects), and this restricted distribution and high sequence similarity between metazoan and Leptospira orthologs strongly suggests that Leptospira acquired the VKD carboxylase by horizontal gene transfer. In metazoans, the VKD carboxylase is bifunctional, acting as an epoxidase that oxygenates vitamin K to a strong base and a carboxylase that uses the base to carboxylate Glu residues in VKD proteins, rendering them active in hemostasis and other physiologies. In contrast, the Leptospira ortholog showed epoxidase but not detectable carboxylase activity and divergence in a region of identity in all known metazoan VKD carboxylases that is important to Glu interaction. Furthermore, although the mammalian carboxylase is regulated so that vitamin K epoxidation does not occur unless Glu substrate is present, the Leptospira VKD epoxidase showed unfettered epoxidation in the absence of Glu substrate. Finally, human VKD protein orthologs were not detected in the L. interrogans genome. The combined data, then, suggest that Leptospira exapted the metazoan VKD carboxylase for some use other than VKD protein carboxylation, such as using the strong vitamin K base to drive a new reaction or to promote oxidative damage or depleting vitamin K to indirectly inhibit host VKD protein carboxylation.	Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, Lerner Res Inst,Dept Mol Cardiol, Cleveland, OH 44195 USA; Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, Lerner Res Inst,Dept Mol Genet, Cleveland, OH 44195 USA; ARS, Bacterial Dis Livestock Res Unit, Natl Anim Dis Ctr, USDA, Ames, IA 50010 USA	Case Western Reserve University; Cleveland Clinic Foundation; Case Western Reserve University; Cleveland Clinic Foundation; United States Department of Agriculture (USDA)	Berkner, KL (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol NB50, 9500 Euclid Ave, Cleveland, OH 44195 USA.	berknek@ccf.org	Runge, Kurt/AAW-9308-2021; Zuerner, Richard/AAG-7645-2021	Runge, Kurt/0000-0001-8492-0530; Berkner, Kathleen/0000-0001-8054-8081	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055666] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG019960] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL055666-08, HL55666] Funding Source: Medline; NIA NIH HHS [R01 AG019960] Funding Source: Medline; NIGMS NIH HHS [R01 GM050752] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bandyopadhyay PK, 2002, P NATL ACAD SCI USA, V99, P1264, DOI 10.1073/pnas.022637099; Berkner KL, 1997, METHOD ENZYMOL, V282, P313; Berkner KL, 2004, J THROMB HAEMOST, V2, P2118, DOI 10.1111/j.1538-7836.2004.00968.x; Blandl T, 2000, FEBS LETT, V470, P139, DOI 10.1016/S0014-5793(00)01309-0; Bracey MH, 2004, FEBS LETT, V567, P159, DOI 10.1016/j.febslet.2004.04.084; Bush KA, 1999, BIOCHEMISTRY-US, V38, P14660, DOI 10.1021/bi991640l; Czerwiec E, 2002, EUR J BIOCHEM, V269, P6162, DOI 10.1046/j.1432-1033.2002.03335.x; DOWD P, 1995, SCIENCE, V269, P1684, DOI 10.1126/science.7569894; Faine S., 1994, LEPTOSPIRA LEPTOSPIR; Jiang Y, 2003, P NATL ACAD SCI USA, V100, P7527, DOI 10.1073/pnas.0932632100; KARUDAPURAM S, 1995, J BACTERIOL, V177, P3235, DOI 10.1128/jb.177.11.3235-3240.1995; Li T, 2000, J BIOL CHEM, V275, P18291, DOI 10.1074/jbc.M001790200; Li T, 2004, NATURE, V427, P541, DOI 10.1038/nature02254; Meganathan R, 2001, VITAM HORM, V61, P173; Morris DP, 1995, J BIOL CHEM, V270, P30491, DOI 10.1074/jbc.270.51.30491; Mutucumarana VP, 2003, J BIOL CHEM, V278, P46488, DOI 10.1074/jbc.M307707200; Nascimento ALTO, 2004, J BACTERIOL, V186, P2164, DOI 10.1128/JB.186.7.2164-2172.2004; Pudota BN, 2000, P NATL ACAD SCI USA, V97, P13033, DOI 10.1073/pnas.97.24.13033; Ren SX, 2003, NATURE, V422, P888, DOI 10.1038/nature01597; Rishavy MA, 2004, P NATL ACAD SCI USA, V101, P13732, DOI 10.1073/pnas.0404989101; Rost S, 2004, NATURE, V427, P537, DOI 10.1038/nature02214; ROTH DA, 1993, P NATL ACAD SCI USA, V90, P8372, DOI 10.1073/pnas.90.18.8372; ROTH DA, 1995, J BIOL CHEM, V270, P5305, DOI 10.1074/jbc.270.10.5305; Schultz J, 2004, TRENDS BIOCHEM SCI, V29, P4, DOI 10.1016/j.tibs.2003.11.002; Stenina O, 2001, BIOCHEMISTRY-US, V40, P10301, DOI 10.1021/bi0107039; Sugiura I, 1997, P NATL ACAD SCI USA, V94, P9069, DOI 10.1073/pnas.94.17.9069; SUTTIE JW, 1985, ANNU REV BIOCHEM, V54, P459, DOI 10.1146/annurev.bi.54.070185.002331; Syvanen M., 2002, HORIZONTAL GENE TRAN; Venter JC, 2004, SCIENCE, V304, P66, DOI 10.1126/science.1093857; Walker CS, 2001, J BIOL CHEM, V276, P7769, DOI 10.1074/jbc.M009576200; WU SM, 1991, SCIENCE, V254, P1634, DOI 10.1126/science.1749935; Zuerner R, 2001, SPIROCHETES: MOLECULAR AND CELLULAR BIOLOGY, P137	32	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34870	34877		10.1074/jbc.M504345200	http://dx.doi.org/10.1074/jbc.M504345200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16061481	hybrid			2022-12-25	WOS:000232403900059
J	Zschocke, J; Bayatti, N; Clement, AM; Witan, H; Figiel, M; Engele, J; Behl, C				Zschocke, J; Bayatti, N; Clement, AM; Witan, H; Figiel, M; Engele, J; Behl, C			Differential promotion of glutamate transporter expression and function by glucocorticoids in astrocytes from various brain regions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRILLARY ACIDIC PROTEIN; GENE-EXPRESSION; DNA METHYLATION; NERVOUS-SYSTEM; RAT-BRAIN; MINERALOCORTICOID RECEPTOR; RESPONSE ELEMENT; NEURAL RETINA; GROWTH-FACTOR; SPINAL-CORD	Steroids that activate glucocorticoid receptors (GRs) and mineralocorticoid receptors have important regulatory effects on neural development, plasticity, and the body's stress response. Here, we investigated the role of corticosteroids in regulating the expression of the glial glutamate transporters glial glutamate transporter-1 (GLT-1) and glutamate-aspartate transporter (GLAST) in rat primary astrocytes. The synthetic glucocorticoid dexamethasone provoked a marked increase of GLT-1 transcription and protein levels in cortical astrocytes, whereas GLAST expression remained unaffected. Up-regulation of GLT-1 expression was accompanied by an enhanced glutamate uptake, which could be blocked by the specific GLT-1 inhibitor dihydrokainate. The promoting effect of dexamethasone on GLT-1 gene expression and function was abolished by the GR antagonist mifepristone. A predominant role of the GR was further supported by the observation that corticosterone could elevate GLT-1 expression in a dose-dependent manner, whereas aldosterone, the physiological ligand of the mineralocorticoid receptor, exerted only weak effects even when applied at high concentrations. Moreover, we monitored brain region-specific differences, since all corticosteroids used in this study failed to alter the expression of GLT-1 in midbrain and cerebellar glia, although expression levels of both corticosteroid receptor subtypes were similar in all brain regions analyzed. Dexamethasone, however, modestly enhanced GLT-1 expression in cerebellar glia in combination with the DNA methyltransferase inhibitor 5-aza-2-deoxycytidine, suggesting that suppression of GLT-1 expression in cerebellar cultures may at least in part be epigenetically mediated by a DNA methylation-dependent process. Taken together, our data highlight a potential role for glucocorticoids in regulating GLT-1 gene expression during central nervous system development or pathophysiogical processes including stress.	Johannes Gutenberg Univ Mainz, Sch Med, Inst Physiol Chem & Pathobiochem, Dept Pathobiochem, D-55099 Mainz, Germany; Univ Leipzig, Inst Anat, D-04103 Leipzig, Germany	Johannes Gutenberg University of Mainz; Leipzig University	Behl, C (corresponding author), Johannes Gutenberg Univ Mainz, Sch Med, Inst Physiol Chem & Pathobiochem, Dept Pathobiochem, D-55099 Mainz, Germany.	cbehl@uni-mainz.de	Zschocke, Johannes/C-5885-2013; Figiel, Maciej/W-6152-2018	Zschocke, Johannes/0000-0002-0046-8274; Behl, Christian/0000-0001-8453-2378; Figiel, Maciej/0000-0003-3961-4635				AHIMA R, 1991, J COMP NEUROL, V313, P522, DOI 10.1002/cne.903130312; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; Butchbach MER, 2004, J BIOL CHEM, V279, P34388, DOI 10.1074/jbc.M403938200; CAMPEN TJ, 1982, CLIN EXP HYPERTENS A, V4, P1627, DOI 10.3109/10641968209061629; CHOU YC, 1991, DEV BRAIN RES, V61, P55, DOI 10.1016/0165-3806(91)90113-W; Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699; COUETTE B, 1992, ENDOCRINOLOGY, V130, P430, DOI 10.1210/en.130.1.430; Crossin KL, 1997, P NATL ACAD SCI USA, V94, P2687, DOI 10.1073/pnas.94.6.2687; De Kloet ER, 1998, ENDOCR REV, V19, P269, DOI 10.1210/er.19.3.269; De Nicola AF, 1998, J STEROID BIOCHEM, V65, P253, DOI 10.1016/S0960-0760(97)00190-8; Dinkel K, 2002, J NEUROVIROL, V8, P513, DOI 10.1080/13550280290100914; EVANS RM, 1989, NEURON, V2, P1105, DOI 10.1016/0896-6273(89)90177-3; Figiel M, 2000, J NEUROSCI, V20, P3596, DOI 10.1523/JNEUROSCI.20-10-03596.2000; Figiel M, 2003, EXP NEUROL, V183, P124, DOI 10.1016/S0014-4886(03)00134-1; Franke B, 1998, HISTOCHEM CELL BIOL, V110, P595, DOI 10.1007/s004180050322; Furuta A, 1997, J NEUROSCI, V17, P8363; Galbiati F, 2000, J BIOL CHEM, V275, P23368, DOI 10.1074/jbc.M002020200; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gegelashvili G, 1997, MOL PHARMACOL, V52, P6, DOI 10.1124/mol.52.1.6; Gegelashvili G, 2001, Prog Brain Res, V132, P267; GOTTSCHALL PE, 1991, AM J PHYSIOL, V261, pE362, DOI 10.1152/ajpendo.1991.261.3.E362; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; Holsboer F, 1996, ENDOCR REV, V17, P187, DOI 10.1210/er.17.2.187; JUNGTESTAS I, 1984, J STEROID BIOCHEM, V20, P301, DOI 10.1016/0022-4731(84)90221-8; Karin M, 1998, CELL, V93, P487, DOI 10.1016/S0092-8674(00)81177-0; Kim DH, 2003, J BIOCHEM MOL BIOL, V36, P110; KNISS DA, 1985, EXP CELL RES, V161, P29, DOI 10.1016/0014-4827(85)90487-2; KUMAR S, 1989, P NATL ACAD SCI USA, V86, P6807, DOI 10.1073/pnas.86.17.6807; LAPING NJ, 1994, ENDOCRINOLOGY, V135, P1928, DOI 10.1210/en.135.5.1928; Levy LM, 1998, J NEUROSCI, V18, P9620, DOI 10.1523/jneurosci.18-23-09620.1998; Liang Z, 2002, J NEUROCHEM, V80, P807, DOI 10.1046/j.0022-3042.2002.00779.x; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mograbi B, 2003, CARCINOGENESIS, V24, P1415, DOI 10.1093/carcin/bgg093; MOSCONA AA, 1975, J STEROID BIOCHEM, V6, P633, DOI 10.1016/0022-4731(75)90044-8; Niu HR, 1997, MOL BRAIN RES, V51, P97, DOI 10.1016/S0169-328X(97)00221-0; OCALLAGHAN JP, 1991, J NEUROCHEM, V57, P860, DOI 10.1111/j.1471-4159.1991.tb08230.x; PAYVAR F, 1982, J CELL BIOCHEM, V19, P241, DOI 10.1002/jcb.240190305; PEARCE D, 1993, SCIENCE, V259, P1161, DOI 10.1126/science.8382376; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; PU HF, 1990, GENE, V89, P259, DOI 10.1016/0378-1119(90)90014-I; Reagan LP, 2004, P NATL ACAD SCI USA, V101, P2179, DOI 10.1073/pnas.0307294101; Reul JMHM, 2000, EUR J PHARMACOL, V405, P235, DOI 10.1016/S0014-2999(00)00677-4; REUL JMHM, 1985, ENDOCRINOLOGY, V117, P2505, DOI 10.1210/endo-117-6-2505; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; Rothstein JD, 2005, NATURE, V433, P73, DOI 10.1038/nature03180; Rozyczka J, 2005, MOL BRAIN RES, V133, P157, DOI 10.1016/j.molbrainres.2004.09.021; Sasaki S, 2000, ACTA NEUROPATHOL, V100, P138, DOI 10.1007/s004019900159; Schlag BD, 1998, MOL PHARMACOL, V53, P355, DOI 10.1124/mol.53.3.355; Schluter K, 2002, EUR J NEUROSCI, V16, P836, DOI 10.1046/j.1460-9568.2002.02130.x; Simard M, 1999, GLIA, V28, P1, DOI 10.1002/(SICI)1098-1136(199910)28:1<1::AID-GLIA1>3.0.CO;2-4; Sims KD, 1999, CRIT REV NEUROBIOL, V13, P169, DOI 10.1615/CritRevNeurobiol.v13.i2.30; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; Takizawa T, 2001, DEV CELL, V1, P749, DOI 10.1016/S1534-5807(01)00101-0; TRAPP T, 1994, NEURON, V13, P1457, DOI 10.1016/0896-6273(94)90431-6; Vardimon L, 1999, J NEUROBIOL, V40, P513, DOI 10.1002/(SICI)1097-4695(19990915)40:4<513::AID-NEU8>3.0.CO;2-D; VARDIMON L, 1986, P NATL ACAD SCI USA, V83, P9060, DOI 10.1073/pnas.83.23.9060; VIELKIND U, 1990, J NEUROSCI RES, V27, P360, DOI 10.1002/jnr.490270315; Zelenaia O, 2000, MOL PHARMACOL, V57, P667, DOI 10.1124/mol.57.4.667; ZHANG HY, 1991, J BIOL CHEM, V266, P24332; Zhu BG, 1998, BIOCHEM BIOPH RES CO, V247, P261, DOI 10.1006/bbrc.1998.8772; Zschocke J, 2005, GLIA, V49, P275, DOI 10.1002/glia.20116	62	103	106	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34924	34932		10.1074/jbc.M502581200	http://dx.doi.org/10.1074/jbc.M502581200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16079146	hybrid			2022-12-25	WOS:000232403900065
J	Glukhov, E; Stark, M; Burrows, LL; Deber, CM				Glukhov, E; Stark, M; Burrows, LL; Deber, CM			Basis for selectivity of cationic antimicrobial peptides for bacterial versus mammalian membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE ENERGY-TRANSFER; ANTIBACTERIAL PEPTIDES; PHOSPHOLIPID-MEMBRANES; TRANSMEMBRANE DOMAIN; LIPID BILAYERS; CDNA SEQUENCE; GRAMICIDIN-S; MOSES SOLE; HYDROPHOBICITY; ANALOGS	Novel cationic antimicrobial peptides typified by structures such as KKKKKKAAXAAWAAXAA- NH2, where X = Phe/Trp, and several of their analogues display high activity against a variety of bacteria but exhibit no hemolytic activity even at high dose levels in mammalian erythrocytes. To elucidate their mechanism of action and source of selectivity for bacterial membranes, phospholipid mixtures mimicking the compositions of natural bacterial membranes ( containing anionic lipids) and mammalian membranes ( containing zwitterionic lipids + cholesterol) were challenged with the peptides. We found that peptides readily inserted into bacterial lipid mixtures, although no insertion was detected in model "mammalian" membranes. The depth of peptide insertion into model bacterial membranes was estimated by Trp fluorescence quenching using doxyl groups variably positioned along the phospholipid acyl chains. Peptide antimicrobial activity generally increased with increasing depth of peptide insertion. The overall results, in conjunction with molecular modeling, support an initial electrostatic interaction step in which bacterial membranes attract and bind peptide dimers onto the bacterial surface, followed by the "sinking" of the hydrophobic core segment to a peptide sequence-dependent depth of similar to 2.5-8 angstrom into the membrane, largely parallel to the membrane surface. Antimicrobial activity was likely enhanced by the fact that the peptide sequences contain AXXXA sequence motifs, which promote their dimerization, and possibly higher oligomerization, as assessed by SDS-polyacrylamide gel analysis and fluorescence resonance energy transfer experiments. The high selectivity of these peptides for nonmammalian membranes, combined with their activity toward a wide spectrum of Gram-negative and Gram-positive bacteria and yeast, while retaining water solubility, represent significant advantages of this class of peptides.	Hosp Sick Children, Div Struct Biol & Biochem, Res Inst, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Div Infect Immun Injury & Repair, Res Inst, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Surg, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto	Deber, CM (corresponding author), Hosp Sick Children, Div Struct Biol & Biochem, Res Inst, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	deber@sickkids.ca	Glukhov, Evgenia/ABB-2769-2020; Burrows, Lori/D-1142-2010	Burrows, Lori/0000-0003-0838-5040; Glukhov, Evgenia/0000-0001-6513-9909				ADAIR BD, 1994, BIOCHEMISTRY-US, V33, P5539, DOI 10.1021/bi00184a024; Adams PD, 1996, PROTEINS, V26, P257, DOI 10.1002/(SICI)1097-0134(199611)26:3<257::AID-PROT2>3.0.CO;2-B; ARGIOLAS A, 1984, J BIOL CHEM, V259, P106; BESSALLE R, 1990, FEBS LETT, V274, P151, DOI 10.1016/0014-5793(90)81351-N; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; CHATTOPADHYAY A, 1987, BIOCHEMISTRY-US, V26, P39, DOI 10.1021/bi00375a006; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; Choi MY, 2004, BIOCHEMISTRY-US, V43, P8077, DOI 10.1021/bi0494525; Dathe M, 1999, BBA-BIOMEMBRANES, V1462, P71, DOI 10.1016/S0005-2736(99)00201-1; Deber CM, 2001, PROTEIN SCI, V10, P212, DOI 10.1110/ps.30301; Dimarcq JL, 1998, BIOPOLYMERS, V47, P465, DOI 10.1002/(SICI)1097-0282(1998)47:6<465::AID-BIP5>3.0.CO;2-#; Gennis R. B., 1989, BIOMEMBRANE, P1; HABERMANN E, 1967, H-S Z PHYSIOL CHEM, V348, P37, DOI 10.1515/bchm2.1967.348.1.37; Hancock R E, 2001, Lancet Infect Dis, V1, P156, DOI 10.1016/S1473-3099(01)00092-5; Hara T, 2001, BIOCHEMISTRY-US, V40, P12395, DOI 10.1021/bi011413v; Johansson J, 1998, J BIOL CHEM, V273, P3718, DOI 10.1074/jbc.273.6.3718; Johnstone SA, 2000, ANTI-CANCER DRUG DES, V15, P151; Kondejewski LH, 2002, J BIOL CHEM, V277, P67, DOI 10.1074/jbc.M107825200; Ladokhin AS, 2000, ANAL BIOCHEM, V285, P235, DOI 10.1006/abio.2000.4773; Lear JD, 2004, BIOPHYS J, V87, P3421, DOI 10.1529/biophysj.103.032839; Lee KH, 2003, BIOCHEM BIOPH RES CO, V309, P591, DOI 10.1016/j.bbrc.2003.08.043; LEE WJ, 1994, ANAL BIOCHEM, V217, P231, DOI 10.1006/abio.1994.1113; Li M, 1999, BIOPHYS J, V76, P2587, DOI 10.1016/S0006-3495(99)77411-4; Liu LP, 1998, J BIOL CHEM, V273, P23645, DOI 10.1074/jbc.273.37.23645; Liu LP, 1997, BIOCHEMISTRY-US, V36, P5476, DOI 10.1021/bi970030n; LONDON E, 1982, MOL CELL BIOCHEM, V45, P181; Ludtke SJ, 1996, BIOCHEMISTRY-US, V35, P13723, DOI 10.1021/bi9620621; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; Melnyk RA, 2002, J MOL BIOL, V315, P63, DOI 10.1006/jmbi.2001.5214; Melnyk RA, 2001, BIOCHEMISTRY-US, V40, P11106, DOI 10.1021/bi010642e; Oren Z, 1998, BIOPOLYMERS, V47, P451; Oren Z, 1996, EUR J BIOCHEM, V237, P303, DOI 10.1111/j.1432-1033.1996.0303n.x; Oren Z, 1997, BIOCHEMISTRY-US, V36, P1826, DOI 10.1021/bi962507l; Papo N, 2004, BIOCHEMISTRY-US, V43, P6393, DOI 10.1021/bi049944h; Papo N, 2003, PEPTIDES, V24, P1693, DOI 10.1016/j.peptides.2003.09.013; Porter EA, 2002, J AM CHEM SOC, V124, P7324, DOI 10.1021/ja0260871; POUNY Y, 1992, BIOCHEMISTRY-US, V31, P12416, DOI 10.1021/bi00164a017; Prenner EJ, 2005, J BIOL CHEM, V280, P2002, DOI 10.1074/jbc.M406509200; Prenner EJ, 1997, BIOCHEMISTRY-US, V36, P7906, DOI 10.1021/bi962785k; Sal-Man N, 2002, BIOCHEMISTRY-US, V41, P11921, DOI 10.1021/bi0260482; Sawai MV, 2001, BIOCHEMISTRY-US, V40, P3810, DOI 10.1021/bi002519d; Schneider D, 2004, J MOL BIOL, V343, P799, DOI 10.1016/j.jmb.2004.08.083; SELSTED ME, 1992, J BIOL CHEM, V267, P4292; SHAI Y, 1988, FEBS LETT, V242, P161, DOI 10.1016/0014-5793(88)81007-X; Stark M, 2002, ANTIMICROB AGENTS CH, V46, P3585, DOI 10.1128/AAC.46.11.3585-3590.2002; STEINER H, 1988, BIOCHIM BIOPHYS ACTA, V939, P260, DOI 10.1016/0005-2736(88)90069-7; STORICI P, 1993, BIOCHEM BIOPH RES CO, V196, P1363, DOI 10.1006/bbrc.1993.2403; VEATCH W, 1977, J MOL BIOL, V113, P89, DOI 10.1016/0022-2836(77)90042-0; VERKLEIJ AJ, 1973, BIOCHIM BIOPHYS ACTA, V323, P178, DOI 10.1016/0005-2736(73)90143-0; Voglino L, 1999, BIOCHEMISTRY-US, V38, P7509, DOI 10.1021/bi990099q; Wieprecht T, 1996, BIOCHEMISTRY-US, V35, P10844, DOI 10.1021/bi960362c; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	53	219	226	2	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33960	33967		10.1074/jbc.M507042200	http://dx.doi.org/10.1074/jbc.M507042200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16043484	hybrid			2022-12-25	WOS:000232229700033
J	Huang, YX; Smith, CA; Song, HB; Morgan, BP; Abagyan, R; Tomlinson, S				Huang, YX; Smith, CA; Song, HB; Morgan, BP; Abagyan, R; Tomlinson, S			Insights into the human CD59 complement binding interface toward engineering new therapeutics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY PROTEIN CD59; SPECIES SELECTIVE ACTIVITY; CELL-SURFACE; VASCULAR COMPLICATIONS; CANCER-IMMUNOTHERAPY; ACTIVE-SITE; 2ND LIGAND; EXPRESSION; INHIBITORS; IDENTIFICATION	CD59 is a 77-amino acid membrane glycoprotein that plays an important role in regulating the terminal pathway of complement by inhibiting formation of the cytolytic membrane attack complex ( MAC or C5b-9). The MAC is formed by the self assembly of C5b, C6, C7, C8, and multiple C9 molecules, with CD59 functioning by binding C5b-8 and C5b-9 in the assembling complex. We performed a scanning alanine mutagenesis screen of residues 16 - 57, a region previously identified to contain the C8/C9 binding interface. We have also created an improved NMR model from previously published data for structural understanding of CD59. Based on the scanning mutagenesis data, refined models, and additional site-specific mutations, we identified a binding interface that is much broader than previously thought. In addition to identifying substitutions that decreased CD59 activity, a surprising number of substitutions significantly enhanced CD59 activity. Because CD59 has significant therapeutic potential for the treatment of various inflammatory conditions, we investigated further the ability to enhance CD59 activity by additional mutagenesis studies. Based on the enhanced activity of membrane-bound mutant CD59 molecules, clinically relevant soluble mutant CD59-based proteins were prepared and shown to have up to a 3-fold increase in complement inhibitory activity.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29403 USA; Cardiff Univ, Sch Med, Dept Med Biochem & Immunol, Cardiff CF14 4XN, S Glam, Wales	Scripps Research Institute; Medical University of South Carolina; Cardiff University	Tomlinson, S (corresponding author), Scripps Res Inst, Dept Mol Biol, 10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.	tomlinss@musc.edu	Song, Hongbin/C-1963-2013; Smith, Colin A/E-5713-2012	Smith, Colin A/0000-0002-4651-167X; Morgan, Paul/0000-0003-4075-7676	NIAID NIH HHS [AI 47386, AI 34451] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047386, R01AI034451, R29AI034451] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABAGYAN R, 1994, J MOL BIOL, V235, P983, DOI 10.1006/jmbi.1994.1052; Acosta J, 2000, P NATL ACAD SCI USA, V97, P5450, DOI 10.1073/pnas.97.10.5450; AKAMI T, 1994, TRANSPL P, V26, P1256; AN J, 2005, IN PRESS MOL CELL PR; Arumugam TV, 2004, SHOCK, V21, P401, DOI 10.1097/00024382-200405000-00002; Bodian DL, 1997, J EXP MED, V185, P507, DOI 10.1084/jem.185.3.507; Chen SH, 2000, CANCER RES, V60, P3013; Davies CS, 2005, IMMUNOLOGY, V114, P280, DOI 10.1111/j.1365-2567.2004.02086.x; DECKERT M, 1992, EUR J IMMUNOL, V22, P2943, DOI 10.1002/eji.1830221128; Fernandez-Recio J, 2005, PROTEINS, V58, P134, DOI 10.1002/prot.20285; Fishelson Z, 2003, MOL IMMUNOL, V40, P109, DOI 10.1016/S0161-5890(03)00112-3; FLETCHER CM, 1994, STRUCTURE, V2, P185, DOI 10.1016/S0969-2126(00)00020-4; FLETCHER CM, 1993, PROTEIN SCI, V2, P2015, DOI 10.1002/pro.5560021203; Gelderman KA, 2004, TRENDS IMMUNOL, V25, P158, DOI 10.1016/j.it.2004.01.008; Ghiran I, 2003, J BIOL CHEM, V278, P21024, DOI 10.1074/jbc.M302306200; Giddings KS, 2004, NAT STRUCT MOL BIOL, V11, P1173, DOI 10.1038/nsmb862; HAHN WC, 1992, SCIENCE, V256, P1805, DOI 10.1126/science.1377404; HARLOW E, 1988, ANTIBODIES LAB MANUA, P92; Hinchliffe SJ, 2000, BIOCHEMISTRY-US, V39, P5831, DOI 10.1021/bi9929608; HUESLER T, 1995, J BIOL CHEM, V270, P3483, DOI 10.1074/JBC.270.8.3483; KIEFFER B, 1994, BIOCHEMISTRY-US, V33, P4471, DOI 10.1021/bi00181a006; LAMBRIS JD, 2000, THERAPEUTIC INTERVEN; LOCKERT DH, 1995, J BIOL CHEM, V270, P19723, DOI 10.1074/jbc.270.34.19723; Marcenaro E, 2003, EUR J IMMUNOL, V33, P3367, DOI 10.1002/eji.200324425; Morgan BP, 2003, MOL IMMUNOL, V40, P159, DOI 10.1016/S0161-5890(03)00111-1; Murray KP, 2000, GYNECOL ONCOL, V76, P176, DOI 10.1006/gyno.1999.5614; NEMETHY G, 1992, J PHYS CHEM-US, V96, P6472, DOI 10.1021/j100194a068; Petranka J, 1996, BLOOD CELL MOL DIS, V22, P281, DOI 10.1006/bcmd.1996.0111; Qin XB, 2004, DIABETES, V53, P2653, DOI 10.2337/diabetes.53.10.2653; Quigg RJ, 2002, TRENDS MOL MED, V8, P430, DOI 10.1016/S1471-4914(02)02386-9; Sahu A, 2000, IMMUNOPHARMACOLOGY, V49, P133, DOI 10.1016/S0162-3109(00)80299-4; SHAPIRO A, 1984, CANCER RES, V44, P3051; Song HB, 2003, J CLIN INVEST, V111, P1875, DOI 10.1172/JCI200317348; Thorsteinsson L, 1998, APMIS, V106, P869, DOI 10.1111/j.1699-0463.1998.tb00233.x; Totrov M, 2004, J COMPUT CHEM, V25, P609, DOI 10.1002/jcc.10392; Xu CL, 2005, PROSTATE, V62, P224, DOI 10.1002/pros.20134; Yu JH, 1997, BIOCHEMISTRY-US, V36, P9423, DOI 10.1021/bi970832i; Yu JH, 1997, J EXP MED, V185, P745, DOI 10.1084/jem.185.4.745; Zhang HF, 1999, J BIOL CHEM, V274, P10969, DOI 10.1074/jbc.274.16.10969; Zhang HF, 1999, J CLIN INVEST, V103, P55, DOI 10.1172/JCI4607; Zhao XJ, 1998, J BIOL CHEM, V273, P10665, DOI 10.1074/jbc.273.17.10665	41	34	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34073	34079		10.1074/jbc.M504922200	http://dx.doi.org/10.1074/jbc.M504922200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16079145	hybrid			2022-12-25	WOS:000232229700047
J	Peng, DQ; Wu, ZP; Brubaker, G; Zheng, LM; Settle, M; Gross, E; Kinter, M; Hazen, SL; Smith, JD				Peng, DQ; Wu, ZP; Brubaker, G; Zheng, LM; Settle, M; Gross, E; Kinter, M; Hazen, SL; Smith, JD			Tyrosine modification is not required for myeloperoxidase-induced loss of apolipoprotein A-I functional activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; HUMAN NEUTROPHILS EMPLOY; CASSETTE TRANSPORTER 1; CHOLESTEROL EFFLUX; HYPOCHLOROUS ACID; CARDIOVASCULAR-DISEASE; LIPID-PEROXIDATION; LYSINE RESIDUES; TANGIER-DISEASE; AMINO-ACIDS	Apolipoprotein A-I ( apoAI), the major protein of high density lipoprotein, plays an important role in reverse cholesterol transport via its activity as an ABCA1-dependent acceptor of cellular cholesterol. We reported recently that myeloperoxidase (MPO) modification of apoAI inhibits its ABCA1-dependent cholesterol acceptor activity (Zheng, L., Nukuna, B., Brennan, M. L., Sun, M., Goormastic, M., Settle, M., Schmitt, D., Fu, X., Thomson, L., Fox, P. L., Ischiropoulos, H., Smith, J. D., Kinter, M., and Hazen, S. L. ( 2004) J. Clin. Invest. 114, 529 - 541). We also reported that MPO-mediated chlorination preferentially modifies two of the seven tyrosines in apoAI, and loss of parent peptides containing these residues dose-dependently correlates with loss in ABCA1-mediated cholesterol acceptor activity ( Zheng, L., Settle, M., Brubaker, G., Schmitt, D., Hazen, S. L., Smith, J. D., and Kinter, M. ( 2005) J. Biol. Chem. 280, 38 - 47). To determine whether oxidative modification of apoA-I tyrosine residues was responsible for the MPO-mediated inactivation of cholesterol acceptor activity, we made recombinant apoAI with site-specific substitutions of all seven tyrosine residues to phenylalanine. ApoAI and the tyrosine-free apoAI were equally susceptible to dose-dependent MPO-mediated loss of ABCA1-dependent cholesterol acceptor activity, as well as lipid binding activity. MPO modification altered the migration of apoAI on SDS gels and decreased its alpha-helix content. MPO-induced modification also targeted apoAI tryptophan and lysine residues. Specifically, we detected apoAI tryptophan oxidation to mono- and dihydroxytryptophan and apoAI lysine modification to chlorolysine and 2-aminoadipic acid. Thus, tyrosine modification of apoAI is not required for its MPO-mediated inhibition of cholesterol acceptor activity.	Cleveland Clin Fdn, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Ctr Cardiovasc Diagnost & Prevent, Cleveland, OH 44195 USA; Cleveland State Univ, Dept Chem, Cleveland, OH 44114 USA; Case Western Reserve Univ, Dept Mol Med, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; University System of Ohio; Cleveland State University; Case Western Reserve University	Smith, JD (corresponding author), Cleveland Clin Fdn, Dept Cell Biol, NC10,9500 Euclid Ave, Cleveland, OH 44195 USA.	smithj4@ccf.org	Hazen, Stanley L/ABD-5845-2021; Smith, Jonathan D./H-9723-2013	Kinter, Michael/0000-0001-7409-8918; Smith, Jonathan D./0000-0002-0415-386X	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR015794, S10RR016794] Funding Source: NIH RePORTER; NCRR NIH HHS [RR15794, RR16794] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Agree AKB, 2002, BBA-PROTEIN STRUCT M, V1594, P286, DOI 10.1016/S0167-4838(01)00317-X; Anderson MM, 1999, J CLIN INVEST, V104, P103, DOI 10.1172/JCI3042; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; Ansell BJ, 2003, CIRCULATION, V108, P2751, DOI 10.1161/01.CIR.0000103624.14436.4B; Bergt C, 1999, FEBS LETT, V452, P295, DOI 10.1016/S0014-5793(99)00677-8; Bergt C, 2004, P NATL ACAD SCI USA, V101, P13032, DOI 10.1073/pnas.0405292101; Bergt C, 2004, J BIOL CHEM, V279, P7856, DOI 10.1074/jbc.M309046200; Bergt C, 2001, EUR J BIOCHEM, V268, P3523, DOI 10.1046/j.1432-1327.2001.02253.x; Bergt C, 2000, BIOCHEM J, V346, P345, DOI 10.1042/0264-6021:3460345; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Bortnick AE, 2000, J BIOL CHEM, V275, P28634, DOI 10.1074/jbc.M003407200; Brennan M, 2003, NEW ENGL J MED, V349, P1595, DOI 10.1056/NEJMoa035003; Brennan ML, 2002, J BIOL CHEM, V277, P17415, DOI 10.1074/jbc.M112400200; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Brouillette CG, 2001, BBA-MOL CELL BIOL L, V1531, P4, DOI 10.1016/S1388-1981(01)00081-6; Carr AC, 2001, FREE RADICAL BIO MED, V30, P526, DOI 10.1016/S0891-5849(00)00495-0; Castellani LW, 1997, J CLIN INVEST, V100, P464, DOI 10.1172/JCI119554; Chen W, 2001, J BIOL CHEM, V276, P43564, DOI 10.1074/jbc.M107938200; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; Chisolm GM, 2000, FREE RADICAL BIO MED, V28, P1815, DOI 10.1016/S0891-5849(00)00344-0; Cogny A, 1996, BIOCHEM J, V314, P285, DOI 10.1042/bj3140285; COGNY A, 1994, EUR J BIOCHEM, V222, P965, DOI 10.1111/j.1432-1033.1994.tb18947.x; DROZDZ R, 1988, BIOCHIM BIOPHYS ACTA, V957, P47, DOI 10.1016/0167-4838(88)90155-0; Ducret A, 1998, PROTEIN SCI, V7, P706, DOI 10.1002/pro.5560070320; Firuzi O, 2003, J PHARM PHARMACOL, V55, P1021, DOI 10.1211/0022357021314; Garner B, 1998, J BIOL CHEM, V273, P6088, DOI 10.1074/jbc.273.11.6088; Gaut JP, 2002, J CLIN INVEST, V109, P1311, DOI 10.1172/JCI200215021; GOODNO CC, 1981, ANAL BIOCHEM, V115, P203, DOI 10.1016/0003-2697(81)90547-9; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; Guidetti P, 2003, MOL BRAIN RES, V118, P132, DOI 10.1016/j.molbrainres.2003.08.004; Hawkins CL, 1998, BIOCHEM J, V332, P617, DOI 10.1042/bj3320617; Hawkins CL, 2003, AMINO ACIDS, V25, P259, DOI 10.1007/s00726-003-0016-x; Hazell LJ, 1999, BIOCHEM J, V339, P489, DOI 10.1042/0264-6021:3390489; HAZELL LJ, 1994, BIOCHEM J, V302, P297, DOI 10.1042/bj3020297; Hazen SL, 1999, CIRC RES, V85, P950; Hazen SL, 1996, J CLIN INVEST, V98, P1283, DOI 10.1172/JCI118914; Jerlich A, 2000, EUR J BIOCHEM, V267, P4137, DOI 10.1046/j.1432-1327.2000.01449.x; Kojima K, 2001, BBA-MOL CELL BIOL L, V1532, P173, DOI 10.1016/S1388-1981(01)00124-X; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Marsche G, 2002, J BIOL CHEM, V277, P32172, DOI 10.1074/jbc.M200503200; McCall MR, 2001, ARTERIOSCL THROM VAS, V21, P1040, DOI 10.1161/01.ATV.21.6.1040; NAGANO Y, 1991, P NATL ACAD SCI USA, V88, P6457, DOI 10.1073/pnas.88.15.6457; Nightingale ZD, 2000, FREE RADICAL BIO MED, V29, P425, DOI 10.1016/S0891-5849(00)00262-8; Panzenbock U, 2000, J BIOL CHEM, V275, P19536, DOI 10.1074/jbc.M000458200; Panzenboeck U, 1997, J BIOL CHEM, V272, P29711, DOI 10.1074/jbc.272.47.29711; Pennathur S, 2004, J BIOL CHEM, V279, P42977, DOI 10.1074/jbc.M406762200; Peskin AV, 2001, FREE RADICAL BIO MED, V30, P572, DOI 10.1016/S0891-5849(00)00506-2; Requena JR, 2001, P NATL ACAD SCI USA, V98, P69, DOI 10.1073/pnas.011526698; Roberts LM, 1997, BIOCHEMISTRY-US, V36, P7615, DOI 10.1021/bi962952g; Rogers DP, 1998, BIOCHEMISTRY-US, V37, P945, DOI 10.1021/bi9713512; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Ryan RO, 2003, PROTEIN EXPRES PURIF, V27, P98, DOI 10.1016/S1046-5928(02)00568-5; Saito H, 2004, J BIOL CHEM, V279, P20974, DOI 10.1074/jbc.M402043200; Saito H, 2003, J BIOL CHEM, V278, P23227, DOI 10.1074/jbc.M303365200; SALMON S, 1992, BIOCHIM BIOPHYS ACTA, V1125, P230, DOI 10.1016/0005-2760(92)90050-6; Shao BH, 2005, J BIOL CHEM, V280, P5983, DOI 10.1074/jbc.M411484200; Shishehbor MH, 2003, JAMA-J AM MED ASSOC, V289, P1675, DOI 10.1001/jama.289.13.1675; Silva RAGD, 2005, BIOCHEMISTRY-US, V44, P8600, DOI 10.1021/bi050421z; Smith JD, 1996, J BIOL CHEM, V271, P30647, DOI 10.1074/jbc.271.48.30647; Smith JD, 2004, J LIPID RES, V45, P635, DOI 10.1194/jlr.M300336-JLR200; Takahashi Y, 2000, BBA-GENE STRUCT EXPR, V1492, P385, DOI 10.1016/S0167-4781(00)00133-0; Van Lenten BJ, 2001, CIRCULATION, V103, P2283; VanLenten BJ, 1995, J CLIN INVEST, V96, P2758, DOI 10.1172/JCI118345; VISSERS MCM, 1991, ARCH BIOCHEM BIOPHYS, V285, P53, DOI 10.1016/0003-9861(91)90327-F; WINTERBOURN CC, 1985, BIOCHIM BIOPHYS ACTA, V840, P204, DOI 10.1016/0304-4165(85)90120-5; Yancey PG, 2003, ARTERIOSCL THROM VAS, V23, P712, DOI 10.1161/01.ATV.0000057572.97137.DD; Zhang RL, 2002, J BIOL CHEM, V277, P46116, DOI 10.1074/jbc.M209124200; Zhang YZ, 2003, CIRCULATION, V108, P661, DOI 10.1161/01.CIR.0000086981.09834.E0; Zhang ZL, 2001, JAMA-J AM MED ASSOC, V286, P2136, DOI 10.1001/jama.286.17.2136; Zheng L, 2005, J BIOL CHEM, V280, P38, DOI 10.1074/jbc.M407019200; Zheng LM, 2004, J CLIN INVEST, V114, P529, DOI 10.1172/JCI200421109; Zheng P, 2001, BBA-MOL CELL BIOL L, V1534, P121, DOI 10.1016/S1388-1981(01)00183-4	72	68	79	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33775	33784		10.1074/jbc.M504092200	http://dx.doi.org/10.1074/jbc.M504092200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16091367	hybrid			2022-12-25	WOS:000232229700013
J	He, JCJ; Gomes, I; Nguyen, T; Jayaram, G; Ram, PT; Devi, LA; Iyengar, R				He, JCJ; Gomes, I; Nguyen, T; Jayaram, G; Ram, PT; Devi, LA; Iyengar, R			The G alpha(o/)i-coupled cannabinoid receptor-mediated neurite outgrowth involves rap regulation of Src and Stat3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH CONE GUIDANCE; PC12 CELLS; MAP KINASE; ACTIVATION; PROTEIN; PATHWAY; GTPASE; JNK; PHOSPHORYLATION; TRANSFORMATION	The study of the signaling pathways regulating neurite outgrowth in culture is important because of their potential role in neuronal differentiation in vivo. We have previously shown that the G alpha(o/i)-coupled CB1 cannabinoid receptor (CB1R) activates Rap1 to induce neurite outgrowth. G alpha(o/i) also activates the Src-Stat3 pathway. Here, we studied the relationship between the G alpha(o/i)-Rap1 and Src-Stat3 pathways and the role of these signaling pathways in CB1R-mediated neurite outgrowth in Neuro-2A cells. The CB1 agonist HU-210 induced pertussis toxin-sensitive Src and Stat3 phosphorylation. Dominant negative (DN) mutants of Src and Stat3 blocked CB1R-induced neurite outgrowth. Constitutively active Rap 1B and Ral-activated Src and CB1R-induced Src phosphorylation was inhibited by Rap1-DN and Ral-DN, indicating that both Rap1 and Ral mediate downstream signaling from G alpha(o/i) for Src activation. Rap1-activated Ral and Ral-DN blocked Rap-induced Src phosphorylation. G alpha(o)-induced Stat3 activation was blocked by Ral-DN, whereas v-Src-induced Stat3 activation was not inhibited by Ral-DN, indicating that the CB1R, through G alpha(o), mediates the sequential activation of Rap1 to Ral to Src to Stat3 in Neuro-2A cells. Downstream of Src, the CB1R also activated Rac1 and JNK, which enhanced CBR1-mediated Stat3 activation. Rac-DN blocked CB1R-induced activation of JNK. Pharmacological inhibition of JNK blocked Src and CB1R activation of Stat3, indicating that Rac and JNK are also involved in CB1R-mediated neurite outgrowth. Overall, this study demonstrated that G alpha(o/i)-coupled CB1R triggers neurite outgrowth in Neuro-2A through the activation of a signaling network containing two pathways that bifurcate at Src and converge at Stat3.	Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Iyengar, R (corresponding author), Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, Box 1215,1 Gustave Levy Pl, New York, NY 10029 USA.	ravi.iyengar@mssm.edu	Devi P, Lakshmi/GXM-5982-2022	Devi P, Lakshmi/0000-0001-9274-4776; Ram, Prahlad/0000-0003-4739-3166; Hwangpo, Tracy Anh/0000-0002-4851-599X	NCI NIH HHS [CA-81050] Funding Source: Medline; NHLBI NIH HHS [HL-07824] Funding Source: Medline; NIDA NIH HHS [DA-019521, DA-08863] Funding Source: Medline; NIDDK NIH HHS [DK-65495] Funding Source: Medline; NIGMS NIH HHS [GM-54508] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081050] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK065495] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R37DA008863, R01DA008863, R56DA008863, K05DA019521] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Anneren C, 2000, J BIOL CHEM, V275, P29153, DOI 10.1074/jbc.M003926200; Arthur WT, 2004, J CELL BIOL, V167, P111, DOI 10.1083/jcb.200404068; Brouns MR, 2001, NAT CELL BIOL, V3, P361, DOI 10.1038/35070042; Causeret F, 2004, DEVELOPMENT, V131, P2841, DOI 10.1242/dev.01162; Chan ASL, 2004, CELL SIGNAL, V16, P823, DOI 10.1016/j.cellsig.2003.12.007; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; De Ruiter ND, 2000, MOL CELL BIOL, V20, P8480, DOI 10.1128/MCB.20.22.8480-8488.2000; Fukuyama T, 2005, J BIOL CHEM, V280, P815, DOI 10.1074/jbc.M411099200; Goi T, 2000, EMBO J, V19, P623, DOI 10.1093/emboj/19.4.623; Goi T, 1999, MOL CELL BIOL, V19, P1731; Harrington AW, 2002, J NEUROSCI, V22, P156, DOI 10.1523/JNEUROSCI.22-01-00156.2002; Ihara S, 1997, EMBO J, V16, P5345, DOI 10.1093/emboj/16.17.5345; Jacinto E, 1998, IMMUNITY, V8, P31, DOI 10.1016/S1074-7613(00)80456-2; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; Jordan JD, 2000, CELL, V103, P193, DOI 10.1016/S0092-8674(00)00112-4; Jordan JD, 2005, J BIOL CHEM, V280, P11413, DOI 10.1074/jbc.M411521200; Jordan JD, 1999, J BIOL CHEM, V274, P21507, DOI 10.1074/jbc.274.31.21507; Katoh H, 2003, NATURE, V424, P461, DOI 10.1038/nature01817; Kawakatsu T, 2005, J BIOL CHEM, V280, P4940, DOI 10.1074/jbc.M408710200; Kishida S, 1997, ONCOGENE, V15, P2899, DOI 10.1038/sj.onc.1201473; Larkum ME, 1999, NATURE, V398, P338, DOI 10.1038/18686; Linnemann T, 2002, J BIOL CHEM, V277, P7831, DOI 10.1074/jbc.M110800200; Lotto B, 1999, NEUROSCI LETT, V269, P87, DOI 10.1016/S0304-3940(99)00422-X; Marignani PA, 2001, J CELL BIOL, V154, P177, DOI 10.1083/jcb.200103134; Neves SR, 2002, SCIENCE, V296, P1636, DOI 10.1126/science.1071550; Ouwens DM, 2002, EMBO J, V21, P3782, DOI 10.1093/emboj/cdf361; Ram PT, 2000, SCIENCE, V287, P142, DOI 10.1126/science.287.5450.142; Reinoso BS, 1996, J NEUROSCI RES, V43, P439, DOI 10.1002/(SICI)1097-4547(19960215)43:4<439::AID-JNR5>3.0.CO;2-G; Rosso SB, 2005, NAT NEUROSCI, V8, P34, DOI 10.1038/nn1374; Servitja JM, 2003, J BIOL CHEM, V278, P34339, DOI 10.1074/jbc.M302960200; Song HJ, 1999, CURR OPIN NEUROBIOL, V9, P355, DOI 10.1016/S0959-4388(99)80052-X; STRITTMATTER SM, 1994, J NEUROSCI, V14, P2327; Waetzig V, 2003, MOL CELL NEUROSCI, V24, P238, DOI 10.1016/S1044-7431(03)00126-X; Wu YY, 2000, J BIOL CHEM, V275, P2147, DOI 10.1074/jbc.275.3.2147; Xiang Y, 2002, NAT NEUROSCI, V5, P843, DOI 10.1038/nn899; Xiao JN, 2003, J NEUROCHEM, V86, P1516, DOI 10.1046/j.1471-4159.2003.01961.x; Yang LT, 2002, J BIOL CHEM, V277, P17406, DOI 10.1074/jbc.M111902200; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Yuan XB, 2003, NAT CELL BIOL, V5, P38, DOI 10.1038/ncb895	39	84	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33426	33434		10.1074/jbc.M502812200	http://dx.doi.org/10.1074/jbc.M502812200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16046413	hybrid			2022-12-25	WOS:000232058100041
J	Yang, JY; Walicki, J; Abderrahmani, A; Cornu, M; Waeber, GR; Thorens, B; Widmann, C				Yang, JY; Walicki, J; Abderrahmani, A; Cornu, M; Waeber, GR; Thorens, B; Widmann, C			Expression of an uncleavable N-terminal RasGAP fragment in insulin-secreting cells increases their resistance toward apoptotic stimuli without affecting their glucose-induced insulin secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B ACTIVATION; CYTOKINE-INDUCED APOPTOSIS; BETA-CELLS; CLEAVAGE; DEATH; SURVIVAL; AKT; PROLIFERATION; INHIBITION; REPRESSOR	Apoptosis of pancreatic beta cells is implicated in the onset of type 1 and type 2 diabetes. Consequently, strategies aimed at increasing the resistance of beta cells toward apoptosis could be beneficial in the treatment of diabetes. RasGAP, a regulator of Ras and Rho GTPases, is an atypical caspase substrate, since it inhibits, rather than favors, apoptosis when it is partially cleaved by caspase-3 at position 455. The antiapoptotic signal generated by the partial processing of RasGAP is mediated by the N-terminal fragment (fragment N) in a Ras-phosphatidylinositol 3-kinase-Akt-dependent, but NF-kappa B-independent, manner. Further cleavage of fragment N at position 157 abrogates its antiapoptotic properties. Here we demonstrate that an uncleavable form of fragment N activates Akt, represses NF-kappa B activity, and protects the conditionally immortalized pancreatic -insulinoma beta TC-tet cell line against various insults, including exposure to genotoxins, trophic support withdrawal, and incubation with inflammatory cytokines. Fragment N also induced Akt activity and protection against cytokine- induced apoptosis in primary pancreatic islet cells. Fragment N did not alter insulin cell content and insulin secretion in response to glucose. These data indicate that fragment N protects beta cells without affecting their function. The pathways regulated by fragment N are therefore promising targets for antidiabetogenic therapy.	Univ Lausanne, Dept Cellular Biol, Biol & Med Fac, CH-1005 Lausanne, Switzerland; Univ Lausanne, Dept Physiol, Biol & Med Fac, CH-1005 Lausanne, Switzerland; Univ Lausanne Hosp, Dept Internal Med, CH-1011 Lausanne, Switzerland	University of Lausanne; University of Lausanne; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Widmann, C (corresponding author), Univ Lausanne, Dept Cellular Biol, Biol & Med Fac, Bugnon 9, CH-1005 Lausanne, Switzerland.	Christian.Widmann@unil.ch	Abderrahmani, Amar/O-3124-2017; Widmann, Christian/N-9851-2013	Abderrahmani, Amar/0000-0003-0752-0343; Widmann, Christian/0000-0002-6881-0363; Waeber, Gerard/0000-0003-4193-788X				Baker MS, 2001, J SURG RES, V97, P117, DOI 10.1006/jsre.2001.6121; BEG AA, 1996, SCIENCE, V274, P784; Bonvin C, 2002, CELL SIGNAL, V14, P123, DOI 10.1016/S0898-6568(01)00219-4; Butler AE, 2003, DIABETES, V52, P102, DOI 10.2337/diabetes.52.1.102; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Donath MY, 2003, J MOL MED-JMM, V81, P455, DOI 10.1007/s00109-003-0450-y; Dor Y, 2004, NATURE, V429, P41, DOI 10.1038/nature02520; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Dupraz P, 1999, GENE THER, V6, P1160, DOI 10.1038/sj.gt.3300922; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Fleischer N, 1998, DIABETES, V47, P1419, DOI 10.2337/diabetes.47.9.1419; Giannoukakis N, 2000, J BIOL CHEM, V275, P36509, DOI 10.1074/jbc.M005943200; Heimberg H, 2001, DIABETES, V50, P2219, DOI 10.2337/diabetes.50.10.2219; Jarpe MB, 1998, ONCOGENE, V17, P1475, DOI 10.1038/sj.onc.1202183; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; Karlsen AE, 2004, DIABETOLOGIA, V47, P1998, DOI 10.1007/s00125-004-1568-3; Lawlor MA, 2001, J CELL SCI, V114, P2903; Mauricio D, 1998, DIABETES, V47, P1537, DOI 10.2337/diabetes.47.10.1537; Ozes ON, 1999, NATURE, V401, P82; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Shapiro AMJ, 2003, IMMUNOL REV, V196, P219, DOI 10.1046/j.1600-065X.2003.00085.x; Tuttle RL, 2001, NAT MED, V7, P1133, DOI 10.1038/nm1001-1133; VALIUS M, 1995, MOL CELL BIOL, V15, P3058; WIDMANN C, 1995, BIOCHEM J, V310, P203, DOI 10.1042/bj3100203; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Yang JY, 2005, MOL BIOL CELL, V16, P3511, DOI 10.1091/mbc.E05-01-0080; Yang JY, 2004, BIOCHEM PHARMACOL, V68, P1027, DOI 10.1016/j.bcp.2004.03.043; Yang JY, 2004, MOL CELL BIOL, V24, P10425, DOI 10.1128/MCB.24.23.10425-10436.2004; Yang JY, 2002, J BIOL CHEM, V277, P14641, DOI 10.1074/jbc.M111540200; Yang JY, 2001, MOL CELL BIOL, V21, P5346, DOI 10.1128/MCB.21.16.5346-5358.2001	31	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32835	32842		10.1074/jbc.M504058200	http://dx.doi.org/10.1074/jbc.M504058200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16046410	hybrid			2022-12-25	WOS:000231920300036
J	Jiang, T; Wang, ZW; Proctor, G; Moskowitz, S; Liebman, SE; Rogers, T; Lucia, MS; Li, JP; Levi, M				Jiang, T; Wang, ZW; Proctor, G; Moskowitz, S; Liebman, SE; Rogers, T; Lucia, MS; Li, JP; Levi, M			Diet-induced obesity in C57BL/6J mice causes increased renal lipid accumulation and glomerulosclerosis via a sterol regulatory element-binding protein-1c-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC KIDNEY-DISEASE; METABOLIC SYNDROME; INSULIN-RESISTANCE; DIABETIC-NEPHROPATHY; LIVER; EXPRESSION; HYPERINSULINEMIA; OVEREXPRESSION; COMPLICATIONS; CHOLESTEROL	Obesity and metabolic syndrome are associated with glomerulosclerosis and proteinuria, but the mechanisms are not known. The purpose of this study was to determine if there is altered renal lipid metabolism and increased expression of sterol regulatory element-binding proteins (SREBPs) in a model of diet-induced obesity. C57BL/6J mice that were fed a high fat, 60 kcal % saturated ( lard) fat diet (HFD) developed obesity, hyperglycemia, and hyperinsulinemia compared with those that were fed a low fat, 10 kcal % fat diet (LFD). In contrast, A/J mice were resistant when fed the same diet. C57BL/6J mice with HFD exhibited significantly higher levels of renal SREBP-1 and SREBP-2 expression than those mice with LFD, whereas in A/J mice there were no changes with the same treatment. The increases in SREBP-1 and SREBP-2 expression in C57BL/6J mice resulted in renal accumulation of triglyceride and cholesterol. There were also significant increases in the renal expression of plasminogen activator inhibitor-1 (PAI-1), vascular endothelial growth factor ( VEGF), type IV collagen, and fibronectin, resulting in glomerulosclerosis and proteinuria. To determine a role for SREBPs per se in modulating renal lipid metabolism and glomerulosclerosis we performed studies in SREBP-1c(-/-) mice. In contrast to control mice, in the SREBP-1c(-/-) mice with HFD the accumulation of triglyceride was prevented, as well as the increases in PAI-1, VEGF, type IV collagen, and fibronectin expression. Our results therefore suggest that diet-induced obesity causes increased renal lipid accumulation and glomerulosclerosis in C57BL/6J mice via an SREBP-1 dependent pathway.	Univ Colorado, Hlth Sci Ctr, Div Renal Dis & Hypertens, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Physiol & Biophys, Denver, CO 80262 USA; Univ Texas, SW Med Ctr, Vet Affairs Med Ctr, Dallas, TX 75216 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Levi, M (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Renal Dis & Hypertens, Dept Med, 4200 E 9th Ave, Denver, CO 80262 USA.	Moshe.Levi@UCHSC.edu	Liebman, Scott/CAH-4604-2022	Levi, Moshe/0000-0002-6225-946X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062209, F32DK065407, T32DK007038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R03AG020361] Funding Source: NIH RePORTER; NIA NIH HHS [7R03-AG20361-2] Funding Source: Medline; NIDDK NIH HHS [T32 DK-07038-29, 5R01-DK062209-02, 1F32 DK065407-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abrass CK, 2004, J AM SOC NEPHROL, V15, P2768, DOI 10.1097/01.ASN.0000141963.04540.3E; Bagby SP, 2004, J AM SOC NEPHROL, V15, P2775, DOI 10.1097/01.ASN.0000141965.28037.EE; BARICOS WH, 1995, KIDNEY INT, V47, P1039, DOI 10.1038/ki.1995.150; Bianchi S, 2003, AM J KIDNEY DIS, V41, P565, DOI 10.1053/ajkd.2003.50140; Biddinger SB, 2005, DIABETES, V54, P1314, DOI 10.2337/diabetes.54.5.1314; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bonnet F, 2000, DIABETES METAB, V26, P254; Chen J, 2004, ANN INTERN MED, V140, P167, DOI 10.7326/0003-4819-140-3-200402030-00007; De Vriese A, 2001, J AM SOC NEPHROL, V12, P993, DOI 10.1681/ASN.V125993; El-Atat FA, 2004, J AM SOC NEPHROL, V15, P2816, DOI 10.1097/01.ASN.0000133698.80390.37; Franckhauser S, 2002, DIABETES, V51, P624, DOI 10.2337/diabetes.51.3.624; Fried LF, 2001, KIDNEY INT, V59, P260, DOI 10.1046/j.1523-1755.2001.00487.x; Gin H, 2000, DIABETES METAB, V26, P45; Guan YF, 2004, J AM SOC NEPHROL, V15, P2801, DOI 10.1097/01.ASN.0000139067.83419.46; Guidance Document on Using In Vitro Data to Estimate In Vivo Starting Doses for Acute Toxicity, 2001, GUID DOC US IN VITR; Harte RA, 1999, HORM METAB RES, V31, P570, DOI 10.1055/s-2007-978797; Henegar JR, 2001, J AM SOC NEPHROL, V12, P1211, DOI 10.1681/ASN.V1261211; Horton JD, 2003, J BIOL CHEM, V278, P36652, DOI 10.1074/jbc.M306540200; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Inman SR, 1999, AM J MED SCI, V317, P215, DOI 10.1097/00000441-199904000-00001; Isomaa B, 2001, DIABETES CARE, V24, P683, DOI 10.2337/diacare.24.4.683; Kimmelstiel P, 1936, AM J PATHOL, V12, P83; Kirschenbaum MA, 1996, MINER ELECTROL METAB, V22, P47; KISSEBAH AH, 1982, J CLIN ENDOCR METAB, V54, P254, DOI 10.1210/jcem-54-2-254; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakka HM, 2002, JAMA-J AM MED ASSOC, V288, P2709, DOI 10.1001/jama.288.21.2709; Le Lay S, 2002, J BIOL CHEM, V277, P35625, DOI 10.1074/jbc.M203913200; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; Lin JD, 2005, CELL, V120, P261, DOI 10.1016/j.cell.2004.11.043; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marcantoni C, 2002, KIDNEY INT, V62, P172, DOI 10.1046/j.1523-1755.2002.00420.x; Mingrone G, 2003, ATHEROSCLEROSIS, V170, P155, DOI 10.1016/S0021-9150(03)00254-5; Molnar J, 2005, CIRC RES, V96, P1178, DOI 10.1161/01.RES.0000168634.74330.ed; MOROOKA H, 1995, J BIOL CHEM, V270, P30084; NARVA AS, 2003, KIDNEY INT S, V83, pS3; Nishida Y, 1999, KIDNEY INT, V56, pS51, DOI 10.1046/j.1523-1755.1999.07113.x; Parekh PI, 1998, METABOLISM, V47, P1089, DOI 10.1016/S0026-0495(98)90283-9; Popov D, 2003, DIABETOLOGIA, V46, P1408, DOI 10.1007/s00125-003-1185-6; Praga M, 2002, NEPHROL DIAL TRANSPL, V17, P1157, DOI 10.1093/ndt/17.7.1157; Rawson RB, 2003, NAT REV MOL CELL BIO, V4, P631, DOI 10.1038/nrm1174; ROVIN BH, 1993, KIDNEY INT, V43, P218, DOI 10.1038/ki.1993.35; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; Smith BK, 2000, AM J PHYSIOL-REG I, V278, pR797, DOI 10.1152/ajpregu.2000.278.4.R797; Spencer MW, 2004, AM J NEPHROL, V24, P20, DOI 10.1159/000075362; Sun LJ, 2002, J BIOL CHEM, V277, P18919, DOI 10.1074/jbc.M110650200; *US DEP HHS, 1996, JAMA-J AM MED ASSOC, V276, P522, DOI DOI 10.1001/JAMA.1996.03540070018010; Virchow R, 1860, CELLULAR PATHOLOGY B, P383; Wang DQH, 1999, J LIPID RES, V40, P2066; Wisse BE, 2004, J AM SOC NEPHROL, V15, P2792, DOI 10.1097/01.ASN.0000141966.69934.21; World Health Organization, 1999, DEF DIAGN CLASS DI 1; Xu J, 2002, J NUTR, V132, P3333, DOI 10.1093/jn/132.11.3333; Yahagi N, 2002, J BIOL CHEM, V277, P19353, DOI 10.1074/jbc.M201584200; Young BA, 2005, J AM SOC NEPHROL, V16, P219, DOI 10.1681/ASN.2004030162	53	272	287	2	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32317	32325		10.1074/jbc.M500801200	http://dx.doi.org/10.1074/jbc.M500801200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16046411	hybrid			2022-12-25	WOS:000231794800035
J	Constable, JRL; Graham, ME; Morgan, A; Burgoyne, RD				Constable, JRL; Graham, ME; Morgan, A; Burgoyne, RD			Amisyn regulates exocytosis and fusion pore stability by both syntaxin-dependent and syntaxin-independent mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; MEMBRANE-FUSION; SNARE COMPLEX; SYNAPTIC VESICLES; CHROMAFFIN CELLS; ALPHA-SNAP; TOMOSYN; RELEASE; SECRETION; LAYER	Amisyn and tomosyn are related by the possession of a C-terminal vesicle-associated membrane protein- like domain that allows them to bind to syntaxin 1 and assemble into SNARE complexes. The formation of inactive complexes may sequester syntaxin and allow tomosyn and amisyn to act as inhibitors of exocytosis. We aimed to use adrenal chromaffin and PC12 cells to probe this possible mode of action of amisyn and tomosyn in dense core granule exocytosis. Although tomosyn is expressed by adrenal chromaffin and PC12 cells, amisyn expression could not be detected allowing examination of the effect of introduction of amisyn expression onto a neuronal-like background. Overexpression of m-tomosyn1 and expression of amisyn both inhibited Ca2+-induced exocytosis in transfected PC12 cells. Surprisingly, this inhibition was not removed when amisyn and tomosyn constructs were used in which key residues required for efficient binding to syntaxin1 were mutated. The effect of amisyn was further characterized using carbon fiber amperometry in chromaffin cells. Expression of amisyn had no effect on the basic characteristics of the amperometric spikes but reduced the number of spikes elicited. This inhibitory action on the extent of exocytosis was also seen with the amisyn mutant deficient in syntaxin1 binding. In addition, expression of amisyn resulted in an increase in the lifetime of the prespike foot, and this effect was abolished by the mutations. These results show that tomosyn and amisyn can negatively regulate exocytosis independently of syntaxin and also that amisyn can regulate the stability of the fusion pore.	Univ Liverpool, Sch Biomed Sci, Physiol Lab, Liverpool L69 3BX, Merseyside, England	University of Liverpool	Burgoyne, RD (corresponding author), Univ Liverpool, Sch Biomed Sci, Physiol Lab, Crown St, Liverpool L69 3BX, Merseyside, England.	burgoyne@liv.ac.uk	Morgan, Alan/AAI-8875-2020; Burgoyne, Robert D/P-6641-2019; Burgoyne, Robert/C-6706-2008	Burgoyne, Robert D/0000-0002-9219-0387; Burgoyne, Robert/0000-0002-9219-0387; Morgan, Alan/0000-0002-0346-1289	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Archer DA, 2002, J BIOL CHEM, V277, P18249, DOI 10.1074/jbc.C200166200; Bai JH, 2004, NEURON, V41, P929, DOI 10.1016/S0896-6273(04)00117-5; Barclay JW, 2003, J BIOL CHEM, V278, P10538, DOI 10.1074/jbc.M211114200; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; Burgoyne RD, 2003, PHYSIOL REV, V83, P581, DOI 10.1152/physrev.00031.2002; BURGOYNE RD, 1992, NEUROMETHODS, V20, P433; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Choi S, 2003, PHILOS T ROY SOC B, V358, P695, DOI 10.1098/rstb.2002.1249; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; Ciufo LF, 2005, MOL BIOL CELL, V16, P470, DOI 10.1091/mbc.E04-08-0685; CORCORAN JJ, 1984, J BIOL CHEM, V259, P6208; DETOLEDO GA, 1993, NATURE, V363, P554, DOI 10.1038/363554a0; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; Fernandez-Chacon R, 2001, NATURE, V410, P41, DOI 10.1038/35065004; Fisher RJ, 2001, SCIENCE, V291, P875, DOI 10.1126/science.291.5505.875; Fujita Y, 1998, NEURON, V20, P905, DOI 10.1016/S0896-6273(00)80472-9; Graham ME, 2000, J NEUROSCI, V20, P1281; Graham ME, 2000, BIOCHIMIE, V82, P469, DOI 10.1016/S0300-9084(00)00196-6; Graham ME, 2004, J BIOL CHEM, V279, P32751, DOI 10.1074/jbc.M400827200; Graham ME, 2001, J CELL SCI, V114, P4397; Groffen AJA, 2005, J NEUROCHEM, V92, P554, DOI 10.1111/j.1471-4159.2004.02890.x; Han X, 2004, SCIENCE, V304, P289, DOI 10.1126/science.1095801; Hatsuzawa K, 2003, J BIOL CHEM, V278, P31159, DOI 10.1074/jbc.M305500200; HOLGADO AM, 2004, W COAST WORM M; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; JANKOWSKI JA, 1992, J BIOL CHEM, V267, P18329; Khvotchev MV, 2003, J NEUROSCI, V23, P10531; Lehman K, 1999, J CELL BIOL, V146, P125, DOI 10.1083/jcb.146.1.125; Masuda ES, 1998, NEURON, V21, P479, DOI 10.1016/S0896-6273(00)80559-0; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; Musch A, 2002, MOL BIOL CELL, V13, P158, DOI 10.1091/mbc.01-10-0496; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; Pobbati AV, 2004, J BIOL CHEM, V279, P47192, DOI 10.1074/jbc.M408767200; Rickman C, 2004, J BIOL CHEM, V279, P12574, DOI 10.1074/jbc.M310710200; Sakisaka T, 2004, J CELL BIOL, V166, P17, DOI 10.1083/jcb.200405002; Scales SJ, 2002, J BIOL CHEM, V277, P28271, DOI 10.1074/jbc.M204929200; Scales SJ, 2001, P NATL ACAD SCI USA, V98, P14262, DOI 10.1073/pnas.251547598; Schluter OM, 2002, J BIOL CHEM, V277, P40919, DOI 10.1074/jbc.M203704200; Schroeder TJ, 1996, BIOPHYS J, V70, P1061, DOI 10.1016/S0006-3495(96)79652-2; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Sorensen JB, 2003, CELL, V114, P75, DOI 10.1016/S0092-8674(03)00477-X; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; Verhage M, 2000, SCIENCE, V287, P864, DOI 10.1126/science.287.5454.864; Wang CT, 2001, SCIENCE, V294, P1111, DOI 10.1126/science.1064002; Wei SH, 2000, EMBO J, V19, P1279, DOI 10.1093/emboj/19.6.1279; WICK PF, 1993, J BIOL CHEM, V268, P10983; Yizhar O, 2004, P NATL ACAD SCI USA, V101, P2578, DOI 10.1073/pnas.0308700100; Yokoyama S, 1999, BIOCHEM BIOPH RES CO, V256, P218, DOI 10.1006/bbrc.1999.0300	53	33	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31615	31623		10.1074/jbc.M505858200	http://dx.doi.org/10.1074/jbc.M505858200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16033762	hybrid			2022-12-25	WOS:000231665200036
J	Shams, I; Nevo, E; Avivi, A				Shams, I; Nevo, E; Avivi, A			Erythropoietin receptor spliced forms differentially expressed in blind subterranean mole rats	FASEB JOURNAL			English	Article						EpoR spliced variants; hypoxia; Epo	SPALAX-EHRENBERGI; HUMAN CANCER; CELL-LINE; HYPOXIA; CALCIUM; BRAIN; MOTIF; IDENTIFICATION; PROLIFERATION; HEMOGLOBIN	Erythropoietin ( Epo) is the primary regulator of erythropoiesis, controlling the proliferation, maturation, and survival of erythroid progenitor cells. The functions of Epo are mediated through its specific receptor ( EpoR) expressed mainly on the surface of erythroid progenitor cells, and the expression of both responds to hypoxia. The subterranean mole rat ( Spalax) is a unique model system to study the molecular mechanisms for adaptation to hypoxia. Here, we cloned two forms of Spalax EpoR: a complete EpoR cDNA as well as a novel truncated bone marrow specific EpoR form. In the full- length Spalax EpoR ( sEpoR), two out of the eight conserved tyrosine- phosphorylation sites were substituted ( Y481F and Y499G), suggesting that Spalax Epo signaling pathways may be modulated. The level of the sEpoR mRNA in the spleen and in bone marrow was relatively low and similar in Spalax newborns and adults, with no significant response to hypoxia. The truncated sEpoR was not detected in the spleen and comprised only similar to 1% of the sEpoR expressed in the bone marrow. In Rattus, the truncated EpoR form was similar to 15% of the total expressed receptor. The level of Rattus EpoR in newborn spleens was three- to fourfold higher than in Spalax newborns and decreased toward adulthood. Severe hypoxia induces a significant increase in adult Rattus EpoR. Our data provide further insight into the adaptive mechanisms of Spalax to the extreme conditions of hypoxia in its subterranean environment.	Univ Haifa, Lab Anim Mol Evolut, Inst Evolut, IL-31905 Haifa, Israel	University of Haifa	Avivi, A (corresponding author), Univ Haifa, Lab Anim Mol Evolut, Inst Evolut, IL-31905 Haifa, Israel.	aaron@esti.haifa.ac.il		Shams, Imad/0000-0001-6496-2928				Arcasoy MO, 2003, BIOCHEM BIOPH RES CO, V307, P999, DOI 10.1016/S0006-291X(03)01303-2; Arcasoy MO, 2002, LAB INVEST, V82, P911, DOI 10.1097/01.LAB.0000020415.72863.40; ARIELI R, 1991, COMP BIOCHEM PHYS A, V100, P543, DOI 10.1016/0300-9629(91)90367-L; ARIELI R, 1986, EXPERIENTIA, V42, P441, DOI 10.1007/BF02118650; ARIELI R, 1977, PHYSIOL ZOOL, V50, P61, DOI 10.1086/physzool.50.1.30155716; Ashur-Fabian C, 2004, P NATL ACAD SCI USA, V101, P12236, DOI 10.1073/pnas.0404998101; Assandri R, 1999, J PHYSIOL-LONDON, V516, P343, DOI 10.1111/j.1469-7793.1999.0343v.x; Avivi A, 2005, CELL CYCLE, V4, P368, DOI 10.4161/cc.4.3.1534; Avivi A, 1999, FEBS LETT, V452, P133, DOI 10.1016/S0014-5793(99)00584-0; BARRON C, 1994, GENE, V147, P263, DOI 10.1016/0378-1119(94)90078-7; Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Bittorf T, 1996, INT J BIOCHEM CELL B, V28, P175, DOI 10.1016/1357-2725(95)00128-X; Bouscary D, 2003, BLOOD, V101, P3436, DOI 10.1182/blood-2002-07-2332; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Chiba S, 1997, BLOOD, V90, P97; DANDREA A, 1990, INT J CELL CLONING, V8, P173, DOI 10.1002/stem.5530080716; EDOUTE Y, 1988, J COMP PHYSIOL B, V158, P575, DOI 10.1007/BF00692566; Farrell F, 2004, ONCOLOGIST, V9, P18, DOI 10.1634/theoncologist.9-90005-18; Flint-Ashtamker G, 2002, FEBS LETT, V518, P189, DOI 10.1016/S0014-5793(02)02691-1; GURNETT AM, 1984, J PROTEIN CHEM, V3, P445, DOI 10.1007/BF01025063; JACOBSON LO, 1957, NATURE, V179, P633, DOI 10.1038/179633a0; Joneja B, 1997, J BIOL CHEM, V272, P11176, DOI 10.1074/jbc.272.17.11176; KLEINSCHMIDT T, 1984, H-S Z PHYSIOL CHEM, V365, P531, DOI 10.1515/bchm2.1984.365.1.531; Lappin T, 2003, ONCOLOGIST, V8, P15, DOI 10.1634/theoncologist.8-suppl_1-15; Levin I, 1998, FEBS LETT, V427, P164, DOI 10.1016/S0014-5793(98)00414-1; Miller BA, 1999, J BIOL CHEM, V274, P20465, DOI 10.1074/jbc.274.29.20465; NAKAMURA Y, 1992, SCIENCE, V257, P1138, DOI 10.1126/science.257.5073.1138; Nevo, 1999, MOSAIC EVOLUTION SUB; NEVO E, 1989, HEREDITY, V62, P85, DOI 10.1038/hdy.1989.11; Nevo E., 1961, Mammalia Paris, V25, P127, DOI 10.1515/mamm.1961.25.2.127; NEVO E., 2001, ADAPTIVE RAD BLIND S; Seta KA, 2004, CELL CALCIUM, V36, P331, DOI 10.1016/j.ceca.2004.02.006; Shams I, 2004, P NATL ACAD SCI USA, V101, P9698, DOI 10.1073/pnas.0403540101; Shams Imad, 2005, FASEB J, V19, P307; Shimizu R, 1999, EXP HEMATOL, V27, P229, DOI 10.1016/S0301-472X(98)00048-4; Siren AL, 2001, ACTA NEUROPATHOL, V101, P271, DOI 10.1007/s004010000297; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Weisinger G, 1999, BBA-GENE STRUCT EXPR, V1446, P225, DOI 10.1016/S0167-4781(99)00091-3; Widmer HR, 1997, P NATL ACAD SCI USA, V94, P2062, DOI 10.1073/pnas.94.5.2062; Wright GL, 2004, FASEB J, V18, P1031, DOI 10.1096/fj.03-1289fje; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Yamaji R, 1998, BBA-MOL CELL RES, V1403, P169, DOI 10.1016/S0167-4889(98)00037-8; YOSHIMURA A, 1992, J BIOL CHEM, V267, P11619; Yu XB, 2002, DEVELOPMENT, V129, P505; ZANJANI ED, 1977, J LAB CLIN MED, V89, P640	45	21	21	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1749	+		10.1096/fj.05-3975fje	http://dx.doi.org/10.1096/fj.05-3975fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16081499				2022-12-25	WOS:000231843700021
J	Bi, XL; Jones, T; Abbasi, F; Lee, H; Stultz, B; Hursh, DA; Mortin, MA				Bi, XL; Jones, T; Abbasi, F; Lee, H; Stultz, B; Hursh, DA; Mortin, MA			Drosophila caliban, a nuclear export mediator, can function as a tumor suppressor in human lung cancer cells	ONCOGENE			English	Article						caliban; Sdccag1; tumor suppressor; nuclear export; lung cancer; interference RNA	PROSPERO GENE; CRM1; LOCALIZATION; HOMOLOG; REVEALS; ENCODES; SIGNALS; PROTEIN; SYSTEM; DOMAIN	We previously showed that the Drosophila DNA binding homeodomain of Prospero included a 28 amino-acid sequence (HDA) that functions as a nuclear export signal. We describe here the identification of a protein we named Caliban, which can directly interact with the HDA. Caliban is homologous to human Sdccag1, which has been implicated in colon and lung cancer. Here we show that Caliban and Sdccag1 are mediators of nuclear export in fly and human cells, as interference RNA abrogates export of EYFP-HDA in normal fly and human lung cells. Caliban functions as a bipartite mediator nuclear export as the carboxy terminus binds HDA and the amino terminus itself functions as an NES, which directly binds the NES receptor Exportin. Finally, while non-cancerous lung cells have functional Sdccag1, five human lung carcinoma cell lines do not, even though Exportin still functions in these cells. Expression of fly Caliban in these human lung cancer cells restores EYFP-HDA nuclear export, reduces a cell's ability to form colonies on soft agar and reduces cell invasiveness. We suggest that Sdccag1 inactivation contributes to the transformed state of human lung cancer cells and that Caliban should be considered a candidate for use in lung cancer gene therapy.	NCI, Biochem Lab, NIH, Bethesda, MD 20892 USA; NICHD, Mol Genet Lab, NIH, Bethesda, MD 20892 USA; US FDA, Ctr Biol Evaluat & Res, Div Cellular & Gene Therapies, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); US Food & Drug Administration (FDA)	Mortin, MA (corresponding author), NCI, Biochem Lab, NIH, Bethesda, MD 20892 USA.	mortinm@mail.nih.gov	Bi, Xiaolin/C-7038-2014; Bi, Xiaolin/E-7469-2010; Mortin, Mark A/B-4251-2008	Bi, Xiaolin/0000-0003-2837-9457; Bi, Xiaolin/0000-0002-7172-7851; Hursh, Deborah/0000-0002-5614-7111	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001005] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [Z01AA000367] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Bi XL, 2003, MOL CELL BIOL, V23, P1014, DOI 10.1128/MCB.23.3.1014-1024.2003; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BURGLIN TR, 1994, TRENDS BIOCHEM SCI, V19, P70, DOI 10.1016/0968-0004(94)90035-3; Carbonnelle D, 2001, INT J CANCER, V92, P388, DOI 10.1002/ijc.1197; Collier S, 2000, GENETICS, V155, P1799; Demidenko Z, 2001, DEVELOPMENT, V128, P1359; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; MATSUZAKI F, 1992, BIOCHEM BIOPH RES CO, V182, P1326, DOI 10.1016/0006-291X(92)91878-T; Misquitta L, 1999, P NATL ACAD SCI USA, V96, P1451, DOI 10.1073/pnas.96.4.1451; Ryter JM, 2002, STRUCTURE, V10, P1541, DOI 10.1016/S0969-2126(02)00883-3; Scanlan MJ, 1998, INT J CANCER, V76, P652, DOI 10.1002/(SICI)1097-0215(19980529)76:5<652::AID-IJC7>3.3.CO;2-9; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; VAESSIN H, 1991, CELL, V67, P941, DOI 10.1016/0092-8674(91)90367-8; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Yousef M, 2005, STRUCTURE, V13, P601, DOI 10.1016/j.str.2005.01.023	21	19	25	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2005	24	56					8229	8239		10.1038/sj.onc.1208962	http://dx.doi.org/10.1038/sj.onc.1208962			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	993LV	16103875				2022-12-25	WOS:000233956500002
J	Post, DMB; Zhang, DS; Eastvold, JS; Teghanemt, A; Gibson, BW; Weiss, JP				Post, DMB; Zhang, DS; Eastvold, JS; Teghanemt, A; Gibson, BW; Weiss, JP			Biochemical and functional characterization of membrane blebs purified from Neisseria meningitidis serogroup B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPOLYSACCHARIDE-BINDING PROTEIN; GRAM-NEGATIVE BACTERIA; OUTER-MEMBRANE; ESCHERICHIA-COLI; CELL ACTIVATION; MENINGOCOCCAL ENDOTOXIN; SALMONELLA-TYPHIMURIUM; (LPS)-BINDING PROTEIN; COMPLEMENT ACTIVATION; MASS-SPECTROMETRY	Studies with purified aggregates of endotoxin have revealed the importance of lipopolysaccharide-binding protein (LBP)-dependent extraction and transfer of individual endotoxin molecules to CD14 in Toll-like receptor 4 (TLR4)-dependent cell activation. Endotoxin is normally embedded in the outer membrane of intact Gram-negative bacteria and shed membrane vesicles ("blebs"). However, the ability of LBP and CD14 to efficiently promote TLR4-dependent cell activation by membrane-associated endotoxin has not been studied extensively. In this study, we used an acetate auxotroph of Neisseria meningitidis serogroup B to facilitate metabolic labeling of bacterial endotoxin and compared interactions of purified endotoxin aggregates and of membrane-associated endotoxin with LBP, CD14, and endotoxin-responsive cells. The endotoxin, phospholipid, and protein composition of the recovered blebs indicate that the blebs derive from the bacterial outer membrane. Proteomic analysis revealed an unusual enrichment in highly cationic (pI > 9) proteins. Both purified endotoxin aggregates and blebs activate monocytes and endothelial cells in a LBP-, CD14-, and TLR4/MD-2-dependent fashion, but the blebs were 3 - 10-fold less potent when normalized for the amount of endotoxin added. Differences in potency correlated with differences in efficiency of LBP-dependent delivery to and extraction of endotoxin by CD14. Both membrane phospholipids and endotoxin are extracted by LBP/soluble CD14 (sCD14) treatment, but only endotoxin center dot sCD14 reacts with MD- 2 and activates cells. These findings indicate that the proinflammatory potency of endotoxin may be regulated not only by the intrinsic structural properties of endotoxin but also by its association with neighboring molecules in the outer membrane.	Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Internal Med, Inflammat Program, Iowa City, IA 52242 USA; Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Microbiol, Iowa City, IA 52242 USA; Vet Affairs Med Ctr, Iowa City, IA 52246 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Buck Inst Age Res, Novato, CA 94945 USA	University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; University of California System; University of California San Francisco; Buck Institute for Research on Aging	Weiss, JP (corresponding author), Univ Iowa, Inflammat Program, 2501 Crosspk Rd,D158 MTF, Coralville, IA 52241 USA.	jerrold-weiss@uiowa.edu		Weiss, Jerrold/0000-0003-1476-4485	NIAID NIH HHS [AI59372, AI18571] Funding Source: Medline; PHS HHS [P0144642] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018571, R01AI059372] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alexander C, 2001, J ENDOTOXIN RES, V7, P167, DOI 10.1179/096805101101532675; Baik SC, 2004, J BACTERIOL, V186, P949, DOI 10.1128/JB.186.4.949-955.2004; Berg OG, 2001, CHEM REV, V101, P2613, DOI 10.1021/cr990139w; Beutler B, 2003, NAT REV IMMUNOL, V3, P169, DOI 10.1038/nri1004; Beutler B, 2004, MOL IMMUNOL, V40, P845, DOI 10.1016/j.molimm.2003.10.005; Beveridge TJ, 1999, J BACTERIOL, V181, P4725, DOI 10.1128/JB.181.16.4725-4733.1999; Bjerre A, 2002, J INFECT DIS, V185, P220, DOI 10.1086/338269; Bjerre A, 2000, J ENDOTOXIN RES, V6, P437, DOI 10.1179/096805100101532397; BOYUM A, 1968, SCAND J CLIN LAB S21, V97, P51; Brandtzaeg P, 2001, J ENDOTOXIN RES, V7, P401, DOI 10.1177/09680519010070060401; BRANDTZAEG P, 1992, J CLIN INVEST, V89, P816, DOI 10.1172/JCI115660; BRANDTZAEG P, 1989, J INFECT DIS, V159, P195, DOI 10.1093/infdis/159.2.195; de Cock H, 1999, J BIOL CHEM, V274, P5114, DOI 10.1074/jbc.274.8.5114; deCock H, 1996, EMBO J, V15, P5567, DOI 10.1002/j.1460-2075.1996.tb00941.x; Denning GM, 1998, INFECT IMMUN, V66, P5777, DOI 10.1128/IAI.66.12.5777-5784.1998; DEVOE IW, 1973, J EXP MED, V138, P1156, DOI 10.1084/jem.138.5.1156; GEGNER JA, 1995, J BIOL CHEM, V270, P5320, DOI 10.1074/jbc.270.10.5320; Giardina PC, 2001, J BIOL CHEM, V276, P5883, DOI 10.1074/jbc.M009273200; Gioannini TL, 2003, J ENDOTOXIN RES, V9, P401, DOI 10.1179/096805103225002773; Gioannini TL, 2002, J BIOL CHEM, V277, P47818, DOI 10.1074/jbc.M206404200; Gioannini TL, 2004, P NATL ACAD SCI USA, V101, P4186, DOI 10.1073/pnas.0306906101; Hirsch J, 2004, AM J PHYSIOL-LUNG C, V287, pL1, DOI 10.1152/ajplung.00301.2003; HOEKSTRA D, 1976, BIOCHIM BIOPHYS ACTA, V455, P889, DOI 10.1016/0005-2736(76)90058-4; HOLZENBURG A, 1989, BIOCHEMISTRY-US, V28, P4187, DOI 10.1021/bi00436a010; Iovine NM, 1997, P NATL ACAD SCI USA, V94, P10973, DOI 10.1073/pnas.94.20.10973; Juretic D, 2002, J CHEM INF COMP SCI, V42, P620, DOI 10.1021/ci010263s; Kadurugamuwa JL, 1997, J ANTIMICROB CHEMOTH, V40, P615, DOI 10.1093/jac/40.5.615; Kahler CM, 1998, CRIT REV MICROBIOL, V24, P281, DOI 10.1080/10408419891294216; Katz SS, 1996, INFECT IMMUN, V64, P3592, DOI 10.1128/IAI.64.9.3592-3600.1996; KNOX KW, 1966, J BACTERIOL, V92, P1206, DOI 10.1128/JB.92.4.1206-1217.1966; Koprivnjak T, 2002, J BIOL CHEM, V277, P47636, DOI 10.1074/jbc.M205104200; Kramer RA, 2002, EUR J BIOCHEM, V269, P1746, DOI 10.1046/j.1432-1327.2002.02820.x; Lamping N, 1998, J CLIN INVEST, V101, P2065, DOI 10.1172/JCI2338; Lamping N, 1996, J IMMUNOL, V157, P4648; Lorenzen DR, 2000, INFECT IMMUN, V68, P6215, DOI 10.1128/IAI.68.11.6215-6222.2000; Massari P, 2003, CELL MICROBIOL, V5, P99, DOI 10.1046/j.1462-5822.2003.00257.x; Massari P, 2002, J IMMUNOL, V168, P1533, DOI 10.4049/jimmunol.168.4.1533; MAYRAND D, 1989, CAN J MICROBIOL, V35, P607, DOI 10.1139/m89-097; Miller SI, 2003, CELL, V115, P2, DOI 10.1016/S0092-8674(03)00767-0; Mirlashari Mohammad Reza, 2003, Med Sci Monit, V9, pBR316; Miyake K, 2003, INT IMMUNOPHARMACOL, V3, P119, DOI 10.1016/S1567-5769(02)00258-8; Molloy MP, 2001, ELECTROPHORESIS, V22, P1686, DOI 10.1002/1522-2683(200105)22:9<1686::AID-ELPS1686>3.0.CO;2-L; Muller A, 2000, EMBO J, V19, P5332, DOI 10.1093/emboj/19.20.5332; MUNFORD RS, 1982, J CLIN INVEST, V70, P877, DOI 10.1172/JCI110684; Nikaido H, 2003, MICROBIOL MOL BIOL R, V67, P593, DOI 10.1128/MMBR.67.4.593-656.2003; NIKAIDO H, 1996, ESCHERICHIA COLI SAL, P29; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; PAUL S, 1992, J GEN MICROBIOL, V138, P755, DOI 10.1099/00221287-138-4-755; Rahman MM, 2000, MICROBIOL-UK, V146, P1901, DOI 10.1099/00221287-146-8-1901; RAHMAN MM, 1996, MICROBIOLOGY, P29; Schromm AB, 1996, FEBS LETT, V399, P267, DOI 10.1016/S0014-5793(96)01338-5; Schumann RR, 1997, J IMMUNOL, V159, P5599; Sprong T, 2004, INFECT IMMUN, V72, P3344, DOI 10.1128/IAI.72.6.3344-3349.2004; Thompson PA, 2003, J BIOL CHEM, V278, P28367, DOI 10.1074/jbc.M302921200; Ulevitch RJ, 1999, CURR OPIN IMMUNOL, V11, P19, DOI 10.1016/S0952-7915(99)80004-1; Vanlandschoot P, 2002, J GEN VIROL, V83, P2279, DOI 10.1099/0022-1317-83-9-2279; Vesy CJ, 2000, INFECT IMMUN, V68, P2410, DOI 10.1128/IAI.68.5.2410-2417.2000; Wai SN, 2003, CELL, V115, P25, DOI 10.1016/S0092-8674(03)00754-2; Weinrauch Y, 1999, INFECT IMMUN, V67, P3376, DOI 10.1128/IAI.67.7.3376-3382.1999; Weiss J, 2003, BIOCHEM SOC T, V31, P785, DOI 10.1042/BST0310785; Yu B, 1997, J CLIN INVEST, V99, P315, DOI 10.1172/JCI119160; Zweigner J, 2001, BLOOD, V98, P3800, DOI 10.1182/blood.V98.13.3800	62	98	104	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38383	38394		10.1074/jbc.M508063200	http://dx.doi.org/10.1074/jbc.M508063200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16103114	hybrid			2022-12-25	WOS:000233239800034
J	Curran, NM; Griffin, BD; O'Toole, D; Brady, KJ; Fitzgerald, SN; Moynagh, PN				Curran, NM; Griffin, BD; O'Toole, D; Brady, KJ; Fitzgerald, SN; Moynagh, PN			The synthetic cannabinoid R(+) WIN 55,212-2 inhibits the interleukin-1 signaling pathway in human astrocytes in a cannabinoid receptor-independent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CELL-ADHESION MOLECULE-1; CENTRAL-NERVOUS-SYSTEM; HUMAN GLIAL-CELLS; MULTIPLE-SCLEROSIS; TRANSCRIPTIONAL ACTIVATION; EXPRESSION; GENE; MODEL	R(+) WIN 55,212-2 is a synthetic cannabinoid that controls disease progression in models of multiple sclerosis. This is associated with its ability to reduce migration of leukocytes into the central nervous system. Because leukocyte migration is dependent on induction of adhesion molecules and chemokines by pro-inflammatory cytokines, we examined the effects of R(+) WIN 55,212-2 on their expression. Using 1321N1 astrocytoma and A-172 glioblastoma as cell models we show that R(+) WIN 55,212-2, but not its inactive chiral form S(-) WIN 55,212-2, strongly inhibits the interleukin-1 (IL-1) induction of the adhesion molecules intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) and the chemokine IL-8. This inhibition is not mediated via the CB1 or CB2 cannabinoid receptors, because their selective antagonists and pertussis toxin failed to affect the inhibitory effects of R(+) WIN 55,212-2. Furthermore reverse transcription-PCR analysis did not detect the expression of either receptor in 1321N1 cells. R(+) WIN 55,212-2 was shown to inhibit adhesion molecule and chemokine expression at the level of transcription, because it strongly inhibited the IL-1 induction of ICAM-1, VCAM-1, and IL-8 mRNAs and blocked the IL-1 activation of their promoters. The NF kappa B pathway was then assessed as a lead target for R(+) WIN 55,212-2. NF kappa B was measured by expression of a transfected NF kappa B-regulated reporter gene. Using this assay, R(+) WIN 55,212-2 strongly inhibited IL-1 activation of NF kappa B. Furthermore R(+) WIN 55,212-2 inhibited the ability of overexpressed Myd88, Tak-1, and IKK-2 to induce the reporter gene suggesting that R(+) WIN 55,212-2 acts at or downstream of IKK-2 in the IL-1 pathway. However R(+) WIN 55,212-2 failed to inhibit IL-1-induced degradation of I kappa B alpha, excluding IKK-2 as a direct target. In addition electrophoretic mobility shift and chromatin immunoprecipitation assays showed that R(+) WIN 55,212-2 does not regulate the IL-1-induced nuclear translocation of NF kappa B or the ability of the latter to bind to promoters regulating expression of ICAM-1 and IL-8. These data suggest that R(+) WIN 55,212-2 blocks IL-1 signaling by inhibiting the transactivation potential of NF kappa B.	Univ Coll Dublin, Conway Inst, UCD Sch Biomol & Biomed Sci, Dublin 4, Ireland	University College Dublin	Moynagh, PN (corresponding author), Univ Coll Dublin, Conway Inst, UCD Sch Biomol & Biomed Sci, Dublin 4, Ireland.	P.Moynagh@ucd.ie		O'Toole, Daniel/0000-0001-5422-8711; Moynagh, Paul/0000-0002-4139-3061				Arevalo-Martin A, 2003, J NEUROSCI, V23, P2511; Basu A, 2004, J NEUROSCI RES, V78, P151, DOI 10.1002/jnr.20266; Bourke E, 1999, J IMMUNOL, V163, P2113; Bourke E, 2000, J BIOL CHEM, V275, P39996, DOI 10.1074/jbc.M007693200; BROSNAN CF, 1995, NEUROLOGY, V45, P16; CANNELLA B, 1995, ANN NEUROL, V37, P424, DOI 10.1002/ana.410370404; Chakrabarti SK, 2002, J BIOL CHEM, V277, P13286, DOI 10.1074/jbc.M111857200; Consroe P, 1997, EUR NEUROL, V38, P44, DOI 10.1159/000112901; Croxford JL, 2003, J CLIN INVEST, V111, P1231, DOI 10.1172/JCI200317652; GALIEGUE S, 1995, EUR J BIOCHEM, V232, P54, DOI 10.1111/j.1432-1033.1995.tb20780.x; HAFLER DA, 1987, IMMUNOL REV, V100, P307, DOI 10.1111/j.1600-065X.1987.tb00537.x; HERY C, 1995, J NEUROIMMUNOL, V57, P101, DOI 10.1016/0165-5728(94)00168-N; Herzberg U, 1997, NEUROSCI LETT, V221, P157, DOI 10.1016/S0304-3940(96)13308-5; Hesselgesser J, 1999, J NEUROVIROL, V5, P13, DOI 10.3109/13550289909029741; KUNSCH C, 1994, J IMMUNOL, V153, P153; Kwon D, 2004, GLIA, V45, P287, DOI 10.1002/glia.10331; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; Martino G, 2002, LANCET NEUROL, V1, P499, DOI 10.1016/S1474-4422(02)00223-5; MEINCK HM, 1989, J NEUROL, V236, P120, DOI 10.1007/BF00314410; Molina-Holgado F, 2003, J NEUROSCI, V23, P6470; MOORE PA, 1993, MOL CELL BIOL, V13, P1666, DOI 10.1128/MCB.13.3.1666; MOYNAGH PN, 1994, J IMMUNOL, V153, P2681; Ni X, 2004, MULT SCLER J, V10, P158, DOI 10.1191/1352458504ms1009oa; ROSENMAN SJ, 1995, J IMMUNOL, V154, P1888; Rothwell NJ, 2000, TRENDS NEUROSCI, V23, P618, DOI 10.1016/S0166-2236(00)01661-1; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; Sagan S, 1999, EUR J NEUROSCI, V11, P691, DOI 10.1046/j.1460-9568.1999.00480.x; Sancho R, 2003, MOL PHARMACOL, V63, P429, DOI 10.1124/mol.63.2.429; Schmitz ML, 2001, TRENDS BIOCHEM SCI, V26, P186, DOI 10.1016/S0968-0004(00)01753-9; SHRIKANT P, 1994, J NEUROIMMUNOL, V51, P209, DOI 10.1016/0165-5728(94)90083-3; SLIPETZ DM, 1995, MOL PHARMACOL, V48, P352; UNGERLEIDER J T, 1987, Advances in Alcohol and Substance Abuse, V7, P39; Walter L, 2003, GLIA, V44, P85, DOI 10.1002/glia.10270; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0	34	51	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35797	35806		10.1074/jbc.M507959200	http://dx.doi.org/10.1074/jbc.M507959200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16105834	Green Accepted, hybrid			2022-12-25	WOS:000232726900005
J	Miranda, M; Wu, CC; Sorkina, T; Korstjens, DR; Sorkin, A				Miranda, M; Wu, CC; Sorkina, T; Korstjens, DR; Sorkin, A			Enhanced ubiquitylation and accelerated degradation of the dopamine transporter mediated by protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENERGY-TRANSFER MICROSCOPY; LIVING CELLS; MEMBRANE-PROTEIN; PHORBOL ESTERS; NEUROTRANSMITTER TRANSPORTERS; REGULATED TRAFFICKING; STRIATAL SYNAPTOSOMES; SEROTONIN TRANSPORTER; PROTEOMIC ANALYSIS; EPITHELIAL-CELLS	Dopamine transporter (DAT) localization in dopaminergic neurons plays an important role in regulating dopamine signaling. However, the mechanisms of DAT trafficking that control DAT localization are still poorly understood. To gain insight into these mechanisms, human DAT was purified in large amounts using a two-step affinity chromatography procedure from untreated HeLa cells or cells treated with phorbol 12-myristate 13-acetate (PMA). Mass spectrometric analysis of purified DAT complexes revealed the presence of several proteins, among which ubiquitin was particularly abundant in the PMA-treated sample. Western blotting of highly purified DAT protein confirmed constitutive ubiquitylation of DAT and a dramatic increase in DAT ubiquitylation in cells treated with PMA. This increase was blocked by pretreatment with the protein kinase C (PKC) inhibitor bis-indolylmaleimide. DAT ubiquitylation by ectopically expressed ubiquitin was demonstrated in cells transiently transfected with yellow fluorescent protein-tagged ubiquitin. In addition, fluorescence resonance energy transfer was detected between cyan fluorescent protein-tagged DAT and yellow fluorescent protein-tagged ubiquitin, indicative of DAT-ubiquitin conjugation. Interestingly, the largest fluorescence resonance energy transfer signals were observed in endosomes. Ubiquitylated DAT was detected in the plasma membrane using cell surface biotinylation as well as in intracellular compartments, suggesting that ubiquitylation begins at the plasma membrane and is maintained in endosomes. In both porcine aortic endothelial and HeLa cells, where PKC-dependent DAT ubiquitylation was observed, PKC activation resulted in rapid degradation of DAT (t(1/2) = 1-2 h). Altogether, these data suggest that PKC-induced DAT ubiquitylation may target DAT to lysosomal degradation.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus	Sorkin, A (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Aurora, CO 80045 USA.	alexander.sorkin@uchsc.edu		Sorkin, Alexander/0000-0002-4446-1920	NIAID NIH HHS [K22AI059076] Funding Source: Medline; NIDA NIH HHS [DA014204] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K22AI059076] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA014204] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Carter S, 2004, J BIOL CHEM, V279, P52835, DOI 10.1074/jbc.M407769200; Chen NH, 2004, PFLUG ARCH EUR J PHY, V447, P519, DOI 10.1007/s00424-003-1064-5; Cooper HJ, 2004, ANAL CHEM, V76, P6982, DOI 10.1021/ac0401063; Copeland BJ, 1996, J PHARMACOL EXP THER, V277, P1527; d'Azzo A, 2005, TRAFFIC, V6, P429, DOI 10.1111/j.1600-0854.2005.00294.x; Daniels GM, 1999, J BIOL CHEM, V274, P35794, DOI 10.1074/jbc.274.50.35794; Doss-Pepe EW, 2005, J BIOL CHEM, V280, P16619, DOI 10.1074/jbc.M413591200; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Fornes A, 2004, J BIOL CHEM, V279, P22934, DOI 10.1074/jbc.M401337200; Foster JD, 2002, J BIOL CHEM, V277, P25178, DOI 10.1074/jbc.M200294200; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; Galperin E, 2004, NAT METHODS, V1, P209, DOI 10.1038/NMETH720; GIROS B, 1993, TRENDS PHARMACOL SCI, V14, P43, DOI 10.1016/0165-6147(93)90029-J; Granas C, 2003, J BIOL CHEM, V278, P4990, DOI 10.1074/jbc.M205058200; Hammond DE, 2003, MOL BIOL CELL, V14, P1346, DOI 10.1091/mbc.E02-09-0578; Hastrup H, 2001, P NATL ACAD SCI USA, V98, P10055, DOI 10.1073/pnas.181344298; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Holton KL, 2005, NAT NEUROSCI, V8, P881, DOI 10.1038/nn1478; Huff RA, 1997, J NEUROCHEM, V68, P225; Jiang HB, 2004, J BIOL CHEM, V279, P54380, DOI 10.1074/jbc.M409282200; Khoshbouei H, 2004, PLOS BIOL, V2, P387, DOI 10.1371/journal.pbio.0020078; Kilic F, 2000, P NATL ACAD SCI USA, V97, P3106, DOI 10.1073/pnas.060408997; Kirkpatrick DS, 2005, METHODS, V35, P265, DOI 10.1016/j.ymeth.2004.08.018; KITAYAMA S, 1994, EUR J PHARM-MOLEC PH, V268, P115, DOI 10.1016/0922-4106(94)90180-5; Leontieva OV, 2004, J BIOL CHEM, V279, P5788, DOI 10.1074/jbc.M308375200; Lin ZC, 2003, J BIOL CHEM, V278, P20162, DOI 10.1074/jbc.M209584200; Loder MK, 2003, J BIOL CHEM, V278, P22168, DOI 10.1074/jbc.M301845200; MacCoss MJ, 2002, P NATL ACAD SCI USA, V99, P7900, DOI 10.1073/pnas.122231399; McCullough J, 2004, J CELL BIOL, V166, P487, DOI 10.1083/jcb.200401141; Melikian HE, 2004, PHARMACOL THERAPEUT, V104, P17, DOI 10.1016/j.pharmthera.2004.07.006; Melikian HE, 1999, J NEUROSCI, V19, P7699; Miranda M, 2004, J BIOL CHEM, V279, P30760, DOI 10.1074/jbc.M312774200; Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849; Perroy J, 2004, NAT METHODS, V1, P203, DOI 10.1038/NMETH722; Raiborg C, 2003, CURR OPIN CELL BIOL, V15, P446, DOI 10.1016/S0955-0674(03)00080-2; Raiborg C, 2002, CELL STRUCT FUNCT, V27, P403, DOI 10.1247/csf.27.403; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Raiborg C, 2001, EMBO J, V20, P5008, DOI 10.1093/emboj/20.17.5008; Robinson MB, 2002, J NEUROCHEM, V80, P1, DOI 10.1046/j.0022-3042.2001.00698.x; Saunders C, 2000, P NATL ACAD SCI USA, V97, P6850, DOI 10.1073/pnas.110035297; Schmid JA, 2001, J BIOL CHEM, V276, P3805, DOI 10.1074/jbc.M007357200; Sorkin A, 2000, CURR BIOL, V10, P1395, DOI 10.1016/S0960-9822(00)00785-5; Sorkina T, 2005, TRAFFIC, V6, P157, DOI 10.1111/j.1600-0854.2005.00259.x; Sorkina T, 2003, J BIOL CHEM, V278, P28274, DOI 10.1074/jbc.M210652200; Torres GE, 2003, NAT REV NEUROSCI, V4, P13, DOI 10.1038/nrn1008; Torres GE, 2003, J BIOL CHEM, V278, P2731, DOI 10.1074/jbc.M201926200; Vaughan RA, 1997, J BIOL CHEM, V272, P15541, DOI 10.1074/jbc.272.24.15541; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Wu CC, 2000, TRAFFIC, V1, P769, DOI 10.1034/j.1600-0854.2000.011004.x; Wu CC, 2003, NAT BIOTECHNOL, V21, P532, DOI 10.1038/nbt819; Yamashita A, 2005, NATURE, V437, P215, DOI 10.1038/nature03978; Zhang L, 1997, BIOCHEM PHARMACOL, V53, P677, DOI 10.1016/S0006-2952(96)00898-2; Zhu SJ, 1997, J PHARMACOL EXP THER, V282, P1358	54	96	97	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35617	35624		10.1074/jbc.M506618200	http://dx.doi.org/10.1074/jbc.M506618200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16109712	hybrid			2022-12-25	WOS:000232561200064
J	Wang, Y; Iordanov, H; Swietlicki, EA; Wang, LH; Fritsch, C; Coleman, T; Semenkovich, CF; Levin, MS; Rubin, DC				Wang, Y; Iordanov, H; Swietlicki, EA; Wang, LH; Fritsch, C; Coleman, T; Semenkovich, CF; Levin, MS; Rubin, DC			Targeted intestinal overexpression of the immediate early gene tis7 in transgenic mice increases triglyceride absorption and adiposity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; POSTNATAL-GROWTH; TRANSFER PROTEIN; PC12 CELLS; 3T3 CELLS; EXPRESSION; DIFFERENTIATION; DISRUPTION; RESECTION; LIVER	Following loss of functional small bowel surface area due to surgical resection, the remnant gut undergoes an adaptive response characterized by increased crypt cell proliferation and enhanced villus height and crypt depth, resulting in augmented intestinal nutrient absorptive capacity. Previous studies showed that expression of the immediate early gene tis7 is markedly up-regulated in intestinal enterocytes during the adaptive response. To study its role in the enterocyte, transgenic mice were generated that specifically overexpress TIS7 in the gut. Nucleotides - 596 to + 21 of the rat liver fatty acid-binding protein promoter were used to direct abundant overexpression of TIS7 into small intestinal upper crypt and villus enterocytes. TIS7 transgenic mice had increased total body adiposity and decreased lean muscle mass compared with normal littermates. Oxygen consumption levels, body weight, surface area, and small bowel weight were decreased. On a high fat diet, transgenic mice exhibited a more rapid and proportionately greater gain in body weight with persistently elevated total body adiposity and increased hepatic fat accumulation. Bolus fat feeding resulted in a greater increase in serum triglyceride levels and an accelerated appearance of enterocytic, lamina propria, and hepatic fat. Changes in fat homeostasis were linked to increased expression of genes involved in enterocytic triglyceride metabolism and changes in growth with decreased insulin-like growth factor-1 expression. Thus, TIS7 overexpression in the intestine altered growth, metabolic rate, adiposity, and intestinal triglyceride absorption. These results suggest that TIS7 is a unique mediator of nutrient absorptive and metabolic adaptation following gut resection.	Washington Univ, Sch Med, Div Gastroenterol, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; St Louis Vet Affairs Med Ctr, Specialty Care Serv Line, St Louis, MO 63106 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Rubin, DC (corresponding author), Washington Univ, Sch Med, Div Gastroenterol, Dept Med, 660 S Euclid Ave,Box 8124, St Louis, MO 63110 USA.	drubin@wustl.edu		Semenkovich, Clay/0000-0003-1163-1871; Rubin, Deborah/0000-0002-4192-909X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046122, P30DK056341, P30DK052574, R01DK061216] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG020091] Funding Source: NIH RePORTER; NIA NIH HHS [AG20091] Funding Source: Medline; NIDDK NIH HHS [DK50466, DK52574, DK46122, DK61216, DK56341] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; Bernal-Mizrachi C, 2002, ARTERIOSCL THROM VAS, V22, P961, DOI 10.1161/01.ATV.0000019404.65403.71; Buhman KK, 2002, J BIOL CHEM, V277, P25474, DOI 10.1074/jbc.M202013200; CARR TP, 1993, CLIN BIOCHEM, V26, P39, DOI 10.1016/0009-9120(93)90015-X; Clark JM, 2003, JAMA-J AM MED ASSOC, V289, P3000, DOI 10.1001/jama.289.22.3000; Dodson BD, 1996, AM J PHYSIOL-GASTR L, V271, pG347, DOI 10.1152/ajpgi.1996.271.2.G347; GORDON DA, 1995, TRENDS CELL BIOL, V5, P317, DOI 10.1016/S0962-8924(00)89054-6; GUARDAVACCARO D, 1995, CELL GROWTH DIFFER, V6, P159; GUARDAVACCARO D, 1994, J NEUROSCI RES, V37, P660, DOI 10.1002/jnr.490370514; Harrison Stephen A, 2002, Semin Gastrointest Dis, V13, P3; HERSCHMAN HR, 1994, PROG NUCLEIC ACID RE, V47, P113, DOI 10.1016/S0079-6603(08)60251-2; Inoue Y, 2004, J BIOL CHEM, V279, P44740, DOI 10.1074/jbc.M405177200; Li B, 2000, NAT MED, V6, P1115, DOI 10.1038/80450; Li YL, 2003, ENDOCRINOLOGY, V144, P3505, DOI 10.1210/en.2003-0236; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; Lupu F, 2001, DEV BIOL, V229, P141, DOI 10.1006/dbio.2000.9975; Narisawa S, 2003, MOL CELL BIOL, V23, P7525, DOI 10.1128/MCB.23.21.7525-7530.2003; Ohneda K, 1997, GASTROENTEROLOGY, V112, P444, DOI 10.1053/gast.1997.v112.pm9024298; Peterson CA, 2000, JPEN-PARENTER ENTER, V24, P288, DOI 10.1177/0148607100024005288; Rubin DC, 1998, AM J PHYSIOL-GASTR L, V275, pG506, DOI 10.1152/ajpgi.1998.275.3.G506; Schwarz M, 1996, J BIOL CHEM, V271, P18024, DOI 10.1074/jbc.271.30.18017; SIMON TC, 1993, J BIOL CHEM, V268, P18345; Smith SJ, 2000, NAT GENET, V25, P87, DOI 10.1038/75651; Stappenbeck TS, 2000, DEVELOPMENT, V127, P2629; Stappenbeck TS, 2001, DEVELOPMENT, V128, P2603; Stone SJ, 2004, J BIOL CHEM, V279, P11767, DOI 10.1074/jbc.M311000200; Swietlicki E, 2003, JPEN-PARENTER ENTER, V27, P123, DOI 10.1177/0148607103027002123; Tang YZ, 2004, GASTROENTEROLOGY, V126, P220, DOI 10.1053/j.gastro.2003.10.077; TIRONE F, 1989, P NATL ACAD SCI USA, V86, P2088, DOI 10.1073/pnas.86.6.2088; Vadivelu SK, 2004, MOL CELL BIOL, V24, P3514, DOI 10.1128/MCB.24.8.3514-3525.2004; VARNUM BC, 1989, ONCOGENE, V4, P1263; Vietor I, 2002, EMBO J, V21, P4621, DOI 10.1093/emboj/cdf461; Wang LC, 2002, GASTROENTEROLOGY, V122, P469, DOI 10.1053/gast.2002.31102; WETTERAU JR, 1992, SCIENCE, V258, P999; Wick N, 2004, J MOL BIOL, V336, P589, DOI 10.1016/j.jmb.2003.11.060; Wong MH, 1998, J CELL BIOL, V141, P765, DOI 10.1083/jcb.141.3.765; Yakar S, 1999, P NATL ACAD SCI USA, V96, P7324, DOI 10.1073/pnas.96.13.7324	37	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34764	34775		10.1074/jbc.M507058200	http://dx.doi.org/10.1074/jbc.M507058200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16085642	hybrid			2022-12-25	WOS:000232403900048
J	Watanabe, T; Blaisdel, JO; Wallace, SS; Bond, JP				Watanabe, T; Blaisdel, JO; Wallace, SS; Bond, JP			Engineering functional changes in Escherichia coli endonuclease III based on phylogenetic and structural analyses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE DNA-DAMAGE; SACCHAROMYCES-CEREVISIAE; EXCISION-REPAIR; HUMAN HOMOLOG; SUBSTRATE SPECIFICITIES; CATALYTIC MECHANISM; MUTY GENE; GLYCOSYLASE; ENZYME; CLONING	Escherichia coli endonuclease III (EcoNth) plays an important cellular role by removing premutagenic pyrimidine damages produced by reactive oxygen species. EcoNth is a bifunctional enzyme that has DNA glycosylase and apurinic/apyrimidinic lyase activities. Using a phylogeny of natural sequences, we selected to study EcoNth serine 39, aspartate 44, and arginine 184, which are presumed to be in the vicinity of the damaged base in the glycosylase-substrate complex. These three amino acids are highly conserved among Nth orthologs, although not among homologous glycosylases, such as MutY, that have different base specificities and no lyase activity. To examine the role of these amino acids in catalysis, we constructed three mutants of EcoNth, in which Ser(39) was replaced with leucine (S39L), Asp(44) was replaced with valine (D44V), and Arg(184) was replaced with alanine (R184A), which are the corresponding residues in EcoMutY. We showed that EcoNth S39L does not have significant glycosylase activity for oxidized pyrimidines, although it maintained AP lyase activity. In contrast, EcoNth D44V retained glycosylase activity against oxidized pyrimidines, but the apparent rate constant for the lyase activity of EcoNth D44V was significantly lower than that of EcoNth, indicating that Asp(44) in EcoNth is required for beta-elimination. Finally, EcoNth R184A maintained lyase activity but exhibited glycosylase specificity different from that of EcoNth. The functional consequences of each of these three substitutions can be rationalized in the context of high resolution protein structures. Thus phylogeny-based scanning mutagenesis has allowed us to identify novel roles for amino acids in the substrate binding pocket of EcoNth in base recognition and/or catalysis.	Univ Vermont, Dept Microbiol & Mol Genet, Markey Ctr Mol Genet, Burlington, VT 05405 USA	University of Vermont	Wallace, SS (corresponding author), Univ Vermont, Dept Microbiol & Mol Genet, Markey Ctr Mol Genet, 95 Carrigan Dr,Stafford Hall, Burlington, VT 05405 USA.	Susan.Wallace@uvm.edu; Jeffrey.Bond@uvm.edu		Wallace, Susan S./0000-0002-3906-0321	NATIONAL CANCER INSTITUTE [R37CA033657, R01CA033657] Funding Source: NIH RePORTER; NCI NIH HHS [CA 33657] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Asagoshi K, 2000, BIOCHEMISTRY-US, V39, P11389, DOI 10.1021/bi000422l; Aspinwall R, 1997, P NATL ACAD SCI USA, V94, P109, DOI 10.1073/pnas.94.1.109; AU KG, 1988, P NATL ACAD SCI USA, V85, P9163, DOI 10.1073/pnas.85.23.9163; Augeri L, 1997, BIOCHEMISTRY-US, V36, P721, DOI 10.1021/bi9625511; Bajek M, 2002, DNA REPAIR, V1, P251, DOI 10.1016/S1568-7864(01)00016-7; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; CUNNINGHAM RP, 1997, CURR BIOL, V7, P576; David SS, 1998, CHEM REV, V98, P1221, DOI 10.1021/cr980321h; DODSON ML, 1994, J BIOL CHEM, V269, P32709; Eide L, 1996, P NATL ACAD SCI USA, V93, P10735, DOI 10.1073/pnas.93.20.10735; Eide L, 2001, BIOCHEMISTRY-US, V40, P6653, DOI 10.1021/bi0028901; Felsenstein J., 2004, PHYLIP VERSION 3 6; Fromme JC, 2004, NATURE, V427, P652, DOI 10.1038/nature02306; Fromme JC, 2003, EMBO J, V22, P3461, DOI 10.1093/emboj/cdg311; Guan Y, 1998, NAT STRUCT BIOL, V5, P1058, DOI 10.1038/4168; Hilbert TP, 1997, J BIOL CHEM, V272, P6733, DOI 10.1074/jbc.272.10.6733; Ikeda S, 1998, J BIOL CHEM, V273, P21585, DOI 10.1074/jbc.273.34.21585; Karahalil B, 1998, BIOCHEMISTRY-US, V37, P590, DOI 10.1021/bi971660s; KUO CF, 1992, SCIENCE, V258, P434, DOI 10.1126/science.1411536; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; LU AL, 1995, J BIOL CHEM, V270, P23582, DOI 10.1074/jbc.270.40.23582; MAZUMDER A, 1991, BIOCHEMISTRY-US, V30, P1119, DOI 10.1021/bi00218a033; McCullough AK, 1999, ANNU REV BIOCHEM, V68, P255, DOI 10.1146/annurev.biochem.68.1.255; MICHAELS ML, 1990, NUCLEIC ACIDS RES, V18, P3841, DOI 10.1093/nar/18.13.3841; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; RoldanArjona T, 1996, NUCLEIC ACIDS RES, V24, P3307, DOI 10.1093/nar/24.17.3307; Sarker AH, 1998, J MOL BIOL, V282, P761, DOI 10.1006/jmbi.1998.2042; Shekhtman A, 1999, STRUCTURE, V7, P919, DOI 10.1016/S0969-2126(99)80119-1; Slupska MM, 1996, J BACTERIOL, V178, P3885, DOI 10.1128/jb.178.13.3885-3892.1996; Slupska MM, 1999, J BACTERIOL, V181, P6210, DOI 10.1128/JB.181.19.6210-6213.1999; SUN B, 1995, J BIOL CHEM, V270, P19501, DOI 10.1074/jbc.270.33.19501; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; VASSYLYEV DG, 1995, CELL, V83, P773, DOI 10.1016/0092-8674(95)90190-6; Wallace SS, 2002, FREE RADICAL BIO MED, V33, P1, DOI 10.1016/S0891-5849(02)00827-4; Wheeler DL, 2005, NUCLEIC ACIDS RES, V33, pD39, DOI 10.1093/nar/gki062; Williams SD, 1998, NUCLEIC ACIDS RES, V26, P5123, DOI 10.1093/nar/26.22.5123; Williams SD, 2000, BIOCHEMISTRY-US, V39, P10098, DOI 10.1021/bi0004652; Yang HJ, 2001, NUCLEIC ACIDS RES, V29, P604, DOI 10.1093/nar/29.3.604; Yang HJ, 2001, NUCLEIC ACIDS RES, V29, P743, DOI 10.1093/nar/29.3.743; You HJ, 1999, BIOCHEMISTRY-US, V38, P11298, DOI 10.1021/bi991121i; You HJ, 1998, BIOCHEMISTRY-US, V37, P6033, DOI 10.1021/bi973042h	41	12	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34378	34384		10.1074/jbc.M504916200	http://dx.doi.org/10.1074/jbc.M504916200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16096281	hybrid			2022-12-25	WOS:000232229700081
J	Adair, JE; Kwon, Y; Dement, GA; Smerdon, MJ; Reeves, R				Adair, JE; Kwon, Y; Dement, GA; Smerdon, MJ; Reeves, R			Inhibition of nucleotide excision repair by high mobility group protein HMGA1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR IIIA; RIBOSOMAL-RNA GENE; GROUP A1A PROTEIN; DNA-REPAIR; UV PHOTOPRODUCTS; POSITIONED NUCLEOSOME; DIMER FORMATION; BREAST-CANCER; THYMINE DIMER; DAMAGED DNA	The mammalian non-histone "high mobility group" A ( HMGA) proteins are the primary nuclear proteins that bind to the minor groove of AT-rich DNA. They may, therefore, influence the formation and/or repair of DNA lesions that occur in AT-rich DNA, such as cyclobutane pyrimidine dimers (CPDs) induced by UV radiation. Employing both stably transfected lines of human MCF7 cells containing tetracycline-regulated HMGA1 transgenes and primary Hs578T tumor cells, which naturally overexpress HMGA1 proteins, we have shown that cells overexpressing HMGA1a protein exhibit increased UV sensitivity. Moreover, we demonstrated that knockdown of intracellular HMGA1 concentrations via two independent methods abrogated this sensitivity. Most significantly, we observed that HMGA1a overexpression inhibited global genomic nucleotide excision repair of UV-induced CPD lesions in MCF-7 cells. Consistent with these findings in intact cells, DNA repair experiments employing Xenopus oocyte nuclear extracts and lesion-containing DNA substrates demonstrated that binding of HMGA1a markedly inhibits removal of CPDs in vitro. Furthermore, UV "photo-footprinting" demonstrated that CPD formation within a long run of Ts (T-18-tract) in a DNA substrate changes significantly when HMGA1 is bound prior to UV irradiation. Together, these results suggest that HMGA1 directly influences both the formation and repair of UV-induced DNA lesions in intact cells. These findings have important implications for the role that HMGA protein overexpression might play in the accumulation of mutations and genomic instabilities associated with many types of human cancers.	Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA	Washington State University	Smerdon, MJ (corresponding author), Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA.	smerdon@mail.wsu.edu; reevesr@wsu.edu		Adair, Jennifer/0000-0003-4599-016X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES002614, R37ES002614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046352, T32GM008336, R01GM071760] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES02614] Funding Source: Medline; NIGMS NIH HHS [T-32 GM008336, GM71760, GM46352] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balajee AS, 2000, GENE, V250, P15, DOI 10.1016/S0378-1119(00)00172-4; Bespalov VA, 2001, ENVIRON MOL MUTAGEN, V38, P166, DOI 10.1002/em.1068; Birger Y, 2003, EMBO J, V22, P1665, DOI 10.1093/emboj/cdg142; Bohr VA, 1988, DNA REPAIR LABORATOR, V3, P347; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; Conconi A, 1999, EMBO J, V18, P1387, DOI 10.1093/emboj/18.5.1387; Cordonnier AM, 1999, MUTAT RES-DNA REPAIR, V435, P111, DOI 10.1016/S0921-8777(99)00047-6; de Gruijl FR, 2001, J PHOTOCH PHOTOBIO B, V63, P19, DOI 10.1016/S1011-1344(01)00199-3; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; Diana F, 2001, J BIOL CHEM, V276, P11354, DOI 10.1074/jbc.M009521200; Douki T, 2000, J BIOL CHEM, V275, P11678, DOI 10.1074/jbc.275.16.11678; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P653; Frit P, 2002, MOL CELL, V10, P1391, DOI 10.1016/S1097-2765(02)00732-3; Gontijo AMDC, 2003, BIOCHIMIE, V85, P1133, DOI 10.1016/j.biochi.2003.10.018; Hara R, 2000, MOL CELL BIOL, V20, P9173, DOI 10.1128/MCB.20.24.9173-9181.2000; Hill DA, 1999, NUCLEIC ACIDS RES, V27, P2135, DOI 10.1093/nar/27.10.2135; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P10394, DOI 10.1073/pnas.91.22.10394; Huth JR, 1997, NAT STRUCT BIOL, V4, P657, DOI 10.1038/nsb0897-657; JOHN S, 1995, MOL CELL BIOL, V15, P1786; Kosmoski JV, 2001, P NATL ACAD SCI USA, V98, P10113, DOI 10.1073/pnas.181073398; Kwon YH, 2003, J BIOL CHEM, V278, P45451, DOI 10.1074/jbc.M308645200; KWON YH, 2005, IN PRESS MUTAT RES; LATHAM KA, 1994, ANN NY ACAD SCI, V726, P181, DOI 10.1111/j.1749-6632.1994.tb52813.x; LATHAM KA, 1994, ANN NY ACAD SCI, V726, P196; Li SS, 2000, METHODS, V22, P170, DOI 10.1006/meth.2000.1058; Liu XQ, 1997, BIOCHEMISTRY-US, V36, P13710, DOI 10.1021/bi9716736; Liu XQ, 2000, J BIOL CHEM, V275, P23729, DOI 10.1074/jbc.M002206200; LYAMICHEV V, 1991, NUCLEIC ACIDS RES, V19, P4491, DOI 10.1093/nar/19.16.4491; Malina J, 2002, CHEM BIOL, V9, P629, DOI 10.1016/S1074-5521(02)00134-5; Nacht M, 1999, CANCER RES, V59, P5464; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; NISSEN MS, 1995, J BIOL CHEM, V270, P4355, DOI 10.1074/jbc.270.9.4355; NISSEN MS, 1991, J BIOL CHEM, V266, P19945; Oda N, 1996, J BIOL CHEM, V271, P13816, DOI 10.1074/jbc.271.23.13816; Park H, 2002, P NATL ACAD SCI USA, V99, P15965, DOI 10.1073/pnas.242422699; Pfeifer GP, 1997, PHOTOCHEM PHOTOBIOL, V65, P270, DOI 10.1111/j.1751-1097.1997.tb08560.x; Reeves R, 1995, Prog Cell Cycle Res, V1, P339; Reeves R, 2001, BBA-GENE STRUCT EXPR, V1519, P13, DOI 10.1016/S0167-4781(01)00215-9; Reeves R, 1999, METHOD ENZYMOL, V304, P155; REEVES R, 1993, J BIOL CHEM, V268, P21137; Reeves R, 2000, MOL CELL BIOL, V20, P4666, DOI 10.1128/MCB.20.13.4666-4679.2000; Reeves R, 1996, BIOCHEMISTRY-US, V35, P5063, DOI 10.1021/bi952424p; Reeves R, 2001, GENE, V277, P63, DOI 10.1016/S0378-1119(01)00689-8; Reeves R, 2001, MOL CELL BIOL, V21, P575, DOI 10.1128/MCB.21.2.575-594.2001; SAMBROOK J, 1989, MOL CLONING LAB MANU, V2, P6; Schieferstein U, 1996, BIOCHEMISTRY-US, V35, P7705, DOI 10.1021/bi953011r; Shimizu M, 2000, EMBO J, V19, P3358, DOI 10.1093/emboj/19.13.3358; Smerdon MJ, 1999, PROG NUCLEIC ACID RE, V62, P227; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; Svejstrup JQ, 2002, NAT REV MOL CELL BIO, V3, P21, DOI 10.1038/nrm703; Takaha N, 2002, CANCER RES, V62, P647; Tallini G, 1999, ADV ANAT PATHOL, V6, P237, DOI 10.1097/00125480-199909000-00001; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Tommasi S, 1996, BIOCHEMISTRY-US, V35, P15693, DOI 10.1021/bi962117z; Tornaletti S, 1999, BIOCHIMIE, V81, P139, DOI 10.1016/S0300-9084(99)80046-7; Treff NR, 2004, ONCOGENE, V23, P777, DOI 10.1038/sj.onc.1207167; Vichi P, 1997, EMBO J, V16, P7444, DOI 10.1093/emboj/16.24.7444; Wang D, 2003, BIOCHEMISTRY-US, V42, P6747, DOI 10.1021/bi034264k; Wellinger RE, 1997, EMBO J, V16, P5046, DOI 10.1093/emboj/16.16.5046; Wood LJ, 2000, CANCER RES, V60, P4256; YOON C, 1988, P NATL ACAD SCI USA, V85, P6332, DOI 10.1073/pnas.85.17.6332	61	40	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32184	32192		10.1074/jbc.M505600200	http://dx.doi.org/10.1074/jbc.M505600200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16033759	hybrid			2022-12-25	WOS:000231794800019
J	Reynolds, PR; Hoidal, JR				Reynolds, PR; Hoidal, JR			Temporal-spatial expression and transcriptional regulation of alpha(7) nicotinic acetylcholine receptor by thyroid transcription factor-1 and early growth response factor-1 during murine lung development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY EPITHELIAL-CELLS; ENHANCER-BINDING PROTEIN; NICOTINIC RECEPTORS; FUNCTIONAL-CHARACTERIZATION; FACTOR EGR-1; MORPHOGENESIS; EXPOSURE; TTF-1; GENE; DIFFERENTIATION	Nicotinic acetylcholine receptors are ligand-gated ion channels formed by five homologous subunits that are involved in processes including signal transduction, proliferation, and apoptosis. The developmental role of these receptors, however, is unclear. In the present investigation, alpha(7) nicotinic acetylcholine receptor expression was assessed by immunohistochemistry in mouse lungs from embryonic day (E)13.5 to postnatal day (PN)20. Transcriptional mechanisms that regulate alpha(7) were assessed by the transfection of murine bronchiolar cells with a reporter containing 1.1 kb of the mouse alpha(7) promoter, TTF- 1, and Egr- 1. alpha(7) was initially detected at E13.5 in pulmonary mesenchymal cells and in the epithelium of the primitive tubules at E15.5. From E18.5 to PN1, alpha(7) was expressed in conducting airway and saccule epithelial cells. By PN10, expression was observed in the peripheral epithelium and on luminal membranes of bronchiolar epithelial cells in the proximal lung, a pattern that continued through PN20. From E15.5 to PN20, type II alveolar cells expressed both prosurfactant protein C and alpha(7). From E18.5 to PN20, Clara cells in the bronchiolar epithelium co-expressed Clara cell secretory protein and alpha(7). TTF-1 dose-dependently activated alpha(7) transcription in vitro by binding specific TTF- 1 regulatory elements in the mouse alpha(7) promoter. Furthermore, alpha(7) was not detected in TTF-1-null mice and markedly increased in TTF-1-overexpressing mice. Conversely, Egr-1 inhibited alpha(7) expression. Temporal-spatial alpha(7) expression supports the concept that these receptors function during normal pulmonary morphogenesis. A model is also supported whereby alpha(7) is induced by the essential pulmonary transcription factor TTF-1 and suppressed by Egr-1 during pulmonary development.	Univ Utah, Hlth Sci Ctr, Div Pulm, Dept Internal Med, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah	Hoidal, JR (corresponding author), 30N 1900 E,Rm 4C107 SOM, Salt Lake City, UT 84132 USA.	john.hoidal@hsc.utah.edu		Reynolds, Paul/0000-0002-0931-3025	NHLBI NIH HHS [HL72903, HL07636] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL072903] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alkondon M, 1997, EUR J NEUROSCI, V9, P2734, DOI 10.1111/j.1460-9568.1997.tb01702.x; BENOWITZ NL, 1982, CLIN PHARMACOL THER, V32, P758, DOI 10.1038/clpt.1982.233; BENOWITZ NL, 1986, ANNU REV MED, V37, P21; Berger F, 1998, J NEUROSCI, V18, P6871; BERTRAND D, 1995, NEUROSCIENCES, V7, P75; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; Carrasco-Serrano C, 2000, J NEUROCHEM, V74, P932, DOI 10.1046/j.1471-4159.2000.0740932.x; CHAN J, 1993, NEUROSCIENCE, V56, P441, DOI 10.1016/0306-4522(93)90344-F; CODIGNOLA A, 1994, FEBS LETT, V342, P286, DOI 10.1016/0014-5793(94)80518-0; Criado M, 1997, J NEUROSCI, V17, P6554; Gahring LC, 2004, J COMP NEUROL, V468, P334, DOI 10.1002/cne.10943; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; HORYLEE F, 1995, J NEUROSCI, V15, P6453; Hsia Shao-Hsuan, 2003, Acta Paediatrica Taiwanica, V44, P150; Huang RP, 1997, J CELL BIOCHEM, V66, P489, DOI 10.1002/(SICI)1097-4644(19970915)66:4<489::AID-JCB8>3.0.CO;2-H; IKEGAMI M, 1992, TRENDS NEUROSCI, V155, P117; Kawai H, 2001, J NEUROCHEM, V78, P1367, DOI 10.1046/j.1471-4159.2001.00526.x; Keijzer R, 2001, DEVELOPMENT, V128, P503; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; Lindstrom J, 1997, MOL NEUROBIOL, V15, P193, DOI 10.1007/BF02740634; Lindstrom J, 1996, PROG BRAIN RES, V109, P125; LIPTON SA, 1988, SCIENCE, V239, P1293, DOI 10.1126/science.3344435; Maus ADJ, 1998, MOL PHARMACOL, V54, P779, DOI 10.1124/mol.54.5.779; MCGEHEE DS, 1995, SCIENCE, V269, P1692, DOI 10.1126/science.7569895; MIZUNO K, 1991, MOL CELL BIOL, V11, P4927, DOI 10.1128/MCB.11.10.4927; Nagavarapu U, 2001, J BIOL CHEM, V276, P16749, DOI 10.1074/jbc.M009712200; Okuda T, 2000, FEBS LETT, V484, P92, DOI 10.1016/S0014-5793(00)02134-7; Olale F, 1997, J PHARMACOL EXP THER, V283, P675; Perl AKT, 1999, CLIN GENET, V56, P14, DOI 10.1034/j.1399-0004.1999.560103.x; Proskocil BJ, 2004, ENDOCRINOLOGY, V145, P2498, DOI 10.1210/en.2003-1728; PUGH PC, 1994, J NEUROSCI, V14, P889; QUICK M, 1994, BRAIN RES, V655, P161; Sandberg K, 2004, PEDIATR RES, V56, P432, DOI 10.1203/01.PDR.0000136276.52104.61; Sekhon HS, 1999, J CLIN INVEST, V103, P637, DOI 10.1172/JCI5232; Sher E, 1998, ANN NY ACAD SCI, V841, P606, DOI 10.1111/j.1749-6632.1998.tb10993.x; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TAGER IB, 1993, AM REV RESPIR DIS, V147, P811, DOI 10.1164/ajrccm/147.4.811; TAYLOR B, 1987, ARCH DIS CHILD, V62, P786, DOI 10.1136/adc.62.8.786; TREININ M, 1995, NEURON, V14, P871, DOI 10.1016/0896-6273(95)90231-7; Wang Y, 2001, MOL PHARMACOL, V60, P1201, DOI 10.1124/mol.60.6.1201; Wert SE, 2002, DEV BIOL, V242, P75, DOI 10.1006/dbio.2001.0540; ZHENG JQ, 1994, NATURE, V368, P140, DOI 10.1038/368140a0; Zhou L, 1996, J HISTOCHEM CYTOCHEM, V44, P1183, DOI 10.1177/44.10.8813084; Zia S, 1997, RES COMMUN MOL PATH, V97, P243	46	28	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32548	32554		10.1074/jbc.M502231200	http://dx.doi.org/10.1074/jbc.M502231200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16033766	hybrid			2022-12-25	WOS:000231794800064
J	Yang, H; Mergler, S; Sun, XC; Wang, Z; Lu, L; Bonanno, JA; Pleyer, U; Reinach, PS				Yang, H; Mergler, S; Sun, XC; Wang, Z; Lu, L; Bonanno, JA; Pleyer, U; Reinach, PS			TRPC4 knockdown suppresses epidermal growth factor-induced store-operated channel activation and growth in human corneal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CA2+ ENTRY; 2-AMINOETHOXYDIPHENYL BORATE; CALCIUM-CHANNELS; PATCH-CLAMP; MUSCLE-CELLS; CURRENTS; RECEPTOR; INFLUX; DEPLETION; PATHWAYS	Epidermal growth factor (EGF) in corneal epithelial cells stimulates proliferation by inducing capacitative calcium entry (CCE). However, neither the identity nor the mechanism of activation of the plasma membrane influx pathway that mediates CCE is known. Accordingly, we determined, in human corneal epithelial cells, whether or not (i) CCE is dependent upon stimulation of store-operated channel (SOC) activity, (ii) the canonical transient receptor potential (TRP) protein isoform TRPC4 is a component of such channels, and (iii) suppression of TRPC4 protein expression decreases EGF-induced stimulation of SOC activity and proliferation. The whole cell patch-clamp technique was used to monitor TRPC4-mediated stimulation of SOC activity following intracellular calcium store depletion and induction of CCE. TRPC4 small interfering RNA transfection suppressed TRPC4 protein expression. Reverse transcription-PCR and Western blot analysis were used to assess knockdown efficiency of mRNA and protein expression. [3H] Thymidine incorporation was used to evaluate EGF-induced mitogenesis. Ca2+ transients were measured by single-cell fluorescence imaging. TRPC4 knockdown decreased mRNA and protein expression by 89 and 87%, respectively. In these cells, EGF-induced SOC activation elicited by intracellular calcium store depletion was obviated; 2) EGF-induced CCE fell by 76%; 3) EGF-induced stimulation of SOC activity was eliminated; and 4) EGF-induced increases in proliferation fell by 54%. Thus, TRPC4 is a component of SOC in human corneal epithelial cells whose activation by EGF is requisite for an optimum mitogenic response to this growth factor.	SUNY, Coll Optometry, New York, NY 10036 USA; Charite, EyeCli, D-13353 Berlin, Germany; Indiana Univ, Sch Optometry, Bloomington, IN 47405 USA; Harbor UCLA Med Ctr, Div Mol Med, Torrance, CA 90502 USA	State University of New York (SUNY) System; SUNY Community College; SUNY Maritime College; SUNY Optometry; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Indiana University System; Indiana University Bloomington; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	Reinach, PS (corresponding author), SUNY, Coll Optometry, 33 W 42nd St, New York, NY 10036 USA.	preinach@sunyopt.edu	Reinach, Peter/AAI-3582-2021	Mergler, Stefan/0000-0001-8608-648X	NATIONAL EYE INSTITUTE [R01EY004795, R01EY008834, R01EY012953, R24EY016661, R56EY004795] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY004795, EY04795, EY08834, R24 EY016661, EY1582, R01 EY008834, EY12953, R01 EY012953, R56 EY004795] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARAKISASAKI K, 1995, INVEST OPHTH VIS SCI, V36, P614; BARRY PH, 1994, J NEUROSCI METH, V51, P107, DOI 10.1016/0165-0270(94)90031-0; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Bradley JE, 2004, AM J PHYSIOL-CELL PH, V286, pC1078, DOI 10.1152/ajpcell.00463.2003; Chung MK, 2004, J NEUROSCI, V24, P5177, DOI 10.1523/JNEUROSCI.0934-04.2004; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Csutora P, 1999, P NATL ACAD SCI USA, V96, P121, DOI 10.1073/pnas.96.1.121; Delmas P, 2002, NEURON, V34, P209, DOI 10.1016/S0896-6273(02)00641-4; Golovina VA, 2001, AM J PHYSIOL-HEART C, V280, pH746, DOI 10.1152/ajpheart.2001.280.2.H746; Gregory RB, 2001, BIOCHEM J, V354, P285, DOI 10.1042/0264-6021:3540285; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Harks EGA, 2003, FASEB J, V17, P941, DOI 10.1096/fj.02-0786fje; Harteneck C, 2003, CELL CALCIUM, V33, P303, DOI 10.1016/S0143-4160(03)00043-5; Hobai IA, 2000, AM J PHYSIOL-HEART C, V279, pH692, DOI 10.1152/ajpheart.2000.279.2.H692; Hu HZ, 2004, J BIOL CHEM, V279, P35741, DOI 10.1074/jbc.M404164200; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; Islam M, 2000, EXP EYE RES, V70, P261, DOI 10.1006/exer.1999.0783; KLYCE SD, 1977, INVEST OPHTH VIS SCI, V16, P968; Landsberg JW, 2004, NEWS PHYSIOL SCI, V19, P44, DOI 10.1152/nips.01457.2003; Larsson KP, 2005, J BIOL CHEM, V280, P1771, DOI 10.1074/jbc.M406073200; Lee YM, 2003, AM J PHYSIOL-GASTR L, V284, pG604, DOI 10.1152/ajpgi.00069.2002; Li WP, 2004, J BIOL CHEM, V279, P4570, DOI 10.1074/jbc.M304334200; Lu L, 2001, EXP BIOL MED, V226, P653, DOI 10.1177/153537020222600711; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Ma R, 2001, J AM SOC NEPHROL, V12, P47, DOI 10.1681/ASN.V12147; McDaniel SS, 2001, AM J PHYSIOL-LUNG C, V280, pL870, DOI 10.1152/ajplung.2001.280.5.L870; Mergler S, 2005, EXP EYE RES, V80, P285, DOI 10.1016/j.exer.2004.09.012; Montell C, 2001, Sci STKE, V2001, pre1, DOI 10.1126/stke.2001.90.re1; Montell Craig, 2005, Sci STKE, V2005, pre3, DOI 10.1126/stke.2722005re3; Ng LC, 2001, CIRC RES, V89, P923, DOI 10.1161/hh2201.100315; NILIUS B, 2004, SCI STKE, pPE36; Padar S, 2005, BIOCHEM PHARMACOL, V69, P1177, DOI 10.1016/j.bcp.2005.01.011; Petkov GV, 2001, ACTA PHYSIOL SCAND, V173, P257, DOI 10.1046/j.1365-201X.2001.00907.x; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; RICH A, 1995, J MEMBRANE BIOL, V144, P177; Rychkov GY, 2005, CELL CALCIUM, V37, P183, DOI 10.1016/j.ceca.2004.09.001; Schindl R, 2002, J BIOL CHEM, V277, P26950, DOI 10.1074/jbc.M203700200; Skryma R, 2000, J PHYSIOL-LONDON, V527, P71, DOI 10.1111/j.1469-7793.2000.00071.x; Spassova MA, 2004, BBA-MOL CELL RES, V1742, P9, DOI 10.1016/j.bbamcr.2004.09.001; Sui GP, 2001, J UROLOGY, V165, P621, DOI 10.1097/00005392-200102000-00084; SUN X, 2004, BMC PHYSL; Sun XC, 2003, EXP EYE RES, V77, P287, DOI 10.1016/S0014-4835(03)00150-7; Sweeney M, 2002, AM J PHYSIOL-LUNG C, V283, pL144, DOI 10.1152/ajplung.00412.2001; Tang Y, 2000, J BIOL CHEM, V275, P37559, DOI 10.1074/jbc.M006635200; Trebak M, 2002, J BIOL CHEM, V277, P21617, DOI 10.1074/jbc.M202549200; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; van Rossum DB, 2000, J BIOL CHEM, V275, P28562, DOI 10.1074/jbc.M003147200; Venkatachalam K, 2004, NOVART FDN SYMP, V258, P185; VENKATACHALAM K, 2004, NOVART FDN SYMP, V258, P263; Venkatachalam Kartik, 2004, Novartis Found Symp, V258, P172; Voets T, 2001, J BIOL CHEM, V276, P47767, DOI 10.1074/jbc.C100607200; Wang XX, 2004, AM J PHYSIOL-CELL PH, V287, pC357, DOI 10.1152/ajpcell.00068.2004; Xu SZ, 2005, BRIT J PHARMACOL, V145, P405, DOI 10.1038/sj.bjp.0706197; Yang H, 2003, J MEMBRANE BIOL, V194, P47, DOI 10.1007/s00232-003-2025-9; Yang H, 2001, J MEMBRANE BIOL, V183, P93, DOI 10.1007/s00232-001-0057-6; Yu Y, 2003, AM J PHYSIOL-CELL PH, V284, pC316, DOI 10.1152/ajpcell.00125.2002; Zhang S, 2004, AM J PHYSIOL-CELL PH, V287, pC1192, DOI 10.1152/ajpcell.00158.2004; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333; Zweifach A, 1996, J GEN PHYSIOL, V107, P597, DOI 10.1085/jgp.107.5.597	63	70	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32230	32237		10.1074/jbc.M504553200	http://dx.doi.org/10.1074/jbc.M504553200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16033767	Green Accepted, hybrid			2022-12-25	WOS:000231794800024
J	Berke, SJS; Chai, YH; Marrs, GL; Wen, H; Paulson, HL				Berke, SJS; Chai, YH; Marrs, GL; Wen, H; Paulson, HL			Defining the role of ubiquitin-interacting motifs in the polyglutamine disease protein, ataxin-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR INCLUSION FORMATION; DEUBIQUITINATING ENZYMES; INTRANUCLEAR INCLUSIONS; PROTEASOME PATHWAY; BINDING; AGGREGATION; NEURODEGENERATION; UBIQUITYLATION; DEGRADATION; PROTEOLYSIS	Polyglutamine (polyQ) expansions cause neurodegeneration that is associated with protein misfolding and influenced by functional properties of the host protein. The polyQ disease protein, ataxin-3, has predicted ubiquitin-specific protease and ubiquitin-binding domains, which suggest that ataxin-3 functions in ubiquitin-dependent protein surveillance. Here we investigate direct links between the ubiquitin-proteasome pathway and ataxin-3. In neural cells we show that, through its ubiquitin interaction motifs (UIMs), normal or expanded ataxin-3 binds a broad range of ubiquitinated proteins that accumulate when the proteasome is inhibited. The expression of a catalytically inactive ataxin-3 (normal or expanded) causes ubiquitinated proteins to accumulate in cells, even in the absence of proteasome inhibitor. This accumulation of ubiquitinated proteins occurs primarily in the cell nucleus in transfected cells and requires intact UIMs in ataxin-3. We further show that both normal and expanded ataxin-3 can undergo oligoubiquitination. Although this post-translational modification occurs in a UIM-dependent manner, it becomes independent of UIMs when the catalytic cysteine residue of ataxin-3 is mutated, suggesting that ataxin-3 ubiquitination is itself regulated in trans by its own de-ubiquitinating activity. Finally, pulse-chase labeling reveals that ataxin-3 is degraded by the proteasome, with expanded ataxin-3 being as efficiently degraded as normal ataxin-3. Mutating the UIMs does not alter degradation, suggesting that UIM-mediated oligoubiquitination of ataxin-3 modulates ataxin-3 function rather than stability. The function of ataxin-3 as a de-ubiquitinating enzyme, its post-translational modification by ubiquitin, and its degradation via the proteasome link this polyQ protein to ubiquitin-dependent pathways already implicated in disease pathogenesis.	Univ Iowa, Dept Neurol, Paulson Lab, Iowa City, IA 52242 USA; Univ Iowa, Grad Program Neurosci, Iowa City, IA 52242 USA; Univ Iowa, Grad Program Genet, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa	Paulson, HL (corresponding author), Univ Iowa, Dept Neurol, Paulson Lab, 240 A EMRB, Iowa City, IA 52242 USA.	henry-paulson@uiowa.edu			NIA NIH HHS [TG32 AG 00214] Funding Source: Medline; NINDS NIH HHS [R01 NS38712, NS043076] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038712, F31NS043076] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Albrecht M, 2003, PROTEINS, V50, P355, DOI 10.1002/prot.10280; Amerik AY, 2004, BBA-MOL CELL RES, V1695, P189, DOI 10.1016/j.bbamcr.2004.10.003; Berke SJS, 2003, CURR OPIN GENET DEV, V13, P253, DOI 10.1016/S0959-437X(03)00053-4; Bevivino AE, 2001, P NATL ACAD SCI USA, V98, P11955, DOI 10.1073/pnas.211305198; Bowman AB, 2005, HUM MOL GENET, V14, P679, DOI 10.1093/hmg/ddi064; Burnett B, 2003, HUM MOL GENET, V12, P3195, DOI 10.1093/hmg/ddg344; Burnett BG, 2005, P NATL ACAD SCI USA, V102, P4330, DOI 10.1073/pnas.0407252102; Chai YH, 2004, J BIOL CHEM, V279, P3605, DOI 10.1074/jbc.M310939200; Chai YH, 1999, HUM MOL GENET, V8, P673, DOI 10.1093/hmg/8.4.673; Chai YH, 2001, J BIOL CHEM, V276, P44889, DOI 10.1074/jbc.M106575200; Chow MKM, 2004, BIOCHEM BIOPH RES CO, V322, P387, DOI 10.1016/j.bbrc.2004.07.131; Chung CH, 1999, BIOCHEM BIOPH RES CO, V266, P633, DOI 10.1006/bbrc.1999.1880; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; Donaldson KM, 2003, P NATL ACAD SCI USA, V100, P8892, DOI 10.1073/pnas.1530212100; Doss-Pepe EW, 2003, MOL CELL BIOL, V23, P6469, DOI 10.1128/MCB.23.18.6469-6483.2003; Fisher RD, 2003, J BIOL CHEM, V278, P28976, DOI 10.1074/jbc.M302596200; Flick K, 2004, NAT CELL BIOL, V6, P634, DOI 10.1038/ncb1143; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Holmberg CI, 2004, EMBO J, V23, P4307, DOI 10.1038/sj.emboj.7600426; Jana NR, 2001, HUM MOL GENET, V10, P1049, DOI 10.1093/hmg/10.10.1049; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; Klapisz E, 2002, J BIOL CHEM, V277, P30746, DOI 10.1074/jbc.M203004200; Kumada S, 2002, J NEUROPATH EXP NEUR, V61, P984, DOI 10.1093/jnen/61.11.984; La Spada AR, 2003, NEURON, V38, P681, DOI 10.1016/S0896-6273(03)00328-3; Li FS, 2002, J BIOL CHEM, V277, P45004, DOI 10.1074/jbc.M205259200; Marchal S, 2003, J BIOL CHEM, V278, P31554, DOI 10.1074/jbc.M304205200; Masino L, 2004, J MOL BIOL, V344, P1021, DOI 10.1016/j.jmb.2004.09.065; Masino L, 2003, FEBS LETT, V549, P21, DOI 10.1016/S0014-5793(03)00748-8; Matsumoto M, 2004, EMBO J, V23, P659, DOI 10.1038/sj.emboj.7600081; Miller SLH, 2004, J BIOL CHEM, V279, P33528, DOI 10.1074/jbc.M313097200; Miller VM, 2003, P NATL ACAD SCI USA, V100, P7195, DOI 10.1073/pnas.1231012100; Oldham CE, 2002, CURR BIOL, V12, P1112, DOI 10.1016/S0960-9822(02)00900-4; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Qin ZH, 2003, HUM MOL GENET, V12, P3231, DOI 10.1093/hmg/ddg346; Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362; Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066; Sanchez I, 2003, NATURE, V421, P373, DOI 10.1038/nature01301; Schmidt T, 1998, BRAIN PATHOL, V8, P669, DOI 10.1111/j.1750-3639.1998.tb00193.x; Schnell JD, 2003, J BIOL CHEM, V278, P35857, DOI 10.1074/jbc.R300018200; Shekhtman A, 2002, BIOCHEM BIOPH RES CO, V296, P1222, DOI 10.1016/S0006-291X(02)02006-5; Takahashi J, 2001, J NEUROPATH EXP NEUR, V60, P369, DOI 10.1093/jnen/60.4.369; Uchihara T, 2001, ACTA NEUROPATHOL, V102, P149; Warrick JM, 2005, MOL CELL, V18, P37, DOI 10.1016/j.molcel.2005.02.030; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; Wing SS, 2003, INT J BIOCHEM CELL B, V35, P590, DOI 10.1016/S1357-2725(02)00392-8; Yamamoto A, 2000, CELL, V101, P57, DOI 10.1016/S0092-8674(00)80623-6	49	79	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					32026	32034		10.1074/jbc.M506084200	http://dx.doi.org/10.1074/jbc.M506084200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16040601	hybrid			2022-12-25	WOS:000231665200083
J	Wajih, N; Hutson, SM; Owen, J; Wallin, R				Wajih, N; Hutson, SM; Owen, J; Wallin, R			Increased production of functional recombinant human clotting factor IX by baby hamster kidney cells engineered to overexpress VKORC1, the vitamin K 2,3-epoxide-reducing enzyme of the vitamin K cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYLATION; EXPRESSION; WARFARIN; COAGULATION; ACTIVATION; PRECURSOR; REDUCTASE; FURIN	Some recombinant vitamin K-dependent blood coagulation factors ( factors VII, IX, and protein C) have become valuable pharmaceuticals in the treatment of bleeding complications and sepsis. Because of their vitamin K-dependent post-translational modification, their synthesis by eukaryotic cells is essential. The eukaryotic cell harbors a vitamin K-dependent gamma-carboxylation system that converts the proteins to gamma-carboxyglutamic acid-containing proteins. However, the system in eukaryotic cells has limited capacity, and cell lines over-expressing vitamin K-dependent clotting factors produce only a fraction of the recombinant proteins as fully gamma-carboxylated, physiologically competent proteins. In this work we have used recombinant human factor IX (r-hFIX)-producing baby hamster kidney (BHK) cells, engineered to stably overexpress various components of the gamma-carboxylation system of the cell, to determine whether increased production of functional r-hFIX can be accomplished. All BHK cell lines secreted r-hFIX into serum-free medium. Overexpression of gamma-carboxylase is shown to inhibit production of functional r-hFIX. On the other hand, cells overexpressing VKORC1,the reduced vitamin K cofactor-producing enzyme of the vitamin K-dependent gamma-carboxylation system, produced 2.9-fold more functional r-hFIX than control BHK cells. The data are consistent with the notion that VKORC1 is the rate-limiting step in the system and is a key regulatory protein in synthesis of active vitamin K-dependent proteins. The data suggest that overexpression of VKORC1 can be utilized for increased cellular production of recombinant vitamin K-dependent proteins.	Wake Forest Univ, Sch Med, Dept Internal Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Biochem, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest University	Wallin, R (corresponding author), Wake Forest Univ, Sch Med, Dept Internal Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.	rwallin@wfubmc.edu	Wajih, Nadeem/GMW-6625-2022		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069331] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL69331] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERKNER KL, 1993, METHOD ENZYMOL, V222, P450; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; BRISTOL JA, 1994, BIOCHEMISTRY-US, V33, P14136, DOI 10.1021/bi00251a024; Cain D, 1997, J BIOL CHEM, V272, P29068, DOI 10.1074/jbc.272.46.29068; Dahlback B, 2005, J INTERN MED, V257, P209, DOI 10.1111/j.1365-2796.2004.01444.x; DISCIPIO RG, 1978, J CLIN INVEST, V61, P1528, DOI 10.1172/JCI109073; Hallgren KW, 2002, BIOCHEMISTRY-US, V41, P15045, DOI 10.1021/bi026016e; Hedner U, 2001, SEMIN HEMATOL, V38, P43, DOI 10.1016/S0037-1963(01)90147-7; KAUFMAN RJ, 1986, J BIOL CHEM, V261, P9622; Li T, 2004, NATURE, V427, P541, DOI 10.1038/nature02254; OUCHTERLONY O, 1948, ACTA PATHOL MIC SC, V25, P186; Preininger A, 1999, CYTOTECHNOLOGY, V30, P1, DOI 10.1023/A:1008030407679; REHEMTULLA A, 1993, P NATL ACAD SCI USA, V90, P4611, DOI 10.1073/pnas.90.10.4611; Rost S, 2004, NATURE, V427, P537, DOI 10.1038/nature02214; Roth DA, 2001, BLOOD, V98, P3600, DOI 10.1182/blood.V98.13.3600; Wajih N, 2005, J BIOL CHEM, V280, P10540, DOI 10.1074/jbc.M413982200; Wallin R, 2004, TRENDS MOL MED, V10, P299, DOI 10.1016/j.molmed.2004.05.003; Wallin R, 2002, THROMB RES, V108, P221, DOI 10.1016/S0049-3848(03)00060-4; WALLIN R, 1977, BIOCHIM BIOPHYS ACTA, V491, P317, DOI 10.1016/0005-2795(77)90067-8; WASLEY LC, 1993, J BIOL CHEM, V268, P8458; WU GY, 1994, J NUTR, V124, P415, DOI 10.1093/jn/124.3.415; WU SM, 1991, SCIENCE, V254, P1634, DOI 10.1126/science.1749935	22	60	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31603	31607		10.1074/jbc.M505373200	http://dx.doi.org/10.1074/jbc.M505373200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16030016	hybrid			2022-12-25	WOS:000231665200034
J	Park, YJ; Chang, LC; Liang, JF; Moon, C; Chung, CP; Yang, VC				Park, YJ; Chang, LC; Liang, JF; Moon, C; Chung, CP; Yang, VC			Nontoxic membrane translocation peptide from protamine, low molecular weight protamine (LMWP), for enhanced intracellular protein delivery: in vitro and in vivo study	FASEB JOURNAL			English	Article						LMWP; PTD; TAT; gene therapy; medical imaging	ARGININE-RICH PEPTIDES; HIV-1 TAT PROTEIN; HEPARIN ANTAGONIST; MAMMALIAN-CELLS; CELLULAR UPTAKE; TRANSDUCTION; EFFICACY; INTERNALIZATION; TRANSPORTERS; ENDOCYTOSIS	Naturally derived, nontoxic peptides from protamine by the authors, termed low molecular weight protamines (LMWPs), possess high arginine content and carry significant sequence similarity to that of TAT, by far the most potent protein transduction domain peptide. Therefore, it was hypothesized that these LMWPs would also inherit the similar translocation activity across the cell membrane, which enables any impermeable species to be transduced into the cells. LMWPs were prepared by enzymatic digestion of protamine, examined their capability of transducing an impermeable protein toxin into the tumor cells by chemical conjugation, and determined cytotoxicity of transduced protein toxin ( e. g., gelonin) against cancer cell lines and a tumor-bearing mouse. In vitro results showed that LMWPs could indeed translocate themselves into several mammalian cell lines as efficiently as TAT, thereby transducing impermeable gelonin into the cells by chemical conjugation. In vivo studies further confirmed that LMWP could carry an impermeable gelonin across the tumor mass and subsequently inhibit the tumor growth. In conclusion, the presence of equivalent cell translocation potency, absence of toxicity of peptide itself, and the suitability for low-cost production by simple enzymatic digestion could expand the range of clinical applications of LMWPs, including medical imaging and gene/protein therapies.	Seoul Natl Univ, Sch Dent, Craniomaxillofacial Reconstruct Sci Major, Seoul 110749, South Korea; Seoul Natl Univ, Intellectual Biointerface Engn Ctr, Seoul 110749, South Korea; Seoul Natl Univ, Sch Dent, Dept Periodontol, Seoul 110749, South Korea; Natl Def Med Ctr, Sch Pharm, Taipei, Taiwan; Stevens Inst Technol, Dept Chem & Chem Biol, Hoboken, NJ 07030 USA; Univ Michigan, Coll Pharm, Ann Arbor, MI 48109 USA	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); National Defense Medical Center; Stevens Institute of Technology; University of Michigan System; University of Michigan	Park, YJ (corresponding author), Seoul Natl Univ, Sch Dent, Craniomaxillofacial Reconstruct Sci Major, 28-2 Yongon Dong, Seoul 110749, South Korea.	parkyj@snu.ac.kr		Moon, Cheol/0000-0003-2342-0860	NATIONAL CANCER INSTITUTE [R01CA114612] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA114612] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Byun Y, 1999, THROMB RES, V94, P53, DOI 10.1016/S0049-3848(98)00201-1; CARLSSON J, 1978, BIOCHEM J, V173, P723, DOI 10.1042/bj1730723; Chang LC, 2001, AAPS PHARMSCI, V3, part. no.; Chang LC, 2001, AAPS PHARMSCI, V3, part. no.; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200; HEEREMANS JLM, 1992, BIOCHIM BIOPHYS ACTA, V1117, P258, DOI 10.1016/0304-4165(92)90022-M; JOLIOT A, 1991, P NATL ACAD SCI USA, V88, P1864, DOI 10.1073/pnas.88.5.1864; Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h; Lee LM, 2001, AAPS PHARMSCI, V3, part. no.; Liang JF, 2003, BIOCHEMISTRY-MOSCOW+, V68, P116, DOI 10.1023/A:1022109905487; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; McGrath MS, 2003, CANCER RES, V63, P72; Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Niesner U, 2002, BIOCONJUGATE CHEM, V13, P729, DOI 10.1021/bc025517+; Park YJ, 2003, J GENE MED, V5, P700, DOI 10.1002/jgm.402; Rosenblum MG, 1999, CLIN CANCER RES, V5, P865; Rothbard JB, 2002, J MED CHEM, V45, P3612, DOI 10.1021/jm0105676; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Selbo PK, 2001, INT J CANCER, V92, P761, DOI 10.1002/1097-0215(20010601)92:5<761::AID-IJC1238>3.0.CO;2-4; Snyder EL, 2001, CURR OPIN MOL THER, V3, P147; Suzuki T, 2002, J BIOL CHEM, V277, P2437, DOI 10.1074/jbc.M110017200; Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498; Tsui B, 2001, THROMB RES, V101, P417, DOI 10.1016/S0049-3848(00)00427-8; Tung CH, 2002, BIOORGAN MED CHEM, V10, P3609, DOI 10.1016/S0968-0896(02)00248-1; Veenendaal LM, 2002, P NATL ACAD SCI USA, V99, P7866, DOI [10.1073/pnas.122157899, 10.1073/pnas.162346299]; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003; Zaro JL, 2003, BIOCHEM BIOPH RES CO, V307, P241, DOI 10.1016/S0006-291X(03)01167-7	31	103	111	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1555	+		10.1096/fj.04-2322fje	http://dx.doi.org/10.1096/fj.04-2322fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16033808	Green Published			2022-12-25	WOS:000230923000016
J	Hass, MR; Yankner, BA				Hass, MR; Yankner, BA			A gamma-secretase-independent mechanism of signal transduction by the amyloid precursor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL DOMAIN; ALZHEIMERS-DISEASE; CELL-SURFACE; PRESENILIN-1 MUTATIONS; INTRACELLULAR DOMAIN; ACETYLTRANSFERASE ACTIVITY; BETA-APP; A-BETA; TIP60; FE65	It has been proposed that gamma-secretase-mediated release of the amyloid precursor protein (APP) intracellular domain ( AICD) results in nuclear translocation and signaling through a complex with the adaptor protein Fe65 and the histone acetyltransferase Tip60. Here, we show that APP and Fe65 activate transcription through a Gal4-Tip60 reporter in presenilin-1/2-deficient cells lacking generation of AICD. APP and Fe65 also activated transcription in the presence of gamma-secretase inhibitors that prevent amyloid beta-peptide production in human embryonic kidney 293 and SH-SY5Y cells. In contrast to the transcriptionally active Notch intracellular domain, expression of AICD did not activate transcription. An alternative mechanism for APP signal transduction is suggested by the identification of essential cyclin-dependent kinase (CDK) phosphorylation sites in Tip60. Mutation of these Tip60 phosphorylation sites or treatment with the CDK inhibitor roscovitine blocked the ability of APP to signal through Tip60. Moreover, APP stabilized Tip60 through CDK-dependent phosphorylation. Subcellular fractionation and confocal immunofluorescence showed that APP recruited Tip60 to membrane compartments. Thus, APP may signal to the nucleus by a gamma-secretase-independent mechanism that involves membrane sequestration and phosphorylation of Tip60.	Harvard Univ, Childrens Hosp, Sch Med, Dept Neurol, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Div Neurosci, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School	Yankner, BA (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, Dept Neurol, Enders 460,300 Longwood Ave, Boston, MA 02115 USA.	Bruce.Yankner@childrens.harvard.edu			NIA NIH HHS [AG0022, T32 AG000222, R01 AG017974, AG17974] Funding Source: Medline; NINDS NIH HHS [R01 NS030352, NS030352] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030352] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017974, T32AG000222] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ando K, 2001, J BIOL CHEM, V276, P40353, DOI 10.1074/jbc.M104059200; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; BREEN KC, 1991, J NEUROSCI RES, V28, P90, DOI 10.1002/jnr.490280109; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Cao XW, 2004, J BIOL CHEM, V279, P24601, DOI 10.1074/jbc.M402248200; Chen FS, 2002, J BIOL CHEM, V277, P36521, DOI 10.1074/jbc.M205093200; CHEN M, 1991, NEUROSCI LETT, V125, P223, DOI 10.1016/0304-3940(91)90034-Q; Creaven M, 1999, BIOCHEMISTRY-US, V38, P8826, DOI 10.1021/bi9907274; DE SB, 1999, NATURE, V398, P518; Ebinu JO, 2002, NEURON, V34, P499, DOI 10.1016/S0896-6273(02)00704-3; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; Gaughan L, 2001, J BIOL CHEM, V276, P46841, DOI 10.1074/jbc.M103710200; Geula C, 1998, NAT MED, V4, P827, DOI 10.1038/nm0798-827; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Iijima K, 2000, J NEUROCHEM, V75, P1085, DOI 10.1046/j.1471-4159.2000.0751085.x; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; JIN LW, 1994, J NEUROSCI, V14, P5461; Kamal A, 2001, NATURE, V414, P643, DOI 10.1038/414643a; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kim HS, 2003, FASEB J, V17, P1951, DOI 10.1096/fj.03-0106fje; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; Kinoshita A, 2002, J NEUROCHEM, V82, P839, DOI 10.1046/j.1471-4159.2002.01016.x; Kinoshita A, 2002, J BIOL CHEM, V277, P28530, DOI 10.1074/jbc.M203372200; Koo EH, 2004, NAT MED, V10, pS26, DOI 10.1038/nm1065; la Cour T, 2003, NUCLEIC ACIDS RES, V31, P393, DOI 10.1093/nar/gkg101; LEBLANC AC, 1992, J NEUROSCI RES, V31, P635, DOI 10.1002/jnr.490310407; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; Lemercier C, 2003, J BIOL CHEM, V278, P4713, DOI 10.1074/jbc.M211811200; Lichtenthaler SF, 2004, J CLIN INVEST, V113, P1384, DOI 10.1172/JCI200421746; McAllister D, 2002, GENE, V289, P169, DOI 10.1016/S0378-1119(02)00546-2; Moehlmann T, 2002, P NATL ACAD SCI USA, V99, P8025, DOI 10.1073/pnas.112686799; Pardossi-Piquard R, 2005, NEURON, V46, P541, DOI 10.1016/j.neuron.2005.04.008; Passer Brent, 2000, Journal of Alzheimer's Disease, V2, P289; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; QIU WQ, 1995, J NEUROSCI, V15, P2157, DOI 10.1523/JNEUROSCI.15-03-02157.1995; Sabo SL, 1999, J BIOL CHEM, V274, P7952, DOI 10.1074/jbc.274.12.7952; Saura CA, 2004, NEURON, V42, P23, DOI 10.1016/S0896-6273(04)00182-5; Schroeter EH, 2003, P NATL ACAD SCI USA, V100, P13075, DOI 10.1073/pnas.1735338100; Selkoe D, 2003, ANNU REV NEUROSCI, V26, P565, DOI 10.1146/annurev.neuro.26.041002.131334; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Tanzi RE, 2005, CELL, V120, P545, DOI 10.1016/j.cell.2005.02.008; von Rotz RC, 2004, J CELL SCI, V117, P4435, DOI 10.1242/jcs.01323; Wiley JC, 2005, J NEUROCHEM, V94, P1189, DOI 10.1111/j.1471-4159.2005.03266.x; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4; Zambrano N, 2004, J BIOL CHEM, V279, P16161, DOI 10.1074/jbc.M311027200; Zambrano N, 2002, J CELL SCI, V115, P1411; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	48	78	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36895	36904		10.1074/jbc.M502861200	http://dx.doi.org/10.1074/jbc.M502861200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16103124	Green Accepted, hybrid			2022-12-25	WOS:000232901800045
J	Quinaud, M; Chabert, J; Faudry, E; Neumann, E; Lemaire, D; Pastor, A; Elsen, S; Dessen, A; Attree, I				Quinaud, M; Chabert, J; Faudry, E; Neumann, E; Lemaire, D; Pastor, A; Elsen, S; Dessen, A; Attree, I			The PscE-PscF-PscG complex controls type III secretion needle biogenesis in Pseudomonas aeruginosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECRETION; YERSINIA-ENTEROCOLITICA; STRUCTURAL-CHARACTERIZATION; SUPRAMOLECULAR STRUCTURE; BACTERIAL INJECTISOMES; SUBSTRATE-SPECIFICITY; TRANSLOCATION PORE; SHIGELLA-FLEXNERI; ESCHERICHIA-COLI; PLASMA-MEMBRANE	Type III secretion (T3S) systems play key roles in pathogenicity of many Gram-negative bacteria and are employed to inject toxins directly into the cytoplasm of target cells. They are composed of over 20 different proteins that associate into a basal structure that traverses both inner and outer bacterial membranes and a hollow, needle-like structure through which toxins travel. The PscF protein is the main component of the Pseudomonas aeruginosa T3S needle. Here we demonstrate that PscF, when purified on its own, is able to form needle-like fibers of 8 nm in width and > 1 mu m in length. In addition, we demonstrate for the first time that the T3S needle subunit requires two cytoplasmic partners, PscE and PscG, in P. aeruginosa, which trap PscF in a ternary, 1: 1: 1 complex, thus blocking it in a monomeric state. Knock-out mutants deficient in PscE and PscG are non-cytotoxic, lack PscF, and are unable to export PscF encoded extrachromosomally. Temperature-scanning circular dichroism measurements show that the PscE-PscF-PscG complex is thermally stable and displays a cooperative unfolding/refolding pattern. Thus, PscE and PscG prevent PscF from polymerizing prematurely in the P. aeruginosa cytoplasm and keep it in a secretion prone conformation, strategies which may be shared by other pathogens that employ the T3S system for infection.	Univ Grenoble 1, CEA Grenoble, Dept Reponse & Dynam Cellulaires, CNRS,UMR 5092, F-38054 Grenoble, France; UJF, CEA, Inst Biol Struct Jean Pierre Ebel, CNRS,UMR 5075, Grenoble, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA	Attree, I (corresponding author), Univ Grenoble 1, CEA Grenoble, Dept Reponse & Dynam Cellulaires, CNRS,UMR 5092, 17 Rue Martyrs, F-38054 Grenoble, France.	iattreedelic@cea.fr	Faudry, Eric/I-9154-2014	Faudry, Eric/0000-0001-9958-6029; Attree, Ina/0000-0002-2580-764X; Lemaire, David/0000-0001-6874-3685; Dessen, Andrea/0000-0001-6487-4020; Elsen, Sylvie/0000-0003-4611-4719				Agrain C, 2005, MOL MICROBIOL, V56, P54, DOI 10.1111/j.1365-2958.2005.04534.x; Auvray F, 2001, J MOL BIOL, V308, P221, DOI 10.1006/jmbi.2001.4597; Berthelot P, 2003, J INFECT DIS, V188, P512, DOI 10.1086/377000; Blocker A, 2003, P NATL ACAD SCI USA, V100, P3027, DOI 10.1073/pnas.0535335100; Blocker A, 2001, MOL MICROBIOL, V39, P652, DOI 10.1046/j.1365-2958.2001.02200.x; Cheng LW, 1999, J BIOL CHEM, V274, P22102, DOI 10.1074/jbc.274.31.22102; Choudhury D, 1999, SCIENCE, V285, P1061, DOI 10.1126/science.285.5430.1061; Cordes FS, 2003, J BIOL CHEM, V278, P17103, DOI 10.1074/jbc.M300091200; Cornelis GR, 2000, ANNU REV MICROBIOL, V54, P735, DOI 10.1146/annurev.micro.54.1.735; Dacheux D, 1999, INFECT IMMUN, V67, P6164, DOI 10.1128/IAI.67.11.6164-6167.1999; Dacheux D, 2002, INFECT IMMUN, V70, P3973, DOI 10.1128/IAI.70.7.3973-3977.2002; Dacheux D, 2001, MOL MICROBIOL, V40, P76, DOI 10.1046/j.1365-2958.2001.02368.x; Day JB, 2000, INFECT IMMUN, V68, P6466, DOI 10.1128/IAI.68.11.6466-6471.2000; FRITHZLINDSTEN E, 1995, MOL MICROBIOL, V16, P635, DOI 10.1111/j.1365-2958.1995.tb02426.x; Galan JE, 1999, SCIENCE, V284, P1322, DOI 10.1126/science.284.5418.1322; Gauthier A, 2003, J BACTERIOL, V185, P6747, DOI 10.1128/JB.185.23.6747-6755.2003; Ghosh P, 2004, MICROBIOL MOL BIOL R, V68, P771, DOI 10.1128/MMBR.68.4.771-795.2004; Goure J, 2004, INFECT IMMUN, V72, P4741, DOI 10.1128/IAI.72.8.4741-4750.2004; Hakansson S, 1996, EMBO J, V15, P5812, DOI 10.1002/j.1460-2075.1996.tb00968.x; Hoiczyk E, 2001, P NATL ACAD SCI USA, V98, P4669, DOI 10.1073/pnas.071065798; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; Ide T, 2001, CELL MICROBIOL, V3, P669, DOI 10.1046/j.1462-5822.2001.00146.x; Jin QL, 2001, SCIENCE, V294, P2556, DOI 10.1126/science.1066397; Jouihri N, 2003, MOL MICROBIOL, V49, P755, DOI 10.1046/j.1365-2958.2003.03590.x; Journet L, 2003, SCIENCE, V302, P1757, DOI 10.1126/science.1091422; Kimbrough TG, 2000, P NATL ACAD SCI USA, V97, P11008, DOI 10.1073/pnas.200209497; KONYECSNI WM, 1988, GENE, V74, P375, DOI 10.1016/0378-1119(88)90171-0; Kubori T, 1998, SCIENCE, V280, P602, DOI 10.1126/science.280.5363.602; Kubori T, 2000, P NATL ACAD SCI USA, V97, P10225, DOI 10.1073/pnas.170128997; Li CM, 2002, EMBO J, V21, P1909, DOI 10.1093/emboj/21.8.1909; Luo Y, 2001, NAT STRUCT BIOL, V8, P1031, DOI 10.1038/nsb717; Lyczak JB, 2000, MICROBES INFECT, V2, P1051, DOI 10.1016/S1286-4579(00)01259-4; Lyczak JB, 2002, CLIN MICROBIOL REV, V15, P194, DOI 10.1128/CMR.15.2.194-222.2002; Magdalena J, 2002, J BACTERIOL, V184, P3433, DOI 10.1128/JB.184.13.3433-3441.2002; Marlovits TC, 2004, SCIENCE, V306, P1040, DOI 10.1126/science.1102610; Mota LJ, 2005, SCIENCE, V307, P1278, DOI 10.1126/science.1107679; Muramoto K, 1998, J MOL BIOL, V277, P871, DOI 10.1006/jmbi.1998.1659; Neyt C, 1999, MOL MICROBIOL, V33, P971, DOI 10.1046/j.1365-2958.1999.01537.x; Pallen MJ, 2005, FEMS MICROBIOL REV, V29, P201, DOI 10.1016/j.femsre.2005.01.001; Parsot C, 2003, CURR OPIN MICROBIOL, V6, P7, DOI 10.1016/S1369-5274(02)00002-4; PASTOR A, 2005, IN PRESS FEMS MICROB; Rosqvist R, 1995, CONTRIB TO MICROBIOL, V13, P230; Roy-Burman A, 2001, J INFECT DIS, V183, P1767, DOI 10.1086/320737; Sawa T, 1998, INFECT IMMUN, V66, P3242, DOI 10.1128/IAI.66.7.3242-3249.1998; Schoehn G, 2003, EMBO J, V22, P4957, DOI 10.1093/emboj/cdg499; SCHWEIZER HP, 1992, MOL MICROBIOL, V6, P1195, DOI 10.1111/j.1365-2958.1992.tb01558.x; Sekiya K, 2001, P NATL ACAD SCI USA, V98, P11638, DOI 10.1073/pnas.191378598; Stebbins CE, 2001, NATURE, V414, P77, DOI 10.1038/35102073; Stover CK, 2000, NATURE, V406, P959, DOI 10.1038/35023079; Sukhan A, 2001, J BACTERIOL, V183, P1159, DOI 10.1128/JB.183.4.1159-1167.2001; Swietnicki W, 2005, PROTEIN EXPRES PURIF, V42, P166, DOI 10.1016/j.pep.2005.02.016; Tamano K, 2000, EMBO J, V19, P3876, DOI 10.1093/emboj/19.15.3876; Tardy F, 1999, EMBO J, V18, P6793, DOI 10.1093/emboj/18.23.6793; Thomas J, 2004, P NATL ACAD SCI USA, V101, P3945, DOI 10.1073/pnas.0307223101; Wattiau P, 1996, MOL MICROBIOL, V20, P255, DOI 10.1111/j.1365-2958.1996.tb02614.x; Yahr TL, 1997, J BACTERIOL, V179, P7165, DOI 10.1128/jb.179.22.7165-7168.1997; Yip CK, 2005, NATURE, V435, P702, DOI 10.1038/nature03554; Yip CK, 2005, NAT STRUCT MOL BIOL, V12, P75, DOI 10.1038/nsmb879; Zavialov AV, 2003, CELL, V113, P587, DOI 10.1016/S0092-8674(03)00351-9	59	63	70	2	11	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36293	36300		10.1074/jbc.M508089200	http://dx.doi.org/10.1074/jbc.M508089200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16115870	hybrid			2022-12-25	WOS:000232726900062
J	Pereira, R; Cerione, RA				Pereira, R; Cerione, RA			A switch 3 point mutation in the alpha subunit of transducin yields a unique dominant-negative inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; HETEROTRIMERIC G-PROTEIN; CRYSTAL-STRUCTURE; CELLULAR-TRANSFORMATION; CGMP PHOSPHODIESTERASE; ONCOGENE PRODUCT; EFFECTOR-BINDING; HELICAL DOMAIN; RGS PROTEINS; ACTIVATION	The rhodopsin/ transducin- coupled vertebrate vision system has served as a paradigm for G protein- coupled signaling. We have taken advantage of this system to identify new types of constitutively active, transducin- alpha(alpha T) subunits. Here we have described a novel dominant- negative mutation, made in the background of a chimera consisting of alpha T and the alpha subunit of G(i1) ( designated alpha T*), which involves the substitution of a conserved arginine residue in the conformationally sensitive Switch 3 region. Changing Arg- 238 to either lysine or alanine had little or no effect on the ability of alpha T* to undergo rhodopsin- stimulated GDP- GTP exchange, whereas substituting glutamic acid for arginine at this position yielded an alpha T* subunit ( alpha T*( R238E)) that was incapable of undergoing rhodopsin-dependent nucleotide exchange and was unable to bind or stimulate the target/ effector enzyme ( cyclic GMP phosphodiesterase). Moreover, unlike the GDP- bound forms of alpha T*, alpha T*( R238A) and alpha T*( R238K), the alpha T*( R238E) mutant did not respond to aluminum fluoride ( AlF4-), as read out by changes in Trp- 207 fluorescence. However, surprisingly, we found that alpha T*( R238E) effectively blocked rhodopsin- catalyzed GDP- GTPexchange on alpha T*, as well as rhodopsin- stimulated phosphodiesterase activity. Analysis by high pressure liquid chromatography indicated that the alpha T*( R238E) mutant exists in a nucleotide- free state. Nucleotide- free forms of G alpha subunits were typically very sensitive to proteolytic degradation, but alpha T*( R238E) exhibited a resistance to trypsin- proteolysis similar to that observed with activated forms of alpha T*. Overall, these findings indicated that by mutating a single residue in Switch 3, it is possible to generate a unique type of dominant- negative G alpha subunit that can effectively block signaling by G protein- coupled receptors.	Cornell Univ, Coll Vet Med, Dept Mol Med, Ithaca, NY 14853 USA; Cornell Univ, Dept Chem & Biol Chem, Ithaca, NY 14853 USA	Cornell University; Cornell University	Cerione, RA (corresponding author), Cornell Univ, Coll Vet Med, Dept Mol Med, Ithaca, NY 14853 USA.	rac1@cornell.edu			NEI NIH HHS [EY06429] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY006429] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Arshavsky VY, 2002, ANNU REV PHYSIOL, V64, P153, DOI 10.1146/annurev.physiol.64.082701.102229; Berlot CH, 2002, J BIOL CHEM, V277, P21080, DOI 10.1074/jbc.M201330200; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; BIGAY J, 1987, EMBO J, V6, P2907, DOI 10.1002/j.1460-2075.1987.tb02594.x; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cherfils J, 2003, TRENDS BIOCHEM SCI, V28, P13, DOI 10.1016/S0968-0004(02)00006-3; Cleator JH, 1999, FEBS LETT, V443, P205, DOI 10.1016/S0014-5793(98)01704-9; Cleator JH, 2004, J BIOL CHEM, V279, P36601, DOI 10.1074/jbc.M406232200; Erickson JW, 2004, BIOCHEMISTRY-US, V43, P837, DOI 10.1021/bi036026v; ERICKSON JW, 1995, BIOCHEMISTRY-US, V34, P8693, DOI 10.1021/bi00027a019; Farfel Z, 1999, NEW ENGL J MED, V340, P1012, DOI 10.1056/NEJM199904013401306; FAUROBERT E, 1993, EMBO J, V12, P4191, DOI 10.1002/j.1460-2075.1993.tb06103.x; FUNG BKK, 1983, J BIOL CHEM, V258, P503; HART MJ, 1994, J BIOL CHEM, V269, P62; Hoffman GR, 2002, FEBS LETT, V513, P85, DOI 10.1016/S0014-5793(01)03310-5; Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527; Iiri T, 1998, NATURE, V394, P35, DOI 10.1038/27831; Iiri T, 1999, P NATL ACAD SCI USA, V96, P499, DOI 10.1073/pnas.96.2.499; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Li QB, 1997, J BIOL CHEM, V272, P21673, DOI 10.1074/jbc.272.35.21673; LIEBMAN PA, 1982, METHOD ENZYMOL, V81, P532; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; Liu W, 1998, J BIOL CHEM, V273, P34284, DOI 10.1074/jbc.273.51.34284; Liu W, 1998, P NATL ACAD SCI USA, V95, P12878, DOI 10.1073/pnas.95.22.12878; Majumdar S, 2004, J BIOL CHEM, V279, P40137, DOI 10.1074/jbc.M405420200; Min KC, 2000, PROTEIN EXPRES PURIF, V20, P514, DOI 10.1006/prep.2000.1326; Muradov KG, 2000, BIOCHEMISTRY-US, V39, P3937, DOI 10.1021/bi992156l; Natochin M, 2003, J NEUROCHEM, V87, P1262, DOI 10.1046/j.1471-4159.2003.02103.x; NEER EJ, 1994, METHOD ENZYMOL, V237, P226; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; PHILLIPS WJ, 1989, J BIOL CHEM, V264, P16679; PREININGER AM, 2004, SCI STKE, pRE3; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; STACEY DW, 1991, ONCOGENE, V6, P2297; STERNWEIS PC, 1982, P NATL ACAD SCI-BIOL, V79, P4888, DOI 10.1073/pnas.79.16.4888; Tu SS, 2002, BIOCHEMISTRY-US, V41, P12350, DOI 10.1021/bi026167h; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WITTINGHOFER A, 1994, CELL, V76, P201, DOI 10.1016/0092-8674(94)90327-1; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014	47	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35696	35703		10.1074/jbc.M504935200	http://dx.doi.org/10.1074/jbc.M504935200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16103122	hybrid			2022-12-25	WOS:000232561200072
J	Saladino, R; Crestini, C; Busiello, V; Ciciriello, F; Costanzo, G; Di Mauro, E				Saladino, R; Crestini, C; Busiello, V; Ciciriello, F; Costanzo, G; Di Mauro, E			Differential stability of 3 '- and 5 '-phosphoester bonds in deoxy monomers and oligomers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BARBERTON GREENSTONE-BELT; DEOXYRIBONUCLEIC-ACID; PREBIOTIC SYNTHESIS; PURINE NUCLEOSIDES; NUCLEIC-ACIDS; SPHERULE BEDS; COLD ORIGIN; DNA ENZYME; FORMAMIDE; LIFE	To survive, an informational macromolecule must solve the major problem set by its very polymeric nature: instability. This is especially true in prebiotic terms because of the presumed initial absence of protective structures ( proteins, lipids, etc.). We have analyzed the stability of the beta-glycosidic and of the 3'- and 5'- phosphoester bonds in both deoxy monomers and deoxy oligomers under a large set of conditions. The results show a strong dependence of the relative stability of these bonds on the physico- chemical environment. A set of conditions has been identified in which the stability of polymers becomes comparable with that of the precursor monomers. In certain instances the stability of the 5'- phosphoester bond is even higher in the polymer than in the mononucleotide.	Univ Roma La Sapienza, Dipartimento Genet & Biol Mol, Fdn Ist Pasteur, Fdn Cenci Bolognetti, I-00185 Rome, Italy; Univ Tuscia, Dipartimento Agrobiol & Agrochim, I-01100 Viterbo, Italy; Univ Tor Vergata, Dipartimento Sci & Tecnol Chim, I-00133 Rome, Italy; CNR, Ist Biol & Patol Mol, I-00185 Rome, Italy	Fondazione Cenci Bolognetti; Sapienza University Rome; Tuscia University; University of Rome Tor Vergata; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR)	Di Mauro, E (corresponding author), Univ Roma La Sapienza, Dipartimento Genet & Biol Mol, Fdn Ist Pasteur, Fdn Cenci Bolognetti, Piazzale Aldo Moro 5, I-00185 Rome, Italy.	Ernesto.dimauro@uniroma1.it	Ciciriello, Fabiana/AAA-8065-2020; Crestini, Claudia/O-6781-2015	Ciciriello, Fabiana/0000-0003-1493-9767; Crestini, Claudia/0000-0001-9903-2675				Arndt N.T., 1994, ARCHEAN CRUSTAL EVOL, P11, DOI [10.1016/ S0166- 2635(08)70219-6, DOI 10.1016/S0166-2635(08)70219-6]; Bada JL, 2002, SCIENCE, V296, P1982, DOI 10.1126/science.1069487; Bhattacharyya AJ, 2001, TALANTA, V55, P943, DOI 10.1016/S0039-9140(01)00493-3; Butlerow A., 1861, ANN CHEM PHARM, V120, P295, DOI [10.1002/jlac.18611200308, DOI 10.1002/JLAC.18611200308]; BUZAYAN JM, 1986, NATURE, V323, P349, DOI 10.1038/323349a0; Carmi N, 2001, BIOORGAN MED CHEM, V9, P2589, DOI 10.1016/S0968-0896(01)00035-9; CECH TR, 1986, ANNU REV BIOCHEM, V55, P599, DOI 10.1146/annurev.biochem.55.1.599; CECH TR, 1985, INT REV CYTOL, V93, P3, DOI 10.1016/S0074-7696(08)61370-4; Cornish EC, 1998, BIOTECHNIQUES, V25, P948, DOI 10.2144/98256bm04; DECKER P, 1982, J CHROMATOGR, V244, P281, DOI 10.1016/S0021-9673(00)85692-7; DUNLOP JSR, 1978, NATURE, V274, P676, DOI 10.1038/274676a0; FORTERRE P, 1995, ORIGINS LIFE EVOL B, V25, P235, DOI 10.1007/BF01581587; Fu AP, 2003, J MOL STRUC-THEOCHEM, V623, P315, DOI 10.1016/S0166-1280(02)00772-8; GARRETT ER, 1972, J AM CHEM SOC, V94, P8542, DOI 10.1021/ja00779a041; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; Hofmann HJ, 1999, GEOL SOC AM BULL, V111, P1256, DOI 10.1130/0016-7606(1999)111<1256:OOGCSI>2.3.CO;2; Imai E, 1999, SCIENCE, V283, P831, DOI 10.1126/science.283.5403.831; JONES AS, 1968, J CHEM SOC C, P2042, DOI 10.1039/j39680002042; JOYCE GF, 1987, P NATL ACAD SCI USA, V84, P4398, DOI 10.1073/pnas.84.13.4398; Knauth LP, 2003, GEOL SOC AM BULL, V115, P566, DOI 10.1130/0016-7606(2003)115<0566:HACTIF>2.0.CO;2; Kochetkov N.K., 1972, ORGANIC CHEM NUCLE B, P425; KOCHETKOV NK, 1972, ORGANIC CHEM NUCLE B, P477; Kyte FT, 2003, GEOLOGY, V31, P283, DOI 10.1130/0091-7613(2003)031<0283:EASBCI>2.0.CO;2; LAWLEY PD, 1964, BIOCHEM J, V92, pC19, DOI 10.1042/bj0920019C; LAZCANO A, 1994, J MOL EVOL, V39, P546, DOI 10.1007/BF00160399; LAZCANO A, 1988, J MOL EVOL, V27, P283, DOI 10.1007/BF02101189; Levy M, 1998, P NATL ACAD SCI USA, V95, P7933, DOI 10.1073/pnas.95.14.7933; Levy M, 2000, ICARUS, V145, P609, DOI 10.1006/icar.2000.6365; LINDAHL T, 1973, BIOCHEMISTRY-US, V12, P5151, DOI 10.1021/bi00749a020; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3610, DOI 10.1021/bi00769a018; Lowe DR, 2003, ASTROBIOLOGY, V3, P7, DOI 10.1089/153110703321632408; Millar TJ, 2004, ASTROPHYS SPACE SC L, V305, P17; MILLER SL, 1988, NATURE, V334, P609, DOI 10.1038/334609a0; Miller SL, 1995, J MOL EVOL, V41, P689; Miyakawa S, 2002, ORIGINS LIFE EVOL B, V32, P209, DOI 10.1023/A:1019514022822; Miyakawa S, 2002, ORIGINS LIFE EVOL B, V32, P195, DOI 10.1023/A:1016514305984; Mojzsis SJ, 1996, NATURE, V384, P55, DOI 10.1038/384055a0; Negri R, 1996, BIOTECHNIQUES, V21, P910; NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210; Nissen P, 2000, SCIENCE, V289, P920, DOI 10.1126/science.289.5481.920; Orgel LE, 1998, TRENDS BIOCHEM SCI, V23, P491, DOI 10.1016/S0968-0004(98)01300-0; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PACE NR, 1985, ORIGINS LIFE EVOL B, V16, P97, DOI 10.1007/BF01809465; PITSCH S, 1995, ORIGINS LIFE EVOL B, V25, P297, DOI 10.1007/BF01581773; Rozas I, 2004, J PHYS CHEM B, V108, P3335, DOI 10.1021/jp036901m; Saladino R, 2005, CHEMBIOCHEM, V6, P1368, DOI 10.1002/cbic.200500035; Saladino R, 2004, ASTROPHYS SPACE SC L, V305, P393; Saladino R, 2004, CHEMBIOCHEM, V5, P1558, DOI 10.1002/cbic.200400119; Saladino R, 2004, CURR ORG CHEM, V8, P1425, DOI 10.2174/1385272043369836; Saladino R, 2003, CHEMBIOCHEM, V4, P514, DOI 10.1002/cbic.200300567; Saladino R, 2001, BIOORGAN MED CHEM, V9, P1249, DOI 10.1016/S0968-0896(00)00340-0; Saladino R, 1997, BIOORGAN MED CHEM, V5, P2041, DOI 10.1016/S0968-0896(97)00140-5; Saladino R, 1996, J AM CHEM SOC, V118, P5615, DOI 10.1021/ja953527y; Santoro SW, 2000, J AM CHEM SOC, V122, P2433, DOI 10.1021/ja993688s; SCHOFFSTALL AM, 1976, ORIGINS LIFE EVOL B, V7, P399, DOI 10.1007/BF00927935; SCHOFFSTALL AM, 1982, ORIGINS LIFE EVOL B, V12, P143, DOI 10.1007/BF00927141; Schoning KU, 2000, SCIENCE, V290, P1347, DOI 10.1126/science.290.5495.1347; Schwartzman DW, 2004, BIOCHEM SOC T, V32, P168, DOI 10.1042/BST0320168; SHAPIRO HS, 1957, BIOCHIM BIOPHYS ACTA, V26, P596, DOI 10.1016/0006-3002(57)90107-5; SHAPIRO R, 1973, BIOCHIM BIOPHYS ACTA, V319, P5, DOI 10.1016/0005-2787(73)90035-X; SHAPIRO R, 1969, BIOCHEMISTRY-US, V8, P1806, DOI 10.1021/bi00833a004; Sheppard TL, 2000, P NATL ACAD SCI USA, V97, P7802, DOI 10.1073/pnas.97.14.7802; Sponer J, 2000, J PHYS CHEM A, V104, P4592, DOI 10.1021/jp9943880; TOWNSEND LB, 1963, J AM CHEM SOC, V85, P242, DOI 10.1021/ja00885a039; TRAVERS A, 1993, DNA PROTEIN INTERACT, P28; van Zuilen MA, 2002, NATURE, V418, P627, DOI 10.1038/nature00934; VENNER H, 1966, H-S Z PHYSIOL CHEM, V344, P189, DOI 10.1515/bchm2.1966.344.1-3.189; WALSH MM, 1992, PRECAMBRIAN RES, V54, P271, DOI 10.1016/0301-9268(92)90074-X; Westall F, 2004, ASTROPHYS SPACE SC L, V305, P287; Westall F, 2004, ESA SPEC PUBL, V545, P37; Westall F, 2001, PRECAMBRIAN RES, V106, P93, DOI 10.1016/S0301-9268(00)00127-3; Wiegel J., 1998, THERMOPHILES KEYS MO; ZAKHARYAN R. A., 1967, BIOKHIMIYA, V32, P1068	73	22	23	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35658	35669		10.1074/jbc.M504537200	http://dx.doi.org/10.1074/jbc.M504537200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16036914	hybrid			2022-12-25	WOS:000232561200069
J	Majovski, RC; Khaperskyy, DA; Ghazy, MA; Ponticelli, AS				Majovski, RC; Khaperskyy, DA; Ghazy, MA; Ponticelli, AS			A functional role for the switch 2 region of yeast RNA polymerase II in transcription start site utilization and abortive initiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL REGION; STRUCTURAL BASIS; SACCHAROMYCES-CEREVISIAE; ELONGATION COMPLEX; TFIIB MUTATIONS; SELECTION; SUBUNIT; RPB9; RESOLUTION; MECHANISM	RNA polymerase II (RNAPII) is responsible for the synthesis of mRNA from eukaryotic protein-encoding genes. In this study, site-directed mutagenesis was employed to probe the function of residues within the Saccharomyces cerevisiae RNAPII active center in the mechanism of transcription start site utilization. We report here the identification of two mutations in the switch 2 region, rpb1-K332A and rpb1-R344A, which conferred conditional growth properties and downstream shifts in start site utilization. Analyses of double mutant strains demonstrated functional interactions between these switch 2 mutations and a mutation in the largest subunit of transcription factor IIF (TFIIF) that confers upstream shifts in start site usage. Importantly, biochemical analyses demonstrated that purified Rpb1-R344A mutant polymerase exhibited impaired ability to stabilize a short RNA-DNA hybrid in the active center, an increased frequency of abortive transcription in runoff assays, and both a downstream shift and increased abortive initiation in reconstituted transcription assays. These results provide evidence for a role of switch 2 during start site utilization and indicate that RNA-DNA hybrid stability at the 3'-end of the transcript is a determinant in this process. We discuss these results within the context of a proposed model regarding the concerted roles of RNAPII, TFIIB, and TFIIF during mRNA 5'-end formation in S. cerevisiae.	SUNY Buffalo, Dept Biochem, Sch Med & Biomed Sci, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Ponticelli, AS (corresponding author), SUNY Buffalo, Dept Biochem, Sch Med & Biomed Sci, Buffalo, NY 14214 USA.	asp@buffalo.edu	Ghazy, Mohamed/ABD-6832-2020	Khaperskyy, Denys/0000-0003-0583-7179	NIGMS NIH HHS [GM51124] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051124, R29GM051124] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bangur CS, 1997, MOL CELL BIOL, V17, P6784, DOI 10.1128/MCB.17.12.6784; BERROTERAN RW, 1994, MOL CELL BIOL, V14, P226, DOI 10.1128/MCB.14.1.226; Bushnell DA, 2004, SCIENCE, V303, P983, DOI 10.1126/science.1090838; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; Faitar SL, 2001, MOL CELL BIOL, V21, P4427, DOI 10.1128/MCB.21.14.4427-4440.2001; Ghazy MA, 2004, MOL CELL BIOL, V24, P10975, DOI 10.1128/MCB.24.24.10975-10985.2004; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; GUARENTE L, 1987, ANNU REV GENET, V21, P425, DOI 10.1146/annurev.genet.21.1.425; Hahn S, 2004, NAT STRUCT MOL BIOL, V11, P394, DOI 10.1038/nsmb763; HULL MW, 1995, GENE DEV, V9, P481, DOI 10.1101/gad.9.4.481; Kettenberger H, 2004, MOL CELL, V16, P955, DOI 10.1016/j.molcel.2004.11.040; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Pardee TS, 1998, J BIOL CHEM, V273, P17859, DOI 10.1074/jbc.273.28.17859; PINTO I, 1992, CELL, V68, P977, DOI 10.1016/0092-8674(92)90040-J; PINTO I, 1994, J BIOL CHEM, V269, P30569; STRUHL K, 1987, CELL, V49, P295, DOI 10.1016/0092-8674(87)90277-7; Sun ZW, 1996, NUCLEIC ACIDS RES, V24, P2560, DOI 10.1093/nar/24.13.2560; Westover KD, 2004, SCIENCE, V303, P1014, DOI 10.1126/science.1090839; Zhang DY, 2002, NUCLEIC ACIDS RES, V30, P3078, DOI 10.1093/nar/gkf422; Ziegler LM, 2003, J BIOL CHEM, V278, P48950, DOI 10.1074/jbc.M309656200	20	26	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34917	34923		10.1074/jbc.M502932200	http://dx.doi.org/10.1074/jbc.M502932200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16081422	hybrid			2022-12-25	WOS:000232403900064
J	Aguiar, RCT; Takeyama, K; He, CY; Kreinbrink, K; Shipp, MA				Aguiar, RCT; Takeyama, K; He, CY; Kreinbrink, K; Shipp, MA			B-aggressive lymphoma family proteins have unique domains that modulate transcription and exhibit poly(ADP-ribose) polymerase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INACTIVE X-CHROMOSOME; CRYSTAL-STRUCTURES; HISTONE MACROH2A; CORE HISTONE; BINDING; CELLS; GENE; PARP; IDENTIFICATION; COREPRESSOR	BAL1 (B-aggressive lymphoma 1) was originally identified as a risk- related gene in diffuse large B-cell lymphoma. BAL1 encodes a nuclear protein with N-terminal macro domains and a putative C-terminal poly( ADP-ribose) polymerase ( PARP) active site. Macro domains are sequences homologous to the non-histone region of histone macroH2A. Several lines of evidence suggest that these domains may modulate transcription, including a high concentration of histone macroH2A in the inactive X chromosome, direct interference with transcription factor binding in a positioned nucleosome, and structural similarity to DNA binding domains. Poly( ADP-ribosyl) ation is a critical post-translational modification that regulates chromatin configuration and transcription. In this report we describe two additional BAL family members, BAL2 and BAL3, with N-terminal macro domains and putative C-terminal PARP active sites and assess the function of these specific regions in BAL family members. Herein, we demonstrate that BAL macro domains repress transcription when tethered to a promoter. In addition, we show that BAL2 and BAL3, but not BAL1, exhibit PARP activity. In agreement with these data, BAL1 lacks several critical donor and acceptor residues that are conserved in the BAL2 and -3 PARP active sites. Of interest, BAL family members with inactive or functional PARP domains differed in their ability to repress transcription. BAL family members are the only described proteins with both PARP and macro domains, underscoring the potential functional significance of this unique combination.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol,Div Hematol Malignancies, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Shipp, MA (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol,Div Hematol Malignancies, 44 Binney St,Rm M513, Boston, MA 02115 USA.	margaret_shipp@dfci.harvard.edu						Aguiar RCT, 1999, BLOOD, V94, P2403, DOI 10.1182/blood.V94.7.2403.419k39_2403_2413; Aguiar RCT, 1997, BLOOD, V90, P3130, DOI 10.1182/blood.V90.8.3130; Aguiar RCT, 2000, BLOOD, V96, P4328, DOI 10.1182/blood.V96.13.4328.h8004328_4328_4334; Allen MD, 2003, J MOL BIOL, V330, P503, DOI 10.1016/S0022-2836(03)00473-X; Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; Angelov D, 2003, MOL CELL, V11, P1033, DOI 10.1016/S1097-2765(03)00100-X; Aravind L, 2001, TRENDS BIOCHEM SCI, V26, P273, DOI 10.1016/S0968-0004(01)01787-X; Augustin A, 2003, J CELL SCI, V116, P1551, DOI 10.1242/jcs.00341; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Chadwick BP, 2001, HUM MOL GENET, V10, P1101, DOI 10.1093/hmg/10.10.1101; Costanzi C, 1998, NATURE, V393, P599, DOI 10.1038/31275; Costanzi C, 2001, J BIOL CHEM, V276, P21776, DOI 10.1074/jbc.M010919200; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Han WD, 2003, ENDOCR-RELAT CANCER, V10, P217, DOI 10.1677/erc.0.0100217; Ju BG, 2004, CELL, V119, P815, DOI 10.1016/j.cell.2004.11.017; Karras GI, 2005, EMBO J, V24, P1911, DOI 10.1038/sj.emboj.7600664; Kim MY, 2004, CELL, V119, P803, DOI 10.1016/j.cell.2004.11.002; Kustatscher G, 2005, NAT STRUCT MOL BIOL, V12, P624, DOI 10.1038/nsmb956; Ladurner AG, 2003, MOL CELL, V12, P1, DOI 10.1016/S1097-2765(03)00284-3; Liu H, 1999, J NEUROCHEM, V72, P1781, DOI 10.1046/j.1471-4159.1999.0721781.x; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; PEHRSON JR, 1992, SCIENCE, V257, P1398; Perche PY, 2000, CURR BIOL, V10, P1531, DOI 10.1016/S0960-9822(00)00832-0; Rolli V, 1997, BIOCHEMISTRY-US, V36, P12147, DOI 10.1021/bi971055p; Ruf A, 1996, P NATL ACAD SCI USA, V93, P7481, DOI 10.1073/pnas.93.15.7481; Ruf A, 1998, J MOL BIOL, V278, P57, DOI 10.1006/jmbi.1998.1673; Ruf A, 1998, BIOCHEMISTRY-US, V37, P3893, DOI 10.1021/bi972383s; Seimiya H, 2005, CANCER CELL, V7, P25, DOI 10.1016/j.ccr.2004.11.021; SIMONIN F, 1993, J BIOL CHEM, V268, P8529; Smith S, 2000, CURR BIOL, V10, P1299, DOI 10.1016/S0960-9822(00)00752-1; Smith S, 2001, TRENDS BIOCHEM SCI, V26, P174, DOI 10.1016/S0968-0004(00)01780-1; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Takeyama K, 2003, J BIOL CHEM, V278, P21930, DOI 10.1074/jbc.M301157200; Tulin A, 2003, SCIENCE, V299, P560, DOI 10.1126/science.1078764; Wang AH, 1999, MOL CELL BIOL, V19, P7816	35	126	131	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33756	33765		10.1074/jbc.M505408200	http://dx.doi.org/10.1074/jbc.M505408200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16061477	hybrid			2022-12-25	WOS:000232229700011
J	Christensen, KE; Mirza, IA; Berghuis, AM; MacKenzie, RE				Christensen, KE; Mirza, IA; Berghuis, AM; MacKenzie, RE			Magnesium and phosphate ions enable NAD binding to methylenetetrahydrofolate dehydrogenase-methenyltetrahydrofolate cyclohydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASCITES TUMOR-CELLS; CRYSTAL-STRUCTURE; FORMIMINOTRANSFERASE-CYCLODEAMINASE; COENZYME SPECIFICITY; ESCHERICHIA-COLI; COFACTOR-BINDING; DEHYDROGENASE/CYCLOHYDROLASE; PROTEINS; ENZYME; PURIFICATION	The mitochondrial NAD-dependent methylenetetrahydrofolate dehydrogenase-cyclohydrolase (NMDMC) is believed to have evolved from a trifunctional NADP-dependent methylenetetrahydrofolate dehydrogenase-cyclohydrolase-synthetase. It is unique in its absolute requirement for inorganic phosphate and magnesium ions to support dehydrogenase activity. To enable us to investigate the roles of these ions, a homology model of human NMDMC was constructed based on the structures of three homologous proteins. The model supports the hypothesis that the absolutely required Pi can bind in close proximity to the 2'-hydroxyl of NAD through interactions with Arg(166) and Arg(198). The characterization of mutants of Arg(166), Asp(190), and Arg(198) show that Arg(166) is primarily responsible for Pi binding, while Arg(198) plays a secondary role, assisting in binding and properly orienting the ion in the cofactor binding site. Asp(190) helps to properly position Arg(166). Mutants of Asp(133) suggest that the magnesium ion interacts with both P-i and the aspartate side chain and plays a role in positioning Pi and NAD. NMDMC uses P-i and magnesium to adapt an NADP binding site for NAD binding. This adaptation represents a novel variation of the classic Rossmann fold.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University	MacKenzie, RE (corresponding author), McGill Univ, Dept Biochem, McIntyre Med Sci Bldg,3655Promenade Sir William O, Montreal, PQ H3G 1Y6, Canada.	robert.mackenzie@mcgill.ca	Berghuis, Albert M/A-6495-2008	Berghuis, Albert/0000-0002-2663-025X				Allaire M, 1998, STRUCTURE, V6, P173, DOI 10.1016/S0969-2126(98)00019-7; Bellamacina CR, 1996, FASEB J, V10, P1257, DOI 10.1096/fasebj.10.11.8836039; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carugo O, 1997, PROTEINS, V28, P10, DOI 10.1002/(SICI)1097-0134(199705)28:1<10::AID-PROT2>3.3.CO;2-R; CHAKRABARTI P, 1993, J MOL BIOL, V234, P463, DOI 10.1006/jmbi.1993.1599; Christensen KE, 2005, J BIOL CHEM, V280, P7597, DOI 10.1074/jbc.M409380200; COPLEY RR, 1994, J MOL BIOL, V242, P321; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Di Pietro E, 2002, MOL CELL BIOL, V22, P4158, DOI 10.1128/MCB.22.12.4158-4166.2002; DRURY EJ, 1975, ARCH BIOCHEM BIOPHYS, V169, P662, DOI 10.1016/0003-9861(75)90210-6; Dudev T, 2003, CHEM REV, V103, P773, DOI 10.1021/cr020467n; Elmore CL, 2002, J BIOL CHEM, V277, P48960, DOI 10.1074/jbc.M210173200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lovell SC, 2000, PROTEINS, V40, P389, DOI 10.1002/1097-0134(20000815)40:3<389::AID-PROT50>3.0.CO;2-2; LUECKE H, 1990, NATURE, V347, P402, DOI 10.1038/347402a0; MEJIA NR, 1986, J BIOL CHEM, V261, P9509; Monzingo AF, 2000, PROTEIN SCI, V9, P1374, DOI 10.1110/ps.9.7.1374; MURLEY LL, 1993, J BIOL CHEM, V268, P22820; PAI EF, 1988, BIOCHEMISTRY-US, V27, P4465, DOI 10.1021/bi00412a038; Patel H, 2003, J BIOL CHEM, V278, P19436, DOI 10.1074/jbc.M301718200; Patel H, 2002, ARCH BIOCHEM BIOPHYS, V403, P145, DOI 10.1016/S0003-9861(02)00203-5; Patel S, 2002, J MOL BIOL, V315, P677, DOI 10.1006/jmbi.2001.5271; Pawelek PD, 1996, BBA-PROTEIN STRUCT M, V1296, P47, DOI 10.1016/0167-4838(96)00052-0; Pawelek PD, 2000, BBA-PROTEIN STRUCT M, V1479, P59, DOI 10.1016/S0167-4838(00)00058-3; Pawelek PD, 1998, BIOCHEMISTRY-US, V37, P1109, DOI 10.1021/bi971906t; PELLETIER JN, 1995, BIOCHEMISTRY-US, V34, P12673, DOI 10.1021/bi00039a025; RIOSORLANDI EM, 1988, J BIOL CHEM, V263, P4662; Saadat D, 1999, STRUCT FOLD DES, V7, P309, DOI 10.1016/S0969-2126(99)80041-0; Schmidt A, 2000, BIOCHEMISTRY-US, V39, P6325, DOI 10.1021/bi992734y; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; Shen BW, 1999, PROTEIN SCI, V8, P1342, DOI 10.1110/ps.8.6.1342; Sundararajan S, 2002, J BIOL CHEM, V277, P18703, DOI 10.1074/jbc.M200127200; TAINER JA, 1991, CURR OPIN BIOTECH, V2, P582, DOI 10.1016/0958-1669(91)90084-I; Tejero J, 2003, J BIOL CHEM, V278, P49203, DOI 10.1074/jbc.M307934200; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; YANG XM, 1993, BIOCHEMISTRY-US, V32, P1118, DOI 10.1021/bi00092a022; ZHANG M, 1994, BIOCHEMISTRY-US, V33, P11097, DOI 10.1021/bi00203a006	40	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34316	34323		10.1074/jbc.M505210200	http://dx.doi.org/10.1074/jbc.M505210200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16100107	hybrid			2022-12-25	WOS:000232229700074
J	Ingham, RJ; Raaijmakers, J; Lim, CSH; Mbamalu, G; Gish, G; Chen, F; Matskova, L; Enrberg, I; Winberg, G; Pawson, T				Ingham, RJ; Raaijmakers, J; Lim, CSH; Mbamalu, G; Gish, G; Chen, F; Matskova, L; Enrberg, I; Winberg, G; Pawson, T			The Epstein-Barr virus protein, latent membrane protein 2A, co-opts tyrosine kinases used by the T cell receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED SIGNAL-TRANSDUCTION; ACTIVE EBV INFECTION; REGULATES REACTIVATION; UBIQUITIN LIGASES; ANTIGEN RECEPTOR; GENETIC-EVIDENCE; FAMILY KINASES; LMP2A; PHOSPHORYLATION; LYMPHOMA	Epstein-Barr virus (EBV) is the causative agent of infectious mononucleosis and is associated with several human malignancies. The EBV protein latent membrane protein 2A (LMP2A) promotes viral latency in memory B cells by interfering with B cell receptor signaling and provides a survival signal for mature B cells that have lost expression of surface immunoglobulin. The latter function has suggested that LMP2A may enhance the survival of EBV-positive tumors. EBV is associated with several T cell malignancies and, since LMP2A has been detected in several of these disorders, we examined the ability of LMP2A to transmit signals and interfere with T cell receptor signaling in T cells. We show that LMP2A is tyrosine-phosphorylated in Jurkat TAg T cells, which requires expression of the Src family tyrosine kinases, Lck and Fyn. Lck and Fyn are recruited to the tyrosine-phosphorylated Tyr(112) site in LMP2A, whereas phosphorylation of an ITAM motif in LMP2A creates a binding site for the ZAP-70/Syk tyrosine kinases. LMP2A also associates through its two PPPPY motifs with AIP4, a NEDD4 family E3 ubiquitin ligase; this interaction results in ubiquitylation of LMP2A and serves to regulate the stability of LMP2A and LMP2A-kinase complexes. Furthermore, stable expression of LMP2A in Jurkat T cells down-regulated T cell receptor levels and attenuated T cell receptor signaling. Thus, through recruiting tyrosine kinases involved in T cell receptor activation, LMP2A may provide a survival signal for EBV-positive T cell tumors, whereas LMP2A-associated NEDD4 E3 ligases probably titer the strength of this signal.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Karolinska Inst, Ctr Microbiol & Tumor Biol, SE-17177 Stockholm, Sweden; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Karolinska Institutet; University of Toronto	Pawson, T (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.	pawson@mshri.on.ca	Pawson, Tony J/E-4578-2013; Winberg, Gosta/I-5686-2013; Matskova, Liudmila/J-3843-2017; Gish, Gerald D/C-7228-2017; Matskova, Liudmila/AAF-4201-2020	Matskova, Liudmila/0000-0002-3174-1560; Matskova, Liudmila/0000-0002-3174-1560; Winberg, Gosta/0000-0002-3371-4056				BURKHARDT AL, 1992, J VIROL, V66, P5161, DOI 10.1128/JVI.66.8.5161-5167.1992; Caldwell RG, 2000, J VIROL, V74, P1101, DOI 10.1128/JVI.74.3.1101-1113.2000; Caldwell RG, 1998, IMMUNITY, V9, P405, DOI 10.1016/S1074-7613(00)80623-8; Casola S, 2004, NAT IMMUNOL, V5, P317, DOI 10.1038/ni1036; Dawson CW, 2001, VIROLOGY, V289, P192, DOI 10.1006/viro.2001.1142; Dykstra ML, 2001, IMMUNITY, V14, P57, DOI 10.1016/S1074-7613(01)00089-9; Fruehling S, 1998, J VIROL, V72, P7796, DOI 10.1128/JVI.72.10.7796-7806.1998; Fruehling S, 1997, VIROLOGY, V235, P241, DOI 10.1006/viro.1997.8690; Fukuda M, 2005, J VIROL, V79, P8655, DOI 10.1128/JVI.79.13.8655-8660.2005; Greenwald RJ, 2005, ANNU REV IMMUNOL, V23, P515, DOI 10.1146/annurev.immunol.23.021704.115611; HAMILTONDUTOIT SJ, 1992, AM J PATHOL, V140, P1315; HENLE G, 1969, J NATL CANCER I, V43, P1147; Higuchi M, 2001, P NATL ACAD SCI USA, V98, P4675, DOI 10.1073/pnas.081075298; HUTCHCROFT JE, 1994, P NATL ACAD SCI USA, V91, P3260, DOI 10.1073/pnas.91.8.3260; Ikeda A, 2003, J VIROL, V77, P5529, DOI 10.1128/JVI.77.9.5529-5534.2003; Ikeda M, 2000, VIROLOGY, V268, P178, DOI 10.1006/viro.1999.0166; Ikeda M, 2002, VIROLOGY, V300, P153, DOI 10.1006/viro.2002.1562; Ikeda M, 2001, J VIROL, V75, P5711, DOI 10.1128/JVI.75.12.5711-5718.2001; Imai S, 1996, BLOOD, V87, P1446, DOI 10.1182/blood.V87.4.1446.bloodjournal8741446; Imashuku S, 2002, CRIT REV ONCOL HEMAT, V44, P259, DOI 10.1016/S1040-8428(02)00117-8; Ingham RJ, 2004, ONCOGENE, V23, P1972, DOI 10.1038/sj.onc.1207436; Kanegane H, 2002, CRIT REV ONCOL HEMAT, V44, P239, DOI 10.1016/S1040-8428(02)00115-4; Kawa K, 2002, CRIT REV ONCOL HEMAT, V44, P251, DOI 10.1016/S1040-8428(02)00116-6; Labrecque N, 2001, IMMUNITY, V15, P71, DOI 10.1016/S1074-7613(01)00170-4; Lay JD, 2003, J BIOMED SCI, V10, P146, DOI 10.1159/000068077; LONGNECKER R, 1991, J VIROL, V65, P3681, DOI 10.1128/JVI.65.7.3681-3692.1991; LONGNECKER R, 1990, J VIROL, V64, P2319, DOI 10.1128/JVI.64.5.2319-2326.1990; Lynch DT, 2002, J GEN VIROL, V83, P1025, DOI 10.1099/0022-1317-83-5-1025; Matskova L, 2001, J VIROL, V75, P10941, DOI 10.1128/JVI.75.22.10941-10949.2001; MILLER AD, 1991, J VIROL, V65, P2220, DOI 10.1128/JVI.65.5.2220-2224.1991; MILLER CL, 1994, INFECT AGENT DIS, V3, P128; MILLER CL, 1995, IMMUNITY, V2, P155, DOI 10.1016/S1074-7613(95)80040-9; MILLER CL, 1994, P NATL ACAD SCI USA, V91, P772, DOI 10.1073/pnas.91.2.772; MILLER CL, 1993, J VIROL, V67, P3087, DOI 10.1128/JVI.67.6.3087-3094.1993; PEH SC, 1995, INT J CANCER, V61, P327, DOI 10.1002/ijc.2910610309; RAAB M, 1995, P NATL ACAD SCI USA, V92, P8891, DOI 10.1073/pnas.92.19.8891; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; Rickinson A, 2002, VIRUS RES, V82, P109; Seddon B, 2002, J IMMUNOL, V169, P2997, DOI 10.4049/jimmunol.169.6.2997; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Thorley-Lawson DA, 2001, NAT REV IMMUNOL, V1, P75, DOI 10.1038/35095584; vanGorp J, 1996, J CLIN PATHOL, V49, P72, DOI 10.1136/jcp.49.1.72; VANGORP J, 1995, HISTOPATHOLOGY, V27, P139; Wakiguchi H, 2002, CRIT REV ONCOL HEMAT, V44, P193, DOI 10.1016/S1040-8428(02)00111-7; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; Winberg G, 2000, MOL CELL BIOL, V20, P8526, DOI 10.1128/MCB.20.22.8526-8535.2000	46	20	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34133	34142		10.1074/jbc.M507831200	http://dx.doi.org/10.1074/jbc.M507831200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16087662	hybrid			2022-12-25	WOS:000232229700054
J	Kwak, YT; Li, R; Becerra, CR; Tripathy, D; Frenkel, EP; Verma, UN				Kwak, YT; Li, R; Becerra, CR; Tripathy, D; Frenkel, EP; Verma, UN			I kappa B kinase alpha regulates subcellular distribution and turnover of cyclin D1 by phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; DEPENDENT GENE-EXPRESSION; IKK-ALPHA; CELL-CYCLE; MICE LACKING; ACTIVATION; COMPLEX; BETA; PATHWAY; PROTEIN	I kappa B kinases (IKKs), IKK alpha and IKK beta, with a regulatory subunit IKK gamma/NEMO constitute a high molecular weight IKK complex that regulates NF-kappa B activity. Although IKK alpha and IKK beta share structural and biochemical similarities, IKK alpha has been shown to have distinct biological roles. Here we show that IKK alpha plays a critical role in regulating cyclin D1 during the cell cycle. Analysis of IKK alpha(-/-) mouse embryo fibroblast cells showed that cyclin D1 is overexpressed and localized in the nucleus compared with parental mouse embryo fibroblasts. IKK alpha associates with and phosphorylates cyclin D1. Analysis on cyclin D1 mutants demonstrated that IKK alpha phosphorylates cyclin D1 at Thr(286). Reconstitution of IKK alpha in knockout cells leads to nuclear export and increased degradation of cyclin D1. Further, RNAi-mediated knockdown of IKK alpha results in similar changes as observed in IKK alpha(-/-) cells. These results suggest a novel role of IKK alpha in regulating subcellular localization and proteolysis of cyclin D1 by phosphorylation of cyclin D1 at Thr286, the same residue earlier found to be a target for glycogen synthase kinase-3 beta-induced phosphorylation.	Univ Texas SW Med Ctr Dallas, Dept Med, Div Hematol Oncol, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas	Verma, UN (corresponding author), UT SW Med Ctr Dallas, Dept Med, Div Hematol Oncol, Dallas, TX 75390 USA.	udit.verma@utsouthwestern.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041860] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI041860] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Albanese C, 2003, MOL BIOL CELL, V14, P585, DOI 10.1091/mbc.02-06-0101; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bartkova J, 1998, ONCOGENE, V17, P1027, DOI 10.1038/sj.onc.1202016; Benzeno S, 2004, J BIOL CHEM, V279, P56061, DOI 10.1074/jbc.M411910200; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Doglioni C, 1998, J PATHOL, V185, P159, DOI 10.1002/(SICI)1096-9896(199806)185:2<159::AID-PATH73>3.0.CO;2-0; Gao CY, 1997, BIOESSAYS, V19, P307, DOI 10.1002/bies.950190408; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kwak YT, 2003, MOL CELL, V11, P1055, DOI 10.1016/S1097-2765(03)00101-1; Kwak YT, 2000, J BIOL CHEM, V275, P14752, DOI 10.1074/jbc.M001039200; Lamberti C, 2001, J BIOL CHEM, V276, P42276, DOI 10.1074/jbc.M104227200; Lawrence T, 2005, NATURE, V434, P1138, DOI 10.1038/nature03491; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Lu FM, 2003, CANCER RES, V63, P7056; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Murray AW, 2004, CELL, V116, P221, DOI 10.1016/S0092-8674(03)01080-8; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pasparakis M, 2002, J EXP MED, V196, P743, DOI 10.1084/jem.20020907; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Ryves W Jonathan, 2003, Prog Cell Cycle Res, V5, P489; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sil AK, 2004, NATURE, V428, P660, DOI 10.1038/nature02421; Solomon DA, 2003, J BIOL CHEM, V278, P30339, DOI 10.1074/jbc.M303969200; Stacey DW, 2003, CURR OPIN CELL BIOL, V15, P158, DOI 10.1016/S0955-0674(03)00008-5; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; Takada Y, 2004, J BIOL CHEM, V279, P39541, DOI 10.1074/jbc.M403449200; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Verma UN, 2004, J BIOL CHEM, V279, P3509, DOI 10.1074/jbc.M309300200; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Yamamoto Y, 2001, J BIOL CHEM, V276, P36327, DOI 10.1074/jbc.M104090200; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; Zou YL, 2004, J BIOL CHEM, V279, P27790, DOI 10.1074/jbc.M403042200	55	54	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33945	33952		10.1074/jbc.M506206200	http://dx.doi.org/10.1074/jbc.M506206200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16103118	hybrid			2022-12-25	WOS:000232229700031
J	Uwabe, KI; Matsumoto, M; Nagata, K				Uwabe, KI; Matsumoto, M; Nagata, K			Monokine induced by interferon-gamma acts as a neurotrophic factor on PC12 cells and rat primary sympathetic neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; CYCLASE-ACTIVATING POLYPEPTIDE; PROTEIN-COUPLED RECEPTOR; CHEMOKINE RECEPTORS; PHEOCHROMOCYTOMA CELLS; SIGNALING CASCADES; KINASE ACTIVATION; NEURITE OUTGROWTH; TYROSINE KINASE; HIV-1 ENTRY	We found that a monokine induced by interferon-gamma (Mig, CXCL9), which belongs to the CXC chemokine subfamily, acts as a neurotrophic factor on PC12 cells and rat primary sympathetic neurons. PC12 cells were shown to express a single class of high affinity binding sites for Mig ( 670 receptors/cell, K-d = 2.9 nM). Mig induced neurite outgrowth in PC12 cells in a dose-dependent manner. Comparison of extracellular signal-regulated kinase signaling pathways between Mig and nerve growth factor (NGF) revealed that these pathways are crucial for Mig action as well as NGF. K252a, an inhibitor of tyrosine autophosphorylation of tyrosine kinase receptors (Trks) did not inhibit the action of Mig, suggesting that Mig action occurs via a different receptor from that of NGF. Furthermore, Mig as well as NGF promoted PC12 survival under serum-free conditions and activated Akt/protein kinase B downstream from phosphatidylinositol 3-kinase (PI3K). Because the PI3K inhibitor LY294002 prevented the Mig- and NGF-induced survival effect, this effect is probably mediated by the PI3K signaling pathway. Mig also promoted survival of rat primary sympathetic neurons that die when deprived of NGF. These results suggest that chemokines, including Mig ( CXCL9) have neurotrophic effects on the nervous system.	Shionogi & Co Ltd, Discovery Res Labs, Fukushima Ku, Osaka 5530002, Japan	Shionogi & Company Limited	Uwabe, KI (corresponding author), Shionogi & Co Ltd, Discovery Res Labs, Fukushima Ku, 12-4 Sagisu 5 Chome, Osaka 5530002, Japan.	ken-ichiro.uwabe@shionogi.co.jp						Ashcroft M, 1999, ONCOGENE, V18, P4586, DOI 10.1038/sj.onc.1202814; Banisadr G, 2002, J NEUROCHEM, V81, P257, DOI 10.1046/j.1471-4159.2002.00809.x; Barrie AP, 1997, J BIOL CHEM, V272, P19666, DOI 10.1074/jbc.272.32.19666; Bibel M, 2000, GENE DEV, V14, P2919, DOI 10.1101/gad.841400; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Cowell RM, 2003, J COMP NEUROL, V457, P7, DOI 10.1002/cne.10554; De Groot C J, 2001, Prog Brain Res, V132, P533; DECKWERTH TL, 1993, J CELL BIOL, V123, P1207, DOI 10.1083/jcb.123.5.1207; DEUTSCH PJ, 1992, J BIOL CHEM, V267, P5108; FARBER JM, 1993, BIOCHEM BIOPH RES CO, V192, P223, DOI 10.1006/bbrc.1993.1403; Farber JM, 1997, J LEUKOCYTE BIOL, V61, P246, DOI 10.1002/jlb.61.3.246; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Harrison JK, 1998, P NATL ACAD SCI USA, V95, P10896, DOI 10.1073/pnas.95.18.10896; Horuk R, 1997, J IMMUNOL, V158, P2882; Kao SC, 2001, J BIOL CHEM, V276, P18169, DOI 10.1074/jbc.M008870200; Klesse LJ, 1999, ONCOGENE, V18, P2055, DOI 10.1038/sj.onc.1202524; KOUBA M, 1993, FEBS LETT, V321, P173, DOI 10.1016/0014-5793(93)80102-Z; Lahrtz F, 1998, J NEUROIMMUNOL, V85, P33, DOI 10.1016/S0165-5728(97)00267-1; LAMOURY JC, 2003, GLIA, V41, P354; LAW NM, 1994, BIOCHEM BIOPH RES CO, V201, P458, DOI 10.1006/bbrc.1994.1723; LEWIS IC, 2003, J BIOL CHEM, V278, P289; LIAO F, 1995, J EXP MED, V182, P1301, DOI 10.1084/jem.182.5.1301; Liu MT, 2001, J IMMUNOL, V166, P1790, DOI 10.4049/jimmunol.166.3.1790; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; Loetscher M, 1996, J EXP MED, V184, P963, DOI 10.1084/jem.184.3.963; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; Mantovani A, 2001, TRENDS IMMUNOL, V22, P328, DOI 10.1016/S1471-4906(01)01941-X; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Matsumoto T, 1997, J LEUKOCYTE BIOL, V62, P581, DOI 10.1002/jlb.62.5.581; Moser B, 2001, NAT IMMUNOL, V2, P123, DOI 10.1038/84219; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Oestreicher AB, 1997, PROG NEUROBIOL, V53, P627, DOI 10.1016/S0301-0082(97)00043-9; Park MK, 2002, J IMMUNOL, V169, P1433, DOI 10.4049/jimmunol.169.3.1433; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; ROVELLI G, 1993, P NATL ACAD SCI USA, V90, P8717, DOI 10.1073/pnas.90.18.8717; Soejima K, 2001, J IMMUNOL, V167, P6576, DOI 10.4049/jimmunol.167.11.6576; Sorensen TL, 1999, J CLIN INVEST, V103, P807, DOI 10.1172/JCI5150; Stumm RK, 2003, J NEUROSCI, V23, P5123; Vaudry D, 1999, P NATL ACAD SCI USA, V96, P9415, DOI 10.1073/pnas.96.16.9415; Vaudry D, 2002, ANN NY ACAD SCI, V971, P491, DOI 10.1111/j.1749-6632.2002.tb04513.x; Wang XK, 1998, J NEUROCHEM, V71, P1194; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	47	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34268	34277		10.1074/jbc.M502667200	http://dx.doi.org/10.1074/jbc.M502667200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16055446	hybrid			2022-12-25	WOS:000232229700069
J	Anderson, RF; Hille, R; Shinde, SS; Cecchini, G				Anderson, RF; Hille, R; Shinde, SS; Cecchini, G			Electron transfer within complex II - Succinate : Ubiquinone oxidoreductase of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PULSE-RADIOLYSIS; BIOCHEMICAL SYSTEMS; FUMARATE REDUCTASE; DEHYDROGENASE; RADICALS; HEME	Electron transfer within Escherichia coli succinate: ubiquinone oxidoreductase has been examined by the pulse radiolysis technique using spectrophotometric detection. Electrons have been introduced into the protein by the bimolecular reaction with quantified concentrations of the low potential N-methylnicotinamide radical at a rate constant of 7 x 10(8) M-1 s(-1). Two redox-active centers in the protein are initially reduced, assigned as the high potential [3Fe-4S] center and the bound ubiquinone, followed by intramolecular equilibration with the b heme in both cases. Electron equilibration at 25 C from the ubisemiquinone proceeds with an observed rate constant of 7,200 s(-1) and from the more distant [3Fe-4S] reduced center at a rate constant of 1,200 s(-1). Temperature dependence studies have revealed that both reactions have large free energies of activation, with Delta G double dagger values of + 0.53 and + 0.58 eV, respectively. Cumulative spectral changes, as well as accompanying decreases in the rates of intramolecular electron transfer, observed upon adding electrons to progressively reduced protein, indicate that 4 electrons must be introduced into the protein before the heme center is fully reduced. Overall, evidence is presented that the heme, far from being a bystander in the efficient transfer of reducing equivalents from succinate to the ubiquinone via the flavin-Fe/S centers, plays a pivotal role in providing a lower energy pathway for the transfer of an electron from the high potential [3Fe4S] center to ubiquinone.	Univ Auckland, Dept Chem, Auckland 1, New Zealand; Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; Vet Affairs Med Ctr, Div Mol Biol, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of Auckland; University System of Ohio; Ohio State University; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco	Anderson, RF (corresponding author), Univ Auckland, Dept Chem, Private Bag 92019, Auckland 1, New Zealand.	r.anderson@auckland.ac.nz	Shinde, Sambhaji/H-6203-2013	Shinde, Sambhaji/0000-0002-3857-7847	NIGMS NIH HHS [GM61606, GM75036] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM075036, R01GM061606] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson RF, 2000, J BIOL CHEM, V275, P30781, DOI 10.1074/jbc.M001256200; Anderson RF, 1997, J PHYS CHEM A, V101, P9704, DOI 10.1021/jp972311a; ANDERSON RF, 1984, J CHEM SOC FARAD T 1, V80, P2693, DOI 10.1039/f19848002693; Cecchini G, 2002, BBA-BIOENERGETICS, V1553, P140, DOI 10.1016/S0005-2728(01)00238-9; Ding H, 1995, BIOCHEMISTRY-US, V34, P15979, DOI 10.1021/bi00049a012; Hederstedt L, 2002, BBA-BIOENERGETICS, V1553, P74, DOI 10.1016/S0005-2728(01)00231-6; HILLE R, 1991, J BIOL CHEM, V266, P5608; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P3640, DOI 10.1073/pnas.71.9.3640; LAND EJ, 1968, BIOCHIM BIOPHYS ACTA, V162, P327, DOI 10.1016/0005-2728(68)90119-9; LAND EJ, 1971, BIOCHIM BIOPHYS ACTA, V226, P239, DOI 10.1016/0005-2728(71)90091-0; LAND EJ, 1970, J BIOL CHEM, V245, P1890; Maklashina E, 1999, ARCH BIOCHEM BIOPHYS, V369, P223, DOI 10.1006/abbi.1999.1359; Maklashina E, 2001, J BIOL CHEM, V276, P18968, DOI 10.1074/jbc.M011270200; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MARCUS RA, 1964, ANNU REV PHYS CHEM, V15, P155, DOI 10.1146/annurev.pc.15.100164.001103; Moser CC, 1997, J BIOL INORG CHEM, V2, P393, DOI 10.1007/s007750050149; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; MULAZZANI QG, 1986, J PHYS CHEM-US, V90, P5347, DOI 10.1021/j100412a090; Nakamura K, 1996, J BIOL CHEM, V271, P521, DOI 10.1074/jbc.271.1.521; Ohnishi T, 2000, STRUCTURE, V8, pR23, DOI 10.1016/S0969-2126(00)00098-8; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; SCHULER RH, 1980, J PHYS CHEM-US, V84, P2088, DOI 10.1021/j100453a020; Sun F, 2005, CELL, V121, P1043, DOI 10.1016/j.cell.2005.05.025; Winkler JR, 1997, J BIOL INORG CHEM, V2, P399, DOI 10.1007/s007750050150; Yankovskaya V, 2003, SCIENCE, V299, P700, DOI 10.1126/science.1079605; YU L, 1987, J BIOL CHEM, V262, P1137	26	21	21	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33331	33337		10.1074/jbc.M506002200	http://dx.doi.org/10.1074/jbc.M506002200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16085649	hybrid			2022-12-25	WOS:000232058100030
J	Yang, L; Xie, SZ; Jamaluddin, MS; Altuwajiri, S; Ni, J; Kim, E; Chen, YT; Hu, YC; Wang, L; Chuang, KH; Wu, CT; Chang, CS				Yang, L; Xie, SZ; Jamaluddin, MS; Altuwajiri, S; Ni, J; Kim, E; Chen, YT; Hu, YC; Wang, L; Chuang, KH; Wu, CT; Chang, CS			Induction of androgen receptor expression by phosphatidylinositol 3-kinase/Akt downstream substrate, FOXO3a, and their roles in apoptosis of LNCaP prostate cancer cells *	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; GENE PROMOTER; BINDING-SITE; PHOSPHO-AKT; GROWTH; PROLIFERATION; PATHWAY; TRANSACTIVATION; SURVIVAL; DIFFERENTIATION	The phosphatidylinositol 3-kinase (PI3K)/Akt pathway plays important roles for prostate cancer cell survival, and the androgen receptor (AR) plays essential roles for prostate cancer cell proliferation. How these two signals cooperate to control cell growth and death, however, remains unclear and debated. Here we provide the first linkage by the identification of Forkhead transcription factor FOXO3a, the PI3K/Akt downstream substrate, as a positive regulator for the induction of AR gene expression. Both Western blot and real time PCR assays demonstrate that FOXO3a can induce AR expression at the protein and mRNA levels, and gel shift and chromatin immunoprecipitation assays further demonstrate that FOXO3a can induce 5' AR promoter activity via binding to the consensus DNA-binding sequence in the AR 5' promoter - 1290 to - 1297 (5'-TTGTTTCA-3'). Under normal growth conditions, blocking PI3K/Akt signals by LY294002 causes LNCaP cell arrest in G(1) phase rather than apoptosis. However, further blocking of AR functions by AR small interfering RNA leads to dramatic LNCaP cell death, suggesting that AR may play important protective roles when the PI3K/Akt signal pathway is blocked by LY294002. Together, our data provide the first model to explain how PI3K/Akt and AR can cooperate to control LNCaP cell growth and death under normal conditions.	Univ Rochester, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Dept Pathol, Rochester, NY 14642 USA; Univ Rochester, Dept Urol, Rochester, NY 14642 USA; Univ Rochester, Dept Radiat Oncol, Rochester, NY 14642 USA; Univ Rochester, Ctr Canc, Rochester, NY 14642 USA; MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77054 USA; Baylor Coll Med, Dept Med, Sect Atherosclerosis, Houston, TX 77030 USA; Chang Gung Univ & Mem Hosp, Dept Urol, Taipei 105, Taiwan	University of Rochester; University of Rochester; University of Rochester; University of Rochester; University of Rochester; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; Chang Gung University	Chang, CS (corresponding author), Univ Rochester, George Whipple Lab Canc Res, 601 Elmwood Ave, Rochester, NY 14642 USA.	Chang@urmc.rochester.edu	Hu, Yueh-Chiang/AAX-2370-2020	Chang, Chawnshang/0000-0001-8510-3516; Hu, Yueh-Chiang/0000-0002-7992-0525; Chen, Yei-Tsung/0000-0002-3891-5172	NCI NIH HHS [CA55639, CA71870] Funding Source: Medline; NIDDK NIH HHS [DK60948, DK67686] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA071870, R29CA055639, R01CA055639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK067686, R01DK060948] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Altuwaijri S, 2003, CANCER RES, V63, P7106; Ayala G, 2004, CLIN CANCER RES, V10, P6572, DOI 10.1158/1078-0432.CCR-04-0477; Birkenkamp KU, 2003, BIOCHEM SOC T, V31, P292, DOI 10.1042/bst0310292; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; CHANG CS, 1995, CRIT REV EUKAR GENE, V5, P97, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.10; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; Godoy-Tundidor S, 2005, PROSTATE, V64, P209, DOI 10.1002/pros.20235; Heinlein CA, 2002, MOL ENDOCRINOL, V16, P2181, DOI 10.1210/me.2002-0070; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Kau TR, 2003, CANCER CELL, V4, P463, DOI 10.1016/S1535-6108(03)00303-9; Keller ET, 1996, FRONT BIOSCI, V1, pd59, DOI DOI 10.2741/A116; Lee DK, 2003, J CLIN ENDOCR METAB, V88, P4043, DOI 10.1210/jc.2003-030261; Li PF, 2003, MOL CELL BIOL, V23, P104, DOI 10.1128/MCB.23.1.104-118.2003; Liao ZM, 2005, PROSTATE, V64, P186, DOI 10.1002/pros.20224; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Lin HK, 2003, J BIOL CHEM, V278, P50902, DOI 10.1074/jbc.M300676200; Lin HK, 2001, P NATL ACAD SCI USA, V98, P7200, DOI 10.1073/pnas.121173298; Lin JQ, 1999, CANCER RES, V59, P2891; Malik SN, 2002, CLIN CANCER RES, V8, P1168; MIZOKAMI A, 1994, MOL ENDOCRINOL, V8, P77, DOI 10.1210/me.8.1.77; Modur V, 2002, J BIOL CHEM, V277, P47928, DOI 10.1074/jbc.M207509200; Ni J, 2003, BIOCHEM BIOPH RES CO, V300, P357, DOI 10.1016/S0006-291X(02)02851-6; Ren FG, 2000, ONCOGENE, V19, P1924, DOI 10.1038/sj.onc.1203511; Sharma M, 2002, J BIOL CHEM, V277, P30935, DOI 10.1074/jbc.M201919200; Song CS, 1999, MOL ENDOCRINOL, V13, P1487, DOI 10.1210/me.13.9.1487; Takane KK, 1996, MOL CELL ENDOCRINOL, V119, P83, DOI 10.1016/0303-7207(96)03800-2; Thomas D, 2002, IEEE SOFTWARE, V19, P22, DOI 10.1109/MS.2002.1003449; Torring N, 2003, PROSTATE, V56, P142, DOI 10.1002/pros.10245; Truica CI, 2000, CANCER RES, V60, P4709; Wang H, 2004, J BIOL CHEM, V279, P22674, DOI 10.1074/jbc.M401257200; Wang L, 2004, J BIOL CHEM, V279, P32444, DOI 10.1074/jbc.M313963200; Wen Y, 2000, CANCER RES, V60, P6841; Xie SZ, 2004, PROSTATE, V60, P61, DOI 10.1002/pros.20048; Yang L, 2003, J BIOL CHEM, V278, P16820, DOI 10.1074/jbc.M213163200; Yang L, 2003, BIOCHEM BIOPH RES CO, V305, P462, DOI 10.1016/S0006-291X(03)00792-7; Yeh SY, 2003, J EXP MED, V198, P1899, DOI 10.1084/jem.20031233; Zegarra-Moro OL, 2002, CANCER RES, V62, P1008; Zhang LY, 2004, ENDOCRINOLOGY, V145, P781, DOI 10.1210/en.2003-0987	41	109	118	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33558	33565		10.1074/jbc.M504461200	http://dx.doi.org/10.1074/jbc.M504461200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16061480	hybrid			2022-12-25	WOS:000232058100056
J	Bayrer, JR; Zhang, W; Weiss, MA				Bayrer, JR; Zhang, W; Weiss, MA			Dimerization of doublesex is mediated by a cryptic ubiquitin-associated domain fold - Implications for sex-specific gene regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; DROSOPHILA-MELANOGASTER; TRANSCRIPTION-FACTOR; PROTEIN MODELS; UBA DOMAINS; C-CBL; DIFFERENTIATION; OLIGOMERIZATION; INTERSEX; ENHANCER	Male- and female-specific isoforms of the Doublesex (DSX) transcription factor regulate somatic sexual differentiation in Drosophila. The isoforms (DSXM and DSXF) share an N-terminal DNA-binding domain ( the DM motif), broadly conserved among metazoan sex-determining pathways. DM-DNA recognition is enhanced by a C-terminal dimerization domain. The crystal structure of this domain, determined at a resolution of 1.6 angstrom, reveals a novel dimeric arrangement of ubiquitin-associated (UBA) folds. Although this alpha-helical motif is well characterized in pathways of DNA repair and subcellular trafficking, to our knowledge this is its first report in a transcription factor. Dimerization is mediated by a non-canonical hydrophobic interface extrinsic to the putative ubiquitin binding surface. Key side chains at this interface, identified by alanine scanning mutagenesis, are conserved among DSX homologs. The mechanism of dimerization is thus unrelated to the low affinity domain swapping observed among ubiquitin-associated CUE domains. The unexpected observation of a ubiquitin-associated fold in DSX extends the repertoire of alpha-helical dimerization elements in transcription factors. The possibility that the ubiquitination machinery participates in the regulation of sexual dimorphism is discussed.	Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA	Case Western Reserve University	Weiss, MA (corresponding author), Case Western Reserve Univ, Sch Med, Dept Biochem, 10900 Euclid Ave, Cleveland, OH 44106 USA.	michael.weiss@case.edu	zhang, wei/A-7015-2011		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007250] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32 GM07250] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AN WQ, 1995, EMBO J, V14, P1221, DOI 10.1002/j.1460-2075.1995.tb07105.x; An WQ, 1996, MOL CELL BIOL, V16, P3106; AN WQ, 1995, GENE DEV, V9, P256, DOI 10.1101/gad.9.2.256; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Bayrer J, 2004, ACTA CRYSTALLOGR D, V60, P1328, DOI 10.1107/S0907444904012223; Bertolaet BL, 2001, J MOL BIOL, V313, P955, DOI 10.1006/jmbi.2001.5105; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURTIS KC, 1989, CELL, V56, P997, DOI 10.1016/0092-8674(89)90633-8; Burtis KC, 1993, CURR OPIN CELL BIOL, V5, P1006, DOI 10.1016/0955-0674(93)90085-5; Calkhoven CF, 1996, BIOCHEM J, V317, P329, DOI 10.1042/bj3170329; Cavey JR, 2005, J BONE MINER RES, V20, P619, DOI 10.1359/JBMR.041205; Cho S, 1997, J BIOL CHEM, V272, P3185, DOI 10.1074/jbc.272.6.3185; Cho S, 1998, BIOCHEMISTRY-US, V37, P11301, DOI 10.1021/bi972916x; Cline TW, 1996, ANNU REV GENET, V30, P637, DOI 10.1146/annurev.genet.30.1.637; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; COSCHIGANO KT, 1993, GENE DEV, V7, P42, DOI 10.1101/gad.7.1.42; Davies GC, 2004, ONCOGENE, V23, P7104, DOI 10.1038/sj.onc.1207952; DeLano WL, 2002, PYMOL USERS MANUAL; Erdman SE, 1996, GENETICS, V144, P1639; ERDMAN SE, 1993, EMBO J, V12, P527, DOI 10.1002/j.1460-2075.1993.tb05684.x; Garrett-Engele CM, 2002, DEVELOPMENT, V129, P4661; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaiser P, 2000, CELL, V102, P303, DOI 10.1016/S0092-8674(00)00036-2; Kang RS, 2003, CELL, V113, P621, DOI 10.1016/S0092-8674(03)00362-3; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; Liu J, 2003, J BIOL CHEM, V278, P36754, DOI 10.1074/jbc.M300664200; Mueller TD, 2004, J BIOL CHEM, V279, P11926, DOI 10.1074/jbc.M312865200; Muratani M, 2005, CELL, V120, P887, DOI 10.1016/j.cell.2004.12.025; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Narayana N, 2001, J MOL BIOL, V310, P635, DOI 10.1006/jmbi.2001.4780; Narendra U, 2002, J BIOL CHEM, V277, P43463, DOI 10.1074/jbc.M204616200; NOTHIGER R, 1987, GENET RES, V50, P113, DOI 10.1017/S001667230002351X; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; Prag G, 2003, CELL, V113, P609, DOI 10.1016/S0092-8674(03)00364-7; Rape M, 2001, CELL, V107, P667, DOI 10.1016/S0092-8674(01)00595-5; Raymond CS, 1998, NATURE, V391, P691, DOI 10.1038/35618; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Sato S, 2003, J BIOL CHEM, V278, P49671, DOI 10.1074/jbc.C300444200; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; van den Akker F, 1999, ACTA CRYSTALLOGR D, V55, P206, DOI 10.1107/S0907444998007161; Waterbury JA, 1999, GENETICS, V152, P1653; ZHU BY, 1993, PROTEIN SCI, V2, P383; Zhu LY, 2000, GENE DEV, V14, P1750	46	40	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32989	32996		10.1074/jbc.M507990200	http://dx.doi.org/10.1074/jbc.M507990200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16049008	hybrid			2022-12-25	WOS:000231920300053
J	Chen, FH; Thomas, AO; Hecht, JT; Goldring, MB; Lawler, J				Chen, FH; Thomas, AO; Hecht, JT; Goldring, MB; Lawler, J			Cartilage oligomeric matrix protein/thrombospondin 5 supports chondrocyte attachment through interaction with integrins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGOMERIC MATRIX PROTEIN; MULTIPLE EPIPHYSEAL DYSPLASIA; HUMAN ARTICULAR-CARTILAGE; ALPHA-5-BETA-1 INTEGRIN; GENE-EXPRESSION; COMP; MUTATIONS; CALCIUM; PSEUDOACHONDROPLASIA; COLLAGEN	Cartilage oligomeric matrix protein/ thrombospondin 5 ( COMP/ TSP5) is a major component of the extracellular matrix of the musculoskeletal system. Although COMP/ TSP5 abnormalities are associated with several pathological conditions, its normal function remains unclear. This study was undertaken to delineate the function( s) of COMP/ TSP5 in cartilage, especially regarding its interaction with chondrocytes. We show that COMP/ TSP5 can support chondrocyte attachment and that the RGD sequence in COMP/ TSP5 and the integrin receptors alpha 5 beta 1 and alpha V beta 3 on the chondrocytes are involved in mediating this attachment. The interactions of COMP/ TSP5 with the integrins are dependent on COMP/ TSP5 conformation. Chondrocyte attachment to COMP/ TSP5 in the calcium- replete conformation was inhibited by function- blocking integrin alpha 5 and beta 1 antibodies, suggesting the involvement of the alpha 5 beta 1 integrin. Under this condition, a function- blocking antibody against alpha V beta 3 did not have any effect on cell attachment. On the other hand, chondrocyte attachment to reduced COMP/ TSP5 was instead sensitive to alpha V beta 3 function- blocking antibodies, suggesting that COMP/ TSP5 mediates attachment through chondrocyte alpha V beta 3 integrin under this condition. Cell attachment to reduced COMP/ TSP5 was not inhibited by beta 1 antibodies. These data indicate that COMP/ TSP5 in different conformations can utilize different integrin receptors. These results are the first to demonstrate that COMP/ TSP5 can mediate chondrocyte attachment through interactions with integrins. Through these interactions, COMP/ TSP5 may be able to regulate cellular activities and respond to environment in the surrounding cartilage matrix.	Columbia Univ, Dept Orthopaed Surg, New York, NY 10032 USA; Univ Texas, Sch Med, Dept Pediat, Houston, TX 77225 USA; Shriners Hosp Children, Houston, TX 77225 USA; Beth Israel Deaconess Med Ctr, Div Rheumatol, Dept Med, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Pathol, Div Tumor Biol & Angiogenesis, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Columbia University; University of Texas System; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Chen, FH (corresponding author), Columbia Univ, Dept Orthopaed Surg, New York, NY 10032 USA.	chenf1@mail.nih.gov			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049081] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG022021, R56AG022021] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL049081, R01 HL049081-12, R01 HL049081-07, R01 HL049081-08, R01 HL049081-13, R01 HL049081-10, R01 HL049081-09, R01 HL049081-11] Funding Source: Medline; NIA NIH HHS [R56 AG022021, R01 AG022021] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adams JC, 2001, ANNU REV CELL DEV BI, V17, P25, DOI 10.1146/annurev.cellbio.17.1.25; Attur MG, 2000, J IMMUNOL, V164, P2684, DOI 10.4049/jimmunol.164.5.2684; Bornstein P, 2002, CURR OPIN CELL BIOL, V14, P608, DOI 10.1016/S0955-0674(02)00361-7; Bornstein P, 2001, J CLIN INVEST, V107, P929, DOI 10.1172/JCI12749; BRIGGS MD, 1995, NAT GENET, V10, P330, DOI 10.1038/ng0795-330; Chen H, 2000, J BIOL CHEM, V275, P26538, DOI 10.1074/jbc.M909780199; CHEN H, 1994, J BIOL CHEM, V269, P32226; Chen H, 2000, MATRIX BIOL, V19, P597, DOI 10.1016/S0945-053X(00)00107-4; CLEMMENSEN I, 1982, HISTOCHEMISTRY, V76, P51, DOI 10.1007/BF00493284; Deere M, 1998, AM J MED GENET, V80, P510, DOI 10.1002/(SICI)1096-8628(19981228)80:5<510::AID-AJMG14>3.0.CO;2-F; Di Cesare PE, 2000, J ORTHOPAED RES, V18, P713, DOI 10.1002/jor.1100180506; Di Cesare PE, 2002, MATRIX BIOL, V21, P461, DOI 10.1016/S0945-053X(02)00015-X; DICESARE P, 1994, FEBS LETT, V354, P237, DOI 10.1016/0014-5793(94)01134-6; DiCesare PE, 1996, J ORTHOPAED RES, V14, P946, DOI 10.1002/jor.1100140615; DICESARE PE, 1995, J ORTHOPAED RES, V13, P422, DOI 10.1002/jor.1100130316; DICESARE PE, 1994, EUR J BIOCHEM, V223, P927, DOI 10.1111/j.1432-1033.1994.tb19070.x; DiCesare PE, 1997, FEBS LETT, V412, P249, DOI 10.1016/S0014-5793(97)00789-8; Dodge GR, 1998, OSTEOARTHR CARTILAGE, V6, P435, DOI 10.1053/joca.1998.0147; DURR J, 1993, EXP CELL RES, V207, P235, DOI 10.1006/excr.1993.1189; Finger F, 2003, ARTHRITIS RHEUM-US, V48, P3395, DOI 10.1002/art.11341; GOLDRING MB, 1994, J CLIN INVEST, V94, P2307, DOI 10.1172/JCI117595; Hauser N, 1995, ACTA ORTHOP SCAND, V66, P71, DOI 10.3109/17453679509157651; Hausler G, 2002, CALCIFIED TISSUE INT, V71, P212, DOI 10.1007/s00223-001-2083-x; Hecht JT, 1998, MATRIX BIOL, V17, P269, DOI 10.1016/S0945-053X(98)90080-4; HECHT JT, 1995, NAT GENET, V10, P325, DOI 10.1038/ng0795-325; HEDBOM E, 1992, J BIOL CHEM, V267, P6132; Holden P, 2001, J BIOL CHEM, V276, P6046, DOI 10.1074/jbc.M009507200; Kipnes J, 2003, OSTEOARTHR CARTILAGE, V11, P442, DOI 10.1016/S1063-4584(03)00055-4; Kokenyesi R, 2000, ARCH BIOCHEM BIOPHYS, V383, P79, DOI 10.1006/abbi.2000.2044; Kvansakul M, 2004, EMBO J, V23, P1223, DOI 10.1038/sj.emboj.7600166; Lawler J, 2000, CURR OPIN CELL BIOL, V12, P634, DOI 10.1016/S0955-0674(00)00143-5; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LAWLER J, 2002, ENCY MOL MED, P481; Lee HS, 2000, J BONE MINER RES, V15, P1501, DOI 10.1359/jbmr.2000.15.8.1501; Loeser RF, 2002, BIORHEOLOGY, V39, P119; LOESER RF, 1993, ARTHRITIS RHEUM, V36, P1103, DOI 10.1002/art.1780360811; Loeser RF, 2000, BIORHEOLOGY, V37, P109; Ma SU, 1998, ANN NY ACAD SCI, V857, P241, DOI 10.1111/j.1749-6632.1998.tb10122.x; Millward-Sadler SJ, 2000, ARTHRITIS RHEUM, V43, P2091, DOI 10.1002/1529-0131(200009)43:9<2091::AID-ANR21>3.0.CO;2-C; Millward-Sadler SJ, 1999, J CELL BIOL, V145, P183, DOI 10.1083/jcb.145.1.183; Millward-Sadler SJ, 2000, OSTEOARTHR CARTILAGE, V8, P272, DOI 10.1053/joca.1999.0301; Murphy JM, 1999, MATRIX BIOL, V18, P487, DOI 10.1016/S0945-053X(99)00042-6; Neidhart M, 1997, BRIT J RHEUMATOL, V36, P1151; NEWTON G, 1994, GENOMICS, V24, P435, DOI 10.1006/geno.1994.1649; OLDBERG A, 1992, J BIOL CHEM, V267, P22346; Petersson IF, 1998, BRIT J RHEUMATOL, V37, P46; Rosenberg K, 1998, J BIOL CHEM, V273, P20397, DOI 10.1074/jbc.273.32.20397; SALTER DM, 1992, BRIT J RHEUMATOL, V31, P231; Salter DM, 2002, BIORHEOLOGY, V39, P97; SALTER DM, 1995, J HISTOCHEM CYTOCHEM, V43, P447, DOI 10.1177/43.4.7897185; Salter DM, 2001, CLIN ORTHOP RELAT R, pS49; Shakibaei M, 1998, EXP CELL RES, V240, P95, DOI 10.1006/excr.1998.3933; Smith RKW, 1997, MATRIX BIOL, V16, P255, DOI 10.1016/S0945-053X(97)90014-7; SOMMARIN Y, 1989, EXP CELL RES, V184, P181, DOI 10.1016/0014-4827(89)90376-5; SUN X, 1992, J CELL BIOL, V118, P693, DOI 10.1083/jcb.118.3.693; Thur J, 2001, J BIOL CHEM, V276, P6083, DOI 10.1074/jbc.M009512200; WOODS VL, 1994, ARTHRITIS RHEUM, V37, P537, DOI 10.1002/art.1780370414; Wright MO, 1997, J ORTHOPAED RES, V15, P742, DOI 10.1002/jor.1100150517	58	104	111	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32655	32661		10.1074/jbc.M504778200	http://dx.doi.org/10.1074/jbc.M504778200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16051604	hybrid, Green Accepted			2022-12-25	WOS:000231920300014
J	Shimada, M; Namikawa-Yamada, C; Nakanishi, M; Murakami, H				Shimada, M; Namikawa-Yamada, C; Nakanishi, M; Murakami, H			Regulation of Cdc2p and Cdc13p is required for cell cycle arrest induced by defective RNA splicing in fission yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; DNA-REPLICATION; S-PHASE; MUTANTS; GENE; CHECKPOINT; MITOSIS; PROTEIN	Screening of cdc mutants of fission yeast for those whose cell cycle arrest is independent of the DNA damage checkpoint identified the RNA splicing- deficient cdc28 mutant. A search for mutants of cdc28 cells that enter mitosis with unspliced RNA resulted in the identification of an orb5 point mutant. The orb5(+) gene, which encodes a catalytic subunit of casein kinase II, was found to be required for cell cycle arrest in other mutants with defective RNA metabolism but not for operation of the DNA replication or DNA damage checkpoints. Loss of function of wee1(+) or rad24(+) also suppressed the arrest of several splicing mutants. Overexpression of the major B- type cyclin Cdc13p induced cdc28 cells to enter mitosis. The abundance of Cdc13p was reduced, and the phosphorylation of Cdc2p on tyrosine 15 was maintained in splicing- defective cells. These results suggest that regulation of Cdc13p and Cdc2p is required for G(2) arrest in splicing mutants.	Nagoya City Univ, Grad Sch Med, Dept Biochem & Cell Biol, Mizuho Ku, Nagoya, Aichi 4678601, Japan	Nagoya City University	Murakami, H (corresponding author), Nagoya City Univ, Grad Sch Med, Dept Biochem & Cell Biol, Mizuho Ku, 1 Kawasumi, Nagoya, Aichi 4678601, Japan.	hmura@med.nagoya-cu.ac.jp						Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Bernstein HS, 1998, J BIOL CHEM, V273, P4666, DOI 10.1074/jbc.273.8.4666; Berry LD, 1997, J CELL BIOL, V137, P1337, DOI 10.1083/jcb.137.6.1337; Brow DA, 2002, ANNU REV GENET, V36, P333, DOI 10.1146/annurev.genet.36.043002.091635; Burns CG, 2002, MOL CELL BIOL, V22, P801, DOI 10.1128/MCB.22.3.801-815.2002; Dahan O, 2002, NUCLEIC ACIDS RES, V30, P4361, DOI 10.1093/nar/gkf563; Elder RT, 2001, VIROLOGY, V287, P359, DOI 10.1006/viro.2001.1007; Gottesfeld JM, 1997, TRENDS BIOCHEM SCI, V22, P197, DOI 10.1016/S0968-0004(97)01045-1; Habara Y, 2001, RNA, V7, P671, DOI 10.1017/S1355838201001200; HAYLES J, 1995, EMBO J, V14, P2760, DOI 10.1002/j.1460-2075.1995.tb07276.x; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; JOHNSTON LH, 1982, MOL GEN GENET, V186, P439, DOI 10.1007/BF00729466; Kellogg DR, 2003, J CELL SCI, V116, P4883, DOI 10.1242/jcs.00908; Lew DJ, 2003, CURR OPIN CELL BIOL, V15, P648, DOI 10.1016/j.ceb.2003.09.001; Lundgren K, 1996, MOL BIOL CELL, V7, P1083, DOI 10.1091/mbc.7.7.1083; MACNEILL SA, 1997, MOL CELLULAR BIOL YE, P697; Masuda M, 2000, J VIROL, V74, P2636, DOI 10.1128/JVI.74.6.2636-2646.2000; McDonald WH, 1999, MOL CELL BIOL, V19, P5352; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Murakami H, 1999, GENE DEV, V13, P2581, DOI 10.1101/gad.13.19.2581; Murakami H, 2000, BIOCHEM J, V349, P1, DOI 10.1042/0264-6021:3490001; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; Nam K, 1997, MOL CELL BIOL, V17, P809, DOI 10.1128/MCB.17.2.809; NASMYTH KA, 1977, CELL, V12, P1109, DOI 10.1016/0092-8674(77)90173-8; NURSE P, 1975, NATURE, V256, P547, DOI 10.1038/256547a0; Ohi R, 1998, MOL CELL BIOL, V18, P4097, DOI 10.1128/MCB.18.7.4097; OHI R, 1994, EMBO J, V13, P471, DOI 10.1002/j.1460-2075.1994.tb06282.x; Okamoto Y, 1998, BIOCHEM BIOPH RES CO, V249, P872, DOI 10.1006/bbrc.1998.9247; OKAZAKI K, 1990, NUCLEIC ACIDS RES, V18, P6485, DOI 10.1093/nar/18.22.6485; Potashkin J, 1998, CURR GENET, V34, P153, DOI 10.1007/s002940050381; ROUSSOU I, 1994, MOL CELL BIOL, V14, P576, DOI 10.1128/MCB.14.1.576; Rowley R, 1996, INT J RADIAT BIOL, V69, P565, DOI 10.1080/095530096145571; Russell P, 1998, TRENDS BIOCHEM SCI, V23, P399, DOI 10.1016/S0968-0004(98)01291-2; Seghezzi W, 1998, MOL CELL BIOL, V18, P4526, DOI 10.1128/MCB.18.8.4526; Shin CS, 2002, CELL, V111, P407, DOI 10.1016/S0092-8674(02)01038-3; SNELL V, 1994, EMBO J, V13, P2066, DOI 10.1002/j.1460-2075.1994.tb06481.x; Sun XJ, 2004, J BIOL CHEM, V279, P32839, DOI 10.1074/jbc.M402522200; Suzuki M, 2004, NAT CELL BIOL, V6, P861, DOI 10.1038/ncb1162; Tanaka K, 2000, MOL CELL BIOL, V20, P3459, DOI 10.1128/MCB.20.10.3459-3469.2000; Urushiyama S, 1996, MOL GEN GENET, V253, P118, DOI 10.1007/s004380050304; VAISMAN N, 1995, MOL GEN GENET, V247, P123, DOI 10.1007/BF00705642; VIJAYRAGHAVAN U, 1989, GENE DEV, V3, P1206, DOI 10.1101/gad.3.8.1206; Wood V, 2002, NATURE, V415, P871, DOI 10.1038/nature724	44	5	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32640	32648		10.1074/jbc.M504746200	http://dx.doi.org/10.1074/jbc.M504746200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16049013	hybrid			2022-12-25	WOS:000231920300012
J	Annicotte, JS; Chavey, C; Servant, N; Teyssier, J; Bardin, A; Licznar, A; Badia, E; Pujol, P; Vignon, F; Maudelonde, T; Lazennec, G; Cavailles, V; Fajas, L				Annicotte, JS; Chavey, C; Servant, N; Teyssier, J; Bardin, A; Licznar, A; Badia, E; Pujol, P; Vignon, F; Maudelonde, T; Lazennec, G; Cavailles, V; Fajas, L			The nuclear receptor liver receptor homolog-1 is an estrogen receptor target gene	ONCOGENE			English	Article						breast cancer; E2; estrogen receptor; Ftz-F1; LRH-1; nuclear receptors; transcription	CYCLIN D1; BREAST-CANCER; INDEPENDENT ACTIVATION; REGULATES EXPRESSION; LRH-1; ELEMENT; PROLIFERATION; RECRUITMENT; PROGRESSION; AROMATASE	Liver receptor homolog-1 (LRH-1) is a nuclear receptor previously known to have distinct functions during mouse development and essential roles in cholesterol homeostasis. Recently, a new role for LRH-1 has been discovered in tumor progression, giving LRH-1 potential transforming functions. In order to identify critical factors stimulating LRH-1 expression leading to deregulated cellular proliferation, we studied its expression and its regulation in several breast cancer cell lines. We observed that LRH-1 expression was increased in estrogen receptor (ER) alpha expressing cell lines, whereas weak-to-no expression was found in nonexpressing ER alpha cell lines. In MCF7, LRH-1 expression was highly induced after treatment with 17 beta-estradiol (E2). This transcriptional regulation was the result of a direct binding of the ER to the LRH-1 promoter, as demonstrated by gelshift and chromatin immunoprecipitation assays. Interestingly, siRNA-mediated inactivation of LRH-1 decreased the E2-dependent proliferation of MCF7 cells. Finally, LRH-1 protein expression was detected by immunohistochemistry in tumor cells of human mammary ductal carcinomas. Altogether, these data demonstrate that LRH-1 is transcriptionally regulated by the ER a and reinforce the hypothesis that LRH-1 could exert potential oncogenic effects during breast cancer formation.	INSERM, Equipe Avenir, U540, F-34090 Montpellier, France; INSERM, Equipe Avenir, F-34090 Montpellier, France; CHU Arnaud Villeneuve, Biol Cellulaire Lab, F-34090 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; CHU de Montpellier	Fajas, L (corresponding author), INSERM, Equipe Avenir, U540, 60 Rue Navacelles, F-34090 Montpellier, France.	fajas@montp.inserm.fr	cavailles, vincent/C-6277-2017; Coll, Lluis Fajas/C-8567-2014; Annicotte, Jean-Sébastien/H-4641-2018; Cavailles, Vincent/Y-5379-2019	Annicotte, Jean-Sébastien/0000-0002-2109-4849; Cavailles, Vincent/0000-0002-7160-3074; Lazennec, Gwendal/0000-0002-8522-1763; Fajas, Lluis/0000-0002-1283-9503; BADIA, Eric/0000-0002-8922-9834; Chavey, Carine/0000-0002-5267-5638				Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; Annicotte JS, 2003, MOL CELL BIOL, V23, P6713, DOI 10.1128/MCB.23.19.6713-6724.2003; Bardin A, 2004, ENDOCR-RELAT CANCER, V11, P537, DOI 10.1677/erc.1.00800; Botrugno OA, 2004, MOL CELL, V15, P499, DOI 10.1016/j.molcel.2004.07.009; Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050; Castro-Rivera E, 2001, J BIOL CHEM, V276, P30853, DOI 10.1074/jbc.M103339200; Cicatiello L, 2004, MOL CELL BIOL, V24, P7260, DOI 10.1128/MCB.24.16.7260-7274.2004; Clyne CD, 2002, J BIOL CHEM, V277, P20591, DOI 10.1074/jbc.M201117200; Falender AE, 2003, ENDOCRINOLOGY, V144, P3598, DOI 10.1210/en.2002-0137; Fayard E, 2004, TRENDS CELL BIOL, V14, P250, DOI 10.1016/j.tcb.2004.03.008; Hinshelwood MM, 2003, MOL CELL ENDOCRINOL, V207, P39, DOI 10.1016/S0303-7207(03)00257-0; Krylova IN, 2005, CELL, V120, P343, DOI 10.1016/j.cell.2005.01.024; Lazennec G, 2001, ENDOCRINOLOGY, V142, P4120, DOI 10.1210/en.142.9.4120; McMahon C, 1999, P NATL ACAD SCI USA, V96, P5382, DOI 10.1073/pnas.96.10.5382; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Pare JF, 2004, J BIOL CHEM, V279, P21206, DOI 10.1074/jbc.M401523200; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; Sabbah M, 1999, P NATL ACAD SCI USA, V96, P11217, DOI 10.1073/pnas.96.20.11217; Sablin EP, 2003, MOL CELL, V11, P1575, DOI 10.1016/S1097-2765(03)00236-3; SCHOONJANS K, 2005, P NATL ACAD SCI US; Zhou J, 2005, CANCER RES, V65, P657; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6; Zwijsen RML, 1998, GENE DEV, V12, P3488, DOI 10.1101/gad.12.22.3488	24	81	87	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2005	24	55					8167	8175		10.1038/sj.onc.1208950	http://dx.doi.org/10.1038/sj.onc.1208950			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	991JL	16091743	Green Accepted, Green Submitted			2022-12-25	WOS:000233809400008
J	Gomez-Bougie, P; Oliver, L; Le Gouill, S; Bataille, R; Amiot, M				Gomez-Bougie, P; Oliver, L; Le Gouill, S; Bataille, R; Amiot, M			Melphalan-induced apoptosis in multiple myeloma cells is associated with a cleavage of Mcl-1 and Bim and a decrease in the Mcl-1/Bim complex	ONCOGENE			English	Article						multiple myeloma; melphalan; Mcl-1; Bcl-2; BH3-only Bim	BCL-2 FAMILY; SURVIVAL; PROTEIN; DEATH; MITOCHONDRIA; AMPLIFICATION; BCL-X(L); MOLECULE	Multiple myeloma ( MM) is a rapidly fatal plasma-cell malignancy that evolves mainly in the bone marrow. Melphalan is widely used to treat patients with MM but as yet its mechanisms of action are poorly documented. In the current study, we demonstrate that melphalan induces a drastic downregulation of Mcl-1L, Bcl-x(L) and BimEL in human melphalan-sensitive myeloma cells while the most potent proapoptotic isoforms, BimL and S, are affected to a lesser extent. Moreover, Mcl-1L and BimEL disappearance is associated with the generation of proapoptotic cleaved forms generated by a caspase cleavage. In myeloma cells, we have previously shown that Mcl-1 neutralizes the proapoptotic function of Bim and therefore, prevents the activation of death effectors. In this study, we demonstrate that melphalan disrupts the Mcl-1/Bim complex whereas the Bcl-2/Bim complex is not modified. The disappearance of full length Mcl-1 allows the release of Bim isoforms, particularly L and S, which can exert their proapoptotic function and leads to Bax activation and cytochrome c release. Thus, we can hypothesize that the cleaved 26 kDa proapoptotic Mcl-1 and the 19 and 12 kDa of Bim, generated during melphalan treatment could contribute to the amplification loop of apoptosis.	INSERM, UMR601, Dept Rech Cancerol, Equipe 5 Labelisee,Inst Biol, F-44093 Nantes, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Amiot, M (corresponding author), INSERM, UMR601, Dept Rech Cancerol, Equipe 5 Labelisee,Inst Biol, LNC 2005,9 Quai Moncousu, F-44093 Nantes, France.	mamiot@nantes.inserm.fr	Oliver, Lisa J/L-3070-2015; Amiot, Martine/K-9076-2015	Oliver, Lisa J/0000-0002-5588-7564; le gouill, steven/0000-0001-9840-2128; Amiot, Martine/0000-0003-0428-7355; Gomez Bougie, Patricia/0000-0002-4846-4782				Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Chen D, 2004, P NATL ACAD SCI USA, V101, P1235, DOI 10.1073/pnas.0308050100; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Craig RW, 2002, LEUKEMIA, V16, P444, DOI 10.1038/sj.leu.2402416; Degterev A, 2001, NAT CELL BIOL, V3, P173, DOI 10.1038/35055085; Derenne S, 2002, BLOOD, V100, P194, DOI 10.1182/blood.V100.1.194; Gomez-Bougie P, 2004, EUR J IMMUNOL, V34, P3156, DOI 10.1002/eji.200424981; Gomez-Bougie P, 2005, EUR J IMMUNOL, V35, P971, DOI 10.1002/eji.200425878; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Herrant M, 2004, ONCOGENE, V23, P7863, DOI 10.1038/sj.onc.1208069; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Jourdan M, 2003, ONCOGENE, V22, P2950, DOI 10.1038/sj.onc.1206423; Michels J, 2004, ONCOGENE, V23, P4818, DOI 10.1038/sj.onc.1207648; Michels J, 2005, INT J BIOCHEM CELL B, V37, P267, DOI 10.1016/j.biocel.2004.04.007; Moreau P, 2002, BLOOD, V99, P731, DOI 10.1182/blood.V99.3.731; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Oliver L, 2000, FEBS LETT, V487, P161, DOI 10.1016/S0014-5793(00)02330-9; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Pei XY, 2003, LEUKEMIA, V17, P2036, DOI 10.1038/sj.leu.2403109; Schmelz K, 2004, ONCOGENE, V23, P6743, DOI 10.1038/sj.onc.1207848; Snowden RT, 2003, LEUKEMIA, V17, P1981, DOI 10.1038/sj.leu.2403088; Tzung SP, 2001, NAT CELL BIOL, V3, P183, DOI 10.1038/35055095; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; Zhang B, 2002, BLOOD, V99, P1885, DOI 10.1182/blood.V99.6.1885; Zhu YN, 2004, P NATL ACAD SCI USA, V101, P7681, DOI 10.1073/pnas.0402293101	27	56	58	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2005	24	54					8076	8079		10.1038/sj.onc.1208949	http://dx.doi.org/10.1038/sj.onc.1208949			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	989EV	16091744				2022-12-25	WOS:000233656600013
J	Laudon, H; Hansson, EM; Melen, K; Bergman, A; Farmery, MR; Winblad, B; Lendahl, U; von Heijne, G; Naslund, J				Laudon, H; Hansson, EM; Melen, K; Bergman, A; Farmery, MR; Winblad, B; Lendahl, U; von Heijne, G; Naslund, J			A nine-transmembrane domain topology for presenilin 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL PEPTIDE PEPTIDASE; GAMMA-SECRETASE COMPLEX; C-TERMINUS; PROTEIN TOPOLOGY; INTRAMEMBRANE PROTEOLYSIS; CAENORHABDITIS-ELEGANS; MEMBRANE TOPOLOGY; PRECURSOR PROTEIN; APH-1 INTERACTS; CELL-SURFACE	Presenilin ( PS) provides the catalytic core of the gamma- secretase complex. gamma- Secretase activity leads to generation of the amyloid beta- peptide, a key event implicated in the pathogenesis of Alzheimer disease. PS has ten hydrophobic regions, which can all theoretically form membrane- spanning domains. Various topology models have been proposed, and the prevalent view holds that PS has an eight-transmembrane ( TM) domain organization; however, the precise topology has not been unequivocally determined. Previous topological studies are based on non- functional truncated variants of PS proteins fused to reporter domains, or immunocytochemical staining. In this study, we used a more subtle N- linked glycosylation scanning approach, which allowed us to assess the topology of functional PS1 molecules. Glycosylation acceptor sequences were introduced into full- length human PS1, and the results showed that the first hydrophilic loop is oriented toward the lumen of the endoplasmic reticulum, whereas the N terminus and large hydrophilic loop are in the cytosol. Although this is in accordance with most current models, our data unexpectedly revealed that the C terminus localized to the luminal side of the endoplasmic reticulum. Additional studies on the glycosylation pattern after TM domain deletions, combined with computer- based TM protein topology predictions and biotinylation assays of different PS1 mutants, led us to conclude that PS1 has nine TM domains and that the C terminus locates to the lumen/ extracellular space.	Karolinska Inst, Novum, Dept Neurotec, Div Expt Geriatr, SE-14186 Huddinge, Sweden; Karolinska Inst, Med Nobel Inst, Dept Cell & Mol Biol, SE-17177 Stockholm, Sweden; Stockholm Univ, Stockholm Bioinformat Ctr, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Stockholm University	Laudon, H (corresponding author), Karolinska Inst, Novum, Dept Neurotec, Div Expt Geriatr, SE-14186 Huddinge, Sweden.	Hanna.Laudon@neurotec.ki.se	von Heijne, Gunnar/AAH-9389-2019; von Heijne, Gunnar/F-5576-2011	von Heijne, Gunnar/0000-0002-4490-8569; Lendahl, Urban/0000-0001-9543-8141				Annaert WG, 2001, NEURON, V32, P579, DOI 10.1016/S0896-6273(01)00512-8; Bergman A, 2004, J BIOL CHEM, V279, P45564, DOI 10.1074/jbc.M407717200; Bergman A, 2004, J BIOL CHEM, V279, P16744, DOI 10.1074/jbc.M313999200; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Buxbaum JD, 1998, NAT MED, V4, P1177, DOI 10.1038/2673; Chyung JH, 2005, J BIOL CHEM, V280, P4383, DOI 10.1074/jbc.M409272200; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Dewji NN, 1997, P NATL ACAD SCI USA, V94, P14025, DOI 10.1073/pnas.94.25.14025; Dewji NN, 2004, P NATL ACAD SCI USA, V101, P1057, DOI 10.1073/pnas.0307290101; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Farmery MR, 2003, J BIOL CHEM, V278, P24277, DOI 10.1074/jbc.M211992200; Fraering PC, 2004, BIOCHEMISTRY-US, V43, P323, DOI 10.1021/bi035748j; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Friedmann E, 2004, J BIOL CHEM, V279, P50790, DOI 10.1074/jbc.M407898200; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Hansson EM, 2005, J NEUROCHEM, V92, P1010, DOI 10.1111/j.1471-4159.2004.02926.x; Kaether C, 2004, EMBO J, V23, P4738, DOI 10.1038/sj.emboj.7600478; Karlstrom H, 2002, J BIOL CHEM, V277, P6763, DOI 10.1074/jbc.C100649200; Kim J, 2004, P NATL ACAD SCI USA, V101, P905, DOI 10.1073/pnas.0307297101; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Lau KF, 2000, MOL CELL NEUROSCI, V16, P557, DOI 10.1006/mcne.2000.0898; Laudon H, 2004, J NEUROCHEM, V89, P44, DOI 10.1046/j.1471-4159.2003.02298.x; Lee SF, 2002, J BIOL CHEM, V277, P45013, DOI 10.1074/jbc.M208164200; Lehmann S, 1997, J BIOL CHEM, V272, P12047, DOI 10.1074/jbc.272.18.12047; Li XJ, 1996, NEURON, V17, P1015, DOI 10.1016/S0896-6273(00)80231-7; Li XJ, 1998, P NATL ACAD SCI USA, V95, P7109, DOI 10.1073/pnas.95.12.7109; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Mathews PM, 2000, MOL MED, V6, P878, DOI 10.1007/BF03401825; Melen K, 2003, J MOL BIOL, V327, P735, DOI 10.1016/S0022-2836(03)00182-7; Nakai T, 1999, J BIOL CHEM, V274, P23647, DOI 10.1074/jbc.274.33.23647; Nilsson I, 2000, J BIOL CHEM, V275, P17338, DOI 10.1074/jbc.M002317200; Nyborg AC, 2004, J BIOL CHEM, V279, P43148, DOI 10.1074/jbc.M405879200; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Prokop S, 2004, J BIOL CHEM, V279, P23255, DOI 10.1074/jbc.M401789200; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; Seeger M, 1997, P NATL ACAD SCI USA, V94, P5090, DOI 10.1073/pnas.94.10.5090; Smine A, 1998, J BIOL CHEM, V273, P16281, DOI 10.1074/jbc.273.26.16281; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Taniguchi Y, 2002, P NATL ACAD SCI USA, V99, P4014, DOI 10.1073/pnas.052017699; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; WELPLY JK, 1983, J BIOL CHEM, V258, P1856; Wolfe MS, 2004, SCIENCE, V305, P1119, DOI 10.1126/science.1096187; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xu XM, 1999, J BIOL CHEM, V274, P32543, DOI 10.1074/jbc.274.46.32543; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009	50	152	156	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35352	35360		10.1074/jbc.M507217200	http://dx.doi.org/10.1074/jbc.M507217200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16046406	hybrid			2022-12-25	WOS:000232561200034
J	Tokumitsu, H; Hatano, N; Inuzuka, H; Sueyoshi, Y; Yokokura, S; Ichimura, T; Nozaki, N; Kobayashi, R				Tokumitsu, H; Hatano, N; Inuzuka, H; Sueyoshi, Y; Yokokura, S; Ichimura, T; Nozaki, N; Kobayashi, R			Phosphorylation of Numb family proteins - Possible involvement of Ca2+/calmodulin-dependent protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN NUMB; REGULATORY MECHANISM; TRANSCRIPTION FACTOR; CAENORHABDITIS-ELEGANS; CORTICAL NEUROGENESIS; MOLECULAR-CLONING; CDNA CLONING; IN-VIVO; CALMODULIN; ACTIVATION	To search for the substrates of Ca2+/calmodulin-dependent protein kinase I (CaM-KI), we performed affinity chromatography purification using either the unphosphorylated or phosphorylated (at Thr(177)) GST-fused CaM-KI catalytic domain (residues 1-293, K49E) as the affinity ligand. Proteomic analysis was then carried out to identify the interacting proteins. In addition to the detection of two known CaM-KI substrates (CREB and synapsin I), we identified two Numb family proteins (Numb and Numb1) from rat tissues. These proteins were unphosphorylated and were bound only to the Thr(177)-phosphorylated CaM-KI catalytic domain. This finding is consistent with the results demonstrating that Numb and Numb1 were efficiently and stoichiometrically phosphorylated in vitro at equivalent Ser residues (Ser(264) in Numb and Ser(304) in Numb1) by activated CaM-KI and also by two other CaM-Ks (CaM-KII and CaM-KIV). Using anti-phospho-Numb/Numb1 antibody, we observed the phosphorylation of Numb family proteins in various rat tissue extracts, and we also detected the ionomycin-induced phosphorylation of endogenous Numb at Ser(264) in COS-7 cells. The present results revealed that the Numb family proteins are phosphorylated in vivo as well as in vitro. Furthermore, we found that the recruitment of 14-3-3 proteins was the functional consequence of the phosphorylation of the Numb family proteins. Interaction of 14-3-3 protein with phosphorylated Numb1-blocked dephosphorylation of Ser(304). Taken together, these results indicate that the Numb family proteins may be intracellular targets for CaM-Ks, and they may also be regulated by phosphorylation-dependent interaction with 14-3-3 protein.	Kagawa Univ, Fac Med, Dept Signal Transduct Sci, Kagawa 7610793, Japan; Kagawa Univ, Fac Med, Dept Cell Physiol, Kagawa 7610793, Japan; Tokyo Metropolitan Univ, Grad Sch Sci, Dept Chem, Hachioji, Tokyo 1920397, Japan; Kanagawa Dent Coll, Dept Biochem & Mol Biol, Yokosuka, Kanagawa 2388580, Japan	Kagawa University; Kagawa University; Tokyo Metropolitan University; Kanagawa Dental College	Tokumitsu, H (corresponding author), Kagawa Univ, Fac Med, Dept Signal Transduct Sci, 1750-1 Miki Cho, Kagawa 7610793, Japan.	tokumit@med.kagawa-u.ac.jp	Hatano, Naoya/F-6147-2011; Tokumitsu, Hiroshi/M-3978-2015	Tokumitsu, Hiroshi/0000-0002-2193-6794				Adams JA, 2003, BIOCHEMISTRY-US, V42, P601, DOI 10.1021/bi020617o; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; CZERNIK AJ, 1987, P NATL ACAD SCI USA, V84, P7518, DOI 10.1073/pnas.84.21.7518; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; Dho SE, 1999, J BIOL CHEM, V274, P33097, DOI 10.1074/jbc.274.46.33097; Eto K, 1999, J BIOL CHEM, V274, P22556, DOI 10.1074/jbc.274.32.22556; Frise E, 1996, P NATL ACAD SCI USA, V93, P11925, DOI 10.1073/pnas.93.21.11925; Hagopian JC, 2001, J BIOL CHEM, V276, P275, DOI 10.1074/jbc.M007337200; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; Hausser A, 1999, J BIOL CHEM, V274, P9258, DOI 10.1074/jbc.274.14.9258; Hayashi N, 1998, PROTEIN EXPRES PURIF, V12, P25, DOI 10.1006/prep.1997.0807; Hook SS, 2001, ANNU REV PHARMACOL, V41, P471, DOI 10.1146/annurev.pharmtox.41.1.471; Ichimura T, 2005, J BIOL CHEM, V280, P13187, DOI 10.1074/jbc.M412884200; ICHIMURA T, 1995, J BIOL CHEM, V270, P28515, DOI 10.1074/jbc.270.48.28515; Ishikawa Y, 2003, FEBS LETT, V550, P57, DOI 10.1016/S0014-5793(03)00817-2; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Joseph JD, 2000, J BIOL CHEM, V275, P38230, DOI 10.1074/jbc.M006422200; Kahl CR, 2004, J BIOL CHEM, V279, P15411, DOI 10.1074/jbc.M312543200; Kikuchi M, 2004, J BIOL CHEM, V279, P421, DOI 10.1074/jbc.M305623200; KIMURA K, 1994, J BIOL CHEM, V269, P24523; Kimura Y, 2002, EMBO REP, V3, P962, DOI 10.1093/embo-reports/kvf191; LEE JC, 1994, P NATL ACAD SCI USA, V91, P6413, DOI 10.1073/pnas.91.14.6413; LEE JSC, 1994, J BIOL CHEM, V269, P2158; Lukas TJ, 1998, CALMODULIN AND SIGNAL TRANSDUCTION, P65; Matsushita M, 1998, J BIOL CHEM, V273, P21473, DOI 10.1074/jbc.273.34.21473; McGill MA, 2003, J BIOL CHEM, V278, P23196, DOI 10.1074/jbc.M302827200; McKinsey TA, 2000, P NATL ACAD SCI USA, V97, P14400, DOI 10.1073/pnas.260501497; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; Nishimura H, 2003, J NEUROCHEM, V85, P1216, DOI 10.1046/j.1471-4159.2003.01760.x; Nishimura T, 2003, NAT CELL BIOL, V5, P819, DOI 10.1038/ncb1039; Petersen PH, 2004, NAT NEUROSCI, V7, P803, DOI 10.1038/nn1289; Petersen PH, 2002, NATURE, V419, P929, DOI 10.1038/nature01124; PICCIOTTO MR, 1995, SYNAPSE, V20, P75, DOI 10.1002/syn.890200111; PICCIOTTO MR, 1993, J BIOL CHEM, V268, P26512; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; Prowse CN, 2001, J BIOL CHEM, V276, P99, DOI 10.1074/jbc.M008137200; Qin H, 2003, J BIOL CHEM, V278, P48570, DOI 10.1074/jbc.M308781200; Rasmussen CD, 2000, J BIOL CHEM, V275, P685, DOI 10.1074/jbc.275.1.685; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; Spana EP, 1996, NEURON, V17, P21, DOI 10.1016/S0896-6273(00)80277-9; Suizu F, 2002, BIOCHEM J, V367, P335, DOI 10.1042/BJ20020536; Sun PQ, 1996, J BIOL CHEM, V271, P3066, DOI 10.1074/jbc.271.6.3066; Takemoto-Kimura S, 2003, J BIOL CHEM, V278, P18597, DOI 10.1074/jbc.M300578200; Tokumitsu H, 2000, J BIOL CHEM, V275, P20090, DOI 10.1074/jbc.M002193200; Tokumitsu H, 2004, J BIOL CHEM, V279, P40296, DOI 10.1074/jbc.M406534200; Tokumitsu H, 2004, J BIOL CHEM, V279, P42, DOI 10.1074/jbc.M309621200; TOKUMITSU H, 1994, J BIOL CHEM, V269, P28640; Tokumitsu H, 2001, BIOCHEMISTRY-US, V40, P13925, DOI 10.1021/bi010863k; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; Ueda T, 1999, J NEUROCHEM, V73, P2119; Verdi J, 1996, CURR BIOL, V6, P1134, DOI 10.1016/S0960-9822(02)70680-5; Wayman GA, 2004, J NEUROSCI, V24, P3786, DOI 10.1523/JNEUROSCI.3294-03.2004; YOKOKURA H, 1995, J BIOL CHEM, V270, P23851, DOI 10.1074/jbc.270.40.23851; Yokokura H, 1997, BBA-PROTEIN STRUCT M, V1338, P8, DOI 10.1016/S0167-4838(97)00004-6; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhong WM, 1997, DEVELOPMENT, V124, P1887	57	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35108	35118		10.1074/jbc.M503912200	http://dx.doi.org/10.1074/jbc.M503912200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16105844	hybrid			2022-12-25	WOS:000232561200007
J	Ceci, P; Ilari, A; Falvo, E; Giangiacomo, L; Chiancone, E				Ceci, P; Ilari, A; Falvo, E; Giangiacomo, L; Chiancone, E			Reassessment of protein stability, DNA binding, and protection of Mycobacterium smegmatis Dps	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI DPS; LISTERIA-INNOCUA; DODECAMERIC FERRITIN; STATIONARY-PHASE; IRON; CELLS; PARATUBERCULOSIS; AGGREGATION; SITE	The structure and function of Mycobacterium smegmatis Dps (DNA-binding proteins from starved cells) and of the protein studied by Gupta and Chatterji ( Gupta, S., and Chatterji, D. ( 2003) J. Biol. Chem. 278, 5235 - 5241), in which the C terminus that is used for binding DNA contains a histidine tag, have been characterized in parallel. The native dodecamer dissociated reversibly into dimers above pH 7.5 and below pH 6.0, with apparent pK(a) values of similar to 7.65 and 4.75; at pH similar to 4.0, dimers formed monomers. Based on structural analysis, the two dissociation steps have been attributed to breakage of the salt bridges between Glu(157) and Arg(99) located at the 3-fold symmetry axes and to protonation of Asp(66) hydrogen-bonded to Lys(36) across the dimer interface, respectively. The C-terminal tag did not affect subunit dissociation, but altered DNA binding dramatically. At neutral pH, protonation of the histidine tag promoted DNA condensation, whereas in the native C terminus, compensation of negative and positive charges led to DNA binding without condensation. This different mode of interaction with DNA has important functional consequences as indicated by the failure of the native protein to protect DNA from DNase-mediated cleavage and by the efficiency of the tagged protein in doing so as a result of DNA sequestration in the condensates. Chemical protection of DNA from oxidative damage is realized by Dps proteins in a multistep iron oxidation/ uptake/ mineralization process. Dimers have a decreased protection efficiency due to disruption of the dodecamer internal cavity, where iron is deposited and mineralized after oxidation at the ferroxidase center.	Univ Roma La Sapienza, Dept Biochem Sci A Rossi Fanelli, Natl Res Council, Inst Mol Biol & Pathol, I-00185 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome	Chiancone, E (corresponding author), Univ Roma La Sapienza, Dipartimento Sci Biochim, CNR, Ist Biol & Patol Mol, Ple A Moro 5, I-00185 Rome, Italy.	emilia.chiancone@uniroma1.it	Ilari, Andrea/AAC-7670-2022; Ilari, Andrea/T-5501-2017	Ilari, Andrea/0000-0002-7754-399X; Ilari, Andrea/0000-0002-7754-399X; Ceci, Pierpaolo/0000-0001-7712-8430; Falvo, Elisabetta/0000-0001-9584-8669				ANTONINI E, 1977, ANNU REV BIOPHYS BIO, V6, P239, DOI 10.1146/annurev.bb.06.060177.001323; Bozzi M, 1997, J BIOL CHEM, V272, P3259, DOI 10.1074/jbc.272.6.3259; Ceci P, 2004, NUCLEIC ACIDS RES, V32, P5935, DOI 10.1093/nar/gkh915; Ceci P, 2003, J BIOL CHEM, V278, P20319, DOI 10.1074/jbc.M302114200; Chacon O, 2004, ANNU REV MICROBIOL, V58, P329, DOI 10.1146/annurev.micro.58.030603.123726; Chiaraluce R, 2000, EUR J BIOCHEM, V267, P5733, DOI 10.1046/j.1432-1327.2000.01639.x; DeLano WL, 2005, DRUG DISCOV TODAY, V10, P213, DOI 10.1016/S1359-6446(04)03363-X; Ergan B, 2004, RESPIROLOGY, V9, P283, DOI 10.1111/j.1440-1843.2004.00570.x; Fitch CA, 2002, BIOPHYS J, V82, P3289, DOI 10.1016/S0006-3495(02)75670-1; Grant RA, 1998, NAT STRUCT BIOL, V5, P294, DOI 10.1038/nsb0498-294; Gupta S, 2003, J BIOL CHEM, V278, P5235, DOI 10.1074/jbc.M208825200; Gupta S, 2002, PROTEIN ENG, V15, P503, DOI 10.1093/protein/15.6.503; Ilari A, 2000, NAT STRUCT BIOL, V7, P38; Ilari A, 2002, J BIOL CHEM, V277, P37619, DOI 10.1074/jbc.M206186200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LARY JW, 1998, REEDIT; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; MCREE DE, 1993, PRACTICAL PROTEIN CR, P365; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Nair S, 2004, J BACTERIOL, V186, P4192, DOI 10.1128/JB.186.13.4192-4198.2004; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Papinutto E, 2002, J BIOL CHEM, V277, P15093, DOI 10.1074/jbc.M112378200; Pulliainen AT, 2003, J BIOL CHEM, V278, P7996, DOI 10.1074/jbc.M210174200; Rao M, 2001, MICROBIOL-UK, V147, P1017, DOI 10.1099/00221287-147-4-1017; Richardson JS, 2002, P NATL ACAD SCI USA, V99, P2754, DOI 10.1073/pnas.052706099; Roy S, 2004, J MOL BIOL, V339, P1103, DOI 10.1016/j.jmb.2004.04.042; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Skiest DJ, 1998, SOUTHERN MED J, V91, P36, DOI 10.1097/00007611-199801000-00007; Whittington RJ, 2004, APPL ENVIRON MICROB, V70, P2989, DOI 10.1128/AEM.70.5.2989-3004.2004; Wolf SG, 1999, NATURE, V400, P83, DOI 10.1038/21918; Yamamoto Y, 2000, J BACTERIOL, V182, P3740, DOI 10.1128/JB.182.13.3740-3747.2000; YPHANTIS DA, 1997, WINNONLIN; Zanotti G, 2002, J MOL BIOL, V323, P125, DOI 10.1016/S0022-2836(02)00879-3; Zhao GH, 2002, J BIOL CHEM, V277, P27689, DOI 10.1074/jbc.M202094200	36	50	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34776	34785		10.1074/jbc.M502343200	http://dx.doi.org/10.1074/jbc.M502343200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16030020	hybrid			2022-12-25	WOS:000232403900049
J	Kim, W; Hecht, MH				Kim, W; Hecht, MH			Sequence determinants of enhanced amyloidogenicity of Alzheimer A beta 42 peptide relative to A beta 40	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOFLAVINE-T INTERACTION; AMYLOID FIBRIL FORMATION; PROTEIN A-BETA; FORMING PROTEINS; IN-VIVO; DISEASE; AGGREGATION; MUTATIONS; PATHOLOGY; BRAIN	Aggregation of proteins into insoluble deposits is associated with a variety of human diseases. In Alzheimer disease, the aggregation of amyloid beta(A beta) peptides is believed to play a key role in pathogenesis. Although the 40-mer (A beta 40) is produced in vivo at higher levels than the 42-mer (A beta 42), senile plaque in diseased brains is composed primarily of A beta 42. Likewise, in vitro, A beta 42 forms fibrils more rapidly than A4 beta 0. The enhanced amyloidogenicity of A beta 42 could be due simply to its greater length. Alternatively, specific properties of residues Ile(41) and Ala(42) might favor aggregation. To distinguish between these two possibilities, we constructed a library of sequences in which residues 41 and 42 were randomized. The aggregation behavior of the resulting sequences was assessed using a high throughput screen, based on the finding that fusions of A beta 42 to green fluorescence protein (GFP) prevent the folding and fluorescence of GFP, whereas mutations in A beta 42 that disrupt aggregation produce green fluorescent fusions. Correlations between the sequences of A beta 42 mutants and the fluorescence of A beta 42-GFP fusions in vivo were confirmed in vitro through biophysical studies of synthetic 42-residue peptides. The data reveal a strong correlation between aggregation propensity and the hydrophobicity and beta-sheet propensities of residues at positions 41 and 42. Moreover, several mutants containing hydrophilic residues and/or beta-sheet breakers at positions 41 and/or 42 were less prone to aggregate than A beta 40 wherein these two residues are deleted entirely. Thus, properties of the side chains at positions 41 and 42, rather than length per se, cause A beta 42 to aggregate more readily than A beta 40.	Princeton Univ, Dept Chem, Princeton, NJ 08544 USA	Princeton University	Hecht, MH (corresponding author), Princeton Univ, Dept Chem, Princeton, NJ 08544 USA.	hecht@princeton.edu		Hecht, Michael/0000-0002-5538-9813				Bitan G, 2003, J BIOL CHEM, V278, P34882, DOI 10.1074/jbc.M300825200; Bitan G, 2003, P NATL ACAD SCI USA, V100, P330, DOI 10.1073/pnas.222681699; Bonifacio MJ, 1996, BBA-MOL BASIS DIS, V1316, P35, DOI 10.1016/0925-4439(96)00014-2; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; BURDICK D, 1992, J BIOL CHEM, V267, P546; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; Chiti F, 2003, NATURE, V424, P805, DOI 10.1038/nature01891; CREIGHTON T, 1992, PROTEINS, P171; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Geula C, 1998, NAT MED, V4, P827, DOI 10.1038/nm0798-827; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; Hecht MH, 2004, PROTEIN SCI, V13, P1711, DOI 10.1110/ps.04690804; Jao SC, 1997, AMYLOID, V4, P240, DOI 10.3109/13506129709003835; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Johansson J, 2004, CELL MOL LIFE SCI, V61, P326, DOI 10.1007/s00018-003-3274-6; Kallberg Y, 2001, J BIOL CHEM, V276, P12945, DOI 10.1074/jbc.M010402200; Koo EH, 1999, P NATL ACAD SCI USA, V96, P9989, DOI 10.1073/pnas.96.18.9989; Kuo YM, 1996, J BIOL CHEM, V271, P4077; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; LEVINE H, 1995, AMYLOID, V2, P1, DOI 10.3109/13506129509031881; Makin OS, 2005, P NATL ACAD SCI USA, V102, P315, DOI 10.1073/pnas.0406847102; MINOR DL, 1994, NATURE, V367, P660, DOI 10.1038/367660a0; Murakami K, 2002, BIOCHEM BIOPH RES CO, V294, P5, DOI 10.1016/S0006-291X(02)00430-8; NAIKI H, 1993, LAB INVEST, V68, P332; Paivio A, 2004, PROTEIN SCI, V13, P1251, DOI 10.1110/ps.03442404; Pawar AP, 2005, J MOL BIOL, V350, P379, DOI 10.1016/j.jmb.2005.04.016; Petkova AT, 2002, P NATL ACAD SCI USA, V99, P16742, DOI 10.1073/pnas.262663499; ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; Serpell LC, 2000, BBA-MOL BASIS DIS, V1502, P16, DOI 10.1016/S0925-4439(00)00029-6; SLIPE JD, 1992, ANNU REV BIOCHEM, V61, P947; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; Waldo GS, 1999, NAT BIOTECHNOL, V17, P691, DOI 10.1038/10904; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Wurth C, 2002, J MOL BIOL, V319, P1279, DOI 10.1016/S0022-2836(02)00399-6	44	104	106	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					35069	35076		10.1074/jbc.M505763200	http://dx.doi.org/10.1074/jbc.M505763200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16079141	hybrid			2022-12-25	WOS:000232403900080
J	Tyson-Capper, AJ; Bailey, J; Krainer, AR; Robson, SC; Europe-Finner, GN				Tyson-Capper, AJ; Bailey, J; Krainer, AR; Robson, SC; Europe-Finner, GN			The switch in alternative splicing of cyclic AMP-response element modulator protein CREM tau(2)alpha (activator) to CREM alpha (repressor) in human myometrial cells is mediated by SRp40	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SR PROTEINS; TRANSCRIPTION FACTORS; ADENOSINE-MONOPHOSPHATE; SIGNAL-TRANSDUCTION; BINDING PROTEIN; PRETERM LABOR; IN-VIVO; IDENTIFICATION; EXPRESSION; GENE	The transcription factor cAMP-response element modulator (CREM) protein, plays a major role in cAMP-responsive gene regulation. Biological consequences resulting from the transcriptional stimuli of CREM are dictated by the expression of multiple protein isoforms generated by extensive alternative splicing of its precursor mRNA. We have previously shown that alternative splicing enables the expression of the CREM gene to be "switched" within the human myometrium during pregnancy from the production of CREM tau(2 alpha), a potent transcriptional activator to the synthesis of CREM alpha, a transcriptional repressor. Furthermore we have recently reported that this change in the expression of CREM spliced variants is likely to have important ramifications on the regulation of downstream cAMP-response element-responsive target genes involved in uterine activity during gestation. We have investigated the splicing factors involved in controlling the expression of myometrial CREM splice variants. Data presented here from transient transfections indicate that the switch in the synthesis of CREM tau(2)alpha to CREM alpha that occurs during pregnancy is regulated primarily by an SR protein family member, SRp40. We also show that expression of this splicing factor is tightly regulated in the myometrium during pregnancy. SRp40 regulates the splicing of CREM via its interactions with multiple ESE motifs present in the alternatively exons of CREM. In vitro splicing and electrophoretic mobility shift assays were employed to confirm the functionality of the SRp40-binding ESEs, thus providing a mechanistic explanation of how SRp40 regulates the switch in splicing from production of CREM tau(2)alpha to CREM alpha.	Newcastle Univ, Sch Med, Sch Surg & Reprod Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Newcastle University - UK; Cold Spring Harbor Laboratory	Tyson-Capper, AJ (corresponding author), Newcastle Univ, Sch Med, Sch Surg & Reprod Sci, 3rd Floor,William Leech Bldg, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	A.J.Tyson-Capper@ncl.ac.uk	Robson, Simon C./AAA-8537-2021; europe-finner, Nicholas/F-2569-2010	Krainer, Adrian/0000-0001-9024-9501	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bailey J, 2005, J MOL ENDOCRINOL, V34, P1, DOI 10.1677/jme.1.01594; Bailey J, 2002, J CLIN ENDOCR METAB, V87, P1717, DOI 10.1210/jcem.87.4.8360; Bailey J, 2000, MOL HUM REPROD, V6, P648, DOI 10.1093/molehr/6.7.648; BERNAL AL, 1995, TRENDS PHARMACOL SCI, V16, P129, DOI 10.1016/S0165-6147(00)89000-8; BORRELLI E, 1992, Critical Reviews in Oncogenesis, V3, P321; Bourgeois CF, 1999, MOL CELL BIOL, V19, P7347; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; CACERES JF, 1997, EUKARYOTIC MRNA PROC, P174; Caputi M, 2004, J VIROL, V78, P6517, DOI 10.1128/JVI.78.12.6517-6526.2004; Cartegni L, 2003, NUCLEIC ACIDS RES, V31, P3568, DOI 10.1093/nar/gkg616; Cooper TA, 2005, CELL, V120, P1, DOI 10.1016/j.cell.2004.12.030; Cowper AE, 2001, J BIOL CHEM, V276, P48908, DOI 10.1074/jbc.M103967200; DE CD, 1999, TRENDS BIOCHEM SCI, V24, P281; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; Don J, 2002, MOL CELL ENDOCRINOL, V187, P115, DOI 10.1016/S0303-7207(01)00696-7; Dong YL, 1999, J CLIN INVEST, V104, P559, DOI 10.1172/JCI6324; Elrick LL, 1998, MOL CELL BIOL, V18, P343, DOI 10.1128/MCB.18.1.343; EUROPEFINNER GN, 1993, ENDOCRINOLOGY, V132, P2484, DOI 10.1210/en.132.6.2484; EUROPEFINNER GN, 1994, J CLIN ENDOCR METAB, V79, P1835, DOI 10.1210/jc.79.6.1835; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Habener JF, 1995, VITAM HORM, V51, P1, DOI 10.1016/S0083-6729(08)61037-7; HAI TW, 1990, GENE DEV, V4, P682; Hanamura A, 1998, RNA, V4, P430; Hastings ML, 2001, CURR OPIN CELL BIOL, V13, P302, DOI 10.1016/S0955-0674(00)00212-X; Isoda T, 2003, FASEB J, V17, P144, DOI 10.1096/fj.01-0981com; KOFINAS AD, 1990, J REPROD MED, V35, P1045; Lam BJ, 2002, RNA, V8, P1233, DOI 10.1017/S1355838202028030; Liu HX, 1998, GENE DEV, V12, P1998, DOI 10.1101/gad.12.13.1998; Mayeda A, 1999, MOL CELL BIOL, V19, P1853; Mayeda A, 1999, METH MOL B, V118, P315; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; Modrek B, 2002, NAT GENET, V30, P13, DOI 10.1038/ng0102-13; PHANEUF S, 1993, J ENDOCRINOL, V136, P497, DOI 10.1677/joe.0.1360497; Pollard AJ, 2000, J CLIN ENDOCR METAB, V85, P1928, DOI 10.1210/jc.85.5.1928; Pollard AJ, 2002, J BIOL CHEM, V277, P15241, DOI 10.1074/jbc.M109046200; Sanborn BM, 1997, J ANDROL, V18, P62; Sanborn BM, 2000, ENDOCRINOLOGY, V141, P3921, DOI 10.1210/en.141.11.3921; Sassone-Corsi P, 1998, INT J BIOCHEM CELL B, V30, P27, DOI 10.1016/S1357-2725(97)00093-9; Schaal TD, 1999, MOL CELL BIOL, V19, P1705; Servillo G, 2002, EXP CELL RES, V275, P143, DOI 10.1006/excr.2002.5491; Servillo G, 1998, GENE DEV, V12, P3639, DOI 10.1101/gad.12.23.3639; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Stamm S, 2005, GENE, V344, P1, DOI 10.1016/j.gene.2004.10.022; SUN PQ, 1992, MOL ENDOCRINOL, V6, P1858, DOI 10.1210/me.6.11.1858; SUN Q, 1993, GENE DEV, V7, P2598, DOI 10.1101/gad.7.12b.2598; TANAKA K, 1994, MOL CELL BIOL, V14, P1347, DOI 10.1128/MCB.14.2.1347; Tenbrock K, 2003, J IMMUNOL, V170, P2971, DOI 10.4049/jimmunol.170.6.2971; WANG J, 1995, RNA, V1, P335; Yang XJ, 1997, MOL ENDOCRINOL, V11, P1053, DOI 10.1210/me.11.8.1053; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G; ZUO J, 1994, J CLIN ENDOCR METAB, V79, P907, DOI 10.1210/jc.79.3.907	53	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34521	34529		10.1074/jbc.M505344200	http://dx.doi.org/10.1074/jbc.M505344200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16103121	hybrid			2022-12-25	WOS:000232403900020
J	Battaglia, V; Salvi, M; Toninello, A				Battaglia, V; Salvi, M; Toninello, A			Oxidative stress is responsible for mitochondrial permeability transition induction by salicylate in liver mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; REYES-SYNDROME; CYCLOSPORINE-A; COLON-CANCER; COMPLEX-I; MECHANISM; INHIBITION; APOPTOSIS; ASPIRIN; GLUTATHIONE	The interaction of salicylate with the respiratory chain of liver mitochondria generates hydrogen peroxide and, most probably, other reactive oxygen species, which in turn oxidize thiol groups and glutathione. This oxidative stress, confirmed by the prevention of action by antioxidant agents, leads to the induction of the mitochondrial permeability transition in the presence of Ca2+. This phenomenon induces further increase of oxidative damage resulting in impairment of oxidative phosphorylation and beta-oxidation, cardinal features of Reye's syndrome in the liver. Mitochondrial permeability transition induction also induces the release of cytochrome c and apoptotic inducing factor from mitochondria, suggesting that salicylate also behaves as a pro-apoptotic agent. The reactive group of salicylate for inducing oxidative stress is the hydroxyl group which, by interacting with a Fe-S cluster of mitochondrial Complex I, the so-called N-2(Fe-S) center, produces reactive oxygen species.	Univ Padua, Dipartimento Chim Biol, Ist Neurosci, CNR,Unita Studio Biomembrane, I-35121 Padua, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Padua	Toninello, A (corresponding author), Univ Padua, Dipartimento Chim Biol, Ist Neurosci, CNR,Unita Studio Biomembrane, Viale G Colombo 3, I-35121 Padua, Italy.	antonio.toninello@unipd.it		Salvi, Mauro/0000-0003-3448-6048				Adlam VJ, 2005, FASEB J, V19, P1088, DOI 10.1096/fj.05-3718com; BIBAN C, 1995, BIOCHEM PHARMACOL, V50, P497, DOI 10.1016/0006-2952(95)00165-V; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; Broekemeier KM, 1995, BIOCHEMISTRY-US, V34, P16440, DOI 10.1021/bi00050a027; Cao GH, 1997, FREE RADICAL BIO MED, V22, P749, DOI 10.1016/S0891-5849(96)00351-6; CARPENTER KJ, 1950, BIOCHEM J, V46, P421, DOI 10.1042/bj0460421; Chernyak BV, 1996, EUR J BIOCHEM, V238, P623, DOI 10.1111/j.1432-1033.1996.0623w.x; Chung YM, 2003, FREE RADICAL BIO MED, V34, P434, DOI 10.1016/S0891-5849(02)01301-1; De Marchi U, 2003, BIOCHEM PHARMACOL, V66, P1749, DOI 10.1016/S0006-2952(03)00474-X; Fiore C, 2004, BBA-BIOENERGETICS, V1658, P195, DOI 10.1016/j.bbabio.2004.05.012; FLOWER RJ, 1985, PHARMACOL BASIS THER, P674; FOURNIER N, 1987, J BIOENERG BIOMEMBR, V19, P297, DOI 10.1007/BF00762419; GORNALL AG, 1949, J BIOL CHEM, V177, P751; Grijalba MT, 1999, BIOCHEMISTRY-US, V38, P13279, DOI 10.1021/bi9828674; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; KAMO N, 1979, J MEMBRANE BIOL, V49, P105, DOI 10.1007/BF01868720; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Kushnareva Y, 2002, BIOCHEM J, V368, P545, DOI 10.1042/BJ20021121; LEMASTERS JJ, 1976, EUR J BIOCHEM, V67, P1, DOI 10.1111/j.1432-1033.1976.tb10625.x; Ligeret H, 2004, FREE RADICAL BIO MED, V36, P919, DOI 10.1016/j.freeradbiomed.2003.12.018; LOSCHEN G, 1973, FEBS LETT, V33, P84, DOI 10.1016/0014-5793(73)80165-6; MARTENS ME, 1984, BIOCHEM PHARMACOL, V33, P2869, DOI 10.1016/0006-2952(84)90209-0; MARTENS ME, 1986, ARCH BIOCHEM BIOPHYS, V244, P773, DOI 10.1016/0003-9861(86)90646-6; McStay GP, 2002, BIOCHEM J, V367, P541, DOI 10.1042/BJ20011672; Nulton-Persson AC, 2004, J CARDIOVASC PHARM, V44, P591, DOI 10.1097/00005344-200411000-00012; PARTIN JC, 1971, NEW ENGL J MED, V285, P1339, DOI 10.1056/NEJM197112092852402; Rigas B, 2000, MED HYPOTHESES, V54, P210, DOI 10.1054/mehy.1999.0023; ROOS I, 1980, EUR J BIOCHEM, V110, P319, DOI 10.1111/j.1432-1033.1980.tb04870.x; Salvi M, 2002, BBA-BIOENERGETICS, V1556, P187, DOI 10.1016/S0005-2728(02)00361-4; Santos AC, 1998, FREE RADICAL BIO MED, V24, P1455, DOI 10.1016/S0891-5849(98)00003-3; Sanz E, 2004, MED SCI MONITOR, V10, pBR477; Sawaoka H, 1998, AM J PHYSIOL-GASTR L, V274, pG1061, DOI 10.1152/ajpgi.1998.274.6.G1061; SCHNEIDER WC, 1950, J BIOL CHEM, V183, P123; SEGALMAN TY, 1995, ARCH BIOCHEM BIOPHYS, V317, P79; Sheng HM, 1998, CANCER RES, V58, P362; Shiff SJ, 1997, GASTROENTEROLOGY, V113, P1992, DOI 10.1016/S0016-5085(97)99999-6; Stark LA, 2001, FASEB J, V15, P1273, DOI 10.1096/fj.00-0529fje; STARKO KM, 1980, PEDIATRICS, V66, P859; Taketo MM, 1998, JNCI-J NATL CANCER I, V90, P1609, DOI 10.1093/jnci/90.21.1609; TETRUD JW, 1989, SCIENCE, V245, P519, DOI 10.1126/science.2502843; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; TOMODA T, 1994, LIVER, V14, P103; TONSGARD JH, 1985, J CLIN INVEST, V76, P816, DOI 10.1172/JCI112039; Trost LC, 1997, TOXICOL APPL PHARM, V147, P431, DOI 10.1006/taap.1997.8313; TROST LC, 2001, MITOCHONDRIA PATHOGE, P425; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; VANE J, 1994, NATURE, V367, P215, DOI 10.1038/367215a0; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; WALDMAN RJ, 1982, JAMA-J AM MED ASSOC, V247, P3089, DOI 10.1001/jama.247.22.3089; WEISS H, 1991, EUR J BIOCHEM, V197, P563, DOI 10.1111/j.1432-1033.1991.tb15945.x; WEISSMANN G, 1991, SCI AM, V264, P84, DOI 10.1038/scientificamerican0191-84; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	53	67	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33864	33872		10.1074/jbc.M502391200	http://dx.doi.org/10.1074/jbc.M502391200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16100122	hybrid			2022-12-25	WOS:000232229700023
J	Santelli, E; Leone, M; Li, CL; Fukushima, T; Preece, NE; Olson, AJ; Ely, KR; Reed, JC; Pellecchia, M; Liddington, RC; Matsuzawa, S				Santelli, E; Leone, M; Li, CL; Fukushima, T; Preece, NE; Olson, AJ; Ely, KR; Reed, JC; Pellecchia, M; Liddington, RC; Matsuzawa, S			Structural analysis of Siah1-Siah-interacting protein interactions and insights into the assembly of an E3 ligase multiprotein complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CATENIN; MAMMALIAN HOMOLOGS; UBIQUITIN LIGASE; TRANSCRIPTIONAL REPRESSOR; PROTEASOME PATHWAY; SIAH-1; DEGRADATION; BINDING; ACTIVATION; REFINEMENT	Siah1 is the central component of a multiprotein E3 ubiquitin ligase complex that targets beta-catenin for destruction in response to p53 activation. The E3 complex comprises, in addition to Siah1, Siah-interacting protein ( SIP), the adaptor protein Skp1, and the F-box protein Ebi. Here we show that SIP engages Siah1 by means of two elements, both of which are required for mediating beta-catenin destruction in cells. An N-terminal dimerization domain of SIP sits across the saddle-shaped upper surface of Siah1, with two extended legs packing against the sides of Siah1 by means of a consensus PXAXVXP motif that is common to a family of Siah-binding proteins. The C-terminal domain of SIP, which binds to Skp1, protrudes from the lower surface of Siah1, and we propose that this surface provides the scaffold for bringing substrate and the E2 enzyme into apposition in the functional complex.	Burnham Inst, La Jolla, CA 92037 USA; Scripps Res Inst, La Jolla, CA 92037 USA; CNR, Ist Biostrutture & Bioimmagini, I-80134 Naples, Italy	Sanford Burnham Prebys Medical Discovery Institute; Scripps Research Institute; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biostrutture e Bioimmagini (IBB-CNR)	Matsuzawa, S (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	rlidding@burnham.org; smatsuzawa@burnham.org	Li, Chenglong/E-7182-2010; Pellecchia, Maurizio/Y-7072-2018	Li, Chenglong/0000-0003-3174-8719; LEONE, MARILISA/0000-0002-3811-6960				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Bhattacharya S, 2005, BIOCHEMISTRY-US, V44, P9462, DOI 10.1021/bi0502689; Boehm J, 2001, EMBO J, V20, P4153, DOI 10.1093/emboj/20.15.4153; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bursen A, 2004, ONCOGENE, V23, P6237, DOI 10.1038/sj.onc.1207837; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; DOMER PH, 1993, P NATL ACAD SCI USA, V90, P7884, DOI 10.1073/pnas.90.16.7884; Fanelli M, 2004, J BIOL CHEM, V279, P5374, DOI 10.1074/jbc.M306407200; Filipek A, 1996, BIOCHEM J, V320, P585, DOI 10.1042/bj3200585; Foadi J, 2000, ACTA CRYSTALLOGR D, V56, P1137, DOI 10.1107/S090744490000932X; FREIRE E, 1990, ANAL CHEM, V62, pA950, DOI 10.1021/ac00217a002; Germani A, 2003, ONCOGENE, V22, P8845, DOI 10.1038/sj.onc.1206994; Germani A, 1999, MOL CELL BIOL, V19, P3798; Germani A, 2000, ONCOGENE, V19, P5997, DOI 10.1038/sj.onc.1204002; Habelhah H, 2004, J BIOL CHEM, V279, P53782, DOI 10.1074/jbc.M410315200; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; House CM, 2003, P NATL ACAD SCI USA, V100, P3101, DOI 10.1073/pnas.0534783100; Hu G, 1999, MOL CELL BIOL, V19, P724; Hu G, 1997, GENOMICS, V46, P103, DOI 10.1006/geno.1997.4997; Hu G, 1997, GENE DEV, V11, P2701, DOI 10.1101/gad.11.20.2701; Isaacs AM, 2003, J NEUROSCI, V23, P1631; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim CJ, 2004, ONCOGENE, V23, P8591, DOI 10.1038/sj.onc.1208113; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li CL, 2002, STRUCTURE, V10, P403, DOI 10.1016/S0969-2126(02)00733-5; Li SH, 1997, CELL, V90, P469, DOI 10.1016/S0092-8674(00)80507-3; Liani E, 2004, P NATL ACAD SCI USA, V101, P5500, DOI 10.1073/pnas.0401081101; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Matsuzawa S, 2003, J BIOL CHEM, V278, P1837, DOI 10.1074/jbc.M210263200; Matsuzawa S, 1998, EMBO J, V17, P2736, DOI 10.1093/emboj/17.10.2736; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Moriyoshi K, 2004, P NATL ACAD SCI USA, V101, P8614, DOI 10.1073/pnas.0403042101; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nagano Y, 2003, J BIOL CHEM, V278, P51504, DOI 10.1074/jbc.M306347200; Nakayama K, 2004, CELL, V117, P941, DOI 10.1016/j.cell.2004.06.001; Okabe H, 2003, CANCER RES, V63, P3043; Oliver PL, 2004, P NATL ACAD SCI USA, V101, P14901, DOI 10.1073/pnas.0406196101; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park TJ, 2003, BIOCHEM BIOPH RES CO, V302, P671, DOI 10.1016/S0006-291X(03)00247-X; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Pellecchia M, 2000, NAT STRUCT BIOL, V7, P298; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; Polekhina G, 2002, NAT STRUCT BIOL, V9, P68, DOI 10.1038/nsb743; Relaix F, 2000, P NATL ACAD SCI USA, V97, P2105, DOI 10.1073/pnas.040378897; Susini L, 2001, P NATL ACAD SCI USA, V98, P15067, DOI 10.1073/pnas.261571998; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; Tang AH, 1997, CELL, V90, P459, DOI 10.1016/S0092-8674(00)80506-1; Tanikawa J, 2000, J BIOL CHEM, V275, P15578, DOI 10.1074/jbc.M000372200; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Tiedt R, 2001, EMBO J, V20, P4143, DOI 10.1093/emboj/20.15.4143; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; Venables JP, 2004, HUM MOL GENET, V13, P1525, DOI 10.1093/hmg/ddh165; Wheeler TC, 2002, J BIOL CHEM, V277, P10273, DOI 10.1074/jbc.M107857200; Zhang JS, 1998, GENE DEV, V12, P1775, DOI 10.1101/gad.12.12.1775; Zhou HY, 2005, NUCLEIC ACIDS RES, V33, pW193, DOI 10.1093/nar/gki360	60	77	80	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34278	34287		10.1074/jbc.M506707200	http://dx.doi.org/10.1074/jbc.M506707200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16085652	hybrid			2022-12-25	WOS:000232229700070
J	Wei, YN; Fu, D				Wei, YN; Fu, D			Selective metal binding to a membrane-embedded aspartate in the Escherichia coli metal transporter YiiP (FieF)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC TRANSPORTER; METALLIDURANS CH34; RESISTANCE; PROTEINS; FAMILY; MECHANISM; SYSTEM; MODEL; UHPT; CZCD	The cation diffusion facilitators (CDF) are a ubiquitous family of metal transporters that play important roles in homeostasis of a wide range of divalent metal cations. Molecular identities of substrate-binding sites and their metal selectivity in the CDF family are thus far unknown. By using isothermal titration calorimetry and stopped-flow spectrofluorometry, we directly examined metal binding to a highly conserved aspartate in the Escherichia coli CDF transporter YiiP (FieF). A D157A mutation abolished a Cd2+-binding site and impaired the corresponding Cd2+ transport. In contrast, substitution of Asp-157 with a cysteinyl coordination residue resulted in intact Cd2+ binding as well as full transport activity. A similar correlation was found for Zn2+ binding and transport, suggesting that Asp-157 is a metal coordination residue required for binding and transport of Cd2+ and Zn2+. The location of Asp-157 was mapped topologically to the hydrophobic core of transmembrane segment 5 (TM-5) where D157C was found partially accessible to thiol-specific labeling of maleimide polyethylene-oxide biotin. Binding of Zn2+ and Cd2+, but not Fe2+, Hg2+, Co2+, Ni2+, Mn2+, Ca2+, and Mg2+, protected D157C from maleimide polyethyleneoxide biotin labeling in a concentration-dependent manner. Furthermore, isothermal titration calorimetry analysis of YiiP(D157A) showed no detectable change in Fe2+ and Hg2+ calorimetric titrations, indicating that Asp-157 is not a coordination residue for Fe2+ and Hg2+ binding. Our results provided direct evidence for selective binding of Zn2+ and Cd2+ to the highly conserved Asp-157 and defined its functional role in metal transport.	Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	United States Department of Energy (DOE); Brookhaven National Laboratory	Wei, YN (corresponding author), Brookhaven Natl Lab, Dept Biol, Bldg 463, Upton, NY 11973 USA.	dax@bnl.gov		Fu, Dax/0000-0002-2663-1316	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065137] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM65137] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anton A, 1999, J BACTERIOL, V181, P6876, DOI 10.1128/JB.181.22.6876-6881.1999; Anton A, 2004, J BACTERIOL, V186, P7499, DOI 10.1128/JB.186.22.7499-7507.2004; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; Bloss T, 2002, PLANTA, V214, P783, DOI 10.1007/s00425-001-0677-1; Chao Y, 2004, J BIOL CHEM, V279, P12043, DOI 10.1074/jbc.M313510200; Chao Y, 2004, J BIOL CHEM, V279, P17173, DOI 10.1074/jbc.M400208200; COLEMAN JE, 1992, ANNU REV BIOCHEM, V61, P897, DOI 10.1146/annurev.bi.61.070192.004341; DASILVA JJR, 2001, BIOL CHEM ELEMENTS I, P39; Delhaize E, 2003, PLANT CELL, V15, P1131, DOI 10.1105/tpc.009134; Fann MC, 1998, J BIOL CHEM, V273, P33735, DOI 10.1074/jbc.273.50.33735; Gaither LA, 2001, BIOMETALS, V14, P251, DOI 10.1023/A:1012988914300; Grass G, 2005, ARCH MICROBIOL, V183, P9, DOI 10.1007/s00203-004-0739-4; Haney CJ, 2005, J IND MICROBIOL BIOT, V32, P215, DOI 10.1007/s10295-005-0224-3; Hantke K, 2001, BIOMETALS, V14, P239, DOI 10.1023/A:1012984713391; Harris ED, 2002, NUTR REV, V60, P121, DOI 10.1301/00296640260085877; JARDETZK.O, 1966, NATURE, V211, P969, DOI 10.1038/211969a0; Kimura T, 1998, J BIOL CHEM, V273, P5243, DOI 10.1074/jbc.273.9.5243; Matos M, 1996, J BIOL CHEM, V271, P18571, DOI 10.1074/jbc.271.31.18571; Munkelt D, 2004, J BACTERIOL, V186, P8036, DOI 10.1128/JB.186.23.8036-8043.2004; Nies DH, 2003, FEMS MICROBIOL REV, V27, P313, DOI 10.1016/S0168-6445(03)00048-2; NIES DH, 1992, J BACTERIOL, V174, P8102, DOI 10.1128/JB.174.24.8102-8110.1992; NIES DH, 1989, P NATL ACAD SCI USA, V86, P7351, DOI 10.1073/pnas.86.19.7351; Paulsen IT, 1997, J MEMBRANE BIOL, V156, P99, DOI 10.1007/s002329900192; Persans MW, 2001, P NATL ACAD SCI USA, V98, P9995, DOI 10.1073/pnas.171039798; STRICKLAND S, 1975, J BIOL CHEM, V250, P4048; Studier FW, 2005, PROTEIN EXPRES PURIF, V41, P207, DOI 10.1016/j.pep.2005.01.016; Wei YN, 2004, J BIOL CHEM, V279, P39251, DOI 10.1074/jbc.M407044200	27	76	77	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33716	33724		10.1074/jbc.M506107200	http://dx.doi.org/10.1074/jbc.M506107200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16049012	hybrid			2022-12-25	WOS:000232229700006
J	Khalili, P; Arakelian, A; Chen, GP; Singh, G; Rabbani, SA				Khalili, P; Arakelian, A; Chen, GP; Singh, G; Rabbani, SA			Effect of Herceptin on the development and progression of skeletal metastases in a xenograft model of human breast cancer	ONCOGENE			English	Article						Her-2; antibody; bone metastases	TRASTUZUMAB HERCEPTIN; ZD1839 IRESSA; NUDE-MICE; IN-VIVO; GROWTH; HER2/NEU; CELLS; BONE; ONCOGENE; KINASE	We examined the effects of Herceptin, a bioengineered monoclonal antibody directed against Her-2/neu oncogene on skeletal metastasis using a xenograft model of breast cancer. Treatment of Her-2 overexpressing human breast cancer cells BT-474 with Herceptin caused a dose-dependent decrease in cell proliferation. In in vivo studies, BT-474 cells (1 x 10(5)) were injected into the left ventricle of female BALB/c nu/nu mice. Intraperitoneal (i.p.) infusion of Herceptin (1 mg/kg twice a week for 5 weeks) from the day of tumor cell inoculation or at the time of radiologically detectable skeletal metastasis either slowed the development or prevented the progression of skeletal metastasis as compared to control groups of animals receiving nonspecific IgG. Bone histological analysis of long bones showed the ability of Herceptin to reduce the ratio of tumor volume to bone volume as well as mitotic index, effects that were more pronounced when Herceptin treatment was initiated from the day of tumor cell inoculation. While immunohistochemical analysis of long bones showed no difference in the production of Her-2, phosphorylated (P) Her-2 and MAPK, a significantly lower level of P-MAPK was seen in bones of Herceptin treated animals. These studies demonstrate the ability of Herceptin to inhibit the development and abrogate the progression of skeletal metastases associated with breast cancer by blocking the HER-2-mediated signaling pathways.	McGill Univ, Ctr Hlth, Dept Med & Oncol, Montreal, PQ H3A 1A1, Canada; Hamilton Reg Canc Ctr, Hamilton, ON L8V 5C2, Canada	McGill University; McMaster University	Rabbani, SA (corresponding author), McGill Univ, Ctr Hlth, Dept Med & Oncol, 687 Pine Ave W,Room H4-61, Montreal, PQ H3A 1A1, Canada.	shafaat.rabbani@mcgill.ca	Singh, Gurmit/C-6744-2014	rabbani, shafaat/0000-0001-5594-3899				ADEWALE A, 2002, CLIN CANCER RES, V8, P1747; Baselga J, 1998, CANCER RES, V58, P2825; Bell R, 2002, ONCOLOGY-BASEL, V63, P39, DOI 10.1159/000066200; Bendre MS, 2002, CANCER RES, V62, P5571; Bernstein L, 2002, J MAMMARY GLAND BIOL, V7, P3, DOI 10.1023/A:1015714305420; Chen CN, 2000, J INF SCI ENG, V16, P1; DiGiovanna MP, 1998, ONCOGENE, V17, P1877, DOI 10.1038/sj.onc.1202091; Duivenvoorden WCM, 2002, CANCER RES, V62, P1588; El Abdaimi K, 2000, CANCER RES, V60, P4412; Esteva FJ, 2001, ONCOLOGIST, V6, P133, DOI 10.1634/theoncologist.6-2-133; KLIJN JGM, 1994, BREAST CANCER RES TR, V29, P73, DOI 10.1007/BF00666183; Kurebayashi  J, 2001, Breast Cancer, V8, P45, DOI 10.1007/BF02967477; Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc; MARGOLESE TG, 2003, CANC MED, P1879; Masood S, 2002, MICROSC RES TECHNIQ, V59, P102, DOI 10.1002/jemt.10181; Mayfield S, 2001, BREAST CANCER RES TR, V70, P123, DOI 10.1023/A:1012999012192; Moasser MM, 2001, CANCER RES, V61, P7184; Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867; Normanno N, 2002, ANN ONCOL, V13, P65, DOI 10.1093/annonc/mdf020; Park JW, 2002, CLIN CANCER RES, V8, P1172; Rabbani SA, 2005, ENDOCRINOLOGY, V146, P2885, DOI 10.1210/en.2005-0062; ROODMAN DG, 2003, CANCER, V97, P733; Ross JS, 1998, STEM CELLS, V16, P413, DOI 10.1002/stem.160413; SHAFIE SM, 1981, J NATL CANCER I, V67, P51; Sliwkowski MX, 1999, SEMIN ONCOL, V26, P60; van der Pluijm G, 2000, CANCER TREAT REV, V26, P11, DOI 10.1053/ctrv.1999.0143; Yakes FM, 2002, CANCER RES, V62, P4132; Yarden Y, 2001, ONCOLOGY-BASEL, V61, P1, DOI 10.1159/000055396; Zhou BP, 2003, SEMIN ONCOL, V30, P38, DOI 10.1053/j.seminoncol.2003.08.006	29	24	26	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2005	24	44					6657	6666		10.1038/sj.onc.1208790	http://dx.doi.org/10.1038/sj.onc.1208790			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	971FL	16091754				2022-12-25	WOS:000232367800007
J	Hirose, M; Tohda, H; Giga-Hama, Y; Tsushima, R; Zako, T; Iizuka, R; Pack, C; Kinjo, M; Ishii, N; Yohda, M				Hirose, M; Tohda, H; Giga-Hama, Y; Tsushima, R; Zako, T; Iizuka, R; Pack, C; Kinjo, M; Ishii, N; Yohda, M			Interaction of a small heat shock protein of the fission yeast, Schizosaccharomyces pombe, with a denatured protein at elevated temperature	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-CRYSTALLIN; SUBSTRATE; DISSOCIATION; HSP16.3; BINDING; ATP; ACTIVATION; EXPRESSION; MECHANISM; GROEL	We have expressed, purified, and characterized one small heat shock protein of the fission yeast Schizosaccharomyces pombe, SpHsp16.0. SpHsp16.0 was able to protect citrate synthase from thermal aggregation at 45 degrees C with high efficiency. It existed as a hexadecameric globular oligomer near the physiological growth temperature. At elevated temperatures, the oligomer dissociated into small species, probably dimers. The dissociation was completely reversible, and the original oligomer reformed immediately after the temperature dropped. Large complexes of SpHsp16.0 and denatured citrate synthase were observed by size exclusion chromatography and electron microscopy following incubation at 45 degrees C and then cooling. However, such large complexes did not elute from the size exclusion column incubated at 45 degrees C. The denatured citrate synthase protected from aggregation was trapped by a GroEL trap mutant at 45 degrees C. These results suggest that the complex of SpHsp16.0 and denatured citrate synthase at elevated temperatures is in the transient state and has a hydrophobic nature. Analyses of the interaction between SpHsp16.0 and denatured citrate synthase by fluorescence cross- correlation spectrometry have also shown that the characteristics of SpHsp16.0- denatured citrate synthase complex at the elevated temperature are different from those of the large complex obtained after the shift to lowered temperatures.	Tokyo Univ Agr & Technol, Dept Biotechnol & Life Sci, Koganei, Tokyo 1848588, Japan; Asahi Glass Co Ltd, ASPEX Div, Kanagawa Ku, Yokohama, Kanagawa 2218755, Japan; Hokkaido Univ, Res Inst Elect Sci, Lab Supramol Biophys, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Natl Inst Adv Ind Sci & Technol, Biol Informat Res Ctr, Tsukuba, Ibaraki 3058566, Japan	Tokyo University of Agriculture & Technology; AGC Inc; Hokkaido University; National Institute of Advanced Industrial Science & Technology (AIST)	Yohda, M (corresponding author), Tokyo Univ Agr & Technol, Dept Biotechnol & Life Sci, 2-24-16 Naka Cho, Koganei, Tokyo 1848588, Japan.	yohda@cc.tuat.ac.jp	Tohda, Hideki/H-3162-2013; Tohda, Hideki/O-5132-2019; Ishii, Noriyuki/E-5661-2011; Yohda, Masafumi/A-5149-2013; Kinjo, Masataka/F-5267-2011; Zako, Tamotsu/C-3004-2012	Ishii, Noriyuki/0000-0002-4120-6203; Yohda, Masafumi/0000-0001-8307-9671; Kinjo, Masataka/0000-0001-8889-8369; Iizuka, Ryo/0000-0002-9328-5628				Buchner J, 1998, METHOD ENZYMOL, V290, P339, DOI 10.1016/S0076-6879(98)90030-1; CASPERS GJ, 1995, J MOL EVOL, V40, P238, DOI 10.1007/BF00163229; Franzmann TM, 2005, J MOL BIOL, V350, P1083, DOI 10.1016/j.jmb.2005.05.034; Fu XM, 2004, BIOCHEM BIOPH RES CO, V316, P291, DOI 10.1016/j.bbrc.2004.02.053; Fu XM, 2005, J BIOL CHEM, V280, P6337, DOI 10.1074/jbc.M406319200; Gu LX, 2002, J MOL BIOL, V319, P517, DOI 10.1016/S0022-2836(02)00311-X; Haley DA, 2000, J MOL BIOL, V298, P261, DOI 10.1006/jmbi.2000.3657; Haslbeck M, 1999, EMBO J, V18, P6744, DOI 10.1093/emboj/18.23.6744; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Iizuka R, 2001, BIOCHEM BIOPH RES CO, V289, P1118, DOI 10.1006/bbrc.2001.6139; JAKOB U, 1993, J BIOL CHEM, V268, P1517; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Lee GJ, 2000, PLANT PHYSIOL, V122, P189, DOI 10.1104/pp.122.1.189; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; Leroux MR, 1997, J BIOL CHEM, V272, P12847, DOI 10.1074/jbc.272.19.12847; Mogk A, 2003, MOL MICROBIOL, V50, P585, DOI 10.1046/j.1365-2958.2003.03710.x; Mogk A, 2003, J BIOL CHEM, V278, P31033, DOI 10.1074/jbc.M303587200; Muchowski PJ, 1998, P NATL ACAD SCI USA, V95, P1004, DOI 10.1073/pnas.95.3.1004; Narberhaus F, 2002, MICROBIOL MOL BIOL R, V66, P64, DOI 10.1128/MMBR.66.1.64-93.2002; Okochi M, 2002, BIOCHEM BIOPH RES CO, V291, P769, DOI 10.1006/bbrc.2002.6523; Pack CG, 2000, BIOCHEM BIOPH RES CO, V267, P300, DOI 10.1006/bbrc.1999.1864; Pack CG, 1999, CYTOMETRY, V36, P247, DOI 10.1002/(SICI)1097-0320(19990701)36:3<247::AID-CYTO15>3.0.CO;2-#; PLESOFSKYVIG N, 1995, P NATL ACAD SCI USA, V92, P5032, DOI 10.1073/pnas.92.11.5032; RIGLER R, 1993, EUR BIOPHYS J BIOPHY, V22, P169, DOI 10.1007/BF00185777; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; Saito K, 2004, BIOCHEM BIOPH RES CO, V324, P849, DOI 10.1016/j.bbrc.2004.09.126; Shashidharamurthy R, 2005, J BIOL CHEM, V280, P5281, DOI 10.1074/jbc.M407236200; Taricani L, 2001, NUCLEIC ACIDS RES, V29, P3030, DOI 10.1093/nar/29.14.3030; Usui K, 2004, PROTEIN SCI, V13, P134, DOI 10.1110/ps.03264204; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; VANDENIJSSEL PRLA, 1994, FEBS LETT, V355, P54, DOI 10.1016/0014-5793(94)01175-3; Veinger L, 1998, J BIOL CHEM, V273, P11032, DOI 10.1074/jbc.273.18.11032; WYATT PJ, 1993, ANAL CHIM ACTA, V272, P1, DOI 10.1016/0003-2670(93)80373-S; Yoshida T, 2002, J MOL BIOL, V315, P73, DOI 10.1006/jmbi.2001.5220	34	17	18	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32586	32593		10.1074/jbc.M504121200	http://dx.doi.org/10.1074/jbc.M504121200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16055437	hybrid			2022-12-25	WOS:000231920300005
J	Kim, Y; Sato, K; Asagiri, M; Morita, I; Soma, K; Takayanagi, H				Kim, Y; Sato, K; Asagiri, M; Morita, I; Soma, K; Takayanagi, H			Contribution of nuclear factor of activated T cells c1 to the transcriptional control of immunoreceptor osteoclast-associated receptor but not triggering receptor expressed by myeloid cells-2 during osteoclastogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; ADAPTER PROTEINS; BONE HOMEOSTASIS; DIFFERENTIATION; RANKL; MOTIF; BEARING; KINASE; FAMILY; LIGAND	Bone homeostasis depends on the coordination of osteoclastic bone resorption and osteoblastic bone formation. Receptor activator of NF-kappa B ligand (RANKL) induces osteoclast differentiation through activating a transcriptional program mediated by the key transcription factor nuclear factor of activated T cells ( NFAT) c1. Immunoreceptors, including osteoclast-associated receptor (OSCAR) and triggering receptor expressed by myeloid cells (TREM)-2, constitute the co-stimulatory signals required for RANKL-mediated activation of calcium signaling, which leads to the activation of NFATc1. However, it remains unknown whether the expression of immunoreceptors are under the control of NFATc1. Here we demonstrate that the expression of OSCAR, but not that of TREM-2, is up-regulated during osteoclastogenesis and markedly suppressed by the calcineurin inhibitor FK506, suggesting that OSCAR is transcriptionally regulated by NFATc1. NFATc1 expression results in the activation of the OSCAR promoter, which was found to be further enhanced by co-expression of PU.1 and microphthalmia-associated transcription factor (MITF). We further provide evidence that NFATc1 specifically regulates OSCAR by chromatin immunoprecipitation assay and quantification of OSCAR and TREM-2 mRNAin NFATc1(-/-) cells. Thus, OSCAR but not TREM-2 is involved in the positive feedback loop of the immunoreceptor-NFATc1 pathway during osteoclastogenesis. Although several immunoreceptors have been identified as co-stimulatory molecules for RANKL, the expression and function are differentially regulated. These mechanisms, possibly together with the delicate regulation of their ligands on osteoblasts, may provide the exquisite machinery for the modulation of osteoclastogenesis in the maintenance of bone homeostasis.	Tokyo Med & Dent Univ, Dept Cell Signaling, Grad Sch, Bunkyo Ku, Tokyo 1138549, Japan; Ctr Excellence COE, Program Frontier Res Mol Destruct & Reconstruct T, Tokyo 1138549, Japan; Grad Sch, Div Oral Hlth Sci, Dept Orofacial Dev & Funct, Tokyo 1138549, Japan; Tokyo Med & Dent Univ, Grad Sch, Dept Cellular Physiol Chem, Tokyo 1138549, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Takayanagi, H (corresponding author), Tokyo Med & Dent Univ, Dept Cell Signaling, Grad Sch, Bunkyo Ku, Yushima 1-5-45, Tokyo 1138549, Japan.	taka.csi@tmd.ac.jp		Sato, Kojiro/0000-0003-4105-3726; Kim, Yoonji/0000-0002-1664-3137				Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; Cella M, 2003, J EXP MED, V198, P645, DOI 10.1084/jem.20022220; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Daws MR, 2001, EUR J IMMUNOL, V31, P783, DOI 10.1002/1521-4141(200103)31:3<783::AID-IMMU783>3.0.CO;2-U; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; DeKoter RP, 2002, IMMUNITY, V16, P297, DOI 10.1016/S1074-7613(02)00269-8; Dietrich J, 2000, J IMMUNOL, V164, P9, DOI 10.4049/jimmunol.164.1.9; Eissner G, 2004, CYTOKINE GROWTH F R, V15, P353, DOI 10.1016/j.cytogfr.2004.03.011; Horejsi V, 2004, NAT REV IMMUNOL, V4, P603, DOI 10.1038/nri1414; Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534-5807(02)00157-0; Karsenty G, 1999, GENE DEV, V13, P3037, DOI 10.1101/gad.13.23.3037; Kim N, 2002, J EXP MED, V195, P201, DOI 10.1084/jem.20011681; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444; Kubagawa H, 1997, P NATL ACAD SCI USA, V94, P5261, DOI 10.1073/pnas.94.10.5261; Lanier LL, 2000, IMMUNOL TODAY, V21, P611, DOI 10.1016/S0167-5699(00)01745-X; Lanier LL, 1998, NATURE, V391, P703, DOI 10.1038/35642; Long EO, 1999, ANNU REV IMMUNOL, V17, P875, DOI 10.1146/annurev.immunol.17.1.875; Matsumoto M, 2004, J BIOL CHEM, V279, P45969, DOI 10.1074/jbc.M408795200; Matsumoto M, 2001, J BIOL CHEM, V276, P33086, DOI 10.1074/jbc.M104299200; Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200; Mocsai A, 2004, P NATL ACAD SCI USA, V101, P6158, DOI 10.1073/pnas.0401602101; Ohtsuka M, 2004, P NATL ACAD SCI USA, V101, P8126, DOI 10.1073/pnas.0401119101; Paloneva J, 2003, J EXP MED, V198, P669, DOI 10.1084/jem.20030027; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Shiratori I, 2004, J EXP MED, V199, P525, DOI 10.1084/jem.20031885; So H, 2003, J BIOL CHEM, V278, P24209, DOI 10.1074/jbc.M302940200; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo-123-5-2600; Takai T, 2002, NAT REV IMMUNOL, V2, P580, DOI 10.1038/nri856; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102; Takayanagi H, 2005, J MOL MED, V83, P170, DOI 10.1007/s00109-004-0612-6; Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a; Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190	38	49	53	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32905	32913		10.1074/jbc.M505820200	http://dx.doi.org/10.1074/jbc.M505820200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16046394	hybrid			2022-12-25	WOS:000231920300045
J	Bach, FH				Bach, FH			Heme oxygenase-1: a therapeutic amplification funnel	FASEB JOURNAL			English	Editorial Material							CARBON-MONOXIDE; MICROSATELLITE POLYMORPHISM; BILIVERDIN REDUCTASE; INDUCTION; PROTECTS; RAPAMYCIN; PROMOTER; GENE; SUSCEPTIBILITY; EXPRESSION		Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Bach, FH (corresponding author), 99 Brookline Ave, Boston, MA 02215 USA.	fritz_bach@hms.harvard.edu						Berberat PO, 2003, FASEB J, V17, P1724, DOI 10.1096/fj.03-0229fje; Bussolati B, 2004, BLOOD, V103, P761, DOI 10.1182/blood-2003-06-1974; Chen YH, 2002, HUM GENET, V111, P1, DOI 10.1007/s00439-002-0769-4; Deng YM, 2004, CIRCULATION, V110, P1855, DOI 10.1161/01.CIR.0000142610.10530.25; Duckers HJ, 2001, NAT MED, V7, P693, DOI 10.1038/89068; Exner M, 2004, FREE RADICAL BIO MED, V37, P1097, DOI 10.1016/j.freeradbiomed.2004.07.008; Grosser N, 2003, BIOCHEM BIOPH RES CO, V308, P956, DOI 10.1016/S0006-291X(03)01504-3; KOIZUMI T, 1992, PROSTAGLANDINS, V43, P121, DOI 10.1016/0090-6980(92)90081-4; Kravets A, 2004, J BIOL CHEM, V279, P19916, DOI 10.1074/jbc.M314251200; Lavitrano M, 2004, FASEB J, V18, P1093, DOI 10.1096/fj.03-0996fje; Lee TS, 2004, CIRCULATION, V110, P1296, DOI 10.1161/01.CIR.0000140694.67251.9C; Lee TS, 2003, J BIOL CHEM, V278, P19325, DOI 10.1074/jbc.M300498200; Lee TS, 2002, NAT MED, V8, P240, DOI 10.1038/nm0302-240; Maines MD, 2004, ANTIOXID REDOX SIGN, V6, P797, DOI 10.1089/1523086041798105; MOORE BA, 2004, EFFECTS CARBON MONOX; Nakao A, 2004, GASTROENTEROLOGY, V127, P595, DOI 10.1053/j.gastro.2004.05.059; Nakao A, 2003, AM J PATHOL, V163, P1587, DOI 10.1016/S0002-9440(10)63515-8; Novotny L, 2003, EXP BIOL MED, V228, P568, DOI 10.1177/15353702-0322805-29; Otterbein LE, 2003, TRENDS IMMUNOL, V24, P449, DOI 10.1016/S1471-4906(03)00181-9; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; OTTERBEIN LE, 2003, NAT MED, V29, P183; Poon M, 1996, J CLIN INVEST, V98, P2277, DOI 10.1172/JCI119038; Redaelli CA, 2002, HEPATOLOGY, V35, P1082, DOI 10.1053/jhep.2002.33067; Ryter SW, 2004, BIOESSAYS, V26, P270, DOI 10.1002/bies.20005; Sarady JK, 2004, FASEB J, V18, P854, DOI 10.1096/fj.03-0643fje; Schillinger M, 2004, J AM COLL CARDIOL, V43, P950, DOI 10.1016/j.jacc.2003.09.058; Sedlak TW, 2004, PEDIATRICS, V113, P1776, DOI 10.1542/peds.113.6.1776; SEHGAL SN, 1993, ANN NY ACAD SCI, V685, P58, DOI 10.1111/j.1749-6632.1993.tb35852.x; Soares MP, 2004, J IMMUNOL, V172, P3553, DOI 10.4049/jimmunol.172.6.3553; Soares MP, 2004, BLOOD, V103, P751, DOI 10.1182/blood-2003-11-3879; Visner GA, 2003, CIRCULATION, V107, P911, DOI 10.1161/01.CIR.0000048191.75585.60; Yamada N, 2000, AM J HUM GENET, V66, P187, DOI 10.1086/302729; Zhuang H, 2003, ANN NY ACAD SCI, V993, P276, DOI 10.1111/j.1749-6632.2003.tb07534.x; Zuckerbraun BS, 2003, J EXP MED, V198, P1707, DOI 10.1084/jem.20031003	34	94	96	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1216	1219		10.1096/fj.04-3485cmt	http://dx.doi.org/10.1096/fj.04-3485cmt			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16051687				2022-12-25	WOS:000231843700027
J	Kobayashi, H; Kromminga, A; Dunlop, TW; Tychsen, B; Conrad, F; Suzuki, N; Memezawa, A; Bettermann, A; Aiba, S; Carlberg, C; Paus, R				Kobayashi, H; Kromminga, A; Dunlop, TW; Tychsen, B; Conrad, F; Suzuki, N; Memezawa, A; Bettermann, A; Aiba, S; Carlberg, C; Paus, R			A role of melatonin in neuroectodermal-mesodermal interactions: the hair follicle synthesizes melatonin and expresses functional melatonin receptors	FASEB JOURNAL			English	Review						melatonin; hair follicles; MT2; ROR alpha; estrogen receptors; C57BL/6 mice; apoptosis	HUMAN-BREAST-CANCER; NITRIC-OXIDE SYNTHASE; UV-INDUCED ERYTHEMA; WINTER FUR GROWTH; PINEAL-GLAND; NUCLEAR RECEPTOR; SEROTONINERGIC SYSTEM; N-ACETYLTRANSFERASE; TOPICAL TREATMENT; GENE-EXPRESSION	Since mammalian skin expresses the enzymatic apparatus for melatonin synthesis, it may be an extrapineal site of melatonin synthesis. However, evidence is still lacking that this is really the case in situ. Here, we demonstrate melatonin-like immunoreactivity (IR) in the outer root sheath (ORS) of mouse and human hair follicles (HFs), which corresponds to melatonin, as shown by radioimmunoassay and liquid chromatography/tandem mass spectrometry (LC/MS/MS). The melatonin concentration in organ-cultured mouse skin, mouse vibrissae follicles, and human scalp HFs far exceeds the respective melatonin serum level and is significantly increased ex vivo by stimulation with norepinephrine ( NE), the key stimulus for pineal melatonin synthesis. By real-time PCR, transcripts for the melatonin membrane receptor MT2 and for the nuclear mediator of melatonin signaling, retinoid orphan receptor alpha(ROR)alpha, are detectable in murine back skin. Transcript levels for these receptors fluctuate in a hair cycle-dependent manner, and are maximal during apoptosis-driven HF regression (catagen). Melatonin may play a role in hair cycle regulation, since its receptors (MT2 and ROR alpha) are expressed in murine skin in a hair cycle-dependent manner, and because it inhibits keratinocyte apoptosis and down-regulates ER alpha expression. Therefore, the HF is both, a prominent extrapineal melatonin source, and an important peripheral melatonin target tissue. Regulated intrafollicular melatonin synthesis and signaling may play a previously unrecognized role in the endogenous controls of hair growth, for example, by modulating keratinocyte apoptosis during catagen and by desensitizing the HF to estrogen signaling. As a prototypic neuroectodermal-mesodermal interaction model, the HF can be exploited for dissecting the obscure role of melatonin in such interactions in peripheral tissues.	Med Univ Lubeck, Univ Hosp Schleswig Holstein, Dept Dermatol, D-23538 Lubeck, Germany; Tohoku Univ Hosp, Dept Pharmaceut Sci, Sendai, Miyagi, Japan; Univ Kuopio, Dept Biochem, FIN-70211 Kuopio, Finland; Inst Immunol Clin Pathol & Mol Med, Hamburg, Germany; Tohoku Univ, Sch Med, Dept Dermatol, Sendai, Miyagi 980, Japan; Univ Hamburg, Hosp Eppendorf, Dept Dermatol, D-20246 Hamburg, Germany	University of Kiel; Schleswig Holstein University Hospital; University of Lubeck; Tohoku University; Finland National Institute for Health & Welfare; University of Eastern Finland; Tohoku University; University of Hamburg	Paus, R (corresponding author), Med Univ Lubeck, Univ Hosp Schleswig Holstein, Dept Dermatol, D-23538 Lubeck, Germany.	paus@uke.uni-hamburg.de	Carlberg, Carsten/C-9075-2011; Paus, Ralf/F-6243-2011	Carlberg, Carsten/0000-0003-2633-0684; 				Acuna-Castroviejo D, 2001, J PINEAL RES, V30, P65, DOI 10.1034/j.1600-079X.2001.300201.x; Bangha E, 1996, ARCH DERMATOL RES, V288, P522, DOI 10.1007/s004030050096; Bangha E, 1997, DERMATOLOGY, V195, P248, DOI 10.1159/000245953; BATES SE, 1988, MOL ENDOCRINOL, V2, P543, DOI 10.1210/mend-2-6-543; BECKERANDRE M, 1993, BIOCHEM BIOPH RES CO, V194, P1371, DOI 10.1006/bbrc.1993.1976; Botchkarev VA, 2004, PROG BRAIN RES, V146, P493; Botchkarev VA, 1998, AM J PATHOL, V153, P785, DOI 10.1016/S0002-9440(10)65621-0; Brzezinski Amnon, 1997, New England Journal of Medicine, V336, P186; Bubenik GA, 2002, DIGEST DIS SCI, V47, P2336, DOI 10.1023/A:1020107915919; Carlberg C, 2000, ANN NY ACAD SCI, V917, P387; Carrillo-Vico A, 2004, FASEB J, V18, P537, DOI 10.1096/fj.03-0694fje; Chanda S, 2000, AM J PHYSIOL-ENDOC M, V278, pE202, DOI 10.1152/ajpendo.2000.278.2.E202; CONRAD F, 2005, IN PRESS J INVESTIG; Conti A, 2000, J PINEAL RES, V28, P193, DOI 10.1034/j.1600-079X.2000.280401.x; COTSARELIS G, 2003, DISORDERS HAIR GROWT; Dai J, 2002, J PINEAL RES, V32, P112, DOI 10.1034/j.1600-079x.2002.1844.x; Dreher F, 1998, BRIT J DERMATOL, V139, P332, DOI 10.1046/j.1365-2133.1998.02447.x; Drijfhout WJ, 1996, NEUROSCI LETT, V202, P185, DOI 10.1016/0304-3940(95)12245-1; FINOCCHIARO LME, 1991, BIOCHEM J, V280, P727, DOI 10.1042/bj2800727; Fischer TW, 2001, J PINEAL RES, V31, P39, DOI 10.1034/j.1600-079X.2001.310106.x; Foitzik K, 2000, FASEB J, V14, P752, DOI 10.1096/fasebj.14.5.752; FOLES A, 1992, ADV PINEAL RES, V6, P235; GAUDET SJ, 1993, J INVEST DERMATOL, V101, P660, DOI 10.1111/1523-1747.ep12371672; Gonzalez R, 1991, Melanoma Res, V1, P237, DOI 10.1097/00008390-199111000-00003; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; IBRAHEEM M, 1994, J ANAT, V185, P135; Ito N, 2005, FASEB J, V19, P1332, DOI 10.1096/fj.04-1968fje; Ito N, 2004, J INVEST DERMATOL, V122, P235, DOI 10.1046/j.1523-1747.2003.22145.x; Itoh MT, 1997, MOL CELL ENDOCRINOL, V136, P7, DOI 10.1016/S0303-7207(97)00206-2; Jin XW, 2003, MOL CELL BIOL, V23, P1054, DOI 10.1128/MCB.23.3.1054-1060.2003; Johnston B, 1999, J EXP ZOOL, V284, P437, DOI 10.1002/(SICI)1097-010X(19990901)284:4&lt;437::AID-JEZ10&gt;3.0.CO;2-X; Jou MJ, 2004, J PINEAL RES, V37, P55, DOI 10.1111/j.1600-079X.2004.00140.x; Kiefer T, 2002, BREAST CANCER RES TR, V71, P37, DOI 10.1023/A:1013301408464; Kobayashi H, 2005, EXP DERMATOL, V14, P157, DOI 10.1111/j.0906-6705.2005.0266p.x; Kobayashi H, 2004, J INVEST DERMATOL, V123; Kobayashi Y, 2003, J PINEAL RES, V35, P71, DOI 10.1034/j.1600-079X.2003.00053.x; Kvetnoy IM, 1999, HISTOCHEM J, V31, P1, DOI 10.1023/A:1003431122334; Lee P. P. N., 1993, Biological Signals, V2, P181; Leon J, 2004, LIFE SCI, V75, P765, DOI 10.1016/j.lfs.2004.03.003; Leon J, 2000, MOL PHARMACOL, V58, P967, DOI 10.1124/mol.58.5.967; LERNER AB, 1958, J AM CHEM SOC, V80, P2587, DOI 10.1021/ja01543a060; Lindner G, 1997, AM J PATHOL, V151, P1601; Liu C, 1997, NEURON, V19, P91, DOI 10.1016/S0896-6273(00)80350-5; LOGAN A, 1980, J INVEST DERMATOL, V74, P47, DOI 10.1111/1523-1747.ep12514608; Magerl M, 2001, J INVEST DERMATOL, V116, P947, DOI 10.1046/j.0022-202x.2001.01368.x; Maronde E, 1997, BIOL CELL, V89, P505, DOI 10.1016/S0248-4900(98)80006-3; MCCLOGHRY E, 1992, J PINEAL RES, V13, P139, DOI 10.1111/j.1600-079X.1992.tb00068.x; MCELHINNEY DB, 1994, J INVEST DERMATOL, V102, P258, DOI 10.1111/1523-1747.ep12371773; MENNENGA K, 1991, J PINEAL RES, V10, P159, DOI 10.1111/j.1600-079X.1991.tb00834.x; MOLIS TM, 1994, MOL ENDOCRINOL, V8, P1681, DOI 10.1210/me.8.12.1681; Muller-Rover S, 2001, J INVEST DERMATOL, V117, P3, DOI 10.1046/j.0022-202x.2001.01377.x; Naji L, 2004, LIFE SCI, V74, P2227, DOI 10.1016/j.lfs.2003.08.046; Nickel A, 2000, ARCH DERMATOL RES, V292, P366, DOI 10.1007/s004030000141; NIXON AJ, 1995, J EXP ZOOL, V272, P435, DOI 10.1002/jez.1402720605; NIXON AJ, 1993, J EXP ZOOL, V267, P47, DOI 10.1002/jez.1402670108; Oh HS, 1996, P NATL ACAD SCI USA, V93, P12525, DOI 10.1073/pnas.93.22.12525; Ohnemus U, 2005, ENDOCRINOLOGY, V146, P1214, DOI 10.1210/en.2004-1219; Paus R, 2004, DIFFERENTIATION, V72, P489, DOI 10.1111/j.1432-0436.2004.07209004.x; PAUS R, 1991, BRIT J DERMATOL, V124, P415, DOI 10.1111/j.1365-2133.1991.tb00618.x; PAUS R, 1990, BRIT J DERMATOL, V122, P777, DOI 10.1111/j.1365-2133.1990.tb06266.x; Paus R, 1997, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 2, NO 1, AUGUST 1997, P61, DOI 10.1038/jidsymp.1997.13; Paus R, 1999, NEW ENGL J MED, V341, P491, DOI 10.1056/NEJM199908123410706; Philpott M P, 1994, J Dermatol Sci, V7 Suppl, pS55, DOI 10.1016/0923-1811(94)90036-1; POEGGELER B, 1994, ANN NY ACAD SCI, V738, P419, DOI 10.1111/j.1749-6632.1994.tb21831.x; POEGGELER B, 1993, J PINEAL RES, V14, P151, DOI 10.1111/j.1600-079X.1993.tb00498.x; Poirel VJ, 2003, NEUROENDOCRINOL LETT, V24, P33; Pozo D, 1997, J CELL BIOCHEM, V65, P430, DOI 10.1002/(SICI)1097-4644(19970601)65:3<430::AID-JCB12>3.0.CO;2-J; Provinciali M, 1996, MECH AGEING DEV, V90, P1, DOI 10.1016/0047-6374(96)01746-0; Reiter RJ, 1998, ANN NY ACAD SCI, V854, P410, DOI 10.1111/j.1749-6632.1998.tb09920.x; Reiter RJ, 2003, BEST PRACT RES CL EN, V17, P273, DOI 10.1016/S1521-690X(03)00016-2; REITER RJ, 1991, MOL CELL ENDOCRINOL, V79, pC153, DOI 10.1016/0303-7207(91)90087-9; REPPERT SM, 1995, P NATL ACAD SCI USA, V92, P8734, DOI 10.1073/pnas.92.19.8734; REPPERT SM, 1994, NEURON, V13, P1177, DOI 10.1016/0896-6273(94)90055-8; Rodriguez C, 2004, J PINEAL RES, V36, P1, DOI 10.1046/j.1600-079X.2003.00092.x; Rose J, 1998, COMP BIOCHEM PHYS A, V121, P263, DOI 10.1016/S1095-6433(98)10127-7; ROSE J, 1987, GEN COMP ENDOCR, V65, P212, DOI 10.1016/0016-6480(87)90168-7; Roseboom PH, 1998, MOL BRAIN RES, V63, P189, DOI 10.1016/S0169-328X(98)00273-3; Sainz RM, 2003, CELL MOL LIFE SCI, V60, P1407, DOI 10.1007/s00018-003-2319-1; Sainz RM, 1999, FASEB J, V13, P1547, DOI 10.1096/fasebj.13.12.1547; Saji S, 2000, P NATL ACAD SCI USA, V97, P337, DOI 10.1073/pnas.97.1.337; Semak I, 2004, ARCH BIOCHEM BIOPHYS, V421, P61, DOI 10.1016/j.abb.2003.08.036; Slominski A, 1994, Exp Dermatol, V3, P45, DOI 10.1111/j.1600-0625.1994.tb00265.x; Slominski A, 2002, FASEB J, V16, P896, DOI 10.1096/fj.01-0952fje; Slominski A, 1996, J BIOL CHEM, V271, P12281, DOI 10.1074/jbc.271.21.12281; Slominski A, 2005, FASEB J, V19, P176, DOI 10.1096/fj.04-2079rev; Slominski A, 2004, BBA-GENE STRUCT EXPR, V1680, P67, DOI 10.1016/j.bbaexp.2004.09.002; Slominski A, 2003, EUR J BIOCHEM, V270, P3335, DOI 10.1046/j.1432-1033.2003.03708.x; Slominski A, 2003, J CELL PHYSIOL, V196, P144, DOI 10.1002/jcp.10287; Slominski A, 2002, J INVEST DERMATOL, V119, P934, DOI 10.1046/j.1523-1747.2002.00156.x; SLOMINSKI A, 1993, EXP CELL RES, V206, P189, DOI 10.1006/excr.1993.1137; Slominski A, 2004, ENDOCRINOLOGY, V145, P941, DOI 10.1210/en.2003-0851; STEINHILBER D, 1995, J BIOL CHEM, V270, P7037, DOI 10.1074/jbc.270.13.7037; Steinmayr M, 1998, P NATL ACAD SCI USA, V95, P3960, DOI 10.1073/pnas.95.7.3960; Stenn KS, 2001, PHYSIOL REV, V81, P449, DOI 10.1152/physrev.2001.81.1.449; Thornton MJ, 2003, EXP DERMATOL, V12, P181, DOI 10.1034/j.1600-0625.2003.120209.x; TILLET Y, 1989, CELL TISSUE RES, V257, P23; Tosini G, 1998, BRAIN RES, V789, P221, DOI 10.1016/S0006-8993(97)01446-7; Vijayalaxmi, 2002, J CLIN ONCOL, V20, P2575, DOI 10.1200/JCO.2002.11.004; VIVIENROELS B, 1981, CELL TISSUE RES, V217, P105, DOI 10.1007/bf00233830; von Gall C, 2002, CELL TISSUE RES, V309, P151, DOI 10.1007/s00441-002-0581-4; von Gall C, 2000, EUR J NEUROSCI, V12, P964, DOI 10.1046/j.1460-9568.2000.00990.x; Warner M, 2003, METHOD ENZYMOL, V364, P448; WIESENBERG I, 1995, NUCLEIC ACIDS RES, V23, P327, DOI 10.1093/nar/23.3.327; WILLIAMS D, 1994, BRIT J DERMATOL, V130, P290, DOI 10.1111/j.1365-2133.1994.tb02923.x; Witt-Enderby PA, 2003, LIFE SCI, V72, P2183, DOI 10.1016/S0024-3205(03)00098-5; Yang SM, 2002, J PHARMACEUT BIOMED, V30, P781, DOI 10.1016/S0731-7085(02)00387-4; YEE D, 1989, MOL ENDOCRINOL, V3, P509, DOI 10.1210/mend-3-3-509	107	97	109	1	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1710	+		10.1096/fj.04-2293fje	http://dx.doi.org/10.1096/fj.04-2293fje			28	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16030176				2022-12-25	WOS:000230923000017
J	Su, M; Bansal, AK; Mantovani, R; Sodek, J				Su, M; Bansal, AK; Mantovani, R; Sodek, J			Recruitment of nuclear factor Y to the inverted CCAAT element (ICE) by c-Jun and E1A stimulates basal transcription of the bone sialoprotein gene in osteosarcoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; HUMAN HSP70 PROMOTER; BOX-BINDING FACTOR; NF-Y; HISTONE ACETYLTRANSFERASES; C/EBP-ALPHA; HUMAN BREAST; HA-RAS; EXPRESSION; ACTIVATION	Bone sialoprotein (BSP), a major protein in the extracellular matrix of bone, is expressed almost exclusively by bone cells and by cancer cells that have a propensity to metastasize to bone. Previous studies have shown that v-src stimulates basal transcription of bsp in osteosarcoma (ROS 17/2.8) cells by targeting the inverted CCAAT element ( ICE) in the proximal promoter. To identify possible downstream effectors of Src we studied the effects of the proto-oncogene c-jun, which functions downstream of Src, on basal transcription of bsp using transient transfection assays. Increased expression of endogenous c-Jun induced by the tumor promoter 12-O-tetradecanoyl-phorbol 13-acetate and ectopic expression of c-Jun increased basal transcription of chimeric reporter constructs encompassing the proximal promoter by 1.5-3-fold in ROS 17/2.8 osteosarcoma cells, with more modest effects in a normal bone cell line, RBMC-D8. The effects of c-Jun were abrogated by mutations in the ICE box and by co-expression of dominant negative nuclear factor Y, subunit A (NF-YA). The increase in bsp transcription did not require phosphorylation of c-Jun and was not altered by trichostatin treatment or by ectopic expression of p300/CREB-binding protein (CBP) or mutated forms lacking histone acetyltransferase ( HAT) activity. Similarly, ectopic expression of p300/CBP-associated factor (P/CAF), which transduces p300/ CBP effects, or of HAT-defective P/CAF did not influence the c-jun effects. Surprisingly, E1A, which competes with P/CAF binding to p300/ CBP, also stimulated BSP transcription through NF-Y independently of c-jun, p300/ CBP, and P/CAF. Collectively, these studies show that c-Jun and E1A regulate basal transcription of bsp in osteosarcoma cells by recruiting the NF-Y transcriptional complex to the ICE box in a mechanism that is independent of p300/ CBP and P/CAF HAT activities.	Univ Toronto, Fac Dent, Canadian Inst Hlth Res Grp Matrix Dynam, Toronto, ON M5S 3E2, Canada; Univ Toronto, Fac Med, Dept Biochem, Toronto, ON M5S 3E2, Canada; Univ Milan, Dipartimento Sci Biomol & Biotecnol, I-20143 Milan, Italy	University of Toronto; University of Toronto; University of Milan	Su, M (corresponding author), Univ Toronto, Fac Dent, Canadian Inst Hlth Res Grp Matrix Dynam, 234 FitzGerald Bldg,150 Coll St, Toronto, ON M5S 3E2, Canada.	m.su@utoronto.ca						AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; Bellahcene A, 2000, CIRC RES, V86, P885, DOI 10.1161/01.RES.86.8.885; Bellahcene A, 1996, J BONE MINER RES, V11, P665; Bellorini M, 1997, NUCLEIC ACIDS RES, V25, P2174, DOI 10.1093/nar/25.11.2174; Besirli CG, 2003, J BIOL CHEM, V278, P22357, DOI 10.1074/jbc.M300742200; Bevilacqua MA, 1997, J BIOL CHEM, V272, P20736, DOI 10.1074/jbc.272.33.20736; Bolognese F, 1999, ONCOGENE, V18, P1845, DOI 10.1038/sj.onc.1202494; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Caretti G, 2003, J BIOL CHEM, V278, P30435, DOI 10.1074/jbc.M304606200; CHANG ZF, 1994, J BIOL CHEM, V269, P17893; Chen BK, 2000, P NATL ACAD SCI USA, V97, P10406, DOI 10.1073/pnas.180321497; Currie RA, 1998, J BIOL CHEM, V273, P1430, DOI 10.1074/jbc.273.3.1430; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; di Silvio A, 1999, NUCLEIC ACIDS RES, V27, P2578; DUTTA A, 1990, GENE DEV, V4, P243, DOI 10.1101/gad.4.2.243; Faniello MC, 1999, J BIOL CHEM, V274, P7623, DOI 10.1074/jbc.274.12.7623; Faniello MC, 2002, BIOCHEM J, V363, P53, DOI 10.1042/0264-6021:3630053; Farina A, 1999, ONCOGENE, V18, P2818, DOI 10.1038/sj.onc.1202472; Fedarko NS, 2004, FASEB J, V18, P734, DOI 10.1096/fj.03-0966fje; Fedarko NS, 2000, J BIOL CHEM, V275, P16666, DOI 10.1074/jbc.M001123200; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; Ganss B, 1999, CRIT REV ORAL BIOL M, V10, P79, DOI 10.1177/10454411990100010401; Good LF, 1996, BIOL SIGNAL, V5, P163; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Imbriano C, 2001, J BIOL CHEM, V276, P26332, DOI 10.1074/jbc.M101553200; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; Kim RH, 1999, CANCER RES, V59, P565; KIM RH, 2000, CHEM BIOL MINERALIZE, P39; KITABAYASHI I, 1991, NUCLEIC ACIDS RES, V19, P649, DOI 10.1093/nar/19.3.649; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; LI JJ, 1995, BIOCHEM J, V310, P33, DOI 10.1042/bj3100033; Liu G, 2003, J BIOL CHEM, V278, P17557, DOI 10.1074/jbc.M210696200; Liu HT, 2003, BLOOD, V101, P3885, DOI 10.1182/blood-2002-07-2212; LUM LSY, 1992, MOL CELL BIOL, V12, P2599, DOI 10.1128/MCB.12.6.2599; LUM LSY, 1990, MOL CELL BIOL, V10, P6709, DOI 10.1128/MCB.10.12.6709; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; Mao DYL, 2004, NUCLEIC ACIDS RES, V32, P3462, DOI 10.1093/nar/gkh669; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; Marziali G, 1997, MOL CELL BIOL, V17, P1387, DOI 10.1128/MCB.17.3.1387; Motta MC, 1999, J BIOL CHEM, V274, P1326, DOI 10.1074/jbc.274.3.1326; Munz C, 2003, J BIOL CHEM, V278, P21510, DOI 10.1074/jbc.M212764200; Naumann M, 1999, J BIOL CHEM, V274, P35297, DOI 10.1074/jbc.274.50.35297; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; Rangatia J, 2003, ONCOGENE, V22, P4760, DOI 10.1038/sj.onc.1206664; Reddy VA, 2002, BLOOD, V100, P483, DOI 10.1182/blood.V100.2.483; Robert F, 1998, MOL CELL, V2, P341, DOI 10.1016/S1097-2765(00)80278-6; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Sodek J, 1996, CONNECT TISSUE RES, V35, P23, DOI 10.3109/03008209609029171; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; Tanimoto A, 1998, CARCINOGENESIS, V19, P1735, DOI 10.1093/carcin/19.10.1735; Tye CE, 2003, J BIOL CHEM, V278, P7949, DOI 10.1074/jbc.M211915200; Tye CE, 2005, J BIOL CHEM, V280, P13487, DOI 10.1074/jbc.M408923200; Waltregny D, 2000, J BONE MINER RES, V15, P834, DOI 10.1359/jbmr.2000.15.5.834; Wang YN, 2003, J BIOL CHEM, V278, P45848, DOI 10.1074/jbc.M302630200; Weiss C, 2003, EMBO J, V22, P3686, DOI 10.1093/emboj/cdg364; WHITE E, 1993, P SOC EXP BIOL MED, V204, P30; WILLIAMS GT, 1989, MOL CELL BIOL, V9, P2574, DOI 10.1128/MCB.9.6.2574; Yamauchi M, 1996, MATRIX BIOL, V15, P119, DOI 10.1016/S0945-053X(96)90153-5; YAO KL, 1994, J BONE MINER RES, V9, P231; Zheng CJ, 1999, J BIOL CHEM, V274, P28966, DOI 10.1074/jbc.274.41.28966	68	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38365	38375		10.1074/jbc.M501609200	http://dx.doi.org/10.1074/jbc.M501609200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16087680	hybrid			2022-12-25	WOS:000233239800032
J	O'Dowd, BF; Ji, XD; Alijaniaram, M; Rajaram, RD; Kong, MMC; Rashid, A; Nguyen, T; George, SR				O'Dowd, BF; Ji, XD; Alijaniaram, M; Rajaram, RD; Kong, MMC; Rashid, A; Nguyen, T; George, SR			Dopamine receptor oligomerization visualized in living cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-LOCALIZATION; OPIOID RECEPTORS; PROTEIN; AGONIST; DIMERS; D1; HETEROOLIGOMERS; GENERATION; RHODOPSIN; SURFACE	G protein-coupled receptors occur as dimers within arrays of oligomers. We visualized ensembles of dopamine receptor oligomers in living cells and evaluated the contributions of receptor conformation to the dynamics of oligomer association and dissociation, using a strategy of trafficking a receptor to another cellular compartment. We incorporated a nuclear localization sequence into the D1 dopamine receptor, which translocated from the cell surface to the nucleus. Receptor inverse agonists blocked this translocation, retaining the modified receptor, D1-nuclear localization signal (NLS), at the cell surface. D1 co-translocated with D1-NLS to the nucleus, indicating formation of homooligomers. (+)-Butaclamol retained both receptors at the cell surface, and removal of the drug allowed translocation of both receptors to the nucleus. Agonist-nonbinding D1(S198A/S199A)-NLS, containing two substituted serine residues in transmembrane 5 also oligomerized with D1, and both were retained on the cell surface by (+)-butaclamol. Drug removal disrupted these oligomerized receptors so that D1 remained at the cell surface while D1(S198A/S199A)-NLS trafficked to the nucleus. Thus, receptor conformational differences permitted oligomer disruption and showed that ligand-binding pocket occupancy by the inverse agonist induced a conformational change. We demonstrated robust heterooligomerization between the D2 dopamine receptor and the D1 receptor. The heterooligomers could not be disrupted by inverse agonists targeting either one of the receptor constituents. However, D2 did not heterooligomerize with the structurally modified D1(S198A/S199A), indicating an impaired interface for their interaction. Thus, we describe a novel method showing that a homogeneous receptor conformation maintains the structural integrity of oligomers, whereas conformational heterogeneity disrupts it.	Univ Toronto, Dept Pharmacol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Ctr Addict & Mental Hlth, Toronto, ON M5T 1R8, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada	O'Dowd, BF (corresponding author), Univ Toronto, Dept Pharmacol, Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	brian.odowd@utoronto.ca	George, Susan R/P-9669-2018; George, Susan/W-7494-2019		NIDA NIH HHS [R01 DA007223] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA007223] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Carrillo JJ, 2004, MOL PHARMACOL, V66, P1123, DOI 10.1124/mol.104.001586; Chen R, 2000, AM J PHYSIOL-RENAL, V279, pF440, DOI 10.1152/ajprenal.2000.279.3.F440; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; Gales C, 2005, NAT METHODS, V2, P177, DOI 10.1038/NMETH743; George SR, 2000, J BIOL CHEM, V275, P26128, DOI 10.1074/jbc.M000345200; George SR, 2002, NAT REV DRUG DISCOV, V1, P808, DOI 10.1038/nrd913; Gomes I, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-22-j0007.2000; Guo W, 2003, J BIOL CHEM, V278, P4385, DOI 10.1074/jbc.C200679200; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Jong YJI, 2005, J BIOL CHEM, V280, P30469, DOI 10.1074/jbc.M501775200; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Lee DK, 2004, J BIOL CHEM, V279, P7901, DOI 10.1074/jbc.M306377200; Lee SP, 2000, MOL PHARMACOL, V58, P120, DOI 10.1124/mol.58.1.120; Lee SP, 2004, J BIOL CHEM, V279, P35671, DOI 10.1074/jbc.M401923200; Lee SP, 2003, BIOCHEMISTRY-US, V42, P11023, DOI 10.1021/bi0345539; Levac BAR, 2002, CURR OPIN PHARMACOL, V2, P76, DOI 10.1016/S1471-4892(02)00124-8; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; Lu D, 1998, ENDOCRINOLOGY, V139, P365, DOI 10.1210/en.139.1.365; MARCHESE A, 1998, REC BIOCH M, P1; Matz MV, 1999, NAT BIOTECHNOL, V17, P969, DOI 10.1038/13657; McVey M, 2001, J BIOL CHEM, V276, P14092, DOI 10.1074/jbc.M008902200; Milligan G, 2004, MOL PHARMACOL, V66, P1, DOI 10.1124/mol.104.000497.; NG GYK, 1995, P NATL ACAD SCI USA, V92, P10157, DOI 10.1073/pnas.92.22.10157; Ng GYK, 1996, BIOCHEM BIOPH RES CO, V227, P200, DOI 10.1006/bbrc.1996.1489; Overton MC, 2002, J BIOL CHEM, V277, P41463, DOI 10.1074/jbc.M205368200; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; So CH, 2005, MOL PHARMACOL, V68, P568, DOI 10.1124/mol.105.012229; TOMIC M, 1993, BIOCHEM BIOPH RES CO, V191, P1020, DOI 10.1006/bbrc.1993.1319; Watson PH, 2000, BONE, V26, P221, DOI 10.1016/S8756-3282(99)00264-1; Zawarynski P, 1998, FEBS LETT, V441, P383, DOI 10.1016/S0014-5793(98)01588-9	32	50	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					37225	37235		10.1074/jbc.M504562200	http://dx.doi.org/10.1074/jbc.M504562200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16115864	hybrid			2022-12-25	WOS:000232901800081
J	Soares, JA; Zhang, LW; Pitsch, RL; Kleinholz, NM; Jones, RB; Wolff, JJ; Amster, J; Green-Church, KB; Krzycki, JA				Soares, JA; Zhang, LW; Pitsch, RL; Kleinholz, NM; Jones, RB; Wolff, JJ; Amster, J; Green-Church, KB; Krzycki, JA			The residue mass of L-pyrrolysine in three distinct methylamine methyltransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHANOSARCINA-BARKERI; CORRINOID PROTEIN; METHIONINE SYNTHASE; TRANSFER-RNA; AMINO-ACID; GENE; MONOMETHYLAMINE; METHANOGENESIS; RECONSTITUTION; SPECTROMETRY	Single in-frame amber (UAG) codons are found in the genes encoding MtmB, MtbB, or MttB, the methyltransferases initiating methane formation from monomethylamine, dimethylamine, or trimethylamine, respectively, in certain Archaea. The crystal structure of MtmB demonstrated that the amber codon codes for pyrrolysine, the 22nd genetically encoded amino acid found in nature. Previous attempts to visualize the amber-encoded residue by mass spectrometry identified only lysine, leaving information on the existence and structure of pyrrolysine resting entirely on crystallography of a single protein. Here we report successful mass spectral characterization of naturally occurring pyrrolysine and the first demonstration of the amber-encoded residue in proteins other than MtmB. The sequencing of chymotryptic fragments from acetonitrile-denatured proteins by tandem mass spectrometry revealed the mass of the amber-encoded residue in MtmB, MtbB, and MttB as 237.2 +/- 0.2 Da. Fourier transform ion cyclotron resonance mass spectrometry produced an accurate measurement for the pyrrolysyl-residue as 237.1456 Da, within error limits of the predicted mass based on the empirical formula C12H19N3O2. These measurements support the structure of pyrrolysine in MtmB as 4-methylpyrroline-5- carboxylate in amide linkage with the N-epsilon of lysine but not the alternative structure in which the 4-substituent of the pyrroline ring is an amine group. The presence of pyrrolysine with statistically identical mass in all three methyltransferases is in keeping with the proposed direct incorporation of pyrrolysine into protein during translation of the UAG codon and suggests that MtbB and MttB may exploit the unusual electrophilicity of pyrrolysine during catalysis.	Ohio State Univ, Mass Spectrometry & Proteom Facil, Fontana Labs 243, Campus Chem Instrument Ctr, Columbus, OH 43210 USA; Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA; Ohio State Univ, Biochem Program, Columbus, OH 43210 USA; Univ Georgia, Dept Chem, Athens, GA 30602 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Georgia; University of Georgia	Krzycki, JA (corresponding author), Ohio State Univ, Mass Spectrometry & Proteom Facil, Fontana Labs 243, Campus Chem Instrument Ctr, 116 W 19th Ave, Columbus, OH 43210 USA.	Krzycki.1@osu.edu	Green, Kari B/H-3541-2011; Amster, Jon/D-6957-2011; Zhang, Liwen/P-1111-2016	Amster, Jon/0000-0001-7523-5144; Pitsch, Rhonda/0000-0002-9218-274X				Atkins JF, 2002, SCIENCE, V296, P1409, DOI 10.1126/science.1073339; Blight SK, 2004, NATURE, V431, P333, DOI 10.1038/nature02895; Breaux GA, 2000, ANAL CHEM, V72, P1169, DOI 10.1021/ac9907282; Burke SA, 1997, J BIOL CHEM, V272, P16570, DOI 10.1074/jbc.272.26.16570; Burke SA, 1998, J BACTERIOL, V180, P3432, DOI 10.1128/JB.180.13.3432-3440.1998; BURKE SA, 1995, J BACTERIOL, V177, P4410, DOI 10.1128/jb.177.15.4410-4416.1995; Commans S, 1999, FEMS MICROBIOL REV, V23, P335, DOI 10.1111/j.1574-6976.1999.tb00403.x; Deppenmeier U, 2002, J MOL MICROB BIOTECH, V4, P453; Deppenmeier U, 2004, J BIOENERG BIOMEMBR, V36, P55, DOI 10.1023/B:JOBB.0000019598.64642.97; DRENNAN CL, 1994, SCIENCE, V266, P1669, DOI 10.1126/science.7992050; Driscoll DM, 2003, ANNU REV NUTR, V23, P17, DOI 10.1146/annurev.nutr.23.011702.073318; Evans JC, 2004, P NATL ACAD SCI USA, V101, P3729, DOI 10.1073/pnas.0308082100; Ferguson DJ, 1997, J BACTERIOL, V179, P846, DOI 10.1128/jb.179.3.846-852.1997; Ferguson DJ, 1996, J BIOL CHEM, V271, P5189; Ferguson DJ, 2000, J BIOL CHEM, V275, P29053, DOI 10.1074/jbc.M910218199; Galagan JE, 2002, GENOME RES, V12, P532, DOI 10.1101/gr.223902; Goodchild A, 2004, MOL MICROBIOL, V53, P309, DOI 10.1111/j.1365-2958.2004.04130.x; Hao B, 2004, CHEM BIOL, V11, P1317, DOI 10.1016/j.chembiol.2004.07.011; Hao B, 2002, SCIENCE, V296, P1462, DOI 10.1126/science.1069556; James CM, 2001, J BIOL CHEM, V276, P34252, DOI 10.1074/jbc.M102929200; Krzycki JA, 2004, CURR OPIN CHEM BIOL, V8, P484, DOI 10.1016/j.cbpa.2004.08.012; KRZYCKI JA, 1989, J BIOL CHEM, V264, P7217; Namy O, 2004, MOL CELL, V13, P157, DOI 10.1016/S1097-2765(04)00031-0; Paul L, 1996, J BACTERIOL, V178, P6599, DOI 10.1128/jb.178.22.6599-6607.1996; Paul L, 2000, J BACTERIOL, V182, P2520, DOI 10.1128/JB.182.9.2520-2529.2000; PAUL L, 2000, THESIS OHIO STATE U; Polycarpo C, 2004, P NATL ACAD SCI USA, V101, P12450, DOI 10.1073/pnas.0405362101; Retey J, 2003, BBA-PROTEINS PROTEOM, V1647, P179, DOI 10.1016/S1570-9639(03)00091-8; Russell WK, 2001, ANAL CHEM, V73, P2682, DOI 10.1021/ac001332p; Srinivasan G, 2002, SCIENCE, V296, P1459, DOI 10.1126/science.1069588; Thauer RK, 1998, MICROBIOL-UK, V144, P2377, DOI 10.1099/00221287-144-9-2377; Theobald-Dietrich A, 2004, NUCLEIC ACIDS RES, V32, P1091, DOI 10.1093/nar/gkh266; Zhang Y, 2005, J BIOL CHEM, V280, P20740, DOI 10.1074/jbc.M501458200	33	47	52	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36962	36969		10.1074/jbc.M506402200	http://dx.doi.org/10.1074/jbc.M506402200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16096277	hybrid			2022-12-25	WOS:000232901800053
J	Mathieu, J; Giraudier, S; Lanotte, M; Besancon, F				Mathieu, J; Giraudier, S; Lanotte, M; Besancon, F			Retinoid-induced activation of NF-kappa B in APL cells is not essential for granulocytic differentiation, but prolongs the life span of mature cells	ONCOGENE			English	Article						apoptosis; NF-kappa B; ROS; JNK; ATRA; APL	ACUTE PROMYELOCYTIC LEUKEMIA; EWING SARCOMA-CELLS; ALPHA-INDUCED APOPTOSIS; TRANSCRIPTION FACTOR; OXIDATIVE STRESS; JNK ACTIVATION; NEUTROPHIL APOPTOSIS; SIGNAL-TRANSDUCTION; MOLECULAR-BIOLOGY; ACID SYNDROME	All-trans retinoic acid (ATRA) significantly improves the survival of patients with acute promyelocytic leukemia (APL) by inducing granulocytic differentiation of leukemia cells. Since an activation of the transcription factor NF-kappa B occurs during ATRA-induced maturation of APL cells, a mechanistic link between these two processes was investigated. Using an in vitro model for APL, we report that ectopic overexpression of a repressor of NF-kappa B activation did not affect granulocytic differentiation. Importantly, NF-kappa B inhibition markedly resulted in a decreased viability of the differentiated cells, which correlated with increased apoptosis. Apoptosis was accompanied by a sustained activation of the c-Jun N-terminal kinase (JNK). Inhibition of JNK by the specific inhibitor SP600125 or by transfection of a dominant-negative mutant of JNK1 reduced the percentage of apoptotic cells, thus showing that JNK activation constitutes a death signal. Furthermore, impairment of NF-kappa B activation resulted in increased levels of reactive oxygen species (ROS) upon ATRA treatment. ROS accumulation was suppressed by the antioxidant butylated hydroxyanisol, which also abolished ATRA-induced JNK activation and apoptosis. Altogether, our results demonstrate an antiapoptotic effect of NF-kappa B activation during ATRA-induced differentiation of NB4 cells and identify repression of ROS-mediated JNK activation as a mechanism for this effect. Our observations also suggest that NF-kappa B signalling may contribute to an accumulation of mature APL cells and participate in the development of ATRA syndrome.	Hop St Louis, INSERM, U685, Ctr Hayem, F-75475 Paris, France; Inst Gustave Roussy, INSERM, U362, F-94805 Villejuif, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy	Besancon, F (corresponding author), Hop St Louis, INSERM, U685, Ctr Hayem, 1 Ave Claude Vellefaux, F-75475 Paris, France.	francoise.besancon@stlouis.inserm.fr						Adcock IM, 2001, PULM PHARMACOL THER, V14, P211, DOI 10.1006/pupt.2001.0283; Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; Akgul C, 2003, CELL MOL LIFE SCI, V60, P2402, DOI 10.1007/s00018-003-3110-z; Altucci L, 2001, NAT MED, V7, P680, DOI 10.1038/89050; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; Bell S, 2003, CELL SIGNAL, V15, P1, DOI 10.1016/S0898-6568(02)00080-3; Benoit GR, 2001, MOL ENDOCRINOL, V15, P1154, DOI 10.1210/me.15.7.1154; Bernard D, 2002, ONCOGENE, V21, P4392, DOI 10.1038/sj.onc.1205536; Berry DM, 2002, EXP CELL RES, V272, P176, DOI 10.1006/excr.2001.5410; Besancon F, 1998, P NATL ACAD SCI USA, V95, P8081, DOI 10.1073/pnas.95.14.8081; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Brouard S, 2002, J BIOL CHEM, V277, P17950, DOI 10.1074/jbc.M108317200; Buccellato LJ, 2004, J BIOL CHEM, V279, P6753, DOI 10.1074/jbc.M310145200; Cai ZZ, 1997, J BIOL CHEM, V272, P96; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chen F, 2003, CANCER RES, V63, P7689; Chen F, 2001, AM J PATHOL, V159, P387, DOI 10.1016/S0002-9440(10)61708-7; Chomienne C, 1996, FASEB J, V10, P1025, DOI 10.1096/fasebj.10.9.8801163; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; De Botton S, 1998, BLOOD, V92, P2712, DOI 10.1182/blood.V92.8.2712.420k03_2712_2718; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; de The H, 2001, ONCOGENE, V20, P7136, DOI 10.1038/sj.onc.1204851; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Djavaheri-Mergny M, 2004, FEBS LETT, V578, P111, DOI 10.1016/j.febslet.2004.10.082; Djavaheri-Mergny M, 2003, ONCOGENE, V22, P2558, DOI 10.1038/sj.onc.1206356; Gebauer F, 2004, NAT REV MOL CELL BIO, V5, P827, DOI 10.1038/nrm1488; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grolleau A, 1999, J IMMUNOL, V162, P3491; Hamasaki A, 1998, J EXP MED, V188, P1985, DOI 10.1084/jem.188.11.1985; Han YQ, 1999, J BIOL CHEM, V274, P787, DOI 10.1074/jbc.274.2.787; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; Iwanaga M, 1998, FREE RADICAL BIO MED, V24, P1256, DOI 10.1016/S0891-5849(97)00443-7; Javelaud D, 2000, ONCOGENE, V19, P61, DOI 10.1038/sj.onc.1203246; Javelaud D, 2001, ONCOGENE, V20, P4365, DOI 10.1038/sj.onc.1204570; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Komura E, 2005, CANCER RES, V65, P3281, DOI 10.1158/0008-5472.CAN-04-2339; Kouba DJ, 2001, J BIOL CHEM, V276, P6214, DOI 10.1074/jbc.M004511200; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; LANOTTE M, 1991, BLOOD, V77, P1080; Larson RS, 2003, BEST PRACT RES CL HA, V16, P453, DOI 10.1016/S1521-6926(03)00043-4; Lin AN, 2002, AGING CELL, V1, P112, DOI 10.1046/j.1474-9728.2002.00014.x; Matsuzawa A, 2002, ANTIOXID REDOX SIGN, V4, P415, DOI 10.1089/15230860260196218; Miyamoto S, 1998, MOL CELL BIOL, V18, P19, DOI 10.1128/MCB.18.1.19; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; Nickols JC, 2003, NAT NEUROSCI, V6, P161, DOI 10.1038/nn995; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Papa S, 2004, J CELL SCI, V117, P5197, DOI 10.1242/jcs.01483; Pham CG, 2004, CELL, V119, P529, DOI 10.1016/j.cell.2004.10.017; Pianetti S, 2001, ONCOGENE, V20, P1287, DOI 10.1038/sj.onc.1204257; Puccetti E, 2004, LEUKEMIA, V18, P1169, DOI 10.1038/sj.leu.2403367; Sakon S, 2003, EMBO J, V22, P3898, DOI 10.1093/emboj/cdg379; Slack JL, 1999, CANC TREAT, V99, P75; Tallman MS, 2000, BLOOD, V95, P90; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Turco MC, 2004, LEUKEMIA, V18, P11, DOI 10.1038/sj.leu.2403171; Wang KKW, 1996, P NATL ACAD SCI USA, V93, P6687, DOI 10.1073/pnas.93.13.6687; Waris G, 2003, J BIOL CHEM, V278, P40778, DOI 10.1074/jbc.M303248200; Witcher M, 2003, BLOOD, V102, P237, DOI 10.1182/blood-2002-09-2725; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	64	20	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2005	24	48					7145	7155		10.1038/sj.onc.1208889	http://dx.doi.org/10.1038/sj.onc.1208889			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	980BY	16044154				2022-12-25	WOS:000232990100004
J	Gao, S; Steffen, J; Laughon, A				Gao, S; Steffen, J; Laughon, A			Dpp-responsive silencers are bound by a trimeric mad-medea complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; SMAD PROTEINS; DNA-BINDING; TRANSCRIPTIONAL REGULATION; STRUCTURAL BASIS; NUCLEAR-LOCALIZATION; MORPHOGEN GRADIENT; CRYSTAL-STRUCTURE; TUMOR-SUPPRESSOR; STEM-CELLS	Transcriptional regulation by transforming growth factor-beta signaling is mediated by the Smad family of transcription factors. It is generally accepted that Smads must interact with other transcription factors to bind to their targets. However, recently it has been shown that a complex of the Drosophila Smad proteins, Mad and Medea, binds with high affinity to silencer elements that repress brinker and bag of marbles in response to Dpp signaling. Here we report that these silencers are bound by a heterotrimer containing two Mad subunits and one Medea subunit. We found that the MH1 domains of all three subunits contributed directly to sequence-specific DNA contact, thus accounting for the exceptionally high stability of the Smad-silencer complex. The Medea MH1 domain binds to a canonical Smad box (GTCT), whereas the Mad MH1 domains bind to a GC-rich sequence resembling Mad binding sites previously identified in Dpp-responsive enhancer elements. The consensus for this sequence, GRCGNC, differs from that of the canonical Smad box, but we found that Mad binding nonetheless required the same beta-hairpin amino acids that mediate base-specific contact with GTCT. Binding was also affected by alanine substitutions in Mad and Med at a subset of basic residues within and flanking helix 2, indicating a contribution to binding of the GRCGNC and GTCT sites. The slight alteration of the Dpp silencers caused them to activate transcription in response to Dpp signaling, indicating that the potential for Smad complexes to recognize specific targets need not be limited to repression.	Univ Wisconsin, Genet Lab, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Laughon, A (corresponding author), Univ Wisconsin, Genet Lab, 445 Henry Mall, Madison, WI 53706 USA.	alaughon@wisc.edu						Affolter M, 2001, EMBO J, V20, P3298, DOI 10.1093/emboj/20.13.3298; Baird GS, 2000, P NATL ACAD SCI USA, V97, P11984, DOI 10.1073/pnas.97.22.11984; Campbell G, 1999, CELL, V96, P553, DOI 10.1016/S0092-8674(00)80659-5; Chacko BM, 2004, MOL CELL, V15, P813, DOI 10.1016/j.molcel.2004.07.016; Chacko BM, 2001, NAT STRUCT BIOL, V8, P248, DOI 10.1038/84995; Chai JJ, 2003, J BIOL CHEM, V278, P20327, DOI 10.1074/jbc.C300134200; Chen DH, 2003, CURR BIOL, V13, P1786, DOI 10.1016/j.cub.2003.09.033; Chen DH, 2003, DEVELOPMENT, V130, P1159, DOI 10.1242/dev.00325; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Dai H, 2000, DEV BIOL, V227, P373, DOI 10.1006/dbio.2000.9901; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Halfon MS, 2000, CELL, V103, P63, DOI 10.1016/S0092-8674(00)00105-7; Hollnagel A, 1999, J BIOL CHEM, V274, P19838, DOI 10.1074/jbc.274.28.19838; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; Inman GJ, 2002, J BIOL CHEM, V277, P51008, DOI 10.1074/jbc.M208532200; Jayaraman L, 2000, J BIOL CHEM, V275, P40710, DOI 10.1074/jbc.M005799200; Jazwinska A, 1999, DEVELOPMENT, V126, P3323; Jazwinska A, 1999, CELL, V96, P563, DOI 10.1016/S0092-8674(00)80660-1; Johnson K, 1999, J BIOL CHEM, V274, P20709, DOI 10.1074/jbc.274.29.20709; Karaulanov E, 2004, EMBO J, V23, P844, DOI 10.1038/sj.emboj.7600101; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Kirkpatrick H, 2001, J BIOL CHEM, V276, P18216, DOI 10.1074/jbc.M101365200; Knirr S, 2001, DEV BIOL, V238, P13, DOI 10.1006/dbio.2001.0397; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; Kowanetz M, 2004, MOL CELL BIOL, V24, P4241, DOI 10.1128/MCB.24.10.4241-4254.2004; Kusanagi K, 2000, MOL BIOL CELL, V11, P555, DOI 10.1091/mbc.11.2.555; Kusanagi K, 2001, J BIOL CHEM, V276, P28155, DOI 10.1074/jbc.M103371200; Kwon C, 2004, DEVELOPMENT, V131, P2681, DOI 10.1242/dev.01127; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lee HH, 2005, DEVELOPMENT, V132, P1429, DOI 10.1242/dev.01687; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Lopez-Rovira T, 2002, J BIOL CHEM, V277, P3176, DOI 10.1074/jbc.M106826200; Marty T, 2000, NAT CELL BIOL, V2, P745, DOI 10.1038/35036383; Minami M, 1999, NATURE, V398, P242, DOI 10.1038/18451; Muller B, 2003, CELL, V113, P221, DOI 10.1016/S0092-8674(03)00241-1; NELSON HB, 1993, ROUX ARCH DEV BIOL, V202, P341, DOI 10.1007/BF00188733; Ohlstein B, 1997, DEVELOPMENT, V124, P3651; Pyrowolakis G, 2004, DEV CELL, V7, P229, DOI 10.1016/j.devcel.2004.07.008; Qin BY, 2001, MOL CELL, V8, P1303, DOI 10.1016/S1097-2765(01)00417-8; Raftery LA, 2003, TRENDS GENET, V19, P701, DOI 10.1016/j.tig.2003.10.009; Rushlow C, 2001, GENE DEV, V15, P340, DOI 10.1101/gad.861401; Saller E, 2001, EMBO REP, V2, P298, DOI 10.1093/embo-reports/kve068; SAWANO A, 2000, NUCLEIC ACIDS RES, V28, P78, DOI DOI 10.1093/NAR/28.16.E78; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Shi YG, 2001, BIOESSAYS, V23, P223, DOI 10.1002/1521-1878(200103)23:3<223::AID-BIES1032>3.3.CO;2-L; Sivasankaran R, 2000, EMBO J, V19, P6162, DOI 10.1093/emboj/19.22.6162; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; Szuts D, 1998, GENE DEV, V12, P2022, DOI 10.1101/gad.12.13.2022; ten Dijke P, 2003, MOL CELL ENDOCRINOL, V211, P105, DOI 10.1016/j.mce.2003.09.016; Torres-Vazquez J, 2001, DEVELOPMENT, V128, P1657; Udagawa Y, 2000, GENES CELLS, V5, P359, DOI 10.1046/j.1365-2443.2000.00328.x; Vogel M, 2005, PROTEINS, V58, P478, DOI 10.1002/prot.20312; Waltzer L, 1999, EMBO J, V18, P1630, DOI 10.1093/emboj/18.6.1630; Wharton SJ, 2004, CURR BIOL, V14, P1550, DOI 10.1016/j.cub.2004.08.053; Wu JW, 2001, MOL CELL, V8, P1277, DOI 10.1016/S1097-2765(01)00421-X; Wu JW, 2001, J BIOL CHEM, V276, P20688, DOI 10.1074/jbc.M100174200; Xiao Z, 2000, P NATL ACAD SCI USA, V97, P7853, DOI 10.1073/pnas.97.14.7853; Xiao Z, 2001, J BIOL CHEM, V276, P39404, DOI 10.1074/jbc.M103117200; Xie T, 2000, SCIENCE, V290, P328, DOI 10.1126/science.290.5490.328; Xie T, 1998, CELL, V94, P251, DOI 10.1016/S0092-8674(00)81424-5; Xu M, 2005, DEVELOPMENT, V132, P1637, DOI 10.1242/dev.01722; Xu X, 1998, GENE DEV, V12, P2354, DOI 10.1101/gad.12.15.2354; Yeo CY, 1999, J BIOL CHEM, V274, P26584, DOI 10.1074/jbc.274.37.26584; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang HL, 2001, GENE DEV, V15, P261, DOI 10.1101/gad.861201; Zhang Y, 1998, NATURE, V396, P491, DOI 10.1038/24911; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	72	48	53	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36158	36164		10.1074/jbc.M506882200	http://dx.doi.org/10.1074/jbc.M506882200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16109720	hybrid			2022-12-25	WOS:000232726900047
J	Musiek, ES; Gao, L; Milne, GL; Han, W; Everhart, MB; Wang, DZ; Backlund, MG; DuBois, RN; Zanoni, G; Vidari, G; Blackwell, TS; Morrow, JD				Musiek, ES; Gao, L; Milne, GL; Han, W; Everhart, MB; Wang, DZ; Backlund, MG; DuBois, RN; Zanoni, G; Vidari, G; Blackwell, TS; Morrow, JD			Cyclopentenone isoprostanes inhibit the inflammatory response in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NEURONAL OXIDATIVE DAMAGE; ACTIVATED RECEPTOR-GAMMA; NITRIC-OXIDE SYNTHASE; 1ST TOTAL-SYNTHESIS; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); IN-VIVO; GENE-EXPRESSION; MURINE MACROPHAGES; LIPID-PEROXIDATION	Although both inflammation and oxidative stress contribute to the pathogenesis of many disease states, the interaction between the two is poorly understood. Cyclopentenone isoprostanes (IsoPs), highly reactive structural isomers of the bioactive cyclopentenone prostaglandins PGA(2) and PGJ(2), are formed non-enzymatically as products of oxidative stress in vivo. We have, for the first time, examined the effects of synthetic 15-A(2)- and 15-J(2)-IsoPs, two groups of endogenous cyclopentenone IsoPs, on the inflammatory response in RAW264.7 and primary murine macrophages. Cyclopentenone IsoPs potently inhibited lipopolysaccharide-stimulated I kappa B alpha degradation and subsequent NF-kappa B nuclear translocation and transcriptional activity. Expression of inducible nitric-oxide synthase and cyclooxygenase-2 were also inhibited by cyclopentenone IsoPs as was nitrite and prostaglandin production (IC50 similar to 360 and 210 nM, respectively). 15-J(2)-IsoPs potently activated peroxisome proliferator-activated receptor gamma (PPAR gamma) nuclear receptors, whereas 15-A(2)-IsoP did not, although the anti-inflammatory effects of both molecules were PPAR gamma-independent. Interestingly 15-A(2)-IsoPs induced oxidative stress in RAW cells that was blocked by the antioxidant 4-hydroxy-TEMPO (TEMPOL) or the mitochondrial uncoupler carbonyl cyanide p-(trifluoromethoxy)phenylhydrazone. TEMPOL also abrogated the inhibitory effect of 15-A(2)-IsoPs on lipopolysaccharide- induced kappa F-kappa B activation, inducible nitric-oxide synthase expression, and nitrite production, suggesting that 15-A(2)-IsoPs inhibit the NF-kappa B pathway at least partially via a redox-dependent mechanism. 15-J(2)-IsoP, but not 15-A(2)-IsoP, also potently induced RAW cell apoptosis again via a PPAR gamma-independent mechanism. These findings suggest that cyclopentenone IsoPs may serve as negative feedback regulators of inflammation and have important implications for defining the role of oxidative stress in the inflammatory response.	Vanderbilt Univ, Sch Med, Div Clin Pharmacol, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37232 USA; Univ Pavia, Dept Organ Chem, I-27100 Pavia, Italy	Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Pavia	Morrow, JD (corresponding author), Vanderbilt Univ, Sch Med, Div Clin Pharmacol, Dept Med, 526 RRB,23rd & Pierce Ave, Nashville, TN 37232 USA.	jason.morrow@vanderbilt.edu	DuBois, Raymond N./AAX-8869-2020; Milne, Ginger/D-7648-2014	Milne, Ginger/0000-0003-3890-151X; Musiek, Erik/0000-0002-8873-0360; Vidari, Giovanni/0000-0003-4606-2154	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM015431, P01GM015431] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48831] Funding Source: Medline; NIGMS NIH HHS [GM15431] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alvarez-Maqueda M, 2004, J BIOL CHEM, V279, P21929, DOI 10.1074/jbc.M400492200; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BANERJEE M, 1992, AM J PHYSIOL, V263, pH660, DOI 10.1152/ajpheart.1992.263.3.H660; Basu S, 2001, ANN RHEUM DIS, V60, P627, DOI 10.1136/ard.60.6.627; BEAL MF, 1995, ANN NEUROL, V38, P357, DOI 10.1002/ana.410380304; Beal MF, 2003, ANN NY ACAD SCI, V991, P120; Byun MS, 2002, EXP MOL MED, V34, P332, DOI 10.1038/emm.2002.47; Castrillo A, 2000, MOL CELL BIOL, V20, P1692, DOI 10.1128/MCB.20.5.1692-1698.2000; Cathcart MK, 2004, ARTERIOSCL THROM VAS, V24, P23, DOI 10.1161/01.ATV.0000097769.47306.12; Cernuda-Morollon E, 2001, J BIOL CHEM, V276, P35530, DOI 10.1074/jbc.M104518200; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Chen Y, 1999, J BIOL CHEM, V274, P10863, DOI 10.1074/jbc.274.16.10863; Chen Y, 1999, BBA-MOL CELL BIOL L, V1436, P550, DOI 10.1016/S0005-2760(98)00168-4; Cuzzocrea S, 2002, MOL PHARMACOL, V61, P997, DOI 10.1124/mol.61.5.997; Fam SS, 2002, J BIOL CHEM, V277, P36076, DOI 10.1074/jbc.M205638200; Flohe L, 1997, FREE RADICAL BIO MED, V22, P1115, DOI 10.1016/S0891-5849(96)00501-1; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Gniwotta C, 1997, ARTERIOSCL THROM VAS, V17, P3236, DOI 10.1161/01.ATV.17.11.3236; Hortelano S, 2000, J IMMUNOL, V165, P6525, DOI 10.4049/jimmunol.165.11.6525; Ianaro A, 2003, MOL PHARMACOL, V64, P85, DOI 10.1124/mol.64.1.85; Ishii T, 2004, CHEM RES TOXICOL, V17, P1313, DOI 10.1021/tx049860+; Janssen-Heininger YMW, 2000, FREE RADICAL BIO MED, V28, P1317, DOI 10.1016/S0891-5849(00)00218-5; Jaspers I, 2001, AM J RESP CELL MOL, V24, P769, DOI 10.1165/ajrcmb.24.6.4344; Ji C, 2001, J BIOL CHEM, V276, P18223, DOI 10.1074/jbc.M101266200; Khadaroo RG, 2003, J BIOL CHEM, V278, P47834, DOI 10.1074/jbc.M302660200; Klaunig JE, 2004, ANNU REV PHARMACOL, V44, P239, DOI 10.1146/annurev.pharmtox.44.101802.121851; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Kondo M, 2001, J BIOL CHEM, V276, P12076, DOI 10.1074/jbc.M009630200; Korn SH, 2001, J BIOL CHEM, V276, P35693, DOI 10.1074/jbc.M104321200; Lee TS, 2003, J BIOL CHEM, V278, P19325, DOI 10.1074/jbc.M300498200; Lennon AM, 2002, J BIOL CHEM, V277, P29681, DOI 10.1074/jbc.M201517200; Li LY, 2001, J BIOL CHEM, V276, P38152; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x; Liu YB, 1997, J NEUROCHEM, V69, P581, DOI 10.1046/j.1471-4159.1997.69020581.x; McLaughlin B, 2001, J NEUROSCI, V21, P3303, DOI 10.1523/JNEUROSCI.21-10-03303.2001; Milatovic D, 2003, J NEUROCHEM, V87, P1518, DOI 10.1046/j.1471-4159.2003.02120.x; Milne GL, 2004, CHEM RES TOXICOL, V17, P17, DOI 10.1021/tx034213o; Montine TJ, 2002, J NEUROCHEM, V83, P463, DOI 10.1046/j.1471-4159.2002.01157.x; Morrow JD, 1999, METHOD ENZYMOL, V300, P3; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; Negishi M, 2002, PROSTAG OTH LIPID M, V68-9, P611, DOI 10.1016/S0090-6980(02)00059-X; Newton R, 1997, BIOCHEM BIOPH RES CO, V237, P28, DOI 10.1006/bbrc.1997.7064; Nishi T, 2002, J BIOL CHEM, V277, P44548, DOI 10.1074/jbc.M202970200; Page S, 1999, J BIOL CHEM, V274, P11611, DOI 10.1074/jbc.274.17.11611; Park HS, 2004, J IMMUNOL, V173, P3589, DOI 10.4049/jimmunol.173.6.3589; Perez-Sala D, 2002, ANN NY ACAD SCI, V973, P533, DOI 10.1111/j.1749-6632.2002.tb04695.x; Petrova TV, 1999, P NATL ACAD SCI USA, V96, P4668, DOI 10.1073/pnas.96.8.4668; Qin LY, 2004, J BIOL CHEM, V279, P1415, DOI 10.1074/jbc.M307657200; Reich EE, 2001, AM J PATHOL, V158, P293, DOI 10.1016/S0002-9440(10)63968-5; Reynaert NL, 2004, P NATL ACAD SCI USA, V101, P8945, DOI 10.1073/pnas.0400588101; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Roberts LJ, 2002, CELL MOL LIFE SCI, V59, P808, DOI 10.1007/s00018-002-8469-8; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Rossi A, 1997, P NATL ACAD SCI USA, V94, P746, DOI 10.1073/pnas.94.2.746; Sadikot RT, 2004, J IMMUNOL, V172, P1801, DOI 10.4049/jimmunol.172.3.1801; Stocker R, 2004, PHYSIOL REV, V84, P1381, DOI 10.1152/physrev.00047.2003; Strassheim D, 2004, AM J PHYSIOL-CELL PH, V286, pC683, DOI 10.1152/ajpcell.00296.2003; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Straus DS, 2001, MED RES REV, V21, P185, DOI 10.1002/med.1006.abs; Willoughby DA, 2000, NAT MED, V6, P137, DOI 10.1038/72224; XIE QW, 1994, J BIOL CHEM, V269, P4705; Yull FE, 2003, J HISTOCHEM CYTOCHEM, V51, P741, DOI 10.1177/002215540305100605; Zamamiri-Davis F, 2002, FREE RADICAL BIO MED, V32, P890, DOI 10.1016/S0891-5849(02)00775-X; Zanoni G, 2003, J ORG CHEM, V68, P6005, DOI 10.1021/jo034658h; Zanoni G, 2002, J ORG CHEM, V67, P4346, DOI 10.1021/jo025652f	66	77	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35562	35570		10.1074/jbc.M504785200	http://dx.doi.org/10.1074/jbc.M504785200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16100121	hybrid			2022-12-25	WOS:000232561200058
J	Wooten, MW; Geetha, T; Seibehener, ML; Babu, JR; Diaz-Meco, MT; Moscat, J				Wooten, MW; Geetha, T; Seibehener, ML; Babu, JR; Diaz-Meco, MT; Moscat, J			The p62 scaffold regulates nerve growth factor-induced NF-kappa B activation by influencing TRAF6 polyubiquitination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; P75 NEUROTROPHIN RECEPTOR; UBIQUITIN LIGASE ACTIVITY; BINDING-PROTEIN; PC12 CELLS; COMPLEX; IKK; DIFFERENTIATION; LOCALIZATION; CHANNELS	Sequestosome 1/p62 is a scaffolding protein with several interaction modules that include a PB1 dimerization domain, a TRAF6 (tumor necrosis factor receptor-associated factor 6) binding site, and a ubiquitin-associating (UBA) domain. Here, we report that p62 functions to facilitate K63-polyubiquitination of TRAF6 and thereby mediates nerve growth factor-induced activation of the NF-kappa B pathway. In brain of p62 knock-out mice we did not recover polyubiquitinated TRAF6. The UBA domain binds polyubiquitin chains and deletion of p62-UBA domain or mutation of F406V within the ubiquitin binding pocket of the UBA domain abolished TRAF6 polyubiquitination. Likewise, deletion of p62 N-terminal dimerization domain or the TRAF6 binding site had similar effects on both polyubiquitination and oligomerization of TRAF6. Nerve growth factor treatment of PC12 cells induced TRAF6 polyubiquitination along with formation of a p62-TRAF6-IKK beta-PKC iota signal complex, while inhibition of the p62/TRAF6 interaction had an opposite effect. These results provide evidence for a mechanism whereby p62 serves to regulate the NF-kappa B pathway.	Auburn Univ, Dept Biol Sci, Program Cell & Mol Biosci, Auburn, AL 36849 USA; Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Auburn University System; Auburn University; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Moscat, J (corresponding author), Auburn Univ, Dept Biol Sci, Program Cell & Mol Biosci, 331 Funchess Hall, Auburn, AL 36849 USA.	wootemw@auburn.edu	Thangiah, Geetha/W-6796-2019; Moscat, Jorge/A-7011-2009	Ramesh Babu, Jeganathan/0000-0002-3719-932X; Diaz-Meco, Maria/0000-0003-0147-0998	DS NIH HHS [NINDS 33661] Funding Source: Medline	DS NIH HHS		Badciong JC, 2002, J BIOL CHEM, V277, P49668, DOI 10.1074/jbc.M208593200; BHAKAR AL, 2002, J NEUROSCI, V22, P8465; Croci C, 2003, J BIOL CHEM, V278, P6128, DOI 10.1074/jbc.M205162200; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Duran A, 2004, DEV CELL, V6, P303, DOI 10.1016/S1534-5807(03)00403-9; Ea CK, 2004, P NATL ACAD SCI USA, V101, P15318, DOI 10.1073/pnas.0404132101; Feng YF, 2005, MOL CELL BIOL, V25, P4010, DOI 10.1128/MCB.25.10.4010-4022.2005; Foehr ED, 2000, J NEUROSCI, V20, P7556; Geetha T, 2002, FEBS LETT, V512, P19, DOI 10.1016/S0014-5793(02)02286-X; Gong JP, 1999, SCIENCE, V285, P1565, DOI 10.1126/science.285.5433.1565; Hocking LJ, 2004, J BONE MINER RES, V19, P1122, DOI 10.1359/JBMR.0403015; Hughes AL, 2001, J NEUROSCI RES, V63, P10, DOI 10.1002/1097-4547(20010101)63:1<10::AID-JNR2>3.0.CO;2-R; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Khursigara G, 1999, J BIOL CHEM, V274, P2597, DOI 10.1074/jbc.274.5.2597; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Lamark T, 2003, J BIOL CHEM, V278, P34568, DOI 10.1074/jbc.M303221200; Mallery DL, 2002, EMBO J, V21, P6755, DOI 10.1093/emboj/cdf691; Mamidipudi V, 2002, J BIOL CHEM, V277, P28010, DOI 10.1074/jbc.M109730200; Moscat J, 2000, EMBO REP, V1, P399, DOI 10.1093/embo-reports/kvd098; ONEILL L, 1997, TRENDS NEUROSCI, V29, P252; Puls A, 1997, P NATL ACAD SCI USA, V94, P6191, DOI 10.1073/pnas.94.12.6191; RASSI S, 2005, NAT STRUCT MOL BIOL, V8, P708; Rothwarf D M, 1999, Sci STKE, V1999, pRE1, DOI 10.1126/stke.1999.5.re1; Samuels IS, 2001, J CELL BIOCHEM, V82, P452, DOI 10.1002/jcb.1177; Sanchez P, 1998, MOL CELL BIOL, V18, P3069, DOI 10.1128/MCB.18.5.3069; Sanz L, 2000, EMBO J, V19, P1576, DOI 10.1093/emboj/19.7.1576; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; Seibenhener ML, 2004, MOL CELL BIOL, V24, P8055, DOI 10.1128/MCB.24.18.8055-8068.2004; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wooten MW, 2001, J BIOL CHEM, V276, P7709, DOI 10.1074/jbc.C000869200; Xia Y, 2003, J BIOL CHEM, V278, P5255, DOI 10.1074/jbc.M204591200; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888	33	165	183	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35625	35629		10.1074/jbc.C500237200	http://dx.doi.org/10.1074/jbc.C500237200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16079148	hybrid			2022-12-25	WOS:000232561200065
J	Armoni, M; Harel, C; Bar-Yoseph, F; Milo, S; Karnieli, E				Armoni, M; Harel, C; Bar-Yoseph, F; Milo, S; Karnieli, E			Free fatty acids repress the GLUT4 gene expression in cardiac muscle via novel response elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATOR-ACTIVATED RECEPTORS; INDUCED INSULIN-RESISTANCE; GLUCOSE TRANSPORTERS; ARACHIDONIC-ACID; 3T3-L1 ADIPOCYTES; PPAR-GAMMA; RAT-HEART; MECHANISM; TRANSLOCATION; TRANSCRIPTION	Hyperlipidemia (HL) impairs cardiac glucose homeostasis, but the molecular mechanisms involved are yet unclear. We examined HL-regulated GLUT4 and peroxisome proliferator-activated receptor (PPAR) gamma gene expression in human cardiac muscle. Compared with control patients, GLUT4 protein levels were 30% lower in human cardiac muscle biopsies from patients with HL and/or type 2 diabetes mellitus, whereas GLUT4 mRNA levels were unchanged. PPAR gamma mRNA levels were 30 - 50% lower in patients with HL and/or diabetes mellitus type 2 than in controls. Reporter studies in H9C2 cardiomyotubes showed that HL in vitro, induced by high levels of arachidonic ( AA) stearic, linoleic, and oleic acids ( 24 h, 200 mu M) repressed transcription from the GLUT4 promoter; AA also repressed transcription from the PPAR gamma 1 and PPAR gamma 2 promoters. Co-expression of PPAR gamma 2 repressed GLUT4 promoter activity, and the addition of AA further enhanced this effect. 5'-Deletion analysis revealed three GLUT4 promoter regions that accounted for AA-mediated effects: two repression-mediating sequences at - 443/ - 423 bp and - 222/ - 197 bp, the deletion of either or both of which led to a partial derepression of promoter activity, and a third derepression-mediating sequence at - 612/ - 587 bp that was required for sustaining this derepression effect. Electromobility shift assay further shows that AA enhanced binding to two of the three regions of cardiac nuclear protein(s), the nature of which is still unknown. We propose that HL, exhibited as a high free fatty acid level, modulates GLUT4 gene expression in cardiac muscle via a complex mechanism that includes: ( a) binding of AA mediator proteins to three newly identified response elements on the GLUT4 promoter gene and (b) repression of GLUT4 and the PPAR gamma genes by AA.	Rambam Med Ctr, Inst Endocrinol Diabet & Metab, IL-31096 Haifa, Israel; Rambam Med Ctr, Dept Cardiac Surg, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel	Rambam Health Care Campus; Technion Israel Institute of Technology; Rambam Health Care Campus; Technion Israel Institute of Technology; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Karnieli, E (corresponding author), Rambam Med Ctr, Inst Endocrinol Diabet & Metab, POB 9602, IL-31096 Haifa, Israel.	eddy@tx.technion.ac.il						Abel ED, 1999, J CLIN INVEST, V104, P1703, DOI 10.1172/JCI7605; Armoni M, 2003, J BIOL CHEM, V278, P30614, DOI 10.1074/jbc.M304654200; Armoni M, 2002, J CLIN ENDOCR METAB, V87, P5312, DOI 10.1210/jc.2002-020318; ARMONI M, 1995, ENDOCRINOLOGY, V136, P3292, DOI 10.1210/en.136.8.3292; Boden G, 1999, P ASSOC AM PHYSICIAN, V111, P241, DOI 10.1046/j.1525-1381.1999.99220.x; Clarke SD, 2001, J NUTR, V131, P1129, DOI 10.1093/jn/131.4.1129; Duplus E, 2000, J BIOL CHEM, V275, P30749, DOI 10.1074/jbc.R000015200; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; Gavin JR, 1999, DIABETES CARE, V22, pS5; Gilde AJ, 2003, ACTA PHYSIOL SCAND, V178, P425, DOI 10.1046/j.1365-201X.2003.01161.x; Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143; Guan HP, 2005, GENE DEV, V19, P453, DOI 10.1101/gad.1263305; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; Hundal RS, 2002, J CLIN INVEST, V109, P1321, DOI 10.1172/JCI200214955; James David E., 1994, Trends in Cell Biology, V4, P120, DOI 10.1016/0962-8924(94)90066-3; KAHN BB, 1992, J CELL BIOCHEM, V48, P122, DOI 10.1002/jcb.240480203; KARNIELI E, 1981, J CLIN INVEST, V68, P811, DOI 10.1172/JCI110318; KARNIELI E, 1990, HORM RES, V33, P99, DOI 10.1159/000181491; Kim JK, 2001, J CLIN INVEST, V108, P437, DOI 10.1172/JCI11559; Kim YB, 2002, J BIOL CHEM, V277, P32915, DOI 10.1074/jbc.M204710200; KLIP A, 1987, FEBS LETT, V224, P224, DOI 10.1016/0014-5793(87)80452-0; Long SD, 1996, J BIOL CHEM, V271, P1138, DOI 10.1074/jbc.271.2.1138; NASCIMBEN L, 1995, CIRCULATION, V91, P1824, DOI 10.1161/01.CIR.91.6.1824; Nugent C, 2001, J BIOL CHEM, V276, P9149, DOI 10.1074/jbc.M009817200; OWEN P, 1990, CIRC RES, V66, P344, DOI 10.1161/01.RES.66.2.344; Pegorier J P, 1998, Curr Opin Clin Nutr Metab Care, V1, P329, DOI 10.1097/00075197-199807000-00003; Pegorier JP, 2004, J NUTR, V134, p2444S, DOI 10.1093/jn/134.9.2444S; REAVEN GM, 1993, ANNU REV MED, V44, P121, DOI 10.1146/annurev.me.44.020193.001005; Sambrook J, 1989, MOL CLONING LABORATO, V9, P16; SCHOPF G, 1986, BIOCHIM BIOPHYS ACTA, V884, P319, DOI 10.1016/0304-4165(86)90180-7; Sessler AM, 1998, J NUTR, V128, P923, DOI 10.1093/jn/128.6.923; SEYMOUR AML, 1990, BIOCHIM BIOPHYS ACTA, V1055, P107, DOI 10.1016/0167-4889(90)90110-Y; Stenbit AE, 2000, AM J PHYSIOL-HEART C, V279, pH313, DOI 10.1152/ajpheart.2000.279.1.H313; TAEGTMEYER H, 1994, CURR PROB CARDIOLOGY, V19, P61, DOI 10.1016/0146-2806(94)90008-6; TEBBEY PW, 1994, J BIOL CHEM, V269, P639; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; WAHLI W, 1995, CHEM BIOL, V2, P261, DOI 10.1016/1074-5521(95)90045-4; Wang CG, 2001, MOL CELL BIOL, V21, P3057, DOI 10.1128/MCB.21.9.3057-3070.2001; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620	40	61	66	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34786	34795		10.1074/jbc.M502740200	http://dx.doi.org/10.1074/jbc.M502740200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16096283	hybrid			2022-12-25	WOS:000232403900050
J	Bedhomme, M; Hoffmann, M; McCarthy, EA; Gambonnet, B; Moran, RG; Rebeille, F; Ravanel, S				Bedhomme, M; Hoffmann, M; McCarthy, EA; Gambonnet, B; Moran, RG; Rebeille, F; Ravanel, S			Folate metabolism in plants - An Arabidopsis homolog of the mammalian mitochondrial folate transporter mediates folate import into chloroplasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONE-CARBON METABOLISM; PROTOZOAN PARASITE LEISHMANIA; INTEGRAL MEMBRANE-PROTEINS; P-AMINOBENZOATE BRANCH; TETRAHYDROFOLATE SYNTHESIS; METHOTREXATE RESISTANCE; THALIANA; BIOSYNTHESIS; EXPRESSION; ENVELOPE	The distribution of folates in plant cells suggests a complex traffic of the vitamin between the organelles and the cytosol. The Arabidopsis thaliana protein AtFOLT1 encoded by the At5g66380 gene is the closest homolog of the mitochondrial folate transporters (MFTs) characterized in mammalian cells. AtFOLT1 belongs to the mitochondrial carrier family, but GFP-tagging experiments and Western blot analyses indicated that it is targeted to the envelope of chloroplasts. By using the glycine auxotroph Chinese hamster ovary glyB cell line, which lacks a functional MFT and is deficient in folates transport into mitochondria, we showed by complementation that AtFOLT1 functions as a folate transporter in a hamster background. Indeed, stable transfectants bearing the AtFOLT1 cDNA have enhanced levels of folates in mitochondria and can support growth in glycine-free medium. Also, the expression of AtFOLT1 in Escherichia coli allows bacterial cells to uptake exogenous folate. Disruption of the AtFOLT1 gene in Arabidopsis does not lead to phenotypic alterations in folate-sufficient or folate-deficient plants. Also, the atfolt1 null mutant contains wild-type levels of folates in chloroplasts and preserves the enzymatic capacity to catalyze folate-dependent reactions in this subcellular compartment. These findings suggest strongly that, despite many common features shared by chloroplasts and mitochondria from mammals regarding folate metabolism, the folate import mechanisms in these organelles are not equivalent: folate uptake by mammalian mitochondria is mediated by a unique transporter, whereas there are alternative routes for folate import into chloroplasts.	Univ Grenoble 1, Dept Reponse & Dynam Cellulaires, Physiol Cellulaire Vegetale Lab, INRA,CNRS,UMR5168,CEA Grenoble, F-38054 Grenoble, France; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Massey Canc Ctr, Richmond, VA 23298 USA	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); INRAE; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Virginia Commonwealth University; Virginia Commonwealth University	Ravanel, S (corresponding author), Univ Grenoble 1, Dept Reponse & Dynam Cellulaires, Physiol Cellulaire Vegetale Lab, INRA,CNRS,UMR5168,CEA Grenoble, 17 Rue Martyrs, F-38054 Grenoble, France.	sravanel@cea.fr		Ravanel, Stephane/0000-0001-9475-4222				ABEL S, 1994, PLANT J, V5, P421, DOI 10.1111/j.1365-313X.1994.00421.x; Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391; APPLING DR, 1991, FASEB J, V5, P2645, DOI 10.1096/fasebj.5.12.1916088; Basset G, 2002, P NATL ACAD SCI USA, V99, P12489, DOI 10.1073/pnas.192278499; Basset GJC, 2004, PLANT J, V40, P453, DOI 10.1111/j.1365-313X.2004.02231.x; Basset GJC, 2004, P NATL ACAD SCI USA, V101, P1496, DOI 10.1073/pnas.0308331100; BAULCOMBE DC, 1986, NATURE, V321, P446, DOI 10.1038/321446a0; Block MA, 2002, EUR J BIOCHEM, V269, P240, DOI 10.1046/j.0014-2956.2001.02643.x; Chiu WL, 1996, CURR BIOL, V6, P325, DOI 10.1016/S0960-9822(02)00483-9; Doyle J.J., 1990, FOCUS, V12, P13, DOI DOI 10.2307/2419362; Emanuelsson O, 1999, PROTEIN SCI, V8, P978, DOI 10.1110/ps.8.5.978; ESTELLE MA, 1987, MOL GEN GENET, V206, P200, DOI 10.1007/BF00333575; Ferro M, 2003, MOL CELL PROTEOMICS, V2, P325, DOI 10.1074/mcp.M300030-MCP200; Ferro M, 2002, P NATL ACAD SCI USA, V99, P11487, DOI 10.1073/pnas.172390399; Gambonnet B, 2001, J SCI FOOD AGR, V81, P835, DOI 10.1002/jsfa.870; Goyer A, 2004, PLANT PHYSIOL, V135, P103, DOI 10.1104/pp.103.038430; Hanson AD, 2001, ANNU REV PLANT PHYS, V52, P119, DOI 10.1146/annurev.arplant.52.1.119; Ishikawa T, 2003, PLANT J, V33, P235, DOI 10.1046/j.1365-313X.2003.01621.x; Jabrin S, 2003, PLANT PHYSIOL, V131, P1431, DOI 10.1104/pp.016915; KAO FT, 1969, P NATL ACAD SCI USA, V64, P1284, DOI 10.1073/pnas.64.4.1284; Klein M, 2004, PLANT J, V39, P219, DOI 10.1111/j.1365-313X.2004.02125.x; Kundig C, 1999, EMBO J, V18, P2342, DOI 10.1093/emboj/18.9.2342; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Matherly LH, 2003, VITAM HORM, V66, P403, DOI 10.1016/S0083-6729(03)01012-4; McCarty EA, 2004, J BIOL CHEM, V279, P33829, DOI 10.1074/jbc.M403677200; Neuburger M, 1996, J BIOL CHEM, V271, P9466, DOI 10.1074/jbc.271.16.9466; Palmieri F, 2004, ADV PHOTO RESPIRAT, V17, P247; Pebay-Peyroula E, 2003, NATURE, V426, P39, DOI 10.1038/nature02056; Prabhu V, 1998, PLANT PHYSIOL, V116, P137, DOI 10.1104/pp.116.1.137; Ravanel S, 2004, ADV PHOTO RESPIRAT, V17, P277; Ravanel S, 2004, J BIOL CHEM, V279, P22548, DOI 10.1074/jbc.M313250200; Ravanel S, 2001, P NATL ACAD SCI USA, V98, P15360, DOI 10.1073/pnas.261585098; Rebeille F, 1997, EMBO J, V16, P947, DOI 10.1093/emboj/16.5.947; Richard D, 2004, J BIOL CHEM, V279, P54494, DOI 10.1074/jbc.M409264200; Richard D, 2002, J BIOL CHEM, V277, P29460, DOI 10.1074/jbc.M204796200; Roje S, 1999, J BIOL CHEM, V274, P36089, DOI 10.1074/jbc.274.51.36089; Sambrook J, 2001, MOL CLONING LAB MANU; Schwacke R, 2003, PLANT PHYSIOL, V131, P16, DOI 10.1104/pp.011577; TAYLOR RT, 1982, ARCH BIOCHEM BIOPHYS, V217, P609, DOI 10.1016/0003-9861(82)90543-4; Titus SA, 2000, J BIOL CHEM, V275, P36811, DOI 10.1074/jbc.M005163200; Weber APM, 2005, ANNU REV PLANT BIOL, V56, P133, DOI 10.1146/annurev.arplant.56.032604.144228; Zeng H, 2001, CANCER RES, V61, P7225; Zeng H, 2000, CANCER RES, V60, P4779; Zimmermann P, 2004, PLANT PHYSIOL, V136, P2621, DOI 10.1104/pp.104.046367	44	94	102	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34823	34831		10.1074/jbc.M506045200	http://dx.doi.org/10.1074/jbc.M506045200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16055441	Green Published, hybrid			2022-12-25	WOS:000232403900054
J	Han, SJ; Hamdan, FF; Kim, SK; Jacobson, KA; Bloodworth, LM; Li, B; Wess, J				Han, SJ; Hamdan, FF; Kim, SK; Jacobson, KA; Bloodworth, LM; Li, B; Wess, J			Identification of an agonist-induced conformational change occurring adjacent to the ligand-binding pocket of the M-3 muscarinic acetylcholine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA(2) ADRENERGIC-RECEPTOR; SITE-DIRECTED MUTAGENESIS; TRANSMEMBRANE DOMAINS III; CROSS-LINKING STRATEGY; CONSTITUTIVE ACTIVATION; RHODOPSIN STRUCTURE; TYROSINE RESIDUES; CRYSTAL-STRUCTURE; M3-MUSCARINIC-RECEPTOR	To study the conformational changes that convert G protein-coupled receptors (GPCRs) from their resting to their active state, we used the M-3 muscarinic acetylcholine receptor, a prototypical class A GPCR, as a model system. Specifically, we employed a recently developed in situ disulfide cross-linking strategy that allows the formation of disulfide bonds in Cys-substituted mutant M-3 muscarinic receptors present in their native membrane environment. At present, little is known about the conformational changes that GPCR ligands induce in the immediate vicinity of the ligand-binding pocket. To address this issue, we generated 11 Cys-substituted mutant M-3 muscarinic receptors and characterized these receptors in transfected COS-7 cells. All analyzed mutant receptors contained an endogenous Cys residue (Cys-532(7.42)) located within the exofacial segment of transmembrane domain (TM) VII, close to the agonist-binding site. In addition, all mutant receptors harbored a second Cys residue that was introduced into the exofacial segment of TM III, within the sequence Leu-142(3.27)-Asn-152(3.37). Disulfide cross-linking studies showed that muscarinic agonists, but not antagonists, promoted the formation of a disulfide bond between S151(3.36)C and Cys-532. A three-dimensional model of the inactive state of the M-3 muscarinic receptor indicated that Cys-532 and Ser-151 face each other in the center of the TM receptor core. Our cross-linking data therefore support the concept that agonist activation pulls the exofacial segments of TMs VII and III closer to each other. This structural change may represent one of the early conformational events triggering the more pronounced structural reorganization of the intracellular receptor surface. To the best of our knowledge, this is the first direct demonstration of a conformational change occurring in the immediate vicinity of the binding site of a GPCR activated by a diffusible ligand.	NIDDK, Mol Signaling Sect, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA; NIDDK, Mol Recognit Sect, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Wess, J (corresponding author), NIDDK, Mol Signaling Sect, Bioorgan Chem Lab, NIH, Bldg 8A,Rm B1A-05,MSC 0810, Bethesda, MD 20892 USA.	jwess@helix.nih.gov	Han, Sung-Jun/B-9547-2012; Jacobson, Kenneth Alan/A-1530-2009	Jacobson, Kenneth Alan/0000-0001-8104-1493	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK032003] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allman K, 2000, MOL PHARMACOL, V58, P175, DOI 10.1124/mol.58.1.175; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; BARLOW RB, 1964, INTRODUCTION CHEMICA, P185; Bissantz C, 2003, J RECEPT SIG TRANSD, V23, P123, DOI 10.1081/RRS-120025192; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; CAREAGA CL, 1992, J MOL BIOL, V226, P1219, DOI 10.1016/0022-2836(92)91063-U; Elling CE, 1999, P NATL ACAD SCI USA, V96, P12322, DOI 10.1073/pnas.96.22.12322; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Foord SM, 2002, CURR OPIN PHARMACOL, V2, P561, DOI 10.1016/S1471-4892(02)00214-X; Fredriksson R, 2003, MOL PHARMACOL, V63, P1256, DOI 10.1124/mol.63.6.1256; Furukawa H, 2002, MOL PHARMACOL, V62, P778, DOI 10.1124/mol.62.4.778; George SR, 2002, NAT REV DRUG DISCOV, V1, P808, DOI 10.1038/nrd913; Gerber BO, 2001, J BIOL CHEM, V276, P3394, DOI 10.1074/jbc.M007748200; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; Ghanouni P, 2001, P NATL ACAD SCI USA, V98, P5997, DOI 10.1073/pnas.101126198; Halgren TA, 1999, J COMPUT CHEM, V20, P730, DOI 10.1002/(SICI)1096-987X(199905)20:7<730::AID-JCC8>3.0.CO;2-T; Hamdan FF, 2002, BIOCHEMISTRY-US, V41, P7647, DOI 10.1021/bi016029c; Han SJ, 2005, J BIOL CHEM, V280, P24870, DOI 10.1074/jbc.M500379200; Heitz F, 1999, EUR J PHARMACOL, V380, P183, DOI 10.1016/S0014-2999(99)00439-2; Holst B, 2000, MOL PHARMACOL, V58, P263, DOI 10.1124/mol.58.2.263; HOLTON P, 1949, BRIT J PHARM CHEMOTH, V4, P190, DOI 10.1111/j.1476-5381.1949.tb00535.x; Hubbell WL, 2003, ADV PROTEIN CHEM, V63, P243; HULME EC, 1990, ANNU REV PHARMACOL, V30, P633, DOI 10.1146/annurev.pa.30.040190.003221; Javitch JA, 1997, J BIOL CHEM, V272, P18546, DOI 10.1074/jbc.272.30.18546; Jensen AD, 2001, J BIOL CHEM, V276, P9279, DOI 10.1074/jbc.M004871200; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; JinsiParimoo A, 1997, ENDOCRINOLOGY, V138, P1471, DOI 10.1210/en.138.4.1471; Li J, 2004, J MOL BIOL, V343, P1409, DOI 10.1016/j.jmb.2004.08.090; Lu ZL, 1999, J BIOL CHEM, V274, P7309, DOI 10.1074/jbc.274.11.7309; Lu ZL, 2002, TRENDS PHARMACOL SCI, V23, P140, DOI 10.1016/S0165-6147(00)01973-8; Ma JC, 1997, CHEM REV, V97, P1303, DOI 10.1021/cr9603744; Meng EC, 2001, TRENDS PHARMACOL SCI, V22, P587, DOI 10.1016/S0165-6147(00)01825-3; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Rasmussen SGF, 1999, MOL PHARMACOL, V56, P175, DOI 10.1124/mol.56.1.175; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; Sakmar TP, 2002, ANNU REV BIOPH BIOM, V31, P443, DOI 10.1146/annurev.biophys.31.082901.134348; SCHADLOW VC, 1992, MOL BIOL CELL, V3, P941, DOI 10.1091/mbc.3.8.941; Scrutton NS, 1996, BIOCHEM J, V319, P1; Sheikh SP, 1999, J BIOL CHEM, V274, P17033, DOI 10.1074/jbc.274.24.17033; Shi L, 2002, ANNU REV PHARMACOL, V42, P437, DOI 10.1146/annurev.pharmtox.42.091101.144224; SRINIVASAN N, 1990, INT J PEPT PROT RES, V36, P147; STEWART JJP, 1990, J COMPUT AID MOL DES, V4, P1, DOI 10.1007/BF00128336; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; Struthers M, 1999, BIOCHEMISTRY-US, V38, P6597, DOI 10.1021/bi9902384; Takeda S, 2002, FEBS LETT, V520, P97, DOI 10.1016/S0014-5793(02)02775-8; Ward SDC, 2002, J BIOL CHEM, V277, P2247, DOI 10.1074/jbc.M107647200; WESS J, 1992, J BIOL CHEM, V267, P19313; WESS J, 1991, EMBO J, V10, P3729, DOI 10.1002/j.1460-2075.1991.tb04941.x; Wess J, 1996, CRIT REV NEUROBIOL, V10, P69, DOI 10.1615/CritRevNeurobiol.v10.i1.40; WESS J, 1990, COMPREHENSIVE MED CH, V3, P423; Zeng FY, 1999, J BIOL CHEM, V274, P19487, DOI 10.1074/jbc.274.27.19487; Zeng FY, 1999, J NEUROCHEM, V72, P2404, DOI 10.1046/j.1471-4159.1999.0722404.x; Zeng FY, 1999, J BIOL CHEM, V274, P16629, DOI 10.1074/jbc.274.23.16629	59	41	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34849	34858		10.1074/jbc.M506711200	http://dx.doi.org/10.1074/jbc.M506711200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16093246	hybrid			2022-12-25	WOS:000232403900057
J	Hebert, RL; Carmosino, M; Saito, O; Yang, GR; Jackson, CA; Qi, ZH; Breyer, RM; Natarajan, C; Hata, AN; Zhang, YH; Guan, YF; Breyer, MD				Hebert, RL; Carmosino, M; Saito, O; Yang, GR; Jackson, CA; Qi, ZH; Breyer, RM; Natarajan, C; Hata, AN; Zhang, YH; Guan, YF; Breyer, MD			Characterization of a rabbit kidney prostaglandin F-2 alpha receptor exhibiting G(i)-restricted signaling that inhibits water absorption in the collecting duct	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CA2+ MOBILIZATION; VASOPRESSIN-ELICITED WATER; PROSTANOID RECEPTORS; MESSENGER-RNA; G-PROTEIN; MOLECULAR-CLONING; SODIUM-TRANSPORT; PGF(2 ALPHA); FP RECEPTOR; EXPRESSION	PGF(2 alpha) is the most abundant prostaglandin detected in urine; however, its renal effects are poorly characterized. The present study cloned a PGF-prostanoid receptor (FP) from the rabbit kidney and determined the functional consequences of its activation. Nuclease protection assay showed that FP mRNA expression predominates in rabbit ovary and kidney. In situ hybridization revealed that renal FP expression predominates in the cortical collecting duct (CCD). Although FP receptor activation failed to increase intracellular Ca2+, it potently inhibited vasopressin-stimulated osmotic water permeability (L-p, 10(-7) cm/(atm.s)) in in vitro microperfused rabbit CCDs. Inhibition of Lp by the FP selective agonist latanoprost was additive to inhibition of vasopressin action by the EP selective agonist sulprostone. Inhibition of Lp by latanoprost was completely blocked by pertussis toxin, consistent with a G(i)-coupled mechanism. Heterologous transfection of the rabbit FPr into HEK293 cells also showed that latanoprost inhibited cAMP generation via a pertussis toxin-sensitive mechanism but did not increase cell Ca2+. These studies demonstrate a functional FP receptor on the basolateral membrane of rabbit CCDs. In contrast to the Ca2+ signal transduced by other FP receptors, this renal FP receptor signals via a PT-sensitive mechanism that is not coupled to cell Ca2+.	Vanderbilt Univ, Med Ctr, Div Nephrol, Nashville, TN 37232 USA; Univ Ottawa, Fac Med, Kidney Res Ctr, Dept Cellular, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Fac Med, Kidney Res Ctr, Dept Mol Med, Ottawa, ON K1H 8M5, Canada; Peking Univ, Hlth Sci Ctr, Dept Physiol, Beijing 100083, Peoples R China	Vanderbilt University; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; Peking University	Breyer, MD (corresponding author), Vanderbilt Univ, Med Ctr, Div Nephrol, Nashville, TN 37232 USA.	matthew.breyer@vanderbilt.edu	YANG, GUANGRUI/F-9693-2013; Carmosino, Monica/O-2594-2014	YANG, GUANGRUI/0000-0002-8310-8257; Carmosino, Monica/0000-0001-7600-8816; guan, youfei/0000-0002-5231-0209	NIDDK NIH HHS [DK46205, DK37097] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037097, R01DK046205] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abramovitz M, 2000, BBA-MOL CELL BIOL L, V1483, P285, DOI 10.1016/S1388-1981(99)00164-X; ABRAMOVITZ M, 1995, ADV PROSTAG THROMB L, V23, P499; ABRAMOVITZ M, 1994, J BIOL CHEM, V269, P2632; Anthony TL, 1998, INVEST OPHTH VIS SCI, V39, P315; Audoly LP, 1999, J PHARMACOL EXP THER, V289, P140; Boie Y, 1997, EUR J PHARMACOL, V340, P227, DOI 10.1016/S0014-2999(97)01383-6; Boonyaprakob U, 2003, REPRODUCTION, V125, P53, DOI 10.1530/reprod/125.1.53; BREYER MD, 1993, KIDNEY INT, V44, P1372, DOI 10.1038/ki.1993.391; Breyer MD, 2000, AM J PHYSIOL-RENAL, V279, pF12, DOI 10.1152/ajprenal.2000.279.1.F12; BREYER MD, 1990, AM J PHYSIOL, V259, pF553, DOI 10.1152/ajprenal.1990.259.4.F553; BREYER RM, 1994, J BIOL CHEM, V269, P6163; Bryer MD, 2001, ANNU REV PHYSIOL, V63, P579, DOI 10.1146/annurev.physiol.63.1.579; Carrasco MP, 1997, J REPROD FERTIL, V111, P309; DUBOIS R, 1976, KIDNEY INT, V10, P478; DUNCAN AMV, 1995, GENOMICS, V25, P740, DOI 10.1016/0888-7543(95)80022-E; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Guan YF, 1998, J CLIN INVEST, V102, P194, DOI 10.1172/JCI2872; Hasumoto K, 1997, J REPROD FERTIL, V109, P45, DOI 10.1530/jrf.0.1090045; HEBERT RL, 1991, J CLIN INVEST, V87, P1992, DOI 10.1172/JCI115227; HEBERT RL, 1993, AM J PHYSIOL, V265, pF643, DOI 10.1152/ajprenal.1993.265.5.F643; HEBERT RL, 1990, AM J PHYSIOL, V259, pF318, DOI 10.1152/ajprenal.1990.259.2.F318; IRIE A, 1994, BIOCHEM BIOPH RES CO, V204, P303, DOI 10.1006/bbrc.1994.2460; Ishikawa TO, 1996, GENOMICS, V32, P285, DOI 10.1006/geno.1996.0118; JOHNSTON HH, 1967, AM J PHYSIOL, V213, P939, DOI 10.1152/ajplegacy.1967.213.4.939; Joost P, 2002, GENOME BIOL, V3; Kelly CR, 2003, J PHARMACOL EXP THER, V304, P238, DOI 10.1124/jpet.102.042556; Kiriyama M, 1997, BRIT J PHARMACOL, V122, P217, DOI 10.1038/sj.bjp.0701367; Knepper MA, 1997, AM J PHYSIOL-RENAL, V272, pF3, DOI 10.1152/ajprenal.1997.272.1.F3; Kunapuli P, 1997, J BIOL CHEM, V272, P27147, DOI 10.1074/jbc.272.43.27147; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; NARAYFEJESTOTH A, 1984, J CLIN INVEST, V74, P120, DOI 10.1172/JCI111391; Ocklind A, 1997, PROSTAG LEUKOTR ESS, V57, P527, DOI 10.1016/S0952-3278(97)90555-X; Pierce KL, 1997, J BIOL CHEM, V272, P883, DOI 10.1074/jbc.272.2.883; Saito O, 2003, AM J PHYSIOL-RENAL, V284, pF1164, DOI 10.1152/ajprenal.00441.2002; SAKAMOTO K, 1994, J BIOL CHEM, V269, P3881; Sakamoto K, 2002, DNA SEQUENCE, V13, P307, DOI 10.1080/1042517021000011645; Sands JM, 1998, AM J PHYSIOL-RENAL, V274, pF978, DOI 10.1152/ajprenal.1998.274.5.F978; SENKFOR SI, 1993, J CLIN INVEST, V92, P786, DOI 10.1172/JCI116651; Sharif NA, 2003, J OCUL PHARMACOL TH, V19, P501, DOI 10.1089/108076803322660422; Sharif NA, 2003, J OCUL PHARMACOL TH, V19, P437, DOI 10.1089/108076803322473006; Sharif NA, 2002, J OCUL PHARMACOL TH, V18, P313, DOI 10.1089/10807680260218489; Siragy HM, 1997, AM J PHYSIOL-REG I, V273, pR1103, DOI 10.1152/ajpregu.1997.273.3.R1103; SONNENBURG WK, 1988, J BIOL CHEM, V263, P6155; SONNENBURG WK, 1990, J BIOL CHEM, V265, P8479; STIER CT, 1987, J PHARMACOL EXP THER, V243, P487; Stjernschantz JW, 2001, INVEST OPHTH VIS SCI, V42, P1134; Stocco CO, 2000, J BIOL CHEM, V275, P37202, DOI 10.1074/jbc.M006016200; STOW JL, 1991, AM J PHYSIOL, V261, pF831, DOI 10.1152/ajprenal.1991.261.5.F831; SUGIMOTO Y, 1994, J BIOL CHEM, V269, P1356; Sugimoto Y, 1997, SCIENCE, V277, P681, DOI 10.1126/science.277.5326.681; Sugimoto Y, 2000, PROG LIPID RES, V39, P289, DOI 10.1016/S0163-7827(00)00008-4; Tabata H, 2002, BIOCHEM BIOPH RES CO, V298, P398, DOI 10.1016/S0006-291X(02)02455-5; TOH H, 1995, FEBS LETT, V361, P17, DOI 10.1016/0014-5793(95)00129-W; Tosun M, 1997, EUR J PHARMACOL, V340, P203, DOI 10.1016/S0014-2999(97)01415-5; Tsai SJ, 1998, J REPROD FERTIL, V114, P69, DOI 10.1530/jrf.0.1140069; Tsuboi K, 2002, PROSTAG OTH LIPID M, V68-9, P535, DOI 10.1016/S0090-6980(02)00054-0; Valenti G, 1998, J BIOL CHEM, V273, P22627, DOI 10.1074/jbc.273.35.22627; Vezza R, 2001, MOL PHARMACOL, V59, P1506, DOI 10.1124/mol.59.6.1506; Ward DT, 1999, ANNU REV PHYSIOL, V61, P683, DOI 10.1146/annurev.physiol.61.1.683; WOODWARD DF, 1994, BIOCHEM PHARMACOL, V47, P1567, DOI 10.1016/0006-2952(94)90533-9; Yew SF, 1998, CARDIOVASC RES, V40, P538; ZOOK TE, 1981, J PHARMACOL EXP THER, V217, P674	62	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					35028	35037		10.1074/jbc.M505852200	http://dx.doi.org/10.1074/jbc.M505852200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16096282	hybrid, Green Published			2022-12-25	WOS:000232403900076
J	Nagahara, N; Katayama, A				Nagahara, N; Katayama, A			Post-translational regulation of mercaptopyruvate sulfurtransferase via a low redox potential cysteine-sulfenate in the maintenance of redox homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE 1B; ACTIVE-SITE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; 3-MERCAPTOPYRUVATE SULFURTRANSFERASE; HYDROGEN-PEROXIDE; ENZYME CATALYSIS; NADH PEROXIDASE; SH-GROUPS; ACID; GLUTATHIONE	3-Mercaptopyruvate sulfurtransferase (MST) (EC 2.8.1.2), a multifunctional enzyme, catalyzes a transsulfuration from mercaptopyruvate to pyruvate in the degradation process of cysteine. A stoichiometric concentration of hydrogen peroxide and of tetrathionate (S4O62-) inhibited rat MST (k(i) = 3.3 min(-1), K-i = 120.5 mu M and k(i) = 2.5 min(-1), K-i = 178.6 mu M, respectively). The activity was completely restored by dithiothreitol or thioredoxin with a reducing system containing thioredoxin reductase and NADPH, but glutathione did not restore the activity. On the other hand, an excess molar ratio dose of hydrogen peroxide inactivated MST. Oxidation with a stoichiometric concentration of hydrogen peroxide protected the enzyme against reaction by iodoacetate, which modifies a catalytic Cys(247), suggesting that Cys(247) is a target of the oxidants. A matrix-assisted laser desorption/ionization - time-of-flight mass spectrometric analysis revealed that hydrogen peroxide- and tetrathionate-inhibited MSTs were increased in molecular mass consistent with the addition of atomic oxygen and with a thiosulfate (S2O3-), respectively. Treatment with dithiothreitol restored modified MST to the original mass. These findings suggested that there was no nearby cysteine with which to form a disulfide, and mild oxidation of MST resulted in formation of a sulfenate (SO-) atCys(247), which exhibited exceptional stability and a lower redox potential than that of glutathione. Oxidative stress decreases MST activity so as to increase the amount of cysteine, a precursor of thioredoxin or glutathione, and furthermore, these cellular reductants restore the activity. Thus the redox state regulates MST activity at the enzymatic level, and on the other hand, MST controls redox to maintain cellular redox homeostasis.	Nippon Med Coll, Dept Environm Med, Bunkyo Ku, Tokyo 1138602, Japan; Nippon Med Coll, Dept Biochem & Mol Biol, Tokyo 1138602, Japan	Nippon Medical School; Nippon Medical School	Nagahara, N (corresponding author), Nippon Med Coll, Dept Environm Med, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138602, Japan.	noriyuki@nms.ac.jp						Alphey MS, 2003, J BIOL CHEM, V278, P48219, DOI 10.1074/jbc.M307187200; AMPOLA MG, 1969, AM J DIS CHILD, V117, P66, DOI 10.1001/archpedi.1969.02100030068007; Aslund F, 1997, J BIOL CHEM, V272, P30780, DOI 10.1074/jbc.272.49.30780; BENITEZ LV, 1974, J BIOL CHEM, V249, P6234; BIRKETT DJ, 1970, FEBS LETT, V6, P346, DOI 10.1016/0014-5793(70)80095-3; CANNELLA C, 1983, FEBS LETT, V162, P180, DOI 10.1016/0014-5793(83)81074-6; Carballal S, 2003, BIOCHEMISTRY-US, V42, P9906, DOI 10.1021/bi027434m; Claiborne A, 1999, BIOCHEMISTRY-US, V38, P15407, DOI 10.1021/bi992025k; CLAIBORNE A, 1993, FASEB J, V7, P1483, DOI 10.1096/fasebj.7.15.8262333; CRAWHALL JC, 1969, AM J DIS CHILD, V117, P71, DOI 10.1001/archpedi.1969.02100030073008; CRAWHALL JC, 1971, BIOCHEM MED METAB B, V5, P109, DOI 10.1016/0006-2944(71)90080-9; CRAWHALL JC, 1968, SCIENCE, V160, P419, DOI 10.1126/science.160.3826.419; Das TN, 1999, J PHYS CHEM A, V103, P3581, DOI 10.1021/jp9900234; Dickinson DA, 2003, BIOL CHEM, V384, P527, DOI 10.1515/BC.2003.061; Ellis HR, 1997, BIOCHEMISTRY-US, V36, P15013, DOI 10.1021/bi972191x; ENGLUND PT, 1968, BIOCHEMISTRY-US, V7, P163, DOI 10.1021/bi00841a021; Griffiths SW, 2002, J BIOL CHEM, V277, P25486, DOI 10.1074/jbc.M203089200; HANNESTAD U, 1981, BIOCHEM MED METAB B, V26, P106, DOI 10.1016/0006-2944(81)90035-1; HOROWITZ PM, 1989, J BIOL CHEM, V264, P3311; Isom GE, 1997, COMPREHENSIVE TOXICO, P477; Jones DP, 2004, FASEB J, V18, P1246, DOI 10.1096/fj.03-0971fje; KITZ R, 1962, J BIOL CHEM, V237, P3245; KRIETER PA, 1984, MOL PHARMACOL, V26, P122; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; LIU TY, 1967, J BIOL CHEM, V242, P4029; Mallett TC, 1999, BIOCHEMISTRY-US, V38, P3000, DOI 10.1021/bi9817717; Mosharov E, 2000, BIOCHEMISTRY-US, V39, P13005, DOI 10.1021/bi001088w; Nagahara N, 2004, BBA-GENE STRUCT EXPR, V1680, P176, DOI 10.1016/j.bbaexp.2004.09.007; NAGAHARA N, 1995, J BIOL CHEM, V270, P16230, DOI 10.1074/jbc.270.27.16230; Nagahara N, 1996, J BIOL CHEM, V271, P27395, DOI 10.1074/jbc.271.44.27395; Nagahara N, 1998, HISTOCHEM CELL BIOL, V110, P243, DOI 10.1007/s004180050286; Nagahara N, 1999, HISTOL HISTOPATHOL, V14, P1277, DOI 10.14670/HH-14.1277; Nandi DL, 2000, INT J BIOCHEM CELL B, V32, P465, DOI 10.1016/S1357-2725(99)00035-7; NIEDERWI.A, 1973, CLIN CHIM ACTA, V43, P405, DOI 10.1016/0009-8981(73)90480-4; PARKER DJ, 1969, J BIOL CHEM, V244, P180; PIHL A, 1962, J BIOL CHEM, V237, P1356; POOLE LB, 1989, J BIOL CHEM, V264, P12330; Poole LB, 2002, METHOD ENZYMOL, V348, P122, DOI 10.1016/S0076-6879(02)48632-6; Rahman I, 2005, ANTIOXID REDOX SIGN, V7, P42, DOI 10.1089/ars.2005.7.42; Salmeen A, 2003, NATURE, V423, P769, DOI 10.1038/nature01680; Skorey K, 1997, J BIOL CHEM, V272, P22472, DOI 10.1074/jbc.272.36.22472; VAIDYANATHAN VV, 1993, MOL CELL BIOCHEM, V129, P57, DOI 10.1007/BF00926576; van Montfort RLM, 2003, NATURE, V423, P773, DOI 10.1038/nature01681; Williams RAM, 2003, J BIOL CHEM, V278, P1480, DOI 10.1074/jbc.M209395200; Yeh JI, 1996, BIOCHEMISTRY-US, V35, P9951, DOI 10.1021/bi961037s	45	84	85	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34569	34576		10.1074/jbc.M505643200	http://dx.doi.org/10.1074/jbc.M505643200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16107337	hybrid			2022-12-25	WOS:000232403900025
J	Cassuto, H; Kochan, K; Chakravarty, K; Cohen, H; Blum, B; Olswang, Y; Hakimi, P; Xu, C; Massillon, D; Hanson, RW; Reshef, L				Cassuto, H; Kochan, K; Chakravarty, K; Cohen, H; Blum, B; Olswang, Y; Hakimi, P; Xu, C; Massillon, D; Hanson, RW; Reshef, L			Glucocorticoids regulate transcription of the gene for phosphoenolpyruvate carboxykinase in the liver via an extended glucocorticoid regulatory unit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC NUCLEAR FACTOR-3; ACTIVATED RECEPTOR-GAMMA; GTP GENE; ACCESSORY FACTORS; BINDING PROTEIN; RESPONSE UNIT; ADIPOSE EXPRESSION; MESSENGER-RNA; PPAR-ALPHA; COUP-TF	The hepatic transcriptional regulation by glucocorticoids of the cytosolic form of phosphoenolpyruvate carboxykinase (PEPCK-C) gene is coordinated by interactions of specific transcription factors at the glucocorticoid regulatory unit (GRU). We propose an extended GRU that consists of four accessory sites, two proximal AF1 and AF2 sites and their distal counterpart dAF1 ( - 993) and a new site, dAF2 ( - 1365); together, these four sites form a palindrome. Sequencing and gel shift binding assays of hepatic nuclear proteins interacting with these sites indicated similarity of dAF1 and dAF2 sites to the GRU proximal AF1 and AF2 sites. Chromatin immunoprecipitation assays demonstrated that glucocorticoids enhanced the binding of FOXO1 and peroxisome proliferator-activated receptor-alpha to AF2 and dAF2 sites and not to dAF1 site but enhanced the binding of hepatic nuclear transcription factor-4 alpha only to the dAF1 site. Insulin inhibited the binding of these factors to their respective sites but intensified the binding of phosphorylated FOXO1. Transient transfections in HepG2 human hepatoma cells showed that glucocorticoid receptor interacts with several non-steroid nuclear receptors, yielding a synergistic response of the PEPCK-C gene promoter to glucocorticoids. The synergistic stimulation by glucocorticoid receptor together with peroxisome proliferator-activated receptor-alpha or hepatic nuclear transcription factor-4 alpha requires all four accessory sites, i.e. a mutation of each of these markedly affects the synergistic response. Mice with a targeted mutation of the dAF1 site confirmed this requirement. This mutation inhibited the full response of hepatic PEPCK-C gene to diabetes by reducing PEPCK-C mRNA level by 3.5-fold and the level of circulating glucose by 25%.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Dev Biochem, IL-91120 Jerusalem, Israel; Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Nutr, Cleveland, OH 44106 USA	Hebrew University of Jerusalem; Case Western Reserve University; Case Western Reserve University	Reshef, L (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, POB 12272, IL-91120 Jerusalem, Israel.	reshef@cc.huji.ac.il	Hakimi, Parvin/AAB-1643-2021	Blum, Barak/0000-0002-5308-4194	NIDDK NIH HHS [DK22541] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEALE EG, 1985, J BIOL CHEM, V260, P748; Bernal-Mizrachi C, 2003, NAT MED, V9, P1069, DOI 10.1038/nm898; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Cassuto H, 1997, FEBS LETT, V412, P597, DOI 10.1016/S0014-5793(97)00867-3; Cassuto H, 2003, GENE, V318, P177, DOI 10.1016/S0378-1119(03)00775-3; Cassuto H, 1999, FEBS LETT, V457, P441, DOI 10.1016/S0014-5793(99)01080-7; Chakravarthy MV, 2005, CELL METAB, V1, P309, DOI 10.1016/j.cmet.2005.04.002; Chakravarty K, 2004, J BIOL CHEM, V279, P15385, DOI 10.1074/jbc.M309905200; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cissell MA, 1999, BBA-GENE STRUCT EXPR, V1445, P299, DOI 10.1016/S0167-4781(99)00049-4; Curthoys NP, 2001, AM J PHYSIOL-RENAL, V281, pF381, DOI 10.1152/ajprenal.2001.281.3.F381; De Martino MU, 2004, MOL ENDOCRINOL, V18, P820, DOI 10.1210/me.2003-0341; Devine JH, 1999, J BIOL CHEM, V274, P13604, DOI 10.1074/jbc.274.19.13604; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; Duong DT, 2002, J BIOL CHEM, V277, P32234, DOI 10.1074/jbc.M204873200; EISENBERGER CL, 1992, MOL CELL BIOL, V12, P1396, DOI 10.1128/MCB.12.3.1396; FRIEDMAN JE, 1993, J BIOL CHEM, V268, P12952; Ghosh AK, 2001, J BIOL CHEM, V276, P8507, DOI 10.1074/jbc.M008541200; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HALL RK, 1992, MOL CELL BIOL, V12, P5527, DOI 10.1128/MCB.12.12.5527; HALL RK, 1995, P NATL ACAD SCI USA, V92, P412, DOI 10.1073/pnas.92.2.412; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; Holcomb T, 1996, AM J PHYSIOL-RENAL, V271, pF340, DOI 10.1152/ajprenal.1996.271.2.F340; IMAI E, 1993, J BIOL CHEM, V268, P5353; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; IP YT, 1989, MOL CELL BIOL, V9, P1289, DOI 10.1128/MCB.9.3.1289; Lechner PS, 2001, J BIOL CHEM, V276, P22675, DOI 10.1074/jbc.M102422200; Leffert H L, 1979, Methods Enzymol, V58, P536; LIU JS, 1990, BIOTECHNIQUES, V9, P738; MACDOUGALD OA, 1994, J BIOL CHEM, V269, P19041; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Massillon D, 2003, J BIOL CHEM, V278, P40694, DOI 10.1074/jbc.M303182200; Matsuzaki H, 2003, P NATL ACAD SCI USA, V100, P11285, DOI 10.1073/pnas.1934283100; MCGRANE MM, 1990, J BIOL CHEM, V265, P22371; MEISNER H, 1985, BIOCHEMISTRY-US, V24, P421, DOI 10.1021/bi00323a027; MITCHELL J, 1994, MOL ENDOCRINOL, V8, P585, DOI 10.1210/me.8.5.585; NECHUSHTAN H, 1987, NUCLEIC ACIDS RES, V15, P6405, DOI 10.1093/nar/15.16.6405; OBrien RM, 1995, BBA-GENE STRUCT EXPR, V1264, P284, DOI 10.1016/0167-4781(95)00194-8; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; Odom DT, 2004, SCIENCE, V303, P1378, DOI 10.1126/science.1089769; Olswang Y, 2003, J BIOL CHEM, V278, P12929, DOI 10.1074/jbc.M300263200; Olswang Y, 2002, P NATL ACAD SCI USA, V99, P625, DOI 10.1073/pnas.022616299; Owen O.E., 1976, GLUCONEOGENESIS ITS, P533; PATEL YM, 1994, J BIOL CHEM, V269, P5619; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Reshef L, 2003, J BIOL CHEM, V278, P30413, DOI 10.1074/jbc.R300017200; Scott DK, 1998, MOL ENDOCRINOL, V12, P482, DOI 10.1210/me.12.4.482; Scott DK, 1996, J BIOL CHEM, V271, P31909, DOI 10.1074/jbc.271.50.31909; Sengupta S, 2001, GENE DEV, V15, P2367, DOI 10.1101/gad.202201; SHORT MK, 1992, MOL CELL BIOL, V12, P1007, DOI 10.1128/MCB.12.3.1007; SLADEK FM, 1993, RECEPTOR, V3, P223; Stafford JM, 2001, J BIOL CHEM, V276, P39885, DOI 10.1074/jbc.M105370200; Stafford JM, 2001, J BIOL CHEM, V276, P3811, DOI 10.1074/jbc.M009389200; Sugiyama T, 1998, MOL ENDOCRINOL, V12, P1487, DOI 10.1210/me.12.10.1487; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; TRUS M, 1990, MOL CELL BIOL, V10, P2418, DOI 10.1128/MCB.10.5.2418; Tsai WC, 2003, ENDOCRINOLOGY, V144, P5615, DOI 10.1210/en.2003-0481; Wang JC, 2000, J BIOL CHEM, V275, P14717, DOI 10.1074/jbc.275.19.14717; Wang JC, 1999, MOL ENDOCRINOL, V13, P604, DOI 10.1210/me.13.4.604; Wang JC, 1996, MOL ENDOCRINOL, V10, P794, DOI 10.1210/me.10.7.794; Williams CP, 1999, MOL CELL ENDOCRINOL, V148, P67, DOI 10.1016/S0303-7207(98)00234-2; Wolfrum C, 2004, NATURE, V432, P1027, DOI 10.1038/nature03047; YANUKAKASHLES O, 1994, MOL CELL BIOL, V14, P7124, DOI 10.1128/MCB.14.11.7124; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050	66	78	80	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33873	33884		10.1074/jbc.M504119200	http://dx.doi.org/10.1074/jbc.M504119200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16100117	hybrid			2022-12-25	WOS:000232229700024
J	Chattopadhyay, S; Santhamma, KR; Sengupta, S; McCue, B; Kinter, M; Sen, GC; Sen, I				Chattopadhyay, S; Santhamma, KR; Sengupta, S; McCue, B; Kinter, M; Sen, GC; Sen, I			Calmodulin binds to the cytoplasmic domain of angiotensin-converting enzyme and regulates its phosphorylation and cleavage secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; L-SELECTIN; PLASMA-MEMBRANE; CELL-SURFACE; PROTEIN; ECTODOMAIN; METALLOPROTEINASE; GROWTH; PRECURSOR; ADAM17	The rate of cleavage secretion of the enzymatically active ectodomain of angiotensin-converting enzyme ( ACE) is regulated by tyrosine phosphorylation of the protein and by the phorbol ester, phorbol 12-myristate 13-acetate (PMA), an activator of protein kinase C. Here, we report that both calmodulin inhibitor (CaMI) and calmodulin kinase inhibitor could also enhance cleavage secretion of ACE. This effect was accompanied by the dissociation of calmodulin from a specific region within the cytoplasmic domain of ACE to which it had been bound. The same domain of ACE was phosphorylated, and both CaMI and PMA caused dephosphorylation of ACE as well. Mass spectrometric and mutational analyses identified Ser(730) as the only phosphorylated residue in the cytoplasmic domain of ACE. The Ser(730) --> Ala mutant of ACE was not phosphorylated, but it still bound calmodulin, and its cleavage secretion was enhanced by both CaMI and PMA. Similarly, when Ser(730) was replaced by the phosphoserine mimetic, Asp, cleavage secretion of the resultant mutant remained susceptible to the enhancing effect of CaMI and PMA. These results demonstrate that, although CaMI and PMA can enhance both cleavage secretion of ACE and its dephosphorylation, the two effects are not mutually interdependent.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Genet, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Sen, I (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol, NB50,9500 Euclid Ave, Cleveland, OH 44195 USA.	seni@ccf.org		Kinter, Michael/0000-0001-7409-8918	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048258, R01HL054297] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48258, HL54297] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allinson TMJ, 2004, EUR J BIOCHEM, V271, P2539, DOI 10.1111/j.1432-1033.2004.04184.x; Annabi B, 2001, BIOCHEM J, V359, P325, DOI 10.1042/0264-6021:3590325; Arribas J, 2003, CURR TOP DEV BIOL, V54, P125, DOI 10.1016/S0070-2153(03)54007-8; Arribas J, 2002, CHEM REV, V102, P4627, DOI 10.1021/cr010202t; Bauvois B, 2004, ONCOGENE, V23, P317, DOI 10.1038/sj.onc.1207124; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; Blobel CP, 2002, INFLAMM RES, V51, P83, DOI 10.1007/BF02684007; Borrell-Pages M, 2003, EMBO J, V22, P1114, DOI 10.1093/emboj/cdg111; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Diaz-Rodriguez E, 2000, BIOCHEM J, V346, P359, DOI 10.1042/0264-6021:3460359; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; Ehlers M R, 1991, Protein Expr Purif, V2, P1, DOI 10.1016/1046-5928(91)90001-Y; Gardiner EE, 2004, BLOOD, V104, P3611, DOI 10.1182/blood-2004-04-1549; Gomez-Gaviro MV, 2002, J BIOL CHEM, V277, P38212, DOI 10.1074/jbc.M205142200; Hinkle CL, 2004, J BIOL CHEM, V279, P24179, DOI 10.1074/jbc.M312141200; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; Kahn J, 1998, CELL, V92, P809, DOI 10.1016/S0092-8674(00)81408-7; Kessler SP, 2003, J BIOL CHEM, V278, P21105, DOI 10.1074/jbc.M3023472000; KINTER M, 2000, PROTEIN SEQUENCING I, P166; Kohlstedt K, 2002, CIRC RES, V91, P749, DOI 10.1161/01.RES.0000038114.17939.C8; KUMAR RS, 1991, J BIOL CHEM, V266, P3854; Matala E, 2001, J IMMUNOL, V167, P1617, DOI 10.4049/jimmunol.167.3.1617; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Nagano O, 2004, J CELL BIOL, V165, P893, DOI 10.1083/jcb.200310024; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; RAMCHANDRAN R, 1995, BIOCHEMISTRY-US, V34, P12645, DOI 10.1021/bi00039a021; Ramchandran R, 1996, AM J PHYSIOL-HEART C, V271, pH744, DOI 10.1152/ajpheart.1996.271.2.H744; RAMCHANDRAN R, 1994, J BIOL CHEM, V269, P2125; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; Sadhukhan R, 1999, J BIOL CHEM, V274, P10511, DOI 10.1074/jbc.274.15.10511; Sadhukhan R, 1998, P NATL ACAD SCI USA, V95, P138, DOI 10.1073/pnas.95.1.138; Sahin U, 2004, J CELL BIOL, V164, P769, DOI 10.1083/jcb.200307137; Santhamma KR, 2000, J BIOL CHEM, V275, P23253, DOI 10.1074/jbc.M000593200; Santhamma KR, 2004, J BIOL CHEM, V279, P40227, DOI 10.1074/jbc.M407176200; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Scarpati EM, 1996, J BIOL CHEM, V271, P3025, DOI 10.1074/jbc.271.6.3025; Schlondorff J, 1999, J CELL SCI, V112, P3603; SEN I, 1991, J BIOL CHEM, V266, P21985; SEN I, 1993, J BIOL CHEM, V268, P25748; Soderling TR, 1999, TRENDS BIOCHEM SCI, V24, P232, DOI 10.1016/S0968-0004(99)01383-3; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Werb Z, 1998, SCIENCE, V282, P1279, DOI 10.1126/science.282.5392.1279	44	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33847	33855		10.1074/jbc.M501718200	http://dx.doi.org/10.1074/jbc.M501718200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16096279	hybrid			2022-12-25	WOS:000232229700021
J	Ishaq, M; DeGray, G; Natarajan, V				Ishaq, M; DeGray, G; Natarajan, V			Evidence for the involvement of tyrosine kinase ZAP 70 in nuclear retinoid receptor-dependent transactivation in T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; SIGNAL-TRANSDUCTION; X-RECEPTOR; PROTEIN; ACTIVATION; PHOSPHORYLATION; PHOSPHATASES; THYMOCYTES; FAMILY; ALPHA	Retinoic acid receptors (RARs) and retinoid X receptors (RXRs) are transcription factors that control diverse cellular functions during development and homeostasis. The biochemical role of these proteins in T lymphocytes is not well known. Here we have studied the role of protein-tyrosine kinase ZAP70, a key enzyme involved in the proximal signaling events during T cell activation, in the modulation of RXRE- and RARE-dependent activation in T lymphocytes. Surprisingly, ZAP 70-negative Jurkat T cells showed considerable loss of both RXRE- and RARE-mediated transactivation as compared with wild type Jurkat cells. In addition, ZAP 70-negative cells failed to exhibit normal protein kinase C theta and calcineurin-induced transcriptional activity. ZAP 70-negative cells that were reconstituted with active ZAP 70 regained the transactivation function, whereas cells expressing kinase-dead form of ZAP 70 failed to do so. Defective transcriptional activation was also observed in actively proliferating human peripheral blood T lymphocytes in which RNA interference was used to induce loss of ZAP 70 expression. In addition, an Lck-deficient Jurkat cell line that cannot efficiently activate ZAP 70 was also found defective in RXRE- mediated transcription. Finally, RNA interference-induced loss of ZAP 70 or Lck protein in Jurkat cells resulted in significant decrease in the RXRE- dependent activation. Together, these results suggest a novel functional role for ZAP 70 in nuclear receptor-driven transactivation in T lymphocytes.	NCI, Mol Cell Biol Lab, SAIC, NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Ishaq, M (corresponding author), NCI, Mol Cell Biol Lab, SAIC, NIH, Frederick, MD 21702 USA.	mishaq@nih.gov			NCI NIH HHS [N01-CO-12400] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alonso A, 2003, NAT IMMUNOL, V4, P44, DOI 10.1038/ni856; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; Elder ME, 1998, SEMIN HEMATOL, V35, P310; Herndon TM, 2001, J IMMUNOL, V166, P5654, DOI 10.4049/jimmunol.166.9.5654; Huang YP, 2004, J BIOL CHEM, V279, P28827, DOI 10.1074/jbc.R400012200; Ishaq M, 2000, J IMMUNOL, V165, P4217, DOI 10.4049/jimmunol.165.8.4217; Ishaq M, 2003, J BIOL CHEM, V278, P39296, DOI 10.1074/jbc.M302767200; Ishaq M, 2002, J IMMUNOL, V169, P732, DOI 10.4049/jimmunol.169.2.732; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Latour S, 2001, CURR OPIN IMMUNOL, V13, P299, DOI 10.1016/S0952-7915(00)00219-3; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; NEGISHI I, 1995, NATURE, V376, P435, DOI 10.1038/376435a0; Pitcher LA, 2003, TRENDS IMMUNOL, V24, P554, DOI 10.1016/j.it.2003.08.003; Rastinejad F, 2001, CURR OPIN STRUC BIOL, V11, P33, DOI 10.1016/S0959-440X(00)00165-2; Samelson LE, 2002, ANNU REV IMMUNOL, V20, P371, DOI 10.1146/annurev.immunol.20.092601.111357; Saxena M, 2000, SEMIN IMMUNOL, V12, P387, DOI 10.1006/smim.2000.0219; SloanLancaster J, 1997, J EXP MED, V186, P1713, DOI 10.1084/jem.186.10.1713; vanOers NSC, 1996, J EXP MED, V183, P1053, DOI 10.1084/jem.183.3.1053; WANGE RL, 1995, J BIOL CHEM, V270, P944, DOI 10.1074/jbc.270.2.944; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388	23	6	7	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34152	34158		10.1074/jbc.M501547200	http://dx.doi.org/10.1074/jbc.M501547200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16096284	hybrid			2022-12-25	WOS:000232229700056
J	Jiang, SX; Lertvorachon, J; Hou, ST; Konishi, Y; Webster, J; Mealing, G; Brunette, E; Tauskela, J; Preston, E				Jiang, SX; Lertvorachon, J; Hou, ST; Konishi, Y; Webster, J; Mealing, G; Brunette, E; Tauskela, J; Preston, E			Chlortetracycline and demeclocycline inhibit calpains and protect mouse neurons against glutamate toxicity and cerebral ischemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMDA-RECEPTOR; TETRACYCLINE DERIVATIVES; PARKINSONS-DISEASE; CORTICAL-NEURONS; FOCAL ISCHEMIA; BRAIN-INJURY; MINOCYCLINE; NEUROPROTECTION; PROTEOLYSIS; ACTIVATION	Minocycline is a potent neuroprotective tetracycline in animal models of cerebral ischemia. We examined the protective properties of chlortetracycline (CTC) and demeclocycline (DMC) and showed that these two tetracyclines were also potent neuroprotective against glutamate-induced neuronal death in vitro and cerebral ischemia in vivo. However, CTC and DMC appeared to confer neuroprotection through a unique mechanism compared with minocycline. Rather than inhibiting microglial activation and caspase, CTC and DMC suppressed calpain activities. In addition, CTC and DMC only weakly antagonized N-methyl-D-aspartate ( NMDA) receptor activities causing 16 and 14%, respectively, inhibition of NMDA-induced whole cell currents and partially blocked NMDA-induced Ca2+ influx, commonly regarded as the major trigger of neuronal death. In vitro and in vivo experiments demonstrated that the two compounds selectively inhibited the activities of calpain I and II activated following glutamate treatment and cerebral ischemia. In contrast, minocycline did not significantly inhibit calpain activity. Taken together, these results suggested that CTC and DMC provide neuroprotection through suppression of a rise in intracellular Ca2+ and inhibition of calpains.	Natl Res Council Canada, NRC Inst Biol Sci, Neurophysiol Grp, Ottawa, ON K1A 0R6, Canada; Natl Res Council Canada, Biotechnol Res Inst, Chem Biol Grp, Montreal, PQ H4P 2R2, Canada	National Research Council Canada; National Research Council Canada	Hou, ST (corresponding author), Natl Res Council Canada, NRC Inst Biol Sci, Neurophysiol Grp, 1200 Montreal Rd Bldg,M54, Ottawa, ON K1A 0R6, Canada.	sheng.hou@nrc-cnrc.gc.ca	Hou, Sheng Tao/O-3202-2018; Hou, Sheng Tao/AAM-7756-2020	Hou, Sheng Tao/0000-0001-9736-342X				AKAMATSU H, 1992, ACTA DERM-VENEREOL, V72, P178; Baptiste DC, 2004, MOL PHARMACOL, V66, P1113, DOI 10.1124/mol.104.001081; BARTUS RT, 1994, STROKE, V25, P2265, DOI 10.1161/01.STR.25.11.2265; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; Domercq M, 2004, TRENDS PHARMACOL SCI, V25, P609, DOI 10.1016/j.tips.2004.10.001; Donkor IO, 2000, CURR MED CHEM, V7, P1171, DOI 10.2174/0929867003374129; Du YS, 2001, P NATL ACAD SCI USA, V98, P14669, DOI 10.1073/pnas.251341998; Fagan SC, 2004, EXP NEUROL, V186, P248, DOI 10.1016/j.expneurol.2003.12.006; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hewitt KE, 1998, J NEUROSCI RES, V54, P223, DOI 10.1002/(SICI)1097-4547(19981015)54:2<223::AID-JNR10>3.0.CO;2-5; HONG SC, 1994, STROKE, V25, P663, DOI 10.1161/01.STR.25.3.663; HONG SC, 1994, BRAIN RES, V661, P43, DOI 10.1016/0006-8993(94)91178-9; Hou ST, 2002, J BIOL CHEM, V277, P48764, DOI 10.1074/jbc.M206336200; Hou ST, 2002, INT REV CYTOL, V221, P93; Hoyte L, 2004, CURR MOL MED, V4, P131, DOI 10.2174/1566524043479248; Huang YH, 2001, TRENDS MOL MED, V7, P355, DOI 10.1016/S1471-4914(01)02049-4; Inserte J, 2004, CARDIOVASC RES, V64, P105, DOI 10.1016/j.cardiores.2004.06.001; KLEIN NC, 1995, MED CLIN N AM, V79, P789, DOI 10.1016/S0025-7125(16)30039-6; Klein NC, 2001, MED CLIN N AM, V85, P125, DOI 10.1016/S0025-7125(05)70307-2; Koistinaho J, 2004, E SCHERING RES FDN W, V47, P101; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; LEE KS, 1991, P NATL ACAD SCI USA, V88, P7233, DOI 10.1073/pnas.88.16.7233; MacManus JP, 2003, J CEREBR BLOOD F MET, V23, P1020, DOI 10.1097/01.WCB.0000084249.20114.FA; Mealing GAR, 2001, J PHARMACOL EXP THER, V297, P906; Patzke H, 2002, J BIOL CHEM, V277, P8054, DOI 10.1074/jbc.M109645200; Popovic N, 2002, ANN NEUROL, V51, P215, DOI 10.1002/ana.10092; Preston E, 2000, J NEUROSCI METH, V94, P187, DOI 10.1016/S0165-0270(99)00146-6; Rami A, 2003, NEUROBIOL DIS, V13, P75, DOI 10.1016/S0969-9961(03)00018-4; RAMI A, 1993, BRAIN RES, V609, P67, DOI 10.1016/0006-8993(93)90856-I; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Ryan M E, 1998, Adv Dent Res, V12, P152; SEUBERT P, 1989, BRAIN RES, V492, P366, DOI 10.1016/0006-8993(89)90921-9; Smith RA, 2003, MOL BRAIN RES, V116, P70, DOI 10.1016/S0169-328X(03)00253-5; Tauskela JS, 2003, AM J PHYSIOL-CELL PH, V285, pC899, DOI 10.1152/ajpcell.00110.2003; Thomas M, 2004, CURR PHARM DESIGN, V10, P679, DOI 10.2174/1381612043453162; Vanderklish PW, 2000, INT J EXP PATHOL, V81, P323, DOI 10.1046/j.1365-2613.2000.00169.x; Weaver JGR, 2005, J CLIN INVEST, V115, P1828, DOI 10.1172/JCI22954; Wells JEA, 2003, BRAIN, V126, P1628, DOI 10.1093/brain/awg178; Xiong ZG, 2004, CELL, V118, P687, DOI 10.1016/j.cell.2004.08.026; Xu L, 2004, BMC NEUROL, V4, DOI 10.1186/1471-2377-4-7; Yamashima T, 2004, CELL CALCIUM, V36, P285, DOI 10.1016/j.ceca.2004.03.001; Yokota M, 2003, BRAIN RES, V984, P122, DOI 10.1016/S0006-8993(03)03121-4; Yokota M, 1999, BRAIN RES, V819, P8, DOI 10.1016/S0006-8993(98)01334-1; Young KW, 2004, J NEUROCHEM, V89, P1537, DOI 10.1111/j.1471-4159.2004.02458.x; Yrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496, DOI 10.1073/pnas.96.23.13496; Zhang C, 2002, NEUROBIOL DIS, V10, P289, DOI 10.1006/nbdi.2002.0526; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857	48	57	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33811	33818		10.1074/jbc.M503113200	http://dx.doi.org/10.1074/jbc.M503113200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16091365	hybrid			2022-12-25	WOS:000232229700017
J	Kragt, A; Voorn-Brouwer, T; van den Berg, M; Distel, B				Kragt, A; Voorn-Brouwer, T; van den Berg, M; Distel, B			Endoplasmic reticulum-directed pex3p routes to peroxisomes and restores peroxisome formation in a Saccharomyces cerevisiae pex3 Delta strain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN PEX13P; TAIL-ANCHORED PROTEIN; SACCHAROMYCES-CEREVISIAE; ZELLWEGER-SYNDROME; TARGETING SIGNALS; FARNESYLATED PROTEIN; PICHIA-PASTORIS; SH3 DOMAIN; BIOGENESIS; IMPORT	Recent studies on the sorting of peroxisomal membrane proteins challenge the long-standing model in which peroxisomes are considered to be autonomous organelles that multiply by growth and division. Here, we present data lending support to the idea that the endoplasmic reticulum ( ER) is involved in sorting of the peroxisomal membrane protein Pex3p, a protein required early in peroxisome biogenesis. First, we show that the introduction of an artificial glycosylation site into the N terminus of Pex3p leads to partial N-linked core glycosylation, indicative of insertion into the ER membrane. Second, when FLAG-tagged Pex3p is equipped with an ER targeting signal, it can restore peroxisome formation in pex3 Delta cells. Importantly, FLAG antibodies that specifically recognize the processed Pex3p show that the signal peptide of the fusion protein is efficiently cleaved off and that the processed protein localizes to peroxisomes. In contrast, a Pex3p construct in which cleavage of the signal peptide is blocked by a mutation localizes to the ER and the cytosol and cannot complement pex3 Delta cells. Together, these results strongly suggest that ER-targeted Pex3p indeed routes via the ER to peroxisomes, and we hypothesize that this pathway is also used by endogenous Pex3p.	Univ Amsterdam, Acad Med Ctr, Dept Med Biochem, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	Distel, B (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Med Biochem, Meibergdreef 15, NL-1105 AZ Amsterdam, Netherlands.	b.distel@amc.uva.nl						Baerends RJS, 1996, J BIOL CHEM, V271, P8887, DOI 10.1074/jbc.271.15.8887; Bascom RA, 2003, MOL BIOL CELL, V14, P939, DOI 10.1091/mbc.E02-10-0633; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Biermanns M, 2001, BIOCHEM BIOPH RES CO, V285, P649, DOI 10.1006/bbrc.2001.5220; Bottger G, 2000, MOL BIOL CELL, V11, P3963, DOI 10.1091/mbc.11.11.3963; Brosius U, 2002, J BIOL CHEM, V277, P774, DOI 10.1074/jbc.M108155200; Coligan JE, 1995, CURRENT PROTOCOLS PR; Dammai V, 2001, CELL, V105, P187, DOI 10.1016/S0092-8674(01)00310-5; Distel B, 1996, J CELL BIOL, V135, P1, DOI 10.1083/jcb.135.1.1; Dyer JM, 1996, J CELL BIOL, V133, P269, DOI 10.1083/jcb.133.2.269; Eitzen GA, 1997, J CELL BIOL, V137, P1265, DOI 10.1083/jcb.137.6.1265; Elgersma Y, 1997, EMBO J, V16, P7326, DOI 10.1093/emboj/16.24.7326; Elgersma Y, 1996, J CELL BIOL, V135, P97, DOI 10.1083/jcb.135.1.97; Elgersma Y, 1996, J BIOL CHEM, V271, P26375, DOI 10.1074/jbc.271.42.26375; Erdmann R, 2002, METHOD ENZYMOL, V351, P365; Faber KN, 2002, J BIOL CHEM, V277, P11026, DOI 10.1074/jbc.M112347200; Fang Y, 2004, J CELL BIOL, V164, P863, DOI 10.1083/jcb.200311131; Geuze HJ, 2003, MOL BIOL CELL, V14, P2900, DOI 10.1091/mbc.E02-11-0734; Ghaedi K, 2000, MOL BIOL CELL, V11, P2085, DOI 10.1091/mbc.11.6.2085; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Gotte K, 1998, MOL CELL BIOL, V18, P616; Hettema EH, 2000, EMBO J, V19, P223, DOI 10.1093/emboj/19.2.223; Hettema EH, 1998, J CELL BIOL, V142, P421, DOI 10.1083/jcb.142.2.421; Hoepfner D, 2005, CELL, V122, P85, DOI 10.1016/j.cell.2005.04.025; HOHFELD J, 1991, J CELL BIOL, V114, P1167, DOI 10.1083/jcb.114.6.1167; Honsho M, 1998, AM J HUM GENET, V63, P1622, DOI 10.1086/302161; Honsho M, 2002, J BIOL CHEM, V277, P44513, DOI 10.1074/jbc.M206139200; JAMES GL, 1994, J BIOL CHEM, V269, P14182; Jones JM, 2004, J CELL BIOL, V164, P57, DOI 10.1083/jcb.200304111; Jones JM, 2001, J CELL BIOL, V153, P1141, DOI 10.1083/jcb.153.6.1141; Kalish JE, 1996, EMBO J, V15, P3275, DOI 10.1002/j.1460-2075.1996.tb00692.x; Kammerer S, 1998, FEBS LETT, V429, P53, DOI 10.1016/S0014-5793(98)00557-2; Kammerer S, 1997, GENOMICS, V45, P200, DOI 10.1006/geno.1997.4914; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; Matsuzono Y, 1999, P NATL ACAD SCI USA, V96, P2116, DOI 10.1073/pnas.96.5.2116; Mullen RT, 1999, PLANT CELL, V11, P2167, DOI 10.1105/tpc.11.11.2167; Muntau AC, 2000, AM J HUM GENET, V67, P967, DOI 10.1086/303071; Purdue PE, 2001, ANNU REV CELL DEV BI, V17, P701, DOI 10.1146/annurev.cellbio.17.1.701; RACCHI M, 1993, J BIOL CHEM, V268, P5735; Sacksteder KA, 2000, J CELL BIOL, V148, P931, DOI 10.1083/jcb.148.5.931; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shimozawa N, 2000, HUM MOL GENET, V9, P1995, DOI 10.1093/hmg/9.13.1995; Shimozawa N, 1998, BIOCHEM BIOPH RES CO, V243, P368, DOI 10.1006/bbrc.1997.8067; Snyder WB, 1999, MOL BIOL CELL, V10, P1745, DOI 10.1091/mbc.10.6.1745; South ST, 2000, J CELL BIOL, V149, P1345, DOI 10.1083/jcb.149.7.1345; South ST, 1999, J CELL BIOL, V144, P255, DOI 10.1083/jcb.144.2.255; South ST, 2001, P NATL ACAD SCI USA, V98, P12027, DOI 10.1073/pnas.221289498; Steel GJ, 2002, BIOCHEMISTRY-US, V41, P11914, DOI 10.1021/bi026105r; Stroobants AK, 1999, FEBS LETT, V453, P210, DOI 10.1016/S0014-5793(99)00721-8; Tabak HF, 2003, TRAFFIC, V4, P512, DOI 10.1034/j.1600-0854.2003.00110.x; Titorenko VI, 1998, MOL CELL BIOL, V18, P2789, DOI 10.1128/MCB.18.5.2789; Vizeacoumar FJ, 2004, MOL BIOL CELL, V15, P665, DOI 10.1091/mbc.E03-09-0681; Voorn-Brouwer T, 2001, J CELL SCI, V114, P2199; Wang XD, 2001, J BIOL CHEM, V276, P10897, DOI 10.1074/jbc.M010883200; Wiemer EAC, 1996, J BIOL CHEM, V271, P18973, DOI 10.1074/jbc.271.31.18973; Yabal M, 2003, J BIOL CHEM, V278, P3489, DOI 10.1074/jbc.M210253200	56	98	99	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34350	34357		10.1074/jbc.M505432200	http://dx.doi.org/10.1074/jbc.M505432200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16100114	hybrid			2022-12-25	WOS:000232229700078
J	Zhou, R; Silverman, N; Hong, M; Liao, DS; Chung, Y; Chen, ZJJ; Maniatis, T				Zhou, R; Silverman, N; Hong, M; Liao, DS; Chung, Y; Chen, ZJJ; Maniatis, T			The role of ubiquitination in Drosophila innate immunity.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PEPTIDOGLYCAN RECOGNITION PROTEIN; SITE-SPECIFIC PHOSPHORYLATION; SIGNALING PATHWAYS; POLYUBIQUITIN CHAINS; PROTEASOME PATHWAY; KINASE-ACTIVITY; DEFICIENCY IMD; CASPASE DREDD; FACTOR RELISH	Infection of Drosophila by Gram-negative bacteria triggers a signal transduction pathway ( the IMD pathway) culminating in the expression of genes encoding antimicrobial peptides. A key component in this pathway is a Drosophila I kappa B kinase (DmIKK) complex, which stimulates the cleavage and activation of the NF-kappa B transcription factor Relish. Activation of the DmIKK complex requires the MAP3K dTAK1, but the mechanism of dTAK1 activation is not understood. In human cells, the activation of TAK1 and IKK requires the human ubiquitin-conjugating enzymes Ubc13 and UEV1a. Here we demonstrate that the Drosophila homologs of Ubc13 and UEV1a are similarly required for the activation of dTAK1 and the DmIKK complex. Surprisingly, we find that the Drosophila caspase DREDD and its partner dFADD are required for the activation of DmIKK and JNK, in addition to their role in Relish cleavage. These studies reveal an evolutionarily conserved role of ubiquitination in IKK activation, and provide new insights into the hierarchy of signaling components in the Drosophila antibacterial immunity pathway.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Univ Massachusetts, Sch Med, Dept Med, Div Infect Dis, Worcester, MA 01605 USA; Univ Texas, SW Med Ctr Dallas, Dept Mol Biol, Dallas, TX 75390 USA	Harvard University; University of Massachusetts System; University of Massachusetts Worcester; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Maniatis, T (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, 7 Divin Ave, Cambridge, MA 02138 USA.	maniatis@mcb.harvard.edu	Chen, Zhijian/C-6039-2012	Chen, Zhijian/0000-0002-8475-8251; Silverman, Neal/0000-0002-4259-456X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI060025, R56AI060025] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063692, R01GM029379, R01GM059919] Funding Source: NIH RePORTER; NIAID NIH HHS [AI060025] Funding Source: Medline; NIGMS NIH HHS [GM29379, GM59919, GM63692] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boutros M, 2002, DEV CELL, V3, P711, DOI 10.1016/S1534-5807(02)00325-8; Cha GH, 2003, MOL CELL BIOL, V23, P7982, DOI 10.1128/MCB.23.22.7982-7991.2003; Chen W, 2002, J BIOL CHEM, V277, P49105, DOI 10.1074/jbc.M204934200; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Choe KM, 2005, P NATL ACAD SCI USA, V102, P1122, DOI 10.1073/pnas.0404952102; Choe KM, 2002, SCIENCE, V296, P359, DOI 10.1126/science.1070216; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Dimarcq JL, 1997, INSECT BIOCHEM MOLEC, V27, P877, DOI 10.1016/S0965-1748(97)00072-6; Georgel P, 2001, DEV CELL, V1, P503, DOI 10.1016/S1534-5807(01)00059-4; Gottar M, 2002, NATURE, V416, P640, DOI 10.1038/nature734; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Hoffmann JA, 2003, NATURE, V426, P33, DOI 10.1038/nature02021; Hoffmann JA, 1997, TRENDS CELL BIOL, V7, P309, DOI 10.1016/S0962-8924(97)01087-8; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; Hu SM, 2000, J BIOL CHEM, V275, P30761, DOI 10.1074/jbc.C000341200; Hultmark D, 2003, CURR OPIN IMMUNOL, V15, P12, DOI 10.1016/S0952-7915(02)00005-5; Ishitani T, 2003, EMBO J, V22, P6277, DOI 10.1093/emboj/cdg605; Kanayama A, 2004, MOL CELL, V15, P535, DOI 10.1016/j.molcel.2004.08.008; Kaneko T, 2004, IMMUNITY, V20, P637, DOI 10.1016/S1074-7613(04)00104-9; Lee TH, 2004, J BIOL CHEM, V279, P33185, DOI 10.1074/jbc.M404206200; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; LEMAITRE B, 1995, P NATL ACAD SCI USA, V92, P9465, DOI 10.1073/pnas.92.21.9465; Leulier F, 2000, EMBO REP, V1, P353, DOI 10.1093/embo-reports/kvd073; Leulier F, 2003, NAT IMMUNOL, V4, P478, DOI 10.1038/ni922; Leulier F, 2002, CURR BIOL, V12, P996, DOI 10.1016/S0960-9822(02)00873-4; Lu YR, 2001, GENE DEV, V15, P104, DOI 10.1101/gad.856901; MURALIDHAR MG, 1993, NEURON, V11, P253, DOI 10.1016/0896-6273(93)90182-Q; Naitza S, 2002, IMMUNITY, V17, P575, DOI 10.1016/S1074-7613(02)00454-5; OH CE, 1994, J NEUROSCI, V14, P3166; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Park JM, 2004, GENE DEV, V18, P584, DOI 10.1101/gad.1168104; Ramet M, 2002, NATURE, V416, P644, DOI 10.1038/nature735; Rutschmann S, 2000, NAT IMMUNOL, V1, P342, DOI 10.1038/79801; Shen BH, 2001, P NATL ACAD SCI USA, V98, P8596, DOI 10.1073/pnas.141235698; Silverman N, 2000, GENE DEV, V14, P2461, DOI 10.1101/gad.817800; Silverman N, 2003, J BIOL CHEM, V278, P48928, DOI 10.1074/jbc.M304802200; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Stoven S, 2000, EMBO REP, V1, P347, DOI 10.1093/embo-reports/kvd072; Stoven S, 2003, P NATL ACAD SCI USA, V100, P5991, DOI 10.1073/pnas.1035902100; Su H, 2005, SCIENCE, V307, P1465, DOI 10.1126/science.1104765; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; VanDemark AP, 2001, CELL, V105, P711, DOI 10.1016/S0092-8674(01)00387-7; Vidal S, 2001, GENE DEV, V15, P1900, DOI 10.1101/gad.203301; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Weber ANR, 2003, NAT IMMUNOL, V4, P794, DOI 10.1038/ni955; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273	48	103	107	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34048	34055		10.1074/jbc.M506655200	http://dx.doi.org/10.1074/jbc.M506655200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16081424	hybrid			2022-12-25	WOS:000232229700044
J	Ceballos-Chavez, M; Vioque, A				Ceballos-Chavez, M; Vioque, A			Sequence-dependent cleavage site selection by RNase Z from the cyanobacterium Synechocystis sp PCC 6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' PROCESSING ENDORIBONUCLEASE; ESCHERICHIA-COLI; THERMOTOGA-MARITIMA; BACILLUS-SUBTILIS; BETA-LACTAMASE; RIBONUCLEASE-P; END MATURATION; TRNASE-Z; CCA; GENOME	Biosynthesis of transfer RNA requires processing from longer precursors at the 5'- and 3'-ends. In eukaryotes, in archaea, and in those bacteria where the 3'-terminal CCA sequence is not encoded, 3' processing is carried out by the endonuclease RNase Z, which cleaves after the discriminator nucleotide to generate a mature 3'-end ready for the addition of the CCA sequence. We have identified and cloned the gene coding for RNase Z in the cyanobacterium Synechocystis sp. PCC 6803. The gene has been expressed in Escherichia coli, and the recombinant protein was purified. The enzymatic activity of RNase Z from Synechocystis has been studied in vitro with a variety of substrates. The presence of C or CC after the discriminator nucleotide modifies the cleavage site of RNase Z so that it is displaced by one and two nucleotides to the 3'-side, respectively. The presence of the complete 3'-terminal CCA sequence in the precursor of the tRNA completely inhibits RNase Z activity. The inactive CCA-containing precursor binds to Synechocystis RNase Z with similar affinity than the mature tRNA. The properties of the enzyme described here could be related with the mechanism by which CCA is added in this organism, with the participation of two separate nucleotidyl transferases, one specific for the addition of C and another for the addition of A. This work is the first characterization of RNase Z from a cyanobacterium, and the first from an organism with two separate nucleotidyl transferases.	Univ Sevilla, CSIC, Inst Bioquim Vegetal & Fotosintesis, E-41092 Seville, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC - Instituto de Bioquimica Vegetal y Fotosintesis (IBVF)	Vioque, A (corresponding author), Univ Sevilla, CSIC, Inst Bioquim Vegetal & Fotosintesis, Amer Vespucio 49, E-41092 Seville, Spain.	vioque@us.es	Vioque, Agustín/K-1809-2014	Vioque, Agustín/0000-0002-3975-7348				Daiyasu H, 2001, FEBS LETT, V503, P1, DOI 10.1016/S0014-5793(01)02686-2; de la Sierra-Gallay IL, 2005, NATURE, V433, P657, DOI 10.1038/nature03284; Deutscher MP, 2001, PROG NUCLEIC ACID RE, V66, P67; Dufresne A, 2003, P NATL ACAD SCI USA, V100, P10020, DOI 10.1073/pnas.1733211100; ELHAI J, 1988, GENE, V68, P119, DOI 10.1016/0378-1119(88)90605-1; Ezraty B, 2005, J BIOL CHEM, V280, P16542, DOI 10.1074/jbc.C500098200; GUERRIERTAKADA C, 1984, BIOCHEMISTRY-US, V23, P6327, DOI 10.1021/bi00321a006; Ishii R, 2005, J BIOL CHEM, V280, P14138, DOI 10.1074/jbc.M500355200; Kaneko T, 1997, PLANT CELL PHYSIOL, V38, P1171, DOI 10.1093/oxfordjournals.pcp.a029103; Kruszka K, 2003, EMBO J, V22, P621, DOI 10.1093/emboj/cdg040; Kunzmann A, 1998, P NATL ACAD SCI USA, V95, P108, DOI 10.1073/pnas.95.1.108; Matsunaga T, 2001, Breast Cancer, V8, P213, DOI 10.1007/BF02967511; Mayer M, 2000, BIOCHEMISTRY-US, V39, P2096, DOI 10.1021/bi992253e; Minagawa A, 2004, J BIOL CHEM, V279, P15688, DOI 10.1074/jbc.M313951200; Mohan A, 1999, RNA, V5, P245, DOI 10.1017/S1355838299981256; Nashimoto M, 1999, J MOL BIOL, V287, P727, DOI 10.1006/jmbi.1999.2639; Ow MC, 2002, GENE DEV, V16, P1102, DOI 10.1101/gad.983502; Pascual A, 1996, EUR J BIOCHEM, V241, P17, DOI 10.1111/j.1432-1033.1996.0017t.x; Pellegrini O, 2003, EMBO J, V22, P4534, DOI 10.1093/emboj/cdg435; Qin H, 2001, BIOCHEMISTRY-US, V40, P11202, DOI 10.1021/bi010076n; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; Rocap G, 2003, NATURE, V424, P1042, DOI 10.1038/nature01947; Schierling K, 2002, J MOL BIOL, V316, P895, DOI 10.1006/jmbi.2001.5395; Schiffer S, 2003, BIOL CHEM, V384, P333, DOI 10.1515/BC.2003.039; Schiffer S, 2002, EMBO J, V21, P2769, DOI 10.1093/emboj/21.11.2769; Schilling O, 2005, J BIOL CHEM, V280, P17857, DOI 10.1074/jbc.M500591200; Takaku H, 2004, NUCLEIC ACIDS RES, V32, P4429, DOI 10.1093/nar/gkh774; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tomita K, 2002, J BIOL CHEM, V277, P48192, DOI 10.1074/jbc.M207527200; Tous C, 2001, J BIOL CHEM, V276, P29059, DOI 10.1074/jbc.M103418200; Vogel A, 2002, J BIOL CHEM, V277, P29078, DOI 10.1074/jbc.M112047200; Wang ZG, 1999, CURR OPIN CHEM BIOL, V3, P614, DOI 10.1016/S1367-5931(99)00017-4; Weiner AM, 2004, CURR BIOL, V14, pR883, DOI 10.1016/j.cub.2004.09.069; Zuo YH, 2001, NUCLEIC ACIDS RES, V29, P1017, DOI 10.1093/nar/29.5.1017	34	10	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33461	33469		10.1074/jbc.M504691200	http://dx.doi.org/10.1074/jbc.M504691200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16051605	hybrid, Green Published			2022-12-25	WOS:000232058100045
J	Koves, TR; Li, P; An, J; Akimoto, T; Slentz, D; Ilkayeva, O; Dohm, GL; Yan, Z; Newgard, CB; Muoio, DM				Koves, TR; Li, P; An, J; Akimoto, T; Slentz, D; Ilkayeva, O; Dohm, GL; Yan, Z; Newgard, CB; Muoio, DM			Peroxisome proliferator-activated receptor-gamma co-activator 1 alpha-mediated metabolic remodeling of skeletal myocytes mimics exercise training and reverses lipid-induced mitochondrial inefficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED INSULIN-RESISTANCE; VASCULAR SMOOTH-MUSCLE; FATTY-ACID-METABOLISM; GENE-EXPRESSION; TRANSCRIPTIONAL COACTIVATOR; NULL MICE; ENERGY-EXPENDITURE; GLUCOSE-METABOLISM; PGC-1-ALPHA; ALPHA	Peroxisome proliferator-activated receptor-gamma co- activator 1 alpha (PGC1 alpha) is a promiscuous co- activator that plays a key role in regulating mitochondrial biogenesis and fuel homeostasis. Emergent evidence links decreased skeletal muscle PGC1 alpha activity and coincident impairments in mitochondrial performance to the development of insulin resistance in humans. Here we used rodent models to demonstrate that muscle mitochondrial efficiency is compromised by diet-induced obesity and is subsequently rescued by exercise training. Chronic high fat feeding caused accelerated rates of incomplete fatty acid oxidation and accumulation of beta-oxidative intermediates. The capacity of muscle mitochondria to fully oxidize a heavy influx of fatty acid depended on factors such as fiber type and exercise training and was positively correlated with expression levels of PGC1 alpha. Likewise, an efficient lipid-induced substrate switch in cultured myocytes depended on adenovirus-mediated increases in PGC1 alpha expression. Our results supported a novel paradigm in which a high lipid supply, occurring under conditions of low PGC1 alpha, provokes a disconnect between mitochondrial beta-oxidation and tricarboxylic acid cycle activity. Conversely, the metabolic remodeling that occurred in response to PGC1 alpha overexpression favored a shift from incomplete to complete beta-oxidation. We proposed that PGC1 alpha enables muscle mitochondria to better cope with a high lipid load, possibly reflecting a fundamental metabolic benefit of exercise training.	Duke Univ, Sarah W Stedman Nutr & Metab Ctr, Durham, NC 27704 USA; Duke Univ, Dept Med, Durham, NC 27704 USA; Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC 27704 USA; Duke Univ, Dept Med, Durham, NC 27710 USA; E Carolina Univ, Brody Med Sch, Dept Physiol, Greenville, NC 27834 USA	Duke University; Duke University; Duke University; Duke University; University of North Carolina; East Carolina University	Muoio, DM (corresponding author), Duke Univ, Sarah W Stedman Nutr & Metab Ctr, 4321 Med Pk Dr,Ste 200, Durham, NC 27704 USA.	muoio@duke.edu	Akimoto, Takayuki/H-6704-2012; Koves, Tim/I-4806-2012; Muoio, Debbie Marie/E-1147-2012	Akimoto, Takayuki/0000-0002-8874-7779; Koves, Tim/0000-0001-8763-5866; Muoio, Deborah/0000-0003-3760-9277; Yan, Zhen/0000-0002-4826-9813	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK058398, R01DK056112] Funding Source: NIH RePORTER; NIDDK NIH HHS [P01 DK58398, DK-56112] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adhihetty PJ, 2003, EXP PHYSIOL, V88, P99, DOI 10.1113/eph8802505; Akimoto T, 2005, J BIOL CHEM, V280, P19587, DOI 10.1074/jbc.M408862200; Almind K, 2004, DIABETES, V53, P3274, DOI 10.2337/diabetes.53.12.3274; An J, 2004, NAT MED, V10, P268, DOI 10.1038/nm995; Astrup A, 2001, Public Health Nutr, V4, P499; Baar K, 2002, FASEB J, V16, P1879, DOI 10.1096/fj.02-0367com; Barron JT, 1998, J MOL CELL CARDIOL, V30, P1571, DOI 10.1006/jmcc.1998.0722; Barron JT, 1999, MOL CELL BIOCHEM, V194, P283, DOI 10.1023/A:1006928516648; BECKER TC, 1994, J BIOL CHEM, V269, P21234; Cortright RN, 1997, J NUTR BIOCHEM, V8, P228, DOI 10.1016/S0955-2863(97)89660-X; de Fourmestraux V, 2004, J BIOL CHEM, V279, P50743, DOI 10.1074/jbc.M408014200; Finck BN, 2005, CELL METAB, V1, P133, DOI 10.1016/j.cmet.2005.01.006; Gilde AJ, 2003, ACTA PHYSIOL SCAND, V178, P425, DOI 10.1046/j.1365-201X.2003.01161.x; Goodpaster BH, 2001, J CLIN ENDOCR METAB, V86, P5755, DOI 10.1210/jc.86.12.5755; Guerre-Millo M, 2001, DIABETES, V50, P2809, DOI 10.2337/diabetes.50.12.2809; Hittel DS, 2005, J APPL PHYSIOL, V98, P168, DOI 10.1152/japplphysiol.00331.2004; Iossa S, 2004, DIABETES, V53, P2861, DOI 10.2337/diabetes.53.11.2861; Jones JP, 1998, J APPL PHYSIOL, V84, P1661, DOI 10.1152/jappl.1998.84.5.1661; Kim JY, 2002, AM J PHYSIOL-ENDOC M, V282, pE1014, DOI 10.1152/ajpendo.00233.2001; Koves TR, 2005, AM J PHYSIOL-CELL PH, V288, pC1074, DOI 10.1152/ajpcell.00391.2004; Lichtenstein AH, 2000, ATHEROSCLEROSIS, V150, P227, DOI 10.1016/S0021-9150(99)00504-3; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Lin JD, 2004, CELL, V119, P121, DOI 10.1016/j.cell.2004.09.013; Lowell BB, 2005, SCIENCE, V307, P384, DOI 10.1126/science.1104343; McGarry JD, 2002, DIABETES, V51, P7, DOI 10.2337/diabetes.51.1.7; Mootha VK, 2004, P NATL ACAD SCI USA, V101, P6570, DOI 10.1073/pnas.0401401101; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Muoio DM, 2002, DIABETES, V51, P901, DOI 10.2337/diabetes.51.4.901; Muoio DM, 2002, J BIOL CHEM, V277, P26089, DOI 10.1074/jbc.M203997200; Muoio DM, 1999, AM J PHYSIOL-ENDOC M, V276, pE913, DOI 10.1152/ajpendo.1999.276.5.E913; Patti ME, 2004, CURR OPIN CLIN NUTR, V7, P383, DOI 10.1097/01.mco.0000134359.23288.72; Patti ME, 2003, P NATL ACAD SCI USA, V100, P8466, DOI 10.1073/pnas.1032913100; Perseghin G, 2003, INT J OBESITY, V27, pS6, DOI 10.1038/sj.ijo.0802491; Petersen KF, 2004, NEW ENGL J MED, V350, P664, DOI 10.1056/NEJMoa031314; Petersen KF, 2003, SCIENCE, V300, P1140, DOI 10.1126/science.1082889; Pilegaard H, 2003, J PHYSIOL-LONDON, V546, P851, DOI 10.1113/jphysiol.2002.034850; Pilegaard H, 2000, AM J PHYSIOL-ENDOC M, V279, pE806; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2; Ritov VB, 2005, DIABETES, V54, P8, DOI 10.2337/diabetes.54.1.8; Schrauwen P, 2004, DIABETES, V53, P1412, DOI 10.2337/diabetes.53.6.1412; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; Spiegelman BM, 2004, CELL, V119, P157, DOI 10.1016/j.cell.2004.09.037; St-Pierre J, 2003, J BIOL CHEM, V278, P26597, DOI 10.1074/jbc.M301850200; Tordjman K, 2001, J CLIN INVEST, V107, P1025, DOI 10.1172/JCI11497; VANHOVE JLK, 1993, AM J HUM GENET, V52, P958; Waters RE, 2004, AM J PHYSIOL-CELL PH, V287, pC1342, DOI 10.1152/ajpcell.00247.2004; Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a	48	361	374	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33588	33598		10.1074/jbc.M507621200	http://dx.doi.org/10.1074/jbc.M507621200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16079133	hybrid			2022-12-25	WOS:000232058100060
J	Stephenson, SEM; Dubach, D; Lim, CM; Mercer, JFB; La Fontaine, S				Stephenson, SEM; Dubach, D; Lim, CM; Mercer, JFB; La Fontaine, S			A single PDZ domain protein interacts with the Menkes copper ATPase, ATP7A - A NEw protein implicated in copper homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE ATPASE; WILSONS-DISEASE PROTEIN; TERMINAL DI-LEUCINE; METAL-BINDING SITES; PLASMA-MEMBRANE; TRANSMEMBRANE PROTEINS; FUNCTIONAL-ANALYSIS; GOLGI PROTEIN; TRAFFICKING; LOCALIZATION	The homeostatic regulation of essential elements such as copper requires many proteins whose activities are often mediated and tightly coordinated through protein-protein interactions. This regulation ensures that cells receive enough copper without intracellular concentrations reaching toxic levels. To date, only a small number of proteins implicated in copper homeostasis have been identified, and little is known of the protein-protein interactions required for this process. To identify other proteins important for copper homeostasis, while also elucidating the protein-protein interactions that are integral to the process, we have utilized a known copper protein, the copper ATPase ATP7A, as a bait in a yeast two-hybrid screen of a human cDNA library to search for interacting partners. One of the ATP7A-interacting proteins identified is a novel protein with a single PDZ domain. This protein was recently identified to interact with the plasma membrane calcium ATPase b-splice variants. We propose a change in name for this protein from PISP ( plasmamembrane calcium ATPase-interacting single-PDZ protein) to AIPP1 ( ATPase-interacting PDZ protein) and suggest that it represents the protein that interacts with the class I PDZ binding motif identified at the ATP7A C terminus. The interaction in mammalian cells was confirmed and an additional splice variant of AIPP1 was identified. This study represents an essential step forward in identifying the proteins and elucidating the network of protein-protein interactions involved in maintaining copper homeostasis and validates the use of the yeast two-hybrid approach for this purpose.	Deakin Univ, Sch Biol & Chem Sci, Ctr Cellular & Mol Biol, Burwood, Vic 3125, Australia	Deakin University	La Fontaine, S (corresponding author), Deakin Univ, Sch Biol & Chem Sci, Ctr Cellular & Mol Biol, 221 Burwood Hwy, Burwood, Vic 3125, Australia.	sharonl@deakin.edu.au	Stephenson, Sarah/O-5742-2015; Mercer, Julian/R-8583-2019; La Fontaine, Sharon/G-7113-2018; Stephenson, Sarah E M/AGK-4623-2022	Stephenson, Sarah/0000-0001-7860-9527; La Fontaine, Sharon/0000-0002-9948-074X; 				AGATEP R, 1998, TECHNICAL TIPS ONLIN, V1, P51; Ahn AH, 1996, J BIOL CHEM, V271, P2724, DOI 10.1074/jbc.271.5.2724; Bellingham SA, 2004, J BIOL CHEM, V279, P20378, DOI 10.1074/jbc.M400805200; Burke D., 2000, METHODS YEAST GENETI, P171; Carr HS, 2003, ACCOUNTS CHEM RES, V36, P309, DOI 10.1021/ar0200807; Cater MA, 2004, BIOCHEM J, V380, P805, DOI 10.1042/BJ20031804; Charest A, 2001, J BIOL CHEM, V276, P29456, DOI 10.1074/jbc.M104137200; Cheng J, 2002, J BIOL CHEM, V277, P3520, DOI 10.1074/jbc.M110177200; Clark HF, 2003, GENOME RES, V13, P2265, DOI 10.1101/gr.1293003; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Francis MJ, 1999, J CELL SCI, V112, P1721; Francis MJ, 1998, HUM MOL GENET, V7, P1245, DOI 10.1093/hmg/7.8.1245; Goellner GM, 2003, ANN NY ACAD SCI, V986, P461, DOI 10.1111/j.1749-6632.2003.tb07230.x; Greenough M, 2004, AM J PHYSIOL-CELL PH, V287, pC1463, DOI 10.1152/ajpcell.00179.2004; Hall T.A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI [DOI 10.1021/BK-1999-0734.CH008, citeulike-article-id:691774, 10.12691/ajmr-6-4-3]; Hamza I, 1999, P NATL ACAD SCI USA, V96, P13363, DOI 10.1073/pnas.96.23.13363; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Harlow E., 1988, ANTIBODIES LAB MANUA; Harris BZ, 2001, J CELL SCI, V114, P3219; Hassel B, 2003, J BIOL CHEM, V278, P40136, DOI 10.1074/jbc.M305577200; Huffman DL, 2001, ANNU REV BIOCHEM, V70, P677, DOI 10.1146/annurev.biochem.70.1.677; Jelen F, 2003, ACTA BIOCHIM POL, V50, P985; Jo K, 1999, J NEUROSCI, V19, P4189, DOI 10.1523/jneurosci.19-11-04189.1999; Kachinsky AM, 1999, J CELL BIOL, V145, P391, DOI 10.1083/jcb.145.2.391; La Fontaine S, 1998, HUM MOL GENET, V7, P1293, DOI 10.1093/hmg/7.8.1293; La Fontaine S, 1998, J BIOL CHEM, V273, P31375; La Fontaine S, 1998, PLASMID, V39, P245, DOI 10.1006/plas.1997.1334; Lumeng C, 1999, NAT NEUROSCI, V2, P611, DOI 10.1038/10165; Lutsenko S, 2002, J BIOENERG BIOMEMBR, V34, P351, DOI 10.1023/A:1021297919034; Lutsenko S, 2003, J MEMBRANE BIOL, V191, P1, DOI 10.1007/s00232-002-1040-6; Mercer JFB, 2003, BIOMETALS, V16, P175, DOI 10.1023/A:1020719016675; Mercer JFB, 2001, TRENDS MOL MED, V7, P64, DOI 10.1016/S1471-4914(01)01920-7; Miles AT, 2000, CRIT REV BIOCHEM MOL, V35, P35, DOI 10.1080/10409230091169168; Muth TR, 2003, ANNU REV CELL DEV BI, V19, P333, DOI 10.1146/annurev.cellbio.19.110701.161425; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Neudauer CL, 2001, BIOCHEM BIOPH RES CO, V280, P541, DOI 10.1006/bbrc.2000.4160; OLSEN O, 2004, AM J PHYSIOL, V288, pF345; Pagel P, 2003, ANN NY ACAD SCI, V986, P360, DOI 10.1111/j.1749-6632.2003.tb07215.x; Pawson T, 2003, SCIENCE, V300, P445, DOI 10.1126/science.1083653; Pawson T, 2002, FEBS LETT, V513, P2, DOI 10.1016/S0014-5793(01)03292-6; PAYNTER JA, 1994, FEBS LETT, V351, P186, DOI 10.1016/0014-5793(94)00868-X; Petris MJ, 1999, HUM MOL GENET, V8, P2107, DOI 10.1093/hmg/8.11.2107; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; Petris MJ, 1998, HUM MOL GENET, V7, P2063, DOI 10.1093/hmg/7.13.2063; Petris MJ, 2004, PFLUG ARCH EUR J PHY, V447, P752, DOI 10.1007/s00424-003-1092-1; Petris MJ, 2002, J BIOL CHEM, V277, P46736, DOI 10.1074/jbc.M208864200; Prohaska JR, 2004, J NUTR, V134, P1003, DOI 10.1093/jn/134.5.1003; Roelofsen H, 2000, GASTROENTEROLOGY, V119, P782, DOI 10.1053/gast.2000.17834; Schaefer M, 1999, GASTROENTEROLOGY, V117, P1380, DOI 10.1016/S0016-5085(99)70288-X; Schaefer M, 1999, AM J PHYSIOL-GASTR L, V276, pG639, DOI 10.1152/ajpgi.1999.276.3.G639; Schlief ML, 2005, J NEUROSCI, V25, P239, DOI 10.1523/JNEUROSCI.3699-04.2005; Sharp PA, 2003, INT J BIOCHEM CELL B, V35, P288, DOI 10.1016/S1357-2725(02)00134-6; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; Straight SW, 2001, MOL BIOL CELL, V12, P1329, DOI 10.1091/mbc.12.5.1329; Strausak D, 1999, J BIOL CHEM, V274, P11170, DOI 10.1074/jbc.274.16.11170; Strausak D, 2003, J BIOL CHEM, V278, P20821, DOI 10.1074/jbc.M212437200; Strausak D, 2001, BRAIN RES BULL, V55, P175, DOI 10.1016/S0361-9230(01)00454-3; Tao TY, 2003, J BIOL CHEM, V278, P41593, DOI 10.1074/jbc.C300391200; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Vaccaro P, 2002, FEBS LETT, V512, P345, DOI 10.1016/S0014-5793(02)02220-2; van Ham M, 2003, MOL BIOL REP, V30, P69, DOI 10.1023/A:1023941703493; Voskoboinik I, 2003, BIOCHEM BIOPH RES CO, V303, P337, DOI 10.1016/S0006-291X(03)00329-2; Voskoboinik I, 2003, BIOCHEM BIOPH RES CO, V301, P488, DOI 10.1016/S0006-291X(03)00010-X; Voskoboinik I, 2002, J BIOENERG BIOMEMBR, V34, P363, DOI 10.1023/A:1021250003104; Voskoboinik I, 2001, J BIOL CHEM, V276, P28620, DOI 10.1074/jbc.M103532200; Voskoboinik N, 1999, J BIOL CHEM, V274, P22008, DOI 10.1074/jbc.274.31.22008; Wijmenga C, 2004, P NUTR SOC, V63, P31, DOI 10.1079/PNS2003316; Yao RJ, 2001, BIOCHEM BIOPH RES CO, V286, P771, DOI 10.1006/bbrc.2001.5430; Zhang QH, 2000, GENOME RES, V10, P1546, DOI 10.1101/gr.140200	69	30	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33270	33279		10.1074/jbc.M505889200	http://dx.doi.org/10.1074/jbc.M505889200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16051599	Green Published, hybrid			2022-12-25	WOS:000232058100022
J	Thammavongsa, V; Mancino, L; Raghavan, M				Thammavongsa, V; Mancino, L; Raghavan, M			Polypeptide substrate recognition by calnexin requires specific conformations of the calnexin protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATITIS-C VIRUS; ENDOPLASMIC-RETICULUM; MOLECULAR CHAPERONE; QUALITY-CONTROL; ALPHA-BETA; ER STRESS; CALRETICULIN; BINDING; PEPTIDE; PATHWAY	Calnexin is an endoplasmic reticulum chaperone that binds to substrates containing monoglucosylated oligosaccharides. Whether calnexin can also directly recognize polypeptide components of substrates is controversial. We found that calnexin displayed significant conformational lability for a chaperone and that heat treatment and calcium depletion induced the formation of calnexin dimers and higher order oligomers. These conditions enhanced the chaperone activity of calnexin toward glycosylated and non-glycosylated major histocompatibility complex (MHC) class I heavy chains, and enhanced calnexin binding to MHC class I heavy chains. In contrast to these observations, calnexin binding to oligosaccharide substrates has been reported to be impaired under calcium-depleting conditions. Calnexin dimers were induced in HeLa cells upon heat shock and under calcium-depleting conditions, and heat shock enhanced calnexin binding to MHC class I heavy chains in HeLa cells. Virus-induced endoplasmic reticulum stress also resulted in the appearance of calnexin dimers. Tunicamycin treatment of HeLa cells induced a slow accumulation of calnexin dimers, the appearance of which correlated with enhanced calnexin binding to deglycosylated MHC class I heavy chains. In vitro, the presence of calnexin-specific oligosaccharides inhibited the formation of calnexin dimers and higher order structures. Together, these data indicate that polypeptide binding is favored by conditions that induce partial unfolding of calnexin monomers, whereas oligosaccharide binding is favored by conditions that enhance the structural stability ( folding) of calnexin monomers. Conditions that induce the calnexin "polypeptide-binding" conformation also induce self-association of calnexin if the concentration is sufficiently high; however, calnexin dimerization/ oligomerization per se is not essential for polypeptide substrate binding.	Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Grad Program Immunol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Raghavan, M (corresponding author), Univ Michigan, Sch Med, Dept Microbiol & Immunol, 5641 Med Sci Bldg 2, Ann Arbor, MI 48109 USA.	malinir@umich.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044115, R56AI044115] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR048310] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI044115, AI44115] Funding Source: Medline; NIAMS NIH HHS [AR48310-02] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARUNACHALAM B, 1995, J BIOL CHEM, V270, P2784, DOI 10.1074/jbc.270.6.2784; Benali-Furet NL, 2005, ONCOGENE, V24, P4921, DOI 10.1038/sj.onc.1208673; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Chae HJ, 2004, MOL CELL, V15, P355, DOI 10.1016/j.molcel.2004.06.038; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Garboczi DN, 1996, J IMMUNOL, V157, P5403; Gong GZ, 2001, P NATL ACAD SCI USA, V98, P9599, DOI 10.1073/pnas.171311298; Guo JT, 2001, J VIROL, V75, P8516, DOI 10.1128/JVI.75.18.8516-8523.2001; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; High S, 2000, FEBS LETT, V476, P38, DOI 10.1016/S0014-5793(00)01666-5; Ihara Y, 1999, MOL CELL, V4, P331, DOI 10.1016/S1097-2765(00)80335-4; Jorgensen CS, 2003, EUR J BIOCHEM, V270, P4140, DOI 10.1046/j.1432-1033.2003.03808.x; Lapinski PE, 2001, J BIOL CHEM, V276, P7526, DOI 10.1074/jbc.M009448200; Leach MR, 2002, J BIOL CHEM, V277, P29686, DOI 10.1074/jbc.M202405200; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Mancino L, 2002, P NATL ACAD SCI USA, V99, P5931, DOI 10.1073/pnas.092031799; Mesaeli N, 1999, J CELL BIOL, V144, P857, DOI 10.1083/jcb.144.5.857; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Ohoka N, 2005, EMBO J, V24, P1243, DOI 10.1038/sj.emboj.7600596; OU WJ, 1995, J BIOL CHEM, V270, P18051, DOI 10.1074/jbc.270.30.18051; Rizvi SM, 2004, MOL CELL, V15, P913, DOI 10.1016/j.molcel.2004.09.001; ROMAGNOLI P, 1995, J EXP MED, V182, P2027, DOI 10.1084/jem.182.6.2027; Saito Y, 1999, EMBO J, V18, P6718, DOI 10.1093/emboj/18.23.6718; Schrag JD, 2001, MOL CELL, V8, P633, DOI 10.1016/S1097-2765(01)00318-5; STAM NJ, 1990, INT IMMUNOL, V2, P113, DOI 10.1093/intimm/2.2.113; Tardif KD, 2005, TRENDS MICROBIOL, V13, P159, DOI 10.1016/j.tim.2005.02.004; Tardif KD, 2002, J VIROL, V76, P7453, DOI 10.1128/JVI.76.15.7453-7459.2002; Vassilakos A, 1998, BIOCHEMISTRY-US, V37, P3480, DOI 10.1021/bi972465g; Yamashita Y, 1996, J VIROL, V70, P2237, DOI 10.1128/JVI.70.4.2237-2246.1996	29	23	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33497	33505		10.1074/jbc.M503648200	http://dx.doi.org/10.1074/jbc.M503648200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16061483	hybrid			2022-12-25	WOS:000232058100049
J	van Thor, JJ; Georgiev, GY; Towrie, M; Sage, JT				van Thor, JJ; Georgiev, GY; Towrie, M; Sage, JT			Ultrafast and low barrier motions in the photoreactions of the green fluorescent protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED STRUCTURAL-CHANGES; CRYSTAL-STRUCTURE; STATE; DYNAMICS; INTERMEDIATE; EXCITATION; SOLVENT	Green fluorescent protein (GFP) fluoresces efficiently under blue excitation despite major electrostatic rearrangements resulting from photoionization of the chromophore and neutralization of Glu-222. A competing phototransformation process, which ionizes the chromophore and decarboxylates Glu-222, mimics the electrostatic and structural changes in the fluorescence photocycle. Structural and spectroscopic analysis of the cryogenically stabilized photoproduct at 100 K and a structurally annealed intermediate of the phototransformed protein at 170 K reveals distinct structural relaxations involving protein, chromophore, solvent, and photogenerated CO2. Strong structural changes of the 100 K photoproduct after decarboxylation appear exclusively within 15 angstrom of the chromophore and include the electrostatically driven perturbations of Gln-69, Cys-70, and water molecules in an H-bonding network connecting the chromophore. X-ray crystallography to 1.85 angstrom resolution and static and picosecond time-resolved IR spectroscopy identify structural mechanisms common to phototransformation and to the fluorescence photocycle. In particular, the appearance of a 1697 cm(-1) (+) difference band in both photocycle and phototransformation intermediates is a spectroscopic signature for the structural perturbation of Gln-69. This is taken as evidence for an electrostatically driven dynamic response that is common to both photoreaction pathways. The interactions between the chromophore and the perturbed residues and solvent are decreased or removed in the T203H single and T203H/Q69L double mutants, resulting in a strong reduction of the fluorescence quantum yield. This suggests that the electrostatic response to the transient formation of a buried charge in the wild type is important for the bright fluorescence.	Univ Oxford, Mol Biophys Lab, Oxford OX1 3QU, England; Northeastern Univ, Dept Phys, Boston, MA 02115 USA; Northeastern Univ, Ctr Interdisciplinary Res Complex Syst, Boston, MA 02115 USA; Rutherford Appleton Lab, Res Councils, Council Cent Lab, Cent Laser Facil, Didcot OX11 0QX, Oxon, England	University of Oxford; Northeastern University; Northeastern University; UK Research & Innovation (UKRI); Science & Technology Facilities Council (STFC); STFC Rutherford Appleton Laboratory	van Thor, JJ (corresponding author), Univ Oxford, Mol Biophys Lab, Rex Richards Bldg,S Parks Rd, Oxford OX1 3QU, England.	jasper@biop.ox.ac.uk		Towrie, Mike/0000-0002-1305-701X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052002, R29GM052002] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-52002] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agmon N, 2005, BIOPHYS J, V88, P2452, DOI 10.1529/biophysj.104.055541; Agmon N, 2005, J PHYS CHEM A, V109, P13, DOI 10.1021/jp047465m; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barth A, 2000, PROG BIOPHYS MOL BIO, V74, P141, DOI 10.1016/S0079-6107(00)00021-3; Baxter RHG, 2004, J AM CHEM SOC, V126, P16728, DOI 10.1021/ja0448115; Benkovic SJ, 2003, SCIENCE, V301, P1196, DOI 10.1126/science.1085515; Brejc K, 1997, P NATL ACAD SCI USA, V94, P2306, DOI 10.1073/pnas.94.6.2306; Chattoraj M, 1996, P NATL ACAD SCI USA, V93, P8362, DOI 10.1073/pnas.93.16.8362; Chu K, 2000, NATURE, V403, P921, DOI 10.1038/35002641; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; DELAGRAVE S, 1995, BIO-TECHNOL, V13, P151, DOI 10.1038/nbt0295-151; Edman K, 1999, NATURE, V401, P822, DOI 10.1038/44623; Fenimore PW, 2004, P NATL ACAD SCI USA, V101, P14408, DOI 10.1073/pnas.0405573101; FORSTER T, 1950, Z ELEKTROCHEM, V54, P531; He X, 2002, ORG LETT, V4, P1523, DOI 10.1021/ol0200403; Kennis JTM, 2004, P NATL ACAD SCI USA, V101, P17988, DOI 10.1073/pnas.0404262102; Kriminski S, 2003, ACTA CRYSTALLOGR D, V59, P697, DOI 10.1107/S0907444903002713; Lamzin V. S., 2001, INT TABLES CRYSTALLO, VF, P720; Leslie A. G. W., 1992, JOINT CCP4 ESF EAMCB; Lippincott-Schwartz J, 2003, SCIENCE, V300, P87, DOI 10.1126/science.1082520; Lippincott-Schwartz J, 2001, NAT REV MOL CELL BIO, V2, P444, DOI 10.1038/35073068; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; Nie BN, 2005, BIOPHYS J, V88, P2833, DOI 10.1529/biophysj.104.047639; Niwa H, 1996, P NATL ACAD SCI USA, V93, P13617, DOI 10.1073/pnas.93.24.13617; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; Palm GJ, 1997, NAT STRUCT BIOL, V4, P361, DOI 10.1038/nsb0597-361; SCHLICHTING I, 1994, NATURE, V371, P808, DOI 10.1038/371808a0; Stoner-Ma D, 2005, J AM CHEM SOC, V127, P2864, DOI 10.1021/ja042466d; Sutcliffe MJ, 2002, EUR J BIOCHEM, V269, P3096, DOI 10.1046/j.1432-1033.2002.03020.x; TENG TY, 1994, NAT STRUCT BIOL, V1, P701, DOI 10.1038/nsb1094-701; Towrie M, 2003, APPL SPECTROSC, V57, P367, DOI 10.1366/00037020360625899; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; van Thor JJ, 2005, J PHYS CHEM B, V109, P16099, DOI 10.1021/jp051315+; van Thor JJ, 1998, BIOCHEMISTRY-US, V37, P16915, DOI 10.1021/bi981170f; van Thor JJ, 2002, NAT STRUCT BIOL, V9, P37, DOI 10.1038/nsb739; Vitkup D, 2000, NAT STRUCT BIOL, V7, P34; WELLER A, 1952, Z ELEKTROCHEM, V56, P662; Xie AH, 2001, BIOCHEMISTRY-US, V40, P1510, DOI 10.1021/bi002449a; Yang F, 1996, NAT BIOTECHNOL, V14, P1246, DOI 10.1038/nbt1096-1246	40	55	58	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33652	33659		10.1074/jbc.M505473200	http://dx.doi.org/10.1074/jbc.M505473200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16033764	hybrid			2022-12-25	WOS:000232058100067
J	Boyanovsky, BB; van der Westhuyzen, DR; Webb, NR				Boyanovsky, BB; van der Westhuyzen, DR; Webb, NR			Group V secretory phospholipase A(2)-modified low density lipoprotein promotes foam cell formation by a SR-A- and CD36-independent process that involves cellular proteoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; HEPARAN-SULFATE PROTEOGLYCANS; MACROPHAGE SCAVENGER RECEPTORS; SMOOTH-MUSCLE CELLS; PHOSPHOLIPASE A(2); IN-VITRO; REMNANT LIPOPROTEINS; CHYLOMICRON REMNANTS; PLASMA-LIPOPROTEINS; LIPID-PEROXIDATION	Accumulating evidence indicates that secretory phospholipase A(2) (sPLA(2)) enzymes promote atherogenic processes. We have previously showed the presence of Group V sPLA(2) (GV sPLA(2)) in human and mouse atherosclerotic lesions, its hydrolysis of low density lipoprotein (LDL) particles, and the ability of GV sPLA(2)-modified LDL (GV- LDL) to induce macrophage foam cell formation in vitro. The goal of this study was to investigate the mechanisms involved in macrophage uptake of GV-LDL. Peritoneal macrophages from C57BL/6 mice (wild type (WT)), C57BL/6 mice deficient in LDL receptor (LDLR-/-), or SR-A and CD36 (DKO) were treated with control LDL, GV-LDL, oxidized LDL (ox-LDL) or LDL aggregated by vortexing (vx-LDL). As expected, ox- LDL induced significantly more cholesterol ester accumulation in WT and LDLR-/- compared with DKO macrophages. In contrast, there was no difference in the accumulation of GV-LDL or vx-LDL in the three cell types. I-125-ox-LDL exhibited high affinity, saturable binding to WT cells that was significantly reduced in DKO cells. Vx-LDL and GV-LDL showed low affinity, non-saturable binding that was similar for both cell types, and significantly higher compared with control LDL. GV-LDL degradation in WT and DKO cells was similar. Analyses by confocal microscopy indicated a distinct intracellular distribution of Alexa-568-labeled GV-LDL and Alexa-488-labeled ox-LDL. Uptake of GV-LDL (but not ox-LDL or vx-LDL) was significantly reduced in cells preincubated with heparin or NaClO3, suggesting a role for proteoglycans in GV-LDL uptake. Our data point to a physiological modification of LDL that has the potential to promote macrophage foam cell formation independent of scavenger receptors.	Univ Kentucky, Med Ctr, Dept Internal Med, Lexington, KY 40536 USA; Univ Kentucky, Med Ctr, Vet Affairs Med Ctr, Lexington, KY 40536 USA; Univ Kentucky, Med Ctr, Grad Ctr Nutrit Sci, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky; US Department of Veterans Affairs; Veterans Health Administration (VHA); Lexington VA Medical Center; University of Kentucky	Webb, NR (corresponding author), Univ Kentucky, Med Ctr, Dept Internal Med, 535 CT Wethington Bldg,900 S Limestone St, Lexington, KY 40536 USA.	nrwebb1@uky.edu	Webb, Nancy/AAL-7030-2021; Boyanovsky, Boris/AAQ-5194-2021		NHLBI NIH HHS [R01 HL071098, HL-65730, HL071098] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065730, R01HL071098] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVIRAM M, 1995, BIOCHEM BIOPH RES CO, V216, P501, DOI 10.1006/bbrc.1995.2651; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1994, ANN NY ACAD SCI, V737, P53, DOI 10.1111/j.1749-6632.1994.tb44301.x; BIERMAN EL, 1974, CIRC RES, V35, P136, DOI 10.1161/01.RES.35.1.136; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; Boren J, 1998, J CLIN INVEST, V101, P2658, DOI 10.1172/JCI2265; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; Chen YJ, 1998, BBA-LIPID LIPID MET, V1394, P57, DOI 10.1016/S0005-2760(98)00098-8; Cho W, 2000, BBA-MOL CELL BIOL L, V1488, P48, DOI 10.1016/S1388-1981(00)00109-8; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; Flood C, 2004, ARTERIOSCL THROM VAS, V24, P564, DOI 10.1161/01.ATV.0000117174.19078.85; Fuki IV, 2000, BIOCHEM J, V351, P607, DOI 10.1042/0264-6021:3510607; Fuki IV, 2000, J BIOL CHEM, V275, P25742, DOI 10.1074/jbc.M909173199; Fuki IV, 2003, J BIOL CHEM, V278, P34331, DOI 10.1074/jbc.M302181200; Fuki IV, 1997, J CLIN INVEST, V100, P1611, DOI 10.1172/JCI119685; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; Gorshkova IN, 1996, BBA-LIPID LIPID MET, V1300, P103, DOI 10.1016/0005-2760(95)00237-5; HAKALA JK, 2001, ARTERIOSCLER THROMB, V21; Han SK, 1998, BIOCHEM J, V331, P353, DOI 10.1042/bj3310353; Hanasaki K, 2002, J BIOL CHEM, V277, P29116, DOI 10.1074/jbc.M202867200; HEINECKE JW, 1984, J CLIN INVEST, V74, P1890, DOI 10.1172/JCI111609; HENRIKSEN T, 1981, P NATL ACAD SCI-BIOL, V78, P6499, DOI 10.1073/pnas.78.10.6499; HOFF HF, 1985, ANN NY ACAD SCI, V454, P183, DOI 10.1111/j.1749-6632.1985.tb11857.x; HOOGEWERF AJ, 1991, J BIOL CHEM, V266, P16564; HUETTINGER M, 1992, J BIOL CHEM, V267, P18551; HUETTINGER M, 1988, CLIN BIOCHEM, V21, P87, DOI 10.1016/S0009-9120(88)80093-6; Hurt-Camejo E, 2000, CURR OPIN LIPIDOL, V11, P465, DOI 10.1097/00041433-200010000-00004; HurtCamejo E, 1997, ARTERIOSCL THROM VAS, V17, P1011, DOI 10.1161/01.ATV.17.6.1011; JI ZS, 1994, J BIOL CHEM, V269, P13429; JI ZS, 1994, ARTERIOSCLER THROMB, V14, P2025, DOI 10.1161/01.ATV.14.12.2025; KHOO JC, 1988, ARTERIOSCLEROSIS, V8, P348, DOI 10.1161/01.ATV.8.4.348; KLEINMAN Y, 1988, J LIPID RES, V29, P729; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; MAHLEY RW, 1994, ANN NY ACAD SCI, V737, P39, DOI 10.1111/j.1749-6632.1994.tb44300.x; MEILINGER M, 1995, FEBS LETT, V360, P70, DOI 10.1016/0014-5793(95)00082-K; Murakami M, 2003, CURR OPIN LIPIDOL, V14, P431, DOI 10.1097/00041433-200310000-00003; Neuzil J, 1998, BIOCHEMISTRY-US, V37, P9203, DOI 10.1021/bi9730745; NOBLE RP, 1968, J LIPID RES, V9, P693; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sartipy P, 1999, J BIOL CHEM, V274, P25913, DOI 10.1074/jbc.274.36.25913; SPARROW CP, 1988, J LIPID RES, V29, P745; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; SUITS AG, 1989, P NATL ACAD SCI USA, V86, P2713, DOI 10.1073/pnas.86.8.2713; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; Tabas I, 2002, J CLIN INVEST, V110, P905, DOI 10.1172/JCI200216452; Tabas I, 1999, ANNU REV NUTR, V19, P123, DOI 10.1146/annurev.nutr.19.1.123; VANDIJK MCM, 1991, BIOCHEM J, V279, P863, DOI 10.1042/bj2790863; WEISGRABER KH, 1987, J BIOL CHEM, V262, P11097; WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; Wooton-Kee CR, 2004, ARTERIOSCL THROM VAS, V24, P762, DOI 10.1161/01.ATV.0000122363.02961.c1; XU XX, 1991, J BIOL CHEM, V266, P24849; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271	54	64	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32746	32752		10.1074/jbc.M502067200	http://dx.doi.org/10.1074/jbc.M502067200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16040605	hybrid			2022-12-25	WOS:000231920300025
J	Hook, P; Mikami, A; Shafer, B; Chait, BT; Rosenfeld, SS; Vallee, RB				Hook, P; Mikami, A; Shafer, B; Chait, BT; Rosenfeld, SS; Vallee, RB			Long range allosteric control of cytoplasmic dynein ATPase activity by the stalk and C-terminal domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN; NUCLEOTIDE-BINDING; ADP RELEASE; SITES; HYDROLYSIS; MECHANISM; DISTINCT; KINESIN	The dynein motor domain consists of a ring of six AAA domains with a protruding microtubule-binding stalk and a C-terminal domain of unknown function. To understand how conformational information is communicated within this complex structure, we produced a series of recombinant and proteolytic rat motor domain fragments, which we analyzed enzymatically. A recombinant 210-kDa half-motor domain fragment surprisingly exhibited a 6-fold higher steady state ATPase activity than a 380-kDa complete motor domain fragment. The increased ATPase activity was associated with a complete loss of sensitivity to inhibition by vanadate and an similar to 100-fold increase in the rate of ADP release. The time course of product release was discovered to be biphasic, and each phase was stimulated similar to 1000-fold by microtubule binding to the 380-kDa motor domain. Both the half-motor and full motor domain fragments were remarkably resistant to tryptic proteolysis, exhibiting either two or three major cleavage sites. Cleavage near the C terminus of the 380-kDa motor domain released a 32-kDa fragment and abolished sensitivity to vanadate. Cleavage at this site was insensitive to ATP or 5'-adenylyl-beta, gamma-imidodiphosphate but was blocked by ADP-AlF3 or ADP-vanadate. Based on these data, we proposed a model for long range allosteric control of product release at AAA1 and AAA3 through the microtubule-binding stalk and the C-terminal domain, the latter of which may interact with AAA1 to close the motor domain ring in a cross-bridge cycle-dependent manner.	Columbia Univ, Dept Pathol & Cell Biol, New York, NY 10032 USA; Rockefeller Univ, Lab Mass Spect & Gaseous Ion Chem, New York, NY 10022 USA; Columbia Univ, Dept Neurol, New York, NY 10032 USA	Columbia University; Rockefeller University; Columbia University	Vallee, RB (corresponding author), Columbia Univ, Dept Pathol & Cell Biol, New York, NY 10032 USA.	rv2025@columbia.edu			NCRR NIH HHS [RR00862] Funding Source: Medline; NIGMS NIH HHS [GM47434] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM047434, R01GM047434] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Burgess SA, 2003, NATURE, V421, P715, DOI 10.1038/nature01377; Cadene M, 2000, ANAL CHEM, V72, P5655, DOI 10.1021/ac000811l; DeLaBarre B, 2005, J MOL BIOL, V347, P437, DOI 10.1016/j.jmb.2005.01.060; Dujardin DL, 2002, CURR OPIN CELL BIOL, V14, P44, DOI 10.1016/S0955-0674(01)00292-7; Fan J, 2001, J MOL BIOL, V307, P1317, DOI 10.1006/jmbi.2001.4566; Gee MA, 1997, NATURE, V390, P636, DOI 10.1038/37663; GIBBONS IR, 1987, J BIOL CHEM, V262, P2780; GIBBONS IR, 1991, NATURE, V352, P640, DOI 10.1038/352640a0; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; HOLZBAUR ELF, 1989, BIOCHEMISTRY-US, V28, P5577, DOI 10.1021/bi00439a036; HOLZBAUR ELF, 1989, BIOCHEMISTRY-US, V28, P7010, DOI 10.1021/bi00443a034; KODAMA T, 1986, J BIOCHEM-TOKYO, V99, P1465, DOI 10.1093/oxfordjournals.jbchem.a135616; Kon T, 2004, BIOCHEMISTRY-US, V43, P11266, DOI 10.1021/bi048985a; LEHRER SS, 1978, METHOD ENZYMOL, V49, P220; Mocz G, 2001, STRUCTURE, V9, P93, DOI 10.1016/S0969-2126(00)00557-8; Neuwald AF, 1999, GENOME RES, V9, P27; Nishiura M, 2004, J BIOL CHEM, V279, P22799, DOI 10.1074/jbc.M313362200; PORTER ME, 1983, J BIOL CHEM, V258, P6582; Reck-Peterson SL, 2004, P NATL ACAD SCI USA, V101, P1491, DOI 10.1073/pnas.2637011100; Rosenfeld SS, 1996, J BIOL CHEM, V271, P30212, DOI 10.1074/jbc.271.47.30212; Samso M, 1998, J MOL BIOL, V276, P927, DOI 10.1006/jmbi.1997.1584; SHPETNER HS, 1988, J CELL BIOL, V107, P1001, DOI 10.1083/jcb.107.3.1001; Silvanovich A, 2003, MOL BIOL CELL, V14, P1355, DOI 10.1091/mbc.E02-10-0675; Straube A, 2001, EMBO J, V20, P5091, DOI 10.1093/emboj/20.18.5091; Takahashi Y, 2004, P NATL ACAD SCI USA, V101, P12865, DOI 10.1073/pnas.0403429101; Tynan SH, 2000, J BIOL CHEM, V275, P32769, DOI 10.1074/jbc.M001537200; Vale RD, 2000, SCIENCE, V288, P88, DOI 10.1126/science.288.5463.88	27	48	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					33045	33054		10.1074/jbc.M504693200	http://dx.doi.org/10.1074/jbc.M504693200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16030013	hybrid			2022-12-25	WOS:000231920300059
J	Ohhashi, Y; Kihara, M; Naiki, H; Goto, Y				Ohhashi, Y; Kihara, M; Naiki, H; Goto, Y			Ultrasonication-induced amyloid fibril formation of beta(2)-microglobulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTENSION IN-VITRO; PROTEIN AGGREGATION; NEUTRAL PH; HYDROPHOBIC INTERACTIONS; PHYSIOLOGICAL CONDITIONS; KINETIC-MODEL; ULTRASOUND; BETA-2-MICROGLOBULIN; PEPTIDE; FIBRILLOGENESIS	To obtain insight into the mechanism of fibril formation, we examined the effects of ultrasonication, a strong agitator, on beta(2)-microglobulin (beta 2-m), a protein responsible for dialysis-related amyloidosis. Upon sonication of an acid-unfolded beta 2-m solution at pH 2.5, thioflavin T fluorescence increased markedly after a lag time of 1 - 2 h with a simultaneous increase of light scattering. Atomic force microscopy images showed the formation of a large number of short fibrils 3 nm in diameter. When the sonication- induced fibrils were used as seeds in the next seeding experiment at pH 2.5, a rapid and intense formation of long fibrils 3 nm in diameter was observed demonstrating seed- dependent fibril growth. We then examined the effects of sonication on the native beta(2)-m at neutral pH, conditions under which amyloid deposits occur in patients. In the presence of 0.5 mM sodium dodecyl sulfate, a model compound of potential trigger and stabilizer of amyloid fibrils in patients, a marked increase of thioflavin T fluorescence was observed after 1 day of sonication at pH 7.0. The products of sonication caused the accelerated fibril formation at pH 7.0. Atomic force microscopy images showed that the fibrils formed at pH 7.0 have a diameter of more than 7 nm, thicker than those prepared at pH 2.5. These results indicate that ultrasonication is one form of agitation triggering the formation of amyloid fibrils of beta 2-m, producing fibrils adapted to the respective pH.	Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan; Japan Sci & Technol Agcy, CREST, Suita, Osaka 5650871, Japan; Univ Fukui, Fac Med Sci, Dept Pathol Sci, Matsuoka, Fukui 9101193, Japan; Japan Sci & Technol Agcy, CREST, Matsuoka, Fukui 9101193, Japan	Osaka University; Japan Science & Technology Agency (JST); University of Fukui; Japan Science & Technology Agency (JST)	Goto, Y (corresponding author), Osaka Univ, Inst Prot Res, Yamadaoka 3-2, Suita, Osaka 5650871, Japan.	ygoto@protein.osaka-u.ac.jp	Naiki, Hironobu/G-5599-2014					Ashush H, 2000, CANCER RES, V60, P1014; Bam NB, 1998, J PHARM SCI, V87, P1554, DOI 10.1021/js980175v; Beerlage HP, 1999, UROLOGY, V54, P273, DOI 10.1016/S0090-4295(99)00104-1; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; Castilla J, 2005, CELL, V121, P195, DOI 10.1016/j.cell.2005.02.011; Chiba T, 2003, J BIOL CHEM, V278, P47016, DOI 10.1074/jbc.M304473200; Chien P, 2003, NATURE, V424, P948, DOI 10.1038/nature01894; Chiti F, 2003, NATURE, V424, P805, DOI 10.1038/nature01891; Chiti F, 2002, P NATL ACAD SCI USA, V99, P16419, DOI 10.1073/pnas.212527999; Chiti F, 2001, J BIOL CHEM, V276, P46714, DOI 10.1074/jbc.M107040200; Corazza A, 2004, J BIOL CHEM, V279, P9176, DOI 10.1074/jbc.M310779200; de la Paz ML, 2002, P NATL ACAD SCI USA, V99, P16052, DOI 10.1073/pnas.252340199; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; Dzwolak W, 2004, PROTEIN SCI, V13, P1927, DOI 10.1110/ps.03607204; Eakin CM, 2004, BIOCHEMISTRY-US, V43, P7808, DOI 10.1021/bi049792q; Esposito G, 2000, PROTEIN SCI, V9, P831, DOI 10.1110/ps.9.5.831; Feril LB, 2004, J RADIAT RES, V45, P479, DOI 10.1269/jrr.45.479; Feril LB, 2004, INT J RADIAT BIOL, V80, P165, DOI 10.1080/09553000310001654684; Ferrone F, 1999, METHOD ENZYMOL, V309, P256; Floege J, 2001, KIDNEY INT, V59, pS164, DOI 10.1046/j.1523-1755.2001.59780164.x; Gejyo F, 1997, KIDNEY INT, V52, pS75; Gupta MN, 2004, EUR J BIOCHEM, V271, P2575, DOI 10.1111/j.1432-1033.2004.04163.x; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; Hoshino M, 2002, NAT STRUCT BIOL, V9, P332, DOI 10.1038/nsb792; Ivanova MI, 2004, P NATL ACAD SCI USA, V101, P10584, DOI 10.1073/pnas.0403756101; Jones S, 2003, J MOL BIOL, V330, P935, DOI 10.1016/S0022-2836(03)00688-0; Kad NM, 2003, J MOL BIOL, V330, P785, DOI 10.1016/S0022-2836(03)00583-7; Kad NM, 2001, J MOL BIOL, V313, P559, DOI 10.1006/jmbi.2001.5071; Katou H, 2002, PROTEIN SCI, V11, P2218, DOI 10.1110/ps.0213202; Kelly JW, 1996, CURR OPIN STRUC BIOL, V6, P11, DOI 10.1016/S0959-440X(96)80089-3; Kihara M, 2005, J BIOL CHEM, V280, P12012, DOI 10.1074/jbc.M411949200; Mason TJ, 2003, ULTRASON SONOCHEM, V10, P175, DOI 10.1016/S1350-4177(03)00086-5; Morgan CJ, 2001, J MOL BIOL, V309, P339, DOI 10.1006/jmbi.2001.4661; Naiki H, 1997, AMYLOID, V4, P223, DOI 10.3109/13506129709003833; Naiki H, 1996, LAB INVEST, V74, P374; NAIKI H, 1991, LAB INVEST, V65, P104; Ohhashi Y, 2004, J BIOL CHEM, V279, P10814, DOI 10.1074/jbc.M310334200; Raman B, 2005, BIOCHEMISTRY-US, V44, P1288, DOI 10.1021/bi048029t; RIESZ P, 1992, FREE RADICAL BIO MED, V13, P247, DOI 10.1016/0891-5849(92)90021-8; Rochet JC, 2000, CURR OPIN STRUC BIOL, V10, P60, DOI 10.1016/S0959-440X(99)00049-4; Saborio GP, 2001, NATURE, V411, P810, DOI 10.1038/35081095; Satheeshkumar KS, 2002, CHEM COMMUN, P2244, DOI 10.1039/b206886a; SLUZKY V, 1991, P NATL ACAD SCI USA, V88, P9377, DOI 10.1073/pnas.88.21.9377; Stathopulos PB, 2004, PROTEIN SCI, V13, P3017, DOI 10.1110/ps.04831804; Tanaka M, 2004, NATURE, V428, P323, DOI 10.1038/nature02392; Uversky VN, 2004, BBA-PROTEINS PROTEOM, V1698, P131, DOI 10.1016/j.bbapap.2003.12.008; YAMAGUCHI K, 2005, IN PRESS J MOL BIOL; Yamamoto S, 2004, BIOCHEMISTRY-US, V43, P11075, DOI 10.1021/bi049262u; Yu TH, 2004, ULTRASON SONOCHEM, V11, P95, DOI 10.1016/S1350-4177(03)00157-3	49	142	144	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32843	32848		10.1074/jbc.M506501200	http://dx.doi.org/10.1074/jbc.M506501200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16046408	hybrid, Green Published			2022-12-25	WOS:000231920300037
J	Wei, S; Kashiwagi, M; Kota, S; Xie, ZH; Nagase, H; Brew, K				Wei, S; Kashiwagi, M; Kota, S; Xie, ZH; Nagase, H; Brew, K			Reactive site mutations in tissue inhibitor of metalloproteinase-3 disrupt inhibition of matrix metalloproteinases but not tumor necrosis factor-alpha-converting enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; POTENT INHIBITOR; ADAM FAMILY; TIMP-1; DOMAIN; TNF; TACE; EXPRESSION; MECHANISM	Tissue inhibitor of metalloproteinase-3 (TIMP-3) is a dual inhibitor of the matrix metalloproteinases (MMPs) and some adamalysins, two families of extracellular and cell surface metalloproteinases that function in extracellular matrix turnover and the shedding of cell surface proteins. The mechanism of inhibition of MMPs by TIMPs has been well characterized, and since the catalytic domains of MMPs and adamalysins are homologous, it was assumed that the interaction of TIMP-3 with adamalysins is closely similar. Here we report that the inhibition of the extracellular region of ADAM-17 (tumor necrosis factor alpha-converting enzyme (TACE)) by the inhibitory domain of TIMP-3 (N-TIMP-3) shows positive cooperativity. Also, mutations in the core of the MMP interaction surface of N-TIMP-3 dramatically reduce the binding affinity for MMPs but have little effect on the inhibitory activity for TACE. These results suggest that the mechanism of inhibition of ADAM-17 by TIMP-3 may be distinct from that for MMPs. The mutant proteins are also effective inhibitors of tumor necrosis factor alpha(TNF-alpha) release from phorbol ester-stimulated cells, indicating that they provide a lead for engineering TACE-specific inhibitors that may reduce side effects arising from MMP inhibition and are possibly useful for treatment of diseases associated with excessive TNF-alpha levels such as rheumatoid arthritis.	Florida Atlantic Univ, Dept Biomed Sci, Boca Raton, FL 33431 USA; Univ London Imperial Coll Sci Technol & Med, Div Rheumatol, Kennedy Inst, Fac Med, London W6 8LH, England	State University System of Florida; Florida Atlantic University; Imperial College London; University of Oxford	Brew, K (corresponding author), Florida Atlantic Univ, Dept Biomed Sci, Boca Raton, FL 33431 USA.	kbrew@fau.edu	Brew, Keith/A-6746-2009; Brew, Keith/W-1643-2019	Brew, Keith/0000-0003-1306-1032; Wei, Shuo/0000-0001-8203-4922	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040994] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR40994] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Baker AH, 2002, J CELL SCI, V115, P3719, DOI 10.1242/jcs.00063; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Coeshott C, 1999, P NATL ACAD SCI USA, V96, P6261, DOI 10.1073/pnas.96.11.6261; Condon TP, 2001, ANTISENSE NUCLEIC A, V11, P107, DOI 10.1089/108729001750171353; Cortes A, 2001, BIOCHEM J, V357, P263, DOI 10.1042/0264-6021:3570263; ENGELBERTS I, 1991, LYMPHOKINE CYTOK RES, V10, P69; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; Gonzales PE, 2004, J BIOL CHEM, V279, P31638, DOI 10.1074/jbc.M401311200; Haro H, 2000, J CLIN INVEST, V105, P143, DOI 10.1172/JCI7091; Higashi S, 1999, J BIOL CHEM, V274, P10497, DOI 10.1074/jbc.274.15.10497; Holmbeck K, 2005, J CELL SCI, V118, P147, DOI 10.1242/jcs.01581; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Jin GX, 2002, ANAL BIOCHEM, V302, P269, DOI 10.1006/abio.2001.5549; Kashiwagi M, 2001, J BIOL CHEM, V276, P12501, DOI 10.1074/jbc.C000848200; Kopp J, 2004, NUCLEIC ACIDS RES, V32, pD230, DOI 10.1093/nar/gkh008; Lee MH, 2005, J BIOL CHEM, V280, P15967, DOI 10.1074/jbc.M500897200; Lee MH, 2004, J BIOL CHEM, V279, P45121, DOI 10.1074/jbc.M406611200; Lee MH, 2003, J BIOL CHEM, V278, P40224, DOI 10.1074/jbc.M305678200; Lee MH, 2003, BIOCHEM J, V371, P369, DOI 10.1042/BJ20021538; Lee MH, 2002, PROTEIN SCI, V11, P2493, DOI 10.1110/ps.0216202; Lee MH, 2002, BIOCHEM J, V364, P227, DOI 10.1042/bj3640227; Lee MH, 2002, FEBS LETT, V520, P102, DOI 10.1016/S0014-5793(02)02776-X; Loechel F, 2000, BIOCHEM BIOPH RES CO, V278, P511, DOI 10.1006/bbrc.2000.3835; Lunn CA, 1997, FEBS LETT, V400, P333, DOI 10.1016/S0014-5793(96)01410-X; Martel-Pelletier J, 2001, BEST PRACT RES CL RH, V15, P805, DOI 10.1053/berh.2001.0195; Martignetti JA, 2001, NAT GENET, V28, P261, DOI 10.1038/90100; Maskos K, 1998, P NATL ACAD SCI USA, V95, P3408, DOI 10.1073/pnas.95.7.3408; Meng Q, 1999, J BIOL CHEM, V274, P10184, DOI 10.1074/jbc.274.15.10184; Milla ME, 1999, J BIOL CHEM, V274, P30563, DOI 10.1074/jbc.274.43.30563; Mohammed FF, 2004, NAT GENET, V36, P969, DOI 10.1038/ng1413; Moss ML, 2004, BIOCHEMISTRY-US, V43, P7227, DOI 10.1021/bi049677f; Nagase H, 2003, BIOCHEM SOC SYMP, V70, P201, DOI 10.1042/bss0700201; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Qi JH, 2003, ADV EXP MED BIOL, V533, P97; Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608; Rosendahl MS, 1997, J BIOL CHEM, V272, P24588, DOI 10.1074/jbc.272.39.24588; Smith KM, 2002, J CELL BIOL, V159, P893, DOI 10.1083/jcb.200206023; Troeberg L, 2002, BIOCHEMISTRY-US, V41, P15025, DOI 10.1021/bi026454l; WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352; Wei S, 2003, BIOCHEMISTRY-US, V42, P12200, DOI 10.1021/bi035358x; Wei S, 2003, J BIOL CHEM, V278, P9831, DOI 10.1074/jbc.M211793200; Wingfield PT, 1999, J BIOL CHEM, V274, P21362, DOI 10.1074/jbc.274.30.21362; Woessner J.F., 2000, PROTEIN PROFILE SER; Zheng YF, 2004, J BIOL CHEM, V279, P42898, DOI 10.1074/jbc.M403193200	49	48	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32877	32882		10.1074/jbc.C500220200	http://dx.doi.org/10.1074/jbc.C500220200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16079149	hybrid			2022-12-25	WOS:000231920300041
J	Zhao, X; Zhuang, SH; Chen, YC; Boss, GR; Pilz, RB				Zhao, X; Zhuang, SH; Chen, YC; Boss, GR; Pilz, RB			Cyclic GMP-dependent protein kinase regulates CCAAT enhancer-binding protein beta functions through inhibition of glycogen synthase kinase-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; NITRIC-OXIDE SYNTHASE; C/EBP-BETA; SIGNAL-TRANSDUCTION; NATRIURETIC PEPTIDE; GENE-TRANSCRIPTION; LEUCINE ZIPPER; BONE-FORMATION; DNA-BINDING; PHOSPHORYLATION	The CCAAT enhancer- binding protein ( C/ EBP beta) plays an important role in the regulation of gene expression during cell proliferation, differentiation, and apoptosis. We previously showed that C/ EBP beta participates in cGMP- regulated transcription of c- fos in osteoblasts ( Chen, Y., Zhuang, S., Cassenaer, S., Casteel, D. E., Gudi, T., Boss, G. R., and Pilz, R. B. ( 2003) Mol. Cell. Biol. 23, 4066 4082). In the present work, we show that cGMP/ cGMP- dependent protein kinase ( PKG) induced dephosphorylation and activation of C/ EBP beta by inhibiting glycogen synthase kinase- 3 beta ( GSK- 3 beta). Phosphorylation of GSK- 3 beta on Ser(9) negatively regulates the enzyme activity, and we found that PKG phosphorylated this site both in vitro and in vivo; the in vivo phosphorylation occurred rapidly and preceded C/ EBP beta dephosphorylation. Previous studies with GSK- 3 inhibitors suggest that GSK- 3 beta is a C/ EBP beta kinase in resting cells. We determined that GSK- 3 beta phosphorylated C/ EBP beta in vitro on Thr(189), Ser(185), Ser(181), and Ser(177); C/ EBP beta was phosphorylated on these same sites in intact, unstimulated osteoblasts, and phosphorylation was decreased in cGMP- treated cells. Mutation of the GSK- 3 phosphorylation sites in C/ EBP beta prevented C/ EBP beta phosphorylation in resting cells, enhanced C/ EBP beta DNA binding, and led to increased target gene transactivation, mimicking the stimulatory effects of cGMP on C/ EBP beta. cGMP regulation of C/ EBP beta was disrupted by a mutant GSK- 3 beta( Ala(9)) resistant to cGMP/ PKG phosphorylation and inhibition. We conclude that cGMP increases the DNA binding potential of C/ EBP beta by preventing the negative effects of GSK- 3 phosphorylation.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Pilz, RB (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	rpilz@ucsd.edu		Boss, Gerry/0000-0002-9758-8714	NATIONAL CANCER INSTITUTE [R01CA090932] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR051300] Funding Source: NIH RePORTER; NCI NIH HHS [CA90932] Funding Source: Medline; NIAMS NIH HHS [AR51300] Funding Source: Medline; NIGMS NIH HHS [GM55586] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aguirre J, 2001, AM J PATHOL, V158, P247, DOI 10.1016/S0002-9440(10)63963-6; Ali A, 2001, CHEM REV, V101, P2527, DOI 10.1021/cr000110o; Armour KE, 2001, ENDOCRINOLOGY, V142, P760, DOI 10.1210/en.142.2.760; Belsham DD, 1996, EMBO J, V15, P538, DOI 10.1002/j.1460-2075.1996.tb00386.x; Bollen M, 2002, TRENDS CELL BIOL, V12, P138, DOI 10.1016/S0962-8924(01)02247-4; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; Bradley MN, 2003, MOL CELL BIOL, V23, P4841, DOI 10.1128/MCB.23.14.4841-4858.2003; Buck M, 1999, MOL CELL, V4, P1087, DOI 10.1016/S1097-2765(00)80237-3; Buck M, 2001, MOL CELL, V8, P807, DOI 10.1016/S1097-2765(01)00374-4; Buck M, 2001, EMBO J, V20, P6712, DOI 10.1093/emboj/20.23.6712; Chen YC, 2003, MOL CELL BIOL, V23, P4066, DOI 10.1128/MCB.23.12.4066-4082.2003; Chinery R, 1997, J BIOL CHEM, V272, P30356, DOI 10.1074/jbc.272.48.30356; Chusho H, 2001, P NATL ACAD SCI USA, V98, P4016, DOI 10.1073/pnas.071389098; Ciani E, 2002, J NEUROCHEM, V81, P218, DOI 10.1046/j.1471-4159.2002.00857.x; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Dowsett M, 2000, EUR J CANCER, V36, P170, DOI 10.1016/S0959-8049(99)00264-6; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Fiedler B, 2002, P NATL ACAD SCI USA, V99, P11363, DOI 10.1073/pnas.162100799; FRENCH PJ, 1995, J BIOL CHEM, V270, P26626, DOI 10.1074/jbc.270.44.26626; Gudi T, 1999, FASEB J, V13, P2143, DOI 10.1096/fasebj.13.15.2143; Gutierrez S, 2002, J BIOL CHEM, V277, P1316, DOI 10.1074/jbc.M106611200; Ha KS, 2003, FASEB J, V17, P1036, DOI 10.1096/fj.02-0738com; Hagiwara H, 1996, AM J PHYSIOL-CELL PH, V270, pC1311, DOI 10.1152/ajpcell.1996.270.5.C1311; Hardt SE, 2002, CIRC RES, V90, P1055, DOI 10.1161/01.RES.0000018952.70505.F1; Hata K, 2005, MOL CELL BIOL, V25, P1971, DOI 10.1128/MCB.25.5.1971-1979.2005; Iyer VV, 2004, EXP CELL RES, V295, P128, DOI 10.1016/j.yexcr.2004.01.004; JARCHAU T, 1994, P NATL ACAD SCI USA, V91, P9426, DOI 10.1073/pnas.91.20.9426; Kawasaki K, 2003, MOL CELL BIOL, V23, P5726, DOI 10.1128/MCB.23.16.5726-5737.2003; Kim KH, 2004, J BIOL CHEM, V279, P51999, DOI 10.1074/jbc.M405522200; Kousteni S, 2003, J CLIN INVEST, V111, P1651, DOI 10.1172/JCI200317261; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; Lincoln TM, 2001, J APPL PHYSIOL, V91, P1421, DOI 10.1152/jappl.2001.91.3.1421; Lohmann SM, 1997, TRENDS BIOCHEM SCI, V22, P307, DOI 10.1016/S0968-0004(97)01086-4; Mancini L, 2000, BIOCHEM BIOPH RES CO, V274, P477, DOI 10.1006/bbrc.2000.3164; Martos-Rodriguez A, 2003, J BONE JOINT SURG BR, V85B, P1190, DOI 10.1302/0301-620X.85B8.13516; McKnight SL, 2001, CELL, V107, P259, DOI 10.1016/S0092-8674(01)00543-8; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; Mo XM, 2004, MOL CELL, V13, P241, DOI 10.1016/S1097-2765(03)00521-5; Munzel T, 2003, CIRCULATION, V108, P2172, DOI 10.1161/01.CIR.0000094403.78467.C3; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; Ogasawara A, 2001, J BIOL CHEM, V276, P7048, DOI 10.1074/jbc.M008070200; PEUNOVA N, 1993, NATURE, V364, P450, DOI 10.1038/364450a0; Pfeifer A, 1996, SCIENCE, V274, P2082, DOI 10.1126/science.274.5295.2082; Pigazzi A, 1999, J BIOL CHEM, V274, P14368, DOI 10.1074/jbc.274.20.14368; Pilz RB, 2005, FRONT BIOSCI-LANDMRK, V10, P1239, DOI 10.2741/1616; Piwien-Pilipuk G, 2001, J BIOL CHEM, V276, P19664, DOI 10.1074/jbc.M010193200; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; Ross SE, 1999, MOL CELL BIOL, V19, P8433; SEARS RC, 1994, MOL CELL BIOL, V14, P4855, DOI 10.1128/MCB.14.7.4855; Shuman JD, 2004, MOL CELL BIOL, V24, P7380, DOI 10.1128/MCB.24.17.7380-7391.2004; SNYDER GL, 1992, J NEUROSCI, V12, P3071, DOI 10.1523/JNEUROSCI.12-08-03071.1992; Suda M, 1998, P NATL ACAD SCI USA, V95, P2337, DOI 10.1073/pnas.95.5.2337; TRAUTWEIN C, 1994, J CLIN INVEST, V93, P2554, DOI 10.1172/JCI117266; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; van't Hof RJ, 2001, IMMUNOLOGY, V103, P255, DOI 10.1046/j.1365-2567.2001.01261.x; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; Zhao ZS, 2000, MOL CELL BIOL, V20, P6354, DOI 10.1128/MCB.20.17.6354-6363.2000	58	37	38	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32683	32692		10.1074/jbc.M505486200	http://dx.doi.org/10.1074/jbc.M505486200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16055922	hybrid			2022-12-25	WOS:000231920300018
J	Kaufmann, A; Musset, B; Limberg, SH; Renigunta, V; Sus, R; Dalpke, AH; Heeg, KM; Robaye, B; Hanley, PJ				Kaufmann, A; Musset, B; Limberg, SH; Renigunta, V; Sus, R; Dalpke, AH; Heeg, KM; Robaye, B; Hanley, PJ			"Host tissue damage" signal ATP promotes non-directional migration and negatively regulates Toll-like receptor signaling in human monocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; PHARMACOLOGICAL CHARACTERIZATION; ALPHA PRODUCTION; IMMUNE-RESPONSE; DENDRITIC CELLS; EXPRESSION; INNATE; LIPOPOLYSACCHARIDE; RESPONSIVENESS; ACTIVATION	The activation of Toll-like receptors (TLRs) by lipopolysaccharide or other ligands evokes a proinflammatory immune response, which is not only capable of clearing invading pathogens but can also inflict damage to host tissues. It is therefore important to prevent an overshoot of the TLR-induced response where necessary, and here we show that extracellular ATP is capable of doing this in human monocytes. Using reverse transcription-PCR, we showed that monocytes express P2Y(1), P2Y(2), P2Y(4), P2Y(11), and P2Y(13) receptors, as well as several P2X receptors. To elucidate the function of these receptors, we first studied Ca2+ signaling in single cells. ATP or UTP induced a biphasic increase in cytosolic Ca2+, which corresponded to internal Ca2+ release followed by activation of store- operated Ca2+ entry. The evoked Ca2+ signals stimulated Ca2+-activated K+ channels, producing transient membrane hyperpolarization. In addition, ATP promoted cytoskeleton reorganization and cell migration; however, unlike chemoattractants, the migration was non-directional and further analysis showed that ATP did not activate Akt, essential for sensing gradients. When TLR2, TLR4, or TLR2/6 were stimulated with their respective ligands, ATP gamma S profoundly inhibited secretion of proinflammatory cytokines (tumor necrosis factor-alpha and monocyte chemoattractant protein-1) but increased the production of interleukin-10, an anti-inflammatory cytokine. In radioimmune assays, we found that ATP ( or ATP gamma S) strongly increased cAMP levels, and, moreover, the TLR- response was inhibited by forskolin, whereas UTP neither increased cAMP nor inhibited the TLR- response. Thus, our data suggest that ATP promotes non-directional migration and, importantly, acts as a "host tissue damage" signal via the Gs protein-coupled P2Y(11) receptor and increased cAMP to negatively regulate TLR signaling.	Univ Marburg, Inst Physiol, D-35037 Marburg, Germany; Univ Marburg, Inst Immunol, D-35037 Marburg, Germany; Inst Hyg, D-69120 Heidelberg, Germany; Univ Libre Bruxelles, Inst Interdisciplinary Res, Inst Biol & Med Mol, B-6041 Gosselies, Belgium	Philipps University Marburg; Philipps University Marburg; Universite Libre de Bruxelles	Hanley, PJ (corresponding author), Univ Marburg, Inst Physiol, Deutschhausstr 2, D-35037 Marburg, Germany.	hanley@mailer.uni-marburg.de	Hanley, Peter J/H-4915-2017; Musset, Boris/J-2520-2013; Musset, Boris/AAD-4158-2022	Musset, Boris/0000-0001-8242-8817; Musset, Boris/0000-0001-8242-8817				Aga M, 2004, AM J PHYSIOL-CELL PH, V286, pC923, DOI 10.1152/ajpcell.00417.2003; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Baetz A, 2004, J BIOL CHEM, V279, P54708, DOI 10.1074/jbc.M410992200; Beutler B, 2003, NAT REV IMMUNOL, V3, P169, DOI 10.1038/nri1004; Bulanova E, 2005, J IMMUNOL, V174, P3880, DOI 10.4049/jimmunol.174.7.3880; Chessell IP, 1998, BRIT J PHARMACOL, V124, P1314, DOI 10.1038/sj.bjp.0701958; Communi D, 1999, BRIT J PHARMACOL, V128, P1199, DOI 10.1038/sj.bjp.0702909; Communi D, 2001, J BIOL CHEM, V276, P41479, DOI 10.1074/jbc.M105912200; Communi D, 1997, J BIOL CHEM, V272, P31969, DOI 10.1074/jbc.272.51.31969; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Elenkov IJ, 2000, PHARMACOL REV, V52, P595; Gingras S, 2004, J BIOL CHEM, V279, P54702, DOI 10.1074/jbc.M411043200; Guerra AN, 2003, J ENDOTOXIN RES, V9, P256, DOI 10.1179/096805103225001468; Guillot L, 2005, J BIOL CHEM, V280, P5571, DOI 10.1074/jbc.M410592200; Hanley PJ, 2004, P NATL ACAD SCI USA, V101, P9479, DOI 10.1073/pnas.0400733101; Hannigan M, 2002, P NATL ACAD SCI USA, V99, P3603, DOI 10.1073/pnas.052010699; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Horrigan LA, 2004, INT IMMUNOPHARMACOL, V4, P1409, DOI 10.1016/j.intimp.2004.06.005; Hoshino K, 1999, J IMMUNOL, V162, P3749; Hu Y, 1998, J BIOL CHEM, V273, P27170, DOI 10.1074/jbc.273.42.27170; Kaufmann A, 1999, INFECT IMMUN, V67, P6303; Kawai T, 2004, NAT IMMUNOL, V5, P1061, DOI 10.1038/ni1118; Khoa ND, 2001, J IMMUNOL, V167, P4026, DOI 10.4049/jimmunol.167.7.4026; Kinjyo I, 2002, IMMUNITY, V17, P583, DOI 10.1016/S1074-7613(02)00446-6; la Sala A, 2001, J IMMUNOL, V166, P1611, DOI 10.4049/jimmunol.166.3.1611; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; Liew FY, 2005, NAT REV IMMUNOL, V5, P446, DOI 10.1038/nri1630; Marteau F, 2004, J LEUKOCYTE BIOL, V76, P796, DOI 10.1189/jlb.0104032; Marteau F, 2003, MOL PHARMACOL, V64, P104, DOI 10.1124/mol.64.1.104; Merlot S, 2003, J CELL SCI, V116, P3471, DOI 10.1242/jcs.00703; Nagai Y, 2002, NAT IMMUNOL, V3, P667, DOI 10.1038/ni809; NAIN M, 1990, J IMMUNOL, V145, P1921; Nakagawa R, 2002, IMMUNITY, V17, P677, DOI 10.1016/S1074-7613(02)00449-1; North RA, 2000, ANNU REV PHARMACOL, V40, P563, DOI 10.1146/annurev.pharmtox.40.1.563; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Ollivier V, 1996, J BIOL CHEM, V271, P20828, DOI 10.1074/jbc.271.34.20828; Ralevic V, 1998, PHARMACOL REV, V50, P413; Salentin R, 2003, J LEUKOCYTE BIOL, V74, P252, DOI 10.1189/jlb.1102565; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; SEVERN A, 1992, J IMMUNOL, V148, P3441; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Sitkovsky MV, 2004, ANNU REV IMMUNOL, V22, P657, DOI 10.1146/annurev.immunol.22.012703.104731; Sprenger H, 1996, J EXP MED, V184, P1191, DOI 10.1084/jem.184.3.1191; SUNDERMAN FW, 1990, ANN CLIN LAB SCI, V20, P123; Suzuki N, 2002, NATURE, V416, P750, DOI 10.1038/nature736; VANDERPOLL T, 1995, SHOCK, V3, P1; Wald D, 2003, NAT IMMUNOL, V4, P920, DOI 10.1038/ni968; Wilkin F, 2002, EUR J IMMUNOL, V32, P2409, DOI 10.1002/1521-4141(200209)32:9<2409::AID-IMMU2409>3.0.CO;2-H	51	68	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32459	32467		10.1074/jbc.M505301200	http://dx.doi.org/10.1074/jbc.M505301200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16030017	hybrid			2022-12-25	WOS:000231794800053
J	Masaki, T; Chiba, S; Tatsukawa, H; Noguchi, H; Kakuma, T; Endo, M; Seike, M; Watanabe, T; Yoshimatsu, H				Masaki, T; Chiba, S; Tatsukawa, H; Noguchi, H; Kakuma, T; Endo, M; Seike, M; Watanabe, T; Yoshimatsu, H			The role of histamine H-1 receptor and H-2 receptor in LPS-induced liver injury	FASEB JOURNAL			English	Article						lipopolysaccharide; histamine receptor; tumor necrosis factor-a; IL-10	TUMOR-NECROSIS-FACTOR; GALACTOSAMINE-TREATED MICE; FULMINANT HEPATIC-FAILURE; BLOOD MONONUCLEAR-CELLS; H2 RECEPTORS; FACTOR-ALPHA; T-CELL; INTERFERON-GAMMA; IL-10 PRODUCTION; GENE-EXPRESSION	To examine the role of histamine H-1 and H-2 receptors in the regulation of lipopolysaccharide ( LPS)- induced liver injury, a combination of D- galactosamine and LPS ( GalN/ LPS) was administered to histamine H-1 receptor knockout ( H-1- R KO) and H-2 receptor knockout ( H-2- R KO) mice. The numbers of necrotic and apoptotic hepatocytes in the liver, as well as the levels of serum aspartate transaminase ( AST) and alanine transaminase ( ALT), were increased significantly by GalN/ LPS treatment compared to the appropriate controls. Pretreatment with histamine ameliorated the GalN/ LPS- induced necrotic and apoptotic changes in the hepatocytes and inhibited the elevation of serum AST and ALT levels. Histamine attenuated the GalN/ LPS- induced increases in the levels of TNF- alpha, but augmented those of IL- 10 both in the liver and serum. Histamine inhibited the GalN/ LPS- induced caspase- 3 activity in the liver. Furthermore, these effects of histamine were completely or partially attenuated in H-2- R KO mice, but not in H-1- R KO mice. Peritoneal macrophages from H-2- R KO mice exhibited blunted changes in the effects of histamine on LPS- induced TNF- alpha and IL- 10 production in vitro compared to the wild- type ( WT) controls. In summary, the present findings suggest that the histamine H-2- R- TNF- alpha and - IL- 10 pathways play protective roles in endotoxin- induced hepatic injury.	Oita Univ, Sch Med, Dept Internal Med, Hasama, Oita 8795593, Japan; RIKEN, Res Ctr Allergy & Immunol, Lab Immune Surveillance, Yokohama, Kanagawa, Japan	Oita University; RIKEN	Yoshimatsu, H (corresponding author), Oita Univ, Sch Med, Dept Internal Med, Hasama, Oita 8795593, Japan.	MASAKI@med.oita-u.ac.jp	Tatsukawa, Hideki/AAE-8377-2020	Masaki, Takayuki/0000-0002-2378-849X				BEER DJ, 1984, ADV IMMUNOL, V35, P209, DOI 10.1016/S0065-2776(08)60577-5; Deaciuc IV, 2000, ALCOHOL CLIN EXP RES, V24, P1557, DOI 10.1111/j.1530-0277.2000.tb04575.x; DELAMATA M, 1990, CLIN EXP IMMUNOL, V82, P479; DELVALLE J, 1992, AM J PHYSIOL, V263, pG967; Elenkov IJ, 1998, J IMMUNOL, V161, P2586; FIEDLER VB, 1992, J LAB CLIN MED, V120, P574; FREUDENBERG MA, 1991, INFECT IMMUN, V59, P2110, DOI 10.1128/IAI.59.6.2110-2115.1991; GALANOS C, 1979, P NATL ACAD SCI USA, V76, P5939, DOI 10.1073/pnas.76.11.5939; GANTNER F, 1995, GASTROENTEROLOGY, V109, P166, DOI 10.1016/0016-5085(95)90282-1; GROENEVELD PHP, 1988, IMMUNOLOGY, V63, P521; Gummuluru S, 1996, VIROLOGY, V225, P21, DOI 10.1006/viro.1996.0571; Hornyak SC, 2003, INFLAMMATION, V27, P317, DOI 10.1023/A:1026032611643; Horvath BV, 1999, IMMUNOL LETT, V70, P95, DOI 10.1016/S0165-2478(99)00126-1; IIMURO Y, 1994, J LEUKOCYTE BIOL, V55, P723, DOI 10.1002/jlb.55.6.723; Inoue I, 1996, P NATL ACAD SCI USA, V93, P13316, DOI 10.1073/pnas.93.23.13316; INOUE Y, 1994, SURGERY, V116, P356; Jirillo E, 2002, J ENDOTOXIN RES, V8, P319, DOI 10.1179/096805102125000641; Jutel M, 2002, CURR OPIN IMMUNOL, V14, P735, DOI 10.1016/S0952-7915(02)00395-3; Jutel M, 2001, NATURE, V413, P420, DOI 10.1038/35096564; KAMIJO R, 1993, J EXP MED, V178, P1435, DOI 10.1084/jem.178.4.1435; Kobayashi T, 2000, J CLIN INVEST, V105, P1741, DOI 10.1172/JCI9441; Kohka H, 2000, J IMMUNOL, V164, P6640, DOI 10.4049/jimmunol.164.12.6640; Kraly FS, 1996, PHARMACOL BIOCHEM BE, V53, P347, DOI 10.1016/0091-3057(95)02033-0; LEHMANN V, 1987, J EXP MED, V165, P657, DOI 10.1084/jem.165.3.657; LEIST M, 1994, J IMMUNOL, V153, P1778; LEIST M, 1995, AM J PATHOL, V146, P1220; LEVI RC, 1988, J PHARMACOL EXP THER, V246, P377; Masaki T, 2004, DIABETES, V53, P2250, DOI 10.2337/diabetes.53.9.2250; Masaki T, 2003, ENDOCRINOLOGY, V144, P2741, DOI 10.1210/en.2003-0031; Masaki T, 2004, HEPATOLOGY, V40, P177, DOI 10.1002/hep.20282; Mazzoni A, 2001, J CLIN INVEST, V108, P1865, DOI 10.1172/JCI13930; McIntyre RC, 1997, SHOCK, V7, P36, DOI 10.1097/00024382-199701000-00004; MOVAT HZ, 1987, CAN J PHYSIOL PHARM, V65, P451, DOI 10.1139/y87-077; Nakama T, 2001, HEPATOLOGY, V33, P1441, DOI 10.1053/jhep.2001.24561; Nakamura T, 1997, EUR J PHARMACOL, V322, P83, DOI 10.1016/S0014-2999(96)00987-9; Okuyama H, 2003, HEPATOLOGY, V37, P1015, DOI 10.1053/jhep.2003.50203; Ostapowicz G, 2000, J GASTROEN HEPATOL, V15, P480, DOI 10.1046/j.1440-1746.2000.02074.x; Pajkrt D, 1997, J IMMUNOL, V158, P3971; Rizzardini M, 1998, HEPATOLOGY, V27, P703, DOI 10.1002/hep.510270311; Sass G, 2002, CYTOKINE, V19, P115, DOI 10.1006/cyto.2002.1948; Sirois J, 2000, J IMMUNOL, V164, P2964, DOI 10.4049/jimmunol.164.6.2964; Takahasi HK, 2003, CLIN IMMUNOL, V108, P274, DOI 10.1016/S1521-6616(03)00140-2; Tanaka M, 1996, J Clin Lab Immunol, V48, P17; Togias Alkis, 2003, Journal of Allergy and Clinical Immunology, V112, pS60, DOI 10.1016/S0091-6749(03)01878-5; VANNIER E, 1991, J EXP MED, V174, P281, DOI 10.1084/jem.174.1.281; Williams R, 1996, SEMIN LIVER DIS, V16, P343, DOI 10.1055/s-2007-1007247; Yamaguchi M, 2001, CLIN DIAGN LAB IMMUN, V8, P1234, DOI 10.1128/CDLI.8.6.1234-1239.2001	47	29	30	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1245	1252		10.1096/fj.04-3195com	http://dx.doi.org/10.1096/fj.04-3195com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16051691				2022-12-25	WOS:000231843700031
J	Weaver, A; da Silva, AG; Nuttall, RK; Edwards, DR; Shapiro, SD; Rivest, S; Yong, VW				Weaver, A; da Silva, AG; Nuttall, RK; Edwards, DR; Shapiro, SD; Rivest, S; Yong, VW			An elevated matrix metalloproteinase (MMP) in an animal model of multiple sclerosis is protective by affecting Th1/Th2 polarization	FASEB JOURNAL			English	Article						autoimmunity; EAE/MS; cytokines; proteases; neuroimmunology	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; MESSENGER-RNA EXPRESSION; UP-REGULATION; GELATINASE B; INHIBITOR; MICE; MATRIX-METALLOPROTEINASE-9; CELLS; PROTEINS	Inflammation in multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis ( EAE), is manifested by changes in matrix metalloproteinase ( MMP) expression and in the ratio of T helper ( Th) 1 and 2 effector cytokines. Here, we provide a comprehensive documentation of MMPs in EAE and report that of all the MMPs that could be measured at peak disease in spinal cord tissue, MMP- 12 was the most highly up- regulated. In contrast to previously published findings of MMPs in EAE, this increase in MMP- 12 expression was associated with protection, as MMP- 12 null mice had significantly worse maximum severity and EAE disease burden compared with wild- type ( WT) controls. When spleen and lymph node cells were removed from EAE- afflicted WT and MMP- 12 null mice at the same disease score before divergence of disease and restimulated in vitro, the MMP- 12 null cells had significantly higher Th1 to Th2 cytokine ratio. Measurements of the transcriptional regulators of T cell polarization revealed that MMP- 12 null cells had increased T- bet and reduced GATA- 3 expression, a condition that favors a Th1 bias. These results emphasize that specific MMPs can have beneficial roles in inflammation, and they implicate MMPs in T effector polarization for the first time.	Univ Calgary, Dept Oncol, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Clin Neurosci, Calgary, AB T2N 4N1, Canada; Univ E Anglia, Norwich NR4 7TJ, Norfolk, England; Harvard Univ, Sch Med, Boston, MA USA; Univ Laval, Quebec City, PQ, Canada	University of Calgary; University of Calgary; University of East Anglia; Harvard University; Harvard Medical School; Laval University	Yong, VW (corresponding author), Univ Calgary, Dept Oncol, 3330 Hosp Dr Calgary, Calgary, AB T2N 4N1, Canada.	vyong@ucalgary.ca	Edwards, Dylan R/B-4734-2009	Edwards, Dylan R/0000-0002-3292-2064; Rivest, Serge/0000-0002-6082-770X; Yong, V. Wee/0000-0002-2600-3563				Anthony DC, 1997, NEUROPATH APPL NEURO, V23, P406, DOI 10.1111/j.1365-2990.1997.tb01315.x; Anthony DC, 1998, J NEUROIMMUNOL, V87, P62, DOI 10.1016/S0165-5728(98)00046-0; Bar-Or A, 2003, BRAIN, V126, P2738, DOI 10.1093/brain/awg285; Brundula V, 2002, BRAIN, V125, P1297, DOI 10.1093/brain/awf133; Clements JM, 1997, J NEUROIMMUNOL, V74, P85, DOI 10.1016/S0165-5728(96)00210-X; Dubois B, 1999, J CLIN INVEST, V104, P1507, DOI 10.1172/JCI6886; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Esparza J, 2004, FASEB J, V18, P1682, DOI 10.1096/fj.04-2445com; GIJBELS K, 1994, J CLIN INVEST, V94, P2177, DOI 10.1172/JCI117578; Hartung HP, 2000, J NEUROIMMUNOL, V107, P140, DOI 10.1016/S0165-5728(00)00225-3; Hatton RD, 2003, SCIENCE, V302, P993, DOI 10.1126/science.1092040; HEWSON AK, 1995, INFLAMM RES, V44, P345, DOI 10.1007/BF01796266; ISSAZADEH S, 1995, J NEUROSCI RES, V40, P579, DOI 10.1002/jnr.490400503; Ito A, 1996, J BIOL CHEM, V271, P14657, DOI 10.1074/jbc.271.25.14657; Ito D, 1998, MOL BRAIN RES, V57, P1, DOI 10.1016/S0169-328X(98)00040-0; KENNEDY MK, 1992, J IMMUNOL, V149, P2496; Kieseier BC, 1998, BRAIN, V121, P159, DOI 10.1093/brain/121.1.159; Larsen PH, 2004, J NEUROSCI, V24, P7597, DOI 10.1523/JNEUROSCI.2092-04.2004; Larsen PH, 2003, J NEUROSCI, V23, P11127, DOI 10.1523/jneurosci.23-35-11127.2003; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; Leppert D, 1998, BRAIN, V121, P2327, DOI 10.1093/brain/121.12.2327; McQuibban GA, 2002, BLOOD, V100, P1160, DOI 10.1182/blood.V100.4.1160.h81602001160_1160_1167; McQuibban GA, 2001, J BIOL CHEM, V276, P43503, DOI 10.1074/jbc.M107736200; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Murphy KM, 2002, NAT REV IMMUNOL, V2, P933, DOI 10.1038/nri954; Nuttall RK, 2003, MOL CANCER RES, V1, P333; Nygardas PT, 2002, CLIN EXP IMMUNOL, V128, P245, DOI 10.1046/j.1365-2249.2002.01855.x; O'Shea JJ, 2002, NAT REV IMMUNOL, V2, P37, DOI 10.1038/nri702; Pagenstecher A, 1998, AM J PATHOL, V152, P729; Parks WC, 2004, NAT REV IMMUNOL, V4, P617, DOI 10.1038/nri1418; Sheu BC, 2001, CANCER RES, V61, P237; Shipley JM, 1996, P NATL ACAD SCI USA, V93, P3942, DOI 10.1073/pnas.93.9.3942; Steinman L, 2002, ANNU REV NEUROSCI, V25, P491, DOI 10.1146/annurev.neuro.25.112701.142913; Stuve O, 1996, ANN NEUROL, V40, P853, DOI 10.1002/ana.410400607; Toft-Hansen H, 2004, J IMMUNOL, V173, P5209, DOI 10.4049/jimmunol.173.8.5209; Tsutsui S, 2004, J NEUROSCI, V24, P1521, DOI 10.1523/JNEUROSCI.4271-03.2004; Vos CMP, 2003, J NEUROIMMUNOL, V138, P106, DOI 10.1016/S0165-5728(03)00036-5; Wells JEA, 2003, J NEUROSCI, V23, P10107, DOI 10.1523/jneurosci.23-31-10107.2003; Yong VW, 2001, NAT REV NEUROSCI, V2, P502, DOI 10.1038/35081571; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158	40	114	128	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1668	+		10.1096/fj.04-2030fje	http://dx.doi.org/10.1096/fj.04-2030fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16081501				2022-12-25	WOS:000231843700022
J	Aguado, T; Monory, K; Palazuelos, J; Stella, N; Cravatt, B; Lutz, B; Marsicano, G; Kokaia, Z; Guzman, M; Galve-Roperh, I				Aguado, T; Monory, K; Palazuelos, J; Stella, N; Cravatt, B; Lutz, B; Marsicano, G; Kokaia, Z; Guzman, M; Galve-Roperh, I			The endocannabinoid system drives neural progenitor proliferation	FASEB JOURNAL			English	Article						cannabinoid; CB1 receptor; NP	CANNABINOID RECEPTORS; ANANDAMIDE; BRAIN; NEUROGENESIS; INVOLVEMENT; ASTROCYTES; BLOCKADE; INJURY; CELLS; BINDS	The discovery of multipotent neural progenitor (NP) cells has provided strong support for the existence of neurogenesis in the adult brain. However, the signals controlling NP proliferation remain elusive. Endocannabinoids, the endogenous counterparts of marijuana-derived cannabinoids, act as neuromodulators via presynaptic CB1 receptors and also control neural cell death and survival. Here we show that progenitor cells express a functional endocannabinoid system that actively regulates cell proliferation both in vitro and in vivo. Specifically, NPs produce endocannabinoids and express the CB1 receptor and the endocannabinoid-inactivating enzyme fatty acid amide hydrolase ( FAAH). CB1 receptor activation promotes cell proliferation and neurosphere generation, an action that is abrogated in CB1-deficient NPs. Accordingly, proliferation of hippocampal NPs is increased in FAAH-deficient mice. Our results demonstrate that endocannabinoids constitute a new group of signaling cues that regulate NP proliferation and thus open novel therapeutic avenues for manipulation of NP cell fate in the adult brain.	Univ Complutense, Sch Biol, Dept Biochem & Mol Biol 1, E-28040 Madrid, Spain; Max Planck Inst Psychiat, D-80804 Munich, Germany; Univ Washington, Seattle, WA 98195 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Univ Lund Hosp, Lund Strateg Res Ctr Stem Cell Biol & Cell Therap, Lab Neurol Stem Cell Biol, SE-22184 Lund, Sweden	Complutense University of Madrid; Max Planck Society; University of Washington; University of Washington Seattle; Scripps Research Institute; Scripps Research Institute; Lund University; Skane University Hospital	Galve-Roperh, I (corresponding author), Univ Complutense, Sch Biol, Dept Biochem & Mol Biol 1, E-28040 Madrid, Spain.	igr@quim.ucm.es	Galve-Roperh, Ismael/AAG-2369-2020; PALAZUELOS, JAVIER/AAD-7313-2020; Lutz, Beat/AFK-6229-2022; Aguado, Tania/AAE-3972-2019; Marsicano, Giovanni/I-9603-2016; Kokaia, Zaal/AAL-6009-2020; PALAZUELOS, JAVIER/D-1211-2013; Lutz, Beat/AAG-4538-2022; AGUADO SANCHEZ, TANIA/ABD-6975-2021	PALAZUELOS, JAVIER/0000-0002-0409-1398; Kokaia, Zaal/0000-0003-2296-2449; AGUADO SANCHEZ, TANIA/0000-0003-4339-0443; Guzman, Manuel/0000-0001-7475-118X; Marsicano, Giovanni/0000-0003-3804-1951				Alvarez-Buylla A, 2004, NEURON, V41, P683, DOI 10.1016/S0896-6273(04)00111-4; Cernak I, 2004, J CEREBR BLOOD F MET, V24, P564, DOI 10.1097/00004647-200405000-00011; Cravatt BF, 2001, P NATL ACAD SCI USA, V98, P9371, DOI 10.1073/pnas.161191698; del Pulgar TG, 2002, J BIOL CHEM, V277, P36527, DOI 10.1074/jbc.M205797200; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Fernandez-Ruiz J, 2000, TRENDS NEUROSCI, V23, P14, DOI 10.1016/S0166-2236(99)01491-5; Galve-Roperh I, 2000, NAT MED, V6, P313, DOI 10.1038/73171; Guzman M, 2003, NAT REV CANCER, V3, P745, DOI 10.1038/nrc1188; Hart S, 2004, CANCER RES, V64, P1943, DOI 10.1158/0008-5472.CAN-03-3720; Howlett AC, 2004, NEUROPHARMACOLOGY, V47, P345, DOI 10.1016/j.neuropharm.2004.07.030; Jin KL, 2004, MOL PHARMACOL, V66, P204, DOI 10.1124/mol.66.2.204; Kathuria S, 2003, NAT MED, V9, P76, DOI 10.1038/nm803; Kempermann G, 2004, TRENDS NEUROSCI, V27, P447, DOI 10.1016/j.tins.2004.05.013; Lie DC, 2004, ANNU REV PHARMACOL, V44, P399, DOI 10.1146/annurev.pharmtox.44.101802.121631; Maccarrone M, 2003, CELL DEATH DIFFER, V10, P946, DOI 10.1038/sj.cdd.4401284; Marsicano G, 2003, SCIENCE, V302, P84, DOI 10.1126/science.1088208; Marsicano G, 2002, NATURE, V418, P530, DOI 10.1038/nature00839; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Mechoulam R, 2002, Sci STKE, V2002, pre5, DOI 10.1126/stke.2002.129.re5; Mignone JL, 2004, J COMP NEUROL, V469, P311, DOI 10.1002/cne.10964; Molina-Holgado E, 2002, J NEUROSCI, V22, P9742, DOI 10.1523/jneurosci.22-22-09742.2002; Muthian S, 2004, NEUROSCIENCE, V129, P743, DOI 10.1016/j.neuroscience.2004.08.044; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Parmentier-Batteur S, 2002, J NEUROSCI, V22, P9771, DOI 10.1523/jneurosci.22-22-09771.2002; Piomelli D, 2003, NAT REV NEUROSCI, V4, P873, DOI 10.1038/nrn1247; Rueda D, 2002, J BIOL CHEM, V277, P46645, DOI 10.1074/jbc.M206590200; Schmidt-Hieber C, 2004, NATURE, V429, P184, DOI 10.1038/nature02553; Stella N, 1997, NATURE, V388, P773, DOI 10.1038/42015; Temple S, 2001, NATURE, V414, P112, DOI 10.1038/35102174; van der Stelt M, 2001, J NEUROSCI, V21, P8765, DOI 10.1523/JNEUROSCI.21-22-08765.2001; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Walter L, 2002, J BIOL CHEM, V277, P20869, DOI 10.1074/jbc.M110813200; Williams EJ, 2003, J CELL BIOL, V160, P481, DOI 10.1083/jcb.200210164	33	243	254	0	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1704	+		10.1096/fj.05-3995fje	http://dx.doi.org/10.1096/fj.05-3995fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16037095				2022-12-25	WOS:000230923000013
J	Stuart, JR; Kawai, H; Tsai, KKC; Chuang, EY; Yuan, ZM				Stuart, JR; Kawai, H; Tsai, KKC; Chuang, EY; Yuan, ZM			c-Abl regulates early growth response protein (EGR1) in response to oxidative stress	ONCOGENE			English	Article						c-Abl; EGR1; oxidative stress; tyrosine kinase	FINGER TRANSCRIPTION FACTOR; TYROSINE KINASE; IONIZING-RADIATION; DNA-DAMAGE; ACTIVATION; GENE; EXPRESSION; P53; UPSTREAM; CELLS	c-Abl is a tyrosine kinase that can act as a regulator of cell growth and apoptosis in response to stress. Using cell lines expressing c-Abl in an inducible manner, we identified genes whose expression was regulated by c-Abl kinase activity. Microarray analysis indicated that Early Growth Response-1 (EGR1) gene expression is induced by c-Abl kinase activity, which was confirmed at the message and protein levels. Promoter mapping experiments revealed that c-Abl utilizes three distal serum response elements (SREs) in the EGR1 promoter, which are transactivated by mitogen/extracellular receptor kinase (MEK/ERK) signaling. PD 95089, a specific inhibitor of MEK/ERK signaling, attenuated c-Abl-mediated upregulation of EGR1 expression in a dose-dependent manner. Similar results were obtained by using a dominant-negative mutant of mitogen/extracellular kinase. Significantly, hydrogen peroxide-induced EGR1 expression appears to be mediated by c-Abl, as cells expressing dominant negative c-Abl, and c-Abl(-/-) murine embryonic fibroblasts, are completely defective in hydrogen peroxide-induced EGR1 expression. In addition, c-Abl-induced apoptosis is partially mitigated by EGR1 activity, as cells devoid of EGR1 expression undergo reduced rates of c-Abl-induced apoptosis. Together, these results indicate that c-Abl promotes the induction of EGR1 through the MEK/ERK pathway in regulating apoptotic response to oxidative stress.	Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA 02115 USA; NCI, Radiat Oncol Branch, Bethesda, MD 20892 USA	Harvard University; Harvard T.H. Chan School of Public Health; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Yuan, ZM (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, 665 Huntington Ave,HSPH-1,Room 508, Boston, MA 02115 USA.	zyuan@hsph.harvard.edu	Tsai, Kun-Chih/C-1371-2010	Tsai, Kelvin/0000-0002-1612-2868; Kawai, Hidehiko/0000-0003-2213-7166	NCI NIH HHS [R29 CA85679] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085679] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Brasher BB, 2000, J BIOL CHEM, V275, P35631, DOI 10.1074/jbc.M005401200; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; Chuaqui RF, 2002, NAT GENET, V32, P509, DOI 10.1038/ng1034; Cibelli G, 2002, J NEUROSCI RES, V67, P450, DOI 10.1002/jnr.10141; DANIEL R, 1995, ONCOGENE, V10, P1607; DATTA R, 1993, P NATL ACAD SCI USA, V90, P2419, DOI 10.1073/pnas.90.6.2419; DATTA R, 1992, P NATL ACAD SCI USA, V89, P10149, DOI 10.1073/pnas.89.21.10149; GOGA A, 1995, ONCOGENE, V11, P791; Gu JJ, 2000, MOL CELL BIOL, V20, P1243, DOI 10.1128/MCB.20.4.1243-1253.2000; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; Houslay MD, 2000, MOL PHARMACOL, V58, P659, DOI 10.1124/mol.58.4.659; Jones N, 2003, J CELL PHYSIOL, V196, P326, DOI 10.1002/jcp.10308; Kaufmann K, 2001, BIOL CHEM, V382, P1077, DOI 10.1515/BC.2001.135; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; Kharbanda S, 2000, MOL CELL BIOL, V20, P4979, DOI 10.1128/MCB.20.14.4979-4989.2000; Krones-Herzig A, 2003, P NATL ACAD SCI USA, V100, P3233, DOI 10.1073/pnas.2628034100; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Nair P, 1997, J BIOL CHEM, V272, P20131, DOI 10.1074/jbc.272.32.20131; Park JO, 2002, J CLIN INVEST, V110, P403, DOI 10.1172/JCI200215548; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; SAKAMOTO KM, 1991, ONCOGENE, V6, P867; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Sun XG, 2000, J BIOL CHEM, V275, P17237, DOI 10.1074/jbc.C000099200; Svaren J, 2000, J BIOL CHEM, V275, P38524, DOI 10.1074/jbc.M005220200; Tanis KQ, 2003, MOL CELL BIOL, V23, P3884, DOI 10.1128/MCB.23.11.3884-3896.2003; Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437	33	28	28	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2005	24	55					8085	8092		10.1038/sj.onc.1208953	http://dx.doi.org/10.1038/sj.onc.1208953			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	991JL	16091742				2022-12-25	WOS:000233809400001
J	Schramm, A; Schulte, JH; Klein-Hitpass, L; Havers, W; Sieverts, H; Berwanger, B; Christiansen, H; Warnat, P; Brors, B; Eils, J; Eils, R; Eggert, A				Schramm, A; Schulte, JH; Klein-Hitpass, L; Havers, W; Sieverts, H; Berwanger, B; Christiansen, H; Warnat, P; Brors, B; Eils, J; Eils, R; Eggert, A			Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling	ONCOGENE			English	Article						neuroblastoma; expression profiling; outcome prediction; microarray	N-MYC; GENES; AMPLIFICATION; CANCER; CLASSIFICATION; IDENTIFICATION; MICROARRAYS; DIAGNOSIS; SURVIVAL; 17Q	Neuroblastoma is a common childhood tumor comprising cases with rapid disease progression as well as spontaneous regression. Although numerous prognostic factors have been identified, risk evaluation in individual patients remains difficult. To de. ne a reliable prognostic predictor and gene signatures characteristic of biological subgroups, we performed mRNA expression profiling of 68 neuroblastomas of all stages. Expression data were analysed using support vector machines (SVM-rbf), prediction analysis of microarrays (PAM), k-nearest neighbors (k-NN) algorithms and multiple decision trees. SVM-rbf performed best of all methods, and predicted recurrence of neuroblastoma with an accuracy of 85% (sensitivity 77%, specificity 94%). PAM identified a classifer of 39 genes reliably predicting outcome with an accuracy of 80%. In comparison, conventional risk strati. cation based on stage, age and MYCN-status only reached a predictive accuracy of 64%. Kaplan-Meier analysis using the PAM classifer indicated a 5-year survival of 20 versus 78% for patients with unfavorably versus favorably predicted neuroblastomas, respectively (P=0.0001). Significance analysis of microarrays (SAM) identified additional genes differentially expressed among subgroups. MYCN-amplification and high expression of NTRK1/TrkA demonstrated a strong association with specific gene expression patterns. Our data suggest that microarray-derived data in addition to traditional clinical factors will be useful for risk assessment and de. ning biological properties of neuroblastoma.	Univ Hosp Essen, Dept Pediat Oncol & Hematol, D-45122 Essen, Germany; Univ Hosp Essen, Inst Cell Biol, Essen, Germany; Univ Childrens Hosp, Dept Pediat Oncol, Heidelberg, Germany; Univ Childrens Hosp, Dept Hematol, Heidelberg, Germany; Univ Childrens Hosp, Marburg, Germany; German Canc Res Ctr, DKFZ, Div Intelligent Bioinformat Syst, Heidelberg, Germany	University of Duisburg Essen; University of Duisburg Essen; Ruprecht Karls University Heidelberg; University of Hamburg; University Medical Center Hamburg-Eppendorf; Ruprecht Karls University Heidelberg; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; Helmholtz Association; German Cancer Research Center (DKFZ)	Eggert, A (corresponding author), Univ Hosp Essen, Dept Pediat Oncol & Hematol, Hufelandstr 55, D-45122 Essen, Germany.	angelika.eggert@uni-essen.de	Eils, Roland/B-6121-2009; Schulte, Johannes H/G-3981-2010; Eggert, Angelika/AAE-6907-2022; Schulte, Johannes H./V-2474-2018; Schramm, Alexander/G-5688-2010; Brors, Benedikt/E-5620-2013	Eils, Roland/0000-0002-0034-4036; Eggert, Angelika/0000-0003-3476-8184; Schramm, Alexander/0000-0001-7670-7529; Brors, Benedikt/0000-0001-5940-3101; Schulte, Johannes Hubertus/0000-0003-0671-1201				Alaminos M, 2003, CANCER RES, V63, P4538; Berwanger B, 2002, CANCER CELL, V2, P377, DOI 10.1016/S1535-6108(02)00179-4; Bown N, 1999, NEW ENGL J MED, V340, P1954, DOI 10.1056/NEJM199906243402504; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; CARON H, 1995, MED PEDIATR ONCOL, V24, P215, DOI 10.1002/mpo.2950240402; Chang CC, 2001, NEURAL COMPUT, V13, P2119, DOI 10.1162/089976601750399335; Draghici S, 2003, NUCLEIC ACIDS RES, V31, P3775, DOI 10.1093/nar/gkg624; Elbaz N, 2000, MOL ENDOCRINOL, V14, P795, DOI 10.1210/me.14.6.795; Godfried MB, 2002, ONCOGENE, V21, P2097, DOI 10.1038/sj.onc.1205259; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Hiyama E, 2004, PEDIATR SURG INT, V20, P33, DOI 10.1007/s00383-003-1077-3; Hiyama E, 2003, J PEDIATR SURG, V38, P1730, DOI 10.1016/j.jpedsurg.2003.08.042; Katoh M, 2003, INT J ONCOL, V23, P1219; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601; Ntzani EE, 2003, LANCET, V362, P1439, DOI 10.1016/S0140-6736(03)14686-7; Nutt CL, 2003, CANCER RES, V63, P1602; Ohira M, 2005, CANCER CELL, V7, P337, DOI 10.1016/j.ccr.2005.03.019; Ohira M, 2003, ONCOGENE, V22, P5525, DOI 10.1038/sj.onc.1206853; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Quinlan J.R., 1993, C4 5 PROGRAMS MACHIN; Rosenwald A, 2002, SEMIN ONCOL, V29, P258, DOI 10.1053/sonc.2002.32901; Schilling FH, 2002, NEW ENGL J MED, V346, P1047, DOI 10.1056/NEJMoa012277; Schoch C, 2002, P NATL ACAD SCI USA, V99, P10008, DOI 10.1073/pnas.142103599; Schulte JH, 2003, KLIN PADIATR, V215, P298; Schwab M, 2003, LANCET ONCOL, V4, P472, DOI 10.1016/S1470-2045(03)01166-5; Scott D, 2003, CANCER LETT, V197, P81, DOI 10.1016/S0304-3835(03)00086-7; Su WT, 2004, CANCER GENET CYTOGEN, V154, P131, DOI 10.1016/j.cancergencyto.2004.02.009; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Thompson PM, 2003, ONCOGENE, V22, P1002, DOI 10.1038/sj.onc.1206211; Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Wei JS, 2004, CANCER RES, V64, P6883, DOI 10.1158/0008-5472.CAN-04-0695; WITTEN A, 2002, DATA MINING PRACTICA; Yamamoto K, 1998, J CLIN ONCOL, V16, P1265, DOI 10.1200/JCO.1998.16.4.1265	40	91	95	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2005	24	53					7902	7912		10.1038/sj.onc.1208936	http://dx.doi.org/10.1038/sj.onc.1208936			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	986PU	16103881				2022-12-25	WOS:000233463000009
J	Banci, L; Bertini, I; D'Amelio, N; Gaggelli, E; Libralesso, E; Matecko, I; Turano, P; Valentine, JS				Banci, L; Bertini, I; D'Amelio, N; Gaggelli, E; Libralesso, E; Matecko, I; Turano, P; Valentine, JS			Fully metallated S134NCu,Zn-superoxide dismutase displays abnormal mobility and intermolecular contacts in solution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; ZINC SUPEROXIDE-DISMUTASE; MOLECULAR-WEIGHT COMPLEXES; MOTOR-NEURON DEGENERATION; MONOMERIC MUTANT; WILD-TYPE; PROTEINS; DYNAMICS; DISEASE; SOD1	S134N copper-zinc superoxide dismutase (SOD1) is one of the many mutant SOD1 proteins known to cause familial amyotrophic lateral sclerosis. Earlier studies demonstrated that partially metal-deficient S134N SOD1 crystallized in filament-like arrays with abnormal contacts between the individual protein molecules. Because protein aggregation is implicated in SOD1-linked familial amyotrophic lateral sclerosis, abnormal intermolecular interactions between mutant SOD1 proteins could be relevant to the mechanism of pathogenesis in the disease. We have therefore applied NMR methods to ascertain whether abnormal contacts also form between S134N SOD1 molecules in solution and whether Cys-6 or Cys-111 plays any role in the aggregation. Our studies demonstrate that the behavior of fully metallated S134N SOD1 is dramatically different from that of fully metallated wild type SOD1 with a region of subnanosecond mobility located close to the site of the mutation. Such a high degree of mobility is usually seen only in the apo form of wild type SOD1, because binding of zinc to the zinc site normally immobilizes that region. In addition, concentration-dependent chemical shift differences were observed for S134N SOD1 that were not observed for wild type SOD1, indicative of abnormal intermolecular contacts in solution. We have here also established that the two free cysteines ( 6 and 111) do not play a role in this behavior.	Univ Florence, Magnet Resonance Ctr, I-50019 Sesto Fiorentino, Italy; Univ Florence, Dept Chem, I-50019 Sesto Fiorentino, Italy; FiorGen Fdn, I-50019 Sesto Fiorentino, Italy; Univ Siena, Dept Chem, I-53100 Siena, Italy; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA	University of Florence; University of Florence; University of Siena; University of California System; University of California Los Angeles	Bertini, I (corresponding author), Univ Florence, Magnet Resonance Ctr, Via Luigi Sacconi 6, I-50019 Sesto Fiorentino, Italy.	ivanobertini@cerm.unifi.it	Valentine, Joan S/B-6665-2008; Turano, Paola/F-9089-2011; D'Amelio, Nicola/AAJ-4369-2021	Valentine, Joan S/0000-0002-7174-925X; Turano, Paola/0000-0002-7683-8614; BANCI, LUCIA/0000-0003-0562-5774; D'Amelio, Nicola/0000-0002-4400-2222	NIGMS NIH HHS [GM28222] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028222] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antonyuk S, 2005, PROTEIN SCI, V14, P1201, DOI 10.1110/ps.041256705; Arnesano F, 2004, J BIOL CHEM, V279, P47998, DOI 10.1074/jbc.M406021200; Arnesano F, 2001, J BIOL CHEM, V276, P41365, DOI 10.1074/jbc.M104807200; Banci L, 2003, BIOCHEMISTRY-US, V42, P9543, DOI 10.1021/bi034324m; Banci L, 2000, BIOCHEMISTRY-US, V39, P9108, DOI 10.1021/bi000067z; Banci L, 1995, EUR J BIOCHEM, V234, P855, DOI 10.1111/j.1432-1033.1995.855_a.x; BANCI L, 1991, EUR J BIOCHEM, V196, P123, DOI 10.1111/j.1432-1033.1991.tb15794.x; Banci L, 2002, PROTEIN SCI, V11, P2479, DOI 10.1110/ps.0210802; Banci L, 2002, EUR J BIOCHEM, V269, P1905, DOI 10.1046/j.1432-1033.2002.02840.x; Banci L, 1997, MAGN RESON CHEM, V35, P845, DOI 10.1002/(SICI)1097-458X(199712)35:12<845::AID-OMR183>3.0.CO;2-O; BEEM KM, 1974, J BIOL CHEM, V249, P7298; Bertini I, 2000, MAGN RESON CHEM, V38, P543, DOI 10.1002/1097-458X(200007)38:7<543::AID-MRC722>3.0.CO;2-#; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; Bruijn LI, 2004, ANNU REV NEUROSCI, V27, P723, DOI 10.1146/annurev.neuro.27.070203.144244; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; Dyson HJ, 2005, NAT REV MOL CELL BIO, V6, P197, DOI 10.1038/nrm1589; Elam JS, 2003, NAT STRUCT BIOL, V10, P461, DOI 10.1038/nsb935; GETZOFF ED, 1992, NATURE, V358, P347, DOI 10.1038/358347a0; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; Hart PJ, 1998, PROTEIN SCI, V7, P545; Hayward LJ, 2002, J BIOL CHEM, V277, P15923, DOI 10.1074/jbc.M112087200; Hough MA, 2004, P NATL ACAD SCI USA, V101, P5976, DOI 10.1073/pnas.0305143101; Johnston JA, 2000, P NATL ACAD SCI USA, V97, P12571, DOI 10.1073/pnas.220417997; Johnston JA, 2004, PROG NEUROBIOL, V73, P227, DOI 10.1016/j.pneurobio.2004.05.004; Kirkitadze MD, 2002, J NEUROSCI RES, V69, P567, DOI 10.1002/jnr.10328; Kneller JM, 2002, J AM CHEM SOC, V124, P1852, DOI 10.1021/ja017461k; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; Lindberg MJ, 2002, P NATL ACAD SCI USA, V99, P16607, DOI 10.1073/pnas.262527099; Morrison BM, 1998, J EXP ZOOL, V282, P32; PARGE HE, 1992, P NATL ACAD SCI USA, V89, P6109, DOI 10.1073/pnas.89.13.6109; Ray SS, 2005, P NATL ACAD SCI USA, V102, P3639, DOI 10.1073/pnas.0408277102; Rowland LP, 2001, NEW ENGL J MED, V344, P1688, DOI 10.1056/NEJM200105313442207; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Shipp EL, 2003, BIOCHEMISTRY-US, V42, P1890, DOI 10.1021/bi026704y; Valentine JS, 2003, P NATL ACAD SCI USA, V100, P3617, DOI 10.1073/pnas.0730423100; Valentine JS, 2005, ANNU REV BIOCHEM, V74, P563, DOI 10.1146/annurev.biochem.72.121801.161647; Wang J, 2002, NEUROBIOL DIS, V10, P128, DOI 10.1006/nbdi.2002.0498; Wang J, 2002, NEUROBIOL DIS, V9, P139, DOI 10.1006/nbdi.2001.0471	39	54	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35815	35821		10.1074/jbc.M506637200	http://dx.doi.org/10.1074/jbc.M506637200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16105836	hybrid			2022-12-25	WOS:000232726900007
J	Greive, SJ; Lins, AF; von Hippel, PH				Greive, SJ; Lins, AF; von Hippel, PH			Assembly of an RNA-protein complex - Binding of NusB and NusE (S10) proteins to boxA RNA nucleates the formation of the antitermination complex involved in controlling rRNA transcription in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEDIMENTATION-VELOCITY ANALYSIS; COEFFICIENT DISTRIBUTIONS C(S); ELONGATION-FACTOR-NUSA; LAMBDA N PROTEIN; PHAGE-LAMBDA; BACTERIOPHAGE-LAMBDA; DEFECTIVE ANTITERMINATION; INTRINSIC TERMINATORS; ANTI-TERMINATION; GENE-EXPRESSION	Analytical ultracentrifugation and fluorescence anisotropy methods have been used to measure the equilibrium parameters that control the formation of the core subcomplex of NusB and NusE proteins and boxA RNA. This subcomplex, in turn, nucleates the assembly of the antitermination complex that is involved in controlling the synthesis of ribosomal RNA in Escherichia coli and that also participates in forming the N protein-dependent antitermination complex in lambdoid phage synthesis. In this study we determined the dissociation constants (K-d values) for the individual binary interactions that participate in the assembly of the ternary NusB-NusE-boxA RNA subassembly, and we showed that multiple equilibria, involving both specific and nonspecific binding, are involved in the assembly pathway of this protein-RNA complex. The measured Kd values were used to model the in vitro assembly reaction and combined with in vivo concentration data to simulate the overall control of the assembly of this complex in E. coli at two different cellular growth rates. The results showed that at both growth rates assembly proceeds via the initial formation of a weak but specific NusB-boxA complex, which is then stabilized by NusE binding. We showed that NusE also binds nonspecifically to available single-stranded RNA sequences and that such nonspecific protein binding to RNA can help to regulate crucial interactions in the assembly of the various macromolecular machines of gene expression.	Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA; Univ Oregon, Dept Chem, Eugene, OR 97403 USA	University of Oregon; University of Oregon	von Hippel, PH (corresponding author), Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.	petevh@molbio.uoregon.edu		von Hippel, Peter H./0000-0003-2512-8097	NIGMS NIH HHS [GM-29158, GM-15792] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029158, R37GM015792, R01GM015792] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERG KL, 1989, J MOL BIOL, V209, P345, DOI 10.1016/0022-2836(89)90002-8; Berglechner F, 1997, EUR J BIOCHEM, V248, P338, DOI 10.1111/j.1432-1033.1997.00338.x; Bonifacio GF, 1997, BIOPHYS J, V73, P1532, DOI 10.1016/S0006-3495(97)78185-2; Bremer H, 1996, ESCHERICHIA COLI SAL; COHEN G, 1968, BIOPOLYMERS, V6, P1077, DOI 10.1002/bip.1968.360060805; CONDON C, 1995, MICROBIOL REV, V59, P623, DOI 10.1128/MMBR.59.4.623-645.1995; COURT DL, 1995, J BACTERIOL, V177, P2589, DOI 10.1128/jb.177.9.2589-2591.1995; Culver GM, 1999, RNA, V5, P832, DOI 10.1017/S1355838299990714; Dam J, 2005, BIOPHYS J, V89, P619, DOI 10.1529/biophysj.105.059568; Dam J, 2005, BIOPHYS J, V89, P651, DOI 10.1529/biophysj.105.059584; Demeler B, 2004, ANAL BIOCHEM, V335, P279, DOI 10.1016/j.ab.2004.08.039; DEVITO J, 1994, P NATL ACAD SCI USA, V91, P8660, DOI 10.1073/pnas.91.18.8660; DODD J, 1991, BIOCHIMIE, V73, P757, DOI 10.1016/0300-9084(91)90055-6; GAUSING K, 1977, J MOL BIOL, V115, P335, DOI 10.1016/0022-2836(77)90158-9; GILL SC, 1991, J MOL BIOL, V220, P307, DOI 10.1016/0022-2836(91)90015-X; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gopal B, 2001, BIOCHEMISTRY-US, V40, P920, DOI 10.1021/bi0018279; GREENBLATT J, 1981, J MOL BIOL, V147, P11, DOI 10.1016/0022-2836(81)90076-0; Greive SJ, 2005, NAT REV MOL CELL BIO, V6, P221, DOI 10.1038/nrm1588; HEINRICH T, 1995, J BACTERIOL, V177, P3793, DOI 10.1128/jb.177.13.3793-3800.1995; HELD WA, 1974, J BIOL CHEM, V249, P3103; Koch A L, 1970, J Theor Biol, V28, P201; Komissarova N, 2002, MOL CELL, V10, P1151, DOI 10.1016/S1097-2765(02)00738-4; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; Lakowicz J., 1999, PRINCIPLES FLUORESCE, P302; LI J, 1992, J BIOL CHEM, V267, P6012; Lucast LJ, 2001, BIOTECHNIQUES, V30, P544, DOI 10.2144/01303st06; Luttgen H, 2002, J MOL BIOL, V316, P875, DOI 10.1006/jmbi.2001.5388; Mah TF, 1999, MOL MICROBIOL, V34, P523, DOI 10.1046/j.1365-2958.1999.01618.x; MASON SW, 1991, GENE DEV, V5, P1504, DOI 10.1101/gad.5.8.1504; MASON SW, 1992, J MOL BIOL, V223, P55, DOI 10.1016/0022-2836(92)90715-V; MIZUSHIMA S, 1970, NATURE, V226, P1214, DOI 10.1038/2261214a0; Mogridge J, 1998, J BIOL CHEM, V273, P4143, DOI 10.1074/jbc.273.7.4143; NODWELL JR, 1993, CELL, V72, P261, DOI 10.1016/0092-8674(93)90665-D; NODWELL JR, 1991, GENE DEV, V5, P2141, DOI 10.1101/gad.5.11.2141; Pellizzoni L, 2002, SCIENCE, V298, P1775, DOI 10.1126/science.1074962; Pfeiffer T, 1997, J MOL BIOL, V265, P385, DOI 10.1006/jmbi.1996.0744; Rees WA, 1997, J MOL BIOL, V273, P797, DOI 10.1006/jmbi.1997.1327; Richardson JP, 2003, CELL, V114, P157, DOI 10.1016/S0092-8674(03)00554-3; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; SHARROCK RA, 1985, P NATL ACAD SCI USA, V82, P5275, DOI 10.1073/pnas.82.16.5275; Stoylov SP, 1997, BIOPOLYMERS, V41, P301, DOI 10.1002/(SICI)1097-0282(199703)41:3&lt;301::AID-BIP5&gt;3.0.CO;2-W; SWINDLE J, 1988, J BIOL CHEM, V263, P10229; Torres M, 2001, EMBO J, V20, P3811, DOI 10.1093/emboj/20.14.3811; Van Gilst M, 1995, NUCL ACIDS S SER, V33, P145; Van Gilst MR, 2000, METHOD ENZYMOL, V323, P1; VanGilst MR, 1997, BIOCHEMISTRY-US, V36, P1514, DOI 10.1021/bi961920q; VanGilst MR, 1997, J MOL BIOL, V274, P160, DOI 10.1006/jmbi.1997.1389; VONHIPPEL PH, 1982, J MOL BIOL, V162, P795, DOI 10.1016/0022-2836(82)90548-4; Weisberg RA, 1999, J BACTERIOL, V181, P359, DOI 10.1128/JB.181.2.359-367.1999; WHALEN W A, 1990, New Biologist, V2, P975; WILSON KS, 1995, P NATL ACAD SCI USA, V92, P8793, DOI 10.1073/pnas.92.19.8793; YAGUCHI M, 1980, FEBS LETT, V121, P113, DOI 10.1016/0014-5793(80)81277-4	53	50	52	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36397	36408		10.1074/jbc.M507146200	http://dx.doi.org/10.1074/jbc.M507146200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16109710	hybrid			2022-12-25	WOS:000232726900074
J	Svegliati, S; Cancello, R; Sambo, P; Luchetti, M; Paroncini, P; Orlandini, G; Discepoli, G; Paterno, R; Santillo, M; Cuozzo, C; Cassano, S; Avvedimento, EV; Gabrielli, A				Svegliati, S; Cancello, R; Sambo, P; Luchetti, M; Paroncini, P; Orlandini, G; Discepoli, G; Paterno, R; Santillo, M; Cuozzo, C; Cassano, S; Avvedimento, EV; Gabrielli, A			Platelet-derived growth factor and reactive oxygen species (ROS) regulate Ras protein levels in primary human fibroblasts via ERK1/2 - Amplification of ROS and Ras in systemic sclerosis fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADPH OXIDASE COMPLEX; OXIDATIVE STRESS; EPITHELIAL-CELLS; SCLERODERMA; GENERATION	The levels of Ras proteins in human primary fibroblasts are regulated by PDGF (platelet-derived growth factor). PDGF induced post-transcriptionally Ha-Ras by stimulating reactive oxygen species (ROS) and ERK1/2. Activation of ERK1/2 and high ROS levels stabilize Ha-Ras protein, by inhibiting proteasomal degradation. We found a remarkable example in vivo of amplification of this circuitry in fibroblasts derived from systemic sclerosis ( scleroderma) lesions, producing vast excess of ROS and undergoing rapid senescence. High ROS, Ha-Ras, and active ERK1/2 stimulated collagen synthesis, DNA damage, and accelerated senescence. Conversely ROS or Ras inhibition interrupted the signaling cascade and restored the normal phenotype. We conclude that in primary fibroblasts stabilization of Ras protein by ROS and ERK1/2 amplifies the response of the cells to growth factors and in systemic sclerosis represents a critical factor in the onset and progression of the disease.	Univ Ancona, Ist Clin Med Gen Ematol & Immunol Clin, I-60020 Ancona, Italy; Univ Parma, Dipartimento Med Sperimentale, Sez Istol, I-43100 Parma, Italy; Osped G Salesi, Lab Citogenet, I-60020 Ancona, Italy; Univ Naples Federico II, Dipartimento Med Clin & Sperimentale, I-80131 Naples, Italy; Univ Naples Federico II, Dipartimento Neurosci, Sez Fisiol, I-80131 Naples, Italy; Univ Naples Federico II, CNR, Ist Endocrinol & Oncol Seprimentale, Dipartimento Biol & Patol Mol & Cellulare, I-80131 Naples, Italy	Marche Polytechnic University; University of Parma; University of Naples Federico II; University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II	Avvedimento, EV (corresponding author), Dept Biol Pat Mol Cell, Via S Pansini 5, I-80121 Naples, Italy.	avvedim@unina.it; a.gabrielli@univpm.it	Gabrielli, Armando/AAC-3173-2019; Svegliati, Silvia/L-2614-2016; Luchetti, Michele Maria/J-6955-2019	Svegliati, Silvia/0000-0001-6863-2600; Luchetti, Michele Maria/0000-0001-9132-7401; CASSANO, SILVANA/0000-0001-9868-7936				Alarcon-Vargas D, 2002, ONCOGENE, V21, P4384, DOI 10.1038/sj.onc.1205543; Bonvini P, 1998, ONCOGENE, V16, P1131, DOI 10.1038/sj.onc.1201625; Chang H, 2003, FREE RADICAL RES, V37, P655, DOI 10.1080/1071576031000094907; Chen KCW, 2004, EXP EYE RES, V78, P1057, DOI 10.1016/j.exer.2004.02.004; Cuda G, 2002, CIRCULATION, V105, P968, DOI 10.1161/hc0802.104324; Feliciello A, 2000, J BIOL CHEM, V275, P303, DOI 10.1074/jbc.275.1.303; Hlavata L, 2003, EMBO J, V22, P3337, DOI 10.1093/emboj/cdg314; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; KAHARI VM, 1984, BIOCHIM BIOPHYS ACTA, V781, P183, DOI 10.1016/0167-4781(84)90136-2; Kreuzer J, 2002, FASEB J, V16, P38, DOI 10.1096/fj.01-1036fje; Ohtsuka T, 1998, DERMATOLOGY, V196, P204, DOI 10.1159/000017899; Orlandini G, 1999, METHOD ENZYMOL, V307, P340; Pani G, 2000, J BIOL CHEM, V275, P38891, DOI 10.1074/jbc.M007319200; Piccinini G, 1999, J INVEST DERMATOL, V112, P191, DOI 10.1046/j.1523-1747.1999.00485.x; Prior IA, 2001, J CELL SCI, V114, P1603; Sambo P, 2001, ARTHRITIS RHEUM-US, V44, P2653, DOI 10.1002/1529-0131(200111)44:11<2653::AID-ART445>3.0.CO;2-1; Sambo P, 1999, J INVEST DERMATOL, V112, P78, DOI 10.1046/j.1523-1747.1999.00476.x; Santillo M, 2001, CURR BIOL, V11, P614, DOI 10.1016/S0960-9822(01)00159-2; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Seru R, 2004, J NEUROCHEM, V91, P613, DOI 10.1111/j.1471-4159.2004.02754.x; SUN JY, 1994, J BIOL CHEM, V269, P18638; Suzukawa K, 2000, J BIOL CHEM, V275, P13175, DOI 10.1074/jbc.275.18.13175; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; VALLETTA EA, 1987, J IMMUNOL, V138, P4366; Yan ZF, 1997, J BIOL CHEM, V272, P30928, DOI 10.1074/jbc.272.49.30928	25	140	147	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36474	36482		10.1074/jbc.M502851200	http://dx.doi.org/10.1074/jbc.M502851200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16081426	hybrid			2022-12-25	WOS:000232726900081
J	Dreier, B; Fuller, RP; Segal, DJ; Lund, CV; Blancafort, P; Huber, A; Koksch, B; Barbas, CF				Dreier, B; Fuller, RP; Segal, DJ; Lund, CV; Blancafort, P; Huber, A; Koksch, B; Barbas, CF			Development of zinc finger domains for recognition of the 5 '-CNN-3 ' family DNA sequences and their use in the construction of artificial transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMBINATORIAL ANTIBODY LIBRARIES; CONTROLLING GENE-EXPRESSION; CRYSTAL-STRUCTURE; BINDING PROTEINS; PHAGE DISPLAY; FACTOR IIIA; COMPLEX; DESIGN; SPECIFICITY; ACTIVATION	Considerable progress has been made in recent years in the design of transcription factors for the directed regulation of endogenous genes. Although many strategies involve selection methods that must be applied for each new target sequence, we have developed an approach based on linkage of predefined zinc finger domains that each recognize a three-base pair DNA sequence to construct artificial transcription factors that bind to a desired sequence. These domains can be assembled to recognize unique 18-base pair DNA sequences with high specificity. Here we report the development and characterization of zinc finger domains that bind to 15 of the 16 5'-CNN-3' subsites. These domains were created through a combination of phage display selection, site-directed mutagenesis, and de novo design. Furthermore, these domains were used to generate a highly specific six-finger protein targeting the ERBB-2 promoter. When fused to regulatory domains, this protein was capable of up- and down-regulating the expression of the endogenous ERBB-2 gene. With the addition of this collection of predefined zinc finger domains, most 5'-CNN-3'-, 5'-GNN-3'-, and 5'-ANN-3'-containing sequences can now be rapidly targeted for directed gene regulation and nuclease cleavage.	Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Univ Calif Davis, Genome Ctr, Davis, CA 95616 USA; Univ Calif Davis, Dept Med Pharmacol, Davis, CA 95616 USA; Univ Calif Davis, Dept Toxicol, Davis, CA 95616 USA; Free Univ Berlin, Inst Chem, D-14195 Berlin, Germany	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; Free University of Berlin	Barbas, CF (corresponding author), Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA.	carlos@scripps.edu	Segal, David/B-6646-2013; Blancafort, Pilar/K-9029-2012; Segal, David/V-9126-2019	Segal, David/0000-0001-8962-3105; Segal, David/0000-0001-8962-3105; Blancafort, Pilar/0000-0002-3881-7396	NCI NIH HHS [CA086258] Funding Source: Medline; NIGMS NIH HHS [GM065059] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA086258] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065059] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; BARBAS CF, 1991, METHODS COMPANION ME, V2, P119; Beerli RR, 2000, J BIOL CHEM, V275, P32617, DOI 10.1074/jbc.M005108200; Beerli RR, 1998, P NATL ACAD SCI USA, V95, P14628, DOI 10.1073/pnas.95.25.14628; Beerli RR, 2000, P NATL ACAD SCI USA, V97, P1495, DOI 10.1073/pnas.040552697; Beerli RR, 2002, NAT BIOTECHNOL, V20, P135, DOI 10.1038/nbt0202-135; Bibikova M, 2003, SCIENCE, V300, P764, DOI 10.1126/science.1079512; Blancafort P, 2004, MOL PHARMACOL, V66, P1361, DOI 10.1124/mol.104.002758; Blancafort P, 2003, NAT BIOTECHNOL, V21, P269, DOI 10.1038/nbt794; Dreier B, 2001, J BIOL CHEM, V276, P29466, DOI 10.1074/jbc.M102604200; Dreier B, 2000, J MOL BIOL, V303, P489, DOI 10.1006/jmbi.2000.4133; ElrodErickson M, 1996, STRUCTURE, V4, P1171, DOI 10.1016/S0969-2126(96)00125-6; FAIRALL L, 1993, NATURE, V366, P483, DOI 10.1038/366483a0; Graslund T, 2005, J BIOL CHEM, V280, P3707, DOI 10.1074/jbc.M406809200; Guan X, 2002, P NATL ACAD SCI USA, V99, P13296, DOI 10.1073/pnas.192412899; HARWERTH IM, 1992, J BIOL CHEM, V267, P15160; Havranek JJ, 2004, J MOL BIOL, V344, P59, DOI 10.1016/j.jmb.2004.09.029; Houbaviy HB, 1996, P NATL ACAD SCI USA, V93, P13577, DOI 10.1073/pnas.93.24.13577; HUDSON LG, 1990, J BIOL CHEM, V265, P4389; Isalan M, 1997, P NATL ACAD SCI USA, V94, P5617, DOI 10.1073/pnas.94.11.5617; Jantz D, 2004, CHEM REV, V104, P789, DOI 10.1021/cr020603o; Kim CA, 1996, NAT STRUCT BIOL, V3, P940, DOI 10.1038/nsb1196-940; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; Liu PQ, 2001, J BIOL CHEM, V276, P11323, DOI 10.1074/jbc.M011172200; Liu Q, 1997, P NATL ACAD SCI USA, V94, P5525, DOI 10.1073/pnas.94.11.5525; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; Nolte RT, 1998, P NATL ACAD SCI USA, V95, P2938, DOI 10.1073/pnas.95.6.2938; Pabo CO, 2000, J MOL BIOL, V301, P597, DOI 10.1006/jmbi.2000.3918; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Porteus MH, 2005, NAT BIOTECHNOL, V23, P967, DOI 10.1038/nbt1125; Rader C, 1997, CURR OPIN BIOTECH, V8, P503, DOI 10.1016/S0958-1669(97)80075-4; Segal DJ, 1999, P NATL ACAD SCI USA, V96, P2758, DOI 10.1073/pnas.96.6.2758; Segal DJ, 2003, BIOCHEMISTRY-US, V42, P2137, DOI 10.1021/bi026806o; Tan SY, 2003, P NATL ACAD SCI USA, V100, P11997, DOI 10.1073/pnas.2035056100; Trauger JW, 2001, METHOD ENZYMOL, V340, P450; Wolfe SA, 1999, J MOL BIOL, V285, P1917, DOI 10.1006/jmbi.1998.2421; Wolfe SA, 2000, ANNU REV BIOPH BIOM, V29, P183, DOI 10.1146/annurev.biophys.29.1.183; WU H, 1995, P NATL ACAD SCI USA, V92, P344, DOI 10.1073/pnas.92.2.344; Wuttke DS, 1997, J MOL BIOL, V273, P183, DOI 10.1006/jmbi.1997.1291; Zhang L, 2000, J BIOL CHEM, V275, P33850, DOI 10.1074/jbc.M005341200	42	142	186	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35588	35597		10.1074/jbc.M506654200	http://dx.doi.org/10.1074/jbc.M506654200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16107335	hybrid			2022-12-25	WOS:000232561200061
J	Kim, K; Kim, JH; Lee, J; Jin, HM; Lee, SH; Fisher, DE; Kook, H; Kim, KK; Choi, YW; Kim, NS				Kim, K; Kim, JH; Lee, J; Jin, HM; Lee, SH; Fisher, DE; Kook, H; Kim, KK; Choi, YW; Kim, NS			Nuclear factor of activated T cells c1 induces osteoclast-associated receptor gene expression during tumor necrosis factor-related activation-induced cytokine-mediated osteoclastogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROPHTHALMIA TRANSCRIPTION FACTOR; FCR-GAMMA; KAPPA-B; TERMINAL DIFFERENTIATION; SIGNAL-TRANSDUCTION; BONE-RESORPTION; PROTEIN-KINASE; FACTOR FAMILY; LIGAND; OSTEOPETROSIS	Osteoclast differentiation from hematopoietic precursors is controlled by the tumor necrosis factor family member tumor necrosis factor-related activation-induced cytokine (TRANCE) via induction of various transcription factors, including nuclear factor of activated T cells (NFAT) c1. During osteoclast differentiation, NFATc1 is further activated via calcium signaling when costimulatory receptors expressed on osteoclast precursors, such as osteoclast-associated receptor (OSCAR), are stimulated. Here we show that NFATc1 expression precedes that of OSCAR during TRANCE-mediated osteoclastogenesis and that inhibition of NFATc1 by cyclosporin A abolishes TRANCE-induced OSCAR expression and subsequent osteoclast differentiation. Moreover, we show that the 1.0-kb promoter region of the OSCAR gene contains three potential NFATc1-binding sites. Induction of an OSCAR promoter-luciferase reporter is significantly increased when transiently transfected into 293T cells in combination with NFATc1 expression plasmid. Deletion and site-directed mutant constructs confirmed that NFATc1-binding sites are both functional and NFATc1-specific. Furthermore, NFATc1 synergistically activates an OSCAR reporter construct together with microphthalmia transcription factor and PU.1, transcription factors previously shown to be critical for osteoclast differentiation. In addition, a plasmid expressing constitutively active MAP kinase kinase 6 enhances the transactivation activity of NFATc1/microphthalmia transcription factor/PU.1 on the OSCAR promoter. Taken together, our results indicate that NFATc1 is an important transcription factor in the induction of OSCAR during osteoclastogenesis. Elucidation of NFATc1 as a transcription factor for OSCAR expression implies the presence of a positive feedback circuit of TRANCE-induced activation of NFATc1, involving NFATc1-mediated OSCAR expression and its subsequent activation of NFATc1, necessary for efficient differentiation of osteoclasts.	Chonnam Natl Univ, Sch Med, Med Res Ctr Gene Regulat, Dong Ku 501746, Gwangju, South Korea; Univ Penn, Sch Med, Dept Pathol & Lab Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA	Chonnam National University; University of Pennsylvania; Pennsylvania Medicine; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Kim, NS (corresponding author), Chonnam Natl Univ, Sch Med, Med Res Ctr Gene Regulat, Hak Dong 5, Dong Ku 501746, Gwangju, South Korea.	nacksung@jnu.ac.kr	Kook, Hyun/AAR-5405-2021	Kook, Hyun/0000-0002-0740-1806	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049078, R01AR048521] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR48521, AR49078] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Hayman AR, 1996, DEVELOPMENT, V122, P3151; Hirotani H, 2004, J BIOL CHEM, V279, P13984, DOI 10.1074/jbc.M213067200; Hock MB, 2003, J BIOL CHEM, V278, P26695, DOI 10.1074/jbc.M301007200; Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200; Ishikawa S, 2004, INT IMMUNOL, V16, P1019, DOI 10.1093/intimm/dxh103; Kim N, 2000, P NATL ACAD SCI USA, V97, P10905, DOI 10.1073/pnas.200294797; Kim N, 2002, J EXP MED, V195, P201, DOI 10.1084/jem.20011681; Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006-291X(03)00695-8; Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105; Luchin A, 2001, J BIOL CHEM, V276, P36703, DOI 10.1074/jbc.M106418200; Luchin A, 2000, J BONE MINER RES, V15, P451, DOI 10.1359/jbmr.2000.15.3.451; Mansky KC, 2002, J BIOL CHEM, V277, P11077, DOI 10.1074/jbc.M111696200; Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200; Matsumoto M, 2004, J BIOL CHEM, V279, P45969, DOI 10.1074/jbc.M408795200; Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200; Merck E, 2004, BLOOD, V104, P1386, DOI 10.1182/blood-2004-03-0850; Mocsai A, 2004, P NATL ACAD SCI USA, V101, P6158, DOI 10.1073/pnas.0401602101; Motyckova G, 2001, P NATL ACAD SCI USA, V98, P5798, DOI 10.1073/pnas.091479298; Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453; So H, 2003, J BIOL CHEM, V278, P24209, DOI 10.1074/jbc.M302940200; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; Takami M, 2002, J IMMUNOL, V169, P1516, DOI 10.4049/jimmunol.169.3.1516; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; Takayanagi H, 2005, J MOL MED, V83, P170, DOI 10.1007/s00109-004-0612-6; Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Yang XL, 2002, TRENDS MOL MED, V8, P340, DOI 10.1016/S1471-4914(02)02340-7; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597	32	199	206	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35209	35216		10.1074/jbc.M505815200	http://dx.doi.org/10.1074/jbc.M505815200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16109714	hybrid			2022-12-25	WOS:000232561200018
J	Barnett, ME; Nagy, M; Kedzierska, S; Zolkiewski, M				Barnett, ME; Nagy, M; Kedzierska, S; Zolkiewski, M			The amino-terminal domain of ClpB supports binding to strongly aggregated proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLUS CHAPERONE CLPB; ESCHERICHIA-COLI; DNAK; THERMOTOLERANCE; OLIGOMERIZATION; SYSTEM; AAA(+); ATPASE; DISAGGREGATION; HSP104	Bacterial heat-shock proteins, ClpB and DnaK form a bichaperone system that efficiently reactivates aggregated proteins. ClpB undergoes nucleotide-dependent self-association and forms ring-shaped oligomers. The ClpB-assisted dissociation of protein aggregates is linked to translocation of substrates through the central channel in the oligomeric ClpB. Events preceding the translocation step, such as recognition of aggregates by ClpB, have not yet been explored, and the location of the aggregate-binding site in ClpB has been under discussion. We investigated the reactivation of aggregated glucose-6-phosphate dehydrogenase (G6PDH) by ClpB and its N-terminally truncated variant ClpB Delta N in the presence of DnaK, DnaJ, and GrpE. We found that the chaperone activity of ClpB Delta N becomes significantly lower than that of the full-length ClpB as the size of G6PDH aggregates increases. Using a "substrate trap" variant of ClpB with mutations of Walker B motifs in both ATP-binding modules (E279Q/E678Q), we demonstrated that ClpB Delta N binds to G6PDH aggregates with a significantly lower affinity than the full-length ClpB. Moreover, we identified two conserved acidic residues at the surface of the N-terminal domain of ClpB that support binding to G6PDH aggregates. Those N-terminal residues (Asp-103, Glu-109) contribute as much substrate-binding capability to ClpB as the conserved Tyr located at the entrance to the ClpB channel. In summary, we provided evidence for an essential role of the N-terminal domain of ClpB in recognition and binding strongly aggregated proteins.	Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA	Kansas State University	Zolkiewski, M (corresponding author), Kansas State Univ, Dept Biochem, 104 Willard Hall, Manhattan, KS 66506 USA.	michalz@ksu.edu	Kędzierska-Mieszkowska, Sabina/AAF-2737-2021	Kędzierska-Mieszkowska, Sabina/0000-0001-5756-3013	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058626] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58626] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akoev V, 2004, PROTEIN SCI, V13, P567, DOI 10.1110/ps.03422604; Barnett ME, 2000, J BIOL CHEM, V275, P37565, DOI 10.1074/jbc.M005211200; Beinker P, 2002, J BIOL CHEM, V277, P47160, DOI 10.1074/jbc.M207853200; Clarke AK, 2000, J BACTERIOL, V182, P7092, DOI 10.1128/JB.182.24.7092-7096.2000; Diamant S, 2000, J BIOL CHEM, V275, P21107, DOI 10.1074/jbc.M001293200; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; Hattendorf DA, 2002, EMBO J, V21, P12, DOI 10.1093/emboj/21.1.12; HESS HH, 1975, ANAL BIOCHEM, V63, P607, DOI 10.1016/0003-2697(75)90388-7; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Lee S, 2003, CELL, V115, P229, DOI 10.1016/S0092-8674(03)00807-9; Li JZ, 2003, STRUCTURE, V11, P323, DOI 10.1016/S0969-2126(03)00030-3; Liu ZH, 2002, J MOL BIOL, V321, P111, DOI 10.1016/S0022-2836(02)00591-0; Mogk A, 2003, J BIOL CHEM, V278, P17615, DOI 10.1074/jbc.M209686200; Mogk A, 2003, MOL MICROBIOL, V50, P585, DOI 10.1046/j.1365-2958.2003.03710.x; Mogk A, 2003, J BIOL CHEM, V278, P31033, DOI 10.1074/jbc.M303587200; Motohashi K, 1999, P NATL ACAD SCI USA, V96, P7184, DOI 10.1073/pnas.96.13.7184; Neuwald AF, 1999, GENOME RES, V9, P27; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; Queitsch C, 2000, PLANT CELL, V12, P479, DOI 10.1105/tpc.12.4.479; Sauer RT, 2004, CELL, V119, P9, DOI 10.1016/j.cell.2004.09.020; Schlieker C, 2004, NAT STRUCT MOL BIOL, V11, P607, DOI 10.1038/nsmb787; SQUIRES CL, 1991, J BACTERIOL, V173, P4254, DOI 10.1128/JB.173.14.4254-4262.1991; Tanaka N, 2004, PROTEIN SCI, V13, P3214, DOI 10.1110/ps.04780704; Tek V, 2002, PROTEIN SCI, V11, P1192, DOI 10.1110/ps.4860102; Vale RD, 2000, J CELL BIOL, V150, pF13, DOI 10.1083/jcb.150.1.F13; Weibezahn J, 2004, CELL, V119, P653, DOI 10.1016/j.cell.2004.11.027; Weibezahn J, 2003, J BIOL CHEM, V278, P32608, DOI 10.1074/jbc.M303653200; WOO KM, 1992, J BIOL CHEM, V267, P20429; Xia D, 2004, J STRUCT BIOL, V146, P166, DOI 10.1016/j.jsb.2003.11.025; Zmijewski MA, 2004, J MOL BIOL, V336, P539, DOI 10.1016/j.jmb.2003.12.053; Zolkiewski M, 1999, J BIOL CHEM, V274, P28083, DOI 10.1074/jbc.274.40.28083; Zolkiewski M, 1999, PROTEIN SCI, V8, P1899, DOI 10.1110/ps.8.9.1899; ZYLICZ M, 1985, J BIOL CHEM, V260, P7591	34	78	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34940	34945		10.1074/jbc.M505653200	http://dx.doi.org/10.1074/jbc.M505653200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16076845	hybrid			2022-12-25	WOS:000232403900067
J	Gomez, GA; Daniotti, JL				Gomez, GA; Daniotti, JL			H-Ras dynamically interacts with recycling endosomes in CHO-K1 cells - Involvement of Rab5 and Rab11 in the trafficking of H-Ras to this pericentriolar endocytic compartment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; NUCLEOTIDE EXCHANGE FACTORS; GPI-ANCHORED PROTEINS; PLASMA-MEMBRANE; K-RAS; LIPID RAFTS; N-RAS; ENDOPLASMIC-RETICULUM; ACTIVATE RAF-1; CAAX MOTIF	H-, N-, and K-Ras are isoforms of Ras proteins, which undergo different lipid modifications at the C terminus. These post-translational events make possible the association of Ras proteins both with the inner plasma membrane and to the cytosolic surface of endoplasmic reticulum and Golgi complex, which is also required for the proper function of these proteins. To better characterize the intracellular distribution and sorting of Ras proteins, constructs were engineered to express the C-terminal domain of H- and K-Ras fused to variants of green fluorescent protein. Using confocal microscopy, we found in CHO-K1 cells that H-Ras, which is palmitoylated and farnesylated, localized at the recycling endosome in addition to the inner leaflet of the plasma membrane. In contrast, K-Ras, which is farnesylated and nonpalmitoylated, mainly localized at the plasma membrane. Moreover, we demonstrate that sorting signals of H- and K-Ras are contained within the C-terminal domain of these proteins and that palmitoylation on this region of H-Ras might operate as a dominant sorting signal for proper subcellular localization of this protein in CHO-K1 cells. Using selective photobleaching techniques, we demonstrate the dynamic nature of H-Ras trafficking to the recycling endosome from plasma membrane. We also provide evidence that Rab5 and Rab11 activities are required for proper delivery of H-Ras to the endocytic recycling compartment. Using a chimera containing the Ras binding domain of c-Raf-1 fused to a fluorescent protein, we found that a pool of GTP-bound H-Ras localized on membranes from Rab11-positive recycling endosome after serum stimulation. These results suggest that H-Ras present in membranes of the recycling endosome might be activating signal cascades essential for the dynamic and function of the organelle.	Univ Nacl Cordoba, Ctr Invest & Quim Biol Cordoba, CIQUIBIC UNC CONICET, Dept Quim Biol,Fac Ciencias Quim, RA-5000 Cordoba, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of Cordoba	Daniotti, JL (corresponding author), Univ Nacl Cordoba, Ctr Invest & Quim Biol Cordoba, CIQUIBIC UNC CONICET, Dept Quim Biol,Fac Ciencias Quim, RA-5000 Cordoba, Argentina.	daniotti@dqb.fcq.unc.edu.ar	Gomez, Guillermo/J-2993-2014	Gomez, Guillermo/0000-0002-0494-2404				Ang AL, 2004, J CELL BIOL, V167, P531, DOI 10.1083/jcb.200408165; Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; Arni S, 1998, J BIOL CHEM, V273, P28478, DOI 10.1074/jbc.273.43.28478; Arozarena I, 2004, MOL CELL BIOL, V24, P1516, DOI 10.1128/MCB.24.4.1516-1530.2004; Bivona TG, 2003, CURR OPIN CELL BIOL, V15, P136, DOI 10.1016/S0955-0674(03)00016-4; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chen W, 1998, MOL BIOL CELL, V9, P3241, DOI 10.1091/mbc.9.11.3241; Chen W, 2001, METHOD ENZYMOL, V329, P165; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Cox AD, 2003, ONCOGENE, V22, P8999, DOI 10.1038/sj.onc.1207111; Crespo PM, 2004, BIOCHEM J, V377, P561, DOI 10.1042/BJ20031016; Crespo PM, 2002, J BIOL CHEM, V277, P44731, DOI 10.1074/jbc.M204604200; D'Souza-Schorey C, 1998, J CELL BIOL, V140, P603, DOI 10.1083/jcb.140.3.603; Edidin M, 2001, TRENDS CELL BIOL, V11, P492, DOI 10.1016/S0962-8924(01)02139-0; Esteban LM, 2001, MOL CELL BIOL, V21, P1444, DOI 10.1128/MCB.21.5.1444-1452.2001; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; GHOMASHCHI F, 1995, BIOCHEMISTRY-US, V34, P11910, DOI 10.1021/bi00037a032; Giraudo CG, 1999, BIOCHEM J, V342, P633, DOI 10.1042/0264-6021:3420633; Goodwin JS, 2005, J CELL BIOL, V170, P261, DOI 10.1083/jcb.200502063; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; Jackson C L, 2000, Subcell Biochem, V34, P233; Jiang XJ, 2002, MOL BIOL CELL, V13, P1522, DOI 10.1091/mbc.01-11-0552; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Koera K, 1997, ONCOGENE, V15, P1151, DOI 10.1038/sj.onc.1201284; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leventis R, 1998, BIOCHEMISTRY-US, V37, P7640, DOI 10.1021/bi973077h; Luo JQ, 1998, P NATL ACAD SCI USA, V95, P3632, DOI 10.1073/pnas.95.7.3632; Martina JA, 2000, NEUROCHEM RES, V25, P725, DOI 10.1023/A:1007527523734; Maxfield FR, 2004, NAT REV MOL CELL BIO, V5, P121, DOI 10.1038/nrm1315; Mayor S, 1998, EMBO J, V17, P4626, DOI 10.1093/emboj/17.16.4626; McCabe JB, 1999, MOL BIOL CELL, V10, P3771, DOI 10.1091/mbc.10.11.3771; Parton RG, 2004, TRENDS CELL BIOL, V14, P141, DOI 10.1016/j.tcb.2004.02.001; Prior IA, 2003, J CELL BIOL, V160, P165, DOI 10.1083/jcb.200209091; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Quilliam LA, 2002, PROG NUCLEIC ACID RE, V71, P391, DOI 10.1016/S0079-6603(02)71047-7; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; Rizzo MA, 2001, J BIOL CHEM, V276, P34928, DOI 10.1074/jbc.M105918200; Rocks O, 2005, SCIENCE, V307, P1746, DOI 10.1126/science.1105654; Roy S, 2002, MOL CELL BIOL, V22, P5128, DOI 10.1128/MCB.22.14.5128-5140.2002; Sabharanjak S, 2002, DEV CELL, V2, P411, DOI 10.1016/S1534-5807(02)00145-4; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Shipitsin M, 2004, MOL CELL BIOL, V24, P5746, DOI 10.1128/MCB.24.13.5746-5756.2004; Silvius JR, 2002, J MEMBRANE BIOL, V190, P83, DOI 10.1007/s00232-002-1026-4; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SKENE JHP, 1989, J CELL BIOL, V108, P613, DOI 10.1083/jcb.108.2.613; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; Teter K, 1998, J BIOL CHEM, V273, P19625, DOI 10.1074/jbc.273.31.19625; Trischler M, 1999, J CELL SCI, V112, P4773; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; URBE S, 1993, FEBS LETT, V334, P175, DOI 10.1016/0014-5793(93)81707-7; Voice JK, 1999, J BIOL CHEM, V274, P17164, DOI 10.1074/jbc.274.24.17164; Walker SA, 2004, J CELL SCI, V117, P2879, DOI 10.1242/jcs.01285; Wilcke M, 2000, J CELL BIOL, V151, P1207, DOI 10.1083/jcb.151.6.1207; Xu LZ, 2003, MOL CELL BIOL, V23, P645, DOI 10.1128/MCB.23.2.645-654.2003; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052; Zheng Yi, 2003, EMBO Reports, V4, P463, DOI 10.1038/sj.embor.embor831	64	46	46	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34997	35010		10.1074/jbc.M506256200	http://dx.doi.org/10.1074/jbc.M506256200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16079139	hybrid			2022-12-25	WOS:000232403900073
J	Levrand, S; Pesse, B; Feihl, F; Waeber, B; Pacher, P; Rolli, J; Schaller, MD; Liaudet, L				Levrand, S; Pesse, B; Feihl, F; Waeber, B; Pacher, P; Rolli, J; Schaller, MD; Liaudet, L			Peroxynitrite is a potent inhibitor of NF-kappa B activation triggered by inflammatory stimuli in cardiac and endothelial cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOTOXIN-BETA-RECEPTOR; NITRIC-OXIDE; IKK-ALPHA; MYOCARDIAL DYSFUNCTION; SYSTEMIC INFLAMMATION; HYDROGEN-PEROXIDE; GENE-EXPRESSION; KINASE-ACTIVITY; PHOSPHORYLATION; DEGRADATION	Peroxynitrite is a potent oxidant and nitrating species proposed as a direct effector of myocardial damage in numerous cardiac pathologies. Whether peroxynitrite also acts indirectly, by modulating cell signal transduction in the myocardium, has not been investigated. Therefore, we examined a possible role for peroxynitrite on the activation of NF-kappa B, a crucial pro-inflammatory transcription factor, in cultured H9C2 cardiomyocytes. H9C2 cells were stimulated with tumor necrosis factor-alpha or lipopolysaccharide following a brief (20-min) exposure to peroxynitrite. NF-kappa B activation ( phosphorylation and degradation of its inhibitor I kappa B alpha, nuclear translocation of NF-kappa B p65, and NF-kappa B DNA binding) triggered by lipopolysaccharide or tumor necrosis factor-alpha was abrogated by peroxynitrite. Peroxynitrite also inhibited NF-kappa B in two human endothelial cell lines activated with tumor necrosis factor-alpha or interleukin-1 beta. These effects were related to oxidative but not nitrative chemistry and were still being observed while nitration was suppressed by epicatechin. The mechanism of NF-kappa B inhibition by peroxynitrite was a complete blockade of phosphorylation and activation of the upstream kinase I kappa B kinase (IKK) beta, required for canonical, pro-inflammatory NF-kappa B activation. At the same time, peroxynitrite activated phosphorylation of NF-kappa B-inducing kinase and IKK alpha, considered as part of an alternative, noncanonical NF-kappa B activation pathway. Suppression of IKK beta-dependent NF-kappa B activation translated into a marked inhibition of the transcription of NF-kappa B-dependent genes by peroxynitrite. Thus, peroxynitrite has a dual effect on NF-kappa B, inhibiting canonical IKK beta-dependent NF-kappa B activation while activating NF-kappa B-inducing kinase and IKK alpha phosphorylation, which suggests its involvement in an alternative pathway of NF-kappa B activation. These findings offer new perspectives for the understanding of the relationships between redox stress and inflammation.	Univ Lausanne Hosp, Dept Internal Med, Div Crit Care, CH-1011 Lausanne, Switzerland; Univ Lausanne Hosp, Dept Internal Med, Div Clin Pathophysiol, CH-1011 Lausanne, Switzerland; NIAAA, Lab Physiol Studies, Bethesda, MD 20892 USA	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	Liaudet, L (corresponding author), Univ Lausanne Hosp, Dept Internal Med, Div Crit Care, CH-1011 Lausanne, Switzerland.	Lucas.Liaudet@chuv.hospvd.ch	Pacher, Pal/B-6378-2008; Liaudet, Lucas/E-1322-2017	Pacher, Pal/0000-0001-7036-8108; Liaudet, Lucas/0000-0003-2670-4930	Intramural NIH HHS [Z01 AA000375-02] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [Z01AA000375] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Bonizzi G, 2004, EMBO J, V23, P4202, DOI 10.1038/sj.emboj.7600391; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Chen LW, 2003, NAT MED, V9, P575, DOI 10.1038/nm849; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Drayton DL, 2004, J IMMUNOL, V173, P6161, DOI 10.4049/jimmunol.173.10.6161; Eaves-Pyles T, 2001, J IMMUNOL, V166, P1248, DOI 10.4049/jimmunol.166.2.1248; Egan LJ, 2004, P NATL ACAD SCI USA, V101, P2452, DOI 10.1073/pnas.0306734101; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Hayakawa M, 2003, EMBO J, V22, P3356, DOI 10.1093/emboj/cdg332; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P451; Janssen-Heininger YMW, 2000, FREE RADICAL BIO MED, V28, P1317, DOI 10.1016/S0891-5849(00)00218-5; Kamata H, 2002, FEBS LETT, V519, P231, DOI 10.1016/S0014-5793(02)02712-6; Kapahi P, 2000, J BIOL CHEM, V275, P36062, DOI 10.1074/jbc.M007204200; Klotz LO, 2002, FREE RADICAL BIO MED, V33, P737, DOI 10.1016/S0891-5849(02)00892-4; Klotz LO, 2000, BIOCHEM J, V352, P219, DOI 10.1042/0264-6021:3520219; Korn SH, 2001, J BIOL CHEM, V276, P35693, DOI 10.1074/jbc.M104321200; Kumar A, 2000, CRIT CARE CLIN, V16, P251, DOI 10.1016/S0749-0704(05)70110-X; Lancel S, 2004, J AM COLL CARDIOL, V43, P2348, DOI 10.1016/j.jacc.2004.01.047; Lawrence T, 2005, NATURE, V434, P1138, DOI 10.1038/nature03491; Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Liaudet L, 2000, CRIT CARE MED, V28, pN37, DOI 10.1097/00003246-200004001-00005; Liaudet L, 2001, MOL MED, V7, P406, DOI 10.1007/BF03402187; Matsushima A, 2001, J EXP MED, V193, P631, DOI 10.1084/jem.193.5.631; Pacher P, 2003, CIRCULATION, V107, P896, DOI 10.1161/01.CIR.0000048192.52098.DD; Pacher P, 2002, J AM COLL CARDIOL, V40, P1006, DOI 10.1016/S0735-1097(02)02062-4; Pesse B, 2005, J MOL CELL CARDIOL, V38, P765, DOI 10.1016/j.yjmcc.2005.02.020; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Schroeder P, 2001, BIOCHEM BIOPH RES CO, V285, P782, DOI 10.1006/bbrc.2001.5210; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; TorreAmione G, 1996, CIRCULATION, V93, P704, DOI 10.1161/01.CIR.93.4.704; Upmacis RK, 2004, AM J PHYSIOL-CELL PH, V286, pC1271, DOI 10.1152/ajpcell.00143.2003; Uppu RM, 1996, METHOD ENZYMOL, V269, P322; van der Vliet A, 1998, J BIOL CHEM, V273, P31860, DOI 10.1074/jbc.273.48.31860; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; Zhang P, 2000, J BIOL CHEM, V275, P22479, DOI 10.1074/jbc.M910425199	41	61	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34878	34887		10.1074/jbc.M501977200	http://dx.doi.org/10.1074/jbc.M501977200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16079150	hybrid, Green Accepted, Green Submitted			2022-12-25	WOS:000232403900060
J	Zhou, QS; Ben-Efraim, I; Bigcas, JL; Junqueira, D; Wiedmer, T; Sims, PJ				Zhou, QS; Ben-Efraim, I; Bigcas, JL; Junqueira, D; Wiedmer, T; Sims, PJ			Phospholipid scramblase 1 binds to the promoter region of the inositol 1,4,5-triphosphate receptor type 1 gene to enhance its expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSBILAYER MOVEMENT; MEMBRANE PROTEIN; PHOSPHATIDYLSERINE; CELLS; MICE; TRANSCRIPTION; APOPTOSIS; INTERACTS; MELANOMA; NUCLEUS	Phospholipid scramblase 1 (PLSCR1) is a multiply palmitoylated, endofacial membrane protein originally identified based on its capacity to promote accelerated transbilayer phospholipid movement in response to Ca2+. Recent evidence suggests that this protein also participates in cell response to various growth factors and cytokines, influencing myeloid differentiation, tumor growth, and the antiviral activity of interferon. Whereas plasma membrane PLSCR1 was shown to be required for normal recruitment and activation of Src kinase by stimulated cell surface growth factor receptors, PLSCR1 was also found to traffic into the nucleus and to tightly bind to genomic DNA, suggesting a possible additional nuclear function. We now report evidence that PLSCR1 directly binds to the 5'-promoter region of the inositol 1,4,5-triphosphate receptor type 1 gene (IP3R1) to enhance expression of the receptor. Probing a CpG island genomic library with PLSCR1 as bait identified four clones with avidity for PLSCR1, including a 191-bp fragment of the IP3R1 promoter. Using electrophoretic mobility shift and transcription reporter assays, the PLSCR1-binding site in IP3R1 was mapped to residues(-101)GTAACCATGTGGA(-89), and the segment spanning Met(86)-Glu(118) in PLSCR1 was identified to mediate its transcriptional activity. The significance of this interaction between PLSCR1 and IP3R1 in situ was confirmed by comparing levels of IP3R1 mRNA and protein in matched cells that either expressed or were deficient in PLSCR1. These data suggest that in addition to its role at the plasma membrane, effects of PLSCR1 on cell proliferative and maturational responses may also relate to alterations in expression of cellular IP3 receptors.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Sims, PJ (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, MEM-275,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	psims@scripps.edu	Bigcas, Jo-Lawrence/GOE-4097-2022	Zhou, Quansheng/0000-0003-4712-0731	NHLBI NIH HHS [HL63819, HL76215, HL36946] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036946, R01HL063819, R01HL076215] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Basse F, 1996, J BIOL CHEM, V271, P17205, DOI 10.1074/jbc.271.29.17205; Ben-Efraim I, 2004, BIOCHEMISTRY-US, V43, P3518, DOI 10.1021/bi0356911; Bertolotto C, 1996, J CELL BIOL, V134, P747, DOI 10.1083/jcb.134.3.747; Bradford Peter G., 2000, Molecular Cell Biology Research Communications, V3, P73, DOI 10.1006/mcbr.2000.0194; Dong BH, 2004, J VIROL, V78, P8983, DOI 10.1128/JVI.78.17.8983-8993.2004; Fadeel B, 1999, BIOCHEM BIOPH RES CO, V266, P504, DOI 10.1006/bbrc.1999.1820; Frasch SC, 2004, J BIOL CHEM, V279, P17625, DOI 10.1074/jbc.M313414200; Furutama D, 1996, J NEUROCHEM, V66, P1793; Goding CR, 2000, GENE DEV, V14, P1712; Grayson TH, 2004, CELL CALCIUM, V36, P447, DOI 10.1016/j.ceca.2004.04.005; Kasukabe T, 1998, BIOCHEM BIOPH RES CO, V249, P449, DOI 10.1006/bbrc.1998.9190; Konishi Y, 1999, J NEUROCHEM, V72, P1717, DOI 10.1046/j.1471-4159.1999.721717.x; Matsumoto M, 1999, J MOL MED, V77, P406, DOI 10.1007/s001090050370; Matsumoto M, 1996, NATURE, V379, P168, DOI 10.1038/379168a0; Nakamaki T, 2002, EXP HEMATOL, V30, P421, DOI 10.1016/S0301-472X(02)00779-8; Nanjundan M, 2003, J BIOL CHEM, V278, P37413, DOI 10.1074/jbc.M306182200; Ohkawa N, 1999, GENE, V229, P11, DOI 10.1016/S0378-1119(99)00048-7; Patterson RL, 2004, ANNU REV BIOCHEM, V73, P437, DOI 10.1146/annurev.biochem.73.071403.161303; Powell LM, 2004, MOL CELL BIOL, V24, P9517, DOI 10.1128/MCB.24.21.9517-9526.2004; Silverman RH, 2002, CANCER RES, V62, P397; Sun J, 2002, BIOCHEMISTRY-US, V41, P6338, DOI 10.1021/bi025610l; Sun J, 2001, J BIOL CHEM, V276, P28984, DOI 10.1074/jbc.M102505200; Vermassen E, 2004, BIOL CELL, V96, P3, DOI 10.1016/j.biolcel.2003.11.004; Wiedmer T, 2000, BBA-BIOMEMBRANES, V1467, P244, DOI 10.1016/S0005-2736(00)00236-4; Wiedmer T, 2004, P NATL ACAD SCI USA, V101, P13296, DOI 10.1073/pnas.0405354101; Wiedmer T, 2003, BIOCHEMISTRY-US, V42, P1227, DOI 10.1021/bi026679w; YAMADA N, 1994, BIOCHEM J, V302, P781, DOI 10.1042/bj3020781; Yasumoto K, 1997, J BIOL CHEM, V272, P503; Yokoyama A, 2004, LEUKEMIA RES, V28, P149, DOI 10.1016/S0145-2126(03)00189-9; Yu A, 2003, J BIOL CHEM, V278, P9706, DOI 10.1074/jbc.M204614200; Zhao J, 1998, J BIOL CHEM, V273, P6603, DOI 10.1074/jbc.273.12.6603; Zhao KW, 2004, BLOOD, V104, P3731, DOI 10.1182/blood-2004-04-1630; Zhou QS, 2000, BLOOD, V95, P2593, DOI 10.1182/blood.V95.8.2593.008k32_2593_2599; Zhou QS, 2002, BLOOD, V99, P4030, DOI 10.1182/blood-2001-12-0271; Zhou QS, 1997, J BIOL CHEM, V272, P18240, DOI 10.1074/jbc.272.29.18240	35	74	77	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					35062	35068		10.1074/jbc.M504821200	http://dx.doi.org/10.1074/jbc.M504821200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16091359	hybrid			2022-12-25	WOS:000232403900079
J	Nyman, U; Sobczak-Pluta, A; Vlachos, P; Perlmann, T; Zhivotovsky, B; Joseph, B				Nyman, U; Sobczak-Pluta, A; Vlachos, P; Perlmann, T; Zhivotovsky, B; Joseph, B			Full-length p73 alpha represses drug-induced apoptosis in small cell lung carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P73; PHYSICAL INTERACTION; SPONTANEOUS TUMORS; SPLICING VARIANTS; C-MYC; P53; DELTA-NP73; EXPRESSION; CANCER; PUMA	The p73 gene, a member of the p53 family, encodes several variants through differential splicing and use of alternative promoters. At the NH2 terminus, two different promoters generate the full-length and the Delta N isoforms, with or without the transactivating domain. At the COOH terminus, seven isoforms generated through alternative splicing have been cloned. Previous studies have demonstrated that Delta Np73 isoforms exert a dominant-negative effect on p73 by blocking their transactivation activity and hence the ability to induce apoptosis. Considerable efforts are made to identify the functional diversity of the COOH-terminal p73 variants. In this study, we found that p73 alpha inhibited drug-induced apoptosis in small cell lung carcinoma cells, whereas p73 beta promoted it. p73 alpha prevented Bax activation, mitochondrial dysfunction, and caspase activation. In addition, p73 alpha was also able to reduce apoptosis induced by the BH3-only protein PUMA ( p53 up-regulated modulator of apoptosis). Furthermore, we discovered that p73 alpha is able to inhibit the pro-apoptotic effect of p73 alpha, demonstrating the existence of equilibrium between these two p73 isoforms. In conclusion, the reported overexpression of p73 alpha in certain tumor types, and our findings that p73 alpha exerts anti-apoptotic functions, indicate a potential oncogenic activity for p73.	Karolinska Inst, Inst Environm Med, S-17177 Stockholm, Sweden; Ludwig Inst Canc Res, S-17177 Stockholm, Sweden	Karolinska Institutet; Ludwig Institute for Cancer Research	Joseph, B (corresponding author), Karolinska Inst, Inst Environm Med, Box 210, S-17177 Stockholm, Sweden.	Bertrand.Joseph@imm.ki.se	Zhivotovsky, Boris/A-4346-2014; Nyman, Ulrika/D-3708-2013	Zhivotovsky, Boris/0000-0002-2238-3482; Joseph, Bertrand/0000-0001-5655-9979				Billon N, 2004, DEVELOPMENT, V131, P1211, DOI 10.1242/dev.01035; Cande C, 2002, J CELL SCI, V115, P4727, DOI 10.1242/jcs.00210; Cartron PF, 2004, MOL CELL, V16, P807, DOI 10.1016/j.molcel.2004.10.028; Casciano I, 2002, CELL DEATH DIFFER, V9, P246, DOI 10.1038/sj.cdd.4400993; Chi SW, 1999, EMBO J, V18, P4438, DOI 10.1093/emboj/18.16.4438; De Laurenzi V, 2000, BIOCHEM BIOPH RES CO, V273, P342, DOI 10.1006/bbrc.2000.2932; De Laurenzi V, 2000, J BIOL CHEM, V275, P15226, DOI 10.1074/jbc.275.20.15226; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Deb D, 2001, INT J ONCOL, V18, P401; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Frasca F, 2003, CANCER RES, V63, P5829; Hackzell A, 2002, J BIOL CHEM, V277, P39769, DOI 10.1074/jbc.M204483200; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Ishimoto O, 2002, CANCER RES, V62, P636; Joseph B, 2002, ONCOGENE, V21, P65, DOI 10.1038/sj/onc/1205018; Joseph B, 2001, ONCOGENE, V20, P2877, DOI 10.1038/sj.onc.1204402; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kang MJ, 2000, CLIN CANCER RES, V6, P1767; Khan QA, 2001, TOXICOL APPL PHARM, V173, P105, DOI 10.1006/taap.2001.9172; Li CY, 2005, J BIOL CHEM, V280, P2159, DOI 10.1074/jbc.M411194200; Liu FT, 2003, BIOCHEM BIOPH RES CO, V310, P956, DOI 10.1016/j.bbrc.2003.09.109; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Melino G, 2004, J BIOL CHEM, V279, P8076, DOI 10.1074/jbc.M307469200; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Moll UM, 2001, BBA-REV CANCER, V1552, P47, DOI 10.1016/S0304-419X(01)00036-1; Niyazi Maynur, 2003, Journal of Nippon Medical School, V70, P234; Novak U, 2001, ANN ONCOL, V12, P981, DOI 10.1023/A:1011153206003; Nozaki M, 2001, BRAIN PATHOL, V11, P296; Ozaki T, 2003, ONCOGENE, V22, P3231, DOI 10.1038/sj.onc.1206382; Petrenko O, 2003, MOL CELL BIOL, V23, P5540, DOI 10.1128/MCB.23.16.5540-5555.2003; Sirzen F, 1999, EUR J CANCER, V35, P111, DOI 10.1016/S0959-8049(98)00289-5; Stiewe T, 2002, CELL DEATH DIFFER, V9, P237, DOI 10.1038/sj.cdd.4400995; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Ueda Y, 2001, BIOCHEM J, V356, P859, DOI 10.1042/0264-6021:3560859; Ugur H, 2004, ONCOL REP, V11, P1337; Vikhanskaya F, 2001, CANCER RES, V61, P935; Viktorsson K, 2003, EXP CELL RES, V289, P256, DOI 10.1016/S0014-4827(03)00264-7; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Watanabe K, 2002, J BIOL CHEM, V277, P15113, DOI 10.1074/jbc.M111281200; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yokomizo A, 1999, ONCOGENE, V18, P1629, DOI 10.1038/sj.onc.1202474; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zaika AI, 1999, CANCER RES, V59, P3257; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; Zamzami N, 2003, CURR BIOL, V13, pR71, DOI 10.1016/S0960-9822(02)01433-1	52	25	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34159	34169		10.1074/jbc.M500394200	http://dx.doi.org/10.1074/jbc.M500394200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16087678	hybrid			2022-12-25	WOS:000232229700057
J	Santaguida, M; Nepveu, A				Santaguida, M; Nepveu, A			Differential regulation of CDP/Cux p110 by cyclin A/Cdk2 and cyclin A/Cdk1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT DISPLACEMENT PROTEIN; FACTOR HINF-D; DEPENDENT KINASE 2; TRANSCRIPTION FACTOR; DNA-BINDING; HOMEODOMAIN PROTEIN; CUT HOMEODOMAIN; GENE PROMOTER; S-PHASE; RETINOBLASTOMA PROTEIN	Previous experiments with peptide fusion proteins suggested that cyclin A/Cdk1 and Cdk2 might exhibit similar yet distinct phosphorylation specificities. Using a physiological substrate, CDP/Cux, our study confirms this notion. Proteolytic processing of CDP/Cux by cathepsin L generates the CDP/Cux p110 isoform at the beginning of S phase. CDP/Cux p110 makes stable interactions with DNA during S phase but is inhibited in G(2) following the phosphorylation of serine 1237 by cyclin A/Cdk1. In this study, we propose that differential phosphorylation by cyclin A/Cdk1 and cyclin A/Cdk2 enables CDP/Cux p110 to exert its function as a transcriptional regulator specifically during S phase. We found that like cyclin A/Cdk1, cyclin A/Cdk2 interacted efficiently with recombinant CDP/Cux proteins that contain the Cut homeodomain and an adjacent cyclin-binding motif (Cy). In contrast to cyclin A/Cdk1, however, cyclin A/Cdk2 did not efficiently phosphorylate CDP/Cux p110 on serine 1237 and did not inhibit its DNA binding activity in vitro. Accordingly, co-expression with cyclin A/Cdk2 in cells did not inhibit the DNA binding and transcriptional activities of CDP/Cux p110. To confirm that the sequence surrounding serine 1237 was responsible for the differential regulation by Cdk1 and Cdk2, we replaced 4 amino acids flanking the phosphorylation site to mimic a known Cdk2 phosphorylation site present in the Cdc6 protein. Both cyclin A/Cdk2 and Cdk1 efficiently phosphorylated the CDP/Cux(Cdc6) mutant and inhibited its DNA binding activity. Altogether our results help explain why the DNA binding activity of CDP/Cux p110 is maximal during S phase and decreases in G2 phase.	McGill Univ, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; McGill Univ, Ctr Hlth, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 1A1, Canada	McGill University; McGill University; McGill University; McGill University; McGill University	Nepveu, A (corresponding author), 687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	alain.nepveu@mcgill.ca	/AAB-8315-2020					Adams PD, 1999, MOL CELL BIOL, V19, P1068; ANDRES V, 1994, GENE DEV, V8, P245, DOI 10.1101/gad.8.2.245; AUFIERO B, 1994, P NATL ACAD SCI USA, V91, P7757, DOI 10.1073/pnas.91.16.7757; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BLOCHLINGER K, 1988, NATURE, V333, P629, DOI 10.1038/333629a0; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; COBRINIK D, 1992, TRENDS BIOCHEM SCI, V17, P312, DOI 10.1016/0968-0004(92)90443-D; Coqueret O, 1998, EMBO J, V17, P4680, DOI 10.1093/emboj/17.16.4680; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DESAI D, 1995, MOL CELL BIOL, V15, P345, DOI 10.1128/MCB.15.1.345; Gaiddon C, 2003, J BIOL CHEM, V278, P27421, DOI 10.1074/jbc.M300251200; Goulet B, 2004, MOL CELL, V14, P207, DOI 10.1016/S1097-2765(04)00209-6; Gupta S, 2003, J CELL PHYSIOL, V196, P541, DOI 10.1002/jcp.10335; Haidweger E, 2001, J MOL BIOL, V306, P201, DOI 10.1006/jmbi.2000.4406; HARADA R, 1994, J BIOL CHEM, V269, P2062; Henneke G, 2003, ONCOGENE, V22, P4301, DOI 10.1038/sj.onc.1206606; Holmes JK, 1996, J BIOL CHEM, V271, P25240, DOI 10.1074/jbc.271.41.25240; Howcroft TK, 1997, ANAL BIOCHEM, V244, P22, DOI 10.1006/abio.1996.9868; Ishimi Y, 2000, J BIOL CHEM, V275, P16235, DOI 10.1074/jbc.M909040199; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LI Y, 1994, MOL CELL BIOL, V14, P1861, DOI 10.1128/MCB.14.3.1861; Liu D, 1998, NAT GENET, V20, P377, DOI 10.1038/3855; Luciani MG, 2000, J MOL BIOL, V300, P503, DOI 10.1006/jmbi.2000.3830; Luo W, 1996, J BIOL CHEM, V271, P18203, DOI 10.1074/jbc.271.30.18203; Luong MX, 2002, MOL CELL BIOL, V22, P1424, DOI 10.1128/MCB.22.5.1424-1437.2002; Moon NS, 2000, J BIOL CHEM, V275, P31325, DOI 10.1074/jbc.M002912200; Moon NS, 2001, MOL CELL BIOL, V21, P6332, DOI 10.1128/MCB.21.18.6332-6345.2001; Murphy M, 1997, NAT GENET, V15, P83, DOI 10.1038/ng0197-83; Nepveu A, 2001, GENE, V270, P1, DOI 10.1016/S0378-1119(01)00485-1; NEUFELD EJ, 1992, NAT GENET, V1, P50, DOI 10.1038/ng0492-50; Nigg Erich A., 1993, Trends in Cell Biology, V3, P296, DOI 10.1016/0962-8924(93)90011-O; Ohtoshi A, 2000, BIOCHEM BIOPH RES CO, V268, P530, DOI 10.1006/bbrc.2000.2167; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Ruffner H, 1999, MOL CELL BIOL, V19, P4843; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Santaguida M, 2001, J BIOL CHEM, V276, P45780, DOI 10.1074/jbc.M107978200; Schulman BA, 1998, P NATL ACAD SCI USA, V95, P10453, DOI 10.1073/pnas.95.18.10453; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; Sorensen CS, 2001, MOL CELL BIOL, V21, P3692, DOI 10.1128/MCB.21.11.3692-3703.2001; Sugimoto N, 2004, J BIOL CHEM, V279, P19691, DOI 10.1074/jbc.M313175200; Takeda DY, 2001, J BIOL CHEM, V276, P1993, DOI 10.1074/jbc.M005719200; Truscott M, 2003, MOL CELL BIOL, V23, P3013, DOI 10.1128/MCB.23.8.3013-3028.2003; VALARCHE I, 1993, DEVELOPMENT, V119, P881; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; vanWijnen AJ, 1996, P NATL ACAD SCI USA, V93, P11516, DOI 10.1073/pnas.93.21.11516; VANWIJNEN AJ, 1994, P NATL ACAD SCI USA, V91, P12882, DOI 10.1073/pnas.91.26.12882; VANWIJNEN AJ, 1991, J CELL BIOCHEM, V46, P174, DOI 10.1002/jcb.240460211; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; WRIGHT KL, 1992, BIOCHEMISTRY-US, V31, P2812, DOI 10.1021/bi00125a023; Yang R, 1997, CANCER RES, V57, P913; YOON SO, 1994, J BIOL CHEM, V269, P18453; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7	57	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32712	32721		10.1074/jbc.M505417200	http://dx.doi.org/10.1074/jbc.M505417200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16081423	hybrid			2022-12-25	WOS:000231920300021
J	Hata, AN; Lybrand, TP; Breyer, RM				Hata, AN; Lybrand, TP; Breyer, RM			Identification of determinants of ligand binding affinity and selectivity in the prostaglandin D-2 receptor CRTH2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-RESIDUES; C5A RECEPTOR; MOLECULAR PHARMACOLOGY; TRANSMEMBRANE DOMAIN; IN-VIVO; CELLS; ACTIVATION; ANTAGONIST; INFLAMMATION; EXPRESSION	The chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) is a G protein-coupled receptor that mediates the pro-inflammatory effects of prostaglandin D-2 (PGD(2)) generated in allergic inflammation. The CRTH2 receptor shares greatest sequence similarity with chemoattractant receptors compared with prostanoid receptors. To investigate the structural determinants of CRTH2 ligand binding, we performed site-directed mutagenesis of putative mCRTH2 ligand-binding residues, and we evaluated mutant receptor ligand binding and functional properties. Substitution of alanine at each of three residues in the transmembrane (TM) helical domains (His-106, TM III; Lys-209, TM V; and Glu-268, TM VI) and one in extracellular loop II (Arg-178) decreased PGD2 binding affinity, suggesting that these residues play a role in binding PGD2. In contrast, the H106A and E268A mutants bound indomethacin, a nonsteroidal anti-inflammatory drug, with an affinity similar to the wild-type receptor. HEK293 cells expressing the H106A, K209A, and E268A mutants displayed reduced inhibition of intracellular cAMP and chemotaxis in response to PGD2, whereas the H106A and E268A mutants had functional responses to indomethacin similar to the wild-type receptor. Binding of PGE2 by the E268A mutant was enhanced compared with the wild-type receptor, suggesting that Glu-268 plays a role in determining prostanoid ligand selectivity. Replacement of Tyr-261 with phenylalanine did not affect PGD2 binding but decreased the binding affinity for indomethacin. These results provided the first details of the ligand binding pocket of an eicosanoid-binding chemoattractant receptor.	Vanderbilt Univ, Sch Med, Div Nephrol, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Chem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ingram Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Str Struct Biol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Breyer, RM (corresponding author), Vanderbilt Univ, Sch Med, Div Nephrol, Dept Pharmacol, S3223 MCN,1161 21st Ave, Nashville, TN 37232 USA.	rich.breyer@vanderbilt.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI059108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046205] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM015431, P50GM015431] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033290] Funding Source: NIH RePORTER; NIAID NIH HHS [AI59108] Funding Source: Medline; NIDDK NIH HHS [DK46205] Funding Source: Medline; NIGMS NIH HHS [GM15431] Funding Source: Medline; NINDS NIH HHS [NS33290] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Audoly L, 1997, MOL PHARMACOL, V51, P61, DOI 10.1124/mol.51.1.61; Audoly L, 1997, J BIOL CHEM, V272, P13475, DOI 10.1074/jbc.272.21.13475; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; Baranski TJ, 1999, J BIOL CHEM, V274, P15757, DOI 10.1074/jbc.274.22.15757; BARR RM, 1988, BRIT J PHARMACOL, V94, P773, DOI 10.1111/j.1476-5381.1988.tb11588.x; Chang CS, 1997, BIOCHEM J, V322, P597, DOI 10.1042/bj3220597; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Cosmi L, 2000, EUR J IMMUNOL, V30, P2972, DOI 10.1002/1521-4141(200010)30:10<2972::AID-IMMU2972>3.0.CO;2-#; DEMARTINO JA, 1995, J BIOL CHEM, V270, P15966, DOI 10.1074/jbc.270.27.15966; Fujitani Y, 2002, J IMMUNOL, V168, P443, DOI 10.4049/jimmunol.168.1.443; FUNK CD, 1993, MOL PHARMACOL, V44, P934; Furse KE, 2003, J MED CHEM, V46, P4450, DOI 10.1021/jm0301437; Gosset P, 2003, J IMMUNOL, V170, P4943, DOI 10.4049/jimmunol.170.10.4943; Hammad H, 2003, J IMMUNOL, V171, P3936, DOI 10.4049/jimmunol.171.8.3936; Hata AN, 2005, MOL PHARMACOL, V67, P640, DOI 10.1124/mol.104.007971; Hata AN, 2003, J PHARMACOL EXP THER, V306, P463, DOI 10.1124/jpet.103.050955; Hata AN, 2004, PHARMACOL THERAPEUT, V103, P147, DOI 10.1016/j.pharmthera.2004.06.003; Hirai H, 2002, J IMMUNOL, V168, P981, DOI 10.4049/jimmunol.168.3.981; Hirai K, 2001, CURR TOP MICROBIOL, V255, P261; Honda K, 2003, J EXP MED, V198, P533, DOI 10.1084/jem.20022218; Huang JL, 2004, HUM MOL GENET, V13, P2691, DOI 10.1093/hmg/ddh279; Iwasaki M, 2002, J INVEST DERMATOL, V119, P609, DOI 10.1046/j.1523-1747.2002.01862.x; Kobayashi T, 2000, J BIOL CHEM, V275, P24294, DOI 10.1074/jbc.M002437200; Kobayashi T, 1997, J BIOL CHEM, V272, P15154, DOI 10.1074/jbc.272.24.15154; LEWIS RA, 1982, J IMMUNOL, V129, P1627; Mandal AK, 2004, J EXP MED, V199, P1317, DOI 10.1084/jem.20031666; Matsuoka T, 2000, SCIENCE, V287, P2013, DOI 10.1126/science.287.5460.2013; Miettinen HM, 1997, J IMMUNOL, V159, P4045; MURRAY JJ, 1986, NEW ENGL J MED, V315, P800, DOI 10.1056/NEJM198609253151304; Nag SS, 2003, J ALLERGY CLIN IMMUN, V111, P558, DOI 10.1067/mai.2003.131; Nagata K, 1999, FEBS LETT, V459, P195, DOI 10.1016/S0014-5793(99)01251-X; Nagata K, 1999, J IMMUNOL, V162, P1278; Narita S, 1996, INT ARCH ALLERGY IMM, V109, P161, DOI 10.1159/000237215; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; Quehenberger O, 1997, BIOCHEM BIOPH RES CO, V238, P377, DOI 10.1006/bbrc.1997.7298; Raffetseder U, 1996, EUR J BIOCHEM, V235, P82, DOI 10.1111/j.1432-1033.1996.00082.x; Rehwald M, 1999, FEBS LETT, V443, P357, DOI 10.1016/S0014-5793(99)00007-1; Sawyer N, 2002, BRIT J PHARMACOL, V137, P1163, DOI 10.1038/sj.bjp.0704973; Shichijo M, 2003, J PHARMACOL EXP THER, V307, P518, DOI 10.1124/jpet.103.055442; Shiraishi Y, 2005, J PHARMACOL EXP THER, V312, P954, DOI 10.1124/jpet.104.078212; SICILIANO SJ, 1994, P NATL ACAD SCI USA, V91, P1214, DOI 10.1073/pnas.91.4.1214; Sugimoto H, 2003, J PHARMACOL EXP THER, V305, P347, DOI 10.1124/jpet.102.046748; Ulven T, 2005, J MED CHEM, V48, P897, DOI 10.1021/jm049036i	43	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32442	32451		10.1074/jbc.M502563200	http://dx.doi.org/10.1074/jbc.M502563200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16030019	hybrid			2022-12-25	WOS:000231794800051
J	Potter, BM; Feng, LS; Parasuram, P; Matskevich, VA; Wilson, JA; Andrews, GK; Laity, JH				Potter, BM; Feng, LS; Parasuram, P; Matskevich, VA; Wilson, JA; Andrews, GK; Laity, JH			The six zinc fingers of metal-responsive element binding transcription factor-1 form stable and quasi-ordered structures with relatively small differences in zinc affinities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETERONUCLEAR NMR-SPECTROSCOPY; MAGNETIC-RESONANCE RELAXATION; MODEL-FREE APPROACH; DNA-BINDING; BACKBONE DYNAMICS; FACTOR MTF-1; METALLOTHIONEIN GENE; CHEMICAL-SHIFT; FUNCTIONAL-HETEROGENEITY; FACTOR IIIA	Six Cys(2)His(2) zinc fingers ( F1-6) comprise the DNA binding domain of metal-responsive element binding transcription factor-1 ( MTF-1). F1-6 is necessary for basal and zinc-induced expression of metallothionein genes. Analysis of NMR structural and dynamic data for an F1-6 protein construct demonstrates that each zinc finger adopts a stable beta beta alpha fold in the presence of stoichiometric Zn( II), provided that all cysteine ligands are in a reduced state. Parallel studies of protein constructs spanning the four N-terminal core DNA binding fingers ( F1-4) and two C-terminal low DNA affinity fingers ( F5-6) reveal similar stable zinc finger structures. In both the F1-6 and F5-6 proteins, the finger 5 cysteines were found to readily oxidize at neutral pH. Detailed spectral density and hydrodynamic analysis of N-15 relaxation data revealed quasi-ordered anisotropic rotational diffusion properties of the six F1-6 zinc fingers that could influence MTF-1 DNA binding function. A more general effect on the rotational diffusion properties of Cys2His2 zinc fingers was also uncovered that is dependent upon the position of each finger within multifinger domains. Analysis of NMR H-1-N-15-heteronuclear single quantum coherence spectral peak intensities measured as a function of added Zn( II) in conjunction with Zn( II) binding modeling studies indicated that the Zn( II) affinities of all MTF-1 zinc fingers are within similar to 10-50-fold. These analyses further suggested that metal sensing by MTF-1 in eukaryotic cells involves multiple zinc fingers and occurs over a 100-fold or less range of accessible Zn( II) concentration.	UMKC, Sch Biol Sci, Div Cell Biol & Biophys, Kansas City, MO 64110 USA; Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA	University of Missouri System; University of Missouri Kansas City; University of Kansas; University of Kansas Medical Center	Laity, JH (corresponding author), UMKC, Sch Biol Sci, Div Cell Biol & Biophys, 103 BSB,5007 Rockhill Rd, Kansas City, MO 64110 USA.	laityj@umkc.edu	Matskevich, Viktor A/AAL-7806-2021		NIEHS NIH HHS [ES05704] Funding Source: Medline	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Andrews GK, 2001, BIOMETALS, V14, P223, DOI 10.1023/A:1012932712483; Apuy JL, 2001, BIOCHEMISTRY-US, V40, P15164, DOI 10.1021/bi0112208; BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005; BERG JM, 1989, J AM CHEM SOC, V111, P3759, DOI 10.1021/ja00192a050; Bird AJ, 2003, EMBO J, V22, P5137, DOI 10.1093/emboj/cdg484; Bittel D, 1998, J BIOL CHEM, V273, P7127, DOI 10.1074/jbc.273.12.7127; Bittel DC, 2000, J BIOL CHEM, V275, P37194, DOI 10.1074/jbc.M003863200; Blasie CA, 2002, BIOCHEMISTRY-US, V41, P15068, DOI 10.1021/bi026621h; BRAUN D, 1994, J AM CHEM SOC, V116, P8466, DOI 10.1021/ja00098a005; BRUGNERA E, 1994, NUCLEIC ACIDS RES, V22, P3167, DOI 10.1093/nar/22.15.3167; BRUSCHWEILER R, 1995, SCIENCE, V268, P886, DOI 10.1126/science.7754375; Chen WY, 2002, BIOCHEM BIOPH RES CO, V291, P798, DOI 10.1006/bbrc.2002.6517; Chen XH, 2004, J BIOL CHEM, V279, P4515, DOI 10.1074/jbc.M308924200; Chen XH, 1999, BIOCHEMISTRY-US, V38, P12915, DOI 10.1021/bi9913000; Chen XH, 1998, BIOCHEMISTRY-US, V37, P11152, DOI 10.1021/bi980843r; CORNELL NW, 1972, ANAL BIOCHEM, V47, P203, DOI 10.1016/0003-2697(72)90293-X; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; CULOTTA VC, 1989, MOL CELL BIOL, V9, P1376, DOI 10.1128/MCB.9.3.1376; Dalton TP, 1997, MOL CELL BIOL, V17, P2781, DOI 10.1128/MCB.17.5.2781; Dalton TP, 2000, COMP BIOCHEM PHYS B, V126, P325, DOI 10.1016/S0305-0491(00)00182-6; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dosset P, 2000, J BIOMOL NMR, V16, P23, DOI 10.1023/A:1008305808620; FARROW NA, 1995, BIOCHEMISTRY-US, V34, P868, DOI 10.1021/bi00003a021; Foster MP, 1997, NAT STRUCT BIOL, V4, P605, DOI 10.1038/nsb0897-605; Foster MP, 1998, J BIOMOL NMR, V12, P51, DOI 10.1023/A:1008290631575; FUSHMAN D, 1994, J BIOMOL NMR, V4, P61, DOI 10.1007/BF00178336; Gaither LA, 2001, BIOMETALS, V14, P251, DOI 10.1023/A:1012988914300; Giedroc DP, 2001, J BIOL CHEM, V276, P42322, DOI 10.1074/jbc.M106517200; GRONENBORN AM, 1994, J BIOMOL NMR, V4, P455; Guerrerio AL, 2004, BIOCHEMISTRY-US, V43, P5437, DOI 10.1021/bi0358418; HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x; Hyre DE, 1998, J MOL BIOL, V279, P929, DOI 10.1006/jmbi.1998.1811; Jiang HM, 2003, J BIOL CHEM, V278, P30394, DOI 10.1074/jbc.M303598200; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; KAY LE, 1994, J MAGN RESON SER A, V109, P129, DOI 10.1006/jmra.1994.1145; Koizumi S, 2000, J CELL PHYSIOL, V185, P464, DOI 10.1002/1097-4652(200012)185:3<464::AID-JCP18>3.0.CO;2-4; KRIZEK BA, 1991, J AM CHEM SOC, V113, P4518, DOI 10.1021/ja00012a021; KRIZEK BA, 1993, PROTEIN SCI, V2, P1313, DOI 10.1002/pro.5560020814; Laity JH, 2000, P NATL ACAD SCI USA, V97, P11932, DOI 10.1073/pnas.97.22.11932; Laity JH, 2000, J MOL BIOL, V295, P719, DOI 10.1006/jmbi.1999.3406; LAITY JH, 2004, HDB METALLOPROTEINS, P307; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; Leopold M. F., 1994, Molecular Biotechnology, V2, P61, DOI 10.1007/BF02789290; LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; Maur AAD, 1999, BIOL CHEM, V380, P175, DOI 10.1515/BC.1999.026; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; OTSUKA F, 1994, J BIOL CHEM, V269, P23700; Outten CE, 2001, SCIENCE, V292, P2488, DOI 10.1126/science.1060331; Palmer AG, 2004, CHEM REV, V104, P3623, DOI 10.1021/cr030413t; Palmer AG, 2001, ANNU REV BIOPH BIOM, V30, P129, DOI 10.1146/annurev.biophys.30.1.129; PALMER AG, 1991, J AM CHEM SOC, V113, P4371, DOI 10.1021/ja00012a001; PALMER AG, 1991, J MAGN RESON, V93, P151, DOI 10.1016/0022-2364(91)90036-S; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELTON JG, 1995, ANNU REV PHYS CHEM, V46, P139; Peng JW, 1995, BIOCHEMISTRY-US, V34, P16733, DOI 10.1021/bi00051a023; POTTER BM, 2005, IN PRESS J BIOMOL NM; RADTKE F, 1993, EMBO J, V12, P1355, DOI 10.1002/j.1460-2075.1993.tb05780.x; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; STONE MJ, 1992, BIOCHEMISTRY-US, V31, P4394, DOI 10.1021/bi00133a003; STUART GW, 1984, P NATL ACAD SCI-BIOL, V81, P7318, DOI 10.1073/pnas.81.23.7318; STUART GW, 1985, NATURE, V317, P828, DOI 10.1038/317828a0; Viles JH, 2001, BIOCHEMISTRY-US, V40, P2743, DOI 10.1021/bi002898a; Volkman BF, 1998, BIOCHEMISTRY-US, V37, P10906, DOI 10.1021/bi980810b; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; Wuttke DS, 1997, J MOL BIOL, V273, P183, DOI 10.1006/jmbi.1997.1291; Zhang B, 2001, MOL CELL BIOL, V21, P4505, DOI 10.1128/MCB.21.14.4505-4514.2001; [No title captured]	72	38	39	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2005	280	31					28529	28540		10.1074/jbc.M505217200	http://dx.doi.org/10.1074/jbc.M505217200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	950KZ	16055450	hybrid			2022-12-25	WOS:000230857300043
J	von Bohlen und Halbach, O; Minichiello, L; Unsicker, K				von Bohlen und Halbach, O; Minichiello, L; Unsicker, K			Haploinsufficiency for trkB and trkC receptors induces cell loss and accumulation of alpha-synuclein in the substantia nigra	FASEB JOURNAL			English	Article						dopamine; mice; neurotrophins; striatum	NERVE GROWTH-FACTOR; NEUROTROPHIC FACTOR; PARKINSONS-DISEASE; TYROSINE-HYDROXYLASE; DOPAMINE NEURONS; MESSENGER-RNA; RAT MODEL; BDNF; ASSOCIATION; EXPRESSION	The neurotrophins brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) have been shown to promote survival and differentiation of midbrain dopaminergic (DAergic) neurons in vitro and in vivo. This is consistent with their expression and that of their cognate receptors, trkB and trkC, in the nigrostriatal system. Degeneration of DAergic neurons of the substantia nigra and alpha-synuclein-positive aggregates in the remaining substantia nigra (SN) neurons are hallmarks of Parkinson's disease (PD). Reduced expression of BDNF has been reported in the SN from PD patients. Moreover, mutations in the BDNF gene have been found to play a role in the development of familial PD. We show now that haploinsufficiencies of the neurotrophin receptors trkB and/or trkC cause a reduction in numbers of SN neurons in aged (21-23 month old) mice, which is accompanied by a reduced density in striatal tyrosine hydroxylase immunoreactive (TH-ir) fibers. These aged mutant mice, in contrast to wild-type littermates, display an accumulation of alpha-synuclein in the remaining TH-positive neurons of the SN. We conclude that impairment in trkB and/or trkC signaling induces a phenotype in the aged SN, which includes two hallmarks of PD, losses of TH-positive neurons and axons along with massive neuronal deposits of alpha-synuclein.	Heidelberg Univ, Dept Neuroanat, Interdisciplinary Ctr Neurosci, D-69120 Heidelberg, Germany; European Mol Biol Lab, I-00016 Monterotondo, Italy	Ruprecht Karls University Heidelberg; European Molecular Biology Laboratory (EMBL)	von Bohlen und Halbach, O (corresponding author), Heidelberg Univ, Dept Neuroanat, Interdisciplinary Ctr Neurosci, Neuenheimer Feld 307, D-69120 Heidelberg, Germany.	O.von_Bohlen@web.de	von Bohlen und Halbach, Oliver/R-3464-2019; Minichiello, Liliana/AAA-7190-2022; von Bohlen und Halbach, Oliver/A-1060-2008	von Bohlen und Halbach, Oliver/0000-0002-6265-9156; von Bohlen und Halbach, Oliver/0000-0002-2613-2517				ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; ALTAR CA, 1994, EUR J NEUROSCI, V6, P1389, DOI 10.1111/j.1460-9568.1994.tb01001.x; Braak H, 2002, J NEUROL, V249, DOI [1007/s00415-002-1301-4, 10.1007/s00415-002-1301-4, DOI 10.1007/S00415-002-1301-4]; Ciechanover A, 2001, NAT MED, V7, P1108, DOI 10.1038/nm1001-1108; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Dunnett SB, 1999, NATURE, V399, pA32, DOI 10.1038/399a032; Eilam R, 1998, P NATL ACAD SCI USA, V95, P12653, DOI 10.1073/pnas.95.21.12653; Emborg ME, 1998, J COMP NEUROL, V401, P253; Galpern WR, 1996, CELL TRANSPLANT, V5, P225, DOI 10.1016/0963-6897(95)02030-6; Goldberg MS, 2000, NAT CELL BIOL, V2, pE115, DOI 10.1038/35017124; GOZLAN H, 1990, NEUROBIOL AGING, V11, P437, DOI 10.1016/0197-4580(90)90011-N; Hagg T, 1998, EXP NEUROL, V149, P183, DOI 10.1006/exnr.1997.6684; Hirsch EC, 2003, J NEURAL TRANSM-SUPP, P89, DOI 10.1007/978-3-7091-0643-3_6; Howells DW, 2000, EXP NEUROL, V166, P127, DOI 10.1006/exnr.2000.7483; Katoh-Semba R, 1998, NEUROSCI RES, V31, P227, DOI 10.1016/S0168-0102(98)00040-6; Kirik D, 2002, J NEUROSCI, V22, P2780, DOI 10.1523/JNEUROSCI.22-07-02780.2002; Klein RL, 1999, BRAIN RES, V847, P314, DOI 10.1016/S0006-8993(99)02116-2; Kohno R, 2004, BIOCHEM BIOPH RES CO, V318, P113, DOI 10.1016/j.bbrc.2004.04.012; Lee HJ, 2002, J BIOL CHEM, V277, P5411, DOI 10.1074/jbc.M105326200; Lee HJ, 2002, J BIOL CHEM, V277, P48976, DOI 10.1074/jbc.M208192200; Levivier M, 1995, J NEUROSCI, V15, P7810, DOI 10.1523/jneurosci.15-12-07810.1995; Lotharius J, 2002, NAT REV NEUROSCI, V3, P932, DOI 10.1038/nrn983; Markham A, 2004, EUR J NEUROSCI, V20, P1189, DOI 10.1111/j.1460-9568.2004.03578.x; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; MASUOKA DT, 1979, BRAIN RES, V169, P335, DOI 10.1016/0006-8993(79)91034-5; Miguez JM, 1999, J NEURAL TRANSM, V106, P1089, DOI 10.1007/s007020050225; Minichiello L, 1996, GENE DEV, V10, P2849, DOI 10.1101/gad.10.22.2849; Mogi M, 1999, NEUROSCI LETT, V270, P45, DOI 10.1016/S0304-3940(99)00463-2; Naoi M, 1999, MECH AGEING DEV, V111, P175, DOI 10.1016/S0047-6374(99)00064-0; Nishio T, 1998, NEUROREPORT, V9, P2847, DOI 10.1097/00001756-199808240-00030; Parain K, 1999, NEUROREPORT, V10, P557, DOI 10.1097/00001756-199902250-00021; Parsian A, 2004, PARKINSONISM RELAT D, V10, P213, DOI 10.1016/j.parkreldis.2003.12.003; TATTON WG, 1991, NEUROBIOL AGING, V12, P543, DOI 10.1016/0197-4580(91)90086-Y; Tompkins MM, 1997, BRAIN RES, V775, P24, DOI 10.1016/S0006-8993(97)00874-3; von Bohlen und Halbach O, 2004, PROG NEUROBIOL, V73, P151, DOI 10.1016/j.pneurobio.2004.05.002; von Bohlen und Halbach O, 2003, CELL TISSUE RES, V311, P139, DOI 10.1007/s00441-002-0662-4; Wakabayashi K, 1998, ACTA NEUROPATHOL, V96, P445, DOI 10.1007/s004010050918; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411	38	67	68	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1740	+		10.1096/fj.05-3845fje	http://dx.doi.org/10.1096/fj.05-3845fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16037097	Green Published			2022-12-25	WOS:000230923000012
J	Baxendale, AJ; Dawson, CW; Stewart, SE; Mudaliar, V; Reynolds, G; Gordon, J; Murray, PG; Young, LS; Eliopoulos, AG				Baxendale, AJ; Dawson, CW; Stewart, SE; Mudaliar, V; Reynolds, G; Gordon, J; Murray, PG; Young, LS; Eliopoulos, AG			Constitutive activation of the CD40 pathway promotes cell transformation and neoplastic growth	ONCOGENE			English	Article						CD40; NF-kappa B; transformation; oncogenesis	EPSTEIN-BARR-VIRUS; TUMOR-NECROSIS-FACTOR; LATENT MEMBRANE-PROTEIN; NF-KAPPA-B; BURKITT-LYMPHOMA CELLS; FACTOR-ALPHA; T-CELLS; RHEUMATOID-ARTHRITIS; EPITHELIAL-CELLS; CARCINOMA-CELLS	CD40, a tumour necrosis factor (TNF) receptor family member, is expressed in a variety of cell types, including B lymphocytes, macrophages, fibroblasts, endothelial and epithelial cells, and this widespread expression is likely to account for its central role in normal physiology and disease pathogenesis. In this study, we provide evidence to support a role for constitutive CD40 signalling in cell transformation. We show that the ligand for CD40 (CD40L/CD154) is expressed in CD40-positive human breast tumour biopsies, suggesting that the constitutive activation of the CD40 receptor in vivo may contribute to the oncogenic process. Coexpression of CD40 and CD40L confers oncogenic effects on immortalized human epithelial cells in vitro, increasing their proliferation, motility and invasion. Expression of LMP:CD40, a hybrid molecule comprising the N-terminus and transmembrane domains of the Epstein-Barr virus-encoded latent membrane protein-1 (LMP1) fused to the cytoplasmic tail of CD40, mimics a constitutively active CD40 receptor and promotes the transformation of immortalized rodent fibroblasts in vitro and their oncogenicity in vivo. The observed effects of aberrant CD40 activation on cell transformation are largely diminished upon suppression of the oncogenic NF-kappa B signalling pathway. Taken together, our results suggest a role for the constitutive engagement of the CD40L/CD40/NF-kappa B activation pathway in cell transformation and neoplastic growth. Strategies that neutralize this pathway may therefore be useful in cancer treatment and prevention.	Univ Birmingham, Sch Med, Canc Res UK, Inst Canc Studies, Birmingham B15 2TA, W Midlands, England; Royal Shrewsbury Hosp, Dept Histopathol, Shrewsbury SY3 8LR, Salop, England; Univ Birmingham, Sch Med, MRC Ctr Immune Regulat, Birmingham B15 2TT, W Midlands, England	Cancer Research UK; University of Birmingham; University of Birmingham	Eliopoulos, AG (corresponding author), Univ Birmingham, Sch Med, Canc Res UK, Inst Canc Studies, Vincent Dr, Birmingham B15 2TA, W Midlands, England.	A.G.Eliopoulos@bham.ac.uk	Reynolds, Gary/F-8641-2014; Young, Lawrence S/B-7213-2009; ELIOPOULOS, ARISTIDES/ABI-6632-2020; ELIOPOULOS, ARISTIDES/R-9449-2018	Reynolds, Gary/0000-0002-3250-0582; Young, Lawrence S/0000-0003-3919-4298; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761				Adawi A, 1998, CLIN IMMUNOL IMMUNOP, V89, P222, DOI 10.1006/clin.1998.4606; Anderson GM, 2004, CURR OPIN PHARMACOL, V4, P314, DOI 10.1016/j.coph.2004.04.004; Baker MP, 1998, BLOOD, V92, P2830, DOI 10.1182/blood.V92.8.2830.420k10_2830_2843; BERBERICH I, 1994, J IMMUNOL, V153, P4357; Brown KD, 2001, J EXP MED, V193, P943, DOI 10.1084/jem.193.8.943; Challa A, 2002, BLOOD, V99, P3411, DOI 10.1182/blood.V99.9.3411; Cooke PW, 1999, J PATHOL, V188, P38; Costello RT, 1999, IMMUNOL TODAY, V20, P488, DOI 10.1016/S0167-5699(99)01507-8; Dilworth SM, 2002, NAT REV CANCER, V2, P951, DOI 10.1038/nrc946; Eggermont AMM, 2003, LANCET ONCOL, V4, P429, DOI 10.1016/S1470-2045(03)01141-0; Eliopoulos AG, 2000, MOL CELL BIOL, V20, P5503, DOI 10.1128/MCB.20.15.5503-5515.2000; Eliopoulos AG, 2004, CURR OPIN PHARMACOL, V4, P360, DOI 10.1016/j.coph.2004.02.008; Eliopoulos AG, 2001, SEMIN CANCER BIOL, V11, P435, DOI 10.1006/scbi.2001.0410; Eliopoulos AG, 2003, J VIROL, V77, P1316, DOI 10.1128/JVI.77.2.1316-1328.2003; Eliopoulos AG, 1996, ONCOGENE, V13, P2243; Eliopoulos AG, 1998, ONCOGENE, V16, P1731, DOI 10.1038/sj.onc.1201694; Floettmann JE, 1996, VIROLOGY, V223, P29, DOI 10.1006/viro.1996.0452; FloresRomo L, 1997, J EXP MED, V185, P341, DOI 10.1084/jem.185.2.341; Fulda S, 2004, CURR OPIN PHARMACOL, V4, P327, DOI 10.1016/j.coph.2004.02.005; FUNAKOSHI S, 1994, BLOOD, V83, P2787, DOI 10.1182/blood.V83.10.2787.2787; Furman RR, 2000, J IMMUNOL, V164, P2200, DOI 10.4049/jimmunol.164.4.2200; Ghamande S, 2001, CANCER RES, V61, P7556; Gires O, 1997, EMBO J, V16, P6131, DOI 10.1093/emboj/16.20.6131; GORDON J, 1995, BLOOD REV, V9, P53, DOI 10.1016/0268-960X(95)90040-3; Grell M, 1999, EMBO J, V18, P3034, DOI 10.1093/emboj/18.11.3034; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HAMMERSCHMIDT W, 1989, J VIROL, V63, P2469, DOI 10.1128/JVI.63.6.2469-2475.1989; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; He ZM, 2000, CANCER RES, V60, P1845; Henriquez NV, 1999, J IMMUNOL, V162, P3298; Hess S, 1996, J EXP MED, V183, P159, DOI 10.1084/jem.183.1.159; Hill SC, 2005, J IMMUNOL, V174, P41, DOI 10.4049/jimmunol.174.1.41; Hirano A, 1999, BLOOD, V93, P2999; Houston A, 2004, CURR OPIN PHARMACOL, V4, P321, DOI 10.1016/j.coph.2004.03.008; Kiener PA, 1997, J IMMUNOL, V159, P1594; Kyburz D, 2000, ARTHRITIS RHEUM, V43, P2571, DOI 10.1002/1529-0131(200011)43:11<2571::AID-ANR26>3.0.CO;2-4; Liao Zhongxing, 2004, Expert Rev Anticancer Ther, V4, P543, DOI 10.1586/14737140.4.4.543; MacDonald KPA, 1997, J CLIN INVEST, V100, P2404, DOI 10.1172/JCI119781; Martinez-Lorenzo MJ, 1998, EUR J IMMUNOL, V28, P2714, DOI 10.1002/(SICI)1521-4141(199809)28:09<2714::AID-IMMU2714>3.0.CO;2-9; Mehling A, 2001, J EXP MED, V194, P615, DOI 10.1084/jem.194.5.615; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; MOHAN C, 1995, J IMMUNOL, V154, P1470; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; O'Byrne KJ, 2001, BRIT J CANCER, V85, P473, DOI 10.1054/bjoc.2001.1943; OHSHIMA H, 1994, MUTAT RES, V305, P253, DOI 10.1016/0027-5107(94)90245-3; Ohta Y, 2004, DERMATOLOGY, V209, P21, DOI 10.1159/000078582; Ottaiano A, 2004, CLIN CANCER RES, V10, P2824, DOI 10.1158/1078-0432.CCR-0139-03; Pham LV, 2002, IMMUNITY, V16, P37, DOI 10.1016/S1074-7613(01)00258-8; Phipps RP, 2000, P NATL ACAD SCI USA, V97, P6930, DOI 10.1073/pnas.97.13.6930; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Tong AW, 2001, CLIN CANCER RES, V7, P691; Tutt AL, 1998, J IMMUNOL, V161, P3176; Uchida J, 1999, SCIENCE, V286, P300, DOI 10.1126/science.286.5438.300; Vonderheide RH, 2001, J CLIN ONCOL, V19, P3280, DOI 10.1200/JCO.2001.19.13.3280; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; Wykes M, 1998, EUR J IMMUNOL, V28, P548, DOI 10.1002/(SICI)1521-4141(199802)28:02<548::AID-IMMU548>3.0.CO;2-2; Young LS, 1998, IMMUNOL TODAY, V19, P502, DOI 10.1016/S0167-5699(98)01340-1; Zhang Y, 1998, J IMMUNOL, V160, P1053; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0	62	47	51	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2005	24	53					7913	7923		10.1038/sj.onc.1208929	http://dx.doi.org/10.1038/sj.onc.1208929			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	986PU	16091748				2022-12-25	WOS:000233463000010
J	Berquin, IM; Min, YN; Wu, RP; Wu, H; Chen, YQ				Berquin, IM; Min, YN; Wu, RP; Wu, H; Chen, YQ			Expression signature of the mouse prostate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANDROGEN-REGULATED EXPRESSION; GENE-EXPRESSION; SECRETORY PROTEIN; COMPLEMENTARY-DNA; SERINE-PROTEASE; SEMINAL-VESICLE; MICE LACKING; CANCER; FIBROBLASTS; HYPERPLASIA	Genetically engineered mice are being used increasingly for delineating the molecular mechanisms of prostate cancer development. Epithelium-stroma interactions play a critical role in prostate development and tumorigenesis. To better understand gene expression patterns in the normal sexually mature mouse prostate, epithelium and stroma were laser-capture microdissected from ventral, dorsolateral, and anterior prostate lobes. Genome-wide expression was measured by DNA microarrays. Our analysis indicated that the gene expression pattern in the mouse dorsolateral lobe was closest to that of the human prostate peripheral zone, supporting the hypothesis that these prostate compartments are functionally equivalent. Stroma from a given lobe had closer gene expression patterns with stroma from other lobes than epithelium from the same lobe. Stroma appeared to have higher expression complexity than epithelium. Specifically, stromal cells had higher expression levels of genes implicated in cell adhesion, muscle development, and contraction, in structural constituents of cytoskeleton and actin binding, and in components such as sarcomere and extracellular matrix collagen. Among the genes that were enriched in the epithelium were secretory proteins, including seminal vesicle protein secretion 2 and 5. Surprisingly, prostate stroma expressed many osteogenic molecules, as confirmed by immunohistochemistry. A "bone-like" environment in the prostate may predispose prostate cells for survival in the bone. Chemokine Cxcl12 but not its receptor, Cxcr4, was expressed in normal prostate. In prostate tumors, interestingly, Cxcl12 was up-regulated in epithelial cells with a concomitant expression of Cxcr4. Expression of both the receptor and ligand may provide an autocrine mechanism for tumor cell migration and invasion.	Wake Forest Univ Hlth Sci, Dept Canc Biol, Winston Salem, NC 27157 USA; Wake Forest Univ Hlth Sci, Dept Pathol, Winston Salem, NC 27157 USA; Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA	Wake Forest University; Wake Forest University School of Medicine; Wake Forest University; Wake Forest University School of Medicine; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Chen, YQ (corresponding author), Wake Forest Univ Hlth Sci, Dept Canc Biol, Med Ctr Blvd, Winston Salem, NC 27157 USA.	yqchen@wfubmc.edu	Chen, Yong Q/AAI-9864-2021	Chen, Yong Q/0000-0003-4747-4708	NATIONAL CANCER INSTITUTE [R01CA107668] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011124] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA107668] Funding Source: Medline; NIEHS NIH HHS [R01ES11124] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abate-Shen Cory, 2002, Trends Genet, V18, pS1, DOI 10.1016/S0168-9525(02)02683-5; Abbott DE, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-12-r79; BENTZ H, 1989, J BIOL CHEM, V264, P20805; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Bhowmick NA, 2005, CURR OPIN GENET DEV, V15, P97, DOI 10.1016/j.gde.2004.12.003; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Brekken RA, 2003, J CLIN INVEST, V111, P487, DOI 10.1172/JCI200316804; Bubendorf L, 1999, J NATL CANCER I, V91, P1758, DOI 10.1093/jnci/91.20.1758; Chen LL, 1998, BIOL REPROD, V59, P1498, DOI 10.1095/biolreprod59.6.1498; CUNHA GR, 1987, ENDOCR REV, V8, P338, DOI 10.1210/edrv-8-3-338; Delany AM, 2000, J CLIN INVEST, V105, P915, DOI 10.1172/JCI7039; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Economides KD, 2003, DEVELOPMENT, V130, P2061, DOI 10.1242/dev.00432; Epstein RJ, 2004, NAT REV CANCER, V4, P901, DOI 10.1038/nrc1473; HO KC, 1992, J BIOL CHEM, V267, P12660; Ivkovic S, 2003, DEVELOPMENT, V130, P2779, DOI 10.1242/dev.00505; Kasper S, 2004, J UROLOGY, V172, P12, DOI 10.1097/01.ju.0000132122.93436.aa; Klezovitch O, 2004, CANCER CELL, V6, P185, DOI 10.1016/j.ccr.2004.07.008; Kwong J, 2003, PROSTATE, V56, P81, DOI 10.1002/pros.10228; Lesche R, 2002, GENESIS, V32, P148, DOI 10.1002/gene.10036; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Li YM, 2004, CANCER CELL, V6, P459, DOI 10.1016/j.ccr.2004.09.027; Lin BY, 1999, CANCER RES, V59, P4180; Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0; Luo J, 2001, CANCER RES, V61, P4683; Magee JA, 2001, CANCER RES, V61, P5692; MCDONALD CJ, 1984, EMBO J, V3, P2517, DOI 10.1002/j.1460-2075.1984.tb02166.x; MCNEAL JE, 1969, CANCER, V23, P24, DOI 10.1002/1097-0142(196901)23:1<24::AID-CNCR2820230103>3.0.CO;2-1; MILLS JS, 1987, NUCLEIC ACIDS RES, V15, P7709, DOI 10.1093/nar/15.19.7709; MILLS JS, 1987, MOL CELL ENDOCRINOL, V53, P111, DOI 10.1016/0303-7207(87)90197-3; Mirosevich J, 2005, PROSTATE, V62, P339, DOI 10.1002/pros.20131; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Nelson PS, 2000, NUCLEIC ACIDS RES, V28, P212, DOI 10.1093/nar/28.1.212; PRICE DOROTHY, 1963, NATL CANCER INST MONOGR, V12, P1; Ross J, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2001-2-2-reviews3004; Sakr WA, 1998, ANAL QUANT CYTOL, V20, P417; Shappell SB, 2004, CANCER RES, V64, P2270, DOI 10.1158/0008-5472.CAN-03-0946; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Sturn A, 2002, BIOINFORMATICS, V18, P207, DOI 10.1093/bioinformatics/18.1.207; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Sung SY, 2002, DIFFERENTIATION, V70, P506, DOI 10.1046/j.1432-0436.2002.700905.x; Taichman RS, 2002, CANCER RES, V62, P1832; Takayama TK, 2001, BIOCHEMISTRY-US, V40, P15341, DOI 10.1021/bi015775e; TAKESHITA S, 1993, BIOCHEM J, V294, P271, DOI 10.1042/bj2940271; Thota A, 2003, J CELL BIOCHEM, V88, P999, DOI 10.1002/jcb.10425; Waghray A, 2002, J BIOL CHEM, V277, P11533, DOI 10.1074/jbc.M109557200; Waghray A, 2001, CANCER RES, V61, P4283; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Welsh JB, 2001, CANCER RES, V61, P5974; Wu XT, 2001, MECH DEVELOP, V101, P61, DOI 10.1016/S0925-4773(00)00551-7; Xu TS, 1998, NAT GENET, V20, P78, DOI 10.1038/1746; Zhao RB, 1999, DEV BIOL, V212, P68, DOI 10.1006/dbio.1999.9326	53	90	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36442	36451		10.1074/jbc.M504945200	http://dx.doi.org/10.1074/jbc.M504945200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16055444	hybrid			2022-12-25	WOS:000232726900078
J	Antoniv, TT; Tanaka, S; Sudan, B; De Val, S; Liu, K; Wang, L; Wells, DJ; Bou-Gharios, G; Ramirez, F				Antoniv, TT; Tanaka, S; Sudan, B; De Val, S; Liu, K; Wang, L; Wells, DJ; Bou-Gharios, G; Ramirez, F			Identification of a repressor in the first intron of the human alpha 2(I) collagen gene (COL1A2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN GENE-EXPRESSION; FAR-UPSTREAM ENHANCER; REPORTER GENES; PROMOTER; PRO-ALPHA-1(I); TRANSCRIPTION; ELEMENTS; SEQUENCE; PROTEIN; REGION	The human and mouse genes that code for the alpha 2 chain of collagen I ( COL1A2 and Col1a2, respectively) share a common chromatin structure and nearly identical proximal promoter and far upstream enhancer sequences. Despite these homologies, species-specific differences have been reported regarding the function of individual cis- acting elements, such as the first intron sequence. In the present study, we have investigated the transcriptional contribution of the unique open chromatin site in the first intron of COL1A2 using a transgenic mouse model. DNase I footprinting identified a cluster of three distinct areas of nuclease protection ( FI1 - 3) that span from nucleotides + 647 to + 760, relative to the transcription start site, and which contain consensus sequences for GATA and interferon regulatory factor ( IRF) transcription factors. Gel mobility shift and chromatin immunoprecipitation assays corroborated this last finding by documenting binding of GATA- 4 and IRF- 1 and IRF- 2 to the first intron sequence. Moreover, a short sequence encompassing the three footprints was found to inhibit expression of transgenic constructs containing the COL1A2 proximal promoter and far upstream enhancer in a position- independent manner. Mutations inserted into each of the footprints restored transgenic expression to different extents. These results therefore indicated that the unique open chromatin site of COL1A2 corresponds to a repressor, the activity of which seems to be mediated by the concerted action of GATA and IRF proteins. More generally, the study reiterated the existence of species- specific difference in the regulatory networks of the mammalian alpha 2( I) collagen coding genes.	Hosp Special Surg, Lab Genet & Organogenesis, Div Res, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Physiol & Biophys, New York, NY 10021 USA; Charing Cross Hosp, Imperial Coll Sch Med, Div Neurosci & Mental Hlth, Gene Targeting Unit, London W6 8RP, England; Imperial Coll Sch Med, London W12 ONN, England; CEINGE Biotecnol Avanzate, I-80131 Naples, Italy	Cornell University; Imperial College London; Imperial College London; CEINGE Biotecnologie Avanzate	Ramirez, F (corresponding author), Hosp Special Surg, Lab Genet & Organogenesis, Div Res, 535 E 70th St, New York, NY 10021 USA.	ramirezf@hss.edu		Wells, Dominic/0000-0002-1425-6344	NCRR NIH HHS [C06-RR12538-01] Funding Source: Medline; NIAMS NIH HHS [AR386481] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR012538] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Antoniv TT, 2001, J BIOL CHEM, V276, P21754, DOI 10.1074/jbc.M101397200; BouGharios G, 1996, J CELL BIOL, V134, P1333, DOI 10.1083/jcb.134.5.1333; De Val S, 2002, J BIOL CHEM, V277, P9286, DOI 10.1074/jbc.M111040200; DICKSON LA, 1985, NUCLEIC ACIDS RES, V13, P3427, DOI 10.1093/nar/13.10.3427; Ghosh AK, 2002, EXP BIOL MED, V227, P301, DOI 10.1177/153537020222700502; HAY ED, 1995, CELL BIOL EXTRACELLU, P419; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; Mamane Y, 1999, GENE, V237, P1, DOI 10.1016/S0378-1119(99)00262-0; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; NAGY A, 2003, MANIPULATING MOUSE E, P289; Ogbourne S, 1998, BIOCHEM J, V331, P1; ROSSERT J, 1995, J CELL BIOL, V129, P1421, DOI 10.1083/jcb.129.5.1421; Rossert JA, 1996, P NATL ACAD SCI USA, V93, P1027, DOI 10.1073/pnas.93.3.1027; ROSSI P, 1987, P NATL ACAD SCI USA, V84, P5590, DOI 10.1073/pnas.84.16.5590; Senger K, 2000, MOL CELL, V6, P931, DOI 10.1016/S1097-2765(05)00081-X; SHERWOOD AL, 1990, GENE, V89, P239, DOI 10.1016/0378-1119(90)90011-F; Smaldone S, 2004, MOL CELL BIOL, V24, P1058, DOI 10.1128/MCB.24.3.1058-1069.2004; Tanaka S, 2004, J BIOL CHEM, V279, P56024, DOI 10.1074/jbc.M411406200; Terraz C, 2002, J BIOL CHEM, V277, P19019, DOI 10.1074/jbc.M200125200; Terraz C, 2001, J BIOL CHEM, V276, P37011, DOI 10.1074/jbc.M104185200; Trojanowska M, 2002, FRONT BIOSCI-LANDMRK, V7, pD608, DOI 10.2741/trojan; TRUTER S, 1992, J BIOL CHEM, V267, P25389; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; VARGA J, 1995, ANN INTERN MED, V122, P60, DOI 10.7326/0003-4819-122-1-199501010-00010; VUUST J, 1985, EUR J BIOCHEM, V151, P449, DOI 10.1111/j.1432-1033.1985.tb09122.x; Wang L, 2005, MATRIX BIOL, V24, P333, DOI 10.1016/j.matbio.2005.06.001	27	12	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35417	35423		10.1074/jbc.M502681200	http://dx.doi.org/10.1074/jbc.M502681200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16091368	hybrid			2022-12-25	WOS:000232561200041
J	Jones, AL; Poon, IKH; Hulett, MD; Parish, CR				Jones, AL; Poon, IKH; Hulett, MD; Parish, CR			Histidine-rich glycoprotein specifically binds to necrotic cells via its amino-terminal domain and facilitates necrotic cell phagocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSOLUBLE IMMUNE-COMPLEXES; APOPTOTIC CELLS; PLASMINOGEN ACTIVATION; PLASMA-PROTEIN; HIGH-AFFINITY; HUMAN-IGG; SURFACE; DEATH; INHIBITION; THROMBOSPONDIN	Cells that become necrotic or apoptotic through tissue damage or during normal cellular turnover are usually rapidly cleared from the circulation and tissues by phagocytic cells. A number of soluble proteins have been identified that facilitate the phagocytosis of apoptotic cells, but few proteins have been defined that selectively opsonize necrotic cells. Previous studies have shown that histidine-rich glycoprotein ( HRG), an abundant ( similar to 100 mu g/ ml) 75- kDa plasma glycoprotein, binds to cell surface heparan sulfate on viable cells and cross- links other ligands, such as plasminogen, to the cell surface. In this study we have demonstrated that HRG also binds very strongly, in a heparan sulfate- independent manner, to cytoplasmic ligand( s) exposed in necrotic cells. This interaction is mediated by the amino- terminal domain of HRG and results in enhanced phagocytosis of the necrotic cells by a monocytic cell line. In contrast, it was found that HRG binds poorly to and does not opsonize early stage apoptotic cells. Thus, HRG has the unique property of selectively recognizing necrotic cells and may play an important physiological role in vivo by facilitating the uptake and clearance of necrotic, but not apoptotic, cells by phagocytes.	Australian Natl Univ, John Curtin Sch Med Res, Div Immunol & Genet, Canc & Vasc Biol Grp, Canberra, ACT 0200, Australia; Univ Uppsala, Ctr Biomed, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden	Australian National University; John Curtin School of Medical Research; Uppsala University	Parish, CR (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Div Immunol & Genet, Canc & Vasc Biol Grp, Bldg 54,Mills Rd, Canberra, ACT 0200, Australia.	christopher.parish@anu.edu.au	Hulett, Mark D/C-4160-2012	Hulett, Mark/0000-0003-2072-5968; Poon, Ivan/0000-0002-9119-7173; Parish, Christopher/0000-0001-7740-0430				Borza DB, 1997, J BIOL CHEM, V272, P5718, DOI 10.1074/jbc.272.9.5718; Borza DB, 2004, BLOOD COAGUL FIBRIN, V15, P663, DOI 10.1097/00001721-200412000-00006; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Dijstelbloem HM, 2001, TRENDS IMMUNOL, V22, P510, DOI 10.1016/S1471-4906(01)02014-2; Donate F, 2004, CANCER RES, V64, P5812, DOI 10.1158/0008-5472.CAN-04-0440; ESKO JD, 1986, J BIOL CHEM, V261, P5725; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Fishelson Z, 2001, MOL IMMUNOL, V38, P207, DOI 10.1016/S0161-5890(01)00055-4; Franc NC, 1999, CURR OPIN IMMUNOL, V11, P47, DOI 10.1016/S0952-7915(99)80009-0; Gaipl US, 2004, ARTHRITIS RHEUM-US, V50, P640, DOI 10.1002/art.20034; Gorgani NN, 1999, IMMUNOLOGY, V98, P456, DOI 10.1046/j.1365-2567.1999.00885.x; Gorgani NN, 1999, J BIOL CHEM, V274, P29633, DOI 10.1074/jbc.274.42.29633; Gorgani NN, 1997, BIOCHEMISTRY-US, V36, P6653, DOI 10.1021/bi962573n; Gorgani NN, 1999, INT IMMUNOL, V11, P1275, DOI 10.1093/intimm/11.8.1275; Gorgani NN, 2002, J IMMUNOL, V169, P4745, DOI 10.4049/jimmunol.169.9.4745; Guan XJ, 2004, THROMB HAEMOSTASIS, V92, P403, DOI 10.1160/TH04-02-0073; Harvey KJ, 2000, J CELL BIOL, V148, P59, DOI 10.1083/jcb.148.1.59; HEIMBURGER N, 1972, H-S Z PHYSIOL CHEM, V353, P1133, DOI 10.1515/bchm2.1972.353.2.1133; Hulett MD, 2000, IMMUNOL CELL BIOL, V78, P280, DOI 10.1046/j.1440-1711.2000.00940.x; Huynh MLN, 2002, J CLIN INVEST, V109, P41, DOI 10.1172/JCI200211638; IERINO FL, 1993, J EXP MED, V178, P1617, DOI 10.1084/jem.178.5.1617; Jones AL, 2005, IMMUNOL CELL BIOL, V83, P106, DOI 10.1111/j.1440-1711.2005.01320.x; Jones AL, 2004, J BIOL CHEM, V279, P38267, DOI 10.1074/jbc.M406027200; Jones AL, 2004, J BIOL CHEM, V279, P30114, DOI 10.1074/jbc.M401996200; Juarez JC, 2002, CANCER RES, V62, P5344; Kagi D, 1995, EUR J IMMUNOL, V25, P3256, DOI 10.1002/eji.1830251209; Kitanaka C, 1999, CELL DEATH DIFFER, V6, P508, DOI 10.1038/sj.cdd.4400526; KLUFT C, 1988, THROMB HAEMOSTASIS, V60, P411; KOIDE T, 1986, BIOCHEMISTRY-US, V25, P2220, DOI 10.1021/bi00356a055; Krysko DV, 2003, J MORPHOL, V258, P336, DOI 10.1002/jmor.10161; LEUNG LLK, 1986, J CLIN INVEST, V77, P1305, DOI 10.1172/JCI112435; LIJNEN HR, 1983, THROMB HAEMOSTASIS, V50, P560; Nauta AJ, 2003, EUR J IMMUNOL, V33, P2853, DOI 10.1002/eji.200323888; Olsson AK, 2004, CANCER RES, V64, P599, DOI 10.1158/0008-5472.CAN-03-1941; Proskuryakov SY, 2003, EXP CELL RES, V283, P1, DOI 10.1016/S0014-4827(02)00027-7; RYLATT DB, 1981, EUR J BIOCHEM, V119, P641, DOI 10.1111/j.1432-1033.1981.tb05655.x; Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957; Shacter E, 2000, BLOOD, V96, P307, DOI 10.1182/blood.V96.1.307.013k47_307_313; SILVERSTEIN RL, 1985, J CLIN INVEST, V75, P2065, DOI 10.1172/JCI111926; Simantov R, 2001, J CLIN INVEST, V107, P45, DOI 10.1172/JCI9061; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; WALZ DA, 1987, SEMIN THROMB HEMOST, V13, P317, DOI 10.1055/s-2007-1003507; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; Zwart B, 2004, AUTOIMMUNITY, V37, P95, DOI 10.1080/0891693042000196183	44	28	31	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35733	35741		10.1074/jbc.M504384200	http://dx.doi.org/10.1074/jbc.M504384200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16107330	hybrid			2022-12-25	WOS:000232561200076
J	Sarrias, MR; Rosello, S; Sanchez-Barbero, F; Sierra, JM; Vila, J; Yelamos, J; Vives, J; Casals, C; Lozano, F				Sarrias, MR; Rosello, S; Sanchez-Barbero, F; Sierra, JM; Vila, J; Yelamos, J; Vives, J; Casals, C; Lozano, F			A role for human SP alpha as a pattern recognition receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-BINDING CHARACTERISTICS; BACTERIA-BINDING; MACROPHAGE SURVIVAL; MOLECULAR-CLONING; SRCR DOMAIN; PROTEIN; MEMBER; FAMILY; ANCIENT; ANTIGEN	Human Sp alpha is a soluble protein belonging to group B of the scavenger receptor cysteine- rich ( SRCR) superfamily for which little functional information is available. It is expressed by macrophages present in lymphoid tissues ( spleen, lymph node, thymus, and bone marrow), and it binds to myelomonocytic and lymphoid cells, which suggests that it may play an important role in the regulation of the innate and adaptive immune systems. In the present study we show that recombinant human Sp alpha( rSp alpha) binds to the surface of several Gram- positive and Gram- negative bacterial strains. Competition studies indicated that such binding is mediated by the recognition of lipoteichoic acid ( LTA) and lipopolysaccharide ( LPS), respectively, through nonoverlapping sites on the Sp alpha molecule. The most conserved part of LPS ( 2- keto- 3- deoxyoctulosonic acid and lipid A) was shown to be involved in the recognition by Sp alpha. Bacterial binding studies using the SRCR domain 1 of Sp alpha showed that this domain retains both the LPS and LTA binding activities, indicating that both bacterial interacting sites are retained in a single SRCR domain. Furthermore, rSp alpha induced aggregation of Gram- positive and Gram- negative bacteria strains. On the other hand, rSp alpha inhibited tumor necrosis factor-alpha secretion by human monocytes stimulated with LPS or LTA. Binding of Sp alpha to conserved components of bacterial surfaces and modulation of the monocyte response indicate that this molecule is an active constituent of the innate immune response of the host.	Hosp Clin Barcelona, Serv Immunol, Inst Invest Biomed August Pi & Sunyer, Barcelona 08036, Spain; Hosp Clin Barcelona, Microbiol Serv, Inst Invest Biomed August Pi & Sunyer, Barcelona 08036, Spain; Univ Murcia, Dept Bioquim Biol Mol & Inmunol, E-30100 Murcia, Spain; Univ Complutense Madrid, Fac Biol, Dept Biochem & Mol Biol 1, E-28040 Madrid, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Murcia; Complutense University of Madrid	Lozano, F (corresponding author), Hosp Clin Barcelona, Serv Immunol, Villarroel 170, Barcelona 08036, Spain.	lozano@ub.edu	Sierra, Josep M/O-3429-2014; Vila, Jordi/P-3613-2016; Lozano-Soto, Francisco/AAB-7930-2019; Casals, Cristina/H-4658-2015; LOZANO, FRANCISCO/AAB-7888-2019; Yelamos, Jose/N-2842-2016; sarrias, maria rosa/D-6205-2014	Sierra, Josep M/0000-0002-0997-5619; Vila, Jordi/0000-0002-8025-3926; Lozano-Soto, Francisco/0000-0003-3714-2304; Casals, Cristina/0000-0003-2696-0918; LOZANO, FRANCISCO/0000-0003-1119-4368; sarrias, maria rosa/0000-0001-6929-8069; Yelamos, Jose/0000-0003-1195-1496				ARUFFO A, 1991, J EXP MED, V174, P949, DOI 10.1084/jem.174.4.949; Aruffo A, 1997, IMMUNOL TODAY, V18, P498, DOI 10.1016/S0167-5699(97)01130-4; Bikker FJ, 2004, J BIOL CHEM, V279, P47699, DOI 10.1074/jbc.M406095200; Bikker FJ, 2002, J BIOL CHEM, V277, P32109, DOI 10.1074/jbc.M203788200; Brannstrom A, 2002, BIOCHEM BIOPH RES CO, V290, P1462, DOI 10.1006/bbrc.2002.6378; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; Carlen A, 1998, J DENT RES, V77, P81, DOI 10.1177/00220345980770011301; DUNNE DW, 1994, P NATL ACAD SCI USA, V91, P1863, DOI 10.1073/pnas.91.5.1863; Elomaa O, 1998, J BIOL CHEM, V273, P4530, DOI 10.1074/jbc.273.8.4530; ELOMAA O, 1995, CELL, V80, P603, DOI 10.1016/0092-8674(95)90514-6; FREEMAN M, 1990, P NATL ACAD SCI USA, V87, P8810, DOI 10.1073/pnas.87.22.8810; GARCIAVERDUGO I, 2005, IN PRESS BIOCH J; Gebe JA, 1997, J BIOL CHEM, V272, P6151, DOI 10.1074/jbc.272.10.6151; Gebe JA, 2000, IMMUNOLOGY, V99, P78, DOI 10.1046/j.1365-2567.2000.00903.x; Gimferrer I, 2003, J BIOL CHEM, V278, P8564, DOI 10.1074/jbc.M209591200; Gordon S, 2002, CELL, V111, P927, DOI 10.1016/S0092-8674(02)01201-1; Haruta I, 2001, J BIOL CHEM, V276, P22910, DOI 10.1074/jbc.M100324200; Hohenester E, 1999, NAT STRUCT BIOL, V6, P228, DOI 10.1038/6669; Holmskov U, 1999, P NATL ACAD SCI USA, V96, P10794, DOI 10.1073/pnas.96.19.10794; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; JONES NH, 1986, NATURE, V323, P346, DOI 10.1038/323346a0; Joseph SB, 2004, CELL, V119, P299, DOI 10.1016/j.cell.2004.09.032; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; KOTHS K, 1993, J BIOL CHEM, V268, P14245; Kuwata Kazuhisa, 2004, Comp Hepatol, V3 Suppl 1, pS44, DOI 10.1186/1476-5926-2-S1-S44; LAW SKA, 1993, EUR J IMMUNOL, V23, P2320, DOI 10.1002/eji.1830230940; Liu Y, 2001, TRENDS IMMUNOL, V22, P227, DOI 10.1016/S1471-4906(01)01902-0; Madsen J, 2003, EUR J IMMUNOL, V33, P2327, DOI 10.1002/eji.200323972; Miyazaki T, 1999, J EXP MED, V189, P413, DOI 10.1084/jem.189.2.413; NISCHT R, 1991, EUR J BIOCHEM, V200, P529, DOI 10.1111/j.1432-1033.1991.tb16214.x; Padilla O, 2002, IMMUNOGENETICS, V54, P621, DOI 10.1007/s00251-002-0507-z; PATEL DD, 1995, J EXP MED, V181, P1563, DOI 10.1084/jem.181.4.1563; Sarrias MR, 2004, CRIT REV IMMUNOL, V24, P1; Sarrias MR, 2004, TISSUE ANTIGENS, V63, P335, DOI 10.1111/j.0001-2815.2004.00193.x; Tissot JD, 2002, ELECTROPHORESIS, V23, P1203, DOI 10.1002/1522-2683(200204)23:7/8<1203::AID-ELPS1203>3.0.CO;2-1; TOBIAS PS, 1995, J BIOL CHEM, V270, P10482, DOI 10.1074/jbc.270.18.10482; WIJNGAARD PLJ, 1992, J IMMUNOL, V149, P3273	37	87	98	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35391	35398		10.1074/jbc.M505042200	http://dx.doi.org/10.1074/jbc.M505042200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16030018	Green Published, hybrid			2022-12-25	WOS:000232561200038
J	Yin, SP; Li, XH; Meng, YH; Finley, RL; Sakr, W; Yang, H; Reddy, N; Sheng, SJ				Yin, SP; Li, XH; Meng, YH; Finley, RL; Sakr, W; Yang, H; Reddy, N; Sheng, SJ			Tumor-suppressive maspin regulates cell response to oxidative stress by direct interaction with glutathione S-transferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR; HUMAN BREAST; EXPRESSION; ANGIOGENESIS; METASTASIS; DROSOPHILA; APOPTOSIS; MAMMARY; PROTEIN; SERPIN	Maspin, a novel serine protease inhibitor, suppresses tumor progression in several cancer models, including an in vivo model for prostate cancer bone metastasis. However, the molecular mechanism of maspin remains illusive, primarily because its molecular targets are unknown. To this end, we used a full-length maspin cDNA bait to screen against both a primary prostate tumor cDNA prey library and a HeLa cDNA prey library by the yeast two-hybrid method. We found that heat shock protein 90, glutathione S-transferase (GST), and heat shock protein 70 interacted with maspin with the highest frequencies. We confirmed the maspin/GST interaction using purified proteins, human epithelial cell lines, and human prostate tissues. A maspin variant that has a point mutation of Arg(340) to Ala (Mas(R340A)) showed a significantly decreased affinity for GST. Although purified maspin had no effect on the activity of purified GST in vitro, intracellular interaction between endogenous maspin and GST correlated with an elevated total GST activity in both MDA-MB-435- and DU145-derived stably transfected cells. Consistently, tumor cells treated with purified wild type maspin, but not Mas(R340A), enhanced cellular GST activity. Maspin expression in cancer cell lines also correlated with decreased basal levels of reactive oxygen species (ROS). Furthermore, H2O2 treatment not only induced GST expression but also increased intracellular maspin/GST interaction, which was inversely correlated with the level of ROS generation. Conversely, maspin knockdown by small interfering RNA increased the basal, as well as H2O2-induced, ROS generation. Furthermore, the maspin effect on ROS generation was completely abolished by a GST inhibitor, indicating an essential role of GST in maspin-mediated cellular response to oxidative stress. Consistently, oxidative stress-induced vascular endothelial growth factor A expression was significantly inhibited in maspin-expressing cells. Together, our data suggest a new mechanism by which maspin, through its direct interaction with GST, may inhibit oxidative stress-induced ROS generation and vascular endothelial growth factor A induction, thus preventing further adverse effects on tumor genetics and stromal reactivity.	Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Ctr Mol Med & Genet, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Protease Program, Karmanos Canc Inst, Detroit, MI 48201 USA	Wayne State University; Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University	Sheng, SJ (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, 540 E Canfield Ave, Detroit, MI 48201 USA.	ssheng@med.wayne.edu	Li, Xiaohua/AAW-4713-2021	Li, Xiaohua/0000-0003-3490-916X; Finley, Russ/0000-0003-1144-6887	NCI NIH HHS [CA84176] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084176] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Al-Ayyoubi M, 2004, J BIOL CHEM, V279, P55540, DOI 10.1074/jbc.M409957200; AUSUBEL QM, 1998, CURRENT PROTOCOLS MO; Biliran H, 2001, CANCER RES, V61, P8676; Blacque OE, 2002, J BIOL CHEM, V277, P10783, DOI 10.1074/jbc.M110992200; Cher ML, 2003, P NATL ACAD SCI USA, V100, P7847, DOI 10.1073/pnas.1331360100; Choi KS, 2003, J BIOCHEM MOL BIOL, V36, P120; Dachs GU, 2000, EUR J CANCER, V36, P1649, DOI 10.1016/S0959-8049(00)00159-3; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; FINLEY RL, 1995, DNA CLONING EXPRESSI, P169; Gaikwad A, 2005, CLIN CANCER RES, V11, P1953, DOI 10.1158/1078-0432.CCR-04-1704; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Habdous M, 2002, CLIN CHIM ACTA, V326, P131, DOI 10.1016/S0009-8981(02)00329-7; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Hojo T, 2001, CANCER LETT, V171, P103, DOI 10.1016/S0304-3835(01)00569-9; Jiang N, 2002, ONCOGENE, V21, P4089, DOI 10.1038/sj.onc.1205507; Jones EL, 2004, INT J HYPERTHER, V20, P835, DOI 10.1080/02656730410001721807; Kolonin MG, 2000, DEV BIOL, V227, P661, DOI 10.1006/dbio.2000.9916; Kolonin MG, 1998, P NATL ACAD SCI USA, V95, P14266, DOI 10.1073/pnas.95.24.14266; Kolonin MG, 2000, METHOD ENZYMOL, V328, P26, DOI 10.1016/S0076-6879(00)28388-2; Latha K, 2005, MOL CELL BIOL, V25, P1737, DOI 10.1128/MCB.25.5.1737-1748.2005; Lefter LP, 2003, CLIN CANCER RES, V9, P5044; Li ZG, 2005, ONCOGENE, V24, P2008, DOI 10.1038/sj.onc.1208449; Liu JY, 2004, CANCER RES, V64, P1703, DOI 10.1158/0008-5472.CAN-03-2568; Maulik N, 2002, FREE RADICAL BIO MED, V33, P1047, DOI 10.1016/S0891-5849(02)01005-5; Maulik N, 2002, ANTIOXID REDOX SIGN, V4, P783, DOI 10.1089/152308602760598927; McGowen R, 2000, CANCER RES, V60, P4771; Muller P, 2005, J BIOL CHEM, V280, P6682, DOI 10.1074/jbc.M412767200; PEMBERTON PA, 1995, J BIOL CHEM, V270, P15832, DOI 10.1074/jbc.270.26.15832; Perquin M, 2000, CANCER LETT, V158, P7, DOI 10.1016/S0304-3835(00)00481-X; Pierson CR, 2002, PROSTATE, V53, P255, DOI 10.1002/pros.10107; ROBINSON JP, 1997, CURRENT PROTOCOLS CH; Seifried HE, 2003, CANCER RES, V63, P4295; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; Sheng SJ, 2004, FRONT BIOSCI-LANDMRK, V9, P2733, DOI 10.2741/1432; SHENG SJ, 1994, J BIOL CHEM, V269, P30988; Shi HY, 2003, HISTOL HISTOPATHOL, V18, P201, DOI 10.14670/HH-18.201; Shi HY, 2001, CANCER RES, V61, P6945; Song SY, 2002, DIGEST DIS SCI, V47, P1831, DOI 10.1023/A:1016409031562; Thomas BJ, 1997, GENE DEV, V11, P1289, DOI 10.1101/gad.11.10.1289; Toussaint-Smith E, 2004, ONCOGENE, V23, P2988, DOI 10.1038/sj.onc.1207442; Ushio-Fukai M, 2004, MOL CELL BIOCHEM, V264, P85, DOI 10.1023/B:MCBI.0000044378.09409.b5; Vanden Berghe T, 2003, J BIOL CHEM, V278, P5622, DOI 10.1074/jbc.M208925200; Zhang M, 2000, ONCOGENE, V19, P6053, DOI 10.1038/sj.onc.1204006; Zou ZQ, 2002, CLIN CANCER RES, V8, P1172; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	45	66	69	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34985	34996		10.1074/jbc.M503522200	http://dx.doi.org/10.1074/jbc.M503522200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16049007	hybrid			2022-12-25	WOS:000232403900072
J	Hiniker, A; Collet, JF; Bardwell, JCA				Hiniker, A; Collet, JF; Bardwell, JCA			Copper stress causes an in vivo requirement for the Escherichia coli disulfide isomerase DsbC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOND FORMATION; PROTEIN; IDENTIFICATION; HOMEOSTASIS; EXPRESSION; REDUCTION; MUTATIONS; CYSTEINE; MUTANTS; OXIDASE	In Escherichia coli, the periplasmic disulfide oxidoreductase DsbA is thought to be a powerful but nonspecific oxidant, joining cysteines together the moment they enter the periplasm. DsbC, the primary disulfide isomerase, likely resolves incorrect disulfides. Given the reliance of protein function on correct disulfide bonds, it is surprising that no phenotype has been established for null mutations in dsbC. Here we demonstrate that mutations in the entire DsbC disulfide isomerization pathway cause an increased sensitivity to the redox-active metal copper. We find that copper catalyzes periplasmic disulfide bond formation under aerobic conditions and that copper catalyzes the formation of disulfide-bonded oligomers in vitro, which DsbC can resolve. Our data suggest that the copper sensitivity of dsbC(-) strains arises from the inability of the cell to rearrange copper-catalyzed non-native disulfides in the absence of functional DsbC. Absence of functional DsbA augments the deleterious effects of copper on a dsbC(-) strain, even though the dsbA(-) single mutant is unaffected by copper. This may indicate that DsbA successfully competes with copper and forms disulfide bonds more accurately than copper does. These findings lead us to a model in which DsbA may be significantly more accurate in disulfide oxidation than previously thought, and in which the primary role of DsbC may be to rearrange incorrect disulfide bonds that are formed during certain oxidative stresses.	Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Program Mol & Cellular Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Med Scientist Training Program, Ann Arbor, MI 48109 USA; Catholic Univ Louvain, Christian de Duve Inst Cellular Pathol, B-1200 Brussels, Belgium	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Universite Catholique Louvain	Bardwell, JCA (corresponding author), Univ Michigan, Dept Mol Cellular & Dev Biol, 4007 Krauss Nat Sci Bldg,830 N Univ, Ann Arbor, MI 48109 USA.	jbardwel@umich.edu	Collet, Jean Francois/F-2105-2010	Collet, Jean-Francois/0000-0001-8069-7036	NIGMS NIH HHS [GM064662] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064662] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALKSNE LE, 1995, J BACTERIOL, V177, P462, DOI 10.1128/jb.177.2.462-464.1995; Bader MW, 2000, J BIOL CHEM, V275, P26082, DOI 10.1074/jbc.M003850200; Bader MW, 2001, EMBO J, V20, P1555, DOI 10.1093/emboj/20.7.1555; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BERKMEN M, 2005, J BIOL CHEM; Bessette PH, 1999, J BIOL CHEM, V274, P7784, DOI 10.1074/jbc.274.12.7784; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cecconi I, 1998, BIOCHEMISTRY-US, V37, P14167, DOI 10.1021/bi981159f; DAILEY FE, 1993, P NATL ACAD SCI USA, V90, P1043, DOI 10.1073/pnas.90.3.1043; Dartigalongue C, 2001, J BIOL CHEM, V276, P20866, DOI 10.1074/jbc.M100464200; Hiniker A, 2004, J BIOL CHEM, V279, P12967, DOI 10.1074/jbc.M311391200; Kachur AV, 1999, FREE RADICAL RES, V31, P23, DOI 10.1080/10715769900300571; Kadokura H, 2004, SCIENCE, V303, P534, DOI 10.1126/science.1091724; Kershaw CJ, 2005, MICROBIOL-SGM, V151, P1187, DOI 10.1099/mic.0.27650-0; Lee ISM, 2000, ARCH BIOCHEM BIOPHYS, V374, P137, DOI 10.1006/abbi.1999.1595; Metheringham R, 1996, MOL GEN GENET, V253, P95; MISSIAKAS D, 1993, P NATL ACAD SCI USA, V90, P7084, DOI 10.1073/pnas.90.15.7084; MISSIAKAS D, 1994, EMBO J, V13, P2013, DOI 10.1002/j.1460-2075.1994.tb06471.x; MISSIAKAS D, 1995, EMBO J, V14, P3415, DOI 10.1002/j.1460-2075.1995.tb07347.x; Pogliano J, 1997, GENE DEV, V11, P1169, DOI 10.1101/gad.11.9.1169; Porat A, 2004, RES MICROBIOL, V155, P617, DOI 10.1016/j.resmic.2004.05.005; Rensing C, 2003, FEMS MICROBIOL REV, V27, P197, DOI 10.1016/S0168-6445(03)00049-4; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; Rietsch A, 1997, J BACTERIOL, V179, P6602, DOI 10.1128/jb.179.21.6602-6608.1997; Rietsch A, 1996, P NATL ACAD SCI USA, V93, P13048, DOI 10.1073/pnas.93.23.13048; Roberts SA, 2002, P NATL ACAD SCI USA, V99, P2766, DOI 10.1073/pnas.052710499; SILHAVY TJ, 1976, P NATL ACAD SCI USA, V73, P3423, DOI 10.1073/pnas.73.10.3423; Sone M, 1997, J BIOL CHEM, V272, P10349; TAKEMOTO LJ, 1982, INVEST OPHTH VIS SCI, V22, P336; Tian HP, 2000, P NATL ACAD SCI USA, V97, P4730, DOI 10.1073/pnas.090087297; WATARAI M, 1995, P NATL ACAD SCI USA, V92, P4927, DOI 10.1073/pnas.92.11.4927; Wedemeyer WJ, 2000, BIOCHEMISTRY-US, V39, P7032, DOI 10.1021/bi005111p; ZAPUN A, 1995, BIOCHEMISTRY-US, V34, P5075, DOI 10.1021/bi00015a019; Zheng M, 2001, J BACTERIOL, V183, P4571, DOI 10.1128/JB.183.15.4571-4579.2001	34	120	122	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33785	33791		10.1074/jbc.M505742200	http://dx.doi.org/10.1074/jbc.M505742200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16087673	hybrid			2022-12-25	WOS:000232229700014
J	Collins, XH; Harmon, SD; Kaduce, TL; Berst, KB; Fang, X; Moore, SA; Raju, TV; Falck, JR; Weintraub, NL; Duester, G; Plapp, BV; Spector, AA				Collins, XH; Harmon, SD; Kaduce, TL; Berst, KB; Fang, X; Moore, SA; Raju, TV; Falck, JR; Weintraub, NL; Duester, G; Plapp, BV; Spector, AA			omega-Oxidation of 20-hydroxyeicosatetraenoic acid (20-HETE) in cerebral microvascular smooth muscle and endothelium by alcohol dehydrogenase 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IV ALCOHOL-DEHYDROGENASE; THICK ASCENDING LIMB; ARACHIDONIC-ACID; SUBSTRATE-SPECIFICITY; ETHANOL-METABOLISM; KINETIC MECHANISM; CYTOCHROME-P450 METABOLITES; RETINOL DEHYDROGENASE; HYDROXYFATTY ACIDS; PROSTAGLANDIN E-2	20-Carboxyeicosatetraenoic acid (20-COOH-AA) is a bioactive metabolite of 20-hydroxyeicosatetraenoic acid (20-HETE), an eicosanoid that produces vasoconstriction in the cerebral circulation. We found that smooth muscle (MSMC) and endothelial (MEC) cultures obtained from mouse brain microvessels convert [H-3] 20-HETE to 20-COOH-AA, indicating that the cerebral vasculature can produce this metabolite. The [H-3] 20-COOH-AA accumulated primarily in the culture medium, together with additional radiolabeled metabolites identified as the chain-shortened dicarboxylic acids 18-COOH-18: 4, 18-COOH-18: 3, and 16-COOH-16: 3. N-Heptylformamide, a potent inhibitor of alcohol dehydrogenase (ADH), decreased the conversion of [H-3] 20-HETE to 20-COOH-AA by the MSMC and MEC and also by isolated mouse brain microvessels. Purified mouse and human ADH4, human ADH3, and horse liver ADH1 efficiently oxidized 20-HETE, and ADH4 and ADH3 were detected in MSMC and MEC by Western blotting. N-Heptylformamide inhibited the oxidation of 20-HETE by mouse and human ADH4 but not by ADH3. These results demonstrated that cerebral microvessels convert 20-HETE to 20-COOH-AA and that ADH catalyzes the reaction. Although ADH4 and ADH3 are expressed in MSMC and MEC, the inhibition produced by N-heptylformamide suggests that ADH4 is primarily responsible for 20-COOH-AA formation in the cerebral microvasculature.	Univ Iowa, Carver Coll Med, Dept Biochem, Iowa City, IA 52242 USA; Univ Iowa, Carver Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Carver Coll Med, Dept Pathol, Iowa City, IA 52242 USA; Vet Affairs Med Ctr, Iowa City, IA 52242 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Burnham Inst, La Jolla, CA 92037 USA	University of Iowa; University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Sanford Burnham Prebys Medical Discovery Institute	Spector, AA (corresponding author), Univ Iowa, Carver Coll Med, Dept Biochem, 4-403 BSB, Iowa City, IA 52242 USA.	arthur-spector@uiowa.edu	Plapp, Bryce V/F-6353-2010; Spector, Arthur/AAG-9860-2020	Weintraub, Neal/0000-0002-5138-3705; Falck, John/0000-0002-9219-7845; Moore, Steven/0000-0002-6353-7900	NCRR NIH HHS [RR13799] Funding Source: Medline; NHLBI NIH HHS [HL76684, HL72845, HL70860, HL62984] Funding Source: Medline; NIAAA NIH HHS [AA09731, AA00279] Funding Source: Medline; NIGMS NIH HHS [GM31278] Funding Source: Medline; NINDS NIH HHS [NS24621] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR013799] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072845, P01HL062984, R01HL076684, R01HL070860] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031278] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS024621] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA009731] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Allali-Hassani A, 1998, FEBS LETT, V426, P362, DOI 10.1016/S0014-5793(98)00374-3; AllaliHassani A, 1997, FEBS LETT, V405, P26, DOI 10.1016/S0014-5793(97)00151-8; BAUMERT T, 1989, EUR J BIOCHEM, V182, P223, DOI 10.1111/j.1432-1033.1989.tb14821.x; BOLEDA MD, 1993, ARCH BIOCHEM BIOPHYS, V307, P85, DOI 10.1006/abbi.1993.1564; BOLEDA MD, 1989, ARCH BIOCHEM BIOPHYS, V274, P74, DOI 10.1016/0003-9861(89)90416-5; Capdevila JH, 2001, BIOCHEM BIOPH RES CO, V285, P571, DOI 10.1006/bbrc.2001.5167; Capdevila JH, 2000, J LIPID RES, V41, P163; CARROLL MA, 1991, J BIOL CHEM, V266, P12306; Chou CF, 2002, J BIOL CHEM, V277, P25209, DOI 10.1074/jbc.M201947200; Cleland W W, 1979, Methods Enzymol, V63, P103; Crosas B, 2000, J BIOL CHEM, V275, P25180, DOI 10.1074/jbc.M910040199; Deltour L, 1999, DEV GENET, V25, P1, DOI 10.1002/(SICI)1520-6408(1999)25:1<1::AID-DVG1>3.0.CO;2-W; ESCALANTE B, 1991, SCIENCE, V251, P799, DOI 10.1126/science.1846705; ESCALANTE B, 1993, J CARDIOVASC PHARM, V22, pS106, DOI 10.1097/00005344-199322002-00034; ESCALANTE B, 1996, AM J PHYSIOL, V266, pC1775; Fang X, 1998, AM J PHYSIOL-HEART C, V275, pH2113, DOI 10.1152/ajpheart.1998.275.6.H2113; Fang X, 2000, J NEUROCHEM, V75, P614, DOI 10.1046/j.1471-4159.2000.0750614.x; Gebremedhin D, 1998, J PHYSIOL-LONDON, V507, P771, DOI 10.1111/j.1469-7793.1998.771bs.x; Gebremedhin D, 2000, CIRC RES, V87, P60, DOI 10.1161/01.RES.87.1.60; Han CL, 1998, EUR J BIOCHEM, V254, P25, DOI 10.1046/j.1432-1327.1998.2540025.x; Hankin JA, 1998, J PHARMACOL EXP THER, V285, P155; HARDER DR, 1995, J VASC RES, V32, P79, DOI 10.1159/000159080; HARDER DR, 1994, AM J PHYSIOL, V266, pH2098, DOI 10.1152/ajpheart.1994.266.5.H2098; Haselbeck RJ, 1997, ALCOHOL CLIN EXP RES, V21, P1484; HATZELMANN A, 1988, EUR J BIOCHEM, V173, P445, DOI 10.1111/j.1432-1033.1988.tb14019.x; HENEHAN GTM, 1993, BIOCHEMISTRY-US, V32, P736, DOI 10.1021/bi00054a001; Hur M W, 1992, DNA Seq, V3, P167, DOI 10.3109/10425179209034012; Kaduce TL, 2004, J BIOL CHEM, V279, P2648, DOI 10.1074/jbc.M306849200; Kedishvili NY, 1998, BIOCHEM BIOPH RES CO, V249, P191, DOI 10.1006/bbrc.1998.9105; KEDISHVILI NY, 1995, J BIOL CHEM, V270, P3625, DOI 10.1074/jbc.270.8.3625; Kroetz DL, 2002, CURR OPIN LIPIDOL, V13, P273, DOI 10.1097/00041433-200206000-00007; Lange A, 1997, J BIOL CHEM, V272, P27345, DOI 10.1074/jbc.272.43.27345; MA YH, 1993, CIRC RES, V72, P126, DOI 10.1161/01.RES.72.1.126; Maier KG, 2001, CURR OPIN NEPHROL HY, V10, P81, DOI 10.1097/00041552-200101000-00013; MANNA S, 1983, TETRAHEDRON LETT, V24, P33, DOI 10.1016/S0040-4039(00)81319-2; Martinez SE, 2001, EUR J BIOCHEM, V268, P5045; Martras S, 2004, ARCH BIOCHEM BIOPHYS, V430, P210, DOI 10.1016/j.abb.2004.07.002; McGiff JC, 1999, AM J PHYSIOL-REG I, V277, pR607, DOI 10.1152/ajpregu.1999.277.3.R607; MOORE SA, 1988, AM J PHYSIOL, V254, pC37, DOI 10.1152/ajpcell.1988.254.1.C37; MOORE SA, 1989, J NEUROCHEM, V53, P376, DOI 10.1111/j.1471-4159.1989.tb07345.x; Moreno C, 2001, AM J HYPERTENS, V14, p90S, DOI 10.1016/S0895-7061(01)02075-1; PLAPP BV, 1970, J BIOL CHEM, V245, P1727; Plapp BV, 2001, CHEM-BIOL INTERACT, V130, P445, DOI 10.1016/S0009-2797(00)00284-2; PLAPP BV, 2005, ENZYMOLOGY MOL BIOL, V12, P187; Roman RJ, 2000, CLIN EXP PHARMACOL P, V27, P855, DOI 10.1046/j.1440-1681.2000.03349.x; Roman RJ, 2002, PHYSIOL REV, V82, P131, DOI 10.1152/physrev.00021.2001; Roman RJ, 1997, AM J HYPERTENS, V10, pS63; Sanghani PC, 2000, BIOCHEMISTRY-US, V39, P10720, DOI 10.1021/bi9929711; Schindler JF, 1998, J MED CHEM, V41, P1696, DOI 10.1021/jm9707380; SHEARER GL, 1993, BIOCHEMISTRY-US, V32, P11186, DOI 10.1021/bi00092a031; Sun CW, 1999, HYPERTENSION, V33, P414, DOI 10.1161/01.HYP.33.1.414; Venkataramaiah TH, 2003, J BIOL CHEM, V278, P36699, DOI 10.1074/jbc.M305419200; WANG WH, 1995, J GEN PHYSIOL, V106, P727, DOI 10.1085/jgp.106.4.727; Xie PG, 1997, J BIOL CHEM, V272, P18558, DOI 10.1074/jbc.272.30.18558; ZGOMBICKNIGHT M, 1995, J BIOL CHEM, V270, P10868, DOI 10.1074/jbc.270.18.10868	55	37	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33157	33164		10.1074/jbc.M504055200	http://dx.doi.org/10.1074/jbc.M504055200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16081420	hybrid			2022-12-25	WOS:000232058100010
J	Fujiwara, K; Toma, S; Okamura-Ikeda, K; Motokawa, Y; Nakagawa, A; Taniguchi, H				Fujiwara, K; Toma, S; Okamura-Ikeda, K; Motokawa, Y; Nakagawa, A; Taniguchi, H			Crystal structure of lipoate-protein ligase a from Escherichia coli - Determination of the lipoic acid-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCINE CLEAVAGE SYSTEM; ACYLTRANSFERASE COMPONENTS; MOLECULAR-CLONING; CARRIER PROTEIN; H-PROTEIN; LIPOYLATION; PROGRAM; IDENTIFICATION; EXPRESSION; SEQUENCE	Lipoate-protein ligase A (LplA) catalyzes the formation of lipoyl-AMP from lipoate and ATP and then transfers the lipoyl moiety to a specific lysine residue on the acyltransferase subunit of alpha-ketoacid dehydrogenase complexes and on H-protein of the glycine cleavage system. The lypoyllysine arm plays a pivotal role in the complexes by shuttling the reaction intermediate and reducing equivalents between the active sites of the components of the complexes. We have determined the X-ray crystal structures of Escherichia coli LplA alone and in a complex with lipoic acid at 2.4 and 2.9 angstrom resolution, respectively. The structure of LplA consists of a large N-terminal domain and a small C-terminal domain. The structure identifies the substrate binding pocket at the interface between the two domains. Lipoic acid is bound in a hydrophobic cavity in the N- terminal domain through hydrophobic interactions and a weak hydrogen bond between carboxyl group of lipoic acid and the Ser-72 or Arg-140 residue of LplA. No large conformational change was observed in the main chain structure upon the binding of lipoic acid.	Univ Tokushima, Inst Enzyme Res, Tokushima 7708503, Japan; Kumamoto Univ, Grad Sch Pharmaceut Sci, Kumamoto 8620973, Japan; Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan; RIKEN, Harima Inst SPring8, Sayo, Hyogo 6795148, Japan	Tokushima University; Kumamoto University; Osaka University; Japan Synchrotron Radiation Research Institute; RIKEN	Fujiwara, K (corresponding author), Univ Tokushima, Inst Enzyme Res, Tokushima 7708503, Japan.	fujiwara@ier.tokushima-u.ac.jp	Nakagawa, Atsushi/D-4329-2009; Taniguchi, Hisaaki/I-9171-2012; Nakagawa, Atsushi/M-5731-2019	Nakagawa, Atsushi/0000-0002-1700-7861; Nakagawa, Atsushi/0000-0002-1700-7861				Aberg A, 1997, BIOCHEMISTRY-US, V36, P3084, DOI 10.1021/bi9618373; Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BROOKFIELD DE, 1991, FEBS LETT, V295, P13, DOI 10.1016/0014-5793(91)81373-G; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Dauter Z, 2002, ACTA CRYSTALLOGR D, V58, P494, DOI 10.1107/S090744490200118X; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Doublie S., 1992, CRYSTALLIZATION NUCL, P311; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Evans P. R., 1993, DATA COLLECTION PROC, P114; FUJIWARA K, 1992, J BIOL CHEM, V267, P20011; Fujiwara K, 1999, EUR J BIOCHEM, V260, P761, DOI 10.1046/j.1432-1327.1999.00204.x; Fujiwara K, 1997, J BIOL CHEM, V272, P31974, DOI 10.1074/jbc.272.51.31974; Fujiwara K, 1996, J BIOL CHEM, V271, P12932, DOI 10.1074/jbc.271.22.12932; FUJIWARA K, 1986, J BIOL CHEM, V261, P8836; GREEN DE, 1995, BIOCHEM J, V309, P853, DOI 10.1042/bj3090853; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jordan SW, 1997, J BIOL CHEM, V272, P17903, DOI 10.1074/jbc.272.29.17903; Jordan SW, 2003, J BACTERIOL, V185, P1582, DOI 10.1128/JB.185.5.1582-1589.2003; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MORRIS TW, 1995, J BACTERIOL, V177, P1; MORRIS TW, 1994, J BIOL CHEM, V269, P16091; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Okamura-Ikeda K, 1999, J BIOL CHEM, V274, P17471, DOI 10.1074/jbc.274.25.17471; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PERHAM RN, 1991, BIOCHEMISTRY-US, V30, P8501, DOI 10.1021/bi00099a001; Quinn J, 1997, METHOD ENZYMOL, V279, P193; REED LJ, 1990, J BIOL CHEM, V265, P8971; Sambrook J., 1989, MOL CLONING LAB MANU, V2; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Tettelin H, 2001, SCIENCE, V293, P498, DOI 10.1126/science.1061217; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tsodikov OV, 2002, J COMPUT CHEM, V23, P600, DOI 10.1002/jcc.10061; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; WILSON KP, 1992, P NATL ACAD SCI USA, V89, P9257, DOI 10.1073/pnas.89.19.9257	42	51	60	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33645	33651		10.1074/jbc.M505010200	http://dx.doi.org/10.1074/jbc.M505010200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16043486	hybrid			2022-12-25	WOS:000232058100066
J	Lynch, MJ; Baillie, GS; Mohamed, A; Li, X; Maisonneuve, C; Klussmann, E; van Heeke, G; Houslay, MD				Lynch, MJ; Baillie, GS; Mohamed, A; Li, X; Maisonneuve, C; Klussmann, E; van Heeke, G; Houslay, MD			RNA silencing identifies PDE4D5 as the functionally relevant cAMP phosphodiesterase interacting with beta arrestin to control the protein kinase A/AKAP79-mediated switching of the beta(2)-adrenergic receptor to activation of ERK in HEK293B2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; CARDIAC MYOCYTES; MICE DEFICIENT; PHOSPHORYLATION; EXPRESSION; ISOFORMS; DESENSITIZATION; INHIBITORS; ROLIPRAM; BINDING	PDE4B and PDE4D provide > 90% of PDE4 cAMP phosphodiesterase activity in human embryonic kidney (HEK293B2) cells. Their selective small interference RNA ( siRNA)-mediated knockdown potentiates isoprenaline-stimulated protein kinase A (PKA) activation. Whereas endogenous PDE4D co-immunoprecipitates with beta arrestin, endogenous PDE4B does not, even upon PDE4D knockdown. Ectopic overexpression of PDE4B2 confers co-immunoprecipitation with beta arrestin. Knockdown of PDE4D, but not PDE4B, amplifies isoprenaline-stimulated phosphorylation of the beta(2)-adrenergic receptor (beta(2)-AR) by PKA and activation of extracellular signal-regulated kinase (ERK) through G(i). Isoform-selective knockdown identifies PDE4D5 as the functionally important species regulating isoprenaline stimulation of both these processes. Ht31-mediated disruption of the tethering of PKA to AKAP scaffold proteins attenuates isoprenaline activation of ERK, even upon PDE4D knockdown. Selective siRNA-mediated knockdown identifies AKAP79, which is constitutively associated with the beta(2)-AR, rather than isoprenaline-recruited gravin, as being the functionally relevant AKAP in this process. Isoprenaline-stimulated membrane recruitment of PDE4D is ablated upon beta arrestin knockdown. A mutation that compromises interactions with beta arrestin prevents catalytically inactive PDE4D5 from performing a dominant negative role in potentiating isoprenaline-stimulated ERK activation. beta arrestin-recruited PDE4D5 desensitizes isoprenaline-stimulated PKA phosphorylation of the beta(2)-AR and the consequential switching of its signaling to ERK. The ability to observe a cellular phenotype upon PDE4D5 knockdown demonstrates that other PDE4 isoforms, expressed at endogenous levels, are unable to afford rescue in HEK293B2 cells.	Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland; Novartis Inst Biomed Res, Resp Dis Area, Horsham RH12 5AB, W Sussex, England; Forschungsinst Mol Pharmakol, D-13125 Berlin, Germany	University of Glasgow; Novartis	Houslay, MD (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Wolfson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	M.Houslay@bio.gla.ac.uk	Houslay, Miles D/A-6825-2011; Houslay, Miles/AAM-5281-2020	Houslay, Miles/0000-0002-3826-8091	Medical Research Council [G8604010] Funding Source: Medline; MRC [G8604010] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ahn S, 2003, P NATL ACAD SCI USA, V100, P1740, DOI 10.1073/pnas.262789099; Ariga M, 2004, J IMMUNOL, V173, P7531, DOI 10.4049/jimmunol.173.12.7531; Baillie GS, 2005, CURR OPIN CELL BIOL, V17, P129, DOI 10.1016/j.ceb.2005.01.003; Baillie GS, 2003, P NATL ACAD SCI USA, V100, P940, DOI 10.1073/pnas.262787199; Banan M, 2004, CURR PHARM BIOTECHNO, V5, P441, DOI 10.2174/1389201043376643; Barber R, 2004, AM J PHYSIOL-LUNG C, V287, pL332, DOI 10.1152/ajplung.00384.2003; Barnette M S, 2000, Curr Opin Pulm Med, V6, P164, DOI 10.1097/00063198-200003000-00014; Beavo JA, 2002, NAT REV MOL CELL BIO, V3, P710, DOI 10.1038/nrm911; Bohn LM, 1999, SCIENCE, V286, P2495, DOI 10.1126/science.286.5449.2495; Bolger GB, 2003, J BIOL CHEM, V278, P49230, DOI 10.1074/jbc.M303772200; Bolger GB, 1997, BIOCHEM J, V328, P539; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; BRUNTON LL, 2003, SCI STKE, pPE44; Burnouf C, 2002, CURR PHARM DESIGN, V8, P1255, DOI 10.2174/1381612023394665; COGHLAN VM, 1994, J BIOL CHEM, V269, P7658; Conner DA, 1997, CIRC RES, V81, P1021; Conti M, 2000, PROG NUCLEIC ACID RE, V63, P1; Conti M, 2003, J BIOL CHEM, V278, P5493, DOI 10.1074/jbc.R200029200; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Feliciello A, 2005, CELL SIGNAL, V17, P279, DOI 10.1016/j.cellsig.2004.09.009; Francis SH, 2001, PROG NUCLEIC ACID RE, V65, P1; Fraser IDC, 2000, CURR BIOL, V10, P409, DOI 10.1016/S0960-9822(00)00419-X; Giembycz M A, 2002, Monaldi Arch Chest Dis, V57, P48; Hansen G, 2000, P NATL ACAD SCI USA, V97, P6751, DOI 10.1073/pnas.97.12.6751; Houslay MD, 2003, BIOCHEM J, V370, P1, DOI 10.1042/BJ20021698; Huston E, 1997, BIOCHEM J, V328, P549, DOI 10.1042/bj3280549; Jin SLC, 2002, P NATL ACAD SCI USA, V99, P7628, DOI 10.1073/pnas.122041599; Jones SW, 2004, CURR OPIN PHARMACOL, V4, P522, DOI 10.1016/j.coph.2004.06.003; Jurevicius J, 2003, J PHYSIOL-LONDON, V551, P239, DOI 10.1113/jphysiol.2003.045211; Klussmann E, 1999, J BIOL CHEM, V274, P4934, DOI 10.1074/jbc.274.8.4934; Klussmann E, 2001, FEBS LETT, V507, P264, DOI 10.1016/S0014-5793(01)02995-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Le Jeune IR, 2002, J BIOL CHEM, V277, P35980, DOI 10.1074/jbc.M204832200; Lefkowitz RJ, 2002, MOL PHARMACOL, V62, P971, DOI 10.1124/mol.62.5.971; Lin FB, 2000, J BIOL CHEM, V275, P19025, DOI 10.1074/jbc.275.25.19025; MacKenzie SJ, 2000, J BIOL CHEM, V275, P16609, DOI 10.1074/jbc.275.22.16609; MacKenzie SJ, 2000, BIOCHEM J, V347, P571, DOI 10.1042/0264-6021:3470571; Manganiello VC, 1999, THROMB HAEMOSTASIS, V82, P407, DOI 10.1055/s-0037-1615860; Marchese A, 2003, TRENDS BIOCHEM SCI, V28, P369, DOI 10.1016/S0968-0004(03)00134-8; MARCHMONT RJ, 1980, BIOCHEM J, V187, P381, DOI 10.1042/bj1870381; Maurice DH, 2003, MOL PHARMACOL, V64, P533, DOI 10.1124/mol.64.3.533; McCahill A, 2005, CELL SIGNAL, V17, P1158, DOI 10.1016/j.cellsig.2005.04.003; McLean AJ, 2000, BRIT J PHARMACOL, V130, P1825, DOI 10.1038/sj.bjp.0703506; McPhee I, 1999, J BIOL CHEM, V274, P11796, DOI 10.1074/jbc.274.17.11796; Mehats C, 2003, FASEB J, V17, P1831, DOI 10.1096/fj.03-0274com; Michel JJC, 2002, ANNU REV PHARMACOL, V42, P235, DOI 10.1146/annurev.pharmtox.42.083101.135801; Mongillo M, 2004, CIRC RES, V95, P67, DOI 10.1161/01.RES.0000134629.84732.11; Nemoz G, 1996, FEBS LETT, V384, P97, DOI 10.1016/0014-5793(96)00300-6; Newlon MG, 1999, NAT STRUCT BIOL, V6, P222; Nikolaev VO, 2004, J BIOL CHEM, V279, P37215, DOI 10.1074/jbc.C400302200; O'Donnell JM, 2004, TRENDS PHARMACOL SCI, V25, P158, DOI 10.1016/j.tips.2004.01.003; Perry SJ, 2002, SCIENCE, V298, P834, DOI 10.1126/science.1074683; Perry SJ, 2002, TRENDS CELL BIOL, V12, P130, DOI 10.1016/S0962-8924(01)02239-5; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Pronin AN, 2002, METHOD ENZYMOL, V343, P547; Rochais F, 2004, J BIOL CHEM, V279, P52095, DOI 10.1074/jbc.M405697200; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; Sette C, 1996, J BIOL CHEM, V271, P16526, DOI 10.1074/jbc.271.28.16526; Shepherd MC, 2004, BRIT J PHARMACOL, V142, P339, DOI 10.1038/sj.bjp.0705770; Spina D, 2003, CURR OPIN PULM MED, V9, P57, DOI 10.1097/00063198-200301000-00010; Tao JC, 2003, EMBO J, V22, P6419, DOI 10.1093/emboj/cdg628; Tasken K, 2004, PHYSIOL REV, V84, P137, DOI 10.1152/physrev.00021.2003; Terrillon S, 2004, EMBO REP, V5, P30, DOI 10.1038/sj.embor.7400052; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311; Vijayaraghavan S, 1997, J BIOL CHEM, V272, P4747, DOI 10.1074/jbc.272.8.4747; Zaccolo M, 2002, SCIENCE, V295, P1711, DOI 10.1126/science.1069982; Zhang HT, 2002, NEUROPSYCHOPHARMACOL, V27, P587; Zhang J, 2001, P NATL ACAD SCI USA, V98, P14997, DOI 10.1073/pnas.211566798	69	167	181	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33178	33189		10.1074/jbc.M414316200	http://dx.doi.org/10.1074/jbc.M414316200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16030021	hybrid			2022-12-25	WOS:000232058100012
J	Ferreira, IA; Mocking, AIM; Urbanus, RT; Varlack, S; Wnuk, M; Akkerman, JWN				Ferreira, IA; Mocking, AIM; Urbanus, RT; Varlack, S; Wnuk, M; Akkerman, JWN			Glucose uptake via glucose transporter 3 by human platelets is regulated by protein kinase B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER-TYPE GLUT2; XENOPUS OOCYTES; PLASMA-MEMBRANE; LIPID RAFTS; CELL-LINE; TRANSPORTERS; TRANSLOCATION; EXPRESSION; RECEPTORS; THROMBIN	In insulin- responsive tissues, insulin is a potent activator of protein kinase B ( PKB)- mediated glucose uptake through the facilitative glucose transporter GLUT4. In platelets, glucose uptake is mediated through GLUT3, which is present in plasma ( 15%) and intracellular alpha- granule ( 85%) membranes. Here we report the PKB- mediated glucose uptake by platelets by agents that do ( thrombin) or do not ( insulin) induce alpha- granule translocation to the plasma membrane. Both thrombin and insulin activate PKB and induce glucose uptake albeit with different kinetics. Inhibition of PKB by the pharmacological inhibitor ML- 9 decreases thrombin- induced alpha- granule release and thrombin- and insulin- induced glucose uptake. At low glucose ( 0.1 mM), both agents stimulate glucose uptake by lowering the K-m for glucose ( thrombin and insulin) and increasing V-max ( thrombin). At high glucose ( 5 mM), stimulation of glucose uptake by insulin disappears, and insulin becomes an inhibitor of thrombin- induced glucose uptake via mechanisms independent of PKB. We conclude that in platelets glucose transport through GLUT3 is regulated by changes in surface expression and affinity modulation, which are both under control of PKB.	Univ Utrecht, Med Ctr, Dept Hematol, Thrombosis & Haemostasis Lab, NL-3584 CX Utrecht, Netherlands; Univ Utrecht, Biomembrane Inst, NL-3584 CX Utrecht, Netherlands	Utrecht University; Utrecht University	Akkerman, JWN (corresponding author), Univ Utrecht, Med Ctr, Dept Hematol, Thrombosis & Haemostasis Lab, HP G03-647,Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.	j.w.n.akkerman@azu.nl	Urbanus, Rolf/AAG-7933-2020	Urbanus, Rolf/0000-0002-1601-9393				AKKERMAN JWN, 1987, PLATELET RESPONSES M, V2, P189; Arbuckle MI, 1996, BIOCHEMISTRY-US, V35, P16519, DOI 10.1021/bi962210n; Bettache N, 2003, J CELL SCI, V116, P2277, DOI 10.1242/jcs.00424; Bickel PE, 2002, AM J PHYSIOL-ENDOC M, V282, pE1, DOI 10.1152/ajpendo.2002.282.1.E1; Cenni V, 2003, CELL MOL LIFE SCI, V60, P2710, DOI 10.1007/s00018-003-3349-4; Chamberlain LH, 2002, J BIOL CHEM, V277, P49750, DOI 10.1074/jbc.M206936200; Chen JH, 2004, BLOOD, V104, P1703, DOI 10.1182/blood-2003-10-3428; Cho MJ, 2002, BLOOD, V99, P2442, DOI 10.1182/blood.V99.7.2442; COLVILLE CA, 1993, BIOCHEM J, V290, P701, DOI 10.1042/bj2900701; Conejo R, 2001, J CELL PHYSIOL, V187, P96, DOI 10.1002/1097-4652(2001)9999:9999<::AID-JCP1058>3.0.CO;2-V; den Dekker E, 2002, J BIOL CHEM, V277, P29321, DOI 10.1074/jbc.M111390200; Dwyer DS, 2001, PROTEINS, V42, P531, DOI 10.1002/1097-0134(20010301)42:4<531::AID-PROT110>3.3.CO;2-0; ESTRADA DE, 1994, METABOLISM, V43, P591, DOI 10.1016/0026-0495(94)90201-1; Ferreira IA, 2004, J BIOL CHEM, V279, P3254, DOI 10.1074/jbc.M305474200; Fiory F, 2004, J BIOL CHEM, V279, P11137, DOI 10.1074/jbc.M308751200; Flaumenhaft R, 2003, ARTERIOSCL THROM VAS, V23, P1152, DOI 10.1161/01.ATV.0000075965.88456.48; Foran PGP, 1999, J BIOL CHEM, V274, P28087, DOI 10.1074/jbc.274.40.28087; FUGMAN DA, 1990, BLOOD, V75, P1252; Gachet C, 2001, THROMB HAEMOSTASIS, V86, P222; GREENBERG SM, 1988, BLOOD, V72, P1968; Grover-McKay M, 1999, BBA-BIOMEMBRANES, V1416, P145, DOI 10.1016/S0005-2736(98)00216-8; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hajduch E, 1998, DIABETES, V47, P1006, DOI 10.2337/diabetes.47.7.1006; Hardy AR, 2004, BLOOD, V104, P1745, DOI 10.1182/blood-2004-02-0534; Heijnen HFG, 1997, J CELL BIOL, V138, P323, DOI 10.1083/jcb.138.2.323; Hill MM, 2002, CURR BIOL, V12, P1251, DOI 10.1016/S0960-9822(02)00973-9; HOFSTEE BHJ, 1959, NATURE, V184, P1296, DOI 10.1038/1841296b0; Hruz PW, 2001, MOL MEMBR BIOL, V18, P183; Joost HG, 2002, AM J PHYSIOL-ENDOC M, V282, pE974, DOI 10.1152/ajpendo.00407.2001; Knott RM, 1996, BIOCHEM J, V318, P313, DOI 10.1042/bj3180313; Kroner C, 2000, J BIOL CHEM, V275, P27790, DOI 10.1074/jbc.M000540200; Mairhofer M, 2002, BLOOD, V100, P897, DOI 10.1182/blood.V100.3.897; Moxham CM, 1996, NATURE, V379, P840, DOI 10.1038/379840a0; Nieuwland R, 1997, CIRCULATION, V96, P3534; NISHIMURA H, 1993, J BIOL CHEM, V268, P8514; OGURA M, 1985, BLOOD, V66, P1384; Rosado JA, 2000, J BIOL CHEM, V275, P9110, DOI 10.1074/jbc.275.13.9110; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Schwarz UR, 2001, BIOCHEM PHARMACOL, V62, P1153, DOI 10.1016/S0006-2952(01)00760-2; Somwar R, 2001, J BIOL CHEM, V276, P46079, DOI 10.1074/jbc.M109093200; Sorbara LR, 1997, BIOCHEM J, V328, P511; Stuart CA, 2001, METABOLISM, V50, P771, DOI 10.1053/meta.2001.24202; Troussard AA, 2003, J BIOL CHEM, V278, P22374, DOI 10.1074/jbc.M303083200; Woulfe D, 2004, J CLIN INVEST, V113, P441, DOI 10.1172/JCI200420267	45	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32625	32633		10.1074/jbc.M507221200	http://dx.doi.org/10.1074/jbc.M507221200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16049004	hybrid			2022-12-25	WOS:000231920300010
J	Grayson, C; Molday, RS				Grayson, C; Molday, RS			Dominant negative mechanism underlies autosomal dominant Stargardt-like macular dystrophy linked to mutations in ELOVL4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA-ELONGASE; RECESSIVE RETINITIS-PIGMENTOSA; PHOTORECEPTOR DISK MEMBRANES; CHAIN FATTY-ACIDS; DOCOSAHEXAENOIC ACID; PARTIAL-PURIFICATION; QUALITY-CONTROL; MUTANT ELOVL4; RIM PROTEIN; GENE ABCR	ELOVL4(elongation of very long chain fatty acids 4) is a member of the ELO family of proteins involved in the biosynthesis of very long chain fatty acids. Protein truncation mutations in ELOVL4 have been identified in patients with autosomal dominant Stargardt-like macular degeneration. To determine whether a dominant negative mechanism is responsible for the autosomal dominant inheritance pattern of this disease, we studied the subcellular localization and interaction of wild type and mutant ELOVL4 in COS-7 and HEK 293T cultured cells by immunofluorescence and co-immunoprecipitation. Wild type ELOVL4 containing an endoplasmic reticulum retention sequence was localized to the endoplasmic reticulum as expected. In contrast, disease-associated C-terminal truncation ELOVL4 mutants accumulated as large inclusions exhibiting aggresome-like characteristics in a juxtanuclear position within COS-7 cells. When the wild type and mutant proteins were co-expressed in cultured cells, wild type ELOVL4 co-purified with mutant ELOVL4 on an immunoaffinity column and co-localized with the mutant protein in aggresome-like inclusions adjacent to the nucleus. These results indicate that wild type and mutant ELOVL4 form a complex that exhibits an abnormal subcellular localization found for individually expressed mutant ELOVL4. From these studies, we conclude that disease-linked C-terminal truncation mutants of ELOVL4 exert a dominant negative effect on wild type ELOVL4, altering its subcellular localization. This dominant negative mechanism contributes to the autosomal dominant inheritance of Stargardt-like macular dystrophy.	Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Ophthalmol & Visual Sci, Ctr Mol Res, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia	Molday, RS (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada.	molday@interchange.ubc.ca			NEI NIH HHS [EY 02422] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY002422] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ahn J, 2000, J BIOL CHEM, V275, P20399, DOI 10.1074/jbc.M000555200; Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805; Ambasudhan R, 2004, GENOMICS, V83, P615, DOI 10.1016/j.ygeno.2003.10.004; Anderson RE, 1999, LIPIDS, V34, pS235, DOI 10.1007/BF02562304; Beharry S, 2004, J BIOL CHEM, V279, P53972, DOI 10.1074/jbc.M405216200; Bernstein PS, 2001, INVEST OPHTH VIS SCI, V42, P3331; BESSOULE JJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P475, DOI 10.1016/0003-9861(89)90315-9; BRAUN A, 1995, AM J HUM GENET, V56, P854; Bungert S, 2001, J BIOL CHEM, V276, P23539, DOI 10.1074/jbc.M101902200; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CINTI DL, 1992, PROG LIPID RES, V31, P1, DOI 10.1016/0163-7827(92)90014-A; CONVERSE CA, 1983, T OPHTHAL SOC UK, V103, P508; Cremers FPM, 1998, HUM MOL GENET, V7, P355, DOI 10.1093/hmg/7.3.355; Domergue F, 2000, LIPIDS, V35, P487, DOI 10.1007/s11745-000-548-4; Donoso LA, 2001, SURV OPHTHALMOL, V46, P149, DOI 10.1016/S0039-6257(01)00251-X; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; FEHLING E, 1992, BIOCHIM BIOPHYS ACTA, V1126, P88, DOI 10.1016/0005-2760(92)90221-G; FLIESLER SJ, 1983, PROG LIPID RES, V22, P79; Garcia-Mata R, 1999, J CELL BIOL, V146, P1239, DOI 10.1083/jcb.146.6.1239; GONG JX, 1992, INVEST OPHTH VIS SCI, V33, P2596; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; HOFFMAN DR, 1995, INVEST OPHTH VIS SCI, V36, P1009; HOLMAN RT, 1994, LIPIDS, V29, P61, DOI 10.1007/BF02537092; Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303; Illing ME, 2002, J BIOL CHEM, V277, P34150, DOI 10.1074/jbc.M204955200; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Karan G, 2005, P NATL ACAD SCI USA, V102, P4164, DOI 10.1073/pnas.0407698102; Karan G, 2004, MOL VIS, V10, P248; Kedzierski W, 2001, P NATL ACAD SCI USA, V98, P7718, DOI 10.1073/pnas.141124198; Klumperman J, 2000, CURR OPIN CELL BIOL, V12, P445, DOI 10.1016/S0955-0674(00)00115-0; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Lagali PS, 2003, INVEST OPHTH VIS SCI, V44, P2841, DOI 10.1167/iovs.02-0991; Loewen CJR, 2003, MOL BIOL CELL, V14, P3400, DOI 10.1091/mbc.e03-02-0077; MACKENZIE D, 1982, J BIOL CHEM, V257, P7100; Mandal MNA, 2004, GENOMICS, V83, P626, DOI 10.1016/j.ygeno.2003.09.020; Martinez-Mir A, 1998, NAT GENET, V18, P11, DOI 10.1038/ng0198-11; Maude MB, 1998, INVEST OPHTH VIS SCI, V39, P2164; Maugeri A, 2000, AM J HUM GENET, V67, P960, DOI 10.1086/303079; Maugeri A, 2004, INVEST OPHTH VIS SCI, V45, P4263, DOI 10.1167/iovs.04-0078; Molday LL, 2001, INVEST OPHTH VIS SCI, V42, P816; MOSSER J, 1994, HUM MOL GENET, V3, P265, DOI 10.1093/hmg/3.2.265; Oh CS, 1997, J BIOL CHEM, V272, P17376, DOI 10.1074/jbc.272.28.17376; Rapp LM, 2000, INVEST OPHTH VIS SCI, V41, P1200; Rivolta C, 2003, MOL VIS, V9, P49; Rotstein NP, 1996, J NEUROCHEM, V66, P1851; Saliba RS, 2002, J CELL SCI, V115, P2907; Sanders CR, 2004, ANNU REV BIOPH BIOM, V33, P25, DOI 10.1146/annurev.biophys.33.110502.140348; SHANKLIN J, 1994, BIOCHEMISTRY-US, V33, P12787, DOI 10.1021/bi00209a009; Sprecher H, 1995, J LIPID RES, V36, P2471; Suh M, 2000, PEDIATR RES, V48, P524, DOI 10.1203/00006450-200010000-00017; Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269; Tvrdik P, 2000, J CELL BIOL, V149, P707, DOI 10.1083/jcb.149.3.707; Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9; Westerberg R, 2004, J BIOL CHEM, V279, P5621, DOI 10.1074/jbc.M310529200; Zhang K, 2001, NAT GENET, V27, P89, DOI 10.1038/83817; Zhang XM, 2003, MOL VIS, V9, P301	58	72	74	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32521	32530		10.1074/jbc.M503411200	http://dx.doi.org/10.1074/jbc.M503411200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16036915	hybrid			2022-12-25	WOS:000231794800061
J	Banelli, B; Gelvi, I; Di Vinci, A; Scaruffi, P; Casciano, I; Allemanni, G; Bonassi, S; Tonini, GP; Romani, M				Banelli, B; Gelvi, I; Di Vinci, A; Scaruffi, P; Casciano, I; Allemanni, G; Bonassi, S; Tonini, GP; Romani, M			Distinct CpG methylation profiles characterize different clinical groups of neuroblastic tumors	ONCOGENE			English	Article						neuroblastoma; ganglioneuroma; methylation; methylator phenotype	RECEPTOR-BETA EXPRESSION; DNA METHYLATION; P73 GENE; PROMOTER METHYLATION; COLORECTAL-CANCER; BREAST-CANCER; HYPERMETHYLATION; DELTA-NP73; TUMORIGENESIS; PHENOTYPE	The hypermethylation of CpG islands within gene promoter regions is an epigenetic phenomenon that is often, but not always, associated with the transcriptional silencing of downstream genes and contributes to carcinogenesis. We have determined the pattern of methylation of several genes involved in distinct biological pathways, including cell proliferation and apoptosis, in neuroblastoma and in the nonmalignant ganglioneuroma. The purpose of this work was to search for epigenetic signatures that could be associated with defined clinical and biological parameters and that, in prospective, could identify specific risk categories among the patients. We have analysed 31 malignant neuroblastoma with or without MYCN amplification and 13 benign ganglioneuroma and we have observed dramatic differences in the methylation pattern of five genes (CASP8, 14.3.3 sigma, Delta N p73, RASSF1A and DCR2) between these tumors indicating that this phenomenon is not tissue-specific and can be considered as cancer-dependent. Furthermore, the methylation pattern of 14.3.3 sigma, RASSF1A and of an intragenic segment of CASP8 was significantly different between MYCN amplified and single copy neuroblastoma suggesting a specific role of epigenetic alterations in aggressive neuroblastoma.	Ist Nazl Ric Canc, IST Genova, Environm Epidemiol & Biostat Lab, I-16132 Genoa, Italy	University of Genoa; IRCCS AOU San Martino IST	Romani, M (corresponding author), Ist Nazl Ric Canc, IST Genova, Environm Epidemiol & Biostat Lab, Largo Rosanna Benzi 10, I-16132 Genoa, Italy.	massimo.romani@istge.it	Bonassi, Stefano/ABI-6281-2020; Banelli, Barbara/Y-1151-2019; Scaruffi, Paola/AAB-3999-2020	Bonassi, Stefano/0000-0003-3833-6717; Banelli, Barbara/0000-0003-1505-7141; casciano, ida/0000-0003-1776-670X; scaruffi, paola/0000-0001-9799-1661				Alaminos M, 2004, JNCI-J NATL CANCER I, V96, P1208, DOI 10.1093/jnci/djh224; Banelli B, 2000, ONCOGENE, V19, P4553, DOI 10.1038/sj.onc.1203807; Banelli B, 2002, NAT MED, V8, P1333, DOI 10.1038/nm1202-1333; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Casciano I, 2002, CELL DEATH DIFFER, V9, P246, DOI 10.1038/sj.cdd.4400993; Casciano I, 2002, CELL DEATH DIFFER, V9, P343, DOI 10.1038/sj.cdd.4400992; Cheung B, 1998, ONCOGENE, V17, P751, DOI 10.1038/sj.onc.1201982; Corn PG, 1999, CANCER RES, V59, P3352; Di Vinci A, 2005, INT J CANCER, V114, P414, DOI 10.1002/ijc.20771; Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024; Esteller M, 2003, LANCET ONCOL, V4, P351, DOI 10.1016/S1470-2045(03)01115-X; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Harada K, 2002, ONCOGENE, V21, P4345, DOI 10.1038/sj.onc.1205446; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; KALBFLEISCH JD, 1980, STAT ANAL FAILTURE T; Kawano S, 1999, BLOOD, V94, P1113; Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Romani M, 1999, INT J CANCER, V84, P365, DOI 10.1002/(SICI)1097-0215(19990820)84:4<365::AID-IJC6>3.0.CO;2-X; Sadri R, 1996, NUCLEIC ACIDS RES, V24, P5058, DOI 10.1093/nar/24.24.5058; Shimada H, 1999, CANCER, V86, P349, DOI 10.1002/(SICI)1097-0142(19990715)86:2<349::AID-CNCR20>3.3.CO;2-P; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; TONINI GP, 1993, EUR J CANCER, V28, P1000; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; van Noesel MM, 2002, CANCER RES, V62, P2157; van Rijnsoever M, 2003, CLIN CANCER RES, V9, P2898; Westermann F, 2002, CANCER LETT, V184, P127, DOI 10.1016/S0304-3835(02)00199-4; Widschwendter M, 1997, CANCER RES, V57, P4158; Yang QW, 2004, CLIN CANCER RES, V10, P8493, DOI 10.1158/1078-0432.CCR-04-1331	32	60	62	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 25	2005	24	36					5619	5628		10.1038/sj.onc.1208722	http://dx.doi.org/10.1038/sj.onc.1208722			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	956JN	16044164				2022-12-25	WOS:000231296100008
J	Cuzzocrea, S; Ayroldi, E; Di Paola, R; Agostini, M; Mazzon, E; Bruscoli, S; Genovese, T; Ronchetti, S; Caputi, AP; Riccardi, C				Cuzzocrea, S; Ayroldi, E; Di Paola, R; Agostini, M; Mazzon, E; Bruscoli, S; Genovese, T; Ronchetti, S; Caputi, AP; Riccardi, C			Role of glucocorticoid-induced TNF receptor family gene (GITR) in collagen-induced arthritis	FASEB JOURNAL			English	Article						rheumatoid arthritis; T lymphocyte activity; chemokines	IMMUNOREGULATORY T-CELLS; RHEUMATOID-ARTHRITIS; II COLLAGEN; AUTOIMMUNE ARTHRITIS; NITRIC-OXIDE; ENHANCED PRODUCTION; INTERFERON-GAMMA; MICE; LIGAND; ACTIVATION	In rheumatoid arthritis (RA), a widespread autoimmune/ inflammatory joint disease, early activation of effector CD4+ T lymphocytes, and cytokine production is followed by recruitment of other inflammatory cells, production of a range of inflammation mediators, tissue damage, and disease. GITR (glucocorticoid- induced TNFR family- related gene), a costimulatory molecule for T lymphocytes, increases CD4+ CD25- effector T cell activation while inhibiting suppressor activity of CD4+ CD25- T regulatory (Treg) cells. We analyzed the role of GITR in type II collagen (CII) - induced arthritis (CIA) using GITR -/- and GITR+/+ mice. Results indicate significantly less CIA induction in GITR+/+ mice than in GITR+/+ mice, with marked differences in erythema, edema, neutrophil infiltration, joint injury, and bone erosion. Production of IFN gamma, IL-6, TNF alpha, MIP-1 alpha, and MIP-2, inducible NOS (iNOS), COX-2, and nitrotyrosine poly-ADP-ribose (PAR) were also less in CII-treated GITR+/+ mice. Although CD4+ CD25+ Treg cells from GITR-/- and GITR-/- CII- challenged mice exerted similar suppressor activity in vitro, GITR triggering abrogated GITR+/+ Treg suppressor activity and costimulated CD4+ CD25- GITR+/+ effector cells. Furthermore, Treg cells from GITR-/- protected more than Treg cells from GITR+/+ mice against CIA when cotransferred with Treg-depleted splenocytes from arthritic GITR+/+ animals into severe combined immunodeficient (SCID) mice. In conclusion, GITR plays a critical role in the immunological response against CII and in the development of CIA.	Policlin Univ, Dipartimento Clin & Sperimentale Med & Farmacol, I-98123 Messina, Italy; Univ Perugia, Dipartimento Med Clin & Sperimentale, Sez Farmacol Tossicol & Chemioterapia, I-06100 Perugia, Italy	AOU Policlinico Gaetano Martino; University of Messina; University of Perugia	Riccardi, C (corresponding author), Policlin Univ, Dipartimento Clin & Sperimentale Med & Farmacol, I-98123 Messina, Italy.	salvator@unime.it; riccardi@unipg.it	Riccardi, Carlo/N-4610-2014; Agostini, Massimiliano/AAE-7971-2019; Ronchetti, Simona/L-2325-2013; di paola, rosanna/U-4356-2019; Agostini, Massimiliano/G-9579-2014; Mazzon, Emanuela/AAL-4334-2020	Riccardi, Carlo/0000-0001-9257-3997; Agostini, Massimiliano/0000-0003-3124-2072; Ronchetti, Simona/0000-0002-5639-4243; di paola, rosanna/0000-0001-6725-8581; Agostini, Massimiliano/0000-0003-3124-2072; GENOVESE, Tiziana/0000-0002-3335-7327; bruscoli, stefano/0000-0003-0313-1615; mazzon, emanuela/0000-0002-5073-717X; Ayroldi, Emira/0000-0002-9073-7297				Alonzi T, 1998, J EXP MED, V187, P461, DOI 10.1084/jem.187.4.461; Bardos T, 2003, ARTHRITIS RES THER, V5, pR106, DOI 10.1186/ar624; Bauerova K, 1999, GEN PHYSIOL BIOPHYS, V18, P15; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Beutler B, 1998, BLOOD CELL MOL DIS, V24, P216, DOI 10.1006/bcmd.1998.0187; BOISSIER MC, 1995, EUR J IMMUNOL, V25, P1184, DOI 10.1002/eji.1830250508; Cannon GW, 1996, ARTHRITIS RHEUM-US, V39, P1677, DOI 10.1002/art.1780391010; Cuzzocrea S, 2003, ARTHRITIS RHEUM-US, V48, P3544, DOI 10.1002/art.11351; Cuzzocrea S, 2001, EUR CYTOKINE NETW, V12, P568; Cuzzocrea S, 2000, AM J PATHOL, V157, P2065, DOI 10.1016/S0002-9440(10)64845-6; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Gerli R, 2001, TRENDS IMMUNOL, V22, P72, DOI 10.1016/S1471-4906(00)01829-9; HARRIS ED, 1990, NEW ENGL J MED, V323, P996; HOLMDAHL R, 1990, IMMUNOL REV, V118, P193, DOI 10.1111/j.1600-065X.1990.tb00817.x; HOLMDAHL R, 1989, CLIN EXP RHEUMATOL, V7, pS51; Jung HW, 2004, EXP MOL MED, V36, P13, DOI 10.1038/emm.2004.2; KADOWAKI KM, 1994, CLIN EXP IMMUNOL, V97, P212; KAKIMOTO K, 1988, J IMMUNOL, V140, P78; KOCH AE, 1994, J CLIN INVEST, V93, P921, DOI 10.1172/JCI117097; KOCH AE, 1992, J CLIN INVEST, V90, P772, DOI 10.1172/JCI115950; Kohm AP, 2004, J IMMUNOL, V172, P4686, DOI 10.4049/jimmunol.172.8.4686; Lamhamedi-Cherradi SE, 2003, NAT IMMUNOL, V4, P255, DOI 10.1038/ni894; Liu ZG, 2003, J CLIN INVEST, V112, P1332, DOI 10.1172/JCI200319209; Luross JA, 2002, ARTHRITIS RHEUM, V46, P1671, DOI 10.1002/art.10328; Mackay F, 2002, CURR OPIN IMMUNOL, V14, P783, DOI 10.1016/S0952-7915(02)00407-7; Mauri C, 1996, EUR J IMMUNOL, V26, P1511, DOI 10.1002/eji.1830260716; McHugh RS, 2002, IMMUNITY, V16, P311, DOI 10.1016/S1074-7613(02)00280-7; MIESEL R, 1995, INFLAMMATION, V19, P379, DOI 10.1007/BF01534394; Morgan ME, 2003, ARTHRITIS RHEUM, V48, P1452, DOI 10.1002/art.11063; Myers LK, 2000, ARTHRITIS RHEUM-US, V43, P2687, DOI 10.1002/1529-0131(200012)43:12<2687::AID-ANR8>3.0.CO;2-9; Nocentini G, 1997, P NATL ACAD SCI USA, V94, P6216, DOI 10.1073/pnas.94.12.6216; Nurieva RI, 2003, J CLIN INVEST, V111, P701, DOI 10.1172/JCI200317321; OCHI T, 2003, BIOCHEM PHARMACOL, V66, P1555; PIGUET PF, 1992, IMMUNOLOGY, V77, P510; Ronchetti S, 2002, BLOOD, V100, P350, DOI 10.1182/blood-2001-12-0276; Ronchetti S, 2004, EUR J IMMUNOL, V34, P613, DOI 10.1002/eji.200324804; Rothstein DM, 2003, IMMUNOL REV, V196, P85, DOI 10.1046/j.1600-065X.2003.00088.x; Rudolphi U, 1997, ARTHRITIS RHEUM, V40, P1409, DOI 10.1002/art.1780400808; Shimizu J, 2002, NAT IMMUNOL, V3, P135, DOI 10.1038/ni759; Sigidin YA, 2001, SCAND J RHEUMATOL, V30, P203; Spinicelli S, 2002, CELL DEATH DIFFER, V9, P1382, DOI 10.1038/sj.cdd.4401140; Stasiuk LM, 1996, CELL IMMUNOL, V173, P269, DOI 10.1006/cimm.1996.0277; Stephens GL, 2004, J IMMUNOL, V173, P5008, DOI 10.4049/jimmunol.173.8.5008; Szabo C, 1997, J EXP MED, V186, P1041, DOI 10.1084/jem.186.7.1041; Szabo C, 1998, P NATL ACAD SCI USA, V95, P3867, DOI 10.1073/pnas.95.7.3867; Tada Y, 1999, J IMMUNOL, V162, P203; Tak PP, 1996, CLIN IMMUNOL IMMUNOP, V80, P129, DOI 10.1006/clin.1996.0106; TAKAI Y, 1989, ARTHRITIS RHEUM, V32, P594, DOI 10.1002/anr.1780320513; THORBECKE GJ, 1992, P NATL ACAD SCI USA, V89, P7375, DOI 10.1073/pnas.89.16.7375; Thornton S, 1999, ARTHRITIS RHEUM, V42, P1109, DOI 10.1002/1529-0131(199906)42:6<1109::AID-ANR7>3.0.CO;2-7; Tone M, 2003, P NATL ACAD SCI USA, V100, P15059, DOI 10.1073/pnas.2334901100; Uraushihara K, 2003, J IMMUNOL, V171, P708, DOI 10.4049/jimmunol.171.2.708; WATSON WC, 1990, J EXP MED, V172, P1331, DOI 10.1084/jem.172.5.1331; Yamanishi Y, 2002, AM J PATHOL, V160, P123, DOI 10.1016/S0002-9440(10)64356-8; Yoshioka T, 2000, EUR J IMMUNOL, V30, P2815, DOI 10.1002/1521-4141(200010)30:10<2815::AID-IMMU2815>3.0.CO;2-#	55	87	100	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1253	1265		10.1096/fj.04-3556com	http://dx.doi.org/10.1096/fj.04-3556com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16051692				2022-12-25	WOS:000231843700032
J	Mahn, K; Borras, C; Knock, GA; Taylor, P; Khan, IY; Sugden, D; Poston, L; Ward, JP; Sharpe, RM; Vina, J; Aaronson, PI; Mann, GE				Mahn, K; Borras, C; Knock, GA; Taylor, P; Khan, IY; Sugden, D; Poston, L; Ward, JP; Sharpe, RM; Vina, J; Aaronson, PI; Mann, GE			Dietary soy isoflavone-induced increases in antioxidant and eNOS gene expression lead to improved endothelial function and reduced blood pressure in vivo	FASEB JOURNAL			English	Article						soy protein; phytoestrogens; oxidative stress	CORONARY-HEART-DISEASE; ESTROGEN-RECEPTOR; POSTMENOPAUSAL WOMEN; ENZYME EXPRESSION; OXIDATIVE STRESS; GENISTEIN; PHYTOESTROGENS; CHANNELS; MODULATION; RELAXATION	Epidemiological evidence suggests that populations consuming large amounts of soy protein have a reduced incidence of coronary heart disease (1-5). The cardiovascular risks associated with conventional hormone replacement therapy in postmenopausal women (5-7) have precipitated a search for alternative estrogen receptor modulators. Here we report that long-term feeding of rats with a soy protein-rich (SP) diet during gestation and adult life results in decreased oxidative stress, improved endothelial function, and reduced blood pressure in vivo measured by radiotelemetry in aged male offspring. Improved vascular reactivity in animals fed an SP diet was paralleled by increased mitochondrial glutathione and mRNA levels for endothelial nitric oxide synthase (eNOS) and the antioxidant enzymes manganese superoxide dismutase and cytochrome c oxidase. Reduced eNOS and antioxidant gene expression, impaired endothelial function, and elevated blood pressure in animals fed a soy-deficient diet was reversed after refeeding them an SP diet for 6 months. Our findings suggest that an SP diet increases eNOS and antioxidant gene expression in the vasculature and other tissues, resulting in reduced oxidative stress and increased NO bioavailability. The improvement in endothelial function, increased gene expression, and reduced blood pressure by soy isoflavones have implications for alternative therapy for postmenopausal women and patients at risk of coronary heart disease.	Kings Coll London, Sch Biomed & Hlth Sci, Cardiovasc Div, London SE1 1UL, England; Kings Coll London, Sch Biomed & Hlth Sci, Reprod Hlth Endocrinol & Dev Div, London SE1 1UL, England; Kings Coll London, Sch Biomed & Hlth Sci, Asthma Allergy & Lung Biol Div, London SE1 1UL, England; Kings Coll London, Sch Med, London SE1 1UL, England; Univ Valencia, Fac Med, Dept Fisiol, Valencia, Spain; Ctr Reprod Biol, Human Reprod Sci Unit, Med Res Council, Edinburgh EH3 9ET, Midlothian, Scotland	University of London; King's College London; University of London; King's College London; University of London; King's College London; University of London; King's College London; University of Valencia; UK Research & Innovation (UKRI); Medical Research Council UK (MRC)	Mann, GE (corresponding author), Kings Coll London, Sch Biomed & Hlth Sci, Cardiovasc Div, Guys Campus, London SE1 1UL, England.	giovanni.mann@kcl.ac.uk	Vina, Jose/AAB-3069-2021; borras, consuelo/Y-3407-2019; Sharpe, Richard M/D-2725-2013	Vina, Jose/0000-0001-9709-0089; borras, consuelo/0000-0003-4606-1792; Sharpe, Richard M/0000-0003-1686-8085; Mann, Giovanni/0000-0001-7311-2044; Taylor, Paul David/0000-0002-4740-4307; Aaronson, Philip Irving/0000-0003-1086-1202	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADLERCREUTZ H, 1993, LANCET, V342, P1209, DOI 10.1016/0140-6736(93)92188-Y; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; ANDERSON JW, 1995, NEW ENGL J MED, V333, P276, DOI 10.1056/NEJM199508033330502; Armitage JA, 2004, J PHYSIOL-LONDON, V561, P355, DOI 10.1113/jphysiol.2004.072009; Atanassova N, 2000, ENDOCRINOLOGY, V141, P3898, DOI 10.1210/en.141.10.3898; BARRETTCONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1861, DOI 10.1001/jama.265.14.1861; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; Borras C, 2005, AGING CELL, V4, P113, DOI 10.1111/j.1474-9726.2005.00151.x; Borras C, 2003, FREE RADICAL BIO MED, V34, P546, DOI 10.1016/S0891-5849(02)01356-4; Chambliss KL, 2002, ENDOCR REV, V23, P665, DOI 10.1210/er.2001-0045; Clark JT, 2004, ENDOCRINE, V25, P173, DOI 10.1385/ENDO:25:2:173; DAS KC, 1995, AM J PHYSIOL-LUNG C, V269, pL588, DOI 10.1152/ajplung.1995.269.5.L588; Dick GM, 2001, J BIOL CHEM, V276, P34594, DOI 10.1074/jbc.M104689200; Doerge DR, 2000, RAPID COMMUN MASS SP, V14, P673, DOI 10.1002/(SICI)1097-0231(20000430)14:8<673::AID-RCM935>3.3.CO;2-6; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Farhat MY, 1996, FASEB J, V10, P615, DOI 10.1096/fasebj.10.5.8621060; Figtree GA, 2000, J AM COLL CARDIOL, V35, P1977, DOI 10.1016/S0735-1097(00)00645-8; Gluckman PD, 2004, SCIENCE, V305, P1733, DOI 10.1126/science.1095292; Griendling KK, 2003, CIRCULATION, V108, P1912, DOI 10.1161/01.CIR.0000093660.86242.BB; Hodgson JM, 1999, AM J HYPERTENS, V12, P47, DOI 10.1016/S0895-7061(98)00216-7; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; JOY S, 2003, J PHYSL P, V547, pC137; Katzenellenbogen BS, 1996, BIOL REPROD, V54, P287, DOI 10.1095/biolreprod54.2.287; Kelly MJ, 2001, TRENDS ENDOCRIN MET, V12, P152, DOI 10.1016/S1043-2760(01)00377-0; Khan LY, 2003, HYPERTENSION, V41, P168, DOI 10.1161/01.HYP.0000047511.97879.FC; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Lee SY, 2003, FASEB J, V17, P947, DOI 10.1096/fj.02-0807fje; Lissin LW, 2000, J AM COLL CARDIOL, V35, P1403; McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884; Mendelsohn ME, 1999, NEW ENGL J MED, V340, P1801, DOI 10.1056/NEJM199906103402306; Mishra SK, 2000, CARDIOVASC RES, V46, P539, DOI 10.1016/S0008-6363(00)00049-3; Montano MM, 2004, ONCOGENE, V23, P2442, DOI 10.1038/sj.onc.1207358; Nestel P, 2003, CURR OPIN LIPIDOL, V14, P3, DOI 10.1097/00041433-200302000-00002; Ritchie MR, 2004, BRIT J NUTR, V91, P447, DOI 10.1079/BJN20031062; Rivas M, 2002, J NUTR, V132, P1900, DOI 10.1093/jn/132.7.1900; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Ruehlmann DO, 1998, FASEB J, V12, P613, DOI 10.1096/fasebj.12.7.613; Setchell KDR, 1999, J NUTR, V129, p758S, DOI 10.1093/jn/129.3.758S; SIMONS LA, 2000, AM J CARDIOL, V3, P47; Squadrito F, 2003, AM J MED, V114, P470, DOI 10.1016/S0002-9343(03)00059-7; STEINBERG KK, 1991, JAMA-J AM MED ASSOC, V265, P1985, DOI 10.1001/jama.265.15.1985; Strehlow K, 2003, CIRC RES, V93, P170, DOI 10.1161/01.RES.0000082334.17947.11; Suzuki K, 2002, INT J CANCER, V99, P846, DOI 10.1002/ijc.10428; Teede HJ, 2003, ARTERIOSCL THROM VAS, V23, P1066, DOI 10.1161/01.ATV.0000072967.97296.4A; Tschugguel W, 2001, J CLIN ENDOCR METAB, V86, P3833, DOI 10.1210/jc.86.8.3833; Valverde MA, 1999, SCIENCE, V285, P1929, DOI 10.1126/science.285.5435.1929; Valverde Miguel A., 2002, Trends in Biochemical Sciences, V27, P172, DOI 10.1016/S0968-0004(02)02075-3; Walker HA, 2001, CIRCULATION, V103, P258, DOI 10.1161/01.CIR.103.2.258; Zhou LZH, 2001, FREE RADICAL BIO MED, V31, P1405, DOI 10.1016/S0891-5849(01)00719-5; Zhu Y, 2002, SCIENCE, V295, P505, DOI 10.1126/science.1065250	50	141	146	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1755	+		10.1096/fj.05-4008fje	http://dx.doi.org/10.1096/fj.05-4008fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16107535				2022-12-25	WOS:000231843700011
J	Yang, WL; Roland, IH; Godwin, AK; Xu, XX				Yang, WL; Roland, IH; Godwin, AK; Xu, XX			Loss of TNF-alpha-regulated COX-2 expression in ovarian cancer cells	ONCOGENE			English	Article						cyclooxygenases; ovarian epithelial cells; ovarian carcinomas; TNF-alpha	TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; CYCLOOXYGENASE-2 EXPRESSION; SIGNAL-TRANSDUCTION; PROSTAGLANDIN E-2; UP-REGULATION; IN-VITRO; INHIBITOR; OVULATION; APOPTOSIS	Cyclooxygenase 2 (COX-2) is often found overexpressed in cancer and is thought to have a role in carcinogenic promotion, and thus is a target for therapeutic intervention. Here, we investigated the regulation of COX-2 expression in normal and cancer ovarian surface epithelial cells. Tumor necrosis factor alpha (TNF-alpha) is a potent inducer of COX-2 expression in the ovarian surface epithelium and this regulation is a critical step in ovulation. We observed that TNF-alpha stimulated COX-2 expression in human primary and immortalized epithelial (HIO) cell lines. The stimulation was suppressed by inhibitors of several signaling pathways, indicating the collaboration of TNF-alpha-activated signaling pathways mediates the regulation of COX-2 expression. In five ovarian cancer cell lines analysed, four did not express detectable COX-2 and TNF-alpha failed to elicit COX-2 expression. In NIH:OVCAR-5, the only ovarian cancer cell line expressing COX-2, signal pathway inhibitors no longer affected TNF-alpha-induced COX-2 expression. Thus, we conclude that TNF-a mediated signaling is uncoupled from the modulation of COX-2 expression in ovarian cancer. The loss of COX-2 expression was also observed to associate closely with epithelial neoplastic morphological transformation. The frequent loss of COX-2 expression suggests in ovarian cancer, unlike in other epithelial cancers, COX-2 expression does not contribute to ovarian cancer malignancy.	Fox Chase Canc Ctr, Ovarian Canc Program, Philadelphia, PA 19111 USA; Fox Chase Canc Ctr, Tumor Cell Biol Program, Philadelphia, PA 19111 USA	Fox Chase Cancer Center; Fox Chase Cancer Center	Xu, XX (corresponding author), Fox Chase Canc Ctr, Ovarian Canc Program, 333 Cottman Ave, Philadelphia, PA 19111 USA.	x_xu@fccc.edu			NCI NIH HHS [R01 CA75389, P50 CA83638, R01 CA79716] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA083638, R01CA079716, R01CA075389] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKHMEDKHANOV AA, 2001, SOC GYNECOL ONCOL, V80, P286; Arnott CH, 2004, ONCOGENE, V23, P1902, DOI 10.1038/sj.onc.1207317; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes MN, 2002, CA-CANCER J CLIN, V52, P216, DOI 10.3322/canjclin.52.4.216; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRANNSTROM M, 1995, REPROD FERT DEVELOP, V7, P67, DOI 10.1071/RD9950067; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Chun KS, 2004, BIOCHEM PHARMACOL, V68, P1089, DOI 10.1016/j.bcp.2004.05.031; Cramer DW, 1998, LANCET, V351, P104, DOI 10.1016/S0140-6736(97)08064-1; Davis BJ, 1999, ENDOCRINOLOGY, V140, P2685, DOI 10.1210/en.140.6.2685; Denkert C, 2002, AM J PATHOL, V160, P893, DOI 10.1016/S0002-9440(10)64912-7; Dore M, 1998, J HISTOCHEM CYTOCHEM, V46, P77, DOI 10.1177/002215549804600110; DOWNS SM, 1982, AM J ANAT, V164, P265, DOI 10.1002/aja.1001640307; Duffy DM, 2001, MOL HUM REPROD, V7, P731, DOI 10.1093/molehr/7.8.731; ESPEY LL, 1994, BIOL REPROD, V50, P233, DOI 10.1095/biolreprod50.2.233; Ferrandina G, 2002, GYNECOL ONCOL, V85, P305, DOI 10.1006/gyno.2002.6620; Fong CY, 2000, AM J PHYSIOL-LUNG C, V279, pL201, DOI 10.1152/ajplung.2000.279.1.L201; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; Gupta RA, 2003, CANCER RES, V63, P906; HAMILTON TC, 1984, CANCER RES, V44, P5286; Howe LR, 2002, SEMIN ONCOL, V29, P111, DOI 10.1053/sonc.2002.34063; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Klimp AH, 2001, CANCER RES, V61, P7305; KOMORI A, 1993, CANCER RES, V53, P1982; Lal G, 2001, CANCER RES, V61, P6131; Leahy KM, 2002, CANCER RES, V62, P625; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; Liu CH, 2001, J BIOL CHEM, V276, P18563, DOI 10.1074/jbc.M010787200; MALIK STA, 1990, EUR J CANCER, V26, P1031, DOI 10.1016/0277-5379(90)90044-T; MALIK STA, 1989, INT J CANCER, V44, P918, DOI 10.1002/ijc.2910440529; Masferrer J, 2001, CANCER J, V7, pS144; Masferrer JL, 2000, CANCER RES, V60, P1306; Matsumoto Y, 2001, INT J MOL MED, V8, P31; Moore BC, 2000, CURR MED CHEM, V7, P1131, DOI 10.2174/0929867003374273; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; Munkarah AR, 2002, J SOC GYNECOL INVEST, V9, P168, DOI 10.1016/S1071-5576(02)00141-7; Murdoch WJ, 1997, J ANIM SCI, V75, P1601; Nabors LLB, 2003, CANCER RES, V63, P4181; Nasi ML, 2002, ANN ONCOL, V13, P1169, DOI 10.1093/annonc/mdf312; Ness RB, 1999, JNCI-J NATL CANCER I, V91, P1459, DOI 10.1093/jnci/91.17.1459; Ness RB, 2000, JNCI-J NATL CANCER I, V92, P163, DOI 10.1093/jnci/92.2.163; Norman RJ, 2001, LANCET, V358, P1287, DOI 10.1016/S0140-6736(01)06455-8; Okamura H, 1985, Adv Prostaglandin Thromboxane Leukot Res, V15, P597; OLD LJ, 1985, SCIENCE, V230, P630, DOI 10.1126/science.2413547; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Pall M, 2001, HUM REPROD, V16, P1323, DOI 10.1093/humrep/16.7.1323; PRESCOTT SM, 2000, BIOCHIM BIOPHYS ACTA, V1470, P69, DOI [10.1016/s0304-419x(00)00006-8), DOI 10.1016/S0304-419X(00)00006-8]; Richards JS, 2002, ANNU REV PHYSIOL, V64, P69, DOI 10.1146/annurev.physiol.64.081501.131029; Rodriguez-Burford C, 2002, CLIN CANCER RES, V8, P202; Roland IH, 2003, CANCER-AM CANCER SOC, V98, P2607, DOI 10.1002/cncr.11847; SCHILDER RJ, 1990, INT J CANCER, V45, P416, DOI 10.1002/ijc.2910450306; Shigemasa K, 2003, INT J ONCOL, V22, P99; SIEMENS CH, 1988, J CELL PHYSIOL, V134, P347, DOI 10.1002/jcp.1041340305; Singer CA, 2003, AM J PHYSIOL-LUNG C, V285, pL1087, DOI 10.1152/ajplung.00409.2002; Smith ER, 2004, CANCER EPIDEM BIOMAR, V13, P144, DOI 10.1158/1055-9965.EPI-461-2; Sorensen HT, 2003, BRIT J CANCER, V88, P1687, DOI 10.1038/sj.bjc.6600945; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Subbaramaiah K, 2003, TRENDS PHARMACOL SCI, V24, P96, DOI 10.1016/S0165-6147(02)00043-3; Suganuma M, 1999, CANCER RES, V59, P4516; Terranova PF, 1997, AM J REPROD IMMUNOL, V37, P50; Tiano HF, 2002, CANCER RES, V62, P3395; Tokuyama O, 2001, INT J MOL MED, V8, P603; Trifan OC, 2003, J CELL MOL MED, V7, P207, DOI 10.1111/j.1582-4934.2003.tb00222.x; Tsafriri A, 1999, EXP CLIN ENDOCR DIAB, V107, P1, DOI 10.1055/s-0029-1212066; Wang HB, 2004, J BIOL CHEM, V279, P10649, DOI 10.1074/jbc.M312203200; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Williams CS, 2000, CANCER RES, V60, P6045; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Yang DH, 2002, CANCER-AM CANCER SOC, V94, P2380, DOI 10.1002/cncr.10497; Yang WL, 2004, CANCER RES, V64, P1534, DOI 10.1158/0008-5472.CAN-03-2928	72	16	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2005	24	54					7991	8002		10.1038/sj.onc.1208943	http://dx.doi.org/10.1038/sj.onc.1208943			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	989EV	16044148				2022-12-25	WOS:000233656600006
J	Bockbrader, KM; Tan, MJ; Sun, Y				Bockbrader, KM; Tan, MJ; Sun, Y			A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells	ONCOGENE			English	Article						apoptosis; IAPs; Smac; anticancer drug; breast cancer	STRUCTURAL BASIS; LUNG-CANCER; CHEMOTHERAPEUTIC-AGENTS; PROTECTS CELLS; IAP FAMILY; XIAP; SMAC/DIABLO; ACTIVATION; INHIBITOR; CASPASE-3	Inhibitor of apoptosis protein (IAP) suppresses apoptosis through binding and inhibiting active caspases-3,-7 and -9 via its baculoviral IAP repeat (BIR) domains. During apoptosis the caspase inhibition by IAPs can be negatively regulated by a mitochondrial protein second mitochondrial-derived activator of caspase (Smac). Smac physically interacts with multiple IAPs and relieves their inhibitory effect on caspases-3,-7 and -9. Recently, a small molecule Smac-mimic compound (Smac-mimic), which potentiates TNF-related apoptosis-inducing ligand (TRAIL) and tumor necrosis factor (TNF)-alpha mediated cell death in glioblastoma T98G cells and HeLa cells, was identified and characterized. To determine the efficacy of this compound in breast cancer cells, we first measured protein expression of three IAPs: XIAP, cIAP-1, and cIAP-2 in nine independent breast cancer cell lines. Three cell lines were chosen: a high IAPs expressing line MDAMB231, and two low IAPs expressing lines, T47D and MDA-MB-453. The cell lines were tested for their sensitivity to Smac-mimic alone or in combination with TRAIL or etoposide. Acting alone, Smac-mimic was quite potent with a cytotoxic IC50 of 3.8 nM in high IAPs expressing MDA-MB-231 cells, but was inactive at a much higher concentration in low IAPs expressing T47D and MDA-MB-453 cells. In fact, as low as 2.5 nM of Smac-mimic alone was sufficient to activate caspase-3 and induce apoptosis in MDA-MB-231 cells. In combinational treatments with TRAIL or etoposide, Smac-mimic significantly sensitized cells to growth suppression in MDA-MB-231 cells, but to a lesser extent in T47D and MDA-MB-453 cells. Furthermore, it significantly synergized MDA-MB-231, but not T47D cells to apoptosis induced by either TRAIL or etoposide. Thus, in these cell lines, Smac-mimic acts in an apparent IAPs dependent manner to induce apoptosis alone as well as sensitizes breast cancer cells to TRAIL or etoposide induced apoptosis via caspase-3 activation.	Univ Michigan, Ctr Comprehens Canc, Div Canc Biol, Dept Radiat Oncol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Sun, Y (corresponding author), Univ Michigan, Ctr Comprehens Canc, Div Canc Biol, Dept Radiat Oncol, 4304 CCGC,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	sunyi@umich.edu	Sun, Yi/K-1025-2014	Sun, Yi/0000-0002-5841-4287				Arnt CR, 2002, J BIOL CHEM, V277, P44236, DOI 10.1074/jbc.M207578200; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Cao C, 2004, ONCOGENE, V23, P7047, DOI 10.1038/sj.onc.1207929; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Duan HJ, 1999, MOL CELL BIOL, V19, P3145; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Garber K, 2005, NAT BIOTECHNOL, V23, P409, DOI 10.1038/nbt0405-409; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Huang YH, 2001, CELL, V104, P781, DOI 10.1016/S0092-8674(01)00273-2; KERR JFR, 1971, J PATHOL, V105, P13, DOI 10.1002/path.1711050103; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Li L, 2004, SCIENCE, V305, P1471, DOI 10.1126/science.1098231; Lima RT, 2004, CANCER GENE THER, V11, P309, DOI 10.1038/sj.cgt.7700706; Makin G, 2000, CELL TISSUE RES, V301, P143, DOI 10.1007/s004419900160; McManus DC, 2004, ONCOGENE, V23, P8105, DOI 10.1038/sj.onc.1207967; McNeish IA, 2003, EXP CELL RES, V286, P186, DOI 10.1016/S0014-4827(03)00073-9; Nguyen JT, 2003, P NATL ACAD SCI USA, V100, P7533, DOI 10.1073/pnas.1031631100; Oost TK, 2004, J MED CHEM, V47, P4417, DOI 10.1021/jm040037k; Pardo OE, 2003, MOL CELL BIOL, V23, P7600, DOI 10.1128/MCB.23.21.7600-7610.2003; Reed JC, 2003, CANCER CELL, V3, P17, DOI 10.1016/S1535-6108(02)00241-6; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(02)02036-6; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Scott FL, 2005, EMBO J, V24, P645, DOI 10.1038/sj.emboj.7600544; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Sun CH, 1999, NATURE, V401, P818, DOI 10.1038/44617; Sun Y, 1997, ONCOGENE, V14, P385, DOI 10.1038/sj.onc.1200834; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Wolf BB, 1999, J BIOL CHEM, V274, P30651, DOI 10.1074/jbc.274.43.30651; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yang L, 2003, CANCER RES, V63, P6815; Yang LL, 2003, CANCER RES, V63, P831; Yang YL, 2000, CELL RES, V10, P169, DOI 10.1038/sj.cr.7290046	37	133	155	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2005	24	49					7381	7388		10.1038/sj.onc.1208888	http://dx.doi.org/10.1038/sj.onc.1208888			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982FA	16044155				2022-12-25	WOS:000233142100014
J	Tsukamoto, K; Kohda, T; Mukamoto, M; Takeuchi, K; Ihara, H; Saito, M; Kozaki, S				Tsukamoto, K; Kohda, T; Mukamoto, M; Takeuchi, K; Ihara, H; Saito, M; Kozaki, S			Binding of Clostridium botulinum type C and D neurotoxins to ganglioside and phospholipid - Novel insights into the receptor for clostridial neurotoxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN SYNAPTOSOMES; FREE FATTY-ACIDS; B NEUROTOXIN; HELICOBACTER-PYLORI; SYNAPTOTAGMIN-I; CELLS; PHOSPHATIDYLETHANOLAMINE; TOXIN; EXOCYTOSIS; GENE	Clostridium botulinum neurotoxins (BoNTs) act on nerve endings to block acetylcholine release. Their potency is due to their enzymatic activity and selective high affinity binding to neurons. Although there are many pieces of data available on the receptor for BoNT, little attempt has been made to characterize the receptors for BoNT/C and BoNT/D. For this purpose, we prepared the recombinant carboxyl-terminal domain of the heavy chain (H-C) and then examined its binding capability to rat brain synaptosomes treated with enzymes and heating. Synaptosomes treated with proteinase K or heating retained binding capability to both H-C/C and H-C/D, suggesting that a proteinaceous substance does not constitute the receptor component. We next performed a thin layer chromatography overlay assay of HC with a lipid extract of synaptosomes. Under physiological or higher ionic strengths, H-C/C bound to gangliosides GD1b and GT1b. These data are in accord with results showing that neuraminidase and endoglycoceramidase treatment decreased H-C/C binding to synaptosomes. On the other hand, H-C/D interacted with phosphatidylethanolamine but not with any ganglioside. Using cerebellar granule cells obtained from GM3 synthase knock-out mice, we found that BoNT/C did not elicit a toxic effect but that BoNT/D still inhibited glutamate release to the same extent as in granule cells from wild type mice. These observations suggested that BoNT/C recognized GD1b and GT1b as functional receptors, whereas BoNT/D induced toxicity in a ganglioside-independent manner, possibly through binding to phosphatidylethanolamine. Our results provide novel insights into the receptor for clostridial neurotoxin.	Osaka Prefecture Univ, Grad Sch Life & Environm Sci, Dept Vet Sci, Osaka 5998531, Japan; Osaka Prefecture Univ, Grad Sch Sci, Dept Biol Sci, Osaka 5998531, Japan; Meiji Pharmaceut Univ, Dept Oncol & Pharmacodynam, Tokyo 2048588, Japan	Osaka Metropolitan University; Osaka Metropolitan University; Meiji Pharmaceutical University	Kozaki, S (corresponding author), Osaka Prefecture Univ, Grad Sch Life & Environm Sci, Dept Vet Sci, 1-1 Gakuen Cho, Osaka 5998531, Japan.	kozaki@center.osakafu-u.ac.jp	Taylor, Graham/A-4027-2012; Tsukamoto, Kentaro/AFQ-2771-2022	Tsukamoto, Kentaro/0000-0002-9254-4632				AIZAWA S, 1990, EMBO J, V9, P2107, DOI 10.1002/j.1460-2075.1990.tb07379.x; AMINOFF D, 1959, VIROLOGY, V7, P355, DOI 10.1016/0042-6822(59)90207-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Busse J, 1997, J INFECT DIS, V175, P77, DOI 10.1093/infdis/175.1.77; Chapman ER, 2002, NAT REV MOL CELL BIO, V3, P498, DOI 10.1038/nrm855; Coffield JA, 1997, J PHARMACOL EXP THER, V280, P1489; Collins MD, 1998, J APPL MICROBIOL, V84, P5, DOI 10.1046/j.1365-2672.1997.00313.x; Dong M, 2003, J CELL BIOL, V162, P1293, DOI 10.1083/jcb.200305098; Foran P, 1996, BIOCHEMISTRY-US, V35, P2630, DOI 10.1021/bi9519009; Foster DB, 1999, MICROB PATHOGENESIS, V27, P289, DOI 10.1006/mpat.1999.0305; GOLD BD, 1993, INFECT IMMUN, V61, P2632, DOI 10.1128/IAI.61.6.2632-2638.1993; GROSS WB, 1971, AVIAN DIS, V15, P716, DOI 10.2307/1588859; Ihara H, 2003, BBA-GENE STRUCT EXPR, V1625, P19, DOI 10.1016/S0167-4781(02)00537-7; Iwamori M, 2004, BIOCHEM J, V380, P75, DOI 10.1042/BJ20031668; Jeannotte ME, 2003, INFECT IMMUN, V71, P4657, DOI 10.1128/IAI.71.8.4657-4663.2003; KAMATA Y, 1986, BIOCHEM BIOPH RES CO, V140, P1015, DOI 10.1016/0006-291X(86)90736-9; KITAMURA M, 1987, BIOCHEM BIOPH RES CO, V143, P928, DOI 10.1016/0006-291X(87)90339-1; KNIGHT DE, 1985, NATURE, V317, P719, DOI 10.1038/317719a0; Koga T, 2002, BRAIN RES, V952, P282, DOI 10.1016/S0006-8993(02)03253-5; Kohda T, 2000, J VET MED SCI, V62, P1133, DOI 10.1292/jvms.62.1133; KONDO H, 1984, JPN J MED SCI BIOL, V37, P131, DOI 10.7883/yoken1952.37.131; Kozaki S, 1998, MICROB PATHOGENESIS, V25, P91, DOI 10.1006/mpat.1998.0214; KOZAKI S, 1979, N-S ARCH PHARMACOL, V308, P67, DOI 10.1007/BF00499721; KRIVAN HC, 1991, BIOCHEM BIOPH RES CO, V175, P1082, DOI 10.1016/0006-291X(91)91676-4; KURAZONO H, 1985, FEMS MICROBIOL LETT, V30, P47; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINGWOOD CA, 1992, INFECT IMMUN, V60, P2470, DOI 10.1128/IAI.60.6.2470-2474.1992; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MONTECUCCO C, 1994, MOL MICROBIOL, V13, P1, DOI 10.1111/j.1365-2958.1994.tb00396.x; Moriishi K, 1996, APPL ENVIRON MICROB, V62, P662, DOI 10.1128/AEM.62.2.662-667.1996; Moriishi K, 1996, BBA-GENE STRUCT EXPR, V1307, P123, DOI 10.1016/0167-4781(96)00006-1; Niemann Heiner, 1994, Trends in Cell Biology, V4, P179, DOI 10.1016/0962-8924(94)90203-8; Nishiki T, 1996, FEBS LETT, V378, P253, DOI 10.1016/0014-5793(95)01471-3; NISHIKI T, 1994, J BIOL CHEM, V269, P10498; OCHANDA JO, 1986, J BIOCHEM-TOKYO, V100, P27, DOI 10.1093/oxfordjournals.jbchem.a121702; OGASAWARA J, 1991, FEMS MICROBIOL LETT, V79, P351, DOI 10.1111/j.1574-6968.1991.tb04554.x; OGUMA K, 1984, INFECT IMMUN, V43, P584, DOI 10.1128/IAI.43.2.584-588.1984; OPDENKAMP JAF, 1979, ANNU REV BIOCHEM, V48, P47, DOI 10.1146/annurev.bi.48.070179.000403; REED L. J., 1938, AMER JOUR HYG, V27, P493; Rummel A, 2004, J BIOL CHEM, V279, P30865, DOI 10.1074/jbc.M403945200; Simpson LL, 2004, ANNU REV PHARMACOL, V44, P167, DOI 10.1146/annurev.pharmtox.44.101802.121554; Svennerholm L, 1980, Adv Exp Med Biol, V125, P11; SVENNERHOLM L, 1968, J LIPID RES, V9, P570; TAKAMIZAWA K, 1986, FEBS LETT, V201, P229, DOI 10.1016/0014-5793(86)80614-7; Takeda M, 2005, AVIAN DIS, V49, P376, DOI 10.1637/7347-022305R1.1; WHITTAKER VP, 1959, BIOCHEM J, V72, P694, DOI 10.1042/bj0720694; Williamson P, 2002, BBA-MOL CELL BIOL L, V1585, P53, DOI 10.1016/S1388-1981(02)00324-4; YABUUCHI H, 1968, J LIPID RES, V9, P65; Yamashita T, 2003, P NATL ACAD SCI USA, V100, P3445, DOI 10.1073/pnas.0635898100; Yowler BC, 2004, BIOCHEMISTRY-US, V43, P9725, DOI 10.1021/bi0494673; ZWAAL RFA, 1973, BIOCHIM BIOPHYS ACTA, V300, P159	51	106	112	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35164	35171		10.1074/jbc.M507596200	http://dx.doi.org/10.1074/jbc.M507596200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16115873	hybrid			2022-12-25	WOS:000232561200013
J	Yu, XP; Zhu, XG; Pi, WH; Ling, JH; Ko, L; Takeda, Y; Tuan, D				Yu, XP; Zhu, XG; Pi, WH; Ling, JH; Ko, L; Takeda, Y; Tuan, D			The long terminal repeat (LTR) of ERV-9 human endogenous retrovirus binds to NF-Y in the assembly of an active LTR enhancer complex NF-Y/MZF1/GATA-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLOBIN LOCUS; ZINC-FINGER GENE; 5' BOUNDARY AREA; DNA-BINDING; TRANSCRIPTIONAL REGULATION; CONTROL REGION; CHAIN GENE; IN-VIVO; EXPRESSION; ACTIVATION	The solitary ERV-9 long terminal repeat (LTR) located upstream of the HS5 site in the human beta-globin locus control region exhibits prominent enhancer activity in embryonic and erythroid cells. The LTR enhancer contains 14 tandemly repeated subunits with recurrent CCAAT, GTGGGGA, and GATA motifs. Here we showed that in erythroid K562 cells these DNA motifs bound the following three transcription factors: ubiquitous NF-Y and hematopoietic MZF1 and GATA-2. These factors and their target DNA motifs exhibited a hierarchy of DNA/protein and protein/protein binding affinities: NF-Y/CCAAT > NF-Y/GATA-2 > NF-Y/MZF1 > MZF1/GTGGGGA; GATA-2/GATA. Through protein/protein interactions, NF-Y bound at the CCAAT motif recruited MZF1 and GATA-2, but not Sp1 and GATA-1, and stabilized their binding to the neighboring GTGGGGA and GATA sites to assemble a novel LTR enhancer complex, NF-Y/MZF1/GATA-2. In the LTR-HS5-epsilon p-GFP plasmid integrated into K562 cells, mutation of the CCAAT motif in the LTR enhancer to abolish NF-Y binding inactivated the enhancer, closed down the chromatin structure of the epsilon-globin promoter, and silenced transcription of the green fluorescent protein gene. The results indicated that NF-Y bound at the CCAAT motifs assembled a robust LTR enhancer complex, which could act over the intervening DNA to remodel the chromatin structure and to stimulate the transcription of the downstream gene locus.	Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA; Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University	Tuan, D (corresponding author), Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA.	dtuanlo@mcg.edu		Yu, Xiuping/0000-0003-2844-7026	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062308] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62308] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anguita E, 2004, EMBO J, V23, P2841, DOI 10.1038/sj.emboj.7600274; Bi WM, 1997, J BIOL CHEM, V272, P26562, DOI 10.1074/jbc.272.42.26562; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Britten RJ, 1996, P NATL ACAD SCI USA, V93, P9374, DOI 10.1073/pnas.93.18.9374; Caretti G, 1999, MOL CELL BIOL, V19, P8591; CHUNG J, 1983, CELL, V74, P505; DICRISTOFANO A, 1995, VIROLOGY, V213, P271, DOI 10.1006/viro.1995.1570; DOOLITTLE WF, 1980, NATURE, V284, P601, DOI 10.1038/284601a0; Duan ZJ, 2001, MOL CELL BIOL, V21, P3083, DOI 10.1128/MCB.21.9.3083-3095.2001; Farina A, 1999, ONCOGENE, V18, P2818, DOI 10.1038/sj.onc.1202472; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; Henikoff S, 1997, SCIENCE, V278, P609, DOI 10.1126/science.278.5338.609; HENTHORN PS, 1986, P NATL ACAD SCI USA, V83, P5194, DOI 10.1073/pnas.83.14.5194; HORTON MA, 1983, GLOBIN GENE EXPRESSI, P305; HROMAS R, 1991, J BIOL CHEM, V266, P14183; Hromas R, 1996, CURR TOP MICROBIOL, V211, P159; Huang DY, 2004, NUCLEIC ACIDS RES, V32, P3935, DOI 10.1093/nar/gkh719; Jackson SM, 1998, J LIPID RES, V39, P767; Johnson KD, 2002, METHODS, V26, P27, DOI 10.1016/S1046-2023(02)00005-1; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; LAMANTIA G, 1991, NUCLEIC ACIDS RES, V19, P1513; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Li Q, 1998, EMBO J, V17, P6300, DOI 10.1093/emboj/17.21.6300; LI QL, 1994, BLOOD, V84, P1399; Liberati C, 1998, J BIOL CHEM, V273, P16880, DOI 10.1074/jbc.273.27.16880; Ling JH, 2003, NUCLEIC ACIDS RES, V31, P4582, DOI 10.1093/nar/gkg646; Ling JH, 2002, J VIROL, V76, P2410, DOI 10.1128/JVI.76.5.2410-2423.2002; Long QM, 1998, GENOMICS, V54, P542, DOI 10.1006/geno.1998.5608; Lower R, 1996, P NATL ACAD SCI USA, V93, P5177, DOI 10.1073/pnas.93.11.5177; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Marziali G, 1997, MOL CELL BIOL, V17, P1387, DOI 10.1128/MCB.17.3.1387; Medstrand P, 2001, J BIOL CHEM, V276, P1896, DOI 10.1074/jbc.M006557200; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; Moran JV, 1999, SCIENCE, V283, P1530, DOI 10.1126/science.283.5407.1530; MORRIS JF, 1994, MOL CELL BIOL, V14, P1786, DOI 10.1128/MCB.14.3.1786; Motta MC, 1999, J BIOL CHEM, V274, P1326, DOI 10.1074/jbc.274.3.1326; ORKIN SH, 1992, BLOOD, V80, P575; Peterson MJ, 2000, GENE, V254, P105, DOI 10.1016/S0378-1119(00)00281-X; Phair RD, 2004, MOL CELL BIOL, V24, P6393, DOI 10.1128/MCB.24.14.6393-6402.2004; Pi WH, 2004, P NATL ACAD SCI USA, V101, P805, DOI 10.1073/pnas.0307698100; Ramchandran R, 2000, AM J HEMATOL, V65, P14, DOI 10.1002/1096-8652(200009)65:1<14::AID-AJH3>3.0.CO;2-F; Reik A, 1998, MOL CELL BIOL, V18, P5992, DOI 10.1128/MCB.18.10.5992; REITH W, 1994, P NATL ACAD SCI USA, V91, P554, DOI 10.1073/pnas.91.2.554; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Romier C, 2003, J BIOL CHEM, V278, P1336, DOI 10.1074/jbc.M209635200; Sambrook J., 2001, MOL CLONING LAB MANU, V3; Schulte AM, 1996, P NATL ACAD SCI USA, V93, P14759, DOI 10.1073/pnas.93.25.14759; Speck NA, 2001, CURR OPIN HEMATOL, V8, P192, DOI 10.1097/00062752-200107000-00002; Strazzullo M, 1998, GENE, V206, P77, DOI 10.1016/S0378-1119(97)00568-4; SVENSSON AC, 1995, IMMUNOGENETICS, V41, P74; TEMIN HM, 1981, CELL, V27, P1, DOI 10.1016/0092-8674(81)90353-6; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; TING CN, 1992, GENE DEV, V6, P1457, DOI 10.1101/gad.6.8.1457; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; WRIGHT KL, 1995, J BIOL CHEM, V270, P20978, DOI 10.1074/jbc.270.36.20978; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; ZEUTHEN J, 1980, INT J CANCER, V25, P19, DOI 10.1002/ijc.2910250104; Zhong ZD, 2000, J BIOL CHEM, V275, P18602, DOI 10.1074/jbc.M001389200; Zhu J, 2003, BLOOD, V102, P2420, DOI 10.1182/blood-2003-01-0251; ZON LI, 1993, BLOOD, V81, P3234	61	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35184	35194		10.1074/jbc.M508138200	http://dx.doi.org/10.1074/jbc.M508138200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16105833	hybrid			2022-12-25	WOS:000232561200015
J	Wattel, S; Mircescu, H; Venet, D; Burniat, A; Franc, B; Frank, S; Andry, G; Van Sande, J; Rocmans, P; Dumont, JE; Detours, V; Maenhaut, C				Wattel, S; Mircescu, H; Venet, D; Burniat, A; Franc, B; Frank, S; Andry, G; Van Sande, J; Rocmans, P; Dumont, JE; Detours, V; Maenhaut, C			Gene expression in thyroid autonomous adenomas provides insight into their physiopathology	ONCOGENE			English	Article						thyroid; autonomous adenoma; gene expression; microarray	THYROTROPIN RECEPTOR MUTATIONS; BLOOD CAPILLARY ENLARGEMENT; DOG PRIMARY THYROCYTES; C-MYC EXPRESSION; PROTEIN-KINASE-A; CYCLIC-AMP; TRANSGENIC MICE; MICROARRAY DATA; GROWTH-FACTORS; TSH RECEPTOR	The purpose of this study was to use the microarray technology to de. ne expression profiles characteristic of thyroid autonomous adenomas and relate these findings to physiological mechanisms. Experiments were performed on a series of separated adenomas and their normal counterparts on Micromax cDNA microarrays covering 2400 genes (analysis I), and on a pool of adenomatous tissues and their corresponding normal counterparts using microarrays of 18 000 spots (analysis II). Results for genes present on the two arrays corroborated and several gene regulations previously determined by Northern blotting or microarrays in similar lesions were confirmed. Five overexpressed and 24 underexpressed genes were also confirmed by real-time RT-PCR in some of the samples used for microarray analysis, and in additional tumor specimens. Our results show: (1) a change in the cell populations of the tumor, with a marked decrease in lymphocytes and blood cells and an increase in endothelial cells. The latter increase would correspond to the establishment of a close relation between thyrocytes and endothelial cells and is related to increased N-cadherin expression. It explains the increased blood flow in the tumor; (2) a homogeneity of tumor samples correlating with their common physiopathological mechanism: the constitutive activation of the thyrotropin (TSH)/cAMP cascade; (3) a low proportion of regulated genes consistent with the concept of a minimal deviation tumor; (4) a higher expression of genes coding for specific functional proteins, consistent with the functional hyperactivity of the tumors; (5) an increase of phosphodiesterase gene expression which explains the relatively low cyclic AMP levels measured in these tumors; (6) an overexpression of antiapoptotic genes and underexpression of proapoptotic genes compatible with their low apoptosis rate; (7) an overexpression of N-cadherin and downregulation of caveolins, which casts doubt about the use of these expressions as markers for malignancy.	Free Univ Brussels, Sch Med, IRIBHM, Int Interdisciplinary Res, B-1070 Brussels, Belgium; Univ Versailles, Hop Ambroise Pare, AP HP, Serv Anat & Cytol Pathol, St Quentin en Yvelines, France; Inst Jules Bordet, Dept Surg, B-1000 Brussels, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; UDICE-French Research Universities; Universite Paris Saclay; Institut Jules Bordet	Maenhaut, C (corresponding author), Free Univ Brussels, Sch Med, IRIBHM, Int Interdisciplinary Res, 808 Route Lennik,Campus Erasme,Bldg C, B-1070 Brussels, Belgium.	cmaenhau@ulb.ac.be						Aldred MA, 2004, J CLIN ONCOL, V22, P3531, DOI 10.1200/JCO.2004.08.127; Aldred MA, 2003, CANCER RES, V63, P2864; Aust G, 2001, J CLIN ENDOCR METAB, V86, P3368, DOI 10.1210/jc.86.7.3368; BAPTIST M, 1995, EXP CELL RES, V221, P160, DOI 10.1006/excr.1995.1363; Barden CB, 2003, CLIN CANCER RES, V9, P1792; Baris O, 2004, J CLIN ENDOCR METAB, V89, P994, DOI 10.1210/jc.2003-031238; Bauch K, 1998, EXP CLIN ENDOCR DIAB, V106, pS16, DOI 10.1055/s-0029-1212050; Becker D, 1997, J CLIN ULTRASOUND, V25, P63, DOI 10.1002/(SICI)1097-0096(199702)25:2<63::AID-JCU3>3.0.CO;2-H; Bourdeau I, 2004, ONCOGENE, V23, P1575, DOI 10.1038/sj.onc.1207277; Carver LA, 2003, NAT REV CANCER, V3, P571, DOI 10.1038/nrc1146; Cho-Chung YS, 2004, BBA-PROTEINS PROTEOM, V1697, P71, DOI 10.1016/j.bbapap.2003.11.014; Corvilain B, 2001, CLIN ENDOCRINOL, V55, P143, DOI 10.1046/j.1365-2265.2001.01365.x; Deleu S, 2000, THYROID, V10, P131, DOI 10.1089/thy.2000.10.131; Detours V, 2005, BRIT J CANCER, V92, P1545, DOI 10.1038/sj.bjc.6602521; DRALLE H, 1977, VIRCHOWS ARCH A, V374, P285, DOI 10.1007/BF00432652; Dremier S, 2002, ANN NY ACAD SCI, V968, P106, DOI 10.1111/j.1749-6632.2002.tb04330.x; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; Eggo MC, 1996, J CLIN ENDOCR METAB, V81, P3056, DOI 10.1210/jc.81.8.3056; ERMANS AM, 1972, ACTA ENDOCRINOL-COP, V70, P463, DOI 10.1530/acta.0.0700463; Eszlinger M, 2004, ONCOGENE, V23, P795, DOI 10.1038/sj.onc.1207186; Eszlinger M, 2001, J CLIN ENDOCR METAB, V86, P4834, DOI 10.1210/jc.86.10.4834; Finley DJ, 2004, J CLIN ENDOCR METAB, V89, P3214, DOI 10.1210/jc.2003-031811; Fuhrer D, 1997, J CLIN ENDOCR METAB, V82, P3885, DOI 10.1210/jc.82.11.3885; Gerard AC, 2002, J CLIN ENDOCR METAB, V87, P1291, DOI 10.1210/jc.87.3.1291; Goffard JC, 2004, MOL ENDOCRINOL, V18, P194, DOI 10.1210/me.2003-0249; HAMBURGER JI, 1987, ENDOCR REV, V8, P439, DOI 10.1210/edrv-8-4-439; HANASAKI K, 1995, J BIOL CHEM, V270, P7533, DOI 10.1074/jbc.270.13.7533; Haugen DRF, 2003, THYROID, V13, P613; Huang Y, 2001, P NATL ACAD SCI USA, V98, P15044, DOI 10.1073/pnas.251547398; Husmark J, 1999, INT J CANCER, V83, P692, DOI 10.1002/(SICI)1097-0215(19991126)83:5<692::AID-IJC21>3.0.CO;2-1; Karsten SL, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.2.e4; KETELBANTBALASSE P, 1976, HORM METAB RES, V8, P212, DOI 10.1055/s-0028-1093662; Knudsen N, 2000, EUR J ENDOCRINOL, V143, P485, DOI 10.1530/eje.0.1430485; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Krohn K, 2000, J PATHOL, V192, P37; Krohn K, 1998, J CLIN ENDOCR METAB, V83, P130, DOI 10.1210/jc.83.1.130; Lania A, 1998, J CLIN ENDOCR METAB, V83, P1624, DOI 10.1210/jc.83.5.1624; LEDENT C, 1992, EMBO J, V11, P537, DOI 10.1002/j.1460-2075.1992.tb05084.x; Mazzanti C, 2004, CANCER RES, V64, P2898, DOI 10.1158/0008-5472.CAN-03-3811; MICHIELS FM, 1994, P NATL ACAD SCI USA, V91, P10488, DOI 10.1073/pnas.91.22.10488; NAMBA H, 1990, J CLIN INVEST, V86, P120, DOI 10.1172/JCI114673; NEVE P, 1970, Experimental Cell Research, V63, P285, DOI 10.1016/0014-4827(70)90215-6; NILSON JH, 1980, ENDOCRINOLOGY, V107, P262, DOI 10.1210/endo-107-1-262; O'Donovan N, 2002, J ENDOCRINOL, V174, P517, DOI 10.1677/joe.0.1740517; Persani L, 2000, J CLIN ENDOCR METAB, V85, P2872, DOI 10.1210/jc.85.8.2872; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; PIRSON I, 1994, EXP CELL RES, V210, P33, DOI 10.1006/excr.1994.1005; Pirson I, 1996, J CELL PHYSIOL, V168, P59, DOI 10.1002/(SICI)1097-4652(199607)168:1<59::AID-JCP8>3.0.CO;2-7; Puskas LG, 2002, BIOTECHNIQUES, V32, P1330, DOI 10.2144/02326mt04; REUSE S, 1990, EXP CELL RES, V189, P33, DOI 10.1016/0014-4827(90)90253-7; Rieger-Christ KM, 2004, ONCOGENE, V23, P4745, DOI 10.1038/sj.onc.1207629; ROGER PP, 1984, MOL CELL ENDOCRINOL, V36, P79, DOI 10.1016/0303-7207(84)90087-X; RUSSO D, 1995, J CLIN ENDOCR METAB, V80, P1347, DOI 10.1210/jc.80.4.1347; Savonet V, 1997, ANAL BIOCHEM, V247, P165, DOI 10.1006/abio.1997.2055; Taniguchi M, 2001, GENOMICS, V71, P34, DOI 10.1006/geno.2000.6427; Tonacchera M, 2000, J CLIN ENDOCR METAB, V85, P2270, DOI 10.1210/jc.85.6.2270; Tonacchera M, 1999, J CLIN ENDOCR METAB, V84, P4155, DOI 10.1210/jc.84.11.4155; VANDENHOVEVANDENBROUCKE MF, 1976, J CLIN ENDOCR METAB, V43, P178, DOI 10.1210/jcem-43-1-178; Vandeput F, 2003, ENDOCRINOLOGY, V144, P1341, DOI 10.1210/en.2001-211316; VANSANDE J, 1980, J CLIN ENDOCR METAB, V50, P776, DOI 10.1210/jcem-50-4-776; VANSANDE J, 1995, J CLIN ENDOCR METAB, V80, P2577, DOI 10.1210/jc.80.9.2577; VANSANDE J, 1988, J CLIN ENDOCR METAB, V66, P570, DOI 10.1210/jcem-66-3-570; Vanvooren V, 2002, EUR J ENDOCRINOL, V147, P287, DOI 10.1530/eje.0.1470287; Venet D, 2001, Bioinformatics, V17 Suppl 1, pS279; Venet D, 2003, BIOINFORMATICS, V19, P659, DOI 10.1093/bioinformatics/btg046; Voigt C, 2004, J ENDOCRINOL, V182, P173, DOI 10.1677/joe.0.1820173; Wang H, 1997, GENE, V199, P39, DOI 10.1016/S0378-1119(97)00343-0; Weber G, 2002, ADV ENZYME REGUL, V42, P83; WOLLMAN SH, 1982, ENDOCRINOLOGY, V111, P1867, DOI 10.1210/endo-111-6-1867; WOLLMAN SH, 1978, ENDOCRINOLOGY, V103, P2306, DOI 10.1210/endo-103-6-2306; Yamazaki K, 2003, THYROID, V13, P149, DOI 10.1089/105072503321319459; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Yano Y, 2004, CLIN CANCER RES, V10, P2035, DOI 10.1158/1078-0432.CCR-0807-03; Zeiger MA, 1997, ENDOCRINOLOGY, V138, P3133, DOI 10.1210/en.138.8.3133	74	21	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 20	2005	24	46					6902	6916		10.1038/sj.onc.1208849	http://dx.doi.org/10.1038/sj.onc.1208849			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	975ZD	16027733				2022-12-25	WOS:000232701700005
J	Carmody, M; Murphy, B; Byrne, B; Power, P; Rai, D; Rawlings, B; Caffrey, P				Carmody, M; Murphy, B; Byrne, B; Power, P; Rai, D; Rawlings, B; Caffrey, P			Biosynthesis of amphotericin derivatives lacking exocyclic carboxyl groups	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-CLUSTER; POLYKETIDE SYNTHASE; MACROLIDES; PIMARICIN; TOXICITY	Amphotericin B is a medically important antifungal antibiotic that is also active against human immunodeficiency virus, Leishmania parasites, and prion diseases. The therapeutic use of amphotericin B is restricted by severe side effects that can be moderated by liposomal formulation or structural alteration. Chemical modification has shown that suppression of charge on the exocyclic carboxyl group of amphotericin B substantially reduces toxicity. We report targeted deletions of the amphN cytochrome P450 gene from the chromosome of the amphotericin-producing bacterium Streptomyces nodosus. The mutant strains produced amphotericin analogues in which methyl groups replace the exocyclic carboxyl groups. These compounds retained antifungal activity and had reduced hemolytic activity.	Univ Coll Dublin, Conway Inst Biomol & Biomed Res, Ctr Synth & Chem Biol, Dept Ind Microbiol, Dublin 4, Ireland; Univ Coll Dublin, Conway Inst Biomol & Biomed Res, Ctr Synth & Chem Biol, Dept Chem, Dublin 4, Ireland; Univ Leicester, Dept Chem, Leicester LE1 7RH, Leics, England	University College Dublin; University College Dublin; University of Leicester	Caffrey, P (corresponding author), Univ Coll Dublin, Conway Inst Biomol & Biomed Res, Ctr Synth & Chem Biol, Dept Ind Microbiol, Dublin 4, Ireland.	Patrick.caffrey@ucd.ie	K., Dilip/E-9022-2011; Caffrey, Patrick/B-1409-2008	K., Dilip/0000-0002-8073-4981; Murphy, Barry/0000-0003-2305-5875				Aparicio JF, 2000, CHEM BIOL, V7, P895, DOI 10.1016/S1074-5521(00)00038-7; Brautaset T, 2000, CHEM BIOL, V7, P395, DOI 10.1016/S1074-5521(00)00120-4; Byrne B, 2003, CHEM BIOL, V10, P1215, DOI 10.1016/j.chembiol.2003.12.001; Caffrey P, 2001, CHEM BIOL, V8, P713, DOI 10.1016/S1074-5521(01)00046-1; CALDERON M, 1970, J LIPID RES, V11, P167; Campelo AB, 2002, MICROBIOL-SGM, V148, P51, DOI 10.1099/00221287-148-1-51; Canuto MM, 2002, LANCET INFECT DIS, V2, P550, DOI 10.1016/S1473-3099(02)00371-7; Carmody M, 2004, GENE, V343, P107, DOI 10.1016/j.gene.2004.08.006; Chen S, 2003, CHEM BIOL, V10, P1065, DOI 10.1016/j.chembiol.2003.10.007; CHERON M, 1988, BIOCHEM PHARMACOL, V37, P827, DOI 10.1016/0006-2952(88)90168-2; Georgopapadakou NH, 1996, ANTIMICROB AGENTS CH, V40, P279, DOI 10.1128/AAC.40.2.279; Hartsel S, 1996, TRENDS PHARMACOL SCI, V17, P445, DOI 10.1016/S0165-6147(96)01012-7; HERVE M, 1989, BIOCHIM BIOPHYS ACTA, V980, P261, DOI 10.1016/0005-2736(89)90312-X; Jones J, 2005, VIROLOGY, V331, P106, DOI 10.1016/j.virol.2004.10.013; KIESER T, 2000, PRACTICAL STREPTOMYC, P289; Lemke A, 2005, APPL MICROBIOL BIOT, V68, P151, DOI 10.1007/s00253-005-1955-9; Maki M, 2002, EUR J BIOCHEM, V269, P593, DOI 10.1046/j.0014-2956.2001.02688.x; Mange A, 2000, J NEUROCHEM, V74, P754, DOI 10.1046/j.1471-4159.2000.740754.x; McNamara CM, 1998, J CHEM SOC PERK T 1, P83, DOI 10.1039/a704545j; Mendes MV, 2001, CHEM BIOL, V8, P635, DOI 10.1016/S1074-5521(01)00033-3; NICOLAOU KC, 1988, J AM CHEM SOC, V110, P4696, DOI 10.1021/ja00222a030; Omura S., 1986, MACROLIDE ANTIBIOTIC, P351; Petit C, 1999, ANTIMICROB AGENTS CH, V43, P390, DOI 10.1128/AAC.43.2.390; POCCHIARI M, 1987, J GEN VIROL, V68, P219, DOI 10.1099/0022-1317-68-1-219; Seco EM, 2004, CHEM BIOL, V11, P357, DOI 10.1016/j.chembiol.2004.02.017; Szlinder-Richert J, 2001, BBA-GEN SUBJECTS, V1528, P15, DOI 10.1016/S0304-4165(01)00166-0; TAYLOR AW, 1993, J ANTIBIOT, V46, P486, DOI 10.7164/antibiotics.46.486; Walsh C, 2003, NAT REV MICROBIOL, V1, P65, DOI 10.1038/nrmicro727	28	87	97	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34420	34426		10.1074/jbc.M506689200	http://dx.doi.org/10.1074/jbc.M506689200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16079135	hybrid, Green Submitted			2022-12-25	WOS:000232403900007
J	Kenski, DM; Zhang, C; von Zastrow, M; Shokat, KM				Kenski, DM; Zhang, C; von Zastrow, M; Shokat, KM			Chemical genetic engineering of G protein-coupled receptor kinase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MU-OPIOID RECEPTOR; BETA-ARRESTIN; BETA(2)-ADRENERGIC RECEPTOR; TYROSINE KINASE; MEDIATED DESENSITIZATION; MEMBRANE TRAFFICKING; DOWN-REGULATION; PHOSPHORYLATION; INTERNALIZATION; MORPHINE	G protein-coupled receptor kinases (GRKs) play a pivotal role in receptor regulation. Efforts to study the acute effects of GRKs in intact cells have been limited by a lack of specific inhibitors. In the present study we have developed an engineered version of GRK2 that is specifically and reversibly inhibited by the substituted nucleotide analog 1-naphthyl-PP1 (1Na-PP1), and we explored GRK2 function in regulated internalization of the mu-opioid receptor (mu OR). A previously described method that conferred analog sensitivity on various kinases, by introducing a space-creating mutation in the conserved active site, failed when applied to GRK2 because the corresponding mutation (L271G) rendered the mutant kinase (GRK2-as1) catalytically inactive. A sequence homology-based approach was used to design second-site suppressor mutations. A C221V second-site mutation produced a mutant kinase (GRK2-as5) with full functional activity and analog sensitivity as compared with wild-type GRK2 in vitro and in intact cells. The role of GRK2-as5 activity in the membrane trafficking of the mu OR was also characterized. Morphine-induced internalization was completely blocked when GRK2-as5 activity was inhibited before morphine application. However, inhibition of GRK2-as5 during recycling and reinternalization of the mu OR did not attenuate these processes. These results suggest there is a difference in the GRK requirement for initial ligand-induced internalization of a G protein-coupled receptor compared with subsequent rounds of reinternalization.	Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Chem & Chem Biol Grad Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Shokat, KM (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, 600 16th St, San Francisco, CA 94143 USA.	shokat@cmp.ucsf.edu			NIAID NIH HHS [AI44009] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044009] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARDEN JR, 1995, J NEUROCHEM, V65, P1636; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; Bishop AC, 2000, NATURE, V407, P395, DOI 10.1038/35030148; Bishop AC, 1998, CURR BIOL, V8, P257, DOI 10.1016/S0960-9822(98)70198-8; Bishop AC, 1999, J AM CHEM SOC, V121, P627, DOI 10.1021/ja983267v; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buzko O, 2002, BIOINFORMATICS, V18, P1274, DOI 10.1093/bioinformatics/18.9.1274; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; Celver JP, 2001, J BIOL CHEM, V276, P4894, DOI 10.1074/jbc.M007437200; Chakrabarti S, 1998, J NEUROCHEM, V71, P231; Chen X, 2005, NEURON, V46, P13, DOI 10.1016/j.neuron.2005.03.009; Diviani D, 1997, J BIOL CHEM, V272, P28712, DOI 10.1074/jbc.272.45.28712; Erdtmann-Vourliotis M, 2001, MOL BRAIN RES, V95, P129, DOI 10.1016/S0006-8993(01)03046-3; Fabian MA, 2005, NAT BIOTECHNOL, V23, P329, DOI 10.1038/nbt1068; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; Fukuto HS, 2004, NEURON, V42, P581, DOI 10.1016/S0896-6273(04)00252-1; Gage RM, 2001, J BIOL CHEM, V276, P44712, DOI 10.1074/jbc.M107417200; Gagnon AW, 1998, J BIOL CHEM, V273, P6976, DOI 10.1074/jbc.273.12.6976; Garby Lars, 1995, BIOENERGETICS ITS TH; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Haberstock-Debic H, 2003, J NEUROSCI, V23, P4324; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hasbi A, 2000, J PHARMACOL EXP THER, V293, P237; Ignatova EG, 1999, J NEUROSCI, V19, P56, DOI 10.1523/JNEUROSCI.19-01-00056.1999; KAUFMAN DL, 1994, GENOMICS, V19, P405, DOI 10.1006/geno.1994.1087; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; KIM CM, 1993, RECEPTOR, V3, P39; Koch T, 1997, J NEUROCHEM, V69, P1767; Krasel C, 2005, J BIOL CHEM, V280, P9528, DOI 10.1074/jbc.M413078200; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Liu Y, 1999, CHEM BIOL, V6, P671, DOI 10.1016/S1074-5521(99)80118-5; Liu Y, 2000, BIOCHEMISTRY-US, V39, P14400, DOI 10.1021/bi000437j; Lodowski DT, 2003, SCIENCE, V300, P1256, DOI 10.1126/science.1082348; McLaughlin JP, 2001, MOL PHARMACOL, V59, P1360, DOI 10.1124/mol.59.6.1360; MESTEK A, 1995, J NEUROSCI, V15, P2396, DOI 10.1523/JNEUROSCI.15-03-02396.1995; Niswender CM, 2002, J BIOL CHEM, V277, P28916, DOI 10.1074/jbc.M203327200; Perry SJ, 2002, TRENDS CELL BIOL, V12, P130, DOI 10.1016/S0962-8924(01)02239-5; Pitcher JA, 1998, J BIOL CHEM, V273, P12316, DOI 10.1074/jbc.273.20.12316; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Polakiewicz RD, 1998, J BIOL CHEM, V273, P12402, DOI 10.1074/jbc.273.20.12402; Qiu Y, 2003, J BIOL CHEM, V278, P36733, DOI 10.1074/jbc.M305857200; Schulz S, 2004, EMBO J, V23, P3282, DOI 10.1038/sj.emboj.7600334; Shah K, 1997, P NATL ACAD SCI USA, V94, P3565, DOI 10.1073/pnas.94.8.3565; Shen J, 2000, SYNAPSE, V38, P322, DOI 10.1002/1098-2396(20001201)38:3<322::AID-SYN11>3.0.CO;2-1; Sreenivasan A, 2003, MOL CELL BIOL, V23, P6327, DOI 10.1128/MCB.23.17.6327-6337.2003; Tanowitz M, 2003, J BIOL CHEM, V278, P45978, DOI 10.1074/jbc.M304504200; Tsao PI, 2000, J BIOL CHEM, V275, P11130, DOI 10.1074/jbc.275.15.11130; von Zastrow M, 2003, LIFE SCI, V74, P217, DOI 10.1016/j.lfs.2003.09.008; Wang H, 2003, P NATL ACAD SCI USA, V100, P4287, DOI 10.1073/pnas.0636870100; Wang Q, 2004, SCIENCE, V304, P1940, DOI 10.1126/science.1098274; Weiss EL, 2002, J CELL BIOL, V158, P885, DOI 10.1083/jcb.200203094; Weiss EL, 2000, NAT CELL BIOL, V2, P677, DOI 10.1038/35036300; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; Zhang C, 2005, NAT METHODS, V2, P435, DOI 10.1038/NMETH764; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zhang L, 1996, J BIOL CHEM, V271, P11449, DOI 10.1074/jbc.271.19.11449	59	23	23	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					35051	35061		10.1074/jbc.M507594200	http://dx.doi.org/10.1074/jbc.M507594200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16081410	hybrid			2022-12-25	WOS:000232403900078
J	Medunjanin, S; Hermani, A; De Servi, B; Grisouard, J; Rincke, G; Mayer, D				Medunjanin, S; Hermani, A; De Servi, B; Grisouard, J; Rincke, G; Mayer, D			Glycogen synthase kinase-3 interacts with and phosphorylates estrogen receptor alpha and is involved in the regulation of receptor activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; ACTIVATED PROTEIN-KINASE; KAPPA-B ACTIVATION; TRANSCRIPTIONAL ACTIVATION; NUCLEAR RECEPTORS; GENE-EXPRESSION; BETA-CATENIN; CELL-GROWTH; ESTRADIOL; INHIBITION	Like other steroid hormone receptors, estrogen receptor-alpha (ER alpha) is a substrate for protein kinases, and phosphorylation has profound effects on the function and activity of this receptor. A number of different kinases have been implicated in ER alpha regulation. In this report we show by mutational analysis and in vitro kinase assays that ER alpha is a substrate for glycogen synthase kinase-3 (GSK-3) in vitro and is phosphorylated on two sites, the Ser-102, -104, and -106 motif and Ser-118, both located in the N-terminal transcription activation function (AF-1) domain. GSK-3 forms a complex with ER alpha in vivo as demonstrated by co-immunoprecipitation from cell lysates. The GSK-3 inhibitor lithium chloride was used to determine the role of GSK-3 in phosphorylation of Ser-102, -104, and -106 and Ser-118 in vivo and to explore the role of these serines in the regulation of ER alpha function. Treatment of cells with lithium chloride resulted in dephosphorylation of Ser-104 and -106 and Ser-118, which suggests these serine residues as targets for GSK-3 in vivo. Our results further suggest that ER alpha phosphorylation by GSK-3 stabilizes ER alpha under resting conditions and modulates ER alpha transcriptional activity upon ligand binding. Inhibition and constitutive activation of GSK-3, both, resulted in inhibition of ER alpha transcriptional activity, indicating a function of active as well as inactive GSK-3 in ER alpha regulation. These findings uncover a novel mechanism for the regulation of ER alpha-mediated estrogen signaling controlled by a dual action of GSK-3.	German Canc Res Ctr, Hormones & Signal Transduct Grp, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Mayer, D (corresponding author), German Canc Res Ctr, Hormones & Signal Transduct Grp, Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	d.mayer@dkfz.de						Agarwal-Mawal A, 2003, J BIOL CHEM, V278, P12722, DOI 10.1074/jbc.M211491200; Balaguer P, 2001, LUMINESCENCE, V16, P153, DOI 10.1002/bio.630; Biondi RM, 2003, BIOCHEM J, V372, P1, DOI 10.1042/BJ20021641; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Cardona-Gomez P, 2004, MOL CELL NEUROSCI, V25, P363, DOI 10.1016/j.mcn.2003.10.008; Castano E, 1998, J STEROID BIOCHEM, V65, P101, DOI 10.1016/S0960-0760(97)00179-9; Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050; Cheng SW, 2000, COMB OPT (SER), V6, P137; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; De Servi B, 2005, ONCOGENE, V24, P4946, DOI 10.1038/sj.onc.1208676; DEGROOT RP, 1993, ONCOGENE, V8, P841; Demarchi F, 2003, J BIOL CHEM, V278, P39583, DOI 10.1074/jbc.M305676200; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dilworth FJ, 2001, ONCOGENE, V20, P3047, DOI 10.1038/sj.onc.1204329; FIOL CJ, 1987, J BIOL CHEM, V262, P14042; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Glass CK, 2000, GENE DEV, V14, P121; GOODE N, 1992, J BIOL CHEM, V267, P16878; Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Joel PB, 1998, J BIOL CHEM, V273, P13317, DOI 10.1074/jbc.273.21.13317; JOEL PB, 1995, MOL ENDOCRINOL, V9, P1041, DOI 10.1210/me.9.8.1041; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KEOWN WA, 1990, METHOD ENZYMOL, V185, P527, DOI 10.1016/0076-6879(90)85043-N; Lannigan DA, 2003, STEROIDS, V68, P1, DOI 10.1016/S0039-128X(02)00110-1; LE GP, 1994, J BIOL CHEM, V269, P4458; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; MacAulay K, 2003, EUR J BIOCHEM, V270, P3829, DOI 10.1046/j.1432-1033.2003.03777.x; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mazor M, 2004, ONCOGENE, V23, P7882, DOI 10.1038/sj.onc.1208068; MIGLIACCIO A, 1993, ONCOGENE, V8, P2183; Nemeth ZH, 2002, J BIOL CHEM, V277, P7713, DOI 10.1074/jbc.M109711200; Rogatsky I, 1999, J BIOL CHEM, V274, P22296, DOI 10.1074/jbc.274.32.22296; Rogatsky I, 1998, J BIOL CHEM, V273, P14315, DOI 10.1074/jbc.273.23.14315; Salas TR, 2004, J BIOL CHEM, V279, P19191, DOI 10.1074/jbc.M309560200; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Stoica GE, 2003, ONCOGENE, V22, P7998, DOI 10.1038/sj.onc.1206769; Takeda K, 2000, HUM MOL GENET, V9, P125, DOI 10.1093/hmg/9.1.125; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; Turenne GA, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-12; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; Viatour P, 2004, MOL CELL, V16, P35, DOI 10.1016/j.molcel.2004.09.004; Wang L, 2004, J BIOL CHEM, V279, P32444, DOI 10.1074/jbc.M313963200; Watcharasit P, 2003, J BIOL CHEM, V278, P48872, DOI 10.1074/jbc.M305870200; WOODGETT JR, 1991, METHOD ENZYMOL, V200, P564	49	111	116	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					33006	33014		10.1074/jbc.M506758200	http://dx.doi.org/10.1074/jbc.M506758200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16076840	hybrid			2022-12-25	WOS:000231920300055
J	Hong, M; Xu, W; Yoshida, T; Tanaka, K; Wolff, DJ; Zhou, FF; Inouye, M; You, GF				Hong, M; Xu, W; Yoshida, T; Tanaka, K; Wolff, DJ; Zhou, FF; Inouye, M; You, GF			Human organic anion transporter hOAT1 forms homooligomers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; MOLECULAR-CLONING; EXPRESSION CLONING; CATION TRANSPORTER; LLC-PK1 CELLS; KIDNEY; CHANNEL; IDENTIFICATION; GLYCOSYLATION; MEMBRANE	Human organic anion transporter hOAT1 belongs to a superfamily of organic anion transporters, which play critical roles in the body disposition of clinically important drugs, including anti-human immunodeficiency virus therapeutics, anti-tumor drugs, antibiotics, anti-hypertensives, and anti-inflammatories. To gain insight into the regulation of hOAT1, detailed information on its structural assembly is essential. In the present study, we investigate the quaternary structure of hOAT1 using combined approaches of chemical cross-linking, gel filtration chromatography, co-immunoprecipitation, cell surface biotinylation, and metabolic labeling. Chemical cross-linking of intact membrane proteins from LLC-PK1 cells stably expressing hOAT1 converted quantitatively hOAT1 monomer to putative trimer and higher order of oligomer, indicating that hOAT1 is present in the membrane as multimeric complexes. When co-expressed in LLC-PK1 cells, FLAG-tagged hOAT1 co-immunoprecipitated with myc-tagged hOAT1. The hOAT1 oligomer was also detected in gel filtration chromatography of total membranes from hOAT1-expressing LLC-PK1 cells. Cell surface biotinylation with membrane-impermeable reagents and metabolic labeling with [S-35] methionine followed by immunoprecipitation showed that the oligomeric hOAT1 did not contain any other proteins. Taken together, this is the first study demonstrating that hOAT1 exists in the plasma membrane as a homooligomer, possibly trimer, and higher order of oligomer.	Rutgers State Univ, Dept Pharmaceut, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	You, GF (corresponding author), Rutgers State Univ, Dept Pharmaceut, 160 Frelinghuysen Rd, Piscataway, NJ 08854 USA.	gyou@rci.rutgers.edu	Zhou, Fanfan/M-4404-2013; Zhou, Fanfan/J-2327-2019	Zhou, Fanfan/0000-0002-1982-1541; Zhou, Fanfan/0000-0002-1982-1541; Yoshida, Takeshi/0000-0003-0133-5067; Hong, Mei/0000-0001-9219-2844	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060034] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK 60034] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brown D, 1996, PHYSIOL REV, V76, P245, DOI 10.1152/physrev.1996.76.1.245; Cha SH, 2000, J BIOL CHEM, V275, P4507, DOI 10.1074/jbc.275.6.4507; Cihlar T, 1999, MOL PHARMACOL, V56, P570, DOI 10.1124/mol.56.3.570; de Jong JC, 2003, J BIOL CHEM, V278, P24302, DOI 10.1074/jbc.M303101200; Ekaratanawong S, 2004, J PHARMACOL SCI, V94, P297, DOI 10.1254/jphs.94.297; Grundemann D, 1997, J BIOL CHEM, V272, P10408; Hong M, 2004, J BIOL CHEM, V279, P31478, DOI 10.1074/jbc.M404686200; HORI R, 1993, AM J PHYSIOL, V264, pF975, DOI 10.1152/ajprenal.1993.264.6.F975; Kedei N, 2001, J BIOL CHEM, V276, P28613, DOI 10.1074/jbc.M103272200; Kilic F, 2000, P NATL ACAD SCI USA, V97, P3106, DOI 10.1073/pnas.060408997; Kusuhara H, 1999, J BIOL CHEM, V274, P13675, DOI 10.1074/jbc.274.19.13675; Kuze K, 1999, J BIOL CHEM, V274, P1519, DOI 10.1074/jbc.274.3.1519; LopezNieto CE, 1997, J BIOL CHEM, V272, P6471, DOI 10.1074/jbc.272.10.6471; Lu R, 1999, AM J PHYSIOL-RENAL, V276, pF295, DOI 10.1152/ajprenal.1999.276.2.F295; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; PRESTON GM, 1993, J BIOL CHEM, V268, P17; Ramjeesingh M, 2001, BIOCHEMISTRY-US, V40, P10700, DOI 10.1021/bi0108195; Regeer RR, 2004, AM J PHYSIOL-CELL PH, V287, pC365, DOI 10.1152/ajpcell.00502.2003; Sekine T, 1998, FEBS LETT, V429, P179, DOI 10.1016/S0014-5793(98)00585-7; Sekine T, 1997, J BIOL CHEM, V272, P18526, DOI 10.1074/jbc.272.30.18526; Sweet DH, 1997, J BIOL CHEM, V272, P30088, DOI 10.1074/jbc.272.48.30088; Tanaka K, 2004, J BIOL CHEM, V279, P14961, DOI 10.1074/jbc.M400197200; Wolff NA, 1997, FEBS LETT, V417, P287, DOI 10.1016/S0014-5793(97)01304-5; Xu JK, 2004, J BIOL CHEM, V279, P19781, DOI 10.1074/jbc.M310785200; You GF, 2004, CURR DRUG METAB, V5, P55, DOI 10.2174/1389200043489207; You GF, 2000, J BIOL CHEM, V275, P10278, DOI 10.1074/jbc.275.14.10278; You GF, 2002, MED RES REV, V22, P602, DOI 10.1002/med.10019; Youngblood GL, 2004, AM J PHYSIOL-RENAL, V287, pF236, DOI 10.1152/ajprenal.00012.2004; Zhou FF, 2005, MOL PHARMACOL, V67, P868, DOI 10.1124/mol.104.007583	29	34	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32285	32290		10.1074/jbc.M501447200	http://dx.doi.org/10.1074/jbc.M501447200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16046403	hybrid			2022-12-25	WOS:000231794800031
J	Ho, JGS; Kitov, PI; Paszkiewicz, E; Sadowska, J; Bundle, DR; Ng, KKS				Ho, JGS; Kitov, PI; Paszkiewicz, E; Sadowska, J; Bundle, DR; Ng, KKS			Ligand-assisted aggregation of proteins - Dimerization of serum amyloid p component by bivalent ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR REPLACEMENT; TARGETED DELETION; MASS-SPECTROMETRY; X-RAY; GENE; AUTOIMMUNITY; COMPLEXES; PROGRAM; TOXINS; MODEL	A comprehensive series of solution and crystallographic studies reveal how simple, achiral, bivalent ligands of the cyclic pyruvate of glycerol promote face-to-face complex formation of the pentraxin, serum amyloid P component (SAP) into decamers. SAP, a protein of the human innate immune system, is universally present in amyloids, including cerebral amyloid deposits found in the brain of Alzheimer disease patients. Removal of SAP through a specific aggregation mechanism mediated by multivalent ligands appears to provide therapeutic benefit in the progression of this disease. Crystallographic studies reveal that in our novel series of ligands only the methyl and carboxylate moieties of the pyruvate ketal directly interact with the protein, but the geometric constraints imposed by the tether dictate which of two chair conformations are adopted by the pyruvate dioxane ring. Solution studies, as interpreted through a simple thermodynamic model, account for the distribution of pentameric and decameric bound states at different ligand concentrations and indicate that differences in the flexibility of the tether determine the geometry and stability of the specific aggregates formed between SAP and two different bivalent ligands. The factors affecting the design of ligands promoting face-to-face protein dimerization as well as potential biological implications are discussed.	Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada; Univ Alberta, Alberta Ingenu Ctr Carbohydrate Sci, Dept Chem, Edmonton, AB T6G 2G2, Canada	University of Calgary; University of Alberta	Ng, KKS (corresponding author), Univ Calgary, Dept Biol Sci, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.	ngk@ucalgary.ca	Kitov, Pavel/J-3714-2014	Ng, Kenneth K.S./0000-0001-7280-8445				Aquilina JA, 2003, BIOCHEM J, V375, P323, DOI 10.1042/BJ20030541; Ashton AW, 1997, J MOL BIOL, V272, P408, DOI 10.1006/jmbi.1997.1271; Bickerstaff MCM, 1999, NAT MED, V5, P694, DOI 10.1038/9544; Boas U, 2004, CHEM SOC REV, V33, P43, DOI 10.1039/b309043b; Botto M, 1997, NAT MED, V3, P855, DOI 10.1038/nm0897-855; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; EMSLEY J, 1994, NATURE, V367, P338, DOI 10.1038/367338a0; Fan EK, 2000, J AM CHEM SOC, V122, P2663, DOI 10.1021/ja993388a; Gargano JM, 2001, J AM CHEM SOC, V123, P12909, DOI 10.1021/ja016305a; Gillmore JD, 2004, IMMUNOLOGY, V112, P255, DOI 10.1111/j.1365-2567.2004.01860.x; Hohenester E, 1997, J MOL BIOL, V269, P570, DOI 10.1006/jmbi.1997.1075; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Hutchinson WL, 2000, MOL MED, V6, P482, DOI 10.1007/BF03401789; Kitov PI, 2003, J AM CHEM SOC, V125, P16271, DOI 10.1021/ja038223n; Kitov PI, 2000, NATURE, V403, P669, DOI 10.1038/35001095; Kitova EN, 2001, GLYCOBIOLOGY, V11, P605, DOI 10.1093/glycob/11.7.605; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Noursadeghi M, 2000, P NATL ACAD SCI USA, V97, P14584, DOI 10.1073/pnas.97.26.14584; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pepys MB, 2002, NATURE, V417, P254, DOI 10.1038/417254a; Pepys MB, 1997, AMYLOID, V4, P274, DOI 10.3109/13506129709003838; Pollock R, 2002, CURR OPIN BIOTECH, V13, P459, DOI 10.1016/S0958-1669(02)00373-7; TENNENT GA, 1995, P NATL ACAD SCI USA, V92, P4299, DOI 10.1073/pnas.92.10.4299; Thompson D, 2002, J MOL BIOL, V320, P1081, DOI 10.1016/S0022-2836(02)00514-4; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Zhang ZS, 2002, J AM CHEM SOC, V124, P12991, DOI 10.1021/ja027584k	31	17	17	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					31999	32008		10.1074/jbc.M504403200	http://dx.doi.org/10.1074/jbc.M504403200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16036920	hybrid			2022-12-25	WOS:000231665200080
J	Tomasini, R; Seux, M; Nowak, J; Bontemps, C; Carrier, A; Dagorn, JC; Pebusque, MJ; Iovanna, JL; Dusetti, NJ				Tomasini, R; Seux, M; Nowak, J; Bontemps, C; Carrier, A; Dagorn, JC; Pebusque, MJ; Iovanna, JL; Dusetti, NJ			TP53INP1 is a novel p73 target gene that induces cell cycle arrest and cell death by modulating p73 transcriptional activity	ONCOGENE			English	Article						TP53INP1; p73; apoptosis; transcriptional activity	TUMOR-SUPPRESSOR P53; INDUCED PROTEIN SIP; C-ABL; P53-DEPENDENT APOPTOSIS; REGULATES P73; CANCER-CELLS; DNA-DAMAGE; EXPRESSION; P63; CISPLATIN	TP53INP1 is an alternatively spliced gene encoding two nuclear protein isoforms (TP53INP1 alpha and TP53INP1 beta), whose transcription is activated by p53. When overexpressed, both isoforms induce cell cycle arrest in G1 and enhance p53-mediated apoptosis. TP53INP1s also interact with the p53 gene and regulate p53 transcriptional activity. We report here that TP53INP1 expression is induced during experimental acute pancreatitis in p53(-/-) mice and in cisplatin-treated p53(-/-) mouse embryo fibroblasts (MEFs). We demonstrate that ectopic expression of p73, a p53 homologue, leads to TP53INP1 induction in p53-deficient cells. In turn, TP53INP1s alters the transactivation capacity of p73 on several p53-target genes, including TP53INP1 itself, demonstrating a functional association between p73 and TP53INP1s. Also, when overexpressed in p53-deficient cells, TP53INP1s inhibit cell growth and promote cell death as assessed by cell cycle analysis and colony formation assays. Finally, we show that TP53INP1s potentiate the capacity of p73 to inhibit cell growth, that effect being prevented when the p53 mutant R175H is expressed or when p73 expression is blocked by a siRNA. These results suggest that TP53INP1s are functionally associated with p73 to regulate cell cycle progression and apoptosis, independently from p53.	Univ Mediterranee, IFR 137,Inst Cancerol & Immunol Marseille, INSERM, U624, F-13288 Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Dusetti, NJ (corresponding author), Univ Mediterranee, IFR 137,Inst Cancerol & Immunol Marseille, INSERM, U624, Parc Sci & Technol Luminy,Case 915, F-13288 Marseille, France.	dusetti@marseille.inserm.fr	tomasini, richard/F-1130-2017; Dusetti, Nelson/O-7919-2017; Iovanna, Juan/M-9805-2017	tomasini, richard/0000-0003-0869-0811; Dusetti, Nelson/0000-0002-6161-8483; Iovanna, Juan/0000-0003-1822-2237				BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Chau BN, 2004, MOL CELL BIOL, V24, P4438, DOI 10.1128/MCB.24.10.4438-4447.2004; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Courtois S, 2004, ONCOGENE, V23, P631, DOI 10.1038/sj.onc.1206929; Das S, 2003, ONCOGENE, V22, P8394, DOI 10.1038/sj.onc.1206908; Das S, 2003, J BIOL CHEM, V278, P18313, DOI 10.1074/jbc.M211704200; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Dusetti NJ, 2000, BIOCHEM BIOPH RES CO, V277, P660, DOI 10.1006/bbrc.2000.3734; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Fontemaggi G, 2002, J BIOL CHEM, V277, P43359, DOI 10.1074/jbc.M205573200; Fontemaggi G, 2001, MOL CELL BIOL, V21, P8461, DOI 10.1128/MCB.21.24.8461-8470.2001; Gong JG, 1999, NATURE, V399, P806; Hamer G, 2001, ONCOGENE, V20, P4298, DOI 10.1038/sj.onc.1204568; Ikawa S, 1999, CELL DEATH DIFFER, V6, P1154, DOI 10.1038/sj.cdd.4400631; IOVANNA J, 1991, J BIOL CHEM, V266, P24664; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Ishida S, 2000, JPN J CANCER RES, V91, P174, DOI 10.1111/j.1349-7006.2000.tb00929.x; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; MIYASHITA T, 1995, CELL, V80, P293; NIEDERAU C, 1985, GASTROENTEROLOGY, V88, P1192, DOI 10.1016/S0016-5085(85)80079-2; Obad S, 2004, ONCOGENE, V23, P4050, DOI 10.1038/sj.onc.1207524; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; Oniscu A, 2004, J CLIN PATHOL, V57, P492, DOI 10.1136/jcp.2003.012559; Rodicker F, 2003, CANCER RES, V63, P2737; Sablina AA, 2003, J BIOL CHEM, V278, P27362, DOI 10.1074/jbc.M300547200; Shimodaira H, 2003, P NATL ACAD SCI USA, V100, P2420, DOI 10.1073/pnas.0438031100; Shinbo J, 2002, BIOCHEM BIOPH RES CO, V295, P501, DOI 10.1016/S0006-291X(02)00707-6; Stiewe T, 2001, APOPTOSIS, V6, P447, DOI 10.1023/A:1012433522902; Strano S, 2001, FEBS LETT, V490, P163, DOI 10.1016/S0014-5793(01)02119-6; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Tomasin R, 2001, J BIOL CHEM, V276, P44185, DOI 10.1074/jbc.M105647200; Tomasini R, 2003, J BIOL CHEM, V278, P37722, DOI 10.1074/jbc.M301979200; Tomasini R, 2002, EUR J CELL BIOL, V81, P294, DOI 10.1078/0171-9335-00248; Torigoe Takayuki, 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P15, DOI 10.2174/1568011053352587; Tsuji K, 2002, J BIOL CHEM, V277, P2951, DOI 10.1074/jbc.M108535200; Tullo A, 2003, ONCOGENE, V22, P8738, DOI 10.1038/sj.onc.1206967; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607	40	107	115	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2005	24	55					8093	8104		10.1038/sj.onc.1208951	http://dx.doi.org/10.1038/sj.onc.1208951			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	991JL	16044147				2022-12-25	WOS:000233809400002
J	Vega, MI; Huerta-Yepez, S; Jazirehi, AR; Garban, H; Bonavida, B				Vega, MI; Huerta-Yepez, S; Jazirehi, AR; Garban, H; Bonavida, B			Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis	ONCOGENE			English	Article						non-Hodgkin's lymphoma; Fas; NF-kappa B; YY1; sensitization	NON-HODGKINS-LYMPHOMA; CHRONIC LYMPHOCYTIC-LEUKEMIA; ACTIVATED PROTEIN-KINASE; FACTOR-KAPPA-B; IN-VIVO; SIGNALING PATHWAY; CONSTITUTIVE ACTIVATION; MONOCLONAL-ANTIBODY; DOWN-REGULATION; UP-REGULATION	Rituximab (chimeric anti-CD20 monoclonal antibodies) is currently being used in the treatment of B non-Hodgkin's lymphoma (NHL). We have recently reported that rituximab triggers and modifies various intracellular signaling pathways in NHL B-cell lines, resulting in reverting the chemoresistant phenotype to a sensitive phenotype. This study investigated whether rituximab also modifies intracellular signaling pathways resulting in the sensitization of NHL cells to Fas-induced apoptosis. Treatment of the Fas-resistant NHL cell lines (2F7, Ramos and Raji) with rituximab sensitized the cells to CH-11 (FasL agonist mAb)-induced apoptosis and synergy was achieved. Fas expression was upregulated by rituximab as early as 6 h post-treatment as determined by flow cytometry, reverse transcriptase-polymerase chain reaction and Western blot. Rituximab inhibited both the expression and activity of the transcription repressor Yin-Yang 1 (YY1) that negatively regulates Fas transcription. Inhibition of YY1 resulted in the upregulation of Fas expression and sensitization of the tumor cells to CH-11-induced apoptosis. The downregulation of YY1 expression was the result of rituximab- induced inhibition of both the p38 mitogen-activated protein kinase (MAPK) signaling pathway and constitutive nuclear factor kappa of B cells (NF-kappa B) activity. The involvement of NF-kappa B and YY1 in the regulation of Fas expression was corroborated by the use of Ramos cells with a dominant-active inhibitor of NF-kappa B (Ramos I kappa B-estrogen receptor (ER) mutant) and by silencing YY1 with YY1 siRNA, respectively. Further, the role of rituximab- mediated inhibition of the p38 MAPK/NF-kappa B/YY1 pathway in the regulation of Fas and sensitization to CH-11-induced apoptosis was validated by the use of specific chemical inhibitors of this pathway and which mimicked rituximab-mediated effects. These findings provide a novel mechanism of rituximab-mediated activity by sensitizing NHL cells to Fas-induced apoptosis.	Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Jonnson Comprehens Canc Ctr, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Bonavida, B (corresponding author), Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, 10833 Le Conte Ave,A2-060 CHS, Los Angeles, CA 90095 USA.	bbonavida@mednet.ucla.edu	Vega, Mario/AAZ-4315-2020	Garban, Hermes/0000-0001-7754-5357; Vega, Mario I/0000-0002-3932-2483	FIC NIH HHS [D43 TW00013-14] Funding Source: Medline; NIAID NIH HHS [AI28697] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [D43TW000013] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI028697] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alas S, 2001, CLIN CANCER RES, V7, P709; Barnhart BC, 2003, SEMIN IMMUNOL, V15, P185, DOI 10.1016/S1044-5323(03)00031-9; BERENBAUM MC, 1981, ADV CANCER RES, V35, P269, DOI 10.1016/S0065-230X(08)60912-4; Byrd JC, 2002, BLOOD, V99, P1038, DOI 10.1182/blood.V99.3.1038; CANFIELD SM, 1991, J EXP MED, V173, P1483, DOI 10.1084/jem.173.6.1483; Cragg MS, 2004, BLOOD, V103, P2738, DOI 10.1182/blood-2003-06-2031; DEANS JP, 1995, J BIOL CHEM, V270, P22632, DOI 10.1074/jbc.270.38.22632; Emmanouilides C, 2003, HEMATOL ONCOL, V21, P99, DOI 10.1002/hon.712; FISHER RI, 1993, NEW ENGL J MED, V328, P1002, DOI 10.1056/NEJM199304083281404; FREEDMAN AS, 1991, HEMATOL ONCOL CLIN N, V5, P871, DOI 10.1016/S0889-8588(18)30390-3; Garban HJ, 2001, J IMMUNOL, V167, P75, DOI 10.4049/jimmunol.167.1.75; Golay J, 2001, BLOOD, V98, P3383, DOI 10.1182/blood.V98.12.3383; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HONGO F, 2004, 95 ANN M AM ASS CANC, V45, P105; Huerta-Yepez S, 2004, ONCOGENE, V23, P4993, DOI 10.1038/sj.onc.1207655; Iida M, 1999, LEUKEMIA, V13, P585, DOI 10.1038/sj.leu.2401369; Iwasaki S, 1999, J BIOL CHEM, V274, P26503, DOI 10.1074/jbc.274.37.26503; Jazirehi AR, 2005, ONCOGENE, V24, P2121, DOI 10.1038/sj.onc.1208349; Jazirehi AR, 2004, CANCER RES, V64, P7117, DOI 10.1158/0008-5472.CAN-03-3500; Jazirehi AR, 2003, MOL CANCER THER, V2, P1183; Jazirehi AR, 2005, CANCER RES, V65, P264; Kennedy AD, 2003, BLOOD, V101, P1071, DOI 10.1182/blood-2002-03-0876; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Li-Weber M, 2003, SEMIN IMMUNOL, V15, P145, DOI 10.1016/S1044-5323(03)00030-7; Martin-Blanco E, 2000, BIOESSAYS, V22, P637, DOI 10.1002/1521-1878(200007)22:7<637::AID-BIES6>3.0.CO;2-E; Mori N, 2001, VIRUS GENES, V22, P279, DOI 10.1023/A:1011158021749; Ogasawara T, 2003, INT J HEMATOL, V77, P364, DOI 10.1007/BF02982645; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; REFF ME, 1994, BLOOD, V83, P435; Shan DM, 2000, CANCER IMMUNOL IMMUN, V48, P673, DOI 10.1007/s002620050016; Vega MI, 2004, ONCOGENE, V23, P3530, DOI 10.1038/sj.onc.1207336	31	81	93	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2005	24	55					8114	8127		10.1038/sj.onc.1208954	http://dx.doi.org/10.1038/sj.onc.1208954			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	991JL	16103877				2022-12-25	WOS:000233809400004
J	Su, ZZ; Emdad, L; Sauane, M; Lebedeva, IV; Sarkar, D; Gupta, P; James, CD; Randolph, A; Valerie, K; Walter, MR; Dent, P; Fisher, PB				Su, ZZ; Emdad, L; Sauane, M; Lebedeva, IV; Sarkar, D; Gupta, P; James, CD; Randolph, A; Valerie, K; Walter, MR; Dent, P; Fisher, PB			Unique aspects of mda-7/IL-24 antitumor bystander activity: establishing a role for secretion of MDA-7/IL-24 protein by normal cells	ONCOGENE			English	Article						cancer gene therapy; apoptosis; radiation sensitization; tumor cell invasion; diffusion bystander assay; normal-cell-secreted mda-7/IL-24	DIFFERENTIATION-ASSOCIATED GENE-7; APOPTOSIS INDUCING CYTOKINE; PROSTATE-CANCER CELLS; HUMAN-MELANOMA CELLS; PANCREATIC-CANCER; MDA-7 GENE; IN-VITRO; SUBTRACTION HYBRIDIZATION; GLIOMA-CELLS; ENHANCES RADIOSENSITIVITY	Melanoma differentiation associated gene-7 (mda-7) was cloned using subtraction hybridization from terminally differentiated human melanoma cells. Based on structural and functional properties, mda-7 is now recognized as interleukin-24 (IL-24), a new member of the expanding IL-10 gene family. Unique properties of mda-7/IL-24 include its ability to selectively induce growth suppression, apoptosis and radiosensitization in diverse human cancer cells, without causing similar effects in normal cells. The utility of mda-7/IL-24, administered by means of a replication-incompetent adenovirus, as a gene therapy for cancer has recently received validation in patients, highlighting an important phenomenon initially observed in pancreatic tumor cells, namely a 'potent bystander apoptosis-inducing effect' in adjacent tumor cells not initially receiving this gene product. We presently investigated the contribution of mda-7/IL-24 secreted by normal cells in mediating this 'bystander effect', and document that normal cells induced to produce mda-7/IL-24 following infection with recombinant adenoviruses expressing this cytokine secrete mda-7/IL-24, which modifies the anchorage-independent growth, invasiveness, survival and sensitivity to radiation of cancer cells that contain functional IL-20/IL-22 receptors, but not in cancer cells that lack a complete set of receptors. Moreover, the combination of secreted mda-7/IL-24 and radiation engenders a 'bystander antitumor effect' not only in inherently mda-7/IL-24 or radiation-sensitive cancer cells, but also in tumor cells overexpressing the antiapoptotic proteins bcl-2 or bcl-xL and displaying resistance to either treatment alone. The present studies provide definitive evidence that secreted mda-7/IL-24 from normal cells can induce direct antitumor and radiation-enhancing effects that are dependent on the presence of canonical receptors for this cytokine on tumor cells. Moreover, we now describe a novel means of enhancing mda-7/IL-24's therapeutic potential by targeting normal cells to produce and release this cancer-specific apoptosis-inducing cytokine, a strategy that could be employed as an innovative way of using this unique gene product for treating metastatic disease.	Columbia Univ, Med Ctr, Coll Phys & Surg, Dept Pathol,Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Mayo Clin, Dept Oncol, Div Med Oncol, Rochester, MN 55905 USA; Virginia Commonwealth Univ, Dept Radiat Oncol, Richmond, VA 23298 USA; Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA; Columbia Univ, Med Ctr, Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr,Dept Neurosurg, New York, NY 10032 USA; Columbia Univ, Med Ctr, Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr,Dept Urol, New York, NY 10032 USA	Columbia University; Mayo Clinic; Virginia Commonwealth University; University of Alabama System; University of Alabama Birmingham; Columbia University; Columbia University	Fisher, PB (corresponding author), Columbia Univ, Med Ctr, Coll Phys & Surg, Dept Pathol,Herbert Irving Comprehens Canc Ctr, 630 W 168th St,Black Bldg,Rm 1501, New York, NY 10032 USA.	pbf1@columbia.edu	Lebedeva, Irina V/A-3156-2008; James, Charles D/E-2721-2012; Valerie, Kristoffer/AAL-8299-2021	Lebedeva, Irina V/0000-0002-1693-9392; James, Charles D/0000-0002-1027-203X; 	NATIONAL CANCER INSTITUTE [R01CA097318, P01CA104177, R01CA088906, R01CA098712] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047300] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052825] Funding Source: NIH RePORTER; NCI NIH HHS [CA098712, CA097318, CA088906, CA104177] Funding Source: Medline; NIAID NIH HHS [AI47300] Funding Source: Medline; NIDDK NIH HHS [DK52825] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAE VL, 1994, INT J CANCER, V58, P721, DOI 10.1002/ijc.2910580517; Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; Blumberg H, 2001, CELL, V104, P9, DOI 10.1016/S0092-8674(01)00187-8; Caudell EG, 2002, J IMMUNOL, V168, P6041, DOI 10.4049/jimmunol.168.12.6041; Chada S, 2005, MOL THER, V11, P724, DOI 10.1016/j.ymthe.2004.12.021; Chada S, 2004, MOL THER, V10, P1085, DOI 10.1016/j.ymthe.2004.08.020; Cunningham CC, 2005, MOL THER, V11, P149, DOI 10.1016/j.ymthe.2004.09.019; Dumoutier L, 2001, J IMMUNOL, V167, P3545, DOI 10.4049/jimmunol.167.7.3545; Emdad L, 2005, J CELL PHYSIOL, V202, P135, DOI 10.1002/jcp.20097; Fisher PB, 2003, CANCER BIOL THER, V2, pS23; Frank DK, 1998, CLIN CANCER RES, V4, P2521; Gazdar AF, 2001, P NATL ACAD SCI USA, V98, P10028, DOI 10.1073/pnas.191379998; Gopalkrishnan RV, 2004, INT IMMUNOPHARMACOL, V4, P635, DOI 10.1016/j.intimp.2004.01.015; Hilgers W, 1999, GENE CHROMOSOME CANC, V26, P1; Holmes Matthew, 2003, Methods Mol Biol, V234, P1; Hruban RH, 2001, CANCER J, V7, P251; Huang EY, 2001, ONCOGENE, V20, P7051, DOI 10.1038/sj.onc.1204897; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; Jiang HP, 1995, ONCOGENE, V11, P2477; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P9160, DOI 10.1073/pnas.93.17.9160; Kawabe S, 2002, MOL THER, V6, P637, DOI 10.1006/mthe.2002.0714; Lebedeva IV, 2005, ONCOGENE, V24, P585, DOI 10.1038/sj.onc.1208183; Lebedeva IV, 2003, SEMIN CANCER BIOL, V13, P169, DOI 10.1016/S1044-579X(02)00134-7; Lebedeva IV, 2003, CANCER RES, V63, P8138; Lebedeva IV, 2003, ONCOGENE, V22, P8758, DOI 10.1038/sj.onc.1206891; Lebedeva IV, 2005, MOL THER, V11, P4, DOI 10.1016/j.ymthe.2004.08.012; Lebedeva IV, 2002, ONCOGENE, V21, P708, DOI 10.1038/sj.onc.1205116; Madireddi MT, 2000, ADV EXP MED BIOL, V465, P239; MELBER K, 1989, CANCER RES, V49, P3650; Mhashilkar AM, 2001, MOL MED, V7, P271, DOI 10.1007/BF03401847; Nishikawa T, 2004, MOL THER, V9, P818, DOI 10.1016/j.ymthe.2004.03.014; Novak JP, 2002, J BIOL CHEM, V277, P47517, DOI 10.1074/jbc.M205114200; Pestka S, 2004, ANNU REV IMMUNOL, V22, P929, DOI 10.1146/annurev.immunol.22.012703.104622; PESTKA S, 2003, ENCY HORMONES, P507; Ramesh R, 2004, MOL THER, V9, P510, DOI 10.1016/j.ymthe.2004.01.019; RAMESH R, 2003, CANCER RES, V63, P5113; Rothstein JD, 2005, NATURE, V433, P73, DOI 10.1038/nature03180; Saeki T, 2002, ONCOGENE, V21, P4558, DOI 10.1038/sj.onc.1205553; Saeki T, 2000, GENE THER, V7, P2051, DOI 10.1038/sj.gt.3301330; Sarkar D, 2002, P NATL ACAD SCI USA, V99, P10054, DOI 10.1073/pnas.152327199; Sauane M, 2004, ONCOGENE, V23, P7679, DOI 10.1038/sj.onc.1207958; Sauane M, 2004, CANCER RES, V64, P2988, DOI 10.1158/0008-5472.CAN-04-0200; Sauane M, 2003, J CELL PHYSIOL, V196, P334, DOI 10.1002/jcp.10309; Sauane M, 2003, CYTOKINE GROWTH F R, V14, P35, DOI 10.1016/S1359-6101(02)00074-6; Sitcheran R, 2005, EMBO J, V24, P510, DOI 10.1038/sj.emboj.7600555; Su ZZ, 1997, P NATL ACAD SCI USA, V94, P9125, DOI 10.1073/pnas.94.17.9125; Su ZZ, 2001, P NATL ACAD SCI USA, V98, P10332, DOI 10.1073/pnas.171315198; Su ZZ, 2003, ONCOGENE, V22, P1164, DOI 10.1038/sj.onc.1206062; Su ZZ, 2002, ONCOGENE, V21, P3592, DOI 10.1038/sj.onc.1205445; Su ZZ, 2003, P NATL ACAD SCI USA, V100, P1955, DOI 10.1073/pnas.0136555100; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; Su ZZ, 2005, P NATL ACAD SCI USA, V102, P1059, DOI 10.1073/pnas.0409141102; Tong AW, 2005, MOL THER, V11, P160, DOI 10.1016/j.ymthe.2004.09.021; Wang M, 2002, J BIOL CHEM, V277, P7341, DOI 10.1074/jbc.M106043200; Yacoub A, 2004, CANCER BIOL THER, V3, P739, DOI 10.4161/cbt.3.8.968; Yacoub A, 2003, CANCER BIOL THER, V2, P347, DOI 10.4161/cbt.2.4.422; Yacoub A, 2003, CLIN CANCER RES, V9, P3272; Yacoub A, 2003, MOL CANCER THER, V2, P623	58	125	136	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2005	24	51					7552	7566		10.1038/sj.onc.1208911	http://dx.doi.org/10.1038/sj.onc.1208911			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	984VQ	16044151				2022-12-25	WOS:000233333800005
J	Lazarus, BD; Roos, MD; Hanover, JA				Lazarus, BD; Roos, MD; Hanover, JA			Mutational analysis of the catalytic domain of O-linked N-acetylglucosaminyl transferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; GIBBERELLIN SIGNAL-TRANSDUCTION; GLCNAC TRANSFERASE; INSULIN-RESISTANCE; TETRATRICOPEPTIDE REPEATS; NUCLEAR-PORE; CRYSTAL-STRUCTURE; BETA-GLUCOSYLTRANSFERASE; SUBSTRATE-SPECIFICITY; CYTOSOLIC PROTEINS	O-Linked N-acetylglucosaminyltransferase (OGT) catalyzes the transfer of O-linked GlcNAc to serine/threonine residues of a variety of target proteins, many of which have been implicated in such diseases as diabetes and neurodegeneration. The addition of O-GlcNAc to proteins occurs in response to fluctuations in cellular concentrations of UDP-GlcNAc, which result from nutrients entering the hexosamine biosynthetic pathway. However, the molecular mechanisms involved in sugar nucleotide recognition and transfer to protein are poorly understood. We employed site-directed mutagenesis to target potentially important amino acid residues within the two conserved catalytic domains of OGT(CDI and CDII), followed by an in vitro glycosylation assay to evaluate N-acetylglucosaminyltransferase activity after bacterial expression. Although many of the amino acid substitutions caused inactivation of the enzyme, we identified three amino acid residues ( two in CD I and one in CD II) that produced viable enzymes when mutated. Structure-based homology modeling revealed that these permissive mutants may be either in or near the sugar nucleotide-binding site. Our findings suggest a model in which the two conserved regions of the catalytic domain, CDI and CDII, contribute to the formation of a UDP-GlcNAc-binding pocket that catalyzes the transfer of O-GlcNAc to substrate proteins. Identification of viable OGT mutants may facilitate examination of its role in nutrient sensing and signal transduction cascades.	NIDDK, Lab Cell Biol & Biochem, NIH, Bethesda, MD 20897 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Hanover, JA (corresponding author), NIDDK, Lab Cell Biol & Biochem, NIH, Bldg 8,Rm 402,9000 Rockville Pike, Bethesda, MD 20897 USA.	jah@helix.nih.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK060000] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arnold CS, 1996, J BIOL CHEM, V271, P28741, DOI 10.1074/jbc.271.46.28741; Beattie BK, 1996, BIOCHEMISTRY-US, V35, P15134, DOI 10.1021/bi961985t; Breton C, 1999, CURR OPIN STRUC BIOL, V9, P563, DOI 10.1016/S0959-440X(99)00006-8; Buse MG, 2002, AM J PHYSIOL-ENDOC M, V283, pE241, DOI 10.1152/ajpendo.00060.2002; Campbell RE, 2000, BIOCHEMISTRY-US, V39, P14993, DOI 10.1021/bi001627x; Cervoni L, 1997, FEBS LETT, V417, P227, DOI 10.1016/S0014-5793(97)01285-4; CHOU TY, 1995, P NATL ACAD SCI USA, V92, P4417, DOI 10.1073/pnas.92.10.4417; Cid E, 2000, J BIOL CHEM, V275, P33614, DOI 10.1074/jbc.M005358200; Cole RN, 1999, J NEUROCHEM, V73, P418, DOI 10.1046/j.1471-4159.1999.0730418.x; Comer FI, 2001, BIOCHEMISTRY-US, V40, P7845, DOI 10.1021/bi0027480; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; DAVIS LI, 1987, P NATL ACAD SCI USA, V84, P7552, DOI 10.1073/pnas.84.21.7552; Ding M, 1996, J BIOL CHEM, V271, P12555, DOI 10.1074/jbc.271.21.12555; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; Hagen FK, 1999, J BIOL CHEM, V274, P6797, DOI 10.1074/jbc.274.10.6797; Haltiwanger RS, 1997, BIOCHEM BIOPH RES CO, V231, P237, DOI 10.1006/bbrc.1997.6110; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; HANOVER JA, 1987, J BIOL CHEM, V262, P9887; Hanover JA, 2003, ARCH BIOCHEM BIOPHYS, V409, P287, DOI 10.1016/S0003-9861(02)00578-7; Hanover JA, 2001, FASEB J, V15, P1865, DOI 10.1096/fj.01-0094rev; Hawkins M, 1997, J CLIN INVEST, V99, P2173, DOI 10.1172/JCI119390; Hawkins M, 1996, DIABETES, V45, P1734, DOI 10.2337/diabetes.45.12.1734; Hazel M, 2004, ENDOCRINOLOGY, V145, P2118, DOI 10.1210/en.2003-0812; Hedden P, 2000, TRENDS PLANT SCI, V5, P523, DOI 10.1016/S1360-1385(00)01790-8; HOLT GD, 1987, J CELL BIOL, V104, P1157, DOI 10.1083/jcb.104.5.1157; Hu YN, 2003, P NATL ACAD SCI USA, V100, P845, DOI 10.1073/pnas.0235749100; Iyer SPN, 2003, J BIOL CHEM, V278, P24608, DOI 10.1074/jbc.M300036200; Iyer SPN, 2003, J BIOL CHEM, V278, P5399, DOI 10.1074/jbc.M209384200; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; Jacobsen SE, 1996, P NATL ACAD SCI USA, V93, P9292, DOI 10.1073/pnas.93.17.9292; JACOBSEN SE, 1993, PLANT CELL, V5, P887, DOI 10.1105/tpc.5.8.887; Jinek M, 2004, NAT STRUCT MOL BIOL, V11, P1001, DOI 10.1038/nsmb833; Kamemura K, 2002, J BIOL CHEM, V277, P19229, DOI 10.1074/jbc.M201729200; KELLY WG, 1993, J BIOL CHEM, V268, P10416; Kreppel LK, 1999, J BIOL CHEM, V274, P32015, DOI 10.1074/jbc.274.45.32015; Kreppel LK, 1997, J BIOL CHEM, V272, P9308; Liu FH, 1999, J BIOL CHEM, V274, P34425, DOI 10.1074/jbc.274.48.34425; Lubas WA, 2000, J BIOL CHEM, V275, P10983, DOI 10.1074/jbc.275.15.10983; LUBAS WA, 1995, BIOCHEMISTRY-US, V34, P1686, DOI 10.1021/bi00005a025; Lubas WA, 1997, J BIOL CHEM, V272, P9316; LUTHI T, 1991, J NEUROCHEM, V56, P1493; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; McClain DA, 2002, P NATL ACAD SCI USA, V99, P10695, DOI 10.1073/pnas.152346899; Medina L, 1998, GLYCOBIOLOGY, V8, P383, DOI 10.1093/glycob/8.4.383; Miller MW, 1999, ARCH BIOCHEM BIOPHYS, V367, P51, DOI 10.1006/abbi.1999.1237; Morera S, 1999, J MOL BIOL, V292, P717, DOI 10.1006/jmbi.1999.3094; Persson K, 2001, NAT STRUCT BIOL, V8, P166, DOI 10.1038/84168; Robertson M, 1998, PLANT CELL, V10, P995, DOI 10.1105/tpc.10.6.995; ROBINSON KA, 1995, DIABETES, V44, P1438, DOI 10.2337/diabetes.44.12.1438; Roos MD, 2000, BIOCHEM BIOPH RES CO, V271, P275, DOI 10.1006/bbrc.2000.2600; ROSSETTI L, 1995, J CLIN INVEST, V96, P132, DOI 10.1172/JCI118013; Shafi R, 2000, P NATL ACAD SCI USA, V97, P5735, DOI 10.1073/pnas.100471497; Shaw P, 1996, ONCOGENE, V12, P921; Takahashi M, 1999, ACTA NEUROPATHOL, V97, P635, DOI 10.1007/s004010051040; Tenno M, 2002, J BIOL CHEM, V277, P47088, DOI 10.1074/jbc.M207369200; VRIELINK A, 1994, EMBO J, V13, P3413, DOI 10.1002/j.1460-2075.1994.tb06646.x; Wells L, 2003, CELL MOL LIFE SCI, V60, P222, DOI 10.1007/s000180300017; Wells L, 2003, FEBS LETT, V546, P154, DOI 10.1016/S0014-5793(03)00641-0; Wrabl JO, 2001, J MOL BIOL, V314, P365, DOI 10.1006/jmbi.2001.5151; Yang XY, 2001, P NATL ACAD SCI USA, V98, P6611, DOI 10.1073/pnas.111099998; Zhang FX, 2003, CELL, V115, P715, DOI 10.1016/S0092-8674(03)00974-7; Zhang YN, 1999, GLYCOBIOLOGY, V9, P815, DOI 10.1093/glycob/9.8.815	62	27	31	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35537	35544		10.1074/jbc.M504948200	http://dx.doi.org/10.1074/jbc.M504948200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16105839	hybrid			2022-12-25	WOS:000232561200055
J	Robinson, MA; Park, S; Sun, ZYJ; Silver, PA; Wagner, G; Hogle, JM				Robinson, MA; Park, S; Sun, ZYJ; Silver, PA; Wagner, G; Hogle, JM			Multiple conformations in the ligand-binding site of the yeast nuclear pore-targeting domain of Nup116p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROMOLECULAR STRUCTURE; NUCLEOPORIN NUP145P; BIOGENESIS PATHWAY; PROTEIN STRUCTURES; COMPLEX; NUP98; NMR; DYNAMICS; PROGRAM; ARCHITECTURE	The yeast nucleoporin Nup116p plays an important role in mRNA export and protein transport. We have determined the solution structure of the C- terminal 147 residues of this protein, the region responsible for targeting the protein to the nuclear pore complex ( NPC). The structure of Nup116p- C consists of a large beta- sheet sandwiched against a smaller one, flanked on both sides by alpha- helical stretches, similar to the structure of its human homolog, NUP98. In unliganded form, Nup116p- C exhibits evidence of exchange among multiple conformations, raising the intriguing possibility that it may adopt distinct conformations when bound to different partners in the NPC. We have additionally shown that a peptide from the N terminus of the nucleoporin Nup145p- C binds Nup116p- C. This previously unknown interaction may explain the unusual asymmetric localization pattern of Nup116p in the NPC. Strikingly, the exchange phenomenon observed in the unbound state is greatly reduced in the corresponding spectra of peptide-bound Nup116p- C, suggesting that the binding interaction stabilizes the domain conformation. This study offers a high resolution view of a yeast nucleoporin structural domain and may provide insights into NPC architecture and function.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Comm Higher Degrees Biophys, Cambridge, MA 02138 USA; Inha Univ, Coll Med, Dept Biochem, Inchon 400712, South Korea	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Inha University	Wagner, G (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.	gerhard_wagner@hms.harvard.edu; james_hogle@hms.harvard.edu	Hogle, James/HIG-9121-2022	Hogle, James/0000-0002-3655-1504	NATIONAL CANCER INSTITUTE [R01CA068262] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM036373, R01GM036373, P01GM047467] Funding Source: NIH RePORTER; NCI NIH HHS [CA68262] Funding Source: Medline; NIGMS NIH HHS [GM36373, GM47467] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen TD, 2000, J CELL SCI, V113, P1651; Bailer SM, 2000, J BIOL CHEM, V275, P23540, DOI 10.1074/jbc.M001963200; Bailer SM, 1998, EMBO J, V17, P1107, DOI 10.1093/emboj/17.4.1107; BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cavanagh J., 1995, PROTEIN NMR SPECTROS; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Emtage JLT, 1997, J CELL SCI, V110, P911; Fabre E, 1997, ANNU REV GENET, V31, P277, DOI 10.1146/annurev.genet.31.1.277; Ferentz AE, 2000, Q REV BIOPHYS, V33, P29, DOI 10.1017/S0033583500003589; Fontoura BMA, 1999, J CELL BIOL, V144, P1097, DOI 10.1083/jcb.144.6.1097; Fontoura BMA, 2001, P NATL ACAD SCI USA, V98, P3208, DOI 10.1073/pnas.061014698; Goh CS, 2004, CURR OPIN STRUC BIOL, V14, P104, DOI 10.1016/j.sbi.2004.01.005; Griffis ER, 2003, MOL BIOL CELL, V14, P600, DOI 10.1091/mbc.E02-09-0582; Griffis ER, 2002, MOL BIOL CELL, V13, P1282, DOI 10.1091/mbc.01-11-0538; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Ho AK, 2000, MOL CELL BIOL, V20, P5736, DOI 10.1128/MCB.20.15.5736-5748.2000; Hodel AE, 2002, MOL CELL, V10, P347, DOI 10.1016/S1097-2765(02)00589-0; HURWITZ ME, 1995, J CELL BIOL, V130, P1275, DOI 10.1083/jcb.130.6.1275; Hyberts SG, 2003, J BIOMOL NMR, V26, P335, DOI 10.1023/A:1024078926886; Iovine MK, 1995, J CELL BIOL, V131, P1699, DOI 10.1083/jcb.131.6.1699; James LC, 2003, SCIENCE, V299, P1362, DOI 10.1126/science.1079731; James LC, 2003, TRENDS BIOCHEM SCI, V28, P361, DOI 10.1016/S0968-0004(03)00135-X; Johnson Bruce A, 2004, Methods Mol Biol, V278, P313; Kiseleva E, 2000, CRIT REV EUKAR GENE, V10, P101; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Ma BY, 2002, PROTEIN SCI, V11, P184, DOI 10.1110/ps.21302; NILGES M, 1993, PROTEINS, V17, P297, DOI 10.1002/prot.340170307; Rosenblum JS, 1999, P NATL ACAD SCI USA, V96, P11370, DOI 10.1073/pnas.96.20.11370; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Stoffler D, 1999, CURR OPIN CELL BIOL, V11, P391, DOI 10.1016/S0955-0674(99)80055-6; Strawn LA, 2001, J BIOL CHEM, V276, P6445, DOI 10.1074/jbc.M008311200; Teixeira MT, 1999, J BIOL CHEM, V274, P32439, DOI 10.1074/jbc.274.45.32439; Teixeira MT, 1997, EMBO J, V16, P5086, DOI 10.1093/emboj/16.16.5086; Tsai CJ, 1999, PROTEIN SCI, V8, P1181, DOI 10.1110/ps.8.6.1181; WENTE SR, 1993, J CELL BIOL, V123, P275, DOI 10.1083/jcb.123.2.275; WENTE SR, 1992, J CELL BIOL, V119, P705, DOI 10.1083/jcb.119.4.705	40	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35723	35732		10.1074/jbc.M505068200	http://dx.doi.org/10.1074/jbc.M505068200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16105837	hybrid			2022-12-25	WOS:000232561200075
J	Pan, YX; Chen, H; Kilberg, MS				Pan, YX; Chen, H; Kilberg, MS			Interaction of RNA-binding proteins HuR and AUF1 with the human ATF3 mRNA 3 '-untranslated region regulates its amino acid limitation-induced stabilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING TRANSCRIPTION FACTOR-3; ASPARAGINE SYNTHETASE GENE; RICH ELEMENT; NUTRITIONAL REGULATION; GENOMIC ORGANIZATION; MAMMALIAN-CELLS; STRESS-RESPONSE; HEPATOMA-CELLS; KINASE; EXPRESSION	ATF3 expression is induced in cells exposed to a variety of stress conditions, including nutrient limitation. Here we demonstrated that the mechanism by which the ATF3 mRNA content is increased following amino acid limitation of human HepG2 hepatoma cells is mRNA stabilization. Analysis of ATF3 mRNA turnover revealed that the half-life was increased from about 1 h in control cells to greater than 8 h in the histidine-deprived state, demonstrating mRNA stabilization in response to nutrient deprivation. Treatment of HepG2 cells with thapsigargin, which causes endoplasmic reticulum stress, also increased the half-life of ATF3 mRNA. HuR is an RNA-binding protein that regulates both the stability and cytoplasmic/ nuclear localization of mRNA species containing AU-rich elements. Another RNA-binding protein, AUF1, regulates target mRNA molecules by enhancing their decay. Amino acid limitation caused a slightly elevated mRNA level for HuR and AUF1 mRNA. The nuclear HuR protein content was unchanged, and AUF1 protein increased slightly after amino acid limitation, whereas the cytoplasmic levels of both HuR and AUF1 protein increased. Immunoprecipitation of HuR-RNA complexes followed by reverse transcriptase-PCR analysis showed that HuR interacted with ATF3 mRNA in vivo and that this interaction increased following amino acid limitation. In contrast, the interaction of AUF1 with the ATF3 mRNA is decreased in histidine-deprived cells relative to control cells. Suppression of HuR expression by RNA interference partially blocked the accumulation of ATF3 mRNA following amino acid deprivation. The results demonstrated that coordinated regulation of mRNA stability by HuR and AUF1 proteins contributes to the observed increase in ATF3 expression following amino acid limitation.	Univ Florida, Coll Med, Dept Biochem & Mol Biol, Genet Inst, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Shands Canc Ctr, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Kilberg, MS (corresponding author), Univ Florida, Coll Med, Dept Biochem & Mol Biol, Genet Inst, Box 100245, Gainesville, FL 32610 USA.	mkilberg@ufl.edu	Pan, Yuan-Xiang/C-6576-2019	Pan, Yuan-Xiang/0000-0003-3219-4367	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052064, R01DK059315] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-59315, DK-52064, R01 DK059315, R01 DK052064] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aslanian AM, 2001, BIOCHEM J, V357, P321, DOI 10.1042/0264-6021:3570321; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; Bruhat A, 1997, J BIOL CHEM, V272, P17588, DOI 10.1074/jbc.272.28.17588; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; Chen CYA, 2002, MOL CELL BIOL, V22, P7268, DOI 10.1128/MCB.22.20.7268-7278.2002; Chen H, 2004, J BIOL CHEM, V279, P50829, DOI 10.1074/jbc.M409173200; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; Giles KM, 2003, J BIOL CHEM, V278, P2937, DOI 10.1074/jbc.M208439200; Hai T, 1999, GENE EXPRESSION, V7, P321; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Hartman MG, 2004, MOL CELL BIOL, V24, P5721, DOI 10.1128/MCB.24.13.5721-5732.2004; Hashimoto Y, 2002, NUCLEIC ACIDS RES, V30, P2398, DOI 10.1093/nar/30.11.2398; HOFFER LJ, 1993, CAN J PHYSIOL PHARM, V71, P633, DOI 10.1139/y93-092; Jiang HY, 2004, MOL CELL BIOL, V24, P1365, DOI 10.1128/MCB.24.3.1365-1377.2004; Jing Q, 2005, CELL, V120, P623, DOI 10.1016/j.cell.2004.12.038; Kilberg Michael S., 2003, P105, DOI 10.1079/9780851996790.0105; Lal A, 2004, EMBO J, V23, P3092, DOI 10.1038/sj.emboj.7600305; Leung-Pineda V, 2004, BIOCHEM J, V379, P79, DOI 10.1042/BJ20031383; Liang GN, 2004, P NATL ACAD SCI USA, V101, P7357, DOI 10.1073/pnas.0401866101; Liang GS, 1996, J BIOL CHEM, V271, P1695, DOI 10.1074/jbc.271.3.1695; Lu JY, 2004, J BIOL CHEM, V279, P12974, DOI 10.1074/jbc.M310433200; Ming XF, 1998, EMBO J, V17, P6039, DOI 10.1093/emboj/17.20.6039; Ming XF, 2001, MOL CELL BIOL, V21, P5778, DOI 10.1128/MCB.21.17.5778-5789.2001; Mizock BA, 1999, NUTRITION, V15, P220, DOI 10.1016/S0899-9007(98)00191-9; Pan YX, 2003, J BIOL CHEM, V278, P38402, DOI 10.1074/jbc.M304574200; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Raineri I, 2004, NUCLEIC ACIDS RES, V32, P1279, DOI 10.1093/nar/gkh282; Sarkar B, 2003, MOL CELL BIOL, V23, P6685, DOI 10.1128/MCB.23.18.6685-6693.2003; Siu F, 2002, J BIOL CHEM, V277, P24120, DOI 10.1074/jbc.M201959200; Straus DS, 2002, CLIN CHEM LAB MED, V40, P1274, DOI 10.1515/CCLM.2002.221; STRAUS DS, 1994, FASEB J, V8, P6, DOI 10.1096/fasebj.8.1.8299891; Vattem KM, 2004, P NATL ACAD SCI USA, V101, P11269, DOI 10.1073/pnas.0400541101; Wagner BJ, 1998, GENOMICS, V48, P195, DOI 10.1006/geno.1997.5142; Wang J, 2003, J BIOL CHEM, V278, P32899, DOI 10.1074/jbc.M305456200; Winzen R, 2004, MOL CELL BIOL, V24, P4835, DOI 10.1128/MCB.24.11.4835-4847.2004; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Yaman I, 2003, CELL, V113, P519, DOI 10.1016/S0092-8674(03)00345-3; Yaman I, 2002, J BIOL CHEM, V277, P41539, DOI 10.1074/jbc.M204850200; Zhan K, 2002, MOL CELL BIOL, V22, P7134, DOI 10.1128/MCB.22.20.7134-7146.2002; Zhang F, 2001, J BIOL CHEM, V276, P24946, DOI 10.1074/jbc.M102108200; Zhang PC, 2002, MOL CELL BIOL, V22, P6681, DOI 10.1128/MCB.22.19.6681-6688.2002	45	59	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34609	34616		10.1074/jbc.M507802200	http://dx.doi.org/10.1074/jbc.M507802200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16109718	Green Accepted, hybrid			2022-12-25	WOS:000232403900029
J	Schmidt, A; Echtermeyer, F; Alozie, A; Brands, K; Buddecke, E				Schmidt, A; Echtermeyer, F; Alozie, A; Brands, K; Buddecke, E			Plasmin- and thrombin-accelerated shedding of syndecan-4 ectodomain generates cleavage sites at Lys(114)-Arg(115) and Lys(129)-Val(130) bonds	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; FIBROBLAST-GROWTH-FACTOR; CELL-SURFACE; CORE PROTEIN; BINDING; GLYCOSAMINOGLYCANS; SELECTIN; ADHESION; DOMAINS	Syndecans are transmembranous heparan sulfate proteoglycans abundant in the surface of all adherent mammalian cells and involved in vital cellular functions. In this study, we found syndecan-1, - 2, - 3, and - 4 to be constitutively expressed by human umbilical vein endothelial cells. The exposure of the ectodomains of syndecan-1 and - 4 to the cell surface and their constitutive shedding into the extracellular compartment was measured by immunoassays. In the presence of plasmin and thrombin, shedding was accelerated and monitored by detection and identification of S-35-labeled proteoglycans. To elucidate the cleavage site of the syndecan ectodomains, we used a cell-free in vitro system with enzyme and substrate as the only reactants. For this purpose, we constructed recombinant fusion proteins of the syndecan-1 and - 4 ectodomain together with maltose-binding protein and enhanced yellow fluorescent protein as reporter proteins attached to the N and C termini via oligopeptide linkers. After protease treatment of the fusion proteins, the electrophoretically resolved split products were sequenced and cleavage sites of the ectodomain were identified. Plasmin generated cleavage sites at Lys(114) down arrow Arg(115\) and Lys(129) down arrow Val(130) in the ectodomain of syndecan-4. In thrombin proteolysates of the syndecan-4 ectodomain, the cleavage site Lys(114) down arrow Arg(115) was also identified. The cleavage sites for plasmin and thrombin within the syndecan-4 ectodomain were not present in the syndecan-1 ectodomain. Cleavage of the syndecan-1 fusion protein by thrombin occurred only at a control cleavage site ( Arg down arrow Gly) introduced into the linker region connecting the ectodomain with the enhanced yellow fluorescent protein. Because both plasmin and thrombin are involved in thrombogenic and thrombolytic processes in the course of the pathogenesis of arteriosclerosis, the detachment of heparan sulfate-bearing ectodomains could be relevant for the development of arteriosclerotic plaques and recruitment of mononuclear blood cells to the plaque.	Univ Munster, Leibniz Inst Arteriosclerosis Res 1, D-48149 Munster, Germany; Univ Munster, Inst Physiol Chem & Pathobiochem, D-48149 Munster, Germany	University of Munster; University of Munster	Schmidt, A (corresponding author), Univ Munster, Inst Arteriosclerosis Res, Dept Mol Cardiol, Domagkstr 3, D-48149 Munster, Germany.	annschm@uni-muenster.de		Locher, Kerstin/0000-0002-0175-3747				AVIEZER D, 1994, J BIOL CHEM, V269, P114; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Carey DJ, 1997, BIOCHEM J, V327, P1; CizmeciSmith G, 1997, ARTERIOSCL THROM VAS, V17, P172, DOI 10.1161/01.ATV.17.1.172; Echtermeyer F, 1999, J CELL SCI, V112, P3433; Echtermeyer F, 2001, J CLIN INVEST, V107, pR9, DOI 10.1172/JCI10559; Endo K, 2003, J BIOL CHEM, V278, P40764, DOI 10.1074/jbc.M306736200; Fitzgerald ML, 2000, J CELL BIOL, V148, P811, DOI 10.1083/jcb.148.4.811; Fuki IV, 1997, J CLIN INVEST, V100, P1611, DOI 10.1172/JCI119685; Giuffre L, 1997, J CELL BIOL, V136, P945, DOI 10.1083/jcb.136.4.945; Gotte M, 2003, FASEB J, V17, P575, DOI 10.1096/fj.02-0739rev; Gotte Martin, 2003, ScientificWorldJournal, V3, P1327; Halden Y, 2004, BIOCHEM J, V377, P533, DOI 10.1042/BJ20030729; Horowitz A, 1998, J BIOL CHEM, V273, P10914, DOI 10.1074/jbc.273.18.10914; Horowitz A, 2002, J CELL BIOL, V157, P715, DOI 10.1083/jcb.200112145; Houston M, 2005, AM J PHYSIOL-CELL PH, V288, pC458, DOI 10.1152/ajpcell.00001.2004; Ishiguro K, 2001, J BIOL CHEM, V276, P47483, DOI 10.1074/jbc.M106268200; JAAKKOLA P, 2000, PROTEOGLYCANS STRUCT, P115; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JALKANEN M, 1987, J CELL BIOL, V105, P3087, DOI 10.1083/jcb.105.6.3087; Kainulainen V, 1998, J BIOL CHEM, V273, P11563, DOI 10.1074/jbc.273.19.11563; Kato M, 1998, NAT MED, V4, P691, DOI 10.1038/nm0698-691; Koenig A, 1998, J CLIN INVEST, V101, P877, DOI 10.1172/JCI1509; Levi E, 1996, P NATL ACAD SCI USA, V93, P7069, DOI 10.1073/pnas.93.14.7069; Li QL, 2002, CELL, V111, P635, DOI 10.1016/S0092-8674(02)01079-6; Mead JR, 1999, FEBS LETT, V462, P1, DOI 10.1016/S0014-5793(99)01495-7; MERTENS G, 1992, J BIOL CHEM, V267, P20435; Park PW, 2000, J BIOL CHEM, V275, P29923, DOI 10.1074/jbc.R000008200; Park PW, 2004, J BIOL CHEM, V279, P251, DOI 10.1074/jbc.M308537200; Park PW, 2000, J BIOL CHEM, V275, P3057, DOI 10.1074/jbc.275.5.3057; Rapraeger AC, 2000, J CELL BIOL, V149, P995, DOI 10.1083/jcb.149.5.995; Rioux V, 2002, J LIPID RES, V43, P167; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; SCHMIDT A, 1992, J BIOL CHEM, V267, P19242; Schmidt A, 2002, ATHEROSCLEROSIS, V164, P57, DOI 10.1016/S0021-9150(02)00053-9; SCHMIDT A, 1992, EUR J CELL BIOL, V59, P322; Subramanian SV, 1997, J BIOL CHEM, V272, P14713, DOI 10.1074/jbc.272.23.14713; Tumova S, 2000, INT J BIOCHEM CELL B, V32, P269, DOI 10.1016/S1357-2725(99)00116-8; WOODS A, 1994, MOL BIOL CELL, V5, P183, DOI 10.1091/mbc.5.2.183; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; Zimmermann P, 1999, FASEB J, V13, pS91	41	50	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34441	34446		10.1074/jbc.M501903200	http://dx.doi.org/10.1074/jbc.M501903200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16087677	hybrid			2022-12-25	WOS:000232403900010
J	Vicente, JB; Teixeira, M				Vicente, JB; Teixeira, M			Redox and spectroscopic properties of the Escherichia coli nitric oxide-detoxifying system involving flavorubredoxin and its NADH-oxidizing redox partner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOOXYGENASE HYDROXYLASE COMPONENT; METHYLOCOCCUS-CAPSULATUS BATH; MOLECULAR-WEIGHT RUBREDOXIN; OXIDATIVE STRESS PROTECTION; METHANE MONOOXYGENASE; ELECTRON-TRANSFER; DESULFOVIBRIO-VULGARIS; NAD(P)H-RUBREDOXIN OXIDOREDUCTASE; PSEUDOMONAS-OLEOVORANS; MOORELLA-THERMOACETICA	Under anaerobic conditions, the flavodiiron NO-reductase from Escherichia coli ( flavorubredoxin, FlRd) constitutes one of the major protective enzymes against nitric oxide. The redox and spectroscopic properties of the rubredoxin (Rd), non-heme diiron, and FMN sites of flavorubredoxin were determined, which was complemented by the study of truncated versions of FlRd: one consisting only of its rubredoxin module, and another consisting of its flavodiiron structural core ( lacking the Rd domain). The studies here reported were performed by a combination of potentiometry with visible and EPR spectroscopies. Moreover, we present the first direct EPR evidence for the presence of the non-heme diiron site in the flavodiiron proteins family. Also, the redox properties of the FlRd physiological partner, the NADH: flavorubredoxin oxidoreductase (FlRd-Red), were determined. It is further shown that the redox properties of this complex electron transfer system are fine-tuned upon interaction of the two enzymes.	Univ Nova Lisboa, Inst Tecnol Quim & Biol, P-2781901 Oeiras, Portugal	Universidade Nova de Lisboa	Teixeira, M (corresponding author), Univ Nova Lisboa, Inst Tecnol Quim & Biol, Av Republ,Apt 127, P-2781901 Oeiras, Portugal.	miguel@itqb.unl.pt	Vicente, João B/B-9623-2014; Vicente, Joao B/L-8732-2016; Teixeira, Miguel/M-1509-2019; Teixeira, Miguel/A-9098-2011	Vicente, João B/0000-0003-3919-8280; Teixeira, Miguel/0000-0003-4124-6237; Teixeira, Miguel/0000-0003-4124-6237; Vicente, Joao/0000-0001-5244-8059				Alric J, 2004, J BIOL CHEM, V279, P47849, DOI 10.1074/jbc.M408888200; ATTA M, 1994, J AM CHEM SOC, V116, P6429, DOI 10.1021/ja00093a051; Berthold DA, 2002, J BIOL CHEM, V277, P43608, DOI 10.1074/jbc.M206724200; Carlton JM, 2002, NATURE, V419, P512, DOI 10.1038/nature01099; Coulter ED, 2001, ARCH BIOCHEM BIOPHYS, V394, P76, DOI 10.1006/abbi.2001.2531; da Costa PN, 2001, MOL MICROBIOL, V41, P217, DOI 10.1046/j.1365-2958.2001.02509.x; Das A, 2001, J BACTERIOL, V183, P1560, DOI 10.1128/JB.183.5.1560-1567.2001; deMare F, 1996, NAT STRUCT BIOL, V3, P539, DOI 10.1038/nsb0696-539; EGGINK G, 1990, J MOL BIOL, V212, P135, DOI 10.1016/0022-2836(90)90310-I; Eidsness MK, 1999, BIOCHEMISTRY-US, V38, P14803, DOI 10.1021/bi991661f; FISCHER DS, 1964, CLIN CHEM, V10, P21, DOI 10.1016/0009-8981(64)90210-4; FOX BG, 1988, J BIOL CHEM, V263, P10553; FOX BG, 1988, BIOCHEM BIOPH RES CO, V154, P165, DOI 10.1016/0006-291X(88)90665-1; Frazao C, 2000, NAT STRUCT BIOL, V7, P1041; Frey AD, 2002, APPL ENVIRON MICROB, V68, P4835, DOI 10.1128/AEM.68.10.4835-4840.2002; Gardner AM, 2002, J BIOL CHEM, V277, P8172, DOI 10.1074/jbc.M110471200; GHISLA S, 2001, ENCY LIFE SCI; Gomes CM, 1997, J BIOL CHEM, V272, P22502, DOI 10.1074/jbc.272.36.22502; Gomes CM, 2002, J BIOL CHEM, V277, P25273, DOI 10.1074/jbc.M203886200; Gomes CM, 2000, BIOCHEMISTRY-US, V39, P16230, DOI 10.1021/bi001844y; HENDRICH MP, 1990, J AM CHEM SOC, V112, P5861, DOI 10.1021/ja00171a029; Justino MC, 2005, J BIOL CHEM, V280, P2636, DOI 10.1074/jbc.M411070200; Kummerle R, 1997, BIOCHEMISTRY-US, V36, P15983, DOI 10.1021/bi971636e; Kurtz DM, 1997, J BIOL INORG CHEM, V2, P159, DOI 10.1007/s007750050120; Lee HJ, 1998, BIOCHEMISTRY-US, V37, P15513, DOI 10.1021/bi981853v; Lee NR, 1996, BIOCHEM BIOPH RES CO, V218, P17, DOI 10.1006/bbrc.1996.0004; LIU KE, 1991, J BIOL CHEM, V266, P12836; Lumppio HL, 2001, J BACTERIOL, V183, P101, DOI 10.1128/JB.183.1.101-108.2001; Ma K, 2001, METHOD ENZYMOL, V334, P55; Ma K, 1999, J BACTERIOL, V181, P5530, DOI 10.1128/JB.181.17.5530-5533.1999; Meyer J., 2001, HDB METALLOPROTEINS, V1, P505; PAULSEN KE, 1994, BIOCHEMISTRY-US, V33, P713, DOI 10.1021/bi00169a013; PETITDEMANGE H, 1981, ANAL BIOCHEM, V116, P564, DOI 10.1016/0003-2697(81)90403-6; Poole RK, 2000, MOL MICROBIOL, V36, P775, DOI 10.1046/j.1365-2958.2000.01889.x; Rodrigues JV, 2005, BIOCHEM BIOPH RES CO, V329, P1300, DOI 10.1016/j.bbrc.2005.02.114; Saraiva LM, 2004, ADV MICROB PHYSIOL, V49, P77, DOI 10.1016/S0065-2911(04)49002-X; Silaghi-Dumitrescu R, 2005, BIOCHEMISTRY-US, V44, P6492, DOI 10.1021/bi0473049; Silaghi-Dumitrescu R, 2003, BIOCHEMISTRY-US, V42, P2806, DOI 10.1021/bi027253k; Solomon EI, 2000, CHEM REV, V100, P235, DOI 10.1021/cr9900275; SUSIN S, 1993, J BIOL CHEM, V268, P20958; Teixeira VH, 2004, BIOPHYS J, V86, P2773, DOI 10.1016/S0006-3495(04)74331-3; van Beilen JB, 2002, J BACTERIOL, V184, P1722, DOI 10.1128/JB.184.6.1722-1732.2002; Wasserfallen A, 1998, EUR J BIOCHEM, V254, P325, DOI 10.1046/j.1432-1327.1998.2540325.x; Wastl J, 2000, FEBS LETT, V471, P191, DOI 10.1016/S0014-5793(00)01399-5; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; WOODLAND MP, 1986, BIOCHIM BIOPHYS ACTA, V873, P237, DOI 10.1016/0167-4838(86)90050-6	46	40	41	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34599	34608		10.1074/jbc.M506349200	http://dx.doi.org/10.1074/jbc.M506349200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16100392	hybrid			2022-12-25	WOS:000232403900028
J	Esteban, R; Vega, L; Fujimura, T				Esteban, R; Vega, L; Fujimura, T			Launching of the yeast 20 S RNA narnavirus by expressing the genomic or antigenomic viral RNA in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; BIPARTITE 3'-CIS-ACTING SIGNAL; SACCHAROMYCES-CEREVISIAE; POLYNUCLEOTIDE PHOSPHORYLASE; POLY(A) POLYMERASE; MESSENGER-RNAS; VIRUS; REPLICATION; POLYMERIZATION; FORM	20 S RNA virus is a persistent positive strand RNA virus found in Saccharomyces cerevisiae. The viral genome encodes only its RNA polymerase, p91, and resides in the cytoplasm in the form of a ribonucleoprotein complex with p91. We succeeded in generating 20 S RNA virus in vivo by expressing, from a vector, genomic strands fused at the 3'-ends to the hepatitis delta virus antigenomic ribozyme. Using this launching system, we analyzed 3'-cis-signals present in the genomic strand for replication. The viral genome has five-nucleotide inverted repeats at both termini ( 5'-GGGGC... GCCCC-OH). The fifth G from the 3'-end was dispensable for replication, whereas the third and fourth Cs were essential. The 3'-terminal and penultimate Cs could be eliminated or modified to other nucleotides; however, the generated viruses recovered these terminal Cs. Furthermore, extra nucleotides added at the viral 3'-end were eliminated in the launched viruses. Therefore, 20 S RNA virus has amechanism(s) to maintain the correct size and sequence of the viral 3'-end. This may contribute to its persistent infection in yeast. We also succeeded in generating 20 S RNA virus similarly from antigenomic strands provided active p91 was supplied from a second vector in trans. Again, a cluster of four Cs at the 3'-end in the antigenomic strand was essential for replication. In this work, we also present the first conclusive evidence that 20 S and 23 S RNA viruses are independent replicons.	Univ Salamanca, CSIC, Inst Microbiol Bioquim, Dept Genet & Microbiol, Salamanca 37007, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Funcional y Genomica (IBFG); University of Salamanca	Esteban, R (corresponding author), Univ Salamanca, CSIC, Inst Microbiol Bioquim, Dept Genet & Microbiol, Avda Campo Charro S-N, Salamanca 37007, Spain.	mrosa@gugu.usal.es	Esteban, Rosa/K-4356-2014; Fujimura, Tsutomu/K-5807-2014	Esteban, Rosa/0000-0001-6804-7209; Fujimura, Tsutomu/0000-0002-9457-6769				Anderson JSJ, 1998, EMBO J, V17, P1497, DOI 10.1093/emboj/17.5.1497; Bressanelli S, 1999, P NATL ACAD SCI USA, V96, P13034, DOI 10.1073/pnas.96.23.13034; Buck KW, 1996, ADV VIRUS RES, V47, P159, DOI 10.1016/S0065-3527(08)60736-8; Butcher SJ, 2001, NATURE, V410, P235, DOI 10.1038/35065653; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; ESTEBAN LM, 1992, J BIOL CHEM, V267, P10874; ESTEBAN LM, 1994, J BIOL CHEM, V269, P29771; ESTEBAN R, 1989, EMBO J, V8, P947, DOI 10.1002/j.1460-2075.1989.tb03456.x; ESTEBAN R, 1993, PROG NUCLEIC ACID RE, V46, P155, DOI 10.1016/S0079-6603(08)61021-1; Esteban R, 2003, P NATL ACAD SCI USA, V100, P2568, DOI 10.1073/pnas.0530167100; Fujimura T, 2005, J BIOL CHEM, V280, P7398, DOI 10.1074/jbc.M412048200; FUJIMURA T, 1990, CELL, V62, P819, DOI 10.1016/0092-8674(90)90125-X; Fujimura T, 2004, J BIOL CHEM, V279, P44219, DOI 10.1074/jbc.M408530200; Fujimura T, 2004, J BIOL CHEM, V279, P13215, DOI 10.1074/jbc.M313797200; GARCIACUELLAR MP, 1995, J BIOL CHEM, V270, P20084, DOI 10.1074/jbc.270.34.20084; GARCIACUELLAR MP, 1996, THESIS U SALAMANCA S; Guan HC, 2000, P NATL ACAD SCI USA, V97, P12451, DOI 10.1073/pnas.97.23.12451; HARTLEY JL, 1980, NATURE, V286, P860, DOI 10.1038/286860a0; KADOWAKI K, 1971, J BACTERIOL, V105, P826, DOI 10.1128/JB.105.3.826-830.1971; Lopez V, 2002, YEAST, V19, P545, DOI 10.1002/yea.848; Maniatis T., 1982, MOL CLONING LAB MANU; MATSUMOTO Y, 1991, J BIOL CHEM, V266, P12779; Mohanty BK, 2000, P NATL ACAD SCI USA, V97, P11966, DOI 10.1073/pnas.220295997; Ng KKS, 2002, J BIOL CHEM, V277, P1381, DOI 10.1074/jbc.M109261200; PERROTTA AT, 1991, NATURE, V350, P434, DOI 10.1038/350434a0; Reuven NB, 1997, J BIOL CHEM, V272, P33255, DOI 10.1074/jbc.272.52.33255; Rodriguez-Cousino N, 1998, J BIOL CHEM, V273, P20363, DOI 10.1074/jbc.273.32.20363; RODRIGUEZCOUSINO N, 1992, NUCLEIC ACIDS RES, V20, P2761, DOI 10.1093/nar/20.11.2761; RODRIGUEZCOUSINO N, 1991, J BIOL CHEM, V266, P12772; Shi PY, 1998, EMBO J, V17, P3197, DOI 10.1093/emboj/17.11.3197; Shi PY, 1998, RNA, V4, P276; Solorzano A, 2000, J BIOL CHEM, V275, P26428, DOI 10.1074/jbc.M002281200; Sprinzl M., 1989, Nucleic Acids Research, V17, P1; VALLE RPC, 1993, J VIROL, V67, P2764, DOI 10.1128/JVI.67.5.2764-2771.1993; VREKEN P, 1992, MOL CELL BIOL, V12, P2986, DOI 10.1128/MCB.12.7.2986; WEJKSNORA PJ, 1978, J BACTERIOL, V134, P246, DOI 10.1128/JB.134.1.246-260.1978; WESOLOWSKI M, 1984, MOL CELL BIOL, V4, P181, DOI 10.1128/MCB.4.1.181; WICKNER RB, 1991, J VIROL, V65, P155, DOI 10.1128/JVI.65.1.155-161.1991; WICKNER RB, 1980, CELL, V21, P217, DOI 10.1016/0092-8674(80)90129-4; WICKNER RB, 2000, VIRUS TAXONOMY, P651; WIDNER WR, 1991, MOL CELL BIOL, V11, P2905, DOI 10.1128/MCB.11.5.2905; YAO WS, 1995, J VIROL, V69, P1917, DOI 10.1128/JVI.69.3.1917-1919.1995; Zuo YH, 2002, J BIOL CHEM, V277, P29654, DOI 10.1074/jbc.M204252200	43	22	26	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33725	33734		10.1074/jbc.M506546200	http://dx.doi.org/10.1074/jbc.M506546200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16049000	hybrid			2022-12-25	WOS:000232229700007
J	Faye, G; Luger, K; Hansen, JC				Faye, G; Luger, K; Hansen, JC			The core histone n-terminal tail domains function independently and additively during salt-dependent oligomerization of nucleosomal arrays	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGHER-ORDER STRUCTURE; CHROMATIN FIBER; RECOMBINANT HISTONES; LINKER HISTONES; VARIANT H2A.Z; ORGANIZATION; ACETYLATION; TRANSCRIPTION; IDENTIFICATION; MECHANISMS	Salt- dependent oligomerization of nucleosomal arrays is related to fiber- fiber interactions and global chromosome structure. Previous studies have shown that the H2A/ H2B and H3/ H4 N- terminal domain ( NTD) pairs are able to mediate array oligomerization. However, because of technical barriers, the function( s) of the individual core histone NTDs have not been investigated. To address this question, all possible combinations of " tailless" nucleosomal arrays were assembled from native and NTD- deleted recombinant Xenopus core histones and tandemly repeated 5 S rDNA. The recombinant arrays were characterized by differential centrifugation over the range of 0 - 50 mM MgCl2 to determine how each NTD affects salt- dependent oligomerization. Results indicate that all core histone NTDs participate in the oligomerization process and that the NTDs function additively and independently. These observations provide direct biochemical evidence linking all four core histone NTDs to the assembly and maintenance of global chromatin structures.	Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	Colorado State University; University of Texas System; University of Texas Health San Antonio	Hansen, JC (corresponding author), Colorado State Univ, Dept Biochem & Mol Biol, Campus Delivery 1870, Ft Collins, CO 80523 USA.	Jeffrey.C.Hansen@colostate.edu	Martin, Faye/I-1759-2012	SCHNIZER-LUGER, KAROLINE/0000-0001-5136-5331	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045916, R29GM045916] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45916] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Carruthers LM, 1998, BIOCHEMISTRY-US, V37, P14776, DOI 10.1021/bi981684e; Carruthers LM, 2000, J BIOL CHEM, V275, P37285, DOI 10.1074/jbc.M006801200; Carruthers LM, 2000, METHOD ENZYMOL, V321, P66; CLARK DJ, 1990, J MOL BIOL, V211, P883, DOI 10.1016/0022-2836(90)90081-V; Demeler B, 1997, BIOPHYS J, V72, P397, DOI 10.1016/S0006-3495(97)78680-6; Dorigo B, 2004, SCIENCE, V306, P1571, DOI 10.1126/science.1103124; Dorigo B, 2003, J MOL BIOL, V327, P85, DOI 10.1016/S0022-2836(03)00025-1; Faast R, 2001, CURR BIOL, V11, P1183, DOI 10.1016/S0960-9822(01)00329-3; Fan JY, 2004, MOL CELL, V16, P655, DOI 10.1016/j.molcel.2004.10.023; Fan JY, 2002, NAT STRUCT BIOL, V9, P172, DOI 10.1038/nsb767; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; FLETCHER TM, 1994, BIOCHEMISTRY-US, V33, P10859, DOI 10.1021/bi00202a002; FLETCHER TM, 1995, J BIOL CHEM, V270, P25359, DOI 10.1074/jbc.270.43.25359; Fletcher TM, 1996, CRIT REV EUKAR GENE, V6, P149, DOI 10.1615/CritRevEukarGeneExpr.v6.i2-3.40; GARCIARAMIREZ M, 1992, J BIOL CHEM, V267, P19587; GARCIARAMIREZ M, 1995, J BIOL CHEM, V270, P17923, DOI 10.1074/jbc.270.30.17923; GEORGEL P, 1993, J BIOL CHEM, V268, P1947; Hansen JC, 2002, ANNU REV BIOPH BIOM, V31, P361, DOI 10.1146/annurev.biophys.31.101101.140858; HANSEN JC, 1993, J BIOL CHEM, V268, P5840; Hansen JC, 1998, BIOCHEMISTRY-US, V37, P17637, DOI 10.1021/bi982409v; Henikoff S, 2005, P NATL ACAD SCI USA, V102, P5308, DOI 10.1073/pnas.0501853102; Horn PJ, 2002, SCIENCE, V297, P1824, DOI 10.1126/science.1074200; Khorasanizadeh S, 2004, CELL, V116, P259, DOI 10.1016/S0092-8674(04)00044-3; Kurdistani SK, 2003, NAT REV MOL CELL BIO, V4, P276, DOI 10.1038/nrm1075; Luger K, 2005, CURR OPIN STRUC BIOL, V15, P188, DOI 10.1016/j.sbi.2005.03.006; Luger K, 1999, METHOD ENZYMOL, V304, P3; Luger K, 1997, J MOL BIOL, V272, P301, DOI 10.1006/jmbi.1997.1235; Luger K, 2003, CURR OPIN GENET DEV, V13, P127, DOI 10.1016/S0959-437X(03)00026-1; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Luger K, 1999, METH MOL B, V119, P1; Moore SC, 1997, BIOCHEM BIOPH RES CO, V230, P136, DOI 10.1006/bbrc.1996.5903; Peterson CL, 2004, CURR BIOL, V14, pR546, DOI 10.1016/j.cub.2004.07.007; Pollard KJ, 1999, EMBO J, V18, P5622, DOI 10.1093/emboj/18.20.5622; Ridgway P, 2004, J BIOL CHEM, V279, P43815, DOI 10.1074/jbc.M408409200; Schwarz PM, 1996, BIOCHEMISTRY-US, V35, P4009, DOI 10.1021/bi9525684; SCHWARZ PM, 1994, J BIOL CHEM, V269, P16284; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; Strick R, 2001, J CELL BIOL, V155, P899, DOI 10.1083/jcb.200105026; Tse C, 1997, BIOCHEMISTRY-US, V36, P11381, DOI 10.1021/bi970801n; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; WIDOM J, 1989, ANNU REV BIOPHYS BIO, V18, P365, DOI 10.1146/annurev.biophys.18.1.365; Wolffe A., 1998, CHROMATIN STRUCTURE; WOODCOCK CL, 1995, TRENDS CELL BIOL, V5, P272, DOI 10.1016/S0962-8924(00)89038-8; Woodcock CL, 2001, CURR OPIN GENET DEV, V11, P130, DOI 10.1016/S0959-437X(00)00169-6	45	103	104	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33701	33706		10.1074/jbc.M507048200	http://dx.doi.org/10.1074/jbc.M507048200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16033758	hybrid			2022-12-25	WOS:000232229700004
J	Heller, RC; Marians, KJ				Heller, RC; Marians, KJ			Unwinding of the nascent lagging strand by rep and PriA enables the direct restart of stalled replication forks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHROMOSOME; COORDINATED LEADING-STRAND; DNA-REPLICATION; PROTEIN PRIA; DOUBLE MUTANTS; IN-VITRO; HELICASE; PURIFICATION; MUTATION; ORIGIN	During origin-independent replisome assembly, the replication restart protein PriC prefers to load the replication fork helicase, DnaB, to stalled replication forks where there is a gap in the nascent leading strand. However, this activity can be obstructed if the 5'-end of the nascent lagging strand is near the template branch point. Here we provide biochemical evidence that the helicase activities of Rep and PriA function to unwind the nascent lagging strand DNA at such stalled replication forks. PriC then loads the replicative helicase, DnaB, onto the newly generated, single-stranded template for the purposes of replisome assembly and duplex unwinding ahead of the replication fork. Direct rescue of replication forks by the Rep-PriC and PriA-PriC pathways in this manner may contribute to genomic stability by avoiding the potential dangers of fork breakage inherent to recombination-dependent restart pathways.	Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA; Cornell Univ, Weill Grad Sch Med Sci, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University	Marians, KJ (corresponding author), Mem Sloan Kettering Canc Ctr, Program Mol Biol, 1275 York Ave, New York, NY 10021 USA.	kmarians@sloankettering.edu			NIGMS NIH HHS [GM34557, R37 GM034557] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034557, R01GM034557] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI N, 1981, J BIOL CHEM, V256, P5294; BAKER TA, 1986, CELL, V45, P53, DOI 10.1016/0092-8674(86)90537-4; BAKER TA, 1987, J BIOL CHEM, V262, P6877; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; COLASANTI J, 1987, MOL GEN GENET, V209, P382, DOI 10.1007/BF00329669; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; Harinarayanan R, 2004, GENETICS, V166, P1165, DOI 10.1534/genetics.166.3.1165; Heller RC, 2005, MOL CELL, V17, P733, DOI 10.1016/j.molcel.2005.01.019; Hiasa H, 1996, J BIOL CHEM, V271, P21529, DOI 10.1074/jbc.271.35.21529; Higuchi K, 2003, GENES CELLS, V8, P437, DOI 10.1046/j.1365-2443.2003.00646.x; Jezewska MJ, 1996, BIOCHEMISTRY-US, V35, P2129, DOI 10.1021/bi952345d; Jones JM, 2001, J MOL BIOL, V312, P935, DOI 10.1006/jmbi.2001.4930; Jones JM, 1999, J MOL BIOL, V289, P503, DOI 10.1006/jmbi.1999.2783; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; LANE HED, 1974, J BACTERIOL, V120, P805, DOI 10.1128/JB.120.2.805-814.1974; LANE HED, 1975, J MOL BIOL, V97, P99; LASKEN RS, 1988, J BIOL CHEM, V263, P5512; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LEE EH, 1991, P NATL ACAD SCI USA, V88, P3029, DOI 10.1073/pnas.88.8.3029; LEE MS, 1987, P NATL ACAD SCI USA, V84, P8345, DOI 10.1073/pnas.84.23.8345; Liu J, 1999, J BIOL CHEM, V274, P25033, DOI 10.1074/jbc.274.35.25033; Liu JI, 1999, P NATL ACAD SCI USA, V96, P3552, DOI 10.1073/pnas.96.7.3552; LOHMAN TM, 1989, J BIOL CHEM, V264, P10139; Maisnier-Patin S, 2001, MOL MICROBIOL, V42, P1371, DOI 10.1046/j.1365-2958.2001.02718.x; Marians KJ, 1995, METHOD ENZYMOL, V262, P507; MATSON SW, 1994, BIOESSAYS, V16, P13, DOI 10.1002/bies.950160103; McCool JD, 2004, GENETICS, V167, P569, DOI 10.1534/genetics.103.025296; McGlynn P, 1997, J MOL BIOL, V270, P212, DOI 10.1006/jmbi.1997.1120; McGlynn P, 2000, CELL, V101, P35, DOI 10.1016/S0092-8674(00)80621-2; Michel B, 1997, EMBO J, V16, P430, DOI 10.1093/emboj/16.2.430; MOK M, 1987, J BIOL CHEM, V262, P16644; Nurse P, 1999, J BIOL CHEM, V274, P25026, DOI 10.1074/jbc.274.35.25026; NURSE P, 1991, J BACTERIOL, V173, P6686, DOI 10.1128/jb.173.21.6686-6693.1991; Sandler SJ, 2000, GENETICS, V155, P487; Sandler SJ, 1999, MOL MICROBIOL, V34, P91, DOI 10.1046/j.1365-2958.1999.01576.x; Sandler SJ, 2001, MOL MICROBIOL, V41, P697, DOI 10.1046/j.1365-2958.2001.02547.x; SCOTT JF, 1978, J BIOL CHEM, V253, P3292; SCOTT JF, 1977, P NATL ACAD SCI USA, V74, P193, DOI 10.1073/pnas.74.1.193; Seigneur M, 1998, CELL, V95, P419, DOI 10.1016/S0092-8674(00)81772-9; SMITH KR, 1989, J BIOL CHEM, V264, P6119; TOUGU K, 1994, J BIOL CHEM, V269, P4675; Trun N, 2003, FEMS MICROBIOL LETT, V226, P187, DOI 10.1016/S0378-1097(03)00595-0; UZEST M, 1995, MOL MICROBIOL, V17, P1177, DOI 10.1111/j.1365-2958.1995.mmi_17061177.x; WICKNER S, 1975, P NATL ACAD SCI USA, V72, P921, DOI 10.1073/pnas.72.3.921; WU CA, 1992, J BIOL CHEM, V267, P4030; WU CA, 1992, J BIOL CHEM, V267, P4074; Xu LW, 2003, MOL CELL, V11, P817, DOI 10.1016/S1097-2765(03)00061-3; YANCEYWRONA JE, 1992, NUCLEIC ACIDS RES, V20, P6713, DOI 10.1093/nar/20.24.6713; YARRANTON GT, 1979, P NATL ACAD SCI USA, V76, P1658, DOI 10.1073/pnas.76.4.1658; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4; ZAVITZ KH, 1992, J BIOL CHEM, V267, P6933	52	75	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34143	34151		10.1074/jbc.M507224200	http://dx.doi.org/10.1074/jbc.M507224200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16079128	hybrid			2022-12-25	WOS:000232229700055
J	Dodd, JR; Christie, DL				Dodd, JR; Christie, DL			Substituted cysteine accessibility of the third transmembrane domain of the creatine transporter - Defining a transport pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE DOMAIN-I; NEUROTRANSMITTER TRANSPORTERS; SEROTONIN TRANSPORTER; GABA TRANSPORTER; CULTURED-CELLS; CLONING; BRAIN; RAT; EXPRESSION; SUBSTRATE	Twenty- two amino acid residues from transmembrane domain 3 of the creatine transporter were replaced, one at a time, with cysteine. The background for mutagenesis was a C144S mutant retaining similar to 75% of wild- type transport activity but resistant to methanethiosulfonate ( MTS) reagents. Each substitution mutant was tested for creatine transport activity and sensitivity to the following MTS reagents: 2- aminoethyl methanethiosulfonate ( MTSEA), 2-( trimethylammonium) ethyl methanethiosulfonate ( MTSET), and 2- sulfonatoethyl methanethiosulfonate ( MTSES). Two mutants ( G134C and Y148C) were inactive, but most mutants showed significant levels of creatine transport. Treatment with MTSEA inhibited the activity of the W154C, Y147C, and I140C mutants. Creatine partially protected I140C from inactivation, and this residue, like Cys- 144 in the wild- type CreaT, is predicted to be close to a creatine binding site. MTSEA inactivation of Y147C was dependent on Na+ and Cl- suggesting that solvent accessibility was ion- dependent. Helical wheel and helical net projections indicate that the three MTSEA- sensitive mutants ( W154C, Y147C, and I140C) and two inactive mutants ( V151C and Y148C) are aligned on a face of an alpha- helix, suggesting that they form part of a substrate pathway. The W154C mutant, located near the external face of the membrane, was accessible to the larger MTS reagents, whereas those implicated in creatine binding were only accessible to the smaller MTSEA. Consideration of our data, together with a study on the serotonin transporter ( Chen, J. G., Sachpatzidis, A., and Rudnick, G. ( 1997) J. Biol. Chem. 272, 28321 - 28327), suggests that involvement of residues from transmembrane domain 3 is a common feature of the substrate pathway of Na+- and Cl+- dependent neurotransmitter transporters.	Univ Auckland, Sch Biol Sci, Cell Biol & Biochem Sect, Auckland, New Zealand	University of Auckland	Christie, DL (corresponding author), Univ Auckland, Sch Biol Sci, Cell Biol & Biochem Sect, Private Bag 92019, Auckland, New Zealand.	d.christie@auckland.ac.nz	Christie, David L/C-8065-2009					AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; Bismuth Y, 1997, J BIOL CHEM, V272, P16096, DOI 10.1074/jbc.272.26.16096; Broer A, 2004, J BIOL CHEM, V279, P24467, DOI 10.1074/jbc.M400904200; Chen JG, 2000, P NATL ACAD SCI USA, V97, P1044, DOI 10.1073/pnas.97.3.1044; Chen JG, 1997, J BIOL CHEM, V272, P28321, DOI 10.1074/jbc.272.45.28321; Chen NH, 2004, PFLUG ARCH EUR J PHY, V447, P519, DOI 10.1007/s00424-003-1064-5; DALY MM, 1980, ARCH BIOCHEM BIOPHYS, V203, P317, DOI 10.1016/0003-9861(80)90182-4; Dodd JR, 2001, J BIOL CHEM, V276, P46983, DOI 10.1074/jbc.M107137200; FITSCH CD, 1968, J BIOL CHEM, V243, P2024; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; GUIMBAL C, 1993, J BIOL CHEM, V268, P8418; Henry LK, 2003, J BIOL CHEM, V278, P37052, DOI 10.1074/jbc.M305514200; Javitch JA, 1998, METHOD ENZYMOL, V296, P331; LOIKE JD, 1986, AM J PHYSIOL, V251, pC128, DOI 10.1152/ajpcell.1986.251.1.C128; Melamed N, 2004, MOL PHARMACOL, V65, P1452, DOI 10.1124/mol.65.6.1452; MOLLER A, 1989, J NEUROCHEM, V52, P544, DOI 10.1111/j.1471-4159.1989.tb09154.x; Nakashima T, 2004, J NEUROCHEM, V89, P1454, DOI 10.1111/j.1471-4159.2004.02437.x; Nelson N, 1998, J NEUROCHEM, V71, P1785; Ohtsuki S, 2002, J CEREBR BLOOD F MET, V22, P1327, DOI 10.1097/01.WCB.0000033966.83623.7D; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; Peral MJ, 2002, J PHYSIOL-LONDON, V545, P133, DOI 10.1113/jphysiol.2002.026377; Rosenberg EH, 2004, AM J HUM GENET, V75, P97, DOI 10.1086/422102; Salomons GS, 2003, J INHERIT METAB DIS, V26, P309, DOI 10.1023/A:1024405821638; Seow HF, 2004, NAT GENET, V36, P1003, DOI 10.1038/ng1406; Wyss M, 2000, PHYSIOL REV, V80, P1107, DOI 10.1152/physrev.2000.80.3.1107; Zhou YG, 2004, J BIOL CHEM, V279, P13800, DOI 10.1074/jbc.M311579200	26	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32649	32654		10.1074/jbc.M506723200	http://dx.doi.org/10.1074/jbc.M506723200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16049011	hybrid			2022-12-25	WOS:000231920300013
J	Goeckeler, ZM; Wysolmerski, RB				Goeckeler, ZM; Wysolmerski, RB			Myosin phosphatase and cofilin mediate cAMP/cAMP-dependent protein kinase-induced decline in endothelial cell isometric tension and myosin II regulatory light chain phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CONTRACTION; INHIBITS RHOA ACTIVATION; ACTIN DYNAMICS; LEADING-EDGE; CYCLIC-AMP; LIM KINASE; CAMP; DEPHOSPHORYLATION; EXPRESSION; SLINGSHOT	This study determined the effects of increased intracellular cAMP and cAMP-dependent protein kinase activation on endothelial cell basal and thrombin-induced isometric tension development. Elevation of cAMP and maximal cAMP-dependent protein kinase activation induced by 10 mu M forskolin, 40 mu M 3-isobutyl-1-methylxanthine caused a 50% reduction in myosin II regulatory light chain (RLC) phosphorylation and a 35% drop in isometric tension, but it did not inhibit thrombin-stimulated increases in RLC phosphorylation and isometric tension. Elevation of cAMP did not alter myosin light chain kinase catalytic activity. However, direct inhibition of myosin light chain kinase with KT5926 resulted in a 90% decrease in RLC phosphorylation and only a minimal decrease in isometric tension, but it prevented thrombin-induced increases in RLC phosphorylation and isometric tension development. We showed that elevated cAMP increases phosphorylation of RhoA 10-fold, and this is accompanied by a 60% decrease in RhoA activity and a 78% increase in RLC phosphatase activity. Evidence is presented that it is this inactivation of RhoA that regulates the decrease in isometric tension through a pathway involving cofilin. Activated cofilin correlates with increased F-actin severing activity in cell extracts from monolayers treated with forskolin/3-isobutyl-1-methylxanthine. Pretreatment of cultures with tautomycin, a protein phosphatase type 1 inhibitor, blocked the effect of cAMP on 1) the dephosphorylation of cofilin, 2) the decrease in RLC phosphorylation, and 3) the decrease in isometric tension. Together, these data provide in vivo evidence that elevated intracellular cAMP regulates endothelial cell isometric tension and RLC phosphorylation through inhibition of RhoA signaling and its downstream pathways that regulate myosin II activity and actin reorganization.	St Louis Univ, Sch Med, Dept Pathol, St Louis, MO 63104 USA	Saint Louis University	Wysolmerski, RB (corresponding author), St Louis Univ, Sch Med, Dept Pathol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	wysolmrb@slu.edu			NHLBI NIH HHS [HL-45788] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL045788, R01HL045788] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELSTEIN RS, 1982, METHOD ENZYMOL, V85, P298; Ambach A, 2000, EUR J IMMUNOL, V30, P3422, DOI 10.1002/1521-4141(2000012)30:12<3422::AID-IMMU3422>3.0.CO;2-J; Bailly M, 1999, J CELL BIOL, V145, P331, DOI 10.1083/jcb.145.2.331; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; BAORTO DM, 1992, J CELL BIOL, V117, P357, DOI 10.1083/jcb.117.2.357; BDELLATIF AA, 2001, EXP BIOL MED, V226, P153; Birukov KG, 1998, J CELL BIOCHEM, V70, P402, DOI 10.1002/(SICI)1097-4644(19980901)70:3<402::AID-JCB13>3.0.CO;2-M; BLUE EK, 2001, AM J PHYSIOL, V282, pC451; BRYAN J, 1986, METHOD ENZYMOL, V134, P13; Carlier MF, 1999, J BIOL CHEM, V274, P33827, DOI 10.1074/jbc.274.48.33827; CARSON MR, 1989, AM J PHYSIOL, V257, pL259, DOI 10.1152/ajplung.1989.257.4.L259; CASNOCHA SA, 1989, J APPL PHYSIOL, V67, P1997, DOI 10.1152/jappl.1989.67.5.1997; Chan AY, 2000, J CELL BIOL, V148, P531, DOI 10.1083/jcb.148.3.531; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; Chew TL, 1998, J MUSCLE RES CELL M, V19, P839, DOI 10.1023/A:1005417926585; Cohen PTW, 2002, J CELL SCI, V115, P241; Condeelis J, 2001, TRENDS CELL BIOL, V11, P288, DOI 10.1016/S0962-8924(01)02008-6; CONTI MA, 1981, J BIOL CHEM, V256, P3178; DELANEROLLE P, 1984, SCIENCE, V223, P1415, DOI 10.1126/science.6322302; DELANEROLLE P, 1991, AM J PHYSIOL, V261, pL1, DOI 10.1152/ajplung.1991.261.2.L1; DELVECCHIO PJ, 1981, J CELL PHYSIOL, V108, P337, DOI 10.1002/jcp.1041080307; Dong JM, 1998, J BIOL CHEM, V273, P22554, DOI 10.1074/jbc.273.35.22554; Ellerbroek SM, 2003, J BIOL CHEM, V278, P19023, DOI 10.1074/jbc.M213066200; Emmert DA, 2004, AM J PHYSIOL-CELL PH, V286, pC8, DOI 10.1152/ajpcell.00428.2002; Endo M, 2003, J NEUROSCI, V23, P2527; Essler M, 2000, J IMMUNOL, V164, P6543, DOI 10.4049/jimmunol.164.12.6543; Essler M, 1998, J BIOL CHEM, V273, P21867, DOI 10.1074/jbc.273.34.21867; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; Fukata Y, 2001, TRENDS PHARMACOL SCI, V22, P32, DOI 10.1016/S0165-6147(00)01596-0; GALLAGHER PJ, 1995, J BIOL CHEM, V270, P29090, DOI 10.1074/jbc.270.49.29090; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23936; GALLINA C, 1997, TUTELA, V1, P16; GARCIA JGN, 1995, J CELL PHYSIOL, V163, P510, DOI 10.1002/jcp.1041630311; Garcia JGN, 1997, AM J RESP CELL MOL, V16, P489, DOI 10.1165/ajrcmb.16.5.9160829; Gehler S, 2004, J NEUROSCI, V24, P10741, DOI 10.1523/JNEUROSCI.2836-04.2004; GOECKELER ZM, 1995, J CELL BIOL, V130, P613, DOI 10.1083/jcb.130.3.613; Goeckeler ZM, 2000, J BIOL CHEM, V275, P18366, DOI 10.1074/jbc.M001339200; Gohla A, 2002, CURR BIOL, V12, P1704, DOI 10.1016/S0960-9822(02)01184-3; Gohla A, 2005, NAT CELL BIOL, V7, P21, DOI 10.1038/ncb1201; Gungabissoon RA, 2003, J HISTOCHEM CYTOCHEM, V51, P411, DOI 10.1177/002215540305100402; Hartshorne DJ, 2004, J BIOL CHEM, V279, P37211, DOI 10.1074/jbc.R400018200; Ito M, 2004, MOL CELL BIOCHEM, V259, P197, DOI 10.1023/B:MCBI.0000021373.14288.00; KELLEY C, 1988, J MUSCLE RES CELL M, V9, P184, DOI 10.1007/BF01773740; KOBAYASHI H, 1992, J BIOCHEM-TOKYO, V112, P786, DOI 10.1093/oxfordjournals.jbchem.a123976; KOLODNEY MS, 1992, J CELL BIOL, V117, P73, DOI 10.1083/jcb.117.1.73; Kuhn TB, 2000, J NEUROBIOL, V44, P126, DOI 10.1002/1097-4695(200008)44:2<126::AID-NEU4>3.0.CO;2-Z; KURISAKI T, 1992, J ANTIBIOT, V45, P252, DOI 10.7164/antibiotics.45.252; LAMB NJC, 1988, J CELL BIOL, V106, P1955, DOI 10.1083/jcb.106.6.1955; LAMPUGNANI MG, 1990, LAB INVEST, V63, P521; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; Laudanna C, 1997, J BIOL CHEM, V272, P24141, DOI 10.1074/jbc.272.39.24141; Lum H, 1996, CAN J PHYSIOL PHARM, V74, P787, DOI 10.1139/cjpp-74-7-787; MCDANIEL NL, 1994, CAN J PHYSIOL PHARM, V72, P1380, DOI 10.1139/y94-199; McGrath JL, 2000, P NATL ACAD SCI USA, V97, P6532, DOI 10.1073/pnas.100023397; Meberg PJ, 1998, CELL MOTIL CYTOSKEL, V39, P172, DOI 10.1002/(SICI)1097-0169(1998)39:2<172::AID-CM8>3.0.CO;2-8; Meyer G, 2002, J NEUROCHEM, V83, P490, DOI 10.1046/j.1471-4159.2002.01185.x; MILLER JR, 1983, MOL PHARMACOL, V24, P235; Moriyama K, 1999, EMBO J, V18, P6752, DOI 10.1093/emboj/18.23.6752; Moriyama K, 2002, BIOCHEM J, V365, P147, DOI 10.1042/BJ20020231; MOY AB, 1993, J CLIN INVEST, V92, P1198, DOI 10.1172/JCI116690; Muranyi A, 2002, BIOCHEM J, V366, P211, DOI 10.1042/BJ20020401; Murthy KS, 2000, AM J PHYSIOL-GASTR L, V279, pG201, DOI 10.1152/ajpgi.2000.279.1.G201; Murthy KS, 2003, AM J PHYSIOL-GASTR L, V284, pG1006, DOI 10.1152/ajpgi.00465.2002; NAKANISHI S, 1990, MOL PHARMACOL, V37, P482; Nakano K, 1999, MOL BIOL CELL, V10, P2481, DOI 10.1091/mbc.10.8.2481; Niwa R, 2002, CELL, V108, P233, DOI 10.1016/S0092-8674(01)00638-9; OLSON NJ, 1990, P NATL ACAD SCI USA, V87, P2284, DOI 10.1073/pnas.87.6.2284; Patterson CE, 2000, ENDOTHELIUM-NEW YORK, V7, P287, DOI 10.3109/10623320009072215; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; Qiao J, 2003, AM J PHYSIOL-LUNG C, V284, pL972, DOI 10.1152/ajplung.00429.2002; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ren XD, 2000, METHOD ENZYMOL, V325, P264; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; SAITO T, 1994, EXP CELL RES, V212, P49, DOI 10.1006/excr.1994.1117; Samstag Y, 2003, ADV ENZYME REGUL, V43, P197, DOI 10.1016/S0065-2571(02)00031-6; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; SATOH M, 1995, GEN PHARMACOL, V26, P357, DOI 10.1016/0306-3623(94)00198-V; Sauzeau V, 2000, J BIOL CHEM, V275, P21722, DOI 10.1074/jbc.M000753200; SHELDON R, 1993, AM J PHYSIOL, V265, pL606, DOI 10.1152/ajplung.1993.265.6.L606; Skuta G, 1999, J BIOL CHEM, V274, P30163, DOI 10.1074/jbc.274.42.30163; Somlyo AP, 2003, PHYSIOL REV, V83, P1325, DOI 10.1152/physrev.00023.2003; Soosairajah J, 2005, EMBO J, V24, P473, DOI 10.1038/sj.emboj.7600543; STULL JT, 1991, HYPERTENSION, V17, P723, DOI 10.1161/01.HYP.17.6.723; Takuma T, 1996, J BIOCHEM, V120, P35; Verin AD, 1998, AM J RESP CELL MOL, V19, P758, DOI 10.1165/ajrcmb.19.5.3125; Verin AD, 1998, AM J RESP CELL MOL, V19, P767, DOI 10.1165/ajrcmb.19.5.3126; Wang Y, 2005, J BIOL CHEM, V280, P12683, DOI 10.1074/jbc.M411494200; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; WATTERSON DM, 1995, FEBS LETT, V373, P217; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Wiggan O, 2005, NAT CELL BIOL, V7, P8, DOI 10.1038/ncb0105-8; WYSOLMERSKI RB, 1991, AM J PHYSIOL, V261, pC32, DOI 10.1152/ajpcell.1991.261.1.C32; Yee HF, 2001, BIOCHEM BIOPH RES CO, V280, P1340, DOI 10.1006/bbrc.2001.4291; Zebda N, 2000, J CELL BIOL, V151, P1119, DOI 10.1083/jcb.151.5.1119	94	42	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					33083	33095		10.1074/jbc.M503173200	http://dx.doi.org/10.1074/jbc.M503173200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16055445				2022-12-25	WOS:000231920300063
J	Miura, P; Thompson, J; Chakkalakal, JV; Holcik, M; Jasmin, BJ				Miura, P; Thompson, J; Chakkalakal, JV; Holcik, M; Jasmin, BJ			The utrophin A 5 '-untranslated region confers internal ribosome entry site-mediated translational control during regeneration of skeletal muscle fibers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHIN-RELATED PROTEIN; MESSENGER-RNA; EXPRESSION; INITIATION; ACETYLCHOLINESTERASE; IRES; RAT; IDENTIFICATION; LOCALIZATION; ACTIVATION	Utrophin up-regulation in muscle fibers of Duchenne muscular dystrophy patients represents a potential therapeutic strategy. It is thus important to delineate the regulatory events presiding over utrophin in muscle in attempts to develop pharmacological interventions aimed at increasing utrophin expression. A number of studies have now shown that under several experimental conditions, the abundance of utrophin is increased without a corresponding elevation in its mRNA. Here, we examine whether utrophin expression is regulated at the translational level in regenerating muscle fibers. Treatment of mouse tibialis anterior muscles with cardiotoxin to induce muscle degeneration/regeneration led to a large (similar to 14-fold) increase in the levels of utrophin A with a modest change in expression of its transcript (40%). Isolation of the mouse utrophin A 5'-untranslated region (UTR) revealed that it is relatively long with a predicted high degree of secondary structure. In control muscles, the 5'-UTR of utrophin A caused an inhibition upon translation of a reporter protein. Strikingly, this inhibition was removed during regeneration, indicating that expression of utrophin A in regenerating muscles is translationally regulated via its 5'-UTR. Using bicistronic reporter vectors, we observed that this translational effect involves an internal ribosome entry site in the utrophin A 5'-UTR. Thus, internal ribosome entry site-mediated translation of utrophin A can, at least partially, account for the discordant expression of utrophin A protein and transcript in regenerating muscle. These findings provide a novel target for up-regulating levels of utrophin A in Duchenne muscular dystrophy muscle fibers via pharmacological interventions.	Univ Ottawa, Fac Med, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Fac Med, Ctr Neuromuscular Dis, Ottawa, ON K1H 8M5, Canada; Childrens Hosp Eastern Ontario, Apoptosis Res Ctr, Ottawa, ON K1H 8L1, Canada; Ottawa Hosp, Ottawa Hlth Res Inst, Ottawa, ON K1H 8L6, Canada	University of Ottawa; University of Ottawa; University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; Ottawa Hospital Research Institute	Jasmin, BJ (corresponding author), Univ Ottawa, Fac Med, Dept Cellular & Mol Med, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.	jasmin@uottawa.ca	Chakkalakal, Joe/ABD-2865-2020; Holcik, Martin/E-5372-2011; Holcik, Martin/AAC-6660-2019; Holcik, Martin/A-9768-2008; Miura, Pedro/N-4604-2013	Chakkalakal, Joe/0000-0002-8440-7312; Holcik, Martin/0000-0002-1922-5299; Miura, Pedro/0000-0002-8434-5027				ANDERSON MS, 1992, TRENDS BIOCHEM SCI, V17, P289, DOI 10.1016/0968-0004(92)90437-E; Belanger G, 2003, J NEUROCHEM, V86, P669, DOI 10.1046/j.1471-4159.2003.01883.x; Bernstein J, 1997, J BIOL CHEM, V272, P9356; BEWICK GS, 1992, NEUROREPORT, V3, P857, DOI 10.1097/00001756-199210000-00009; Brank M, 1998, EUR J BIOCHEM, V251, P374, DOI 10.1046/j.1432-1327.1998.2510374.x; Burton EA, 1999, P NATL ACAD SCI USA, V96, P14025, DOI 10.1073/pnas.96.24.14025; Chakkalakal JV, 2005, FASEB J, V19, P880, DOI 10.1096/fj.04-1956rev; Chakkalakal JV, 2004, HUM MOL GENET, V13, P379, DOI 10.1093/hmg/ddh037; Chakkalakal JV, 2003, P NATL ACAD SCI USA, V100, P7791, DOI 10.1073/pnas.0932671100; Chakkalakal JV, 2003, BIOESSAYS, V25, P25, DOI 10.1002/bies.10205; Charge SBP, 2004, PHYSIOL REV, V84, P209, DOI 10.1152/physrev.00019.2003; Chen YW, 2000, J CELL BIOL, V151, P1321, DOI 10.1083/jcb.151.6.1321; Cohn RD, 2000, MUSCLE NERVE, V23, P1456, DOI 10.1002/1097-4598(200010)23:10<1456::AID-MUS2>3.0.CO;2-T; Courdier-Fruh I, 2002, NEUROMUSCULAR DISORD, V12, pS95, DOI 10.1016/S0960-8966(02)00089-5; Creancier L, 2000, J CELL BIOL, V150, P275, DOI 10.1083/jcb.150.1.275; Deconinck N, 1997, NAT MED, V3, P1216, DOI 10.1038/nm1197-1216; Dennis CL, 1996, NUCLEIC ACIDS RES, V24, P1646, DOI 10.1093/nar/24.9.1646; Eberwine J, 2001, P NATL ACAD SCI USA, V98, P7080, DOI 10.1073/pnas.121146698; Emery A E, 1991, Neuromuscul Disord, V1, P19, DOI 10.1016/0960-8966(91)90039-U; Giraud S, 2001, J BIOL CHEM, V276, P5668, DOI 10.1074/jbc.M005928200; Gramolini AO, 1999, J NEUROPATH EXP NEUR, V58, P235, DOI 10.1097/00005072-199903000-00003; Gramolini AO, 1998, J BIOL CHEM, V273, P736, DOI 10.1074/jbc.273.2.736; Gramolini AO, 2001, J CELL BIOL, V154, P1173, DOI 10.1083/jcb.200101108; Gramolini AO, 2001, AM J PHYSIOL-CELL PH, V281, pC1300, DOI 10.1152/ajpcell.2001.281.4.C1300; Gramolini AO, 1999, P NATL ACAD SCI USA, V96, P3223, DOI 10.1073/pnas.96.6.3223; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; HELLIWELL TR, 1992, NEUROMUSCULAR DISORD, V2, P177, DOI 10.1016/0960-8966(92)90004-P; Holcik M, 2000, MOL CELL BIOL, V20, P4648, DOI 10.1128/MCB.20.13.4648-4657.2000; Holcik M, 1999, NAT CELL BIOL, V1, P190, DOI 10.1038/11109; Holcik M, 2005, NAT REV MOL CELL BIO, V6, P318, DOI 10.1038/nrm1618; HOROVITZ O, 1989, J CELL BIOL, V108, P1817, DOI 10.1083/jcb.108.5.1817; Jasmin BJ, 2002, J PHYSIOL-PARIS, V96, P31, DOI 10.1016/S0928-4257(01)00078-X; JASMIN BJ, 1993, NEURON, V11, P467, DOI 10.1016/0896-6273(93)90151-G; Johannes G, 1999, P NATL ACAD SCI USA, V96, P13118, DOI 10.1073/pnas.96.23.13118; Kelleher RJ, 2004, NEURON, V44, P59, DOI 10.1016/j.neuron.2004.09.013; Khurana TS, 2003, NAT REV DRUG DISCOV, V2, P379, DOI 10.1038/nrd1085; Khurana TS, 1999, MOL BIOL CELL, V10, P2075, DOI 10.1091/mbc.10.6.2075; Klann E, 2004, NAT REV NEUROSCI, V5, P931, DOI 10.1038/nrn1557; Lefaucheur JP, 1995, NEUROSCI LETT, V202, P121, DOI 10.1016/0304-3940(95)12223-0; LEVINOVITZ A, 1992, MOL ENDOCRINOL, V6, P1227, DOI 10.1210/me.6.8.1227; Lu JY, 2004, J BIOL CHEM, V279, P12974, DOI 10.1074/jbc.M310433200; Martineau Y, 2004, MOL CELL BIOL, V24, P7622, DOI 10.1128/MCB.24.17.7622-7635.2004; Menon KP, 2004, NEURON, V44, P663, DOI 10.1016/j.neuron.2004.10.028; Merrick WC, 2004, GENE, V332, P1, DOI 10.1016/j.gene.2004.02.051; MICHEL RN, 1994, J CELL BIOL, V127, P1061, DOI 10.1083/jcb.127.4.1061; Moghadaszadeh B, 2003, HUM MOL GENET, V12, P2467, DOI 10.1093/hmg/ddg264; OHLENDIECK K, 1991, NEURON, V7, P499, DOI 10.1016/0896-6273(91)90301-F; Pedersen SK, 2002, BIOCHEM J, V363, P37, DOI 10.1042/0264-6021:3630037; Pinkstaff JK, 2001, P NATL ACAD SCI USA, V98, P2770, DOI 10.1073/pnas.051623398; Pozner A, 2000, MOL CELL BIOL, V20, P2297, DOI 10.1128/MCB.20.7.2297-2307.2000; Preiss T, 2003, BIOESSAYS, V25, P1201, DOI 10.1002/bies.10362; Roma J, 2004, ACTA NEUROPATHOL, V108, P443, DOI 10.1007/s00401-004-0908-1; Sachs AB, 2000, CELL, V101, P243, DOI 10.1016/S0092-8674(00)80834-X; Shao Y, 2001, ARCH BIOCHEM BIOPHYS, V390, P78, DOI 10.1006/abbi.2001.2354; Sigrist SJ, 2000, NATURE, V405, P1062, DOI 10.1038/35016598; Teshima-Kondo S, 2004, FASEB J, V18, P1583, DOI 10.1096/fj.03-1118fje; TINSLEY JM, 1992, NATURE, V360, P591, DOI 10.1038/360591a0; Tinsley JM, 1996, NATURE, V384, P349, DOI 10.1038/384349a0; Vagner S, 2001, EMBO REP, V2, P893, DOI 10.1093/embo-reports/kve208; VITADELLO M, 1994, HUM GENE THER, V5, P11, DOI 10.1089/hum.1994.5.1-11; Waheed I, 2005, HUM GENE THER, V16, P489, DOI 10.1089/hum.2005.16.489; Weir AP, 2002, J BIOL CHEM, V277, P45285, DOI 10.1074/jbc.M205177200; Yan Z, 2003, J BIOL CHEM, V278, P8826, DOI 10.1074/jbc.M209879200; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	64	50	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32997	33005		10.1074/jbc.M503994200	http://dx.doi.org/10.1074/jbc.M503994200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16061482	hybrid			2022-12-25	WOS:000231920300054
J	Nabokina, SM; Reidling, JC; Said, HM				Nabokina, SM; Reidling, JC; Said, HM			Differentiation-dependent up-regulation of intestinal thiamin uptake - Cellular and molecular mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; CACO-2 CELLS; POLARIZED EXPRESSION; IN-VITRO; TRANSPORTER; GENE; SLC19A2; ABSORPTION; ANEMIA; FAMILY	Differentiation of intestinal epithelial cells is associated with up- and- down regulation of expression of a variety of genes including those involved in nutrient uptake. Nothing is known about possible differentiation- dependent regulation of the intestinal thiamin uptake process and the cellular and molecular mechanisms involved in such regulation. Using as models human- derived intestinal epithelial Caco- 2 cells and crypt/ villus epithelial cells isolated from wild- type and transgenic mice carrying promoters for human thiamin transporter- 1 and - 2 ( hTHTR- 1 and hTHTR- 2), we addressed this issue. Our results showed that differentiation of Caco- 2 cells is associated with a significant up- regulation in carrier- mediated thiamin uptake. Up- regulation was associated with a significant increase in the level of expression of hTHTR- 1 and hTHTR- 2 protein and mRNA as well as in activity of the corresponding transfected human thiamin transporter- 1 ( SLC19A2) and - 2 ( SLC19A3) promoters. Deletion analysis identified the differentiation- responsive region to be at position -356 to -275 bp for the SLC19A2 promoter and at position -77 to -13 bp for the SLC19A3 promoter. In addition, a critical and specific role in the differentiation- mediated effects for an NF1 binding site ( -348 to -345 bp) in the SLC19A2 promoter and a SP1/ GC- box binding site ( -48 to -45 bp) in the SLC19A3 promoter were established using mutational analysis. The physiological relevance of in vitro findings with Caco- 2 cells was confirmed in wild- type and transgenic mice by demonstrating that thiamin uptake and mRNA levels of the mouse THTR- 1 and THTR- 2, as well as activity of human SLC19A2 and SLC19A3 promoters expressed in transgenic mice, were all significantly higher in intestinal villus compared with crypt epithelial cells. These studies demonstrate for the first time that differentiation of intestinal epithelial cells is associated with an up- regulation in thiamin uptake process and that this up- regulation appears to be mediated via transcriptional regulatory mechanisms that involve the SLC19A2 and SLC19A3 genes.	Vet Affairs Healthcare Syst, Long Beach, CA 90822 USA; Univ Calif Irvine, Coll Med, Irvine, CA 92697 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; University of California System; University of California Irvine	Said, HM (corresponding author), Vet Affairs Med Ctr 151, Long Beach, CA 90822 USA.	hmsaid@uci.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056061, F32DK062629, R01DK058057, R37DK056061] Funding Source: NIH RePORTER; NIDDK NIH HHS [1-F32-DK062629, DK56061, DK58057] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bedrine-Ferran H, 2004, GENOMICS, V83, P772, DOI 10.1016/j.ygeno.2003.11.014; Berdanier C.D., 2018, ADV NUTR MACRONUTRIE; Boulware MJ, 2003, BIOCHEM J, V376, P43, DOI 10.1042/BJ20031220; Costa C, 2000, BBA-BIOMEMBRANES, V1509, P95, DOI 10.1016/S0005-2736(00)00281-9; Diaz GA, 1999, NAT GENET, V22, P309, DOI 10.1038/10385; Dudeja PK, 2003, DIGEST DIS SCI, V48, P109, DOI 10.1023/A:1021794600864; Dudeja PK, 2001, AM J PHYSIOL-CELL PH, V281, pC786, DOI 10.1152/ajpcell.2001.281.3.C786; Dutta B, 1999, J BIOL CHEM, V274, P31925, DOI 10.1074/jbc.274.45.31925; Eudy JD, 2000, MOL GENET METAB, V71, P581, DOI 10.1006/mgme.2000.3112; Fleming JC, 1999, NAT GENET, V22, P305, DOI 10.1038/10379; Fleming JC, 2001, MOL GENET METAB, V74, P273, DOI 10.1006/mgme.2001.3241; HOPFER U, 1973, J BIOL CHEM, V248, P25; Labay V, 1999, NAT GENET, V22, P300, DOI 10.1038/10372; Laforenza U, 1997, AM J CLIN NUTR, V66, P320, DOI 10.1093/ajcn/66.2.320; Maulen NP, 2003, J BIOL CHEM, V278, P9035, DOI 10.1074/jbc.M205119200; Nabokina SM, 2004, AM J PHYSIOL-GASTR L, V287, pG822, DOI 10.1152/ajpgi.00234.2004; NABOKINA SM, 2003, AM J PHYSIOL, V284, pG737; Oishi K, 2001, MOL GENET METAB, V73, P149, DOI 10.1006/mgme.2001.3184; Pinkus L M, 1981, Methods Enzymol, V77, P154; Rajgopal A, 2001, BBA-MOL BASIS DIS, V1537, P175, DOI 10.1016/S0925-4439(01)00073-4; REIDLING CJ, 2005, AM J PHYSIOL, V288, pG1127; Reidling JC, 2004, GASTROENTEROLOGY, V126, pA659; Reidling JC, 2003, AM J PHYSIOL-CELL PH, V285, pC633, DOI 10.1152/ajpcell.00076.2003; Reidling JC, 2002, BBA-BIOMEMBRANES, V1561, P180, DOI 10.1016/S0005-2736(02)00341-3; RINDI G, 1977, EXPERIENTIA, V33, P211, DOI 10.1007/BF02124072; Said HM, 1999, AM J PHYSIOL-CELL PH, V277, pC645, DOI 10.1152/ajpcell.1999.277.4.C645; Said HM, 2004, AM J PHYSIOL-GASTR L, V286, pG491, DOI 10.1152/ajpgi.00361.2003; Said HM, 2001, AM J PHYSIOL-GASTR L, V281, pG144, DOI 10.1152/ajpgi.2001.281.1.G144; Subramanian VS, 2003, J BIOL CHEM, V278, P3976, DOI 10.1074/jbc.M210717200; TALLAKSEN CME, 1993, ALCOHOL CLIN EXP RES, V17, P712, DOI 10.1111/j.1530-0277.1993.tb00825.x; Tanphaichirt V., 1994, MODERN NUTR HLTH DIS; TOMASULO PA, 1968, AM J CLIN NUTR, V21, P1341, DOI 10.1093/ajcn/21.11.1341; VACHON PH, 1992, GASTROENTEROLOGY, V103, P414, DOI 10.1016/0016-5085(92)90829-N; Wang LY, 2004, AM J PHYSIOL-GASTR L, V287, pG943, DOI 10.1152/ajpgi.00121.2004; Wong WK, 2003, J BIOL CHEM, V278, P36227, DOI 10.1074/jbc.M305549200	35	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32676	32682		10.1074/jbc.M505243200	http://dx.doi.org/10.1074/jbc.M505243200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16055442	hybrid			2022-12-25	WOS:000231920300017
J	Chen, YC; Su, YN; Chou, PC; Chiang, WC; Chang, MC; Wang, LS; Teng, SC; Wu, KJ				Chen, YC; Su, YN; Chou, PC; Chiang, WC; Chang, MC; Wang, LS; Teng, SC; Wu, KJ			Overexpression of NBS1 contributes to transformation through the activation of phosphatidylinositol 3-kinase/Akt	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAKAGE-SYNDROME GENE; C-MYC; MRE11 COMPLEX; TARGETED DISRUPTION; IN-VITRO; CANCER; EXPRESSION; AKT; PATHWAY; GROWTH	Nijmegen breakage syndrome (NBS) is a chromosomal instability syndrome associated with cancer predisposition, radiosensitivity, microcephaly, and growth retardation. The NBS gene product, NBS1 (p95) or nibrin, is a part of the hMre11 complex, a central player associated with double strand break repair. We previously demonstrated that c-Myc directly activates NBS1 expression. Here we have shown that constitutive expression of NBS1 in Rat1a and HeLa cells induces/enhances their transformation. Repression of endogenous NBS1 levels using short interference RNA reduces the transformation activity of two tumor cell lines. Increased NBS1 expression is observed in 40-52% of non-small cell lung carcinoma, hepatoma, and esophageal cancer samples. NBS1 overexpression stimulates phosphatidylinositol ( PI) 3-kinase activity, leading to increased phosphorylation levels of Akt and its downstream targets such as glycogen synthase kinase 3 beta and mammalian target of rapamycin in different cell lines and tumor samples. Transformation induced by NBS1 overexpression can be inhibited by a PI3-kinase inhibitor (LY294002). Repression of endogenous Akt expression by short interference RNA decreases the transformation activity of Rat1a cells overexpressing NBS1. These results indicate that overexpression of NBS1 is an oncogenic event that contributes to transformation through the activation of PI3-kinase/Akt.	Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei 112, Taiwan; Natl Taiwan Univ Hosp, Dept Med Genet, Taipei 100, Taiwan; Natl Taiwan Univ Hosp, Dept Obstet & Gynecol, Taipei 100, Taiwan; Taipei Vet Gen Hosp, Div Thorac Surg, Dept Surg, Taipei 112, Taiwan; Natl Taiwan Univ, Grad Inst Microbiol, Coll Med, Taipei 100, Taiwan	National Yang Ming Chiao Tung University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; Taipei Veterans General Hospital; National Taiwan University	Wu, KJ (corresponding author), Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei 112, Taiwan.	kjwu2@ym.edu.tw	Wu, Kou-Juey/P-4654-2015	Chiang, Wei-Chung/0000-0003-3149-435X; TENG, SHU-CHUN/0000-0002-6492-2560				Bao SD, 2004, CANCER CELL, V5, P329, DOI 10.1016/S1535-6108(04)00081-9; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Bitzer M, 2003, ANTICANCER RES, V23, P1489; Brognard J, 2001, CANCER RES, V61, P3986; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cerosaletti KM, 2002, GENE CHROMOSOME CANC, V35, P282, DOI 10.1002/gcc.10114; Chiang YC, 2003, J BIOL CHEM, V278, P19286, DOI 10.1074/jbc.M212043200; Costanzo V, 2001, MOL CELL, V8, P137, DOI 10.1016/S1097-2765(01)00294-5; Crowell JA, 2003, J NATL CANCER I, V95, P252, DOI 10.1093/jnci/95.4.252; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; Dang CV, 1999, MOL CELL BIOL, V19, P1; Ehlers JP, 2005, CLIN CANCER RES, V11, P1849, DOI 10.1158/1078-0432.CCR-04-2054; Hu LM, 2002, CANCER RES, V62, P1087; Kang J, 2002, EMBO J, V21, P1447, DOI 10.1093/emboj/21.6.1447; Karran P, 2000, CURR OPIN GENET DEV, V10, P144, DOI 10.1016/S0959-437X(00)00069-1; Lee SH, 2002, APMIS, V110, P587, DOI 10.1034/j.1600-0463.2002.11007811.x; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Maser RS, 2001, MOL CELL BIOL, V21, P6006, DOI 10.1128/MCB.21.17.6006-6016.2001; Nakanishi K, 2002, CANCER RES, V62, P2971; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Petrini JHJ, 2000, CURR OPIN CELL BIOL, V12, P293, DOI 10.1016/S0955-0674(00)00091-0; Plisiecka-Halasa J, 2002, ANN HUM GENET, V66, P353, DOI [10.1046/j.1469-1809.2002.00122.x, 10.1017/S0003480002001227]; Rieger-Christ KM, 2004, ONCOGENE, V23, P4745, DOI 10.1038/sj.onc.1207629; ROBINSON WS, 1994, ANNU REV MED, V45, P297; Sekido Y, 2003, ANNU REV MED, V54, P73, DOI 10.1146/annurev.med.54.101601.152202; Shih JY, 2001, JNCI-J NATL CANCER I, V93, P1392, DOI 10.1093/jnci/93.18.1392; Stumm P, 2001, CANCER GENET CYTOGEN, V126, P60, DOI 10.1016/S0165-4608(00)00390-3; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Ueki K, 2000, MOL CELL BIOL, V20, P8035, DOI 10.1128/MCB.20.21.8035-8046.2000; VANDERZWET MK, 1999, MUTAT RES, V434, P17; Varon R, 2001, CANCER RES, V61, P3570; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wilda M, 2000, HUM MOL GENET, V9, P1739, DOI 10.1093/hmg/9.12.1739; Williams BR, 2002, CURR BIOL, V12, P648, DOI 10.1016/S0960-9822(02)00763-7; Wood LJ, 2000, MOL CELL BIOL, V20, P5490, DOI 10.1128/MCB.20.15.5490-5502.2000; Wu KJ, 1999, SCIENCE, V283, P676, DOI 10.1126/science.283.5402.676; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Zhao JJ, 2003, CANCER CELL, V3, P483, DOI 10.1016/S1535-6108(03)00088-6; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Zhu J, 2001, CURR BIOL, V11, P105, DOI 10.1016/S0960-9822(01)00019-7	42	56	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32505	32511		10.1074/jbc.M501449200	http://dx.doi.org/10.1074/jbc.M501449200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16036916	hybrid			2022-12-25	WOS:000231794800059
J	Mulvenna, JP; Foley, FM; Craik, DJ				Mulvenna, JP; Foley, FM; Craik, DJ			Discovery, structural determination, and putative processing of the precursor protein that produces the cyclic trypsin inhibitor sunflower trypsin inhibitor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMR STRUCTURE CALCULATION; SPIN COUPLING-CONSTANTS; BOWMAN-BIRK INHIBITOR; COMMON AMINO-ACIDS; CIRCULAR PROTEINS; MOMORDICA-COCHINCHINENSIS; ASPARAGINYL ENDOPEPTIDASE; SPECTROSCOPY; CYCLOTIDES; RESOLUTION	Backbone-cyclized proteins are becoming increasingly well known, although the mechanism by which they are processed from linear precursors is poorly understood. In this report the sequence and structure of the linear precursor of a cyclic trypsin inhibitor, sunflower trypsin inhibitor 1 (SFTI-1) from sunflower seeds, is described. The structure indicates that the major elements of the reactive site loop of SFTI-1 are present before processing. This may have importance for a protease-mediated cyclizing reaction as the rigidity of SFTI-1 may drive the equilibrium of the reaction catalyzed by proteolytic enzymes toward the formation of a peptide bond rather than the normal cleavage reaction. The occurrence of residues in the SFTI-1 precursor susceptible to cleavage by asparaginyl proteases strengthens theories that involve this enzyme in the processing of SFTI-1 and further implicates it in the processing of another family of plant cyclic proteins, the cyclotides. The precursor reported here also indicates that despite strong active site sequence homology, SFTI-1 has no other similarities with the Bowman-Birk trypsin inhibitors, presenting interesting evolutionary questions.	Univ Queensland, Inst Mol Biosci, Asutralian Res Council, Ctr Funct & Appl Genom, Brisbane, Qld 4072, Australia	University of Queensland	Craik, DJ (corresponding author), Univ Queensland, Inst Mol Biosci, Asutralian Res Council, Ctr Funct & Appl Genom, Brisbane, Qld 4072, Australia.	d.craik@imb.uq.edu.au	Mulvenna, Jason/H-7110-2014; Craik, David/B-1695-2010	Mulvenna, Jason/0000-0003-3521-8061; Craik, David/0000-0003-0007-6796				BIRK Y, 1985, INT J PEPT PROT RES, V25, P113, DOI 10.1111/j.1399-3011.1985.tb02155.x; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; Brunger AT, 1997, STRUCTURE, V5, P325, DOI 10.1016/S0969-2126(97)00190-1; Craik DJ, 2004, CURR PROTEIN PEPT SC, V5, P297, DOI 10.2174/1389203043379512; Craik DJ, 2002, CURR OPIN DRUG DI DE, V5, P251; Dutton JL, 2004, J BIOL CHEM, V279, P46858, DOI 10.1074/jbc.M407421200; Eisenbrandt R, 2000, J BACTERIOL, V182, P6751, DOI 10.1128/JB.182.23.6751-6761.2000; Felizmenio-Quimio ME, 2001, J BIOL CHEM, V276, P22875, DOI 10.1074/jbc.M101666200; Fliess A, 2002, PROTEINS, V48, P377, DOI 10.1002/prot.10156; GODDARD TC, 2004, SPARKY 3 MANUAL; GRIESINGER C, 1987, J MAGN RESON, V75, P474, DOI 10.1016/0022-2364(87)90102-8; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Haase J, 1997, J BACTERIOL, V179, P5728, DOI 10.1128/jb.179.18.5728-5735.1997; HARAHISHIMURA I, 1993, PLANT J, V4, P793, DOI 10.1046/j.1365-313X.1993.04050793.x; Hernandez JF, 2000, BIOCHEMISTRY-US, V39, P5722, DOI 10.1021/bi9929756; ISHII S, 1994, METHOD ENZYMOL, V244, P604; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Jennings C, 2001, P NATL ACAD SCI USA, V98, P10614, DOI 10.1073/pnas.191366898; Kalkum M, 2002, TRENDS MICROBIOL, V10, P382, DOI 10.1016/S0966-842X(02)02399-5; Konarev A. V., 1999, Genetics and breeding for crop quality and resistance. Proceedings of the XV EUCARPIA Congress, Viterbo, Italy, September 20-25, 1998., P135; Konarev AV, 2002, PHYTOCHEMISTRY, V59, P279, DOI 10.1016/S0031-9422(01)00463-0; Korsinczky MLJ, 2004, CURR PROTEIN PEPT SC, V5, P351, DOI 10.2174/1389203043379594; Korsinczky MLJ, 2001, J MOL BIOL, V311, P579, DOI 10.1006/jmbi.2001.4887; Linge JP, 1999, J BIOMOL NMR, V13, P51, DOI 10.1023/A:1008365802830; Luckett S, 1999, J MOL BIOL, V290, P525, DOI 10.1006/jmbi.1999.2891; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; Marx UC, 2003, J BIOL CHEM, V278, P21782, DOI 10.1074/jbc.M212996200; McBride JD, 2002, BIOPOLYMERS, V66, P79, DOI 10.1002/bip.10228; Mello MO, 2003, MOL PHYLOGENET EVOL, V27, P103, DOI 10.1016/S1055-7903(02)00373-1; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; ODANI S, 1986, J BIOCHEM-TOKYO, V100, P975, DOI 10.1093/oxfordjournals.jbchem.a121810; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Prakash B, 1996, J MOL EVOL, V42, P560, DOI 10.1007/BF02352286; Prakash S, 2004, NAT STRUCT MOL BIOL, V11, P830, DOI 10.1038/nsmb814; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCOTT MP, 1992, P NATL ACAD SCI USA, V89, P658, DOI 10.1073/pnas.89.2.658; Song HK, 1999, J MOL BIOL, V293, P1133, DOI 10.1006/jmbi.1999.3239; TAKEDA O, 1994, J BIOCHEM-TOKYO, V116, P541, DOI 10.1093/oxfordjournals.jbchem.a124559; Trabi M, 2002, TRENDS BIOCHEM SCI, V27, P132, DOI 10.1016/S0968-0004(02)02057-1; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; Wuthrich K., 1986, NMR PROTEINS NUCL AC, P130; Zhou HX, 2004, ACCOUNTS CHEM RES, V37, P123, DOI 10.1021/ar0302282; Zhu SY, 2003, FASEB J, V17, P1765, DOI 10.1096/fj.02-1044fje	45	33	41	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32245	32253		10.1074/jbc.M506060200	http://dx.doi.org/10.1074/jbc.M506060200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16036912	hybrid			2022-12-25	WOS:000231794800026
J	Ueki, T; Inouye, S				Ueki, T; Inouye, S			Identification of a gene involved in polysaccharide export as a transcription target of FruA, an essential factor for Myxococcus xanthus development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRUITING-BODY DEVELOPMENT; SIGNALING PROTEIN; ESCHERICHIA-COLI; C-FACTOR; EXPRESSION; LOCUS; PHOSPHORYLATION; MORPHOGENESIS; BINDING; SYSTEM	Fruiting body development in Myxococcus xanthus is a multicellular event that is coordinated by exchanging intercellular signals. FruA is a transcription factor essential for fruiting body development and is thought to play a key role in the C-signal pathway. Here we present the first identification of a gene regulated by FruA. The gene was isolated from a genomic library via in vitro selection in a DNA binding assay by using the DNA-binding domain of FruA tagged with His(8) at the C-terminal end (FruA-DBD-H-8). The gene, named fdgA (FruA-dependent gene A), encodes a protein homologous to the outer-membrane auxiliary family protein involved in the polysaccharide export system. FruA-DBD-H8 bound the upstream promoter region of the fdgA gene from nucleotide -89 to nucleotide -64 with respect to the transcription initiation site, which was required for the induction of fdgA expression during development. fdgA mRNA induced during development was absent in a fruA deletion strain. The deletion of fdgA resulted in defective fruiting body formation and reduced sporulation efficiency (1% that of the parent strain). Moreover, FruA was required for the developmental expression of sasA, which is also involved in the biosynthesis of the lipopolysaccharide O-antigen and is required for fruiting body development. Furthermore, the expression of both fdgA and sasA was partially dependent on the C-signal. These findings expand our understanding of the signal transduction pathway mediated by FruA during development in M. xanthus.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Inouye, S (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Lane, Piscataway, NJ 08854 USA.	inouyesu@umdnj.edu	Inouye, Sharon/R-7216-2019					CAMPOS JM, 1978, J MOL BIOL, V119, P167, DOI 10.1016/0022-2836(78)90431-X; DOWNARD J, 1993, J BACTERIOL, V175, P7762, DOI 10.1128/JB.175.24.7762-7770.1993; Dworkin M, 1993, MYXOBACTERIA, P63; Ellehauge E, 1998, MOL MICROBIOL, V30, P807, DOI 10.1046/j.1365-2958.1998.01113.x; FORST S, 1989, P NATL ACAD SCI USA, V86, P6052, DOI 10.1073/pnas.86.16.6052; Guo DC, 1996, J BACTERIOL, V178, P1631, DOI 10.1128/jb.178.6.1631-1639.1996; HAGAN DC, 1978, DEV BIOL, V64, P284; HAGEN TJ, 1990, J BACTERIOL, V172, P15, DOI 10.1128/JB.172.1.15-23.1990; Horiuchi T, 2002, J BIOL CHEM, V277, P26753, DOI 10.1074/jbc.M111214200; INOUE S, 1999, TRANSCRIPTION FACTOR, P165; INOUYE M, 1979, DEV BIOL, V68, P579, DOI 10.1016/0012-1606(79)90228-8; Kaiser D, 2004, ANNU REV MICROBIOL, V58, P75, DOI 10.1146/annurev.micro.58.030603.123620; KAPLAN HB, 1991, J BACTERIOL, V173, P1460, DOI 10.1128/jb.173.4.1460-1470.1991; KIM SK, 1990, CELL, V61, P19, DOI 10.1016/0092-8674(90)90211-V; KROOS L, 1986, DEV BIOL, V117, P252, DOI 10.1016/0012-1606(86)90368-4; Lobedanz S, 2003, GENE DEV, V17, P2151, DOI 10.1101/gad.274203; Miller J. H., 1972, EXPT MOL GENETICS, P439; Ogawa M, 1996, MOL MICROBIOL, V22, P757, DOI 10.1046/j.1365-2958.1996.d01-1725.x; Paulsen IT, 1997, MICROBIOL-SGM, V143, P2685, DOI 10.1099/00221287-143-8-2685; SAGER B, 1994, GENE DEV, V8, P2793, DOI 10.1101/gad.8.23.2793; Shimkets LJ, 1999, ANNU REV MICROBIOL, V53, P525, DOI 10.1146/annurev.micro.53.1.525; Sogaard-Andersen L, 2003, MOL MICROBIOL, V48, P1, DOI 10.1046/j.1365-2958.2003.03399.x; SogaardAndersen L, 1996, P NATL ACAD SCI USA, V93, P2675, DOI 10.1073/pnas.93.7.2675; SogaardAndersen L, 1996, GENE DEV, V10, P740, DOI 10.1101/gad.10.6.740; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Sun H, 2001, J BACTERIOL, V183, P6733, DOI 10.1128/JB.183.23.6733-6739.2001; Sun H, 2001, J BACTERIOL, V183, P4786, DOI 10.1128/JB.183.16.4786-4795.2001; Ueki T, 2003, P NATL ACAD SCI USA, V100, P8782, DOI 10.1073/pnas.1533026100; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WEISS V, 1992, P NATL ACAD SCI USA, V89, P5088, DOI 10.1073/pnas.89.11.5088; WHITE D, 1993, MYXOBACTERIA, V2, P307; Wu HC, 1996, ESCHERICHIA COLI SAL, V1, P1005	32	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32279	32284		10.1074/jbc.M507191200	http://dx.doi.org/10.1074/jbc.M507191200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16040607	hybrid			2022-12-25	WOS:000231794800030
J	Vihanto, MM; Plock, J; Erni, D; Frey, BM; Frey, FJ; Huynh-Do, U				Vihanto, MM; Plock, J; Erni, D; Frey, BM; Frey, FJ; Huynh-Do, U			Hypoxia up-regulates expression of Eph receptors and ephrins in mouse skin	FASEB JOURNAL			English	Article						angiogenesis; gene regulation; hypoxia; RNA interference	INDUCIBLE FACTOR-1; VASCULAR MORPHOGENESIS; TYROSINE KINASES; CELL-MIGRATION; GROWTH-FACTOR; TUMOR-GROWTH; RAT-BRAIN; IN-VIVO; ANGIOGENESIS; ACTIVATION	Eph receptor tyrosine kinases and their ligands ( ephrins) are key players during the development of the embryonic vasculature; however, their role and regulation in adult angiogenesis remain to be defined. Both receptors and ligands have been shown to be up- regulated in a variety of tumors. To address the hypothesis that hypoxia is an important regulator of Ephs/ ephrins expression, we developed a mouse skin flap model of hypoxia. We demonstrate that our model truly represents segmental skin hypoxia by applying four independent methods: continuous measurement of partial cutaneous oxygen tension, monitoring of tissue lactate/ pyruvate ratio, time course of hypoxia- inducible factor- 1 alpha ( HIF- 1 alpha) induction, and localization of stabilized HIF- 1a by immunofluorescence in the hypoxic skin flap. Our experiments indicate that hypoxia up- regulates not only HIF- 1 alpha and vascular endothelial growth factor ( VEGF) expression, but also Ephs and ephrins of both A and B subclasses in the skin. In addition, we show that in Hep3B and PC- 3 cells, the hypoxia- induced up- regulation of Ephs and ephrins is abrogated by small interfering RNA- mediated down- regulation of HIF- 1 alpha. These novel findings shed light on the role of this versatile receptor/ ligand family in adult angiogenesis. Furthermore, our model offers considerable potential for analyzing distinct mechanisms of neovascularization in gene- targeted mice.	Univ Bern, Dept Hypertens & Nephrol, Inselspital, CH-3010 Bern, Switzerland; Univ Bern, Dept Clin Res, Inselspital, CH-3010 Bern, Switzerland; Univ Bern, Dept Plast Surg, Inselspital, CH-3010 Bern, Switzerland	University of Bern; University of Bern; University of Bern	Huynh-Do, U (corresponding author), Univ Bern, Dept Hypertens & Nephrol, Inselspital, CH-3010 Bern, Switzerland.	uyen.huynh-do@insel.ch	Plock, Jan A./I-2451-2017; Plock, Jan/ABE-9876-2020	Plock, Jan A./0000-0002-9495-6198; 				Adams RH, 1999, GENE DEV, V13, P295, DOI 10.1101/gad.13.3.295; ANDRES AC, 1994, ONCOGENE, V9, P1461; Bergeron M, 1999, EUR J NEUROSCI, V11, P4159, DOI 10.1046/j.1460-9568.1999.00845.x; Brantley DM, 2002, ONCOGENE, V21, P7011, DOI 10.1038/sj.onc.1205679; Dobrzanski P, 2004, CANCER RES, V64, P910, DOI 10.1158/0008-5472.CAN-3430-2; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; GERDES J, 1984, J IMMUNOL, V133, P1710; Han DC, 2002, J BIOL CHEM, V277, P45655, DOI 10.1074/jbc.M203165200; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; Huynh-Do U, 1999, EMBO J, V18, P2165, DOI 10.1093/emboj/18.8.2165; Jin KL, 2000, NEUROSCIENCE, V99, P577, DOI 10.1016/S0306-4522(00)00207-4; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Mao WG, 2004, CANCER RES, V64, P781, DOI 10.1158/0008-5472.CAN-03-1047; Martiny-Baron G, 2004, NEOPLASIA, V6, P248, DOI 10.1593/neo.03457; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; Minh TC, 2002, J RECONSTR MICROSURG, V18, P115, DOI 10.1055/s-2002-19892; Moritz W, 2002, FASEB J, V16, P745, DOI 10.1096/fj.01-0403fje; Nakada M, 2004, CANCER RES, V64, P3179, DOI 10.1158/0008-5472.CAN-03-3667; Nawrocki AR, 2002, J BIOL CHEM, V277, P14647, DOI 10.1074/jbc.M111549200; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Rosenberger C, 2003, KIDNEY INT, V64, P874, DOI 10.1046/j.1523-1755.2003.00159.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; Straume O, 2002, AM J PATHOL, V160, P1009, DOI 10.1016/S0002-9440(10)64922-X; Stroka DM, 2001, FASEB J, V15, P2445, DOI 10.1096/fj.01-0125com; Suenobu S, 2002, BIOCHEM BIOPH RES CO, V293, P1124, DOI 10.1016/S0006-291X(02)00330-3; UNGERSTEDT U, 1991, J INTERN MED, V230, P365, DOI 10.1111/j.1365-2796.1991.tb00459.x; Uyen HD, 2002, J CELL SCI, V115, P3073; Vindis C, 2004, J BIOL CHEM, V279, P27965, DOI 10.1074/jbc.M401295200; Vindis C, 2003, J CELL BIOL, V162, P661, DOI 10.1083/jcb.200302073; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wenger RH, 1997, KIDNEY INT, V51, P560, DOI 10.1038/ki.1997.79; Zelinski DP, 2001, CANCER RES, V61, P2301	36	107	111	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1689	+		10.1096/fj.04-3647fje	http://dx.doi.org/10.1096/fj.04-3647fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16081502				2022-12-25	WOS:000231843700023
J	Bolon, ML; Ouellette, Y; Li, FY; Tyml, K				Bolon, ML; Ouellette, Y; Li, FY; Tyml, K			Abrupt reoxygenation following hypoxia reduces electrical coupling between endothelial cells of wild-type but not connexin40 null mice in oxidant- and PKA-dependent manner	FASEB JOURNAL			English	Article						vascular resistance; Bessel function model; cremaster muscle	GAP-JUNCTION CHANNELS; ANTI-HYPOXIA/REOXYGENATION AGENTS; TYROSINE KINASE ACTIVATION; IN-VITRO; INTERCELLULAR COMMUNICATION; FEED ARTERIES; PATHWAY; VASODILATION; INJURY; REPERFUSION	Although electrical coupling along the arteriolar endothelium is central in arteriolar conducted response and in control of vascular resistance, little is known about the pathophysiological effect of hypoxia and reoxygenation (H/R) on this coupling. We examined this effect in a monolayer of cultured microvascular endothelial cells (ECs) derived from wild-type (WT) or connexin (Cx)40(-/-) mice (Cx40 is a key gap junction protein in ECs). To assess electrical coupling, we used a current injection technique and Bessel function model to compute the monolayer intercellular resistance. Hypoxia (0.1% O-2, 1 h) followed by abrupt reoxygenation (5-90 min) reduced coupling (i.e., increased resistance) in WT but not in Cx40(-/-) monolayer. H/R increased superoxide production and reduced protein kinase A (PKA) activity in both monolayers. Activation of PKA by 8-bromo-cAMP prevented the reduction in coupling. Preloading of the WT monolayer with the antioxidant ascorbate prevented reductions in both PKA activity and cell coupling. Inhibition of PKA with 6-22 amide during normoxia mimicked the reduction in coupling. Finally, hypoxia followed by slow reoxygenation caused no change in superoxide level, PKA activity, or coupling. Using intravital microscopy, we assessed the physiological relevance of these findings in terms of KCl-induced conducted vasoconstriction in arterioles of WT mouse cremaster muscle in vivo. Ischemia ( 1 h) followed by abrupt reperfusion (15-30 min) reduced conduction. 8-bromo-cAMP prevented this reduction, while 6-22 amide mimicked this reduction in control nonischemic arterioles. We propose that abrupt reoxygenation reduces interendothelial electrical coupling via oxidant- and PKA-dependent signaling that targets Cx40. We suggest that this mechanism contributes to compromised arteriolar function after H/R.	Lawson Hlth Res Inst, Ctr Crit Illness Res, Victoria Res Lab, London, ON N6C 2V5, Canada; Univ Western Ontario, Dept Physiol & Pharmacol, London, ON, Canada; Mayo Clin & Mayo Fdn, Coll Med, Dept Pediat, Rochester, MN 55905 USA; Univ Western Ontario, Dept Med Biophys, London, ON, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Mayo Clinic; Western University (University of Western Ontario)	Tyml, K (corresponding author), Lawson Hlth Res Inst, Ctr Crit Illness Res, Victoria Res Lab, 6th Floor,800 Commissioners Rd, London, ON N6C 2V5, Canada.	ktyml@lhsc.on.ca						Burt JM, 2003, CELL COMMUN ADHES, V10, P287, DOI 10.1080/714040441; de Wit C, 2000, CIRC RES, V86, P649, DOI 10.1161/01.RES.86.6.649; Dimon-Gadal S, 1998, J BIOL CHEM, V273, P22833, DOI 10.1074/jbc.273.35.22833; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; El Jamali A, 2004, FASEB J, V18, P1096, DOI 10.1096/fj.03-1054fje; Emerson GG, 2001, AM J PHYSIOL-HEART C, V280, pH160; Figueroa XF, 2003, CIRC RES, V92, P793, DOI 10.1161/01.RES.0000065918.90271.9A; Gustafsson F, 1999, ACTA PHYSIOL SCAND, V167, P11; Haefliger JA, 2004, CARDIOVASC RES, V62, P345, DOI 10.1016/j.cardiores.2003.11.015; HASHIMOTO Y, 1994, J SURG RES, V57, P693, DOI 10.1006/jsre.1994.1203; Hastie LE, 1997, J CELL PHYSIOL, V172, P373, DOI 10.1002/(SICI)1097-4652(199709)172:3<373::AID-JCP11>3.0.CO;2-7; Lee YN, 2002, TOXICOLOGY, V179, P51, DOI 10.1016/S0300-483X(02)00289-5; Li JM, 2004, AM J PHYSIOL-REG I, V287, pR1014, DOI 10.1152/ajpregu.00124.2004; Lidington D, 2000, J CELL PHYSIOL, V185, P117, DOI 10.1002/1097-4652(200010)185:1<117::AID-JCP11>3.0.CO;2-7; Lidington D, 2003, J VASC RES, V40, P149, DOI 10.1159/000070712; Lidington D, 2002, J CELL PHYSIOL, V193, P373, DOI 10.1002/jcp.10179; Martinez AD, 2000, BRAIN RES REV, V32, P250, DOI 10.1016/S0165-0173(99)00086-7; Meneshian A, 2002, MICROCIRCULATION, V9, P161, DOI 10.1038/sj.mn.7800136; Mottet D, 2003, J BIOL CHEM, V278, P31277, DOI 10.1074/jbc.M300763200; Musa H, 2004, J PHYSIOL-LONDON, V557, P863, DOI 10.1113/jphysiol.2003.059386; Musa H, 2003, BIOPHYS J, V84, P205, DOI 10.1016/S0006-3495(03)74843-7; Nishida M, 2000, ENDOTHELIUM-NEW YORK, V7, P279, DOI 10.3109/10623320009072214; Rose K, 2005, J CELL PHYSIOL, V204, P131, DOI 10.1002/jcp.20283; Sandow SL, 2003, CARDIOVASC RES, V60, P643, DOI 10.1016/j.cardiores.2003.09.017; Seko Y, 1996, BIOCHEM BIOPH RES CO, V226, P530, DOI 10.1006/bbrc.1996.1389; Simon AM, 1998, CURR BIOL, V8, P295, DOI 10.1016/S0960-9822(98)70113-7; TRAUB O, 1994, EUR J CELL BIOL, V64, P101; Tyml K, 2001, AM J PHYSIOL-HEART C, V281, pH1397; van Rijen HVM, 2000, CARDIOVASC RES, V45, P941, DOI 10.1016/S0008-6363(99)00373-9; Wu F, 2002, FEBS LETT, V520, P122, DOI 10.1016/S0014-5793(02)02804-1; Yamakoshi Y, 2003, J AM CHEM SOC, V125, P12803, DOI 10.1021/ja0355574; Yamamoto Y, 2001, J PHYSIOL-LONDON, V535, P181, DOI 10.1111/j.1469-7793.2001.00181.x; Zhang YW, 2000, PLANTA MED, V66, P119, DOI 10.1055/s-2000-11126; Zhang YW, 2000, PLANTA MED, V66, P114, DOI 10.1055/s-2000-11128; Zhang YW, 2002, PROSTAG LEUKOTR ESS, V67, P253, DOI 10.1054/plef.2002.0427; Zhang YW, 1999, PROSTAG LEUKOTR ESS, V61, P33, DOI 10.1054/plef.1999.0070; Zhou L, 1999, J CELL BIOL, V144, P1033, DOI 10.1083/jcb.144.5.1033	37	27	28	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1725	+		10.1096/fj.04-3446fje	http://dx.doi.org/10.1096/fj.04-3446fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16037099				2022-12-25	WOS:000230923000011
J	Girardin, EP; HajMohammadi, S; Birmele, B; Helisch, A; Shworak, NW; de Agostini, AI				Girardin, EP; HajMohammadi, S; Birmele, B; Helisch, A; Shworak, NW; de Agostini, AI			Synthesis of anticoagulantly active heparan sulfate proteoglycans by glomerular epithelial cells involves multiple 3-O-sulfotransferase isoforms and a limiting precursor pool	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPES-SIMPLEX-VIRUS; D-GLUCOSAMINYL 3-O-SULFOTRANSFERASE; ANTI-THROMBIN-III; BASEMENT-MEMBRANE; ANTITHROMBIN-BINDING; INCREASED PERMEABILITY; ENDOTHELIAL-CELLS; MOLECULAR-CLONING; HIGH-AFFINITY; HUMAN CDNAS	Endothelial and other select cell types synthesize a subpopulation of heparan sulfate (HS) proteoglycans (HSPGs), anticoagulant HSPGs (aHSPGs) that bear aHS-HS chains with the cognate 3-O-sulfated pentasaccharide motif that can bind and activate antithrombin ( AT). Endothelial cells regulate aHSPG production by limiting levels of HS 3-O-sulfotransferase-1 (3-OST-1), which modifies a non-limiting pool of aHS-precursors. By probing kidney cryosections with I-125-AT and fluorescently tagged AT we found that the glomerular basement membrane contains aHSPGs, with the staining pattern implicating synthesis by glomerular epithelial cells (GECs). Indeed, cultured GECs synthesized aHS with high AT affinity that was comparable with the endothelial product. Disaccharide analyses of human GEC (hGEC) HS in conjunction with transcript analyses revealed that hGECs express predominantly 3-OST-1 and 3-OST-3A. aHS production has not been previously examined in cells expressing multiple 3-OST isoforms. This unusual situation appears to involve novel mechanisms to regulate aHS production, as HS structural analyses suggest hGECs exhibit excess levels of 3-OST-1 and an extremely limiting pool of aHS-precursor. A limiting aHS-precursor pool may serve to minimize aHS synthesis by non-3-OST-1 isoforms. Indeed, we show that high in vitro levels of 3-OST-3(A) can efficiently generate aHS. Non-3-OST-1 isoforms can generate aHS in vivo, as the probing of kidney sections from 3-OST-1-deficient mice revealed GEC synthesis of aHSPGs. Surprisingly, Hs3st1(-/-) kidney only expresses 3-OST isoforms having a low specificity for aHS synthesis. Thus, our analyses reveal a cell type that expresses multiple 3-OST isoforms and produces minimal amounts of aHS-precursor. In part, this mechanism should prevent aHS overproduction by non-3-OST-1 isoforms. Such a role may be essential, as 3-OST isoforms that have a low specificity for aHS synthesis can generate substantial levels of aHSPGs in vivo.	Univ Hosp Geneva, Dept Pediat, CH-1211 Geneva, Switzerland; Univ Hosp Geneva, Dept Obstet & Gynecol, CH-1211 Geneva, Switzerland; Dartmouth Coll Sch Med, Dept Med, Cardiol Sect, Lebanon, NH 03756 USA	University of Geneva; University of Geneva; Dartmouth College	Girardin, EP (corresponding author), Univ Hosp Geneva, Dept Pediat, CH-1211 Geneva, Switzerland.	Eric.girardin@hcuge.ch	Shworak, Nicholas/AAJ-6770-2020	Shworak, Nicholas/0000-0001-7783-4634; Helisch, Armin/0000-0002-6507-8226; Girardin, Eric/0000-0002-5443-3640	NCI NIH HHS [CA 23108, P30 CA023108] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA023108] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Belting M, 2003, TRENDS BIOCHEM SCI, V28, P145, DOI 10.1016/S0968-0004(03)00031-8; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Chen JH, 2003, GLYCOBIOLOGY, V13, P785, DOI 10.1093/glycob/cwg101; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; COLLIECJOUAULT S, 1994, J BIOL CHEM, V269, P24953; Cunningham MA, 2000, J EXP MED, V191, P455, DOI 10.1084/jem.191.3.455; Daniels RJ, 2001, HUM MOL GENET, V10, P339, DOI 10.1093/hmg/10.4.339; DEAGOSTINI AI, 1990, J CELL BIOL, V111, P1293, DOI 10.1083/jcb.111.3.1293; DEAGOSTINI AL, 1990, P NATL ACAD SCI USA, V87, P9784, DOI 10.1073/pnas.87.24.9784; EDGE ASB, 1990, J BIOL CHEM, V265, P15874; Edge ASB, 2000, DIABETOLOGIA, V43, P1056, DOI 10.1007/s001250051489; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Gallagher JT, 2001, J CLIN INVEST, V108, P357, DOI 10.1172/JCI13713; Groffen AJ, 1998, J HISTOCHEM CYTOCHEM, V46, P19, DOI 10.1177/002215549804600104; GUO YC, 1988, ANAL BIOCHEM, V168, P54, DOI 10.1016/0003-2697(88)90009-7; HajMohammadi S, 2003, J CLIN INVEST, V111, P989, DOI 10.1172/JCI200315809; HISCOCK DRR, 1995, BBA-GEN SUBJECTS, V1244, P104, DOI 10.1016/0304-4165(94)00206-D; Hosseini G, 1996, J BIOL CHEM, V271, P22090, DOI 10.1074/jbc.271.36.22090; Iozzo RV, 2001, J CLIN INVEST, V108, P349, DOI 10.1172/JCI13738; Iozzo RV, 2001, J CLIN INVEST, V108, P165, DOI 10.1172/JCI13560; JAT PS, 1991, P NATL ACAD SCI USA, V88, P5096, DOI 10.1073/pnas.88.12.5096; KANWAR YS, 1983, EUR J CELL BIOL, V31, P290; KANWAR YS, 1980, J CELL BIOL, V86, P688, DOI 10.1083/jcb.86.2.688; KANWAR YS, 1981, RENAL PHYSIOL BIOCH, V4, P121; KINSELLA MG, 1988, BIOCHEMISTRY-US, V27, P2136, DOI 10.1021/bi00406a048; KOJIMA T, 1992, J BIOL CHEM, V267, P4859; KOJIMA T, 1992, J BIOL CHEM, V267, P4870; KRIZ W, 1995, KIDNEY INT, V48, P1435, DOI 10.1038/ki.1995.433; KUSCHE M, 1990, J BIOL CHEM, V265, P7292; LEE MK, 1991, P NATL ACAD SCI USA, V88, P2768, DOI 10.1073/pnas.88.7.2768; LINDAHL U, 1980, P NATL ACAD SCI-BIOL, V77, P6551, DOI 10.1073/pnas.77.11.6551; LINHARDT RJ, 1992, J BIOL CHEM, V267, P2380; Liu J, 1996, J BIOL CHEM, V271, P27072, DOI 10.1074/jbc.271.43.27072; Liu J, 2002, J BIOL CHEM, V277, P33456, DOI 10.1074/jbc.M202034200; Liu JA, 1999, J BIOL CHEM, V274, P5185, DOI 10.1074/jbc.274.8.5185; LYON M, 1990, ANAL BIOCHEM, V185, P63, DOI 10.1016/0003-2697(90)90255-8; Mani K, 2000, GLYCOBIOLOGY, V10, P577, DOI 10.1093/glycob/10.6.577; MARCUM JA, 1986, EXP CELL RES, V166, P253, DOI 10.1016/0014-4827(86)90525-2; MARCUM JA, 1986, J BIOL CHEM, V261, P7507; MARCUM JA, 1984, BIOCHEMISTRY-US, V23, P1730, DOI 10.1021/bi00303a023; MARCUM JA, 1983, AM J PHYSIOL, V245, pH725, DOI 10.1152/ajpheart.1983.245.5.H725; Miyamoto K, 2003, ONCOGENE, V22, P274, DOI 10.1038/sj.onc.1206146; MURDOCH AD, 1994, J HISTOCHEM CYTOCHEM, V42, P239, DOI 10.1177/42.2.7507142; Pahl MV, 1996, J AM SOC NEPHROL, V7, P2249; PEJLER G, 1987, BIOCHEM J, V248, P69, DOI 10.1042/bj2480069; PEJLER G, 1987, J BIOL CHEM, V262, P5036; Pfeiffer S, 2002, CURR BIOL, V12, P957, DOI 10.1016/S0960-9822(02)00867-9; Princivalle M, 2001, GLYCOBIOLOGY, V11, P183, DOI 10.1093/glycob/11.3.183; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; ROSENZWEIG LJ, 1982, LAB INVEST, V47, P177; RUEF C, 1990, KIDNEY INT, V38, P249, DOI 10.1038/ki.1990.193; Sasisekharan R, 2002, NAT REV CANCER, V2, P521, DOI 10.1038/nrc842; SHEN GQ, 1995, ARCH BIOCHEM BIOPHYS, V321, P83, DOI 10.1006/abbi.1995.1371; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; SHWORAK NW, 1994, J BIOL CHEM, V269, P21204; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; Shworak NW, 1999, J BIOL CHEM, V274, P5170, DOI 10.1074/jbc.274.8.5170; SHWORAK NW, 1994, J BIOL CHEM, V269, P24941; Shworak NW, 1998, TRENDS GLYCOSCI GLYC, V10, P175, DOI 10.4052/tigg.10.175; SHWORAK NW, 1993, J BIOL CHEM, V268, P24460; Shworak NW, 1996, J BIOL CHEM, V271, P27063, DOI 10.1074/jbc.271.43.27063; STRIKER GE, 1985, LAB INVEST, V53, P122; TAKEUCHI Y, 1990, J BIOL CHEM, V265, P13661; Torry RJ, 1999, J HISTOCHEM CYTOCHEM, V47, P313, DOI 10.1177/002215549904700305; Torry RJ, 1998, TRANSPLANTATION, V66, P797, DOI 10.1097/00007890-199809270-00016; Wu ZLL, 2004, J BIOL CHEM, V279, P1861, DOI 10.1074/jbc.M311398200; Xia GQ, 2002, J BIOL CHEM, V277, P37912, DOI 10.1074/jbc.M204209200; Xu D, 2005, BIOCHEM J, V385, P451, DOI 10.1042/BJ20040908; XU YH, 1994, J HISTOCHEM CYTOCHEM, V42, P1365, DOI 10.1177/42.10.7930519; Yabe T, 2001, BIOCHEM J, V359, P235, DOI 10.1042/0264-6021:3590235; Ye S, 2001, BIOCHEMISTRY-US, V40, P14429, DOI 10.1021/bi011000u; Zhang LJ, 1999, J BIOL CHEM, V274, P5681, DOI 10.1074/jbc.274.9.5681; Zhang LJ, 1998, J BIOL CHEM, V273, P27998, DOI 10.1074/jbc.273.43.27998	74	27	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 11	2005	280	45					38059	38070		10.1074/jbc.M507997200	http://dx.doi.org/10.1074/jbc.M507997200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	980UU	16107334	hybrid			2022-12-25	WOS:000233044500089
J	Okada, T; Ding, G; Sonoda, H; Kajimoto, T; Haga, Y; Khosrowbeygi, A; Gao, SY; Miwa, N; Jahangeer, S; Nakamura, S				Okada, T; Ding, G; Sonoda, H; Kajimoto, T; Haga, Y; Khosrowbeygi, A; Gao, SY; Miwa, N; Jahangeer, S; Nakamura, S			Involvement of N-terminal-extended form of sphingosine kinase 2 in serum-dependent regulation of cell proliferation and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-CHARACTERIZATION; MOLECULAR-CLONING; KINASE TYPE-2; PROTEIN; SPHINGOSINE-1-PHOSPHATE; 1-PHOSPHATE; FTY720	Sphingosine kinase (SPHK) 1 is implicated in the regulation of cell proliferation and anti-apoptotic processes by catalyzing the formation of an important bioactive messenger, sphingosine 1-phosphate. Unlike the proliferative action of SPHK1, another isozyme, SPHK2, has been shown to possess anti-proliferative or pro-apoptotic action. Molecular mechanisms of SPHK2 action, however, are largely unknown. The present studies were undertaken to characterize the N-terminal-extended form of SPHK2 (SPHK2-L) by comparing it with the originally reported form, SPHK2-S. Real-time quantitative PCR analysis revealed that SPHK2-L mRNA is the major form in several human cell lines and tissues. From sequence analyses it was concluded that SPHK2-L is a species-specific isoform that is expressed in human but not in mouse. At the protein level it has been demonstrated by immunoprecipitation studies that SPHK2-L is the major isoform in human hepatoma HepG2 cells. SPHK2-L, when expressed in human embryonic kidney (HEK) 293 cells, did not show any inhibition of DNA synthesis in the presence of serum, whereas it showed marked inhibition in the absence of serum. Moreover, serum deprivation resulted in the translocation of SPHK2-L into the nuclei. In addition, serum deprivation induced SPHK2-L expression in HEK293 cells. Furthermore, suppression of SPHK2 by small interfering RNA treatment prevented serum deprivation- or drug-induced apoptosis in HEK293 cells. Taken together, these results indicate that a major form of SPHK2 splice variant, SPHK2-L, in human cells does not inhibit DNA synthesis under normal conditions and that SPHK2- L accumulation in the nucleus induced by serum deprivation may be involved in the cessation of cell proliferation or apoptosis depending on the cell type.	Kobe Univ, Grad Sch Med, Dept Mol & Cellular Biol, Div Biochem, Kobe, Hyogo 6500017, Japan	Kobe University	Nakamura, S (corresponding author), Kobe Univ, Grad Sch Med, Dept Mol & Cellular Biol, Div Biochem, Kobe, Hyogo 6500017, Japan.	snakamur@kobe-u.ac.jp		Sonoda, Hirofumi/0000-0003-3353-1783				Billich A, 2003, J BIOL CHEM, V278, P47408, DOI 10.1074/jbc.M307687200; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Fujita T, 2004, BIOCHEM J, V382, P717, DOI 10.1042/BJ20040141; Hayashi S, 2002, J BIOL CHEM, V277, P33319, DOI 10.1074/jbc.M201442200; Heringdorf DMZ, 1997, FEBS LETT, V410, P34, DOI 10.1016/S0014-5793(97)00320-7; Igarashi N, 2003, J BIOL CHEM, V278, P46832, DOI 10.1074/jbc.M306577200; Igarashi Y, 1997, J BIOCHEM-TOKYO, V122, P1080; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Le Stunff H, 2002, BBA-MOL CELL BIOL L, V1582, P8, DOI 10.1016/S1388-1981(02)00132-4; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Liu H, 2003, J BIOL CHEM, V278, P40330, DOI 10.1074/jbc.M304455200; MATTIE M, 1994, J BIOL CHEM, V269, P3181; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Paugh SW, 2003, FEBS LETT, V554, P189, DOI 10.1016/S0014-5793(03)01168-2; Pitson SM, 2005, J EXP MED, V201, P49, DOI 10.1084/jem.20040559; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Safadi-Chamberlain F, 2005, BIOCHEM J, V388, P827, DOI 10.1042/BJ20041726; Xia P, 1999, J BIOL CHEM, V274, P34499, DOI 10.1074/jbc.274.48.34499; Yoshimoto T, 2003, J IMMUNOL, V171, P1352, DOI 10.4049/jimmunol.171.3.1352	19	128	144	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36318	36325		10.1074/jbc.M504507200	http://dx.doi.org/10.1074/jbc.M504507200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16103110	hybrid			2022-12-25	WOS:000232726900065
J	Low, LY; Yang, C; Perego, M; Osterman, A; Liddington, RC				Low, LY; Yang, C; Perego, M; Osterman, A; Liddington, RC			Structure and lytic activity of a Bacillus anthracis prophage endolysin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-WALL; STAPHYLOCOCCUS-AUREUS; BACTERIOPHAGE; RECOGNITION; HYDROLASES; LYSOZYME; HOMOLOGY; AMIDASE; PROGRAM; DOMAINS	We report a structural and functional analysis of the lambda prophage Ba02 endolysin ( PlyL) encoded by the Bacillus anthracis genome. We show that PlyL comprises two autonomously folded domains, an N- terminal catalytic domain and a C- terminal cell wall- binding domain. We determined the crystal structure of the catalytic domain; its three- dimensional fold is related to that of the cell wall amidase, T7 lysozyme, and contains a conserved zinc coordination site and other components of the catalytic machinery. We demonstrate that PlyL is an N- acetylmuramoyl- L- alanine amidase that cleaves the cell wall of several Bacillus species when applied exogenously. We show, unexpectedly, that the catalytic domain of PlyL cleaves more efficiently than the full- length protein, except in the case of Bacillus cereus, and using GFP- tagged cell wall- binding domain, we detected strong binding of the cell wall- binding domain to B. cereus but not to other species tested. We further show that a related endolysin ( Ply21) from the B. cereus phage, TP21, shows a similar pattern of behavior. To explain these data, and the species specificity of PlyL, we propose that the C- terminal domain inhibits the activity of the catalytic domain through intramolecular interactions that are relieved upon binding of the C- terminal domain to the cell wall. Furthermore, our data show that ( when applied exogenously) targeting of the enzyme to the cell wall is not a prerequisite of its lytic activity, which is inherently high. These results may have broad implications for the design of endolysins as therapeutic agents.	Burnham Inst, Infect & Inflammatory Dis Ctr, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol & Expt Med, Div Cellular Biol, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute; Scripps Research Institute	Liddington, RC (corresponding author), Burnham Inst, Infect & Inflammatory Dis Ctr, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	rlidding@burnham.org						Baba T, 1996, EMBO J, V15, P4789, DOI 10.1002/j.1460-2075.1996.tb00859.x; BROWN ER, 1955, J INFECT DIS, V96, P34, DOI 10.1093/infdis/96.1.34; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHENG XD, 1994, P NATL ACAD SCI USA, V91, P4034, DOI 10.1073/pnas.91.9.4034; Ghuysen J-M., 1966, METHOD ENZYMOL, P685, DOI DOI 10.1016/0076-6879(66)08124-2; Inglesby TV, 2002, JAMA-J AM MED ASSOC, V287, P2236, DOI 10.1001/jama.287.17.2236; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim MS, 2003, NAT IMMUNOL, V4, P787, DOI 10.1038/ni952; Kleywegt GJ, 1996, STRUCTURE, V4, P897, DOI 10.1016/S0969-2126(96)00097-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Liepinsh E, 2003, J MOL BIOL, V327, P833, DOI 10.1016/S0022-2836(03)00185-2; Loessner MJ, 1999, J BACTERIOL, V181, P4452, DOI 10.1128/JB.181.15.4452-4460.1999; Loessner MJ, 1997, J BACTERIOL, V179, P2845, DOI 10.1128/jb.179.9.2845-2851.1997; Loessner MJ, 2002, MOL MICROBIOL, V44, P335, DOI 10.1046/j.1365-2958.2002.02889.x; Loessner MJ, 1998, FEMS MICROBIOL LETT, V162, P265, DOI 10.1016/S0378-1097(98)00131-1; Lopez R, 1997, MICROB DRUG RESIST, V3, P199, DOI 10.1089/mdr.1997.3.199; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Schuch R, 2002, NATURE, V418, P884, DOI 10.1038/nature01026; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876	22	133	140	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35433	35439		10.1074/jbc.M502723200	http://dx.doi.org/10.1074/jbc.M502723200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16103125	hybrid			2022-12-25	WOS:000232561200043
J	Vigil, D; Blumenthal, DK; Taylor, SS; Trewhella, J				Vigil, D; Blumenthal, DK; Taylor, SS; Trewhella, J			The conformationally dynamic C helix of the RI alpha subunit of protein kinase A mediates isoform-specific domain reorganization upon C subunit binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMIDE H/H-2 EXCHANGE; REGULATORY SUBUNIT; CATALYTIC SUBUNIT; I-ALPHA; CRYSTAL-STRUCTURE; BIOLOGICAL MACROMOLECULES; SOLUTION SCATTERING; DIMERIC COMPLEX; MOLECULAR-BASIS; CAMP	Different isoforms of the full- length protein kinase A ( PKA) regulatory subunit homodimer ( R-2) and the catalytic ( C) subunit-bound holoenzyme ( R2C2) have very different global structures despite similar molecular weights and domain organization within their primary sequences. To date, it has been the linker sequence between the R subunit dimerization/ docking domain and cAMP-binding domain A that has been implicated in modulating domain interactions to give rise to these differences in global structure. The small angle solution scattering data presented here for three different isoforms of PKA heterodimer ( Delta R- C) complexes reveal a role for another conformationally dynamic sequence in modulating inter-subunit and domain interactions, the C helix that connects the cAMP- binding domains A and B of the R subunit. The Delta R- C heterodimer complexes studied here were each formed with a monomeric N- terminal deletion mutant of the R subunit ( Delta R) that contains the inhibitor sequence and both cAMP- binding domains. The scattering data show that type II alpha and type II beta Delta R- C heterodimers are relatively compact and globular, with the C subunit contacting the inhibitor sequence and both cAMP- binding domains. In contrast, the type I alpha heterodimer is significantly more extended, with the C subunit interacting with the inhibitor sequence and cAMP-binding domain A, whereas domain B extends out such that its surface is almost completely solvent exposed. These data implicate the C helix of RI alpha in modulating isoform- specific interdomain communication in the PKA holoenzyme, adding another layer of structural complexity to our understanding of signaling dynamics in this multisubunit, multidomain protein kinase.	Univ Utah, Dept Chem, Salt Lake City, UT 84112 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92037 USA; Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92037 USA; Univ Utah, Dept Pharmacol & Toxicol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Biochem, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Trewhella, J (corresponding author), Univ Utah, Dept Chem, 315 S 1400 E,Rm 1124 HEB, Salt Lake City, UT 84112 USA.	Jill.Trewhella@chemistry.utah.edu		Blumenthal, Donald/0000-0002-8614-1167; Trewhella, Jill/0000-0002-8555-6766	NIGMS NIH HHS [GM34921-19A1, GM34921] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034921] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amieux PS, 2002, ANN NY ACAD SCI, V968, P75, DOI 10.1111/j.1749-6632.2002.tb04328.x; Anand GS, 2003, P NATL ACAD SCI USA, V100, P13264, DOI 10.1073/pnas.2232255100; Banky P, 2003, J MOL BIOL, V330, P1117, DOI 10.1016/S0022-2836(03)00552-7; Berman HM, 2005, P NATL ACAD SCI USA, V102, P45, DOI 10.1073/pnas.0408579102; Canaves JM, 2002, J MOL EVOL, V54, P17, DOI 10.1007/s00239-001-0013-1; Cheng XD, 2001, J BIOL CHEM, V276, P4102, DOI 10.1074/jbc.M006447200; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; Cummings DE, 1996, NATURE, V382, P622, DOI 10.1038/382622a0; Diller TC, 2001, STRUCTURE, V9, P73, DOI 10.1016/S0969-2126(00)00556-6; Gekko K, 2004, BIOCHEMISTRY-US, V43, P3844, DOI 10.1021/bi036271e; Guinier A., 1939, ANN PHYS, V12, P166; Hamuro Y, 2003, J MOL BIOL, V327, P1065, DOI 10.1016/S0022-2836(03)00234-1; HEIDORN DB, 1988, BIOCHEMISTRY-US, V27, P909, DOI 10.1021/bi00403a011; Heller WT, 2004, J BIOL CHEM, V279, P19084, DOI 10.1074/jbc.M313405200; Heller WT, 2002, BIOCHEMISTRY-US, V41, P15654, DOI 10.1021/bi026687c; Herberg FW, 1996, BIOCHEMISTRY-US, V35, P2934, DOI 10.1021/bi951647c; Hoeflich KP, 2002, CELL, V108, P739, DOI 10.1016/S0092-8674(02)00682-7; KANDEL E, 2001, SCIENCE, V294, P5544; Kim C, 2005, SCIENCE, V307, P690, DOI 10.1126/science.1104607; Kirschner LS, 2000, NAT GENET, V26, P89, DOI 10.1038/79238; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; Kozin MB, 2001, J APPL CRYSTALLOGR, V34, P33, DOI 10.1107/S0021889800014126; Laxminarayana D, 2000, INT IMMUNOL, V12, P1521, DOI 10.1093/intimm/12.11.1521; Newlon MG, 1999, NAT STRUCT BIOL, V6, P222; Porod G., 1982, SMALL ANGLE XRAY SCA, P18; Qin ZH, 2001, BIOPHYS J, V81, P2908, DOI 10.1016/S0006-3495(01)75931-0; Skalhegg BS, 2000, FRONT BIOSCI-LANDMRK, V5, pD678, DOI 10.2741/Skalhegg; SLICE LW, 1989, J BIOL CHEM, V264, P20940; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; SVERGUN DI, 1988, ACTA CRYSTALLOGR A, V44, P244, DOI 10.1107/S0108767387011255; Tung CS, 2002, J BIOL CHEM, V277, P12423, DOI 10.1074/jbc.M110298200; Vigil D, 2004, J MOL BIOL, V337, P1183, DOI 10.1016/j.jmb.2004.02.028; Volkov VV, 2003, J APPL CRYSTALLOGR, V36, P860, DOI 10.1107/S0021889803000268; Wong W, 2004, NAT REV MOL CELL BIO, V5, P959, DOI 10.1038/nrm1527; Wu J, 2004, STRUCTURE, V12, P1057, DOI 10.1016/j.str.2004.03.022; Yu SN, 2004, BIOCHEMISTRY-US, V43, P1908, DOI 10.1021/bi0354435; Zhao JK, 1998, J BIOL CHEM, V273, P30448, DOI 10.1074/jbc.273.46.30448	40	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35521	35527		10.1074/jbc.M506769200	http://dx.doi.org/10.1074/jbc.M506769200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16109722	hybrid			2022-12-25	WOS:000232561200053
J	Lee, NV; Rodriguez-Manzaneque, JC; Thai, SNM; Twal, WO; Luque, A; Lyons, KM; Argraves, WS; Iruela-Arispe, ML				Lee, NV; Rodriguez-Manzaneque, JC; Thai, SNM; Twal, WO; Luque, A; Lyons, KM; Argraves, WS; Iruela-Arispe, ML			Fibulin-1 acts as a cofactor for the matrix metalloprotease ADAMTS-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBOTIC THROMBOCYTOPENIC PURPURA; EXTRACELLULAR-MATRIX; IN-VIVO; BINDING-PROTEIN; AGGRECAN; DOMAIN; FIBRONECTIN; VERSICAN; INHIBITORS; ABNORMALITIES	ADAMTS-1 is a metalloprotease that has been implicated in the inhibition of angiogenesis and is a mediator of proteolytic cleavage of the hyaluronan binding proteoglycans, aggrecan and versican. In an attempt to further understand the biological function of ADAMTS-1, a yeast two-hybrid screen was performed using the carboxyl-terminal region of ADAMTS-1 as bait. As a result, the extracellular matrix protein fibulin-1 was identified as a potential interacting molecule. Through a series of analyses that included ligand affinity chromatography, co-immunoprecipitation, pulldown assays, and enzyme-linked immunosorbent assay, the ability of these two proteins to interact was substantiated. Additional studies showed that ADAMTS-1 and fibulin-1 colocalized in vivo. Furthermore, fibulin-1 was found to enhance the capacity of ADAMTS-1 to cleave aggrecan, a proteoglycan known to bind to fibulin-1. We confirmed that fibulin-1 was not a proteolytic substrate for ADAMTS-1. Together, these findings indicate that fibulin-1 is a new regulator of ADAMTS-1-mediated proteoglycan proteolysis and thus may play an important role in proteoglycan turnover in tissues where there is overlapping expression.	Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA; Med Univ S Carolina, Dept Cell Biol & Anat, Charleston, SC 29425 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Medical University of South Carolina	Iruela-Arispe, ML (corresponding author), Univ Calif Los Angeles, Inst Mol Biol, Paul D Boyer Hall,611 Charles Young Dr E, Los Angeles, CA 90095 USA.	arispe@mbi.ucla.edu	Rodriguez-Manzaneque, Juan Carlos/F-3899-2012; Iruela-Arispe, M. Luisa/AAJ-1297-2020; Luque, Alfonso/C-5846-2018	Rodriguez-Manzaneque, Juan Carlos/0000-0001-5951-7029; Iruela-Arispe, M. Luisa/0000-0002-3050-4168; 	NATIONAL CANCER INSTITUTE [R01CA077420] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL052813, R01HL061873] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007185] Funding Source: NIH RePORTER; NCI NIH HHS [CA077420] Funding Source: Medline; NHLBI NIH HHS [HL52813, HL61873] Funding Source: Medline; NIGMS NIH HHS [GM07185] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Argraves WS, 2003, EMBO REP, V4, P1127, DOI 10.1038/sj.embor.7400033; ARGRAVES WS, 1989, CELL, V58, P623, DOI 10.1016/0092-8674(89)90097-4; Aspberg A, 1999, J BIOL CHEM, V274, P20444, DOI 10.1074/jbc.274.29.20444; BALBONA K, 1992, J BIOL CHEM, V267, P20120; Fernandes RJ, 2001, J BIOL CHEM, V276, P31502, DOI 10.1074/jbc.M103466200; Gao G, 2004, J BIOL CHEM, V279, P10042, DOI 10.1074/jbc.M312100200; Godyna S, 1996, BLOOD, V88, P2569, DOI 10.1182/blood.V88.7.2569.bloodjournal8872569; Hashimoto G, 2004, J BIOL CHEM, V279, P32483, DOI 10.1074/jbc.M314216200; Heissig B, 2003, CURR OPIN HEMATOL, V10, P136, DOI 10.1097/00062752-200303000-00007; Hesselson D, 2004, CURR BIOL, V14, P2005, DOI 10.1016/j.cub.2004.11.006; Hulmes DJS, 1997, MATRIX BIOL, V16, P41, DOI 10.1016/S0945-053X(97)90115-3; Jonnsson-Rylander AC, 2005, ARTERIOSCL THROM VAS, V25, P180, DOI 10.1161/01.ATV.0000150045.27127.37; Kashiwagi M, 2004, J BIOL CHEM, V279, P10109, DOI 10.1074/jbc.M312123200; Kostka G, 2001, MOL CELL BIOL, V21, P7025, DOI 10.1128/MCB.21.20.7025-7034.2001; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; Kuno K, 1998, J BIOL CHEM, V273, P13912, DOI 10.1074/jbc.273.22.13912; Kuno K, 1999, J BIOL CHEM, V274, P18821, DOI 10.1074/jbc.274.26.18821; Kuno K, 2000, FEBS LETT, V478, P241, DOI 10.1016/S0014-5793(00)01854-8; Levy GG, 2001, NATURE, V413, P488, DOI 10.1038/35097008; Li SW, 2001, BIOCHEM J, V355, P271, DOI 10.1042/0264-6021:3550271; Little CB, 2005, ARTHRITIS RHEUM-US, V52, P1461, DOI 10.1002/art.21022; Liu B, 2003, GROWTH HORM IGF RES, V13, P89, DOI 10.1016/S1096-6374(03)00007-8; Miosge N, 1999, FASEB J, V13, P1743, DOI 10.1096/fasebj.13.13.1743; Mittaz L, 2004, BIOL REPROD, V70, P1096, DOI 10.1095/biolreprod.103.023911; Murphy G, 1997, MATRIX BIOL, V15, P511, DOI 10.1016/S0945-053X(97)90025-1; Nguyen AD, 2004, CIRC RES, V95, P1067, DOI 10.1161/01.RES.0000149568.85071.FB; Olin AI, 2001, J BIOL CHEM, V276, P1253, DOI 10.1074/jbc.M006783200; Overall CM, 2004, BIOL CHEM, V385, P493, DOI 10.1515/BC.2004.058; Overall CM, 2002, BIOL CHEM, V383, P1059, DOI 10.1515/BC.2002.114; Oxford JT, 2004, J BIOL CHEM, V279, P10939, DOI 10.1074/jbc.M310291200; Parks WC, 1999, WOUND REPAIR REGEN, V7, P423, DOI 10.1046/j.1524-475X.1999.00423.x; Porter S, 2004, BIOCH J; Rodriguez-Manzaneque JC, 2000, J BIOL CHEM, V275, P33471, DOI 10.1074/jbc.M002599200; Rodriguez-Manzaneque JC, 2002, BIOCHEM BIOPH RES CO, V293, P501; Russell DL, 2003, J BIOL CHEM, V278, P42330, DOI 10.1074/jbc.M300519200; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; Shindo T, 2000, J CLIN INVEST, V105, P1345, DOI 10.1172/JCI8635; Stanton H, 2005, NATURE, V434, P648, DOI 10.1038/nature03417; Thai SNM, 2002, MECH DEVELOP, V115, P181, DOI 10.1016/S0925-4773(02)00115-6; TIMPL R, 1994, MATRIX BIOL, V14, P275, DOI 10.1016/0945-053X(94)90192-9; TRAN H, 1995, J BIOL CHEM, V270, P19458, DOI 10.1074/jbc.270.33.19458; Tran H, 1997, J BIOL CHEM, V272, P22600, DOI 10.1074/jbc.272.36.22600; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; Werneck CC, 2004, J BIOL CHEM, V279, P23045, DOI 10.1074/jbc.M402656200; Zhang HY, 1996, DEV DYNAM, V205, P348, DOI 10.1002/(SICI)1097-0177(199603)205:3<348::AID-AJA13>3.0.CO;2-0; Zheng XL, 2001, J BIOL CHEM, V276, P41059, DOI 10.1074/jbc.C100515200; Zheng XL, 2002, CURR OPIN HEMATOL, V9, P389, DOI 10.1097/00062752-200209000-00001	47	76	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34796	34804		10.1074/jbc.M506980200	http://dx.doi.org/10.1074/jbc.M506980200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16061471	hybrid			2022-12-25	WOS:000232403900051
J	Bailey, CM; Khalkhali-Ellis, Z; Kondo, S; Margaryan, NV; Seftor, REB; Wheaton, WW; Amir, S; Pins, MR; Schutte, BC; Hendrix, MJC				Bailey, CM; Khalkhali-Ellis, Z; Kondo, S; Margaryan, NV; Seftor, REB; Wheaton, WW; Amir, S; Pins, MR; Schutte, BC; Hendrix, MJC			Mammary serine protease inhibitor (maspin) binds directly to interferon regulatory factor 6 - Identification of a novel serpin partnership	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; TRANSACTIVATION DOMAIN; DNA-BINDING; PHOSPHORYLATION; LOCALIZATION; EXPRESSION; APOPTOSIS; INVASION; GLAND; ACTIVATION	Since its reported discovery in 1994, maspin ( mammary serine protease inhibitor) has been characterized as a class II tumor suppressor by its ability to promote apoptosis and inhibit cell invasion. Maspin is highly expressed in normal mammary epithelial cells but reduced or absent in aggressive breast carcinomas. However, despite efforts to characterize the mechanism(s) by which maspin functions as a tumor suppressor, its molecular characterization has remained somewhat elusive. Therefore, in an attempt to identify maspin-interacting proteins and thereby gain insight into the functional pathways of maspin, we employed amaspin-baited yeast two-hybrid system and subsequently identified Interferon Regulatory Factor 6 (IRF6) as a maspin-binding protein. IRF6 belongs to the IRF family of transcription factors, which is best known for its regulation of interferon and interferon-inducible genes following a pathogenic stimulus. Although many of the IRF family members have been well characterized, IRF6 remains poorly understood. We report that IRF6 is expressed in normal mammary epithelial cells and that it directly associates with maspin in a yeast two-hybrid system and in vitro. The interaction occurs via the conserved IRF protein association domain and is regulated by phosphorylation of IRF6. We have shown that, similar to maspin, IRF6 expression is inversely correlated with breast cancer invasiveness. We further demonstrated that the transient re-expression of IRF6 in breast cancer cells results in an increase of N-cadherin and a redistribution of vimentin commensurate with changes in cell morphology, suggestive of an epithelial-to-mesenchymal transition event. Concomitantly, we showed that maspin acts as a negative regulator of this process. These findings help to elucidate the molecular mechanisms of maspin and suggest an interactive role between maspin and IRF6 in regulating cellular phenotype, the loss of which can lead to neoplastic transformation.	Univ Iowa, Roy A & Lucille J Carver Coll Med, Dept Anat & Cell Biol, Iowa City, IA 52242 USA; Univ Iowa, Roy A & Lucille J Carver Coll Med, Dept Pediat, Iowa City, IA 52242 USA; Northwestern Univ, Childrens Mem Res Ctr, Chicago, IL 60011 USA; Northwestern Univ, Dept Pathol & Urol, Chicago, IL 60011 USA; Northwestern Univ, Feinberg Sch Med, Chicago, IL 60011 USA	University of Iowa; University of Iowa; Northwestern University; Northwestern University; Northwestern University; Feinberg School of Medicine	Hendrix, MJC (corresponding author), Childrens Mem Res Ctr, 2300 Childrens Plaza,Box 222, Chicago, IL 60614 USA.	mjchendrix@childrensmemorial.org			NATIONAL CANCER INSTITUTE [R01CA075681] Funding Source: NIH RePORTER; NCI NIH HHS [CA 75681, R01 CA075681-10, R01 CA075681] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barnes BJ, 2003, CANCER RES, V63, P6424; Barnes BJ, 2002, MOL CELL BIOL, V22, P5721, DOI 10.1128/MCB.22.16.5721-5740.2002; Boecker W, 2003, CELL PROLIFERAT, V36, P73, DOI 10.1046/j.1365-2184.36.s.1.7.x; Civas A, 2002, BIOCHIMIE, V84, P643, DOI 10.1016/S0300-9084(02)01431-1; Cuervo R, 2002, DEV BIOL, V245, P145, DOI 10.1006/dbio.2002.0620; De Creus A, 2002, J IMMUNOL, V168, P6486, DOI 10.4049/jimmunol.168.12.6486; Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5; Duguay D, 2002, CANCER RES, V62, P5148; Eroshkin A, 1999, J MOL MED, V77, P403, DOI 10.1007/s001090050369; FITCHETT JE, 1989, DEV BIOL, V131, P455, DOI 10.1016/S0012-1606(89)80017-X; Fulda S, 2002, ONCOGENE, V21, P2295, DOI 10.1038/sj.onc.1205255; Hatada S, 1997, GENE, V203, P183, DOI 10.1016/S0378-1119(97)00512-X; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Hendrix MJC, 1997, AM J PATHOL, V150, P483; Jiang N, 2002, ONCOGENE, V21, P4089, DOI 10.1038/sj.onc.1205507; Khalkhali-Ellis Z, 2004, CLIN CANCER RES, V10, P449, DOI 10.1158/1078-0432.CCR-1002-03; Kim TY, 2003, J BIOL CHEM, V278, P15272, DOI 10.1074/jbc.M205792200; Kirschmann DA, 2002, CANCER RES, V62, P4478; Knudsen KA, 2005, J CELL BIOCHEM, V95, P488, DOI 10.1002/jcb.20419; Kondo S, 2002, NAT GENET, V32, P285, DOI 10.1038/ng985; Lau JF, 2000, P NATL ACAD SCI USA, V97, P7278, DOI 10.1073/pnas.97.13.7278; Lin RT, 2000, J BIOL CHEM, V275, P34320, DOI 10.1074/jbc.M002814200; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Marie I, 2000, MOL CELL BIOL, V20, P8803, DOI 10.1128/MCB.20.23.8803-8814.2000; Martinez-Alvarez C, 2000, DEV BIOL, V220, P343, DOI 10.1006/dbio.2000.9644; Masumi A, 2003, J BIOL CHEM, V278, P25401, DOI 10.1074/jbc.M213037200; Meraro D, 1999, J IMMUNOL, V163, P6468; Mori M, 2004, J BIOL CHEM, V279, P9698, DOI 10.1074/jbc.M310616200; Moriyama Y, 2001, CLIN CANCER RES, V7, P1293; Qin BY, 2003, NAT STRUCT BIOL, V10, P913, DOI 10.1038/nsb1002; Reich NC, 2002, J INTERF CYTOK RES, V22, P103, DOI 10.1089/107999002753452719; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; Strizzi L, 2004, J CELL PHYSIOL, V201, P266, DOI 10.1002/jcp.20062; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Williams BRG, 2003, SCIENCE, V300, P1100, DOI 10.1126/science.1085277; Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303; Zhang M, 1999, DEV BIOL, V215, P278, DOI 10.1006/dbio.1999.9442; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962; Zucchero TM, 2004, NEW ENGL J MED, V351, P769, DOI 10.1056/NEJMoa032909	39	77	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34210	34217		10.1074/jbc.M503523200	http://dx.doi.org/10.1074/jbc.M503523200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16049006	Green Accepted, hybrid			2022-12-25	WOS:000232229700063
J	Cadoret, JC; Rousseau, B; Perewoska, I; Sicora, C; Cheregi, O; Vass, I; Houmard, J				Cadoret, JC; Rousseau, B; Perewoska, I; Sicora, C; Cheregi, O; Vass, I; Houmard, J			Cyclic nucleotides, the photosynthetic apparatus and response to a UV-B stress in the cyanobacterium Synechocystis sp PCC 6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II REACTION-CENTER; CAMP SIGNAL-TRANSDUCTION; PHOTOSYSTEM-II; ULTRAVIOLET-B; ADENYLATE-CYCLASE; ISOLATED THYLAKOIDS; RECEPTOR PROTEIN; ACCEPTOR-SIDE; CELL MOTILITY; SIGMA-FACTORS	Cyclic nucleotides cAMP and cGMP are ubiquitous signaling molecules that mediate many adaptative responses in eukaryotic cells. Cyanobacteria present the peculiarity among the prokaryotes of having the two types of cyclic nucleotide. Cellular homeostasis requires both cyclases (adenylyl/guanylyl, for their synthesis) and phosphodiesterases ( for their degradation). Fully segregated null mutants have been obtained for the two genes, sll1624 and slr2100, which encode putative cNMP phosphodiesterases. We present physiological evidence that the Synechocystis PCC 6803 open reading frame slr2100 could be a cGMP phosphodiesterase. In addition, we show that Slr2100, but not Sll1624, is required for the adaptation of the cells to a UV-B stress. UV-B radiation has deleterious effects for photosynthetic organisms, in particular on the photosystem II, through damaging the protein structure of the reaction center. Using biophysical and biochemical approaches, it was found that Slr2100 is involved in the signal transduction events which permit the repair of the UV-B-damaged photosystem II. This was confirmed by quantitative reverse transcriptase-PCR analyses. Altogether, the data point to an important role for cGMP in signal transduction and photoacclimation processes during a UV-B stress.	Ecole Normale Super, CNRS, FRE 2433, Dept Biol, F-75230 Paris, France; Biol Res Ctr, Inst Plant Biol, H-6701 Szeged, Hungary	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center	Houmard, J (corresponding author), Ecole Normale Super, CNRS, FRE 2433, Dept Biol, 46 Rue Ulm, F-75230 Paris, France.	jhoumard@biologie.ens.fr	Vass, Imre/AAS-6171-2021; Cheregi, Otilia/AAP-2474-2021	Vass, Imre/0000-0003-4987-7842; Cadoret, Jean-Charles/0000-0002-3827-5208				Abdollahi M, 2003, MOL CELL BIOCHEM, V252, P205, DOI 10.1023/A:1025568714217; ARO EM, 1993, BIOCHIM BIOPHYS ACTA, V1143, P113, DOI 10.1016/0005-2728(93)90134-2; Cann MJ, 2004, NEW PHYTOL, V161, P23, DOI 10.1046/j.1469-8137.2003.00916.x; de Alda JAGO, 2000, J BACTERIOL, V182, P3839, DOI 10.1128/JB.182.13.3839-3842.2000; de Alda JAGO, 2000, MICROBIOL-SGM, V146, P3183, DOI 10.1099/00221287-146-12-3183; DEMARSAC NT, 1993, FEMS MICROBIOL LETT, V104, P119; DOHLER G, 1994, Z NATURFORSCH C, V49, P607; ELMORJANI K, 1987, J GEN MICROBIOL, V133, P1685; FRISO G, 1994, BBA-BIOENERGETICS, V1184, P78, DOI 10.1016/0005-2728(94)90156-2; Galperin MY, 2001, FEMS MICROBIOL LETT, V205, P17, DOI 10.1016/S0378-1097(01)00424-4; Giacometti GM, 1996, EUR J BIOCHEM, V242, P799, DOI 10.1111/j.1432-1033.1996.0799r.x; GOLDEN SS, 1987, METHOD ENZYMOL, V153, P215; GREENBERG BM, 1989, P NATL ACAD SCI USA, V86, P6617, DOI 10.1073/pnas.86.17.6617; Grossman AR, 2001, J BIOL CHEM, V276, P11449, DOI 10.1074/jbc.R100003200; He YY, 2002, PHOTOCH PHOTOBIO SCI, V1, P729, DOI 10.1039/b110365m; HOUMARD J, 1990, P NATL ACAD SCI USA, V87, P2152, DOI 10.1073/pnas.87.6.2152; Huang LX, 2002, J BACTERIOL, V184, P6845, DOI 10.1128/JB.184.24.6845-6858.2002; Imamura S, 2003, FEBS LETT, V554, P357, DOI 10.1016/S0014-5793(03)01188-8; Kaneko T, 1996, DNA Res, V3, P185, DOI 10.1093/dnares/3.3.185; Katayama M, 1997, J BACTERIOL, V179, P3588, DOI 10.1128/jb.179.11.3588-3593.1997; Komenda J, 2002, EUR J BIOCHEM, V269, P610, DOI 10.1046/j.0014-2956.2001.02693.x; KULANDAIVELU G, 1983, PHYSIOL PLANTARUM, V58, P389, DOI 10.1111/j.1399-3054.1983.tb04199.x; Lao KQ, 1996, P NATL ACAD SCI USA, V93, P5258, DOI 10.1073/pnas.93.11.5258; Mate Z, 1998, J BIOL CHEM, V273, P17439, DOI 10.1074/jbc.273.28.17439; MOHAMED A, 1989, PLANT MOL BIOL, V13, P693, DOI 10.1007/BF00016024; Nakamura Y, 2000, NUCLEIC ACIDS RES, V28, P72, DOI 10.1093/nar/28.1.72; Nedunchezhian N, 1996, ACTA PHYSIOL PLANT, V18, P39; Ohmori M, 2004, PHOTOCH PHOTOBIO SCI, V3, P503, DOI 10.1039/b401623h; Ohmori M, 2002, PHOTOCHEM PHOTOBIOL, V75, P675, DOI 10.1562/0031-8655(2002)075<0675:ROCMPB>2.0.CO;2; Ohmori M, 2001, DNA RES, V8, P271, DOI 10.1093/dnares/8.6.271; Okamoto S, 2004, PHOTOCHEM PHOTOBIOL, V80, P429, DOI 10.1562/0031-8655(2004)080&lt;0429:APPATT&gt;2.0.CO;2; Omagari K, 2004, FEBS LETT, V563, P55, DOI 10.1016/S0014-5793(04)00248-0; PORRA RJ, 1974, ANAL BIOCHEM, V57, P255, DOI 10.1016/0003-2697(74)90071-2; Post A, 1996, PHOTOSYNTH RES, V49, P21, DOI 10.1007/BF00029424; RENGER G, 1989, PHOTOCHEM PHOTOBIOL, V49, P97, DOI 10.1111/j.1751-1097.1989.tb04083.x; RIPPKA R, 1988, METHOD ENZYMOL, V167, P3; SAKAMOTO T, 1991, PLANT CELL PHYSIOL, V32, P581; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sass L, 1997, PHOTOSYNTH RES, V54, P55, DOI 10.1023/A:1005895924892; SICORA C, 2005, IN PRESS PHYTOSYNTHE; Silva P, 2003, PLANT CELL, V15, P2152, DOI 10.1105/tpc.012609; Spetea C, 1996, PLANT SCI, V115, P207, DOI 10.1016/0168-9452(96)04347-6; TERAMURA AH, 1980, PLANT PHYSIOL, V65, P483, DOI 10.1104/pp.65.3.483; Terauchi K, 2004, MOL MICROBIOL, V52, P303, DOI 10.1111/j.1365-2958.2003.03980.x; Terauchi K, 1999, PLANT CELL PHYSIOL, V40, P248, DOI 10.1093/oxfordjournals.pcp.a029534; Tichy M, 2003, BBA-BIOENERGETICS, V1605, P55, DOI 10.1016/S0005-2728(03)00064-1; TREBST A, 1990, Z NATURFORSCH C, V45, P765; Trewavas AJ, 2002, CURR OPIN PLANT BIOL, V5, P425, DOI 10.1016/S1369-5266(02)00281-9; Tu CJ, 2004, J BACTERIOL, V186, P3889, DOI 10.1128/JB.186.12.3889-3902.2004; Tuominen I, 2003, J BACTERIOL, V185, P1116, DOI 10.1128/JB.185.3.1116-1119.2003; Unsal-Kacmaz K, 2002, P NATL ACAD SCI USA, V99, P6673, DOI 10.1073/pnas.102167799; Vass I, 1999, BIOCHEMISTRY-US, V38, P12786, DOI 10.1021/bi991094w; Vazquez-Bermudez MF, 2002, BBA-GENE STRUCT EXPR, V1578, P95, DOI 10.1016/S0167-4781(02)00506-7; VLADIMIROV YA, 1970, PHOTOCHEM PHOTOBIOL, V11, P227, DOI 10.1111/j.1751-1097.1970.tb05992.x; Yoshimura H, 2002, PLANT CELL PHYSIOL, V43, P460, DOI 10.1093/pcp/pcf050	55	31	36	0	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33935	33944		10.1074/jbc.M503153200	http://dx.doi.org/10.1074/jbc.M503153200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16096278	hybrid			2022-12-25	WOS:000232229700030
J	Ikejiri, M; Bernardo, MM; Bonfil, RD; Toth, M; Chang, ML; Fridman, R; Mobashery, S				Ikejiri, M; Bernardo, MM; Bonfil, RD; Toth, M; Chang, ML; Fridman, R; Mobashery, S			Potent mechanism-based inhibitors for matrix metalloproteinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE INHIBITOR; BINDING INHIBITORS; IV COLLAGENASE; ACTIVATION; SLOW; TIMP-2; MATRIX-METALLOPROTEINASE-9; PROGRESSION; PRO-MMP-2; DESIGN	Matrix metalloproteinases ( MMPs) are zinc-dependent endopeptidases that play important roles in physiological and pathological conditions. Both gelatinases (MMP-2 and - 9) and membrane-type 1 MMP (MMP-14) are important targets for inhibition, since their roles in various diseases, including cancer, have been well established. We describe herein a set of mechanism-based inhibitors that show high selectivity to gelatinases and MMP-14( inhibitor 3) and to only MMP-2 ( inhibitors 5 and 7). These molecules bind to the active sites of these enzymes, initiating a slow binding profile for the onset of inhibition, which leads to covalent enzyme modification. The full kinetic analysis for the inhibitors is reported. These are nanomolar inhibitors (K-i) for the formation of the noncovalent enzyme-inhibitor complexes. The onset of slow binding inhibition is rapid (k(on) of 10(2) to 10(4) M-1 s(-1)), and the reversal of the process is slow (k(off) of 10(-3) to 10(-4) s(-1)). However, with the onset of covalent chemistry with the best of these inhibitors ( e. g. inhibitor 3), very little recovery of activity (< 10%) was seen over 48 h of dialysis. We previously reported that broad spectrum MMP inhibitors like GM6001 enhance MT1-MMP-dependent activation of pro-MMP-2 in the presence of tissue inhibitor of metalloproteinases-2. Herein, we show that inhibitor 3, in contrast to GM6001, had no effect on pro-MMP-2 activation by MT1-MMP. Furthermore, inhibitor 3 reduced tumor cell migration and invasion in vitro. These results show that these new inhibitors are promising candidates for selective inhibition of MMPs in animal models of relevant human diseases.	Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46565 USA; Univ Notre Dame, Walther Canc Res Ctr, Notre Dame, IN 46565 USA; Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA; Karmanos Canc Inst, Proteases & Canc Program, Detroit, MI 48201 USA	University of Notre Dame; University of Notre Dame; Walther Cancer Institute; Wayne State University; Barbara Ann Karmanos Cancer Institute	Mobashery, S (corresponding author), Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46565 USA.	mobashery@nd.edu		Bonfil, R. Daniel/0000-0002-1605-8317	NCI NIH HHS [CA-100475] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100475] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bernardo MM, 2002, J BIOL CHEM, V277, P11201, DOI 10.1074/jbc.M111021200; Brown S, 2004, CURR TOP MED CHEM, V4, P1227, DOI 10.2174/1568026043387854; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; DUGGLEBY RG, 1982, BIOCHEMISTRY-US, V21, P3364, DOI 10.1021/bi00257a018; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; FUERST TR, 1987, MOL CELL BIOL, V7, P2538, DOI 10.1128/MCB.7.7.2538; Gervasi DC, 1996, BIOCHEM BIOPH RES CO, V228, P530, DOI 10.1006/bbrc.1996.1694; GOUX C, 1994, TETRAHEDRON, V50, P10321, DOI 10.1016/S0040-4020(01)81764-6; Gu ZZ, 2005, J NEUROSCI, V25, P6401, DOI 10.1523/JNEUROSCI.1563-05.2005; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; Kleifeld O, 2001, J BIOL CHEM, V276, P17125, DOI 10.1074/jbc.M011604200; KNIGHT CG, 1995, METHOD ENZYMOL, V248, P18; Kruger A, 2005, CANCER RES, V65, P3523, DOI 10.1158/0008-5472.CAN-04-3570; Matrisian Lynn M., 2003, Cancer Research, V63, P6105; McCawley LJ, 2000, MOL MED TODAY, V6, P149, DOI 10.1016/S1357-4310(00)01686-5; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MULLERSTEFFNER HM, 1992, J BIOL CHEM, V267, P9606; Olson MW, 1997, J BIOL CHEM, V272, P29975, DOI 10.1074/jbc.272.47.29975; Pavlaki M, 2003, CANCER METAST REV, V22, P177, DOI 10.1023/A:1023047431869; Segel I.H., 1975, ENZYME KINETICS; Skiles JW, 2004, CURR MED CHEM, V11, P2911, DOI 10.2174/0929867043364018; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; SZEDLACSEK SE, 1995, METHOD ENZYMOL, V249, P144; Toth M, 2000, J BIOL CHEM, V275, P41415, DOI 10.1074/jbc.M006871200; Toth M, 1997, CANCER RES, V57, P3159; WESTHEIMER FH, 1987, SCIENCE, V235, P1173, DOI 10.1126/science.2434996; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119	28	117	123	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33992	34002		10.1074/jbc.M504303200	http://dx.doi.org/10.1074/jbc.M504303200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16046398	hybrid			2022-12-25	WOS:000232229700037
J	Zhu, H; Wang, LK; Shuman, S				Zhu, H; Wang, LK; Shuman, S			Essential constituents of the 3 '-phosphoesterase domain of bacterial DNA ligase D, a nonhomologous end-joining enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T4 POLYNUCLEOTIDE KINASE; ACID PHOSPHATASE-EXONUCLEASE; STRAND BREAK REPAIR; ESCHERICHIA-COLI; MUTATIONAL ANALYSIS; CRYSTAL-STRUCTURE; GENETIC-ANALYSIS; TRANSFER-RNA; KU; TOPOISOMERASE	DNA ligase D (LigD) catalyzes end-healing and end-sealing steps during nonhomologous end joining in bacteria. Pseudomonas aeruginosa LigD consists of a central ATP-dependent ligase domain fused to a C-terminal polymerase domain and an N-terminal 3'-phosphoesterase ( PE) module. The PE domain catalyzes manganese-dependent phosphodiesterase and phosphomonoesterase reactions at a duplex primer-template with a short 3'-ribonucleotide tract. The phosphodiesterase, which cleaves a 3'-terminal diribonucleotide to yield a primer strand with a ribonucleoside 3'-PO4 terminus, requires the vicinal 2'-OH of the penultimate ribose. The phosphomonoesterase converts the terminal ribonucleoside 3'-PO4 to a 3'-OH. Here we show that the PE domain has a 3'-phosphatase activity on an all-DNA primer-template, signifying that the phosphomonoesterase reaction does not depend on a 2'-OH. The distinctions between the phosphodiesterase and phosphomonoesterase activities are underscored by the results of alanine-scanning, limited proteolysis, and deletion analysis, which show that the two reactions depend on overlapping but nonidentical ensembles of protein functional groups, including: (i) side chains essential for both ribonuclease and phosphatase activity ( His-42, His-48, Asp-50, Arg-52, His-84, and Tyr-88); ( ii) side chains important for 3'-phosphatase activity but not for 3' ribonucleoside removal (Arg-14, Asp-15, Glu-21, Gln-40, and Glu-82); and ( iii) side chains required selectively for the 3'-ribonuclease (Lys-66 and Arg-76). These constellations of critical residues are unique to LigD-like proteins, which we propose comprise a new bifunctional phosphoesterase family.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.	s-shuman@ski.mskcc.org			NIGMS NIH HHS [GM63611] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063611] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMITSUR M, 1987, EMBO J, V6, P2499, DOI 10.1002/j.1460-2075.1987.tb02532.x; Aravind L, 2001, GENOME RES, V11, P1365, DOI 10.1101/gr.181001; Bernstein NK, 2005, MOL CELL, V17, P657, DOI 10.1016/j.molcel.2005.02.012; CAMERON V, 1977, BIOCHEMISTRY-US, V16, P5120, DOI 10.1021/bi00642a027; CUNNINGHAM RP, 1986, J BACTERIOL, V168, P1120, DOI 10.1128/jb.168.3.1120-1127.1986; Davies DR, 2003, CHEM BIOL, V10, P139, DOI 10.1016/S1074-5521(03)00021-8; Della M, 2004, SCIENCE, V306, P683, DOI 10.1126/science.1099824; Doherty AJ, 2001, FEBS LETT, V500, P186, DOI 10.1016/S0014-5793(01)02589-3; El-Khamisy SF, 2005, NATURE, V434, P108, DOI 10.1038/nature03314; Evans CJ, 2003, GENE, V322, P1, DOI 10.1016/j.gene.2003.08.022; Galburt EA, 2002, STRUCTURE, V10, P1249, DOI 10.1016/S0969-2126(02)00835-3; Gong CL, 2005, NAT STRUCT MOL BIOL, V12, P304, DOI 10.1038/nsmb915; Gong CL, 2004, J BIOL CHEM, V279, P20594, DOI 10.1074/jbc.M401841200; HENNER WD, 1983, J BIOL CHEM, V258, P711; HENNER WD, 1983, J BIOL CHEM, V258, P5198; HENNER WD, 1982, J BIOL CHEM, V257, P1750; Interthal H, 2005, EMBO J, V24, P2224, DOI 10.1038/sj.emboj.7600694; Krogh BO, 2000, BIOCHEMISTRY-US, V39, P6422, DOI 10.1021/bi000184u; Lisby M, 1998, BIOCHEMISTRY-US, V37, P10815, DOI 10.1021/bi980757r; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; Mossessova E, 2000, MOL CELL, V5, P865, DOI 10.1016/S1097-2765(00)80326-3; Rasouli-Nia A, 2004, P NATL ACAD SCI USA, V101, P6905, DOI 10.1073/pnas.0400099101; RICHARDSON CC, 1964, J BIOL CHEM, V239, P251; RICHARDSON CC, 1964, J BIOL CHEM, V239, P242; Wang LK, 2002, NUCLEIC ACIDS RES, V30, P1073, DOI 10.1093/nar/30.4.1073; Wang LK, 2001, J BIOL CHEM, V276, P26868, DOI 10.1074/jbc.M103663200; WEBER DJ, 1992, PROTEINS, V13, P275, DOI 10.1002/prot.340130402; Weller GR, 2002, SCIENCE, V297, P1686, DOI 10.1126/science.1074584; Wiederhold L, 2004, MOL CELL, V15, P209, DOI 10.1016/j.molcel.2004.06.003; Yang SW, 1996, P NATL ACAD SCI USA, V93, P11534, DOI 10.1073/pnas.93.21.11534; Zharkov DO, 2003, DNA REPAIR, V2, P839, DOI 10.1016/S1568-7864(03)00084-3; Zhu H, 2005, J BIOL CHEM, V280, P25973, DOI 10.1074/jbc.M504002200; Zhu H, 2005, J BIOL CHEM, V280, P418, DOI 10.1074/jbc.M410110200	33	30	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33707	33715		10.1074/jbc.M506838200	http://dx.doi.org/10.1074/jbc.M506838200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16046407	hybrid			2022-12-25	WOS:000232229700005
J	Zong, XG; Eckert, C; Yuan, HX; Wahl-Schott, C; Abicht, H; Fang, LF; Li, RX; Mistrik, P; Gerstner, A; Much, B; Baumann, L; Michalakis, S; Zeng, R; Chen, ZJ; Biel, M				Zong, XG; Eckert, C; Yuan, HX; Wahl-Schott, C; Abicht, H; Fang, LF; Li, RX; Mistrik, P; Gerstner, A; Much, B; Baumann, L; Michalakis, S; Zeng, R; Chen, ZJ; Biel, M			A novel mechanism of modulation of hyperpolarization-activated cyclic nucleotide-gated channels by Src kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTION; CARDIAC-PACEMAKER CHANNELS; RABBIT SINOATRIAL NODE; TYROSINE KINASE; CATION CHANNELS; HCN CHANNELS; SH3 DOMAIN; FUNCTIONAL-CHARACTERIZATION; TERMINAL REGION; CAMP MODULATION	Hyperpolarization-activated cyclic nucleotide-gated channels (HCN1-4) play a crucial role in the regulation of cell excitability. Importantly, they contribute to spontaneous rhythmic activity in brain and heart. HCN channels are principally activated by membrane hyperpolarization and binding of cAMP. Here, we identify tyrosine phosphorylation by Src kinase as another mechanism affecting channel gating. Inhibition of Src by specific blockers slowed down activation kinetics of native and heterologously expressed HCN channels. The same effect on HCN channel activation was observed in cells cotransfected with a dominant-negative Src mutant. Immunoprecipitation demonstrated that Src binds to and phosphorylates native and heterologously expressed HCN2. Src interacts via its SH3 domain with a sequence of HCN2 encompassing part of the C-linker and the cyclic nucleotide binding domain. We identified a highly conserved tyrosine residue in the C-linker of HCN channels ( Tyr(476) in HCN2) that confers modulation by Src. Replacement of this tyrosine by phenylalanine in HCN2 or HCN4 abolished sensitivity to Src inhibitors. Mass spectrometry confirmed that Tyr476 is phosphorylated by Src. Our results have functional implications for HCN channel gating. Furthermore, they indicate that tyrosine phosphorylation contributes in vivo to the fine tuning of HCN channel activity.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China; Univ Munich, Dept Pharm Pharmakol Nat Wissensch, D-81377 Munich, Germany	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; University of Munich	Biel, M (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.	mbiel@cup.uni-muenchen.de	Fang, Longhou/G-6582-2013; Mistrik, Pavel/Q-3947-2019; Mistrik, Pavel/A-9999-2008; Michalakis, Stylianos/M-4677-2019; Wahl-Schott, Christian A/J-2623-2015; Biel, Martin/G-1175-2014; Michalakis, Stylianos/W-2094-2018	Mistrik, Pavel/0000-0002-0448-4730; Michalakis, Stylianos/0000-0001-5092-9238; Biel, Martin/0000-0002-9974-3052; Michalakis, Stylianos/0000-0001-5092-9238				Bender RA, 2003, J NEUROSCI, V23, P6826, DOI 10.1523/jneurosci.23-17-06826.2003; Biel M, 2002, TRENDS CARDIOVAS MED, V12, P206, DOI 10.1016/S1050-1738(02)00162-7; Claycomb WC, 1998, P NATL ACAD SCI USA, V95, P2979, DOI 10.1073/pnas.95.6.2979; Craven KB, 2004, J GEN PHYSIOL, V124, P663, DOI 10.1085/jgp.200409178; Davis MJ, 2001, AM J PHYSIOL-HEART C, V281, pH1835, DOI 10.1152/ajpheart.2001.281.5.H1835; DIFRANCESCO D, 1986, J PHYSIOL-LONDON, V377, P61, DOI 10.1113/jphysiol.1986.sp016177; DIFRANCESCO D, 1991, NATURE, V351, P145, DOI 10.1038/351145a0; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Frere SGA, 2004, MOL NEUROBIOL, V30, P279, DOI 10.1385/MN:30:3:279; Gauss R, 1998, NATURE, V393, P583, DOI 10.1038/31248; GORDON SE, 1995, NEURON, V14, P857, DOI 10.1016/0896-6273(95)90229-5; Gravante B, 2004, J BIOL CHEM, V279, P43847, DOI 10.1074/jbc.M401598200; Hua L, 2005, J GEN PHYSIOL, V125, P335, DOI 10.1085/jgp.200409187; Johnson JP, 2005, P NATL ACAD SCI USA, V102, P2742, DOI 10.1073/pnas.0408323102; Kaneko T, 2003, J BIOL CHEM, V278, P48162, DOI 10.1074/jbc.M306677200; Kang H, 2000, EMBO J, V19, P2889, DOI 10.1093/emboj/19.12.2889; Kaupp UB, 2001, ANNU REV PHYSIOL, V63, P235, DOI 10.1146/annurev.physiol.63.1.235; Kimura K, 2004, GENES CELLS, V9, P631, DOI 10.1111/j.1356-9597.2004.00752.x; Ludwig A, 1998, NATURE, V393, P587, DOI 10.1038/31255; Ludwig A, 1999, EMBO J, V18, P2323, DOI 10.1093/emboj/18.9.2323; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Ma YC, 2002, CELL MOL LIFE SCI, V59, P456, DOI 10.1007/s00018-002-8438-2; Michalakis S, 2005, INVEST OPHTH VIS SCI, V46, P1516, DOI 10.1167/iovs.04-1503; Molokanova E, 1999, J NEUROSCI, V19, P4786; Mongiovi AM, 1999, EMBO J, V18, P5300, DOI 10.1093/emboj/18.19.5300; Moosmang S, 2001, EUR J BIOCHEM, V268, P1646, DOI 10.1046/j.1432-1327.2001.02036.x; Much B, 2003, J BIOL CHEM, V278, P43781, DOI 10.1074/jbc.M306958200; Pape HC, 1996, ANNU REV PHYSIOL, V58, P299, DOI 10.1146/annurev.ph.58.030196.001503; Poolos Nicholas P., 2004, Epilepsy Curr, V4, P3, DOI 10.1111/j.1535-7597.2004.04101.x; Robinson RB, 2003, ANNU REV PHYSIOL, V65, P453, DOI 10.1146/annurev.physiol.65.092101.142734; Roskoski R, 2004, BIOCHEM BIOPH RES CO, V324, P1155, DOI 10.1016/j.bbrc.2004.09.171; Salter MW, 2004, NAT REV NEUROSCI, V5, P317, DOI 10.1038/nrn1368; Santoro B, 2004, J NEUROSCI, V24, P10750, DOI 10.1523/JNEUROSCI.3300-04.2004; Santoro B, 1999, ANN NY ACAD SCI, V868, P741, DOI 10.1111/j.1749-6632.1999.tb11353.x; Santoro B, 1998, CELL, V93, P717, DOI 10.1016/S0092-8674(00)81434-8; Santoro B, 1997, P NATL ACAD SCI USA, V94, P14815, DOI 10.1073/pnas.94.26.14815; Sartiani L, 2002, J PHYSIOL-LONDON, V545, P81, DOI 10.1113/jphysiol.2002.021535; Savchenko A, 2001, P NATL ACAD SCI USA, V98, P5880, DOI 10.1073/pnas.101524998; Schulze-Bahr E, 2003, J CLIN INVEST, V111, P1537, DOI 10.1172/JCI200316387; Shibata S, 1999, BRIT J PHARMACOL, V128, P1284, DOI 10.1038/sj.bjp.0702903; SNYDER MA, 1985, MOL CELL BIOL, V5, P1772, DOI 10.1128/MCB.5.7.1772; Stieber J, 2003, P NATL ACAD SCI USA, V100, P15235, DOI 10.1073/pnas.2434235100; Tibbs GR, 1997, NATURE, V386, P612, DOI 10.1038/386612a0; Tu HY, 2004, J NEUROSCI RES, V76, P713, DOI 10.1002/jnr.20109; Ueda K, 2004, J BIOL CHEM, V279, P27194, DOI 10.1074/jbc.M311953200; Wahl-Schott C, 2005, J BIOL CHEM, V280, P13694, DOI 10.1074/jbc.M413197200; Wainger BJ, 2001, NATURE, V411, P805, DOI 10.1038/35081088; Wang J, 2001, J GEN PHYSIOL, V118, P237, DOI 10.1085/jgp.118.3.237; Wu JY, 1997, PFLUG ARCH EUR J PHY, V434, P509, DOI 10.1007/s004240050430; WU JY, 2000, BIOCHIM BIOPHYS ACTA, V463, P15; Wu ZZ, 2004, BRAIN RES, V1029, P251, DOI 10.1016/j.brainres.2004.09.051; Yu H, 2001, CIRC RES, V88, pE84, DOI 10.1161/hh1201.093511; Yu HG, 2004, PFLUG ARCH EUR J PHY, V447, P392, DOI 10.1007/s00424-003-1204-y; Zagotta WN, 2003, NATURE, V425, P200, DOI 10.1038/nature01922; Zhou L, 2004, NEURON, V44, P823, DOI 10.1016/j.neuron.2004.11.012; Zong XG, 1998, EMBO J, V17, P353, DOI 10.1093/emboj/17.2.353	56	83	87	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34224	34232		10.1074/jbc.M506544200	http://dx.doi.org/10.1074/jbc.M506544200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16079136	hybrid			2022-12-25	WOS:000232229700065
J	Silipo, A; Molinaro, A; Sturiale, L; Dow, JM; Erbs, G; Lanzetta, R; Newman, MA; Parrilli, M				Silipo, A; Molinaro, A; Sturiale, L; Dow, JM; Erbs, G; Lanzetta, R; Newman, MA; Parrilli, M			The elicitation of plant innate immunity by lipooligosaccharide of Xanthomonas campestris	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTORS; MASS-SPECTROMETRY; BACTERIAL LIPOPOLYSACCHARIDES; ABSOLUTE-CONFIGURATION; RESISTANCE; GENE; RECOGNITION; MODULATION; EXTRACTION; EXPRESSION	Lipopolysaccharides (LPSs) and lipooligosaccharides (LOSs) are major components of the cell surface of Gram-negative bacteria with diverse roles in bacterial pathogenesis of animals and plants that include elicitation of host defenses. Little is known about the mechanisms of perception of these molecules by plants and about the associated signal transduction pathways that trigger plant immunity. Here we address the issue of the molecular basis of elicitation of plant defenses through the structural determination of the LOS of the plant pathogen Xanthomonas campestris pv. campestris strain 8004 and examination of the effects of LOS and fragments obtained by chemical treatments on the immune response in Arabidopsis thaliana. The structure shows a strong accumulation of negatively charged groups in the lipid A-inner core region and has a number of novel features, including a galacturonyl phosphate attached at a 3-deoxy-D-manno-oct-2-ulosonic acid residue and a unique phosphoramide group in the inner core region. Intact LOS and the lipid A and core oligosaccharides derived from it were all able to induce the defense-related genes PR1 and PR2 in Arabidopsis and to prevent the hypersensitive response caused by avirulent bacteria. Although LOS induced defense-related gene transcription in two temporal phases, the core oligosaccharide induced only the earlier phase, and lipid A induced only the later phase. These findings suggest that plant cells can recognize lipid A and core oligosaccharide structures within LOS to trigger defensive cellular responses and that this may occur via two distinct recognition events.	Univ Naples Federico II, Dipartimento Chim Organ & Biochim, I-80126 Naples, Italy; CNR, ICTMP, I-95123 Catania, Italy; Natl Univ Ireland, BioSci Inst, Dept Microbiol, BIOMERIT Res Ctr, Cork, Ireland; Royal Vet & Agr Univ, Sect Plant Pathol, DK-1871 Copenhagen, Denmark	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); University College Cork; University of Copenhagen	Molinaro, A (corresponding author), Univ Naples Federico II, Dipartimento Chim Organ & Biochim, Complesso Univ Monte Sant Angelo,Via Cintia 4, I-80126 Naples, Italy.	molinaro@unina.it	Newman, Mari-Anne/M-1550-2013; Molinaro, Antonio/J-1866-2012; Silipo, Alba/L-5929-2014	Newman, Mari-Anne/0000-0001-5782-6071; LANZETTA, Rosa/0000-0002-1472-5825; STURIALE, LUISELLA/0000-0002-3996-1138; Erbs, Gitte/0000-0003-3764-6473; silipo, alba/0000-0002-5394-6532; Molinaro, Antonio/0000-0002-3456-7369; Parrilli, Michelangelo/0000-0001-8858-3623				Aarts N, 1998, P NATL ACAD SCI USA, V95, P10306, DOI 10.1073/pnas.95.17.10306; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Alexander C, 2001, J ENDOTOXIN RES, V7, P167, DOI 10.1179/096805101101532675; Bedini E, 2005, J AM CHEM SOC, V127, P2414, DOI 10.1021/ja0452166; BIRNBAUM GI, 1987, J CARBOHYD CHEM, V6, P17, DOI 10.1080/07328308708058858; Borregaard N, 2000, IMMUNOL TODAY, V21, P68, DOI 10.1016/S0167-5699(99)01570-4; Conrath U, 2001, EUR J PLANT PATHOL, V107, P113, DOI 10.1023/A:1008768516313; DOW JM, 1995, MOL PLANT MICROBE IN, V8, P768, DOI 10.1094/MPMI-8-0768; Dow M, 2000, ANNU REV PHYTOPATHOL, V38, P241, DOI 10.1146/annurev.phyto.38.1.241; Erbs G, 2003, MOL PLANT PATHOL, V4, P421, DOI [10.1046/j.1364-3703.2003.00179.x, 10.1046/J.1364-3703.2003.00179.X]; GALANOS C, 1969, EUR J BIOCHEM, V9, P245, DOI 10.1111/j.1432-1033.1969.tb00601.x; Gibson BW, 1997, J AM SOC MASS SPECTR, V8, P645, DOI 10.1016/S1044-0305(97)00042-1; Gilard V, 1999, J MED CHEM, V42, P2542, DOI 10.1021/jm980587g; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; Hinsch M, 1996, MOL PLANT MICROBE IN, V9, P55, DOI 10.1094/MPMI-9-0055; HOLST O, 2000, METHODS MOL BIOL BAC, P345; Korner R, 1998, J MASS SPECTROM, V33, P836; LEONTEIN K, 1978, CARBOHYD RES, V62, P359, DOI 10.1016/S0008-6215(00)80882-4; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Miyake K, 2004, TRENDS MICROBIOL, V12, P186, DOI 10.1016/j.tim.2004.02.009; Molinaro A, 2003, CARBOHYD RES, V338, P277, DOI 10.1016/S0008-6215(02)00433-0; Molinaro A, 2002, J BIOL CHEM, V277, P10058, DOI 10.1074/jbc.M110283200; Newman MA, 1997, MOL PLANT MICROBE IN, V10, P926, DOI 10.1094/MPMI.1997.10.7.926; Newman MA, 2002, PLANT J, V29, P487, DOI 10.1046/j.0960-7412.2001.00233.x; NEWMAN MA, 1995, MOL PLANT MICROBE IN, V8, P778, DOI 10.1094/MPMI-8-0778; Nurnberger T, 2002, CURR OPIN PLANT BIOL, V5, P318, DOI 10.1016/S1369-5266(02)00265-0; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; RIETSCHEL ET, 1976, EUR J BIOCHEM, V64, P423, DOI 10.1111/j.1432-1033.1976.tb10318.x; RITTER E, 1991, MOL GEN GENET, V227, P81, DOI 10.1007/BF00260710; Schromm AB, 2000, EUR J BIOCHEM, V267, P2008, DOI 10.1046/j.1432-1327.2000.01204.x; Schromm AB, 1998, J IMMUNOL, V161, P5464; Silipo A, 2004, EUR J ORG CHEM, V2004, P1336, DOI 10.1002/ejoc.200300721; Silipo A, 2002, J LIPID RES, V43, P2188, DOI 10.1194/jlr.D200021-JLR200; Silipo A, 2002, EUR J BIOCHEM, V269, P2498, DOI 10.1046/j.1432-1033.2002.02914.x; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; Stern AS, 2002, J AM CHEM SOC, V124, P1982, DOI 10.1021/ja011669o; Sturiale L, 2005, RAPID COMMUN MASS SP, V19, P1829, DOI 10.1002/rcm.1994; Szymanski CM, 2003, J BIOL CHEM, V278, P24509, DOI 10.1074/jbc.M301273200; Triantafilou M, 2002, TRENDS IMMUNOL, V23, P301, DOI 10.1016/S1471-4906(02)02233-0; Zeidler D, 2004, P NATL ACAD SCI USA, V101, P15811, DOI 10.1073/pnas.0404536101	42	141	147	0	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33660	33668		10.1074/jbc.M506254200	http://dx.doi.org/10.1074/jbc.M506254200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16048996	hybrid			2022-12-25	WOS:000232058100068
J	Kunzler, D; Sasso, S; Gamper, M; Hilvert, D; Kast, P				Kunzler, D; Sasso, S; Gamper, M; Hilvert, D; Kast, P			Mechanistic insights into the isochorismate pyruvate lyase activity of the catalytically promiscuous PchB from combinatorial mutagenesis and selection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOFUNCTIONAL CHORISMATE MUTASE; SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; BACILLUS-SUBTILIS; PSEUDOMONAS-AERUGINOSA; GENETIC SELECTION; TRANSITION-STATE; ELECTROSTATIC CATALYSIS; SALICYLATE BIOSYNTHESIS; ACID	PchB from Pseudomonas aeruginosa possesses isochorismate pyruvate lyase (IPL) and weak chorismate mutase (CM) activity. Homology modeling based on a structurally characterized CM, coupled with randomization of presumed key active site residues (Arg(54), Glu(90), Gln(91)) and in vivo selection for CM activity, was used to derive mechanistic insights into the IPL activity of PchB. Mutation of Arg(54) was incompatible with viability, and the CM and IPL activities of an engineered R54K variant were reduced 1,000-fold each. The observation that position 90 was tolerant to substitution but position 91 was essentially confined to Gln or Glu in functional variants rules out involvement of Glu90 in general base catalysis. Counter to the generally accepted mechanistic hypothesis for pyruvate lyases, we propose for PchB a rare [ 1,5]- sigmatropic reaction mechanism that invokes electrostatic catalysis in analogy to the [ 3,3]- pericyclic rearrangement of chorismate in CMs. A common catalytic principle for both PchB functions is also supported by the covariance of the catalytic parameters for the CM and IPL activities and the shared functional requirement for a protonated Glu(91) in Q91E variants. The experiments demonstrate that focusing directed evolution strategies on the readily accessible surrogate activity of an enzyme can provide valuable insights into the mechanism of the primary reaction.	ETH Honggerberg, Swiss Fed Inst Technol, Organ Chem Lab, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Kast, P (corresponding author), ETH Honggerberg, Swiss Fed Inst Technol, Organ Chem Lab, HCI F333, CH-8093 Zurich, Switzerland.	kast@org.chem.ethz.ch		Sasso, Severin/0000-0002-2226-845X				BARTLETT PA, 1988, J ORG CHEM, V53, P3195, DOI 10.1021/jo00249a013; BARTLETT PA, 1985, J AM CHEM SOC, V107, P7792, DOI 10.1021/ja00311a111; Benson DA, 2005, NUCLEIC ACIDS RES, V33, pD34, DOI 10.1093/nar/gki063; CHAO HSI, 1982, BIOCHEMISTRY-US, V21, P2778, DOI 10.1021/bi00540a031; CHOTHIA C, 1984, ANNU REV BIOCHEM, V53, P537; Copley SD, 2003, CURR OPIN CHEM BIOL, V7, P265, DOI 10.1016/S1367-5931(03)00032-2; Creighton T. E., 1993, PROTEINS STRUCTURES; Crosa JH, 2002, MICROBIOL MOL BIOL R, V66, P223, DOI 10.1128/MMBR.66.2.223-249.2002; Durrant WE, 2004, ANNU REV PHYTOPATHOL, V42, P185, DOI 10.1146/annurev.phyto.42.040803.140421; EGGERTSSON G, 1988, MICROBIOL REV, V52, P354, DOI 10.1128/MMBR.52.3.354-374.1988; Gaille C, 2002, J BIOL CHEM, V277, P21768, DOI 10.1074/jbc.M202410200; GAJEWSKI JJ, 1987, J AM CHEM SOC, V109, P1170, DOI 10.1021/ja00238a029; Gallagher DT, 2001, PROTEINS, V44, P304, DOI 10.1002/prot.1095; Gamper M, 2000, BIOCHEMISTRY-US, V39, P14087, DOI 10.1021/bi0016570; GRAY JV, 1990, BIOCHEMISTRY-US, V29, P8872, DOI 10.1021/bi00489a051; Grisostomi C, 1997, BIOORG CHEM, V25, P297, DOI 10.1006/bioo.1997.1073; Gu W, 1997, Microb Comp Genomics, V2, P141, DOI 10.1089/omi.1.1997.2.141; Gustin DJ, 1999, J AM CHEM SOC, V121, P1756, DOI 10.1021/ja9841759; Kast P, 2000, J BIOL CHEM, V275, P36832, DOI 10.1074/jbc.M006351200; Kast P, 1997, CURR OPIN STRUC BIOL, V7, P470, DOI 10.1016/S0959-440X(97)80109-1; Kast P, 1996, TETRAHEDRON LETT, V37, P2691, DOI 10.1016/0040-4039(96)00338-3; Kast P, 1996, J AM CHEM SOC, V118, P3069, DOI 10.1021/ja953701i; Kast P, 1996, P NATL ACAD SCI USA, V93, P5043, DOI 10.1073/pnas.93.10.5043; KAST P, 1994, GENE, V138, P109, DOI 10.1016/0378-1119(94)90790-0; Kast P, 1996, PURE APPL CHEM, V68, P2017, DOI 10.1351/pac199668112017; Kienhofer A, 2003, J AM CHEM SOC, V125, P3206, DOI 10.1021/ja0341992; LEE AY, 1995, J AM CHEM SOC, V117, P3627, DOI 10.1021/ja00117a038; Liu DR, 1996, J AM CHEM SOC, V118, P1789, DOI 10.1021/ja953151o; MacBeath G, 1998, BIOTECHNIQUES, V24, P789, DOI 10.2144/98245st02; MacBeath G, 1998, BIOCHEMISTRY-US, V37, P10062, DOI 10.1021/bi980449t; MacBeath G, 1998, PROTEIN SCI, V7, P325; Mandal A, 2003, J AM CHEM SOC, V125, P5598, DOI 10.1021/ja029447t; MARSHALL BJ, 1972, BIOCHIM BIOPHYS ACTA, V264, P106, DOI 10.1016/0304-4165(72)90122-5; Mattei P, 1999, EUR J BIOCHEM, V261, P25, DOI 10.1046/j.1432-1327.1999.00169.x; Nakai T, 2000, J BIOCHEM, V128, P29, DOI 10.1093/oxfordjournals.jbchem.a022727; OKUJO N, 1994, BIOMETALS, V7, P109; Patrick WM, 2003, PROTEIN ENG, V16, P451, DOI 10.1093/protein/gzg057; Payne RJ, 2005, ORG BIOMOL CHEM, V3, P1825, DOI 10.1039/b503800f; Pelludat C, 2003, J BACTERIOL, V185, P5648, DOI 10.1128/JB.185.18.5648-5653.2003; Reimmann C, 2001, J BACTERIOL, V183, P813, DOI 10.1128/JB.183.3.813-820.2001; RUSNAK F, 1990, BIOCHEMISTRY-US, V29, P1425, DOI 10.1021/bi00458a013; Sambrook J, 2001, MOL CLONING LAB MANU; Sasso S, 2005, FEBS J, V272, P375, DOI 10.1111/j.1742-4658.2004.04478.x; SCHELL MA, 1986, J BACTERIOL, V166, P9, DOI 10.1128/jb.166.1.9-14.1986; SCHMIDT K, 1995, BIOTECHNOL BIOENG, V45, P285, DOI 10.1002/bit.260450402; Schnappauf G, 1997, P NATL ACAD SCI USA, V94, P8491, DOI 10.1073/pnas.94.16.8491; Segel I.H., 1976, BIOCH CALCULATIONS S; SERINO L, 1995, MOL GEN GENET, V249, P217, DOI 10.1007/BF00290369; Serino L, 1997, J BACTERIOL, V179, P248, DOI 10.1128/jb.179.1.248-257.1997; SHARP PM, 1988, NUCLEIC ACIDS RES, V16, P8207, DOI 10.1093/nar/16.17.8207; SNOW GA, 1970, BACTERIOL REV, V34, P99, DOI 10.1128/MMBR.34.2.99-125.1970; Spraggon G, 2001, P NATL ACAD SCI USA, V98, P6021, DOI 10.1073/pnas.111150298; Taylor SV, 2001, ANGEW CHEM INT EDIT, V40, P3310, DOI 10.1002/1521-3773(20010917)40:18<3310::AID-ANIE3310>3.0.CO;2-P; Taylor SV, 2001, P NATL ACAD SCI USA, V98, P10596, DOI 10.1073/pnas.191159298; WALSH CT, 1990, CHEM REV, V90, P1105, DOI 10.1021/cr00105a003; Wildermuth MC, 2001, NATURE, V414, P562, DOI 10.1038/35107108; WRIGHT SK, IN PRESS J AM CHEM S; Zhang S, 1996, BIOORGAN MED CHEM, V4, P1015, DOI 10.1016/0968-0896(96)00099-5	58	45	46	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32827	32834		10.1074/jbc.M506883200	http://dx.doi.org/10.1074/jbc.M506883200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16036918	hybrid			2022-12-25	WOS:000231920300035
J	Carlson, AE; Quill, TA; Westenbroek, RE; Schuh, SM; Hille, B; Babcock, DF				Carlson, AE; Quill, TA; Westenbroek, RE; Schuh, SM; Hille, B; Babcock, DF			Identical phenotypes of CatSper1 and CatSper2 null sperm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLDEN-HAMSTER SPERMATOZOA; DEPENDENT CA2+ CHANNEL; GUINEA-PIG SPERMATOZOA; MICE LACKING; MOUSE SPERM; HYPERACTIVATED MOTILITY; CALCIUM-CHANNEL; GENE-EXPRESSION; ION CHANNELS; ACTIVATION	Among several candidate Ca2+ entry channels in sperm, only CatSper1 and CatSper2 are known to have required roles in male fertility. Past work with CatSper1 null sperm indicates that a critical lesion in hyperactivated motility underlies the infertility phenotype and is associated with an absence of depolarization-evoked Ca2+ entry. Here we show that failure of hyperactivation of CatSper2 null sperm similarly correlates with an absence of depolarization-evoked Ca2+ entry. Additional shared aspects of the phenotypes of CatSper1 and -2 null sperm include unperturbed regional distributions of conventional voltage-gated Ca2+ channel proteins and robust acceleration of the flagellar beat by bicarbonate. Further study reveals that treatment of both wild-type and CatSper2 null sperm with procaine increases beat asymmetry, a characteristic of the flagellar waveform of hyperactivation. This partial rescue of the loss-of-hyperactivation phenotype suggests that an absence of CatSper2 precludes hyperactivation by preventing delivery of needed Ca2+ messenger rather than by preventing flagellar responses to Ca2+. CatSper2 null sperm also have an increased basal cAMP content and beat frequency. Protein kinase A inhibitor H89 lowers beat frequency to that of wild-type sperm, suggesting that CatSper2 is required for protein kinase A-mediated, tonic control of resting cAMP content. Relative to wild-type testis, CatSper1 and -2 null testes contain normal amounts of CatSper2 and -1 transcripts, respectively. However, CatSper1 null sperm lack CatSper2 protein and CatSper2 null sperm lack CatSper1 protein. Hence, stable expression of CatSper1 protein requires CatSper2 and vice versa. This co-dependent expression dictates identical loss-of-function sperm phenotypes for CatSper1 and -2 null mutants.	Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA; Univ Texas, SW Med Ctr, Cecil H & Ida Green Ctr Reprod Biol Sci, Dept Pharmacol, Dallas, TX 75390 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Washington; University of Washington Seattle	Babcock, DF (corresponding author), Univ Washington, Dept Physiol & Biophys, MS 357290, Seattle, WA 98195 USA.	donner@u.washington.edu	Oka, Yoshitaka/C-9670-2010; Schuh, Sonya/W-2941-2019; Carlson, Anne/I-9495-2019	Oka, Yoshitaka/0000-0002-3482-3051; Carlson, Anne/0000-0003-2724-1325; Babcock, Donner/0000-0002-4461-4544	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007183] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD012629, R01HD036022] Funding Source: NIH RePORTER; NICHD NIH HHS [5R01-HD36022, U54 HD12629, T32 HD007183] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Avidan N, 2003, EUR J HUM GENET, V11, P497, DOI 10.1038/sj.ejhg.5200991; BABCOCK DF, 1987, J BIOL CHEM, V262, P15041; Biel M, 1999, P NATL ACAD SCI USA, V96, P7553, DOI 10.1073/pnas.96.13.7553; BROKAW CJ, 1979, J CELL BIOL, V82, P401, DOI 10.1083/jcb.82.2.401; Carlson AE, 2003, P NATL ACAD SCI USA, V100, P14864, DOI 10.1073/pnas.2536658100; Chen CC, 2003, SCIENCE, V302, P1416, DOI 10.1126/science.1089268; COOPER TG, 1984, GAMETE RES, V9, P55, DOI 10.1002/mrd.1120090106; DOMINO SE, 1991, METHOD ENZYMOL, V195, P345; Esposito G, 2004, P NATL ACAD SCI USA, V101, P2993, DOI 10.1073/pnas.0400050101; FRASER LR, 1982, J ANDROL, V3, P412; Freichel M, 2001, NAT CELL BIOL, V3, P121, DOI 10.1038/35055019; Fukuda N, 2004, J CELL SCI, V117, P5835, DOI 10.1242/jcs.01507; Garbers DL, 2001, NATURE, V413, P579, DOI 10.1038/35098164; GARBERS DL, 1982, J BIOL CHEM, V257, P8980; Gu Y, 2004, DEV BIOL, V274, P308, DOI 10.1016/j.ydbio.2004.06.025; Ho HC, 2003, BIOL REPROD, V68, P1590, DOI 10.1095/biolreprod.102.011320; Ino M, 2001, P NATL ACAD SCI USA, V98, P5323, DOI 10.1073/pnas.081089398; Ishijima S, 2002, MOL REPROD DEV, V61, P376, DOI 10.1002/mrd.10017; Jun K, 1999, P NATL ACAD SCI USA, V96, P15245, DOI 10.1073/pnas.96.26.15245; Kim D, 2001, NEURON, V31, P35, DOI 10.1016/S0896-6273(01)00343-9; LINDEMANN CB, 1987, CELL MOTIL CYTOSKEL, V8, P324, DOI 10.1002/cm.970080405; Lobley Anna, 2003, Reprod Biol Endocrinol, V1, P53, DOI 10.1186/1477-7827-1-53; Marquez B, 2004, BIOL REPROD, V70, P1626, DOI 10.1095/biolreprod.103.026476; Nikpoor P, 2004, HUM REPROD, V19, P124, DOI 10.1093/humrep/deh043; Nolan MA, 2004, P NATL ACAD SCI USA, V101, P13483, DOI 10.1073/pnas.0405580101; Platzer J, 2000, CELL, V102, P89, DOI 10.1016/S0092-8674(00)00013-1; Quill TA, 2003, P NATL ACAD SCI USA, V100, P14869, DOI 10.1073/pnas.2136654100; Quill TA, 2001, P NATL ACAD SCI USA, V98, P12527, DOI 10.1073/pnas.221454998; Ren DJ, 2001, NATURE, V413, P603, DOI 10.1038/35098027; Saegusa H, 2000, P NATL ACAD SCI USA, V97, P6132, DOI 10.1073/pnas.100124197; Schultz N, 2003, P NATL ACAD SCI USA, V100, P12201, DOI 10.1073/pnas.1635054100; Seisenberger C, 2000, J BIOL CHEM, V275, P39193, DOI 10.1074/jbc.M006467200; Serrano CJ, 1999, FEBS LETT, V462, P171, DOI 10.1016/S0014-5793(99)01518-5; Shima JE, 2004, BIOL REPROD, V71, P319, DOI 10.1095/biolreprod.103.026880; SINGH JP, 1983, ARCH BIOCHEM BIOPHYS, V221, P291, DOI 10.1016/0003-9861(83)90146-7; Stowers L, 2002, SCIENCE, V295, P1493, DOI 10.1126/science.1069259; SUAREZ SS, 1983, BIOL REPROD, V29, P1277, DOI 10.1095/biolreprod29.5.1277; VIJAYARAGHAVAN S, 1985, BIOL REPROD, V32, P489, DOI 10.1095/biolreprod32.3.489; Wang D, 2003, NAT CELL BIOL, V5, P1117, DOI 10.1038/ncb1072; Wennemuth G, 2000, J BIOL CHEM, V275, P21210, DOI 10.1074/jbc.M002068200; Wennemuth G, 2003, J GEN PHYSIOL, V122, P115, DOI 10.1085/jgp.200308839; Wennemuth G, 2003, DEVELOPMENT, V130, P1317, DOI 10.1242/dev.00353; Westenbroek RE, 1999, DEV BIOL, V207, P457, DOI 10.1006/dbio.1998.9172; YANAGIMA.R, 1970, J REPROD FERTIL, V23, P193, DOI 10.1530/jrf.0.0230193; YANAGIMACHI R, 1974, EXP CELL RES, V89, P161, DOI 10.1016/0014-4827(74)90199-2; Yanagimachi R., 1994, P189	46	132	143	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32238	32244		10.1074/jbc.M501430200	http://dx.doi.org/10.1074/jbc.M501430200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16036917	hybrid			2022-12-25	WOS:000231794800025
J	Morin, S; Pozzulo, G; Robitaille, L; Cross, J; Nemer, M				Morin, S; Pozzulo, G; Robitaille, L; Cross, J; Nemer, M			MEF2-dependent recruitment of the HAND1 transcription factor results in synergistic activation of target promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURAL CREST DERIVATIVES; LOOP-HELIX PROTEINS; CARDIAC MORPHOGENESIS; GENE-EXPRESSION; COOPERATIVE INTERACTION; VASCULAR DEVELOPMENT; BHLH PROTEINS; FACTOR MEF2C; MADS-BOX; HEART	HAND proteins are tissue-restricted members of the basic helix-loop-helix transcription factor family that play critical roles in cell differentiation and organogenesis including placental, cardiovascular, and craniofacial development. Nevertheless, the molecular basis underlying the developmental action of HAND proteins remains undefined. Within the embryo, HAND1 is first detected in the developing heart where it becomes restricted to the atrial and left ventricular compartments, a pattern identical to that of the Nppa gene, which encodes atrial natriuretic factor, the major secretory product of the heart. We hereby report that the cardiac atrial natriuretic factor promoter is directly activated by HAND1, making it the first known HAND1 transcriptional target. The action of HAND1 does not require heterodimerization with class I basic helix-loop-helix factors or DNA binding through E-box elements. Instead, HAND1 is recruited to the promoter via physical interaction with MEF2 proteins. MEF2/HAND1 interaction results in synergistic activation of MEF2-dependent promoters, and MEF2 binding sites are sufficient to mediate this synergy. MEF2 binding to DNA is not enhanced in the presence of HAND1. Instead, cooper-ativity likely results from corecruitment of co-activators such as CREB-binding protein. The related HAND2 protein can also synergize with MEF2. Thus, HAND proteins act as cell-specific developmental co-activators of the MEF2 family of transcription factors. These findings identify a novel mechanism for HAND action in the heart and provide a general paradigm to understand the mechanism of HAND action in organogenesis.	Inst Rech Clin Montreal, Lab Cardiac Growth & Differentiat, Montreal, PQ H2W 1R7, Canada; Univ Montreal, Dept Pharmacol, Montreal, PQ H3C 3J7, Canada; Univ Calgary, Hlth Sci Ctr, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba	Nemer, M (corresponding author), Inst Rech Clin Montreal, Lab Cardiac Growth & Differentiat, 110 Ave Pins Ouest, Montreal, PQ H2W 1R7, Canada.	mona.nemer@ircm.qc.ca	Cross, James/AAU-2973-2020; Cross, James/F-4814-2011	Cross, James/0000-0003-0956-9378; Cross, James/0000-0003-0956-9378				Bi WZ, 1999, DEV BIOL, V211, P255, DOI 10.1006/dbio.1999.9307; Black BL, 1996, J BIOL CHEM, V271, P26659, DOI 10.1074/jbc.271.43.26659; Charron F, 1999, MOL CELL BIOL, V19, P4355; Cohen-Kaminsky S, 1998, EMBO J, V17, P5151, DOI 10.1093/emboj/17.17.5151; CSERJESI P, 1995, DEV BIOL, V170, P664, DOI 10.1006/dbio.1995.1245; Dai YS, 2002, J BIOL CHEM, V277, P12604, DOI 10.1074/jbc.M200283200; Dai YS, 2002, J BIOL CHEM, V277, P24390, DOI 10.1074/jbc.M202490200; Fernandez-Teran M, 2003, DEV DYNAM, V226, P690, DOI 10.1002/dvdy.10271; Firulli AB, 2003, GENE, V312, P27, DOI 10.1016/S0378-1119(03)00669-3; Firulli AB, 1998, NAT GENET, V18, P266, DOI 10.1038/ng0398-266; Firulli BA, 2003, MOL CELL, V12, P1225, DOI 10.1016/S1097-2765(03)00425-8; Hill AA, 2004, MOL CELL BIOL, V24, P9835, DOI 10.1128/MCB.24.22.9835-9847.2004; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Knofler M, 2002, BIOCHEM J, V361, P641, DOI 10.1042/0264-6021:3610641; Lemercier C, 2000, J BIOL CHEM, V275, P15594, DOI 10.1074/jbc.M908437199; Lin Q, 1998, DEVELOPMENT, V125, P4565; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; LYONS GE, 1995, J NEUROSCI, V15, P5727, DOI 10.1523/jneurosci.15-08-05727.1995; Mao ZX, 1996, J BIOL CHEM, V271, P14371, DOI 10.1074/jbc.271.24.14371; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; McFadden DG, 2005, DEVELOPMENT, V132, P189, DOI 10.1242/dev.01562; McFadden DG, 2002, DEVELOPMENT, V129, P3077; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; Morikawa Y, 2004, DEVELOPMENT, V131, P2195, DOI 10.1242/dev.01091; Morin S, 2000, EMBO J, V19, P2046, DOI 10.1093/emboj/19.9.2046; Morin S, 2001, MOL CELL BIOL, V21, P1036, DOI 10.1128/MCB.21.4.1036-1044.2001; Naya FJ, 1999, DEVELOPMENT, V126, P2045; Naya FJ, 2002, NAT MED, V8, P1303, DOI 10.1038/nm789; Nemer G, 2002, DEVELOPMENT, V129, P4045; Riley P, 1998, NAT GENET, V18, P271, DOI 10.1038/ng0398-271; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Scott IC, 2000, MOL CELL BIOL, V20, P530, DOI 10.1128/MCB.20.2.530-541.2000; Smith SJ, 2000, DEV DYNAM, V219, P575, DOI 10.1002/1097-0177(200012)219:4<575::AID-DVDY1075>3.0.CO;2-Y; Sparrow DB, 1999, EMBO J, V18, P5085, DOI 10.1093/emboj/18.18.5085; Sparrow DB, 1998, MECH DEVELOP, V71, P151, DOI 10.1016/S0925-4773(98)00010-0; SRIVASTAVA D, 1995, SCIENCE, V270, P1995, DOI 10.1126/science.270.5244.1995; Srivastava D, 1997, NAT GENET, V16, P154, DOI 10.1038/ng0697-154; Thattaliyath BD, 2002, J MOL CELL CARDIOL, V34, P1335, DOI 10.1006/jmcc.2002.2085; Thattaliyath BD, 2002, BIOCHEM BIOPH RES CO, V297, P870, DOI 10.1016/S0006-291X(02)02297-0; Togi K, 2004, MOL CELL BIOL, V24, P4627, DOI 10.1128/MCB.24.11.4627-4635.2004; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Wang LJ, 2003, SCIENCE, V302, P1578, DOI 10.1126/science.1088477; Yamagishi H, 2000, J CLIN INVEST, V105, P261, DOI 10.1172/JCI8856; Yanagisawa H, 2003, DEVELOPMENT, V130, P1069, DOI 10.1242/dev.00337; Yelon D, 2000, DEVELOPMENT, V127, P2573	46	38	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32272	32278		10.1074/jbc.M507640200	http://dx.doi.org/10.1074/jbc.M507640200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16043483	hybrid			2022-12-25	WOS:000231794800029
J	McColl, G; Vantipalli, MC; Lithgow, GJ				McColl, G; Vantipalli, MC; Lithgow, GJ			C-elegans ortholog of mammalian Ku70 interacts with insulin-like signaling to modulate stress resistance and life span	FASEB JOURNAL			English	Article						cku-70; cku-80; daf-2; daf-16; aging; stress response; DNA repair	HEAT-SHOCK FACTOR; CAENORHABDITIS-ELEGANS; INDUCIBLE HEAT-SHOCK-PROTEIN-70; OXIDATIVE STRESS; LONGEVITY; DAF-2; GENE; LONG; DNA; EXPRESSION	The mammalian Ku heterodimer has important roles in DNA double strand break repair, telomere maintenance, cell cycle checkpoint-arrest, tumor suppression, and cellular stress resistance. To investigate the evolutionarily conserved functions of Ku, we knocked down expression by RNA interference (RNAi) of Ku genes in C. elegans. We found that C. elegans Ku70 (CKU-70) is required for resistance to genotoxic stress, regulates cytotoxic stress responses, and influences aging. The latter effects are dependent on an IGF-1/insulin-like signaling pathway previously shown to affect life span. Reduction of CKU-70 activity amplifies the aging phenotype of long-lived insulin receptor daf-2 mutations in a daf-16-dependent manner. These observations support the view that organismal stress resistance determines life span and Ku70 modulates these effects.	Buck Inst Age Res, Novato, CA 94945 USA	Buck Institute for Research on Aging	McColl, G (corresponding author), Buck Inst Age Res, 8001 Redwood Blvd, Novato, CA 94945 USA.	gmccoll@buckinstitute.org	McColl, Gawain/Y-8959-2018	McColl, Gawain/0000-0002-6347-6722	NATIONAL INSTITUTE ON AGING [R01AG029631, R01AG021069] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG029631, R01AG21069, R01 AG021069] Funding Source: Medline; PHS HHS [R0-122868] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Barsyte D, 2001, FASEB J, V15, P627, DOI 10.1096/fj.99-0966com; BEANAN MJ, 1992, DEVELOPMENT, V116, P755; Boulton SJ, 2002, SCIENCE, V295, P127, DOI 10.1126/science.1065986; Calini V, 2003, TOXICOL IN VITRO, V17, P561, DOI 10.1016/S0887-2333(03)00116-4; Campisi J, 2003, NAT REV CANCER, V3, P339, DOI 10.1038/nrc1073; Gems D, 1998, GENETICS, V150, P129; Glaab WE, 1999, MUTAT RES-FUND MOL M, V427, P67, DOI 10.1016/S0027-5107(99)00091-3; Gu YS, 2000, P NATL ACAD SCI USA, V97, P2668, DOI 10.1073/pnas.97.6.2668; HARTMAN PS, 1982, GENETICS, V102, P159; Honda Y, 1999, FASEB J, V13, P1385, DOI 10.1096/fasebj.13.11.1385; Hsu AL, 2003, SCIENCE, V300, P1142, DOI 10.1126/science.1083701; Hunt CR, 2004, MOL CELL BIOL, V24, P899, DOI 10.1128/MCB.24.2.899-911.2004; Jeong YS, 2003, DNA REPAIR, V2, P1309, DOI 10.1016/j.dnarep.2003.07.003; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kenny MK, 2001, J BIOL CHEM, V276, P9532, DOI 10.1074/jbc.M009297200; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; LARSEN PL, 1995, GENETICS, V139, P1567; Lee SJ, 2001, CELL STRESS CHAPERON, V6, P273, DOI 10.1379/1466-1268(2001)006<0273:ROIHSP>2.0.CO;2; Leroux MR, 1997, J BIOL CHEM, V272, P24646, DOI 10.1074/jbc.272.39.24646; Li GC, 1998, MOL CELL, V2, P1, DOI 10.1016/S1097-2765(00)80108-2; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; LITHGOW GJ, 1995, P NATL ACAD SCI USA, V92, P7540, DOI 10.1073/pnas.92.16.7540; LITHGOW GJ, 1994, J GERONTOL, V49, pB270, DOI 10.1093/geronj/49.6.B270; Lithgow GJ, 1996, BIOESSAYS, V18, P809, DOI 10.1002/bies.950181007; McElwee J, 2003, AGING CELL, V2, P111, DOI 10.1046/j.1474-9728.2003.00043.x; McElwee JJ, 2004, J BIOL CHEM, V279, P44533, DOI 10.1074/jbc.M406207200; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Morley JF, 2004, MOL BIOL CELL, V15, P657, DOI 10.1091/mbc.E03-07-0532; Murakami S, 1996, GENETICS, V143, P1207; Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Park SH, 2000, RADIAT RES, V153, P318, DOI 10.1667/0033-7587(2000)153[0318:IHSPII]2.0.CO;2; SIERRARIVERA E, 1993, RADIAT RES, V135, P40, DOI 10.2307/3578394; Sijen T, 2001, CELL, V107, P465, DOI 10.1016/S0092-8674(01)00576-1; STERNAGLE T, 1999, C ELEGANS PRACTICAL, P51; Tang D, 2001, BIOCHEM BIOPH RES CO, V280, P280, DOI 10.1006/bbrc.2000.4118; VANFLETEREN JR, 1993, BIOCHEM J, V292, P605, DOI 10.1042/bj2920605; Vogel H, 1999, P NATL ACAD SCI USA, V96, P10770, DOI 10.1073/pnas.96.19.10770; Walker DW, 2000, NATURE, V405, P296, DOI 10.1038/35012693; Walker GA, 2003, AGING CELL, V2, P131, DOI 10.1046/j.1474-9728.2003.00045.x; Walker GA, 2003, FASEB J, V17, P1960, DOI 10.1096/fj.03-0164fje; Walker GA, 2001, J GERONTOL A-BIOL, V56, pB281, DOI 10.1093/gerona/56.7.B281; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; Yang SH, 1996, MOL CELL BIOL, V16, P3799, DOI 10.1128/mcb.16.7.3799; Yang SH, 1996, RADIAT RES, V146, P603, DOI 10.2307/3579375; Yokoyama K, 2002, FEBS LETT, V516, P53, DOI 10.1016/S0014-5793(02)02470-5; Yu H, 2001, J MOL BIOL, V314, P1017, DOI 10.1006/jmbi.2000.5210	49	16	21	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1716	+		10.1096/fj.04-2447fje	http://dx.doi.org/10.1096/fj.04-2447fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16099946	Green Accepted			2022-12-25	WOS:000231843700016
J	Movahed, P; Jonsson, BAG; Birnir, B; Wingstrand, JA; Jorgensen, TD; Ermund, A; Sterner, O; Zygmunt, PM; Hogestatt, ED				Movahed, P; Jonsson, BAG; Birnir, B; Wingstrand, JA; Jorgensen, TD; Ermund, A; Sterner, O; Zygmunt, PM; Hogestatt, ED			Endogenous unsaturated C18N-acylethanolamines are vanilloid receptor (TRPV1) agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED ION-CHANNEL; PROTEIN-KINASE-C; CAPSAICIN-RECEPTOR; CANNABINOID RECEPTOR; SENSORY NEURONS; ANANDAMIDE; RELEASE; ANALOGS; BRAIN; HEAT	The endogenous C18 N-acylethanolamines (NAEs) N-linolenoylethanolamine ( 18: 3 NAE), N-linoleoylethanolamine ( 18: 2 NAE), N-oleoylethanolamine ( 18: 1 NAE), and N-stearoylethanolamine ( 18: 0 NAE) are structurally related to the endocannabinoid anandamide ( 20: 4 NAE), but these lipids are poor ligands at cannabinoid CB1 receptors. Anandamide is also an activator of the transient receptor potential (TRP) vanilloid 1 (TRPV1) on primary sensory neurons. Here we show that C18 NAEs are present in rat sensory ganglia and vascular tissue. With the exception of 18: 3 NAE in rat sensory ganglia, the levels of C18 NAEs are equal to or substantially exceed those of anandamide. At submicromolar concentrations, 18: 3 NAE, 18: 2 NAE, and 18: 1 NAE, but not 18: 0 NAE and oleic acid, activate native rTRPV(1) on perivascular sensory nerves. 18: 1 NAE does not activate these nerves in TRPV1 gene knock-out mice. Only the unsaturated C18 NAEs elicit whole cell currents and fluorometric calcium responses in HEK293 cells expressing hTRPV(1). Molecular modeling revealed a low energy cluster of U-shaped unsaturated NAE conformers, sharing several pharmacophoric elements with capsaicin. Furthermore, one of the two major low energy conformational families of anandamide also overlaps with the cannabinoid CB1 receptor ligand HU210, which is in line with anandamide being a dual activator of TRPV1 and the cannabinoid CB1 receptor. This study shows that several endogenous non-cannabinoid NAEs, many of which are more abundant than anandamide in rat tissues, activate TRPV1 and thus may play a role as endogenous TRPV1 modulators.	Lund Univ, Dept Lab Med, SE-22185 Lund, Sweden; Lund Univ, Dept Expt Med Sci, SE-22184 Lund, Sweden; Lund Univ, Dept Organ Chem, SE-22100 Lund, Sweden; NeuroSearch AS, DK-2750 Ballerup, Denmark	Lund University; Lund University; Lund University	Zygmunt, PM (corresponding author), Univ Lund Hosp, Dept Lab Med, SE-22185 Lund, Sweden.	peter.zygmunt@med.lu.se	Ermund, Anna/AAG-3160-2020	Dyhring, Tino/0000-0002-9607-0577; Ermund, Anna/0000-0002-3233-043X; Movahed, Pouya/0000-0003-2041-3550; Jonsson, Bo/0000-0002-8767-0589; Zygmunt, Peter/0000-0002-5102-8199; Birnir, Bryndis/0000-0002-1763-0266				Ahern GP, 2003, J BIOL CHEM, V278, P30429, DOI 10.1074/jbc.M305051200; Ahluwalia J, 2003, J NEUROCHEM, V84, P585, DOI 10.1046/j.1471-4159.2003.01550.x; Appendino G, 2002, J MED CHEM, V45, P3739, DOI 10.1021/jm020844o; Bandell M, 2004, NEURON, V41, P849, DOI 10.1016/S0896-6273(04)00150-3; Bridges D, 2003, NEUROSCIENCE, V119, P803, DOI 10.1016/S0306-4522(03)00200-8; Busch-Petersen J, 1996, J MED CHEM, V39, P3790, DOI 10.1021/jm950934b; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Chuang HH, 2001, NATURE, V411, P957, DOI 10.1038/35082088; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076; de Fonseca FR, 2001, NATURE, V414, P209, DOI 10.1038/35102582; De Petrocellis L, 2001, J NEUROCHEM, V77, P1660, DOI 10.1046/j.1471-4159.2001.00406.x; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; Dinis P, 2004, J NEUROSCI, V24, P11253, DOI 10.1523/JNEUROSCI.2657-04.2004; Evans RM, 2004, BRIT J PHARMACOL, V141, P1223, DOI 10.1038/sj.bjp.0705723; Gavva NR, 2004, J BIOL CHEM, V279, P20283, DOI 10.1074/jbc.M312577200; Gomez R, 2002, J NEUROSCI, V22, P9612; Hwang SW, 2000, P NATL ACAD SCI USA, V97, P6155, DOI 10.1073/pnas.97.11.6155; JANUSZ JM, 1993, J MED CHEM, V36, P2595, DOI 10.1021/jm00070a002; Jordt SE, 2002, CELL, V108, P421, DOI 10.1016/S0092-8674(02)00637-2; Jordt SE, 2004, NATURE, V427, P260, DOI 10.1038/nature02282; Jung J, 1999, J NEUROSCI, V19, P529; Kedei N, 2001, J BIOL CHEM, V276, P28613, DOI 10.1074/jbc.M103272200; Lin SY, 1998, J MED CHEM, V41, P5353, DOI 10.1021/jm970257g; Lopshire JC, 1998, J NEUROSCI, V18, P6081; Maccarrone M, 2002, MOL CELL NEUROSCI, V21, P126, DOI 10.1006/mcne.2002.1164; McKemy DD, 2002, NATURE, V416, P52, DOI 10.1038/nature719; McVey DC, 2001, PEPTIDES, V22, P1439, DOI 10.1016/S0196-9781(01)00463-6; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; MOVAHED P, 2002, PHARMACOLOGIST, V44, pA152; Nagy I, 2004, EUR J PHARMACOL, V500, P351, DOI 10.1016/j.ejphar.2004.07.037; Okamoto Y, 2004, J BIOL CHEM, V279, P5298, DOI 10.1074/jbc.M306642200; Peier AM, 2002, CELL, V108, P705, DOI 10.1016/S0092-8674(02)00652-9; Premkumar LS, 2000, NATURE, V408, P985, DOI 10.1038/35050121; Reggio PH, 2002, PROSTAG LEUKOTR ESS, V66, P143, DOI 10.1054/plef.2001.0343; Schmid HHO, 2002, CHEM PHYS LIPIDS, V121, P111, DOI 10.1016/S0009-3084(02)00157-3; SCHMID PC, 1983, J BIOL CHEM, V258, P9302; SCHMID PC, 1995, FEBS LETT, V375, P117, DOI 10.1016/0014-5793(95)01194-J; SHENKIN PS, 1994, J COMPUT CHEM, V15, P899, DOI 10.1002/jcc.540150811; Sheskin T, 1997, J MED CHEM, V40, P659, DOI 10.1021/jm960752x; Shin J, 2002, P NATL ACAD SCI USA, V99, P10150, DOI 10.1073/pnas.152002699; Smart D, 2002, BRIT J PHARMACOL, V136, P452, DOI 10.1038/sj.bjp.0704732; Smith M, 2003, EUR J PHARMACOL, V478, P21, DOI 10.1016/j.ejphar.2003.08.034; Stella N, 2001, EUR J PHARMACOL, V425, P189, DOI 10.1016/S0014-2999(01)01182-7; Story GM, 2003, CELL, V112, P819, DOI 10.1016/S0092-8674(03)00158-2; Sun YX, 2004, BIOCHEM J, V380, P749, DOI 10.1042/BJ20040031; Szallasi A, 1999, PHARMACOL REV, V51, P159; Tian XY, 2005, J BIOL CHEM, V280, P29788, DOI 10.1074/jbc.M502925200; Tong WD, 1998, J MED CHEM, V41, P4207, DOI 10.1021/jm970239z; Vellani V, 2001, J PHYSIOL-LONDON, V534, P813, DOI 10.1111/j.1469-7793.2001.00813.x; Wang XB, 2005, J PHYSIOL-LONDON, V564, P541, DOI 10.1113/jphysiol.2004.081844; XIE XQ, 1994, J MED CHEM, V37, P1418, DOI 10.1021/jm00036a006; Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761; Zygmunt PM, 2002, J NEUROSCI, V22, P4720, DOI 10.1523/JNEUROSCI.22-11-04720.2002	57	144	153	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38496	38504		10.1074/jbc.M507429200	http://dx.doi.org/10.1074/jbc.M507429200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16081411	hybrid			2022-12-25	WOS:000233239800047
J	Gao, XD; Tachikawa, H; Sato, T; Jigami, Y; Dean, N				Gao, XD; Tachikawa, H; Sato, T; Jigami, Y; Dean, N			Alg14 recruits alg13 to the cytoplasmic face of the endoplasmic reticulum to form a novel bipartite UDP-N-acetylglucosamine transferase required for the second step of N-linked glycosylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST MUTANTS DEFICIENT; SACCHAROMYCES-CEREVISIAE; GENE DELETION; OLIGOSACCHARIDE; BIOSYNTHESIS; PATHWAY; CLONING; LOCUS; GLYCOSYLTRANSFERASES; GLUCOSYLATION	N-linked glycosylation requires the synthesis of an evolutionarily conserved lipid-linked oligosaccharide (LLO) precursor that is essential for glycoprotein folding and stability. Despite intense research, several of the enzymes required for LLO synthesis have not yet been identified. Here we show that two poorly characterized yeast proteins known to be required for the synthesis of the LLO precursor, GlcNAc(2)-PP-dolichol, interact to form an unusual hetero-oligomeric UDP-GlcNAc transferase. Alg13 contains a predicted catalytic domain, but lacks any membrane-spanning domains. Alg14 spans the membrane but lacks any sequences predicted to play a direct role in sugar catalysis. We show that Alg14 functions as a membrane anchor that recruits Alg13 to the cytosolic face of the ER, where catalysis of GlcNAc(2)-PP-dol occurs. Alg13 and Alg14 physically interact and under normal conditions, are associated with the ER membrane. Overexpression of Alg13 leads to its cytosolic partitioning, as does reduction of Alg14 levels. Concomitant Alg14 overproduction suppresses this cytosolic partitioning of Alg13, demonstrating that Alg14 is both necessary and sufficient for the ER localization of Alg13. Further evidence for the functional relevance of this interaction comes from our demonstration that the human ALG13 and ALG14 orthologues fail to pair with their yeast partners, but when co-expressed in yeast can functionally complement the loss of either ALG13 or ALG14. These results demonstrate that this novel UDP-GlcNAc transferase is a unique eukaryotic ER glycosyltransferase that is comprised of at least two functional polypeptides, one that functions in catalysis and the other as a membrane anchor.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; Natl Inst Adv Ind Sci & Technol, Res Ctr Glycosci, Tsukuba, Ibaraki 3058566, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Fac Agr & Life Sci, Dept Appl Biol Chem,Lab Biol Chem,Bunkyo Ku, Tokyo 1138657, Japan	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; National Institute of Advanced Industrial Science & Technology (AIST); University of Tokyo	Dean, N (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.	Neta.Dean@stonybrook.edu	Sato, Takashi/M-2577-2018	Sato, Takashi/0000-0002-9973-8923; TACHIKAWA, HIROYUKI/0000-0002-4815-9964				ABEIJON C, 1992, TRENDS BIOCHEM SCI, V17, P32, DOI 10.1016/0968-0004(92)90424-8; Aebi M, 2001, TRENDS CELL BIOL, V11, P136, DOI 10.1016/S0962-8924(01)01925-0; Aebi M, 1996, GLYCOBIOLOGY, V6, P439, DOI 10.1093/glycob/6.4.439; BARNES G, 1984, MOL CELL BIOL, V4, P2381, DOI 10.1128/MCB.4.11.2381; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Burda P, 1999, BBA-GEN SUBJECTS, V1426, P239, DOI 10.1016/S0304-4165(98)00127-5; Burda P, 1998, GLYCOBIOLOGY, V8, P455, DOI 10.1093/glycob/8.5.455; Burda P, 1996, P NATL ACAD SCI USA, V93, P7160, DOI 10.1073/pnas.93.14.7160; Burda P, 1999, GLYCOBIOLOGY, V9, P617, DOI 10.1093/glycob/9.6.617; Chantret I, 2005, J BIOL CHEM, V280, P9236, DOI 10.1074/jbc.M413941200; Cipollo JF, 2001, J BIOL CHEM, V276, P21828, DOI 10.1074/jbc.M010896200; COUTO JR, 1984, J BIOL CHEM, V259, P378; de Graffenried CL, 2004, CURR OPIN CELL BIOL, V16, P356, DOI 10.1016/j.ceb.2004.06.007; FRANK CG, 2005, IN PRESS GLYCOBIOLOG; Freeze HH, 2002, BBA-GEN SUBJECTS, V1573, P388, DOI 10.1016/S0304-4165(02)00408-7; Gao XD, 2000, J BIOL CHEM, V275, P17718, DOI 10.1074/jbc.M909946199; Gao XD, 2004, GLYCOBIOLOGY, V14, P559, DOI 10.1093/glycob/cwh072; Guthrie C, 1991, METHOD ENZYMOL, V194, P3; Hebert DN, 2005, TRENDS CELL BIOL, V15, P364, DOI 10.1016/j.tcb.2005.05.007; Heesen S, 1994, EUR J BIOCHEM, V224, P71; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; HUFFAKER TC, 1982, J BIOL CHEM, V257, P3203; HUFFAKER TC, 1983, P NATL ACAD SCI-BIOL, V80, P7466, DOI 10.1073/pnas.80.24.7466; JACKSON BJ, 1993, GLYCOBIOLOGY, V3, P357, DOI 10.1093/glycob/3.4.357; Kean EL, 1999, J BIOL CHEM, V274, P34072, DOI 10.1074/jbc.274.48.34072; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LEHRMAN M A, 1991, Glycobiology, V1, P553, DOI 10.1093/glycob/1.6.553; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; PEREZ M, 1986, J BIOL CHEM, V261, P6822; Reiss G, 1996, GLYCOBIOLOGY, V6, P493, DOI 10.1093/glycob/6.5.493; Samuelson J, 2005, P NATL ACAD SCI USA, V102, P1548, DOI 10.1073/pnas.0409460102; SIKORSKI RS, 1989, GENETICS, V122, P19; SNIDER MD, 1984, CELL, V36, P753, DOI 10.1016/0092-8674(84)90355-6; STAGLJAR I, 1994, P NATL ACAD SCI USA, V91, P5977, DOI 10.1073/pnas.91.13.5977; THOMAS BJ, 1989, GENETICS, V123, P725; Yan AX, 2005, J BIOL CHEM, V280, P3121, DOI 10.1074/jbc.R400036200	37	79	86	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36254	36262		10.1074/jbc.M507569200	http://dx.doi.org/10.1074/jbc.M507569200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16100110	hybrid			2022-12-25	WOS:000232726900058
J	Eriste, E; Norberg, A; Nepomuceno, D; Kuei, C; Kamme, F; Tran, DT; Strupat, K; Jornvall, H; Liu, CL; Lovenberg, TW; Sillard, R				Eriste, E; Norberg, A; Nepomuceno, D; Kuei, C; Kamme, F; Tran, DT; Strupat, K; Jornvall, H; Liu, CL; Lovenberg, TW; Sillard, R			A novel form of neurotensin post-translationally modified by arginylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; PORCINE INTESTINE; NEUROPEPTIDE-Y; ACTIVE PEPTIDE; BRAIN PEPTIDE; NEUROMEDIN-N; RAT-BRAIN; RECEPTOR; SECRETIN; PROTEIN	A novel bioactive form of neurotensin post-translationally modified at a Glu residue was isolated from porcine intestine. Purification of the peptide was guided by detection of intracellular Ca2+ release in SK-N-SH neuroblastoma cells. Using high resolution accurate mass analysis on an ion trap Fourier transform mass spectrometer, the post-translational modification was identified as arginine linked to the gamma-carboxyl of Glu via an isopeptide bond, and we named the newly identified peptide "arginylated neurotensin" (R-NT, N-(neurotensin-C5-4-yl)arginine). Although arginylation is a known modification of N- terminal amino groups in proteins, its presence at a Glu side chain is unique. The finding places neurotensin among the few physiologically active peptides that occur both in post-translationally modified and unmodified forms. Pharmacologically, we characterized R-NT for its ligand activity on three known neurotensin receptors, NTR1, -2, and -3, and found that R-NT has similar pharmacological properties to those of neurotensin, however, with a slightly higher affinity to all three receptors. We expressed the intracellular receptor NTR3 as a soluble protein secreted into the cell culture medium, which allowed characterization of its R-NT and neurotensin binding properties. The creation of soluble NTR3 also provides a potential tool for neutralizing neurotensin action in vivo and in vitro. We have shown that SK-N-SH neuroblastoma cells express NTR1 and NTR3 but not NTR2, suggesting that the Ca2+ mobilization elicited by R-NT is via NTR1.	Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; Johnson & Johnson Pharmaceut Res & Dev, San Diego, CA 92121 USA; Thermo Electron Bremen GmbH, D-28197 Bremen, Germany	Karolinska Institutet; Johnson & Johnson; Johnson & Johnson USA	Sillard, R (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden.	rannar@ki.se						AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; BARRA HS, 1973, J NEUROCHEM, V20, P97, DOI 10.1111/j.1471-4159.1973.tb12108.x; BENNETT HPJ, 1981, BIOCHEMISTRY-US, V20, P4530, DOI 10.1021/bi00519a004; BISSETTE G, 1976, NATURE, V262, P607, DOI 10.1038/262607a0; Bonetto V, 2001, ARCH BIOCHEM BIOPHYS, V385, P276, DOI 10.1006/abbi.2000.2165; Bonetto V, 1995, P NATL ACAD SCI USA, V92, P11985, DOI 10.1073/pnas.92.26.11985; BONETTO V, 1997, ANAL CHEM, V69, P1314; Botto JM, 1998, BIOCHEM BIOPH RES CO, V243, P585, DOI 10.1006/bbrc.1997.8071; BOUBLIK J, 1989, INT J PEPT PROT RES, V33, P11; CARRAWAY R, 1973, J BIOL CHEM, V248, P6854; CARRAWAY RE, 1991, PEPTIDES, V12, P601, DOI 10.1016/0196-9781(91)90108-2; Chalon P, 1996, FEBS LETT, V386, P91, DOI 10.1016/0014-5793(96)00397-3; Chen ZW, 2001, FEBS LETT, V492, P119, DOI 10.1016/S0014-5793(01)02234-7; Dubuc I, 1999, J NEUROSCI, V19, P503, DOI 10.1523/JNEUROSCI.19-01-00503.1999; Eriste E, 1999, CELL MOL LIFE SCI, V56, P709, DOI 10.1007/s000180050464; FEURLE GE, 1987, GUT, V28, P19, DOI 10.1136/gut.28.Suppl.19; GARVER DL, 1991, AM J PSYCHIAT, V148, P484; Gobom J, 2000, ANAL CHEM, V72, P3320, DOI 10.1021/ac991122g; JORPES JE, 1962, BIOCHEM BIOPH RES CO, V9, P275, DOI 10.1016/0006-291X(62)90073-6; KAJI H, 1963, Biochim Biophys Acta, V76, P474; KITABGI P, 1977, P NATL ACAD SCI USA, V74, P1846, DOI 10.1073/pnas.74.5.1846; KITABGI P, 1976, J BIOL CHEM, V251, P7053; Krause A, 2003, PROTEIN SCI, V12, P143, DOI 10.1110/ps.0213603; Kwon YT, 1999, MOL CELL BIOL, V19, P182; Kwon YT, 2002, SCIENCE, V297, P96, DOI 10.1126/science.1069531; Liu CL, 1997, ENDOCRINOLOGY, V138, P3548, DOI 10.1210/en.138.8.3548; Liu CL, 2003, J BIOL CHEM, V278, P50765, DOI 10.1074/jbc.M308996200; Mazella J, 1998, J BIOL CHEM, V273, P26273, DOI 10.1074/jbc.273.41.26273; MITRA SP, 1990, REGUL PEPTIDES, V28, P11, DOI 10.1016/0167-0115(90)90060-A; MOGARD MH, 1986, REGUL PEPTIDES, V14, P313, DOI 10.1016/0167-0115(86)90173-4; Morris NJ, 1998, J BIOL CHEM, V273, P3582, DOI 10.1074/jbc.273.6.3582; MUTT V, 1968, EUR J BIOCHEM, V6, P156, DOI 10.1111/j.1432-1033.1968.tb00433.x; MUTT V, 1970, EUR J BIOCHEM, V15, P513, DOI 10.1111/j.1432-1033.1970.tb01034.x; MUTT V, 1974, EUR J BIOCHEM, V42, P581, DOI 10.1111/j.1432-1033.1974.tb03373.x; Petersen CM, 1997, J BIOL CHEM, V272, P3599, DOI 10.1074/jbc.272.6.3599; SAID SI, 1972, EUR J BIOCHEM, V28, P199, DOI 10.1111/j.1432-1033.1972.tb01903.x; SHAW C, 1990, COMP BIOCHEM PHYS C, V95, P291, DOI 10.1016/0742-8413(90)90120-X; SOFFER RL, 1969, J MOL BIOL, V43, P163, DOI 10.1016/0022-2836(69)90086-2; TANAKA K, 1990, NEURON, V4, P847, DOI 10.1016/0896-6273(90)90137-5; TATEMOTO K, 1980, NATURE, V285, P417, DOI 10.1038/285417a0; TATEMOTO K, 1983, FEBS LETT, V164, P124, DOI 10.1016/0014-5793(83)80033-7; TATEMOTO K, 1982, P NATL ACAD SCI-BIOL, V79, P2514, DOI 10.1073/pnas.79.8.2514; TATEMOTO K, 1982, NATURE, V296, P659, DOI 10.1038/296659a0; TATEMOTO K, 1982, P NATL ACAD SCI-BIOL, V79, P5485, DOI 10.1073/pnas.79.18.5485; TATEMOTO K, 1981, P NATL ACAD SCI-BIOL, V78, P6603, DOI 10.1073/pnas.78.11.6603; Vincent JP, 1999, TRENDS PHARMACOL SCI, V20, P302, DOI 10.1016/S0165-6147(99)01357-7; Vita N, 1998, EUR J PHARMACOL, V360, P265, DOI 10.1016/S0014-2999(98)00678-5; WATKINSON A, 1993, BIOCHEM J, V295, P649, DOI 10.1042/bj2950649; YAMASHITA Y, 1987, PEPTIDES, V8, P639, DOI 10.1016/0196-9781(87)90038-6	49	27	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35089	35097		10.1074/jbc.M502567200	http://dx.doi.org/10.1074/jbc.M502567200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16087676	hybrid			2022-12-25	WOS:000232561200005
J	Furumatsu, T; Tsuda, M; Yoshida, K; Taniguchi, N; Ito, T; Hashimoto, M; Ito, T; Asahara, H				Furumatsu, T; Tsuda, M; Yoshida, K; Taniguchi, N; Ito, T; Hashimoto, M; Ito, T; Asahara, H			Sox9 and p300 cooperatively regulate chromatin-mediated transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSOME ASSEMBLY PROTEIN-1; RUBINSTEIN-TAYBI SYNDROME; AUTOSOMAL SEX REVERSAL; SRY-RELATED GENE; CHONDROCYTE DIFFERENTIATION; COLLAGEN GENE; IN-VITRO; CAMPOMELIC DYSPLASIA; HISTONE CHAPERONE; EXPRESSION	Chromatin structure is a fundamental component of gene regulation, expression, and cellular differentiation. We have previously reported that the multifunctional coactivator p300 is a member of the Sox9 (Sry-type high mobility group box 9)-related transcriptional apparatus and activates Sox9-dependent transcription during chondrogenesis. However, the mechanism of synergy between Sox9 and p300 in chromatin-mediated transcription has not been elucidated. In the present study we investigated the activity of Sox9 and p300 on chromatinized templates in vitro. Recombinant Sox9 was shown to be associated with several transcriptional cofactors including p300. In vitro transcription assays revealed that p300 potentiated Sox9-dependent transcription on chromatinized DNA and, importantly, was associated with hyperacetylated histones. Consistent with these results, the histone deacetylase inhibitor trichostatin A stimulated the expression of Sox9-regulated cartilage matrix genes and induced histone acetylation around the enhancer region of the collagen alpha 1 (II) gene in chondrocytes. These findings suggest that Sox9 interacts with chromatin and activates transcription via regulation of chromatin modification.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Nagasaki Univ, Sch Med, Dept Biochem, Nagasaki 8528523, Japan; Natl Ctr Child Hlth & Dev, Setagaya Ku, Tokyo 1578535, Japan; Japan Sci & Technol Agcy, Solut Oriented Res Sci & Technol Project, Kawaguchi, Saitama 3320012, Japan	Scripps Research Institute; Nagasaki University; National Center for Child Health & Development - Japan; Japan Science & Technology Agency (JST)	Asahara, H (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd,MEM 161, La Jolla, CA 92037 USA.	asahara@scripps.edu	FURUMATSU, Takayuki/B-2233-2011		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R56AR050631, R01AR050631] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR50631] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Akiyama H, 2002, GENE DEV, V16, P2813, DOI 10.1101/gad.1017802; Akiyama H, 2004, GENE DEV, V18, P1072, DOI 10.1101/gad.1171104; Alsalameh S, 2004, ARTHRITIS RHEUM-US, V50, P1522, DOI 10.1002/art.20269; Asahara H, 2002, MOL CELL BIOL, V22, P2974, DOI 10.1128/MCB.22.9.2974-2983.2002; Asahara H, 2001, MOL CELL BIOL, V21, P7892, DOI 10.1128/MCB.21.23.7892-7900.2001; Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; Bradney C, 2003, J BIOL CHEM, V278, P2370, DOI 10.1074/jbc.M211464200; Canettieri G, 2003, NAT STRUCT BIOL, V10, P175, DOI 10.1038/nsb895; Chan HM, 2001, J CELL SCI, V114, P2363; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dilworth FJ, 2004, P NATL ACAD SCI USA, V101, P11593, DOI 10.1073/pnas.0404192101; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; Furumatsu T, 2005, J BIOL CHEM, V280, P8343, DOI 10.1074/jbc.M413913200; Furumatsu T, 2002, INT J CANCER, V97, P313, DOI 10.1002/ijc.1607; Haushalter KA, 2003, NAT REV MOL CELL BIO, V4, P613, DOI 10.1038/nrm1177; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Ito T, 2000, GENE DEV, V14, P1899; Ito T, 1999, GENE DEV, V13, P1529, DOI 10.1101/gad.13.12.1529; Ito T, 1996, MOL CELL BIOL, V16, P3112; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Kawakami Y, 2005, P NATL ACAD SCI USA, V102, P2414, DOI 10.1073/pnas.0407510102; Kitagawa H, 2003, CELL, V113, P905, DOI 10.1016/S0092-8674(03)00436-7; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kou I, 2004, J BIOL CHEM, V279, P50942, DOI 10.1074/jbc.M406786200; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; Kundu TK, 2000, MOL CELL, V6, P551, DOI 10.1016/S1097-2765(00)00054-X; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Liu CJ, 2004, J BIOL CHEM, V279, P47081, DOI 10.1074/jbc.M405288200; Liu Y, 2000, J BIOL CHEM, V275, P12712, DOI 10.1074/jbc.275.17.12712; Nakagawa T, 2001, J BIOL CHEM, V276, P27384, DOI 10.1074/jbc.M101331200; Narayanan K, 2004, J BIOL CHEM, V279, P44294, DOI 10.1074/jbc.M403511200; Perissi V, 2004, CELL, V116, P511, DOI 10.1016/S0092-8674(04)00133-3; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; Sekiya I, 2000, J BIOL CHEM, V275, P10738, DOI 10.1074/jbc.275.15.10738; Song MR, 2004, NAT NEUROSCI, V7, P229, DOI 10.1038/nn1192; Stricker S, 2002, DEV BIOL, V245, P95, DOI 10.1006/dbio.2002.0640; Tan LJ, 2003, J BIOL CHEM, V278, P17688, DOI 10.1074/jbc.M301676200; Tanaka Y, 1997, P NATL ACAD SCI USA, V94, P10215, DOI 10.1073/pnas.94.19.10215; Tsuda M, 2003, J BIOL CHEM, V278, P27224, DOI 10.1074/jbc.M303471200; Turner BM, 2002, CELL, V111, P285, DOI 10.1016/S0092-8674(02)01080-2; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Zhang P, 2003, J BIOL CHEM, V278, P117, DOI 10.1074/jbc.M208049200	48	117	124	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35203	35208		10.1074/jbc.M502409200	http://dx.doi.org/10.1074/jbc.M502409200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16109717	hybrid			2022-12-25	WOS:000232561200017
J	Gomez-Merino, FC; Arana-Ceballos, FA; Trejo-Tellez, LI; Skirycz, A; Brearley, CA; Dormann, P; Mueller-Roeber, B				Gomez-Merino, FC; Arana-Ceballos, FA; Trejo-Tellez, LI; Skirycz, A; Brearley, CA; Dormann, P; Mueller-Roeber, B			Arabidopsis AtDGK7, the smallest member of plant diacylglycerol kinases (DGKs), displays unique biochemical features and saturates at low substrate concentration - The DGK inhibitor R59022 differentially affects AtDGK2 and AtDGK7 activity in vitro and alters plant growth and development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDIC-ACID; PHOSPHOLIPASE-C; PLASMA-MEMBRANE; RICH REGION; PROTEIN; PHOSPHATIDYLINOSITOL; ACCUMULATION; GTPASE; CELLS; TRANSDUCTION	Diacylglycerol kinase (DGK) regulates the level of the second messenger diacylglycerol and produces phosphatidic acid (PA), another signaling molecule. The Arabidopsis thaliana genome encodes seven putative diacylglycerol kinase isozymes (named AtDGK1 to -7), structurally falling into three major clusters. So far, enzymatic activity has not been reported for any plant Cluster II DGK. Here, we demonstrate that a representative of this cluster, AtDGK7, is biochemically active when expressed as a recombinant protein in Escherichia coli. AtDGK7, encoded by gene locus At4g30340, contains 374 amino acids with an apparent molecular mass of 41.2 kDa. AtDGK7 harbors an N-terminal catalytic domain, but in contrast to various characterized DGKs (including AtDGK2), it lacks a cysteine-rich domain at its N terminus, and, importantly, its C-terminal DGK accessory domain is incomplete. Recombinant AtDGK7 expressed in E. coli exhibits Michaelis-Menten type kinetics with 1,2-dioleoyl-sn-glycerol as substrate. AtDGK7 activity was affected by pH, detergents, and the DGK inhibitor R59022. We demonstrate that both AtDGK2 and AtDGK7 phosphorylate diacylglycerol molecular species that are typically found in plants, indicating that both enzymes convert physiologically relevant substrates. AtDGK7 is expressed throughout the Arabidopsis plant, but expression is strongest in flowers and young seedlings. Expression of AtDGK2 is transiently induced by wounding. R59022 at similar to 80 mu M inhibits root elongation and lateral root formation and reduces plant growth, indicating that DGKs play an important role in plant development.	Univ Potsdam, Inst Biochem & Biol, D-14476 Golm, Germany; Coll Postgrad Agr Sci, Montecillo 56230, Mexico; Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England; Max Planck Inst Mol Plant Physiol, Dept Mol Physiol, D-14476 Golm, Germany; Max Planck Inst Mol Plant Physiol, Cooperat Res Grp, D-14476 Golm, Germany	University of Potsdam; Colegio de Postgraduados - Mexico; University of East Anglia; Max Planck Society; Max Planck Society	Mueller-Roeber, B (corresponding author), Univ Potsdam, Inst Biochem & Biol, Karl Liebknecht Str 24-25,Haus 20, D-14476 Golm, Germany.	bmr@rz.uni-potsdam.de	TREJO-TÉLLEZ, LIBIA/B-2635-2015; Gómez-Merino, Fernando Carlos/D-2224-2014; Mueller-Roeber, Bernd/Z-4052-2019; LIBIA, TREJO-TÉLLEZ/AAV-8118-2021; Skirycz, Aleksandra/AAM-7911-2021	Skirycz, Aleksandra/0000-0002-7627-7925; Brearley, Charles/0000-0001-6179-9109				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREARLEY CA, 1992, BIOCHEM J, V283, P255, DOI 10.1042/bj2830255; Czechowski T, 2004, PLANT J, V38, P366, DOI 10.1111/j.1365-313X.2004.02051.x; Deak M, 1999, FEBS LETT, V451, P220, DOI 10.1016/S0014-5793(99)00556-6; DEEMS RA, 1975, J BIOL CHEM, V250, P9013; Farmer PK, 1999, BBA-PROTEIN STRUCT M, V1434, P6, DOI 10.1016/S0167-4838(99)00166-1; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; Gilroy S, 2001, NAT REV MOL CELL BIO, V2, P307, DOI 10.1038/35067109; Gomez-Merino FC, 2003, PROCEEDINGS OF THE XII INTERNATIONAL CONGRESS ON GENES, GENE FAMILIES, AND ISOZYMES, P247; Gomez-Merino FC, 2004, J BIOL CHEM, V279, P8230, DOI 10.1074/jbc.M312187200; HAWKINS PT, 1986, BIOCHEM J, V238, P507, DOI 10.1042/bj2380507; HEIM S, 1987, PLANT SCI, V49, P159, DOI 10.1016/0168-9452(87)90036-7; Houssa B, 1997, J BIOL CHEM, V272, P10422; Igal RA, 2001, J LIPID RES, V42, P88; JEFFERSON RA, 1987, EMBO J, V6, P3901; Jiang Y, 2000, BIOCHEM PHARMACOL, V59, P763, DOI 10.1016/S0006-2952(99)00395-0; Jones MA, 2002, PLANT CELL, V14, P763, DOI 10.1105/tpc.010359; KAMADA Y, 1991, BIOCHIM BIOPHYS ACTA, V1093, P72, DOI 10.1016/0167-4889(91)90140-S; KANOH H, 1981, ARCH BIOCHEM BIOPHYS, V209, P266, DOI 10.1016/0003-9861(81)90280-0; Katagiri T, 1996, PLANT MOL BIOL, V30, P647, DOI 10.1007/BF00049339; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE Y, 1991, P NATL ACAD SCI USA, V88, P2127, DOI 10.1073/pnas.88.6.2127; Li H, 2001, PLANT PHYSIOL, V126, P670, DOI 10.1104/pp.126.2.670; LUNDBERG GA, 1992, BIOCHIM BIOPHYS ACTA, V1123, P177, DOI 10.1016/0005-2760(92)90109-9; MARECHAL E, 1994, J BIOL CHEM, V269, P5788; Martelli AM, 2002, CELL MOL LIFE SCI, V59, P1129, DOI 10.1007/s00018-002-8492-9; Meijer HJG, 2003, ANNU REV PLANT BIOL, V54, P265, DOI 10.1146/annurev.arplant.54.031902.134748; Meyers BC, 2004, PLANT PHYSIOL, V135, P801, DOI 10.1104/pp.104.039495; Miege C, 1999, PLANT PHYSIOL BIOCH, V37, P795, DOI 10.1016/S0981-9428(99)00118-7; Munnik T, 2001, TRENDS PLANT SCI, V6, P227, DOI 10.1016/S1360-1385(01)01918-5; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; QUEST AFG, 1994, J BIOL CHEM, V269, P2953; Ruelland E, 2002, PLANT PHYSIOL, V130, P999, DOI 10.1104/pp.006080; SAMBROOK J, 2000, MOL CLONING LAB MANU; Shirai Y, 2000, J BIOL CHEM, V275, P24760, DOI 10.1074/jbc.M003151200; Snedden WA, 2000, PLANT J, V24, P317, DOI 10.1046/j.1365-313x.2000.00877.x; Testerink C, 2004, PLANT J, V39, P527, DOI 10.1111/j.1365-313X.2004.02152.x; Topham MK, 2002, THROMB HAEMOSTASIS, V88, P912; Toyoda K, 2000, J PHYTOPATHOL, V148, P633, DOI 10.1046/j.1439-0434.2000.00568.x; Undie AS, 1999, BRAIN RES, V816, P286, DOI 10.1016/S0006-8993(98)01076-2; van Blitterswijk WJ, 2000, CELL SIGNAL, V12, P595, DOI 10.1016/S0898-6568(00)00113-3; Vernoud V, 2003, PLANT PHYSIOL, V131, P1191, DOI 10.1104/pp.013052; Wang CX, 2000, PLANT CELL, V12, P2237, DOI 10.1105/tpc.12.11.2237; Wang XM, 2004, CURR OPIN PLANT BIOL, V7, P329, DOI 10.1016/j.pbi.2004.03.012; Winge P, 2000, GENETICS, V156, P1959; WISSING JB, 1992, PLANT PHYSIOL, V98, P1148, DOI 10.1104/pp.98.3.1148; Zhang WH, 2004, P NATL ACAD SCI USA, V101, P9508, DOI 10.1073/pnas.0402112101; Zimmermann P, 2004, PLANT PHYSIOL, V136, P2621, DOI 10.1104/pp.104.046367	48	61	68	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34888	34899		10.1074/jbc.M506859200	http://dx.doi.org/10.1074/jbc.M506859200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16081412	hybrid			2022-12-25	WOS:000232403900061
J	Lu, JC; Piazza, TM; Schuler, LA				Lu, JC; Piazza, TM; Schuler, LA			Proteasomes mediate prolactin-induced receptor down-regulation and fragment generation in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE RECEPTOR; NUCLEAR-LOCALIZATION; SIGNAL-TRANSDUCTION; UBIQUITIN LIGASE; BINDING-PROTEIN; ENDOCYTOSIS; EXPRESSION; INTERNALIZATION; ERYTHROPOIETIN; IDENTIFICATION	Prolactin regulates a variety of physiological processes, including mammary gland growth and differentiation, and recent findings support an important role in breast cancer development and progression. However, little is known about the trafficking of its receptor, a member of the cytokine receptor superfamily. In the present study, we examined the effect of ligand on the endogenous "long" isoform of the prolactin receptor in breast cancer cells. We found that prolactin caused rapid and prolonged down-regulation of this receptor. The prolactin-induced increase in degradation was blocked by inhibitors of both proteasomes and lysosomes. However, the ubiquitin-conjugating system was not required for internalization. Prolactin also resulted in the concomitant appearance of a cell-associated prolactin receptor fragment containing the extracellular domain. This latter process required proteasomal, but not metalloprotease, activity, distinguishing it from ectodomain "shedding" of other membrane receptors, which are secreted as binding proteins. The prolactin receptor fragment was labeled by surface biotinylation and independent of protein synthesis. Together, these data indicated that prolactin binding initiates limited proteasomal cleavage of its receptor, generating a cell-associated fragment containing the extracellular domain. Our findings described a new potential mediator of prolactin action and a novel mechanism whereby proteasomes modulate cellular processes.	Univ Wisconsin, Dept Comparat Biosci, Madison, WI 53706 USA; Univ Wisconsin, Endocrinol Reprod Physiol Program, Madison, WI 53706 USA; Univ Wisconsin, Comparat Biomed Sci Program, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Schuler, LA (corresponding author), Univ Wisconsin, Dept Comparat Biosci, 2015 Linden Dr, Madison, WI 53706 USA.	schulerl@svm.vetmed.wisc.edu	Lu, Juu-Chin/ABB-3198-2020	Lu, Juu-Chin/0000-0001-8523-6992	NATIONAL CANCER INSTITUTE [R01CA078312] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062783] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA078312, R01 CA78312] Funding Source: Medline; NIDDK NIH HHS [R01 DK62783, R01 DK062783] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguilar RC, 2003, CURR OPIN CELL BIOL, V15, P184, DOI 10.1016/S0955-0674(03)00010-3; Althoff K, 2000, EUR J BIOCHEM, V267, P2624, DOI 10.1046/j.1432-1327.2000.01278.x; Baron M, 2002, MOL MEMBR BIOL, V19, P27, DOI 10.1080/09687680110112929; Baumann G, 2002, J ENDOCRINOL, V174, P361, DOI 10.1677/joe.0.1740361; Beckman DL, 1999, BLOOD, V94, P2667, DOI 10.1182/blood.V94.8.2667.420k27_2667_2675; Bole-Feysot C, 1998, ENDOCR REV, V19, P225, DOI 10.1210/edrv.19.3.0334; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; CAHOREAU C, 1994, FEBS LETT, V350, P230, DOI 10.1016/0014-5793(94)00772-1; Chen L, 2001, EMBO REP, V2, P933, DOI 10.1093/embo-reports/kve203; Clevenger CV, 2003, BREAST CANCER RES, V5, P181, DOI 10.1186/bcr601; Clevenger CV, 2003, ENDOCR REV, V24, P1, DOI 10.1210/er.2001-0036; COHEN H, 1993, ENDOCRINOLOGY, V132, P2601, DOI 10.1210/en.132.6.2601; Cook LB, 2003, MOL ENDOCRINOL, V17, P1777, DOI 10.1210/me.2003-0073; Cowan JW, 2005, J BIOL CHEM, V280, P19331, DOI 10.1074/jbc.M500621200; Di Fiore PP, 2003, NAT REV MOL CELL BIO, V4, P491, DOI 10.1038/nrm1124; DJIANE J, 1982, MOL CELL ENDOCRINOL, V25, P163, DOI 10.1016/0303-7207(82)90049-1; Edery M, 2001, ENDOCRIN UPDAT, V12, P341; Fang S, 2004, CELL MOL LIFE SCI, V61, P1546, DOI 10.1007/s00018-004-4129-5; Felberbaum-Corti M, 2003, NAT CELL BIOL, V5, P382, DOI 10.1038/ncb0503-382; Fielding CJ, 2003, BBA-BIOMEMBRANES, V1610, P219, DOI 10.1016/S0005-2736(03)00020-8; Freeman ME, 2000, PHYSIOL REV, V80, P1523, DOI 10.1152/physrev.2000.80.4.1523; Friedman AD, 2003, J BIOL CHEM, V278, P26851, DOI 10.1074/jbc.M210039200; GENTY N, 1994, MOL CELL ENDOCRINOL, V99, P221, DOI 10.1016/0303-7207(94)90011-6; Gill S, 2001, J CLIN PATHOL, V54, P956, DOI 10.1136/jcp.54.12.956; Goffin V, 1999, MOL CELL ENDOCRINOL, V151, P79, DOI 10.1016/S0303-7207(99)00023-4; Goffin V, 2002, ANNU REV PHYSIOL, V64, P47, DOI 10.1146/annurev.physiol.64.081501.131049; Gonzallez-Gaitan M, 2003, NAT REV MOL CELL BIO, V4, P213, DOI 10.1038/nrm1053; Gutzman JH, 2004, J STEROID BIOCHEM, V88, P69, DOI 10.1016/j.jsbmb.2003.10.008; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Hu ZZ, 2001, J BIOL CHEM, V276, P41086, DOI 10.1074/jbc.M102109200; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; Kline JB, 1999, J BIOL CHEM, V274, P35461, DOI 10.1074/jbc.274.50.35461; Kline JB, 2001, J BIOL CHEM, V276, P24760, DOI 10.1074/jbc.M011786200; Kostova Z, 2003, EMBO J, V22, P2309, DOI 10.1093/emboj/cdg227; KULKA RG, 1988, J BIOL CHEM, V263, P15726; Kumar KGS, 2003, EMBO J, V22, P5480; Li Y, 2004, MOL CELL BIOL, V24, P4038, DOI 10.1128/MCB.24.9.4038-4048.2004; Lu JC, 2002, MOL ENDOCRINOL, V16, P2515, DOI 10.1210/me.2002-0077; Marmor MD, 2004, ONCOGENE, V23, P2057, DOI 10.1038/sj.onc.1207390; Martinez-Moczygemba M, 2001, J CLIN INVEST, V108, P1797, DOI 10.1172/JCI200113877; Mertani HC, 1998, INT J CANCER, V79, P202; Mullberg J, 2000, EUR CYTOKINE NETW, V11, P27; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; PerrotApplanat M, 1997, MOL ENDOCRINOL, V11, P1020, DOI 10.1210/me.11.8.1020; PerrotApplanat M, 1997, J CELL SCI, V110, P1123; POSTELVINAY MC, 1991, P NATL ACAD SCI USA, V88, P6687, DOI 10.1073/pnas.88.15.6687; Raben DM, 2002, TRENDS ENDOCRIN MET, V13, P93, DOI 10.1016/S1043-2760(02)00573-8; RAO Y, 1993, ENDOCRINOLOGY, V133, P3062, DOI 10.1210/en.133.6.3062; RAO YP, 1995, ARCH BIOCHEM BIOPHYS, V322, P506, DOI 10.1006/abbi.1995.1494; Rape M, 2002, NAT CELL BIOL, V4, pE113, DOI 10.1038/ncb0502-e113; Reynolds C, 1997, ENDOCRINOLOGY, V138, P5555, DOI 10.1210/en.138.12.5555; Rocca A, 2001, MOL BIOL CELL, V12, P1293, DOI 10.1091/mbc.12.5.1293; Saltiel AR, 2003, TRAFFIC, V4, P711, DOI 10.1034/j.1600-0854.2003.00119.x; Schroeder MD, 2002, MOL ENDOCRINOL, V16, P45, DOI 10.1210/me.16.1.45; Schroeder MD, 2001, MOL CELL ENDOCRINOL, V175, P173, DOI 10.1016/S0303-7207(01)00385-9; Seals DF, 2003, GENE DEV, V17, P7, DOI 10.1101/gad.1039703; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Strous GJ, 2002, MOL CELL ENDOCRINOL, V197, P143, DOI 10.1016/S0303-7207(02)00258-7; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Touraine P, 1998, J CLIN ENDOCR METAB, V83, P667, DOI 10.1210/jc.83.2.667; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; van Kerkhof P, 2000, J BIOL CHEM, V275, P1575, DOI 10.1074/jbc.275.3.1575; Verdier F, 2000, J BIOL CHEM, V275, P18375, DOI 10.1074/jbc.275.24.18375; Vincent V, 1997, J BIOL CHEM, V272, P7062, DOI 10.1074/jbc.272.11.7062; Vonderhaar BK, 2000, CONT ENDOCRINOL, P101; Yu AX, 2001, J BIOL CHEM, V276, P381, DOI 10.1074/jbc.M007991200	69	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33909	33916		10.1074/jbc.M508118200	http://dx.doi.org/10.1074/jbc.M508118200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16103113	hybrid, Green Accepted			2022-12-25	WOS:000232229700027
J	Krebstakies, T; Zimmermann, B; Graber, P; Altendorf, K; Borsch, M; Greie, JC				Krebstakies, T; Zimmermann, B; Graber, P; Altendorf, K; Borsch, M; Greie, JC			Both rotor and stator subunits are necessary for efficient binding of F-1 to F-0 in functionally assembled Escherichia coli ATP synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-MOLECULE FLUORESCENCE; SITE-DIRECTED MUTAGENESIS; GAMMA-SUBUNIT; CROSS-LINKING; B-SUBUNIT; F1F0-ATP SYNTHASE; EPSILON-SUBUNIT; DELTA-SUBUNIT; QUANTITATIVE-DETERMINATION; F0F1-ATP SYNTHASE	In F1F0-ATP synthase, the subunit b(2)delta complex comprises the peripheral stator bound to subunit a in F-0 and to the alpha(3)beta(3) hexamer of F-1. During catalysis, ATP turnover is coupled via an elastic rotary mechanism to proton translocation. Thus, the stator has to withstand the generated rotor torque, which implies tight interactions of the stator and rotor subunits. To quantitatively characterize the contribution of the F-0 subunits to the binding of F-1 within the assembled holoenzyme, the isolated subunit b dimer, ab(2) subcomplex, and fully assembled F-0 complex were specifically labeled with tetramethylrhodamine- 5-maleimide at bCys(64) and functionally reconstituted into liposomes. Proteoliposomes were then titrated with increasing amounts of Cy5-maleimide-labeled F-1 ( at gamma Cys(106)) and analyzed by single-molecule fluorescence resonance energy transfer. The data revealed F-1 dissociation constants of 2.7 nM for the binding of F-0 and 9 - 10 nM for both the ab(2) subcomplex and subunit b dimer. This indicates that both rotor and stator components of F-0 contribute to F-1 binding affinity in the assembled holoenzyme. The subunit c ring plays a crucial role in the binding of F-1 to F-0, whereas subunit a does not contribute significantly.	Univ Stuttgart, Inst Phys, D-70569 Stuttgart, Germany; Univ Osnabruck, Abt Mikrobiol, Fachbereich Biol Chem, D-49069 Osnabruck, Germany; Univ Freiburg, Inst Phys Chem, D-79104 Freiburg, Germany	University of Stuttgart; University Osnabruck; University of Freiburg	Borsch, M (corresponding author), Univ Stuttgart, Inst Phys, Pfaffenwaldring 57, D-70569 Stuttgart, Germany.	m.boersch@physik.uni-stuttgart.de; greie@biologie.uni-osnabrueck.de		Borsch, Michael/0000-0002-0634-2963				AGGELER R, 1992, J BIOL CHEM, V267, P21355; Altendorf K, 2000, J EXP BIOL, V203, P19; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; Borsch M, 1998, FEBS LETT, V437, P251, DOI 10.1016/S0014-5793(98)01247-2; Borsch M, 2002, FEBS LETT, V527, P147, DOI 10.1016/S0014-5793(02)03198-8; Bulygin VV, 2004, J BIOL CHEM, V279, P35616, DOI 10.1074/jbc.M405012200; Diez M, 2004, BIOCHEMISTRY-US, V43, P1054, DOI 10.1021/bi0357098; Diez M, 2004, NAT STRUCT MOL BIOL, V11, P135, DOI 10.1038/nsmb718; Dmitriev O, 1999, J BIOL CHEM, V274, P15598, DOI 10.1074/jbc.274.22.15598; Dunn SD, 2000, J BIOENERG BIOMEMBR, V32, P347, DOI 10.1023/A:1005571818730; DUNN SD, 1992, J BIOL CHEM, V267, P7630; Dunn SD, 1998, J BIOL CHEM, V273, P8646, DOI 10.1074/jbc.273.15.8646; Fillingame RH, 2000, BBA-BIOENERGETICS, V1458, P387, DOI 10.1016/S0005-2728(00)00089-X; Fillingame RH, 2002, BBA-BIOMEMBRANES, V1565, P232, DOI 10.1016/S0005-2736(02)00572-2; Fischer S, 2000, J BIOL CHEM, V275, P30157, DOI 10.1074/jbc.275.39.30157; Fischer S, 1999, FEBS LETT, V457, P327, DOI 10.1016/S0014-5793(99)01060-1; FISCHER S, 1994, EUR J BIOCHEM, V225, P167, DOI 10.1111/j.1432-1033.1994.00167.x; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4709, DOI 10.1021/bi00437a030; Greie JC, 2000, J BIOENERG BIOMEMBR, V32, P357, DOI 10.1023/A:1005523902800; Greie JC, 2000, EUR J BIOCHEM, V267, P3040, DOI 10.1046/j.1432-1327.2000.01327.x; Greie JC, 2004, EUR J BIOCHEM, V271, P3036, DOI 10.1111/j.1432-1033.2004.04235.x; Hasler K, 1999, BIOCHEMISTRY-US, V38, P13759, DOI 10.1021/bi991236m; Hermolin J, 1999, J BIOL CHEM, V274, P17011, DOI 10.1074/jbc.274.24.17011; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IWAMOTO A, 1991, J BIOL CHEM, V266, P16350; Junge W, 1999, P NATL ACAD SCI USA, V96, P4735, DOI 10.1073/pnas.96.9.4735; KAUFFER S, 1991, EUR J BIOCHEM, V202, P1307, DOI 10.1111/j.1432-1033.1991.tb16504.x; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; Long JC, 2002, J BIOL CHEM, V277, P27288, DOI 10.1074/jbc.M202118200; McLachlin DT, 2000, BIOCHEMISTRY-US, V39, P3486, DOI 10.1021/bi992586b; McLachlin DT, 2000, J BIOL CHEM, V275, P17571, DOI 10.1074/jbc.M000375200; Meier T, 2005, SCIENCE, V308, P659, DOI 10.1126/science.1111199; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Panke O, 2001, BIOPHYS J, V81, P1220, DOI 10.1016/S0006-3495(01)75780-3; Rodgers AJW, 1997, J BIOL CHEM, V272, P31058, DOI 10.1074/jbc.272.49.31058; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHNEIDER E, 1984, P NATL ACAD SCI-BIOL, V81, P7279, DOI 10.1073/pnas.81.23.7279; Stalz WD, 2003, J BIOL CHEM, V278, P27068, DOI 10.1074/jbc.M302027200; Turina P, 2003, EMBO J, V22, P418, DOI 10.1093/emboj/cdg073; WATTS SD, 1995, FEBS LETT, V368, P235, DOI 10.1016/0014-5793(95)00658-V; Watts SD, 1996, J BIOL CHEM, V271, P28341, DOI 10.1074/jbc.271.45.28341; Weber J, 2002, J BIOL CHEM, V277, P18390, DOI 10.1074/jbc.M201047200; Weber J, 2004, J BIOL CHEM, V279, P11253, DOI 10.1074/jbc.M312576200; Weber J, 2003, J BIOL CHEM, V278, P13623, DOI 10.1074/jbc.C300061200; Weber J, 2003, FEBS LETT, V545, P61, DOI 10.1016/S0014-5793(03)00394-6; Wilkens S, 1998, NATURE, V393, P29, DOI 10.1038/29908; Yasuda R, 2001, NATURE, V410, P898, DOI 10.1038/35073513; Zhou YT, 1997, P NATL ACAD SCI USA, V94, P10583, DOI 10.1073/pnas.94.20.10583; Zimmermann B, 2005, EMBO J, V24, P2053, DOI 10.1038/sj.emboj.7600682	51	39	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33338	33345		10.1074/jbc.M506251200	http://dx.doi.org/10.1074/jbc.M506251200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16085645	hybrid			2022-12-25	WOS:000232058100031
J	Berzat, AC; Buss, JE; Chenette, EJ; Weinbaum, CA; Shutes, A; Der, CJ; Minden, A; Cox, AD				Berzat, AC; Buss, JE; Chenette, EJ; Weinbaum, CA; Shutes, A; Der, CJ; Minden, A; Cox, AD			Transforming activity of the Rho family GTPase, Wrch-1, a Wnt-regulated Cdc42 homolog, is dependent on a novel carboxyl-terminal palmitoylation motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTORS; PLASMA-MEMBRANE; H-RAS; PROTEIN PALMITOYLATION; BIOLOGICAL-ACTIVITY; FARNESYLTRANSFERASE INHIBITORS; SACCHAROMYCES-CEREVISIAE; GERANYLGERANYLATED RHOB; PALMITATE TURNOVER; POLYBASIC DOMAIN	Wrch-1 is a Rho family GTPase that shares strong sequence and functional similarity with Cdc42. Like Cdc42, Wrch-1 can promote anchorage-independent growth transformation. We determined that activated Wrch-1 also promoted anchorage-dependent growth transformation of NIH 3T3 fibroblasts. Wrch-1 contains a distinct carboxyl-terminal extension not found in Cdc42, suggesting potential differences in subcellular location and function. Consistent with this, we found that Wrch-1 associated extensively with plasma membrane and endosomes, rather than with cytosol and perinuclear membranes like Cdc42. Like Cdc42, Wrch-1 terminates in a CAAX tetrapeptide (where C is cysteine, A is aliphatic amino acid, and X is any amino acid) motif (CCFV), suggesting that Wrch-1 may be prenylated similarly to Cdc42. Most surprisingly, unlike Cdc42, Wrch-1 did not incorporate isoprenoid moieties, and Wrch-1 membrane localization was not altered by inhibitors of protein prenylation. Instead, we showed that Wrch-1 is modified by the fatty acid palmitate, and pharmacologic inhibition of protein palmitoylation caused mislocalization of Wrch-1. Most interestingly, mutation of the second cysteine of the CCFV motif (CCFV > CSFV), but not the first, abrogated both Wrch-1 membrane localization and transformation. These results suggest that Wrch-1 membrane association, subcellular localization, and biological activity are mediated by a novel membrane-targeting mechanism distinct from that of Cdc42 and other isoprenylated Rho family GTPases.	Univ N Carolina, Dept Radiat Oncol, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Iowa State Univ, Dept Biochem Biophys & Mol Phys, Ames, IA 50011 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Iowa State University; Duke University; Columbia University	Cox, AD (corresponding author), Univ N Carolina, Dept Radiat Oncol, 101 Manning Dr,1050 NCCCC,CB 7512, Chapel Hill, NC 27599 USA.	adricox@med.unc.edu		Chenette, Emily/0000-0003-0393-395X; Buss, Janice/0000-0002-8086-265X; Cox, Adrienne D./0000-0002-4901-2454; Der, Channing/0000-0002-7751-2747	NCI NIH HHS [CA103143, CA63071, CA67771, CA51890, CA109550] Funding Source: Medline; NIGMS NIH HHS [GM46372] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F31CA103143, R01CA051890, R01CA109550, U19CA067771, R01CA063071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046372] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; ADAMSON P, 1992, J BIOL CHEM, V267, P20033; Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; Aronheim A, 1998, CURR BIOL, V8, P1125, DOI 10.1016/S0960-9822(98)70468-3; Aspenstrom P, 2004, BIOCHEM J, V377, P327, DOI 10.1042/BJ20031041; Baker TL, 2003, J BIOL CHEM, V278, P19292, DOI 10.1074/jbc.M206956200; Baker TL, 2000, J BIOL CHEM, V275, P22037, DOI 10.1074/jbc.M001813200; Boettner B, 2002, GENE, V286, P155, DOI 10.1016/S0378-1119(02)00426-2; Booden MA, 1999, J BIOL CHEM, V274, P1423, DOI 10.1074/jbc.274.3.1423; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; Chen Z, 2000, J BIOL CHEM, V275, P17974, DOI 10.1074/jbc.C000145200; Chenette EJ, 2005, J BIOL CHEM, V280, P13784, DOI 10.1074/jbc.M411300200; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Cox AD, 2002, CURR OPIN PHARMACOL, V2, P388, DOI 10.1016/S1471-4892(02)00181-9; Drisdel RC, 2004, BIOTECHNIQUES, V36, P276, DOI 10.2144/04362RR02; Du W, 1999, MOL CELL BIOL, V19, P1831; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Finlin BS, 2000, BIOCHEM J, V347, P223, DOI 10.1042/0264-6021:3470223; Fiordalisi JJ, 2001, METHOD ENZYMOL, V332, P3; Fu HW, 1999, RECENT PROG HORM RES, V54, P315; Fukata M, 2004, NEURON, V44, P987, DOI 10.1016/j.neuron.2004.12.005; Geyer M, 1997, CURR OPIN STRUC BIOL, V7, P786, DOI 10.1016/S0959-440X(97)80147-9; Gomes AQ, 2003, MOL BIOL CELL, V14, P1882, DOI 10.1091/mbc.E02-10-0639; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Huang K, 2004, NEURON, V44, P977, DOI 10.1016/j.neuron.2004.11.027; Ivanchenko M, 2000, PLANT J, V24, P79, DOI 10.1046/j.1365-313x.2000.00855.x; Joyce PL, 2003, CANCER RES, V63, P7959; KHOSRAVIFAR R, 1992, J BIOL CHEM, V267, P24363; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Lavy M, 2002, PLANT CELL, V14, P2431, DOI 10.1105/tpc.005561; Lebowitz PF, 1997, J BIOL CHEM, V272, P16093, DOI 10.1074/jbc.272.26.16093; Lee CHJ, 1996, J NEUROSCI, V16, P6784; Linder ME, 2003, BIOCHEMISTRY-US, V42, P4311, DOI 10.1021/bi034159a; Linder ME, 2004, J CELL SCI, V117, P521, DOI 10.1242/jcs.00989; Magee T, 2005, CURR OPIN CELL BIOL, V17, P190, DOI 10.1016/j.ceb.2005.02.003; MAGUIRE J, 1994, SCIENCE, V265, P241, DOI 10.1126/science.7912851; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; MITCHELL DA, 1994, J BIOL CHEM, V269, P21540; Moon SY, 2003, TRENDS CELL BIOL, V13, P13, DOI 10.1016/S0962-8924(02)00004-1; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Ridley AJ, 2004, BREAST CANCER RES TR, V84, P13, DOI 10.1023/B:BREA.0000018423.47497.c6; Rocks O, 2005, SCIENCE, V307, P1746, DOI 10.1126/science.1105654; Rotblat B, 2004, MOL CELL BIOL, V24, P6799, DOI 10.1128/MCB.24.15.6799-6810.2004; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Saras J, 2004, EXP CELL RES, V299, P356, DOI 10.1016/j.yexcr.2004.05.029; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Schweizer A, 2000, J BIOL CHEM, V275, P29694, DOI 10.1074/jbc.M000571200; Sebti SM, 2000, ONCOGENE, V19, P6584, DOI 10.1038/sj.onc.1204146; Shutes A, 2004, CURR BIOL, V14, P2052, DOI 10.1016/j.cub.2004.11.011; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Solski PA, 2002, CELL GROWTH DIFFER, V13, P363; Symons M, 2000, TRENDS CELL BIOL, V10, P415, DOI 10.1016/S0962-8924(00)01832-8; Tao WK, 2001, GENE DEV, V15, P1796, DOI 10.1101/gad.894301; VAN AL, 1997, GENE DEV, V11, P2295; van Golen KL, 2000, CANCER RES, V60, P5832; Wang L, 2003, J BIOL CHEM, V278, P44617, DOI 10.1074/jbc.M308929200; Watson RT, 2003, MOL CELL BIOL, V23, P961, DOI 10.1128/MCB.23.3.961-974.2003; Watson RT, 2001, J CELL BIOL, V154, P829, DOI 10.1083/jcb.200102078; Webb Y, 2000, J BIOL CHEM, V275, P261, DOI 10.1074/jbc.275.1.261; Wennerberg K, 2004, J CELL SCI, V117, P1301, DOI 10.1242/jcs.01118; Whitehead IP, 1998, MOL CELL BIOL, V18, P4689, DOI 10.1128/MCB.18.8.4689; Willumsen BM, 1996, ONCOGENE, V13, P1901; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9; ZIMAN M, 1993, MOL BIOL CELL, V4, P1307, DOI 10.1091/mbc.4.12.1307; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	73	57	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					33055	33065		10.1074/jbc.M507362200	http://dx.doi.org/10.1074/jbc.M507362200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16046391	hybrid, Green Published			2022-12-25	WOS:000231920300060
J	Gonzalez-Polo, RA; Carvalho, G; Braun, T; Decaudin, D; Fabre, C; Larochette, N; Perfettini, JL; Djavaheri-Mergny, M; Youlyouz-Marfak, I; Codogno, P; Raphael, M; Feuillard, J; Kroemer, G				Gonzalez-Polo, RA; Carvalho, G; Braun, T; Decaudin, D; Fabre, C; Larochette, N; Perfettini, JL; Djavaheri-Mergny, M; Youlyouz-Marfak, I; Codogno, P; Raphael, M; Feuillard, J; Kroemer, G			PK11195 potently sensitizes to apoptosis induction independently from the peripheral benzodiazepin receptor	ONCOGENE			English	Article						autophagy; caspase; Bcl-2; NF-kappaB	DEPENDENT ANION CHANNEL; CELL-CYCLE ARREST; MITOCHONDRIAL-MEMBRANE PERMEABILIZATION; CANCER-CELLS; LEUKEMIA-CELLS; LIGAND; BCL-2; RESISTANCE; LONIDAMINE; INHIBITOR	1-(2-Chlorophenyl-N-methylpropyl)-3-isoquinolinecarboxamide (PK11195) is a prototypic ligand of the peripheral benzodiazepine receptor (PBR), a mitochondrial outer membrane protein. PK11195 can be used to chemosensitize tumor cells to a variety of chemotherapeutic agents, both in vitro and in vivo. PK11195 has been suggested to exert this effect via inhibition of the multiple drug resistance (MDR) pump and by direct mitochondrial effects which could be mediated by the PBR. Here, we established a model system in which PK11195 and another PBR ligand, 7-chloro-5-(4-chlorophenyl)- 1,3-dihydro-1-methyl-2H-1,4-benzodiazepin-2- one (Ro5-4864), sensitize to nutrient depletion-induced cell death. In this MDR-independent model, PK11195 and Ro5-4864 are fully active even when the PBR is knocked down by small interfering RNA. Cells that lack PBR possess low-affinity binding sites for PK11195 and Ro5-4864. The starvation-sensitizing effects of PK11195 are not due to a modulation of the adaptive response of starved cells, namely autophagy and NF-kappa B activation. Rather, it appears that the combination of PK11195 with autophagy or NF-kappa B inhibitors has a potent synergistic death-inducing effect. Starved cells treated with PK11195 exhibit characteristics of apoptosis, including loss of the mitochondrial transmembrane potential, mitochondrial cytochrome c release, caspase activation and chromatin condensation. Accordingly, stabilization of mitochondria by overexpression of Bcl-2 or expression of the viral mitochondrial inhibitor (vMIA) from cytomegalovirus inhibits cell death induced by PK11195 plus starvation. Thus, PK11195 potently sensitizes to apoptosis via a pathway that involves mitochondria, yet does not involve the PBR.	Inst Gustave Roussy, CNRS, UMR 8125, F-94805 Villejuif, France; Inst Curie, Dept Hematol, F-75005 Paris, France; Inst Andre Lwoff, INSERM, U504, F-94807 Villejuif, France; CNRS, UMR 6101, Limoges, France; Fac Med, Hematol Lab, Limoges, France; CHU Dupuytren, Limoges, France; CHU Kremlin Bicetre, U473, Serv Hematol Biol, Le Kremlin Bicetre, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CHU Limoges; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, UMR 8125, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	Codogno, Patrice/G-1384-2013; González-Polo, Rosa A./I-6076-2016; Djavaheri-Mergny, Mojgan/N-6315-2017; KROEMER, Guido/B-4263-2013; Braun, Thorsten/GRJ-8918-2022; LAROCHETTE, Nathanael/R-4298-2017; Djavaheri-Mergny, Mojgan/L-3890-2019; PERFETTINI, Jean-Luc/N-4699-2017; Kroemer, Guido/AAY-9859-2020; Feuillard, Jean/O-8587-2016	Codogno, Patrice/0000-0002-5492-3180; González-Polo, Rosa A./0000-0002-0163-2953; Djavaheri-Mergny, Mojgan/0000-0003-4893-6505; KROEMER, Guido/0000-0002-9334-4405; LAROCHETTE, Nathanael/0000-0002-7936-678X; Djavaheri-Mergny, Mojgan/0000-0003-4893-6505; PERFETTINI, Jean-Luc/0000-0002-2427-2604; Youlyouz-Marfak, Ibtissam/0000-0002-9853-1592; Feuillard, Jean/0000-0001-6223-2454				ANSSEAU M, 1991, PHARMACOPSYCHIATRY, V24, P8, DOI 10.1055/s-2007-1014425; Banker DE, 2002, LEUKEMIA RES, V26, P91, DOI 10.1016/S0145-2126(01)00112-6; Baran-Marszak F, 2004, BLOOD, V104, P2475, DOI 10.1182/blood-2003-10-3508; BARON U, 1995, NUCLEIC ACIDS RES, V23, P3605, DOI 10.1093/nar/23.17.3605; Belzacq AS, 2003, CANCER RES, V63, P541; Belzacq AS, 2001, ONCOGENE, V20, P7579, DOI 10.1038/sj.onc.1204953; Boitano A, 2003, CANCER RES, V63, P6870; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Boya P, 2003, ONCOGENE, V22, P3927, DOI 10.1038/sj.onc.1206622; Carayon P, 1996, BLOOD, V87, P3170, DOI 10.1182/blood.V87.8.3170.bloodjournal8783170; Casellas P, 2002, NEUROCHEM INT, V40, P475, DOI 10.1016/S0197-0186(01)00118-8; Castedo M, 2002, J EXP MED, V196, P1121, DOI 10.1084/jem.20021758; Chauhan D, 2004, BLOOD, V104, P2458, DOI 10.1182/blood-2004-02-0547; Chen J, 2002, MOL CANCER THER, V1, P981; Cregan SP, 2002, J CELL BIOL, V158, P507, DOI 10.1083/jcb.200202130; Decaudin D, 2004, ANTI-CANCER DRUG, V15, P737, DOI 10.1097/00001813-200409000-00001; Decaudin D, 2002, CANCER RES, V62, P1388; Fennell DA, 2001, BRIT J CANCER, V84, P1397, DOI 10.1054/bjoc.2001.1788; FERRY A, 1989, FUNDAM CLIN PHARM, V3, P383, DOI 10.1111/j.1472-8206.1989.tb00679.x; Feuillard J, 2000, BLOOD, V95, P2068, DOI 10.1182/blood.V95.6.2068.2068; Galiegue S, 2004, CLIN CANCER RES, V10, P2058, DOI 10.1158/1078-0432.CCR-03-0988; Goldmacher VS, 1999, P NATL ACAD SCI USA, V96, P12536, DOI 10.1073/pnas.96.22.12536; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Harborth J, 2001, J CELL SCI, V114, P4557; Hirsch T, 1998, EXP CELL RES, V241, P426, DOI 10.1006/excr.1998.4084; Jakubikova J, 2002, NEOPLASMA, V49, P231; Jorda EG, 2005, APOPTOSIS, V10, P91, DOI 10.1007/s10495-005-6064-9; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Larochette N, 1999, EXP CELL RES, V249, P413, DOI 10.1006/excr.1999.4519; Lebedeva IV, 2003, CANCER RES, V63, P8138; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Maaser K, 2005, CLIN CANCER RES, V11, P1751, DOI 10.1158/1078-0432.CCR-04-1955; MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170; Miccoli L, 1998, J NATL CANCER I, V90, P1400, DOI 10.1093/jnci/90.18.1400; Miccoli L, 1998, CANCER RES, V58, P5777; Muscarella DE, 2003, TOXICOL SCI, V74, P66, DOI 10.1093/toxsci/kfg052; Okaro AC, 2002, GUT, V51, P556, DOI 10.1136/gut.51.4.556; Pattingre S, 2003, J BIOL CHEM, V278, P16667, DOI 10.1074/jbc.M210998200; Poncet D, 2004, J BIOL CHEM, V279, P22605, DOI 10.1074/jbc.M308408200; Ravagnan L, 1999, ONCOGENE, V18, P2537, DOI 10.1038/sj.onc.1202625; Rochard P, 2004, GENE EXPRESSION, V12, P13, DOI 10.3727/000000004783992170; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Shimizu S, 2001, J CELL BIOL, V152, P237, DOI 10.1083/jcb.152.2.237; SNYDER SH, 1990, NEUROCHEM RES, V15, P119, DOI 10.1007/BF00972201; Sutter AP, 2004, J HEPATOL, V41, P799, DOI 10.1016/j.jhep.2004.07.015; Sutter AP, 2003, BRIT J CANCER, V89, P564, DOI 10.1038/sj.bjc.6601125; Vieira HLA, 2000, CELL DEATH DIFFER, V7, P1146, DOI 10.1038/sj.cdd.4400778; Walter RB, 2004, BLOOD, V103, P4276, DOI 10.1182/blood-2003-11-3825; Weisinger G, 2004, BIOCHEMISTRY-US, V43, P12315, DOI 10.1021/bi030251v	50	83	87	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2005	24	51					7503	7513		10.1038/sj.onc.1208907	http://dx.doi.org/10.1038/sj.onc.1208907			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	984VQ	16091749				2022-12-25	WOS:000233333800001
J	Hamdane, D; Kiger, L; Hoa, GHB; Dewilde, S; Uzan, J; Burmester, T; Hankeln, T; Moens, L; Marden, MC				Hamdane, D; Kiger, L; Hoa, GHB; Dewilde, S; Uzan, J; Burmester, T; Hankeln, T; Moens, L; Marden, MC			High pressure enhances hexacoordination in neuroglobin and other globins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON-MONOXIDE; LIGAND-BINDING; MYOGLOBIN; HEMOPROTEINS; HEMOGLOBIN; DYNAMICS; OXYGEN; STATE; PHOTOLYSIS; MECHANISM	The techniques of high applied pressure and flash photolysis have been combined to study ligand rebinding to neuroglobin (Ngb) and tomato Hb, globins that may display a His-Fe-His hexacoordination in the absence of external ligands. High pressure induces a moderate decrease in the His association rate and a large decrease in His dissociation rate, thus leading to an enhancement of the overall His affinity. The overall structural difference between penta- and hexacoordinated globins may be rather small and can be overcome by external modifications such as high pressure. Over the pressure range 0.1 - 700 MPa ( 7 kbar), the globins may show a loss of over a factor of 100 in the amplitude of the bimolecular rebinding phase after photodissociation. The kinetic data show that pressure induces a moderate increase of the rate for ligand binding from the correlated pair state ( just after photodissociation) and a large ( factor of 1000) decrease in rate for migration through the protein. The effect on the ligand migration phase was similar for both the external ligands ( such as oxygen) as for the internal ( histidine) ligand, suggesting the dominant role of protein fluctuations, rather than specific chemical barriers. Thus high pressure efficiently closes the protein migration channels; however, contrary to the effect of high viscosity, high pressure induces a greater decrease in rate for ligand migration toward the exterior ( heme to the solvent) versus inward migration, as if the presence of the ligand itself induces an additional steric constraint.	INSERM, U473, F-94275 Le Kremlin Bicetre, France; Univ Antwerp, Dept Biomed Sci, B-2610 Antwerp, Belgium; Johannes Gutenberg Univ Mainz, Inst Zool, D-55099 Mainz, Germany; Johannes Gutenberg Univ Mainz, Inst Mol Genet, D-55099 Mainz, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm); University of Antwerp; Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz	Marden, MC (corresponding author), INSERM, U473, 78 Rue Gen Leclerc, F-94275 Le Kremlin Bicetre, France.	marden@kb.inserm.fr	Burmester, Thorsten/I-7225-2013; Marden, Michael/AAA-5923-2020; Kiger, Laurent/Q-1686-2018; Marden, Michael C/G-3139-2012	Burmester, Thorsten/0000-0002-5772-7863; Marden, Michael C/0000-0002-5254-6385				ADACHI S, 1989, J BIOL CHEM, V264, P18896; ALDEN RG, 1989, J BIOL CHEM, V264, P1933; ArredondoPeter R, 1997, PLANT PHYSIOL, V115, P1259, DOI 10.1104/pp.115.3.1259; AUSTIN RH, 1975, BIOCHEMISTRY-US, V14, P5355, DOI 10.1021/bi00695a021; BASHFORD D, 1987, J MOL BIOL, V196, P199, DOI 10.1016/0022-2836(87)90521-3; BEECE D, 1980, BIOCHEMISTRY-US, V19, P5147, DOI 10.1021/bi00564a001; Burmester T, 2002, MOL BIOL EVOL, V19, P416, DOI 10.1093/oxfordjournals.molbev.a004096; Burmester T, 2000, NATURE, V407, P520, DOI 10.1038/35035093; Couture M, 2001, J BIOL CHEM, V276, P36377, DOI 10.1074/jbc.M103907200; Dewilde S, 2001, J BIOL CHEM, V276, P38949, DOI 10.1074/jbc.M106438200; Fenimore PW, 2002, P NATL ACAD SCI USA, V99, P16047, DOI 10.1073/pnas.212637899; FRAUENFELDER H, 1990, J PHYS CHEM-US, V94, P1024, DOI 10.1021/j100366a002; Hamdane D, 2003, J BIOL CHEM, V278, P51713, DOI 10.1074/jbc.M309396200; HASINOFF BB, 1974, BIOCHEMISTRY-US, V13, P3111, DOI 10.1021/bi00712a017; KEILIN J, 1949, BIOCHEM J, V45, P440, DOI 10.1042/bj0450440; MARDEN MC, 1988, BIOCHEMISTRY-US, V27, P1659, DOI 10.1021/bi00405a041; Mentre P, 2001, INT REV CYTOL, V201, P1, DOI 10.1016/S0074-7696(01)01001-4; MORISHIMA I, 1980, BIOCHEMISTRY-US, V19, P1569, DOI 10.1021/bi00549a006; NEUMAN RC, 1973, J PHYS CHEM-US, V77, P2687, DOI 10.1021/j100640a025; Pesce A, 2003, STRUCTURE, V11, P1087, DOI 10.1016/S0969-2126(03)00166-7; TAUBE DJ, 1990, J AM CHEM SOC, V112, P6880, DOI 10.1021/ja00175a023; Teeter MM, 2004, PROTEIN SCI, V13, P313, DOI 10.1110/ps.03334304; Trent JT, 2002, J BIOL CHEM, V277, P19538, DOI 10.1074/jbc.M201934200; UNNO M, 1991, BIOCHEMISTRY-US, V30, P10679, DOI 10.1021/bi00108a011; UNNO M, 1990, BIOCHEMISTRY-US, V29, P10199, DOI 10.1021/bi00496a007; UNNO M, 1994, BIOCHEMISTRY-US, V33, P9762, DOI 10.1021/bi00198a047; Uzan J, 2004, BIOPHYS J, V87, P1196, DOI 10.1529/biophysj.104.042168; Vallone B, 2004, PROTEINS, V56, P85, DOI 10.1002/prot.20113; Vallone B, 2004, P NATL ACAD SCI USA, V101, P17351, DOI 10.1073/pnas.0407633101; VEDAM R, 1968, J ACOUST SOC AM, V43, P108, DOI 10.1121/1.1910740; Wakasugi K, 2003, J BIOL CHEM, V278, P36505, DOI 10.1074/jbc.M305519200	31	26	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36809	36814		10.1074/jbc.M506253200	http://dx.doi.org/10.1074/jbc.M506253200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16100391	hybrid			2022-12-25	WOS:000232901800035
J	Hawthorne, R; Lynch, JW				Hawthorne, R; Lynch, JW			A picrotoxin-specific conformational change in the glycine receptor M2-M3 loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHANNEL-LINING RESIDUES; NICOTINIC ACETYLCHOLINE-RECEPTOR; BETA-SUBUNIT; SURFACE ACCESSIBILITY; CHLORIDE CHANNELS; IDENTIFICATION; ACTIVATION; PORE; MECHANISM; BLOCK	The external loop linking the M2 and M3 transmembrane domains is crucial for coupling agonist binding to channel gating in the glycine receptor chloride channel (GlyR). A substituted cysteine accessibility scan previously showed that glycine activation increased the surface accessibility of 6 contiguous residues (Arg(271) Lys(276)) toward the N-terminal end of the homomeric alpha 1 GlyR M2 - M3 loop. In the present study we used a similar approach to determine whether the allosteric antagonist, picrotoxin, could impose conformational changes to this domain that cannot be induced by varying agonist concentrations alone. Picrotoxin slowed the reaction rate of a sulfhydryl-containing compound ( MTSET) with A272C, S273C, and L274C. Before interpreting this as a picrotoxin-specific conformational change, it was necessary to eliminate the possibility of steric competition between picrotoxin and MTSET. Accordingly, we showed that picrotoxin and the structurally unrelated blocker, bilobalide, were both trapped in the R271C GlyR in the closed state and that a point mutation to the pore-lining Thr(6') residue abolished inhibition by both compounds. We also demonstrated that the picrotoxin dissociation rate was linearly related to the channel open probability. These observations constitute a strong case for picrotoxin binding in the pore. We thus conclude that the picrotoxin-specific effects on the M2 - M3 loop are mediated allosterically. This suggests that the M2 - M3 loop responds differently to the occupation of different binding sites.	Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia	University of Queensland	Lynch, JW (corresponding author), Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia.	j.lynch@uq.edu.au	Lynch, Joseph/C-8636-2009					AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; ARMSTRONG CM, 1971, J GEN PHYSIOL, V58, P413, DOI 10.1085/jgp.58.4.413; AUERBACH A, 2003, SCI STKE, pRE11; Barry PH, 2005, IEEE T NANOBIOSCI, V4, P70, DOI 10.1109/TNB.2004.842497; Beato M, 2002, J GEN PHYSIOL, V119, P443, DOI 10.1085/jgp.20028530; Chang YC, 2002, NAT NEUROSCI, V5, P1163, DOI 10.1038/nn926; Dibas MI, 2002, J BIOL CHEM, V277, P9112, DOI 10.1074/jbc.M111356200; Etter A, 1999, J NEUROCHEM, V72, P318, DOI 10.1111/jnc.1999.72.1.318; FFRENCHCONSTANT RH, 1993, NATURE, V363, P449, DOI 10.1038/363449a0; Grosman C, 2000, NATURE, V403, P773, DOI 10.1038/35001586; GURLEY D, 1995, RECEPTOR CHANNEL, V3, P13; Holmgren M, 1997, J GEN PHYSIOL, V109, P527, DOI 10.1085/jgp.109.5.527; Horenstein J, 2001, NAT NEUROSCI, V4, P477, DOI 10.1038/87425; Ivic L, 2003, J BIOL CHEM, V278, P49279, DOI 10.1074/jbc.M304034200; Karlin A, 2002, NAT REV NEUROSCI, V3, P102, DOI 10.1038/nrn731; Kash TL, 2004, BIOCHEM SOC T, V32, P540, DOI 10.1042/BST0320540; Kash TL, 2003, NATURE, V421, P272, DOI 10.1038/nature01280; Kondratskaya EL, 2002, NEUROCHEM INT, V40, P647, DOI 10.1016/S0197-0186(01)00109-7; Legendre P, 1997, J NEUROPHYSIOL, V77, P2400, DOI 10.1152/jn.1997.77.5.2400; Legendre P, 2001, CELL MOL LIFE SCI, V58, P760, DOI 10.1007/PL00000899; Lynch JW, 1997, EMBO J, V16, P110, DOI 10.1093/emboj/16.1.110; LYNCH JW, 1995, J BIOL CHEM, V270, P13799, DOI 10.1074/jbc.270.23.13799; Lynch JW, 2001, J NEUROSCI, V21, P2589, DOI 10.1523/JNEUROSCI.21-08-02589.2001; Lynch JW, 2004, PHYSIOL REV, V84, P1051, DOI 10.1152/physrev.00042.2003; MILLER C, 1987, BIOPHYS J, V52, P123, DOI 10.1016/S0006-3495(87)83196-X; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; NEWLAND CF, 1992, J PHYSIOL-LONDON, V447, P191, DOI 10.1113/jphysiol.1992.sp018998; Panicker S, 2004, J BIOL CHEM, V279, P28149, DOI 10.1074/jbc.M403545200; Panicker S, 2002, J NEUROSCI, V22, P1629, DOI 10.1523/JNEUROSCI.22-05-01629.2002; Phillips LR, 2003, J GEN PHYSIOL, V122, P795, DOI 10.1085/jgp.200308953; PRIBILLA I, 1992, EMBO J, V11, P4305, DOI 10.1002/j.1460-2075.1992.tb05529.x; Qian HH, 2005, MOL PHARMACOL, V67, P470, DOI 10.1124/mol.104.003996; RUNDSTROM N, 1994, P NATL ACAD SCI USA, V91, P8950, DOI 10.1073/pnas.91.19.8950; Shan Q, 2002, J BIOL CHEM, V277, P44845, DOI 10.1074/jbc.M208647200; Shan Q, 2001, J NEUROCHEM, V76, P1109, DOI 10.1046/j.1471-4159.2001.00124.x; Unwin N, 2003, FEBS LETT, V555, P91, DOI 10.1016/S0014-5793(03)01084-6; Unwin N, 2005, J MOL BIOL, V346, P967, DOI 10.1016/j.jmb.2004.12.031; WANG TL, 1995, P NATL ACAD SCI USA, V92, P11751, DOI 10.1073/pnas.92.25.11751; Wilson GG, 1998, NEURON, V20, P1269, DOI 10.1016/S0896-6273(00)80506-1; Xu M, 1995, BIOPHYS J, V69, P1858, DOI 10.1016/S0006-3495(95)80056-1; Xu M, 1996, J GEN PHYSIOL, V107, P195, DOI 10.1085/jgp.107.2.195; YOON KW, 1993, J PHYSIOL-LONDON, V464, P423, DOI 10.1113/jphysiol.1993.sp019643; ZHANG DX, 1995, P NATL ACAD SCI USA, V92, P11756, DOI 10.1073/pnas.92.25.11756; Zhorov BS, 2000, BIOPHYS J, V78, P1786, DOI 10.1016/S0006-3495(00)76729-4	44	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35836	35843		10.1074/jbc.M506645200	http://dx.doi.org/10.1074/jbc.M506645200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16109711	hybrid			2022-12-25	WOS:000232726900010
J	Navaneetham, D; Jin, L; Pandey, P; Strickler, JE; Babine, RE; Abdel-Meguid, SS; Walsh, PN				Navaneetham, D; Jin, L; Pandey, P; Strickler, JE; Babine, RE; Abdel-Meguid, SS; Walsh, PN			Structural and mutational analyses of the molecular interactions between the catalytic domain of factor XIa and the Kunitz protease inhibitor domain of protease nexin 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; COAGULATION-FACTOR-XIA; PANCREATIC TRYPSIN-INHIBITOR; ALZHEIMERS-DISEASE; HUMAN-PLATELETS; BLOOD-COAGULATION; BINDING-SITE; ACTIVATED PLATELETS; CRYSTAL-STRUCTURES; HAGEMAN-FACTOR	Factor XIa (FXIa) is a serine protease important for initiating the intrinsic pathway of blood coagulation. Protease nexin 2 (PN2) is a Kunitz-type protease inhibitor secreted by activated platelets and a physiologically important inhibitor of FXIa. Inhibition of FXIa by PN2 requires interactions between the two proteins that are confined to the catalytic domain of the enzyme and the Kunitz protease inhibitor (KPI) domain of PN2. Recombinant PN2KPI and a mutant form of the FXI catalytic domain (FXIac) were expressed in yeast, purified to homogeneity, co-crystallized, and the structure of the complex was solved at 2.6 angstrom ( Protein Data Bank code 1ZJD). In this complex, PN2KPI has a characteristic, disulfide-stabilized double loop structure that fits into the FXIac active site. To determine the contributions of residues within PN2KPI to its inhibitory activity, selected point mutations in PN2KPI loop 1 (11)TGPCRAMISR(20) and loop 2 (34)FYGGC(38) were tested for their ability to inhibit FXIa. The P1 site mutation R15A completely abolished its ability to inhibit FXIa. IC50 values for the wild type protein and the remaining mutants were as follows: PN2KPI WT, 1.28 nM; P13A, 5.92 nM; M17A, 1.62 nM; S19A, 1.86 nM; R20A, 5.67 nM; F34A, 9.85 nM. The IC50 values for the M17A and S19A mutants were not significantly different from those obtained with wild type PN2KPI. These functional studies and activated partial thromboplastin time analysis validate predictions made from the PN2KPI-FXIac co-crystal structure and implicate PN2KPI residues, in descending order of importance, Arg(15), Phe(34), Pro(13), and Arg(20) in FXIa inhibition by PN2KPI.	Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Med, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; Daiichi Asubio Med Res Labs LLC, Cambridge, MA 02139 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Jin, L (corresponding author), 8 Harris Ave, Wellesley, MA 02481 USA.	leijin05@yahoo.com; pnw@temple.edu			NHLBI NIH HHS [HL46213, HL74124, HL70683, HL64943] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL074124, R01HL046213, P01HL064943, R01HL070683] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Badellino KO, 2000, BIOCHEMISTRY-US, V39, P4769, DOI 10.1021/bi9925468; Badellino KO, 2001, BIOCHEMISTRY-US, V40, P7569, DOI 10.1021/bi0027433; Baglia FA, 2000, J BIOL CHEM, V275, P20514, DOI 10.1074/jbc.M000464200; Baglia FA, 2003, J BIOL CHEM, V278, P21744, DOI 10.1074/jbc.M212991200; Baglia FA, 2002, J BIOL CHEM, V277, P1662, DOI 10.1074/jbc.M108319200; BAGLIA FA, 1995, J BIOL CHEM, V270, P6734, DOI 10.1074/jbc.270.12.6734; Baglia FA, 1996, J BIOL CHEM, V271, P3652; Baglia FA, 1998, BIOCHEMISTRY-US, V37, P2271, DOI 10.1021/bi972113+; Baird TR, 2002, J BIOL CHEM, V277, P38462, DOI 10.1074/jbc.M205902200; BUSH AI, 1990, J BIOL CHEM, V265, P15977; DAMUS PS, 1973, NATURE, V246, P355, DOI 10.1038/246355a0; DENNIS MS, 1995, J BIOL CHEM, V270, P25411, DOI 10.1074/jbc.270.43.25411; DENNIS MS, 1994, J BIOL CHEM, V269, P22137; Evin G, 2003, J NEUROSCI RES, V74, P386, DOI 10.1002/jnr.10745; FORBES CD, 1970, J LAB CLIN MED, V76, P809; GREENGARD JS, 1986, BIOCHEMISTRY-US, V25, P3884, DOI 10.1021/bi00361a022; Grzesiak A, 2000, J BIOL CHEM, V275, P33346, DOI 10.1074/jbc.M006085200; HECK LW, 1974, J EXP MED, V140, P1615, DOI 10.1084/jem.140.6.1615; Ho DH, 2000, BIOCHEMISTRY-US, V39, P316, DOI 10.1021/bi991851q; HYNES TR, 1990, BIOCHEMISTRY-US, V29, P10018, DOI 10.1021/bi00495a002; Jin L, 2005, J BIOL CHEM, V280, P4704, DOI 10.1074/jbc.M411309200; Knauer DJ, 2000, J BIOL CHEM, V275, P37340, DOI 10.1074/jbc.M003909200; LI QX, 1995, J BIOL CHEM, V270, P14140, DOI 10.1074/jbc.270.23.14140; LI QX, 1994, BLOOD, V84, P133, DOI 10.1182/blood.V84.1.133.133; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Radisky ES, 2002, P NATL ACAD SCI USA, V99, P10316, DOI 10.1073/pnas.112332899; SAITO H, 1979, P NATL ACAD SCI USA, V76, P2013, DOI 10.1073/pnas.76.4.2013; Scandura JM, 1997, BIOCHEMISTRY-US, V36, P412, DOI 10.1021/bi9612576; Scheidig AJ, 1997, PROTEIN SCI, V6, P1806, DOI 10.1002/pro.5560060902; SCOTT CF, 1982, J CLIN INVEST, V69, P844, DOI 10.1172/JCI110524; SINHA S, 1991, J BIOL CHEM, V266, P21011; SMITH RP, 1990, SCIENCE, V248, P1126, DOI 10.1126/science.2111585; Song HK, 1998, J MOL BIOL, V275, P347, DOI 10.1006/jmbi.1997.1469; vandeLocht A, 1997, EMBO J, V16, P2977, DOI 10.1093/emboj/16.11.2977; VANNOSTRAND WE, 1995, J BIOL CHEM, V270, P22827, DOI 10.1074/jbc.270.39.22827; VANNOSTRAND WE, 1990, SCIENCE, V248, P745, DOI 10.1126/science.2110384; VANNOSTRAND WE, 1990, J BIOL CHEM, V265, P9591; Walsh P. N., 2001, HEMOSTASIS THROMBOSI, P191; WALSH PN, 1981, BLOOD, V57, P106; Wuillemin WA, 1996, J BIOL CHEM, V271, P12913, DOI 10.1074/jbc.271.22.12913; Zhang E, 1999, J MOL BIOL, V285, P2089, DOI 10.1006/jmbi.1998.2452; Zhang Y, 1997, J BIOL CHEM, V272, P26139, DOI 10.1074/jbc.272.42.26139	43	53	63	5	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36165	36175		10.1074/jbc.M504990200	http://dx.doi.org/10.1074/jbc.M504990200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16085935	hybrid			2022-12-25	WOS:000232726900048
J	McNicoll, F; Muller, M; Cloutier, S; Boilard, N; Rochette, A; Dube, M; Papadopoulou, B				McNicoll, F; Muller, M; Cloutier, S; Boilard, N; Rochette, A; Dube, M; Papadopoulou, B			Distinct 3 '-untranslated region elements regulate stage-specific mRNA accumulation and translation in Leishmania	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILY ENCODING AMASTIN; 60S RIBOSOMAL-SUBUNIT; IN-VITRO MODEL; GENE-EXPRESSION; UNTRANSLATED REGIONS; AXENIC AMASTIGOTES; DONOVANI; PROTEIN; RESISTANCE; INFANTUM	We recently characterized a large developmentally regulated gene family in Leishmania encoding the amastin surface proteins. While studying the regulation of these genes, we identified a region of 770 nucleotides (nt) within the 2055-nt 3'-untranslated region (3'-UTR) that regulates stage-specific gene expression at the level of translation. An intriguing feature of this 3'-UTR regulatory region is the presence of a similar to 450-nt element that is highly conserved among several Leishmania mRNAs. Here we show, using a luciferase reporter system and polysome profiling experiments, that the 450-nt element stimulates translation initiation of the amastin mRNA in response to heat shock, which is the main environmental change that the parasite encounters upon its entry into the mammalian host. Deletional analyses depicted a second region of similar to 100 nucleotides located at the 3'-end of several amastin transcripts, which also activates translation in response to elevated temperature. Both 3'-UTR regulatory elements act in an additive manner to stimulate amastin mRNA translation. In addition, we show that acidic pH encountered in the phagolysosomes of macrophages, the location of parasitic differentiation, triggers the accumulation of amastin transcripts by a distinct mechanism that is independent of the 450-nt and 100-nt elements. Overall, these important findings support the notion that stage-specific post-transcriptional regulation of the amastin mRNAs in Leishmania is complex and involves the coordination of distinct mechanisms controlling mRNA stability and translation that are independently triggered by key environmental signals inducing differentiation of the parasite within macrophages.	Univ Laval, Res Ctr, Ctr Hosp, Infect Dis Res Ctr, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Fac Med, Dept Med Biol, Quebec City, PQ G1V 4G2, Canada	Laval University; Laval University	Papadopoulou, B (corresponding author), Univ Laval, Res Ctr, Ctr Hosp Univ Quebec, Infect Dis Res Ctr,Res Ctr,Ctr Hosp, 2705 Laurier Blvd, Quebec City, PQ G1V 4G2, Canada.	barbara.papadopoulou@crchul.ulaval.ca	Müller-McNicoll, Michaela/AAC-6125-2019	Müller-McNicoll, Michaela/0000-0002-7174-8310				Akopyants NS, 2004, MOL BIOCHEM PARASIT, V136, P71, DOI 10.1016/j.molbiopara.2004.03.002; ALY R, 1994, NUCLEIC ACIDS RES, V22, P2922, DOI 10.1093/nar/22.15.2922; Ashford RW, 2000, INT J PARASITOL, V30, P1269, DOI 10.1016/S0020-7519(00)00136-3; ASHFORD RW, 1992, PARASITOL TODAY, V8, P104, DOI 10.1016/0169-4758(92)90249-2; Barak E, 2005, MOL BIOCHEM PARASIT, V141, P99, DOI 10.1016/j.molbiopara.2005.02.004; Barends S, 2004, J VIROL, V78, P4003, DOI 10.1128/JVI.78.8.4003-4010.2004; Barends S, 2003, CELL, V112, P123, DOI 10.1016/S0092-8674(02)01256-4; BATES PA, 1994, PARASITOLOGY, V108, P1, DOI 10.1017/S0031182000078458; Bente M, 2003, PROTEOMICS, V3, P1811, DOI 10.1002/pmic.200300462; Boucher N, 2002, J BIOL CHEM, V277, P19511, DOI 10.1074/jbc.M200500200; Charest H, 1996, J BIOL CHEM, V271, P17081, DOI 10.1074/jbc.271.29.17081; Clayton CE, 2002, EMBO J, V21, P1881, DOI 10.1093/emboj/21.8.1881; Clemens MJ, 2001, J CELL MOL MED, V5, P221, DOI 10.1111/j.1582-4934.2001.tb00157.x; Diehl S, 2002, MOL BIOCHEM PARASIT, V123, P115, DOI 10.1016/S0166-6851(02)00138-X; El Fadili K, 2005, ANTIMICROB AGENTS CH, V49, P1988, DOI 10.1128/AAC.49.5.1988-1993.2005; El Fakhry Y, 2002, PROTEOMICS, V2, P1007, DOI 10.1002/1615-9861(200208)2:8<1007::AID-PROT1007>3.0.CO;2-G; Gebauer F, 2003, MOL CELL, V11, P1397, DOI 10.1016/S1097-2765(03)00176-X; Glaser B, 1998, TIERARZTL PRAX K H, V26, P55; Goyard S, 2003, MOL BIOCHEM PARASIT, V130, P31, DOI 10.1016/S0166-6851(03)00142-7; Guo L, 2001, MOL CELL, V7, P1103, DOI 10.1016/S1097-2765(01)00252-0; Herwaldt BL, 1999, LANCET, V354, P1191, DOI 10.1016/S0140-6736(98)10178-2; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; Kaufman RJ, 2004, TRENDS BIOCHEM SCI, V29, P152, DOI 10.1016/j.tibs.2004.01.004; Khandjian EW, 1996, NAT GENET, V12, P91, DOI 10.1038/ng0196-91; Kundig C, 1999, EMBO J, V18, P2342, DOI 10.1093/emboj/18.9.2342; Larreta R, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-3; Ling J, 2002, MOL CELL BIOL, V22, P7853, DOI 10.1128/MCB.22.22.7853-7867.2002; MACFARLANE J, 1990, EUR J BIOCHEM, V190, P377, DOI 10.1111/j.1432-1033.1990.tb15586.x; Mangus DA, 1999, METHODS, V17, P28, DOI 10.1006/meth.1998.0704; Mangus DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-7-223; Mathews MB, 2000, COLD SPRING HARBOR M, V39, P1; Mazumder B, 2003, CELL, V115, P187, DOI 10.1016/S0092-8674(03)00773-6; Mazumder B, 2003, TRENDS BIOCHEM SCI, V28, P91, DOI 10.1016/S0968-0004(03)00002-1; Mishra KK, 2003, EUKARYOT CELL, V2, P1009, DOI 10.1128/EC.2.5.1009-1017.2003; Ostareck DH, 2001, CELL, V104, P281, DOI 10.1016/S0092-8674(01)00212-4; PAPADOPOULOU B, 1992, EMBO J, V11, P3601, DOI 10.1002/j.1460-2075.1992.tb05444.x; Papadopoulou B, 2002, INFECT IMMUN, V70, P62, DOI 10.1128/IAI.70.1.62-68.2002; PAPADOPOULOU B, 2003, J PARASITOL, V89, pS174; Rochette A, 2005, MOL BIOCHEM PARASIT, V140, P205, DOI 10.1016/j.molbiopara.2005.01.006; Roy G, 2000, MOL BIOCHEM PARASIT, V110, P195, DOI 10.1016/S0166-6851(00)00270-X; Saar Y, 1998, MOL BIOCHEM PARASIT, V95, P9, DOI 10.1016/S0166-6851(98)00062-0; Sachs A, 2000, COLD SPRING HARBOR M, V39, P447; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Saxena A, 2003, MOL BIOCHEM PARASIT, V129, P103, DOI 10.1016/S0166-6851(03)00100-2; Schneider RJ, 2000, COLD SPRING HARBOR M, V39, P581; Sereno D, 1998, ANTIMICROB AGENTS CH, V42, P3097, DOI 10.1128/AAC.42.12.3097; Sereno D, 1997, ANTIMICROB AGENTS CH, V41, P972, DOI 10.1128/AAC.41.5.972; Sereno D, 2001, ANTIMICROB AGENTS CH, V45, P1168, DOI 10.1128/AAC.45.4.1168-1173.2001; Shen RZ, 2004, J VIROL, V78, P4655, DOI 10.1128/JVI.78.9.4655-4664.2004; Sundar S, 2001, TROP MED INT HEALTH, V6, P849, DOI 10.1046/j.1365-3156.2001.00778.x; TEIXEIRA SMR, 1994, J BIOL CHEM, V269, P20509; TEIXEIRA SMR, 1995, J BIOL CHEM, V270, P22586, DOI 10.1074/jbc.270.38.22586; TURCO SJ, 1991, MOL BIOCHEM PARASIT, V45, P91, DOI 10.1016/0166-6851(91)90030-A; Wells SE, 1998, MOL CELL, V2, P135, DOI 10.1016/S1097-2765(00)80122-7; Wilkie GS, 2003, TRENDS BIOCHEM SCI, V28, P182, DOI 10.1016/S0968-0004(03)00051-3; Wu Y, 2000, MOL BIOCHEM PARASIT, V110, P345, DOI 10.1016/S0166-6851(00)00290-5; Yaman I, 2003, CELL, V113, P519, DOI 10.1016/S0092-8674(03)00345-3; ZILBERSTEIN D, 1994, ANNU REV MICROBIOL, V48, P449, DOI 10.1146/annurev.mi.48.100194.002313; Zilka A, 2001, J BIOL CHEM, V276, P47922, DOI 10.1074/jbc.M108271200	59	76	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35238	35246		10.1074/jbc.M507511200	http://dx.doi.org/10.1074/jbc.M507511200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16115874	hybrid			2022-12-25	WOS:000232561200021
J	Nguyen, MTA; Satoh, H; Favelyukis, S; Babendure, JL; Imamura, T; Sbodio, JI; Zalevsky, J; Dahiyat, BI; Chi, NW; Olefsky, JM				Nguyen, MTA; Satoh, H; Favelyukis, S; Babendure, JL; Imamura, T; Sbodio, JI; Zalevsky, J; Dahiyat, BI; Chi, NW; Olefsky, JM			JNK and tumor necrosis factor-alpha mediate free fatty acid-induced insulin resistance in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C-LAMBDA/ZETA; KAPPA-B KINASE; ADIPOSE-TISSUE; TNF-ALPHA; SKELETAL-MUSCLE; RECEPTOR SUBSTRATE-1; 3T3-L1 ADIPOCYTES; ACTIVATION; OBESITY; SENSITIVITY	Lipid infusion and high fat feeding are established causes of systemic and adipose tissue insulin resistance. In this study, we treated 3T3- L1 adipocytes with a mixture of free fatty acids ( FFAs) to investigate the molecular mechanisms underlying fat- induced insulin resistance. FFA treatment impaired insulin receptor- mediated signal transduction and decreased insulin- stimulated GLUT4 translocation and glucose transport. FFAs activated the stress/ inflammatory kinases c- Jun N- terminal kinase ( JNK) and IKK beta, and the suppressor of cytokine signaling protein 3, increased secretion of the inflammatory cytokine tumor necrosis factor ( TNF)-alpha, and decreased secretion of adiponectin into the medium. RNA interference-mediated down- regulation of JNK blocked JNK activation and prevented most of the FFA- induced defects in insulin action. Blockade of TNF-alpha signaling with neutralizing antibodies to TNF-alpha or its receptors or with a dominant negative TNF-alpha peptide had a partial effect to inhibit FFA- induced cellular insulin resistance. We found that JNK activation by FFAs was not inhibited by blocking TNF-alpha signaling, whereas the FFA- induced increase in TNF-alpha secretion was inhibited by RNA interference- mediated JNK knockdown. Together, these results indicate that 1) JNK can be activated by FFAs through TNF-alpha- independent mechanisms, 2) activated JNK is a major contributor to FFA- induced cellular insulin resistance, and 3) TNF-alpha is an autocrine/ paracrine downstream effector of activated JNK that can also mediate insulin resistance.	Univ Calif San Diego, Div Endocrinol Metab, La Jolla, CA 92093 USA; Xencor, Monrovia, CA 91016 USA	University of California System; University of California San Diego	Olefsky, JM (corresponding author), Univ Calif San Diego, Div Endocrinol Metab, 9500 Gilman Dr, La Jolla, CA 92093 USA.	jolefsky@ucsd.edu	Nguyen, Minh Tho/N-9582-2019; Satoh, Hiroaki/E-9096-2017	Nguyen, Minh Tho/0000-0002-3803-0569; Satoh, Hiroaki/0000-0002-0353-5807	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033651, R01DK033651] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33651] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; Alarcon-Vargas D, 2004, J BIOL CHEM, V279, P5008, DOI 10.1074/jbc.M312054200; Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Bays H, 2004, J CLIN ENDOCR METAB, V89, P463, DOI 10.1210/jc.2003-030723; BEUTLER BA, 1985, J IMMUNOL, V135, P3972; Boden G, 1997, DIABETES, V46, P3, DOI 10.2337/diabetes.46.1.3; Cacalano NA, 2001, NAT CELL BIOL, V3, P460, DOI 10.1038/35074525; Chavez JA, 2003, ARCH BIOCHEM BIOPHYS, V419, P101, DOI 10.1016/j.abb.2003.08.020; Dai Y, 2005, BLOOD, V105, P1706, DOI 10.1182/blood-2004-07-2767; de Alvaro C, 2004, J BIOL CHEM, V279, P17070, DOI 10.1074/jbc.M312021200; Di Rocco P, 2004, OBES RES, V12, P734, DOI 10.1038/oby.2004.86; Egawa K, 1999, J BIOL CHEM, V274, P14306, DOI 10.1074/jbc.274.20.14306; Emanuelli B, 2001, J BIOL CHEM, V276, P47944, DOI 10.1074/jbc.M104602200; FLICK DA, 1986, J IMMUNOPHARMACOL, V8, P89; Gao ZG, 2004, MOL ENDOCRINOL, V18, P2024, DOI 10.1210/me.2003-0383; Griffin ME, 1999, DIABETES, V48, P1270, DOI 10.2337/diabetes.48.6.1270; Grimble RF, 2002, CURR OPIN CLIN NUTR, V5, P551, DOI 10.1097/00075197-200209000-00015; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Kappes A, 2000, HORM METAB RES, V32, P548, DOI 10.1055/s-2007-978684; Kershaw EE, 2004, J CLIN ENDOCR METAB, V89, P2548, DOI 10.1210/jc.2004-0395; Kim YB, 2002, J BIOL CHEM, V277, P32915, DOI 10.1074/jbc.M204710200; Kim YB, 2003, DIABETES, V52, P1935, DOI 10.2337/diabetes.52.8.1935; Kraegen EW, 2001, EXP CLIN ENDOCR DIAB, V109, pS189, DOI 10.1055/s-2001-18581; KREBS DL, 2003, SCI STKE, pPE6; Miura A, 1999, BBA-MOL CELL RES, V1449, P227, DOI 10.1016/S0167-4889(99)00016-6; Ofei F, 1996, DIABETES, V45, P881, DOI 10.2337/diabetes.45.7.881; Peraldi P, 1998, MOL CELL BIOCHEM, V182, P169, DOI 10.1023/A:1006865715292; Perseghin G, 2003, INT J OBESITY, V27, pS6, DOI 10.1038/sj.ijo.0802491; Petersen KF, 2004, NEW ENGL J MED, V350, P664, DOI 10.1056/NEJMoa031314; Riccardi G, 2000, BRIT J NUTR, V83, pS143; Ruan H, 2003, CYTOKINE GROWTH F R, V14, P447, DOI 10.1016/S1359-6101(03)00052-2; Rui LY, 2002, J BIOL CHEM, V277, P42394, DOI 10.1074/jbc.C200444200; Sasaki A, 2003, J BIOL CHEM, V278, P2432, DOI 10.1074/jbc.C200608200; Sewter CP, 1999, J ENDOCRINOL, V163, P33, DOI 10.1677/joe.0.1630033; Steed PM, 2003, SCIENCE, V301, P1895, DOI 10.1126/science.1081297; Subtil A, 2000, J BIOL CHEM, V275, P4787, DOI 10.1074/jbc.275.7.4787; Tremblay F, 2001, DIABETES, V50, P1901, DOI 10.2337/diabetes.50.8.1901; Ueki K, 2004, MOL CELL BIOL, V24, P5434, DOI 10.1128/MCB.24.12.5434-5446.2004; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; Watson RT, 2001, EXP CELL RES, V271, P75, DOI 10.1006/excr.2001.5375; Worrall DS, 2002, MOL ENDOCRINOL, V16, P378, DOI 10.1210/me.16.2.378; Xu HY, 2002, DIABETES, V51, P1876, DOI 10.2337/diabetes.51.6.1876; Yu CL, 2002, J BIOL CHEM, V277, P50230, DOI 10.1074/jbc.M200958200; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620; Zagariya A, 1998, MOL CELL BIOL, V18, P2815, DOI 10.1128/MCB.18.5.2815	45	316	339	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35361	35371		10.1074/jbc.M504611200	http://dx.doi.org/10.1074/jbc.M504611200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16085647	hybrid			2022-12-25	WOS:000232561200035
J	O'Byrne, SM; Wongsiriroj, N; Libien, J; Vogel, S; Goldberg, IJ; Baehr, W; Palczewski, K; Blaner, WS				O'Byrne, SM; Wongsiriroj, N; Libien, J; Vogel, S; Goldberg, IJ; Baehr, W; Palczewski, K; Blaner, WS			Retinoid absorption and storage is impaired in mice lacking lecithin : retinol acyltransferase (LRAT)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MICROSOMES; BINDING-PROTEIN; ACYL-COA; HEPATIC-FIBROSIS; STELLATE CELLS; ESTERIFICATION; ACID; EXPRESSION; METABOLISM; BIOSYNTHESIS	Lecithin: retinol acyltransferase (LRAT) is believed to be the predominant if not the sole enzyme in the body responsible for the physiologic esterification of retinol. We have studied Lrat-deficient (Lrat(-/-)) mice to gain a better understanding of how these mice take up and store dietary retinoids and to determine whether other enzymes may be responsible for retinol esterification in the body. Although the Lrat(-/-) mice possess only trace amounts of retinyl esters in liver, lung, and kidney, they possess elevated (by 2-3-fold) concentrations of retinyl esters in adipose tissue compared with wild type mice. These adipose retinyl ester depots are mobilized in times of dietary retinoid insufficiency. We further observed an up-regulation (3-4- fold) in the level of cytosolic retinol-binding protein type III (CRBPIII) in adipose tissue of Lrat(-/-) mice. Examination by electron microscopy reveals a striking total absence of large lipid-containing droplets that normally store hepatic retinoid within the hepatic stellate cells of Lrat(-/-) mice. Despite the absence of significant retinyl ester stores and stellate cell lipid droplets, the livers of Lrat(-/-) mice upon histologic analysis appear normal and show no histological signs of liver fibrosis. Lrat(-/-) mice absorb dietary retinol primarily as free retinol in chylomicrons; however, retinyl esters are also present within the chylomicron fraction obtained from Lrat(-/-) mice. The fatty acyl composition of these chylomicron retinyl esters suggests that they are synthesized via an acyl-CoA-dependent process suggesting the existence of a physiologically significant acyl-CoA: retinol acyltransferase.	Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Inst Human Nutr, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Univ Utah, Hlth Sci Ctr, Dept Ophthalmol, Salt Lake City, UT 84112 USA; Univ Washington, Dept Ophthalmol, Seattle, WA 98185 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98185 USA; Univ Washington, Dept Chem, Seattle, WA 98185 USA	Columbia University; Columbia University; Columbia University; Utah System of Higher Education; University of Utah; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Blaner, WS (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Med, 701 W 168th St, New York, NY 10032 USA.	wsb2@columbia.edu		Libien, Jenny/0000-0001-6291-4391	NEI NIH HHS [R01 EY009339, R01 EY008123, R01 EY09339, R01 EY08123] Funding Source: Medline; NIDDK NIH HHS [R01 DK068437, R01 DK067512, R01 DK061310] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009339, R01EY008123] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK068437, R01DK067512, R01DK061310] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Balmer JE, 2002, J LIPID RES, V43, P1773, DOI 10.1194/jlr.R100015-JLR200; Batten ML, 2004, J BIOL CHEM, V279, P10422, DOI 10.1074/jbc.M312410200; Berriot-Varoqueaux N, 2000, ANNU REV NUTR, V20, P663, DOI 10.1146/annurev.nutr.20.1.663; Blaner William S., 1994, P229; BLANER WS, 1990, METHOD ENZYMOL, V189, P270; BLANER WS, 1994, J BIOL CHEM, V269, P16559; Cases S, 1998, P NATL ACAD SCI USA, V95, P13018, DOI 10.1073/pnas.95.22.13018; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHAMBON P, 1994, CELL BIOL, V5, P115; Dickman ED, 1997, DEVELOPMENT, V124, P3111; Duester G, 2000, EUR J BIOCHEM, V267, P4315, DOI 10.1046/j.1432-1327.2000.01497.x; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; Friedman SL, 2000, J BIOL CHEM, V275, P2247, DOI 10.1074/jbc.275.4.2247; Geerts A, 2001, SEMIN LIVER DIS, V21, P311, DOI 10.1055/s-2001-17550; Geerts Albert, 1994, P819; Goodman DS, 1984, RETINOIDS, P41, DOI DOI 10.1016/B978-0-12-658102-7.50008-7; Gudas Lorraine J., 1994, P443; Guo XJ, 2000, CARCINOGENESIS, V21, P1925, DOI 10.1093/carcin/21.11.1925; HERR FM, 1992, BIOCHEMISTRY-US, V31, P6748, DOI 10.1021/bi00144a014; Johnston TP, 2004, J CARDIOVASC PHARM, V43, P595, DOI 10.1097/00005344-200404000-00016; KURLANDSKY SB, 1995, J BIOL CHEM, V270, P17850, DOI 10.1074/jbc.270.30.17850; Kurlandsky SB, 1996, J BIOL CHEM, V271, P15346, DOI 10.1074/jbc.271.26.15346; Li D, 1999, J GASTROEN HEPATOL, V14, P618, DOI 10.1046/j.1440-1746.1999.01928.x; Liang JJ, 2004, J BIOL CHEM, V279, P44938, DOI 10.1074/jbc.M408507200; Mangelsdorf David J., 1994, P319; McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7; Molotkov A, 2002, J BIOL CHEM, V277, P13804, DOI 10.1074/jbc.M112039200; Moore T., 1957, VITAMIN; MORIWAKI H, 1988, J LIPID RES, V29, P1523; MULLER H, 1986, BRIT J NUTR, V55, P37, DOI 10.1079/BJN19860007; Napoli JL, 2000, PROG NUCLEIC ACID RE, V63, P139, DOI 10.1016/S0079-6603(08)60722-9; *NAT RES COUNC, 1996, GUID CAR US LAB AN; OBYRNE SM, 2005, CAROTENOIDS RETINOID, P1; ONG DE, 1988, J BIOL CHEM, V263, P5789; Piantedosi R, 2005, J BIOL CHEM, V280, P24286, DOI 10.1074/jbc.M503906200; RANDOLPH RK, 1991, ARCH BIOCHEM BIOPHYS, V288, P500, DOI 10.1016/0003-9861(91)90227-A; ROSS AC, 1982, J BIOL CHEM, V257, P2453; ROSS AC, 1982, J LIPID RES, V23, P133; Ruiz A, 1999, J BIOL CHEM, V274, P3834, DOI 10.1074/jbc.274.6.3834; SAARI JC, 1989, J BIOL CHEM, V264, P8636; Soprano Dianne Robert, 1994, P257; SUHARA A, 1990, J LIPID RES, V31, P1669; TSUTSUMI C, 1992, J BIOL CHEM, V267, P1805; VOGEL S, 1999, HANDB EXP PHARM, V139, P31; WALD G, 1968, NATURE, V219, P800, DOI 10.1038/219800a0; Wasan KM, 2003, J PHARM PHARM SCI, V6, P189; YAMADA M, 1987, HEPATOLOGY, V7, P1224, DOI 10.1002/hep.1840070609; Yen CLE, 2005, J LIPID RES, V46, P1502, DOI 10.1194/jlr.M500036-JLR200; YOST RW, 1988, J BIOL CHEM, V263, P18693; ZOVICH DC, 1992, J BIOL CHEM, V267, P13884	50	216	227	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35647	35657		10.1074/jbc.M507924200	http://dx.doi.org/10.1074/jbc.M507924200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16115871	Green Accepted, hybrid			2022-12-25	WOS:000232561200068
J	Hubmacher, D; Tiedemann, K; Bartels, R; Brinckmann, J; Vollbrandt, T; Batge, B; Notbohm, H; Reinhardt, DP				Hubmacher, D; Tiedemann, K; Bartels, R; Brinckmann, J; Vollbrandt, T; Batge, B; Notbohm, H; Reinhardt, DP			Modification of the structure and function of fibrillin-1 by homocysteine suggests a potential pathogenetic mechanism in homocystinuria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-LIKE DOMAINS; CALCIUM-BINDING PROPERTIES; GROWTH-FACTOR MODULES; MARFAN-SYNDROME; IN-VITRO; TERMINAL DOMAIN; PROTEIN; MUTATIONS; MICROFIBRILS; ORGANIZATION	Homocystinuria, a disorder originating in defects in the methionine metabolism, is characterized by an elevated plasma concentration of homocysteine. Most patients have a defect in the cystathionine-beta-synthase, the key enzyme in the conversion of homocysteine to cysteine. Many abnormalities in the connective tissue of patients with homocystinuria resemble those seen in Marfan syndrome, caused by mutations in fibrillin-1. These observations led to the hypothesis that the structure and function of fibrillin-1 is compromised in patients with homocystinuria. To test this hypothesis we produced recombinant human fibrillin-1 fragments spanning the central portion of the molecule (8-Cys/transforming growth factor-beta binding domain 3 to calcium binding EGF domain 22) and extensively analyzed the potential of homocysteine to modify structural and functional properties of these proteins. Circular dichroism spectroscopy revealed moderate changes of their secondary structures after incubation with homocysteine. Equilibrium dialysis demonstrated a number of high affinity calcium binding sites in the tandemly repeated calcium binding epidermal growth factor-like domains 11-22. Calcium binding of homocysteine-modified fragments was completely abolished. Incubation of the recombinant proteins with homocysteine rendered the analyzed calcium binding EGF domains as well as the 8-Cys/transforming growth factor-beta binding domain 3 significantly more susceptible to proteolytic degradation. Furthermore, data were obtained demonstrating that homocysteine can covalently modify fibrillin-1 via disulfide bonds. These data strongly suggest that structural and functional modifications as well as degradation processes of fibrillin-1 in the connective tissues of patients with homocystinuria play a major role in the pathogenesis of this disorder.	McGill Univ, Dept Anat & Cell Biol, Fac Med, Montreal, PQ H3A 2B2, Canada; McGill Univ, Fac Dent, Montreal, PQ H3A 2B2, Canada; Med Univ Lubeck, Dept Med Mol Biol, D-23538 Lubeck, Germany; Med Univ Lubeck, Dept Dermatol, D-23538 Lubeck, Germany; Forschungszentrum Borstel, D-23845 Borstel, Germany; Klinikum Neustadt, D-23730 Neustadt, Germany	McGill University; McGill University; University of Lubeck; University of Lubeck; Forschungszentrum Borstel	Reinhardt, DP (corresponding author), McGill Univ, Dept Anat & Cell Biol, Fac Med, Montreal, PQ H3A 2B2, Canada.	dieter.reinhardt@mcgill.ca	Hubmacher, Dirk/AAE-1875-2020; Reinhardt, Dieter P/A-3102-2008; Tiedemann, one/A-9739-2016	Reinhardt, Dieter P/0000-0001-6535-9872; Hubmacher, Dirk/0000-0003-1569-9451				Adam S, 1997, J MOL BIOL, V272, P226, DOI 10.1006/jmbi.1997.1244; Ashworth JL, 1999, BIOCHEM J, V340, P171, DOI 10.1042/0264-6021:3400171; Booms P, 2000, HUM GENET, V107, P216, DOI 10.1007/s004390000368; Collod-Beroud G, 2003, HUM MUTAT, V22, P199, DOI 10.1002/humu.10249; Corson GM, 2004, GENOMICS, V83, P461, DOI 10.1016/j.ygeno.2003.08.023; CORSON GM, 1993, GENOMICS, V17, P476, DOI 10.1006/geno.1993.1350; Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3; DUERRE JA, 1966, ANAL BIOCHEM, V17, P310, DOI 10.1016/0003-2697(66)90209-0; GLANVILLE RW, 1994, J BIOL CHEM, V269, P26630; HANDFORD P, 1995, J BIOL CHEM, V270, P6751, DOI 10.1074/jbc.270.12.6751; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; Hill CH, 2002, J NUTR, V132, P2143, DOI 10.1093/jn/132.8.2143; Hutchinson S, 2005, J MOL BIOL, V346, P833, DOI 10.1016/j.jmb.2004.11.038; Isogai Z, 2003, J BIOL CHEM, V278, P2750, DOI 10.1074/jbc.M209256200; Jensen SA, 2005, J BIOL CHEM, V280, P14076, DOI 10.1074/jbc.M412832200; Jensen SA, 2001, J BIOL CHEM, V276, P39661, DOI 10.1074/jbc.M104533200; Julenius K, 2005, GLYCOBIOLOGY, V15, P153, DOI 10.1093/glycob/cwh151; Kettle S, 1999, J MOL BIOL, V285, P1277, DOI 10.1006/jmbi.1998.2368; Knott V, 1996, J MOL BIOL, V255, P22, DOI 10.1006/jmbi.1996.0003; Lee SSJ, 2004, STRUCTURE, V12, P717, DOI 10.1016/j.str.2004.02.023; LENTZ SR, 1991, J CLIN INVEST, V88, P1906, DOI 10.1172/JCI115514; Lin GQ, 2002, J BIOL CHEM, V277, P50795, DOI 10.1074/jbc.M210611200; Majors AK, 2000, MOL GENET METAB, V70, P252, DOI 10.1006/mgme.2000.3024; Marson A, 2005, J BIOL CHEM, V280, P5013, DOI 10.1074/jbc.M409029200; McGettrick AJ, 2000, HUM MOL GENET, V9, P1987, DOI 10.1093/hmg/9.13.1987; Mecham R. P., 1994, EXTRACELLULAR MATRIX, P281; Nagase T, 2001, DNA RES, V8, P85, DOI 10.1093/dnares/8.2.85; PEREIRA L, 1993, HUM MOL GENET, V2, P961, DOI 10.1093/hmg/2.7.961; Pyeritz R., 2002, CONNECTIVE TISSUE IT, P585, DOI [10.1002/0471221929.ch12, DOI 10.1002/0471221929.CH12]; Pyeritz RE, 2000, ANNU REV MED, V51, P481, DOI 10.1146/annurev.med.51.1.481; Refsum H, 1998, ANNU REV MED, V49, P31, DOI 10.1146/annurev.med.49.1.31; Reinhardt DP, 2000, J BIOL CHEM, V275, P2205, DOI 10.1074/jbc.275.3.2205; Reinhardt DP, 2000, J BIOL CHEM, V275, P12339, DOI 10.1074/jbc.275.16.12339; Reinhardt DP, 1996, J BIOL CHEM, V271, P19489, DOI 10.1074/jbc.271.32.19489; Reinhardt DP, 1996, J MOL BIOL, V258, P104, DOI 10.1006/jmbi.1996.0237; Reinhardt DP, 1997, J BIOL CHEM, V272, P1231, DOI 10.1074/jbc.272.2.1231; Reinhardt DP, 1997, J BIOL CHEM, V272, P7368, DOI 10.1074/jbc.272.11.7368; Ritty TM, 2003, BIOCHEM J, V375, P425, DOI 10.1042/BJ20030649; Ritty TM, 1999, J BIOL CHEM, V274, P8933, DOI 10.1074/jbc.274.13.8933; Robinson PN, 2002, HUM MUTAT, V20, P153, DOI 10.1002/humu.10113; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; Schrijver I, 1999, AM J HUM GENET, V65, P1007, DOI 10.1086/302582; SEDLAK J, 1968, ANAL BIOCHEM, V25, P192, DOI 10.1016/0003-2697(68)90092-4; SKOVBY F, 2002, CONNECTIVE TISSUE IT, P627; Smallridge RS, 1999, J MOL BIOL, V286, P661, DOI 10.1006/jmbi.1998.2536; Tiedemann K, 2001, J BIOL CHEM, V276, P36035, DOI 10.1074/jbc.M104985200; Ueland PM., 1992, ATHEROSCLEROTIC CARD, P183; VANSTOKKUM IHM, 1990, ANAL BIOCHEM, V191, P110, DOI 10.1016/0003-2697(90)90396-Q; Vollbrandt T, 2004, J BIOL CHEM, V279, P32924, DOI 10.1074/jbc.M405239200; Whiteman P, 2003, HUM MOL GENET, V12, P727, DOI 10.1093/hmg/ddg081; Whiteman P, 1998, J BIOL CHEM, V273, P7807, DOI 10.1074/jbc.273.14.7807; Yuan XM, 1997, EMBO J, V16, P6659, DOI 10.1093/emboj/16.22.6659; ZHANG H, 1994, J CELL BIOL, V124, P855, DOI 10.1083/jcb.124.5.855	53	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34946	34955		10.1074/jbc.M504748200	http://dx.doi.org/10.1074/jbc.M504748200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16096271	hybrid, Green Published			2022-12-25	WOS:000232403900068
J	Ren, JG; Li, ZG; Crimmins, DL; Sacks, DB				Ren, JG; Li, ZG; Crimmins, DL; Sacks, DB			Self-association of IQGAP1 - Characterization and functional sequelae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; PROTEIN; CALMODULIN; CDC42; DIMERIZATION; IDENTIFICATION; TARGET; BINDS; RAC1	The scaffolding protein IQGAP1 participates in numerous cellular functions by binding to target proteins such as actin, calmodulin, E-cadherin, beta-catenin, Cdc42, Rac1, and CLIP-170. IQGAP1 regulates the cytoskeleton, promotes cell motility, and modulates E-cadherin-mediated cell-cell adhesion. However, how IQGAP1 exerts its functions in vivo is still unclear. In this study we investigate the self-association of IQGAP1 and its role in IQGAP1 function. Endogenous IQGAP1 co-immunoprecipitated from MCF-7 cells with IQGAP1 tagged with enhanced green fluorescent protein, indicating that IQGAP1 self-associates in cells. In vitro assays confirmed that IQGAP1 can self-associate and that this effect is mediated by the N-terminal half of the protein. Gel filtration analysis suggested that full-length IQGAP1 exists as a combination of monomers, dimers, and larger oligomers. Analysis performed with multiple fragments of IQGAP1 narrowed the self-association region to amino acids 763 - 863. In support of this observation, a peptide comprising residues 763 - 863 disrupted self-association of full-length IQGAP1 in a dose-dependent manner. Similarly, deleting this sequence from IQGAP1 abolished binding to full-length IQGAP1. In addition, the ability of IQGAP1 to increase the amount of active Cdc42 in cells is abrogated upon removal of this region. Consistent with these findings, transfection into cells of a peptide containing the self-association domain significantly reduced the amount of active Cdc42 in cell lysates. These observations define a sequence of IQGAP1 that is necessary for its oligomerization and demonstrate that self-association is required for the normal cellular function of IQGAP1.	Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Washington University (WUSTL)	Sacks, DB (corresponding author), Brigham & Womens Hosp, Dept Pathol, Thorn 530,75 Francis St, Boston, MA 02115 USA.	dsacks@rics.bwh.harvard.edu		Sacks, David/0000-0003-3100-0735				Bashour AM, 1997, J CELL BIOL, V137, P1555, DOI 10.1083/jcb.137.7.1555; Briggs MW, 2003, EMBO REP, V4, P571, DOI 10.1038/sj.embor.embor867; Briggs MW, 2003, FEBS LETT, V542, P7, DOI 10.1016/S0014-5793(03)00333-8; Briggs MW, 2002, J BIOL CHEM, V277, P7453, DOI 10.1074/jbc.M104315200; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; Copeland JW, 2004, J BIOL CHEM, V279, P50250, DOI 10.1074/jbc.M404429200; FISH WW, 1969, J BIOL CHEM, V244, P4989; Fukata M, 2002, CELL, V109, P873, DOI 10.1016/S0092-8674(02)00800-0; Fukata M, 1997, J BIOL CHEM, V272, P29579, DOI 10.1074/jbc.272.47.29579; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; Ho YD, 1999, J BIOL CHEM, V274, P464, DOI 10.1074/jbc.274.1.464; Joyal JL, 1997, J BIOL CHEM, V272, P15419, DOI 10.1074/jbc.272.24.15419; Kim SH, 2000, J BIOL CHEM, V275, P36999, DOI 10.1074/jbc.M003430200; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; Li ZG, 2003, J BIOL CHEM, V278, P4347, DOI 10.1074/jbc.M208579200; Li ZG, 1999, J BIOL CHEM, V274, P37885, DOI 10.1074/jbc.274.53.37885; Marianayagam NJ, 2004, TRENDS BIOCHEM SCI, V29, P618, DOI 10.1016/j.tibs.2004.09.006; Mataraza JM, 2003, J BIOL CHEM, V278, P41237, DOI 10.1074/jbc.M304838200; Mateer SC, 2003, CELL MOTIL CYTOSKEL, V55, P147, DOI 10.1002/cm.10118; Mateer SC, 2002, J BIOL CHEM, V277, P12324, DOI 10.1074/jbc.M109535200; Meller N, 2004, J BIOL CHEM, V279, P37470, DOI 10.1074/jbc.M404535200; Roy M, 2004, J BIOL CHEM, V279, P17329, DOI 10.1074/jbc.M308405200; So CW, 2003, CANCER CELL, V4, P99, DOI 10.1016/S1535-6108(03)00188-0; Sokol SY, 2001, J BIOL CHEM, V276, P48425, DOI 10.1074/jbc.M107975200; Swart-Mataraza JM, 2002, J BIOL CHEM, V277, P24753, DOI 10.1074/jbc.M111165200; Thornton C, 2004, J BIOL CHEM, V279, P31357, DOI 10.1074/jbc.M402316200; Veselovsky AV, 2002, J MOL RECOGNIT, V15, P405, DOI 10.1002/jmr.597; Wang YZ, 2004, J CELL BIOL, V164, P973, DOI 10.1083/jcb.200401010; WEISSBACH L, 1994, J BIOL CHEM, V269, P20517; Yablonski D, 1996, P NATL ACAD SCI USA, V93, P13864, DOI 10.1073/pnas.93.24.13864	31	54	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34548	34557		10.1074/jbc.M507321200	http://dx.doi.org/10.1074/jbc.M507321200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16105843	hybrid			2022-12-25	WOS:000232403900023
J	Sleeman, MC; Sorensen, JL; Batchelar, ET; McDonough, MA; Schofield, CJ				Sleeman, MC; Sorensen, JL; Batchelar, ET; McDonough, MA; Schofield, CJ			Structural and mechanistic studies on carboxymethylproline synthase (CarB), a unique member of the crotonase superfamily catalyzing the first step in carbapenem biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLAVULANIC ACID BIOSYNTHESIS; BETA-LACTAM SYNTHETASE; CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; DELTA(3)-DELTA(2)-ENOYL-COA ISOMERASE; STREPTOMYCES-CLAVULIGERUS; MACROMOLECULAR STRUCTURES; COA HYDRATASE; FATTY-ACID; ENZYME	The first step in the biosynthesis of the medicinally important carbapenem family of beta-lactam antibiotics is catalyzed by carboxymethylproline synthase (CarB), a unique member of the crotonase superfamily. CarB catalyzes formation of (2S,5S)-carboxymethylproline [(2S,5S)-t-CMP] from malonyl-CoA and L-glutamate semialdehyde. In addition to using a cosubstrate, CarB catalyzes C-C and C-N bond formation processes as well as an acyl-coenzyme A hydrolysis reaction. We describe the crystal structure of CarB in the presence and absence of acetyl-CoA at 2.24 angstrom and 3.15 angstrom resolution, respectively. The structures reveal that CarB contains a conserved oxy-anion hole probably required for decarboxylation of malonyl-CoA and stabilization of the resultant enolate. Comparison of the structures reveals that conformational changes (involving His(229)) in the cavity predicted to bind L-glutamate semialdehyde occur on (co)substrate binding. Mechanisms for the formation of the carboxymethylproline ring are discussed in the light of the structures and the accompanying studies using isotopically labeled substrates; cyclization via 1,4-addition is consistent with the observed labeling results (providing that hydrogen exchange at the C-6 position of carboxymethylproline does not occur). The side chain of Glu(131) appears to be positioned to be involved in hydrolysis of the carboxymethylproline-CoA ester intermediate. Labeling experiments ruled out the possibility that hydrolysis proceeds via an anhydride in which water attacks a carbonyl derived from Glu(131), as proposed for 3-hydroxyisobutyryl-CoA hydrolase. The structural work will aid in mutagenesis studies directed at altering the selectivity of CarB to provide intermediates for the production of clinically useful carbapenems.	Univ Oxford, Dept Chem, Chem Res Lab, Oxford OX1 3TA, England; Univ Oxford, Oxford Ctr Mol Sci, Chem Res Lab, Oxford OX1 3TA, England	University of Oxford; University of Oxford	Schofield, CJ (corresponding author), Univ Oxford, Dept Chem, Chem Res Lab, Mansfield Rd, Oxford OX1 3TA, England.	christopher.schofield@chem.ox.ac.uk	McDonough, Michael/N-8913-2019; McDonough, Michael A/G-2744-2013	McDonough, Michael/0000-0003-4664-6942; McDonough, Michael A/0000-0003-4664-6942; Schofield, Christopher/0000-0002-0290-6565	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bachmann BO, 1998, P NATL ACAD SCI USA, V95, P9082, DOI 10.1073/pnas.95.16.9082; Baggaley KH, 1997, NAT PROD REP, V14, P309, DOI 10.1039/np9971400309; BALDWIN JE, 1976, J CHEM SOC CHEM COMM, P736, DOI 10.1039/c39760000736; Benning MM, 1996, BIOCHEMISTRY-US, V35, P8103, DOI 10.1021/bi960768p; Benning MM, 2000, BIOCHEMISTRY-US, V39, P4630, DOI 10.1021/bi9928896; *BRUK AXS INC, 2003, XPREP DAT PREP REC S; Carreras CW, 1997, TOP CURR CHEM, V188, P85; Cianci M, 2005, J SYNCHROTRON RADIAT, V12, P455, DOI 10.1107/S0909049505009131; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; COLLADO I, 1994, TETRAHEDRON LETT, V35, P8037; DOUGLAS KT, 1981, J CHEM SOC PERK T 2, P171, DOI 10.1039/p29810000171; DOUGLAS KT, 1986, ACCOUNTS CHEM RES, V19, P186, DOI 10.1021/ar00126a005; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Engel CK, 1998, J MOL BIOL, V275, P847, DOI 10.1006/jmbi.1997.1491; Engel CK, 1996, EMBO J, V15, P5135, DOI 10.1002/j.1460-2075.1996.tb00897.x; Gerratana B, 2004, BIOCHEMISTRY-US, V43, P15936, DOI 10.1021/bi0483662; Gerratana B, 2003, BIOCHEMISTRY-US, V42, P7836, DOI 10.1021/bi034361d; HODGSON JE, 1995, GENE, V166, P49, DOI 10.1016/0378-1119(95)00560-9; Holden HM, 2001, ACCOUNTS CHEM RES, V34, P145, DOI 10.1021/ar000053l; Jensen SE, 2000, ANTIMICROB AGENTS CH, V44, P720, DOI 10.1128/AAC.44.3.720-726.2000; Jensen SE, 1999, ANTON LEEUW INT J G, V75, P125, DOI 10.1023/A:1001755724055; Khaleeli N, 1999, J AM CHEM SOC, V121, P9223, DOI 10.1021/ja9923134; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; Kurimoto K, 2001, STRUCTURE, V9, P1253, DOI 10.1016/S0969-2126(01)00686-4; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie A. G. W., 1992, JOINT CCP4 ESF EAMCB; Li RF, 2000, J AM CHEM SOC, V122, P9296, DOI 10.1021/ja001723l; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; McDaniel R, 2005, CHEM REV, V105, P543, DOI 10.1021/cr0301189; McGowan SJ, 1996, MOL MICROBIOL, V22, P415, DOI 10.1046/j.1365-2958.1996.00125.x; McNaughton HJ, 1998, CHEM COMMUN, P2325, DOI 10.1039/a806713i; Modis Y, 1998, STRUCTURE, V6, P957, DOI 10.1016/S0969-2126(98)00098-7; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Mursula AM, 2004, FEBS LETT, V557, P81, DOI 10.1016/S0014-5793(03)01450-9; Mursula AM, 2001, J MOL BIOL, V309, P845, DOI 10.1006/jmbi.2001.4671; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAGE MI, 1992, CHEM BETA LACTAMS, P1; Schofield CJ, 1997, CURR OPIN STRUC BIOL, V7, P857, DOI 10.1016/S0959-440X(97)80158-3; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Sleeman MC, 2004, CHEMBIOCHEM, V5, P879, DOI 10.1002/cbic.200300908; Sleeman MC, 2004, J BIOL CHEM, V279, P6730, DOI 10.1074/jbc.M311824200; Sorensen JL, 2005, CHEM COMMUN, P1155, DOI 10.1039/b416423g; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Townsend CA, 2002, CURR OPIN CHEM BIOL, V6, P583, DOI 10.1016/S1367-5931(02)00392-7; Truglio JJ, 2003, J BIOL CHEM, V278, P42352, DOI 10.1074/jbc.M307399200; Verdonk ML, 2003, PROTEINS, V52, P609, DOI 10.1002/prot.10465; Walter TS, 2005, ACTA CRYSTALLOGR D, V61, P651, DOI 10.1107/S0907444905007808; Whittingham JL, 2003, J BIOL CHEM, V278, P1744, DOI 10.1074/jbc.M211188200; Wong BJ, 2003, J AM CHEM SOC, V125, P12076, DOI 10.1021/ja037652i; YAGGI NF, 1977, J AM CHEM SOC, V99, P4844, DOI 10.1021/ja00456a061	52	26	27	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34956	34965		10.1074/jbc.M507196200	http://dx.doi.org/10.1074/jbc.M507196200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16096274	hybrid			2022-12-25	WOS:000232403900069
J	Xu, BE; Stippec, S; Lazrak, A; Huang, CL; Cobb, MH				Xu, BE; Stippec, S; Lazrak, A; Huang, CL; Cobb, MH			WNK1 activates SGK1 by a phosphatidylinositol 3-kinase-dependent and non-catalytic mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL SODIUM-CHANNEL; GLUCOCORTICOID-INDUCIBLE KINASE; PROTEIN-KINASE; NA+ CHANNEL; SIGNALING PATHWAY; BLOOD-PRESSURE; SERUM; EXPRESSION; PHOSPHORYLATION; CELLS	WNK1 ( with no lysine ( K) 1) is a protein-serine/threonine kinase with a unique catalytic site organization. Deletions in the first intron of the WNK1 gene were found in a group of hypertensive patients with pseudohypoaldosteronism type II. No changes in coding sequence of WNK1 were found, but its expression was increased severalfold. We have been investigating actions of WNK1 and have found that WNK1 activates the serum- and glucocorticoid-induced protein kinase SGK1, which impacts membrane expression of the epithelial sodium channel. Here we explore the role of WNK1 in SGK1 regulation. Activation of SGK1 by WNK1 is blocked by phosphatidylinositol 3-kinase inhibitors. Neither the catalytic activity nor the kinase domain of WNK1 is required; rather the N-terminal 220 residues of WNK1 are necessary and sufficient to activate SGK1. Phosphorylation of WNK1 on Thr-58 contributes to SGK1 activation. Finally, we show that WNK1 is required for the activation of SGK1 by insulin-like growth factor 1.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Cobb, MH (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 6001 Forest Pk Rd, Dallas, TX 75390 USA.	Melanie.Cobb@UTSouthwestern.edu		Lazrak, Ahmed/0000-0002-4127-1937; Cobb, Melanie/0000-0003-0833-5473	NIDDK NIH HHS [DK54368, DK59530] Funding Source: Medline; NIGMS NIH HHS [GM53032] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054368, R01DK059530] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahn YJ, 1999, AM J PHYSIOL-RENAL, V277, pF121, DOI 10.1152/ajprenal.1999.277.1.F121; Arteaga MF, 2005, AM J PHYSIOL-RENAL, V289, pF90, DOI 10.1152/ajprenal.00390.2004; Bell LM, 2000, J BIOL CHEM, V275, P25262, DOI 10.1074/jbc.M002076200; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; de la Rosa DA, 1999, J BIOL CHEM, V274, P37834, DOI 10.1074/jbc.274.53.37834; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; Delaloy C, 2003, MOL CELL BIOL, V23, P9208, DOI 10.1128/MCB.23.24.9208-9221.2003; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; Gonzalez-Robayna IJ, 2000, MOL ENDOCRINOL, V14, P1283, DOI 10.1210/me.14.8.1283; Hayashi M, 2001, J BIOL CHEM, V276, P8631, DOI 10.1074/jbc.C000838200; Jiang ZY, 2005, J BIOL CHEM, V280, P21622, DOI 10.1074/jbc.m414464200; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; Lee BH, 2004, MOL CELL, V15, P741, DOI 10.1016/j.molcel.2004.07.018; Lenertz LY, 2005, J BIOL CHEM, V280, P26653, DOI 10.1074/jbc.M502598200; Leong MLL, 2003, J BIOL CHEM, V278, P5871, DOI 10.1074/jbc.M211649200; Min XS, 2004, STRUCTURE, V12, P1303, DOI 10.1016/j.str.2004.04.014; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; Rotin D, 2000, CURR OPIN NEPHROL HY, V9, P529, DOI 10.1097/00041552-200009000-00012; Snyder PM, 2002, J BIOL CHEM, V277, P5, DOI 10.1074/jbc.C100623200; Verissimo F, 2001, ONCOGENE, V20, P5562, DOI 10.1038/sj.onc.1204726; Vitari AC, 2004, BIOCHEM J, V378, P257, DOI 10.1042/BJ20031692; Wilson FH, 2001, SCIENCE, V293, P1107, DOI 10.1126/science.1062844; Xu BE, 2005, P NATL ACAD SCI USA, V102, P10315, DOI 10.1073/pnas.0504422102; Xu BE, 2004, J BIOL CHEM, V279, P7826, DOI 10.1074/jbc.M313465200; Xu BE, 2002, J BIOL CHEM, V277, P48456, DOI 10.1074/jbc.M207917200; Xu BE, 2000, J BIOL CHEM, V275, P16795, DOI 10.1074/jbc.275.22.16795; Xu BE, 1999, J BIOL CHEM, V274, P34029, DOI 10.1074/jbc.274.48.34029; Xu Q, 2002, NUCLEIC ACIDS RES, V30, P3754, DOI 10.1093/nar/gkf492; Zambrowicz BP, 2003, P NATL ACAD SCI USA, V100, P14109, DOI 10.1073/pnas.2336103100; Zeng WZ, 2003, J BIOL CHEM, V278, P16852, DOI 10.1074/jbc.M300619200	31	74	77	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34218	34223		10.1074/jbc.M505735200	http://dx.doi.org/10.1074/jbc.M505735200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16081417	hybrid			2022-12-25	WOS:000232229700064
J	Mandal, AK; Ray, R; Zhang, ZJ; Chowdhury, B; Pattabiraman, N; Mukherjee, AB				Mandal, AK; Ray, R; Zhang, ZJ; Chowdhury, B; Pattabiraman, N; Mukherjee, AB			Uteroglobin inhibits prostaglandin F-2 alpha receptor-mediated expression of genes critical for the production of pro-inflammatory lipid mediators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; RECOMBINANT HUMAN UTEROGLOBIN; CYTOSOLIC PHOSPHOLIPASE A(2); ENDOPEROXIDE-H SYNTHASE-1; INVITRO CHARACTERIZATION; PROSTANOID RECEPTOR; HUMAN MYOMETRIUM; BINDING-PROTEIN; AMNIOTIC-FLUID; NUCLEAR-FACTOR	Prematurity is one of the leading causes of infant mortality. It may result from intrauterine infection, which mediates premature labor by stimulating the production of inflammatory lipid mediators such as prostaglandin F-2 alpha (PGF2(alpha)). The biological effects of PGF(2 alpha) are mediated via the G protein-coupled receptor FP; however, the molecular mechanism(s) of FP signaling that mediates inflammatory lipid mediator production remains unclear. We reported previously that in the human uterus, a composite organ in which fibroblast, epithelial, and smooth muscle cells are the major constituents, an inverse relationship exists between the levels of PGF(2 alpha) and a steroid-inducible anti-inflammatory protein, uteroglobin. Here we report that, in NIH 3T3 fibroblasts and human uterine smooth muscle cells, FP signaling is mediated via multi-kinase pathways in a cell type-specific manner to activate NF-kappa B, thus stimulating the expression of cyclooxygenase-2. Cyclooxygenase-2 is a critical enzyme for the production of prostaglandins from arachidonic acid, which is released from membrane phospholipids by phospholipase A(2), the expression of which is also stimulated by PGF(2 alpha). Most importantly, uteroglobin inhibits FP-mediated NF-kappa B activation and cyclooxygenase- 2 gene expression by binding and most likely by sequestering PGF(2 alpha) into its central hydrophobic cavity, thereby preventing FP-PGF(2 alpha) interaction and suppressing the production of inflammatory lipid mediators. We propose that uteroglobin plays important roles in maintaining homeostasis in organs that are vulnerable to inadvertent stimulation of FP-mediated inflammatory response.	NICHD, Sect Dev Genet, Heritable Disorders Branch, NIH, Bethesda, MD 20892 USA; Georgetown Univ, Vincent T Lombardi Canc Res Ctr, Dept Oncol, Washington, DC 20057 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Georgetown University	Mukherjee, AB (corresponding author), NICHD, Sect Dev Genet, Heritable Disorders Branch, NIH, Bethesda, MD 20892 USA.	mukherja@exchange.nih.gov						BEATO M, 1976, J STEROID BIOCHEM, V7, P327, DOI 10.1016/0022-4731(76)90091-1; CSEPLI J, 1975, PROSTAGLANDINS, V10, P689, DOI 10.1016/S0090-6980(75)80017-7; DAcquisto F, 1997, FEBS LETT, V418, P175, DOI 10.1016/S0014-5793(97)01377-X; DEASUA LJ, 1977, NATURE, V265, P450, DOI 10.1038/265450a0; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; Fujino H, 2003, EUR J PHARMACOL, V465, P39, DOI 10.1016/S0014-2999(03)01485-7; GOLDBERG VJ, 1975, PHYSIOL REV, V55, P325, DOI 10.1152/physrev.1975.55.3.325; GU W, 1990, PROSTAG LEUKOTR ESS, V40, P27, DOI 10.1016/0952-3278(90)90112-X; HARD T, 1995, NAT STRUCT BIOL, V2, P983, DOI 10.1038/nsb1195-983; Hewetson A, 1997, MOL CELL ENDOCRINOL, V136, P1, DOI 10.1016/S0303-7207(97)00203-7; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; KEIRSE MJNC, 1977, BRIT J OBSTET GYNAEC, V84, P743, DOI 10.1111/j.1471-0528.1977.tb12484.x; KIKUKAWA T, 1988, J CLIN ENDOCR METAB, V67, P315, DOI 10.1210/jcem-67-2-315; KLUG J, 2000, ANN NY ACAD SCI, V923, P349; KRISHNAN RS, 1967, SCIENCE, V158, P490, DOI 10.1126/science.158.3800.490; Kundu GC, 1996, P NATL ACAD SCI USA, V93, P2915, DOI 10.1073/pnas.93.7.2915; Kundu GC, 1998, J BIOL CHEM, V273, P22819, DOI 10.1074/jbc.273.35.22819; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; Lin X, 2000, MOL CELL BIOL, V20, P2933, DOI 10.1128/MCB.20.8.2933-2940.2000; Mandal AK, 2004, J EXP MED, V199, P1317, DOI 10.1084/jem.20031666; MANTILE G, 1993, J BIOL CHEM, V268, P20343; McCracken J A, 1973, Adv Biosci, V9, P599; MIELE L, 1990, J BIOL CHEM, V265, P6427; MIELE L, 1988, NATURE, V335, P726, DOI 10.1038/335726a0; MINAMI T, 1992, PAIN, V50, P223, DOI 10.1016/0304-3959(92)90166-9; MONCADA S, 1985, PHARMACOL BASIS THER, V7, P660; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; Mukherjee AB, 1999, CELL MOL LIFE SCI, V55, P771, DOI 10.1007/s000180050331; Murakami M, 2003, ADV EXP MED BIOL, V525, P87; NAKAO A, 1993, J CELL PHYSIOL, V155, P257, DOI 10.1002/jcp.1041550206; NORDLUNDMOLLER L, 1990, J BIOL CHEM, V265, P12690; Norman RJ, 2004, FERTIL STERIL, V81, P493, DOI 10.1016/j.fertnstert.2003.10.016; Pattabiraman N, 2000, ANN NY ACAD SCI, V923, P113; PERI A, 1995, J CLIN INVEST, V96, P343, DOI 10.1172/JCI118040; POYSER NL, 1995, PROSTAG LEUKOTR ESS, V53, P147, DOI 10.1016/0952-3278(95)90115-9; QUARLES LD, 1993, ENDOCRINOLOGY, V132, P1505, DOI 10.1210/en.132.4.1505; Rice GE, 1998, PLACENTA, V19, P13, DOI 10.1016/S0143-4004(98)90093-5; ROMERO R, 1987, AM J OBSTET GYNECOL, V157, P1461, DOI 10.1016/S0002-9378(87)80245-4; Romero Roberto, 2002, Semin Neonatol, V7, P259, DOI 10.1053/siny.2002.0121; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Sapirstein A, 1996, J BIOL CHEM, V271, P21505, DOI 10.1074/jbc.271.35.21505; SCHLAFF S, 1983, PROSTAGLANDINS, V26, P111, DOI 10.1016/0090-6980(83)90079-5; SENIOR J, 1993, BRIT J PHARMACOL, V108, P501, DOI 10.1111/j.1476-5381.1993.tb12832.x; SENIOR J, 1992, BRIT J PHARMACOL, V107, P215, DOI 10.1111/j.1476-5381.1992.tb14489.x; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; Soloff MS., 1989, BIOL UTERUS, P559; Sontag E, 1997, EMBO J, V16, P5662, DOI 10.1093/emboj/16.18.5662; Sugimoto Y, 1997, SCIENCE, V277, P681, DOI 10.1126/science.277.5326.681; Tsuboi K, 2000, ENDOCRINOLOGY, V141, P315, DOI 10.1210/en.141.1.315; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; Vielhauer GA, 2004, ARCH BIOCHEM BIOPHYS, V421, P175, DOI 10.1016/j.abb.2003.10.021; Warner TD, 2004, FASEB J, V18, P790, DOI 10.1096/fj.03-0645rev; Watanabe T, 1996, J CELL PHYSIOL, V169, P401, DOI 10.1002/(SICI)1097-4652(199611)169:2<401::AID-JCP20>3.0.CO;2-A; WEINGES K, 1984, LIEBIGS ANN CHEM, P761; Wu KK, 2005, PROSTAG LEUKOTR ESS, V72, P89, DOI 10.1016/j.plefa.2004.11.001; Wu WX, 2004, ENDOCRINOLOGY, V145, P1444, DOI 10.1210/en.2003-1142; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315	58	15	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32897	32904		10.1074/jbc.M502375200	http://dx.doi.org/10.1074/jbc.M502375200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16061484	hybrid			2022-12-25	WOS:000231920300044
J	Marwaha, V; Chen, YH; Helms, E; Arad, S; Inoue, H; Bord, E; Kishore, R; Sarkissian, RD; Gilchrest, BA; Goukassian, DA				Marwaha, V; Chen, YH; Helms, E; Arad, S; Inoue, H; Bord, E; Kishore, R; Sarkissian, RD; Gilchrest, BA; Goukassian, DA			T-oligo treatment decreases constitutive and UVB-induced COX-2 levels through p53- and NF kappa B-dependent repression of the COX-2 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							CYCLOOXYGENASE-2 GENE-EXPRESSION; NITRIC-OXIDE SYNTHASE-2; BASAL-CELL CARCINOMAS; INDUCED SKIN TUMORS; NUCLEAR-FACTOR; DNA-DAMAGE; THYMIDINE DINUCLEOTIDES; WILD-TYPE; ENDOTHELIAL-CELLS; MOUSE SKIN	Chronically irradiated murine skin and UV light-induced squamous cell carcinomas overexpress the inducible isoform of cyclooxygenase (COX-2), and COX-2 inhibition reduces photocarcinogenesis in mice. We have reported previously that DNA oligonucleotides substantially homologous to the telomere 3'-overhang (T-oligos) induce DNA repair capacity and multiple other cancer prevention responses, in part through up-regulation and activation of p53. To determine whether T-oligos affect COX-2 expression, human newborn keratinocytes and fibroblasts were pretreated with T-oligos or diluent alone for 24 h, UV-irradiated, and processed for Western blotting. In both cell types, T-oligos transcriptionally down-regulated base-line and UV light-induced COX2 expression, coincident with p53 activation. In fibroblasts with wild type versus dominant negative p53 (p53(WT) versus p53(DN)), T-oligos decreased constitutive expression of a COX-2 reporter plasmid by>50%. Wethen examined NF kappa B, a known positive regulator of COX-2 transcription. In p53WT but not in p53DN fibroblasts and in human keratinocytes, T-oligos decreased readout of an NF kappa B promoter driven reporter plasmid and decreased NF kappa B binding to DNA. After T-oligo treatment and subsequent UV irradiation, binding of the transcriptional co-activator protein p300 to NF kappa B was decreased, whereas binding of p300 to p53 was increased. Human skin explants provided with T-oligos had markedly decreased COX-2 immunostaining both at base-line and post-UV light, coincident with increased p53 immunostaining. We conclude that T-oligos transcriptionally down-regulate COX-2 expression in human skin via activation and up-regulation of p53, at least in part by inhibiting NF kappa B transcriptional activation. Decreased COX-2 expression may contribute to the observed ability of T-oligos to reduce photocarcinogenesis.	Boston Univ, Sch Med, Dept Dermatol, Boston, MA 02118 USA; Boston Univ, Sch Med, Div Facial Plast & Reconstruct Surg, Boston, MA 02118 USA; Nara Womens Univ, Nara 6308506, Japan; St Elizabeths Med Ctr, Div Cardiovasc Res, Boston, MA 02135 USA	Boston University; Boston University; Nara Womens University; St. Elizabeth's Medical Center	Gilchrest, BA (corresponding author), Boston Univ, Sch Med, Dept Dermatol, 609 Albany St, Boston, MA 02118 USA.	bgilchre@bu.edu; dgoukass@bu.edu		Goukassian, David/0000-0001-5270-5270	NATIONAL CANCER INSTITUTE [R01CA105156] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; Ahmed S, 2002, FREE RADICAL BIO MED, V33, P1097, DOI 10.1016/S0891-5849(02)01004-3; Albert MR, 2003, CA-CANCER J CLIN, V53, P292, DOI 10.3322/canjclin.53.5.292; An KP, 2002, PHOTOCHEM PHOTOBIOL, V76, P73, DOI 10.1562/0031-8655(2002)076<0073:CEIMAH>2.0.CO;2; Aszterbaum M, 1999, NAT MED, V5, P1285, DOI 10.1038/15242; Athar M, 2001, BIOCHEM BIOPH RES CO, V280, P1042, DOI 10.1006/bbrc.2000.4201; Aubin F, 2003, EUR J DERMATOL, V13, P515; Bielenberg DR, 1998, J INVEST DERMATOL, V111, P864, DOI 10.1046/j.1523-1747.1998.00378.x; Brash DE, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P136; Brash DE, 1998, CANCER SURV, V32, P69; Brecher Alexandra R, 2002, J Drugs Dermatol, V1, P44; Buckman SY, 1998, CARCINOGENESIS, V19, P723, DOI 10.1093/carcin/19.5.723; Caba E, 2004, ACTA NEUROPATHOL, V108, P173, DOI 10.1007/s00401-004-0876-5; Campbell KJ, 2001, BIOCHEM SOC T, V29, P688; Castelao JE, 2003, ANN THORAC SURG, V76, P1327, DOI 10.1016/S0003-4975(03)00334-5; CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1; Chen WX, 2001, ONCOGENE, V20, P3921, DOI 10.1038/sj.onc.1204530; Cruz PD, 2000, J INVEST DERMATOL, V114, P253, DOI 10.1046/j.1523-1747.2000.00866.x; Culmsee C, 2003, J NEUROSCI, V23, P8586; Curiel-Lewandrowski C, 2003, EXP DERMATOL, V12, P145, DOI 10.1034/j.1600-0625.2003.120204.x; Dannenberg AJ, 2003, CANCER CELL, V4, P431, DOI 10.1016/S1535-6108(03)00310-6; de Gruijl FR, 2001, J PHOTOCH PHOTOBIO B, V63, P19, DOI 10.1016/S1011-1344(01)00199-3; Dormond O, 2001, NAT MED, V7, P1041, DOI 10.1038/nm0901-1041; Eller MS, 2003, FASEB J, V17, P152, DOI 10.1096/fj.02-0197com; Eller MS, 2002, EXP CELL RES, V276, P185, DOI 10.1006/excr.2002.5531; ELLER MS, 1994, NATURE, V372, P413, DOI 10.1038/372413a0; Eller MS, 1996, P NATL ACAD SCI USA, V93, P1087, DOI 10.1073/pnas.93.3.1087; Eller MS, 1997, P NATL ACAD SCI USA, V94, P12627, DOI 10.1073/pnas.94.23.12627; Ferrandez A, 2003, CURR PHARM DESIGN, V9, P2229, DOI 10.2174/1381612033454036; Fischer SM, 1999, MOL CARCINOGEN, V25, P231; Fischer SM, 2003, CARCINOGENESIS, V24, P945, DOI 10.1093/carcin/bgg046; Fischer Susan M., 2002, Journal of Environmental Pathology Toxicology and Oncology, V21, P183; Fosslien E, 2001, ANN CLIN LAB SCI, V31, P325; FURSTENBERGER G, 1989, CARCINOGENESIS, V10, P91, DOI 10.1093/carcin/10.1.91; Gallo O, 2003, AM J PATHOL, V163, P723, DOI 10.1016/S0002-9440(10)63699-1; Gately S, 2004, SEMIN ONCOL, V31, P2, DOI 10.1053/j.seminoncol.2004.03.040; Geller AC, 2003, J AM ACAD DERMATOL, V48, P34, DOI 10.1067/mjd.2003.9; Gilchrest BA, 1999, NEW ENGL J MED, V340, P1341, DOI 10.1056/NEJM199904293401707; GILCHREST BA, 1993, J INVEST DERMATOL, V101, P666, DOI 10.1111/1523-1747.ep12371673; GILES G, 1996, CANC FORUM, V20, P188; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Goukassian DA, 1999, J INVEST DERMATOL, V112, P25, DOI 10.1046/j.1523-1747.1999.00468.x; Goukassian DA, 2004, P NATL ACAD SCI USA, V101, P3933, DOI 10.1073/pnas.0306389101; Goukassian DA, 2002, FASEB J, V16, P754, DOI 10.1096/fj.01-0829fje; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Hadshiew IM, 2001, J DERMATOL SCI, V25, P127, DOI 10.1016/S0923-1811(00)00125-0; HALL PA, 1993, ONCOGENE, V8, P203; Han JA, 2002, EMBO J, V21, P5635, DOI 10.1093/emboj/cdf591; Han SJ, 2002, J BIOL CHEM, V277, P44715, DOI 10.1074/jbc.M202524200; Howe LR, 2001, ENDOCR-RELAT CANCER, V8, P97, DOI 10.1677/erc.0.0080097; HRUZA LL, 1993, J INVEST DERMATOL, V100, pS35, DOI 10.1111/1523-1747.ep12355240; Huang J, 2004, J BIOL CHEM, V279, P16847, DOI 10.1074/jbc.M309491200; Ikeda A, 2000, BIOCHEM BIOPH RES CO, V272, P375, DOI 10.1006/bbrc.2000.2786; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; Inoue H, 2002, ARTERIOSCL THROM VAS, V22, P1415, DOI 10.1161/01.ATV.0000028816.13582.13; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Kishore R, 2003, CIRC RES, V93, P932, DOI 10.1161/01.RES.0000102400.22370.20; Kishore R, 2002, CIRC RES, V91, P307, DOI 10.1161/01.RES.0000031744.06353.D3; KLEY N, 1992, NUCLEIC ACIDS RES, V20, P4083, DOI 10.1093/nar/20.15.4083; Koki Alane T, 2002, Cancer Control, V9, P28; Kopnin BP, 2000, BIOCHEMISTRY-MOSCOW+, V65, P2; Kulkarni S, 2001, CLIN CANCER RES, V7, P429; Kundu M, 1997, J BIOL CHEM, V272, P29468, DOI 10.1074/jbc.272.47.29468; Kuper H, 2000, J INTERN MED, V248, P171, DOI 10.1046/j.1365-2796.2000.00742.x; LAVKER RM, 1995, J AM ACAD DERMATOL, V32, P53, DOI 10.1016/0190-9622(95)90184-1; Li GZ, 2004, EXP CELL RES, V301, P189, DOI 10.1016/j.yexcr.2004.08.019; Li GZ, 2003, P NATL ACAD SCI USA, V100, P527, DOI 10.1073/pnas.0235444100; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; Maeda T, 1999, MUTAT RES-DNA REPAIR, V433, P137, DOI 10.1016/S0921-8777(98)00071-8; MARGULIES L, 1993, J BIOL CHEM, V268, P15096; Marnett LJ, 2002, ANNU REV PHARMACOL, V42, P55, DOI 10.1146/annurev.pharmtox.42.082301.164620; McCormick Frank, 1999, Trends in Cell Biology, V9, pM53, DOI 10.1016/S0962-8924(99)01668-2; MILLER DL, 1994, J AM ACAD DERMATOL, V30, P774, DOI 10.1016/S0190-9622(08)81509-5; MIYASHITA T, 1994, CANCER RES, V54, P3131; Muller-Decker K, 2002, P NATL ACAD SCI USA, V99, P12483, DOI 10.1073/pnas.192323799; Orengo IF, 2002, ARCH DERMATOL, V138, P751, DOI 10.1001/archderm.138.6.751; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Osada H, 2002, ONCOGENE, V21, P7421, DOI 10.1038/sj.onc.1205802; Ospina JA, 2004, AM J PHYSIOL-HEART C, V286, pH2010, DOI 10.1152/ajpheart.00481.2003; Parente L, 2003, BIOCHEM PHARMACOL, V65, P153, DOI 10.1016/S0006-2952(02)01422-3; PATRICK MH, 1977, PHOTOCHEM PHOTOBIOL, V25, P357, DOI 10.1111/j.1751-1097.1977.tb07355.x; Pedeux R, 1998, J INVEST DERMATOL, V111, P472, DOI 10.1046/j.1523-1747.1998.00324.x; Pentland AP, 1999, CARCINOGENESIS, V20, P1939, DOI 10.1093/carcin/20.10.1939; Pentland AP, 2004, CANCER RES, V64, P5587, DOI 10.1158/0008-5472.CAN-04-1045; Pentland AP, 2002, ARCH DERMATOL, V138, P823, DOI 10.1001/archderm.138.6.823; Perfettini JL, 2004, J EXP MED, V199, P629, DOI 10.1084/jem.20031216; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Puri N, 2004, FASEB J, V18, P1373, DOI 10.1096/fj.04-1774com; RAGIMOV N, 1993, ONCOGENE, V8, P1183; Ramsay RG, 2003, INT J IMMUNOPATH PH, V16, P59; Ravi R, 1998, CANCER RES, V58, P4531; Remenyik E, 2003, ONCOGENE, V22, P6369, DOI 10.1038/sj.onc.1206657; Rheinwald JG, 2002, MOL CELL BIOL, V22, P5157, DOI 10.1128/MCB.22.14.5157-5172.2002; Rodel F, 2004, INT J RADIAT BIOL, V80, P115, DOI 10.1080/09553000310001654701; Sachs DL, 2001, CLIN GERIATR MED, V17, P715, DOI 10.1016/S0749-0690(05)70095-1; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; Schwarz T, 2002, PHOTODERMATOL PHOTO, V18, P141, DOI 10.1034/j.1600-0781.2002.180307.x; Scotto J, 1987, CANCER INVEST, V5, P275; Seo JY, 2003, MECH AGEING DEV, V124, P903, DOI 10.1016/S0047-6374(03)00150-7; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Shiota G, 1999, HEPATO-GASTROENTEROL, V46, P407; Soslow RA, 2000, CANCER, V89, P2637, DOI 10.1002/1097-0142(20001215)89:12<2637::AID-CNCR17>3.0.CO;2-B; Stansel RM, 2001, EMBO J, V20, P5532; STERENBORG HJCM, 1986, PHOTODERMATOLOGY, V3, P206; Subbaramaiah K, 1999, J BIOL CHEM, V274, P10911, DOI 10.1074/jbc.274.16.10911; Tanaka H, 2002, MOL CELL, V9, P1017, DOI 10.1016/S1097-2765(02)00522-1; TUBO RA, 1987, ONCOGENE RES, V1, P407; Tucker ON, 1999, CANCER RES, V59, P987; Turini ME, 2002, ANNU REV MED, V53, P35, DOI 10.1146/annurev.med.53.082901.103952; VANDERVEEN EE, 1986, ARCH DERMATOL, V122, P407, DOI 10.1001/archderm.122.4.407; Wang QJ, 1998, CANCER RES, V58, P5762; Webster GA, 1999, MOL CELL BIOL, V19, P3485; WERNINGHAUS K, 1991, PHOTODERMATOL PHOTO, V8, P236; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; Yoshimura R, 2000, CANCER-AM CANCER SOC, V89, P589, DOI 10.1002/1097-0142(20000801)89:3<589::AID-CNCR14>3.0.CO;2-C; Zhang WG, 2001, P NATL ACAD SCI USA, V98, P13948, DOI 10.1073/pnas.241353198; Zoumpourlis V, 2003, CARCINOGENESIS, V24, P1159, DOI 10.1093/carcin/bgg067	118	29	33	1	12	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32379	32388		10.1074/jbc.M503245200	http://dx.doi.org/10.1074/jbc.M503245200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16046401	hybrid			2022-12-25	WOS:000231794800043
J	van den Heuvel, RHH; Tahallah, N; Kamerbeek, NM; Fraaije, MW; van Berkel, WJH; Janssen, DB; Heck, AJR				van den Heuvel, RHH; Tahallah, N; Kamerbeek, NM; Fraaije, MW; van Berkel, WJH; Janssen, DB; Heck, AJR			Coenzyme binding during catalysis is beneficial for the stability of 4-hydroxyacetophenone monooxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BAEYER-VILLIGER MONOOXYGENASES; IONIZATION MASS-SPECTROMETRY; VANILLYL-ALCOHOL OXIDASE; ELECTROSPRAY-IONIZATION; ESCHERICHIA-COLI; METHYLENETETRAHYDROFOLATE REDUCTASE; CYCLOHEXANONE MONOOXYGENASE; SYNTHETIC APPLICATIONS; PROTEIN COMPLEXES; SPECIFICITY	The NADPH-dependent dimeric flavoenzyme 4-hydroxyacetophenone monooxygenase ( HAPMO) catalyzes Baeyer-Villiger oxidations of a wide range of ketones, thereby generating esters or lactones. In the current work, we probed HAPMO-coenzyme complexes present during the enzyme catalytic cycle with the aim to gain mechanistic insight. Moreover, we investigated the structural role of the nicotinamide coenzyme. For these studies, we used (i) wild type HAPMO, (ii) the R339A variant, which is active but has a low affinity toward NADPH, and (iii) the R440A variant, which is inactive but has a high affinity toward NADPH. Electrospray ionization mass spectrometry was used as the primary tool to directly observe noncovalent protein-coenzyme complexes in real time. These analyzes showed for the first time that the nicotinamide coenzyme remains bound to HAPMO during the entire catalytic cycle of the NADPH oxidase reaction. This may also have implications for other homologous Baeyer-Villiger monooxygenases. Together with the observations that NADP(+) only weakly interacts with oxidized enzyme and that HAPMO is mainly in the reduced form during catalysis, we concluded that NADP(+) interacts tightly with the reduced form of HAPMO. We also demonstrated that the association with the coenzyme is crucial for enzyme stability. The interaction with the coenzyme analog 3-aminopyridine adenine dinucleotide phosphate ( AADP(+)) strongly enhanced the thermal stability of wild type HAPMO. This coenzyme-induced stabilization may also be important for related enzymes.	Univ Utrecht, Bijvoet Ctr Biomol Res, Dept Biomol Mass Spect, NL-3584 CA Utrecht, Netherlands; Univ Utrecht, Inst Pharmaceut Sci, NL-3584 CA Utrecht, Netherlands; Univ Groningen, Biomol Sci & Biotechnol Inst, Biochem Lab, NL-9747 AG Groningen, Netherlands; Univ Wageningen & Res Ctr, Biochem Lab, NL-6703 HA Wageningen, Netherlands	Utrecht University; Utrecht University; University of Groningen; Wageningen University & Research	van den Heuvel, RHH (corresponding author), Univ Utrecht, Bijvoet Ctr Biomol Res, Dept Biomol Mass Spect, Sorbonnelaan 16, NL-3584 CA Utrecht, Netherlands.	r.h.h.vandenheuvel@chem.uu.nl	van Berkel, Willem J.H./O-2431-2014; Fraaije, Marco/E-8421-2014; Heck, Albert/D-7098-2011	van Berkel, Willem J.H./0000-0002-6551-2782; Heck, Albert/0000-0002-2405-4404; Fraaije, Marco/0000-0001-6346-5014				Alphand V, 2003, TRENDS BIOTECHNOL, V21, P318, DOI 10.1016/S0167-7799(03)00144-6; Bollen YJM, 2005, J BIOL CHEM, V280, P7836, DOI 10.1074/jbc.M412871200; Bossi RT, 2002, BIOCHEMISTRY-US, V41, P8807, DOI 10.1021/bi025858a; Cattani L, 1994, Boll Soc Ital Biol Sper, V70, P75; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; Fraaije MW, 2002, FEBS LETT, V518, P43, DOI 10.1016/S0014-5793(02)02623-6; Fraaije MW, 2000, J BIOL CHEM, V275, P38654, DOI 10.1074/jbc.M004753200; Georlette D, 2003, J BIOL CHEM, V278, P49945, DOI 10.1074/jbc.M307761200; Grandori R, 2002, J MASS SPECTROM, V37, P191, DOI 10.1002/jms.272; Guenther BD, 1999, NAT STRUCT BIOL, V6, P359, DOI 10.1038/7594; Heck AJR, 2004, MASS SPECTROM REV, V23, P368, DOI 10.1002/mas.10081; Hefti MH, 2003, EUR J BIOCHEM, V270, P4227, DOI 10.1046/j.1432-1033.2003.03802.x; Kamerbeek NM, 2004, EUR J BIOCHEM, V271, P2107, DOI 10.1111/j.1432-1033.2004.04126.x; Kamerbeek NM, 2003, APPL ENVIRON MICROB, V69, P419, DOI 10.1128/AEM.69.1.419-426.2003; Kamerbeek NM, 2001, EUR J BIOCHEM, V268, P2547, DOI 10.1046/j.1432-1327.2001.02137.x; KAMERGBEEK NM, 2002, FLAVINS FLAVOPROTEIN, P1005; Loo JA, 1997, MASS SPECTROM REV, V16, P1; Malito E, 2004, P NATL ACAD SCI USA, V101, P13157, DOI 10.1073/pnas.0404538101; Mihovilovic MD, 2003, BIOORG MED CHEM LETT, V13, P1479, DOI 10.1016/S0960-894X(03)00137-9; Mulrooney SB, 1997, PROTEIN SCI, V6, P2188; Pai EF, 1991, CURR OPIN STRUC BIOL, V1, P796, DOI 10.1016/0959-440X(91)90181-R; Park IK, 1998, INT J BIOCHEM CELL B, V30, P1223, DOI 10.1016/S1357-2725(98)00088-0; PELLETIER JN, 1994, BIOCHEMISTRY-US, V33, P1900, DOI 10.1021/bi00173a037; POULSEN LL, 1995, CHEM-BIOL INTERACT, V96, P57, DOI 10.1016/0009-2797(94)03583-T; POULSEN LL, 1979, J BIOL CHEM, V254, P6449; Schmidt A, 2001, ANAL CHEM, V73, P6040, DOI 10.1021/ac010451h; Sheng DW, 2001, BIOCHEMISTRY-US, V40, P11156, DOI 10.1021/bi011153h; SHRAKE A, 1990, J BIOL CHEM, V265, P5055; Sulzenbacher G, 2004, J MOL BIOL, V342, P489, DOI 10.1016/j.jmb.2004.07.034; Tahallah N, 2002, J BIOL CHEM, V277, P36425, DOI 10.1074/jbc.M205841200; Tahallah N, 2001, RAPID COMMUN MASS SP, V15, P596, DOI 10.1002/rcm.275; van den Bremer ETJ, 2002, PROTEIN SCI, V11, P1738, DOI 10.1110/ps.0200502; VANBERKEL WJH, 1991, EUR J BIOCHEM, V197, P769; WIERENGA RK, 1983, J MOL BIOL, V167, P725, DOI 10.1016/S0022-2836(83)80106-5; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; Willetts A, 1997, TRENDS BIOTECHNOL, V15, P55, DOI 10.1016/S0167-7799(97)84204-7; Woodyer R, 2003, BIOCHEMISTRY-US, V42, P11604, DOI 10.1021/bi035018b; Yamada K, 2001, P NATL ACAD SCI USA, V98, P14853, DOI 10.1073/pnas.261469998; Zambianchi F, 2002, BIOTECHNOL BIOENG, V78, P489, DOI 10.1002/bit.10207	39	23	28	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32115	32121		10.1074/jbc.M503758200	http://dx.doi.org/10.1074/jbc.M503758200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16049018	hybrid, Green Published			2022-12-25	WOS:000231794800011
J	Joshi, MB; Philippova, M; Ivanov, D; Allenspach, R; Erne, P; Resink, TSJ				Joshi, MB; Philippova, M; Ivanov, D; Allenspach, R; Erne, P; Resink, TSJ			T-cadherin protects endothelial cells from oxidative stress-induced apoptosis	FASEB JOURNAL			English	Article						serum-withdrawal; survival; signaling	SMOOTH-MUSCLE; DOWN-REGULATION; N-CADHERIN; EXPRESSION; ADHESION; SURVIVAL; GROWTH; DEATH; ACTIVATION; SIGNAL	In vascular tissue, T-cadherin (T-cad) is up-regulated in vivo under disease conditions associated with oxidative stress and concomitant cell migration, proliferation and apoptosis/ survival. Using cultures of human umbilical vein endothelial cells (HUVEC), we examined whether there is a functional relationship between oxidative stress, T-cad expression, and cell survival status. Culture of HUVEC under conditions of oxidative stress (e. g., serum deprivation, inclusion of H2O2) resulted in increased T-cad expression. Oxidative stress-induced increases in T-cad were inhibited by the free radical-scavenging antioxidant, N-acetylcysteine, and the flavin-containing oxidase inhibitor, diphenyleneiodonium. Thus reactive oxygen species (ROS) contribute to stress-induced elevation of T-cad in HUVEC. Compared with control cells, HUVEC overexpressing T-cad (T-cad+-HUVEC) had higher phosphorylation levels for phosphatidylinositol 3-kinase (PI3K) target Akt and mTOR target p70(S6K) (survival pathway regulators), but lower levels for p38MAPK (death pathway regulator). T-cad+-HUVEC exposed to stress (serum-deprivation, TNF-alpha, actinomycin D, staurosporine) exhibited reduced caspase activation together with increased cell survival. Protection against stress-induced apoptosis in T-cad+-HUVEC was abrogated by either PI3K-inhibitor wortmannin or mTOR-inhibitor rapamycin. We conclude that T-cad overexpression in HUVEC protects against stress-induced apoptosis through activation of the PI3K/Akt/mTOR survival signal pathway and concomitant suppression of the p38 MAPK proapoptotic pathway. ROS-induced changes in T-cad expression may play an important role in controlling tissue cellularity during vascular remodeling.	Univ Basel Hosp, Cardiovasc Labs, Dept Res, CH-4031 Basel, Switzerland; Luzern Kantonsspital, Div Cardiol, Luzern, Switzerland	University of Basel; Lucerne Cantonal Hospital	Resink, TSJ (corresponding author), Univ Basel Hosp, Cardiovasc Labs, Dept Res, Hebelstr 20, CH-4031 Basel, Switzerland.	Therese-J.Resink@unibas.ch	Joshi, Manjunath B/G-2052-2012; Filippova, Maria/GXH-7313-2022	Joshi, Manjunath/0000-0002-1310-5480; Filippova, Maria/0000-0003-3124-3155				ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Beohar N, 2004, CIRCULATION, V109, P108, DOI 10.1161/01.CIR.0000105724.30980.CD; Bezzi M, 2003, J BIOL CHEM, V278, P43603, DOI 10.1074/jbc.M308114200; Blanc A, 2003, INT J MOL MED, V11, P229; Bochkov VN, 1996, BIOCHEM J, V317, P297, DOI 10.1042/bj3170297; Cantara S, 2004, J VASC RES, V41, P202, DOI 10.1159/000077408; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Chan S, 2004, BRIT J CANCER, V91, P1420, DOI 10.1038/sj.bjc.6602162; Choy JC, 2001, J MOL CELL CARDIOL, V33, P1673, DOI 10.1006/jmcc.2001.1419; Corda S, 2001, AM J RESP CELL MOL, V24, P762, DOI 10.1165/ajrcmb.24.6.4228; Das DK, 2004, BIOCHEMISTRY-MOSCOW+, V69, P10, DOI 10.1023/B:BIRY.0000016345.19027.54; de Nigris F, 2003, TRENDS MOL MED, V9, P351, DOI 10.1016/S1471-4914(03)00139-4; Fredette BJ, 1996, DEVELOPMENT, V122, P3163; Geng YH, 2002, ARTERIOSCL THROM VAS, V22, P1370, DOI 10.1161/01.ATV.0000031341.84618.A4; Gil J, 2003, FREE RADICAL BIO MED, V35, P1500, DOI 10.1016/j.freeradbiomed.2003.08.022; Gratton JP, 2001, J BIOL CHEM, V276, P30359, DOI 10.1074/jbc.M009698200; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; Hao JH, 2004, CANCER RES, V64, P3607, DOI 10.1158/0008-5472.CAN-03-3648; Harfouche R, 2003, FASEB J, V17, P1523, DOI 10.1096/fj.02-0698fje; Irani K, 2000, CIRC RES, V87, P179, DOI 10.1161/01.RES.87.3.179; Iurlaro M, 2004, AM J PATHOL, V165, P181, DOI 10.1016/S0002-9440(10)63287-7; Ivanov D, 2004, CARDIOVASC RES, V64, P132, DOI 10.1016/j.cardiores.2004.06.010; Ivanov D, 2004, EXP CELL RES, V293, P207, DOI 10.1016/j.yexcr.2003.09.030; Ivanov D, 2001, HISTOCHEM CELL BIOL, V115, P231; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; King AR, 2003, LAB INVEST, V83, P1497, DOI 10.1097/01.LAB.0000093096.62765.85; Koller E, 1996, J BIOL CHEM, V271, P30061, DOI 10.1074/jbc.271.47.30061; Kudrjashova E, 2002, HISTOCHEM CELL BIOL, V118, P281, DOI 10.1007/s00418-002-0463-6; Kuzmenko YS, 1998, FEBS LETT, V434, P183, DOI 10.1016/S0014-5793(98)00977-6; Laprise P, 2004, J CELL PHYSIOL, V199, P32, DOI 10.1002/jcp.10432; Li AE, 1999, CIRC RES, V85, P304, DOI 10.1161/01.RES.85.4.304; Ling SH, 2002, ENDOCRINOLOGY, V143, P1119, DOI 10.1210/en.143.3.1119; Lum H, 2001, AM J PHYSIOL-CELL PH, V280, pC719; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Mattiussi S, 2004, CARDIOVASC RES, V61, P693, DOI 10.1016/j.cardiores.2003.12.008; Papadakis CM, 2000, EUR PHYS J E, V1, P275, DOI 10.1007/s101890050029; Philippova M, 2005, FASEB J, V19, P588, DOI 10.1096/fj.04-2430fje; Philippova M, 2003, HISTOCHEM CELL BIOL, V120, P353, DOI 10.1007/s00418-003-0584-6; Philippova MP, 1998, FEBS LETT, V429, P207, DOI 10.1016/S0014-5793(98)00598-5; Recchioni R, 2002, METABOLISM, V51, P1384, DOI 10.1053/meta.2002.35579; Resink TJ, 1999, FEBS LETT, V463, P29, DOI 10.1016/S0014-5793(99)01594-X; Shen XD, 2004, AM J PATHOL, V165, P1315, DOI 10.1016/S0002-9440(10)63390-1; Sorenson CM, 2004, BBA-MOL CELL RES, V1644, P169, DOI 10.1016/j.bbamcr.2003.08.010; Tran NL, 2002, J BIOL CHEM, V277, P32905, DOI 10.1074/jbc.M200300200; Tsuruga M, 2003, MOL CELL BIOCHEM, V250, P131, DOI 10.1023/A:1024912806686; VESTAL DJ, 1992, J CELL BIOL, V119, P451, DOI 10.1083/jcb.119.2.451; Wang ZS, 2001, CANCER RES, V61, P7171; Wyder L, 2000, CANCER RES, V60, P4682; Yilmaz A, 2003, BIOCHEM BIOPH RES CO, V306, P730, DOI 10.1016/S0006-291X(03)01064-7; Zafarullah M, 2003, CELL MOL LIFE SCI, V60, P6, DOI 10.1007/s000180300001; Zajchowski LD, 2002, EUR J BIOCHEM, V269, P737, DOI 10.1046/j.0014-2956.2001.02715.x	51	72	80	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1737	+		10.1096/fj.05-3834fje	http://dx.doi.org/10.1096/fj.05-3834fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16099944				2022-12-25	WOS:000231843700017
J	Siatskas, C; Underwood, J; Ramezani, A; Hawley, RG; Medin, JA				Siatskas, C; Underwood, J; Ramezani, A; Hawley, RG; Medin, JA			Specific pharmacological dimerization of KDR in lentivirally transduced human hematopoietic cells activates antiapoptotic and proliferative mechanisms	FASEB JOURNAL			English	Article						heat shock proteins; selective growth advantage; gene therapy; microarray analysis; AP20187	ENDOTHELIAL GROWTH-FACTOR; HEAT-SHOCK-PROTEIN; IN-VIVO SELECTION; SIGNAL-TRANSDUCTION; MOLECULAR CHAPERONES; GENE-EXPRESSION; C-KIT; RECEPTOR; SURVIVAL; APOPTOSIS	Selective and regulatable expansion of transduced cells could augment gene therapy for many disorders. The activation of modified growth factor receptors via synthetic chemical inducers of dimerization allows for the coordinated growth of transduced cells. This system can also provide information on specific receptor- mediated signaling without interference from other family members. Although several receptor subunits have been investigated in this context, little is known about the precise molecular events associated with dimerizer- initiated signaling. We have constructed and expressed an AP20187- regulated KDR chimeric receptor in human TF1 cells and analyzed activation of this gene switch using functional, biochemical, and microarray analyses. When deprived of natural ligands, GM- CSF, interleukin- 3, or erythropoietin, AP20187 prevented apoptosis of transduced TF1 cells, induced dose- dependent proliferation, and supported long- term growth. In addition, AP20187 stimulation activated the signaling molecules associated with mitogen- activated protein kinase and phosphatidyl- inositol 3- kinase/ Akt pathways. Microarray analysis determined that a number of transcripts involved in a variety of cellular processes were differentially expressed. Notably, mRNAs affiliated with heat stress, including Hsp70 and Hsp105, were up- regulated. Functional assays showed that Hsp70 and Hsp105 protected transduced TF1 cells from apoptosis and premature senescence, in part through regulation of Akt. These observations delineate specific roles for kinase insert domain- containing receptor, or KDR, signaling and suggest strategies to endow genetically modified cells with a survival advantage enabling the generation of adequate cell numbers for therapeutic outcomes.	Univ Hlth Network, Ontario Canc Inst, Div Stem Cell & Dev Biol, Toronto, ON M5G 2M1, Canada; George Washington Univ, Med Ctr, Dept Anat & Cell Biol, Washington, DC 20037 USA; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; George Washington University; University of Toronto; University of Toronto	Medin, JA (corresponding author), Univ Hlth Network, Ontario Canc Inst, Div Stem Cell & Dev Biol, 67 Coll St,Room 406, Toronto, ON M5G 2M1, Canada.	jmedin@uhnres.utoronto.ca		Hawley, Robert/0000-0003-3512-5818	NHLBI NIH HHS [HL70569] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe Mayumi, 2001, Angiogenesis, V4, P289, DOI 10.1023/A:1016018617152; ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Birkenkamp KU, 2003, J IMMUNOL, V171, P1623, DOI 10.4049/jimmunol.171.4.1623; Blau CA, 1997, P NATL ACAD SCI USA, V94, P3076, DOI 10.1073/pnas.94.7.3076; Bornfeldt KE, 2000, CIRC RES, V86, P1101, DOI 10.1161/01.RES.86.11.1101; Clackson T, 1997, CURR OPIN CHEM BIOL, V1, P210, DOI 10.1016/S1367-5931(97)80012-9; Cortes F, 1999, MECH DEVELOP, V83, P161, DOI 10.1016/S0925-4773(99)00030-1; Coulombe P, 2003, MOL CELL BIOL, V23, P4542, DOI 10.1128/MCB.23.13.4542-4558.2003; Damjanovich S, 1997, P NATL ACAD SCI USA, V94, P13134, DOI 10.1073/pnas.94.24.13134; Dias S, 2000, J CLIN INVEST, V106, P511, DOI 10.1172/JCI8978; Dias S, 2002, BLOOD, V99, P2532, DOI 10.1182/blood.V99.7.2532; Dorsam ST, 2004, BLOOD, V103, P1676, DOI 10.1182/blood-2003-07-2202; Follenzi A, 2002, METHOD ENZYMOL, V346, P454; Follenzi A, 2000, NAT GENET, V25, P217, DOI 10.1038/76095; GADELLA TWJ, 1995, J CELL BIOL, V129, P1543, DOI 10.1083/jcb.129.6.1543; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; GUO CM, 1995, J BIOL CHEM, V270, P27562, DOI 10.1074/jbc.270.46.27562; Halene S, 2000, HUM GENE THER, V11, P1259, DOI 10.1089/10430340050032366; Hattori K, 2001, J EXP MED, V193, P1005, DOI 10.1084/jem.193.9.1005; Helmbrecht K, 2000, CELL PROLIFERAT, V33, P341, DOI 10.1046/j.1365-2184.2000.00189.x; Huang HM, 1999, BLOOD, V93, P2569, DOI 10.1182/blood.V93.8.2569.408k08_2569_2577; Iuliucci JD, 2001, J CLIN PHARMACOL, V41, P870, DOI 10.1177/00912700122010771; Jin LQ, 1998, P NATL ACAD SCI USA, V95, P8093, DOI 10.1073/pnas.95.14.8093; Jin LQ, 2000, NAT GENET, V26, P64, DOI 10.1038/79194; Jin LQ, 1998, BLOOD, V91, P890, DOI 10.1182/blood.V91.3.890.890_890_897; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Kabrun N, 1997, DEVELOPMENT, V124, P2039; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; Knight EL, 2000, ONCOGENE, V19, P5398, DOI 10.1038/sj.onc.1203915; Koishi M, 2001, CLIN CANCER RES, V7, P215; Kwak HJ, 1998, CELL IMMUNOL, V187, P1, DOI 10.1006/cimm.1998.1309; KWARTA MM, 1992, BIOCHIM BIOPHYS ACTA, V1134, P178; Larrivee B, 2003, J BIOL CHEM, V278, P22006, DOI 10.1074/jbc.M212158200; Li B, 2000, J BIOL CHEM, V275, P29823, DOI 10.1074/jbc.M002015200; Li ZY, 2002, MOL THER, V5, P420, DOI 10.1006/mthe.2002.0565; MAVILIO F, 1994, BLOOD, V83, P1988; MCCLOSKEY P, 1994, CELL GROWTH DIFFER, V5, P1105; Nakamura N, 1996, J BIOL CHEM, V271, P19483, DOI 10.1074/jbc.271.32.19483; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Neff T, 2002, BLOOD, V100, P2026, DOI 10.1182/blood-2002-03-0792; Neff T, 2001, BLOOD, V97, P2535, DOI 10.1182/blood.V97.9.2535; Nollen EAA, 2002, J CELL SCI, V115, P2809; Otto KG, 2001, BLOOD, V97, P3662, DOI 10.1182/blood.V97.11.3662; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; Ramezani A, 2000, MOL THER, V2, P458, DOI 10.1006/mthe.2000.0190; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; Rosas M, 2005, FEBS LETT, V579, P191, DOI 10.1016/j.febslet.2004.11.074; Santos SCR, 2004, BLOOD, V103, P3883, DOI 10.1182/BLOOD-2003-05-1634; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Temple R, 2001, AM J RESP CELL MOL, V25, P425, DOI 10.1165/ajrcmb.25.4.4456; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Whitney ML, 2001, J BIOL CHEM, V276, P41191, DOI 10.1074/jbc.M103191200; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; Yang SY, 2002, ARTERIOSCL THROM VAS, V22, P1797, DOI 10.1161/01.ATV.0000038995.31179.24; Yao Q, 2003, CLIN CANCER RES, V9, P4483; Yokota S, 2000, CANCER RES, V60, P2942; Zachary I, 2001, CARDIOVASC RES, V49, P568, DOI 10.1016/S0008-6363(00)00268-6; Zhang H T, 1999, Angiogenesis, V3, P211, DOI 10.1023/A:1009085422384; Zhao SM, 2004, MOL THER, V10, P456, DOI 10.1016/j.ymthe.2004.05.014; Zhao SM, 2002, EMBO J, V21, P2159, DOI 10.1093/emboj/21.9.2159; Ziegler BL, 1999, SCIENCE, V285, P1553, DOI 10.1126/science.285.5433.1553; Zippo A, 2004, BLOOD, V103, P4536, DOI 10.1182/blood-2003-11-3827	68	10	12	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1752	+		10.1096/fj.05-4006fje	http://dx.doi.org/10.1096/fj.05-4006fje			31	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16076962				2022-12-25	WOS:000231843700024
J	Yatsiv, I; Grigoriadis, N; Simeonidou, C; Stahel, PF; Schmidt, OI; Alexandrovich, AG; Tsenter, J; Shohami, E				Yatsiv, I; Grigoriadis, N; Simeonidou, C; Stahel, PF; Schmidt, OI; Alexandrovich, AG; Tsenter, J; Shohami, E			Erythropoietin is neuroprotective, improves functional recovery, and reduces neuronal apoptosis and inflammation in a rodent model of experimental closed head injury	FASEB JOURNAL			English	Article						apoptosis; traumatic brain injury; cytokines; therapy	TRAUMATIC BRAIN-INJURY; RECOMBINANT-HUMAN-ERYTHROPOIETIN; PERMANENT CEREBRAL-ISCHEMIA; COGNITIVE FUNCTION; DIALYSIS PATIENTS; NERVOUS-SYSTEM; MOUSE-BRAIN; MICE; RECEPTOR; RATS	Traumatic brain injury (TBI) is a leading cause of morbidity and mortality in young people in industrialized countries. Although various anti-inflammatory and antiapoptotic modalities have shown neuroprotective effects in experimental models of TBI, to date, no specific pharmacological agent aimed at blocking the progression of secondary brain damage has been approved for clinical use. Erythropoietin (Epo) belongs to the cytokine superfamily and has traditionally been viewed as a hematopoiesis-regulating hormone. The newly discovered neuroprotective properties of Epo lead us to investigate its effect in TBI in a mouse model of closed head injury. Recombinant human erythropoietin (rhEpo) was injected at 1 and 24 h after TBI, and the effect on recovery of motor and cognitive functions, tissue inflammation, axonal degeneration, and apoptosis was evaluated up to 14 days. Motor deficits were lower, cognitive function was restored faster, and less apoptotic neurons and caspase-3 expression were found in rhEpo-treated as compared with vehicle-treated animals (P<0.05). Axons at the trauma area in rhEpo-treated mice were relatively well preserved compared with controls (shown by their density; P<0.01). Immunohistochemical analysis revealed a reduced activation of glial cells by staining for GFAP and complement receptor type 3 (CD11b/CD18) in the injured hemisphere of Epo- vs. vehicle-treated animals. We propose that further studies on Epo in TBI should be conducted in order to consider it as a novel therapy for TBI.	Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Med Ctr, Dept Rehabil Med, Jerusalem, Israel; AHEPA Univ Hosp, Dept Neurol, Thessaloniki, Greece; Aritotle Univ, Fac Med, Dept Physiol, Thessaloniki, Greece; Chairte Univ Med Sch, Dept Trauma & Reconstruct Surg, Berlin, Germany	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hadassah University Medical Center; Aristotle University of Thessaloniki; Ahepa University Hospital	Shohami, E (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel.	esty@cc.huji.ac.il						Adembri C, 2004, J NEUROTRAUM, V21, P1103, DOI 10.1089/0897715041651079; Agnello D, 2002, BRAIN RES, V952, P128, DOI 10.1016/S0006-8993(02)03239-0; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Bernaudin M, 2000, GLIA, V30, P271, DOI 10.1002/(SICI)1098-1136(200005)30:3<271::AID-GLIA6>3.3.CO;2-8; Bernaudin M, 2002, J CEREBR BLOOD F MET, V22, P393, DOI 10.1097/00004647-200204000-00003; Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Buemi M, 2002, CLIN SCI, V103, P275, DOI 10.1042/cs1030275; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Catania MA, 2002, EUR J PHARMACOL, V437, P147, DOI 10.1016/S0014-2999(02)01292-X; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Coleman T, 2004, CRIT CARE, V8, P337, DOI 10.1186/cc2897; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; DIGICAYLIOGLU M, 1995, P NATL ACAD SCI USA, V92, P3717, DOI 10.1073/pnas.92.9.3717; Ehrenreich H, 2004, METAB BRAIN DIS, V19, P195, DOI 10.1023/B:MEBR.0000043969.96895.3c; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Erbayraktar Serhat, 2003, Curr Hematol Rep, V2, P465; Genc S, 2004, BRAIN RES, V1000, P19, DOI 10.1016/j.brainres.2003.12.037; Genc S, 2001, NEUROSCI LETT, V298, P139, DOI 10.1016/S0304-3940(00)01716-X; Ghezzi P, 2004, CELL DEATH DIFFER, V11, pS37, DOI 10.1038/sj.cdd.4401450; Gorio A, 2002, P NATL ACAD SCI USA, V99, P9450, DOI 10.1073/pnas.142287899; Juul SE, 1999, PEDIATR RES, V46, P543, DOI 10.1203/00006450-199911000-00009; Juul SE, 1998, PEDIATR RES, V43, P40, DOI 10.1203/00006450-199801000-00007; Juul SE, 2000, CLIN PERINATOL, V27, P527, DOI 10.1016/S0095-5108(05)70037-3; Kumral A, 2004, BEHAV BRAIN RES, V153, P77, DOI 10.1016/j.bbr.2003.11.002; Kumral A, 2003, BIOL NEONATE, V83, P224, DOI 10.1159/000068926; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Litchfield S, 2001, ACTA NEUROPATHOL, V101, P17; Macdougall Iain C, 2003, Curr Hematol Rep, V2, P459; MARSH JT, 1991, KIDNEY INT, V39, P155, DOI 10.1038/ki.1991.20; MASUDA S, 1994, J BIOL CHEM, V269, P19488; Matsushita H, 2003, NEUROREPORT, V14, P1757, DOI 10.1097/00001756-200309150-00020; Mogensen J, 2004, PHARMACOL BIOCHEM BE, V77, P381, DOI 10.1016/j.pbb.2003.11.017; Morishita E, 1997, NEUROSCIENCE, V76, P105, DOI 10.1016/s0306-4522(96)00306-5; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; *NAT CTR INJ PREV, 2001, INJ FACT BOOK 2001 2, P1; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Otto VI, 2001, NEUROREPORT, V12, P2059, DOI 10.1097/00001756-200107030-00053; Pickett JL, 1999, AM J KIDNEY DIS, V33, P1122, DOI 10.1016/S0272-6386(99)70150-2; Prass K, 2003, STROKE, V34, P1981, DOI 10.1161/01.STR.0000080381.76409.B2; Ribatti D, 1999, BLOOD, V93, P2627, DOI 10.1182/blood.V93.8.2627.408k21_2627_2636; Schmidt O., 2004, EUR J TRAUMA, V30, P135, DOI DOI 10.1007/S00068-004-1394-9; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Silva M, 1996, BLOOD, V88, P1576, DOI 10.1182/blood.V88.5.1576.1576; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Smith KJ, 2003, CARDIOVASC RES, V59, P538, DOI 10.1016/S0008-6363(03)00468-1; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stahel PF, 2000, J NEUROIMMUNOL, V109, P164, DOI 10.1016/S0165-5728(00)00304-0; TEMPLE RM, 1995, NEPHROL DIAL TRANSPL, V10, P1733; Villa P, 2003, J EXP MED, V198, P971, DOI 10.1084/jem.20021067; Wagner KU, 2000, DEVELOPMENT, V127, P4949; Wojchowski DM, 1999, EXP CELL RES, V253, P143, DOI 10.1006/excr.1999.4673; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; Yu XB, 2002, DEVELOPMENT, V129, P505; 2004, PHARMOS ANNOUNCES RE	60	192	220	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1701	+		10.1096/fj.05-3907fje	http://dx.doi.org/10.1096/fj.05-3907fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16099948				2022-12-25	WOS:000231843700015
J	D'Eon, TM; Souza, SC; Aronovitz, M; Obin, MS; Fried, SK; Greenberg, AS				D'Eon, TM; Souza, SC; Aronovitz, M; Obin, MS; Fried, SK; Greenberg, AS			Estrogen regulation of adiposity and fuel partitioning - Evidence of genomic and non-genomic regulation of lipogenic and oxidative pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE REPLACEMENT THERAPY; ACTIVATED PROTEIN-KINASE; EARLY POSTMENOPAUSAL WOMEN; CONGENITAL AROMATASE DEFICIENCY; ABDOMINAL FAT DISTRIBUTION; DIET-INDUCED OBESITY; RECEPTOR-ALPHA; BODY-COMPOSITION; ADIPOCYTE LIPOLYSIS; METABOLIC SYNDROME	Menopause is associated with increased adiposity and greater risk of metabolic disease. In the ovariectomized (OVX) rodent model of menopause, increased adiposity is prevented by estrogen (E2) replacement, reflecting both anorexigenic and potentially metabolic actions of E2. To elucidate metabolic and molecular mechanisms by which E2 regulates fat storage and fat mobilization independently of reduced energy intake, C57 BL/6 mice were ovariectomized, randomized to estrogen (OVX-E2) or control pellet implants (OVX-C), and pairfed for 40 days. E2 treatment was associated with reduced adipose mass and adipocyte size and downregulation of lipogenic genes in adipocytes under the control of sterol-regulatory element-binding protein 1c. Adipocytes of OVX-E2 mice contained > 3-fold more perilipin protein than adipocytes of pairfed control ( OVX) mice, and this difference was associated with enhanced ex vivo lipolytic response to catecholamines and with greater levels of serum-free fatty acids following fasting. As in adipose tissue, E2 decreased the expression of lipogenic genes in liver and skeletal muscle. In the latter, E2 appears to promote the partitioning of free fatty acids toward oxidation and away from triglyceride storage by up-regulating the expression of peroxisome proliferation activator receptor-delta and its downstream targets and also by directly and rapidly activating AMP-activated protein kinase. Thus, novel genomic and non-genomic actions of E2 promote leanness in OVX mice independently of reduced energy intake.	Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA; Tufts New England Med Ctr, Mol Cardiol Res Inst, Boston, MA 02111 USA; Univ Maryland, Sch Med, Dept Med, Div Gerontol, Baltimore, MD 21201 USA; Baltimore Vet Affairs Med Ctr, Baltimore, MD 21201 USA	Tufts University; United States Department of Agriculture (USDA); Tufts Medical Center; University System of Maryland; University of Maryland Baltimore; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baltimore VA Medical Center	Greenberg, AS (corresponding author), Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA.	Andrew.greenberg@tufts.edu		Fried, Susan K./0000-0003-1101-9332				Bajic VB, 2003, NUCLEIC ACIDS RES, V31, P3605, DOI 10.1093/nar/gkg517; Banerjee RR, 2004, SCIENCE, V303, P1195, DOI 10.1126/science.1092341; Bastie CC, 2005, J BIOL CHEM, V280, P14222, DOI 10.1074/jbc.M413625200; Bjornstrom L, 2005, MOL ENDOCRINOL, V19, P833, DOI 10.1210/me.2004-0486; Campbell SE, 2003, J MOL ENDOCRINOL, V31, P37, DOI 10.1677/jme.0.0310037; Carr MC, 2003, J CLIN ENDOCR METAB, V88, P2404, DOI 10.1210/jc.2003-030242; Cooke PS, 2004, EXP BIOL MED, V229, P1127, DOI 10.1177/153537020422901107; Darimont C, 1997, ENDOCRINOLOGY, V138, P1092, DOI 10.1210/en.138.3.1092; DIGIROLAMO M, 1971, AM J PHYSIOL, V221, P850, DOI 10.1152/ajplegacy.1971.221.3.850; Djouadi F, 1998, J CLIN INVEST, V102, P1083, DOI 10.1172/JCI3949; Dressel U, 2003, MOL ENDOCRINOL, V17, P2477, DOI 10.1210/me.2003-0151; Field FJ, 2002, BIOCHEM J, V368, P855, DOI 10.1042/BJ20020731; Gambacciani M, 2001, MATURITAS, V39, P125, DOI 10.1016/S0378-5122(01)00194-3; Gregoire FM, 2002, AM J PHYSIOL-ENDOC M, V282, pE703, DOI 10.1152/ajpendo.00072.2001; Heine PA, 2000, P NATL ACAD SCI USA, V97, P12729, DOI 10.1073/pnas.97.23.12729; Herrmann BL, 2005, HORM METAB RES, V37, P178, DOI 10.1055/s-2005-861292; Herrmann BL, 2002, J CLIN ENDOCR METAB, V87, P5476, DOI 10.1210/jc.2002-020498; HONNOR RC, 1985, J BIOL CHEM, V260, P5122; Horton JD, 2002, BIOCHEM SOC T, V30, P1091, DOI 10.1042/bst0301091; Jensen L, 2003, J BONE MINER RES, V18, P333, DOI 10.1359/jbmr.2003.18.2.333; Jones MEE, 2000, P NATL ACAD SCI USA, V97, P12735, DOI 10.1073/pnas.97.23.12735; Jones MEE, 2001, J STEROID BIOCHEM, V79, P3, DOI 10.1016/S0960-0760(01)00136-4; Karas RH, 2001, CIRC RES, V89, P534, DOI 10.1161/hh1801.097239; Kelly M, 2004, BIOCHEM BIOPH RES CO, V320, P449, DOI 10.1016/j.bbrc.2004.05.188; Kelly MJ, 2001, TRENDS ENDOCRIN MET, V12, P152, DOI 10.1016/S1043-2760(01)00377-0; Kershaw EE, 2004, J CLIN ENDOCR METAB, V89, P2548, DOI 10.1210/jc.2004-0395; Kliewer SA, 2001, RECENT PROG HORM RES, V56, P239, DOI 10.1210/rp.56.1.239; Krauss S, 2005, NAT REV MOL CELL BIO, V6, P248, DOI 10.1038/nrm1592; KritzSilverstein D, 1996, JAMA-J AM MED ASSOC, V275, P46; LAZZARINI SJ, 1991, AM J PHYSIOL, V260, pR47, DOI 10.1152/ajpregu.1991.260.1.R47; Liang YQ, 2002, INT J OBESITY, V26, P1103, DOI 10.1038/sj.ijo.0802054; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lundholm L, 2004, J MOL ENDOCRINOL, V32, P879, DOI 10.1677/jme.0.0320879; Luquet S, 2003, FASEB J, V17, P2299, DOI 10.1096/fj.03-0269fje; Margolis KL, 2004, DIABETOLOGIA, V47, P1175, DOI 10.1007/s00125-004-1448-x; Meli R, 2004, ENDOCRINOLOGY, V145, P3115, DOI 10.1210/en.2004-0129; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Misso ML, 2003, ENDOCRINOLOGY, V144, P1474, DOI 10.1210/en.2002-221123; Mottagui-Tabar S, 2003, DIABETOLOGIA, V46, P789, DOI 10.1007/s00125-003-1112-x; Muoio DM, 2002, J BIOL CHEM, V277, P26089, DOI 10.1074/jbc.M203997200; PAPPAS TC, 1995, FASEB J, V9, P404, DOI 10.1096/fasebj.9.5.7896011; Park YW, 2003, ARCH INTERN MED, V163, P427, DOI 10.1001/archinte.163.4.427; Perrone G, 1999, GYNECOL OBSTET INVES, V48, P52, DOI 10.1159/000010134; Pold R, 2005, DIABETES, V54, P928, DOI 10.2337/diabetes.54.4.928; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; REUBINOFF BE, 1995, FERTIL STERIL, V64, P963, DOI 10.1016/S0015-0282(16)57910-2; Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943; RICHARD D, 1986, AM J PHYSIOL, V250, pR245, DOI 10.1152/ajpregu.1986.250.2.R245; Sayegh RA, 1999, MENOPAUSE, V6, P312, DOI 10.1097/00042192-199906040-00007; Schulz E, 2005, CIRCULATION, V111, P3473, DOI 10.1161/CIRCULATIONAHA.105.546812; Seo JB, 2004, J BIOL CHEM, V279, P22108, DOI 10.1074/jbc.M400238200; Shih HH, 1998, MOL CELL BIOL, V18, P4732, DOI 10.1128/MCB.18.8.4732; Shimomura K, 2002, ENDOCR J, V49, P417, DOI 10.1507/endocrj.49.417; Shulman GI, 2004, PHYSIOLOGY, V19, P183, DOI 10.1152/physiol.00007.2004; Souza SC, 1998, J BIOL CHEM, V273, P24665, DOI 10.1074/jbc.273.38.24665; Souza SC, 2002, J BIOL CHEM, V277, P8267, DOI 10.1074/jbc.M108329200; SPACEIIIQQ AJE, 2005, STEROIDS, V70, P361; Sugden MC, 2003, AM J PHYSIOL-ENDOC M, V284, pE855, DOI 10.1152/ajpendo.00526.2002; SULLIVAN TR, 1995, J CLIN INVEST, V96, P2482, DOI 10.1172/JCI118307; Sumino H, 2003, INT J OBESITY, V27, P1044, DOI 10.1038/sj.ijo.0802371; Tansey JT, 2001, P NATL ACAD SCI USA, V98, P6494, DOI 10.1073/pnas.101042998; Tchernof A, 2004, J CLIN ENDOCR METAB, V89, P3425, DOI 10.1210/jc.2003-031561; Tchernof A, 1998, OBES RES, V6, P246, DOI 10.1002/j.1550-8528.1998.tb00344.x; Thomas P, 2005, ENDOCRINOLOGY, V146, P624, DOI 10.1210/en.2004-1064; Tomas E, 2002, P NATL ACAD SCI USA, V99, P16309, DOI 10.1073/pnas.222657499; Toth MJ, 2000, INT J OBESITY, V24, P226, DOI 10.1038/sj.ijo.0801118; WADE GN, 1985, INT J OBESITY, V9, P83; Wang YX, 2003, OBES RES, V11, P930, DOI 10.1038/oby.2003.128; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Zhang HH, 2003, J BIOL CHEM, V278, P51535, DOI 10.1074/jbc.M309591200; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505	71	385	394	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35983	35991		10.1074/jbc.M507339200	http://dx.doi.org/10.1074/jbc.M507339200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16109719	hybrid			2022-12-25	WOS:000232726900026
J	Hui, L; Rodrik, V; Pielak, RM; Knirr, S; Zheng, Y; Foster, DA				Hui, L; Rodrik, V; Pielak, RM; Knirr, S; Zheng, Y; Foster, DA			mTOR-dependent suppression of protein phosphatase 2A is critical for phospholipase D survival signals in human breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION; PATHWAY; ANTIGEN; KINASE; GROWTH; BAD; PHOSPHORYLATION; COMPLEXES	A critical aspect of tumor progression is the generation of survival signals that overcome default apoptotic programs. Recent studies have revealed that elevated phospholipase D activity generates survival signals in breast and perhaps other human cancers. We report here that the elevated phospholipase D activity in the human breast cancer cell line MDA-MB-231 suppresses the activity of the putative tumor suppressor protein phosphatase 2A in a mammalian target of rapamycin ( mTOR)-dependent manner. Increasing the phospholipase D activity in MCF7 cells also suppressed protein phosphatase 2A activity. Elevated phospholipase D activity suppressed association of protein phosphatase 2A with both ribosomal subunit S6-kinase and eukaryotic initiation factor 4E-binding protein 1. Suppression of protein phosphatase 2A by SV40 small t-antigen has been reported to be critical for the transformation of human cells with SV40 early region genes. Consistent with a critical role for protein phosphatase 2A in phospholipase D survival signals, either SV40 small t-antigen or pharmacological suppression of protein phosphatase 2A restored survival signals lost by the suppression of either phospholipase D or mTOR. Blocking phospholipase D signals also led to reduced phosphorylation of the pro-apoptotic protein BAD at the protein phosphatase 2A dephosphorylation site at Ser-112. The ability of phospholipase D to suppress protein phosphatase 2A identifies a critical target of an emerging phospholipase D/mTOR survival pathway in the transformation of human cells.	CUNY Hunter Coll, Dept Biol Sci, New York, NY 10021 USA	City University of New York (CUNY) System; Hunter College (CUNY)	Foster, DA (corresponding author), CUNY Hunter Coll, Dept Biol Sci, 695 Pk Ave, New York, NY 10021 USA.	foster@genectr.hunter.cuny.edu	Pielak, Rafal/B-2761-2013		NCI NIH HHS [CA46677] Funding Source: Medline; NCRR NIH HHS [RR-03037] Funding Source: Medline; NIGMS NIH HHS [GM60654] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046677, R29CA046677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM060654] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anthony B, 1996, INT J CANCER, V65, P858, DOI 10.1002/(SICI)1097-0215(19960315)65:6<858::AID-IJC25>3.0.CO;2-Z; Avdulov S, 2004, CANCER CELL, V5, P553, DOI 10.1016/j.ccr.2004.05.024; BALLOU LM, 1988, J BIOL CHEM, V263, P1188; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; Chen W, 2003, HISTOL HISTOPATHOL, V18, P541, DOI 10.14670/HH-18.541; Chen YH, 2005, ONCOGENE, V24, P672, DOI 10.1038/sj.onc.1208099; Chen YH, 2003, ONCOGENE, V22, P3937, DOI 10.1038/sj.onc.1206565; Chiang CW, 2003, MOL CELL BIOL, V23, P6350, DOI 10.1128/MCB.23.18.6350-6362.2003; Chiang CW, 2001, BLOOD, V97, P1289, DOI 10.1182/blood.V97.5.1289; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002; Fang YM, 2003, CURR BIOL, V13, P2037, DOI 10.1016/j.cub.2003.11.021; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; FAVRE B, 1994, J BIOL CHEM, V269, P16311; Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004; Foster DA, 2003, MOL CANCER RES, V1, P789; Foster David A, 2004, Expert Rev Anticancer Ther, V4, P691, DOI 10.1586/14737140.4.4.691; FROST JA, 1994, MOL CELL BIOL, V14, P6244, DOI 10.1128/MCB.14.9.6244; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Hui L, 2004, MOL CELL BIOL, V24, P5677, DOI 10.1128/MCB.24.13.5677-5686.2004; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Joseph T, 2001, BIOCHEM BIOPH RES CO, V289, P1019, DOI 10.1006/bbrc.2001.6118; Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc; Lu ZM, 2000, MOL CELL BIOL, V20, P462, DOI 10.1128/MCB.20.2.462-467.2000; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Polunovsky VA, 2000, J BIOL CHEM, V275, P24776, DOI 10.1074/jbc.M001938200; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Sawyers CL, 2003, CANCER CELL, V4, P343, DOI 10.1016/S1535-6108(03)00275-7; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Shen YJ, 2001, MOL CELL BIOL, V21, P595, DOI 10.1128/MCB.21.2.595-602.2001; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; TUROWSKI P, 1995, J CELL BIOL, V129, P397, DOI 10.1083/jcb.129.2.397; Van Hoof C, 2004, CANCER CELL, V5, P105, DOI 10.1016/S1535-6108(04)00027-3; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhong MG, 2003, BIOCHEM BIOPH RES CO, V302, P615, DOI 10.1016/S0006-291X(03)00229-8	44	45	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35829	35835		10.1074/jbc.M504192200	http://dx.doi.org/10.1074/jbc.M504192200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16109716	hybrid			2022-12-25	WOS:000232726900009
J	Takahashi, Y; Kikuchi, Y				Takahashi, Y; Kikuchi, Y			Yeast PIAS-type Ull1/Siz1 is composed of SUMO ligase and regulatory domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PORE COMPLEX; SACCHAROMYCES-CEREVISIAE; CONJUGATING ENZYME; BUDDING YEAST; PROTEIN SMT3P; DNA-REPAIR; UBIQUITIN; MOTIF; GENE; COMPONENTS	SUMO ( small ubiquitin-like modifier)/Smt3 ( suppressor of mif two) is a member of the ubiquitin-related protein family and is known to conjugate with many proteins. In the sumoylation pathway, SUMO/Smt3 is transferred to substrate lysine residues through the thioester cascade of E1 ( activating enzyme) and E2 ( conjugating enzyme), and E3 ( SUMO ligase) functions as an adaptor between E2 and each substrate. Yeast Ull1 (ubiquitin-like protein ligase 1)/Siz1, a PIAS ( protein inhibitor of activated STAT)type SUMO ligase, modifies both cytoplasmic and nuclear proteins. In this paper, we performed a domain analysis of Ull1/Siz1 by constructing various deletion mutants. A novel conserved N-terminal domain, called PINIT, as well as the RING-like domain (SP-RING) were required for the SUMO ligase activity in the in vitro conjugation system and for interaction with Smt3 in an in vitro binding assay. The most distal N-terminal region, which contains a putative DNA-binding SAF-A/B, Acinus, and PIAS ( SAP) motif, was not required for the ligase activity but was involved in nuclear localization. A strong SUMO-binding motif was identified, which interacted with Smt3 in the two-hybrid system but was not necessary for the ligase activity. The most distal C-terminal domain was important for stable localization at the bud neck region and thereby for the substrate recognition of septins. Furthermore, the C-terminal half conferred protein instability on Ull1/Siz1. Taken together, we conclude that the SP-RING and PINIT of Ull1/Siz1 are core domains of the SUMO ligase, and the other domains are regulatory for protein stability and subcellular localization.	Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Kikuchi, Y (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	kikuchi@biol.s.u-tokyo.ac.jp						Bachant J, 2002, MOL CELL, V9, P1169, DOI 10.1016/S1097-2765(02)00543-9; CAIRNS BR, 1992, GENE DEV, V6, P1305, DOI 10.1101/gad.6.7.1305; DOHMEN RJ, 1995, J BIOL CHEM, V270, P18099, DOI 10.1074/jbc.270.30.18099; Duval D, 2003, FEBS LETT, V554, P111, DOI 10.1016/S0014-5793(03)01116-5; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; James P, 1996, GENETICS, V144, P1425; JENSEN K, 2004, SUMOYLATION MOL BIOL; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kushnirov VV, 2000, YEAST, V16, P857, DOI 10.1002/1097-0061(20000630)16:9<857::AID-YEA561>3.0.CO;2-B; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MELUH PB, 1995, MOL BIOL CELL, V6, P793, DOI 10.1091/mbc.6.7.793; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Okubo S, 2004, J BIOL CHEM, V279, P31455, DOI 10.1074/jbc.M403561200; Reverter D, 2005, NATURE, V435, P687, DOI 10.1038/nature03588; Sasaki T, 2000, MOL CELL BIOL, V20, P7971, DOI 10.1128/MCB.20.21.7971-7979.2000; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Song J, 2004, P NATL ACAD SCI USA, V101, P14373, DOI 10.1073/pnas.0403498101; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; SUTTON A, 1991, MOL CELL BIOL, V11, P2133, DOI 10.1128/MCB.11.4.2133; Takahashi Y, 1999, BIOCHEM BIOPH RES CO, V259, P582, DOI 10.1006/bbrc.1999.0821; Takahashi Y, 2003, J BIOCHEM, V133, P415, DOI 10.1093/jb/mvg054; Takahashi Y, 2001, J BIOL CHEM, V276, P48973, DOI 10.1074/jbc.M109295200; Takahashi Y, 2001, GENE, V275, P223, DOI 10.1016/S0378-1119(01)00662-X; UESONO Y, 1994, GENE, V143, P135; Zhao XL, 2005, P NATL ACAD SCI USA, V102, P4777, DOI 10.1073/pnas.0500537102	37	45	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35822	35828		10.1074/jbc.M506794200	http://dx.doi.org/10.1074/jbc.M506794200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16109721	hybrid			2022-12-25	WOS:000232726900008
J	Mitsuzuka, K; Handa, K; Satoh, M; Arai, Y; Hakomori, S				Mitsuzuka, K; Handa, K; Satoh, M; Arai, Y; Hakomori, S			A specific microdomain ("glycosynapse 3") controls phenotypic conversion and reversion of bladder cancer cells through GM3-mediated interaction of alpha 3 beta 1 integrin with CD9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METASTASIS SUPPRESSOR GENE; ALPHA-5-BETA-1 INTEGRIN RECEPTOR; C-GAMMA ACTIVITY; GM3 GANGLIOSIDE; GLUCOSYLCERAMIDE SYNTHASE; INTERFERING RNAS; MAMMALIAN-CELLS; DOWN-REGULATION; TUMOR-CELLS; MOTILITY	Cell motility is highly dependent on the organization and function of microdomains composed of integrin, proteolipid/tetraspanin CD9, and ganglioside (Ono, M., Handa, K., Sonnino, S., Withers, D. A., Nagai, H., and Hakomori, S. (2001) Biochemistry 40, 6414-6421; Kawakami, Y., Kawakami, K., Steelant, W. F. A., Ono, M., Baek, R. C., Handa, K., Withers, D. A., and Hakomori, S. (2002) J. Biol. Chem. 277, 34349-34358), later termed "glycosynapse 3" (Hakomori, S., and Handa, K. (2002) FEBS Lett. 531, 88-92, 2002). Human bladder cancer cell lines KK47 (noninvasive and nonmetastatic) and YTS1 (highly invasive and metastatic), both derived from transitional bladder epithelia, are very similar in terms of integrin composition and levels of tetraspanin CD9. Tetraspanin CD82 is absent in both. The major difference is in the level of ganglioside GM3, which is several times higher in KK47 than in YTS1. We now report that the GM3 level reflects glycosynapse function as follows: (i) a stronger interaction of integrin alpha 3 with CD9 in KK47 than in YTS1; (ii) conversion of benign, low motility KK47 to invasive, high motility cells by depletion of GM3 by P4 (D-threo-1-phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol) treatment or by knockdown of CD9 by the RNA interference method; (iii) reversion of high motility YTS1 to low motility phenotype like that of KK47 by exogenous GM3 addition, whereby the alpha 3-to-CD9 interaction was enhanced; (iv) low GM3 level activated c-Src in YTS1 or in P4-treated KK47, and high GM3 level by exogenous addition caused Csk translocation into glycosynapse, with subsequent inhibition of c-Src activation; (v) inhibition of c-Src by "PP2" in YTS1 greatly reduced cell motility. Thus, GM3 in glycosynapse 3 plays a dual role in defining glycosynapse 3 function. One is by modulating the interaction of alpha 3 with CD9; the other is by activating or inhibiting the c-Src activity, possibly through Csk translocation. High GM3 level decreases tumor cell motility/invasiveness, whereas low GM3 level enhances tumor cell motility/invasiveness. Oncogenic transformation and its reversion can be explained through the difference in glycosynapse organization.	Pacific NW Res Inst, Seattle, WA 98122 USA; Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA; Tohoku Univ, Sch Med, Dept Urol, Sendai, Miyagi 9808574, Japan	University of Washington; University of Washington Seattle; Tohoku University	Hakomori, S (corresponding author), Pacific NW Res Inst, 720 Broadway, Seattle, WA 98122 USA.	hakomori@u.washington.edu			NATIONAL CANCER INSTITUTE [R01CA080054] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA80054] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBRECHTBUEHLER G, 1977, CELL, V11, P395, DOI 10.1016/0092-8674(77)90057-5; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Aoki H, 2004, FEBS LETT, V567, P203, DOI 10.1016/j.febslet.2004.04.060; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; CARTER BZ, 1991, LAB INVEST, V65, P610; CHERESH DA, 1987, J CELL BIOL, V105, P1163, DOI 10.1083/jcb.105.3.1163; DOHI T, 1988, CANCER RES, V48, P5680; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Dong JT, 1996, CANCER RES, V56, P4387; FOLCH J, 1951, J BIOL CHEM, V191, P807; Frank M, 2000, PROG NEUROBIOL, V60, P531, DOI 10.1016/S0301-0082(99)00039-8; Gu JG, 2002, J BIOL CHEM, V277, P19922, DOI 10.1074/jbc.M200383200; Gu JG, 2004, GLYCOCONJUGATE J, V21, P9, DOI 10.1023/B:GLYC.0000043741.47559.30; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P225, DOI 10.1073/pnas.012540899; Hakomori S, 2004, AN ACAD BRAS CIENC, V76, P553, DOI 10.1590/S0001-37652004000300010; HAKOMORI S, 1968, P NATL ACAD SCI USA, V59, P254, DOI 10.1073/pnas.59.1.254; Hakomori S, 2002, FEBS LETT, V531, P88, DOI 10.1016/S0014-5793(02)03479-8; HAKOMORI SI, 1977, VIROLOGY, V76, P485, DOI 10.1016/0042-6822(77)90231-8; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; HANNUN YA, 1997, SPHINGOLIPID MED SIG; Hemler ME, 2003, ANNU REV CELL DEV BI, V19, P397, DOI 10.1146/annurev.cellbio.19.111301.153609; HISAZUMI H, 1979, JPN J UROL, V70, P485, DOI 10.5980/jpnjurol1928.70.5_485; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Isaji T, 2004, J BIOL CHEM, V279, P19747, DOI 10.1074/jbc.M311627200; Jaffe LF, 2003, ADV CANCER RES, V90, P209, DOI 10.1016/S0065-230X(03)90007-8; KAKIZAKI H, 1986, JPN J UROL, V77, P1790; Kakizaki H., 1990, JPN J UROL, V81, P204; Kawakami Y, 2002, J BIOL CHEM, V277, P34349, DOI 10.1074/jbc.M200771200; Kenny PA, 2003, INT J CANCER, V107, P688, DOI 10.1002/ijc.11491; KINGSLEY DM, 1986, CELL, V44, P749, DOI 10.1016/0092-8674(86)90841-X; Krummel MF, 2002, CURR OPIN IMMUNOL, V14, P66, DOI 10.1016/S0952-7915(01)00299-0; Lee L, 1999, J BIOL CHEM, V274, P14662, DOI 10.1074/jbc.274.21.14662; Li RX, 2000, J BIOL CHEM, V275, P34213, DOI 10.1074/jbc.M906368199; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Lotem J, 2002, SEMIN CANCER BIOL, V12, P339, DOI 10.1016/S1044-579X(02)00054-8; Mannion BA, 1996, J IMMUNOL, V157, P2039; MASTERS JRW, 1986, CANCER RES, V46, P3630; Mhawech P, 2003, CANCER, V98, P1649, DOI 10.1002/cncr.11698; Miura Y, 2004, P NATL ACAD SCI USA, V101, P16204, DOI 10.1073/pnas.0407297101; MIYAKE M, 1991, J EXP MED, V174, P1347, DOI 10.1084/jem.174.6.1347; Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774; NAKAMURA K, 1991, J BIOCHEM-TOKYO, V110, P832, DOI 10.1093/oxfordjournals.jbchem.a123667; OKADA M, 1991, J BIOL CHEM, V266, P24249; Ono M, 1999, CANCER RES, V59, P2335; Ono M, 2001, BIOCHEMISTRY-US, V40, P6414, DOI 10.1021/bi0101998; Ono M, 2000, BIOCHEM BIOPH RES CO, V279, P744, DOI 10.1006/bbrc.2000.4030; RANI CSS, 1995, J BIOL CHEM, V270, P2859, DOI 10.1074/jbc.270.6.2859; Satoh M, 2001, INT J ONCOL, V19, P723; SCHLESINGER MJ, 1981, ANNU REV BIOCHEM, V50, P193, DOI 10.1146/annurev.bi.50.070181.001205; Scott WN, 2000, ANAL BIOCHEM, V287, P343, DOI 10.1006/abio.2000.4866; SHAYMAN JA, 1990, J BIOL CHEM, V265, P12135; Shu LM, 2003, J BIOL CHEM, V278, P31419, DOI 10.1074/jbc.M303783200; Shu LM, 2002, J BIOL CHEM, V277, P18447, DOI 10.1074/jbc.M111363200; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Su JS, 2004, INT J UROL, V11, P74, DOI 10.1111/j.1442-2042.2004.00752.x; Sui DX, 2004, BIOCHEM BIOPH RES CO, V319, P768, DOI 10.1016/j.bbrc.2004.04.198; Toledo MS, 2005, J BIOL CHEM, V280, P16227, DOI 10.1074/jbc.M413713200; Toledo MS, 2004, J BIOL CHEM, V279, P34655, DOI 10.1074/jbc.M403857200; Tsuji T, 2002, CLIN EXP METASTAS, V19, P127, DOI 10.1023/A:1014573204062; ZHENG MZ, 1994, J BIOL CHEM, V269, P12325; ZHENG MZ, 1993, J BIOL CHEM, V268, P2217	62	91	95	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35545	35553		10.1074/jbc.M505630200	http://dx.doi.org/10.1074/jbc.M505630200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16103120	hybrid			2022-12-25	WOS:000232561200056
J	Tapodi, A; Debreceni, B; Hanto, K; Bognar, Z; Wittmann, I; Gallyas, F; Varbiro, G; Sumegi, B				Tapodi, A; Debreceni, B; Hanto, K; Bognar, Z; Wittmann, I; Gallyas, F; Varbiro, G; Sumegi, B			Pivotal role of Akt activation in mitochondrial protection and cell survival by poly(ADP-ribose) polymerase-1 inhibition in oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOSIS-INDUCING FACTOR; NF-KAPPA-B; POLY ADP-RIBOSYLATION; AKT/PROTEIN KINASE-B; DNA-BINDING ACTIVITY; PERMEABILITY TRANSITION; NAD(+) DEPLETION; MICE RESISTANT; DEATH; MECHANISM	According to the classical view, the cytoprotective effect of inhibitors of poly( ADP- ribose) polymerase ( PARP) in oxidative stress was based on the prevention of NAD(+) and ATP depletion, thus the attenuation of necrosis. Our previous data on PARP inhibitors in an inflammatory model suggested that PARP- catalyzed ADP- ribosylations may affect signaling pathways, which can play a significant role in cell survival. To clarify the molecular mechanism of cytoprotection, PARP activity was inhibited pharmacologically by suppressing PARP- 1 expression by a small interfering RNA ( siRNA) technique or by transdominantly expressing the N- terminal DNA-binding domain of PARP- 1 ( PARP- DBD) in cultured cells. Cell survival, activation of the phosphatidylinositol 3- kinase ( PI3- kinase)/ Akt system, and the preservation of mitochondrial membrane potential were studied in hydrogen peroxide- treated WRL- 68 cells. Our data showed that suppression of the single- stranded DNA break- induced PARP- 1 activation by pharmacological inhibitor, siRNA, or by the transdominant expression of PARP- DBD protected cells from oxidative stress and induced the phosphorylation and activation of Akt. Furthermore, prevention of Akt activation by inhibiting PI3- kinase counteracted the cytoprotective effect of PARP inhibition. Microscopy data showed that PARP inhibition-induced Akt activation was responsible for protection of mitochondria in oxidative stress because PI3- kinase inhibitors diminished the protective effect of PARP inhibition. Similarly, Src kinase inhibitors, which decrease Akt phosphorylation, also counteracted the protection of mitochondrial membrane potential supporting the pivotal role of Akt in cytoprotection. These data together with the finding that PARP inhibition in the absence of oxidative stress induced the phosphorylation and activation of Akt indicate that PARP inhibition- induced Akt activation is dominantly responsible for the cytoprotection in oxidative stress.	Univ Pecs, Dept Biochem & Med Chem, H-7624 Pecs, Hungary; Univ Pecs, Dept Med 1, Div Cardiol, H-7624 Pecs, Hungary; Univ Pecs, Fac Med, Dept Med 2, H-7624 Pecs, Hungary; Univ Pecs, Fac Med, Hungarian Acad Sci, Res Grp Mitochondrial Funct & Mitochondrial Dis, H-7624 Pecs, Hungary	University of Pecs; University of Pecs; University of Pecs; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Institute of Experimental Medicine; University of Pecs	Sumegi, B (corresponding author), Univ Pecs, Dept Biochem & Med Chem, 12 Szigeti St, H-7624 Pecs, Hungary.	balazs.sumegi@aok.pte.hu	Varbiro, Gabor/AAH-5587-2021; Gallyas, Ferenc/AAY-5343-2020; Gallyas, Ferenc/C-2272-2012	Varbiro, Gabor/0000-0001-5907-3472; Gallyas, Ferenc/0000-0002-1906-4333				Alano CC, 2004, J BIOL CHEM, V279, P18895, DOI 10.1074/jbc.M313329200; Althaus FR, 1999, MOL CELL BIOCHEM, V193, P5, DOI 10.1023/A:1006975002262; AMSTAD PA, 1992, CANCER RES, V52, P3952; Batandier C, 2004, J BIOL CHEM, V279, P17197, DOI 10.1074/jbc.M310329200; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; Burkart V, 1999, NAT MED, V5, P314, DOI 10.1038/6535; Butler AJ, 1999, MOL CELL BIOL, V19, P296; Cervellera MN, 2000, J BIOL CHEM, V275, P10692, DOI 10.1074/jbc.275.14.10692; Chang WJ, 2001, J BIOL CHEM, V276, P47664, DOI 10.1074/jbc.M104666200; Chen M, 2004, CARDIOVASC RES, V63, P682, DOI 10.1016/j.cardiores.2004.04.018; Cui QL, 2005, J BIOL CHEM, V280, P8918, DOI 10.1074/jbc.M414267200; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; Du LN, 2003, J BIOL CHEM, V278, P18426, DOI 10.1074/jbc.M301295200; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; Esposito G, 2002, J BIOL CHEM, V277, P50348, DOI 10.1074/jbc.M207170200; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; Halmosi R, 2001, MOL PHARMACOL, V59, P1497, DOI 10.1124/mol.59.6.1497; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hassa PO, 2001, J BIOL CHEM, V276, P45588, DOI 10.1074/jbc.M106528200; Hong SJ, 2004, TRENDS PHARMACOL SCI, V25, P259, DOI 10.1016/j.tips.2004.03.005; Jagtap P, 2005, NAT REV DRUG DISCOV, V4, P421, DOI 10.1038/nrd1718; Kameoka M, 2000, BIOCHEM J, V346, P641, DOI 10.1042/0264-6021:3460641; Kannan P, 1999, NUCLEIC ACIDS RES, V27, P866, DOI 10.1093/nar/27.3.866; Kim JW, 2000, J CELL SCI, V113, P955; Komjati K, 2004, INT J MOL MED, V13, P373; Liaudet L, 2002, AM J RESP CRIT CARE, V165, P372, DOI 10.1164/ajrccm.165.3.2106050; Lu S, 2004, APPL BIOCHEM BIOTECH, V118, P133, DOI 10.1385/ABAB:118:1-3:133; Martin D, 2002, J BIOL CHEM, V277, P42943, DOI 10.1074/jbc.M201070200; Masutani M, 1999, P NATL ACAD SCI USA, V96, P2301, DOI 10.1073/pnas.96.5.2301; MCCORD JM, 1987, FASEB J, V46, P2402; MULLER WEG, 1976, MOL CELL BIOCHEM, V12, P147, DOI 10.1007/BF01741713; Murriel CL, 2004, J BIOL CHEM, V279, P47985, DOI 10.1074/jbc.M405071200; Nie J, 1998, FEBS LETT, V424, P27, DOI 10.1016/S0014-5793(98)00131-8; Oei SL, 1997, BIOCHEM BIOPH RES CO, V240, P108, DOI 10.1006/bbrc.1997.7621; OLEINICK NL, 1985, RADIAT RES, V101, P29, DOI 10.2307/3576301; PALFI A, 2005, J PHARM EXP THER JUN; Pieper AA, 1999, P NATL ACAD SCI USA, V96, P3059, DOI 10.1073/pnas.96.6.3059; POWIS G, 1994, CANCER RES, V54, P2419; ROWE GT, 1983, CIRC RES, V53, P584, DOI 10.1161/01.RES.53.5.584; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; SHAH GM, 1995, ANAL BIOCHEM, V227, P1, DOI 10.1006/abio.1995.1245; Soriano FG, 2002, SHOCK, V17, P286, DOI 10.1097/00024382-200204000-00008; Szabo C, 1997, J EXP MED, V186, P1041, DOI 10.1084/jem.186.7.1041; TANIGUCHI T, 1985, BIOCHEM BIOPH RES CO, V127, P526, DOI 10.1016/S0006-291X(85)80191-1; TURNERS JF, 1980, BIOCHEM J, V156, P434; Ullrich O, 2001, NAT CELL BIOL, V3, P1035, DOI 10.1038/ncb1201-1035; Veres B, 2003, BIOCHEM PHARMACOL, V65, P1373, DOI 10.1016/S0006-2952(03)00077-7; Veres B, 2004, J PHARMACOL EXP THER, V310, P247, DOI 10.1124/jpet.104.065151; Virag L, 1998, J IMMUNOL, V161, P3753; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Werner E, 2004, J CELL SCI, V117, P143, DOI 10.1242/jcs.00937; Wesierska-Gadek J, 2001, CELL MOL BIOL LETT, V6, P117; Xia Y, 1996, J BIOL CHEM, V271, P10096, DOI 10.1074/jbc.271.17.10096; Xiao CY, 2005, J PHARMACOL EXP THER, V312, P891, DOI 10.1124/jpet.104.077164; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zingarelli B, 1998, CIRC RES, V83, P85, DOI 10.1161/01.RES.83.1.85	59	144	149	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35767	35775		10.1074/jbc.M507075200	http://dx.doi.org/10.1074/jbc.M507075200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16115861	hybrid			2022-12-25	WOS:000232561200080
J	Urquiza, M; Lopez, R; Patino, H; Rosas, JE; Patarroyo, ME				Urquiza, M; Lopez, R; Patino, H; Rosas, JE; Patarroyo, ME			Identification of three gp350/220 regions involved in Epstein-Barr virus invasion of host cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 MONOCLONAL-ANTIBODY; SYNTHETIC PEPTIDES; RECEPTOR CR-2; B-LYMPHOCYTES; ANTIGENIC DETERMINANTS; ENVELOPE GLYCOPROTEINS; ESCHERICHIA-COLI; EBV/C3D RECEPTOR; VIRAL BINDING; CLASS-II	Epstein-Barr virus (EBV) invasion of B-lymphocytes involves EBV gp350/220 binding to B-lymphocyte CR2. The anti-gp350 monoclonal antibody (mAb)-72A1 Fab inhibits this binding and therefore blocks EBV invasion of target cells. However, gp350/220 regions interacting with mAb 72A1 and involved in EBV invasion of target cells have not yet been identified. This work reports three gp350/220 regions, defined by peptide 11382, 11389, and 11416 sequences, that are involved in EBV binding to B-lymphocytes. Peptides 11382, 11389, and 11416 bound to CR2(+) but not to CR2(-) cells, inhibited EBV invasion of cord blood lymphocytes (CBLs), were recognized by mAb 72A1, and inhibited mAb 72A1 binding to EBV. Peptides 11382 and 11416 binding to peripheral blood lymphocytes (PBLs) induced interleukin-6 protein synthesis in these cells, this phenomenon being inhibited by mAb 72A1. The same behavior has been reported for gp350/220 binding to PBLs. Anti-peptide 11382, 11389, and 11416 antibodies inhibited EBV binding and EBV invasion of PBLs and CBLs. Peptide 11382, 11389, and 11416 sequences presented homology with the C3dg regions coming into contact with CR2 (C3dg and gp350 bound to similar CR2 regions). These peptides could be used in designing strategies against EBV infection.	Fdn Inst Inmunol Colombia, Virol Grp, Bogota, Colombia; Univ Nacl Colombia, Dept Chem, Bogota 030405, Colombia; Univ Nacl Colombia, Fac Med, Bogota 030405, Colombia	Universidad Nacional de Colombia; Universidad Nacional de Colombia	Urquiza, M (corresponding author), Fdn Inst Inmunol Colombia, Virol Grp, Cra 50,26-00, Bogota, Colombia.	mauricio_urquiza@fidic.org.co	; Patarroyo, Manuel-Elkin/S-1422-2017	Urquiza, Mauricio/0000-0001-5478-606X; Patarroyo, Manuel-Elkin/0000-0002-1119-6040				AHEARN JM, 1988, P NATL ACAD SCI USA, V85, P9307, DOI 10.1073/pnas.85.23.9307; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BAUMANN H, 1988, J BIOL CHEM, V263, P17390; BEISEL C, 1985, J VIROL, V54, P665, DOI 10.1128/JVI.54.3.665-674.1985; BERTONI G, 1990, INTERVIROLOGY, V31, P290, DOI 10.1159/000150164; Chen PCH, 2002, J PATHOL, V197, P684, DOI 10.1002/path.1141; D'Addario M, 2001, J MOL BIOL, V308, P501, DOI 10.1006/jmbi.2001.4589; DELVES PJ, 1997, ANTIBODY PRODUCTIONS, P64; DUNCAN MR, 1978, J VIROL, V28, P444, DOI 10.1128/JVI.28.2.444-449.1978; Egelhofer M, 2004, J VIROL, V78, P568, DOI 10.1128/JVI.78.2.568-575.2004; EMINI EA, 1989, J MED VIROL, V27, P120, DOI 10.1002/jmv.1890270210; EPSTEIN MA, 1966, J NATL CANCER I, V37, P547; Fraczkiewicz R, 1998, J COMPUT CHEM, V19, P319, DOI 10.1002/(SICI)1096-987X(199802)19:3<319::AID-JCC6>3.0.CO;2-W; FREEMAN CB, 1982, CLIN IMMUNOL IMMUNOP, V25, P103, DOI 10.1016/0090-1229(82)90169-6; Garcia JE, 2002, J HEPATOL, V36, P254, DOI 10.1016/S0168-8278(01)00262-8; Grandi P, 2004, MOL THER, V9, P419, DOI 10.1016/j.ymthe.2003.12.010; Hardy N, 2004, PHARMACOTHERAPY, V24, P198, DOI 10.1592/phco.24.2.198.33141; HEDRICK JA, 1994, J IMMUNOL, V153, P4418; HINUMA YORIO, 1967, J VIROL, V1, P1203; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; Hu CL, 2004, BIOCHEM BIOPH RES CO, V316, P698, DOI 10.1016/j.bbrc.2004.02.106; Keitel T, 1997, CELL, V91, P811, DOI 10.1016/S0092-8674(00)80469-9; Khanna R, 1999, J IMMUNOL, V162, P3063; KLEIN E, 1990, MOL IMMUNOL, V27, P1343, DOI 10.1016/0161-5890(90)90041-W; KOIZUMI S, 1992, VIROLOGY, V188, P859, DOI 10.1016/0042-6822(92)90542-W; Kramer A, 1997, CELL, V91, P799, DOI 10.1016/S0092-8674(00)80468-7; Li QX, 1997, J VIROL, V71, P4657, DOI 10.1128/JVI.71.6.4657-4662.1997; Maruo S, 2001, J GEN VIROL, V82, P2373, DOI 10.1099/0022-1317-82-10-2373; MCKINNEY MM, 1987, J IMMUNOL METHODS, V96, P271, DOI 10.1016/0022-1759(87)90324-3; MOORE MD, 1989, J BIOL CHEM, V264, P20576; NEMEROW GR, 1987, J VIROL, V61, P1416, DOI 10.1128/JVI.61.5.1416-1420.1987; NEMEROW GR, 1989, CELL, V56, P369, DOI 10.1016/0092-8674(89)90240-7; NUEBLING CM, 1992, VIROLOGY, V191, P443; PATEL RA, 1993, VIROLOGY, V195, P121, DOI 10.1006/viro.1993.1352; PITHER RJ, 1992, J VIROL, V66, P1246, DOI 10.1128/JVI.66.2.1246-1251.1992; PITHER RJ, 1992, J GEN VIROL, V73, P1409, DOI 10.1099/0022-1317-73-6-1409; PRIETO I, 1995, EUR J IMMUNOL, V25, P877, DOI 10.1002/eji.1830250403; REISERT PS, 1985, J IMMUNOL, V134, P3776; Roberge CJ, 1996, J IMMUNOL, V156, P4884; Salek-Ardakani S, 2004, J IMMUNOL, V173, P321, DOI 10.4049/jimmunol.173.1.321; Salimi B, 2002, PEDIATR PATHOL MOL M, V21, P433, DOI 10.1080/15227950290097199; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sarrias MR, 2001, J IMMUNOL, V167, P1490, DOI 10.4049/jimmunol.167.3.1490; SERVIS C, 1989, J IMMUNOL, V142, P2207; STOCCO R, 1990, INTERVIROLOGY, V31, P295, DOI 10.1159/000150165; Szakonyi G, 2001, SCIENCE, V292, P1725, DOI 10.1126/science.1059118; TAM JP, 1983, INT J PEPT PROT RES, V21, P57; TANNER J, 1988, J VIROL, V62, P4452, DOI 10.1128/JVI.62.12.4452-4464.1988; TANNER J, 1987, CELL, V50, P203, DOI 10.1016/0092-8674(87)90216-9; TANNER JE, 1994, BLOOD, V84, P3956, DOI 10.1182/blood.V84.11.3956.bloodjournal84113956; Tanner JE, 1996, J VIROL, V70, P570, DOI 10.1128/JVI.70.1.570-575.1996; THORLEYLAWSON DA, 1982, J VIROL, V43, P730, DOI 10.1128/JVI.43.2.730-736.1982; THORLEYLAWSON DA, 1980, P NATL ACAD SCI-BIOL, V77, P5307, DOI 10.1073/pnas.77.9.5307; Urquiza M, 2004, BIOCHEM BIOPH RES CO, V319, P221, DOI 10.1016/j.bbrc.2004.04.177; Vera-Bravo R, 2003, INT J CANCER, V107, P416, DOI 10.1002/ijc.11433; WEILAND GA, 1981, LIFE SCI, V29, P313, DOI 10.1016/0024-3205(81)90324-6; WEIS JJ, 1984, P NATL ACAD SCI-BIOL, V81, P881, DOI 10.1073/pnas.81.3.881; WELLS A, 1981, INT J CANCER, V27, P303, DOI 10.1002/ijc.2910270308; ZHANG PF, 1991, J GEN VIROL, V72, P2747, DOI 10.1099/0022-1317-72-11-2747; ZHANG PF, 1993, J GEN VIROL, V74, P2171, DOI 10.1099/0022-1317-74-10-2171	60	25	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35598	35605		10.1074/jbc.M504544200	http://dx.doi.org/10.1074/jbc.M504544200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16087675	hybrid			2022-12-25	WOS:000232561200062
J	Bratt, A; Birot, O; Sinha, I; Veitonmaki, N; Aase, K; Ernkvist, M; Holmgren, L				Bratt, A; Birot, O; Sinha, I; Veitonmaki, N; Aase, K; Ernkvist, M; Holmgren, L			Angiomotin regulates endothelial cell-cell junctions and cell motility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESION MOLECULE; GROWTH-FACTOR; ANGIOSTATIN; PROTEIN; ANGIOGENESIS; CANCER; TIGHT; SECRETION; MIGRATION; DOMAINS	We have previously identified angiomotin by its ability to bind to and mediate the anti-angiogenic properties of angiostatin. In vivo and in vitro data indicate an essential role of angiomotin in endothelial cell motility. Here we show that angiostatin binds angiomotin on the cell surface and provide evidence for a transmembrane model for the topology of both p80 and p130 angiomotin isoforms. Immunofluorescence analysis shows that angiomotin co-localized with ZO-1 in cell-cell contacts in endothelial cells in vitro and in angiogenic blood vessels of the postnatal mouse retina in vivo. Transfection of p80 as well as p130 angiomotin in Chinese hamster ovary cells resulted in junctional localization of both isoforms. Furthermore, p130 angiomotin could recruit ZO-1 to actin stress fibers. The p130 but not p80 isoform could be coprecipitated with MAGI-1b, a component of endothelial tight junctions. Paracellular permeability, as measured by diffusion of fluorescein isothiocyanate-dextran, was reduced by p80 and p130 angiomotin expression with 70 and 88%, respectively, compared with control. Angiostatin did not have any effect on cell permeability but inhibited the migration of angiomotin-expressing cells in the Boyden chamber assay. We conclude that angiomotin, in addition to controlling cell motility, may play a role in the assembly of endothelial cell-cell junctions.	Karolinska Univ Hosp, Karolinska Inst, Canc Ctr Karolinska, Dept Pathol & Oncol, S-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital	Holmgren, L (corresponding author), Karolinska Univ Hosp, Karolinska Inst, Canc Ctr Karolinska, Dept Pathol & Oncol, R8-03, S-17176 Stockholm, Sweden.	Lars.Holmgren@cck.ki.se						Amzallag N, 2004, J BIOL CHEM, V279, P46104, DOI 10.1074/jbc.M404850200; Beerepoot LV, 2003, CLIN CANCER RES, V9, P4025; BONIFACINO JS, 2005, CURRENT PROTOCOLS CE; Bouquet C, 2003, MOL THER, V7, P174, DOI 10.1016/S1525-0016(02)00057-6; Braga VMM, 2002, CURR OPIN CELL BIOL, V14, P546, DOI 10.1016/S0955-0674(02)00373-3; Bratt A, 2002, GENE, V298, P69, DOI 10.1016/S0378-1119(02)00928-9; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; CHANLING T, 1990, CURR EYE RES, V9, P459, DOI 10.3109/02713689008999612; Chen XY, 2005, NAT CELL BIOL, V7, P262, DOI 10.1038/ncb1226; Claesson-Welsh L, 1998, P NATL ACAD SCI USA, V95, P5579, DOI 10.1073/pnas.95.10.5579; Corada M, 2002, BLOOD, V100, P905, DOI 10.1182/blood.V100.3.905; Dejana E, 2004, NAT REV MOL CELL BIO, V5, P261, DOI 10.1038/nrm1357; Denny PW, 2000, J BIOL CHEM, V275, P11017, DOI 10.1074/jbc.275.15.11017; Dobrosotskaya IY, 2000, BIOCHEM BIOPH RES CO, V270, P903, DOI 10.1006/bbrc.2000.2471; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Gupta N, 2001, EMBO REP, V2, P536, DOI 10.1093/embo-reports/kve115; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hirata K, 2001, J BIOL CHEM, V276, P16223, DOI 10.1074/jbc.M100630200; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Ji WDR, 1998, FASEB J, V12, P1731, DOI 10.1096/fasebj.12.15.1731; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Keenan RJ, 2001, ANNU REV BIOCHEM, V70, P755, DOI 10.1146/annurev.biochem.70.1.755; Langen R, 1998, P NATL ACAD SCI USA, V95, P14060, DOI 10.1073/pnas.95.24.14060; Levchenko T, 2004, ONCOGENE, V23, P1469, DOI 10.1038/sj.onc.1207264; Levchenko T, 2003, J CELL SCI, V116, P3803, DOI 10.1242/jcs.00694; Lucas R, 1998, BLOOD, V92, P4730; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; Moreau J, 2005, GENE, V350, P137, DOI 10.1016/j.gene.2005.02.001; Moser TL, 2001, P NATL ACAD SCI USA, V98, P6656, DOI 10.1073/pnas.131067798; Naik MU, 2003, BLOOD, V102, P2108, DOI 10.1182/blood-2003-04-1114; Naik MU, 2003, ARTERIOSCL THROM VAS, V23, P2165, DOI 10.1161/01.ATV.0000093982.84451.87; Nickel W, 2003, EUR J BIOCHEM, V270, P2109, DOI 10.1046/j.1432-1033.2003.03577.x; Nishimura M, 2002, J BIOL CHEM, V277, P5583, DOI 10.1074/jbc.M110154200; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718; Patrie KM, 2002, J BIOL CHEM, V277, P30183, DOI 10.1074/jbc.M203072200; Prudovsky I, 2002, J CELL BIOL, V158, P201, DOI 10.1083/jcb.200203084; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; Ruffer C, 2004, BIOCHEMISTRY-US, V43, P5360, DOI 10.1021/bi035517c; Satchi-Fainaro R, 2005, CANCER CELL, V7, P251, DOI 10.1016/j.ccr.2005.02.007; SCHULZE C, 1993, J CELL SCI, V104, P773; Shimono A, 2003, CURR BIOL, V13, P613, DOI 10.1016/S0960-9822(03)00204-5; Tanudji M, 2003, AM J PHYSIOL-CELL PH, V284, pC1272, DOI 10.1152/ajpcell.00521.2002; Tarui T, 2001, J BIOL CHEM, V276, P39562, DOI 10.1074/jbc.M101815200; Troyanovsky B, 2001, J CELL BIOL, V152, P1247, DOI 10.1083/jcb.152.6.1247; Wajih N, 2003, BLOOD, V101, P1857, DOI 10.1182/blood-2002-02-0582; Wegmann F, 2004, EXP CELL RES, V300, P121, DOI 10.1016/j.yexcr.2004.07.010; Whitley P, 1996, J BIOL CHEM, V271, P7583, DOI 10.1074/jbc.271.13.7583	49	115	126	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34859	34869		10.1074/jbc.M503915200	http://dx.doi.org/10.1074/jbc.M503915200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16043488	hybrid			2022-12-25	WOS:000232403900058
J	Sasaki, CY; Barberi, TJ; Ghosh, P; Longo, DL				Sasaki, CY; Barberi, TJ; Ghosh, P; Longo, DL			Phosphorylation of RelA/p65 on serine 536 defines an I kappa B alpha-independent NF-kappa B pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; NUCLEAR-FACTOR; P65 SUBUNIT; TRANSCRIPTIONAL ACTIVATION; IKK-BETA; T-CELLS; KINASE; GENE; MECHANISM; PROTEIN	The association of the NF-kappa B p65/p50 dimer with I kappa B alpha plays a pivotal role in regulating its nuclear translocation and gene transcription. In addition, serine phosphorylation at various sites of the p65 subunit has been shown to be important in initiating transcription. Here we demonstrate that the regulation of nuclear translocation of p65 phosphorylated at serine 536 is not dependent on I kappa B alpha. Stimulation of either Jurkat or normal human T cells resulted in the nuclear translocation of phospho-p65 (Ser(536)). In addition, the phospho-p65 (Ser(536)) was not associated with either I kappa B alpha or p50, and the nuclear translocation of phospho-p65 (Ser(536)), but not total p65, was unaffected by the proteosome inhibitor MG-132, which blocks I kappa B protein degradation and prevents p65/p50 dimer nuclear translocation. Accordingly, the co-expression of a dominant negative mutant of I kappa B alpha blocked the transcriptional activity mediated by wild type but not the dominant positive p65 mutant (S536D). Furthermore, the transfection of the S536D form of p65 led to the induction of interleukin-8 transcription following stimulation, whereas the S536A form, which cannot be phosphorylated at this site, did not. Together, the findings suggest that p65 phosphorylated on serine 536 is not associated with or regulated by I kappa B alpha, that it has a distinct set of target genes, and that it may represent a noncanonical NF-kappa B pathway that is independent of I kappa B alpha regulation.	NIA, Immunol Lab, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Sasaki, CY (corresponding author), NIA, Immunol Lab, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	sasakic@grc.nia.nih.gov	Longo, Dan L./F-6022-2011		NATIONAL INSTITUTE ON AGING [Z01AG000426, ZIAAG000426, Z01AG000912, ZICAG000912] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Akiyama M, 2003, CANCER RES, V63, P18; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Bohuslav J, 2004, J BIOL CHEM, V279, P26115, DOI 10.1074/jbc.M313509200; BUSS H, 2004, J BIOL CHEM; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Duran A, 2003, EMBO J, V22, P3910, DOI 10.1093/emboj/cdg370; Ghosh P, 2002, BLOOD, V99, P4517, DOI 10.1182/blood-2001-11-0062; GHOSH P, 1993, P NATL ACAD SCI USA, V90, P1696, DOI 10.1073/pnas.90.5.1696; Ghosh P, 1996, J BIOL CHEM, V271, P7700, DOI 10.1074/jbc.271.13.7700; Grisham MB, 1999, METHOD ENZYMOL, V300, P345; Haller D, 2002, J BIOL CHEM, V277, P38168, DOI 10.1074/jbc.M205737200; Harhaj EW, 1999, MOL CELL BIOL, V19, P7088; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hoffmann A, 2003, EMBO J, V22, P5530, DOI 10.1093/emboj/cdg534; Jiang X, 2003, J BIOL CHEM, V278, P919, DOI 10.1074/jbc.M208696200; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; KUNSCH C, 1994, J IMMUNOL, V153, P153; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; Leung TH, 2004, CELL, V118, P453, DOI 10.1016/j.cell.2004.08.007; LI CCH, 1994, J BIOL CHEM, V269, P30089; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Marshall HE, 2004, P NATL ACAD SCI USA, V101, P8841, DOI 10.1073/pnas.0403034101; Marshall HE, 2002, J BIOL CHEM, V277, P34223, DOI 10.1074/jbc.M201638200; Mattioli I, 2004, J IMMUNOL, V172, P6336, DOI 10.4049/jimmunol.172.10.6336; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; O'Mahony AM, 2004, J BIOL CHEM, V279, P18137, DOI 10.1074/jbc.M401397200; Okazaki T, 2003, BIOCHEM BIOPH RES CO, V300, P807, DOI 10.1016/S0006-291X(02)02932-7; Ryo A, 2003, MOL CELL, V12, P1413, DOI 10.1016/S1097-2765(03)00490-8; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Sakurai H, 2003, J BIOL CHEM, V278, P36916, DOI 10.1074/jbc.M301598200; Schmittgen TD, 2000, ANAL BIOCHEM, V285, P194, DOI 10.1006/abio.2000.4753; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Tam WF, 2001, MOL CELL BIOL, V21, P4837, DOI 10.1128/MCB.21.14.4837-4846.2001; Tam WF, 2001, J BIOL CHEM, V276, P7701, DOI 10.1074/jbc.C000916200; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Vermeulen L, 2002, BIOCHEM PHARMACOL, V64, P963, DOI 10.1016/S0006-2952(02)01161-9; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Yang F, 2003, J IMMUNOL, V170, P5630, DOI 10.4049/jimmunol.170.11.5630; Yano S, 2003, J IMMUNOL, V171, P2510, DOI 10.4049/jimmunol.171.5.2510; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	46	270	276	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34538	34547		10.1074/jbc.M504943200	http://dx.doi.org/10.1074/jbc.M504943200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16105840	hybrid			2022-12-25	WOS:000232403900022
J	Thomas, J; Cronan, JE				Thomas, J; Cronan, JE			The enigmatic acyl carrier protein phosphodiesterase of Escherichia coli - Genetic and enzymological characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID BIOSYNTHESIS; PROSTHETIC GROUP; ACP SYNTHASE; PURIFICATION; EXPRESSION; ENZYME; CLONES; TRANSFERASES; DERIVATIVES; SYNTHETASE	The acyl carrier proteins (ACPs) of fatty acid synthesis are functional only when modified by attachment of the prosthetic group, 4'-phosphopantetheine (4'-PP), which is transferred from CoA to the hydroxyl group of a specific serine residue. Almost 40 years ago Vagelos and Larrabee ( Vagelos, P. R., and Larrabee, A. ( 1967) J. Biol. Chem. 242, 1776 - 1781) reported an enzyme from Escherichia coli that removed the prosthetic group. We report that this enzyme, called ACP hydrolyase or ACP phosphodiesterase, is encoded by a gene (yajB) of previously unknown function that we have renamed acpH. A mutant E. coli strain having a total deletion of the acpH gene has been constructed that grows normally, showing that phosphodiesterase activity is not essential for growth, although it is required for turnover of the ACP prosthetic group in vivo. ACP phosphodiesterase (AcpH) has been purified to homogeneity for the first time and is a soluble protein that very readily aggregates upon overexpression in vivo or concentration in vitro. The purified enzyme has been shown to cleave acyl-ACP species with acyl chains of 6 - 16 carbon atoms and is active on some, but not all, non-native ACP species tested. Possible physiological roles for AcpH are discussed.	Univ Illinois, Dept Microbiol, Chem & Life Sci Lab B103, Urbana, IL 61801 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Cronan, JE (corresponding author), Univ Illinois, Dept Microbiol, Chem & Life Sci Lab B103, 601 S Goodwin Ave, Urbana, IL 61801 USA.	j-cronan@life.uiuc.edu	Cronan, John/V-6626-2019	Thomas, Jacob/0000-0002-7436-8962				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chirgadze NY, 2000, EMBO J, V19, P5281, DOI 10.1093/emboj/19.20.5281; Choi-Rhee E, 2003, J BIOL CHEM, V278, P30806, DOI 10.1074/jbc.M302507200; Clarke L, 1979, Methods Enzymol, V68, P436; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; DIGUAN C, 1988, GENE, V67, P21, DOI 10.1016/0378-1119(88)90004-2; FISCHL AS, 1990, J BACTERIOL, V172, P5445, DOI 10.1128/jb.172.9.5445-5449.1990; Flugel RS, 2000, J BIOL CHEM, V275, P959, DOI 10.1074/jbc.275.2.959; Gehring AM, 1997, CHEM BIOL, V4, P17, DOI 10.1016/S1074-5521(97)90233-7; Golovanov AP, 2004, J AM CHEM SOC, V126, P8933, DOI 10.1021/ja049297h; GRANA D, 1988, GENETICS, V120, P319; HOLAK TA, 1988, EUR J BIOCHEM, V175, P9, DOI 10.1111/j.1432-1033.1988.tb14159.x; JACKOWSKI S, 1984, J BACTERIOL, V158, P115, DOI 10.1128/JB.158.1.115-120.1984; JACKOWSKI S, 1981, J BACTERIOL, V148, P926, DOI 10.1128/JB.148.3.926-932.1981; JACKOWSKI S, 1983, J BIOL CHEM, V258, P5186; JACKOWSKI S, 1984, J BIOL CHEM, V259, P1891; Jiang YF, 2005, J BIOL CHEM, V280, P2244, DOI 10.1074/jbc.M408612200; KEATING DH, 1995, J BIOL CHEM, V270, P22229, DOI 10.1074/jbc.270.38.22229; KIM YM, 1990, PROTEINS, V8, P377, DOI 10.1002/prot.340080411; Lambalot RH, 1997, METHOD ENZYMOL, V279, P254; Lambalot RH, 1996, CHEM BIOL, V3, P923, DOI 10.1016/S1074-5521(96)90181-7; Lan R, 2004, INFECT IMMUN, V72, P5080, DOI 10.1128/IAI.72.9.5080-5088.2004; Lu ZJ, 1996, J BIOL CHEM, V271, P5059; McAllister KA, 2000, J BIOL CHEM, V275, P30864, DOI 10.1074/jbc.M004475200; Mofid MR, 2002, J BIOL CHEM, V277, P17023, DOI 10.1074/jbc.M200120200; Nakanishi M, 2001, J BIOL CHEM, V276, P46394, DOI 10.1074/jbc.M104483200; OHLROGGE JB, 1985, J BIOL CHEM, V260, P8032; Parris KD, 2000, STRUCT FOLD DES, V8, P883, DOI 10.1016/S0969-2126(00)00178-7; POLACCO ML, 1981, J BIOL CHEM, V256, P5750; POSTBEITTENMILLER D, 1991, J BIOL CHEM, V266, P1858; POWELL GL, 1969, J BIOL CHEM, V244, P5616; Pupo GM, 2000, P NATL ACAD SCI USA, V97, P10567, DOI 10.1073/pnas.180094797; Quadri LEN, 1998, BIOCHEMISTRY-US, V37, P1585, DOI 10.1021/bi9719861; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; RAWLINGS M, 1993, THESIS U ILLINOIS UR; ROCK CO, 1979, J BIOL CHEM, V254, P9778; ROCK CO, 1980, ANAL BIOCHEM, V102, P362, DOI 10.1016/0003-2697(80)90168-2; ROCK CO, 1981, J BIOL CHEM, V256, P2669; Rock CO, 2002, BIOCHEM BIOPH RES CO, V292, P1155, DOI 10.1006/bbrc.2001.2022; SHEN ZW, 1992, ANAL BIOCHEM, V204, P34, DOI 10.1016/0003-2697(92)90135-T; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAKIFF HE, 1992, J BACTERIOL, V174, P1544, DOI 10.1128/jb.174.5.1544-1553.1992; Trent MS, 2004, BIOCHEM CELL BIOL, V82, P71, DOI 10.1139/o03-070; VAGELOS PR, 1967, J BIOL CHEM, V242, P1776; VALLARI DS, 1988, J BACTERIOL, V170, P3961, DOI 10.1128/jb.170.9.3961-3966.1988; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; Wada H, 1997, P NATL ACAD SCI USA, V94, P1591, DOI 10.1073/pnas.94.4.1591; Walsh CT, 1997, CURR OPIN CHEM BIOL, V1, P309, DOI 10.1016/S1367-5931(97)80067-1; Waters NC, 2002, MOL BIOCHEM PARASIT, V123, P85, DOI 10.1016/S0166-6851(02)00140-8; WERTMAN KF, 1986, GENE, V49, P253, DOI 10.1016/0378-1119(86)90286-6; Wild J, 2002, GENOME RES, V12, P1434, DOI 10.1101/gr.130502	51	44	50	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34675	34683		10.1074/jbc.M505736200	http://dx.doi.org/10.1074/jbc.M505736200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16107329	hybrid			2022-12-25	WOS:000232403900037
J	Tomura, H; Wang, JQ; Komachi, M; Damirin, A; Mogi, C; Tobo, M; Kon, J; Misawa, N; Sato, K; Okajima, F				Tomura, H; Wang, JQ; Komachi, M; Damirin, A; Mogi, C; Tobo, M; Kon, J; Misawa, N; Sato, K; Okajima, F			Prostaglandin I-2 production and cAMP accumulation in response to acidic extracellular pH through OGR1 in human aortic smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; SPHINGOSINE 1-PHOSPHATE RECEPTORS; SENSITIVE POTASSIUM CHANNELS; K-ATP CHANNELS; INTRACELLULAR ACIDOSIS; LYSOPHOSPHATIDYLCHOLINE; G2A; SPHINGOSYLPHOSPHORYLCHOLINE; IDENTIFICATION; ACTIVATION	Ovarian cancer G-protein-coupled receptor 1 (OGR1) and GPR4 have recently been identified as proton-sensing or extracellular pH-responsive G-protein-coupled receptors stimulating inositol phosphate production and cAMP accumulation, respectively. In the present study, we found that OGR1 and GPR4 mRNAs were expressed in human aortic smooth muscle cells (AoSMCs). Acidic extracellular pH induced inositol phosphate production, a transient increase in intracellular Ca2+ concentration ([Ca2+](i)), and cAMP accumulation in these cells. When small interfering RNAs (siRNAs) targeted for OGR1 and GPR4 were transfected to the cells, the acid-induced inositol phosphate production and [Ca2+](i) increase were markedly inhibited by the OGR1 siRNA but not by the GPR4 siRNA. Unexpectedly, the acid-induced cAMP accumulation was also largely inhibited by OGR1 siRNA but only slightly by GPR4 siRNA. Acidic extracellular pH also stimulated prostaglandin I-2 (PGI(2)) production, which was again inhibited by OGR1 siRNA. The specific inhibitors for extracellular signal-regulated kinase kinase and cyclooxygenase attenuated the acid-induced PGI(2) production and cAMP accumulation without changes in the inositol phosphate production. A specific inhibitor of phospholipase C also inhibited the acid-induced cAMP accumulation. In conclusion, OGR1 is a major receptor involved in the extracellular acid-induced stimulation of PGI(2) production and cAMP accumulation in AoSMCs. The cAMP accumulation may occur through OGR1-mediated stimulation of the phospholipase C/cyclooxygenase/ PGI(2) pathway.	Gunma Univ, Inst Mol & Cellular Regulat, Lab Signal Transduct, Maebashi, Gumma 3718512, Japan; Kirin Brewery Co Ltd, Cent Labs Key Technol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan	Gunma University; Kirin Brewery Company Limited	Tomura, H (corresponding author), Gunma Univ, Inst Mol & Cellular Regulat, Lab Signal Transduct, Maebashi, Gumma 3718512, Japan.	tomurah@showa.gunma-u.ac.jp		Misawa, Norihiko/0000-0003-1373-0769; Sato, Koichi/0000-0001-7694-4014				BATLLE DC, 1993, AM J PHYSIOL, V264, pC932, DOI 10.1152/ajpcell.1993.264.4.C932; Bektas M, 2003, BIOCHEMISTRY-US, V42, P12181, DOI 10.1021/bi035051y; Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C200176200; Bunemann M, 1996, EMBO J, V15, P5527, DOI 10.1002/j.1460-2075.1996.tb00937.x; Damirin A, 2005, MOL PHARMACOL, V67, P1177, DOI 10.1124/mol.104.004317; FITZGERALD GA, 1987, HUM PATHOL, V18, P248, DOI 10.1016/S0046-8177(87)80007-2; Han KH, 2004, J LEUKOCYTE BIOL, V76, P195, DOI 10.1189/jlb.1103563; Hayabuchi Y, 1998, PFLUG ARCH EUR J PHY, V436, P509, DOI 10.1007/s004240050665; Heringdorf DMZ, 2002, BBA-MOL CELL BIOL L, V1582, P178, DOI 10.1016/S1388-1981(02)00154-3; Hyvelin JM, 2004, AM J PHYSIOL-LUNG C, V287, pL673, DOI 10.1152/ajplung.00331.2003; Im DS, 2001, J CELL BIOL, V153, P429, DOI 10.1083/jcb.153.2.429; Ishii S, 2005, J BIOL CHEM, V280, P9083, DOI 10.1074/jbc.M407832200; Ishizaka H, 1999, CIRCULATION, V99, P558, DOI 10.1161/01.CIR.99.4.558; Iwasawa K, 1997, J PHYSIOL-LONDON, V503, P237, DOI 10.1111/j.1469-7793.1997.237bh.x; KIMURA T, 1995, J CARDIOVASC PHARM, V26, P333, DOI 10.1097/00005344-199508000-00021; Klemm DJ, 2001, J BIOL CHEM, V276, P46132, DOI 10.1074/jbc.M104769200; Kon J, 1999, J BIOL CHEM, V274, P23940, DOI 10.1074/jbc.274.34.23940; KRAMPETZ IK, 1991, AM J PHYSIOL, V260, P516; Kyaw H, 1998, DNA CELL BIOL, V17, P493, DOI 10.1089/dna.1998.17.493; Le LQ, 2001, IMMUNITY, V14, P561, DOI 10.1016/S1074-7613(01)00145-5; Leffler CW, 1999, AM J PHYSIOL-HEART C, V277, pH1878, DOI 10.1152/ajpheart.1999.277.5.H1878; Lin P, 2003, J BIOL CHEM, V278, P14379, DOI 10.1074/jbc.M209101200; Ludwig MG, 2003, NATURE, V425, P93, DOI 10.1038/nature01905; Murakami N, 2004, J BIOL CHEM, V279, P42484, DOI 10.1074/jbc.M406561200; Murata N, 2000, ANAL BIOCHEM, V282, P115, DOI 10.1006/abio.2000.4580; Okajima F, 2002, BBA-MOL CELL BIOL L, V1582, P132, DOI 10.1016/S1388-1981(02)00147-6; Ozkara HA, 2004, BRAIN DEV-JPN, V26, P497, DOI 10.1016/j.braindev.2004.01.005; Radu CG, 2005, P NATL ACAD SCI USA, V102, P1632, DOI 10.1073/pnas.0409415102; Rosenblum WI, 2003, STROKE, V34, P1547, DOI 10.1161/01.STR.0000070425.98202.B5; Sato K, 1999, MOL PHARMACOL, V55, P126, DOI 10.1124/mol.55.1.126; TIAN R, 1995, CIRC RES, V76, P269, DOI 10.1161/01.RES.76.2.269; Tokumura A, 2004, J CELL BIOCHEM, V92, P869, DOI 10.1002/jcb.20147; WALLEY KR, 1990, CIRC RES, V67, P628, DOI 10.1161/01.RES.67.3.628; Wang JQ, 2004, J BIOL CHEM, V279, P45626, DOI 10.1074/jbc.M406966200; Wang XR, 2003, CIRC RES, V92, P1225, DOI 10.1161/01.RES.0000075601.95738.6D; Weber AA, 1998, BASIC RES CARDIOL, V93, P54; Weng ZG, 1998, P NATL ACAD SCI USA, V95, P12334, DOI 10.1073/pnas.95.21.12334; Xu HX, 2001, J BIOL CHEM, V276, P12898, DOI 10.1074/jbc.M009631200; Xu Y, 1996, GENOMICS, V35, P397, DOI 10.1006/geno.1996.0377; Xu Y, 2000, NAT CELL BIOL, V2, P261, DOI 10.1038/35010529; Yamada T, 2004, J BIOL CHEM, V279, P6595, DOI 10.1074/jbc.M308133200; Yan JJ, 2004, NAT MED, V10, P161, DOI 10.1038/nm989; Yang LV, 2005, BLOOD, V105, P1127, DOI 10.1182/blood-2004-05-1916; Zhu K, 2001, J BIOL CHEM, V276, P41325, DOI 10.1074/jbc.M008057200	44	74	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34458	34464		10.1074/jbc.M505287200	http://dx.doi.org/10.1074/jbc.M505287200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16087674	hybrid			2022-12-25	WOS:000232403900012
J	Barker, S; Weinfeld, M; Zheng, J; Li, L; Murray, D				Barker, S; Weinfeld, M; Zheng, J; Li, L; Murray, D			Identification of mammalian proteins cross-linked to DNA by ionizing radiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHINESE-HAMSTER CELLS; DOUBLE-STRAND; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; BIOLOGICAL CONSEQUENCES; THIOREDOXIN PEROXIDASE; HYPOXIC CONDITIONS; HYDROGEN-PEROXIDE; NUCLEAR PROTEINS; HISTONE H3; IN-VITRO	Ionizing radiation (IR) is an important environmental risk factor for various cancers and also a major therapeutic agent for cancer treatment. Exposure of mammalian cells to IR induces several types of damage to DNA, including double- and single-strand breaks, base and sugar damage, as well as DNA-DNA and DNA-protein cross-links (DPCs). Little is known regarding the biological consequences of DPCs. Identifying the proteins that become cross-linked to DNA by IR would be an important first step in this regard. We have therefore undertaken a proteomics study to isolate and identify proteins involved in IR-induced DPCs. DPCs were induced in AA8 Chinese hamster ovary or GM00637 human fibroblast cells using 0 - 4 gray of gamma-rays under either aerated or hypoxic conditions. DPCs were isolated using a recently developed method, and proteins were identified by mass spectrometry. We identified 29 proteins as being cross-linked to DNA by IR under aerated and/or hypoxic conditions. The identified proteins include structural proteins, actin-associated proteins, transcription regulators, RNA-splicing components, stress-response proteins, cell cycle regulatory proteins, and GDP/GTP-binding proteins. The involvement of several proteins ( actin, histone H2B, and others) in DPCs was confirmed by using Western blot analysis. The dose responsiveness of DPC induction was examined by staining one-dimensional SDS-polyacrylamide gels with SYPRO Tangerine followed by analysis using fluorescence imaging. Quantitation of the fluorescence signal indicated no significant difference in total yields of IR-induced DPCs generated under aerated or hypoxic conditions, although differences were observed for several individual protein bands.	Cross Canc Inst, Div Expt Oncol, Dept Oncol, Edmonton, AB T6G 1Z2, Canada; Univ Alberta, Dept Chem W3 39, Edmonton, AB T6G 2G2, Canada	University of Alberta; University of Alberta	Murray, D (corresponding author), Cross Canc Inst, Div Expt Oncol, Dept Oncol, 11560 Univ Ave, Edmonton, AB T6G 1Z2, Canada.	davem@cancerboard.ab.ca	Li, Liang/D-1822-2011					ABBATE M, 1993, EUR J CELL BIOL, V61, P139; Akhmedov AT, 2000, NUCLEIC ACIDS RES, V28, P3022, DOI 10.1093/nar/28.16.3022; ALEXANDER P, 1960, NATURE, V187, P933, DOI 10.1038/187933b0; AlNabulsi I, 1997, RADIAT RES, V148, P568, DOI 10.2307/3579732; Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; Araki M, 2001, J BIOL CHEM, V276, P18665, DOI 10.1074/jbc.M100855200; Barker S, 2005, ANAL BIOCHEM, V344, P204, DOI 10.1016/j.ab.2005.06.039; Barker S, 2005, MUTAT RES-REV MUTAT, V589, P111, DOI 10.1016/j.mrrev.2004.11.003; Batchelor CL, 2004, EXP CELL RES, V296, P208, DOI 10.1016/j.yexcr.2004.02.010; Belyaev IY, 2001, RADIAT RES, V156, P355, DOI 10.1667/0033-7587(2001)156[0355:CICCDR]2.0.CO;2; Berggren MI, 2001, ARCH BIOCHEM BIOPHYS, V392, P103, DOI 10.1006/abbi.2001.2435; Bertrand P, 1999, ONCOGENE, V18, P4515, DOI 10.1038/sj.onc.1203048; Bill CA, 2001, MUTAT RES-DNA REPAIR, V487, P41; BillautMulot O, 1996, GENE, V174, P19, DOI 10.1016/0378-1119(96)00254-5; BOLE DG, 1989, J HISTOCHEM CYTOCHEM, V37, P1817, DOI 10.1177/37.12.2685110; Bouchard WJ, 2003, EXP HEMATOL, V31, P446, DOI 10.1016/S0301-472X(03)00083-3; BoucksonCastaing V, 1996, J CELL SCI, V109, P179; Chai Q, 2003, BIOCHEMISTRY-US, V42, P15045, DOI 10.1021/bi035364t; CHIU SM, 1986, INT J RADIAT ONCOL, V12, P1529, DOI 10.1016/0360-3016(86)90209-9; CHIU SM, 1986, RADIAT RES, V107, P24, DOI 10.2307/3576847; CHIU SM, 1990, INT J RADIAT BIOL, V58, P235, DOI 10.1080/09553009014551591; CHIU SM, 1984, INT J RADIAT BIOL, V46, P681, DOI 10.1080/09553008414551921; Coulombe RA, 1999, TOXICOL APPL PHARM, V154, P198, DOI 10.1006/taap.1998.8552; DIZDAROGLU M, 1989, BIOCHEMISTRY-US, V28, P3625, DOI 10.1021/bi00434a071; Downs JA, 2004, MOL CELL, V16, P979, DOI 10.1016/j.molcel.2004.12.003; ELIA MC, 1992, CANCER RES, V52, P1580; Elphinstone MS, 2003, MOL ECOL NOTES, V3, P317, DOI 10.1046/j.1471-8286.2003.00397.x; Fanta M, 2001, HYBRIDOMA, V20, P237, DOI 10.1089/027245701753179811; FIDLEROVA H, 2005, IN PRESS J CELL BIOC; Ford LP, 2002, ONCOGENE, V21, P580, DOI 10.1038/sj.onc.1205086; FORNACE AJ, 1977, BIOCHIM BIOPHYS ACTA, V477, P343, DOI 10.1016/0005-2787(77)90253-2; FORNACE AJ, 1982, CANCER RES, V42, P145; Friedberg ECW GC, 1995, DNA REPAIR MUTAGENES, P19; GAJEWSKI E, 1988, INT J RADIAT BIOL, V54, P445, DOI 10.1080/09553008814551821; Gruenheid S, 1999, J EXP MED, V189, P831, DOI 10.1084/jem.189.5.831; Hermann Ralph, 2001, Human Antibodies, V10, P83; Hockel M, 2001, SEMIN ONCOL, V28, P36, DOI 10.1016/S0093-7754(01)90211-8; Huang ME, 2003, P NATL ACAD SCI USA, V100, P11529, DOI 10.1073/pnas.2035018100; KOCH CJ, 1984, RADIAT RES, V98, P141, DOI 10.2307/3576058; KOLLURI R, 1992, NUCLEIC ACIDS RES, V20, P111, DOI 10.1093/nar/20.1.111; Krynetski EY, 2003, CANCER RES, V63, P100; Kwak IH, 2004, CANCER RES, V64, P572, DOI 10.1158/0008-5472.CAN-03-1856; Laz EV, 2004, MOL CELL PROTEOMICS, V3, P1170, DOI 10.1074/mcp.M400102-MCP200; Lejnine S, 1999, NUCLEIC ACIDS RES, V27, P3676, DOI 10.1093/nar/27.18.3676; Lemos TA, 2003, FEBS LETT, V533, P14, DOI 10.1016/S0014-5793(02)03737-7; Lowell JE, 2004, J CELL SCI, V117, P5937, DOI 10.1242/jcs.01515; Maniatis T., 1982, MOL CLONING LAB MANU; Matsumoto A, 2000, CANCER RES, V60, P3921; Mattagajasingh SN, 1999, MOL CELL BIOCHEM, V199, P149, DOI 10.1023/A:1006910732307; MEE LK, 1981, P NATL ACAD SCI-BIOL, V78, P2194, DOI 10.1073/pnas.78.4.2194; MEYN RE, 1987, RADIAT RES, V109, P419, DOI 10.2307/3577042; MEYN RE, 1986, DNA DAMAGE REPAIR IM, P151; MILLER CA, 1991, CARCINOGENESIS, V12, P269, DOI 10.1093/carcin/12.2.269; Mitsuzawa H, 2005, FEBS LETT, V579, P48, DOI 10.1016/j.febslet.2004.11.045; Murphy GA, 2001, CELL GROWTH DIFFER, V12, P157; Murray D, 1996, INT J RADIAT BIOL, V69, P319, DOI 10.1080/095530096145878; NACKERDIEN Z, 1991, BIOCHEMISTRY-US, V30, P4873, DOI 10.1021/bi00234a006; OCONNOR PM, 1989, J BIOL CHEM, V264, P6391; OLINSKI R, 1992, ARCH BIOCHEM BIOPHYS, V297, P139, DOI 10.1016/0003-9861(92)90651-C; Pouget JP, 2001, EUR J NUCL MED, V28, P541, DOI 10.1007/s002590100484; Przewloka MR, 2003, MOL BIOL CELL, V14, P685, DOI 10.1091/mbc.e01-11-0117; Quievryn G, 2000, CARCINOGENESIS, V21, P1573, DOI 10.1093/carcin/21.8.1573; QUINTILIANI M, 1986, INT J RADIAT BIOL, V50, P573, DOI 10.1080/09553008614550981; RADFORD IR, 1986, INT J RADIAT BIOL, V49, P621; Radyuk SN, 2003, BIOCHEM J, V371, P743, DOI 10.1042/BJ20021522; RAMAKRISHNAN N, 1987, CANCER RES, V47, P2032; Ramirez P, 2000, CARCINOGENESIS, V21, P701, DOI 10.1093/carcin/21.4.701; Ross SJ, 2000, MOL BIOL CELL, V11, P2631, DOI 10.1091/mbc.11.8.2631; Sadacharan SK, 2001, HISTOCHEM CELL BIOL, V116, P507, DOI 10.1007/s00418-001-0344-4; Samuel SK, 1998, CANCER RES, V58, P3004; Tolstonog GV, 2002, DNA CELL BIOL, V21, P213, DOI 10.1089/10445490252925459; Tolstonog GV, 2001, DNA CELL BIOL, V20, P531, DOI 10.1089/104454901317094954; Tsuda M, 2004, J BIOL CHEM, V279, P46843, DOI 10.1074/jbc.M401476200; Vaupel P, 2001, SEMIN ONCOL, V28, P29, DOI 10.1016/S0093-7754(01)90210-6; VERMEULEN W, 1996, HELIX, V1, P22; Voitkun V, 1999, MUTAT RES-FUND MOL M, V424, P97, DOI 10.1016/S0027-5107(99)00011-1; Vorum H, 1999, EXP CELL RES, V248, P473, DOI 10.1006/excr.1999.4431; WOUDSTRA E, 1999, THESIS U GRONINGEN; XUE LY, 1994, INT J RADIAT BIOL, V66, P11, DOI 10.1080/09553009414550901; XUE LY, 1988, RADIAT RES, V116, P89, DOI 10.2307/3577480; You YJ, 2004, AM J PHYSIOL-LUNG C, V286, pL650, DOI 10.1152/ajplung.00170.2003; Zahn RK, 1999, MECH AGEING DEV, V108, P99, DOI 10.1016/S0047-6374(98)00151-1; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5; Zimber A, 2004, CELL SIGNAL, V16, P1085, DOI 10.1016/j.cellsig.2004.03.020; Zinszner H, 1997, ONCOGENE, V14, P451, DOI 10.1038/sj.onc.1200854; Zinszner H, 1997, J CELL SCI, V110, P1741	86	90	95	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33826	33838		10.1074/jbc.M502477200	http://dx.doi.org/10.1074/jbc.M502477200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16093242	hybrid			2022-12-25	WOS:000232229700019
J	Halverson, KM; Panchal, RG; Nguyen, TL; Gussio, R; Little, SF; Misakian, M; Bavari, S; Kasianowicz, JJ				Halverson, KM; Panchal, RG; Nguyen, TL; Gussio, R; Little, SF; Misakian, M; Bavari, S; Kasianowicz, JJ			Anthrax biosensor, protective antigen ion channel asymmetric blockade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYMMETRICAL TETRAALKYLAMMONIUM IONS; PHOSPHOLIPID-BILAYER MEMBRANES; VOLTAGE-DEPENDENT BLOCK; PLANAR LIPID-BILAYERS; LETHAL FACTOR; TOXIN CHANNELS; MONOCLONAL-ANTIBODIES; CRYSTAL-STRUCTURE; MAMMALIAN-CELLS; FACTOR-BINDING	The significant threat posed by biological agents ( e. g. anthrax, tetanus, botulinum, and diphtheria toxins) (Inglesby, T. V., O'Toole, T., Henderson, D. A., Bartlett, J. G., Ascher, M. S., Eitzen, E., Friedlander, A. M., Gerberding, J., Hauer, J., Hughes, J., McDade, J., Osterholm, M. T., Parker, G., Perl, T. M., Russell, P. K., and Tonat, K. ( 2002) J. Am. Med. Assoc. 287, 2236 - 2252) requires innovative technologies and approaches to understand the mechanisms of toxin action and to develop better therapies. Anthrax toxins are formed from three proteins secreted by fully virulent Bacillus anthracis, protective antigen (PA, 83 kDa), lethal factor (LF, 90 kDa), and edema factor (EF, 89 kDa). Here we present electrophysiological measurements demonstrating that full-length LF and EF convert the current-voltage relationship of the heptameric PA(63) ion channel from slightly nonlinear to highly rectifying and diode-like at pH 6.6. This effect provides a novel method for characterizing functional toxin interactions. The method confirms that a previously well characterized PA(63) monoclonal antibody, which neutralizes anthrax lethal toxin in animals in vivo and in vitro, prevents the binding of LF to the PA(63) pore. The technique can also detect the presence of anthrax lethal toxin complex from plasma of infected animals. The latter two results suggest the potential application of PA(63) nanopore-based biosensors in anthrax therapeutics and diagnostics.	Natl Inst Stand & Technol, Adv Chem Sci Lab, Gaithersburg, MD 20899 USA; Natl Inst Stand & Technol, Elect & Elect Engn Lab, Semicond Engn Div, Gaithersburg, MD 20899 USA; USA, Med Res Inst Infect Dis, Frederick, MD 21702 USA; NCI, Dev Therapeut Program, Target Struct Based Drug Discovery Grp, Sci Applicat Int Corp, Frederick, MD 21702 USA	National Institute of Standards & Technology (NIST) - USA; National Institute of Standards & Technology (NIST) - USA; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC)	Kasianowicz, JJ (corresponding author), Natl Inst Stand & Technol, Adv Chem Sci Lab, Bldg 225,Rm B326, Gaithersburg, MD 20899 USA.	john.kasianowicz@nist.gov	Bavari, Sina/L-3642-2019; Panchal, Rekha/None	Bavari, Sina/0000-0001-8424-5635; Panchal, Rekha/0000-0001-8621-9078				Benson EL, 1998, BIOCHEMISTRY-US, V37, P3941, DOI 10.1021/bi972657b; BLAUSTEIN RO, 1990, J GEN PHYSIOL, V96, P921, DOI 10.1085/jgp.96.5.921; BLAUSTEIN RO, 1990, J GEN PHYSIOL, V96, P905, DOI 10.1085/jgp.96.5.905; BLAUSTEIN RO, 1990, J GEN PHYSIOL, V96, P943, DOI 10.1085/jgp.96.5.943; Bradley KA, 2001, NATURE, V414, P225, DOI 10.1038/n35101999; Chauhan V, 2002, INFECT IMMUN, V70, P4477, DOI 10.1128/IAI.70.8.4477-4484.2002; Cunningham K, 2002, P NATL ACAD SCI USA, V99, P7049, DOI 10.1073/pnas.062160399; Elliott JL, 2000, BIOCHEMISTRY-US, V39, P6706, DOI 10.1021/bi000310u; EZZELL JW, 1992, J GEN MICROBIOL, V138, P543, DOI 10.1099/00221287-138-3-543; FINKELSTEIN A, 1994, TOXICOLOGY, V87, P29, DOI 10.1016/0300-483X(94)90153-8; Inglesby TV, 2002, JAMA-J AM MED ASSOC, V287, P2236, DOI 10.1001/jama.287.17.2236; Kasianowicz JJ, 1996, P NATL ACAD SCI USA, V93, P13770, DOI 10.1073/pnas.93.24.13770; KASIANOWICZ JJ, 1995, BIOPHYS J, V69, P94, DOI 10.1016/S0006-3495(95)79879-4; Kasianowicz JJ, 2001, ANAL CHEM, V73, P2268, DOI 10.1021/ac000958c; KLIMPEL KR, 1992, P NATL ACAD SCI USA, V89, P10277, DOI 10.1073/pnas.89.21.10277; Leppla S.H., 1991, SOURCEBOOK BACTERIAL, P277; Little SF, 1996, MICROBIOL-SGM, V142, P707, DOI 10.1099/13500872-142-3-707; LITTLE SF, 1988, INFECT IMMUN, V56, P1807, DOI 10.1128/IAI.56.7.1807-1813.1988; Lu Z, 2004, ANNU REV PHYSIOL, V66, P103, DOI 10.1146/annurev.physiol.66.032102.150822; MILNE JC, 1993, MOL MICROBIOL, V10, P647, DOI 10.1111/j.1365-2958.1993.tb00936.x; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; MONTAL M, 1972, P NATL ACAD SCI USA, V69, P3561, DOI 10.1073/pnas.69.12.3561; Mourez M, 2002, TRENDS MICROBIOL, V10, P287, DOI 10.1016/S0966-842X(02)02369-7; Nguyen TL, 2004, J BIOMOL STRUCT DYN, V22, P253, DOI 10.1080/07391102.2004.10531226; Panchal RG, 2005, J BIOL CHEM, V280, P10834, DOI 10.1074/jbc.M412210200; Panchal RG, 2004, NAT STRUCT MOL BIOL, V11, P67, DOI 10.1038/nsmb711; Pannifer AD, 2001, NATURE, V414, P229, DOI 10.1038/n35101998; Petosa C, 1997, NATURE, V385, P833, DOI 10.1038/385833a0; QUINN CP, 1991, J BIOL CHEM, V266, P20124; Scobie HM, 2003, P NATL ACAD SCI USA, V100, P5170, DOI 10.1073/pnas.0431098100; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; Singh Y, 1999, INFECT IMMUN, V67, P1853; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; Zhang S, 2004, BIOPHYS J, V87, P3842, DOI 10.1529/biophysj.104.050864; ZHAO JM, 1995, J BIOL CHEM, V270, P18626, DOI 10.1074/jbc.270.31.18626	35	69	76	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34056	34062		10.1074/jbc.M507928200	http://dx.doi.org/10.1074/jbc.M507928200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16087661	hybrid			2022-12-25	WOS:000232229700045
J	Groth, S; Schulze, M; Kalthoff, H; Fandrich, F; Ungefroren, H				Groth, S; Schulze, M; Kalthoff, H; Fandrich, F; Ungefroren, H			Adhesion and Rac1-dependent regulation of biglycan gene expression by transforming growth factor-beta - Evidence for oxidative signaling through NADPH oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RHO-FAMILY GTPASES; CANCER CELL-LINES; TGF-BETA; PANCREATIC-CANCER; DIABETIC-NEPHROPATHY; HUMAN NEUTROPHILS; PROTEOGLYCANS; GENERATION; MIGRATION	Both transforming growth factor-beta(TGF-beta)-induced expression of biglycan (BGN) and activation of p38 MAPK have been implicated in cellular adhesion and migration. Here, we analyzed the role of adhesive events and the small GTPase Rac1 in TGF-beta regulation of BGN. TGF-beta 1 induction of BGN expression and activation of p38 was abolished or strongly reduced when cells were kept in suspension or exposed to either the actin cytoskeleton-disrupting agent cytochalasin D or a specific chemical Rac1 inhibitor. Ectopic expression of a dominant negative mutant (T17N) of Rac1 abrogated both TGF-beta-induced p38 MAPK activation and BGN up-regulation but did not affect TGF-beta-induced phosphorylation of Smad3 or transcriptional induction of Growth Arrest DNA Damage 45 beta, previously shown to be crucial for TGF-beta regulation of BGN. Overexpression of wild type Rac1 greatly enhanced the TGF-beta effect on BGN in adherent cells, whereas ectopic expression of constitutively active Rac1 (Q61L) activated p38 and in the presence of exogenous TGF-beta was able to rescue BGN expression in nonadherent cells. Endogenous Rac1 was activated by TGF-beta treatment in PANC-1 cells in an adhesion-dependent fashion. Like Rac1-T17N, the NADPH oxidase inhibitor diphenylene iodonium and the tyrosine kinase inhibitor herbimycin A blocked TGF-beta-induced p38 activation and BGN expression, suggesting that Rac1 exerts its effect on BGN and p38 through increasing NADPH oxidase activity and subsequent production of reactive oxygen species. These results show that the TGF-beta effect on BGN is dependent on cell adhesion and that activated Rac1, presumably acting through NADPH oxidase(s), is necessary but not sufficient for TGF-beta-induced BGN expression.	Univ Hosp Schleswig Holstein, Dept Gen Surg & Thorac Surg, D-24105 Kiel, Germany	University of Kiel; Schleswig Holstein University Hospital	Ungefroren, H (corresponding author), Univ Hosp Schleswig Holstein, Dept Gen Surg & Thorac Surg, Campus Kiel,Arnold Heller Str 7, D-24105 Kiel, Germany.	hungefroren@chirurgie-sh.de	Kalthoff, Holger/B-1618-2010; Ungefroren, Hendrik/E-2933-2010; Faendrich, Fred/B-1705-2010; Goletz, Stephanie/K-1358-2014	Schulze, Maren/0000-0002-4577-6473				Bakin AV, 2002, J CELL SCI, V115, P3193; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Berrier AL, 2002, J CELL SCI, V115, P4285, DOI 10.1242/jcs.00109; Bhowmick NA, 2001, J BIOL CHEM, V276, P46707, DOI 10.1074/jbc.M106176200; Bokoch GM, 2002, BLOOD, V100, P2692, DOI 10.1182/blood-2002-04-1149; Bokoch GM, 2003, TRENDS BIOCHEM SCI, V28, P502, DOI 10.1016/S0968-0004(03)00194-4; Chen WB, 2002, J BIOL CHEM, V277, P36118, DOI 10.1074/jbc.M203709200; Chiu C, 2001, INT J MOL MED, V8, P251; Crnogorac-Jurcevic T, 2001, ONCOGENE, V20, P7437, DOI 10.1038/sj.onc.1204935; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Di-Poi N, 2001, BIOCHEMISTRY-US, V40, P10014, DOI 10.1021/bi010289c; Dusi S, 1996, J IMMUNOL, V157, P4615; Edlund S, 2002, MOL BIOL CELL, V13, P902, DOI 10.1091/mbc.01-08-0398; Ellenrieder V, 2001, CANCER RES, V61, P4222; Geiszt M, 2004, J BIOL CHEM, V279, P51715, DOI 10.1074/jbc.R400024200; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; Kinsella MG, 1997, J BIOL CHEM, V272, P318; Kinsella MG, 2004, CRIT REV EUKAR GENE, V14, P203, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i3.40; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; Lehnert L, 2001, J CELL BIOL, V152, P911, DOI 10.1083/jcb.152.5.911; Lohr M, 2001, CANCER RES, V61, P550; Major MB, 2004, J BIOL CHEM, V279, P5278, DOI 10.1074/jbc.M311517200; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Menke A, 2002, J GASTROINTEST CANC, V31, P41, DOI 10.1385/IJGC:31:1-3:41; Menke A, 2001, CANCER RES, V61, P3508; Moustakas A, 2002, IMMUNOL LETT, V82, P85, DOI 10.1016/S0165-2478(02)00023-8; Schaefer L, 2001, FASEB J, V15, P559; Shin I, 2005, J BIOL CHEM, V280, P14675, DOI 10.1074/jbc.M411625200; Takekawa M, 2002, EMBO J, V21, P6473, DOI 10.1093/emboj/cdf643; Thannickal VJ, 2003, J BIOL CHEM, V278, P12384, DOI 10.1074/jbc.M208544200; Tufvesson E, 2003, J CELL SCI, V116, P4857, DOI 10.1242/jcs.00808; Ungefroren H, 2005, J BIOL CHEM, V280, P2644, DOI 10.1074/jbc.M411925200; Ungefroren H, 2003, J BIOL CHEM, V278, P11041, DOI 10.1074/jbc.M300035200; Wadhwa S, 2004, CRIT REV EUKAR GENE, V14, P301, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i4.50; Weber CK, 2001, GASTROENTEROLOGY, V121, P657, DOI 10.1053/gast.2001.27222; Wennerberg K, 2004, J CELL SCI, V117, P1301, DOI 10.1242/jcs.01118; YAMAMOTO T, 1993, P NATL ACAD SCI USA, V90, P1814, DOI 10.1073/pnas.90.5.1814; Yang S, 2000, BIOCHEM CELL BIOL, V78, P11; Yokoyama H, 1996, DIABETIC MED, V13, P313, DOI 10.1002/(SICI)1096-9136(199604)13:4<313::AID-DIA56>3.3.CO;2-Z; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhao TM, 2003, J CLIN INVEST, V112, P1732, DOI 10.1172/JCI200319108	42	39	41	3	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33190	33199		10.1074/jbc.M504249200	http://dx.doi.org/10.1074/jbc.M504249200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16051607	hybrid			2022-12-25	WOS:000232058100013
J	Mussig, K; Staiger, H; Fiedler, H; Moeschel, K; Beck, A; Kellerer, M; Haring, HU				Mussig, K; Staiger, H; Fiedler, H; Moeschel, K; Beck, A; Kellerer, M; Haring, HU			Shp2 is required for protein kinase C-dependent phosphorylation of serine 307 in insulin receptor substrate-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR SUBSTRATE-1; PHORBOL ESTERS INCREASE; TYROSINE-PHOSPHATASE; RAT ADIPOCYTES; PHOSPHOTYROSINE PHOSPHATASE; GLYCOGEN-SYNTHESIS; DIABETES-MELLITUS; CELLS; ACTIVATION; MODULATION	The function of insulin receptor substrate-1 (IRS-1), a key molecule of insulin signaling, is modulated by phosphorylation at multiple serine/threonine residues. Phorbol ester stimulation of cells induces phosphorylation of two inhibitory serine residues in IRS-1, i.e. Ser-307 and Ser-318, suggesting that both sites may be targets of protein kinase C ( PKC) isoforms. However, in an in vitro system using a broad spectrum of PKC isoforms (alpha, beta 1, beta 2, delta, epsilon, eta, mu), we detected only Ser-318, but not Ser-307 phosphorylation, suggesting that phorbol ester-induced phosphorylation of this site in intact cells requires additional signaling elements and serine kinases that link PKC activation to Ser-307 phosphorylation. As we have observed recently that the tyrosine phosphatase Shp2, a negative regulator of insulin signaling, is a substrate of PKC, we studied the role of Shp2 in this context. We found that phorbol ester-induced Ser-307 phosphorylation is reduced markedly in Shp2-deficient mouse embryonic fibroblasts (Shp2(-/-)) whereas Ser-318 phosphorylation is unaltered. The Ser-307 phosphorylation was rescued by transfection of mouse embryonic fibroblasts with wild-type Shp2 or with a phosphatase-inactive Shp2 mutant, respectively. In this cell model, tumor necrosis factor-alpha-induced Ser-307 phosphorylation as well depended on the presence of Shp2. Furthermore, Shp2-dependent phorbol ester effects on Ser-307 were blocked by wortmannin, rapamycin, and the c-Jun NH2-terminal kinase (JNK) inhibitor SP600125. This suggests an involvement of the phosphatidylinositol 3-kinase/mammalian target of rapamycin cascade and of JNK in this signaling pathway resulting in IRS-1 Ser-307 phosphorylation. Because the activation of these kinases does not depend on Shp2, it is concluded that the function of Shp2 is to direct these activated kinases to IRS-1	Univ Tubingen Hosp, Dept Internal Med, Div Endocrinol Metab & Pathobiochem, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Haring, HU (corresponding author), Med Univ Klin Tubingen, Otfried Muller Str 10, D-72076 Tubingen, Germany.	Hans-Ulrich.Haering@med.uni-tuebingen.de	Staiger, Harald/N-5871-2014	Staiger, Harald/0000-0002-9507-5333				Adachi M, 1996, CELL, V85, P15; Aguirre V, 2002, J BIOL CHEM, V277, P1531, DOI 10.1074/jbc.M101521200; Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; AHMAD F, 1995, METABOLISM, V44, P1175, DOI 10.1016/0026-0495(95)90012-8; AHMAD F, 1995, AM J PHYSIOL, V268, P932; Andreozzi F, 2004, CIRC RES, V94, P1211, DOI 10.1161/01.RES.0000126501.34994.96; Andreozzi F, 2004, ENDOCRINOLOGY, V145, P2845, DOI 10.1210/en.2003-0939; Avignon A, 1996, DIABETES, V45, P1396, DOI 10.2337/diabetes.45.10.1396; Beck A, 2003, J AM SOC MASS SPECTR, V14, P401, DOI 10.1016/S1044-0305(03)00122-3; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BERTI L, 1994, J BIOL CHEM, V269, P3381; Bifulco G, 2003, GYNECOL ENDOCRINOL, V17, P239; Bossenmaier B, 1997, DIABETOLOGIA, V40, P863, DOI 10.1007/s001250050761; Carlson CJ, 2004, BIOCHEM BIOPH RES CO, V316, P533, DOI 10.1016/j.bbrc.2004.02.082; CARO JF, 1992, MOL CELL BIOCHEM, V109, P115; CONSIDINE RV, 1995, J CLIN INVEST, V95, P2938, DOI 10.1172/JCI118001; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; Desbois-Mouthon C, 1998, BIOCHEM BIOPH RES CO, V243, P765, DOI 10.1006/bbrc.1998.8181; DUBYAK GR, 1980, J BIOL CHEM, V255, P5306; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; Gao ZG, 2002, J BIOL CHEM, V277, P48115, DOI 10.1074/jbc.M209459200; Greene MW, 2004, BIOCHEM J, V378, P105, DOI 10.1042/BJ20031493; Gual P, 2003, J BIOL CHEM, V278, P26550, DOI 10.1074/jbc.M212273200; HARING H, 1986, J BIOL CHEM, V261, P3869; Idris I, 2001, DIABETOLOGIA, V44, P659, DOI 10.1007/s001250051675; Jiang GQ, 2003, J BIOL CHEM, V278, P180, DOI 10.1074/jbc.M205565200; Kellerer M, 1998, DIABETOLOGIA, V41, P833, DOI 10.1007/s001250050995; KHARITONENKOV A, 1995, J BIOL CHEM, V270, P29189, DOI 10.1074/jbc.270.49.29189; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Miller BS, 1996, BIOCHEMISTRY-US, V35, P8769, DOI 10.1021/bi952651r; Moeschel K, 2004, J BIOL CHEM, V279, P25157, DOI 10.1074/jbc.M402477200; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; Nakajima K, 2000, J BIOL CHEM, V275, P20880, DOI 10.1074/jbc.M905410199; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; Ouwens DM, 2001, MOL CELL ENDOCRINOL, V175, P131, DOI 10.1016/S0303-7207(01)00389-6; Pugazhenthi S, 1996, ARCH BIOCHEM BIOPHYS, V335, P273, DOI 10.1006/abbi.1996.0508; Rocchi S, 1996, ENDOCRINOLOGY, V137, P4944, DOI 10.1210/en.137.11.4944; Ross SA, 1998, BIOCHEM BIOPH RES CO, V247, P487, DOI 10.1006/bbrc.1998.8821; Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934; STAUBS PA, 1994, J BIOL CHEM, V269, P27186; Strack V, 2002, BIOCHEMISTRY-US, V41, P603, DOI 10.1021/bi011327v; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; Ugi S, 1996, J BIOL CHEM, V271, P12595, DOI 10.1074/jbc.271.21.12595; VANDEWERVE G, 1985, BIOCHEM J, V225, P523, DOI 10.1042/bj2250523; Walter AO, 1999, ONCOGENE, V18, P1911, DOI 10.1038/sj.onc.1202513; Werner ED, 2004, J BIOL CHEM, V279, P35298, DOI 10.1074/jbc.M405203200; Wu CJ, 2001, ONCOGENE, V20, P6018, DOI 10.1038/sj.onc.1204699; Yart A, 2003, CURR CANCER DRUG TAR, V3, P177, DOI 10.2174/1568009033481976	53	24	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32693	32699		10.1074/jbc.M506549200	http://dx.doi.org/10.1074/jbc.M506549200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16055440	hybrid			2022-12-25	WOS:000231920300019
J	Bewick, GA; Gardiner, JV; Dhillo, WS; Kent, AS; White, NE; Webster, Z; Ghatei, MA; Bloom, SR				Bewick, GA; Gardiner, JV; Dhillo, WS; Kent, AS; White, NE; Webster, Z; Ghatei, MA; Bloom, SR			Postembryonic ablation of AgRP neurons in mice leads to a lean, hypophagic phenotype	FASEB JOURNAL			English	Article						neuropeptide Y; hypothalamic arcuate nucleus; food intake regulation; neuroendocrinology; gut hormone	AGOUTI-RELATED-PROTEIN; AMPHETAMINE-REGULATED TRANSCRIPT; DISEASE GENE-PRODUCT; INHIBITS FOOD-INTAKE; IN-VIVO; NEUROPEPTIDE-Y; HYPOTHALAMIC NEURONS; ENERGY HOMEOSTASIS; MESSENGER-RNA; MALE RATS	Agouti-related protein ( AgRP) and neuropeptide Y ( NPY) are colocalized in arcuate nucleus ( arcuate) neurons implicated in the regulation of energy balance. Both AgRP and NPY stimulate food intake when administered into the third ventricle and are up- regulated in states of negative energy balance. However, mice with targeted deletion of either NPY or AgRP or both do not have major alterations in energy homeostasis. Using bacterial artificial chromosome ( BAC) transgenesis we have targeted expression of a neurotoxic CAG expanded form of ataxin- 3 to AgRP- expressing neurons in the arcuate. This resulted in a 47% loss of AgRP neurons by 16 weeks of age, a significantly reduced body weight, ( wild- type mice ( WT) 34.7 +/- 0.7 g vs. transgenic mice ( Tg) 28.6 +/- 0.6 g, P < 0.001), and reduced food intake ( WT 5.0 +/- 0.2 vs. Tg 3.6 +/- 0.1 g per day, P < 0.001). Transgenic mice had significantly reduced total body fat, plasma insulin, and increased brown adipose tissue UCP1 expression. Transgenic mice failed to respond to peripherally administered ghrelin but retained sensitivity to PYY 3- 36. These data suggest that postembryonic partial loss of AgRP/ NPY neurons leads to a lean, hypophagic phenotype.	Hammersmith Hosp, Ctr Clin Sci, MRC, Core Transgen Facil, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Metab Med, London SW7 2AZ, England	Imperial College London; Imperial College London	Bloom, SR (corresponding author), Hammersmith Hosp, Dept Metab Med, Fac Med, Imperial Coll London, 6th Floor,Commonwealth Bldg,Du Cane Rd, London W12 0NN, England.	s.bloom@imperial.ac.uk		Gardiner, James/0000-0001-9357-1387; Bewick, Gavin/0000-0002-4335-8403; Dhillo, Waljit/0000-0001-5950-4316	National Institute for Health Research [03/DHCS/03/G121/48] Funding Source: researchfish	National Institute for Health Research(National Institute for Health Research (NIHR))		ADRIAN TE, 1983, NATURE, V306, P584, DOI 10.1038/306584a0; Batterham RL, 2002, NATURE, V418, P650, DOI 10.1038/nature00887; Bouret SG, 2004, SCIENCE, V304, P108, DOI 10.1126/science.1095004; BRADY LS, 1990, NEUROENDOCRINOLOGY, V52, P441, DOI 10.1159/000125626; Challis BG, 2004, P NATL ACAD SCI USA, V101, P4695, DOI 10.1073/pnas.0306931101; Challis BG, 2003, BIOCHEM BIOPH RES CO, V311, P915, DOI 10.1016/j.bbrc.2003.10.089; Chen HY, 2004, ENDOCRINOLOGY, V145, P2607, DOI 10.1210/en.2003-1596; CLARK JT, 1984, ENDOCRINOLOGY, V115, P427, DOI 10.1210/endo-115-1-427; Clarke DC, 2004, PHYSIOL GENOMICS, V17, P31, DOI 10.1152/physiolgenomics.00190.2003; Cowley MA, 2003, NEURON, V37, P649, DOI 10.1016/S0896-6273(03)00063-1; EGAWA M, 1991, AM J PHYSIOL, V260, P328; Elias CF, 1998, J COMP NEUROL, V402, P442, DOI 10.1002/(SICI)1096-9861(19981228)402:4<442::AID-CNE2>3.0.CO;2-R; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; Hahn TM, 1998, NAT NEUROSCI, V1, P271, DOI 10.1038/1082; Halatchev IG, 2004, ENDOCRINOLOGY, V145, P2585, DOI 10.1210/en.2003-1754; Hara J, 2001, NEURON, V30, P345, DOI 10.1016/S0896-6273(01)00293-8; Hewson AK, 2000, J NEUROENDOCRINOL, V12, P1047, DOI 10.1046/j.1365-2826.2000.00584.x; JONES PM, 1989, ENDOCRINOLOGY, V125, P334, DOI 10.1210/endo-125-1-334; Kaelin CB, 2004, ENDOCRINOLOGY, V145, P5798, DOI 10.1210/en.2004-0956; Kong WM, 2003, FASEB J, V17, P1688, DOI 10.1096/fj.02-0805fje; Magin-Lachmann C, 2003, BMC BIOTECHNOL, V3, DOI 10.1186/1472-6750-3-2; Makimura H, 2002, BMC NEUROSCI, V3, DOI 10.1186/1471-2202-3-18; Mejia JE, 2000, GENOMICS, V70, P165, DOI 10.1006/geno.2000.6372; Mizuno TM, 1999, ENDOCRINOLOGY, V140, P814, DOI 10.1210/en.140.2.814; Murphy KG, 2000, J ENDOCRINOL, V166, P659, DOI 10.1677/joe.0.1660659; Nakazato M, 2001, NATURE, V409, P194, DOI 10.1038/35051587; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; Paulson HL, 1997, ANN NEUROL, V41, P453, DOI 10.1002/ana.410410408; Perreault M, 2004, INT J OBESITY, V28, P879, DOI 10.1038/sj.ijo.0802640; Qian S, 2002, MOL CELL BIOL, V22, P5027, DOI 10.1128/MCB.22.14.5027-5035.2002; Rossi M, 1998, ENDOCRINOLOGY, V139, P4428, DOI 10.1210/en.139.10.4428; SALMON DMW, 1985, INT J OBESITY, V9, P443; Shah Eliza Mountcastle, 1993, Current Opinion in Neurobiology, V3, P738, DOI 10.1016/0959-4388(93)90146-P; Shutter JR, 1997, GENE DEV, V11, P593, DOI 10.1101/gad.11.5.593; Stanley SA, 2004, AM J PHYSIOL-ENDOC M, V287, pE583, DOI 10.1152/ajpendo.00576.2003; Stanley SA, 1999, ENDOCRINOLOGY, V140, P5459, DOI 10.1210/en.140.11.5459; Stanley SA, 2001, BRAIN RES, V893, P186, DOI 10.1016/S0006-8993(00)03312-6; Taheri S, 2001, NEUROREPORT, V12, P459, DOI 10.1097/00001756-200103050-00008; Tschop M, 2000, NATURE, V407, P908, DOI 10.1038/35038090; Wren AM, 2001, J CLIN ENDOCR METAB, V86, P5992, DOI 10.1210/jc.86.12.5992; Wren AM, 2001, DIABETES, V50, P2540, DOI 10.2337/diabetes.50.11.2540; Yasuda T, 2004, EXP BIOL MED, V229, P235, DOI 10.1177/153537020422900303; Yoshizawa T, 2001, BRAIN RES BULL, V56, P349, DOI 10.1016/S0361-9230(01)00578-0; Zhang YM, 1998, NAT GENET, V20, P123, DOI 10.1038/2417	44	180	183	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1680	+		10.1096/fj.04-3434fje	http://dx.doi.org/10.1096/fj.04-3434fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16099943				2022-12-25	WOS:000231843700019
J	Sudo, R; Mitaka, T; Ikeda, M; Tanishita, K				Sudo, R; Mitaka, T; Ikeda, M; Tanishita, K			Reconstruction of 3D stacked-up structures by rat small hepatocytes on microporous membranes	FASEB JOURNAL			English	Article						bile canaliculus; three-dimensional culture; tissue engineering	HEPATIC NONPARENCHYMAL CELLS; ORGANIC ANION TRANSPORTER; LIVER-CELLS; MULTICELLULAR SPHEROIDS; EXTRACELLULAR-MATRIX; BILE CANALICULI; DIFFERENTIATION; CULTURE; GROWTH; TISSUE	The three-dimensional (3D) culture of hepatocytes is essential for the reconstruction of functional hepatic tissues in vitro. In the present experiment, we developed a 3D-culture method in order to reconstruct hepatic cordlike structures by stacking up two-dimensional (2D) tissues composed of rat small hepatocytes (SHs), which are hepatic progenitor cells. Pairs of membranes were prepared and the cells were separately cultured on each membrane. After the SH colonies had developed, one membrane was inverted on top of the other to form an SH bilayer. Thereafter, we investigated whether the stacked cells were organized into differentiated tissues. In the 3D stacked-up structures, bile canaliculi (BC) started to form and gradually developed into anastomosing networks. Transmission electron microscopy revealed that the SHs of the upper and lower layers adhered to one another, and that BC formed between them. Bile canalicular proteins localized on the lumina of the tubular structures. Furthermore, the cells within the structures exhibited mRNA transcription of the hepatic-differentiation markers and maintained a relatively high level of albumin secretion. We conclude that highly differentiated 3D tissues, including functional BC, can be reconstructed by stacking up layers of SHs. This 3D stacked-up culture is useful for the reconstruction of tissue-engineered livers.	Keio Univ, Sch Fundamental Sci & Technol, Ctr Life Sci & Technol, Kohoku Ku, Yokohama, Kanagawa 2238522, Japan; Sapporo Med Univ, Sch Med, Canc Res Inst, Dept Pathophysiol, Sapporo, Hokkaido, Japan	Keio University; Sapporo Medical University	Sudo, R (corresponding author), Keio Univ, Sch Fundamental Sci & Technol, Ctr Life Sci & Technol, Kohoku Ku, 3-14-1 Hiyoshi, Yokohama, Kanagawa 2238522, Japan.	rsudo@2000.jukuin.keio.ac.jp	Mitaka, Toshihiro/K-9424-2013; Sudo, Ryo/D-2319-2010	Mitaka, Toshihiro/0000-0001-9467-4871; Sudo, Ryo/0000-0002-1053-9662				Abu-Absi SF, 2002, EXP CELL RES, V274, P56, DOI 10.1006/excr.2001.5467; BARTH CA, 1982, P NATL ACAD SCI-BIOL, V79, P4985, DOI 10.1073/pnas.79.16.4985; BENZEEV A, 1988, P NATL ACAD SCI USA, V85, P2161, DOI 10.1073/pnas.85.7.2161; Cereghini S, 1996, FASEB J, V10, P267, DOI 10.1096/fasebj.10.2.8641560; CLAYTON DF, 1985, MOL CELL BIOL, V5, P2623, DOI 10.1128/MCB.5.10.2623; Desmet VJ, 2001, LIVER BIOL PATHOBIOL, P3; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; GERLACH JC, 1995, HEPATOLOGY, V22, P546, DOI 10.1002/hep.1840220226; Gordon GJ, 2000, AM J PATHOL, V157, P771, DOI 10.1016/S0002-9440(10)64591-9; Griffith LG, 2002, SCIENCE, V295, P1009, DOI 10.1126/science.1069210; Harada K, 2003, J HEPATOL, V39, P716, DOI 10.1016/S0168-8278(03)00412-4; Jiang JL, 2002, CELL TRANSPLANT, V11, P403, DOI 10.3727/000000002783985648; KOIDE N, 1990, EXP CELL RES, V186, P227, DOI 10.1016/0014-4827(90)90300-Y; LANDRY J, 1985, J CELL BIOL, V101, P914, DOI 10.1083/jcb.101.3.914; MATSUSHITA T, 1991, APPL MICROBIOL BIOT, V36, P324; Mitaka T, 1999, HEPATOLOGY, V29, P111, DOI 10.1002/hep.510290103; MITAKA T, 1995, BIOCHEM BIOPH RES CO, V214, P310, DOI 10.1006/bbrc.1995.2289; MITAKA T, 1992, HEPATOLOGY, V16, P440, DOI 10.1002/hep.1840160224; Mitaka Toshihiro, 2002, J Hepatobiliary Pancreat Surg, V9, P697, DOI 10.1007/s005340200096; Mizuguchi T, 2000, ARTIF ORGANS, V24, P271, DOI 10.1046/j.1525-1594.2000.06506.x; MOONEY D, 1992, J CELL PHYSIOL, V151, P497, DOI 10.1002/jcp.1041510308; MOONEY DJ, 1995, J BIOMED MATER RES, V29, P959, DOI 10.1002/jbm.820290807; Ogawa K, 2004, TRANSPLANTATION, V77, P1783, DOI 10.1097/01.tp.0000131153.78169.24; OSHIO C, 1981, SCIENCE, V212, P1041, DOI 10.1126/science.7015506; Powers MJ, 2002, TISSUE ENG, V8, P499, DOI 10.1089/107632702760184745; Roelofsen H, 1998, J CELL SCI, V111, P1137; Sakai Y, 1996, INT J ARTIF ORGANS, V19, P294; SINGHVI R, 1994, SCIENCE, V264, P696, DOI 10.1126/science.8171320; Sudo R, 2005, ANN BIOMED ENG, V33, P696, DOI 10.1007/s10439-005-1690-5; Sudo R, 2004, J CELL PHYSIOL, V199, P252, DOI 10.1002/jcp.10407; Sugimoto S, 2002, J CELL BIOCHEM, V87, P16, DOI 10.1002/jcb.10274; Sundback CA, 2000, GASTROENTEROLOGY, V118, P438; Vos TA, 1998, HEPATOLOGY, V28, P1637, DOI 10.1002/hep.510280625; WATT FM, 1988, P NATL ACAD SCI USA, V85, P5576, DOI 10.1073/pnas.85.15.5576; Yamashita Y, 2003, CELL TRANSPLANT, V12, P101, DOI 10.3727/000000003108746687	35	42	47	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1695	+		10.1096/fj.04-3269fje	http://dx.doi.org/10.1096/fj.04-3269fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16107536				2022-12-25	WOS:000231843700010
J	Johnson, EF; Mukhopadhyay, B				Johnson, EF; Mukhopadhyay, B			A new type of sulfite reductase, a novel coenzyme F-420-dependent enzyme, from the methanarchaeon Methanocaldococcus jannaschii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; BACTERIAL LUCIFERASE FAMILY; METHANOCOCCUS-JANNASCHII; ARCHAEOGLOBUS-FULGIDUS; METHANOBACTERIUM-THERMOAUTOTROPHICUM; DESULFOVIBRIO-VULGARIS; METHANOGENIC BACTERIA; METHANOSARCINA-MAZEI; MYCOBACTERIUM-SMEGMATIS; F420H2 DEHYDROGENASE	Methanocaldococcus jannaschii is a hypertheromphilic, strictly hydrogenotrophic, methanogenic archaeon of ancient lineage isolated from a deep-sea hydrothermal vent. It requires sulfide for growth. Sulfite is inhibitory to the methanogens. Yet, we observed that M. jannaschii grows and produces methane with sulfite as the sole sulfur source. We found that in this organism sulfite induces a novel, highly active, coenzyme F-420-dependent sulfite reductase (Fsr) with a cell extract specific activity of 0.57 mu mol sulfite reduced min(-1) mg(-1) protein. The cellular level of Fsr protein is comparable to that of methyl-coenzyme M reductase, an enzyme essential for methanogenesis and a possible target for sulfite. Purified Fsr reduces sulfite to sulfide using reduced F-420 (H2F420) as the electron source (K-m: sulfite, 12 mu M; H2F420, 21 mu M). Therefore, Fsr provides M. jannaschii an anabolic ability and protection from sulfite toxicity. The N-terminal half of the 70-kDa Fsr polypeptide represents a H2F420 dehydrogenase and the C-terminal half a dissimilatory-type siroheme sulfite reductase, and Fsr catalyzes the corresponding partial reactions. Previously described sulfite reductases use nicotinamides and cytochromes as electron carriers. Therefore, this is the first report of a coenzyme F-420-dependent sulfite reductase. Fsr homologs were found only in Methanopyrus kandleri and Methanothermobacter thermautotrophicus, two strictly hydrogenotrophic thermophilic methanogens. fsr is the likely ancestor of H2F420 dehydrogenases, which serve as electron input units for membranebased energy transduction systems of certain late evolving archaea, and dissimilatory sulfite reductases of bacteria and archaea. fsr could also have arisen from lateral gene transfer and gene fusion events.	Virginia Polytech Inst & State Univ, Virginia Bioinformat Inst, Blacksburg, VA 24061 USA; Virginia Polytech Inst & State Univ, Dept Biochem, Blacksburg, VA 24061 USA; Virginia Polytech Inst & State Univ, Dept Biol, Blacksburg, VA 24061 USA	Virginia Polytechnic Institute & State University; Virginia Polytechnic Institute & State University; Virginia Polytechnic Institute & State University	Mukhopadhyay, B (corresponding author), Virginia Polytech Inst & State Univ, Virginia Bioinformat Inst, 0477 Washington St, Blacksburg, VA 24061 USA.	biswarup@vt.edu		Mukhopadhyay, Biswarup/0000-0003-0736-0298				Abken HJ, 1997, FEMS MICROBIOL LETT, V154, P231, DOI 10.1111/j.1574-6968.1997.tb12649.x; APPLEBY CA, 1969, DATA BIOCH RES, P380; Aufhammer SW, 2005, PROTEIN SCI, V14, P1840, DOI 10.1110/ps.041289805; Aufhammer SW, 2004, STRUCTURE, V12, P361, DOI 10.1016/j.str.2004.02.010; BALDERSTON WL, 1976, APPL ENVIRON MICROB, V32, P264, DOI 10.1128/AEM.32.2.264-269.1976; Baumer S, 2000, J BIOL CHEM, V275, P17968, DOI 10.1074/jbc.M000650200; Becker DF, 1998, BIOCHEMISTRY-US, V37, P2639, DOI 10.1021/bi972145x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bruggemann H, 2000, EUR J BIOCHEM, V267, P5810, DOI 10.1046/j.1432-1327.2000.01657.x; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CANTOR CR, 1980, TECHNIQUES STUDY BIO, V2, P674; CORLISS JB, 1979, SCIENCE, V203, P1073, DOI 10.1126/science.203.4385.1073; Crane BR, 1996, CURR OPIN STRUC BIOL, V6, P744, DOI 10.1016/S0959-440X(96)80003-0; DAHL C, 1993, J GEN MICROBIOL, V139, P1817, DOI 10.1099/00221287-139-8-1817; DANIELS L, 1986, APPL ENVIRON MICROB, V51, P703, DOI 10.1128/AEM.51.4.703-709.1986; Deppenmeier U, 2004, J BIOENERG BIOMEMBR, V36, P55, DOI 10.1023/B:JOBB.0000019598.64642.97; Dhillon A, 2005, ASTROBIOLOGY, V5, P18, DOI 10.1089/ast.2005.5.18; DIMARCO AA, 1990, ANNU REV BIOCHEM, V59, P355, DOI 10.1146/annurev.biochem.59.1.355; EIRICH LD, 1978, BIOCHEMISTRY-US, V17, P4583, DOI 10.1021/bi00615a002; FELSENSTEIN J, 1992, GENET RES, V60, P209, DOI 10.1017/S0016672300030962; HAASE P, 1992, EUR J BIOCHEM, V203, P527, DOI 10.1111/j.1432-1033.1992.tb16579.x; Hendrickson EL, 2004, J BACTERIOL, V186, P6956, DOI 10.1128/JB.186.20.6956-6969.2004; HUANG CJ, 1991, J BACTERIOL, V173, P1544, DOI 10.1128/jb.173.4.1544-1553.1991; Huber H, 1997, SYST APPL MICROBIOL, V20, P374, DOI 10.1016/S0723-2020(97)80005-7; HUBER R, 1989, NATURE, V342, P833, DOI 10.1038/342833a0; HUYNH BH, 1984, J BIOL CHEM, V259, P5373; JACOBSON FS, 1982, J BIOL CHEM, V257, P3385; JANNASCH HW, 1985, SCIENCE, V229, P717, DOI 10.1126/science.229.4715.717; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; JONES WJ, 1983, ARCH MICROBIOL, V136, P254, DOI 10.1007/BF00425213; Kah LC, 2004, NATURE, V431, P834, DOI 10.1038/nature02974; KARKHOFFSCHWEIZER RR, 1995, APPL ENVIRON MICROB, V61, P290, DOI 10.1128/AEM.61.1.290-296.1995; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JP, 1973, J BACTERIOL, V115, P453, DOI 10.1128/JB.115.1.453-455.1973; LEE JP, 1973, J BACTERIOL, V115, P529, DOI 10.1128/JB.115.2.529-542.1973; LeGall J., 1988, BIOL ANAEROBIC MICRO, P587; Leigh JA, 2002, BIODIVERSITY MICROBI, P103; Leustek T, 2000, ANNU REV PLANT PHYS, V51, P141, DOI 10.1146/annurev.arplant.51.1.141; Mahlert F, 2002, J BIOL INORG CHEM, V7, P500, DOI 10.1007/s00775-001-0325-z; MOURA I, 1986, BIOCHEM BIOPH RES CO, V141, P1032, DOI 10.1016/S0006-291X(86)80148-6; Mukhopadhyay B, 1999, APPL ENVIRON MICROB, V65, P5059; Mukhopadhyay B, 2000, P NATL ACAD SCI USA, V97, P11522, DOI 10.1073/pnas.97.21.11522; Mukhopadhyay B, 2000, ARCH MICROBIOL, V174, P406, DOI 10.1007/s002030000225; Mukhopadhyay B, 2000, BBA-GEN SUBJECTS, V1475, P191, DOI 10.1016/S0304-4165(00)00064-7; MUKHOPADHYAY B, 1989, CAN J MICROBIOL, V35, P499, DOI 10.1139/m89-077; Nakayama M, 2000, J INORG BIOCHEM, V82, P27, DOI 10.1016/S0162-0134(00)00138-0; Neumann A, 1996, J BIOL CHEM, V271, P16515, DOI 10.1074/jbc.271.28.16515; OLSEN GJ, 1994, J BACTERIOL, V176, P1, DOI 10.1128/JB.176.1.1-6.1994; Perriere G, 1996, BIOCHIMIE, V78, P364, DOI 10.1016/0300-9084(96)84768-7; Poulton SW, 2004, NATURE, V431, P173, DOI 10.1038/nature02912; Purwantini E, 1996, J BACTERIOL, V178, P2861, DOI 10.1128/jb.178.10.2861-2866.1996; PURWANTINI E, 1992, ANAL BIOCHEM, V205, P342, DOI 10.1016/0003-2697(92)90446-E; Rothe O, 2000, EXTREMOPHILES, V4, P247, DOI 10.1007/PL00010716; ROUVIERE PE, 1987, ARCH MICROBIOL, V148, P253, DOI 10.1007/BF00456701; Shen Y, 2003, NATURE, V423, P632, DOI 10.1038/nature01651; Shen YA, 2001, NATURE, V410, P77, DOI 10.1038/35065071; Slesarev AI, 2002, P NATL ACAD SCI USA, V99, P4644, DOI 10.1073/pnas.032671499; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; Stahl DA, 2002, ANTON LEEUW INT J G, V81, P189, DOI 10.1023/A:1020506415921; Tchong SI, 2005, BIOCHEMISTRY-US, V44, P1659, DOI 10.1021/bi0484769; THAUER RK, 1977, BACTERIOL REV, V41, P100, DOI 10.1128/MMBR.41.1.100-180.1977; THOMAS I, 1987, ARCH MICROBIOL, V148, P193, DOI 10.1007/BF00414811; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TRUEPER H G, 1964, Antonie Van Leeuwenhoek, V30, P225; WEAST RC, 1979, HDB CHEM PHYS, pD167; WEDZICHA BL, 1992, FOOD ADDIT CONTAM, V9, P449, DOI 10.1080/02652039209374097; WOLFE RS, 1992, BIOCHEM SOC SYMP, P41; ZEIKUS JG, 1972, J BACTERIOL, V109, P707, DOI 10.1128/JB.109.2.707-713.1972	70	61	65	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 18	2005	280	46					38776	38786		10.1074/jbc.M503492200	http://dx.doi.org/10.1074/jbc.M503492200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	983NR	16048999	hybrid			2022-12-25	WOS:000233239800079
J	Nakamura, Y; Yujiri, T; Nawata, R; Tagami, K; Tanizawa, Y				Nakamura, Y; Yujiri, T; Nawata, R; Tagami, K; Tanizawa, Y			MEK kinase 1 is essential for Bcr-Abl-induced STAT3 and self-renewal activity in embryonic stem cells	ONCOGENE			English	Article						Bcr-Abl; MEKK1; STAT3; embryonic stem cell	CHRONIC MYELOID-LEUKEMIA; CYTOKINE RECEPTORS; ACTIVATION; SURVIVAL; BINDING; GROWTH; RAC	BCR-ABL oncogene, the molecular hallmark of chronic myelogenous leukemia, arises in a primitive hematopoietic stem cell that has the capacity for both differentiation and self-renewal. Its product, Bcr-Abl protein, has been shown to activate signal transducers and activators of transcription 3 (STAT3) and to promote self-renewal in embryonic stem (ES) cells, even in the absence of leukemia inhibitory factor (LIF). MEK kinase 1 (MEKK1) is a 196-kDa mitogen-activated protein kinase (MAPK) kinase kinase involved in Bcr-Abl signal transduction. To investigate the role of MEKK1 in Bcr-Abl-induced transformation of stem cells, p210 Bcr-Abl was stably transfected into wildtype (WTp210) and MEKK1-/- (MEKK1-/-(p210)) ES cells. Bcr-Abl enhanced MEKK1 expression in ES transfectants, as it does in other Bcr-Abl-transformed cells. In the absence of LIF, WTp210 cells showed constitutive STAT3 activation and formed rounded, compact colonies having strong alkaline phosphatase activity, a characteristic phenotype of undifferentiated ES cells. MEKK1-/-(p210) cells, by contrast, showed less STAT3 activity than WTp210 cells and formed large, flattened colonies having weak alkaline phosphatase activity, a phenotype of differentiated ES cells. These results indicate that MEKK1 plays a key role in Bcr-Abl-induced STAT3 activation and in ES cells' capacity for LIF-independent self-renewal, and may thus be involved in Bcr-Abl-mediated leukemogenesis in stem cells.	Yamaguchi Univ, Grad Sch Med, Dept Bio Signal Anal, Ube, Yamaguchi 7558505, Japan	Yamaguchi University	Yujiri, T (corresponding author), Yamaguchi Univ, Grad Sch Med, Dept Bio Signal Anal, 1-1-1 Minami Kogushi, Ube, Yamaguchi 7558505, Japan.	yujirit@yamaguchi-u.ac.jp	Yujiri, Toshiaki/AAY-8150-2020	Yujiri, Toshiaki/0000-0001-6838-3456				Burdon T, 2002, TRENDS CELL BIOL, V12, P432, DOI 10.1016/S0962-8924(02)02352-8; Coppo P, 2003, ONCOGENE, V22, P4102, DOI 10.1038/sj.onc.1206607; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; Druker BJ, 2002, ONCOGENE, V21, P8541, DOI 10.1038/sj.onc.1206081; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; Hagemann C, 2001, CELL SIGNAL, V13, P863, DOI 10.1016/S0898-6568(01)00220-0; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Holyoake T, 1999, BLOOD, V94, P2056, DOI 10.1182/blood.V94.6.2056; Lim CP, 2001, J BIOL CHEM, V276, P21004, DOI 10.1074/jbc.M007592200; Nawata R, 2003, ONCOGENE, V22, P7774, DOI 10.1038/sj.onc.1206901; Ogihara T, 1997, J BIOL CHEM, V272, P12868, DOI 10.1074/jbc.272.19.12868; Okamoto H, 2000, MOL CELL BIOL, V20, P9247, DOI 10.1128/MCB.20.24.9247-9261.2000; PEASE S, 1990, DEV BIOL, V141, P344, DOI 10.1016/0012-1606(90)90390-5; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Simon AR, 2000, SCIENCE, V290, P144, DOI 10.1126/science.290.5489.144; Skorski T, 1998, P NATL ACAD SCI USA, V95, P11858, DOI 10.1073/pnas.95.20.11858; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911	18	14	14	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2005	24	51					7592	7598		10.1038/sj.onc.1208899	http://dx.doi.org/10.1038/sj.onc.1208899			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	984VQ	16044153				2022-12-25	WOS:000233333800008
J	Kegel, KB; Sapp, E; Yoder, J; Cuiffo, B; Sobin, L; Kim, YJ; Qin, ZH; Hayden, MR; Aronin, N; Scott, DL; Isenberg, F; Goldmann, WH; DiFiglia, M				Kegel, KB; Sapp, E; Yoder, J; Cuiffo, B; Sobin, L; Kim, YJ; Qin, ZH; Hayden, MR; Aronin, N; Scott, DL; Isenberg, F; Goldmann, WH; DiFiglia, M			Huntingtin associates with acidic phospholipids at the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTANT HUNTINGTIN; HOMOLOGY DOMAINS; BINDING-PROTEIN; HEAT REPEATS; SWISS-MODEL; WILD-TYPE; CLATHRIN; HIP1; ENDOCYTOSIS; EXPRESSION	We have identified a domain in the N terminus of huntingtin that binds to membranes. A three-dimensional homology model of the structure of the binding domain predicts helical HEAT repeats, which emanate a positive electrostatic potential, consistent with a charge-based mechanism for membrane association. An amphipathic helix capable of inserting into pure lipid bilayers may serve to anchor huntingtin to the membrane. In cells, N-terminal huntingtin fragments targeted to regions of plasma membrane enriched in phosphatidylinositol 4,5-bisphosphate, receptor bound-transferrin, and endogenous huntingtin. N-terminal huntingtin fragments with an expanded polyglutamine tract aberrantly localized to intracellular regions instead of plasma membrane. Our data support a new model in which huntingtin directly binds membranes through electrostatic interactions with acidic phospholipids.	Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA; Univ British Columbia, Vancouver, BC V5Z 4H4, Canada; Univ Massachusetts, Sch Med, Dept Med & Cell Biol, Worcester, MA 01655 USA; Massachusetts Gen Hosp, Renal Unit, Charlestown, MA 02129 USA; Tech Univ Munich E22, Dept Biophys, D-85747 Garching, Germany; Univ Erlangen Nurnberg, Zent Inst Biomed Tech, D-91052 Erlangen, Germany	Harvard University; Massachusetts General Hospital; University of British Columbia; University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Massachusetts General Hospital; Technical University of Munich; University of Erlangen Nuremberg	Kegel, KB (corresponding author), MA Gen Hosp E, Dept Neurol, 114 CNY 16th St,Rm 2125, Charlestown, MA 02129 USA.	kegel@helix.mgh.harvard.edu	Hayden, Michael R/D-8581-2011; Kim, Yun Joong/E-7117-2015; Goldmann, Wolfgang H/H-5572-2013	Hayden, Michael R/0000-0001-5159-1419; Kim, Yun Joong/0000-0002-2956-1552; 	NINDS NIH HHS [NS38194, NS35711, NS16367] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038194, P01NS016367, P50NS016367, R01NS035711] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; BANUELOS S, 1995, J BIOL CHEM, V270, P29910, DOI 10.1074/jbc.270.50.29910; DIFIGLIA M, 1995, NEURON, V14, P1075, DOI 10.1016/0896-6273(95)90346-1; Gaidarov I, 1999, J CELL BIOL, V146, P755, DOI 10.1083/jcb.146.4.755; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Harjes P, 2003, TRENDS BIOCHEM SCI, V28, P425, DOI 10.1016/S0968-0004(03)00168-3; Hennig L, 1999, BIOTECHNIQUES, V26, P1170, DOI 10.2144/99266bc02; Huang SH, 2004, MOL CELL BIOL, V24, P9102, DOI 10.1128/MCB.24.20.9102-9123.2004; Hyman J, 2000, J CELL BIOL, V149, P537, DOI 10.1083/jcb.149.3.537; Hyun TS, 2004, J BIOL CHEM, V279, P14294, DOI 10.1074/jbc.M312645200; Kalchman MA, 1997, NAT GENET, V16, P44, DOI 10.1038/ng0597-44; Kegel KB, 2000, J NEUROSCI, V20, P7268, DOI 10.1523/jneurosci.20-19-07268.2000; Kegel KB, 2002, J BIOL CHEM, V277, P7466, DOI 10.1074/jbc.M103946200; Kim M, 1999, J NEUROSCI, V19, P964; Kim YJ, 2001, P NATL ACAD SCI USA, V98, P12784, DOI 10.1073/pnas.221451398; Laux T, 2000, J CELL BIOL, V149, P1455, DOI 10.1083/jcb.149.7.1455; Lemmon MA, 2003, TRAFFIC, V4, P201, DOI 10.1034/j.1600-0854.2004.00071.x; Mao YX, 2001, CELL, V104, P433, DOI 10.1016/S0092-8674(01)00230-6; Mishra SK, 2001, J BIOL CHEM, V276, P46230, DOI 10.1074/jbc.M108177200; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Niggli V, 2001, TRENDS BIOCHEM SCI, V26, P604, DOI 10.1016/S0968-0004(01)01927-2; Okamoto Y, 2002, J BIOL CHEM, V277, P46470, DOI 10.1074/jbc.M207779200; Padron D, 2003, J CELL BIOL, V162, P693, DOI 10.1083/jcb.200302051; Qin ZH, 2003, HUM MOL GENET, V12, P3231, DOI 10.1093/hmg/ddg346; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Seelig A, 2000, J BIOL CHEM, V275, P17954, DOI 10.1074/jbc.M002264200; SHARP AH, 1995, NEURON, V14, P1065, DOI 10.1016/0896-6273(95)90345-3; Stevenson JM, 1998, J BIOL CHEM, V273, P22761, DOI 10.1074/jbc.273.35.22761; Szebenyi G, 2003, NEURON, V40, P41, DOI 10.1016/S0896-6273(03)00569-5; TEMPEL M, 1995, BIOPHYS J, V69, P228, DOI 10.1016/S0006-3495(95)79894-0; TEMPEL M, 1994, BIOCHEMISTRY-US, V33, P12565, DOI 10.1021/bi00208a006; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; Velier J, 1998, EXP NEUROL, V152, P34, DOI 10.1006/exnr.1998.6832; Waelter S, 2001, HUM MOL GENET, V10, P1807, DOI 10.1093/hmg/10.17.1807; WAINWRIGHT MS, 1995, J NEUROSCI, V15, P676; Wang YQ, 2005, J BIOL CHEM, V280, P284, DOI 10.1074/jbc.M411624200; Wanker EE, 1997, HUM MOL GENET, V6, P487, DOI 10.1093/hmg/6.3.487; Wenk MR, 2004, P NATL ACAD SCI USA, V101, P8262, DOI 10.1073/pnas.0401874101	39	121	123	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36464	36473		10.1074/jbc.M503672200	http://dx.doi.org/10.1074/jbc.M503672200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16085648	hybrid			2022-12-25	WOS:000232726900080
J	Cho, J; Degen, JL; Coller, BS; Mosher, DF				Cho, J; Degen, JL; Coller, BS; Mosher, DF			Fibrin but not adsorbed fibrinogen supports fibronectin assembly by spread platelets - Effects of the interaction of alpha IIb beta 3 with the C terminus of the fibrinogen gamma-chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; VON-WILLEBRAND-FACTOR; FLOWING WHOLE-BLOOD; MURINE MONOCLONAL-ANTIBODY; CROSS-LINKING; CELL-ADHESION; LYSOPHOSPHATIDIC ACID; EXTRACELLULAR-MATRIX; VONWILLEBRAND-FACTOR; ADHERENT PLATELETS	We investigated the assembly of soluble fibronectin by lysophosphatidic acid- activated platelets adherent to fibrinogen or fibrin. More fibronectin was assembled by activated platelets spread on fibrin matrices than by platelets spread on adsorbed fibrinogen. The difference between platelets adherent to fibrinogen and fibrin occurred under both static and flow conditions. Similar differences were seen in binding of the 70- kDa N- terminal fragment of fibronectin that recognizes fibronectin assembly sites on adherent cells. Antibody and peptide blocking studies demonstrated that alpha IIb beta 3 integrin mediates platelet adhesion to fibrinogen, whereas both alpha v beta 3 and alpha IIb beta 3 mediate platelet adhesion to fibrin. The hypothesis that engagement of the C- terminal QAGDV sequence of the fibrinogen gamma-chain by alpha IIb beta 3 inhibits the ability of the platelet to assemble fibronectin was tested by several experiments. Activated platelets adherent to adsorbed mutant fibrinogen lacking the QAGDV sequence ( gamma Delta 5FG) were assembly- competent, as were platelets adherent to adsorbed normal fibrinogen that had been pretreated with the 7E9 antibody to the C terminus of the gamma- chain. Moreover, adsorbed normal fibrinogen but not gamma Delta 5FG suppressed the ability of co- adsorbed fibronectin to direct assembly of soluble fibronectin by spread platelets. The suppressive effect was lost when a surface of co- adsorbed fibronectin and fibrinogen was pretreated with 7E9. These results support a model in which the engagement of alpha IIb beta 3 by the C- terminal sequence of the fibrinogen gamma-chain initiates signals that suppress subsequent fibronectin assembly by spread platelets. This interaction is less dominant when platelets adhere to fibrin, resulting in enhanced fibronectin assembly.	Univ Wisconsin, Dept Med, Med Sci Ctr 4285, Sch Med, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Mol & Cellular Pharmacol Program, Madison, WI 53706 USA; Univ Cincinnati, Coll Med, Childrens Hosp Res Fdn, Cincinnati, OH 45229 USA; Rockefeller Univ, Lab Blood & Vasc Biol, New York, NY 10021 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; Rockefeller University	Mosher, DF (corresponding author), Univ Wisconsin, Dept Med, Med Sci Ctr 4285, Sch Med, 1300 Univ Ave, Madison, WI 53706 USA.	dfmosher@wisc.edu		Cho, Jaehyung/0000-0003-2404-3446				Bach TL, 1998, J BIOL CHEM, V273, P30719, DOI 10.1074/jbc.273.46.30719; Bae E, 2004, J BIOL CHEM, V279, P35749, DOI 10.1074/jbc.M406283200; BARRY ELR, 1988, J BIOL CHEM, V263, P10464; BARRY ELR, 1989, J BIOL CHEM, V264, P4179; Belkin AM, 2005, BLOOD, V105, P3561, DOI 10.1182/blood-2004-10-4089; BITTORF SV, 1993, J BIOL CHEM, V268, P24838; Brown D C, 2001, BMC Immunol, V2, P9, DOI 10.1186/1471-2172-2-9; BUNCE LA, 1992, J CLIN INVEST, V89, P842, DOI 10.1172/JCI115663; CHEN R, 1969, P NATL ACAD SCI USA, V63, P420, DOI 10.1073/pnas.63.2.420; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; COLLER BS, 1991, BLOOD, V77, P75; COLLER BS, 1985, J CLIN INVEST, V76, P101, DOI 10.1172/JCI111931; COLLER BS, 1983, J CLIN INVEST, V72, P325, DOI 10.1172/JCI110973; COLLER BS, 1993, J CLIN INVEST, V92, P2796, DOI 10.1172/JCI116899; Corbett SA, 1996, BLOOD, V88, P158; Corbett SA, 1999, J BIOL CHEM, V274, P20943, DOI 10.1074/jbc.274.30.20943; CROUCH SPM, 1993, J IMMUNOL METHODS, V160, P81, DOI 10.1016/0022-1759(93)90011-U; DiazGonzalez F, 1996, MOL BIOL CELL, V7, P1939, DOI 10.1091/mbc.7.12.1939; Doolittle RF, 2001, ANN NY ACAD SCI, V936, P31; Dubois C, 2004, THROMB HAEMOSTASIS, V91, P233, DOI 10.1160/TH03-03-0126; ENDENBURG SC, 1993, BLOOD COAGUL FIBRIN, V4, P139, DOI 10.1097/00001721-199304010-00024; Farrell DH, 2004, CURR OPIN HEMATOL, V11, P151, DOI 10.1097/01.moh.0000131440.02397.a4; HAMAGUCHI M, 1993, BLOOD, V81, P2348; HANTGAN RR, 1990, BLOOD, V76, P345; HANTGAN RR, 1992, THROMB HAEMOSTASIS, V68, P694; Holmback K, 1996, EMBO J, V15, P5760, DOI 10.1002/j.1460-2075.1996.tb00962.x; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 1990, FIBRONECTINS; Jirouskova M, 1997, THROMB HAEMOSTASIS, V78, P1125; Jirouskova M, 2001, ANN NY ACAD SCI, V936, P464; Jirouskova M, 2001, THROMB HAEMOSTASIS, V86, P1047; Lengweiler S, 1999, BIOCHEM BIOPH RES CO, V262, P167, DOI 10.1006/bbrc.1999.1172; Li F, 2003, EUKARYOT CELL, V2, P1266, DOI 10.1128/EC.2.6.1266-1273.2003; LIMPER AH, 1991, J BIOL CHEM, V266, P9697; Litjens PEMH, 2003, J THROMB HAEMOST, V1, P2014, DOI 10.1046/j.1538-7836.2003.00381.x; MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364; MOON KY, 1994, J BIOL CHEM, V269, P7651; Mosesson MW, 2003, J THROMB HAEMOST, V1, P231, DOI 10.1046/j.1538-7836.2003.00063.x; Mosesson MW, 2001, ANN NY ACAD SCI, V936, P11; MOSHER DF, 1975, J BIOL CHEM, V250, P6614; MOSHER DF, 1995, THROMB HAEMOSTASIS, V74, P529; MOSHER DF, 1973, J BIOL CHEM, V248, P6896; Mosher DF, 1989, FIBRONECTIN; Moskowitz KA, 1998, THROMB HAEMOSTASIS, V79, P824, DOI 10.1055/s-0037-1615072; Ni HY, 2000, J CLIN INVEST, V106, P385, DOI 10.1172/JCI9896; Ni HY, 2003, P NATL ACAD SCI USA, V100, P2415, DOI 10.1073/pnas.2628067100; Olorundare OE, 2001, BLOOD, V98, P117, DOI 10.1182/blood.V98.1.117; PLOW EF, 1985, BLOOD, V66, P724; Ruggeri ZM, 2002, NAT MED, V8, P1227, DOI 10.1038/nm1102-1227; SAVAGE B, 1991, J BIOL CHEM, V266, P11227; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; SHIMIZU A, 1992, P NATL ACAD SCI USA, V89, P2888, DOI 10.1073/pnas.89.7.2888; SPORN LA, 1995, BLOOD, V86, P1802, DOI 10.1182/blood.V86.5.1802.bloodjournal8651802; Suehiro K, 1996, J BIOL CHEM, V271, P10365, DOI 10.1074/jbc.271.17.10365; Wagner CL, 1996, BLOOD, V88, P907; Wang XN, 1996, J BIOL CHEM, V271, P17785, DOI 10.1074/jbc.271.30.17785; WAYNER EA, 1988, J CELL BIOL, V107, P1881, DOI 10.1083/jcb.107.5.1881; Wonerow P, 2003, J BIOL CHEM, V278, P37520, DOI 10.1074/jbc.M305077200; Xiao T, 2004, NATURE, V432, P59, DOI 10.1038/nature02976; Yang W, 1999, THROMB RES, V93, P279, DOI 10.1016/S0049-3848(98)00185-6; Yang Z, 2002, BIOCHEMISTRY-US, V41, P15610, DOI 10.1021/bi026666i; Yee KO, 1998, CIRC RES, V83, P241, DOI 10.1161/01.RES.83.3.241; Yokoyama K, 2000, J BIOL CHEM, V275, P16891, DOI 10.1074/jbc.M000610200; Zhang QH, 1996, J BIOL CHEM, V271, P33284, DOI 10.1074/jbc.271.52.33284; Zhang QH, 1999, J BIOL CHEM, V274, P368, DOI 10.1074/jbc.274.1.368	66	27	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35490	35498		10.1074/jbc.M506289200	http://dx.doi.org/10.1074/jbc.M506289200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16051597	hybrid			2022-12-25	WOS:000232561200049
J	Grinchuk, O; Kozmik, Z; Wu, XF; Tomarev, S				Grinchuk, O; Kozmik, Z; Wu, XF; Tomarev, S			The Optimedin gene is a downstream target of Pax6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRABECULAR MESHWORK CELLS; OLFACTOMEDIN-RELATED PROTEIN; HOMEOBOX-CONTAINING GENE; SEQUENCE TAG ANALYSIS; OPEN-ANGLE GLAUCOMA; DNA-BINDING; ALPHA-LATROTOXIN; SECRETED GLYCOPROTEIN; EXPRESSION PROFILE; COUPLED RECEPTORS	The Optimedin gene, also known as Olfactomedin 3, encodes an olfactomedin domain-containing protein. There are two major splice variants of the Optimedin mRNA, Optimedin A and Optimedin B, transcribed from different promoters. The expression pattern of the Optimedin A variant in the eye and brain overlaps with that for Pax6, which encodes a protein containing the paired and homeobox DNA-binding domains. The Pax6 gene plays a critical role for the development of eyes, central nervous system, and endocrine glands. The proximal promoter of the Optimedin A variant contains a putative Pax6 binding site in position -86/-70. Pax6 binds this site through the paired domain in vitro as judged by electrophoretic mobility shift assay. Mutations in this site eliminate Pax6 binding as well as stimulation of the Optimedin promoter activity by Pax6 in transfection experiments. Pax6 occupies the binding site in the proximal promoter in vivo as demonstrated by the chromatin immunoprecipitation assay. Altogether these results identify the Optimedin gene as a downstream target regulated by Pax6. Although the function of optimedin is still not clear, it is suggested to be involved in cell-cell adhesion and cell attachment to the extracellular matrix. Pax6 regulation of Optimedin in the eye and brain may directly affect multiple developmental processes, including cell migration and axon growth.	NEI, Sect Mol Mech Glaucoma, Mol & Dev Biol Lab, NIH, Bethesda, MD 20892 USA; Acad Sci Czech Republ, Inst Mol Genet, CR-14220 Prague, Czech Republic	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences	Tomarev, S (corresponding author), Bldg 7,Rm 103,7 Mem Dr,MSC 0704, Bethesda, MD 20892 USA.	tomarevs@nei.nih.gov	Kozmik, Zbynek/I-8807-2014; Kozmik, Zbynek/G-3581-2014	Wu, Xiaofang/0000-0002-3782-7701; Kozmik, Zbynek/0000-0002-5850-2105	Intramural NIH HHS Funding Source: Medline; NATIONAL EYE INSTITUTE [Z01EY000311, ZIAEY000311] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Adam MF, 1997, HUM MOL GENET, V6, P2091, DOI 10.1093/hmg/6.12.2091; Ahmed F, 2004, INVEST OPHTH VIS SCI, V45, P3081, DOI 10.1167/iovs.04-0302; Azuma N, 2005, HUM MOL GENET, V14, P735, DOI 10.1093/hmg/ddi069; Barembaum M, 2000, NAT CELL BIOL, V2, P219, DOI 10.1038/35008643; Caballero M, 2000, BBA-MOL BASIS DIS, V1502, P447, DOI 10.1016/S0925-4439(00)00068-5; CARRIERE C, 1993, MOL CELL BIOL, V13, P7257, DOI 10.1128/MCB.13.12.7257; Chauhan BK, 2004, NUCLEIC ACIDS RES, V32, P1696, DOI 10.1093/nar/gkh334; Cheung M, 2000, MOL BRAIN RES, V79, P180, DOI 10.1016/S0169-328X(00)00109-1; Cvekl A, 1999, INVEST OPHTH VIS SCI, V40, P1343; Cvekl A, 1996, BIOESSAYS, V18, P621, DOI 10.1002/bies.950180805; DANIELSON PE, 1994, J NEUROSCI RES, V38, P468, DOI 10.1002/jnr.490380413; Davis JA, 1996, J NEUROSCI, V16, P5082; Davletov BA, 1996, J BIOL CHEM, V271, P23239, DOI 10.1074/jbc.271.38.23239; Edelman GM, 1998, BRAIN RES REV, V26, P337, DOI 10.1016/S0165-0173(97)00034-9; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; ESCRIBANO J, 1995, J BIOCHEM-TOKYO, V118, P921, DOI 10.1093/jb/118.5.921; Gan L, 1999, DEV BIOL, V210, P469, DOI 10.1006/dbio.1999.9280; Gobeil S, 2004, INVEST OPHTH VIS SCI, V45, P3560, DOI 10.1167/iovs.04-0300; Gong G, 2004, HUM MOL GENET, V13, pR91, DOI 10.1093/hmg/ddh074; Gonzalez MI, 2002, MOL CELL ENDOCRINOL, V190, P39, DOI 10.1016/S0303-7207(02)00035-7; Graveel CR, 2003, ONCOGENE, V22, P1730, DOI 10.1038/sj.onc.1206309; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; HARLEY VR, 1994, NUCLEIC ACIDS RES, V22, P1500, DOI 10.1093/nar/22.8.1500; Hatakeyama J, 2004, SEMIN CELL DEV BIOL, V15, P83, DOI 10.1016/j.semcdb.2003.09.005; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; Hillier BJ, 2003, J CELL BIOL, V160, P597, DOI 10.1083/jcb.200210053; Jacobson N, 2001, HUM MOL GENET, V10, P117, DOI 10.1093/hmg/10.2.117; Joe MK, 2003, BIOCHEM BIOPH RES CO, V312, P592, DOI 10.1016/j.bbrc.2003.10.162; Kamachi Y, 2001, GENE DEV, V15, P1272, DOI 10.1101/gad.887101; Kirstein L, 2000, GENES CELLS, V5, P661, DOI 10.1046/j.1365-2443.2000.00355.x; Kondo D, 2000, J AM SOC NEPHROL, V11, P803, DOI 10.1681/ASN.V115803; Koroma BM, 1997, INVEST OPHTH VIS SCI, V38, P108; Kozmik Z, 1997, EMBO J, V16, P6793, DOI 10.1093/emboj/16.22.6793; Krasnoperov VG, 1997, NEURON, V18, P925, DOI 10.1016/S0896-6273(00)80332-3; Krishnamoorthy RR, 2001, MOL BRAIN RES, V86, P1, DOI 10.1016/S0169-328X(00)00224-2; Kuhlbrodt K, 1998, J BIOL CHEM, V273, P16050, DOI 10.1074/jbc.273.26.16050; Kulkarni NH, 2000, GENET RES, V76, P41, DOI 10.1017/S0016672300004584; Lelianova VG, 1997, J BIOL CHEM, V272, P21504, DOI 10.1074/jbc.272.34.21504; LI HS, 1994, DEV BIOL, V162, P181, DOI 10.1006/dbio.1994.1077; Liu YH, 2004, HUM MOL GENET, V13, P1193, DOI 10.1093/hmg/ddh128; Matsushita H, 1999, FEBS LETT, V443, P348, DOI 10.1016/S0014-5793(99)00005-8; Meech R, 1999, P NATL ACAD SCI USA, V96, P2420, DOI 10.1073/pnas.96.5.2420; Moreno TA, 2002, MECH DEVELOP, V119, P121, DOI 10.1016/S0925-4773(02)00308-8; Moreno TA, 2001, DEV BIOL, V240, P340, DOI 10.1006/dbio.2001.0472; Mukhopadhyay A, 2004, MOL VIS, V10, P304; Ohto H, 1999, MOL CELL BIOL, V19, P6815; Planque N, 2001, J BIOL CHEM, V276, P29330, DOI 10.1074/jbc.M101812200; Plaza S, 1997, CELL GROWTH DIFFER, V8, P1115; Polansky JR, 1997, OPHTHALMOLOGICA, V211, P126, DOI 10.1159/000310780; Polansky JR, 2000, EYE, V14, P503, DOI 10.1038/eye.2000.137; Rosenbauer F, 2004, BLOOD, V103, P4294, DOI 10.1182/blood-2003-08-2688; Sato M, 2005, P NATL ACAD SCI USA, V102, P5874, DOI 10.1073/pnas.0501972102; Sato S, 2002, HUM MOL GENET, V11, P1045, DOI 10.1093/hmg/11.9.1045; Schedl A, 1996, CELL, V86, P71, DOI 10.1016/S0092-8674(00)80078-1; Schepers GE, 2000, NUCLEIC ACIDS RES, V28, P1473, DOI 10.1093/nar/28.6.1473; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shepard AR, 2001, INVEST OPHTH VIS SCI, V42, P3173; Simpson TI, 2002, BIOESSAYS, V24, P1041, DOI 10.1002/bies.10174; SNYDER DA, 1991, BIOCHEMISTRY-US, V30, P9143, DOI 10.1021/bi00102a004; Stone EM, 1997, SCIENCE, V275, P668, DOI 10.1126/science.275.5300.668; STOYKOVA A, 1994, J NEUROSCI, V14, P1395, DOI 10.1523/JNEUROSCI.14-03-01395.1994; Sudhof TC, 2001, ANNU REV NEUROSCI, V24, P933, DOI 10.1146/annurev.neuro.24.1.933; Swiderski RE, 2000, INVEST OPHTH VIS SCI, V41, P3420; Tomarev SI, 1997, P NATL ACAD SCI USA, V94, P2421, DOI 10.1073/pnas.94.6.2421; Tomarev SI, 2003, INVEST OPHTH VIS SCI, V44, P2588, DOI 10.1167/iovs.02-1099; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; Torrado M, 2002, HUM MOL GENET, V11, P1291, DOI 10.1093/hmg/11.11.1291; Tsuda H, 2002, NEURON, V33, P515, DOI 10.1016/S0896-6273(02)00590-1; UWANOGHO D, 1995, MECH DEVELOP, V49, P23, DOI 10.1016/0925-4773(94)00299-3; WALTHER C, 1991, DEVELOPMENT, V113, P1435; Wiebe MS, 2003, J BIOL CHEM, V278, P17901, DOI 10.1074/jbc.M212211200; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; XIANG MQ, 1993, NEURON, V11, P689, DOI 10.1016/0896-6273(93)90079-7; Zeng LC, 2004, FEBS LETT, V571, P74, DOI 10.1016/j.febslet.2004.06.059; Zhang JC, 2002, GENE, V283, P83, DOI 10.1016/S0378-1119(01)00763-6; Zhang WY, 2001, MOL VIS, V7, P1	76	26	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35228	35237		10.1074/jbc.M506195200	http://dx.doi.org/10.1074/jbc.M506195200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16115881	hybrid			2022-12-25	WOS:000232561200020
J	Zhu, ZY; Ramos, J; Kampa, K; Adimoolam, S; Sirisawad, M; Yu, ZY; Chen, DX; Naumovski, L; Lopez, CD				Zhu, ZY; Ramos, J; Kampa, K; Adimoolam, S; Sirisawad, M; Yu, ZY; Chen, DX; Naumovski, L; Lopez, CD			Control of ASPP2/(53BP2L) protein levels by proteasomal degradation modulates p53 apoptotic function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTHRACYCLINE ANTICANCER AGENTS; MULTIPLE-MYELOMA CELLS; NF-KAPPA-B; INHIBITOR PS-341; DNA-DAMAGE; THERAPEUTIC TARGET; 53BP2; CANCER; INDUCTION; ARREST	The p53 pathway is a central mediator of the apoptotic response. ASPP2/(53BP2L) (apoptosis-stimulating protein of p53 2, also known as 53BP2L) enhances apoptosis through selective stimulation of p53 transactivation of proapoptotic target genes. Although the Rb/E2F pathway regulates ASPP2/(53BP2L) transcription, the complex mechanisms controlling ASPP2/(53BP2L) levels and function remain unknown. We now report that proteasomal degradation modulates ASPP2/(53BP2L) protein levels and apoptotic function. Treatment of cells with proteasomal inhibitors, including the clinically utilized proteasomal inhibitor bortezomib, increases ASPP2/(53BP2L) protein but not RNA levels. Likewise, anthracycline-based chemotherapy, which has multiple mechanisms of action, including proteasomal inhibition, increases ASPP2/(53BP2L) protein but not RNA levels. Proteasomal inhibition or anthracycline treatment increases ASPP2/(53BP2L) protein stability and half-life. Furthermore, the central region of the ASPP2/(53BP2L) protein is ubiquitinated as would be expected for a proteasomal substrate. More importantly, small interfering RNA knockdown of ASPP2/(53BP2L) levels attenuated bortezomib-induced apoptosis, and this effect was greater in wildtype p53 cells. Because elevated levels of ASPP2/(53BP2L) are proapoptotic, these results described an important new molecular mechanism that modulates the p53-ASPP2/(53BP2L) apoptotic pathway.	Pharmacyclics Inc, Sunnyvale, CA 94085 USA; Oregon Hlth & Sci Univ, Dept Med, Div Hematol & Med Oncol, Portland, OR 97239 USA	Pharmacyclics; Oregon Health & Science University	Naumovski, L (corresponding author), Pharmacyclics Inc, Sunnyvale, CA 94085 USA.	lnaumovski@pcyc.com; lopezc@ohsu.edu		Kampa-Schittenhelm, Kerstin/0000-0003-0958-5140	NCI NIH HHS [CA104997, CA076316] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA104997, R01CA076316] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams J, 2004, CANCER CELL, V5, P417, DOI 10.1016/S1535-6108(04)00120-5; An WG, 2000, LEUKEMIA, V14, P1276, DOI 10.1038/sj.leu.2401812; Ao Y, 2001, ONCOGENE, V20, P2720, DOI 10.1038/sj.onc.1204352; Bergamaschi D, 2004, MOL CELL BIOL, V24, P1341, DOI 10.1128/MCB.24.3.1341-1350.2004; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chen D, 2005, CELL DEATH DIFFER, V12, P358, DOI 10.1038/sj.cdd.4401536; Fogal V, 2005, CELL DEATH DIFFER, V12, P369, DOI 10.1038/sj.cdd.4401562; Fribley A, 2004, MOL CELL BIOL, V24, P9695, DOI 10.1128/MCB.24.22.9695-9704.2004; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Hershko T, 2005, CELL DEATH DIFFER, V12, P377, DOI 10.1038/sj.cdd.4401575; Hideshima T, 2001, CANCER RES, V61, P3071; Hideshima T, 2003, BLOOD, V101, P1530, DOI 10.1182/blood-2002-08-2543; Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Iwabuchi K, 1998, J BIOL CHEM, V273, P26061, DOI 10.1074/jbc.273.40.26061; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kiyomiya KI, 2002, INT J ONCOL, V20, P1205; Kiyomiya KI, 2002, INT J ONCOL, V21, P1081; Lin WC, 2001, GENE DEV, V15, P1833; Ling YH, 2003, CLIN CANCER RES, V9, P1145; Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893; Lopez CD, 2000, MOL CELL BIOL, V20, P8018, DOI 10.1128/MCB.20.21.8018-8025.2000; Mitsiades N, 2002, P NATL ACAD SCI USA, V99, P14374, DOI 10.1073/pnas.202445099; Mori T, 2000, FEBS LETT, V465, P124, DOI 10.1016/S0014-5793(99)01726-3; Oren M, 2002, BIOCHEM PHARMACOL, V64, P865, DOI 10.1016/S0006-2952(02)01149-8; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Rajkumar SV, 2005, J CLIN ONCOL, V23, P630, DOI 10.1200/JCO.2005.11.030; Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Sears RC, 2004, CELL CYCLE, V3, P1133, DOI 10.4161/cc.3.9.1145; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Takahashi N, 2004, BIOCHEM BIOPH RES CO, V315, P434, DOI 10.1016/j.bbrc.2004.01.079; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Williams SA, 2003, CANCER RES, V63, P7338; Yang JP, 1999, ONCOGENE, V18, P5177, DOI 10.1038/sj.onc.1202904; Yin D, 2005, ONCOGENE, V24, P344, DOI 10.1038/sj.onc.1208225; YU J, 2003, CANCER BIOL THER, V2, P50	39	27	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34473	34480		10.1074/jbc.M503736200	http://dx.doi.org/10.1074/jbc.M503736200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16091363	hybrid			2022-12-25	WOS:000232403900014
J	Chen, Y; Shertzer, HG; Schneider, SN; Nebert, DW; Dalton, TP				Chen, Y; Shertzer, HG; Schneider, SN; Nebert, DW; Dalton, TP			Glutamate cysteine ligase catalysis - Dependence on ATP and modifier subunit for regulation of tissue glutathione levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; INDUCED OXIDATIVE STRESS; EPITHELIAL L2 CELLS; RAT-KIDNEY; PARKINSONS-DISEASE; MYOCARDIAL-INFARCTION; GENE-EXPRESSION; S-NITROSOTHIOLS; LIGHT SUBUNIT; POLYMORPHISM	Glutamate cysteine ligase (GCL), which synthesizes gamma-glutamyl-cysteine (gamma-GC), is the rate-limiting enzyme in GSH biosynthesis. gamma-GC may be produced by the catalytic subunit GCLC or by the holoenzyme (GCLholo), which comprises GCLC and the modifier subunit GCLM. The Gclm(-/-) knock-out mouse shows tissue levels of GSH that are between 9 and 40% of the Gclm(-/-) wild-type mouse. In the present study, we used recombinant GCLC and GCLM and Gclm(-/-) mice to examine the role of GCLM on gamma-GC synthesis by GCLholo. GCLM decreased the K-m for ATP by similar to 6-fold and, similar to other species, decreased the K-m for glutamate and increased the K-i for feedback inhibition by GSH. Furthermore, GCLM increased by 4.4-fold the K-cat for gamma-GC synthesis; this difference in catalytic efficiency of GCLholo versus GCLC allowed us to derive a mathematical relationship for gamma-GC production and to determine the relative levels of GCLholo and GCLC; in homogenates of brain, liver, and lung, the ratio of GCLC to GCLholo was 7.0, 2.0, and 3.5, respectively. In kidney, however, the relationship between GCLC and GCLholo was complicated. Kidney contains GCLholo, free GCLC, and free GCLM, and free GCLC in kidney cannot interact with GCLM. Taken together, we conclude that, in most tissues, GCLM is limiting, suggesting that an increase in GCLM alone would increase gamma-GC synthesis. On the other hand, our results from kidney suggest that gamma-GC synthesis may be controlled post-translationally.	Univ Cincinnati, Med Ctr, Dept Environm Hlth, Cincinnati, OH 45267 USA; Univ Cincinnati, Med Ctr, Ctr Environm Genet, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Dalton, TP (corresponding author), Univ Cincinnati, Med Ctr, Dept Environm Hlth, Cincinnati, OH 45267 USA.	daltontp@ucmail.uc.edu			NIEHS NIH HHS [R01 ES012463, P30 ES06096, R01 ES10133] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096, R01ES010133, R01ES012463] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arthur JR, 2000, CELL MOL LIFE SCI, V57, P1825; Berman SB, 1999, J NEUROCHEM, V73, P1127, DOI 10.1046/j.1471-4159.1999.0731127.x; Bharath S, 2002, BIOCHEM PHARMACOL, V64, P1037, DOI 10.1016/S0006-2952(02)01174-7; Cai JX, 1997, BIOCHEM J, V326, P167, DOI 10.1042/bj3260167; CAI JX, 1995, MOL PHARMACOL, V48, P212; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Dalton TP, 2000, BIOCHEM BIOPH RES CO, V279, P324, DOI 10.1006/bbrc.2000.3930; Dalton TP, 2004, FREE RADICAL BIO MED, V37, P1511, DOI 10.1016/j.freeradbiomed.2004.06.040; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; Divino JC, 1998, J ENDOCRINOL, V156, P519, DOI 10.1677/joe.0.1560519; Fraser JA, 2002, J BIOL CHEM, V277, P1158, DOI 10.1074/jbc.M106683200; Geerts WJC, 1997, J HISTOCHEM CYTOCHEM, V45, P1217, DOI 10.1177/002215549704500905; GOLDSTEIN L, 1966, AM J PHYSIOL, V210, P661, DOI 10.1152/ajplegacy.1966.210.3.661; Gribble FM, 2000, J BIOL CHEM, V275, P30046, DOI 10.1074/jbc.M001010200; Hogg N, 2002, ANNU REV PHARMACOL, V42, P585, DOI 10.1146/annurev.pharmtox.42.092501.104328; HUANG CS, 1993, J BIOL CHEM, V268, P19675; HUANG CS, 1993, J BIOL CHEM, V268, P20578; Kaplowitz N, 1996, BIOL CHEM H-S, V377, P267; Ko SH, 1997, ANESTHESIOLOGY, V87, P68, DOI 10.1097/00000542-199707000-00010; Koide S, 2003, J AM COLL CARDIOL, V41, P539, DOI 10.1016/S0735-1097(02)02866-8; Kosower N S, 1978, Int Rev Cytol, V54, P109, DOI 10.1016/S0074-7696(08)60166-7; Krzywanski DM, 2004, ARCH BIOCHEM BIOPHYS, V423, P116, DOI 10.1016/j.abb.2003.11.004; Kugiyama K, 2001, AM J PHYSIOL-HEART C, V280, pH264, DOI 10.1152/ajpheart.2001.280.1.H264; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Lipton AJ, 2001, NATURE, V413, P171, DOI 10.1038/35093117; Liu RM, 1996, AM J RESP CELL MOL, V14, P192, DOI 10.1165/ajrcmb.14.2.8630270; Lu SC, 1999, FASEB J, V13, P1169, DOI 10.1096/fasebj.13.10.1169; Marcussen M, 1996, CELL MOTIL CYTOSKEL, V35, P94, DOI 10.1002/(SICI)1097-0169(1996)35:2<94::AID-CM2>3.0.CO;2-I; MEISTER A, 1988, J BIOL CHEM, V263, P17205; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Merad-Boudia M, 1998, BIOCHEM PHARMACOL, V56, P645, DOI 10.1016/S0006-2952(97)00647-3; Moellering D, 1998, ARCH BIOCHEM BIOPHYS, V358, P74, DOI 10.1006/abbi.1998.0854; Nakamura S, 2002, CIRCULATION, V105, P2968, DOI 10.1161/01.CIR.0000019739.66514.1E; Nakamura S, 2003, CIRCULATION, V108, P1425, DOI 10.1161/01.CIR.0000091255.63645.98; Oja SS, 2000, NEUROCHEM INT, V37, P299, DOI 10.1016/S0197-0186(00)00031-0; Pompella A, 2003, BIOCHEM PHARMACOL, V66, P1499, DOI 10.1016/S0006-2952(03)00504-5; Rinaldi R, 2002, DRUG METAB DISPOS, V30, P1053, DOI 10.1124/dmd.30.10.1053; SEELIG GF, 1984, J BIOL CHEM, V259, P9345; SHI MM, 1994, J BIOL CHEM, V269, P26512; Shi ZZ, 2000, P NATL ACAD SCI USA, V97, P5101, DOI 10.1073/pnas.97.10.5101; SMITH JE, 1980, ENZYME, V25, P236, DOI 10.1159/000459258; Sun WM, 1996, BIOCHEM J, V320, P321, DOI 10.1042/bj3200321; Tu ZH, 1998, ARCH BIOCHEM BIOPHYS, V354, P247, DOI 10.1006/abbi.1998.0676; WEBER K, 1969, J BIOL CHEM, V244, P4406; WOODS JS, 1995, BIOCHEM PHARMACOL, V50, P1719, DOI 10.1016/0006-2952(95)02075-6; Yang Y, 2002, J BIOL CHEM, V277, P49446, DOI 10.1074/jbc.M209372200; ZOCCARATO F, 2005, J BIOL CHEM	47	162	166	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33766	33774		10.1074/jbc.M504604200	http://dx.doi.org/10.1074/jbc.M504604200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16081425	hybrid			2022-12-25	WOS:000232229700012
J	Dasgupta, S; Jana, M; Liu, XJ; Pahan, K				Dasgupta, S; Jana, M; Liu, XJ; Pahan, K			Myelin basic protein-primed T cells of female but not male mice induce nitric-oxide synthase and proinflammatory cytokines in microglia - Implications for gender bias in multiple sclerosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; NECROSIS-FACTOR-ALPHA; NF-KAPPA-B; LIPOPOLYSACCHARIDE INDUCTION; EXPRESSION; MACROPHAGES; ACTIVATION; DISEASES; PEROXYNITRITE	Females are more susceptible than males to multiple sclerosis ( MS). However, the underlying mechanism behind this gender difference is poorly understood. Because the presence of neuroantigen- primed T cells within the CNS is necessary for the development of MS, the present study was undertaken to investigate the activation of microglia by myelin basic protein ( MBP)- primed T cells of male, female, and castrated male mice. Interestingly, MBP- primed T cells isolated from female and castrated male but not from male mice induced the expression of inducible nitric- oxide synthase ( iNOS) and proinflammatory cytokines ( interleukin- 1 beta ( IL- 1 beta), IL- 1 alpha, IL- 6, and tumor necrosis factor- alpha) in microglia by cell- cell contact. Again there was no apparent defect in male microglia, because MBP- primed T cells isolated from female and castrated male but not male mice were capable of inducing the production of NO in male primary microglia. Inhibition of female T cell contact- mediated microglial expression of proinflammatory molecules by dominant- negative mutants of p65 and C/ EBP beta suggest that female MBP- primed T cells induce microglial expression of proinflammatory molecules through the activation of NF- kappa B and C/ EBP beta. Interestingly, MBP- primed T cells of male, female, and castrated male mice were able to induce microglial activation of NF- kappa B. However, MBP- primed T cells of female and castrated male but not male mice induced microglial activation of C/ EBP beta. These studies suggest that microglial activation of C/ EBP beta but not NF- kappa B by T cell: microglial contact is a gender- specific event and that male MBP- primed T cells are not capable of inducing microglial expression of proinflammatory molecules due to their inability to induce the activation of C/ EBP beta in microglia. This novel gender- sensitive activation of microglia by neuroantigen- primed T cell contact could be one of the mechanisms behind the female- loving nature of MS.	Univ Nebraska, Med Ctr, Dept Oral Biol, Sect Neurosci, Lincoln, NE 68583 USA	University of Nebraska System; University of Nebraska Lincoln; University of Nebraska Medical Center	Pahan, K (corresponding author), Univ Nebraska, Med Ctr, Dept Oral Biol, Sect Neurosci, 40th & Holdrege, Lincoln, NE 68583 USA.	kpahan@unmc.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018759] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039940] Funding Source: NIH RePORTER; NCRR NIH HHS [P20RR18759, P20 RR018759] Funding Source: Medline; NINDS NIH HHS [R01 NS039940, R01 NS039940-05A1, R01NS39940] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAGSRA O, 1996, P NATL ACAD SCI USA, V92, P12041; Benveniste EN, 1997, J MOL MED-JMM, V75, P165, DOI 10.1007/s001090050101; BO L, 1994, ANN NEUROL, V36, P778, DOI 10.1002/ana.410360515; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brenner T, 1997, J IMMUNOL, V158, P2940; Brosnan CF, 1996, BRAIN PATHOL, V6, P243, DOI 10.1111/j.1750-3639.1996.tb00853.x; Chabot S, 2000, NEUROLOGY, V55, P1497, DOI 10.1212/WNL.55.10.1497; CROSS AH, 1993, NEUROLOGY, V43, P1028, DOI 10.1212/WNL.43.5.1028; Dasgupta S, 2003, J BIOL CHEM, V278, P22424, DOI 10.1074/jbc.M301789200; Dasgupta S, 2002, J BIOL CHEM, V277, P39327, DOI 10.1074/jbc.M111841200; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ding MZ, 1997, J NEUROIMMUNOL, V77, P99, DOI 10.1016/S0165-5728(97)00065-9; DUQUETTE P, 1992, CAN J NEUROL SCI, V19, P466, DOI 10.1017/S0317167100041664; ESIRI MM, 1997, MULTIPLE SCLEROSIS C, P173; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GIULIAN D, 1986, J NEUROSCI, V6, P2163; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; Heiss E, 2001, J BIOL CHEM, V276, P32008, DOI 10.1074/jbc.M104794200; Hooper DC, 1998, P NATL ACAD SCI USA, V95, P675, DOI 10.1073/pnas.95.2.675; Hooper DC, 1997, P NATL ACAD SCI USA, V94, P2528, DOI 10.1073/pnas.94.6.2528; Hu HM, 2000, J BIOL CHEM, V275, P16373, DOI 10.1074/jbc.M910269199; Iglesias A, 2001, GLIA, V36, P220, DOI 10.1002/glia.1111; Jacobson DL, 1997, CLIN IMMUNOL IMMUNOP, V84, P223, DOI 10.1006/clin.1997.4412; Jana M, 2003, J NEUROCHEM, V86, P519, DOI 10.1046/j.1471-4159.2003.01864.x; Jana M, 2002, J NEUROCHEM, V80, P197, DOI 10.1046/j.0022-3042.2001.00691.x; Jana M, 2001, J BIOL CHEM, V276, P44527, DOI 10.1074/jbc.M106771200; Liu HB, 2001, J NEUROIMMUNOL, V116, P83, DOI 10.1016/S0165-5728(01)00284-3; Liu XJ, 2002, J BIOL CHEM, V277, P39312, DOI 10.1074/jbc.M205107200; MAIMONE D, 1991, J NEUROIMMUNOL, V32, P67, DOI 10.1016/0165-5728(91)90073-G; Makino S, 1981, Jikken Dobutsu, V30, P137; MARTIN R, 1992, ANNU REV IMMUNOL, V10, P153, DOI 10.1146/annurev.iy.10.040192.001101; Pahan K, 2001, J BIOL CHEM, V276, P7899, DOI 10.1074/jbc.M008262200; ROUBINIAN JR, 1978, J EXP MED, V147, P1568, DOI 10.1084/jem.147.6.1568; RUDDLE NH, 1990, J EXP MED, V172, P1193, DOI 10.1084/jem.172.4.1193; Samoilova EB, 1998, J IMMUNOL, V161, P6480; SATO EH, 1992, INVEST OPHTH VIS SCI, V33, P2537; Sedgwick JD, 1998, J IMMUNOL, V160, P5320; SHARIEF MK, 1991, NEW ENGL J MED, V325, P467, DOI 10.1056/NEJM199108153250704; TRAUGOTT U, 1983, SCIENCE, V219, P308, DOI 10.1126/science.6217550; TYOR WR, 1993, NEUROLOGY, V43, P1002, DOI 10.1212/WNL.43.5.1002; Udalova IA, 1998, J BIOL CHEM, V273, P21178, DOI 10.1074/jbc.273.33.21178; UTZ U, 1994, J NEUROPATH EXP NEUR, V53, P351, DOI 10.1097/00005072-199407000-00005; Voskuhl RR, 1996, ANN NEUROL, V39, P724, DOI 10.1002/ana.410390608; Voskuhl RR, 2001, NEUROSCIENTIST, V7, P258, DOI 10.1177/107385840100700310; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795	45	22	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32609	32617		10.1074/jbc.M500299200	http://dx.doi.org/10.1074/jbc.M500299200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16046404	hybrid, Green Accepted			2022-12-25	WOS:000231920300008
J	Kandori, H; Nakamura, H; Yamazaki, Y; Mogi, T				Kandori, H; Nakamura, H; Yamazaki, Y; Mogi, T			Redox-induced protein structural changes in cytochrome bo revealed by Fourier transform infrared spectroscopy and [C-13]Tyr labeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FTIR DIFFERENCE SPECTROSCOPY; HEME-COPPER OXIDASES; RESONANCE RAMAN CHARACTERIZATION; SITE-DIRECTED MUTAGENESIS; DIOXYGEN REDUCTION SITE; AMINO-ACID-RESIDUES; SUBUNIT-I PERTURB; C-OXIDASE; ESCHERICHIA-COLI; PARACOCCUS-DENITRIFICANS	Cytochrome bo is a heme-copper terminal ubiquinol oxidase of Escherichia coli under highly aerated growth conditions. Tyr-288 present at the end of the K- channel forms a C-epsilon-N-epsilon covalent bond with one of the Cu-B ligand histidines and has been proposed to be an acid-base catalyst essential for the O-O bond cleavage at the Oxy-to-P transition of the dioxygen reduction cycle ( Uchida, T., Mogi, T., and Kitagawa, T. (2000) Biochemistry 39, 6669 - 6678). To probe structural changes at tyrosine residues, we examined redox difference Fourier transform infrared difference spectra of the wild-type enzyme in which either L-[1-C-13] Tyr or L-[4-C-13] Tyr has been biosynthetically incorporated in the tyrosine auxotroph. Spectral comparison between [1-C-13] Tyr-labeled and unlabeled proteins indicated that substitution of the main chain carbonyl of a Tyr residue(s) significantly affected changes in the amide-I (similar to 1620 - 1680 cm(-1)) and -II (similar to 1540 - 1560 cm(-1)) regions. In contrast, spectral comparison between [4-C-13] Tyr-labeled and unlabeled proteins showed only negligible changes, which was the case for both the pulsed and the resting forms. Thus, protonation of an OH group of tyrosines including Tyr- 288 in the vicinity of the heme o-Cu-B binuclear center was not detected at pH 7.4 upon full reduction of cytochrome bo. Redox-induced main chain changes at a Tyr residue(s) are associated with structural changes at Glu-286 near the binuclear metal centers and may be related to switching of the K-channel operative at the reductive phase to D-channel at the oxidative phase of the dioxygen reduction cycle via conformational changes in the middle of helix VI.	Nagoya Inst Technol, Dept Mat Sci & Engn, Showa Ku, Nagoya, Aichi 4668555, Japan; RIKEN, Harima Inst, Mikazuki, Hyogo 6795148, Japan; Yokohama City Univ, Grad Sch Integrated Sci, Yokohama, Kanagawa 2300045, Japan; Nara Inst Sci & Technol, Grad Sch Mat Sci, Dept Mat Sci, Ikoma, Nara 6300101, Japan; Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Bunkyo Ku, Tokyo 1130033, Japan; Japan Sci & Technol Org, JST, ATP Syst Project, ERATO,Midori Ku, Yokohama, Kanagawa 2260026, Japan; Tokyo Inst Technol, Chem Resources Lab, Midori Ku, Yokohama, Kanagawa 2268503, Japan	Nagoya Institute of Technology; RIKEN; Yokohama City University; Nara Institute of Science & Technology; University of Tokyo; Japan Science & Technology Agency (JST); Tokyo Institute of Technology	Kandori, H (corresponding author), Nagoya Inst Technol, Dept Mat Sci & Engn, Showa Ku, Nagoya, Aichi 4668555, Japan.	kandori@nitech.ac.jp						Abramson J, 2000, NAT STRUCT BIOL, V7, P910; Aki M, 2002, J PHYS CHEM A, V106, P3436, DOI 10.1021/jp012492n; Behr J, 2000, BIOCHEMISTRY-US, V39, P1356, DOI 10.1021/bi991504g; Berthomieu C, 1998, BIOCHEMISTRY-US, V37, P10547, DOI 10.1021/bi980788m; Blomberg MRA, 2000, J INORG BIOCHEM, V80, P261, DOI 10.1016/S0162-0134(00)00080-5; Buse G, 1999, PROTEIN SCI, V8, P985, DOI 10.1110/ps.8.5.985; Cappuccio JA, 2002, J AM CHEM SOC, V124, P1750, DOI 10.1021/ja011852h; Chen YR, 1999, J BIOL CHEM, V274, P3308, DOI 10.1074/jbc.274.6.3308; Colthup N. B., 1990, INTRO INFRARED RAMAN; FABIAN M, 1995, BIOCHEMISTRY-US, V34, P13802, DOI 10.1021/bi00042a011; FergusonMiller S, 1996, CHEM REV, V96, P2889, DOI 10.1021/cr950051s; Gennis RB, 1998, BBA-BIOENERGETICS, V1365, P241, DOI 10.1016/S0005-2728(98)00075-9; Harada I, 1986, SPECTROSCOPY BIOL SY, P113; Harrenga A, 1999, J BIOL CHEM, V274, P33296, DOI 10.1074/jbc.274.47.33296; Hellwig P, 1996, FEBS LETT, V385, P53, DOI 10.1016/0014-5793(96)00342-0; Hellwig P, 1998, BIOCHEMISTRY-US, V37, P7390, DOI 10.1021/bi9725576; Hellwig P, 2002, BIOCHEMISTRY-US, V41, P9116, DOI 10.1021/bi012056r; Helwig P, 1999, FEBS LETT, V458, P83, DOI 10.1016/S0014-5793(99)01133-3; Hienerwadel R, 1997, BIOCHEMISTRY-US, V36, P14712, DOI 10.1021/bi971521a; HIROTA S, 1994, FEBS LETT, V352, P67, DOI 10.1016/0014-5793(94)00919-8; Iwaki M, 2005, BIOCHEMISTRY-US, V44, P4230, DOI 10.1021/bi047533v; Iwaki M, 2003, BIOCHEMISTRY-US, V42, P8809, DOI 10.1021/bi034522d; Iwaki M, 2002, BBA-BIOENERGETICS, V1555, P116, DOI 10.1016/S0005-2728(02)00265-7; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; KANDORI H, 1995, BIOCHEMISTRY-US, V34, P14220, DOI 10.1021/bi00043a029; Kannt A, 1998, J BIOENERG BIOMEMBR, V30, P81, DOI 10.1023/A:1020563629032; Karpefors M, 1998, BBA-BIOENERGETICS, V1365, P159, DOI 10.1016/S0005-2728(98)00058-9; Kawasaki M, 1997, J BIOCHEM, V122, P422; Kobayashi K, 2000, BIOCHEMISTRY-US, V39, P15620, DOI 10.1021/bi0014094; Konstantinov AA, 1997, P NATL ACAD SCI USA, V94, P9085, DOI 10.1073/pnas.94.17.9085; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lee HM, 2000, BIOCHEMISTRY-US, V39, P2989, DOI 10.1021/bi9924821; Lubben M, 1999, BIOCHEMISTRY-US, V38, P2048, DOI 10.1021/bi981859k; Lubben M, 1996, FEBS LETT, V397, P303, DOI 10.1016/S0014-5793(96)01174-X; Ma JX, 1998, BIOCHEMISTRY-US, V37, P11806, DOI 10.1021/bi9809977; MacMillan F, 1999, BIOCHEMISTRY-US, V38, P9179, DOI 10.1021/bi9911987; McCauley KM, 2000, J AM CHEM SOC, V122, P2403, DOI 10.1021/ja993774s; McMahon BH, 2004, BBA-BIOENERGETICS, V1655, P321, DOI 10.1016/j.bbabio.2004.01.007; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Michel H, 1999, BIOCHEMISTRY-US, V38, P15129, DOI 10.1021/bi9910934; MITCHELL R, 1994, BBA-BIOENERGETICS, V1186, P19, DOI 10.1016/0005-2728(94)90130-9; Mogi T, 1998, BIOCHEMISTRY-US, V37, P1632, DOI 10.1021/bi971978k; Mogi T, 1999, FEBS LETT, V457, P61, DOI 10.1016/S0014-5793(99)01007-8; Mogi T., 1998, J BIOCH MOL BIOL BIO, V2, P79; MOODY AJ, 1994, EUR J BIOCHEM, V226, P731, DOI 10.1111/j.1432-1033.1994.tb20102.x; Noguchi T, 1997, BIOCHEMISTRY-US, V36, P14705, DOI 10.1021/bi971760y; Nyquist RM, 2003, P NATL ACAD SCI USA, V100, P8715, DOI 10.1073/pnas.1530408100; Nyquist RM, 2001, FEBS LETT, V505, P63, DOI 10.1016/S0014-5793(01)02769-7; Ogura T, 2004, BBA-BIOENERGETICS, V1655, P290, DOI 10.1016/j.bbabio.2003.10.013; Okuno D, 2003, J AM CHEM SOC, V125, P7209, DOI 10.1021/ja021302z; Ostermeier C, 1997, P NATL ACAD SCI USA, V94, P10547, DOI 10.1073/pnas.94.20.10547; Pfitzner U, 2000, BIOCHEMISTRY-US, V39, P6756, DOI 10.1021/bi992235x; Proshlyakov DA, 2000, SCIENCE, V290, P1588, DOI 10.1126/science.290.5496.1588; Proshlyakov DA, 1998, P NATL ACAD SCI USA, V95, P8020, DOI 10.1073/pnas.95.14.8020; Prutsch A, 2002, BBA-BIOENERGETICS, V1554, P22, DOI 10.1016/S0005-2728(02)00207-4; Puustinen A, 1997, BIOCHEMISTRY-US, V36, P13195, DOI 10.1021/bi971091o; PUUSTINEN A, 1989, FEBS LETT, V249, P163, DOI 10.1016/0014-5793(89)80616-7; Rich PR, 2002, BIOCHEMISTRY-US, V41, P967, DOI 10.1021/bi0109717; Riistama S, 1997, FEBS LETT, V414, P275, DOI 10.1016/S0014-5793(97)01003-X; ROTHSCHILD KJ, 1986, P NATL ACAD SCI USA, V83, P347, DOI 10.1073/pnas.83.2.347; Ruitenberg M, 2000, P NATL ACAD SCI USA, V97, P4632, DOI 10.1073/pnas.080079097; Sato-Watanabe M, 1998, BIOCHEMISTRY-US, V37, P5356, DOI 10.1021/bi9727592; Sato-Watanabe M, 1998, BIOCHEMISTRY-US, V37, P12744, DOI 10.1021/bi981184l; SATOWATANABE M, 1994, J BIOL CHEM, V269, P28908; Schmidt B, 2004, BBA-BIOENERGETICS, V1655, P248, DOI 10.1016/j.bbabio.2003.11.008; Soulimane T, 2000, EMBO J, V19, P1766, DOI 10.1093/emboj/19.8.1766; Svensson-Ek M, 2002, J MOL BIOL, V321, P329, DOI 10.1016/S0022-2836(02)00619-8; Tomson F, 2002, BIOCHEMISTRY-US, V41, P14383, DOI 10.1021/bi026370c; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; Tsatsos PH, 1998, BIOCHEMISTRY-US, V37, P9884, DOI 10.1021/bi9809270; Tsubaki M, 2000, J INORG BIOCHEM, V82, P19, DOI 10.1016/S0162-0134(00)00140-9; TSUBAKI M, 1993, BIOCHEMISTRY-US, V32, P6065, DOI 10.1021/bi00074a018; Uchida T, 2004, J BIOL CHEM, V279, P53613, DOI 10.1074/jbc.M409719200; Uchida T, 2000, BIOCHEMISTRY-US, V39, P6669, DOI 10.1021/bi992538r; Verkhovskaya ML, 1997, P NATL ACAD SCI USA, V94, P10128, DOI 10.1073/pnas.94.19.10128; WANG JL, 1995, BIOCHEMISTRY-US, V34, P9819, DOI 10.1021/bi00031a001; Wikstrom M, 2000, BBA-BIOENERGETICS, V1459, P514, DOI 10.1016/S0005-2728(00)00191-2; Yamazaki Y, 1999, J BIOCHEM-TOKYO, V126, P194, DOI 10.1093/oxfordjournals.jbchem.a022423; Yoshikawa S, 1998, SCIENCE, V280, P1723, DOI 10.1126/science.280.5370.1723	79	9	9	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32821	32826		10.1074/jbc.M502072200	http://dx.doi.org/10.1074/jbc.M502072200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16040612	hybrid			2022-12-25	WOS:000231920300034
J	Lee, J; Sayegh, J; Daniel, J; Clarke, S; Bedford, MT				Lee, J; Sayegh, J; Daniel, J; Clarke, S; Bedford, MT			PRMT8, a new membrane-bound tissue-specific member of the protein arginine methyltransferase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; N-METHYLTRANSFERASE; GENE-EXPRESSION; METHYLATION; IDENTIFICATION; BINDING; OLIGOMERIZATION; MYRISTOYLATION; RESIDUES; SMN	Protein arginine methylation is a common post-translational modification that has been implicated in signal transduction, RNA processing, transcriptional regulation, and DNA repair. A search of the human genome for additional members of the protein arginine N-methyltransferase (PRMT) family of enzymes has identified a gene on chromosome 12 that we have termed PRMT8. This novel enzyme is most closely related to PRMT1, although it has a distinctive N-terminal region. The unique N-terminal end harbors a myr-istoylation motif, and we have shown here that PRMT8 is indeed modified by the attachment of a myristate to the glycine residue after the initiator methionine. The myristoylation of PRMT8 results in its association with the plasma membrane. The second singular property of PRMT8 is its tissue-specific expression pattern; it is largely expressed in the brain. A glutathione S-transferase fusion protein of PRMT8 has type I PRMT activity, catalyzing the formation of omega-N-G- monomethylated and asymmetrically omega-N-G, N-G-dimethylated arginine residues on a recombinant glycine- and arginine-rich substrate. PRMT8 is thus an active arginine methyltransferase that is membrane-associated and tissue-specific, two firsts for this family of enzymes.	Univ Texas, MD Anderson Canc Ctr, Div Sci Pk Res, Smithville, TX 78957 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA	University of Texas System; UTMD Anderson Cancer Center; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Clarke, S (corresponding author), Univ Texas, MD Anderson Canc Ctr, Div Sci Pk Res, Smithville, TX 78957 USA.	clarke@mbi.ucla.edu; mtbedford@mdanderson.org	Bedford, Mark T/E-7856-2011		NIEHS NIH HHS [ES07784] Funding Source: Medline; NIGMS NIH HHS [GM26020] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026020, R37GM026020] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aubert J, 2003, P NATL ACAD SCI USA, V100, P11836, DOI 10.1073/pnas.1734197100; Bedford MT, 2005, MOL CELL, V18, P263, DOI 10.1016/j.molcel.2005.04.003; Bedford MT, 2000, J BIOL CHEM, V275, P16030, DOI 10.1074/jbc.M909368199; BOISVERT FM, 2005, SCI STKE, pRE2, DOI DOI 10.1126/STKE.2712005RE2; Branscombe TL, 2001, J BIOL CHEM, V276, P32971, DOI 10.1074/jbc.M105412200; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Cho WH, 2005, ANNU REV BIOPH BIOM, V34, P119, DOI 10.1146/annurev.biophys.33.110502.133337; Cimato TR, 1997, J CELL BIOL, V138, P1089, DOI 10.1083/jcb.138.5.1089; Cimato TR, 2002, J NEUROSCI RES, V67, P435, DOI 10.1002/jnr.10123; Frankel A, 2002, J BIOL CHEM, V277, P3537, DOI 10.1074/jbc.M108786200; Friesen WJ, 2001, MOL CELL, V7, P1111, DOI 10.1016/S1097-2765(01)00244-1; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; Gary JD, 1996, J BIOL CHEM, V271, P12585, DOI 10.1074/jbc.271.21.12585; Gros L, 2003, CANCER RES, V63, P164; Henry MF, 1996, MOL CELL BIOL, V16, P3668; Hung CM, 2004, GENE, V340, P179, DOI 10.1016/j.gene.2004.07.039; Katz JE, 2003, MOL CELL PROTEOMICS, V2, P525, DOI 10.1074/mcp.M300037-MCP200; KUJUBU DA, 1993, J NEUROSCI RES, V36, P58, DOI 10.1002/jnr.490360107; Kwak YT, 2003, MOL CELL, V11, P1055, DOI 10.1016/S1097-2765(03)00101-1; Lee J, 2002, EMBO REP, V3, P268, DOI 10.1093/embo-reports/kvf052; Lee JH, 2005, J BIOL CHEM, V280, P3656, DOI 10.1074/jbc.M405295200; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; Miranda TB, 2004, BIOCHEM BIOPH RES CO, V323, P382, DOI 10.1016/j.bbrc.2004.08.107; Miranda TB, 2004, J BIOL CHEM, V279, P22902, DOI 10.1074/jbc.M312904200; Niewmierzycka A, 1999, J BIOL CHEM, V274, P814, DOI 10.1074/jbc.274.2.814; Pal S, 2004, MOL CELL BIOL, V24, P9630, DOI 10.1128/MCB.24.21.9630-9645.2004; Perez M, 2004, J VIROL, V78, P11443, DOI 10.1128/JVI.78.20.11443-11448.2004; Pollack BP, 1999, J BIOL CHEM, V274, P31531, DOI 10.1074/jbc.274.44.31531; Resh MD, 2004, SUB CELL BIOCHEM, V37, P217; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Schurter BT, 2001, BIOCHEMISTRY-US, V40, P5747, DOI 10.1021/bi002631b; Scott HS, 1998, GENOMICS, V48, P330, DOI 10.1006/geno.1997.5190; SEELEY PJ, 1984, J CELL BIOL, V98, P417, DOI 10.1083/jcb.98.2.417; Selenko P, 2001, NAT STRUCT BIOL, V8, P27; SIWERCZ R, 2005, BIOCHEM J, V386, P85; Tang J, 1998, J BIOL CHEM, V273, P16935, DOI 10.1074/jbc.273.27.16935; Tang J, 2000, J BIOL CHEM, V275, P7723, DOI 10.1074/jbc.275.11.7723; Utsumi T, 2004, EUR J BIOCHEM, V271, P863, DOI 10.1111/j.1432-1033.2004.03991.x; Weiss VH, 2000, NAT STRUCT BIOL, V7, P1165; Xu W, 2004, GENE DEV, V18, P144, DOI 10.1101/gad.1141704; Yadav N, 2003, P NATL ACAD SCI USA, V100, P6464, DOI 10.1073/pnas.1232272100; Zhang X, 2003, STRUCTURE, V11, P509, DOI 10.1016/S0969-2126(03)00071-6	42	182	189	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32890	32896		10.1074/jbc.M506944200	http://dx.doi.org/10.1074/jbc.M506944200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16051612	Green Published, hybrid			2022-12-25	WOS:000231920300043
J	Ja, WW; Adhikari, A; Austin, RJ; Sprang, SR; Roberts, RW				Ja, WW; Adhikari, A; Austin, RJ; Sprang, SR; Roberts, RW			A peptide core motif for binding to heterotrimeric G protein alpha subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO SELECTION; REGULATORY MOTIF; GAMMA-SUBUNIT; GDP; AGS3; DISSOCIATION; SIGNALING-3; INHIBITION; ACTIVATION; DISCOVERY	Recently, in vitro selection using mRNA display was used to identify a novel peptide sequence that binds with high affinity to G alpha(i1). The peptide was minimized to a 9-residue sequence (R6A-1) that retains high affinity and specificity for the GDP-bound state of G alpha(i1) and acts as a guanine nucleotide dissociation inhibitor (GDI). Here, we demonstrate that the R6A-1 peptide interacts with G alpha subunits representing all four G protein classes, acting as a core motif for G alpha interaction. This contrasts with the consensus G protein regulatory ( GPR) sequence, a 28-mer peptide GDI derived from the GoLoco (G alpha(i/o)-Loco interaction)/GPR motif that shares no homology with R6A-1 and binds only to G alpha(i1-3) in this assay. Binding of R6A-1 is generally specific to the GDP-bound state of the G alpha subunits and excludes association with G beta gamma. R6A-G alpha(i1) complexes are resistant to trypsin digestion and exhibit distinct stability in the presence of Mg2+, suggesting that the R6A and GPR peptides exert their activities using different mechanisms. Studies using G alpha(i1)/G alpha(s) chimeras identify two regions of G alpha(i1) (residues 1-35 and 57-88) as determinants for strong R6A-G(i alpha 1) interaction. Residues flanking the R6A-1 peptide confer unique binding properties, indicating that the core motif could be used as a starting point for the development of peptides exhibiting novel activities and/or specificity for particular G protein subclasses or nucleotide-bound states.	CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Mol Biophys Grad Program, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA	California Institute of Technology; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Roberts, RW (corresponding author), CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA.	rroberts@caltech.edu		Ja, William/0000-0002-4003-7356	NIDDK NIH HHS [R01 DK046371] Funding Source: Medline; NIGMS NIH HHS [R01 GM 60416] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046371] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060416] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adhikari A, 2003, J BIOL CHEM, V278, P51825, DOI 10.1074/jbc.M306300200; Bernard ML, 2001, J BIOL CHEM, V276, P1585, DOI 10.1074/jbc.M005291200; Coleman DE, 1998, BIOCHEMISTRY-US, V37, P14376, DOI 10.1021/bi9810306; De Vries L, 2000, P NATL ACAD SCI USA, V97, P14364, DOI 10.1073/pnas.97.26.14364; Dower WJ, 2002, CURR OPIN CHEM BIOL, V6, P390, DOI 10.1016/S1367-5931(02)00332-0; Drews J, 2000, SCIENCE, V287, P1960, DOI 10.1126/science.287.5460.1960; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GarciaHiguera I, 1996, J BIOL CHEM, V271, P528, DOI 10.1074/jbc.271.1.528; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; Holler C, 1999, CELL MOL LIFE SCI, V55, P257, DOI 10.1007/s000180050288; Howard AD, 2001, TRENDS PHARMACOL SCI, V22, P132, DOI 10.1016/S0165-6147(00)01636-9; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; Ja WW, 2005, TRENDS BIOCHEM SCI, V30, P318, DOI 10.1016/j.tibs.2005.04.001; Ja WW, 2004, BIOCHEMISTRY-US, V43, P9265, DOI 10.1021/bi0498398; Kimple RJ, 2002, NATURE, V416, P878, DOI 10.1038/416878a; Lin HN, 2002, ANGEW CHEM INT EDIT, V41, P4403; MENDE U, 1995, J BIOL CHEM, V270, P15892, DOI 10.1074/jbc.270.26.15892; Natochin M, 2002, BIOCHEMISTRY-US, V41, P258, DOI 10.1021/bi015708k; Natochin M, 2000, J BIOL CHEM, V275, P40981, DOI 10.1074/jbc.M006478200; Natochin M, 2001, BIOCHEMISTRY-US, V40, P5322, DOI 10.1021/bi015505w; NEER EJ, 1994, METHOD ENZYMOL, V237, P226; Neves SR, 2002, SCIENCE, V296, P1636, DOI 10.1126/science.1071550; Nurnberg B, 1999, EUR J MED CHEM, V34, P5, DOI 10.1016/S0223-5234(99)80037-3; Peterson YK, 2000, J BIOL CHEM, V275, P33193, DOI 10.1074/jbc.C000509200; Peterson YK, 2002, J BIOL CHEM, V277, P6767, DOI 10.1074/jbc.C100699200; Radhika V, 2001, ONCOGENE, V20, P1607, DOI 10.1038/sj.onc.1204274; SCHMIDT CJ, 1991, J BIOL CHEM, V266, P4538; Spiegel AM, 2004, ANNU REV MED, V55, P27, DOI 10.1146/annurev.med.55.091902.103843; Tsao KL, 1996, GENE, V169, P59, DOI 10.1016/0378-1119(95)00762-8	30	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32057	32060		10.1074/jbc.C500319200	http://dx.doi.org/10.1074/jbc.C500319200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16051611	Green Accepted, hybrid			2022-12-25	WOS:000231794800004
J	Song, JN; da Costa, KA; Fischer, LM; Kohlmeier, M; Kwock, L; Wang, SL; Zeisel, SH				Song, JN; da Costa, KA; Fischer, LM; Kohlmeier, M; Kwock, L; Wang, SL; Zeisel, SH			Polymorphism of the PEMT gene and susceptibility to nonalcoholic fatty liver disease (NAFLD)	FASEB JOURNAL			English	Article						choline; liver function; single nucleotide polymorphism (SNP); nonalcoholic fatty liver disease pregnancy; NTD; transfection; site-directed mutagenesis	PHOSPHATIDYLETHANOLAMINE N-METHYLTRANSFERASE; DENSITY LIPOPROTEIN SECRETION; CHOLINE DEFICIENCY; HEPATIC STEATOSIS; PLASMODIUM-FALCIPARUM; MALARIA PARASITE; PHOSPHATIDYLCHOLINE; RAT; BIOSYNTHESIS; HEPATOCYTES	Phosphatidylethanolamine N-methyltransferase (PEMT) catalyzes phosphatidylcholine synthesis. PEMT knockout mice have fatty livers, and it is possible that, in humans, nonalcoholic fatty liver disease (NAFLD) might be associated with PEMT gene polymorphisms. DNA samples from 59 humans without fatty liver and from 28 humans with NAFLD were genotyped for a single nucleotide polymorphism in exon 8 of PEMT, which leads to a V175M substitution. V175M is a loss of function mutation, as determined by transiently transfecting McArdle-RH7777 cells with constructs of wild-type PEMT open reading frame or the V175M mutant. Met/Met at residue 175 (loss of function SNP) occurred in 67.9% of the NAFLD subjects and in only 40.7% of control subjects (P < 0.03). For the first time we report that a polymorphism of the human PEMT gene (V175M) is associated with diminished activity and may confer susceptibility to NAFLD.	Univ N Carolina, Sch Publ Hlth, Dept Nutr, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Radiol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Zeisel, SH (corresponding author), Univ N Carolina, Sch Publ Hlth, Dept Nutr, CB 7461,McGavran Greenberg Bldg, Chapel Hill, NC 27599 USA.	zeisel@unc.edu			NIA NIH HHS [P01 AG009525, AG09525] Funding Source: Medline; NIDDK NIH HHS [P30 DK056350, DK56350, R01 DK055865, DK55865] Funding Source: Medline; NIEHS NIH HHS [P30 ES010126, ES10126] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055865, P30DK056350] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES010126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG009525] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		*AN IT MICR EXC, 2004, AN IT MICR EXC; Ancelin ML, 1998, BLOOD, V91, P1426, DOI 10.1182/blood.V91.4.1426; BJORNSTAD P, 1966, J LIPID RES, V7, P38; Bravo AA, 2001, NEW ENGL J MED, V344, P495, DOI 10.1056/NEJM200102153440706; BREMER J, 1961, BIOCHIM BIOPHYS ACTA, V46, P205, DOI 10.1016/0006-3002(61)90745-4; Browning JD, 2004, J CLIN INVEST, V114, P147, DOI 10.1172/JCI200422422; Brunt EM, 2001, SEMIN LIVER DIS, V21, P3, DOI 10.1055/s-2001-12925; BUCHMAN AL, 1995, HEPATOLOGY, V22, P1399, DOI 10.1002/hep.1840220510; DACOSTA KA, 1995, CARCINOGENESIS, V16, P327, DOI 10.1093/carcin/16.2.327; DIXON WT, 1984, RADIOLOGY, V153, P189, DOI 10.1148/radiology.153.1.6089263; DROUVA SV, 1986, ENDOCRINOLOGY, V119, P2611, DOI 10.1210/endo-119-6-2611; Falck-Ytter Y, 2001, SEMIN LIVER DIS, V21, P17, DOI 10.1055/s-2001-12926; Fishbein MH, 1997, MAGN RESON IMAGING, V15, P287, DOI 10.1016/S0730-725X(96)00224-X; Goldenberger D, 1997, J CLIN MICROBIOL, V35, P2733, DOI 10.1128/JCM.35.11.2733-2739.1997; KIRK K, 1991, BIOCHEM J, V278, P521, DOI 10.1042/bj2780521; LEE JKT, 1984, RADIOLOGY, V153, P195, DOI 10.1148/radiology.153.1.6089264; Lehane AM, 2004, BIOCHEM BIOPH RES CO, V320, P311, DOI 10.1016/j.bbrc.2004.05.164; LYMAN RL, 1971, CAN J BIOCHEM CELL B, V49, P71, DOI 10.1139/o71-011; Noga AA, 2002, J BIOL CHEM, V277, P42358, DOI 10.1074/jbc.M204542200; Reo NV, 2002, BBA-MOL CELL BIOL L, V1580, P171, DOI 10.1016/S1388-1981(01)00202-5; RIDGWAY ND, 1988, J BIOL CHEM, V263, P16864; RIDGWAY ND, 1988, J BIOL CHEM, V263, P16856; Saito S, 2001, J HUM GENET, V46, P529, DOI 10.1007/s100380170035; SAS Institute Inc, 1999, SAS STAT US GUID VER; Schwahn BC, 2003, FASEB J, V17, P512, DOI 10.1096/fj.02-0456fje; Shen L, 2003, WORLD J GASTROENTERO, V9, P1106; TESSITORE L, 1995, INT J EXP PATHOL, V76, P125; TING A, 1971, VOX SANG, V20, P561, DOI 10.1111/j.1423-0410.1971.tb00469.x; Vance DE, 1997, BBA-LIPID LIPID MET, V1348, P142, DOI 10.1016/S0005-2760(97)00108-2; Waite KA, 2002, J NUTR, V132, P68, DOI 10.1093/jn/132.1.68; Walkey CJ, 1998, J BIOL CHEM, V273, P27043, DOI 10.1074/jbc.273.42.27043; Walkey CJ, 1997, P NATL ACAD SCI USA, V94, P12880, DOI 10.1073/pnas.94.24.12880; YAO Z, 1990, BIOCHEM CELL BIOL, V68, P552, DOI 10.1139/o90-079; YAO ZM, 1988, J BIOL CHEM, V263, P2998; YAO ZM, 1989, J BIOL CHEM, V264, P11373; Yates Z, 2002, HAEMATOLOGICA, V87, P751; YOUNG DL, 1971, J LIPID RES, V12, P590; ZEISEL SH, 1994, ANNU REV NUTR, V14, P269, DOI 10.1146/annurev.nu.14.070194.001413; Zeisel SH, 2003, J NUTR, V133, P1302; ZEISEL SH, 1991, FASEB J, V5, P2093, DOI 10.1096/fasebj.5.7.2010061; Zhu XN, 2004, DEV BRAIN RES, V149, P121, DOI 10.1016/j.devbrainres.2004.01.004; Zhu XN, 2003, BIOCHEM J, V370, P987, DOI 10.1042/BJ20021523; [No title captured]	43	165	171	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1266	1271		10.1096/fj.04-3580com	http://dx.doi.org/10.1096/fj.04-3580com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16051693	Green Accepted			2022-12-25	WOS:000231843700033
J	Schwabe, RF; Sakurai, H				Schwabe, RF; Sakurai, H			IKK beta phosphorylates p65 at S468 in transactivaton domain 2	FASEB JOURNAL			English	Article						signal transduction; inflammation	NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; TATA-BINDING PROTEIN; TRANSCRIPTIONAL ACTIVITY; LINKS INFLAMMATION; ACTIVATION; KINASE; SUBUNIT; SERINE-536; RELA/P65	The transcription factor nuclear factor-kappa B (NF-kappa B) subunit p65 is phosphorylated by I kappa B kinase (IKK) at S536 in transactivation domain (TAD) 1. In this study, we investigate the presence of IKK sites in TAD2 of p65. Recombinant IKK beta, but not IKK alpha, phosphorylated a GST-p65 substrate in which TAD1 was deleted. Mutational analysis revealed S468 as the only IKK site in TAD2. S468 phosphorylation occurred rapidly after TNF-alpha and IL-1 beta in T cell, B cell, cervix carcinoma, hepatoma, breast cancer, and astrocytoma lines and in primary hepatic stellate cells as well as peripheral blood mononuclear cells. S468-phosphorylated p65 coimmunoprecipitated with I kappa B alpha, indicating that p65 is phosphorylated while bound to I kappa B alpha. Dominant negative IKK beta or pharmacological IKK inhibition blocked S468 phosphorylation after TNF-a or IL-1 beta, whereas dominant negative IKK beta or inhibitors of MEK, p38, JNK, PI-3 kinase, or GSK-3 had no effect. p65S468A-reconstituted p65-/- mouse embryonic fibroblasts (MEFs) showed a small, but significant, elevation of NF-kappa B-driven luciferase activity and RANTES mRNA levels after TNF-alpha and IL-1 beta in comparison to wtp65-reconstituted MEFs. p65 nuclear translocation was not altered in p65S468A-expressing MEFs. In conclusion, our results indicate that 1) IKK beta phosphorylates multiple p65 sites, 2) IKK beta phosphorylates p65 in an I kappa B-p65 complex, and 3) S468 phosphorylation slightly reduces TNF-alpha- and IL-1 beta-induced NF-kappa B activation.	Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Toyama Med & Pharmaceut Univ, Dept Pathogen Biochem, Toyama, Japan	Columbia University; University of Toyama	Schwabe, RF (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, 630 W 168th St, New York, NY 10032 USA.	rfs2102@columbia.edu	Schwabe, Robert/AAY-6506-2021; Sakurai, Hiroaki/AAE-4294-2019	Sakurai, Hiroaki/0000-0003-0657-9570				Arkan MC, 2005, NAT MED, V11, P191, DOI 10.1038/nm1185; Bae JS, 2003, BIOCHEM BIOPH RES CO, V305, P1094, DOI 10.1016/S0006-291X(03)00869-6; Bonizzi G, 2004, EMBO J, V23, P4202, DOI 10.1038/sj.emboj.7600391; Buss H, 2004, J BIOL CHEM, V279, P55633, DOI 10.1074/jbc.M409825200; Buss H, 2004, J BIOL CHEM, V279, P49571, DOI 10.1074/jbc.C400442200; Cai DS, 2005, NAT MED, V11, P183, DOI 10.1038/nm1166; Chen LF, 2002, EMBO J, V21, P6539, DOI 10.1093/emboj/cdf660; Duran A, 2003, EMBO J, V22, P3910, DOI 10.1093/emboj/cdg370; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Guttridge DC, 2000, SCIENCE, V289, P2363, DOI 10.1126/science.289.5488.2363; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; Mattioli I, 2004, J IMMUNOL, V172, P6336, DOI 10.4049/jimmunol.172.10.6336; Moriyoshi K, 1996, NEURON, V16, P255, DOI 10.1016/S0896-6273(00)80044-6; Okazaki T, 2003, BIOCHEM BIOPH RES CO, V300, P807, DOI 10.1016/S0006-291X(02)02932-7; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Sakurai H, 2003, J BIOL CHEM, V278, P36916, DOI 10.1074/jbc.M301598200; Sanlioglu S, 2001, J BIOL CHEM, V276, P30188, DOI 10.1074/jbc.M102061200; Schmitz ML, 2004, CHEMBIOCHEM, V5, P1348, DOI 10.1002/cbic.200400144; SCHMITZ ML, 1995, J BIOL CHEM, V270, P7219, DOI 10.1074/jbc.270.13.7219; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; Schwabe RF, 2002, AM J PHYSIOL-GASTR L, V283, pG204, DOI 10.1152/ajpgi.00016.2002; Schwabe RF, 2001, J IMMUNOL, V166, P6812, DOI 10.4049/jimmunol.166.11.6812; Schwabe RF, 2001, HEPATOLOGY, V33, P81, DOI 10.1053/jhep.2001.20799; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Takada Y, 2004, J BIOL CHEM, V279, P15096, DOI 10.1074/jbc.M311192200; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Vermeulen L, 2002, BIOCHEM PHARMACOL, V64, P963, DOI 10.1016/S0006-2952(02)01161-9; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Yang F, 2003, J IMMUNOL, V170, P5630, DOI 10.4049/jimmunol.170.11.5630; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	33	63	68	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1758	+		10.1096/fj.05-3736fje	http://dx.doi.org/10.1096/fj.05-3736fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16046471				2022-12-25	WOS:000230923000008
J	Shilling, R; Federici, L; Walas, F; Venter, H; Velamakanni, S; Woebking, B; Balakrishnan, L; Luisi, B; van Veen, HW				Shilling, R; Federici, L; Walas, F; Venter, H; Velamakanni, S; Woebking, B; Balakrishnan, L; Luisi, B; van Veen, HW			A critical role of a carboxylate in proton conduction by the ATP-binding cassette multidrug transporter LmrA	FASEB JOURNAL			English	Article						molecular mechanism; multidrug resistance; protein structure	RESISTANCE P-GLYCOPROTEIN; RETRACTED ARTICLE. SEE; ABC TRANSPORTER; LACTOCOCCUS-LACTIS; ESCHERICHIA-COLI; MUTATIONAL ANALYSIS; CROSS-LINKING; PROTEIN; SUBSTRATE; DOMAIN	The ATP binding cassette (ABC) transporter LmrA from the bacterium Lactococcus lactis is a homolog of the human multidrug resistance P-glycoprotein (ABCB1), the activity of which impairs the efficacy of chemotherapy. In a previous study, LmrA was shown to mediate ethidium efflux by an ATP-dependent proton-ethidium symport reaction in which the carboxylate E314 is critical. The functional importance of this key residue for ABC proteins was suggested by its conservation in a wider family of related transporters; however, the structural basis of its role was not apparent. Here, we have used homology modeling to define the structural environment of E314. The residue is nested in a hydrophobic environment that probably elevates its pK(a), accounting for the pH dependency of drug efflux that we report in this work. Functional analyses of wild-type and mutant proteins in cells and proteoliposomes support our proposal for the mechanistic role of E314 in proton-coupled ethidium transport. As the carboxylate is known to participate in proton translocation by secondary-active transporters, our observations suggest that this substituent can play a similar role in the activity of ABC transporters.	Univ Cambridge, Dept Pharmacol, Cambridge CB2 1PD, England; Univ Cambridge, Dept Biochem, Cambridge CB2 1PD, England	University of Cambridge; University of Cambridge	van Veen, HW (corresponding author), Univ Cambridge, Dept Pharmacol, Tennis Court Rd, Cambridge CB2 1PD, England.	hwv20@cam.ac.uk	Venter, Rietie/E-4795-2013; van Veen, Hendrik W./A-4162-2008	Venter, Rietie/0000-0001-5569-7755; van Veen, Hendrik W./0000-0002-9658-8077	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Alqwai O, 2003, BIOCHEM BIOPH RES CO, V311, P696, DOI 10.1016/j.bbrc.2003.10.049; Balakrishnan L, 2004, J BIOL CHEM, V279, P11273, DOI 10.1074/jbc.M308494200; Bolhuis H, 1996, EMBO J, V15, P4239, DOI 10.1002/j.1460-2075.1996.tb00798.x; Brown MH, 2001, J MOL MICROB BIOTECH, V3, P163; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; Checover S, 2001, BIOCHEMISTRY-US, V40, P4281, DOI 10.1021/bi002574m; deRuyter PGGA, 1996, APPL ENVIRON MICROB, V62, P3662, DOI 10.1128/AEM.62.10.3662-3667.1996; Dong JH, 2005, SCIENCE, V308, P1023, DOI 10.1126/science.1106592; Ecker GF, 2004, MOL PHARMACOL, V66, P1169, DOI 10.1124/mol.104.001420; Edgar R, 1999, EMBO J, V18, P822, DOI 10.1093/emboj/18.4.822; Hafkemeyer P, 1998, BIOCHEMISTRY-US, V37, P16400, DOI 10.1021/bi980871+; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Huda N, 2003, ANTIMICROB AGENTS CH, V47, P2413, DOI 10.1128/AAC.47.8.2413-2417.2003; Janvilisri T, 2005, BIOCHEM J, V385, P419, DOI 10.1042/BJ20040791; Kaback HR, 2001, NAT REV MOL CELL BIO, V2, P610, DOI 10.1038/35085077; Kaiser RD, 1998, BIOCHEMISTRY-US, V37, P8180, DOI 10.1021/bi980064a; Kerr ID, 2002, BBA-BIOMEMBRANES, V1561, P47, DOI 10.1016/S0304-4157(01)00008-9; Kim SH, 2004, MICROBIOL-SGM, V150, P2493, DOI 10.1099/mic.0.27312-0; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Loo TW, 2001, J BIOL CHEM, V276, P31800, DOI 10.1074/jbc.M103498200; Margolles A, 1999, BIOCHEMISTRY-US, V38, P16298, DOI 10.1021/bi990855s; Mehler EL, 2002, PROTEINS, V48, P283, DOI 10.1002/prot.10153; Morrill JA, 1999, J GEN PHYSIOL, V114, P71, DOI 10.1085/jgp.114.1.71; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Periole X, 2004, BIOCHEMISTRY-US, V43, P6858, DOI 10.1021/bi049949e; Pleban K, 2004, BIOORG MED CHEM LETT, V14, P5823, DOI 10.1016/j.bmcl.2004.09.040; Rastogi VK, 1999, NATURE, V402, P263, DOI 10.1038/46224; Reuter G, 2003, J BIOL CHEM, V278, P35193, DOI 10.1074/jbc.M306226200; Reyes CL, 2005, SCIENCE, V308, P1028, DOI 10.1126/science.1107733; Sakaeda T, 2001, BIOL PHARM BULL, V24, P935, DOI 10.1248/bpb.24.935; Sakamoto K, 2001, J BACTERIOL, V183, P5371, DOI 10.1128/JB.183.18.5371-5375.2001; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schumacher MA, 2001, SCIENCE, V294, P2158, DOI 10.1126/science.1066020; Shilling RA, 2003, INT J ANTIMICROB AG, V22, P200, DOI 10.1016/S0924-8579(03)00212-7; Situ D, 2004, J BIOL CHEM, V279, P38871, DOI 10.1074/jbc.M403832200; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Steinfels E, 2004, BIOCHEMISTRY-US, V43, P7491, DOI 10.1021/bi0362018; Stenham DR, 2003, FASEB J, V17, P2287, DOI 10.1096/fj.03-0107fje; Strautnieks SS, 1998, NAT GENET, V20, P233, DOI 10.1038/3034; Tamura N, 2003, CURR OPIN CHEM BIOL, V7, P570, DOI 10.1016/j.cbpa.2003.08.014; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; van Veen HW, 2000, EMBO J, V19, P2503, DOI 10.1093/emboj/19.11.2503; van Veen HW, 1998, NATURE, V391, P291, DOI 10.1038/34669; VANVEEN HW, 1993, J BIOL CHEM, V268, P19377; VanVeen HW, 1996, P NATL ACAD SCI USA, V93, P10668, DOI 10.1073/pnas.93.20.10668; Vazquez-Laslop N, 1999, BIOCHEMISTRY-US, V38, P16925, DOI 10.1021/bi991988g; Venter H, 2003, NATURE, V426, P866, DOI 10.1038/nature02173; WOOD WB, 1981, BIOCH PROBLEMS APPR; Yerushalmi H, 2000, BIOCHEMISTRY-US, V39, P14711, DOI 10.1021/bi001892i; ZANI ML, 1993, J BIOL CHEM, V268, P3216; Zhang DW, 2003, J BIOL CHEM, V278, P46052, DOI 10.1074/jbc.M308403200; ZHANG XP, 1995, J BIOL CHEM, V270, P5441, DOI 10.1074/jbc.270.10.5441	57	26	26	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1698	+		10.1096/fj.04-3558fje	http://dx.doi.org/10.1096/fj.04-3558fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16040836				2022-12-25	WOS:000230923000009
J	Wang, WG; Graeler, MH; Goetzl, EJ				Wang, WG; Graeler, MH; Goetzl, EJ			Type 4 sphingosine 1-phosphate G protein-coupled receptor (S1P(4)) transduces S1P effects on T cell proliferation and cytokine secretion without signaling migration	FASEB JOURNAL			English	Article						lipid mediators; immunoregulation; chemotaxis; chemokines; proliferation	SPHINGOSINE-1-PHOSPHATE; SUPPRESSION; ACTIVATION; EXPRESSION; LIGAND	Sphingosine 1-phosphate (S1P) has diverse effects on T cells that are mediated by the predominant S1P(1) and S1P(4) G protein-coupled receptors (GPCRs). S1P(4) is expressed principally by leukocytes, but little is known of its T cell effects in immunity. Two approaches were used to investigate S1P(4) signals in T cells. First, S1P(4) was introduced into D10G4.1 mouse Th2 cells and EL4. IL-2 mouse T cells lacking endogenous S1P GPCRs. Second, mouse splenic CD4 T cells were treated with FTY720 to suppress S1P1 and leave S1P(4) GPCRs as the only functionally relevant S1P receptor. Unlike S1P(1), S1P(4) failed to transduce chemotactic responses of any of the S1P(4)- only T cells to S1P or the phyto-S1P ligand selective for S1P(4), or to suppress their chemotactic responses to chemokines. The S1P-S1P(4) axis significantly inhibited T cell proliferation in each of the S1P(4)- only T cells activated by anti-CD3 and anti-CD28 MoAbs. Secretion of IL-4 by S1P(4)-D10G4.1 cells, IL-2 by S1P(4)-EL4. IL-2, and IFN-gamma by FTY720-treated CD4 T cells were significantly inhibited by S1P. In contrast, S1P enhanced secretion of IL- 10 by stimulated S1P(4)- D10G4.1 T cells. Thus, S1P(4) mediates immunosuppressive effects of S1P by inhibiting proliferation and secretion of effector cytokines, while enhancing secretion of the suppressive cytokine IL-10.	Univ Calif San Francisco, Dept Med & Microbiol Immunol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Goetzl, EJ (corresponding author), Univ Calif San Francisco, Dept Med & Microbiol Immunol, UB8B,Box 0711,533 Parnassus 4th Ave, San Francisco, CA 94143 USA.	egoetzl@itsa.ucsf.edu	Gräler, Markus/ABH-1905-2021	Gräler, Markus/0000-0001-6650-7849	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031809] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-31809] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allende ML, 2004, J BIOL CHEM, V279, P15396, DOI 10.1074/jbc.M314291200; Candelore MR, 2002, BIOCHEM BIOPH RES CO, V297, P600; DELPRETE G, 1993, J IMMUNOL, V150, P353; Dorsam G, 2003, J IMMUNOL, V171, P3500, DOI 10.4049/jimmunol.171.7.3500; Goetzl EJ, 2004, J CELL BIOCHEM, V92, P1104, DOI 10.1002/jcb.20053; Goetzl EJ, 1999, J IMMUNOL, V162, P2049; Graeler M, 2002, FASEB J, V16, P1874, DOI 10.1096/fj.02-0548com; Graeler M, 2002, J IMMUNOL, V169, P4084, DOI 10.4049/jimmunol.169.8.4084; Graeler MH, 2003, J BIOL CHEM, V278, P27737, DOI 10.1074/jbc.C300147200; Graler MH, 2004, FASEB J, V18, P551, DOI 10.1096/fj.03-0910fje; Graler MH, 2003, J CELL BIOCHEM, V89, P507, DOI 10.1002/jcb.10537; Huang MC, 2002, BBA-MOL CELL BIOL L, V1582, P161, DOI 10.1016/S1388-1981(02)00151-8; Jin YX, 2003, BLOOD, V101, P4909, DOI 10.1182/blood-2002-09-2962; Kluk MJ, 2002, BBA-MOL CELL BIOL L, V1582, P72, DOI 10.1016/S1388-1981(02)00139-7; MALABARBA MG, 1995, J BIOL CHEM, V270, P9630, DOI 10.1074/jbc.270.16.9630; Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284; Thomson AW, 1998, CYTOKINE HDB; Van Brocklyn JR, 2000, BLOOD, V95, P2624; Wang WG, 2004, FASEB J, V18, P1043, DOI 10.1096/fj.04-1555fje	19	114	122	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1731	+		10.1096/fj.05-3730fje	http://dx.doi.org/10.1096/fj.05-3730fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16046470				2022-12-25	WOS:000230923000007
J	Xu, GH; Sztalryd, C; Lu, XY; Tansey, JT; Gan, JW; Dorward, H; Kimmel, AR; Londos, C				Xu, GH; Sztalryd, C; Lu, XY; Tansey, JT; Gan, JW; Dorward, H; Kimmel, AR; Londos, C			Post-translational regulation of adipose differentiation-related protein by the ubiquitin/proteasome pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; HORMONE-SENSITIVE LIPASE; A-MEDIATED LIPOLYSIS; LIPID DROPLETS; PERILIPIN-A; MESSENGER-RNA; ADIPOCYTE LIPOLYSIS; CELLS; DEGRADATION; EXPRESSION	Adipose differentiation-related protein ( ADRP) is localized to lipid droplets in most mammalian cells. ADRP, proposed to regulate fatty acid mobilization and lipid droplet formation, is linked to lipid accumulation in foam cells of human atherosclerotic lesions. In this report, we show that ADRP protein accumulates in Chinese hamster ovary fibroblastic cells cultured in the presence of oleic acid but is destabilized when fatty acid sources are removed from culture serum. The latter effect was blocked by the proteasome inhibitor MG132, whereas inhibitors of other proteolytic processes were ineffective. Pulse-chase experiments confirmed that ADRP degradation is inhibited by MG132. Conditions that stimulate ADRP degradation also promoted the covalent modification of ADRP by ubiquitin, whereas the addition of oleic acid to culture media, which promotes triacylglycerol deposition, blunted the appearance of ubiquitinated-ADRP. Treatment with MG132 increased the levels of ADRP associated with lipid droplets, as well as throughout the cytosol. Finally, we demonstrate that the disappearance of ADRP protein after the onset of perilipin expression during adipocyte differentiation is due to degradation by proteasomes Thus, proteolytic degradation of ADRP mediated through the ubiquitin/proteasome pathway appears to be a major mode for the post-translational regulation of ADRP.	NIDDK, Cellular & Dev Biol Lab, NIH, Bethesda, MD 20892 USA; Peking Univ, Hlth Sci Ctr, Dept Physiol & Pathophysiol, Beijing 100083, Peoples R China; Minist Educ, Key Lab Mol Cardiovasc Sci, Beijing 100083, Peoples R China	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Peking University	Londos, C (corresponding author), NIDDK, Cellular & Dev Biol Lab, NIH, Bldg 50,Rm 3140, Bethesda, MD 20892 USA.	DeanL@intra.niddk.nih.gov			Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK015505, ZIADK015505, Z01DK015503] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLANCHETTEMACKIE EJ, 1995, J LIPID RES, V36, P1211; Brasaemle DL, 1997, J LIPID RES, V38, P2249; Brasaemle DL, 2000, J BIOL CHEM, V275, P38486, DOI 10.1074/jbc.M007322200; Brasaemle DL, 1997, J BIOL CHEM, V272, P9378; Brown DA, 2001, CURR BIOL, V11, pR446, DOI 10.1016/S0960-9822(01)00257-3; Buechler C, 2001, BBA-MOL CELL BIOL L, V1532, P97, DOI 10.1016/S1388-1981(01)00121-4; Ciechanover A, 1998, P NATL ACAD SCI USA, V95, P2727, DOI 10.1073/pnas.95.6.2727; Diaz E, 1998, CELL, V93, P433, DOI 10.1016/S0092-8674(00)81171-X; Du EZ, 1999, J BIOL CHEM, V274, P1856, DOI 10.1074/jbc.274.3.1856; Faber BCG, 2001, CIRC RES, V89, P547, DOI 10.1161/hh1801.096340; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; FOLCH J, 1957, J BIOL CHEM, V226, P497; Gao J, 1999, J BIOL CHEM, V274, P16825, DOI 10.1074/jbc.274.24.16825; Gao J, 2000, J CELL PHYSIOL, V182, P297; GREENBERG AS, 1993, P NATL ACAD SCI USA, V90, P12035, DOI 10.1073/pnas.90.24.12035; Heid HW, 1998, CELL TISSUE RES, V294, P309, DOI 10.1007/s004410051181; Hickenbottom SJ, 2004, STRUCTURE, V12, P1199, DOI 10.1016/j.str.2004.04.021; Imamura M, 2002, AM J PHYSIOL-ENDOC M, V283, pE775, DOI 10.1152/ajpendo.00040.2002; JIANG HP, 1992, CELL GROWTH DIFFER, V3, P21; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Londos C, 1999, SEMIN CELL DEV BIOL, V10, P51, DOI 10.1006/scdb.1998.0275; Londos C, 1999, ANN NY ACAD SCI, V892, P155, DOI 10.1111/j.1749-6632.1999.tb07794.x; Lu XY, 2001, MAMM GENOME, V12, P741, DOI 10.1007/s00335-01-2055-5; Martinez-Botas J, 2000, NAT GENET, V26, P474, DOI 10.1038/82630; Mimnaugh EG, 1999, ELECTROPHORESIS, V20, P418, DOI 10.1002/(SICI)1522-2683(19990201)20:2<418::AID-ELPS418>3.0.CO;2-N; Mitchell DM, 1998, P NATL ACAD SCI USA, V95, P14733, DOI 10.1073/pnas.95.25.14733; Miura S, 2002, J BIOL CHEM, V277, P32253, DOI 10.1074/jbc.M204410200; Murphy DJ, 1999, TRENDS BIOCHEM SCI, V24, P109, DOI 10.1016/S0968-0004(98)01349-8; Pariyarath R, 2001, J BIOL CHEM, V276, P541, DOI 10.1074/jbc.M007944200; Schultz CJ, 2002, AM J PHYSIOL-LUNG C, V283, pL288, DOI 10.1152/ajplung.00204.2001; Serrero G, 2000, BBA-MOL CELL BIOL L, V1488, P245, DOI 10.1016/S1388-1981(00)00128-1; SERVETNICK DA, 1995, J BIOL CHEM, V270, P16970, DOI 10.1074/jbc.270.28.16970; Souza SC, 2002, J BIOL CHEM, V277, P8267, DOI 10.1074/jbc.M108329200; Steiner S, 1996, BIOCHEM BIOPH RES CO, V218, P777, DOI 10.1006/bbrc.1996.0138; Sztalryd C, 2003, J CELL BIOL, V161, P1093, DOI 10.1083/jcb.200210169; Taghibiglou C, 2000, J LIPID RES, V41, P499; Tansey JT, 2004, IUBMB LIFE, V56, P379, DOI 10.1080/15216540400009968; Tansey JT, 2001, P NATL ACAD SCI USA, V98, P6494, DOI 10.1073/pnas.101042998; Tansey JT, 2003, J BIOL CHEM, V278, P8401, DOI 10.1074/jbc.M211005200; Wang XK, 1999, FEBS LETT, V462, P145, DOI 10.1016/S0014-5793(99)01521-5; Wenner C, 2001, BIOCHEM BIOPH RES CO, V282, P608, DOI 10.1006/bbrc.2001.4611; White AL, 1999, J LIPID RES, V40, P275; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; Wilkinson KD, 1999, J NUTR, V129, P1933, DOI 10.1093/jn/129.11.1933; Wolins NE, 2001, J BIOL CHEM, V276, P5101, DOI 10.1074/jbc.M006775200; Wolins NE, 2003, J BIOL CHEM, V278, P37713, DOI 10.1074/jbc.M304025200; Zhou MY, 1998, J BIOL CHEM, V273, P24649, DOI 10.1074/jbc.273.38.24649; Zweytick D, 2000, BBA-REV BIOMEMBRANES, V1469, P101, DOI 10.1016/S0005-2736(00)00294-7	48	198	210	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 30	2005	280	52					42841	42847		10.1074/jbc.M506569200	http://dx.doi.org/10.1074/jbc.M506569200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	996UO	16115879	hybrid			2022-12-25	WOS:000234200800046
J	Popov, N; Wahlstrom, T; Hurlin, PJ; Henriksson, M				Popov, N; Wahlstrom, T; Hurlin, PJ; Henriksson, M			Mnt transcriptional repressor is functionally regulated during cell cycle progression	ONCOGENE			English	Article						Myc; Mnt; mSin3; transcriptional repression; phosphorylation; HDAC activity	MAX-INTERACTING PROTEIN; HISTONE DEACETYLASE ACTIVITY; DNA-BINDING ACTIVITY; C-MYC; INDUCED-DIFFERENTIATION; MYC/MAX/MAD NETWORK; GENE-EXPRESSION; DROSOPHILA MYC; GROWTH; DOMAIN	The Myc/Max/Mad network of transcription factors regulates cell proliferation, differentiation, and transformation. Similar to other proteins of the network, Mnt forms heterodimers with Max and binds CACGTG E-Box elements. Transcriptional repression by Mnt is mediated through association with mSin3, and deletion of the mSin3-interacting domain (SID) converts Mnt to a transcriptional activator. Mnt is coexpressed with Myc in proliferating cells and has been suggested to be a modulator of Myc function. We report that Mnt is expressed both in growth-arrested and proliferating mouse fibroblasts and is phosphorylated when resting cells are induced to re-enter the cell cycle. Importantly, the interaction between Mnt and mSin3 is disrupted upon serum stimulation resulting in decreased Mnt-associated HDAC activity. Furthermore, we demonstrate that Mnt binds and recruits mSin3 to the Myc target gene cyclin D2 in quiescent mouse fibroblasts. Interference with Mnt expression by RNAi resulted in upregulation of cyclin D2 expression in growth-arrested fibroblasts, supporting the view that Mnt represses cyclin D2 transcription in quiescent cells. Our data suggest a model in which phosphorylation of Mnt at cell cycle entry results in disruption of Mnt-mSin3-HDAC1 interaction, which allows induction of Myc target genes by release of Mnt-mediated transcriptional repression.	Karolinska Inst, Microbiol & Tumor Biol Ctr, SE-17177 Stockholm, Sweden; Shriners Hosp Children, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA	Karolinska Institutet; Oregon Health & Science University	Henriksson, M (corresponding author), Karolinska Inst, Microbiol & Tumor Biol Ctr, Box 280, SE-17177 Stockholm, Sweden.	Marie.Henriksson@mtc.ki.se	Henriksson, Marie Arsenian/F-5010-2015	Arsenian Henriksson, Marie/0000-0001-6376-7792				AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, GENE DEV, V7, P2120; Barrera-Hernandez G, 2000, MOL CELL BIOL, V20, P4253, DOI 10.1128/MCB.20.12.4253-4264.2000; Bejarano MT, 2000, EXP CELL RES, V260, P61, DOI 10.1006/excr.2000.4996; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; BOUSSET K, 1993, ONCOGENE, V8, P3211; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; Cvekl A, 2004, EUR J CANCER, V40, P2525, DOI 10.1016/j.ejca.2004.08.005; Eberhardy SR, 2000, J BIOL CHEM, V275, P33798, DOI 10.1074/jbc.M005154200; Ellenrieder V, 2002, EMBO J, V21, P2451, DOI 10.1093/emboj/21.10.2451; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hurlin PJ, 1997, CURR TOP MICROBIOL, V224, P115; Hurlin PJ, 1999, EMBO J, V18, P7019, DOI 10.1093/emboj/18.24.7019; Hurlin PJ, 2004, CELL CYCLE, V3, P97; Hurlin PJ, 2003, EMBO J, V22, P4584, DOI 10.1093/emboj/cdg442; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Imai Y, 2004, MOL CELL BIOL, V24, P1033, DOI 10.1128/MCB.24.3.1033-1043.2004; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LARSSON LG, 1994, ONCOGENE, V9, P1247; Mao DYL, 2003, CURR BIOL, V13, P882, DOI 10.1016/S0960-9822(03)00297-5; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; Nigro Cristina Lo, 1998, Genomics, V49, P275, DOI 10.1006/geno.1998.5241; Nilsson JA, 2004, CELL CYCLE, V3, P588; Nilsson JA, 2004, MOL CELL BIOL, V24, P1560, DOI 10.1128/MCB.24.4.1560-1569.2004; O'Connell BC, 2003, J BIOL CHEM, V278, P12563, DOI 10.1074/jbc.M210462200; Orian A, 2003, GENE DEV, V17, P1101, DOI 10.1101/gad.1066903; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Park J, 2001, GENE DEV, V15, P1619, DOI 10.1101/gad.900101; Peyrefitte S, 2001, MECH DEVELOP, V104, P99, DOI 10.1016/S0925-4773(01)00360-4; Queva C, 1998, ONCOGENE, V16, P967, DOI 10.1038/sj.onc.1201611; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Smith AG, 2004, J CELL BIOCHEM, V92, P1282, DOI 10.1002/jcb.20121; Sommer A, 1999, INT J CANCER, V82, P810, DOI 10.1002/(SICI)1097-0215(19990909)82:6<810::AID-IJC7>3.0.CO;2-V; Sommer A, 1997, CURR BIOL, V7, P357, DOI 10.1016/S0960-9822(06)00183-7; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Takahashi T, 1998, JPN J CANCER RES, V89, P347, DOI 10.1111/j.1349-7006.1998.tb00569.x; Toyo-oka K, 2004, HUM MOL GENET, V13, P1057, DOI 10.1093/hmg/ddh116; Walker W, 2005, J CELL BIOL, V169, P405, DOI 10.1083/jcb.200411013; Wanzel M, 2003, TRENDS CELL BIOL, V13, P146, DOI 10.1016/S0962-8924(03)00003-5; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	53	26	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2005	24	56					8326	8337		10.1038/sj.onc.1208961	http://dx.doi.org/10.1038/sj.onc.1208961			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	993LV	16103876				2022-12-25	WOS:000233956500011
J	Luo, XM; Ross, AC				Luo, XM; Ross, AC			Physiological and receptor-selective retinoids modulate interferon gamma signaling by increasing the expression, nuclear localization, and functional activity of interferon regulatory factor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; IFN-GAMMA; VITAMIN-A; CROSS-TALK; ACID; IRF-1; ACTIVATION; REQUIRES; INDUCTION; APOPTOSIS	Synergistic actions between all-trans-retinoic acid (atRA) and interferon gamma(IFN gamma) on modulation of cellular functions have been reported both in vitro and in vivo. However, the mechanism of atRA-mediated regulation of IFN gamma signaling is poorly understood. In this study, we have used the human lung epithelial cell line A549 to examine the effect of atRA on IFN gamma-induced expression of IFN regulatory factor-1 (IRF-1), an important transcription factor involved in cell growth and apoptosis, differentiation, and antiviral and antibacterial immune responses. At least 4 h of pretreatment with atRA followed by suboptimal concentrations of IFN gamma induced a faster, higher, and more stable expression of IRF-1 than IFN gamma alone. Actinomycin D completely blocked the induction of IRF-1 by the combination, suggesting regulation at the transcriptional level. Further, we found that activation of signal transducer and activator of transcription-1 was induced more dramatically by atRA and IFN gamma than by IFN gamma alone. Expression of IFN gamma receptor-1 on the cell surface was also increased upon atRA pretreatment. Experiments using receptor-selective retinoids revealed that ligands for retinoic acid receptor-alpha (RAR alpha), including atRA, 9-cis-retinoic acid, and Am580, sequentially increased the levels of IFN gamma receptor-1, activated signal transducer and activator of transcription-1, and IRF-1 and that an RAR alpha antagonist was able to inhibit the effects of atRA and Am580. In addition, atRA pretreatment affected the transcriptional functions of IFN gamma-induced IRF-1, increasing its nuclear localization and DNA binding activity as well as the transcript levels of IRF-1 target genes. These results suggest that atRA, an RAR alpha ligand, regulates IFN gamma-induced IRF-1 by affecting multiple components of the IFN gamma signaling pathway, from the plasma membrane to the nuclear transcription factors.	Penn State Univ, Dept Nutr Sci, University Pk, PA 16802 USA; Penn State Univ, Grad Program Integrat Biosci, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Ross, AC (corresponding author), Penn State Univ, Dept Nutr Sci, 126-S Henderson Bldg, University Pk, PA 16802 USA.	acr6@psu.edu	Luo, Xin M/J-6544-2016	Luo, Xin M/0000-0002-2809-5836	NATIONAL CANCER INSTITUTE [R01CA090214] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK041479, R01DK041479] Funding Source: NIH RePORTER; NCI NIH HHS [CA 90214, R01 CA090214] Funding Source: Medline; NIDDK NIH HHS [R01 DK041479, R56 DK041479, DK41479] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arany I, 2002, CLIN DIAGN LAB IMMUN, V9, P1102, DOI 10.1128/CDLI.9.5.1102-1106.2002; Austenaa LMI, 2001, J LEUKOCYTE BIOL, V70, P121; Beaton G, 1993, ACC SCN STATE OF THE, V1993; Chelbi-Alix MK, 1999, LEUKEMIA, V13, P1167, DOI 10.1038/sj.leu.2401469; Chen QY, 2002, IMMUNOLOGY, V107, P199, DOI 10.1046/j.1365-2567.2002.01485.x; Clarke N, 2004, EMBO J, V23, P3051, DOI 10.1038/sj.emboj.7600302; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Decicco KL, 2001, IMMUNOLOGY, V104, P341, DOI 10.1046/j.1365-2567.2001.01317.x; DeCicco KL, 2000, J INFECT DIS, V182, pS29, DOI 10.1086/315908; Garattini E, 1998, LEUKEMIA LYMPHOMA, V30, P467, DOI 10.3109/10428199809057559; Ghayur T, 1997, NATURE, V386, P619, DOI 10.1038/386619a0; Gianni M, 1997, BLOOD, V89, P1001, DOI 10.1182/blood.V89.3.1001; Hamamoto S, 2003, J LAB CLIN MED, V141, P58, DOI 10.1067/mlc.2003.8; Harada H, 1998, BIOCHIMIE, V80, P641, DOI 10.1016/S0300-9084(99)80017-0; HOWARD AD, 1991, J IMMUNOL, V147, P2964; Iwase S, 1999, FEBS LETT, V450, P263, DOI 10.1016/S0014-5793(99)00515-3; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; KIMURA T, 1994, SCIENCE, V264, P1921, DOI 10.1126/science.8009222; Kroger A, 2003, ONCOGENE, V22, P1045, DOI 10.1038/sj.onc.1206260; Magram J, 1996, IMMUNITY, V4, P471, DOI 10.1016/S1074-7613(00)80413-6; Maruvada P, 2003, J BIOL CHEM, V278, P12425, DOI 10.1074/jbc.M202752200; Matikainen S, 1996, BLOOD, V88, P114; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; Nakagawa K, 2000, EUR J BIOCHEM, V267, P1680, DOI 10.1046/j.1432-1327.2000.01163.x; Obora A, 2002, HEPATOLOGY, V36, P1115, DOI 10.1053/jhep.2002.36369; Pelicano L, 1997, ONCOGENE, V15, P2349, DOI 10.1038/sj.onc.1201410; Percario ZA, 1999, CELL GROWTH DIFFER, V10, P263; Pestka Sidney, 1997, Cytokine and Growth Factor Reviews, V8, P189, DOI 10.1016/S1359-6101(97)00009-9; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; Romeo G, 2002, J INTERF CYTOK RES, V22, P39, DOI 10.1089/107999002753452647; Ross AC, 1996, FASEB J, V10, P979, DOI 10.1096/fasebj.10.9.8801180; ROSS DA, 1993, LANCET, V342, P7, DOI 10.1016/0140-6736(93)91879-Q; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Semba RD, 1999, J NUTR, V129, P783, DOI 10.1093/jn/129.4.783; Sen GC, 2001, ANNU REV MICROBIOL, V55, P255, DOI 10.1146/annurev.micro.55.1.255; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; Sommer A, 1995, B WORLD HEALTH ORGAN, V73, P609; SOMMER A, 1984, AM J CLIN NUTR, V40, P1090, DOI 10.1093/ajcn/40.5.1090; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; vandenBroek MF, 1995, IMMUNOL REV, V148, P5; Villamor E, 2000, J INFECT DIS, V182, pS122, DOI 10.1086/315921; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wu J, 2003, J BIOCHEM MOL BIOL, V36, P354	45	22	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36228	36236		10.1074/jbc.M505749200	http://dx.doi.org/10.1074/jbc.M505749200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16085646	hybrid, Green Accepted			2022-12-25	WOS:000232726900055
J	Taniguchi, N; Matsuyama, S; Tokuda, H				Taniguchi, N; Matsuyama, S; Tokuda, H			Mechanisms underlying energy-independent transfer of lipoproteins from LolA to LolB, which have similar unclosed beta-barrel structures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI LIPOPROTEINS; OUTER-MEMBRANE LIPOPROTEIN; GRAM-NEGATIVE BACTERIA; CYTOPLASMIC MEMBRANE; MOLECULAR CHAPERONE; INNER MEMBRANE; LOCALIZATION; RELEASE; MUTANT; ACCUMULATION	The Lol system, comprising five Lol proteins, transfers lipoproteins from the inner to the outer membrane of Escherichia coli. Periplasmic LolA accepts lipoproteins from LolCDE in the inner membrane and immediately transfers them to LolB, a receptor anchored to the outer membrane. The unclosed beta-barrel structures of LolA and LolB are very similar to each other and form hydrophobic cavities for lipoproteins. The lipoprotein transfer between these similar structures is unidirectional and very efficient, but requires no energy input. To reveal the mechanisms underlying this lipoprotein transfer, Arg and Phe at positions 43 and 47, respectively, of LolA were systematically mutagenized. The two residues were previously found to affect abilities to accept and transfer lipoproteins. Substitution of Phe-47 with polar residues inhibited the ability to accept lipoproteins from the inner membrane. No derivatives caused periplasmic accumulation of lipoproteins. In contrast, many Arg-43 derivatives caused unusual periplasmic accumulation of lipoproteins to various extents. However, all derivatives, except one having Leu instead of Arg, supported the growth of cells. All Arg-43 derivatives retained the ability to accept lipoproteins from the inner membrane, whereas their abilities to transfer associated lipoproteins to LolB were variously reduced. Assessment of the intensity of the hydrophobic interaction between lipoproteins and Arg-43 derivatives revealed that the LolA-lipoprotein interaction should be weak, otherwise lipoprotein transfer to LolB is inhibited, causing accumulation of lipoproteins in the periplasm.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Rikkyo Univ, Dept Life Sci, Toshima Ku, Tokyo 1718501, Japan	University of Tokyo; Rikkyo University	Tokuda, H (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	htokuda@iam.u-tokyo.ac.jp						Brokx SJ, 2004, J BACTERIOL, V186, P3254, DOI 10.1128/JB.186.10.3254-3258.2004; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; Hara T, 2003, J BIOL CHEM, V278, P40408, DOI 10.1074/jbc.M307836200; HAYASHI S, 1990, J BIOENERG BIOMEMBR, V22, P451, DOI 10.1007/BF00763177; HIROTA Y, 1977, P NATL ACAD SCI USA, V74, P1417, DOI 10.1073/pnas.74.4.1417; HUSSAIN M, 1980, J BIOL CHEM, V255, P3707; Juncker AS, 2003, PROTEIN SCI, V12, P1652, DOI 10.1110/ps.0303703; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUYAMA S, 1993, EMBO J, V12, P265, DOI 10.1002/j.1460-2075.1993.tb05652.x; MATSUYAMA S, 1995, EMBO J, V14, P3365, DOI 10.1002/j.1460-2075.1995.tb07342.x; Matsuyama S, 1997, EMBO J, V16, P6947, DOI 10.1093/emboj/16.23.6947; Miyadai H, 2004, J BIOL CHEM, V279, P39807, DOI 10.1074/jbc.M406390200; Miyamoto A, 2002, FEBS LETT, V528, P193, DOI 10.1016/S0014-5793(02)03305-7; Miyamoto A, 2001, BIOCHEM BIOPH RES CO, V287, P1125, DOI 10.1006/bbrc.2001.5705; Narita S, 2002, J BACTERIOL, V184, P1417, DOI 10.1128/JB.184.5.1417-1422.2002; Osborn M J, 1974, Methods Enzymol, V31, P642; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; SANKARAN K, 1994, J BIOL CHEM, V269, P19701; Seydel A, 1999, MOL MICROBIOL, V34, P810, DOI 10.1046/j.1365-2958.1999.01647.x; Tajima T, 1998, FEBS LETT, V439, P51, DOI 10.1016/S0014-5793(98)01334-9; Takeda K, 2003, EMBO J, V22, P3199, DOI 10.1093/emboj/cdg324; Tanaka K, 2001, J BACTERIOL, V183, P6538, DOI 10.1128/JB.183.22.6538-6542.2001; Terada M, 2001, J BIOL CHEM, V276, P47690, DOI 10.1074/jbc.M109307200; Yakushi T, 2000, NAT CELL BIOL, V2, P212, DOI 10.1038/35008635; YAMAGUCHI K, 1988, CELL, V53, P423, DOI 10.1016/0092-8674(88)90162-6; Yokota N, 1999, J BIOL CHEM, V274, P30995, DOI 10.1074/jbc.274.43.30995	26	46	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34481	34488		10.1074/jbc.M507388200	http://dx.doi.org/10.1074/jbc.M507388200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16091355	hybrid			2022-12-25	WOS:000232403900015
J	Tauskela, JS; Brunette, E; O'Reilly, N; Mealing, G; Comas, T; Gendron, TF; Monette, R; Morley, P				Tauskela, JS; Brunette, E; O'Reilly, N; Mealing, G; Comas, T; Gendron, TF; Monette, R; Morley, P			An alternative Ca2+-dependent mechanism of neuroprotection by the metalloporphyrin class of superoxide dismutase mimetics	FASEB JOURNAL			English	Article						NMDA; ischemia; antioxidants; oxygen-glucose deprivation	CYTOCHROME-C RELEASE; PEROXYNITRITE DECOMPOSITION; CATALYTIC ANTIOXIDANTS; MITOCHONDRIAL DYSFUNCTION; OXIDATIVE STRESS; NITRIC-OXIDE; GLUTAMATE EXCITOTOXICITY; MANGANESE PORPHYRINS; HIPPOCAMPAL-NEURONS; IRON PORPHYRINS	This study challenges the conventional view that metalloporphyrins protect cultured cortical neurons in models of cerebral ischemia by acting as intracellular catalytic antioxidants [ superoxide dismutase ( SOD) mimetics]. High SOD- active Mn(III)porphyrins meso- substituted with N, N'- dimethylimidazolium or N- alkylpyridinium groups did not protect neurons against oxygen- glucose deprivation ( OGD), although lower SOD- active and - inactive para isomers protected against N- methyl- D- aspartate ( NMDA) exposure. Mn(III)meso- tetrakis( 4- benzoic acid) porphyrin ( Mn(III)TBAP), as well as SOD- inactive metalloTBAPs and other phenyl ring- or beta- substituted metalloporphyrins that contained redox- insensitive metals, protected cultures against OGD and NMDA neurotoxicity. Crucially, neuroprotective metalloporphyrins suppressed OGD- or NMDA- induced rises in intracellular Ca2+ concentration in the same general rank order as observed for neuroprotection. Results from paraquat toxicity, intracellular fluorescence quenching, electrophysiology, mitochondrial Ca2+, and spontaneous synaptic activity experiments suggest a model in which metalloporphyrins, acting at the plasma membrane, protect neurons against OGD by suppressing postsynaptic NMDA receptor- mediated Ca2+ rises, thereby indirectly preventing accumulation of neurotoxic mitochondrial Ca2+ levels. Though neuroprotective in a manner not originally intended, SOD- inactive metalloporphyrins may represent promising therapeutic agents in diseases such as cerebral ischemia, in which Ca2+ toxicity is implicated. Conventional syntheses aimed at improving the catalytic antioxidant capability and/ or intracellular access of metalloporphyrins may not yield improved efficacy in some disease models.	Natl Res Council Canada, Inst Biol Sci, Synapt Pathophysiol Grp, Ottawa, ON K1A 0R6, Canada	National Research Council Canada	Tauskela, JS (corresponding author), Natl Res Council Canada, Inst Biol Sci, Synapt Pathophysiol Grp, Montreal Rd Campus,Bldg M-54, Ottawa, ON K1A 0R6, Canada.	joe.tauskela@nrc-cnrc.gc.ca						Batainic-Haberle I, 2004, DALTON T, P1696, DOI 10.1039/b400818a; BATINCHABERLE I, 2005, INORG CHEM, V38, P4011; Batinic-Haberle I, 1998, J BIOL CHEM, V273, P24521, DOI 10.1074/jbc.273.38.24521; BatinicHaberle I, 1997, ARCH BIOCHEM BIOPHYS, V343, P225, DOI 10.1006/abbi.1997.0157; Bloodsworth A, 2000, FREE RADICAL BIO MED, V28, P1017, DOI 10.1016/S0891-5849(00)00194-5; Bossy-Wetzel E, 2004, NEURON, V41, P351, DOI 10.1016/S0896-6273(04)00015-7; Budd SL, 1996, J NEUROCHEM, V66, P403, DOI 10.1046/j.1471-4159.1996.66010403.x; Castilho RF, 1999, J NEUROCHEM, V72, P1394, DOI 10.1046/j.1471-4159.1999.721394.x; Crow JP, 2000, FREE RADICAL BIO MED, V28, P1487, DOI 10.1016/S0891-5849(00)00249-5; Crow JP, 1999, ARCH BIOCHEM BIOPHYS, V371, P41, DOI 10.1006/abbi.1999.1414; Day BJ, 2004, DRUG DISCOV TODAY, V9, P557, DOI 10.1016/S1359-6446(04)03139-3; Day BJ, 1995, J PHARMACOL EXP THER, V275, P1227; Day BJ, 1999, FREE RADICAL BIO MED, V26, P730, DOI 10.1016/S0891-5849(98)00261-5; Day BJ, 1997, ARCH BIOCHEM BIOPHYS, V347, P256, DOI 10.1006/abbi.1997.0341; FAULKNER KM, 1994, J BIOL CHEM, V269, P23471; Ferrer-Sueta G, 2003, J BIOL CHEM, V278, P27432, DOI 10.1074/jbc.M213302200; Galindo MF, 2003, BRIT J PHARMACOL, V139, P797, DOI 10.1038/sj.bjp.0705309; Gardner PR, 1996, ARCH BIOCHEM BIOPHYS, V325, P20, DOI 10.1006/abbi.1996.0003; Gauuan PJF, 2002, BIOORGAN MED CHEM, V10, P3013, DOI 10.1016/S0968-0896(02)00153-0; Grima G, 2001, EUR J NEUROSCI, V14, P1762, DOI 10.1046/j.0953-816x.2001.01799.x; Haghighi SS, 1996, NEUROL RES, V18, P509; Halliwell B, 1978, BIOCHEM SOC T, V6, P1342, DOI 10.1042/bst0061342; Hongpaisan J, 2004, J NEUROSCI, V24, P10878, DOI 10.1523/JNEUROSCI.3278-04.2004; Hurtado O, 2003, FASEB J, V17, P2082, DOI 10.1096/fj.02-1086fje; Ikeda J, 1996, J NEUROSCI RES, V43, P613; Jensen MP, 2002, INORG CHEM, V41, P4788, DOI 10.1021/ic011089s; Kachadourian R, 2004, BIOCHEM PHARMACOL, V67, P77, DOI 10.1016/j.bcp.2003.08.036; Kachadourian R, 2003, J INORG BIOCHEM, V95, P240, DOI 10.1016/S0162-0134(03)00135-1; Khodorov B, 2004, PROG BIOPHYS MOL BIO, V86, P279, DOI 10.1016/j.pbiomolbio.2003.10.002; Klann E, 1998, J NEUROPHYSIOL, V80, P452, DOI 10.1152/jn.1998.80.1.452; Konorev EA, 2002, FREE RADICAL BIO MED, V33, P988, DOI 10.1016/S0891-5849(02)00989-9; Li QY, 2001, J NEUROCHEM, V78, P746, DOI 10.1046/j.1471-4159.2001.00457.x; LIU DX, 1995, FREE RADICAL BIO MED, V18, P861, DOI 10.1016/0891-5849(94)00214-5; Luetjens CM, 2000, J NEUROSCI, V20, P5715; Mackensen GB, 2001, J NEUROSCI, V21, P4582, DOI 10.1523/JNEUROSCI.21-13-04582.2001; Mealing GAR, 2001, J PHARMACOL EXP THER, V297, P906; MURPHY TH, 1992, J NEUROSCI, V12, P4834; Muscoli C, 2003, BRIT J PHARMACOL, V140, P445, DOI 10.1038/sj.bjp.0705430; OGURA A, 1987, NEUROSCI LETT, V78, P69, DOI 10.1016/0304-3940(87)90563-5; Okado-Matsumoto A, 2004, FREE RADICAL BIO MED, V37, P401, DOI 10.1016/j.freeradbiomed.2004.04.040; Osakada F, 2004, J PHARMACOL EXP THER, V311, P51, DOI 10.1124/jpet.104.070334; PASTERNACK RF, 1981, J INORG BIOCHEM, V15, P261, DOI 10.1016/S0162-0134(00)80161-0; Patel M, 1996, NEURON, V16, P345, DOI 10.1016/S0896-6273(00)80052-5; Patel M, 1999, TRENDS PHARMACOL SCI, V20, P359, DOI 10.1016/S0165-6147(99)01336-X; PELLEGRINIGIAMPIETRO DE, 1990, J NEUROSCI, V10, P1035, DOI 10.1523/jneurosci.10-03-01035.1990; Pfeiffer S, 1998, MOL PHARMACOL, V53, P795, DOI 10.1124/mol.53.4.795; REYNOLDS IJ, 1995, J NEUROSCI, V15, P3318, DOI 10.1523/jneurosci.15-05-03318.1995; RICCHELLI F, 1995, J PHOTOCH PHOTOBIO B, V29, P109, DOI 10.1016/1011-1344(95)07155-U; Ross AD, 2002, FREE RADICAL BIO MED, V33, P1657, DOI 10.1016/S0891-5849(02)01140-1; Sharma SS, 2004, J NEUROSURG, V101, P669, DOI 10.3171/jns.2004.101.4.0669; Sheng HX, 2002, DRUG NEWS PERSPECT, V15, P654, DOI 10.1358/dnp.2002.15.10.740236; Sheng HX, 2002, FREE RADICAL BIO MED, V33, P947, DOI 10.1016/S0891-5849(02)00979-6; Spasojevic I, 2003, J BIOL CHEM, V278, P6831, DOI 10.1074/jbc.M211346200; STRICKLAND JA, 1988, BIOCHEMISTRY-US, V27, P8870, DOI 10.1021/bi00424a027; Tauskela JS, 2003, AM J PHYSIOL-CELL PH, V285, pC899, DOI 10.1152/ajpcell.00110.2003; Thiyagarajan M, 2004, BRIT J PHARMACOL, V142, P899, DOI 10.1038/sj.bjp.0705811; Trackey JL, 2001, J NEUROCHEM, V79, P445, DOI 10.1046/j.1471-4159.2001.00584.x; Trostchansky A, 2003, FREE RADICAL BIO MED, V35, P1293, DOI 10.1016/j.freeradbiomed.2003.07.004; Trova MP, 2003, BIOORGAN MED CHEM, V11, P2695, DOI 10.1016/S0968-0896(03)00272-4; TSIEN RY, 1981, NATURE, V290, P527, DOI 10.1038/290527a0; Urushitani M, 2001, J NEUROSCI RES, V63, P377, DOI 10.1002/1097-4547(20010301)63:5<377::AID-JNR1032>3.0.CO;2-#; Vergun O, 2001, J PHYSIOL-LONDON, V531, P147, DOI 10.1111/j.1469-7793.2001.0147j.x; Vesce S, 2004, J NEUROCHEM, V90, P683, DOI 10.1111/j.1471-4159.2004.02516.x; Vornov JJ, 1998, EXP NEUROL, V149, P109, DOI 10.1006/exnr.1997.6673; Warner DS, 2004, J EXP BIOL, V207, P3221, DOI 10.1242/jeb.01022; Zhang YM, 2004, J NEUROSCI, V24, P10616, DOI 10.1523/JNEUROSCI.2469-04.2004	66	28	31	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1734	+		10.1096/fj.05-3795fje	http://dx.doi.org/10.1096/fj.05-3795fje			36	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16081500				2022-12-25	WOS:000231843700020
J	Baker, EK; Johnstone, RW; Zalcberg, JR; El-Osta, A				Baker, EK; Johnstone, RW; Zalcberg, JR; El-Osta, A			Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs	ONCOGENE			English	Article						cancer; chemotherapy; multidrug resistance; epigenetic modifications; chromatin	ACUTE MYELOID-LEUKEMIA; P-GLYCOPROTEIN EXPRESSION; MESSENGER-RNA STABILIZATION; MULTIDRUG-RESISTANCE MDR1; GENE-EXPRESSION; HISTONE H3; PROMOTER REGION; ANTHRACYCLINE ANALOGS; DEOXYCYTIDINE KINASE; METHYLATION PATTERNS	The mechanism of action of chemotherapeutic drugs and their ability to induce multidrug resistance (MDR) are of relevance to cancer treatment. Overexpression of P-glycoprotein (Pgp) encoded by the MDR1 gene following chemotherapy can severely limit the efficacy of anticancer agents; however, the manner by which cells acquire high levels of Pgp has not been defined. Herein, we demonstrate that chemotherapeutic drugs induce specific epigenetic modifications at the MDR1 locus, concomitant with MDR1 upregulation mediated by transcriptional activation, and a potential post-transcriptional component. We have established that the mechanisms are not mutually exclusive and are dependent on the methylation state of the MDR1 promoter. MDR1 upregulation did not result in further changes to the CpG methylation profile. However, dramatic changes in the temporal and spatial patterning of histone modi. cations occurred within the 50 hypomethylated region of MDR1, directly correlating with MDR1 upregulation. Specifically, drug-induced upregulation of MDR1 was associated with increases in H3 acetylation and induction of methylated H3K4 within discrete regions of the MDR1 locus. Our results demonstrate that chemotherapeutic drugs can actively induce epigenetic changes within the MDR1 promoter, and enhance the MDR phenotype.	Baker Med Res Inst, Alfred Med Res & Educ Project, Epigenet Human Hlth & Dis Lab, Prahran, Vic 3181, Australia; Peter MacCallum Canc Ctr, Canc Immunol Program, Gene Regulat Lab, Melbourne 3002, Australia; Peter MacCallum Canc Ctr, Dept Med Oncol & Haematol, Melbourne 3002, Australia	Baker Heart and Diabetes Institute; Peter Maccallum Cancer Center; Peter Maccallum Cancer Center	El-Osta, A (corresponding author), Baker Med Res Inst, Alfred Med Res & Educ Project, Epigenet Human Hlth & Dis Lab, Commercial Rd, Prahran, Vic 3181, Australia.	assam.el-osta@baker.edu.au	Johnstone, Ricky w/H-3748-2014	Johnstone, Ricky w/0000-0001-7053-9237; El-Osta, Assam/0000-0003-2969-9137; Zalcberg, John/0000-0002-6624-0782; El-Osta, Assam/0000-0001-7968-7375				Abolhoda A, 1999, CLIN CANCER RES, V5, P3352; Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499; Boggs BA, 2002, NAT GENET, V30, P73, DOI 10.1038/ng787; CAMPOS L, 1992, BLOOD, V79, P473; CHAUDHARY PM, 1993, J NATL CANCER I, V85, P632, DOI 10.1093/jnci/85.8.632; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Christenson LK, 2001, J BIOL CHEM, V276, P27392, DOI 10.1074/jbc.M101650200; El-Osta A, 2001, MOL BIOL REP, V28, P209, DOI 10.1023/A:1015744625049; El-Osta A, 2002, MOL CELL BIOL, V22, P1844, DOI 10.1128/MCB.22.6.1844-1857.2002; FERGUSON PJ, 1988, CANCER RES, V48, P5956; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Garcia-Manero G, 2002, CLIN CANCER RES, V8, P2217; GOLDIE JH, 1984, CANCER RES, V44, P3643; Harikrishnan KN, 2005, NAT GENET, V37, P254, DOI 10.1038/ng1516; Hu XF, 1999, BLOOD, V93, P4086, DOI 10.1182/blood.V93.12.4086.412k43_4086_4095; HU XF, 1995, BRIT J CANCER, V71, P931, DOI 10.1038/bjc.1995.180; Hu XF, 1999, BRIT J CANCER, V79, P831, DOI 10.1038/sj.bjc.6690133; Iervolino A, 2002, FASEB J, V16, P1453, DOI 10.1096/fj.02-0122fje; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kantharidis P, 1997, CLIN CANCER RES, V3, P2025; Kinkel MD, 2003, J CELL BIOCHEM, V88, P941, DOI 10.1002/jcb.10442; Kusaba H, 1999, EUR J BIOCHEM, V262, P924, DOI 10.1046/j.1432-1327.1999.00469.x; KUWAZURU Y, 1990, CANCER, V66, P868, DOI 10.1002/1097-0142(19900901)66:5<868::AID-CNCR2820660510>3.0.CO;2-Z; Leegwater PAJ, 1998, CANCER LETT, V130, P169, DOI 10.1016/S0304-3835(98)00131-1; Leith CP, 1997, BLOOD, V89, P3323; Li JW, 2002, MOL CELL BIOL, V22, P5688, DOI 10.1128/MCB.22.16.5688-5697.2002; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; Mansson E, 2002, LEUKEMIA, V16, P386, DOI 10.1038/sj.leu.2402388; MARIE JP, 1991, BLOOD, V78, P586; Nakayama M, 1998, BLOOD, V92, P4296, DOI 10.1182/blood.V92.11.4296.423k25_4296_4307; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; Parekh BS, 1999, MOL CELL, V3, P125, DOI 10.1016/S1097-2765(00)80181-1; PIRKER R, 1991, J NATL CANCER I, V83, P708, DOI 10.1093/jnci/83.10.708; Radosevic N, 2001, LEUKEMIA, V15, P559, DOI 10.1038/sj.leu.2402092; Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Schneider R, 2004, NAT CELL BIOL, V6, P73, DOI 10.1038/ncb1076; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strahl BD, 1999, P NATL ACAD SCI USA, V96, P14967, DOI 10.1073/pnas.96.26.14967; Tada Y, 2000, CLIN CANCER RES, V6, P4618; TEBOEKHORST PAW, 1993, BLOOD, V82, P3157; Toyota M, 2001, BLOOD, V97, P2823, DOI 10.1182/blood.V97.9.2823; van den Heuvel-Eibrink MM, 2002, LEUKEMIA, V16, P833, DOI 10.1038/sj.leu.2402496; vandenHeuvelEibrink MM, 1997, BRIT J HAEMATOL, V99, P76, DOI 10.1046/j.1365-2141.1997.3343148.x; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; WONG H, 1994, ANAL BIOCHEM, V223, P251, DOI 10.1006/abio.1994.1581; WOOD P, 1994, BRIT J HAEMATOL, V87, P509, DOI 10.1111/j.1365-2141.1994.tb08305.x; Yague E, 2003, J BIOL CHEM, V278, P10344, DOI 10.1074/jbc.M211093200; ZHOU DC, 1992, LEUKEMIA, V6, P879; ZOCHBAUER S, 1994, LEUKEMIA, V8, P974	52	159	176	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2005	24	54					8061	8075		10.1038/sj.onc.1208955	http://dx.doi.org/10.1038/sj.onc.1208955			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	989EV	16091741				2022-12-25	WOS:000233656600012
J	Xiao, H; Goodrich, DW				Xiao, H; Goodrich, DW			The retinoblastoma tumor suppressor protein is required for efficient processing and repair of trapped topoisomerase II-DNA-cleavable complexes	ONCOGENE			English	Article						retinoblastoma tumor suppressor gene; topoisomerase II; etoposide; DNA damage; DNA repair	DOUBLE-STRAND BREAKS; E2F TARGET GENES; DAMAGE RESPONSE; LIGASE ACTIVITY; RB PROTEIN; FAMILIAL RETINOBLASTOMA; INCOMPLETE PENETRANCE; GENOMIC INSTABILITY; BRCA1; BETA	Type II topoisomerases (TOP2) introduce transient double-stranded DNA breaks through a covalent TOP2 DNA intermediate. Anticancer agents like etoposide kill cells by trapping covalent TOP2-DNA cleavable complexes. Pathways influencing the repair of cleavable complexes are expected to be major determinants of therapeutic response to etoposide. Rb1 is required to enforce cell cycle checkpoints in response to DNA damage, but evidence for a direct role in the processing and repair of DNA lesions is lacking. We observe that degradation of trapped TOP2-cleavable complexes, liberation of DNA strand breaks, and repair of those breaks occurs more efficiently in cells expressing Rb1 protein (pRb). Cells lacking pRb are more sensitive to etoposide-induced cytotoxicity. Rb1-mediated processing and repair of TOP2-cleavable complexes is genetically separable from its ability to bind E2F and enforce DNA damage-induced cell cycle checkpoints. Rb1 protein binds both TOP2 and BRCA1 in intact cells, and pRb is required for association between TOP2 and BRCA1. These results suggest that pRb facilitates processing and repair of TOP2-cleavable complexes by recruiting proteins like BRCA1 to the damaged site. The functional status of pRb, therefore, may influence sensitivity to etoposide by facilitating the repair of trapped TOP2-DNA complexes as well as by enforcing cell cycle checkpoints.	Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Goodrich, DW (corresponding author), Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Elm & Carlton St, Buffalo, NY 14263 USA.	david.goodrich@roswellpark.org			NCI NIH HHS [R01 CA070292, R01 CA070292-07, CA70292] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070292] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi N, 2003, J BIOL CHEM, V278, P35897, DOI 10.1074/jbc.M306500200; Adachi N, 2004, BIOCHEM BIOPH RES CO, V318, P856, DOI 10.1016/j.bbrc.2004.04.099; Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; Bhat UG, 1999, P NATL ACAD SCI USA, V96, P7859, DOI 10.1073/pnas.96.14.7859; Bosco EE, 2004, NUCLEIC ACIDS RES, V32, P25, DOI 10.1093/nar/gkg919; Bracken AP, 2004, TRENDS BIOCHEM SCI, V29, P409, DOI 10.1016/j.tibs.2004.06.006; Brugarolas J, 1999, P NATL ACAD SCI USA, V96, P1002, DOI 10.1073/pnas.96.3.1002; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; Cortes F, 2003, MUTAT RES-REV MUTAT, V543, P59, DOI 10.1016/S1383-5742(02)00070-4; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Doostzadeh-Cizeron J, 1999, MOL BIOL CELL, V10, P3251, DOI 10.1091/mbc.10.10.3251; Fan SJ, 2001, ONCOGENE, V20, P4827, DOI 10.1038/sj.onc.1204666; GOVONI M, 1995, BIOCHEM BIOPH RES CO, V213, P282, DOI 10.1006/bbrc.1995.2127; Harbour JW, 2001, ARCH OPHTHALMOL-CHIC, V119, P1699; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Harrington EA, 1998, P NATL ACAD SCI USA, V95, P11945, DOI 10.1073/pnas.95.20.11945; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jasin M, 2002, ONCOGENE, V21, P8981, DOI 10.1038/sj.onc.1206176; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; Lee EY, 2002, CANCER CELL, V2, P463, DOI 10.1016/S1535-6108(02)00207-6; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; Mao Y, 2001, J BIOL CHEM, V276, P40652, DOI 10.1074/jbc.M104009200; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; Motoyama N, 2004, CURR OPIN GENET DEV, V14, P11, DOI 10.1016/j.gde.2003.12.003; Naderi S, 2002, CELL CYCLE, V1, P193, DOI 10.4161/cc.1.3.125; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Niimi A, 2001, CHROMOSOMA, V110, P102, DOI 10.1007/s004120100140; Otterson GA, 1997, P NATL ACAD SCI USA, V94, P12036, DOI 10.1073/pnas.94.22.12036; Otterson GA, 1999, AM J HUM GENET, V65, P1040, DOI 10.1086/302581; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Stevens C, 2004, DNA REPAIR, V3, P1071, DOI 10.1016/j.dnarep.2004.03.034; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Tsutsui K, 2001, J BIOL CHEM, V276, P5769, DOI 10.1074/jbc.M008517200; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Whitaker LL, 1998, MOL CELL BIOL, V18, P4032, DOI 10.1128/MCB.18.7.4032; WOESSNER RD, 1991, CELL GROWTH DIFFER, V2, P209; Xia Y, 2003, J BIOL CHEM, V278, P5255, DOI 10.1074/jbc.M204591200; Xiao H, 2003, P NATL ACAD SCI USA, V100, P3239, DOI 10.1073/pnas.0736401100; Yamamoto Y, 1998, ONCOL REP, V5, P447; Yang X, 2000, SCIENCE, V287, P131, DOI 10.1126/science.287.5450.131; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Zhong Q, 2002, J BIOL CHEM, V277, P28641, DOI 10.1074/jbc.M200748200; Zhong Q, 2002, CANCER RES, V62, P3966; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	51	25	25	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2005	24	55					8105	8113		10.1038/sj.onc.1208958	http://dx.doi.org/10.1038/sj.onc.1208958			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	991JL	16091739	Green Accepted			2022-12-25	WOS:000233809400003
J	Stahelin, RV; Wang, JY; Blatner, NR; Raftner, JD; Murray, D; Cho, WH				Stahelin, RV; Wang, JY; Blatner, NR; Raftner, JD; Murray, D; Cho, WH			The origin of C1A-C2 interdomain interactions in protein kinase C alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; CYSTEINE-RICH DOMAIN; MEMBRANE-BINDING; ACTIVATION MECHANISMS; PHORBOL ESTER; PKC-ALPHA; MACROMOLECULAR INTERACTIONS; DIFFERENTIAL ROLES; MOLECULAR-BASIS; DIACYLGLYCEROL	The regulatory domain of protein kinase C alpha (PKC alpha) contains three membrane-targeting modules, two C1 domains (C1A and C1B) that bind diacylglycerol and phorbol ester, and the C2 domain that is responsible for the Ca2+-dependent membrane binding. Accumulating evidence suggests that C1A and C2 domains of PKC alpha are tethered in the resting state and that the tethering is released upon binding to the membrane containing phosphatidylserine. The homology modeling and the docking analysis of C1A and C2 domains of PKC alpha revealed a highly complementary interface that comprises Asp(55) - Arg(252) and Arg(42) - Glu(282) ion pairs and a Phe(72) Phe(255) aromatic pair. Mutations of these residues in the predicted C1A-C2 interface showed large effects on in vitro membrane binding, enzyme activity, phosphatidylserine selectivity, and cellular membrane translocation of PKC alpha, supporting their involvement in interdomain interactions. In particular, D55A ( or D55K) and R252A ( or R252E) mutants showed much higher basal membrane affinity and enzyme activity and faster subcellular translocation than wild type, whereas a double charge-reversal mutant (D55K/ R252E) behaved analogously to wild type, indicating that a direct electrostatic interaction between the two residues is essential for the C1A-C2 tethering. Collectively, these studies provide new structural insight into PKC alpha C1A- C2 interdomain interactions and the mechanism of lipid-mediated PKC alpha activation.	Univ Illinois, Dept Chem, Chicago, IL 60607 USA; Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Cornell University	Cho, WH (corresponding author), Univ Illinois, Dept Chem MC 111, 845 W Taylor St, Chicago, IL 60607 USA.	wcho@uic.edu	Stahelin, Robert/L-3567-2019		NIGMS NIH HHS [GM66147, GM53987] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053987, R01GM066147] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ananthanarayanan B, 2003, J BIOL CHEM, V278, P46886, DOI 10.1074/jbc.M307853200; Ananthanarayanan B, 2002, J BIOL CHEM, V277, P3568, DOI 10.1074/jbc.M109705200; BAZZI MD, 1988, BIOCHEMISTRY-US, V27, P6776, DOI 10.1021/bi00418a020; BERS DM, 1982, AM J PHYSIOL, V242, P404; Bittova L, 2001, J BIOL CHEM, V276, P4218, DOI 10.1074/jbc.M008491200; BLUME A, 1979, BIOCHIM BIOPHYS ACTA, V557, P32, DOI 10.1016/0005-2736(79)90087-7; Brose N, 2002, J CELL SCI, V115, P4399, DOI 10.1242/jcs.00122; Canagarajah B, 2004, CELL, V119, P407, DOI 10.1016/j.cell.2004.10.012; Cho W, 2001, J BIOL CHEM, V276, P32407, DOI 10.1074/jbc.R100007200; Cho WW, 2001, ANAL BIOCHEM, V296, P153, DOI 10.1006/abio.2001.5225; CHOW W, 2005, ANNU REV BIOPH BIOM, V34, P119; Conesa-Zamora P, 2000, BBA-MOL CELL BIOL L, V1487, P246, DOI 10.1016/S1388-1981(00)00099-8; Conesa-Zamora P, 2001, BIOCHEMISTRY-US, V40, P13898, DOI 10.1021/bi011303o; DEMEL RA, 1975, BIOCHIM BIOPHYS ACTA, V406, P97, DOI 10.1016/0005-2736(75)90045-0; Eswar N, 2003, NUCLEIC ACIDS RES, V31, P3375, DOI 10.1093/nar/gkg543; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOMMEL U, 1994, NAT STRUCT BIOL, V1, P383, DOI 10.1038/nsb0694-383; Irie K, 1998, J AM CHEM SOC, V120, P9159, DOI 10.1021/ja981087f; Johnson JE, 2000, BIOCHEMISTRY-US, V39, P11360, DOI 10.1021/bi000902c; Kates M., 1986, TECHNIQUES LIPIDOLOG, P114; Kohout SC, 2002, BIOCHEMISTRY-US, V41, P11411, DOI 10.1021/bi026041k; KUNTZ ID, 1992, SCIENCE, V257, P1078, DOI 10.1126/science.257.5073.1078; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; Marsh D, 1996, BBA-REV BIOMEMBRANES, V1286, P183, DOI 10.1016/S0304-4157(96)00009-3; Medkova M, 1999, J BIOL CHEM, V274, P19852, DOI 10.1074/jbc.274.28.19852; Medkova M, 1998, J BIOL CHEM, V273, P17544, DOI 10.1074/jbc.273.28.17544; Medkova M, 1998, BIOCHEMISTRY-US, V37, P4892, DOI 10.1021/bi972495j; Mott HR, 1996, P NATL ACAD SCI USA, V93, P8312, DOI 10.1073/pnas.93.16.8312; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Nalefski EA, 2001, BIOCHEMISTRY-US, V40, P13216, DOI 10.1021/bi010761u; NEWTON AC, 1994, BIOCHEMISTRY-US, V33, P6651, DOI 10.1021/bi00187a035; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Ochoa WF, 2002, J MOL BIOL, V320, P277, DOI 10.1016/S0022-2836(02)00464-3; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4667, DOI 10.1021/bi00134a019; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Petrey D, 2003, PROTEINS, V53, P430, DOI 10.1002/prot.10550; Raghunath A, 2003, BIOCHEM J, V370, P901, DOI 10.1042/BJ20021420; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; Rodriguez-Alfaro JA, 2004, J MOL BIOL, V335, P1117, DOI 10.1016/j.jmb.2003.10.080; Russell RB, 2004, CURR OPIN STRUC BIOL, V14, P313, DOI 10.1016/j.sbi.2004.04.006; Schneidman-Duhovny D, 2004, CURR MED CHEM, V11, P91, DOI 10.2174/0929867043456223; Shen N, 2005, BIOCHEMISTRY-US, V44, P1089, DOI 10.1021/bi0476127; Shirai Y, 2002, J BIOCHEM, V132, P663, DOI 10.1093/oxfordjournals.jbchem.a003271; Slater SJ, 2002, J BIOL CHEM, V277, P15277, DOI 10.1074/jbc.M112207200; Slater SJ, 1999, BIOCHEMISTRY-US, V38, P3804, DOI 10.1021/bi982778r; SOUVIGNET C, 1991, J BIOL CHEM, V266, P40; Stahelin RV, 2005, J BIOL CHEM, V280, P19784, DOI 10.1074/jbc.M411285200; Stahelin RV, 2004, J BIOL CHEM, V279, P29501, DOI 10.1074/jbc.M403191200; Stahelin RV, 2003, J BIOL CHEM, V278, P14469, DOI 10.1074/jbc.M212579200; Stahelin RV, 2003, J BIOL CHEM, V278, P12452, DOI 10.1074/jbc.M212864200; Stahelin RV, 2001, BIOCHEMISTRY-US, V40, P4672, DOI 10.1021/bi0020325; Tovchigrechko A, 2002, PROTEIN SCI, V11, P1888, DOI 10.1110/ps.4730102; Vakser IA, 1999, P NATL ACAD SCI USA, V96, P8477, DOI 10.1073/pnas.96.15.8477; Vakser IA, 1997, PROTEINS, P226; Vakser IA, 2002, METHOD ENZYMOL, V343, P313; Verdaguer N, 1999, EMBO J, V18, P6329, DOI 10.1093/emboj/18.22.6329; VERGER R, 1982, CHEM PHYS LIPIDS, V30, P189, DOI 10.1016/0009-3084(82)90052-4; Xu RX, 1997, BIOCHEMISTRY-US, V36, P10709, DOI 10.1021/bi970833a; Yang CF, 2003, TRENDS PHARMACOL SCI, V24, P602, DOI 10.1016/j.tips.2003.09.003; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X; Zhou M, 2002, J MOL BIOL, V315, P435, DOI 10.1006/jmbi.2001.5263	66	44	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36452	36463		10.1074/jbc.M506224200	http://dx.doi.org/10.1074/jbc.M506224200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16079140	hybrid			2022-12-25	WOS:000232726900079
J	Al-Khouri, AM; Ma, YL; Togo, SH; Williams, S; Mustelin, T				Al-Khouri, AM; Ma, YL; Togo, SH; Williams, S; Mustelin, T			Cooperative phosphorylation of the tumor suppressor phosphatase and tensin homologue (PTEN) by casein kinases and glycogen synthase kinase 3 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; CELL-SURVIVAL; GENE; STABILITY; BINDING; IDENTIFICATION; SITES; AKT	The phosphatase and tensin homologue (PTEN) tumor suppressor is a phosphatidylinositol D3-phosphatase that counteracts the effects of phosphatidylinositol 3-kinase and negatively regulates cell growth and survival. PTEN is itself regulated by phosphorylation on multiple serine and threonine residues in its C terminus. Previous work has implicated casein kinase 2 (CK2) as the kinase responsible for this phosphorylation. Here we showed that CK2 does not phosphorylate all sites in PTEN and that glycogen synthase kinase 3 beta (GSK3 beta) also participates in PTEN phosphorylation. Although CK2 mainly phosphorylated PTEN at Ser-370 and Ser-385, GSK3 beta phosphorylated Ser-362 and Thr-366. More importantly, prior phosphorylation of PTEN at Ser-370 by CK2 strongly increased its phosphorylation at Thr-366 by GSK3 beta, suggesting that the two may synergize. Using RNA interference, we showed that GSK3 phosphorylates PTEN in intact cells. Finally, PTEN phosphorylation was affected by insulin-like growth factor in intact cells. We concluded that multiple kinases, including CK2 and GSK3 beta, participate in PTEN phosphorylation and that GSK3 beta may provide feedback regulation of PTEN.	Burnham Inst, Inflammatory & Infect Dis Ctr, Program Inflammat, La Jolla, CA 92037 USA; Burnham Inst, Program Signal Transduct, Ctr Canc, La Jolla, CA 92037 USA; Burnham Inst, Prote Facil, Ctr Canc, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute; Sanford Burnham Prebys Medical Discovery Institute; Sanford Burnham Prebys Medical Discovery Institute	Mustelin, T (corresponding author), Burnham Inst, Inflammatory & Infect Dis Ctr, Program Inflammat, N Torrey Pines Rd, La Jolla, CA 92037 USA.	tmustelin@burnham-inst.org		Mustelin, Tomas/0000-0001-5912-8840	NCI NIH HHS [CA96949] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA096949] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alonso A, 2003, NAT IMMUNOL, V4, P44, DOI 10.1038/ni856; Bijur GN, 2001, J BIOL CHEM, V276, P37436, DOI 10.1074/jbc.M105725200; Birle D, 2002, J IMMUNOL, V169, P286, DOI 10.4049/jimmunol.169.1.286; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Das S, 2003, P NATL ACAD SCI USA, V100, P7491, DOI 10.1073/pnas.0932835100; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Gronbaek K, 1998, BLOOD, V91, P4388; Huynh H, 2004, NAT CELL BIOL, V6, P831, DOI 10.1038/ncb1164; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; LUO K, 1990, ONCOGENE, V5, P921; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Miller SJ, 2002, FEBS LETT, V528, P145, DOI 10.1016/S0014-5793(02)03274-X; Okumura K, 2005, P NATL ACAD SCI USA, V102, P2703, DOI 10.1073/pnas.0409370102; Sakai A, 1998, BLOOD, V92, P3410, DOI 10.1182/blood.V92.9.3410.421a06_3410_3415; Saxena M, 1999, NAT CELL BIOL, V1, P305, DOI 10.1038/13024; SPEAKS SL, 1992, GENE CHROMOSOME CANC, V5, P239, DOI 10.1002/gcc.2870050311; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; TAKEUCHI S, 1995, CANCER RES, V55, P5377; Teng DHF, 1997, CANCER RES, V57, P5221; Tolkacheva T, 2001, CANCER RES, V61, P4985; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Valiente M, 2005, J BIOL CHEM, V280, P28936, DOI 10.1074/jbc.M504761200; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Vazquez F, 2001, J BIOL CHEM, V276, P48627, DOI 10.1074/jbc.C100556200; Wang XD, 2000, J IMMUNOL, V164, P1934, DOI 10.4049/jimmunol.164.4.1934	29	184	198	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35195	35202		10.1074/jbc.M503045200	http://dx.doi.org/10.1074/jbc.M503045200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16107342	hybrid			2022-12-25	WOS:000232561200016
J	Rahmani, M; Davis, EM; Bauer, C; Dent, P; Grant, S				Rahmani, M; Davis, EM; Bauer, C; Dent, P; Grant, S			Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; INITIATION-FACTOR 4E; MULTIPLE-MYELOMA CELLS; BCL-2 FAMILY; HEMATOPOIETIC-CELLS; TRANSCRIPTION FACTOR; RAF/MEK/ERK PATHWAY; MEDIATED APOPTOSIS; IMATINIB MESYLATE; SIGNALING PATHWAY	BAY 43-9006 is a kinase inhibitor that induces apoptosis in a variety of tumor cells. Here we report that treatment with BAY 43-9006 results in marked cytochrome c and AIF release into the cytosol, caspase-9, -8, -7, and -3 activation, and apoptosis in human leukemia cells (U937, Jurkat, and K562). Pronounced apoptosis was also observed in blasts from patients with acute myeloid leukemia. These events were accompanied by ERK1/2 inactivation and caspase-independent down-regulation of Mcl-1. Inducible expression of a constitutively active MEK1 construct did not prevent Mcl-1 down-regulation, suggesting that this event is not related to MEK/ERK pathway inactivation. Furthermore, BAY 43-9006 did not induce major changes in Mcl-1 mRNA levels monitored by real-time PCR or Mcl-1 promoter activity demonstrated by luciferase reporter assays, but it did enhance Mcl-1 down-regulation in actinomycin D-treated cells. Inhibition of protein synthesis by cycloheximide or proteasome function with MG132 and pulse-chase studies with [S-35]methionine demonstrated that BAY 43-9006 did not diminish Mcl-1 protein stability, nor did it enhance Mcl-1 ubiquitination, but instead markedly attenuated Mcl-1 translation in association with the rapid and potent dephosphorylation of the eIF4E translation initiation factor. Finally, ectopic expression of Mcl-1 in leukemic cells markedly inhibited BAY 43-9006-mediated cytochrome c cytosolic release, caspase-9, -7, and -3 activation, as well as cell death, indicating that Mcl-1 operates upstream of cytochrome c release and caspase activation. Together, these findings demonstrate that BAY 43-9006 mediates cell death in human leukemia cells, at least in part, through down-regulation of Mcl-1 via inhibition of translation.	Virginia Commonwealth Univ, Div Hematol Oncol, Sch Med, Dept Med, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Sch Med, Dept Biochem, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Sch Med, Dept Pharmacol, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University	Grant, S (corresponding author), Virginia Commonwealth Univ, Div Hematol Oncol, Sch Med, Dept Med, MCV Stn Box 230, Richmond, VA 23298 USA.	stgrant@hsc.vcu.edu		Rahmani, Mohamed/0000-0002-3992-8039	NCI NIH HHS [CA-100866, CA-63753, CA-88906, CA-93738] Funding Source: Medline; NIDDK NIH HHS [DK52825] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063753, R01CA093738, R01CA088906, R01CA100866] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052825] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmad T, 2004, CLIN CANCER RES, V10, p6388S, DOI 10.1158/1078-0432.CCR-040028; Aichberger KJ, 2005, BLOOD, V105, P3303, DOI 10.1182/blood-2004-02-0749; Alvi AJ, 2005, BLOOD, V105, P4484, DOI 10.1182/blood-2004-07-2713; Blalock WL, 2000, ONCOGENE, V19, P526, DOI 10.1038/sj.onc.1203337; Chang F, 2003, LEUKEMIA, V17, P1263, DOI 10.1038/sj.leu.2402945; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chao JR, 1998, MOL CELL BIOL, V18, P4883, DOI 10.1128/MCB.18.8.4883; Chao SH, 2000, J BIOL CHEM, V275, P28345, DOI 10.1074/jbc.C000446200; Cohen J, 2003, J NATL CANCER I, V95, P625, DOI 10.1093/jnci/95.8.625; Croxton R, 2002, ONCOGENE, V21, P1359, DOI 10.1038/sj.onc.1205157; Croxton R, 2002, ONCOGENE, V21, P1563, DOI 10.1038/sj.onc.1205232; Dai Y, 2004, J BIOL CHEM, V279, P34227, DOI 10.1074/jbc.M402290200; Dai Y, 2003, ONCOGENE, V22, P7108, DOI 10.1038/sj.onc.1206863; Dai Y, 2001, CANCER RES, V61, P5106; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; De Benedetti A, 1999, INT J BIOCHEM CELL B, V31, P59, DOI 10.1016/S1357-2725(98)00132-0; Derenne S, 2002, BLOOD, V100, P194, DOI 10.1182/blood.V100.1.194; Derouet M, 2004, J BIOL CHEM, V279, P26915, DOI 10.1074/jbc.M313875200; Gojo I, 2002, CLIN CANCER RES, V8, P3527; Graff JR, 2003, CLIN EXP METASTAS, V20, P265, DOI 10.1023/A:1022943419011; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Han J, 2004, J BIOL CHEM, V279, P22020, DOI 10.1074/jbc.M313234200; Hirasawa K, 2003, J VIROL, V77, P5649, DOI 10.1128/JVI.77.10.5649-5656.2003; Hoyle PE, 2000, LEUKEMIA, V14, P642, DOI 10.1038/sj.leu.2401720; Huang HM, 2000, BLOOD, V96, P1764, DOI 10.1182/blood.V96.5.1764.h8001764_1764_1771; Iglesias-Serret D, 2003, ARCH BIOCHEM BIOPHYS, V417, P141, DOI 10.1016/S0003-9861(03)00345-X; Kang CD, 2000, LEUKEMIA RES, V24, P527, DOI 10.1016/S0145-2126(00)00010-2; Karasarides M, 2004, ONCOGENE, V23, P6292, DOI 10.1038/sj.onc.1207785; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; Knauf U, 2001, MOL CELL BIOL, V21, P5500, DOI 10.1128/MCB.21.16.5500-5511.2001; Kramer BW, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-24; Le Gouill S, 2004, BLOOD, V104, P2886, DOI 10.1182/blood-2004-05-1760; Leu CM, 2000, ONCOGENE, V19, P1665, DOI 10.1038/sj.onc.1203452; Martin KA, 2002, ADV CANCER RES, V86, P1, DOI 10.1016/S0065-230X(02)86001-8; Moulding DA, 2000, BLOOD, V96, P1756, DOI 10.1182/blood.V96.5.1756.h8001756_1756_1763; Moulding DA, 2001, J LEUKOCYTE BIOL, V70, P783; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; OKUDA K, 1994, EXP HEMATOL, V22, P1111; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Opferman JT, 2005, SCIENCE, V307, P1101, DOI 10.1126/science.1106114; Orlowski RZ, 2002, J BIOL CHEM, V277, P27864, DOI 10.1074/jbc.M201519200; Othumpangat S, 2005, J BIOL CHEM, V280, P25162, DOI 10.1074/jbc.M414303200; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Poruchynsky MS, 2001, BIOCHEM PHARMACOL, V62, P1469, DOI 10.1016/S0006-2952(01)00804-8; Proud CG, 2005, CELL DEATH DIFFER, V12, P541, DOI 10.1038/sj.cdd.4401588; Rahmani M, 2005, MOL PHARMACOL, V67, P1166, DOI 10.1124/mol.104.007831; Rahmani M, 2003, ONCOGENE, V22, P6231, DOI 10.1038/sj.onc.1206646; Rahmani M, 2002, EXP CELL RES, V277, P31, DOI 10.1006/excr.2002.5548; Rahmani M, 2005, CANCER RES, V65, P2422, DOI 10.1158/0008-5472.CAN-04-2440; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Richter JD, 2005, NATURE, V433, P477, DOI 10.1038/nature03205; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Selzer E, 2002, MOL MED, V8, P877, DOI 10.1007/BF03402094; Sharma A, 2005, CANCER RES, V65, P2412, DOI 10.1158/0008-5472.CAN-04-2423; Singer G, 2003, J NATL CANCER I, V95, P484, DOI 10.1093/jnci/95.6.484; Sridhar SS, 2005, MOL CANCER THER, V4, P677, DOI 10.1158/1535-7163.MCT-04-0297; Strumberg D, 2005, ONKOLOGIE, V28, P101, DOI 10.1159/000083373; Ueda T, 2004, MOL CELL BIOL, V24, P6539, DOI 10.1128/MCB.24.15.6539-6549.2004; Wang JM, 2003, MOL CELL BIOL, V23, P1896, DOI 10.1128/MCB.23.6.1896-1909.2003; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Wang XM, 2001, EMBO J, V20, P4370, DOI 10.1093/emboj/20.16.4370; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Weng CJ, 2005, J BIOL CHEM, V280, P10491, DOI 10.1074/jbc.M412819200; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Wu JH, 2004, CANCER RES, V64, P6461, DOI 10.1158/0008-5472.CAN-04-0866; Xu Z, 2000, MOL CELL BIOL, V20, P5285, DOI 10.1128/MCB.20.14.5285-5299.2000; Yu CR, 2002, CANCER RES, V62, P188; Zhang B, 2002, BLOOD, V99, P1885, DOI 10.1182/blood.V99.6.1885; Zhou P, 1997, BLOOD, V89, P630, DOI 10.1182/blood.V89.2.630; Zhou P, 1998, BLOOD, V92, P3226, DOI 10.1182/blood.V92.9.3226.421k49_3226_3239	70	256	265	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35217	35227		10.1074/jbc.M506551200	http://dx.doi.org/10.1074/jbc.M506551200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16109713	hybrid			2022-12-25	WOS:000232561200019
J	Fan, B; Wu, TD; Li, W; Kirchhofer, D				Fan, B; Wu, TD; Li, W; Kirchhofer, D			Identification of hepatocyte growth factor activator inhibitor-1B as a potential physiological inhibitor of prostasin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-PROTEASE INHIBITOR; CELLULAR-LOCALIZATION; FACTOR/SCATTER FACTOR; KUNITZ DOMAINS; OVARIAN-CANCER; TYPE-1 HAI-1; EXPRESSION; MATRIPTASE; CELLS; PURIFICATION	Prostasin is a trypsin-like serine protease that is glycosylphosphatidyl-inositol-anchored to the epithelial cell surface, from where it can be released in a soluble form. We undertook a co-expression search using the Genesis Enterprise System Database from Gene Logic to identify prostasin inhibitors, on the assumption that prostasin and its natural inhibitors may have a similar gene expression pattern. We found the expression profile of prostasin in normal human tissues to correlate highly with hepatocyte growth factor activator inhibitor-1B (HAI-1B) and its splice variant HAI-1. Soluble HAI-1B (sHAI-1B), comprising the entire extracellular domain, formed a 1: 1 complex with purified prostasin in protein binding assays and inhibited prostasin enzymatic activity with an IC50 of 66 +/- 15 nM. Two sHAI-1B mutants with inactivated N- and C-terminal Kunitz domains ( KD1 and KD2) were used to show that the interaction of sHAI-1B with prostasin is mediated by KD1. In agreement, KD1 (Thr(246)- Val(303)) alone potently inhibited prostasin activity (IC50 = 4.7 +/- 0.5 nM). Furthermore, prostasin was isolated with two major HAI-1/1B fragments (40 and 58 kDa) from OVCAR3 cell medium, demonstrating that prostasin center dot HAI- 1/ 1B complexes are formed naturally. Moreover, when prostasin and HAI- 1B were coexpressed in Chinese hamster ovary cells, complexes of prostasin with HAI- 1B were detected on the cell membrane as well as in the culture medium, suggesting that preformed complexes were shed from the cell surface. The identification of HAI- 1B as a potential physiological regulator of prostasin function, as described herein, may further the investigation of the role of prostasin in normal physiology and cancer.	Genentech Inc, Dept Prot Engn, San Francisco, CA 94080 USA; Genentech Inc, Dept Bioinformat, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech	Kirchhofer, D (corresponding author), Genentech Inc, Dept Prot Engn, 1 DNA Way, San Francisco, CA 94080 USA.	dak@gene.com						Benaud C, 2002, J BIOL CHEM, V277, P10539, DOI 10.1074/jbc.M109064200; Bouton MC, 2003, ARTERIOSCL THROM VAS, V23, P142, DOI 10.1161/01.ATV.0000047867.98019.2D; Chen LM, 2001, J BIOL CHEM, V276, P21434, DOI 10.1074/jbc.M011423200; Chen LM, 2001, PROSTATE, V48, P93, DOI 10.1002/pros.1085; Chen LM, 2004, PROSTATE, V59, P1, DOI 10.1002/pros.10346; Chen LM, 2002, INT J CANCER, V97, P323, DOI 10.1002/ijc.1601; Denda K, 2002, J BIOL CHEM, V277, P14053, DOI 10.1074/jbc.M112263200; DENNIS MS, 1995, J BIOL CHEM, V270, P25411, DOI 10.1074/jbc.270.43.25411; Donaldson SH, 2002, J BIOL CHEM, V277, P8338, DOI 10.1074/jbc.M105044200; Graeber TG, 2001, NAT GENET, V29, P295, DOI 10.1038/ng755; Herter S, 2005, BIOCHEM J, V390, P125, DOI 10.1042/BJ20041955; Itoh H, 2000, AM J PHYSIOL-GASTR L, V278, pG635, DOI 10.1152/ajpgi.2000.278.4.G635; Kataoka H, 2000, CANCER RES, V60, P6148; Kataoka H, 2000, J BIOL CHEM, V275, P40453, DOI 10.1074/jbc.M006412200; Kataoka H, 1998, CANCER LETT, V128, P219, DOI 10.1016/S0304-3835(98)00067-6; Kataoka H, 1999, J HISTOCHEM CYTOCHEM, V47, P673, DOI 10.1177/002215549904700509; Kawaguchi T, 1997, J BIOL CHEM, V272, P27558, DOI 10.1074/jbc.272.44.27558; Kirchhofer D, 2005, FEBS LETT, V579, P1945, DOI 10.1016/j.febslet.2005.01.085; Kirchhofer D, 2003, J BIOL CHEM, V278, P36341, DOI 10.1074/jbc.M304643200; Klezovitch O, 2004, CANCER CELL, V6, P185, DOI 10.1016/j.ccr.2004.07.008; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Lee SL, 2000, J BIOL CHEM, V275, P36720, DOI 10.1074/jbc.M007802200; Lin CY, 1999, J BIOL CHEM, V274, P18237, DOI 10.1074/jbc.274.26.18237; Lin CY, 1997, J BIOL CHEM, V272, P9147; Liu GY, 2003, NUCLEIC ACIDS RES, V31, P82, DOI 10.1093/nar/gkg121; Marlor CW, 1997, J BIOL CHEM, V272, P12202, DOI 10.1074/jbc.272.18.12202; Miyazawa K, 1996, J BIOL CHEM, V271, P3615; Mok SC, 2001, J NATL CANCER I, V93, P1458, DOI 10.1093/jnci/93.19.1458; Muthukumar T, 2003, TRANSPLANTATION, V75, P1565, DOI 10.1097/01.TP.0000058230.91518.2F; Oberst MD, 2002, CLIN CANCER RES, V8, P1101; Parr C, 2001, INT J ONCOL, V19, P857; Phillips T, 2004, J IMMUNOL, V173, P3801, DOI 10.4049/jimmunol.173.6.3801; Shia S, 2005, J MOL BIOL, V346, P1335, DOI 10.1016/j.jmb.2004.12.048; Shimomura T, 1999, J BIOCHEM-TOKYO, V126, P821, DOI 10.1093/oxfordjournals.jbchem.a022522; Shimomura T, 1997, J BIOL CHEM, V272, P6370, DOI 10.1074/jbc.272.10.6370; Shipway A, 2004, BIOCHEM BIOPH RES CO, V324, P953, DOI 10.1016/j.bbrc.2004.09.123; Takahashi S, 2003, PROSTATE, V54, P187, DOI 10.1002/pros.10178; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Tanaka H, 2005, MOL CELL BIOL, V25, P5687, DOI 10.1128/MCB.25.13.5687-5698.2005; Tong ZY, 2004, AM J PHYSIOL-LUNG C, V287, pL928, DOI 10.1152/ajplung.00160.2004; TYAGI SC, 1995, J MOL CELL CARDIOL, V27, P2177, DOI 10.1016/S0022-2828(95)91443-9; YU JX, 1995, J BIOL CHEM, V270, P13483, DOI 10.1074/jbc.270.22.13483; YU JX, 1994, J BIOL CHEM, V269, P18843	43	70	71	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34513	34520		10.1074/jbc.M502119200	http://dx.doi.org/10.1074/jbc.M502119200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16103126	hybrid			2022-12-25	WOS:000232403900019
J	Ferrao-Gonzales, AD; Robbs, BK; Moreau, VH; Ferreira, A; Juliano, L; Valente, AP; Almeida, FCL; Silva, JL; Foguel, D				Ferrao-Gonzales, AD; Robbs, BK; Moreau, VH; Ferreira, A; Juliano, L; Valente, AP; Almeida, FCL; Silva, JL; Foguel, D			Controlling beta-amyloid oligomerization by the use of naphthalene sulfonates - Trapping low molecular weight oligomeric species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; FIBRIL FORMATION; COMMON MECHANISM; DYES ATTENUATE; PRION PROTEIN; PEPTIDE; AGGREGATION; DEPOSITION; INHIBITION; TOXICITY	Aggregation of proteins and peptides has been shown to be responsible for several diseases known as amyloidoses, which include Alzheimer disease ( AD), prion diseases, among several others. AD is a neurodegenerative disorder caused primarily by the aggregation of beta-amyloid peptide (A beta). Here we describe the stabilization of small oligomers of A beta by the use of sulfonated hydrophobic molecules such as AMNS (1-amino-5-naphthalene sulfonate); 1,8-ANS (1-anilinonaphthalene-8-sulfonate) and bis-ANS (4,4'-dianilino1,1'-binaphthyl-5,5'-disulfonate). The experiments were performed with either A beta-1-42 or with A beta-13-23, a shorter version of A beta that is still able to form amyloid fibrils in vitro and contains amino acid residues 16 - 20, previously shown to be essential to peptide-peptide interaction and fibril formation. All sulfonated molecules tested were able to prevent A beta aggregation in a concentration dependent fashion in the following order of efficacy: 1,8ANS< AMNS< bis-ANS. Size exclusion chromatography revealed that in the presence of bis-ANS, A beta forms a heterogeneous population of low molecular weight species that proved to be toxic to cell cultures. Since the ANS compounds all have apolar rings and negative charges ( sulfonate groups), both hydrophobic and electrostatic interactions may contribute to interpeptide contacts that lead to aggregation. We also performed NMR experiments to investigate the structure of A beta-13-23 in SDSmicelles and found features of an alpha-helix from Lys(16) to Phe(20). H-1 TOCSY spectra of A beta-13 - 23 in the presence of AMNS displayed a chemical-shift dispersion quite similar to that observed in SDS, which suggests that in the presence of AMNS this peptide might adopt a conformation similar to that reported in the presence of SDS. Taken together, our studies provide evidence for the crucial role of small oligomers and their stabilization by sulfonate hydrophobic compounds.	Univ Fed Rio de Janeiro, Inst Bioquim Med, Programa Biol Estrutural, BR-21941590 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Ctr Nacl Ressonancia Magnet Nucl, BR-21941590 Rio De Janeiro, Brazil; Univ Fed Sao Paulo, Dept Biofis, BR-04023900 Sao Paulo, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Universidade Federal de Sao Paulo (UNIFESP)	Foguel, D (corresponding author), Univ Fed Rio de Janeiro, Inst Bioquim Med, Programa Biol Estrutural, Av Bauhinia 400, BR-21941590 Rio De Janeiro, Brazil.	foguel@bioqmed.ufrj.br	Valente, Ana Paula/J-3010-2017; Moreau, Vitor Hugo/B-8865-2009; Silva, Jerson/J-8984-2014; Gonzales, Astria Dias Ferrão-/D-3288-2015; Almeida, Fabio/O-4989-2018; Moreau, Vitor Hugo/J-4829-2015; Robbs, Bruno/H-5553-2013; SILVA, JERSON Lima/GRF-1442-2022; Juliano, Luiz/D-7204-2012	Valente, Ana Paula/0000-0001-7219-1123; Silva, Jerson/0000-0001-9523-9441; Gonzales, Astria Dias Ferrão-/0000-0003-4144-5244; Almeida, Fabio/0000-0001-6046-7006; Moreau, Vitor Hugo/0000-0002-5393-0645; SILVA, JERSON Lima/0000-0001-9523-9441; Juliano, Luiz/0000-0002-5589-2822; Robbs, Bruno Kaufmann/0000-0002-3972-5530; Foguel, Debora/0000-0001-7312-7115				Bornemann KD, 2000, ANN NY ACAD SCI, V908, P260; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Cleary JP, 2005, NAT NEUROSCI, V8, P79, DOI 10.1038/nn1372; Coles M, 1998, BIOCHEMISTRY-US, V37, P11064, DOI 10.1021/bi972979f; Cordeiro Y, 2004, J BIOL CHEM, V279, P5346, DOI 10.1074/jbc.M312262200; Cordeiro Y, 2001, J BIOL CHEM, V276, P49400, DOI 10.1074/jbc.M106707200; De Felice FG, 2001, FASEB J, V15, P1297, DOI 10.1096/fj.00-0676fje; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Demuro A, 2005, J BIOL CHEM, V280, P17294, DOI 10.1074/jbc.M500997200; Dobson CM, 2004, METHODS, V34, P4, DOI 10.1016/j.ymeth.2004.03.002; Dong MQ, 1996, J BIOL CHEM, V271, P28875, DOI 10.1074/jbc.271.46.28875; Esler WP, 1997, NAT BIOTECHNOL, V15, P258, DOI 10.1038/nbt0397-258; Fletcher TG, 1997, PROTEIN SCI, V6, P666; Foguel B, 2004, BIOCHEMISTRY-US, V43, P11361; Foguel D, 2003, P NATL ACAD SCI USA, V100, P9831, DOI 10.1073/pnas.1734009100; GarzonRodriguez W, 1997, J BIOL CHEM, V272, P21037, DOI 10.1074/jbc.272.34.21037; Gong YS, 2003, P NATL ACAD SCI USA, V100, P10417, DOI 10.1073/pnas.1834302100; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; HILBICH C, 1992, J MOL BIOL, V228, P460, DOI 10.1016/0022-2836(92)90835-8; Howlett DR, 1999, BIOCHEM J, V340, P283, DOI 10.1042/0264-6021:3400283; Ippel JH, 2002, P NATL ACAD SCI USA, V99, P8648, DOI 10.1073/pnas.132098999; JARRETT JT, 1993, ANN NY ACAD SCI, V695, P144, DOI 10.1111/j.1749-6632.1993.tb23043.x; JOACHIM CL, 1989, NATURE, V341, P226, DOI 10.1038/341226a0; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; Kirkitadze MD, 2002, J NEUROSCI RES, V69, P567, DOI 10.1002/jnr.10328; KIRSCHNER DA, 1986, P NATL ACAD SCI USA, V83, P503, DOI 10.1073/pnas.83.2.503; KISILEVSKY R, 1995, NAT MED, V1, P143, DOI 10.1038/nm0295-143; Klein WL, 2004, NEUROBIOL AGING, V25, P569, DOI 10.1016/j.neurobiolaging.2004.02.010; Klein WL, 2002, NEUROBIOL AGING, V23, P231, DOI 10.1016/S0197-4580(01)00312-8; Klein WL, 2001, TRENDS NEUROSCI, V24, P219, DOI 10.1016/S0166-2236(00)01749-5; Kuo YM, 1996, J BIOL CHEM, V271, P4077; Lacor PN, 2004, J NEUROSCI, V24, P10191, DOI 10.1523/JNEUROSCI.3432-04.2004; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai ZH, 1996, BIOCHEMISTRY-US, V35, P6470, DOI 10.1021/bi952501g; LeVine H, 2002, ARCH BIOCHEM BIOPHYS, V404, P106; Li LP, 1999, BIOPHYS J, V76, P2871, DOI 10.1016/S0006-3495(99)77442-4; Liu YB, 1997, J NEUROCHEM, V69, P2285; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; MAY PC, 1992, NEUROBIOL AGING, V13, P605, DOI 10.1016/0197-4580(92)90064-5; MAZUMDAR M, 1992, BIOCHEMISTRY-US, V31, P6470, DOI 10.1021/bi00143a016; Montserret R, 2000, BIOCHEMISTRY-US, V39, P8362, DOI 10.1021/bi000208x; Nakagami Y, 2002, EUR J PHARMACOL, V457, P11, DOI 10.1016/S0014-2999(02)02657-2; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; POLLACK SJ, 1995, NEUROSCI LETT, V184, P113, DOI 10.1016/0304-3940(94)11182-I; POLLACK SJ, 1995, NEUROSCI LETT, V197, P211, DOI 10.1016/0304-3940(95)11939-T; Porat Y, 2004, BIOCHEMISTRY-US, V43, P14454, DOI 10.1021/bi048582a; Riek R, 2001, EUR J BIOCHEM, V268, P5930, DOI 10.1046/j.0014-2956.2001.02537.x; Roher AE, 1996, J BIOL CHEM, V271, P20631, DOI 10.1074/jbc.271.34.20631; Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066; Serpell LC, 2000, BBA-MOL BASIS DIS, V1502, P16, DOI 10.1016/S0925-4439(00)00029-6; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SNOW AD, 1994, NEURON, V12, P219, DOI 10.1016/0896-6273(94)90165-1; Solomon B, 1997, P NATL ACAD SCI USA, V94, P4109, DOI 10.1073/pnas.94.8.4109; STICHT H, 1995, EUR J BIOCHEM, V233, P293, DOI 10.1111/j.1432-1033.1995.293_1.x; SUMNERMAKIN O, 2005, P NATL ACAD SCI USA, V102, P315; TALAFOUS J, 1994, BIOCHEMISTRY-US, V33, P7788, DOI 10.1021/bi00191a006; TESCHKE CM, 1993, BIOCHEMISTRY-US, V32, P10658, DOI 10.1021/bi00091a016; Tjernberg LO, 1996, J BIOL CHEM, V271, P8545, DOI 10.1074/jbc.271.15.8545; Tjernberg LO, 1999, J BIOL CHEM, V274, P12619, DOI 10.1074/jbc.274.18.12619; Urbanc B, 2004, P NATL ACAD SCI USA, V101, P17345, DOI 10.1073/pnas.0408153101; Vassar R, 2000, NEURON, V27, P419, DOI 10.1016/S0896-6273(00)00051-9; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; WOOD SJ, 1995, BIOCHEMISTRY-US, V34, P724, DOI 10.1021/bi00003a003	67	60	69	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34747	34754		10.1074/jbc.M501651200	http://dx.doi.org/10.1074/jbc.M501651200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16041062	hybrid			2022-12-25	WOS:000232403900046
J	Kim, KS; Sim, S; Ko, JH; Lee, Y				Kim, KS; Sim, S; Ko, JH; Lee, Y			Processing of M1 RNA at the 3 ' end protects its primary transcript from degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO ANALYSIS; ESCHERICHIA-COLI; MESSENGER-RNA; RIBONUCLEASE-P; CATALYTIC SUBUNIT; GENE; MATURATION; POLYADENYLATION; INITIATION; COMPONENT	M1 RNA, the catalytic subunit of Escherichia coli RNase P, is an essential ribozyme that processes the 5' leader sequence of precursor tRNAs. It is generated by the removal of 36 nucleotides from the 3' end of the primary rnpB transcript (pM1 RNA), but the biological significance of this reaction in bacterial metabolism remains obscure. In this study, we constructed and analyzed bacterial strains carrying mutations in the rne-dependent site of their rnpB genes, showing that the 3' processing of M1 RNA is essential for cell viability. Furthermore, we demonstrate that pM1 RNA can undergo not only 3' processing but also poly(A)-dependent degradation. Therefore, our results suggest that the 3' processing of M1 RNA provides a functional mechanism for the protection of its primary transcript against degradation.	Korea Adv Inst Sci & Technol, Dept Chem, Taejon 305701, South Korea; Korea Adv Inst Sci & Technol, Ctr Mol Design & Synth, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Korea Advanced Institute of Science & Technology (KAIST)	Lee, Y (corresponding author), Korea Adv Inst Sci & Technol, Dept Chem, Taejon 305701, South Korea.	Younghoon.Lee@kaist.ac.kr	Lee, Younghoon/C-1991-2011; Kim, Kwang-sun/AAB-6478-2020	Lee, Younghoon/0000-0002-3841-719X; Kim, Kwang-sun/0000-0003-3703-5461				Bensing BA, 1996, P NATL ACAD SCI USA, V93, P7794, DOI 10.1073/pnas.93.15.7794; Bernstein JA, 2002, P NATL ACAD SCI USA, V99, P9697, DOI 10.1073/pnas.112318199; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BOURGAIZE DB, 1987, NATURE, V325, P281, DOI 10.1038/325281a0; CAO GJ, 1992, P NATL ACAD SCI USA, V89, P10380, DOI 10.1073/pnas.89.21.10380; Coburn GA, 1999, PROG NUCLEIC ACID RE, V62, P55; EHRETSMANN CP, 1992, GENE DEV, V6, P149, DOI 10.1101/gad.6.1.149; Frank DN, 1998, ANNU REV BIOCHEM, V67, P153, DOI 10.1146/annurev.biochem.67.1.153; GHORA BK, 1978, CELL, V15, P1055, DOI 10.1016/0092-8674(78)90289-1; GUERRIERTAKADA C, 1984, SCIENCE, V223, P285, DOI 10.1126/science.6199841; GUERRIERTAKADA C, 1986, CELL, V45, P177, DOI 10.1016/0092-8674(86)90381-8; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; JAIN SK, 1982, J MOL BIOL, V162, P515, DOI 10.1016/0022-2836(82)90386-2; Kim KS, 2004, NUCLEIC ACIDS RES, V32, P6057, DOI 10.1093/nar/gkh939; Kim S, 1996, J BIOL CHEM, V271, P19330, DOI 10.1074/jbc.271.32.19330; Kim S, 1999, NUCLEIC ACIDS RES, V27, P895, DOI 10.1093/nar/27.3.895; KOMINE Y, 1994, P NATL ACAD SCI USA, V73, P1912; Kurz JC, 2000, CURR OPIN CHEM BIOL, V4, P553, DOI 10.1016/S1367-5931(00)00131-9; Kushner SR, 2002, J BACTERIOL, V184, P4658, DOI 10.1128/JB.184.17.4658-4665.2002; Lee K, 2002, MOL MICROBIOL, V43, P1445, DOI 10.1046/j.1365-2958.2002.02848.x; LEE Y, 1989, J BIOL CHEM, V264, P5098; Li Y, 2003, P NATL ACAD SCI USA, V100, P13213, DOI 10.1073/pnas.2235589100; Li ZW, 1998, P NATL ACAD SCI USA, V95, P2856, DOI 10.1073/pnas.95.6.2856; Li ZW, 2002, EMBO J, V21, P1132, DOI 10.1093/emboj/21.5.1132; Li ZW, 2002, RNA, V8, P97, DOI 10.1017/S1355838202014929; Li ZW, 1998, P NATL ACAD SCI USA, V95, P12158, DOI 10.1073/pnas.95.21.12158; Lin-Chao S, 1999, P NATL ACAD SCI USA, V96, P12406, DOI 10.1073/pnas.96.22.12406; LUNDBERG U, 1995, RNA, V1, P327; Mohanty BK, 2004, MOL MICROBIOL, V54, P905, DOI 10.1111/j.1365-2958.2004.04337.x; Ow MC, 2002, GENE DEV, V16, P1102, DOI 10.1101/gad.983502; Park JW, 1996, J BIOCHEM MOL BIOL, V29, P221; REED RE, 1982, CELL, V30, P627, DOI 10.1016/0092-8674(82)90259-8; ROBERTSON HD, 1972, J BIOL CHEM, V247, P5243; SAKAMOTO H, 1983, P NATL ACAD SCI-BIOL, V80, P6187, DOI 10.1073/pnas.80.20.6187; SAKANO H, 1974, NUCLEIC ACIDS RES, V1, P355, DOI 10.1093/nar/1.3.355; Sarkar N, 1997, ANNU REV BIOCHEM, V66, P173, DOI 10.1146/annurev.biochem.66.1.173; Silhavy T.J., 1984, EXPT GENE FUSIONS, P303; Sim S, 2002, FEBS LETT, V529, P225, DOI 10.1016/S0014-5793(02)03345-8; Sim S, 2001, FEBS LETT, V505, P291, DOI 10.1016/S0014-5793(01)02822-8; SINGER M, 1989, MICROBIOL REV, V53, P1; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yu DG, 2000, P NATL ACAD SCI USA, V97, P5978, DOI 10.1073/pnas.100127597	42	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34667	34674		10.1074/jbc.M505005200	http://dx.doi.org/10.1074/jbc.M505005200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16105832	hybrid			2022-12-25	WOS:000232403900036
J	Zabel, BA; Allen, SJ; Kulig, P; Allen, JA; Cichy, J; Handel, TM; Butcher, EC				Zabel, BA; Allen, SJ; Kulig, P; Allen, JA; Cichy, J; Handel, TM; Butcher, EC			Chemerin activation by serine proteases of the coagulation, fibrinolytic, and inflammatory cascades	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMACYTOID DENDRITIC CELLS; PLASMINOGEN-ACTIVATOR; HUMAN BLOOD; RECEPTOR; CHEMOKINE; CHEMOATTRACTANT; COMPLEMENT; CHEMOTAXIS; INHIBITOR; CLEAVAGE	Proteases function at every level in host defense, from regulating vascular hemostasis and inflammation to mobilizing the "rapid responder" leukocytes of the immune system by regulating the activities of various chemoattractants. Recent studies implicate proteolysis in the activation of a ubiquitous plasma chemoattractant, chemerin, a ligand for the G-protein-coupled receptor CMKLR1 present on plasmacytoid dendritic cells and macrophages. To define the pathophysiologic triggers of chemerin activity, we evaluated the ability of serum- and inflammation-associated proteases to cleave chemerin and stimulate CMKLR1-mediated chemotaxis. We showed that serine proteases factor XIIa and plasmin of the coagulation and fibrinolytic cascades, elastase and cathepsin G released from activated neutrophil granules and mast cell tryptase are all potent activators of chemerin. Activation results from cleavage of the labile carboxyl terminus of the chemoattractant at any of several different sites. Activation of chemerin by the serine protease cascades that trigger rapid defenses in the body may direct CMKLR1-positive plasmacytoid dendritic cell and tissue macrophage recruitment to sterile sites of tissue damage, as well as trafficking to sites of infectious and allergic inflammation.	Stanford Univ, Sch Med, Dept Pathol, Lab Immunol & Vasc Biol, Stanford, CA 94305 USA; Vet Affairs Palo Alto Hlth Care Syst, Ctr Mol Biol & Med, Palo Alto, CA 94304 USA; Univ Calif Berkeley, Berkeley, CA 94720 USA; Jagiellonian Univ, Fac Biotechnol, PL-30387 Krakow, Poland	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; University of California System; University of California Berkeley; Jagiellonian University	Zabel, BA (corresponding author), Stanford Univ, Dept Pathol 5234, Med Ctr, Stanford, CA 94305 USA.	bazabel@alum.mit.edu		Cichy, Joanna/0000-0002-0552-8344	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL067674, P01HL067674] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI059635, R01AI059635, R37AI047822, R01AI037113, R01AI037832, R21AI047822, R01AI047822] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056339] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM037734, R01GM037734] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-67674] Funding Source: Medline; NIAID NIH HHS [AI-37832, AI-59635, AI37113-09, AI-47822] Funding Source: Medline; NIDDK NIH HHS [DK56339] Funding Source: Medline; NIGMS NIH HHS [GM-37734] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bajzar L, 2004, CRIT CARE MED, V32, pS320, DOI 10.1097/01.CCM.0000126361.00450.B1; Bangert K, 2000, THROMB HAEMOSTASIS, V84, P299, DOI 10.1055/s-0037-1614011; Busmann A, 2004, J CHROMATOGR B, V811, P217, DOI 10.1016/j.jchromb.2004.09.006; CAR BD, 1991, BIOCHEM J, V275, P581, DOI 10.1042/bj2750581; Colonna M, 2004, NAT IMMUNOL, V5, P1219, DOI 10.1038/ni1141; de la Rosa G, 2003, J LEUKOCYTE BIOL, V73, P639, DOI 10.1189/jlb.1002516; DRAKE TA, 1989, AM J PATHOL, V134, P1087; Dybendal T, 2003, ACTA ANAESTH SCAND, V47, P1211, DOI 10.1046/j.1399-6576.2003.00237.x; EKDAHL KN, 1990, J IMMUNOL, V144, P4269; ELLIS V, 1993, J BIOL CHEM, V268, P4806; FALK W, 1980, INFECT IMMUN, V29, P953; FERNANDEZ HN, 1978, J IMMUNOL, V120, P109; FRANK MM, 1991, IMMUNOL TODAY, V12, P322, DOI 10.1016/0167-5699(91)90009-I; Gilliet M, 2002, J EXP MED, V195, P695, DOI 10.1084/jem.20011603; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Gudmundsson GH, 1996, EUR J BIOCHEM, V238, P325, DOI 10.1111/j.1432-1033.1996.0325z.x; Guimaraes AHC, 2004, THROMB HAEMOSTASIS, V91, P473, DOI 10.1160/TH03-06-0377; Hartmann K, 1997, BLOOD, V89, P2863, DOI 10.1182/blood.V89.8.2863; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; JANDL JH, 1996, BLOOD TXB HEMATOLOGY, P1213; Joost P, 2002, GENOME BIOL, V3; Kardos J, 2001, J IMMUNOL, V167, P5202, DOI 10.4049/jimmunol.167.9.5202; Kawamura T, 2002, MICROBIOL IMMUNOL, V46, P225, DOI 10.1111/j.1348-0421.2002.tb02690.x; Matthews KW, 2004, MOL IMMUNOL, V40, P785, DOI 10.1016/j.molimm.2003.10.002; McQuibban GA, 2000, SCIENCE, V289, P1202, DOI 10.1126/science.289.5482.1202; Meder W, 2003, FEBS LETT, V555, P495, DOI 10.1016/S0014-5793(03)01312-7; Myles T, 2003, J BIOL CHEM, V278, P51059, DOI 10.1074/jbc.M306977200; NAGASAWA S, 1977, P NATL ACAD SCI USA, V74, P2998, DOI 10.1073/pnas.74.7.2998; Oravecz T, 1997, J EXP MED, V186, P1865, DOI 10.1084/jem.186.11.1865; Penna G, 2001, J IMMUNOL, V167, P1862, DOI 10.4049/jimmunol.167.4.1862; Proost P, 1998, FEBS LETT, V432, P73, DOI 10.1016/S0014-5793(98)00830-8; Samson M, 1998, EUR J IMMUNOL, V28, P1689, DOI 10.1002/(SICI)1521-4141(199805)28:05<1689::AID-IMMU1689>3.0.CO;2-I; SchulzKnappe P, 1996, J EXP MED, V183, P295, DOI 10.1084/jem.183.1.295; Sim RB, 2004, BIOCHEM SOC T, V32, P21, DOI 10.1042/BST0320021; Stoy N, 2001, PATHOBIOLOGY, V69, P179, DOI 10.1159/000055944; Syrovets T, 1997, BLOOD, V89, P4574, DOI 10.1182/blood.V89.12.4574; Tani Kenji, 2001, Journal of Medical Investigation, V48, P133; Taylor FR, 1999, BIOCHEMISTRY-US, V38, P2849, DOI 10.1021/bi982140f; Vakili J, 2001, J IMMUNOL, V167, P3406, DOI 10.4049/jimmunol.167.6.3406; Wittamer V, 2004, J BIOL CHEM, V279, P9956, DOI 10.1074/jbc.M313016200; Wittamer V, 2003, J EXP MED, V198, P977, DOI 10.1084/jem.20030382; Yang D, 2000, J EXP MED, V192, P1069, DOI 10.1084/jem.192.7.1069; YEE JA, 1993, J CELL PHYSIOL, V157, P528, DOI 10.1002/jcp.1041570312; Zabel BA, 2005, J IMMUNOL, V174, P244, DOI 10.4049/jimmunol.174.1.244	44	283	301	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34661	34666		10.1074/jbc.M504868200	http://dx.doi.org/10.1074/jbc.M504868200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16096270	hybrid			2022-12-25	WOS:000232403900035
J	Hatters, DM; Budamagunta, MS; Voss, JC; Weisgraber, KH				Hatters, DM; Budamagunta, MS; Voss, JC; Weisgraber, KH			Modulation of apolipoprotein E structure by domain interaction - Differences in lipid-bound and lipid-free forms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; RECEPTOR-BINDING DOMAIN; N-TERMINAL DOMAIN; ALZHEIMERS-DISEASE; E ISOFORMS; CONFORMATIONAL-CHANGES; AQUEOUS-SOLUTION; E APOPROTEIN; IN-VITRO; A-I	Interaction of the amino- and carboxyl-terminal domains in apolipoprotein (apo) E, referred to as domain interaction, is predicted to be more pronounced in apoE4 than in apoE3 and to underlie the association of apoE4 with Alzheimer and cardiovascular diseases. However, direct physical proof for the domain interaction concept is lacking. To address this issue, fluorescence resonance energy transfer and electron paramagnetic resonance spectroscopy were used to probe the spatial proximity of the two domains of apoE. Both methods demonstrated that the two domains are closer in both lipid-free and phospholipid-bound apoE4 than in apoE3 as a result of domain interaction. In addition, as shown by electron paramagnetic resonance, the domains of apoE4 move apart to resemble more closely the distance in apoE3 when the isoforms are bound to triglyceride-rich emulsion particles. These results demonstrate that domain interaction is a structural property of apoE4 and that apoE adopts different conformations when complexed to different lipids.	Gladstone Inst Neurol Dis, San Francisco, CA 94158 USA; Gladstone Inst Cardiovasc Dis, San Francisco, CA 94158 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; Univ Calif Davis, Sch Med, Dept Biol Chem, Davis, CA 95616 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California Davis	Weisgraber, KH (corresponding author), Gladstone Inst Neurol Dis, 1650 Owens St, San Francisco, CA 94158 USA.	kweisgraber@gladstone.ucsf.edu	Budamagunta, Madhu S/C-4628-2011	Voss, John/0000-0001-9279-209X; Hatters, Danny/0000-0002-9965-2847	NIA NIH HHS [R01 AG029246, P01 AG022074, R01 AG020235] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG022074, R01AG029246, R01AG020235] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AGGERBECK LP, 1988, J BIOL CHEM, V263, P6249; Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15471, DOI 10.1021/bi011544w; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DONG LM, 1994, J BIOL CHEM, V269, P22358; Dong LM, 1996, J BIOL CHEM, V271, P19053, DOI 10.1074/jbc.271.32.19053; Drury J, 2005, J BIOL CHEM, V280, P14605, DOI 10.1074/jbc.M414019200; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.278.16.1349; Fisher CA, 1999, J LIPID RES, V40, P93; Fisher CA, 2000, J BIOL CHEM, V275, P33601, DOI 10.1074/jbc.M002643200; GIANTURCO SH, 1983, J BIOL CHEM, V258, P4526; Hatters DM, 2005, J BIOL CHEM, V280, P26477, DOI 10.1074/jbc.M503910200; Hess JF, 2004, J BIOL CHEM, V279, P44841, DOI 10.1074/jbc.M406257200; Hubbell WL, 2000, NAT STRUCT BIOL, V7, P735, DOI 10.1038/78956; HUDSON EN, 1973, BIOCHEMISTRY-US, V12, P4154, DOI 10.1021/bi00745a019; INNERARITY TL, 1979, J BIOL CHEM, V254, P4186; Kirby E. P., 1970, J PHYS CHEM-US, V74, P4480, DOI DOI 10.1021/J100720A004; Langen R, 2000, BIOCHEMISTRY-US, V39, P8396, DOI 10.1021/bi000604f; Lu B, 2000, J BIOL CHEM, V275, P20775, DOI 10.1074/jbc.M003508200; MATZ CE, 1982, J BIOL CHEM, V257, P4535; Morrow JA, 2000, BIOCHEMISTRY-US, V39, P11657, DOI 10.1021/bi000099m; Morrow JA, 1999, PROTEIN EXPRES PURIF, V16, P224, DOI 10.1006/prep.1999.1069; Narayanaswami V, 2001, J BIOL CHEM, V276, P37853; Narayanaswami V, 2004, J BIOL CHEM, V279, P14273, DOI 10.1074/jbc.M313318200; Narayanaswami V, 2000, BBA-MOL CELL BIOL L, V1483, P15, DOI 10.1016/S1388-1981(99)00176-6; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Oda MN, 2003, NAT STRUCT BIOL, V10, P455, DOI 10.1038/nsb931; Perugini MA, 2002, EUR J BIOCHEM, V269, P5939, DOI 10.1046/j.1432-1033.2002.03319.x; RABENSTEIN MD, 1995, P NATL ACAD SCI USA, V92, P8239, DOI 10.1073/pnas.92.18.8239; Raffai RL, 2001, P NATL ACAD SCI USA, V98, P11587, DOI 10.1073/pnas.201279298; Raussens V, 1998, J BIOL CHEM, V273, P25825, DOI 10.1074/jbc.273.40.25825; Saito H, 2001, J BIOL CHEM, V276, P40949, DOI 10.1074/jbc.M106337200; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; STRITTMATTER WJ, 1995, P NATL ACAD SCI USA, V92, P4725, DOI 10.1073/pnas.92.11.4725; TAJIMA S, 1983, J BIOL CHEM, V258, P73; WEISGRABER KH, 1990, J BIOL CHEM, V265, P22453; WEISGRABER KH, 1990, J LIPID RES, V31, P1503; WEISGRABER KH, 1981, J BIOL CHEM, V256, P9077; Weisgraber KH, 1996, FASEB J, V10, P1485, DOI 10.1096/fasebj.10.13.8940294; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WETTERAU JR, 1988, J BIOL CHEM, V263, P6240; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; Xu Q, 2004, J BIOL CHEM, V279, P25511, DOI 10.1074/jbc.M311256200; YOKOYAMA S, 1985, J BIOL CHEM, V260, P6375	44	68	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34288	34295		10.1074/jbc.M506044200	http://dx.doi.org/10.1074/jbc.M506044200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16076841	hybrid			2022-12-25	WOS:000232229700071
J	Horng, YC; Leary, SC; Cobine, PA; Young, FBJ; George, GN; Shoubridge, EA; Winge, DR				Horng, YC; Leary, SC; Cobine, PA; Young, FBJ; George, GN; Shoubridge, EA; Winge, DR			Human Sco1 and Sco2 function as copper-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; SACCHAROMYCES-CEREVISIAE; CU(I)-BINDING PROTEIN; CRYSTAL-STRUCTURE; YEAST; DEFICIENCY; MUTATIONS; METALLOCHAPERONE; CHAPERONE; COX17	The function of human Sco1 and Sco2 is shown to be dependent on copper ion binding. Expression of soluble domains of human Sco1 and Sco2 either in bacteria or the yeast cytoplasm resulted in the recovery of copper-containing proteins. The metallation of human Sco1, but not Sco2, when expressed in the yeast cytoplasm is dependent on the co-expression of human Cox17. Two conserved cysteines and a histidyl residue, known to be important for both copper binding and in vivo function in yeast Sco1, are also critical for in vivo function of human Sco1 and Sco2. Human and yeast Sco proteins can bind either a single Cu(I) or Cu(II) ion. The Cu( II) site yields S-Cu(II) charge transfer transitions that are not bleached by weak reductants or chelators. The Cu( I) site exhibits trigonal geometry, whereas the Cu( II) site resembles a type II Cu( II) site with a higher coordination number. To identify additional potential ligands for the Cu( II) site, a series of mutant proteins with substitutions in conserved residues in the vicinity of the Cu( I) site were examined. Mutation of several conserved carboxylates did not alter either in vivo function or the presence of the Cu( II) chromophore. In contrast, replacement of Asp(238) in human or yeast Sco1 abrogated the Cu( II) visible transitions and in yeast Sco1 attenuated Cu( II), but not Cu( I), binding. Both the mutant yeast and human proteins were nonfunctional, suggesting the importance of this aspartate for normal function. Taken together, these data suggest that both Cu( I) and Cu( II) binding are critical for normal Sco function.	McGill Univ, Dept Human Genet, Montreal, PQ H3A 2B4, Canada; Univ Utah, Hlth Sci Ctr, Dept Med, Salt Lake City, UT 84132 USA; McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada; Univ Saskatchewan, Saskatoon, SK S7N 5E2, Canada	McGill University; Utah System of Higher Education; University of Utah; McGill University; University of Saskatchewan	Winge, DR (corresponding author), McGill Univ, Dept Human Genet, 3801 Univ St,Rm 660, Montreal, PQ H3A 2B4, Canada.	eric@ericpc.mni.mcgill.ca; dennis.winge@hsc.utah.edu	Cobine, Paul/AAH-6619-2020; Winge, Dennis/G-3611-2010; Leary, Scot/B-3036-2012; Horng, Yih-Chern/I-6682-2018; George, Graham N/E-3290-2013; Cobine, Paul A/G-3107-2011	Cobine, Paul/0000-0001-6012-0985; Horng, Yih-Chern/0000-0001-9558-3189; Cobine, Paul A/0000-0001-6012-0985; George, Graham/0000-0002-0420-7493; Young, Fiona/0000-0002-3534-6875	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES003817, R01ES003817] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 03817] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arnesano F, 2001, J BIOL CHEM, V276, P41365, DOI 10.1074/jbc.M104807200; Arnesano F, 2001, BIOCHEMISTRY-US, V40, P1528, DOI 10.1021/bi0014711; Balatri E, 2003, STRUCTURE, V11, P1431, DOI 10.1016/j.str.2003.10.004; Basumallick L, 2005, J AM CHEM SOC, V127, P3531, DOI 10.1021/ja044412+; Beers J, 2002, J BIOL CHEM, V277, P22185, DOI 10.1074/jbc.M202545200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; Capaldi RA, 1995, METHOD ENZYMOL, V260, P117, DOI 10.1016/0076-6879(95)60134-1; Carr HS, 2003, ACCOUNTS CHEM RES, V36, P309, DOI 10.1021/ar0200807; Carr HS, 2002, J BIOL CHEM, V277, P31237, DOI 10.1074/jbc.M204854200; Carroll MC, 2004, P NATL ACAD SCI USA, V101, P5964, DOI 10.1073/pnas.0308298101; Dickinson EK, 2000, J BIOL CHEM, V275, P26780; Foltopoulou PF, 2004, MOL GENET METAB, V81, P225, DOI 10.1016/j.ymgme.2003.11.006; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; Heaton DN, 2001, BIOCHEMISTRY-US, V40, P743, DOI 10.1021/bi002315x; Hiser L, 2000, J BIOL CHEM, V275, P619, DOI 10.1074/jbc.275.1.619; Horng YC, 2004, J BIOL CHEM, V279, P35334, DOI 10.1074/jbc.M404747200; Jaksch M, 2000, HUM MOL GENET, V9, P795, DOI 10.1093/hmg/9.5.795; Jaksch M, 2001, HUM MOL GENET, V10, P3025, DOI 10.1093/hmg/10.26.3025; Jaksch M, 2001, NEUROLOGY, V57, P1440, DOI 10.1212/WNL.57.8.1440; KLEMENT P, 1995, ANAL BIOCHEM, V231, P218, DOI 10.1006/abio.1995.1523; Leary SC, 2004, HUM MOL GENET, V13, P1839, DOI 10.1093/hmg/ddh197; Lieberman RL, 2001, BIOCHEMISTRY-US, V40, P5674, DOI 10.1021/bi0102611; Lode A, 2000, FEBS LETT, V485, P19, DOI 10.1016/S0014-5793(00)02176-1; Lowenstein JM, 1969, METHOD ENZYMOL, P3, DOI [10.1016/0076-6879(69)13005-0, DOI 10.1016/0076-6879(69)13005-0]; Maxfield AB, 2004, J BIOL CHEM, V279, P5072, DOI 10.1074/jbc.M311772200; Nittis T, 2001, J BIOL CHEM, V276, P42520, DOI 10.1074/jbc.M107077200; Papadopoulou LC, 1999, NAT GENET, V23, P333; Paret C, 1999, FEBS LETT, V447, P65, DOI 10.1016/S0014-5793(99)00266-5; Poyton RO, 1995, METHOD ENZYMOL, V260, P97, DOI 10.1016/0076-6879(95)60133-3; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Rentzsch A, 1999, CURR GENET, V35, P103, DOI 10.1007/s002940050438; SALVIATI L, 2002, BIOCHEM J, V15, P321; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; Valnot I, 2000, AM J HUM GENET, V67, P1104; Wernimont AK, 2004, J BIOL CHEM, V279, P12269, DOI 10.1074/jbc.M311213200; Williams JC, 2005, J BIOL CHEM, V280, P15202, DOI 10.1074/jbc.M410705200; Xiao ZG, 2004, J AM CHEM SOC, V126, P3081, DOI 10.1021/ja0390350; Ye QL, 2005, BIOCHEMISTRY-US, V44, P2934, DOI 10.1021/bi0480537	40	132	133	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34113	34122		10.1074/jbc.M506801200	http://dx.doi.org/10.1074/jbc.M506801200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16091356	hybrid			2022-12-25	WOS:000232229700052
J	Zhang, Y; Takami, K; Lo, MS; Huang, GM; Yu, Q; Roswit, WT; Holtzman, MJ				Zhang, Y; Takami, K; Lo, MS; Huang, GM; Yu, Q; Roswit, WT; Holtzman, MJ			Modification of the stat1 SH2 domain broadly improves interferon efficacy in proportion to p300/CREB-binding protein coactivator recruitment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNATE IMMUNITY; DNA-BINDING; SIGNAL TRANSDUCER; VIRAL DISEASE; ACTIVATION; ALPHA; GAMMA; TRANSCRIPTION; EXPRESSION; MECHANISMS	A normal level of interferon (IFN) responsiveness via the Stat1 transcription factor is critical to the host, since decreased Stat1 signaling causes immune compromise and increased signaling is associated with inflammatory and neoplastic disease. Here we report how this balance may be influenced by novel alterations in the efficiency of Stat1 signaling. To enable disulfide-dependent and spontaneous formation of active Stat1 homodimer ( as was done previously for Stat3), we engineered Stat1-CC with double-cysteine substitutions in the Src homology 2 (SH2)-homodimerization domain ( at Ala-656 and Asn-658). In this case, however, mutant and wild-type Stat1 exhibited no difference in spontaneous dimerization. Moreover, Stat1-CCstill required ligand-dependent Tyr-701 phosphorylation for function and exhibited hyperresponsiveness to IFN-beta ( that depends on Stat1/Stat2 heterodimerization) as well as IFN-gamma (that depends on Stat1/Stat1 homodimerization). Hyperresponsivenss of Stat1-CC was accompanied by increased capacities for Tyr-701 phosphorylation and DNA binding, but these features were also found in a similarly substituted serine mutant (Stat1-SS) that showed no hyperresponsiveness to IFN-gamma. This finding raised the possibility that SH2 domain mutations also influence downstream transcriptional efficiency. Indeed, each of these mutations also enhanced recruitment of the normally rate-limiting p300/CREB-binding Protein (CBP) coactivator to the transcriptional complex in proportion to the level of IFN-driven transactivation and gene expression. Additional modifications indicated that the mutant residues in the SH2 domain appeared to cooperate with Ser-727 in the C-terminal domain to regulate p300/ CBP interaction with Stat1. The profile of IFN responsiveness translated into the same progressive increase in the level of viral clearance from Stat1- to Stat1- SS-to Stat1- CC-expressing cells. Thus, SH2 domain determinants may be modified to direct better Stat1 phosphorylation, DNA binding, and coactivator recruitment to fully improve IFN efficacy.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Holtzman, MJ (corresponding author), Washington Univ, Sch Med, Dept Med, Campus Box 8052,660 S Euclid Ave, St Louis, MO 63110 USA.	holtzman@im.wustl.edu						Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Chen XM, 2003, PROTEIN SCI, V12, P361, DOI 10.1110/ps.0218903; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Dunn GP, 2004, IMMUNITY, V21, P137, DOI 10.1016/j.immuni.2004.07.017; Dupuis S, 2003, NAT GENET, V33, P388, DOI 10.1038/ng1097; Dupuis S, 2001, SCIENCE, V293, P300, DOI 10.1126/science.1061154; Durbin JE, 2000, J IMMUNOL, V164, P4220, DOI 10.4049/jimmunol.164.8.4220; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Frank DA, 1997, J CLIN INVEST, V100, P3140, DOI 10.1172/JCI119869; Guo FH, 2000, J IMMUNOL, V164, P5970, DOI 10.4049/jimmunol.164.11.5970; Haga S, 2003, J CLIN INVEST, V112, P989, DOI 10.1172/JCI200317970; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Inoue H, 2004, NAT MED, V10, P168, DOI 10.1038/nm980; Jayaraman S, 1999, J IMMUNOL, V162, P1717; KITAMURA T, 1995, P NATL ACAD SCI USA, V92, P9146, DOI 10.1073/pnas.92.20.9146; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Li XX, 1996, J BIOL CHEM, V271, P5790, DOI 10.1074/jbc.271.10.5790; Liu B, 2004, NAT IMMUNOL, V5, P891, DOI 10.1038/ni1104; Lo MS, 2005, J VIROL, V79, P9315, DOI 10.1128/JVI.79.14.9315-9319.2005; Look DC, 1998, IMMUNITY, V9, P871, DOI 10.1016/S1074-7613(00)80652-4; Megidish T, 2002, J BIOL CHEM, V277, P8255, DOI 10.1074/jbc.C200001200; Meyer T, 2003, GENE DEV, V17, P1992, DOI 10.1101/gad.268003; Mowen K, 2000, MOL CELL BIOL, V20, P7273, DOI 10.1128/MCB.20.19.7273-7281.2000; Ota N, 2004, NAT IMMUNOL, V5, P208, DOI 10.1038/ni1032; Park C, 2000, IMMUNITY, V13, P795, DOI 10.1016/S1074-7613(00)00077-7; Paulson M, 1999, J BIOL CHEM, V274, P25343, DOI 10.1074/jbc.274.36.25343; Pilz A, 2003, EMBO REP, V4, P368, DOI 10.1038/sj.embor.embor802; Sakamoto S, 2004, J BIOL CHEM, V279, P3245, DOI 10.1074/jbc.M309631200; Sampath D, 1999, J CLIN INVEST, V103, P1353, DOI 10.1172/JCI6130; Sano S, 2005, NAT MED, V11, P43, DOI 10.1038/nm1162; Sen GC, 2001, ANNU REV MICROBIOL, V55, P255, DOI 10.1146/annurev.micro.55.1.255; Shimoda K, 2000, IMMUNITY, V13, P561, DOI 10.1016/S1074-7613(00)00055-8; Sironi JJ, 2004, J BIOL CHEM, V279, P4066, DOI 10.1074/jbc.M307774200; Ting LM, 1999, J IMMUNOL, V163, P3898; Varinou L, 2003, IMMUNITY, V19, P793, DOI 10.1016/S1074-7613(03)00322-4; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; Walter MJ, 1997, J BIOL CHEM, V272, P28582, DOI 10.1074/jbc.272.45.28582; Wang TH, 2004, NAT MED, V10, P48, DOI 10.1038/nm976; Yang E, 2002, J BIOL CHEM, V277, P13455, DOI 10.1074/jbc.M112038200; Yasukawa H, 2003, J CLIN INVEST, V111, P469, DOI 10.1172/JCI200316491; Yuan ZL, 2005, SCIENCE, V307, P269, DOI 10.1126/science.1105166; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhong MH, 2005, P NATL ACAD SCI USA, V102, P3966, DOI 10.1073/pnas.0501063102; Zong C, 1996, EMBO J, V15, P4515, DOI 10.1002/j.1460-2075.1996.tb00829.x	50	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34306	34315		10.1074/jbc.M503263200	http://dx.doi.org/10.1074/jbc.M503263200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16107341	hybrid			2022-12-25	WOS:000232229700073
J	Dominguez-Soto, A; Puig-Kroger, A; Vega, MA; Corbi, AL				Dominguez-Soto, A; Puig-Kroger, A; Vega, MA; Corbi, AL			PU.1 regulates the tissue-specific expression of dendritic cell-specific intercellular adhesion molecule (ICAM)-3-grabbing nonintegrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TYPE LECTIN; TRANSCRIPTION FACTOR PU.1; MANNOSE RECEPTOR PROMOTER; DC-SIGN; T-CELLS; (ICAM-3)-GRABBING NONINTEGRIN; SELECTIVE RECOGNITION; TGF-BETA; IN-VITRO; MACROPHAGE	Dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN) is a cell surface C-type lectin expressed on myeloid dendritic cells and certain tissue macrophages, which mediates antigen capture for processing and presentation and participates in intercellular interactions with naive T lymphocytes or endothelial cells. In their strategy to evade immunosurveillance, numerous pathogenic microorganisms, including human immunodeficiency virus and Mycobacterium, bind to DC-SIGN in order to gain access to dendritic cells. We present evidence that PU.1 dictates the basal and cell-specific activity of DC-SIGN gene-regulatory region through in vivo occupancy of two functional Ets elements, whose integrity is required for PU.1 responsiveness and for the cooperative actions of PU.1 and other transcription factors (Myb, RUNX) on the DC-SIGN gene proximal regulatory region. In addition, protein analysis and gene profiling experiments indicate that DC-SIGN and PU.1 are coordinately expressed upon classical and alternative macrophage activation and during dendritic cell maturation. Moreover, small interfering RNA-mediated reduction of PU.1 expression results in diminished DC-SIGN cellular levels. Altogether, these results indicate that PU.1 is involved in the myeloid-specific expression of DC-SIGN inmyeloid cells, a contribution that can be framed within the role that PU.1 has on the acquisition of the antigen uptake molecular repertoire by dendritic cells and macrophages.	CSIC, Ctr Invest Biol, Madrid 28040, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Corbi, AL (corresponding author), CSIC, Ctr Invest Biol, Ramiro de Maeztu 9, Madrid 28040, Spain.	acorbi@cib.csic.es	Corbi, Angel/B-7194-2011; Vega, Miguel A/M-1367-2016; Puig, Amaya/B-6164-2015; DOMINGUEZ-SOTO, ANGELES/K-5937-2014; Corbí, Angel L./ABC-8146-2020	Corbi, Angel/0000-0003-1980-5733; Vega, Miguel A/0000-0001-6151-4193; Puig, Amaya/0000-0003-2943-9757; Corbí, Angel L./0000-0003-1980-5733; Dominguez Soto, Angeles/0000-0003-1299-5992				Anderson KL, 2000, J IMMUNOL, V164, P1855, DOI 10.4049/jimmunol.164.4.1855; Appelmelk BJ, 2003, J IMMUNOL, V170, P1635, DOI 10.4049/jimmunol.170.4.1635; Benjamini Y, 2001, ANN STAT, V29, P1165; Cambi A, 2003, CURR OPIN CELL BIOL, V15, P539, DOI 10.1016/j.ceb.2003.08.004; Chehimi J, 2003, J LEUKOCYTE BIOL, V74, P757, DOI 10.1189/jlb.0503231; CURTIS BM, 1992, P NATL ACAD SCI USA, V89, P8356, DOI 10.1073/pnas.89.17.8356; DeKoter RP, 2000, SCIENCE, V288, P1439, DOI 10.1126/science.288.5470.1439; Durst KL, 2004, ONCOGENE, V23, P4220, DOI 10.1038/sj.onc.1207122; Egan BS, 1999, J BIOL CHEM, V274, P9098, DOI 10.1074/jbc.274.13.9098; Eichbaum Q, 1997, BLOOD, V90, P4135, DOI 10.1182/blood.V90.10.4135; Engering A, 2004, AM J PATHOL, V164, P1587, DOI 10.1016/S0002-9440(10)63717-0; Engering A, 2002, J IMMUNOL, V168, P2118, DOI 10.4049/jimmunol.168.5.2118; Engering A, 2002, BLOOD, V100, P1780, DOI 10.1182/blood-2001-12-0179; Fainaru O, 2004, EMBO J, V23, P969, DOI 10.1038/sj.emboj.7600085; Feinberg H, 2001, SCIENCE, V294, P2163, DOI 10.1126/science.1066371; Figdor CG, 2002, NAT REV IMMUNOL, V2, P77, DOI 10.1038/nri723; Friedman AD, 2002, ONCOGENE, V21, P3377, DOI 10.1038/sj.onc.1205324; Frison N, 2003, J BIOL CHEM, V278, P23922, DOI 10.1074/jbc.M302483200; Geijtenbeek TBH, 2004, ANNU REV IMMUNOL, V22, P33, DOI 10.1146/annurev.immunol.22.012703.104558; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; Geijtenbeek TBH, 2000, NAT IMMUNOL, V1, P353, DOI 10.1038/79815; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Guerriero A, 2000, BLOOD, V95, P879, DOI 10.1182/blood.V95.3.879.003k13_879_885; Huang Q, 2001, SCIENCE, V294, P870, DOI 10.1126/science.294.5543.870; Iwama A, 2002, J EXP MED, V195, P547, DOI 10.1084/jem.20011465; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Li AC, 1998, J BIOL CHEM, V273, P5389, DOI 10.1074/jbc.273.9.5389; Liu HB, 2003, GENE, V313, P149, DOI 10.1016/S0378-1119(03)00674-7; Liu HL, 2004, J INFECT DIS, V190, P1055, DOI 10.1086/423209; LopezRodriguez C, 1997, EUR J IMMUNOL, V27, P1843, DOI 10.1002/eji.1830270804; Martin MP, 2004, J VIROL, V78, P14053, DOI 10.1128/JVI.78.24.14053-14056.2004; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Mummidi S, 2001, J BIOL CHEM, V276, P33196, DOI 10.1074/jbc.M009807200; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; O'Reilly D, 2003, J BIOL CHEM, V278, P21909, DOI 10.1074/jbc.M212150200; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; PAHL HL, 1993, J BIOL CHEM, V268, P5014; Park CG, 2001, INT IMMUNOL, V13, P1283, DOI 10.1093/intimm/13.10.1283; Pauleau AL, 2004, J IMMUNOL, V172, P7565, DOI 10.4049/jimmunol.172.12.7565; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; Puig-Kroger A, 2003, BLOOD, V102, P3252, DOI 10.1182/blood-2003-02-0618; Puig-Kroger A, 2004, J BIOL CHEM, V279, P25680, DOI 10.1074/jbc.M311516200; Rehli M, 2000, J BIOL CHEM, V275, P9773, DOI 10.1074/jbc.275.13.9773; Relloso M, 2002, J IMMUNOL, V168, P2634, DOI 10.4049/jimmunol.168.6.2634; Rosenbauer F, 2004, NAT GENET, V36, P624, DOI 10.1038/ng1361; Schjetne KW, 2002, INT IMMUNOL, V14, P1423, DOI 10.1093/intimm/dxf110; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Soilleux EJ, 2002, J LEUKOCYTE BIOL, V71, P445; Tsujimura H, 2003, BLOOD, V101, P961, DOI 10.1182/blood-2002-05-1327; Turville SG, 2001, BLOOD, V98, P2482, DOI 10.1182/blood.V98.8.2482; van Kooyk Y, 2003, NAT REV IMMUNOL, V3, P697, DOI 10.1038/nri1182; van Lent PLEM, 2003, ARTHRITIS RHEUM, V48, P360, DOI 10.1002/art.10786	54	30	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33123	33131		10.1074/jbc.M503401200	http://dx.doi.org/10.1074/jbc.M503401200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16051608	hybrid, Green Published			2022-12-25	WOS:000232058100006
J	Kreikemeyer, B; Nakata, M; Oehmcke, S; Gschwendtner, C; Normann, J; Podbielski, A				Kreikemeyer, B; Nakata, M; Oehmcke, S; Gschwendtner, C; Normann, J; Podbielski, A			Streptococcus pyogenes collagen type I-binding Cpa surface protein - Expression profile, binding characteristics, biological functions, and potential clinical impact	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A STREPTOCOCCUS; VIRULENCE FACTOR REGULATION; COMPLETE GENOME SEQUENCE; TUMOR-NECROSIS-FACTOR; ANTIGEN I/II FAMILY; STAPHYLOCOCCUS-AUREUS; SECONDARY STRUCTURE; RHEUMATIC-FEVER; GENE FAMILY; ADHESIN	The Streptococcus pyogenes collagen type I-binding protein Cpa (collagen-binding protein of group A streptococci) expressed by 28 serotypes of group A streptococci has been extensively characterized at the gene and protein levels. Evidence for three distinct families of cpa genes was found, all of which shared a common sequence encoding a 60-amino acid domain that accounted for selective binding to type I collagen. Surface plasmon resonance-based affinity measurements and functional studies indicated that the expression of Cpa was consistent with an attachment role for bacteria to tissue containing collagen type I. A cpa mutant displayed a significantly decreased internalization rate when incubated with HEp-2 cells but had no effect on the host cell viability. By utilizing serum from patients with a positive titer for streptolysin/DNase antibody, an increased anti-Cpa antibody titer was noted for patients with a clinical history of arthritis or osteomyelitis. Taken together, these results suggest Cpa may be a relevant matrix adhesin contributing to the pathogenesis of S. pyogenes infection of bones and joints.	Hosp Rostock Univ, Dept Med Microbiol & Hosp Hyg, D-18057 Rostock, Germany	University of Rostock	Podbielski, A (corresponding author), Hosp Rostock Univ, Dept Med Microbiol & Hosp Hyg, Schillingallee 70, D-18057 Rostock, Germany.	andreas.podbielski@med.uni-rostock.de		Kreikemeyer, Bernd/0000-0001-9527-5098; Nakata, Masanobu/0000-0003-1686-5415				Baev D, 1999, INFECT IMMUN, V67, P4510, DOI 10.1128/IAI.67.9.4510-4516.1999; Banks DJ, 2004, J INFECT DIS, V190, P727, DOI 10.1086/422697; Barnett TC, 2004, J BACTERIOL, V186, P5865, DOI 10.1128/JB.186.17.5865-5875.2004; Batchelor E, 2004, J BACTERIOL, V186, P7618, DOI 10.1128/JB.186.22.7618-7625.2004; Beres SB, 2002, P NATL ACAD SCI USA, V99, P10078, DOI 10.1073/pnas.152298499; BERGEY EJ, 1988, INFECT IMMUN, V56, P1715, DOI 10.1128/IAI.56.7.1715-1721.1988; Bessen DE, 1996, J INFECT DIS, V173, P896, DOI 10.1093/infdis/173.4.896; Bessen DE, 2002, INFECT IMMUN, V70, P1159, DOI 10.1128/IAI.70.3.1159-1167.2002; BROOKS W, 1994, J MED MICROBIOL, V40, P330, DOI 10.1099/00222615-40-5-330; Chatenay-Rivauday C, 1998, MOL MICROBIOL, V29, P39, DOI 10.1046/j.1365-2958.1998.00881.x; COLMAN G, 1993, J MED MICROBIOL, V39, P165, DOI 10.1099/00222615-39-3-165; Courtney HS, 2002, ANN MED, V34, P77, DOI 10.1080/07853890252953464; COURTNEY HS, 2004, BACTERIAL INVASION H, P239; Crowley PJ, 1999, INFECT IMMUN, V67, P1201, DOI 10.1128/IAI.67.3.1201-1206.1999; Darmstadt GL, 2000, INFECT IMMUN, V68, P1215, DOI 10.1128/IAI.68.3.1215-1221.2000; Deivanayagam CCS, 2000, STRUCTURE, V8, P67, DOI 10.1016/S0969-2126(00)00081-2; Dinkla K, 2003, J CLIN INVEST, V111, P1905, DOI 10.1172/JCI200317247; Dinkla K, 2003, MOL MICROBIOL, V47, P861, DOI 10.1046/j.1365-2958.2003.03352.x; Elasri MO, 2002, BONE, V30, P275, DOI 10.1016/S8756-3282(01)00632-9; Ferretti JJ, 2001, P NATL ACAD SCI USA, V98, P4658, DOI 10.1073/pnas.071559398; Foster TJ, 1998, TRENDS MICROBIOL, V6, P484, DOI 10.1016/S0966-842X(98)01400-0; FRICK IM, 1994, MOL MICROBIOL, V12, P143, DOI 10.1111/j.1365-2958.1994.tb01003.x; Gelse K, 2003, ADV DRUG DELIVER REV, V55, P1531, DOI 10.1016/j.addr.2003.08.002; Gillaspy AF, 1997, GENE, V196, P239, DOI 10.1016/S0378-1119(97)00256-4; GLURICH I, 1991, MICROB PATHOGENESIS, V10, P209, DOI 10.1016/0882-4010(91)90055-F; Hajishengallis G, 2002, CLIN DIAGN LAB IMMUN, V9, P403, DOI 10.1128/CDLI.9.2.403-411.2002; Hamada T, 2004, INFECT IMMUN, V72, P4819, DOI 10.1128/IAI.72.8.4819-4826.2004; Heddle C, 2003, MOL MICROBIOL, V50, P597, DOI 10.1046/j.1365-2958.2003.03711.x; Hienz SA, 1996, J INFECT DIS, V174, P83, DOI 10.1093/infdis/174.1.83; Holmes AR, 1998, INFECT IMMUN, V66, P4633, DOI 10.1128/IAI.66.10.4633-4639.1998; Hubble TS, 2003, ORAL MICROBIOL IMMUN, V18, P121, DOI 10.1034/j.1399-302X.2003.00059.x; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; Jenkinson HF, 1997, MOL MICROBIOL, V23, P183, DOI 10.1046/j.1365-2958.1997.2021577.x; Joh D, 1998, EUR J BIOCHEM, V258, P897, DOI 10.1046/j.1432-1327.1998.2580897.x; Joh D, 1999, MATRIX BIOL, V18, P211, DOI 10.1016/S0945-053X(99)00025-6; Johansson MU, 1997, J MOL BIOL, V266, P859, DOI 10.1006/jmbi.1996.0856; JOHNSON DR, 1992, J INFECT DIS, V166, P374, DOI 10.1093/infdis/166.2.374; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; KAPLAN EL, 1994, J INFECT DIS, V170, P1346, DOI 10.1093/infdis/170.5.1346; KAUFHOLD A, 1992, J CLIN MICROBIOL, V30, P2391, DOI 10.1128/JCM.30.9.2391-2397.1992; KOSTRZYNSKA M, 1989, FEMS MICROBIOL LETT, V59, P229; Kreikemeyer B, 2004, INT J MED MICROBIOL, V294, P177, DOI 10.1016/j.ijmm.2004.06.017; Kreikemeyer B, 2004, J BIOL CHEM, V279, P15850, DOI 10.1074/jbc.M313613200; Kreikemeyer B, 2003, TRENDS MICROBIOL, V11, P224, DOI 10.1016/S0966-842X(03)00098-2; Kreikemeyer B, 2002, MICROBIOL-SGM, V148, P1501, DOI 10.1099/00221287-148-5-1501; KREIKEMEYER B, 1995, MOL MICROBIOL, V17, P137, DOI 10.1111/j.1365-2958.1995.mmi_17010137.x; Kreikemeyer B, 2001, MOL MICROBIOL, V39, P392, DOI 10.1046/j.1365-2958.2001.02226.x; Lannergard J, 2003, FEMS MICROBIOL LETT, V222, P69, DOI 10.1016/S0378-1097(03)00222-2; Love RM, 1997, INFECT IMMUN, V65, P5157, DOI 10.1128/IAI.65.12.5157-5164.1997; MAXTED WR, 1978, STREPTOCOCCI, P107; Mohamed JA, 2004, INFECT IMMUN, V72, P3658, DOI 10.1128/IAI.72.6.3658-3663.2004; Molinari G, 2000, CELL MICROBIOL, V2, P145, DOI 10.1046/j.1462-5822.2000.00040.x; Molinari G, 2001, MOL MICROBIOL, V40, P99, DOI 10.1046/j.1365-2958.2001.02373.x; Myszka DG, 1998, TRENDS BIOCHEM SCI, V23, P149, DOI 10.1016/S0968-0004(98)01183-9; Myszyka DG, 1999, J MOL RECOGNIT, V12, P279, DOI 10.1002/(SICI)1099-1352(199909/10)12:5<279::AID-JMR473>3.0.CO;2-3; Nallapareddy SR, 2000, INFECT IMMUN, V68, P5218, DOI 10.1128/IAI.68.9.5218-5224.2000; Nallapareddy SR, 2003, MOL MICROBIOL, V47, P1733, DOI 10.1046/j.1365-2958.2003.03417.x; Oehmcke S, 2004, INFECT IMMUN, V72, P4302, DOI 10.1128/IAI.72.7.4302-4308.2004; PATTI JM, 1994, ANNU REV MICROBIOL, V48, P585, DOI 10.1146/annurev.mi.48.100194.003101; PATTI JM, 1993, BIOCHEMISTRY-US, V32, P11428, DOI 10.1021/bi00093a021; PATTI JM, 1995, J BIOL CHEM, V270, P12005, DOI 10.1074/jbc.270.20.12005; PATTI JM, 1994, INFECT IMMUN, V62, P152, DOI 10.1128/IAI.62.1.152-161.1994; PODBIELSKI A, 1991, MED MICROBIOL IMMUN, V180, P213; Podbielski A, 1999, MOL MICROBIOL, V31, P1051, DOI 10.1046/j.1365-2958.1999.01241.x; PODBIELSKI A, 1993, IMMUNOMETHODS, V2, P55; Pollastri G, 2002, PROTEINS, V47, P228, DOI 10.1002/prot.10082; Ponnuraj K, 2002, BBA-PROTEIN STRUCT M, V1596, P173, DOI 10.1016/S0167-4838(01)00328-4; Ramachandran V, 2004, J BACTERIOL, V186, P7601, DOI 10.1128/JB.186.22.7601-7609.2004; Rhem MN, 2000, INFECT IMMUN, V68, P3776, DOI 10.1128/IAI.68.6.3776-3779.2000; Rich RL, 1999, J BIOL CHEM, V274, P26939, DOI 10.1074/jbc.274.38.26939; Rich RL, 1999, J BIOL CHEM, V274, P24906, DOI 10.1074/jbc.274.35.24906; Rich RL, 1998, BIOCHEMISTRY-US, V37, P15423, DOI 10.1021/bi981773r; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Ryding U, 1997, J INFECT DIS, V176, P1096, DOI 10.1086/516520; Samen U, 2004, J BACTERIOL, V186, P1398, DOI 10.1128/JB.186.5.1398-1408.2004; SCHMIDT KH, 1993, ZBL BAKT-INT J MED M, V279, P472, DOI 10.1016/S0934-8840(11)80419-6; Sciotti MA, 1997, FEMS MICROBIOL LETT, V153, P439, DOI 10.1016/S0378-1097(97)00287-5; Smeltzer MS, 1997, GENE, V196, P249, DOI 10.1016/S0378-1119(97)00237-0; Smeltzer MS, 1996, J CLIN MICROBIOL, V34, P1364, DOI 10.1128/JCM.34.6.1364-1372.1996; Smoot JC, 2002, P NATL ACAD SCI USA, V99, P4668, DOI 10.1073/pnas.062526099; Snodgrass JL, 1999, INFECT IMMUN, V67, P3952, DOI 10.1128/IAI.67.8.3952-3959.1999; SOELL M, 1994, INFECT IMMUN, V62, P1805, DOI 10.1128/IAI.62.5.1805-1812.1994; SWITALSKI LM, 1993, MOL MICROBIOL, V7, P99, DOI 10.1111/j.1365-2958.1993.tb01101.x; Symersky J, 1997, NAT STRUCT BIOL, V4, P833, DOI 10.1038/nsb1097-833; Towers RJ, 2003, J CLIN MICROBIOL, V41, P5398, DOI 10.1128/JCM.41.12.5398-5406.2003; VERCELLOTTI GM, 1985, AM J PATHOL, V120, P13; Vernier-Georgenthum A, 1998, CELL IMMUNOL, V187, P145, DOI 10.1006/cimm.1998.1327; VISAI L, 1995, J BIOL CHEM, V270, P347, DOI 10.1074/jbc.270.1.347; WANNAMAKER LW, 1970, NEW ENGL J MED, V282, P23, DOI 10.1056/NEJM197001082820206; WESTERLUND B, 1993, MOL MICROBIOL, V9, P687, DOI 10.1111/j.1365-2958.1993.tb01729.x; Widdowson JP, 1980, STREPTOCOCCAL DISEAS, P125; Xu Y, 2004, J INFECT DIS, V189, P2323, DOI 10.1086/420851	92	79	79	1	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33228	33239		10.1074/jbc.M502896200	http://dx.doi.org/10.1074/jbc.M502896200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16040603	hybrid			2022-12-25	WOS:000232058100018
J	Tondu, AL; Robichon, C; Yvan-Charvet, L; Donne, N; Le Liepvre, X; Hajduch, E; Ferre, P; Dugail, I; Dagher, G				Tondu, AL; Robichon, C; Yvan-Charvet, L; Donne, N; Le Liepvre, X; Hajduch, E; Ferre, P; Dugail, I; Dagher, G			Insulin and angiotensin II induce the translocation of scavenger receptor class B, type I from intracellular sites to the plasma membrane of adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; SELECTIVE LIPID UPTAKE; SR-BI; CHOLESTERYL ESTERS; TARGETED MUTATION; SKELETAL-MUSCLE; ACID-TRANSPORT; ADIPOSE-TISSUE; GLUCOSE; CELLS	Scavenger receptor class B, type I (SR-BI) mediates the selective uptake of lipids from high density lipoproteins and is expressed in several types of tissues. However, to date little is known about its role in adipocytes. In this study, we investigated the cellular distribution of SR-BI in 3T3-L1 adipocytes and its regulation by hormones known to increase lipid storage such as angiotensin II ( Ang II) and insulin. SR-BI was mainly distributed in the cytoplasm as determined by laser-scanning confocal analysis of the immunofluorescence labeling of SR-BI or the study of an enhanced green fluorescent protein-tagged SR-BI fusion protein. Exposure of cells to either insulin or Ang II ( 1 - 2 h) induced the mobilization of SR-BI from intracellular pools to the plasma membrane. This was further confirmed by Western blotting on purified plasma membrane and by fluorescence-activated cell sorter analysis of the SR-BI receptor. Similar results were also observed in primary adipocytes. We also demonstrated that, in the presence of either insulin or Ang II, SR-BI translocation to the cell membrane is functional, because insulin and Ang II induced a significant increase in the high density lipoprotein-delivered 22-(N-7-nitrobenz-2-oxa-1,3-diazo-4-yl)amino- 23,24-bisnor-5-cholen-3-ol uptake and in total cholesterol content. These data demonstrate that SR-BI can be acutely mobilized from intracellular stores to the cell surface by insulin or Ang II, two hormones that exert lipogenic effects in adipocytes. This suggests that SR-BI might participate in the storage of lipids in the adipose tissue.	Univ Paris 06, Inst Biomed Cordeliers, INSERM, U671, F-75006 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite	Dagher, G (corresponding author), Univ Paris 06, Inst Biomed Cordeliers, INSERM, U671, 15 Rue Ecole Med, F-75006 Paris, France.	dagher@ccr.jussieu.fr	Dugail, Isabelle/L-1567-2017; Ferré, Pascal/K-1250-2013; Dagher, Georges/AAC-1556-2020; Hajduch, Eric/B-7332-2008	Dugail, Isabelle/0000-0003-3631-2252; Ferré, Pascal/0000-0003-0115-7045; Hajduch, Eric/0000-0002-0125-7751; Yvan-Charvet, Laurent/0000-0002-7748-4942				Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Azhar S, 1998, J LIPID RES, V39, P1616; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; Backer Jonathan M., 2000, Molecular Cell Biology Research Communications, V3, P193, DOI 10.1006/mcbr.2000.0202; Boizard M, 1998, J BIOL CHEM, V273, P29164, DOI 10.1074/jbc.273.44.29164; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cherradi N, 2001, ENDOCRINOLOGY, V142, P4540, DOI 10.1210/en.142.10.4540; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; Dagher G, 2003, J LIPID RES, V44, P1811, DOI 10.1194/jlr.M300267-JLR200; FOLCH J, 1957, J BIOL CHEM, V226, P497; GOLDSTEIN JL, 1974, J BIOL CHEM, V249, P5153; Hajduch E, 1998, DIABETES, V47, P1006, DOI 10.2337/diabetes.47.7.1006; Hyde R, 2001, BIOCHEM J, V355, P563, DOI 10.1042/bj3550563; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Krieger M, 1999, ANNU REV BIOCHEM, V68, P523, DOI 10.1146/annurev.biochem.68.1.523; Landschulz KT, 1996, J CLIN INVEST, V98, P984, DOI 10.1172/JCI118883; Le Lay S, 2001, J BIOL CHEM, V276, P16904, DOI 10.1074/jbc.M010955200; Li XL, 1998, ENDOCRINOLOGY, V139, P3043, DOI 10.1210/en.139.7.3043; Martys JL, 1996, J BIOL CHEM, V271, P10953, DOI 10.1074/jbc.271.18.10953; Massiera F, 2001, FASEB J, V15, P2727, DOI 10.1096/fj.01-0457fje; NISHIMURA H, 1993, J BIOL CHEM, V268, P19246; PITAS RE, 1981, ARTERIOSCLEROSIS, V1, P177, DOI 10.1161/01.ATV.1.3.177; Reaven E, 1998, ENDOCRINOLOGY, V139, P2847, DOI 10.1210/en.139.6.2847; Rigotti A, 2003, ENDOCR REV, V24, P357, DOI 10.1210/er.2001-0037; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Ruan H, 2001, DIABETES, V50, P233, DOI 10.2337/diabetes.50.2.233; Sato Y, 1996, TISSUE CELL, V28, P637, DOI 10.1016/S0040-8166(96)80067-X; Stahl A, 2002, DEV CELL, V2, P477, DOI 10.1016/S1534-5807(02)00143-0; Trigatti BL, 2000, BBA-MOL CELL BIOL L, V1529, P276, DOI 10.1016/S1388-1981(00)00154-2; Varban ML, 1998, P NATL ACAD SCI USA, V95, P4619, DOI 10.1073/pnas.95.8.4619; Vassiliou G, 2004, J LIPID RES, V45, P1683, DOI 10.1194/jlr.M400051-JLR200; Wang N, 1998, J BIOL CHEM, V273, P32920, DOI 10.1074/jbc.273.49.32920; Wu-Wong JSR, 1999, J BIOL CHEM, V274, P8103, DOI 10.1074/jbc.274.12.8103	34	41	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33536	33540		10.1074/jbc.M502392200	http://dx.doi.org/10.1074/jbc.M502392200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16033765	hybrid			2022-12-25	WOS:000232058100053
J	Byfield, MP; Murray, JT; Backer, JM				Byfield, MP; Murray, JT; Backer, JM			hVps34 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUBEROUS SCLEROSIS COMPLEX; PHOSPHATIDYLINOSITOL 3-KINASE; MAMMALIAN TARGET; PROTEIN-KINASE; CELL-GROWTH; DISTINCT ROLES; PHOSPHORYLATION SITE; ACTIN CYTOSKELETON; BINDING PARTNER; RAPAMYCIN MTOR	Mammalian cells respond to nutrient deprivation by inhibiting energy consuming processes, such as proliferation and protein synthesis, and by stimulating catabolic processes, such as autophagy. p70 S6 kinase (S6K1) plays a central role during nutritional regulation of translation. S6K1 is activated by growth factors such as insulin, and by mammalian target of rapamycin (mTOR), which is itself regulated by amino acids. The Class IA phosphatidylinositol (PI) 3-kinase plays a well recognized role in the regulation of S6K1. We now present evidence that the Class III PI 3-kinase, hVps34, also regulates S6K1, and is a critical component of the nutrient sensing apparatus. Overexpression of hVps34 or the associated hVps15 kinase activates S6K1, and insulin stimulation of S6K1 is blocked by microinjection of inhibitory anti-hVps34 antibodies, overexpression of a FYVE domain construct that sequesters the hVps34 product PI(3) P, or small interfering RNA-mediated knock-down of hVps34. hVps34 is not part of the insulin input to S6K1, as it is not stimulated by insulin, and inhibition of hVps34 has no effect on phosphorylation of Akt or TSC2 in insulin-stimulated cells. However, hVps34 is inhibited by amino acid or glucose starvation, suggesting that it lies on the nutrient-regulated pathway to S6K1. Consistent with this, hVps34 is also inhibited by activation of the AMP-activated kinase, which inhibits mTOR/S6K1 in glucose-starved cells. hVps34 appears to lie upstream of mTOR, as small interfering RNA knock- down of hVps34 inhibits the phosphorylation of another mTOR substrate, eIF4E-binding protein-1 (4EBP1). Our data suggest that hVps34 is a nutrient-regulated lipid kinase that integrates amino acid and glucose inputs to mTOR and S6K1.	Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Univ Dundee, MRC, Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland	Yeshiva University; Albert Einstein College of Medicine; University of Dundee	Backer, JM (corresponding author), Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	Backer@aecom.yu.edu	Murray, James/AAC-6612-2019	Murray, James/0000-0002-6928-2347	NIGMS NIH HHS [T32 GM07491] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007491] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Carling D, 2004, TRENDS BIOCHEM SCI, V29, P18, DOI 10.1016/j.tibs.2003.11.005; Cheng SWY, 2004, J BIOL CHEM, V279, P15719, DOI 10.1074/jbc.C300534200; Christoforidis S, 1999, NAT CELL BIOL, V1, P249, DOI 10.1038/12075; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Eskelinen EL, 2002, TRAFFIC, V3, P878, DOI 10.1034/j.1600-0854.2002.31204.x; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; FLOTOW H, 1992, J BIOL CHEM, V267, P3074; Fratti RA, 2001, J CELL BIOL, V154, P631, DOI 10.1083/jcb.200106049; Futter CE, 2001, J CELL BIOL, V155, P1251, DOI 10.1083/jcb.200108152; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; Gingras AC, 2001, GENE DEV, V15, P2852; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Jaeschke A, 2002, J CELL BIOL, V159, P217, DOI 10.1083/jcb.jcb.200206108; KAPELLER R, 1991, MOL ENDOCRINOL, V5, P769, DOI 10.1210/mend-5-6-769; Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061; Kihara A, 2001, J CELL BIOL, V152, P519, DOI 10.1083/jcb.152.3.519; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kozma SC, 2002, BIOESSAYS, V24, P65, DOI 10.1002/bies.10031; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; Lehman JA, 2003, J BIOL CHEM, V278, P28130, DOI 10.1074/jbc.M300376200; Leslie NR, 2001, CHEM REV, V101, P2365, DOI 10.1021/cr000091i; Li Y, 2004, TRENDS BIOCHEM SCI, V29, P32, DOI 10.1016/j.tibs.2003.11.007; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; Liang XH, 2001, CANCER RES, V61, P3443; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Long X, 2005, CURR BIOL, V15, P702, DOI 10.1016/j.cub.2005.02.053; Long X, 2003, CURR TOP MICROBIOL, V279, P115; Long XM, 2005, J BIOL CHEM, V280, P23433, DOI 10.1074/jbc.C500169200; Maffucci T, 2003, EMBO J, V22, P4178, DOI 10.1093/emboj/cdg402; Manning BD, 2003, TRENDS BIOCHEM SCI, V28, P573, DOI 10.1016/j.tibs.2003.09.003; Michell BJ, 1996, J BIOL CHEM, V271, P28445, DOI 10.1074/jbc.271.45.28445; Murray JT, 2002, TRAFFIC, V3, P416, DOI 10.1034/j.1600-0854.2002.30605.x; Pan DJ, 2004, TRENDS CELL BIOL, V14, P78, DOI 10.1016/j.tcb.2003.12.006; Panaretou C, 1997, J BIOL CHEM, V272, P2477; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Pelkmans L, 2005, NATURE, V436, P78, DOI 10.1038/nature03571; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; POLLARD JW, 1979, J CELL PHYSIOL, V98, P571, DOI 10.1002/jcp.1040980315; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Saito K, 2005, J BIOCHEM, V137, P423, DOI 10.1093/jb/mvi046; Samari HR, 1998, J BIOL CHEM, V273, P23758, DOI 10.1074/jbc.273.37.23758; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Scott RC, 2004, DEV CELL, V7, P167, DOI 10.1016/j.devcel.2004.07.009; Siddhanta U, 1998, J CELL BIOL, V143, P1647, DOI 10.1083/jcb.143.6.1647; Smith EM, 2005, J BIOL CHEM, V280, P18717, DOI 10.1074/jbc.M414499200; STACK JH, 1993, EMBO J, V12, P2195, DOI 10.1002/j.1460-2075.1993.tb05867.x; Tassa A, 2003, BIOCHEM J, V376, P577, DOI 10.1042/BJ20030826; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Tolias KF, 1998, J BIOL CHEM, V273, P18040, DOI 10.1074/jbc.273.29.18040; Tuma PL, 2001, J CELL BIOL, V154, P1197, DOI 10.1083/jcb.200105138; Vieira OV, 2001, J CELL BIOL, V155, P19, DOI 10.1083/jcb.200107069; Wang Z, 2001, MOL CELL BIOL, V21, P5742, DOI 10.1128/MCB.21.17.5742-5752.2001; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100; Zhang XL, 1997, J BIOL CHEM, V272, P17756, DOI 10.1074/jbc.272.28.17756; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999	65	419	438	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					33076	33082		10.1074/jbc.M507201200	http://dx.doi.org/10.1074/jbc.M507201200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16049009	hybrid			2022-12-25	WOS:000231920300062
J	Turkson, J; Zhang, SM; Mora, LB; Burns, A; Sebti, S; Jove, R				Turkson, J; Zhang, SM; Mora, LB; Burns, A; Sebti, S; Jove, R			A novel platinum compound inhibits constitutive Stat3 signaling and induces cell cycle arrest and apoptosis of malignant cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CARCINOMA CELLS; CANCER DRUG DISCOVERY; DNA-BINDING ACTIVITY; HUMAN SERUM-ALBUMIN; U266 MYELOMA CELLS; MOLECULAR TARGETS; SRC ONCOPROTEIN; KINASE-ACTIVITY; GENE-REGULATION; TRANSCRIPTIONAL ACTIVATION	Previous studies have established constitutive activation of Stat3 protein as one of the molecular changes required for tumorigenesis. To develop novel therapeutics for tumors harboring constitutively active Stat3, compounds from the NCI 2000 diversity set were evaluated for inhibition of Stat3 DNA-binding activity in vitro. Of these, a novel platinum (IV) compound, IS3 295, interacted with Stat3 and inhibited its binding to specific DNA-response elements. Further analysis suggested noncompetitive-type kinetics for the inhibition of Stat3 binding to DNA. In human and mouse tumor cell lines with constitutively active Stat3, IS3 295 selectively attenuated Stat3 signaling, thereby inducing cell growth arrest at G(0)/G(1) phase and apoptosis. Moreover, in transformed cells, IS3 295 repressed expression of cyclin D1 and bcl-x(L), two of the known Stat3-regulated genes that are overexpressed in malignant cells, suggesting that IS3 295 mediates anti-tumor cell activity in part by blocking Stat3-mediated subversion of cell growth and apoptotic signals. Together, our findings provide evidence for the inhibition of Stat3 activity and biological functions by IS3 295 through interaction with Stat3 protein. This study represents a significant advance in small molecule-based approaches to target Stat3 and suggests potential new applications for platinum (IV) complexes as modulators of the Stat3 pathway for cancer therapy.	Univ S Florida, Mol Oncol Program, Coll Med, Tampa, FL 33612 USA; Univ S Florida, Drug Discovery Programs, Coll Med, H Lee Moffit Canc Ctr & Res Inst, Tampa, FL 33612 USA; Univ S Florida, Dept Oncol, Coll Med, Tampa, FL 33612 USA; Univ S Florida, Dept Biochem & Mol Biol, Coll Med, Tampa, FL 33612 USA; Univ S Florida, Dept Pathol, Coll Med, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Turkson, J (corresponding author), Univ Cent Florida, Dept Mol Biol & Microbiol, BioMol Sci Ctr, 12722 Res Pkwy, Orlando, FL 32826 USA.	jturkson@mail.ucf.edu			NATIONAL CANCER INSTITUTE [R01CA055652] Funding Source: NIH RePORTER; NCI NIH HHS [CA55652] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akira S, 2000, ONCOGENE, V19, P2607, DOI 10.1038/sj.onc.1203478; Allain P, 2000, DRUG METAB DISPOS, V28, P1379; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Bose RN, 2002, MINI-REV MED CHEM, V2, P103, DOI 10.2174/1389557024605500; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, BREAST CANCER RES, V2, P86, DOI 10.1186/bcr38; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Buettner R, 2002, CLIN CANCER RES, V8, P945; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Coffer PJ, 2000, ONCOGENE, V19, P2511, DOI 10.1038/sj.onc.1203479; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; GOUILLEUX F, 1995, ENDOCRINOLOGY, V136, P5700, DOI 10.1210/en.136.12.5700; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Heudi O, 1999, BIOPHARM DRUG DISPOS, V20, P107, DOI 10.1002/(SICI)1099-081X(199903)20:2<107::AID-BDD161>3.0.CO;2-0; Heudi O, 2001, INT J CLIN PHARM TH, V39, P344; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; Karras JG, 2000, CELL IMMUNOL, V202, P124, DOI 10.1006/cimm.2000.1661; Kotenko SV, 2000, ONCOGENE, V19, P2557, DOI 10.1038/sj.onc.1203524; Lin TS, 2000, ONCOGENE, V19, P2496, DOI 10.1038/sj.onc.1203486; Mora LB, 2002, CANCER RES, V62, P6659; Nielsen M, 1997, P NATL ACAD SCI USA, V94, P6764, DOI 10.1073/pnas.94.13.6764; Nielsen M, 1999, LEUKEMIA, V13, P735, DOI 10.1038/sj.leu.2401415; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Niu GL, 1999, CANCER RES, V59, P5059; Oshiro MM, 2001, CLIN CANCER RES, V7, P4262; Oyajobi BO, 2003, BLOOD, V102, P311, DOI 10.1182/blood-2002-12-3905; Perez JM, 2003, MOL PHARMACOL, V63, P933, DOI 10.1124/mol.63.4.933; Persons DL, 1999, CLIN CANCER RES, V5, P1007; Sanchez-Perez I, 1998, ONCOGENE, V16, P533, DOI 10.1038/sj.onc.1201578; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; Smithgall TE, 2000, ONCOGENE, V19, P2612, DOI 10.1038/sj.onc.1203477; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; Song LX, 2003, ONCOGENE, V22, P4150, DOI 10.1038/sj.onc.1206479; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Trynda-Lemiesz L, 2004, J INORG BIOCHEM, V98, P1851, DOI 10.1016/j.jinorgbio.2004.08.015; Trynda-Lemiesz L, 1999, J INORG BIOCHEM, V77, P141, DOI 10.1016/S0162-0134(99)00183-X; Turkson J, 2004, MOL CANCER THER, V3, P1533; Turkson J, 2004, MOL CANCER THER, V3, P261; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Turkson J, 2001, J BIOL CHEM, V276, P45443, DOI 10.1074/jbc.M107527200; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; Turkson J, 2004, EXPERT OPIN THER TAR, V8, P409, DOI 10.1517/14728222.8.5.409; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Wang GD, 2004, ONCOL REP, V12, P955; Wang TH, 2004, NAT MED, V10, P48, DOI 10.1038/nm976; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Zhang DX, 1996, J BIOL CHEM, V271, P9503, DOI 10.1074/jbc.271.16.9503; Zhang Y, 2000, J BIOL CHEM, V275, P24935, DOI 10.1074/jbc.M002383200	64	149	166	2	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32979	32988		10.1074/jbc.M502694200	http://dx.doi.org/10.1074/jbc.M502694200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16046414	Green Published, hybrid			2022-12-25	WOS:000231920300052
J	Sjoberg, A; Onnerfjord, P; Morgelin, M; Heinegard, D; Blom, AM				Sjoberg, A; Onnerfjord, P; Morgelin, M; Heinegard, D; Blom, AM			The extracellular matrix and inflammation - Fibromodulin activates the classical pathway of complement by directly binding C1q	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN-INDUCED ARTHRITIS; SHORT CONSENSUS REPEAT; C-REACTIVE PROTEIN; FACTOR-H; ALTERNATIVE PATHWAY; MONOCLONAL-ANTIBODY; ELECTRON-MICROSCOPY; 1ST COMPONENT; ALPHA-CHAIN; SITE	Components that propagate inflammation in joint disease may be derived from cartilage since the inflammation resolves after joint replacement. We found that the cartilage component fibromodulin has the ability to activate an inflammatory cascade, i.e. complement. Fibromodulin and immunoglobulins cause comparable deposition of C1q, C4b, and C3b from human serum. Using C1q and factor B-deficient sera in combination with varying contents of metal ions, we established that fibromodulin activates both the classical and the alternative pathways of complement. Further studies revealed that fibromodulin binds directly to the globular heads of C1q, leading to activation of C1. However, deposition of the membrane attack complex and C5a release were lower in the presence of fibromodulin as compared with IgG. This can be explained by the fact that fibromodulin also binds complement inhibitor factor H. Factor H and C1q bind to non-overlapping sites on fibromodulin, but none of the interactions is mediated by the negatively charged keratan sulfate substituents of fibromodulin. C1q but not factor H binds to an N-terminal fragment of fibromodulin previously implicated to be affected in cartilage stimulated with the inflammatory cytokine interleukin 1. Taken together our observations indicate fibromodulin as one factor involved in the sustained inflammation of the joint.	Lund Univ, Div Cell & Matrix Biol, Dept Expt Med Sci, BMC, SE-22184 Lund, Sweden; Malmo Univ Hosp, Dept Lab Med, SE-22184 Lund, Sweden	Lund University; Lund University; Skane University Hospital	Heinegard, D (corresponding author), Lund Univ, Div Cell & Matrix Biol, Dept Expt Med Sci, BMC, BMC Plan C12, SE-22184 Lund, Sweden.	dick.heinegard@med.lu.se	Blom, Anna/B-9607-2009; Onnerfjord, Patrik/R-3131-2019; Blom, Anna/AFS-7369-2022	Blom, Anna/0000-0002-1348-1734; Onnerfjord, Patrik/0000-0002-2345-2937; 				ANTONOPOULOS CA, 1969, ACTA CHEM SCAND, V23, P2616, DOI 10.3891/acta.chem.scand.23-2616; ANTONSSON P, 1991, J BIOL CHEM, V266, P16859; BASCHONG W, 1985, HISTOCHEMISTRY, V83, P409, DOI 10.1007/BF00509201; BING DH, 1982, P NATL ACAD SCI-BIOL, V79, P4198, DOI 10.1073/pnas.79.13.4198; Blackmore TK, 1996, J IMMUNOL, V157, P5422; Blom AM, 2003, J BIOL CHEM, V278, P43437, DOI 10.1074/jbc.M306620200; Blom AM, 2003, MOL IMMUNOL, V39, P547, DOI 10.1016/S0161-5890(02)00213-4; BOHNSACK JF, 1985, P NATL ACAD SCI USA, V82, P3824, DOI 10.1073/pnas.82.11.3824; Bradley K, 1996, IMMUNOLOGY, V88, P648; CROCKARD AD, 1992, CLIN IMMUNOL IMMUNOP, V65, P135, DOI 10.1016/0090-1229(92)90216-B; ENGEL J, 1987, METHOD ENZYMOL, V145, P3; Gaboriaud C, 2004, TRENDS IMMUNOL, V25, P368, DOI 10.1016/j.it.2004.04.008; Gewurz H, 1993, BEHRING I MITT, P138; Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541; Heathfield TF, 2004, J BIOL CHEM, V279, P6286, DOI 10.1074/jbc.M307765200; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HEDLUND H, 1994, MATRIX BIOL, V14, P227, DOI 10.1016/0945-053X(94)90186-4; HEINEGARD D, 1986, J BIOL CHEM, V261, P3866; Heinegard D., 2002, CONNECTIVE TISSUE IT, P271; Hellwage J, 2002, J IMMUNOL, V169, P6935, DOI 10.4049/jimmunol.169.12.6935; Hietala MA, 2004, EUR J IMMUNOL, V34, P1208, DOI 10.1002/eji.200424895; HOEKZEMA R, 1988, MOL IMMUNOL, V25, P485, DOI 10.1016/0161-5890(88)90169-1; Jarva H, 1999, J IMMUNOL, V163, P3957; Kemp P A, 1992, J Clin Lab Immunol, V37, P147; Kohl J, 2001, MOL IMMUNOL, V38, P175, DOI 10.1016/S0161-5890(01)00041-4; KRUMDIECK R, 1992, J IMMUNOL, V149, P3695; Mabbott NA, 2001, NAT MED, V7, P485, DOI 10.1038/86562; MERI S, 1990, P NATL ACAD SCI USA, V87, P3982, DOI 10.1073/pnas.87.10.3982; MERI S, 1994, BIOCHEM BIOPH RES CO, V198, P52, DOI 10.1006/bbrc.1994.1008; MORGAN BP, 1991, IMMUNOL TODAY, V12, P301, DOI 10.1016/0167-5699(91)90003-C; MORGAN BP, 1995, CRIT REV CL LAB SCI, V32, P265, DOI 10.3109/10408369509084686; Nadesalingam J, 2003, J BIOL CHEM, V278, P25678, DOI 10.1074/jbc.M210186200; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; Onnerfjord P, 2004, J BIOL CHEM, V279, P26, DOI 10.1074/jbc.M308689200; Onuma H, 2002, RHEUMATOL INT, V22, P52, DOI 10.1007/s00296-002-0199-6; PAQUES EP, 1979, H-S Z PHYSIOL CHEM, V360, P177, DOI 10.1515/bchm2.1979.360.1.177; PILLEMER L, 1954, SCIENCE, V120, P279, DOI 10.1126/science.120.3112.279; REID KBM, 1976, BIOCHEM J, V155, P19, DOI 10.1042/bj1550019; ROGERS J, 1992, P NATL ACAD SCI USA, V89, P10016, DOI 10.1073/pnas.89.21.10016; Smith BO, 2002, CELL, V108, P769, DOI 10.1016/S0092-8674(02)00672-4; SORVILLO J, 1985, BIOCHEM J, V226, P207, DOI 10.1042/bj2260207; Svensson L, 1999, J BIOL CHEM, V274, P9636, DOI 10.1074/jbc.274.14.9636; TENNER AJ, 1981, J IMMUNOL, V127, P648; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; WANG Y, 1995, P NATL ACAD SCI USA, V92, P8955, DOI 10.1073/pnas.92.19.8955; Wang Y, 2000, J IMMUNOL, V164, P4340, DOI 10.4049/jimmunol.164.8.4340	46	141	142	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32301	32308		10.1074/jbc.M504828200	http://dx.doi.org/10.1074/jbc.M504828200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16046396	hybrid			2022-12-25	WOS:000231794800033
J	Nahin, RL				Nahin, RL			Identifying and pursuing research priorities at the National Center for Complementary and Alternative Medicine	FASEB JOURNAL			English	Article						disease burden; NCCAM funding; public health	OBSTRUCTIVE PULMONARY-DISEASE; CHRONIC KIDNEY-DISEASE; UNITED-STATES; CARE EXPENDITURES; ECONOMIC BURDEN; ALZHEIMERS-DISEASE; PREVALENCE; COSTS; HEALTH; DISORDERS	As part of its planning process, the National Center for Complementary and Alternative Medicine ( NCCAM), a component of the National Institutes of Health, periodically evaluates how well it applies its criteria for setting research priorities. For its most recent evaluation, NCCAM compared funding levels in fiscal years 2000 and 2003 for 18 diseases with a substantial public health burden including Alzheimer's disease, arthritis, back pain, cancer, diabetes, coronary heart disease, HIV/ AIDS, migraine, and stroke, with 7 measures of disease burden: 1) prevalence, 2) mortality, 3) years of life lost ( YLL), 4) years lost to disability ( YLD), 5) disability- adjusted life years ( DALY's), 6) direct costs of illness ( COI), and 7) total COI. There is an increasing relationship between NCCAM research funding and disease burden over the 4- year study period that reflects funding of specific research initiatives. The strength of the individual correlations varied among measures, with the strongest correlations seen with total COI and the weakest seen with mortality. When applied with its other criteria, measures of disease burden aid identification and matching of NCCAM priorities with levels of support.	NIH, Natl Ctr Complementary & Alternat Med, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Center for Complementary & Alternative Medicine	Nahin, RL (corresponding author), NIH, Natl Ctr Complementary & Alternat Med, 9000 Rockville Pike,Bldg 31,Room 2B-11, Bethesda, MD 20892 USA.	nahinr@mail.nih.gov		Nahin, Richard/0000-0002-3682-4816				ADAMS PF, 1995, VITAL HLTH STAT, V10, P193; Adelmann PK, 2003, ADM POLICY MENT HLTH, V31, P111, DOI 10.1023/B:APIH.0000003017.78877.56; *AG HEALTHC RES QU, 2004, 1996 EXP COND; *AM HEART ASS, 2004, AM HEART ASS HEART D; [Anonymous], 2001, JAMA, V285, P1571; Barnes Patricia M, 2004, Adv Data, P1; Bedir E, 2002, J AGR FOOD CHEM, V50, P3150, DOI 10.1021/jf011682s; Berman JD, 2004, ANNU REV MED, V55, P239, DOI 10.1146/annurev.med.55.091902.103657; BLAZER DG, 1994, AM J PSYCHIAT, V151, P979; BOLEN J, 2001, MMWR-MORBID MORTAL W, V51, P948; Bozzette SA, 1998, NEW ENGL J MED, V339, P1897, DOI 10.1056/NEJM199812243392606; Bozzette SA, 2001, NEW ENGL J MED, V344, P817, DOI 10.1056/NEJM200103153441107; Brookmeyer R, 1998, AM J PUBLIC HEALTH, V88, P1337, DOI 10.2105/AJPH.88.9.1337; Brown ML, 2001, ANNU REV PUBL HEALTH, V22, P91, DOI 10.1146/annurev.publhealth.22.1.91; BROWN ML, 2002, MED CARE, V40, pIV17; Burton WN, 2002, J OCCUP ENVIRON MED, V44, P523, DOI 10.1097/00043764-200206000-00013; *CDC, 2000, HIV AIDS SURV REP 20, P12; *CDC PREV, 1999, HIV AIDS SURV SUPPL, P7; *CDC PREV, 2002, HIV AIDS SURV REP, P8; Chilcott LA, 1996, PHARMACOECONOMICS, V10, P1, DOI 10.2165/00019053-199600101-00003; CISTERNAN M, 2003, MMWR-MORBID MORTAL W, V52, P1124; Cohen JW, 2003, HEALTH AFFAIR, V22, P129, DOI 10.1377/hlthaff.22.2.129; Colice GL, 2004, CHEST, V125, P2140, DOI 10.1378/chest.125.6.2140; Coresh J, 2003, AM J KIDNEY DIS, V41, P1, DOI 10.1053/ajkd.2003.50007; Druss BG, 2002, HEALTH AFFAIR, V21, P105, DOI 10.1377/hlthaff.21.4.105; Druss BG, 2001, HEALTH AFFAIR, V20, P233, DOI 10.1377/hlthaff.20.6.233; Dunlop DD, 2003, ARTHRIT RHEUM-ARTHR, V49, P101, DOI 10.1002/art.10913; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; ERNST RL, 1994, AM J PUBLIC HEALTH, V84, P1261, DOI 10.2105/AJPH.84.8.1261; FRIED VM, 2003, CHARTBOOK TRENDS HLT; Greenberg PE, 2003, J CLIN PSYCHIAT, V64, P1465, DOI 10.4088/JCP.v64n1211; GREENBERG PE, 1993, J CLIN PSYCHIAT, V54, P405; Gross CP, 1999, NEW ENGL J MED, V340, P1881, DOI 10.1056/NEJM199906173402406; HARDY M, 2002, AHRQ PUBLICATION; Hellinger FJ, 2000, J ACQ IMMUN DEF SYND, V24, P182; Hodgson TA, 1999, PREV MED, V29, P173, DOI 10.1006/pmed.1999.0534; Hodgson TA, 1999, MED CARE, V37, P994, DOI 10.1097/00005650-199910000-00004; Hodgson TA, 2001, MED CARE, V39, P599, DOI 10.1097/00005650-200106000-00008; Hodgson TA, 1999, HEALTH CARE FINANC R, V21, P119; HOGAN P, 2002, DIABETES CARE, V26, P917; Hu XH, 1999, ARCH INTERN MED, V159, P813, DOI 10.1001/archinte.159.8.813; Hui KKS, 2000, HUM BRAIN MAPP, V9, P13, DOI 10.1002/(SICI)1097-0193(2000)9:1<13::AID-HBM2>3.0.CO;2-F; *I MED, 1998, SCI OPP PUBL NEEDS I; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Kessler RC, 2003, JAMA-J AM MED ASSOC, V289, P3095, DOI 10.1001/jama.289.23.3095; Kleinman A., 2002, SCI PLACEBO INTERDIS, P1; Lawrence RC, 1998, ARTHRITIS RHEUM-US, V41, P778, DOI 10.1002/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V; Levey AS, 2003, ANN INTERN MED, V139, P137, DOI 10.7326/0003-4819-139-2-200307150-00013; Lin MC, 2001, CIRCULATION, V103, P2038; Lipton RB, 2001, HEADACHE, V41, P646, DOI 10.1046/j.1526-4610.2001.041007646.x; Luo XM, 2004, SPINE, V29, P79, DOI 10.1097/01.BRS.0000105527.13866.0F; MATHERS CD, 2002, 50 WORLD HLTH; Mathews WC, 2000, MED CARE, V38, P750, DOI 10.1097/00005650-200007000-00007; McNeil JM, 2001, JAMA-J AM MED ASSOC, V285, P1571; Michaud CM, 2001, JAMA-J AM MED ASSOC, V285, P535, DOI 10.1001/jama.285.5.535; Minino Arialdi M, 2002, Natl Vital Stat Rep, V50, P1; Nahin RL, 2001, BRIT MED J, V322, P161, DOI 10.1136/bmj.322.7279.161; Narrow WE, 2002, ARCH GEN PSYCHIAT, V59, P115, DOI 10.1001/archpsyc.59.2.115; *NAT CTR HLTH STAT, 1999, MMWR-MORBID MORTAL W, V48, P349; *NAT HEART LUNG BL, 2004, 2004 CHART BOOK CARD; Niederman MS, 1998, CLIN THER, V20, P820, DOI 10.1016/S0149-2918(98)80144-6; *NIH, 1997, PUBLICATION; *NIH, 2000, DIS SPEC EST DIR IND; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; PLEIS JR, 2003, NATL HLTH INTERVIEW, V10; PLEIS JR, 2003, VITAL HLTH STAT, V10; Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518; Richmond J, 1996, JAMA-J AM MED ASSOC, V276, P313; Rizzo JA, 1998, MED CARE, V36, P1471, DOI 10.1097/00005650-199810000-00006; Rost K, 1998, AM J PSYCHIAT, V155, P883, DOI 10.1176/ajp.155.7.883; Russell MW, 1998, AM J CARDIOL, V81, P1110, DOI 10.1016/S0002-9149(98)00136-2; Sandler RS, 2002, GASTROENTEROLOGY, V122, P1500, DOI 10.1053/gast.2002.32978; Snedecor GW., 1968, STAT METHODS; Thom TJ, 1996, IN VIVO, V10, P255; Trupin L, 2003, EUR RESPIR J, V22, P462, DOI 10.1183/09031936.03.00094203; *US CENS BUR, 2004, STAT ABSTR US; Varmus H, 1999, NEW ENGL J MED, V340, P1914, DOI 10.1056/NEJM199906173402411; Walsh JK, 1999, SLEEP, V22, pS386; Ward MM, 2000, RESP MED, V94, P1123, DOI 10.1053/rmed.2000.0933; Watanabe CMH, 2001, P NATL ACAD SCI USA, V98, P6577, DOI 10.1073/pnas.111126298; *WHO, 2002, RED RISKS PROM HEALT, P228; *WHO, 2002, WORLD HLTH REPORT 20, P228; *WHO, 1997, MAJ FIND REC AD HOC; Wilson L, 2000, RESP MED, V94, P204, DOI 10.1053/rmed.1999.0720; Wilson T, 2004, MON LABOR REV, V127, P3; Yelin E, 2002, EUR RESPIR J, V19, P414, DOI 10.1183/09031936.02.00522001; YELIN E, 2003, DIRECT INDIRECT COST; 1997, MMWR MORB MORTAL WKL, V50, P334	89	9	9	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1209	1215		10.1096/fj.05-3727LFE	http://dx.doi.org/10.1096/fj.05-3727LFE			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16051686				2022-12-25	WOS:000231843700026
J	Nicchia, GP; Srinivas, M; Li, W; Brosnan, CF; Frigeri, A; Spray, DC				Nicchia, GP; Srinivas, M; Li, W; Brosnan, CF; Frigeri, A; Spray, DC			New possible roles for aquaporin-4 in astrocytes: cell cytoskeleton and functional relationship with connexin43	FASEB JOURNAL			English	Article						AQP4; Cx43; gap junctions; siRNA	FIBRILLARY ACIDIC PROTEIN; REACTIVE ASTROCYTES; WATER TRANSPORT; ASTROGLIAL MORPHOLOGY; NEURONAL REGULATION; ACTIN CYTOSKELETON; MESSENGER-RNA; BRAIN-INJURY; GLIAL-CELLS; EXPRESSION	Aquaporin-4 (AQP4), the main water channel in the brain, is expressed in the perivascular membranes of mouse, rat, and human astrocytes. In a previous study, we used small interfering RNA (siRNA) to specifically knock down AQP4 in rat astrocyte primary cultures and found that together with reduced osmotic permeability, AQP4 knockdown (KD) led to altered cell morphology. However, a recent report on primary cultured astrocytes from AQP4 null mice (KO) showed no morphological differences compared with wild types. In this study, we compared the effect of AQP4 KD in mouse, rat, and human astrocyte primary cultures and found that AQP4 KD in human astrocytes resulted in a morphological phenotype similar to that found in rat. In contrast, AQP4 KD in mouse astrocytes caused only very mild morphological changes. The actin cytoskeleton of untreated astrocytes exhibited strong species-specific differences, with F-actin being organized in cortical bands in mouse and in stress fibers in rat and human astrocytes. Surprisingly, as a consequence of AQP4 KD, F-actin cytoskeleton was depolymerized in rat and human whereas it was completely rearranged in mouse astrocytes. Although AQP4 KD induced alterations of the cell cytoskeleton, we found that the expression of dystrophin (DP71), beta-dystroglycan, and alpha-syntrophin was not altered. AQP4 KD in cultured mouse astrocytes produced strong down-regulation of connexin43 (Cx43) with a concomitant reduction in cell coupling while no major alterations in Cx43 expression were found in rat and human cells. Taken together, these results demonstrate that with regard to these properties, human astrocytes in culture are more similar to rat than to mouse astrocytes. Moreover, even though AQP4 KD in mouse astrocytes did not result in a dramatic morphological phenotype, it induced a remarkable rearrangement of F-actin, not related to disruption of the dystrophin complex, indicating a primary role of this water channel in the cytoskeleton changes observed. Finally, the strong down-regulation of Cx43 and cell coupling in AQP4 KD mouse astrocytes indicate that a functional relationship likely exists between water channels and gap junctions in brain astrocytes.	Univ Bari, Dipartimento Fisiol Gen & Ambientale, I-70126 Bari, Italy; Univ Bari, CEGBA, I-70126 Bari, Italy; Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10464 USA; Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10464 USA	Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Nicchia, GP (corresponding author), Univ Bari, Dipartimento Fisiol Gen & Ambientale, Via Amendola 165-A, I-70126 Bari, Italy.	p.nicchia@biologia.uniba.it	frigeri, Antonio/AAC-6336-2022	Frigeri, Antonio/0000-0002-5284-2934; Spray, David/0000-0001-8368-5073; Li, Wei/0000-0002-7941-7022	NINDS NIH HHS [NS41282] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Al-Ghoul KJ, 2003, ANAT REC PART A, V273A, P714, DOI 10.1002/ar.a.10080; Allansson L, 2001, J NEUROCHEM, V76, P472, DOI 10.1046/j.1471-4159.2001.00097.x; Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P13615, DOI 10.1073/pnas.2336064100; Badaut J, 2003, ACTA NEUROCHIR SUPPL, V86, P495; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; De Pina-Benabou MH, 2001, J NEUROSCI, V21, P6635; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; ELFOULY MH, 1987, EXP CELL RES, V168, P422, DOI 10.1016/0014-4827(87)90014-0; ENKVIST MOK, 1994, J NEUROCHEM, V62, P489; Frigeri A, 2002, FASEB J, V16, P1120, DOI 10.1096/fj.01-0797fje; FRIGERI A, 1995, J CELL SCI, V108, P2993; GOLDMAN JE, 1990, BRAIN RES, V528, P189, DOI 10.1016/0006-8993(90)91657-3; HATTEN ME, 1985, J CELL BIOL, V100, P384, DOI 10.1083/jcb.100.2.384; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; Hawrylak N, 1998, GLIA, V22, P260, DOI 10.1002/(SICI)1098-1136(199803)22:3<260::AID-GLIA5>3.0.CO;2-9; John GR, 2004, J NEUROSCI, V24, P2837, DOI 10.1523/JNEUROSCI.4789-03.2004; Kielian T, 2004, NEUROCHEM INT, V45, P429, DOI 10.1016/j.neuint.2003.09.010; LaDu MJ, 2001, NEUROCHEM INT, V39, P427, DOI 10.1016/S0197-0186(01)00050-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SHC, 1992, LAB INVEST, V67, P465; Leis JA, 2005, GLIA, V50, P407, DOI 10.1002/glia.20145; Liberto CM, 2004, J NEUROCHEM, V89, P1092, DOI 10.1111/j.1471-4159.2004.02420.x; Matsutani S, 1997, GLIA, V20, P1, DOI 10.1002/(SICI)1098-1136(199705)20:1<1::AID-GLIA1>3.0.CO;2-E; MCMILLIAN MK, 1994, TRENDS NEUROSCI, V17, P138, DOI 10.1016/0166-2236(94)90086-8; Moran J, 1996, AM J PHYSIOL-CELL PH, V271, pC1901, DOI 10.1152/ajpcell.1996.271.6.C1901; Nagelhus EA, 1999, GLIA, V26, P47, DOI 10.1002/(SICI)1098-1136(199903)26:1<47::AID-GLIA5>3.0.CO;2-5; Nicchia GP, 2003, FASEB J, V17, P1508, DOI 10.1096/fj.02-1183fje; Nicchia GP, 2000, GLIA, V31, P29, DOI 10.1002/(SICI)1098-1136(200007)31:1<29::AID-GLIA30>3.0.CO;2-3; Nielsen S, 1997, J NEUROSCI, V17, P171; Paul S, 1996, EUR J NEUROSCI, V8, P2361, DOI 10.1111/j.1460-9568.1996.tb01199.x; Pu PY, 2004, CLIN NEUROL NEUROSUR, V107, P49, DOI 10.1016/j.clineuro.2004.03.006; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Saadoun S, 2002, J NEUROL NEUROSUR PS, V72, P262, DOI 10.1136/jnnp.72.2.262; Scemes E, 1998, GLIA, V24, P65, DOI 10.1002/(SICI)1098-1136(199809)24:1<65::AID-GLIA7>3.0.CO;2-#; SHAO YP, 1994, GLIA, V11, P1, DOI 10.1002/glia.440110103; Solenov E, 2004, AM J PHYSIOL-CELL PH, V286, pC426, DOI 10.1152/ajpcell.00298.2003; Soroceanu L, 2001, GLIA, V33, P107, DOI 10.1002/1098-1136(200102)33:2<107::AID-GLIA1010>3.0.CO;2-4; Spray DC, 1998, CIRC RES, V83, P679, DOI 10.1161/01.RES.83.6.679; Taniguchi M, 2000, MOL BRAIN RES, V78, P131, DOI 10.1016/S0169-328X(00)00084-X; Tomimoto H, 1997, ACTA NEUROPATHOL, V94, P146, DOI 10.1007/s004010050686; TORANALLERAND CD, 1991, BRAIN RES, V558, P296; Vila M, 2001, CURR OPIN NEUROL, V14, P483, DOI 10.1097/00019052-200108000-00009; Vizuete ML, 1999, NEUROBIOL DIS, V6, P245, DOI 10.1006/nbdi.1999.0246; WARTH A, 2005, ACTA NEUROPATHOL; Wu VW, 1998, J NEUROSCI RES, V51, P675, DOI 10.1002/(SICI)1097-4547(19980315)51:6<675::AID-JNR2>3.3.CO;2-N; Yu XS, 2004, J CELL SCI, V117, P871, DOI 10.1242/jcs.00945; YU XS, 2005, J BIOL CHEM	47	131	140	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1674	+		10.1096/fj.04-3281fje	http://dx.doi.org/10.1096/fj.04-3281fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16103109				2022-12-25	WOS:000231843700012
J	Bhattacharya, R; Decker, NK; Hughes, DA; Mukherjee, P; Shah, V; McNiven, MA; Mukhopadhyay, D				Bhattacharya, R; Decker, NK; Hughes, DA; Mukherjee, P; Shah, V; McNiven, MA; Mukhopadhyay, D			Regulatory role of dynamin-2 in VEGFR-2/KDR-mediated endothelial signaling	FASEB JOURNAL			English	Article						VPF; endothelial cells; cell cycle; receptor endocytosis	VASCULAR-PERMEABILITY FACTOR; GROWTH-FACTOR RECEPTOR-2; TYROSINE KINASE; TUMOR-CELLS; VEGF; VASCULOGENESIS; ANGIOGENESIS; TRAFFICKING; ASSOCIATION; ENDOCYTOSIS	Vascular endothelial growth factor receptor-2 (VEGFR-2, also known as KDR) is a receptor tyrosine kinase (RTK) regulating mitogenic, chemotactic, permeability, and survival signals in vascular endothelial cells (EC) in response to its ligand, vascular permeability factor/VEGF (VPF/VEGF), arguably the most important angiogenic cytokine. However, the compartmentalization of KDR in EC and the mechanisms regulating this process have not been well defined. Here, we demonstrate that KDR is present on the plasma membrane, on endosomes, and in the perinuclear region of EC and colocalizes with early endosomal antigen (EEA1), caveolin-1, and dynamin-2, a signal transducing GTPase involved in receptor endocytosis. Furthermore, we also observed that dynamin-2 coimmunoprecipitates with KDR and is required for EC signaling/survival. Interestingly, EC overexpressing a mutant form of dynamin deficient in GTP binding ( K44A) caused a selective inhibition in KDR protein level and endosomal vesicle formation and induced cell cycle arrest by inducing p21. Taken together, our findings suggest that dynamin-2 regulates KDR expression and function and hence plays an important role in VPF/VEGF mediated angiogenesis.	Mayo Clin & Mayo Fdn, Ctr Canc, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Med, GI Res Unit, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Mukhopadhyay, D (corresponding author), Mayo Clin & Mayo Fdn, Ctr Canc, Dept Biochem & Mol Biol, 200 1st St SW, Rochester, MN 55905 USA.	mukhopadhyay.debabrata@mayo.edu			NCI NIH HHS [CA-78383] Funding Source: Medline; NHLBI NIH HHS [HL-072178, HL-70567] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA078383, R01CA078383] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072178, R01HL070567] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Altschuler Y, 1998, J CELL BIOL, V143, P1871, DOI 10.1083/jcb.143.7.1871; Cao S, 2001, J BIOL CHEM, V276, P14249, DOI 10.1074/jbc.M006258200; Chatterjee S, 2003, J CELL SCI, V116, P3645, DOI 10.1242/jcs.00664; Chaturvedi K, 2001, J BIOL CHEM, V276, P12345, DOI 10.1074/jbc.M008054200; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Datta K, 2004, CANCER RES, V64, P456, DOI 10.1158/0008-5472.CAN-03-2706; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DVORAK HF, 1979, JNCI-J NATL CANCER I, V62, P1459; DVORAK HF, 1991, J EXP MED, V174, P1275, DOI 10.1084/jem.174.5.1275; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Fish KN, 2000, J CELL BIOL, V150, P145, DOI 10.1083/jcb.150.1.145; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; GUIDI AJ, 1995, J NATL CANCER I, V87, P1237, DOI 10.1093/jnci/87.16.1237; Henley JR, 1996, J CELL BIOL, V133, P761, DOI 10.1083/jcb.133.4.761; Jones SM, 1998, SCIENCE, V279, P573, DOI 10.1126/science.279.5350.573; KOCH AE, 1994, J IMMUNOL, V152, P4149; Kreitzer G, 2000, NAT CELL BIOL, V2, P125, DOI 10.1038/35000081; Labrecque L, 2003, MOL BIOL CELL, V14, P334, DOI 10.1091/mbc.E02-07-0379; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Li SW, 1996, J BIOL CHEM, V271, P3863; Maier O, 1996, BIOCHEM BIOPH RES CO, V223, P229, DOI 10.1006/bbrc.1996.0876; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MEHDI S, 1991, TRENDS BIOCHEM SCI, V16, P150, DOI 10.1016/0968-0004(91)90058-4; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Minshall RD, 2000, J CELL BIOL, V150, P1057, DOI 10.1083/jcb.150.5.1057; MORI S, 1995, J BIOL CHEM, V270, P29447, DOI 10.1074/jbc.270.49.29447; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Muro S, 2003, J CELL SCI, V116, P1599, DOI 10.1242/jcs.00367; Nichols BJ, 2001, TRENDS CELL BIOL, V11, P406, DOI 10.1016/S0962-8924(01)02107-9; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SENGER DR, 1986, CANCER RES, V46, P5629; Shajahan AN, 2004, J BIOL CHEM, V279, P20392, DOI 10.1074/jbc.M308710200; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; Wheeler YRY, 2003, FASEB J, V17, P1733, DOI 10.1096/fj.02-0942fje; Zeng HY, 2001, J BIOL CHEM, V276, P26969, DOI 10.1074/jbc.M103213200; Zezula J, 1997, J BIOL CHEM, V272, P29967, DOI 10.1074/jbc.272.47.29967	42	67	69	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1692	+		10.1096/fj.05-3889fje	http://dx.doi.org/10.1096/fj.05-3889fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16049137				2022-12-25	WOS:000230923000004
J	Guichard, C; Pedruzzi, E; Dewas, C; Fay, M; Pouzet, C; Bens, M; Vandewalle, A; Ogier-Denis, E; Gougerot-Pocidalo, MA; Elbim, C				Guichard, C; Pedruzzi, E; Dewas, C; Fay, M; Pouzet, C; Bens, M; Vandewalle, A; Ogier-Denis, E; Gougerot-Pocidalo, MA; Elbim, C			Interleukin-8-induced priming of neutrophil oxidative burst requires sequential recruitment of NADPH oxidase components into lipid rafts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; TUMOR-NECROSIS-FACTOR; ACTIVATED PROTEIN-KINASE; SUPEROXIDE ANION PRODUCTION; RESPIRATORY BURST; INTRAMOLECULAR INTERACTION; PARTIAL PHOSPHORYLATION; HUMAN-GRANULOCYTES; PHOSPHATIDIC-ACID; SUBUNIT P47(PHOX)	The superoxide-producing phagocyte NADPH oxidase consists of a membrane-bound flavocytochrome b(558), the cytosol factors p47(phox), p67(phox), p40(phox), and the small GTPase Rac2, which translocate to the membrane to assemble the active complex following neutrophil activation. Interleukin-8 (IL-8) does not activate NADPH oxidase, but potentiates the oxidative burst induced by stimuli such as formyl-methionyl-leucyl-phenylalanine ( fMLP) via a priming mechanism. The effect of IL-8 on the components of NADPH oxidase during the priming process has never been investigated in human neutrophils. Here we showed that within 3 min, IL-8 treatment enhanced the Btk- and ERK1/2-dependent phosphorylation of p47(phox), as well as the recruitment of flavocytochrome b558, p47(phox), and Rac2 into cholesterol-enriched detergent-resistant microdomains ( or lipid rafts). Conversely, IL-8 treatment lasting 15 min failed to recruit flavocytochrome b(558), p47(phox), or Rac2, but did enhance the Btk- and p38 MAPK-dependent phosphorylation and the translocation of p67(phox) into detergent-resistant microdomains. Moreover, methyl-beta-cyclodextrin, which disrupts lipid rafts, inhibited IL-8-induced priming in response to fMLP. Our findings indicate that IL-8-induced priming of the oxidative burst in response to fMLP involves a sequential assembly of the NADPH oxidase components in the lipid rafts of neutrophils.	Univ Paris 07, INSERM, U683, F-75870 Paris, France; Univ Paris 07, INSERM, U478, F-75870 Paris, France; Univ Paris 07, IFR02, F-75870 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Guichard, C (corresponding author), Univ Paris 07, INSERM, U683, BP 416, F-75870 Paris, France.	guichard@bichat.inserm.fr	Ogier-Denis, Eric/E-5030-2016; pedruzzi, eric/B-6050-2017	Ogier-Denis, Eric/0000-0002-0057-7593				Ago T, 1999, J BIOL CHEM, V274, P33644, DOI 10.1074/jbc.274.47.33644; AMAR M, 1990, J IMMUNOL, V144, P4749; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Babior BM, 2004, CURR OPIN IMMUNOL, V16, P42, DOI 10.1016/j.coi.2003.12.001; BERKOW RL, 1988, J LEUKOCYTE BIOL, V44, P345, DOI 10.1002/jlb.44.5.345; Bokoch GM, 2002, BLOOD, V100, P2692, DOI 10.1182/blood-2002-04-1149; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; Brown GE, 2004, J BIOL CHEM, V279, P27059, DOI 10.1074/jbc.M314258200; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; Chen QD, 2003, J IMMUNOL, V170, P5302, DOI 10.4049/jimmunol.170.10.5302; Dang PMC, 1999, J BIOL CHEM, V274, P20704, DOI 10.1074/jbc.274.29.20704; Dang PMC, 2003, BIOCHEMISTRY-US, V42, P4520, DOI 10.1021/bi0205754; Dang PMC, 2001, P NATL ACAD SCI USA, V98, P3001, DOI 10.1073/pnas.061029698; DANIELS RH, 1992, IMMUNOLOGY, V75, P157; DeLeo FR, 1998, J CLIN INVEST, V101, P455, DOI 10.1172/JCI949; Dewas C, 2000, J IMMUNOL, V165, P5238, DOI 10.4049/jimmunol.165.9.5238; Dewas C, 2003, J IMMUNOL, V171, P4392, DOI 10.4049/jimmunol.171.8.4392; ElBenna J, 1996, J BIOL CHEM, V271, P6374; ElBenna J, 1997, J BIOL CHEM, V272, P17204, DOI 10.1074/jbc.272.27.17204; Forbes LV, 1999, FEBS LETT, V449, P225, DOI 10.1016/S0014-5793(99)00444-5; Gilbert C, 2003, J IMMUNOL, V170, P5235, DOI 10.4049/jimmunol.170.10.5235; HALLETT MB, 1995, IMMUNOL TODAY, V16, P264, DOI 10.1016/0167-5699(95)80178-2; Karathanassis D, 2002, EMBO J, V21, P5057, DOI 10.1093/emboj/cdf519; Katsumata O, 2001, J IMMUNOL, V167, P5814, DOI 10.4049/jimmunol.167.10.5814; KITAGAWA S, 1987, BIOCHEM BIOPH RES CO, V144, P1143, DOI 10.1016/0006-291X(87)91430-6; Knall C, 1997, P NATL ACAD SCI USA, V94, P3052, DOI 10.1073/pnas.94.7.3052; Lian JP, 1999, J IMMUNOL, V163, P4527; MCCOLL SR, 1990, J IMMUNOL, V145, P3047; METZNER B, 1995, J INVEST DERMATOL, V104, P789, DOI 10.1111/1523-1747.ep12606993; Nauseef WM, 2004, HISTOCHEM CELL BIOL, V122, P277, DOI 10.1007/s00418-004-0679-8; Nisimoto Y, 1999, J BIOL CHEM, V274, P22999, DOI 10.1074/jbc.274.33.22999; OKAMURA N, 1988, J BIOL CHEM, V263, P6777; Park HS, 2001, BIOCHEM J, V358, P783, DOI 10.1042/0264-6021:3580783; PARK JW, 1992, J BIOL CHEM, V267, P19901; PARK JW, 1994, BIOCHEMISTRY-US, V33, P2907, DOI 10.1021/bi00176a021; PEVERI P, 1988, J EXP MED, V167, P1547, DOI 10.1084/jem.167.5.1547; Rietveld A, 1998, BBA-REV BIOMEMBRANES, V1376, P467, DOI 10.1016/S0304-4157(98)00019-7; ROTROSEN D, 1990, J BIOL CHEM, V265, P8745; Shao DM, 2003, FEBS LETT, V550, P101, DOI 10.1016/S0014-5793(03)00845-7; Stahelin RV, 2003, J BIOL CHEM, V278, P14469, DOI 10.1074/jbc.M212579200; Tuluc F, 2003, INT IMMUNOPHARMACOL, V3, P1775, DOI 10.1016/j.intimp.2003.08.002; van Bruggen R, 2004, J BIOL CHEM, V279, P9097, DOI 10.1074/jbc.M309284200; VANLINT J, 1993, MOL CELL BIOCHEM, V128, P171, DOI 10.1007/BF01076768; Varnai P, 1999, J BIOL CHEM, V274, P10983, DOI 10.1074/jbc.274.16.10983; Vilhardt F, 2004, EMBO J, V23, P739, DOI 10.1038/sj.emboj.7600066; Waite KA, 1997, J BIOL CHEM, V272, P15569, DOI 10.1074/jbc.272.24.15569; Ward RA, 2000, J BIOL CHEM, V275, P36713, DOI 10.1074/jbc.M003017200; WEISBART RH, 1985, NATURE, V314, P361, DOI 10.1038/314361a0; WOODMAN RC, 1991, J CLIN INVEST, V87, P1345, DOI 10.1172/JCI115138; WOZNIAK A, 1993, IMMUNOLOGY, V79, P608; YUO A, 1991, BLOOD, V78, P2708; YUO A, 1990, BIOCHEM BIOPH RES CO, V171, P491, DOI 10.1016/0006-291X(90)91420-W; YUO A, 1989, J IMMUNOL, V142, P1678	53	93	97	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					37021	37032		10.1074/jbc.M506594200	http://dx.doi.org/10.1074/jbc.M506594200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16115878	hybrid			2022-12-25	WOS:000232901800060
J	Markova, M; Peneff, C; Hewlins, MJE; Schirmer, T; John, RA				Markova, M; Peneff, C; Hewlins, MJE; Schirmer, T; John, RA			Determinants of substrate specificity in omega-aminotransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ORNITHINE	Ornithine aminotransferase and 4-aminobutyrate aminotransferase are related pyridoxal phosphate-dependent enzymes having different substrate specificities. The atomic structures of these enzymes have shown (i) that active site differences are limited to the steric positions occupied by two tyrosine residues in ornithine aminotransferase and (ii) that, uniquely among related, structurally characterized aminotransferases, the conserved arginine that binds the alpha-carboxylate of alpha-amino acids interacts tightly with a glutamate residue. To determine the contribution of these residues to the specificities of the enzymes, we analyzed site-directed mutants of ornithine aminotransferase by rapid reaction kinetics, x-ray crystallography, and C-13 NMR spectroscopy. Mutation of one tyrosine (Tyr-85) to isoleucine, as found in aminobutyrate aminotransferase, decreased the rate of the reaction of the enzyme with ornithine 1000-fold and increased that with 4-aminobutyrate 16-fold, indicating that Tyr-85 is amajor determinant of specificity toward ornithine. Unexpectedly, the limiting rate of the second half of the reaction, conversion of ketoglutarate to glutamate, was greatly increased, although the kinetics of the reverse reaction were unaffected. A mutant in which the glutamate (Glu-235) that interacts with the conserved arginine was replaced by alanine retained its regiospecificity for the delta-amino group of ornithine, but the glutamate reaction was enhanced 650-fold, whereas only a 5-fold enhancement of the ketoglutarate reaction rate resulted. A model is proposed in which conversion of the enzyme to its pyridoxamine phosphate form disrupts the internal glutamate-arginine interaction, thus enabling ketoglutarate but not glutamate to be a good substrate.	Cardiff Univ, Sch Biosci, Cardiff CF23 6QU, Wales; Cardiff Univ, Sch Chem, Cardiff CF23 6QU, Wales; Univ Basel, Biozentrum, Abt Strukturbiol, CH-4056 Basel, Switzerland	Cardiff University; Cardiff University; University of Basel	John, RA (corresponding author), Cardiff Univ, Sch Biosci, Museum Ave,POB 911, Cardiff CF10 3US, S Glam, Wales.	JohnRA@cf.ac.uk						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BANKS BEC, 1966, PYRIDOXAL CATALYSIS, P191; DUNATHAN HC, 1966, P NATL ACAD SCI USA, V55, P712, DOI 10.1073/pnas.55.4.712; FORD GC, 1980, P NATL ACAD SCI-BIOL, V77, P2559, DOI 10.1073/pnas.77.5.2559; JOHN RA, 1976, BIOCHEM J, V155, P645, DOI 10.1042/bj1550645; JOHN RA, 1985, TRANSAMINASES, P413; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIU W, 1994, BIOCHEMISTRY-US, V43, P10896; Liu WS, 2005, BIOCHEMISTRY-US, V44, P2982, DOI 10.1021/bi048657a; MEHTA PK, 1993, EUR J BIOCHEM, V214, P549, DOI 10.1111/j.1432-1033.1993.tb17953.x; Mehta PK, 2000, ADV ENZYMOL RAMB, V74, P129; PERAINO C, 1969, J BIOL CHEM, V255, P10284; PHILIPPSEN A, 1998, DINO VISUALIZATION S; Shen BW, 1998, J MOL BIOL, V277, P81, DOI 10.1006/jmbi.1997.1583; SILVERMAN RB, 1981, BIOCHEMISTRY-US, V20, P1197, DOI 10.1021/bi00508a022; Storici P, 1999, J MOL BIOL, V285, P297, DOI 10.1006/jmbi.1998.2289; Storici P, 1999, BIOCHEMISTRY-US, V38, P8628, DOI 10.1021/bi990478j; WILLIAMS JA, 1982, BIOCHEM J, V201, P221, DOI 10.1042/bj2010221	20	39	41	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36409	36416		10.1074/jbc.M506977200	http://dx.doi.org/10.1074/jbc.M506977200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16096275	hybrid, Green Published			2022-12-25	WOS:000232726900075
J	Merino, E; Montserrat, V; Paradela, A; de Castro, JAL				Merino, E; Montserrat, V; Paradela, A; de Castro, JAL			Two HLA-B14 subtypes (B*1402 and b*1403) differentially associated with ankylosing spondylitis differ substantially in peptide specificity but have limited peptide and T-cell epitope sharing with HLA-B27	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-I MOLECULES; ANTIGEN; MHC; HLA; BINDING; POLYMORPHISM; REPERTOIRE; DIVERSITY; RESIDUES; SPONDYLOARTHROPATHIES	The peptide specificity of HLA-B*1403, an allotype associated with ankylosing spondylitis (Lopez-Larrea, C., Mijiyawa, M., Gonzalez, S., Fernandez-Morera, J. L., Blanco-Gelaz, M. A., Martinez- Borra, J., and Lopez-Vazquez, A. ( 2002) Arthritis Rheum. 46, 2968 - 2971) was compared with those of the non-associated B*1402 and the prototypic disease-associated B*2705 allotypes. Although differing by a single residue (L156R), B*1402 and B*1403 shared only 32 - 35% of their peptide repertoires. Subtype-related differences observed in multiple peptide positions, including P3 and P7, were largely explained by a direct effect of the L156R change on peptide specificity. The HLA-B14 subtypes sharedonly similar to 3% of their peptide repertoires with B*2705. This was due to distinct residue usage at most positions, as revealed by statistical comparison of B*1402, B*1403, and B*2705-bound nonamers. Nevertheless, shared ligands between B*2705 and B*1403 were formally identified, although ligands common to B*2705 and B* 1403, but absent from B* 1402, were not found. Alloreactive T-cells were used as a tool to analyze epitope sharing among B* 1402, B* 1403, and B*2705. The percentage of cross-reactive T-cell clones closely paralleled peptide overlap, suggesting that shared ligands tend to maintain their antigenic features when bound to the different allotypes. Our results indicate that B* 1403 and B* 2705 can present common peptides. However, both the disparity of their peptide repertoires and the lack of binding features shared by these two allotypes, but not B* 1402, argue against, although do not exclude, a mechanism of spondyloarthritis mediated by specific ligands of B* 2705 and B* 1403.	Univ Autonoma Madrid, Fac Ciencias, E-28049 Madrid, Spain	Autonomous University of Madrid	de Castro, JAL (corresponding author), Consejo Super Invest Cient, Ctr Biol Mol Severo Ochoa, Madrid 28049, Spain.	aldecastro@cbm.uam.es	Paradela, Alberto/H-2113-2015	Paradela, Alberto/0000-0001-6837-7056				BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; BENJAMIN R, 1990, IMMUNOL TODAY, V11, P137, DOI 10.1016/0167-5699(90)90051-A; BREWERTON DA, 1973, LANCET, V1, P904; BRODSKY FM, 1979, EUR J IMMUNOL, V9, P536, DOI 10.1002/eji.1830090709; CALVO V, 1990, J IMMUNOL, V144, P4038; Clauser KR, 1999, ANAL CHEM, V71, P2871, DOI 10.1021/ac9810516; Colbert RA, 2004, CURR MOL MED, V4, P21, DOI 10.2174/1566524043479293; CRIVELLATO E, 1987, ACTA DERM-VENEREOL, V67, P249; Daniel S, 1997, J IMMUNOL, V159, P2350; Daniel S, 1998, J IMMUNOL, V161, P617; de Castro JAL, 2004, TISSUE ANTIGENS, V63, P424, DOI 10.1111/j.0001-2815.2004.00220.x; DIBRINO M, 1994, J BIOL CHEM, V269, P32426; Ellis JM, 2000, TISSUE ANTIGENS, V56, P291, DOI 10.1034/j.1399-0039.2000.560401.x; EVAVOLD BD, 1995, IMMUNITY, V2, P655, DOI 10.1016/1074-7613(95)90010-1; FALK K, 1995, IMMUNOGENETICS, V41, P162, DOI 10.1007/BF00182332; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GAUCHATFEISS D, 1994, TISSUE ANTIGENS, V44, P261, DOI 10.1111/j.1399-0039.1994.tb02392.x; HEATH WR, 1991, P NATL ACAD SCI USA, V88, P5101, DOI 10.1073/pnas.88.12.5101; Hulsmeyer M, 2005, J MOL BIOL, V346, P1367, DOI 10.1016/j.jmb.2004.12.047; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; Khan MA, 2002, ANN INTERN MED, V136, P896, DOI 10.7326/0003-4819-136-12-200206180-00011; Lankat-Buttgereit B, 2002, PHYSIOL REV, V82, P187, DOI 10.1152/physrev.00025.2001; LOPEZ D, 1994, J IMMUNOL, V152, P5557; Lopez-Larrea C, 2002, ARTHRITIS RHEUM-US, V46, P2968, DOI 10.1002/art.10584; Macdonald WA, 2003, J EXP MED, V198, P679, DOI 10.1084/jem.20030066; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; Marina A, 1999, J MASS SPECTROM, V34, P17, DOI 10.1002/(SICI)1096-9888(199901)34:1<17::AID-JMS746>3.3.CO;2-Y; Neisig A, 1996, J IMMUNOL, V156, P3196; Ortmann B, 1997, SCIENCE, V277, P1306, DOI 10.1126/science.277.5330.1306; Paradela A, 2000, J IMMUNOL, V164, P329, DOI 10.4049/jimmunol.164.1.329; Paradela A, 1998, J IMMUNOL, V161, P5481; Pohlmann T, 2004, J BIOL CHEM, V279, P28197, DOI 10.1074/jbc.C400128200; Ramos M, 2002, J BIOL CHEM, V277, P28749, DOI 10.1074/jbc.M204155200; Ramos M, 2002, TISSUE ANTIGENS, V60, P191, DOI 10.1034/j.1399-0039.2002.600301.x; ROTZSCHKE O, 1991, J EXP MED, V174, P1059, DOI 10.1084/jem.174.5.1059; SCHLOSSTEIN L, 1973, NEW ENGL J MED, V288, P704, DOI 10.1056/NEJM197304052881403; Serwold T, 2002, NATURE, V419, P480, DOI 10.1038/nature01074; Sesma L, 2002, J BIOL CHEM, V277, P16744, DOI 10.1074/jbc.M200371200; SHERMAN LA, 1988, IMMUNOL REV, V101, P115, DOI 10.1111/j.1600-065X.1988.tb00734.x; Sobao Y, 1999, ARTHRITIS RHEUM, V42, P175, DOI 10.1002/1529-0131(199901)42:1<175::AID-ANR21>3.0.CO;2-7; STORKUS WJ, 1987, J IMMUNOL, V138, P1657; Tynan FE, 2005, J BIOL CHEM, V280, P23900, DOI 10.1074/jbc.M503060200; Urvater JA, 2001, J IMMUNOL, V166, P3334, DOI 10.4049/jimmunol.166.5.3334; VANENDERT PM, 1995, J EXP MED, V182, P1883, DOI 10.1084/jem.182.6.1883; Wang W, 1998, J IMMUNOL, V160, P1091; Yague J, 1998, TISSUE ANTIGENS, V52, P416, DOI 10.1111/j.1399-0039.1998.tb03067.x; YAMAGUCHI A, 1995, ARTHRITIS RHEUM-US, V38, P1672, DOI 10.1002/art.1780381120; York IA, 2002, NAT IMMUNOL, V3, P1177, DOI 10.1038/ni860; ZEMMOUR J, 1992, J IMMUNOL, V148, P1941	50	24	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35868	35880		10.1074/jbc.M505641200	http://dx.doi.org/10.1074/jbc.M505641200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16115862	hybrid			2022-12-25	WOS:000232726900013
J	Nogales, J; Canales, A; Jimenez-Barbero, J; Garcia, JL; Diaz, E				Nogales, J; Canales, A; Jimenez-Barbero, J; Garcia, JL; Diaz, E			Molecular characterization of the gallate dioxygenase from Pseudomonas putida KT2440 - The prototype of a new subgroup of extradiol dioxygenases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPHINGOMONAS-PAUCIMOBILIS SYK-6; PSEUDOMONAS-PUTIDA KT2440; ESCHERICHIA-COLI; PROTOCATECHUATE 4,5-DIOXYGENASE; 2-AMINOPHENOL 1,6-DIOXYGENASE; BIOCHEMICAL-PROPERTIES; CATABOLIC PATHWAYS; CLONING VECTORS; PURIFICATION; DEGRADATION	In this work we have characterized the galA gene product from Pseudomonas putida KT2440, a ring- cleavage dioxygenase that acts specifically on gallate to produce 4- oxalomesaconate. The protein is a trimer composed by three identical subunits of 47.6 kDa ( 419 amino acids) that uses Fe2+ as the main cofactor. The gallate dioxygenase showed maximum activity at pH 7.0, and the K-m and V-max values for gallate were 144 mu M and 53.2 mu mol/ min/ mg of protein, respectively. A phylogenetic study suggests that the gallate dioxygenase from P. putida KT2440 is the prototype of a new subgroup of type II extradiol dioxygenases that share a common ancestor with protocatechuate 4,5- dioxygenases and whose two- domain architecture might have evolved from the fusion of the large and small subunits of the latter. A three- dimensional model for the N- terminal domain ( residues 1 - 281) and C- terminal domain ( residues 294 - 420) of the gallate dioxygenase from P. putida KT2440 was generated by comparison with the crystal structures of the large ( LigB) and small ( LigA) subunits of the protocatechuate 4,5- dioxygenase from Sphingomonas paucimobilis SYK- 6. The expression of the galA gene was specifically induced when P. putida KT2440 cells grew in the presence of gallate. A P. putida KT2440 galA mutant strain was unable to use gallate as the sole carbon source and it did not show gallate dioxygenase activity, suggesting that the GalA protein is the only dioxygenase involved in gallate cleavage in this bacterium. This work points to the existence of a new pathway that is devoted to the catabolism of gallic acid and that remained unknown in the paradigmatic P. putida KT2440 strain.	CSIC, Ctr Invest Biol, Dept Mol Microbiol, Madrid 28040, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Diaz, E (corresponding author), CSIC, Ctr Invest Biol, Dept Mol Microbiol, Ramiro Maeztu 9, Madrid 28040, Spain.	ediaz@cib.csic.es	Canales, Angeles/K-7499-2015; JIMENEZ-BARBERO, JESUS/D-4431-2014; Nogales, Juan/Y-8829-2019; Garcia Lopez, Jose Luis/G-9139-2015; Diaz, Eduardo/F-8605-2016	Canales, Angeles/0000-0003-0542-3080; JIMENEZ-BARBERO, JESUS/0000-0001-5421-8513; Garcia Lopez, Jose Luis/0000-0002-9238-2485; Nogales, Juan/0000-0002-4961-0833; Diaz, Eduardo/0000-0002-9731-6524				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Arias-Barrau E, 2004, J BACTERIOL, V186, P5062, DOI 10.1128/jb.186.15.5062-5077.2004; BAGDASARIAN M, 1981, GENE, V16, P237, DOI 10.1016/0378-1119(81)90080-9; Barragan MJL, 2004, J BACTERIOL, V186, P5762, DOI 10.1128/JB.186.17.5762-5774.2004; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; DeLong EF, 2004, ENVIRON MICROBIOL, V6, P875, DOI 10.1111/j.1462-2920.2004.00668.x; DELORENZO V, 1994, METHOD ENZYMOL, V235, P386; dos Santos VAPM, 2004, ENVIRON MICROBIOL, V6, P1264, DOI 10.1111/j.1462-2920.2004.00734.x; Eaton RW, 2001, J BACTERIOL, V183, P3689, DOI 10.1128/JB.183.12.3689-3703.2001; Felsenstein J., 1993, PHYLIP PHYLOGENETIC; FRANKLIN FCH, 1981, P NATL ACAD SCI-BIOL, V78, P7458, DOI 10.1073/pnas.78.12.7458; Hara H, 2000, J BACTERIOL, V182, P6950, DOI 10.1128/JB.182.24.6950-6957.2000; JAMALUDDIN MP, 1977, J BACTERIOL, V129, P690, DOI 10.1128/JB.129.2.690-697.1977; Jimenez JI, 2004, PSEUDOMONAS, VOL 3: BIOSYNTHESIS OF MACROMOLECULES AND MOLECULAR METABOLISM, P425; Jimenez JI, 2002, ENVIRON MICROBIOL, V4, P824, DOI 10.1046/j.1462-2920.2002.00370.x; Kasai D, 2004, J BACTERIOL, V186, P4951, DOI 10.1128/JB.186.15.4951-4959.2004; KERSTEN PJ, 1982, J BACTERIOL, V152, P1154; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LEE YLT, 1977, J BACTERIOL, V131, P1016, DOI 10.1128/JB.131.3.1016-1017.1977; Maruyama K, 2004, BIOSCI BIOTECH BIOCH, V68, P1434, DOI 10.1271/bbb.68.1434; MARUYAMA K, 1983, J BIOCHEM, V93, P557, DOI 10.1093/oxfordjournals.jbchem.a134210; Minton A.P., 1994, MODERN ANAL ULTRACEN, P81; Nelson KE, 2002, ENVIRON MICROBIOL, V4, P799, DOI 10.1046/j.1462-2920.2002.00366.x; NODA Y, 1990, J BACTERIOL, V172, P2704, DOI 10.1128/jb.172.5.2704-2709.1990; Peng X, 1998, APPL ENVIRON MICROB, V64, P2520; Providenti MA, 2001, MICROBIOL-SGM, V147, P2157, DOI 10.1099/00221287-147-8-2157; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sambrook J, 2001, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO J, 1992, J MAGN RESON, V97, P202, DOI 10.1016/0022-2364(92)90250-B; SCHAFER A, 1994, GENE, V145, P69, DOI 10.1016/0378-1119(94)90324-7; SCHMIDT SR, 1995, EUR J BIOCHEM, V228, P425, DOI 10.1111/j.1432-1033.1995.00425.x; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; SPARNINS VL, 1975, J BACTERIOL, V124, P1374, DOI 10.1128/JB.124.3.1374-1381.1975; Speicher David W., 1994, Methods (Orlando), V6, P262, DOI 10.1006/meth.1994.1028; Spence EL, 1996, J BACTERIOL, V178, P5249, DOI 10.1128/jb.178.17.5249-5256.1996; Sugimoto K, 1999, STRUCTURE, V7, P953, DOI 10.1016/S0969-2126(99)80122-1; Takenaka S, 1997, J BIOL CHEM, V272, P14727, DOI 10.1074/jbc.272.23.14727; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vaillancourt FH, 2004, PSEUDOMONAS, VOL 3: BIOSYNTHESIS OF MACROMOLECULES AND MOLECULAR METABOLISM, P359; Wackett LP, 2003, NAT BIOTECHNOL, V21, P136, DOI 10.1038/nbt0203-136; Wattiau P, 2001, RES MICROBIOL, V152, P861, DOI 10.1016/S0923-2508(01)01269-4; WOLGEL SA, 1993, J BACTERIOL, V175, P4414, DOI 10.1128/JB.175.14.4414-4426.1993; Wu JF, 2005, ARCH MICROBIOL, V183, P1, DOI 10.1007/s00203-004-0738-5; ZABINSKI R, 1972, BIOCHEMISTRY-US, V11, P3212, DOI 10.1021/bi00767a012	48	43	45	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35382	35390		10.1074/jbc.M502585200	http://dx.doi.org/10.1074/jbc.M502585200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16030014	hybrid, Green Published			2022-12-25	WOS:000232561200037
J	Anborgh, PH; Godin, C; Pampillo, M; Dhami, GK; Dale, LB; Cregan, SP; Truant, R; Ferguson, SSG				Anborgh, PH; Godin, C; Pampillo, M; Dhami, GK; Dale, LB; Cregan, SP; Truant, R; Ferguson, SSG			Inhibition of metabotropic glutamate receptor signaling by the huntingtin-binding protein optineurin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMOLOGY DOMAIN; DISEASE; DEGENERATION; ACTIVATION; LESIONS; MODEL; ONSET	Huntington disease is caused by a polyglutamine expansion in the huntingtin protein (Htt) and is associated with excitotoxic death of striatal neurons. Group I metabotropic glutamate receptors (mGluRs) that are coupled to inositol 1,4,5-triphosphate formation and the release of intracellular Ca2+ stores play an important role in regulating neuronal function. We show here that mGluRs interact with the Htt-binding protein optineurin that is also linked to normal pressure open angled glaucoma and, when expressed in HEK 293 cells, optineurin functions to antagonize agonist-stimulated mGluR1a signaling. We find that Htt is co-precipitated with mGluR1a and that mutant Htt functions to facilitate optineurin-mediated attenuation of mGluR1a signaling. In striatal cell lines derived from Htt(Q111/Q111) mutant knock-in mice mGluR5-stimulated inositol phosphate formation is also severely impaired when compared with striatal cells derived from Htt(Q7/Q7) knock-in mice. In addition, we show that a missense single nucleotide polymorphism optineurin H486R variant previously identified to be associated with glaucoma is selectively impaired in mutant Htt binding. Although optineurin H486R retains the capacity to bind to mGluR1a, optineurin H486R-dependent attenuation of mGluR1a signaling is not enhanced by the expression of mutant Htt. Because G protein-coupled receptor kinase 2 (GRK2) protein expression is relatively low in striatal tissue, we propose that optineurin may substitute for GRK2 in the striatum to mediate mGluR desensitization. Taken together, these studies identify a novel mechanism for mGluR desensitization and an additional biochemical link between altered glutamate receptor signaling and Huntington disease.	John P Robarts Res Inst, Cell Biol Res Grp, London, ON N6A 5K8, Canada; Univ Western Ontario, Dept Physiol & Pharmacol, London, ON N6A 5K8, Canada; McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); McMaster University	Ferguson, SSG (corresponding author), John P Robarts Res Inst, Cell Biol Res Grp, 100 Perth Dr,POB 5015, London, ON N6A 5K8, Canada.	ferguson@robarts.ca	Cregan, Sean/M-3205-2013					Anborgh PH, 1999, MOL CELL BIOL, V19, P4611; Arning L, 2005, NEUROGENETICS, V6, P25, DOI 10.1007/s10048-004-0198-8; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; Battaglia G, 2002, J NEUROSCI, V22, P2135, DOI 10.1523/JNEUROSCI.22-06-02135.2002; Battaglia G, 2004, J NEUROSCI, V24, P828, DOI 10.1523/JNEUROSCI.3831-03.2004; BEAL MF, 1991, J NEUROSCI, V11, P1649; Bhattacharya M, 2004, J NEUROSCI, V24, P8752, DOI 10.1523/JNEUROSCI.3155-04.2004; Bordi F, 1999, PROG NEUROBIOL, V59, P55, DOI 10.1016/S0301-0082(98)00095-1; BRUNO V, 2001, EUR J NEUROSCI, V13, P69; Calabresi P, 1999, EXP NEUROL, V158, P97, DOI 10.1006/exnr.1999.7092; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Dale LB, 2004, J BIOL CHEM, V279, P13110, DOI 10.1074/jbc.M313333200; Dale LB, 2000, J BIOL CHEM, V275, P38213, DOI 10.1074/jbc.M006075200; Dhami GK, 2004, J BIOL CHEM, V279, P16614, DOI 10.1074/jbc.M314090200; Dhami GK, 2002, J BIOL CHEM, V277, P25266, DOI 10.1074/jbc.M203593200; DIFIGLIA M, 1990, TRENDS NEUROSCI, V13, P286, DOI 10.1016/0166-2236(90)90111-M; Dyka FM, 2004, J NEUROCHEM, V90, P190, DOI 10.1111/j.1471-4159.2004.02474.x; Faber PW, 1998, HUM MOL GENET, V7, P1463, DOI 10.1093/hmg/7.9.1463; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Ferguson Stephen S. G., 2003, V237, P121; Harjes P, 2003, TRENDS BIOCHEM SCI, V28, P425, DOI 10.1016/S0968-0004(03)00168-3; Hattula K, 2000, CURR BIOL, V10, P1603, DOI 10.1016/S0960-9822(00)00864-2; Helmlinger D, 2002, HUM MOL GENET, V11, P3351, DOI 10.1093/hmg/11.26.3351; Jackson GR, 1998, NEURON, V21, P633, DOI 10.1016/S0896-6273(00)80573-5; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Li SH, 2004, TRENDS GENET, V20, P146, DOI 10.1016/j.tig.2004.01.008; Li YG, 1998, MOL CELL BIOL, V18, P1601, DOI 10.1128/MCB.18.3.1601; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Melki R, 2003, J MED GENET, V40, P842, DOI 10.1136/jmg.40.11.842; Moreland RJ, 2000, NUCLEIC ACIDS RES, V28, P1986, DOI 10.1093/nar/28.9.1986; Nicoletti F, 1999, NEUROPHARMACOLOGY, V38, P1477, DOI 10.1016/S0028-3908(99)00102-1; Nicoletti F, 1996, TRENDS NEUROSCI, V19, P267, DOI 10.1016/S0166-2236(96)20019-0; PAULUS W, 1993, ANN NEUROL, V34, P574, DOI 10.1002/ana.410340411; Rezaie T, 2002, SCIENCE, V295, P1077, DOI 10.1126/science.1066901; Schlefer J, 2004, BRAIN RES, V1019, P246, DOI 10.1016/j.brainres.2004.06.005; STOREY E, 1992, ANN NEUROL, V32, P526, DOI 10.1002/ana.410320408; Tang TS, 2005, P NATL ACAD SCI USA, V102, P2602, DOI 10.1073/pnas.0409402102; Tang TS, 2003, NEURON, V39, P227, DOI 10.1016/S0896-6273(03)00366-0; Trettel F, 2000, HUM MOL GENET, V9, P2799, DOI 10.1093/hmg/9.19.2799; Willoughby CE, 2004, INVEST OPHTH VIS SCI, V45, P3122, DOI 10.1167/iovs.04-0107; Young AB, 2003, J CLIN INVEST, V111, P299, DOI 10.1172/JCI200317742; Zeron MM, 2002, NEURON, V33, P849, DOI 10.1016/S0896-6273(02)00615-3	42	116	120	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34840	34848		10.1074/jbc.M504508200	http://dx.doi.org/10.1074/jbc.M504508200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16091361	hybrid			2022-12-25	WOS:000232403900056
J	Gascon, S; Deogracias, R; Sobrado, M; Roda, JM; Renart, J; Rodriguez-Pena, A; Diaz-Guerra, M				Gascon, S; Deogracias, R; Sobrado, M; Roda, JM; Renart, J; Rodriguez-Pena, A; Diaz-Guerra, M			Transcription of the NR1 subunit of the N-methyl-D-aspartate receptor is down-regulated by excitotoxic stimulation and cerebral ischemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMDA RECEPTORS; CORTICAL-NEURONS; MESSENGER-RNA; RAT; EXPRESSION; TRAFFICKING; ACTIVATION; CALPAIN; GENE; CLEAVAGE	The N-methyl-D-aspartate (NMDA) type of glutamate receptor (NMDAR) plays central roles in normal and pathological neuronal functioning. We have examined the regulation of the NR1 subunit of the NMDAR in response to excessive activation of this receptor in in vitro and in vivo models of excitotoxicity. NR1 protein expression in cultured cortical neurons was specifically reduced by stimulation with 100 mu M NMDA or glutamate. NMDA decreased NR1 protein amounts by 71% after 8 h. Low NMDA concentrations (<= 10 mu M) had no effect. NR1 down-regulation was inhibited by the general NMDAR antagonist DL-AP5 and also by ifenprodil, which specifically antagonizes NMDARs containing NR2B subunits. Arrest of NMDAR signaling with DL-AP5 after brief exposure to NMDA did not prevent subsequent NR1 decrease. Down-regulation of NR1 did not involve calpain cleavage but resulted from a decrease in de novo synthesis consequence of reduced mRNA amounts. In contrast, NMDA did not alter the expression of NR2A mRNA or newly synthesized protein. In neurons transiently transfected with an NR1 promoter/luciferase reporter construct, promoter activity was reduced by 68% after 2 h of stimulation with NMDA, and its inhibition required extracellular calcium. A similar mechanism of autoregulation of the receptor probably operates during cerebral ischemia, because NR1 mRNA and protein were strongly decreased at early stages of blood reperfusion in the infarcted brains of rats subjected to occlusion of the middle cerebral artery. Because NR1 is the obligatory subunit of NMDARs, this regulatory mechanism will be fundamental to NMDAR functioning.	UAM, CSIC, Inst Invest Biomed Alberto Sols, Madrid 28029, Spain; Hosp La Paz, Unidad Invest Cerebrovasc, Madrid 28029, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Hospital Universitario La Paz	Diaz-Guerra, M (corresponding author), UAM, CSIC, Inst Invest Biomed Alberto Sols, Arturo Duperier 4, Madrid 28029, Spain.	mdiazguerra@iib.uam.es	Deogracias, Ruben/I-5751-2015; Renart, Jaime/B-7661-2009; Díaz-Guerra, Margarita/F-3212-2018; SOBRADO, MONICA/B-4482-2017	Deogracias, Ruben/0000-0002-9279-7867; Renart, Jaime/0000-0001-6620-3706; Díaz-Guerra, Margarita/0000-0002-4478-0956; Rodriguez-Pena, Angeles/0000-0002-2515-4626; Gascon, Sergio/0000-0001-8756-7082				Adamec E, 1998, MOL BRAIN RES, V54, P35, DOI 10.1016/S0169-328X(97)00304-5; Awobuluyi M, 2003, J NEUROCHEM, V87, P1066, DOI 10.1046/j.1471-4159.2003.02048.x; Bai G, 2003, J NEUROCHEM, V86, P992, DOI 10.1046/j.1471-4159.2003.01922.x; BAI G, 1995, J BIOL CHEM, V270, P7737, DOI 10.1074/jbc.270.13.7737; Barria A, 2002, NEURON, V35, P345, DOI 10.1016/S0896-6273(02)00776-6; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; BULLER AL, 1994, J NEUROSCI, V14, P5471; Calderone A, 2003, J NEUROSCI, V23, P2112; Carroll RC, 2002, TRENDS NEUROSCI, V25, P571, DOI 10.1016/S0166-2236(02)02272-5; Chazot PL, 1997, J NEUROCHEM, V68, P507; CHEN ST, 1986, STROKE, V17, P738, DOI 10.1161/01.STR.17.4.738; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Dong YN, 2004, J NEUROSCI, V24, P11035, DOI 10.1523/JNEUROSCI.3722-04.2004; Fukaya M, 2003, P NATL ACAD SCI USA, V100, P4855, DOI 10.1073/PNAS.0830996100; Hall RA, 1997, J BIOL CHEM, V272, P4135, DOI 10.1074/jbc.272.7.4135; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Huh KH, 1999, J BIOL CHEM, V274, P151, DOI 10.1074/jbc.274.1.151; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; ISHII T, 1993, J BIOL CHEM, V268, P2836; Kim JB, 2004, J NEUROCHEM, V89, P1271, DOI 10.1111/j.1471-4159.2004.02429.x; KOH JY, 1988, J NEUROSCI, V8, P2153, DOI 10.1523/jneurosci.08-06-02153.1988; Lau GC, 2004, J NEUROCHEM, V88, P564, DOI 10.1046/j.1471-4159.2003.02156.x; Li B, 2002, NAT NEUROSCI, V5, P833, DOI 10.1038/nn912; Li JH, 1998, EUR J NEUROSCI, V10, P1704, DOI 10.1046/j.1460-9568.1998.00169.x; LIU TH, 1989, AM J PHYSIOL, V256, pH589, DOI 10.1152/ajpheart.1989.256.2.H589; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORI H, 1995, NEUROPHARMACOLOGY, V34, P1219, DOI 10.1016/0028-3908(95)00109-J; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; Mu YY, 2003, NEURON, V40, P581, DOI 10.1016/S0896-6273(03)00676-7; Prybylowski K, 2002, J NEUROSCI, V22, P8902; ROSE K, 1993, METHODS TOXICOLOGY, V1, P46; Rumbaugh G, 1999, J NEUROSCI, V19, P10603, DOI 10.1523/JNEUROSCI.19-24-10603.1999; Simpkins KL, 2003, J NEUROSCI, V23, P11322; Stocca G, 1998, J PHYSIOL-LONDON, V507, P13, DOI 10.1111/j.1469-7793.1998.013bu.x; Tovar KR, 1999, J NEUROSCI, V19, P4180; Tovar KR, 2002, NEURON, V34, P253; Walton MR, 2000, TRENDS NEUROSCI, V23, P48, DOI 10.1016/S0166-2236(99)01500-3; Wenthold RJ, 2003, ANNU REV PHARMACOL, V43, P335, DOI 10.1146/annurev.pharmtox.43.100901.135803; Westbrook Gary L., 1994, Current Opinion in Neurobiology, V4, P337, DOI 10.1016/0959-4388(94)90094-9; WILLIAMS K, 1993, MOL PHARMACOL, V44, P851; Wu HY, 2005, J BIOL CHEM, V280, P21588, DOI 10.1074/jbc.M501603200	44	58	62	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					35018	35027		10.1074/jbc.M504108200	http://dx.doi.org/10.1074/jbc.M504108200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16049015	hybrid			2022-12-25	WOS:000232403900075
J	Castillo-Flores, A; Weinberger, A; Robinson, M; Gerst, JE				Castillo-Flores, A; Weinberger, A; Robinson, M; Gerst, JE			Mso1 is a novel component of the yeast exocytic SNARE complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE EXOCYTOSIS; MEMBRANE-FUSION; SACCHAROMYCES-CEREVISIAE; SEC1/MUNC18 PROTEINS; VESICULAR TRANSPORT; SYNTAXIN HOMOLOG; MUNC13 ISOFORM; C-ELEGANS; SECRETION; GOLGI	The yeast exocytic SNARE complex consists of one molecule each of the Sso1/ 2 target SNAREs, Snc1/2 vesicular SNAREs, and the Sec9 target SNARE, which form a fusion complex that is conserved in evolution. Another protein, Sec1, binds to the SNARE complex to facilitate assembly. We show that Mso1, a Sec1-interacting protein, also binds to the SNARE complex and plays a role in mediating Sec1 functions. Like Sec1, Mso1 bound to SNAREs in cells containing SNARE complexes (i.e. wild-type, sec1-1, and sec18-1 cells), but not in cells in which complex formation is inhibited (i.e. sec4-8 cells). Nevertheless, Mso1 remained associated with Sec1 even in sec4-8 cells, indicating that they act as a pair. Mso1 localized primarily to the plasma membrane of the bud when SNARE complex formation was not impaired but was mostly in the cytoplasm when assembly was prevented. Genetic studies suggest that Mso1 enhances Sec1 function while attenuating Sec4 GTPase function. This dual action may impart temporal regulation between Sec4 turnoff and Sec1-mediated SNARE assembly. Notably, a small region at the C terminus of Mso1 is conserved in the mammalian Munc13/Mint proteins and is necessary for proper membrane localization. Overexpression of Mso1 lacking this domain (Mso1-(1-193)) inhibited the growth of cells bearing an attenuated Sec4 GTPase. These results suggest that Mso1 is a component of the exocytic SNARE complex and a possible ortholog of the Munc13/Mint proteins.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Gerst, JE (corresponding author), Weizmann Inst Sci, Dept Mol Genet, Belfer Bldg, IL-76100 Rehovot, Israel.	jeffrey.gerst@weizmann.ac.il						Aalto MK, 1997, P NATL ACAD SCI USA, V94, P7331, DOI 10.1073/pnas.94.14.7331; AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; Augustin I, 2001, J NEUROSCI, V21, P10, DOI 10.1523/JNEUROSCI.21-01-00010.2001; Augustin I, 1999, NATURE, V400, P457, DOI 10.1038/22768; Betz A, 1997, J BIOL CHEM, V272, P2520; Biederer T, 2000, J BIOL CHEM, V275, P39803, DOI 10.1074/jbc.C000656200; BOWSER R, 1992, J CELL BIOL, V118, P1041, DOI 10.1083/jcb.118.5.1041; BRENNWALD P, 1994, CELL, V79, P245, DOI 10.1016/0092-8674(94)90194-5; Bryant NJ, 2001, EMBO J, V20, P3380, DOI 10.1093/emboj/20.13.3380; Carr CM, 1999, J CELL BIOL, V146, P333, DOI 10.1083/jcb.146.2.333; COUVE A, 1994, J BIOL CHEM, V269, P23391; Darsow T, 1997, J CELL BIOL, V138, P517, DOI 10.1083/jcb.138.3.517; Fasshauer D, 2003, BBA-MOL CELL RES, V1641, P87, DOI 10.1016/S0167-4889(03)00090-9; Feldmann J, 2003, CELL, V115, P461, DOI 10.1016/S0092-8674(03)00855-9; Fix M, 2004, P NATL ACAD SCI USA, V101, P7311, DOI 10.1073/pnas.0401779101; Gao XD, 2003, J CELL BIOL, V162, P635, DOI 10.1083/jcb.200302038; Gerst JE, 2003, BBA-MOL CELL RES, V1641, P99, DOI 10.1016/S0167-4889(03)00096-X; GERST JE, 1992, P NATL ACAD SCI USA, V89, P4338, DOI 10.1073/pnas.89.10.4338; Grote E, 2000, J CELL BIOL, V151, P439, DOI 10.1083/jcb.151.2.439; Gurunathan S, 2000, MOL BIOL CELL, V11, P3629, DOI 10.1091/mbc.11.10.3629; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; Ho A, 2003, P NATL ACAD SCI USA, V100, P1409, DOI 10.1073/pnas.252774899; Holthuis JCM, 1998, EMBO J, V17, P113, DOI 10.1093/emboj/17.1.113; Hu C, 2003, SCIENCE, V300, P1745, DOI 10.1126/science.1084909; Jahn R, 2000, NEURON, V27, P201, DOI 10.1016/S0896-6273(00)00029-5; Jahn R, 2002, CURR OPIN CELL BIOL, V14, P488, DOI 10.1016/S0955-0674(02)00356-3; Jantti J, 2002, J CELL SCI, V115, P409; Katz L, 2000, MOL BIOL CELL, V11, P3849, DOI 10.1091/mbc.11.11.3849; Kauppi M, 2004, TOP CURR GENET, V10, P115; KNOP M, 2005, IN PRESS MOL BIOL CE; Koch H, 2000, BIOCHEM J, V349, P247, DOI 10.1042/0264-6021:3490247; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Marash M, 2001, EMBO J, V20, P411, DOI 10.1093/emboj/20.3.411; Neeft M, 2005, MOL BIOL CELL, V16, P731, DOI 10.1091/mbc.E04-10-0923; Novick P, 2002, TRENDS CELL BIOL, V12, P247, DOI 10.1016/S0962-8924(02)02293-6; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; Ossig R, 2000, EMBO J, V19, P6000, DOI 10.1093/emboj/19.22.6000; Peng RW, 2002, J CELL BIOL, V157, P645, DOI 10.1083/jcb.200202006; PROTOPOPOV V, 1993, CELL, V74, P855, DOI 10.1016/0092-8674(93)90465-3; Richmond JE, 2002, CURR OPIN NEUROBIOL, V12, P499, DOI 10.1016/S0959-4388(02)00360-4; Richmond JE, 2001, NATURE, V412, P338, DOI 10.1038/35085583; Richmond JE, 1999, NAT NEUROSCI, V2, P959, DOI 10.1038/12160; Rizo J, 2002, NAT REV NEUROSCI, V3, P641, DOI 10.1038/nrn898; Rose MD., 1990, METHODS YEAST GENETI; Rossi G, 1997, J BIOL CHEM, V272, P16610, DOI 10.1074/jbc.272.26.16610; Rossner S, 2004, J BIOL CHEM, V279, P27841, DOI 10.1074/jbc.C400122200; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SALMINEN A, 1989, J CELL BIOL, V109, P1023, DOI 10.1083/jcb.109.3.1023; Sassa T, 1999, J NEUROSCI, V19, P4772; Scott BL, 2004, J CELL BIOL, V167, P75, DOI 10.1083/jcb.200405018; Sheu L, 2003, J BIOL CHEM, V278, P27556, DOI 10.1074/jbc.M303203200; Shirakawa R, 2004, J BIOL CHEM, V279, P10730, DOI 10.1074/jbc.M309426200; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; Sollner TH, 2003, MOL MEMBR BIOL, V20, P209, DOI 10.1080/0968768031000104953; Sudhof TC, 2004, ANNU REV NEUROSCI, V27, P509, DOI 10.1146/annurev.neuro.26.041002.131412; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; Ungar D, 2003, ANNU REV CELL DEV BI, V19, P493, DOI 10.1146/annurev.cellbio.19.110701.155609; Varoqueaux F, 2002, P NATL ACAD SCI USA, V99, P9037, DOI 10.1073/pnas.122623799; WalchSolimena C, 1997, J CELL BIOL, V137, P1495, DOI 10.1083/jcb.137.7.1495; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Yamaguchi T, 2002, DEV CELL, V2, P295, DOI 10.1016/S1534-5807(02)00125-9	62	12	12	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34033	34041		10.1074/jbc.M507142200	http://dx.doi.org/10.1074/jbc.M507142200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16087665	hybrid			2022-12-25	WOS:000232229700042
J	Chang, AN; Harada, K; Ackerman, MJ; Potter, JD				Chang, AN; Harada, K; Ackerman, MJ; Potter, JD			Functional consequences of hypertrophic and dilated cardiomyopathy-causing mutations in alpha-tropomyosin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC-MUSCLE CONTRACTION; TROPONIN-T; THIN FILAMENT; ADENOSINE-TRIPHOSPHATASE; FORCE DEVELOPMENT; ESCHERICHIA-COLI; CA2+ REGULATION; COILED-COIL; MYOSIN; BINDING	To study the functional consequences of various cardiomyopathic mutations in human cardiac alpha-tropomyosin (Tm), a method of depletion/reconstitution of native Tm and troponin (Tn) complex (Tm-Tn) in cardiac myofibril preparations has been developed. The endogenous Tm-Tn complex was selectively removed from myofibrils and replaced with recombinant wild-type or mutant proteins. Successful depletion and reconstitution steps were verified by SDS-gel electrophoresis and by the loss and regain of Ca2+-dependent regulation of ATPase activity. Five Tm mutations were chosen for this study: the hypertrophic cardiomyopathy (HCM) mutations E62Q, E180G, and L185R and the dilated cardiomyopathy (DCM) mutations E40K and E54K. Through the use of this new depletion/ reconstitution method, the functional consequences of these mutations were determined utilizing myofibrillar ATPase measurements. The results of our studies showed that 1) depletion of > 80% of Tm-Tn from myofibrils resulted in a complete loss of the Ca2+-regulated ATPase activity and a significant loss in the maximal ATPase activity, 2) reconstitution of exogenous wild-type Tm-Tn resulted in complete regain in the calcium regulation and in the maximal ATPase activity, and 3) all HCM-associated Tm mutations increased the Ca2+ sensitivity of ATPase activity and all had decreased abilities to inhibit ATPase activity. In contrast, the DCM-associated mutations both decreased the Ca2+ sensitivity of ATPase activity and had no effect on the inhibition of ATPase activity. These findings have demonstrated that the mutations which cause HCM and DCM disrupt discrete mechanisms, which may culminate in the distinct cardiomyopathic phenotypes.	Univ Miami, Miller Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA; Mayo Clin & Mayo Fdn, Mayo Clin Coll Med, Dept Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Clin Coll Med, Dept Pediat, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Clin Coll Med, Dept Mol Pharmacol, Rochester, MN 55905 USA	University of Miami; Mayo Clinic; Mayo Clinic; Mayo Clinic	Potter, JD (corresponding author), Univ Miami, Miller Sch Med, Dept Mol & Cellular Pharmacol, 1600 NW 10th Ave R-189, Miami, FL 33136 USA.	jdpotter@miami.edu			NHLBI NIH HHS [HL67415] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067415] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bing W, 2000, J MOL CELL CARDIOL, V32, P1489, DOI 10.1006/jmcc.2000.1182; Bing W, 1997, BIOCHEM BIOPH RES CO, V236, P760, DOI 10.1006/bbrc.1997.7045; Golitsina N, 1999, BIOCHEMISTRY-US, V38, P3850, DOI 10.1021/bi9950701; Golitsina N, 1997, BIOCHEMISTRY-US, V36, P4637, DOI 10.1021/bi962970y; Gomes AV, 2002, J BIOL CHEM, V277, P35341, DOI 10.1074/jbc.M204118200; Hilario E, 2004, EUR J BIOCHEM, V271, P4132, DOI 10.1111/j.1432-1033.2004.04351.x; HITCHCOCKDEGREGORI SE, 1987, J BIOL CHEM, V262, P9730; Jongbloed RJ, 2003, J AM COLL CARDIOL, V41, P981, DOI 10.1016/S0735-1097(02)03005-X; Kamisago M, 2000, NEW ENGL J MED, V343, P1688, DOI 10.1056/NEJM200012073432304; KENTISH JC, 1984, J PHYSIOL-LONDON, V352, P353, DOI 10.1113/jphysiol.1984.sp015296; Knollmann BC, 2001, J BIOL CHEM, V276, P10039, DOI 10.1074/jbc.M006745200; KOMINZ DR, 1969, ARCH BIOCHEM BIOPHYS, V129, P609, DOI 10.1016/0003-9861(69)90221-5; Kremneva E, 2004, BIOPHYS J, V87, P3922, DOI 10.1529/biophysj.104.048793; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lang R, 2002, J BIOL CHEM, V277, P11670, DOI 10.1074/jbc.M108912200; MCKILLOP DFA, 1993, BIOPHYS J, V65, P693, DOI 10.1016/S0006-3495(93)81110-X; Mestroni L, 1999, J AM COLL CARDIOL, V34, P181, DOI 10.1016/S0735-1097(99)00172-2; Michele DE, 2002, CIRC RES, V91, P255, DOI 10.1161/01.RES.0000027530.58419.82; MIZRA M, 2004, J MUSCLE RES CELL M, V25, P276; MONTEIRO PB, 1994, J BIOL CHEM, V269, P10461; Olson TM, 2001, J MOL CELL CARDIOL, V33, P723, DOI 10.1006/jmcc.2000.1339; PERRY SV, 1958, BIOCHEM J, V68, P5, DOI 10.1042/bj0680005; PERRY SV, 1966, BIOCHEM J, V99, pC1, DOI 10.1042/bj0990001C; POTTER JD, 1995, J BIOL CHEM, V270, P2557, DOI 10.1074/jbc.270.6.2557; Prabhakar R, 2001, J MOL CELL CARDIOL, V33, P1815, DOI 10.1006/jmcc.2001.1445; SCHAUB MC, 1967, BIOCHEM J, V104, P263, DOI 10.1042/bj1040263; SHENG ZL, 1992, J BIOL CHEM, V267, P25407; Singh A, 2003, BIOCHEMISTRY-US, V42, P14114, DOI 10.1021/bi0348462; SOLARO RJ, 1971, BIOCHIM BIOPHYS ACTA, V245, P259, DOI 10.1016/0005-2728(71)90033-8; Szczesna D, 1996, J BIOL CHEM, V271, P8381, DOI 10.1074/jbc.271.14.8381; Szczesna D, 2000, J BIOL CHEM, V275, P624, DOI 10.1074/jbc.275.1.624; Szczesna-Cordary D, 2004, J BIOL CHEM, V279, P3535, DOI 10.1074/jbc.M307092200; Takahashi-Yanaga F, 2001, J MOL CELL CARDIOL, V33, P2095, DOI 10.1006/jmcc.2001.1473; Tobacman LS, 2002, J BIOL CHEM, V277, P27636, DOI 10.1074/jbc.M201768200; Tripet B, 2000, J MOL BIOL, V300, P377, DOI 10.1006/jmbi.2000.3866; URBANCIKOVA M, 1994, J BIOL CHEM, V269, P24310; Van Driest SL, 2005, MAYO CLIN PROC, V80, P463, DOI 10.4065/80.4.463; Van Driest SL, 2002, CIRCULATION, V106, P3085, DOI 10.1161/01.CIR.0000042675.59901.14; Van Driest SL, 2002, AM J CARDIOL, V90, P1123, DOI 10.1016/S0002-9149(02)02780-7; Yanaga F, 1999, J BIOL CHEM, V274, P8806, DOI 10.1074/jbc.274.13.8806	40	68	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34343	34349		10.1074/jbc.M505014200	http://dx.doi.org/10.1074/jbc.M505014200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16043485	hybrid			2022-12-25	WOS:000232229700077
J	Contestabile, A; Fila, T; Bartesaghi, R; Ciani, E				Contestabile, A; Fila, T; Bartesaghi, R; Ciani, E			Cyclic AMP-mediated regulation of transcription factor Lot1 expression in cerebellar granule cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLASE-ACTIVATING POLYPEPTIDE; ZINC-FINGER PROTEIN; ELEMENT-BINDING PROTEIN; FOS GENE-EXPRESSION; KINASE-A PATHWAY; C-FOS; MAP KINASE; RAT-BRAIN; DEPENDENT TRANSCRIPTION; NEUROTROPHIC ACTIVITY	Lot1, a zinc finger transcription factor acting as a tumor suppressor gene on tumoral cells, is highly expressed during brain development. In developing rat cerebellum, Lot1 expression is high in cerebellar granule cells (CGC), a neuronal population undergoing postnatal neurogenesis. The time course of Lot1 cerebellar expression closely matches the expression of pituitary adenylate cyclase-activating polypeptide ( PACAP) receptors coupled to adenylyl cyclase. The aim of this study was to ascertain whether Lot1 expression is regulated by cAMP-dependent pathways and to identify mechanisms of Lot1 activation in CGC cultures. Our results show that Lot1 expression in CGC is cAMP-dependent, as treatments with either forskolin or PACAP-38 induced an increase in its expression at both the mRNA and protein levels. This effect on Lot1 expression was mimicked by dibutyryl cAMP and suppressed by protein kinase A and MEK inhibitors. In parallel, we found that treatments with forskolin and PACAP-38 in precursor CGC inhibited bromodeoxyuridine incorporation by 25 and 35%, respectively, indicating a negative effect on neuronal precursor proliferation. Luciferase reporter analysis and mutagenesis of the Lot1 promoter region indicated a crucial role of the AP1-binding site ( located at - 268 bp) in cAMP- induced Lot1 transcription. In addition, cotransfection experiments indicated that the c-Fos/c-Jun heterodimer is responsible for cAMP- dependent Lot1 transcriptional activation. In conclusion, our data demonstrate that, in CGC, Lot1 is under the transcriptional control of cAMP through an AP1 site regulated by the c-Fos/c-Jun heterodimer and suggest that this gene may be an important element of the cAMP- mediated pathway that regulates neuronal proliferation through the protein kinase A-MEK signaling cascade.	Univ Bologna, Dept Human & Gen Physiol, I-40126 Bologna, Italy	University of Bologna	Ciani, E (corresponding author), Univ Bologna, Dept Human & Gen Physiol, Piazza Porta San Donato 2, I-40126 Bologna, Italy.	elisabetta.ciani@unibo.it	Ciani, Elisabetta/AAL-6462-2020; Contestabile, Andrea/F-9908-2013	Contestabile, Andrea/0000-0002-5417-4722; ciani, elisabetta/0000-0003-3130-5168				Abdollahi A, 1997, CANCER RES, V57, P2029; Abdollahi A, 1997, ONCOGENE, V14, P1973, DOI 10.1038/sj.onc.1201034; Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BASILLE M, 1993, NEUROSCIENCE, V57, P329, DOI 10.1016/0306-4522(93)90066-O; Basille M, 2000, J COMP NEUROL, V425, P495; BASILLE M, 1995, J NEUROCHEM, V65, P1318; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Campard PK, 1997, DNA CELL BIOL, V16, P323, DOI 10.1089/dna.1997.16.323; Chang JY, 1996, NEUROSCI LETT, V206, P181, DOI 10.1016/S0304-3940(96)12468-X; Ciani E, 2003, DEV BRAIN RES, V142, P193, DOI 10.1016/S0165-3806(03)00092-0; Ciani E, 1995, J MOL NEUROSCI, V6, P131, DOI 10.1007/BF02736772; Ciani E, 2002, J NEUROCHEM, V82, P1282, DOI 10.1046/j.1471-4159.2002.01080.x; Contestabile Antonio, 2002, Cerebellum, V1, P41, DOI 10.1080/147342202753203087; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Dicicco-Bloom E, 1998, ANN NY ACAD SCI, V865, P274, DOI 10.1111/j.1749-6632.1998.tb11188.x; DIDIER M, 1992, MOL BRAIN RES, V12, P249, DOI 10.1016/0169-328X(92)90091-O; Dugan LL, 1999, J BIOL CHEM, V274, P25842, DOI 10.1074/jbc.274.36.25842; FAVIT A, 1995, NEUROENDOCRINOLOGY, V61, P377, DOI 10.1159/000126859; Fujioka T, 2004, J NEUROSCI, V24, P319, DOI 10.1523/JNEUROSCI.1065.03.2004; Gabellini N, 2004, MOL NEUROBIOL, V30, P91, DOI 10.1385/MN:30:1:091; GALLO V, 1982, P NATL ACAD SCI-BIOL, V79, P7919, DOI 10.1073/pnas.79.24.7919; Gillardon F, 1998, MOL BRAIN RES, V61, P207, DOI 10.1016/S0169-328X(98)00202-2; Harmar AJ, 1998, PHARMACOL REV, V50, P265; Hoffmann A, 1998, ANN NY ACAD SCI, V865, P49, DOI 10.1111/j.1749-6632.1998.tb11162.x; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; Huang SM, 2000, MOL CELL BIOL, V20, P1855, DOI 10.1128/MCB.20.5.1855-1867.2000; Impey S, 1998, NEURON, V21, P869, DOI 10.1016/S0896-6273(00)80602-9; Jaworski DM, 2000, DEV BRAIN RES, V120, P27, DOI 10.1016/S0165-3806(99)00192-3; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kas K, 1998, J BIOL CHEM, V273, P23026, DOI 10.1074/jbc.273.36.23026; Kas K, 1997, NAT GENET, V15, P170, DOI 10.1038/ng0297-170; Kenney AM, 2003, DEVELOPMENT, V130, P15, DOI 10.1242/dev.00182; Lioudyno M, 1998, J NEUROSCI RES, V51, P243, DOI 10.1002/(SICI)1097-4547(19980115)51:2<243::AID-JNR13>3.0.CO;2-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu NR, 1997, P NATL ACAD SCI USA, V94, P3357, DOI 10.1073/pnas.94.7.3357; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MASUO Y, 1994, NEUROSCI LETT, V170, P43, DOI 10.1016/0304-3940(94)90234-8; MASUO Y, 1992, BRAIN RES, V575, P113, DOI 10.1016/0006-8993(92)90430-H; Moody TW, 2003, PEPTIDES, V24, P163, DOI 10.1016/S0196-9781(02)00290-5; MULLER R, 1984, NATURE, V311, P438, DOI 10.1038/311438a0; Nakagawa S, 2002, J NEUROSCI, V22, P3673; Nicot A, 2002, J NEUROSCI, V22, P9244; Nielsen HS, 1998, NEUROREPORT, V9, P2639, DOI 10.1097/00001756-199808030-00039; Pagotto U, 1999, ENDOCRINOLOGY, V140, P987, DOI 10.1210/en.140.2.987; Pandey SC, 2004, PHARMACOL THERAPEUT, V104, P47, DOI 10.1016/j.pharmthera.2004.08.002; Pennuto M, 2002, MOL BIOL CELL, V13, P2706, DOI 10.1091/mbc.E02-01-0036; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rodriguez-Henche N, 2002, BBA-GENE STRUCT EXPR, V1576, P157, DOI 10.1016/S0167-4781(02)00303-2; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; Spengler D, 1997, EMBO J, V16, P2814, DOI 10.1093/emboj/16.10.2814; Suh JH, 2001, NAT NEUROSCI, V4, P123, DOI 10.1038/83936; Tabuchi A, 2001, NEUROSCI RES, V39, P85, DOI 10.1016/S0168-0102(00)00200-5; Taubenfeld SM, 2001, J NEUROSCI, V21, P84, DOI 10.1523/JNEUROSCI.21-01-00084.2001; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Valente T, 2004, NEUROSCIENCE, V128, P323, DOI 10.1016/j.neuroscience.2004.06.056; Valente T, 2001, MECH DEVELOP, V108, P207, DOI 10.1016/S0925-4773(01)00492-0; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Varrault A, 1998, P NATL ACAD SCI USA, V95, P8835, DOI 10.1073/pnas.95.15.8835; Vaudry D, 2000, P NATL ACAD SCI USA, V97, P13390, DOI 10.1073/pnas.97.24.13390; Vaudry D, 1998, NEUROSCIENCE, V84, P801, DOI 10.1016/S0306-4522(97)00545-9; Vaudry D, 1999, P NATL ACAD SCI USA, V96, P9415, DOI 10.1073/pnas.96.16.9415; Vaudry D, 1998, ANN NY ACAD SCI, V865, P92, DOI 10.1111/j.1749-6632.1998.tb11167.x; Villalba M, 1997, J NEUROSCI, V17, P83, DOI 10.1523/JNEUROSCI.17-01-00083.1997; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Waschek JA, 2002, DEV NEUROSCI-BASEL, V24, P14, DOI 10.1159/000064942; Waschek JA, 1998, P NATL ACAD SCI USA, V95, P9602, DOI 10.1073/pnas.95.16.9602; West AE, 2001, P NATL ACAD SCI USA, V98, P11024, DOI 10.1073/pnas.191352298	69	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33541	33551		10.1074/jbc.M413323200	http://dx.doi.org/10.1074/jbc.M413323200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16061485	hybrid			2022-12-25	WOS:000232058100054
J	Khanna, H; Hurd, TW; Lillo, C; Shu, XH; Parapuram, SK; He, S; Akimoto, M; Wright, AF; Margolis, B; Williams, DS; Swaroop, A				Khanna, H; Hurd, TW; Lillo, C; Shu, XH; Parapuram, SK; He, S; Akimoto, M; Wright, AF; Margolis, B; Williams, DS; Swaroop, A			RPGR-ORF15, which is mutated in retinitis pigmentosa, associates with SMC1, SMC3, and microtubule transport proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCHANGE FACTOR; GTPASE REGULATOR; DELTA-SUBUNIT; KINESIN-II; SUBCELLULAR-LOCALIZATION; MYOSIN-VIIA; RPGR EXON; MUTATIONS; INTERACTS; POLARITY	Mutations in the retinitis pigmentosa GTPase regulator ( RPGR) gene account for almost 20% of patients with retinitis pigmentosa. Most mutations are detected in alternatively spliced RPGR-ORF15 isoform(s), which are primarily but not exclusively expressed in the retina. We show that, in addition to the axoneme, the RPGR-ORF15 protein is localized to the basal bodies of photoreceptor connecting cilium and to the tip and axoneme of sperm flagella. Mass spectrometric analysis of proteins that were immunoprecipitated from the retinal axoneme-enriched fraction using an anti-ORF15 antibody identified two chromosome-associated proteins, structural maintenance of chromosomes (SMC) 1 and SMC3. Using pulldown assays, we demonstrate that the interaction of RPGR with SMC1 and SMC3 is mediated, at least in part, by the RCC1-like domain of RPGR. This interaction was not observed with phosphorylation-deficient mutants of SMC1. Both SMC1 and SMC3 localized to the cilia of retinal photoreceptors and Madin-Darby canine kidney cells, suggesting a broader physiological relevance of this interaction. Additional immunoprecipitation studies revealed the association of RPGR-ORF15 isoform( s) with the intraflagellar transport polypeptide IFT88 as well as microtubule motor proteins, including KIF3A, p150(Glued), and p50-dynamitin. Inhibition of dynein function by overexpressing p50 abrogated the localization of RPGR-ORF15 to basal bodies. Taken together, these results provide novel evidence for the possible involvement of RPGR-ORF15 in microtubule organization and regulation of transport in primary cilia.	Univ Michigan, Dept Ophthalmol & Visual Sci, WK Kellogg Eye Ctr, Ann Arbor, MI 48105 USA; Univ Michigan, Dept Human Genet, Ann Arbor, MI 48105 USA; Univ Michigan, Sch Med, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Calif San Diego, Sch Med, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Neurosci, La Jolla, CA 92093 USA; Western Gen Hosp, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland; Kyoto Univ Hosp, Translat Res Ctr, Sakyo Ku, Kyoto 6068507, Japan	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Edinburgh; Kyoto University	Swaroop, A (corresponding author), Univ Michigan, Dept Ophthalmol & Visual Sci, WK Kellogg Eye Ctr, 1000 Wall St, Ann Arbor, MI 48105 USA.	swaroop@umich.edu	Akimoto, Masayuki/AAP-3676-2020; Lillo, Concepcion/A-6321-2009	Lillo, Concepcion/0000-0001-5814-9826; Akimoto, Masayuki/0000-0002-5899-2925; Swaroop, Anand/0000-0002-1975-1141	NATIONAL EYE INSTITUTE [R29EY007961, R01EY007961, P30EY007003, P30EY012598, R01EY013408, F31EY007003] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK069605] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY013408, F31 EY007003, P30 EY007003, EY13408, EY07961, P30 EY012598, R01 EY007961, EY07003, EY12598] Funding Source: Medline; NIDDK NIH HHS [R01 DK069605, DK069605] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARSHAVSKY VY, 2003, SCI STKE, pPE43; Avidor-Reiss T, 2004, CELL, V117, P527, DOI 10.1016/S0092-8674(04)00412-X; Baas PW, 1999, NEURON, V22, P23, DOI 10.1016/S0896-6273(00)80675-3; Baker SA, 2003, J BIOL CHEM, V278, P34211, DOI 10.1074/jbc.M300156200; Besharse JC, 2003, ADV EXP MED BIOL, V533, P157; Blacque OE, 2005, CURR BIOL, V15, P935, DOI 10.1016/j.cub.2005.04.059; Boylan JP, 2000, HUM MOL GENET, V9, P2085, DOI 10.1093/hmg/9.14.2085; Breuer DK, 2002, AM J HUM GENET, V70, P1545, DOI 10.1086/340848; Buraczynska M, 1997, AM J HUM GENET, V61, P1287, DOI 10.1086/301646; Cole CN, 1998, CURR BIOL, V8, pR368, DOI 10.1016/S0960-9822(98)70239-8; Cook TA, 2001, J BIOL CHEM, V276, P5248, DOI 10.1074/jbc.M004690200; Dammermann A, 2002, J CELL BIOL, V159, P255, DOI 10.1083/jcb.200204023; Dryja TP, 2001, AM J HUM GENET, V68, P1295, DOI 10.1086/320113; Fan SL, 2004, CURR BIOL, V14, P1451, DOI 10.1016/j.cub.2004.08.025; FISHMAN GA, 1978, ARCH OPHTHALMOL-CHIC, V96, P822, DOI 10.1001/archopht.1978.03910050428005; Friedman JS, 2004, J BIOL CHEM, V279, P47233, DOI 10.1074/jbc.M408298200; Gibbs D, 2004, J CELL SCI, V117, P6473, DOI 10.1242/jcs.01580; Hong DH, 2001, J BIOL CHEM, V276, P12091, DOI 10.1074/jbc.M009351200; Hong DH, 2002, INVEST OPHTH VIS SCI, V43, P3373; Hong DH, 2000, P NATL ACAD SCI USA, V97, P3649, DOI 10.1073/pnas.060037497; Hong DH, 2003, INVEST OPHTH VIS SCI, V44, P2413, DOI 10.1167/iovs.02-1206; HUNTER DG, 1988, ARCH OPHTHALMOL-CHIC, V106, P362; Hurd TW, 2003, NAT CELL BIOL, V5, P137, DOI 10.1038/ncb923; Iannaccone A, 2003, J MED GENET, V40, DOI 10.1136/jmg.40.11.e118; Kim JC, 2004, NAT GENET, V36, P462, DOI 10.1038/ng1352; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Kirschner R, 1999, HUM MOL GENET, V8, P1571, DOI 10.1093/hmg/8.8.1571; Lin FM, 2003, P NATL ACAD SCI USA, V100, P5286, DOI 10.1073/pnas.0836980100; Linari M, 1999, P NATL ACAD SCI USA, V96, P1315, DOI 10.1073/pnas.96.4.1315; Liu Q, 2004, J NEUROSCI, V24, P6427, DOI 10.1523/JNEUROSCI.1335-04.2004; Marszalek JR, 2000, CELL, V102, P175, DOI 10.1016/S0092-8674(00)00023-4; Mavlyutov TA, 2002, HUM MOL GENET, V11, P1899, DOI 10.1093/hmg/11.16.1899; Meindl A, 1996, NAT GENET, V13, P35, DOI 10.1038/ng0596-35; Mitton KP, 2003, HUM MOL GENET, V12, P365, DOI 10.1093/hmg/ddg035; Otto EA, 2005, NAT GENET, V37, P282, DOI 10.1038/ng1520; Pazour GJ, 2002, J CELL BIOL, V157, P103, DOI 10.1083/jcb.200107108; Roepman R, 1996, HUM MOL GENET, V5, P1035, DOI 10.1093/hmg/5.7.1035; Roepman R, 2000, HUM MOL GENET, V9, P2095, DOI 10.1093/hmg/9.14.2095; Rosenbaum JL, 2002, NAT REV MOL CELL BIO, V3, P813, DOI 10.1038/nrm952; Scholey JM, 2003, ANNU REV CELL DEV BI, V19, P423, DOI 10.1146/annurev.cellbio.19.111401.091318; Schroer TA, 2004, ANNU REV CELL DEV BI, V20, P759, DOI 10.1146/annurev.cellbio.20.012103.094623; Sharon D, 2003, AM J HUM GENET, V73, P1131, DOI 10.1086/379379; Shu X, 2005, HUM MOL GENET, V14, P1183, DOI 10.1093/hmg/ddi129; Strunnikov AV, 1998, TRENDS CELL BIOL, V8, P454, DOI 10.1016/S0962-8924(98)01370-1; SZCZESNY PJ, 1995, GRAEF ARCH CLIN EXP, V233, P275, DOI 10.1007/BF00177649; VANDORP DB, 1992, HUM GENET, V88, P331, DOI 10.1007/BF00197269; Vaughan PS, 2002, J CELL BIOL, V158, P305, DOI 10.1083/jcb.200201029; Vervoort R, 2000, NAT GENET, V25, P462, DOI 10.1038/78182; Vervoort R, 2002, HUM MUTAT, V19, P486, DOI 10.1002/humu.10057; Williams DS, 2002, VISION RES, V42, P455, DOI 10.1016/S0042-6989(01)00228-0; Yan D, 1998, J BIOL CHEM, V273, P19656, DOI 10.1074/jbc.273.31.19656; Zhang HB, 2004, J BIOL CHEM, V279, P407, DOI 10.1074/jbc.M306559200; Zhang Q, 2002, HUM MOL GENET, V11, P993, DOI 10.1093/hmg/11.9.993	53	125	136	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33580	33587		10.1074/jbc.M505827200	http://dx.doi.org/10.1074/jbc.M505827200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16043481	hybrid, Green Published, Green Accepted			2022-12-25	WOS:000232058100059
J	Kuroyanagi, M; Yamada, K; Hatsugai, N; Kondo, M; Nishimura, M; Hara-Nishimura, I				Kuroyanagi, M; Yamada, K; Hatsugai, N; Kondo, M; Nishimura, M; Hara-Nishimura, I			Vacuolar processing enzyme is essential for mycotoxin-induced cell death in Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEED STORAGE PROTEINS; CASPASE-LIKE ACTIVITY; SALICYLIC-ACID; ACTIVATION; FAMILY; VPE; PRECURSOR; EXPRESSION; FUMONISINS; PROTEASES	Some compatible pathogens secrete toxins to induce host cell death and promote their growth. The toxin-induced cell death is a pathogen strategy for infection. To clarify the executioner of the toxin-induced cell death, we examined a fungal toxin (fumonisin B1 (FB1))-induced cell death of Arabidopsis plants. FB1-induced cell death was accompanied with disruption of vacuolar membrane followed by lesion formation. The features of FB1-induced cell death were completely abolished in the Arabidopsis vacuolar processing enzyme (VPE)-null mutant, which lacks all four VPE genes of the genome. Interestingly, an inhibitor of caspase-1 abolished FB1-induced lesion formation, as did a VPE inhibitor. The VPE-null mutant had no detectable activities of caspase-1 or VPE in the FB1-treated leaves, although wild-type leaves had the caspase-1 and VPE activities, both of which were inhibited by a caspase-1 inhibitor. gamma VPE is the most essential among the four VPE homologues for FB1-induced cell death in Arabidopsis leaves. Recombinant gamma VPE recognized a VPE substrate with K-m = 30.3 mu M and a caspase-1 substrate with K-m = 44.2 mu M, which is comparable with the values for mammalian caspase-1. The gamma VPE precursor was self-catalytically converted into the mature form exhibiting caspase-1 activity. These in vivo and in vitro analyses demonstrate that gamma VPE is the proteinase that exhibits a caspase-1 activity. We show that VPE exhibiting a caspase-1 activity is a key molecule in toxin-induced cell death. Our findings suggest that a susceptible response of toxin-induced cell death is caused by the VPE-mediated vacuolar mechanism similar to a resistance response of hypersensitive cell death.	Kyoto Univ, Grad Sch Sci, Sakyo Ku, Kyoto 6068502, Japan; Natl Inst Basic Biol, Dept Cell Biol, Okazaki, Aichi 4448585, Japan	Kyoto University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)	Hara-Nishimura, I (corresponding author), Kyoto Univ, Grad Sch Sci, Sakyo Ku, Kyoto 6068502, Japan.	ihnishi@gr.bot.kyoto-u.ac.jp	Yamada, Kenji/C-4336-2018; Hatsugai, Noriyuki/O-9156-2015	Yamada, Kenji/0000-0003-4872-3729; Hatsugai, Noriyuki/0000-0002-5708-4263; Nishimura, Mikio/0000-0001-7960-9721; Kuroyanagi, Miwa/0000-0003-4362-8415				Asai T, 2000, PLANT CELL, V12, P1823, DOI 10.1105/tpc.12.10.1823; Coffeen WC, 2004, PLANT CELL, V16, P857, DOI 10.1105/tpc.017947; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Danon A, 2000, PLANT PHYSIOL BIOCH, V38, P647, DOI 10.1016/S0981-9428(00)01178-5; del Pozo O, 1998, CURR BIOL, V8, P1129, DOI 10.1016/S0960-9822(98)70469-5; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Gilchrist DG, 1998, ANNU REV PHYTOPATHOL, V36, P393, DOI 10.1146/annurev.phyto.36.1.393; Greenberg JT, 2004, CELL MICROBIOL, V6, P201, DOI 10.1111/j.1462-5822.2004.00361.x; Gruis D, 2002, PLANT CELL, V14, P2863, DOI 10.1105/tpc.005009; Gruis DF, 2004, PLANT CELL, V16, P270, DOI 10.1105/tpc.016378; Hara-Nishimura I, 1998, HDB PROTEOLYTIC ENZY, P746; HARANISHIMURA I, 1991, FEBS LETT, V294, P89, DOI 10.1016/0014-5793(91)81349-D; HARANISHIMURA I, 1993, PLANT CELL, V5, P1651, DOI 10.1105/tpc.5.11.1651; Hatsugai N, 2004, SCIENCE, V305, P855, DOI 10.1126/science.1099859; Hiraiwa N, 1999, FEBS LETT, V447, P213, DOI 10.1016/S0014-5793(99)00286-0; Hiraiwa N, 1997, PLANT J, V12, P819, DOI 10.1046/j.1365-313X.1997.12040819.x; Jones AM, 2001, PLANT PHYSIOL, V125, P94, DOI 10.1104/pp.125.1.94; Kawai-Yamada M, 2004, PLANT CELL, V16, P21, DOI 10.1105/tpc.014613; Kinoshita T, 1999, PLANT J, V19, P43, DOI 10.1046/j.1365-313X.1999.00497.x; Kuroyanagi M, 2002, PLANT CELL PHYSIOL, V43, P143, DOI 10.1093/pcp/pcf035; Lam E, 2004, NAT REV MOL CELL BIO, V5, P305, DOI 10.1038/nrm1358; Lam E, 2000, PLANT MOL BIOL, V44, P417, DOI 10.1023/A:1026509012695; Lam E, 2001, NATURE, V411, P848, DOI 10.1038/35081184; Lincoln JE, 2002, P NATL ACAD SCI USA, V99, P15217, DOI 10.1073/pnas.232579799; Mitsuhashi N, 2001, PLANT CELL, V13, P2361; MOLINEAUX SM, 1993, P NATL ACAD SCI USA, V90, P1809, DOI 10.1073/pnas.90.5.1809; Nakaune S, 2005, PLANT CELL, V17, P876, DOI 10.1105/tpc.104.026872; NELSON PE, 1993, ANNU REV PHYTOPATHOL, V31, P233, DOI 10.1146/annurev.py.31.090193.001313; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Raff M, 1998, NATURE, V396, P119, DOI 10.1038/24055; Ratcliffe OJ, 2003, PLANT CELL, V15, P1159, DOI 10.1105/tpc.009506; Rojo E, 2004, CURR BIOL, V14, P1897, DOI 10.1016/j.cub.2004.09.056; Shimada T, 2003, J BIOL CHEM, V278, P32292, DOI 10.1074/jbc.M305740200; Shirahama-Noda K, 2003, J BIOL CHEM, V278, P33194, DOI 10.1074/jbc.M302742200; Stone JM, 2000, PLANT CELL, V12, P1811, DOI 10.1105/tpc.12.10.1811; Suarez MF, 2004, CURR BIOL, V14, pR339, DOI 10.1016/j.cub.2004.04.019; Talanian RV, 1997, J BIOL CHEM, V272, P9677; TAVERNIER E, 1993, BIOCHIM BIOPHYS ACTA, V1167, P242, DOI 10.1016/0005-2760(93)90225-X; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(05)00086-9; WANG E, 1991, J BIOL CHEM, V266, P14486; Wang H, 1996, PLANT CELL, V8, P375, DOI 10.1105/tpc.8.3.375; Woltering EJ, 2004, TRENDS PLANT SCI, V9, P469, DOI 10.1016/j.tplants.2004.08.001; Yamada K, 2004, PLANTA, V218, P599, DOI 10.1007/s00425-003-1131-3; Yamada K, 1999, J BIOL CHEM, V274, P2563, DOI 10.1074/jbc.274.4.2563; Yamin TT, 1996, J BIOL CHEM, V271, P13273, DOI 10.1074/jbc.271.22.13273; Zhou Q, 1998, BIOCHEMISTRY-US, V37, P10757, DOI 10.1021/bi980893w	46	167	187	1	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32914	32920		10.1074/jbc.M504476200	http://dx.doi.org/10.1074/jbc.M504476200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16043487	hybrid			2022-12-25	WOS:000231920300046
J	Rezaie, AR; Manithody, C; Yang, LK				Rezaie, AR; Manithody, C; Yang, LK			Identification of factor Xa residues critical for interaction with protein Z-dependent protease inhibitor - Both active site and exosite interactions are required for inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCES HEPARIN CATALYSIS; ANTITHROMBIN-FACTOR XA; COAGULATION FACTOR-XA; FACTOR VA BINDING; BLOOD-COAGULATION; PROTHROMBINASE COMPLEX; BASIC RESIDUES; CONFORMATIONAL-CHANGE; MOLECULAR-BASIS; AUTOLYSIS LOOP	Protein Z-dependent protease inhibitor (ZPI) is a plasma serpin, which can rapidly inactivate factor Xa (fXa) in the presence of protein Z (PZ), negatively charged phospholipids, and Ca2+ . To investigate the mechanism by which ZPI inactivates fXa, we expressed the serpin in mammalian cells and characterized its reactivity with both wild-type and selected mutants of fXa that 1) contained substitutions in the autolysis loop and the heparin binding exosite, 2) lacked the first EGF-like domain (fXa-des-EGF-1), or 3) contained the Gla domain of protein C (fXa/PC-Gla). Inhibition studies in both the presence and absence of PZ revealed that Arg-143, Lys-147, and Arg-154 of the autolysis loop and Lys-96, Lys-169, and Lys-236 of the heparin binding exosite are required for recognition of ZPI, with Arg-143 being essential for the interaction. Similar studies with fXa-des-EGF-1 and fXa/PC-Gla suggested that protein-protein interaction with either the Gla or the EGF-1 domain may not play a dominant role in the PZ-dependent recognition of fXa by the serpin on phospholipid vesicles. Further studies showed that an inactive Ser-195 to Ala mutant of fXa effectively competes with wild-type fXa for binding to the non-serpin inhibitors tissue factor pathway inhibitor and recombinant tick anticoagulant peptide, but does not compete for binding to ZPI. This suggests that the catalytic residue of fXa is required for interaction with ZPI.	St Louis Univ, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63104 USA	Saint Louis University	Rezaie, AR (corresponding author), St Louis Univ, Sch Med, Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	rezaiear@slu.edu			NHLBI NIH HHS [R01 HL068571, R01 HL062565, HL 68571, HL 62565] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068571, R01HL062565] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Belzar KJ, 2002, J BIOL CHEM, V277, P8551, DOI 10.1074/jbc.M110807200; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BROZE GJ, 1990, BIOCHEMISTRY-US, V29, P7539, DOI 10.1021/bi00485a001; Chen L, 2004, PROTEIN SCI, V13, P431, DOI 10.1110/ps.03406904; DAMUS PS, 1973, NATURE, V246, P355, DOI 10.1038/246355a0; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DEAGOSTINI AI, 1990, J CELL BIOL, V111, P1293, DOI 10.1083/jcb.111.3.1293; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; FURIE B, 1982, J BIOL CHEM, V257, P3875; GETTINS PGW, 1993, BIOCHEMISTRY-US, V32, P8385, DOI 10.1021/bi00084a001; Han X, 1999, BIOCHEMISTRY-US, V38, P11073, DOI 10.1021/bi990641a; Han X, 2000, BLOOD, V96, P3049; Han X, 1998, P NATL ACAD SCI USA, V95, P9250, DOI 10.1073/pnas.95.16.9250; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; JACKSON CM, 1980, ANNU REV BIOCHEM, V49, P765, DOI 10.1146/annurev.bi.49.070180.004001; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; Kittur FS, 2004, J BIOL CHEM, V279, P24189, DOI 10.1074/jbc.M402302200; Manithody C, 2002, BIOCHEMISTRY-US, V41, P6780, DOI 10.1021/bi0255367; NESHEIM ME, 1981, J BIOL CHEM, V256, P6537; OLSON ST, 1995, J BIOL CHEM, V270, P30007; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1992, THROMBIN STRUCTURE F, P159; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; Rezaie AR, 1998, J BIOL CHEM, V273, P16824, DOI 10.1074/jbc.273.27.16824; Rezaie AR, 2000, BIOCHEMISTRY-US, V39, P12083, DOI 10.1021/bi0011126; Rezaie AR, 2000, J BIOL CHEM, V275, P3320, DOI 10.1074/jbc.275.5.3320; Rezaie AR, 2004, J BIOL CHEM, V279, P48262, DOI 10.1074/jbc.M409964200; Rezaie AR, 2004, BIOCHEMISTRY-US, V43, P3368, DOI 10.1021/bi036177y; Rezaie AR, 2004, BIOCHEMISTRY-US, V43, P2898, DOI 10.1021/bi036145a; REZAIE AR, 1992, J BIOL CHEM, V267, P26104; Rezaie AR, 2001, BBA-GEN SUBJECTS, V1528, P167, DOI 10.1016/S0304-4165(01)00189-1; Rudolph AE, 2001, J BIOL CHEM, V276, P5123, DOI 10.1074/jbc.M006961200; SEJIMA H, 1990, BIOCHEM BIOPH RES CO, V171, P661, DOI 10.1016/0006-291X(90)91197-Z; SMIRNOV MD, 1994, J BIOL CHEM, V269, P816; STENFLO J, 1991, BLOOD, V78, P1637; Yang LK, 2004, BLOOD, V104, P1753, DOI 10.1182/blood-2004-03-1092; Yang LK, 2002, BIOCHEMISTRY-US, V41, P6149, DOI 10.1021/bi015899r; Yin ZF, 2000, P NATL ACAD SCI USA, V97, P6734, DOI 10.1073/pnas.120081897	39	30	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32722	32728		10.1074/jbc.M505517200	http://dx.doi.org/10.1074/jbc.M505517200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16079143	Green Accepted, hybrid			2022-12-25	WOS:000231920300022
J	Zhang, YM; Rock, CO; Jackowski, S				Zhang, YM; Rock, CO; Jackowski, S			Feedback regulation of murine pantothenate kinase 3 by coenzyme A and coenzyme A thioesters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-ASSOCIATED NEURODEGENERATION; HALLERVORDEN-SPATZ-SYNDROME; STAPHYLOCOCCUS-AUREUS; RAT-LIVER; DISULFIDE REDUCTASE; IRON ACCUMULATION; ESCHERICHIA-COLI; GENE; COA; BIOSYNTHESIS	Pantothenate kinase catalyzes a key regulatory step in coenzyme A biosynthesis, and there are four mammalian genes that encode isoforms of this enzyme. Pantothenate kinase isoform PanK3 is highly related to the previously characterized PanK1 beta isoform ( 79% identical, 91% similar), and these two almost identical proteins are expressed most highly in the same tissues. PanK1 beta and PanK3 had very similar molecular sizes, oligomeric form, cytoplasmic cellular location, and kinetic constants for ATP and pantothenate. However, these two PanK isoforms possessed distinct regulatory properties. PanK3 was significantly more sensitive to feedback regulation by acetyl- CoA ( IC50 = 1 mu M) than PanK1 beta ( IC50 = 10 mu M), and PanK3 was stringently regulated by long- chain acyl- CoA ( IC50 = 2 mu M), whereas PanK1 beta was not. Domain swapping experiments localized the difference in the two proteins to a 48- amino- acid domain, where they are the most divergent. Consistent with these more stringent regulatory properties, metabolic labeling experiments showed that coenzyme A ( CoA) levels in cells overexpressing PanK3 were lower than in cells overexpressing an equivalent amount of PanK1 beta. Thus, the distinct regulatory properties exhibited by the family of the pantothenate kinases allowed the rate of CoA biosynthesis to be controlled by regulatory signals from CoA thioesters involved in different branches of intermediary metabolism.	St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Jackowski, S (corresponding author), St Jude Childrens Res Hosp, Dept Infect Dis, 332 N Lauderdale St, Memphis, TN 38105 USA.	suzanne.jackowski@stjude.org	Jackowski, Suzanne/N-8168-2018	Jackowski, Suzanne/0000-0002-6855-1429	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062896] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM62896] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BHUIYAN AKMJ, 1988, BIOCHEM J, V253, P337, DOI 10.1042/bj2530337; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; delCardayre SB, 1998, J BIOL CHEM, V273, P5752, DOI 10.1074/jbc.273.10.5752; delCardayre SB, 1998, J BIOL CHEM, V273, P5744, DOI 10.1074/jbc.273.10.5744; Eppig JT, 2005, NUCLEIC ACIDS RES, V33, pD471, DOI 10.1093/nar/gki113; HALVORSEN O, 1982, EUR J BIOCHEM, V124, P211, DOI 10.1111/j.1432-1033.1982.tb05927.x; HALVORSEN O, 1983, BIOCHEM PHARMACOL, V32, P1126, DOI 10.1016/0006-2952(83)90638-X; HORIE S, 1986, J BIOCHEM, V99, P1345, DOI 10.1093/oxfordjournals.jbchem.a135602; Hortnagel K, 2003, HUM MOL GENET, V12, P321, DOI 10.1093/hmg/ddg026; IDELLWENGER JA, 1978, J BIOL CHEM, V253, P4310; JACKOWSKI S, 1994, J BIOL CHEM, V269, P3858; JACKOWSKI S, 1981, J BACTERIOL, V148, P926, DOI 10.1128/JB.148.3.926-932.1981; Johnson MA, 2004, ANN NY ACAD SCI, V1012, P282, DOI 10.1196/annals.1306.023; Karim M, 2003, BBA-MOL CELL BIOL L, V1633, P1, DOI 10.1016/S1388-1981(03)00067-2; KONDRUP J, 1973, BIOCHEM J, V132, P373, DOI 10.1042/bj1320373; Kotzbauer PT, 2005, J NEUROSCI, V25, P689, DOI 10.1523/JNEUROSCI.4265-04.2005; Kuo YM, 2005, HUM MOL GENET, V14, P49, DOI 10.1093/hmg/ddi005; Leonardi R, 2005, J BIOL CHEM, V280, P3314, DOI 10.1074/jbc.M411608200; Luba J, 1999, BIOCHEMISTRY-US, V38, P2725, DOI 10.1021/bi9825899; LUND H, 1986, BIOCHIM BIOPHYS ACTA, V876, P685, DOI 10.1016/0005-2760(86)90058-5; Ni XH, 2002, INT J BIOCHEM CELL B, V34, P109, DOI 10.1016/S1357-2725(01)00114-5; Ramaswamy G, 2004, J LIPID RES, V45, P17, DOI 10.1194/jlr.M300279-JLR200; REIBEL DK, 1981, AM J PHYSIOL, V240, pE597, DOI 10.1152/ajpendo.1981.240.6.E597; REIBEL DK, 1981, AM J PHYSIOL, V240, P606; ROBISHAW JD, 1982, J BIOL CHEM, V257, P967; Rock CO, 2003, J BACTERIOL, V185, P3410, DOI 10.1128/JB.185.11.3410-3415.2003; Rock CO, 2002, GENE, V291, P35, DOI 10.1016/S0378-1119(02)00564-4; Rock CO, 2000, J BIOL CHEM, V275, P1377, DOI 10.1074/jbc.275.2.1377; SAVOLAINEN MJ, 1977, BIOCHEM PHARMACOL, V26, P425, DOI 10.1016/0006-2952(77)90202-7; SKREDE S, 1979, EUR J BIOCHEM, V98, P223, DOI 10.1111/j.1432-1033.1979.tb13180.x; SMITH CM, 1980, BIOCHEM J, V188, P175, DOI 10.1042/bj1880175; SMITH CM, 1978, J NUTR, V108, P854, DOI 10.1093/jn/108.5.854; SONG WJ, 1994, J BIOL CHEM, V269, P27051; SONG WJ, 1992, J BACTERIOL, V174, P6411, DOI 10.1128/JB.174.20.6411-6417.1992; Stolz LE, 1998, GENETICS, V148, P1715; Thomas M, 2004, MOVEMENT DISORD, V19, P36, DOI 10.1002/mds.10650; VANBROEKHOVEN A, 1981, BIOCHEM BIOPH RES CO, V100, P305, DOI 10.1016/S0006-291X(81)80097-6; VANVELDHOVEN PP, 1986, BIOCHEM BIOPH RES CO, V139, P1195, DOI 10.1016/S0006-291X(86)80304-7; VOLTTI H, 1979, BIOCHEM J, V182, P95, DOI 10.1042/bj1820095; WANG HY, 1991, ARCH BIOCHEM BIOPHYS, V289, P274, DOI 10.1016/0003-9861(91)90472-U; Williamson J R, 1979, Methods Enzymol, V55, P200; Yang D, 2003, J LEUKOCYTE BIOL, V74, P448, DOI 10.1189/jlb.0103024; Zhou B, 2001, NAT GENET, V28, P345, DOI 10.1038/ng572	43	61	64	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32594	32601		10.1074/jbc.M506275200	http://dx.doi.org/10.1074/jbc.M506275200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16040613	hybrid			2022-12-25	WOS:000231920300006
J	Opresko, PL; Mason, PA; Podell, ER; Lei, M; Hickson, ID; Cech, TR; Bohr, VA				Opresko, PL; Mason, PA; Podell, ER; Lei, M; Hickson, ID; Cech, TR; Bohr, VA			POT1 stimulates RecQ helicases WRN and BLM to unwind telomeric DNA substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; WERNER-SYNDROME; SYNDROME PROTEIN; BINDING PROTEIN; FISSION YEAST; CELLS; TRF1; END; LENGTH; RECOGNITION	Defects in human RecQ helicases WRN and BLM are responsible for the cancer-prone disorders Werner syndrome and Bloom syndrome. Cellular phenotypes of Werner syndrome and Bloom syndrome, including genomic instability and premature senescence, are consistent with telomere dysfunction. RecQ helicases are proposed to function in dissociating alternative DNA structures during recombination and/or replication at telomeric ends. Here we report that the telomeric single-strand DNA-binding protein, POT1, strongly stimulates WRN and BLM to unwind long telomeric forked duplexes and D-loop structures that are otherwise poor substrates for these helicases. This stimulation is dependent on the presence of telomeric sequence in the duplex regions of the substrates. In contrast, POT1 failed to stimulate a bacterial 3'-5'-helicase. We find that purified POT1 binds to WRN and BLM in vitro and that full-length POT1 ( splice variant 1) precipitates a higher amount of endogenous WRN protein, compared with BLM, from the HeLa nuclear extract. We propose roles for the cooperation of POT1 with RecQ helicases WRN and BLM in resolving DNA structures at telomeric ends, in a manner that protects the telomeric 3' tail as it is exposed during unwinding.	NIA, Lab Mol Gerontol, Baltimore, MD 21224 USA; Univ Colorado, Howard Hughes Med Inst, Dept Chem & Biochem, Boulder, CO 80309 USA; Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Canc Res UK Labs, Oxford OX3 9DS, England	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; Cancer Research UK; University of Oxford	Bohr, VA (corresponding author), NIA, Lab Mol Gerontol, Baltimore, MD 21224 USA.	vbohr@nih.gov	Hickson, Ian/AAJ-7548-2020; Bohr, Vilhelm/AAP-5931-2020	Opresko, Patricia/0000-0002-6470-2189; Hickson, Ian/0000-0002-0583-566X	NATIONAL INSTITUTE ON AGING [Z01AG000726, ZIAAG000726] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Armbruster BN, 2004, MOL CELL BIOL, V24, P3552, DOI 10.1128/MCB.24.8.3552-3561.2004; Bai YL, 2003, HUM GENET, V113, P337, DOI 10.1007/s00439-003-0972-y; Baumann P, 2002, MOL CELL BIOL, V22, P8079, DOI 10.1128/MCB.22.22.8079-8087.2002; Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Brosh RM, 2000, J BIOL CHEM, V275, P23500, DOI 10.1074/jbc.M001557200; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; Campisi J, 2001, EXP GERONTOL, V36, P1619, DOI 10.1016/S0531-5565(01)00160-7; Chang S, 2004, NAT GENET, V36, P877, DOI 10.1038/ng1389; Colgin L, 2004, CURR BIOL, V14, pR901, DOI 10.1016/j.cub.2004.09.075; Colgin LM, 2003, CURR BIOL, V13, P942, DOI 10.1016/S0960-9822(03)00339-7; Crabbe L, 2004, SCIENCE, V306, P1951, DOI 10.1126/science.1103619; Davalos AR, 2003, J CELL BIOL, V162, P1197, DOI 10.1083/jcb.200304016; de Lange T, 2004, NAT REV MOL CELL BIO, V5, P323, DOI 10.1038/nrm1359; Du XB, 2004, MOL CELL BIOL, V24, P8437, DOI 10.1128/MCB.24.19.8437-8446.2004; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Erzberger JP, 1998, NUCLEIC ACIDS RES, V26, P2771, DOI 10.1093/nar/26.11.2771; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Henson JD, 2002, ONCOGENE, V21, P598, DOI 10.1038/sj.onc.1205058; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; Hockemeyer D, 2005, EMBO J, V24, P2667, DOI 10.1038/sj.emboj.7600733; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Johnson FB, 2001, EMBO J, V20, P905, DOI 10.1093/emboj/20.4.905; Karow JK, 1999, CURR BIOL, V9, P597, DOI 10.1016/S0960-9822(99)80264-4; Lei M, 2004, NAT STRUCT MOL BIOL, V11, P1223, DOI 10.1038/nsmb867; Lei M, 2003, NATURE, V426, P198, DOI 10.1038/nature02092; Lillard-Wetherell K, 2004, HUM MOL GENET, V13, P1919, DOI 10.1093/hmg/ddh193; Liu D, 2004, J BIOL CHEM, V279, P51338, DOI 10.1074/jbc.M409293200; Loayza D, 2004, J BIOL CHEM, V279, P13241, DOI 10.1074/jbc.M312309200; Loayza D, 2003, NATURE, V423, P1013, DOI 10.1038/nature01688; Mandell JG, 2005, J BIOL CHEM, V280, P5249, DOI 10.1074/jbc.M412756200; Mandell JG, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2004-6-1-r1; Martin G M, 1978, Birth Defects Orig Artic Ser, V14, P5; Mattern KA, 2004, MOL CELL BIOL, V24, P5587, DOI 10.1128/MCB.24.12.5587-5594.2004; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; Opresko PL, 2004, MOL CELL, V14, P763, DOI 10.1016/j.molcel.2004.05.023; Opresko PL, 2004, J BIOL CHEM, V279, P18099, DOI 10.1074/jbc.R300034200; Opresko PL, 2003, CARCINOGENESIS, V24, P791, DOI 10.1093/carcin/bgg034; Opresko PL, 2002, J BIOL CHEM, V277, P41110, DOI 10.1074/jbc.M205396200; Opresko PL, 2001, J BIOL CHEM, V276, P44677, DOI 10.1074/jbc.M107548200; Orren DK, 1999, NUCLEIC ACIDS RES, V27, P3557, DOI 10.1093/nar/27.17.3557; Shen JC, 2003, MECH AGEING DEV, V124, P921, DOI 10.1016/S0047-6374(03)00164-7; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; Stavropoulos DJ, 2002, HUM MOL GENET, V11, P3135, DOI 10.1093/hmg/11.25.3135; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Veldman T, 2004, CURR BIOL, V14, P2264, DOI 10.1016/j.cub.2004.12.031; von Kobbe C, 2002, J BIOL CHEM, V277, P22035, DOI 10.1074/jbc.M200914200; Wyllie FS, 2000, NAT GENET, V24, P16, DOI 10.1038/71630; Yang Q, 2005, MOL CELL BIOL, V25, P1070, DOI 10.1128/MCB.25.3.1070-1080.2005	49	145	152	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32069	32080		10.1074/jbc.M505211200	http://dx.doi.org/10.1074/jbc.M505211200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16030011	hybrid			2022-12-25	WOS:000231794800006
J	Zeller, A; Arras, M; Lazaris, A; Jurd, R; Rudolph, U				Zeller, A; Arras, M; Lazaris, A; Jurd, R; Rudolph, U			Distinct molecular targets for the central respiratory and cardiac actions of the general anesthetics etomidate and propofol	FASEB JOURNAL			English	Article						anesthesia; respiratory depression; animal model; GABA(A) receptor	A RECEPTOR; MICE; GABA(A); SITES	General anesthetics are among the most widely used and important therapeutic agents. The molecular targets mediating different endpoints of the anesthetic state in vivo are currently largely unknown. The analysis of mice carrying point mutations in neurotransmitter receptor subunits is a powerful tool to assess the contribution of the respective receptor subtype to the pharmacological actions of clinically used general anesthetics. We examined the involvement of beta 3-containing GABA(A) receptors in the respiratory, cardiovascular, hypothermic, and sedative actions of etomidate and propofol using beta 3(N265M) knock-in mice carrying etomidate- and propofol-insensitive beta 3-containing GABA(A) receptors. Although the respiratory depressant action of etomidate and propofol, as determined by blood gas analysis, was almost absent in beta 3(N265M) mice, the cardiac depressant and hypothermic effects, as determined by radiotelemetry, and the sedative effect, as determined by decrease of motor activity, were still present. Taken together with previous findings, our results show that both immobilization and respiratory depression are mediated by beta 3-containing GABA(A) receptors, hypnosis by both beta 3 and beta 2-containing GABA(A) receptors, while the hypothermic, cardiac depressant, and sedative actions are largely independent of beta 3-containing GABA(A) receptors.	Univ Zurich, Inst Pharmacol & Toxicol, CH-8057 Zurich, Switzerland; Univ Zurich, Inst Lab Anim Sci, CH-8057 Zurich, Switzerland	University of Zurich; University of Zurich	Rudolph, U (corresponding author), Univ Zurich, Inst Pharmacol & Toxicol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	rudolph@pharma.unizh.ch		Arras, Margarete/0000-0003-3864-9879				Arras M, 2001, COMPARATIVE MED, V51, P443; Barnard EA, 1998, PHARMACOL REV, V50, P291; Belelli D, 1997, P NATL ACAD SCI USA, V94, P11031, DOI 10.1073/pnas.94.20.11031; Bergen Joseph M., 1997, Journal of Emergency Medicine, V15, P221, DOI 10.1016/S0736-4679(96)00350-2; Cirone J, 2004, ANESTHESIOLOGY, V100, P1438, DOI 10.1097/00000542-200406000-00016; ERHARDT W, 1984, RES EXP MED, V184, P159, DOI 10.1007/BF01852390; Franks NP, 2004, TRENDS PHARMACOL SCI, V25, P601, DOI 10.1016/j.tips.2004.09.003; Jurd R, 2002, FASEB J, V16, P250, DOI 10.1096/fj.02-0611fje; Keyl C, 2000, ANESTH ANALG, V91, P1188, DOI 10.1097/00000539-200011000-00027; Krasowski MD, 1999, CELL MOL LIFE SCI, V55, P1278, DOI 10.1007/s000180050371; Krasowski MD, 1998, MOL PHARMACOL, V53, P530, DOI 10.1124/mol.53.3.530; KRASSIOUKOV AV, 1993, CAN J ANAESTH, V40, P761, DOI 10.1007/BF03009773; Lichtenbelt BJ, 2004, CLIN PHARMACOKINET, V43, P577, DOI 10.2165/00003088-200443090-00002; Manzke T, 2003, SCIENCE, V301, P226, DOI 10.1126/science.1084674; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; Paris A, 2003, ANESTHESIOLOGY, V99, P889, DOI 10.1097/00000542-200310000-00022; Reynolds DS, 2003, J NEUROSCI, V23, P8608; Richter DW, 2003, TRENDS MOL MED, V9, P542, DOI 10.1016/j.molmed.2003.10.010; Rudolph U, 2004, NAT REV NEUROSCI, V5, P709, DOI 10.1038/nrn1496; SELLGREN J, 1994, ANESTHESIOLOGY, V80, P534, DOI 10.1097/00000542-199403000-00009; Sessler DI, 1997, NEW ENGL J MED, V336, P1730, DOI 10.1056/NEJM199706123362407; Siegwart R, 2002, J NEUROCHEM, V80, P140, DOI 10.1046/j.0022-3042.2001.00682.x; Siegwart Roberta, 2003, BMC Pharmacol, V3, P13, DOI 10.1186/1471-2210-3-13; Spani D, 2003, LAB ANIM-UK, V37, P54, DOI 10.1258/002367703762226692; Zuperku EJ, 2002, RESP PHYSIOL NEUROBI, V131, P121, DOI 10.1016/S1569-9048(02)00042-3	25	48	56	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1677	+		10.1096/fj.04-3443fje	http://dx.doi.org/10.1096/fj.04-3443fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16046472				2022-12-25	WOS:000230923000005
J	Ishiko, J; Mizuki, M; Matsumura, I; Shibayama, H; Sugahara, H; Scholz, G; Serve, H; Kanakura, Y				Ishiko, J; Mizuki, M; Matsumura, I; Shibayama, H; Sugahara, H; Scholz, G; Serve, H; Kanakura, Y			Roles of tyrosine residues 845, 892 and 922 in constitutive activation of murine FLT3 kinase domain mutant	ONCOGENE			English	Article						FLT3; activation loop; receptor tyrosine kinase; leukemia; Hsp90; Cdc37	ACUTE MYELOID-LEUKEMIA; INTERNAL TANDEM DUPLICATION; RECEPTOR TYROSINE KINASE; GASTROINTESTINAL STROMAL TUMORS; C-KIT MUTATION; CELL-LINES; INSULIN-RECEPTOR; GENE; IDENTIFICATION; JUXTAMEMBRANE	FLT3 tyrosine kinase domain ( TKD) mutations are detected in similar to 7% of acute myeloid leukemia patients, and suggested to correlate with poor prognosis and confer resistance to FLT3 inhibitors. To explore activation mechanism of FLT3 TKD mutation, we analysed critical tyrosine residues for the constitutive activation and downstream signaling of the mutant by generating a series of single Tyr -> Phe substitution mutant of all 22 cytoplasmic tyrosine residues of murine FLT3 TKD-mutant (mFLT3(Asp838Val)). Tyr845Phe, Tyr892Phe and Tyr922Phe substitutions suppressed the phosphorylation of mFLT3(Asp838Val) itself, the activation of Erk1/2, STAT3 and STAT5, and the factor-independent cell proliferation and survival. In contrast, these three Tyr -> Phe mutations partially suppressed but maintained the ligand-dependent activation and anti-apoptotic activity of wild-type FLT3, suggesting that these tyrosine residues were more critical for the constitutive activation and signaling of mFLT3(Asp838Val). These three Tyr -> Phe mutations also inhibited the constitutive activation of other FLT3 mutants bearing internal tandem duplication, Asp838Tyr or Ile839del. The suppression of mFLT3(Asp838Val) activation and signaling by these substitutions was partially recovered by shifting the culture temperature from 37 to 33 degrees C, or by the introduction of Cdc37 and Hsp90. Taken together, Tyr(845), Tyr(892) and Tyr(922) are the critical residues in mFLT3(Asp838Val) activation, possibly through stabilizing the active conformation of mFLT3(Asp838Val).	Osaka Univ, Grad Sch Med, Dept Hematol & Oncol, Suita, Osaka 5650871, Japan; Univ Melbourne, Royal Melbourne Hosp, Dept Med, Parkville, Vic 3050, Australia; Univ Munster, Dept Med Hematol & Oncol, D-48129 Munster, Germany	Osaka University; Royal Melbourne Hospital; University of Melbourne; University of Munster	Mizuki, M (corresponding author), Osaka Univ, Grad Sch Med, Dept Hematol & Oncol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	mizuki@bldon.med.osaka-u.ac.jp		ISHIKO, JUN/0000-0003-3518-5108; Scholz, Glen/0000-0003-2722-6344				Abu-Duhier FM, 2001, BRIT J HAEMATOL, V113, P983, DOI 10.1046/j.1365-2141.2001.02850.x; Abu-Duhier FM, 2000, BRIT J HAEMATOL, V111, P190, DOI 10.1046/j.1365-2141.2000.02317.x; Beslu N, 1996, J BIOL CHEM, V271, P20075, DOI 10.1074/jbc.271.33.20075; Care RS, 2003, BRIT J HAEMATOL, V121, P775, DOI 10.1046/j.1365-2141.2003.04362.x; CARLESSO N, 1994, ONCOGENE, V9, P149; Fenski R, 2000, BRIT J HAEMATOL, V108, P322; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; Griffith J, 2004, MOL CELL, V13, P169, DOI 10.1016/S1097-2765(03)00505-7; Grundler R, 2003, BLOOD, V102, P646, DOI 10.1182/blood-2002-11-3441; Hashimoto K, 2003, BLOOD, V101, P1094, DOI 10.1182/blood-2002-01-0177; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Hirota S, 2003, GASTROENTEROLOGY, V125, P660, DOI 10.1016/S0016-5085(03)01046-1; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; Kiyoi H, 1999, BLOOD, V93, P3074; Li SQ, 2003, J BIOL CHEM, V278, P26007, DOI 10.1074/jbc.M302425200; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; Ma YS, 2002, BLOOD, V99, P1741, DOI 10.1182/blood.V99.5.1741; MAYER BJ, 1986, J VIROL, V60, P858, DOI 10.1128/JVI.60.3.858-867.1986; Mizuki M, 2003, BLOOD, V101, P3164, DOI 10.1182/blood-2002-06-1677; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Moreno I, 2003, HAEMATOLOGICA, V88, P19; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Muller C, 2000, MOL CELL BIOL, V20, P3316, DOI 10.1128/MCB.20.9.3316-3329.2000; Nakao M, 1996, LEUKEMIA, V10, P1911; Reilly JT, 2002, BRIT J HAEMATOL, V116, P744, DOI 10.1046/j.0007-1048.2001.03294.x; Schnittger S, 2002, BLOOD, V100, P59, DOI 10.1182/blood.V100.1.59; Scholz G, 2000, MOL CELL BIOL, V20, P6984, DOI 10.1128/MCB.20.18.6984-6995.2000; Scholz GM, 2001, CELL GROWTH DIFFER, V12, P409; Spiekermann K, 2003, BLOOD, V101, P1494, DOI 10.1182/blood-2002-04-1045; Thiede C, 2002, BLOOD, V99, P4326, DOI 10.1182/blood.V99.12.4326; Ueda S, 2002, INT J HEMATOL, V76, P427, DOI 10.1007/BF02982808; Worobec AS, 1998, CANCER, V83, P2120, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2120::AID-CNCR10>3.0.CO;2-C; Yamamoto Y, 2001, BLOOD, V97, P2434, DOI 10.1182/blood.V97.8.2434; Yokota S, 1997, LEUKEMIA, V11, P1605, DOI 10.1038/sj.leu.2400812; Yu JC, 2003, BLOOD, V102, p348A	35	12	12	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2005	24	55					8144	8153		10.1038/sj.onc.1208957	http://dx.doi.org/10.1038/sj.onc.1208957			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	991JL	16091740				2022-12-25	WOS:000233809400006
J	Bin Fang, W; Brantley-Sieders, DM; Parker, MA; Reith, AD; Chen, J				Bin Fang, W; Brantley-Sieders, DM; Parker, MA; Reith, AD; Chen, J			A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis	ONCOGENE			English	Article						EphA2 receptor tyrosine kinase; ephrin-A1; ligand; kinase activity; tumor malignancy; metastasis	TYROSINE KINASE; CELL-ADHESION; MULTISTAGE CARCINOGENESIS; PANCREATIC ADENOCARCINOMA; MALIGNANT-CELLS; SMALL GTPASES; KIT RECEPTOR; E-CADHERIN; IN-VIVO; PROTEIN	Receptor tyrosine kinases of the Eph family are upregulated in several different types of cancer. One family member in particular, the EphA2 receptor, has been linked to breast, prostate, lung and colon cancer, as well as melanoma. However, mechanisms by which EphA2 contributes to tumor progression are far from clear. In certain tumor cell lines, EphA2 receptor is underphosphorylated, raising the question of whether ligand-induced receptor phosphorylation and its kinase activity play a role in oncogenesis. To test directly the role of EphA2 receptor phosphorylation/kinase activity in tumor progression, we generated EphA2 receptor variants that were either lacking the cytoplasmic domain or carrying a point mutation that inhibits its kinase activity. Expression of these EphA2 mutants in breast cancer cells resulted in decreased tumor volume and increased tumor apoptosis in primary tumors. In addition, the numbers of lung metastases were significantly reduced in both experimental and spontaneous metastasis models. Reduced tumor volume and metastasis are not due to defects in tumor angiogenesis, as there is no significant difference in tumor vessel density between wild-type tumors and tumors expressing EphA2-signaling-defective mutants. In contrast, tumor cells expressing the EphA2 mutants are defective in RhoA GTPase activation and cell migration. Taken together, these results suggest that receptor phosphorylation and kinase activity of the EphA2 receptor, at least in part, contribute to tumor malignancy.	Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Div Rheumatol & Immunol, Nashville, TN 37232 USA; UCL Branch, Ludwig Inst Canc Res, London, England; Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Ludwig Institute for Cancer Research; University of London; University College London; Vanderbilt University; Vanderbilt University	Chen, J (corresponding author), Vanderbilt Univ, Sch Med, Dept Canc Biol, A-4323 MCN,1161 21st Ave S, Nashville, TN 37232 USA.	jin.chen@vanderbilt.edu		Chen, Jin/0000-0002-5557-2079	NATIONAL CANCER INSTITUTE [T32CA078136, R01CA095004, R01CA114301] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL074517] Funding Source: NIH RePORTER; NCI NIH HHS [CA114301, CA95004, 2T32 CA78136] Funding Source: Medline; NHLBI NIH HHS [5F32 HL074517] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Berclaz G, 1996, BIOCHEM BIOPH RES CO, V226, P869, DOI 10.1006/bbrc.1996.1442; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Birgbauer E, 2000, DEVELOPMENT, V127, P1231; Brantley DM, 2002, ONCOGENE, V21, P7011, DOI 10.1038/sj.onc.1205679; Brantley-Sieders D, 2004, CURR PHARM DESIGN, V10, P3431, DOI 10.2174/1381612043383160; Brantley-Sieders Dana M., 2004, Angiogenesis, V7, P17, DOI 10.1023/B:AGEN.0000037340.33788.87; Brantley-Sieders DM, 2004, J CELL SCI, V117, P2037, DOI 10.1242/jcs.01061; Carles-Kinch K, 2002, CANCER RES, V62, P2840; Cheng N, 2002, MOL CANCER RES, V1, P2; Cheng N, 2003, NEOPLASIA, V5, P445, DOI 10.1016/S1476-5586(03)80047-7; Coffman KT, 2003, CANCER RES, V63, P7907; Dalva MB, 2000, CELL, V103, P945, DOI 10.1016/S0092-8674(00)00197-5; Davy A, 2000, EMBO J, V19, P5396, DOI 10.1093/emboj/19.20.5396; Davy A, 1999, GENE DEV, V13, P3125, DOI 10.1101/gad.13.23.3125; Dobrzanski P, 2004, CANCER RES, V64, P910, DOI 10.1158/0008-5472.CAN-3430-2; Duxbury MS, 2004, BIOCHEM BIOPH RES CO, V320, P1096, DOI 10.1016/j.bbrc.2004.06.054; Duxbury MS, 2004, ONCOGENE, V23, P1448, DOI 10.1038/sj.onc.1207247; Fukata M, 2003, CURR OPIN CELL BIOL, V15, P590, DOI 10.1016/S0955-0674(03)00097-8; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Grunwald IC, 2001, NEURON, V32, P1027, DOI 10.1016/S0896-6273(01)00550-5; Gu C, 2001, MOL CELL BIOL, V21, P4579, DOI 10.1128/MCB.21.14.4579-4597.2001; Gurniak CB, 1996, ONCOGENE, V13, P777; Holder N, 1999, DEVELOPMENT, V126, P2033; Huai JS, 2001, J BIOL CHEM, V276, P6689, DOI 10.1074/jbc.M008127200; Ireton RC, 2005, CURR CANCER DRUG TAR, V5, P149, DOI 10.2174/1568009053765780; Kinch MS, 2003, CLIN CANCER RES, V9, P613; Koolpe M, 2002, J BIOL CHEM, V277, P46974, DOI 10.1074/jbc.M208495200; Kullander K, 2001, NEURON, V29, P73, DOI 10.1016/S0896-6273(01)00181-7; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Lozano E, 2003, BIOESSAYS, V25, P452, DOI 10.1002/bies.10262; Madhusudan S, 2004, CLIN BIOCHEM, V37, P618, DOI 10.1016/j.clinbiochem.2004.05.006; Malliri A, 2003, CURR OPIN CELL BIOL, V15, P583, DOI 10.1016/S0955-0674(03)00098-X; Manning G, 2002, TRENDS BIOCHEM SCI, V27, P514, DOI 10.1016/S0968-0004(02)02179-5; Miao H, 2005, J BIOL CHEM, V280, P923, DOI 10.1074/jbc.M411383200; Miyazaki T, 2003, INT J CANCER, V103, P657, DOI 10.1002/ijc.10860; Munarini N, 2002, J CELL SCI, V115, P25; Nakamoto M, 2002, MICROSC RES TECHNIQ, V59, P58, DOI 10.1002/jemt.10177; Noren NK, 2004, CELL SIGNAL, V16, P655, DOI 10.1016/j.cellsig.2003.10.006; Noren NK, 2004, P NATL ACAD SCI USA, V101, P5583, DOI 10.1073/pnas.0401381101; Ogawa K, 2000, ONCOGENE, V19, P6043, DOI 10.1038/sj.onc.1204004; Pasquale EB, 2005, NAT REV MOL CELL BIO, V6, P462, DOI 10.1038/nrm1662; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; REITH AD, 1993, ONCOGENE, V8, P45; Ridley AJ, 2001, J CELL SCI, V114, P2713; Saito T, 2004, ONCOL REP, V11, P605; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; Walker-Daniels J, 2003, AM J PATHOL, V162, P1037, DOI 10.1016/S0002-9440(10)63899-0; Walker-Daniels J, 2002, MOL CANCER RES, V1, P79; Wicki A, 2001, INT J CANCER, V91, P763, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1128>3.0.CO;2-B; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Zantek ND, 1999, CELL GROWTH DIFFER, V10, P629; Zelinski DP, 2001, CANCER RES, V61, P2301; Zisch AH, 1997, CELL TISSUE RES, V290, P217, DOI 10.1007/s004410050926	54	105	118	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 24	2005	24	53					7859	7868		10.1038/sj.onc.1208937	http://dx.doi.org/10.1038/sj.onc.1208937			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	986PU	16103880				2022-12-25	WOS:000233463000005
J	Uddin, S; Hussain, AR; Manogaran, PS; Al-Hussein, K; Platanias, LC; Gutierrez, MI; Bhatia, KG				Uddin, S; Hussain, AR; Manogaran, PS; Al-Hussein, K; Platanias, LC; Gutierrez, MI; Bhatia, KG			Curcumin suppresses growth and induces apoptosis in primary effusion lymphoma	ONCOGENE			English	Article						PEL; curcumin; cell death; NHL therapy	FACTOR-KAPPA-B; CYTOCHROME-C RELEASE; TRANSCRIPTION FACTOR; CELL-PROLIFERATION; SIGNAL TRANSDUCER; DIETARY CURCUMIN; IN-VITRO; ACTIVATION; INHIBITION; KINASE	The mechanisms that regulate induction of the antiapoptotic state and mitogenic signals in primary effusion lymphoma (PEL) are not well known. In efforts to identify novel approaches to block the proliferation of PEL cells, we found that curcumin (diferuloylmethane), a natural compound isolated from the plant Curcuma Ionga, inhibits cell proliferation and induces apoptosis in a dose dependent manner in several PEL cell lines. Such effects of curcumin appear to result from suppression of the constitutively active STAT3 through inhibition of Janus kinase 1 (JAK1). Our data also demonstrate that curcumin induces loss of mitochondrial membrane potential with subsequent release of cytochrome c and activation of caspase-3, followed by polyadenosin-5'-diphosphate-ribose polymerase (PARP) cleavage. Altogether, our findings suggest a novel function for curcumin, acting as a suppressor of JAK-1 and STAT3 activation in PEL cells, leading to inhibition of proliferation and induction of caspase-dependent apoptosis. Therefore, curcumin may have a future therapeutic role in PEL and possibly other malignancies with constitutive activation of STAT3.	King Fahad Natl Ctr Childrens Canc & Res, Riyadh 11211, Saudi Arabia; King Faisal Specialist Hosp & Res Ctr, BMR, Riyadh 11211, Saudi Arabia; Northwestern Univ, Sch Med, Div Hematol Oncol, Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA; NCI, Canc Diagnosis Program, Rockville, MD USA	King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Uddin, S (corresponding author), King Fahad Natl Ctr Childrens Canc & Res, MBC98-16,POB 3354, Riyadh 11211, Saudi Arabia.	Shahab@kfshrc.edu.sa; Bhatiak@mail.nih.gov		Uddin, Shahab/0000-0003-1886-6710				Anto RJ, 2002, CARCINOGENESIS, V23, P143, DOI 10.1093/carcin/23.1.143; Aoki Y, 2000, BLOOD, V96, P1599, DOI 10.1182/blood.V96.4.1599.h8001599_1599_1601; Aoki Y, 2003, BLOOD, V101, P1535, DOI 10.1182/blood-2002-07-2130; Barton BE, 2004, MOL CANCER THER, V3, P1183; Benekli M, 2003, BLOOD, V101, P2940, DOI 10.1182/blood-2002-04-1204; Bharti AC, 2004, BLOOD, V103, P3175, DOI 10.1182/blood-2003-06-2151; Bharti AC, 2003, J IMMUNOL, V171, P3863, DOI 10.4049/jimmunol.171.7.3863; Bharti AC, 2003, BLOOD, V101, P1053, DOI 10.1182/blood-2002-05-1320; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Buettner R, 2002, CLIN CANCER RES, V8, P945; Bush JA, 2001, EXP CELL RES, V271, P305, DOI 10.1006/excr.2001.5381; Cannon ML, 2004, ONCOGENE, V23, P514, DOI 10.1038/sj.onc.1207021; Chen H, 1999, ANTICANCER RES, V19, P3675; Cheong JW, 2003, LEUKEMIA RES, V27, P1159, DOI 10.1016/S0145-2126(03)00102-4; Chuang SE, 2000, CARCINOGENESIS, V21, P331, DOI 10.1093/carcin/21.2.331; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Drexler HG, 1998, LEUKEMIA, V12, P1507, DOI 10.1038/sj.leu.2401160; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; Huang MT, 1998, CARCINOGENESIS, V19, P1697, DOI 10.1093/carcin/19.9.1697; Jones KD, 1999, BLOOD, V94, P2871; Kalechman Y, 2004, J BIOL CHEM, V279, P24724, DOI 10.1074/jbc.M312006200; Kawamori T, 1999, CANCER RES, V59, P597; Keller SA, 2000, BLOOD, V96, P2537; Kim HY, 2003, J IMMUNOL, V171, P6072, DOI 10.4049/jimmunol.171.11.6072; Klepfish A, 2001, LEUKEMIA LYMPHOMA, V41, P439, DOI 10.3109/10428190109058002; Li L, 2004, CANCER-AM CANCER SOC, V101, P2351, DOI 10.1002/cncr.20605; Limtrakul P, 1997, CANCER LETT, V116, P197, DOI 10.1016/S0304-3835(97)00187-0; Lodha R., 2000, Annals Academy of Medicine Singapore, V29, P37; MASOOD R, 1995, BLOOD, V85, P3423, DOI 10.1182/blood.V85.12.3423.bloodjournal85123423; Mukhopadhyay A, 2001, ONCOGENE, V20, P7597, DOI 10.1038/sj.onc.1204997; Nador RG, 1996, BLOOD, V88, P645, DOI 10.1182/blood.V88.2.645.bloodjournal882645; Pene F, 2002, ONCOGENE, V21, P6587, DOI 10.1038/sj.onc.1205923; Prakash O, 2002, JNCI-J NATL CANCER I, V94, P926; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; Sredni B, 2004, CANCER RES, V64, P1843, DOI 10.1158/0008-5472.CAN-03-3179; Syng-ai C, 2004, MOL CANCER THER, V3, P1101; Tomlinson CC, 2004, J VIROL, V78, P1918, DOI 10.1128/JVI.78.4.1918-1927.2004; Uddin S, 2005, CLIN CANCER RES, V11, P3102, DOI 10.1158/1078-0432.CCR-04-1857; Uddin S, 1997, J IMMUNOL, V158, P2390; Uddin S, 2004, BIOCHEM BIOPH RES CO, V320, P932, DOI 10.1016/j.bbrc.2004.06.038; Uddin S, 2004, P NATL ACAD SCI USA, V101, P147, DOI 10.1073/pnas.0307075101; Zhang CL, 2002, CLIN CANCER RES, V8, P1234	44	104	108	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2005	24	47					7022	7030		10.1038/sj.onc.1208864	http://dx.doi.org/10.1038/sj.onc.1208864			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	977WC	16044161				2022-12-25	WOS:000232833200004
J	Tarran, R; Button, B; Picher, M; Paradiso, AM; Ribeiro, CM; Lazarowski, ER; Zhang, LQ; Collins, PL; Pickles, RJ; Fredberg, JJ; Boucher, RC				Tarran, R; Button, B; Picher, M; Paradiso, AM; Ribeiro, CM; Lazarowski, ER; Zhang, LQ; Collins, PL; Pickles, RJ; Fredberg, JJ; Boucher, RC			Normal and cystic fibrosis airway surface liquid homeostasis - The effects of phasic shear stress and viral infections	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY SYNCYTIAL VIRUS; TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMAN BRONCHIAL EPITHELIA; ION-TRANSPORT; MUCOCILIARY CLEARANCE; MUCUS CLEARANCE; LUNG-DISEASE; WILD-TYPE; PERICILIARY LIQUID; CHLORIDE SECRETION	Mammalian airways normally regulate the volume of a thin liquid layer, the periciliary liquid ( PCL), to facilitate the mucus clearance component of lung defense. Studies under standard ( static) culture conditions revealed that normal airway epithelia possess an adenosine-regulated pathway that blends Na+ absorption and Cl- secretion to optimize PCL volume. In cystic fibrosis ( CF), the absence of CF transmembrane conductance regulator results in a failure of adenosine regulation of PCL volume, which is predicted to initiate mucus stasis and infection. However, under conditions that mimic the phasic motion of the lung in vivo, ATP release into PCL was increased, CF ion transport was rebalanced, and PCL volume was restored to levels adequate for lung defense. This ATP signaling system was vulnerable, however, to insults that trigger CF bacterial infections, such as viral ( respiratory syncitial virus) infections, which up- regulated extracellular ATPase activity and abolished motion- dependent ATP regulation of CF PCL height. These studies demonstrate ( i) how the normal coordination of opposing ion transport pathways to maintain PCL volume is disrupted in CF, ( ii) the hitherto unknown role of phasic motion in regulating key aspects of normal and CF innate airways defense, and ( iii) that maneuvers directed at increasing motion- induced nucleotide release may be therapeutic in CF patients.	Univ N Carolina, Cyct Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA; NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Harvard University; Harvard T.H. Chan School of Public Health	Tarran, R (corresponding author), Univ N Carolina, Cyct Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA.	robert_tarran@med.unc.edu	Ribeiro, Carla Maria P/A-6955-2009; Zhang, Liqun/A-6861-2011; Fredberg, Jeffrey/M-9877-2019		NHLBI NIH HHS [HL60280, HL34322, R01 HL076303-01A2, R01 HL076303, P01 HL034322, R01 HL074158, P50 HL060280, HL074158] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074158, P50HL060280, R01HL076303, P01HL034322] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABMAN SH, 1988, J PEDIATR-US, V113, P826, DOI 10.1016/S0022-3476(88)80008-8; ALSUWAIDAN S, 1994, THORAX, V49, P1249, DOI 10.1136/thx.49.12.1249; Armstrong D, 1998, PEDIATR PULM, V26, P371, DOI 10.1002/(SICI)1099-0496(199812)26:6<371::AID-PPUL1>3.3.CO;2-E; BASSER PJ, 1989, J BIOMECH ENG-T ASME, V111, P288, DOI 10.1115/1.3168381; BENNETT WD, 1990, J APPL PHYSIOL, V69, P1670, DOI 10.1152/jappl.1990.69.5.1670; Boucher RC, 1999, J PHYSIOL-LONDON, V516, P631, DOI 10.1111/j.1469-7793.1999.0631u.x; BOUCHER RC, 1994, AM J RESP CRIT CARE, V150, P271, DOI 10.1164/ajrccm.150.1.8025763; BRADLEY J, 2002, COCHRANE DATABASE SY; Burnstock G, 2002, CLIN MED, V2, P45, DOI 10.7861/clinmedicine.2-1-45; Caldwell RA, 2002, J GEN PHYSIOL, V119, P3, DOI 10.1085/jgp.119.1.3; Carpenter LR, 2002, BMC INFECT DIS, V2, DOI 10.1186/1471-2334-2-5; Clancy JP, 1999, AM J PHYSIOL-CELL PH, V276, pC361, DOI 10.1152/ajpcell.1999.276.2.C361; Davis IC, 2004, AM J PHYSIOL-LUNG C, V286, pL112, DOI 10.1152/ajplung.00218.2003; Devor DC, 2000, AM J PHYSIOL-CELL PH, V279, pC461, DOI 10.1152/ajpcell.2000.279.2.C461; Devor DC, 1999, AM J PHYSIOL-CELL PH, V276, pC827, DOI 10.1152/ajpcell.1999.276.4.C827; Dietl P, 2001, NEWS PHYSIOL SCI, V16, P239; Gibson RL, 2003, AM J RESP CRIT CARE, V168, P918, DOI 10.1164/rccm.200304-505SO; Gondor M, 1999, PEDIATR PULM, V28, P255, DOI 10.1002/(SICI)1099-0496(199910)28:4<255::AID-PPUL4>3.3.CO;2-B; Guggino WB, 2001, NAT MED, V7, P888, DOI 10.1038/90914; Guyot A, 2002, J PHYSIOL-LONDON, V545, P199, DOI 10.1113/jphysiol.2002.030148; Hebestreit A, 2001, AM J RESP CRIT CARE, V164, P443, DOI 10.1164/ajrccm.164.3.2007168; Hiatt PW, 1999, PEDIATRICS, V103, P619, DOI 10.1542/peds.103.3.619; Huang PB, 2001, P NATL ACAD SCI USA, V98, P14120, DOI 10.1073/pnas.241318498; Ji HL, 2000, J BIOL CHEM, V275, P27947; Joo NS, 2002, J BIOL CHEM, V277, P50710, DOI 10.1074/jbc.M208826200; KILBURN KH, 1968, AM REV RESPIR DIS, V98, P449; Knowles MR, 2002, J CLIN INVEST, V109, P571, DOI 10.1172/JCI200215217; Knowles MR, 1997, J CLIN INVEST, V100, P2588, DOI 10.1172/JCI119802; Kunzelmann K, 2000, PFLUG ARCH EUR J PHY, V440, P193, DOI 10.1007/s004240000255; Lazarowski ER, 2004, J BIOL CHEM, V279, P36855, DOI 10.1074/jbc.M405367200; Lazarowski ER, 2000, J BIOL CHEM, V275, P31061, DOI 10.1074/jbc.M003255200; LAZAROWSKI ER, 1992, BRIT J PHARMACOL, V106, P774, DOI 10.1111/j.1476-5381.1992.tb14412.x; Lechner J F, 1985, J TISSUE CULT METHOD, V9, P43; MASON SJ, 1991, BRIT J PHARMACOL, V103, P1649, DOI 10.1111/j.1476-5381.1991.tb09842.x; Mastronarde JG, 1998, J INFECT DIS, V177, P1275, DOI 10.1086/515279; Matsui H, 1998, J CLIN INVEST, V102, P1125, DOI 10.1172/JCI2687; Matsui H, 2000, J CLIN INVEST, V105, P1419, DOI 10.1172/JCI4546; Matsui H, 1998, CELL, V95, P1005, DOI 10.1016/S0092-8674(00)81724-9; McShane D, 2004, EUR RESPIR J, V24, P95, DOI 10.1183/09031936.04.00097503; MILICEMI.J, 1966, J APPL PHYSIOL, V21, P749, DOI 10.1152/jappl.1966.21.3.749; Paradiso AM, 2001, J GEN PHYSIOL, V117, P53, DOI 10.1085/jgp.117.1.53; PARR CE, 1994, P NATL ACAD SCI USA, V91, P3275, DOI 10.1073/pnas.91.8.3275; Picher M, 2000, AM J RESP CELL MOL, V23, P255, DOI 10.1165/ajrcmb.23.2.4088; Picher M, 2003, J BIOL CHEM, V278, P11256, DOI 10.1074/jbc.M208071200; PUCHELLE E, 1995, RESPIRATION, V62, P2; REGNIS JA, 1994, AM J RESP CRIT CARE, V150, P66, DOI 10.1164/ajrccm.150.1.8025774; REISMAN JJ, 1988, J PEDIATR-US, V113, P632, DOI 10.1016/S0022-3476(88)80370-6; Robinson M, 2002, PEDIATR PULM, V33, P293, DOI 10.1002/ppul.10079; SANTIS G, 1991, CLIN RADIOL, V44, P20, DOI 10.1016/S0009-9260(05)80220-X; Schneiderman-Walker J, 2000, J PEDIATR-US, V136, P304, DOI 10.1067/mpd.2000.103408; Song YL, 2001, J GEN PHYSIOL, V117, P573, DOI 10.1085/jgp.117.6.573; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; Tarran R, 2001, J GEN PHYSIOL, V118, P223, DOI 10.1085/jgp.118.2.223; Tarran R, 2001, MOL CELL, V8, P149, DOI 10.1016/S1097-2765(01)00286-6; Tarran Robert, 2002, Methods Mol Med, V70, P479; Thiagarajah JR, 2004, FASEB J, V18, P875, DOI 10.1096/fj.03-1248fje; Thomas WE, 2002, CELL, V109, P913, DOI 10.1016/S0092-8674(02)00796-1; Verkman AS, 2001, AM J PHYSIOL-LUNG C, V281, pL306, DOI 10.1152/ajplung.2001.281.2.L306; Wine JJ, 1999, J CLIN INVEST, V103, P309, DOI 10.1172/JCI6222; Zhang LQ, 2002, J VIROL, V76, P5654, DOI 10.1128/JVI.76.11.5654-5666.2002; Zsembery A, 2004, J BIOL CHEM, V279, P10720, DOI 10.1074/jbc.M313391200	61	273	281	0	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35751	35759		10.1074/jbc.M505832200	http://dx.doi.org/10.1074/jbc.M505832200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16087672	Green Accepted, hybrid			2022-12-25	WOS:000232561200078
J	Zhang, XH; Li, PF; Bao, JY; Nicosia, SV; Wang, HG; Enkemann, SA; Bai, WL				Zhang, XH; Li, PF; Bao, JY; Nicosia, SV; Wang, HG; Enkemann, SA; Bai, WL			Suppression of death receptor-mediated apoptosis by 1,25-dihydroxyvitamin D-3 revealed by microarray analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVARIAN-CANCER CELLS; VITAMIN-D-RECEPTOR; SQUAMOUS CARCINOMA-CELLS; GENE-EXPRESSION; PROSTATE-CANCER; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; ANALOG EB1089; LYSOPHOSPHATIDIC ACID; HUMAN KERATINOCYTES; GROWTH-INHIBITION	Recent studies suggest that growth inhibition by 1,25- dihydroxyvitamin D-3 represents an innovative approach to ovarian cancer therapy. To understand the molecular mechanism of 1,25- dihydroxyvitamin D-3 action, we profiled the hormone- induced changes in the transcriptome of ovarian cancer cells using microarray technology. More than 200 genes were identified to be regulated by 1,25-dihydroxyvitamin D-3. Reverse transcription- PCR analyses confirmed the regulation of a group of apoptosis- related genes, including the up- regulation of the decoy receptor that inhibits tumor necrosis factor- related apoptosis- inducing ligand ( TRAIL) action, TRAIL receptor 4, and the down- regulation of Fas, the receptor that mediates the action of Fas ligand. The regulation was further confirmed at the protein level. Consistent with the regulation of the death receptors, pretreatment with 1,25- dihydroxyvitamin D-3 decreased apoptosis induced by TRAIL and Fas ligand. Because persistent 1,25- dihydroxyvitamin D-3 treatment has been shown to induce apoptosis in ovarian cancer, the hormone appears to exert a dual effect on the death of ovarian cancer cells. Knockdown of TRAIL receptor 4 by RNA interference or ectopic expression of Fas relieved the suppressive effect of 1,25- dihydroxyvitamin D-3, showing that molecular manipulation of death receptors is a viable approach to overcome the protective effect of 1,25- dihydroxyvitamin D-3 on the apoptosis of ovarian cancer. These strategies may allow ovarian cancer patients to benefit from therapy with both 1,25- dihydroxyvitamin D-3 and ligands for death receptors, such as TRAIL, shown to selectively induce apoptosis in cancer but not normal cells.	Univ S Florida, Coll Med, Dept Pathol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; H Lee Moffitt Canc Ctr, Program Mol Oncol, Tampa, FL 33612 USA; H Lee Moffitt Canc Ctr, Program Drug Discovery, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute	Bai, WL (corresponding author), Univ S Florida, Coll Med, Dept Pathol, 12901 Bruce B Downs Blvd,MDC 11, Tampa, FL 33612 USA.	wbai@hsc.usf.edu	Wang, Hong-Gang/A-3018-2015; Bai, Wenlong/A-8977-2013	Wang, Hong-Gang/0000-0003-0551-0571; Bai, Wenlong/0000-0002-9536-0556	NATIONAL CANCER INSTITUTE [R01CA093666, R01CA111334] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA111334-01A1, R01 CA093666, 1R01 CA111334, R01 CA093666-02, R01 CA111334] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akutsu N, 2001, MOL ENDOCRINOL, V15, P1127, DOI 10.1210/me.15.7.1127; BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; Barila D, 2003, MOL CELL BIOL, V23, P2790, DOI 10.1128/MCB.23.8.2790-2799.2003; Baudet C, 1996, J NEUROSCI RES, V46, P540, DOI 10.1002/(SICI)1097-4547(19961201)46:5<540::AID-JNR3>3.0.CO;2-J; Behrens P, 2003, APOPTOSIS, V8, P39, DOI 10.1023/A:1021644918117; Belcredito S, 2001, BRAIN RES REV, V37, P335, DOI 10.1016/S0165-0173(01)00138-2; Boyle BJ, 2001, J UROLOGY, V165, P1319, DOI 10.1016/S0022-5347(01)69892-6; Cippitelli M, 2002, J IMMUNOL, V168, P1154, DOI 10.4049/jimmunol.168.3.1154; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; De Haes P, 2003, J CELL BIOCHEM, V89, P663, DOI 10.1002/jcb.10540; Devesa SS, 1999, NIH PUBLICATION; Diker-Cohen T, 2003, ANN NY ACAD SCI, V1010, P350, DOI 10.1196/annals.1299.064; Duque G, 2004, BONE, V35, P57, DOI 10.1016/j.bone.2004.03.005; Fang XJ, 2000, ANN NY ACAD SCI, V905, P188; Gianfrancesco F, 1999, CYTOGENET CELL GENET, V84, P164, DOI 10.1159/000015247; Gurlek A, 2002, ENDOCR REV, V23, P763, DOI 10.1210/er.2001-0044; Guzey M, 2002, MOL CANCER THER, V1, P667; Hansen CM, 2001, J STEROID BIOCHEM, V77, P1, DOI 10.1016/S0960-0760(01)00033-4; Harbig J, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni027; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; HASKILL S, 1990, P NATL ACAD SCI USA, V87, P7732, DOI 10.1073/pnas.87.19.7732; HAVRILESKY LJ, 1995, CANCER RES, V55, P944; Hedlund TE, 1996, ENDOCRINOLOGY, V137, P1554, DOI 10.1210/en.137.5.1554; Jiang F, 2004, J BIOL CHEM, V279, P53213, DOI 10.1074/jbc.M410395200; Jiang F, 2003, J BIOL CHEM, V278, P48030, DOI 10.1074/jbc.M308430200; Johansen C, 2003, J INVEST DERMATOL, V120, P561, DOI 10.1046/j.1523-1747.2003.12095.x; Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200; Krishnan AV, 2004, PROSTATE, V59, P243, DOI 10.1002/pros.20006; Lankat-Buttgereit B, 2004, MOL CELL ENDOCRINOL, V214, P149, DOI 10.1016/j.mce.2003.10.058; Li PF, 2004, J BIOL CHEM, V279, P25260, DOI 10.1074/jbc.M311052200; Lin R, 2002, MOL ENDOCRINOL, V16, P1243, DOI 10.1210/me.16.6.1243; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Loukinova E, 2000, ONCOGENE, V19, P3477, DOI 10.1038/sj.onc.1203687; Maurer U, 2001, J BIOL CHEM, V276, P3727, DOI 10.1074/jbc.M005292200; Miettinen S, 2004, INT J CANCER, V108, P367, DOI 10.1002/ijc.11520; MUIR CS, 1987, IARC SCI PUBLICATION, V88; O'Donovan N, 1999, CYTOGENET CELL GENET, V84, P39, DOI 10.1159/000015209; ONATE SA, 1995, SCIENCE, V270, P1354; Palmer HG, 2003, CANCER RES, V63, P7799; Rachez C, 2000, GENE, V246, P9, DOI 10.1016/S0378-1119(00)00052-4; ROSS TK, 1994, VITAM HORM, V49, P281; Shen ZZ, 2001, GYNECOL ONCOL, V83, P25, DOI 10.1006/gyno.2001.6357; So J, 2004, GYNECOL ONCOL, V95, P314, DOI 10.1016/j.ygyno.2004.08.001; Stewart LV, 2004, EXP BIOL MED, V229, P277, DOI 10.1177/153537020422900401; Suzuki T, 2000, INT J CANCER, V88, P992, DOI 10.1002/1097-0215(20001215)88:6<992::AID-IJC24>3.0.CO;2-9; Swami S, 2003, BREAST CANCER RES TR, V80, P49, DOI 10.1023/A:1024487118457; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wang SH, 1999, ENDOCRINOLOGY, V140, P1649, DOI 10.1210/en.140.4.1649; WEBB AR, 1988, J CLIN ENDOCR METAB, V67, P373, DOI 10.1210/jcem-67-2-373; Weitsman GE, 2003, ANN NY ACAD SCI, V1010, P437, DOI 10.1196/annals.1299.079; Wood RJ, 2004, PHYSIOL GENOMICS, V17, P122, DOI 10.1152/physiolgenomics.00002.2003; Zhang XH, 2005, CLIN CANCER RES, V11, P323; Zou AH, 1997, J BIOL CHEM, V272, P19027, DOI 10.1074/jbc.272.30.19027	53	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35458	35468		10.1074/jbc.M506648200	http://dx.doi.org/10.1074/jbc.M506648200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16093247	Green Accepted, hybrid			2022-12-25	WOS:000232561200046
J	Fujimoto, M; Takaki, E; Hayashi, T; Kitaura, Y; Tanaka, Y; Inouye, S; Nakai, A				Fujimoto, M; Takaki, E; Hayashi, T; Kitaura, Y; Tanaka, Y; Inouye, S; Nakai, A			Active HSF1 significantly suppresses polyglutamine aggregate formation in cellular and mouse models	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK TRANSCRIPTION FACTOR-1; NEURONAL INTRANUCLEAR INCLUSIONS; TRUNCATED ANDROGEN RECEPTOR; HUNTINGTONS-DISEASE GENE; EXPANDED CAG REPEAT; HEAT-SHOCK; MOLECULAR CHAPERONES; PROTEIN AGGREGATION; HSP40 CHAPERONES; MICE	Polyglutamine diseases are inherited neurodegenerative diseases characterized by misfolding and aggregation of proteins possessing expanded polyglutamine repeats. As overexpression of some heat shock protein (Hsp) suppresses polyglutamine aggregates and cell death, it is assumed that combined overexpression of Hsps will suppress that more effectively. Here, we examined the impact of active forms of heat shock transcription factor 1 (HSF1), which induces a set of Hsps, on polyglutamine inclusion formation and disease progression. We found that active HSF1 suppressed polyglutamine inclusion formation more significantly than any combination of Hsps in culture cells, possibly by regulating expression of unknown genes, as well as major Hsps. We crossed R6/2 Huntington disease mice with transgenic mice expressing an active HSF1 (HSF1Tg). Analysis of the skeletal muscle revealed that the polyglutamine inclusion formation and its weight loss were improved in R6/2/HSF1Tg mice. Unexpectedly, the life span of R6/2/HSF1Tg mice was significantly improved, although active HSF1 is not expressed in the brain. These results indicated that active HSF1 has a strong inhibitory effect on polyglutamine aggregate formation in vivo and in vitro.	Yamaguchi Univ, Sch Med, Dept Biochem & Mol Biol, Ube, Yamaguchi 7758505, Japan; Osaka Med Coll, Dept Med 3, Osaka 5698686, Japan	Yamaguchi University; Osaka Medical College	Nakai, A (corresponding author), Yamaguchi Univ, Sch Med, Dept Biochem & Mol Biol, Ube, Yamaguchi 7758505, Japan.	anakai@yamaguchi-u.ac.jp	Longo, Kenneth A/A-5631-2010					Adachi H, 2003, J NEUROSCI, V23, P2203; Arrasate M, 2004, NATURE, V431, P805, DOI 10.1038/nature02998; BROOKE MH, 1970, ARCH NEUROL-CHICAGO, V23, P369, DOI 10.1001/archneur.1970.00480280083010; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Carmichael J, 2000, P NATL ACAD SCI USA, V97, P9701, DOI 10.1073/pnas.170280697; Chai YH, 1999, J NEUROSCI, V19, P10338; Chan HYE, 2000, HUM MOL GENET, V9, P2811, DOI 10.1093/hmg/9.19.2811; Cummings CJ, 2001, HUM MOL GENET, V10, P1511, DOI 10.1093/hmg/10.14.1511; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Fujimoto M, 2004, EMBO J, V23, P4297, DOI 10.1038/sj.emboj.7600435; Gutekunst CA, 1999, J NEUROSCI, V19, P2522; Hansson O, 2003, BRAIN RES, V970, P47, DOI 10.1016/S0006-8993(02)04275-0; Hay DG, 2004, HUM MOL GENET, V13, P1389, DOI 10.1093/hmg/ddh144; HAYASHI T, 1995, AM HEART J, V129, P946, DOI 10.1016/0002-8703(95)90116-7; Helmlinger D, 2004, J BIOL CHEM, V279, P55969, DOI 10.1074/jbc.M409062200; Hsu AL, 2003, SCIENCE, V300, P1142, DOI 10.1126/science.1083701; Hurlbert MS, 1999, DIABETES, V48, P649, DOI 10.2337/diabetes.48.3.649; Inouye S, 2004, J BIOL CHEM, V279, P38701, DOI 10.1074/jbc.M405986200; Inouye S, 2003, MOL CELL BIOL, V23, P5882, DOI 10.1128/MCB.23.16.5882-5895.2003; Ishihara K, 2003, J BIOL CHEM, V278, P25143, DOI 10.1074/jbc.M302975200; Jana NR, 2000, HUM MOL GENET, V9, P2009, DOI 10.1093/hmg/9.13.2009; Kato K, 1998, J BIOL CHEM, V273, P28346, DOI 10.1074/jbc.273.43.28346; Katoh Y, 2004, FEBS LETT, V565, P28, DOI 10.1016/j.febslet.2003.12.085; Katsuki K, 2004, FEBS LETT, V571, P187, DOI 10.1016/j.febslet.2004.06.087; Kazemi-Esfarjani P, 2000, SCIENCE, V287, P1837, DOI 10.1126/science.287.5459.1837; Kieran D, 2004, NAT MED, V10, P402, DOI 10.1038/nm1021; Kobayashi Y, 2000, J BIOL CHEM, V275, P8772, DOI 10.1074/jbc.275.12.8772; Komatsuda A, 1999, NEPHROL DIAL TRANSPL, V14, P1385, DOI 10.1093/ndt/14.6.1385; Krobitsch S, 2000, P NATL ACAD SCI USA, V97, P1589, DOI 10.1073/pnas.97.4.1589; Landles C, 2004, EMBO REP, V5, P958, DOI 10.1038/sj.embor.7400250; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Meriin AB, 2001, J CELL BIOL, V153, P851, DOI 10.1083/jcb.153.4.851; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Muchowski PJ, 2000, P NATL ACAD SCI USA, V97, P7841, DOI 10.1073/pnas.140202897; Myers RH, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P301; Nakai A, 2000, EMBO J, V19, P1545, DOI 10.1093/emboj/19.7.1545; NAKAI A, 1995, MOL CELL BIOL, V15, P5168; OHTSUKA K, 1993, BIOCHEM BIOPH RES CO, V197, P235, DOI 10.1006/bbrc.1993.2466; Onodera O, 1997, BIOCHEM BIOPH RES CO, V238, P599, DOI 10.1006/bbrc.1997.7337; Orth M, 2003, J NEUROCHEM, V87, P1, DOI 10.1046/j.1471-4159.2003.02009.x; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; Rimoldi M, 2001, BRAIN RES BULL, V56, P353, DOI 10.1016/S0361-9230(01)00602-5; Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066; Sakahira H, 2002, P NATL ACAD SCI USA, V99, P16412, DOI 10.1073/pnas.182426899; Sanchez I, 2003, NATURE, V421, P373, DOI 10.1038/nature01301; Sathasivam K, 1999, HUM MOL GENET, V8, P813, DOI 10.1093/hmg/8.5.813; Satyal SH, 2000, P NATL ACAD SCI USA, V97, P5750, DOI 10.1073/pnas.100107297; Stenoien DL, 1999, HUM MOL GENET, V8, P731, DOI 10.1093/hmg/8.5.731; STRONG TV, 1993, NAT GENET, V5, P259, DOI 10.1038/ng1193-259; Trinklein ND, 2004, MOL BIOL CELL, V15, P1254, DOI 10.1091/mbc.E03-10-0738; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; Warrick JM, 1998, CELL, V93, P939, DOI 10.1016/S0092-8674(00)81200-3; Wyttenbach A, 2000, P NATL ACAD SCI USA, V97, P2898, DOI 10.1073/pnas.97.6.2898; Wyttenbach A, 2002, HUM MOL GENET, V11, P1137, DOI 10.1093/hmg/11.9.1137; Xia WL, 1999, CELL STRESS CHAPERON, V4, P8, DOI 10.1054/csac.1998.0113; ZUO JR, 1995, MOL CELL BIOL, V15, P4319	59	163	171	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34908	34916		10.1074/jbc.M506288200	http://dx.doi.org/10.1074/jbc.M506288200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16051598	hybrid			2022-12-25	WOS:000232403900063
J	Tam, YYC; Fagarasanu, A; Fagarasanu, M; Rachubinski, RA				Tam, YYC; Fagarasanu, A; Fagarasanu, M; Rachubinski, RA			Pex3p initiates the formation of a preperoxisomal compartment from a subdomain of the endoplasmic reticulum in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXISOMAL MEMBRANE-PROTEINS; YARROWIA-LIPOLYTICA; HANSENULA-POLYMORPHA; FLUORESCENT PROTEIN; BIOGENESIS; YEAST; PEX19; DELETION; PATHWAYS; STRAINS	Peroxisomes are dynamic organelles that often proliferate in response to compounds that they metabolize. Peroxisomes can proliferate by two apparent mechanisms, division of preexisting peroxisomes and de novo synthesis of peroxisomes. Evidence for de novo peroxisome synthesis comes from studies of cells lacking the peroxisomal integral membrane peroxin Pex3p. These cells lack peroxisomes, but peroxisomes can assemble upon reintroduction of Pex3p. The source of these peroxisomes has been the subject of debate. Here, we show that the amino-terminal 46 amino acids of Pex3p of Saccharomyces cerevisiae target to a subdomain of the endoplasmic reticulum and initiate the formation of a preperoxisomal compartment for de novo peroxisome synthesis. In vivo video microscopy showed that this preperoxisomal compartment can import both peroxisomal matrix and membrane proteins leading to the formation of bona fide peroxisomes through the continued activity of full-length Pex3p. Peroxisome formation from the preperoxisomal compartment depends on the activity of the genes PEX14 and PEX19, which are required for the targeting of peroxisomal matrix and membrane proteins, respectively. Our findings support a direct role for the endoplasmic reticulum in de novo peroxisome formation.	Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2H7, Canada	University of Alberta	Rachubinski, RA (corresponding author), Univ Alberta, Dept Cell Biol, Med Sci Bldg 5-14, Edmonton, AB T6G 2H7, Canada.	rick.rachubinski@ualberta.ca						Adames NR, 2001, J CELL BIOL, V153, P159, DOI 10.1083/jcb.153.1.159; AITCHISON JD, 1992, YEAST, V8, P721, DOI 10.1002/yea.320080905; Albertini M, 1997, CELL, V89, P83, DOI 10.1016/S0092-8674(00)80185-3; Baerends RJS, 1996, J BIOL CHEM, V271, P8887, DOI 10.1074/jbc.271.15.8887; Bascom RA, 2003, MOL BIOL CELL, V14, P939, DOI 10.1091/mbc.E02-10-0633; Bevis BJ, 2002, NAT CELL BIOL, V4, P750, DOI 10.1038/ncb852; Brachmann CB, 1998, YEAST, V14, P115; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Dilworth DJ, 2001, J CELL BIOL, V153, P1465, DOI 10.1083/jcb.153.7.1465; Eckert JH, 2003, REV PHYSIOL BIOCH P, V147, P75, DOI 10.1007/s10254-003-0007-z; Eitzen GA, 1996, J BIOL CHEM, V271, P20300, DOI 10.1074/jbc.271.34.20300; Eitzen GA, 1997, J CELL BIOL, V137, P1265, DOI 10.1083/jcb.137.6.1265; Fang Y, 2004, J CELL BIOL, V164, P863, DOI 10.1083/jcb.200311131; Geuze HJ, 2003, MOL BIOL CELL, V14, P2900, DOI 10.1091/mbc.E02-11-0734; Ghaedi K, 2000, MOL BIOL CELL, V11, P2085, DOI 10.1091/mbc.11.6.2085; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Gotte K, 1998, MOL CELL BIOL, V18, P616; Hammond AT, 2000, TRAFFIC, V1, P935, DOI 10.1034/j.1600-0854.2000.011203.x; Hettema EH, 2000, EMBO J, V19, P223, DOI 10.1093/emboj/19.2.223; HOHFELD J, 1991, J CELL BIOL, V114, P1167, DOI 10.1083/jcb.114.6.1167; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; Lisenbee CS, 2003, PLANT PHYSIOL, V132, P870, DOI 10.1104/pp.103.019976; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Matsuzono Y, 1999, P NATL ACAD SCI USA, V96, P2116, DOI 10.1073/pnas.96.5.2116; Sacksteder KA, 2000, J CELL BIOL, V148, P931, DOI 10.1083/jcb.148.5.931; Salomons FA, 1997, FEBS LETT, V411, P133, DOI 10.1016/S0014-5793(97)00679-0; Scholz O, 2000, EUR J BIOCHEM, V267, P1565, DOI 10.1046/j.1432-1327.2000.01170.x; SIKORSKI RS, 1989, GENETICS, V122, P19; Smith JJ, 2002, J CELL BIOL, V158, P259, DOI 10.1083/jcb.200204059; South ST, 2000, J CELL BIOL, V149, P1345, DOI 10.1083/jcb.149.7.1345; South ST, 1999, J CELL BIOL, V144, P255, DOI 10.1083/jcb.144.2.255; South ST, 2001, P NATL ACAD SCI USA, V98, P12027, DOI 10.1073/pnas.221289498; Tabak HF, 1999, TRENDS CELL BIOL, V9, P447, DOI 10.1016/S0962-8924(99)01650-5; Tam YYC, 2002, MOL BIOL CELL, V13, P2681, DOI 10.1091/mbc.E02-02-0117; Titorenko VI, 2000, J CELL BIOL, V148, P29, DOI 10.1083/jcb.148.1.29; Titorenko VI, 1997, MOL CELL BIOL, V17, P5210, DOI 10.1128/MCB.17.9.5210; Titorenko VI, 2001, NAT REV MOL CELL BIO, V2, P357, DOI 10.1038/35073063; Voorn-Brouwer T, 2001, J CELL SCI, V114, P2199	38	132	134	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34933	34939		10.1074/jbc.M506208200	http://dx.doi.org/10.1074/jbc.M506208200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16087670	hybrid			2022-12-25	WOS:000232403900066
J	Tiesong, SS; Joseph, J; Hillard, CJ; Kalyanaraman, B				Tiesong, SS; Joseph, J; Hillard, CJ; Kalyanaraman, B			Death-associated protein kinase as a sensor of mitochondrial membrane potential - Role of lysosome in mitochondrial toxin-induced cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUNTINGTONS-DISEASE; PARKINSONS-DISEASE; DAP-KINASE; TRANSPORT; APOPTOSIS; CHAIN; IRON; NEURODEGENERATION; ANTIOXIDANT; OXIDATION	We have investigated here the mechanism of dephosphorylation and activation of death-associated protein kinase ( DAPK) and the role of lysosome in neuroblastoma cells (SH-SY5Y) treated with mitochondrial toxins, such as MPP+ and rotenone. Mitochondrial respiratory chain inhibitors and uncouplers decreased mitochondrial membrane potential leading to DAPK dephosphorylation and activation. The class III phosphoinositide 3-kinase inhibitors attenuated DAPK dephosphorylation induced by mitochondrial toxins. Complex I inhibition by mitochondrial toxins ( e. g. MPP+) resulted in mitochondrial swelling and lysosome reduction. Inhibition of class III phosphoinositide 3-kinase attenuated MPP+-induced lysosome reduction and cell death. The role of DAPK as a sensor of mitochondrial membrane potential in mitochondrial diseases was addressed.	Med Coll Wisconsin, Dept Biophys, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Free Rad Res Ctr, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin	Kalyanaraman, B (corresponding author), Med Coll Wisconsin, Dept Biophys, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	balarama@mcw.edu	Hillard, Cecilia J/O-6693-2018		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039958] Funding Source: NIH RePORTER; NINDS NIH HHS [NS39958, R01 NS039958] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Bizat N, 2003, J NEUROSCI, V23, P5020; Brookes PS, 2002, FREE RADICAL BIO MED, V33, P755, DOI 10.1016/S0891-5849(02)00901-2; BURNS RS, 1983, P NATL ACAD SCI-BIOL, V80, P4546, DOI 10.1073/pnas.80.14.4546; Cohen I, 2002, TRENDS CELL BIOL, V12, P293, DOI 10.1016/S0962-8924(02)02299-7; Connor KM, 2005, J BIOL CHEM, V280, P16916, DOI 10.1074/jbc.M410690200; Dan Z, 2005, FASEB J, V19, P845, DOI 10.1096/fj.04-2809fje; Davis RE, 1997, P NATL ACAD SCI USA, V94, P4526, DOI 10.1073/pnas.94.9.4526; De Vos KJ, 2003, MOL BIOL CELL, V14, P3636, DOI 10.1091/mbc.E02-10-0638; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Desai BN, 2002, P NATL ACAD SCI USA, V99, P4319, DOI 10.1073/pnas.261702698; Dhanasekaran A, 2004, J BIOL CHEM, V279, P37575, DOI 10.1074/jbc.M404003200; Di Paolo G, 2004, NATURE, V431, P415, DOI 10.1038/nature02896; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Gu M, 1996, ANN NEUROL, V39, P385, DOI 10.1002/ana.410390317; Gunter TE, 2004, FEBS LETT, V567, P96, DOI 10.1016/j.febslet.2004.03.071; Habermann A, 2001, J CELL SCI, V114, P229; Inbal B, 2002, J CELL BIOL, V157, P455, DOI 10.1083/jcb.200109094; Kalivendi SV, 2003, BIOCHEM J, V371, P151, DOI 10.1042/BJ20021525; Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200; Lenaz G, 2002, ANN NY ACAD SCI, V959, P199, DOI 10.1111/j.1749-6632.2002.tb02094.x; Li QY, 2001, J NEUROCHEM, V78, P746, DOI 10.1046/j.1471-4159.2001.00457.x; LIPSKY NG, 1981, J BIOL CHEM, V256, P8652; Lockwood AH, 2000, CURR OPIN NEUROL, V13, P687, DOI 10.1097/00019052-200012000-00013; Mazzio E, 2003, BRAIN RES, V962, P48, DOI 10.1016/S0006-8993(02)03695-8; Miller KE, 2004, J CELL SCI, V117, P2791, DOI 10.1242/jcs.01130; Muller FL, 2004, J BIOL CHEM, V279, P49064, DOI 10.1074/jbc.M407715200; Nakai M, 2003, EXP NEUROL, V179, P103, DOI 10.1006/exnr.2002.8056; NICKLAS WJ, 1992, ANN NY ACAD SCI, V648, P28, DOI 10.1111/j.1749-6632.1992.tb24521.x; Paraskeva E, 1996, FEBS LETT, V389, P40, DOI 10.1016/0014-5793(96)00574-1; PARKER WD, 1994, NEUROLOGY, V44, P1090, DOI 10.1212/WNL.44.6.1090; SCHAPIRA AHV, 1989, LANCET, V1, P1269, DOI 10.1016/S0140-6736(89)92366-0; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Shohat G, 2002, BBA-PROTEINS PROTEOM, V1600, P45, DOI 10.1016/S1570-9639(02)00443-0; Smith RAJ, 1999, EUR J BIOCHEM, V263, P709, DOI 10.1046/j.1432-1327.1999.00543.x; Storch A, 2000, BRAIN RES, V855, P67, DOI 10.1016/S0006-8993(99)02272-6; Stumvoll M, 2005, LANCET, V365, P1333, DOI 10.1016/S0140-6736(05)61032-X; Tanaka Y, 1998, CELL, V93, P1147, DOI 10.1016/S0092-8674(00)81459-2; van Gurp M, 2003, BIOCHEM BIOPH RES CO, V304, P487, DOI 10.1016/S0006-291X(03)00621-1; Verma M, 2003, NAT REV CANCER, V3, P789, DOI 10.1038/nrc1192; Wiedemann FR, 2002, J NEUROCHEM, V80, P616, DOI 10.1046/j.0022-3042.2001.00731.x; Wright AF, 2004, NAT GENET, V36, P1153, DOI 10.1038/ng1448; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Xue L, 2001, CURR BIOL, V11, P361, DOI 10.1016/S0960-9822(01)00100-2; Yamamoto M, 1999, J NEUROSCI RES, V58, P674, DOI 10.1002/(SICI)1097-4547(19991201)58:5<674::AID-JNR8>3.0.CO;2-3	45	34	39	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34644	34653		10.1074/jbc.M506466200	http://dx.doi.org/10.1074/jbc.M506466200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16085644	hybrid			2022-12-25	WOS:000232403900033
J	Tudor, EL; Perkinton, MS; Schmidt, A; Ackerley, S; Brownlees, J; Jacobsen, NJO; Byers, HL; Ward, M; Hall, A; Leigh, PN; Shaw, CE; McLoughlin, DM; Miller, CCJ				Tudor, EL; Perkinton, MS; Schmidt, A; Ackerley, S; Brownlees, J; Jacobsen, NJO; Byers, HL; Ward, M; Hall, A; Leigh, PN; Shaw, CE; McLoughlin, DM; Miller, CCJ			ALS2/Alsin regulates Rac-PAK signaling and neurite outgrowth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; NUCLEOTIDE EXCHANGE FACTOR; ACTIVATED PROTEIN-KINASE; GROWTH CONE COLLAPSE; CU,ZN SUPEROXIDE-DISMUTASE; RHO-GTPASES; ADAPTER PROTEIN; ALS2 GENE; PHOSPHATASE EXPRESSION; SPASTIC PARALYSIS	Rac and its downstream effectors p21-activated kinase (PAK) family kinases regulate actin dynamics within growth cones to control neurite outgrowth during development. The activity of Rac is stimulated by guanine nucleotide exchange factors ( GEFs) that promote GDP release and GTP binding. ALS2/Alsin is a recently described GEF that contains a central domain that is predicted to regulate the activities of Rac and/or Rho and Cdc42 activities. Mutations in ALS2 cause some recessive familial forms of amyotrophic lateral sclerosis (ALS) but the function of ALS2 is poorly understood. Here we demonstrate that ALS2 is present within growth cones of neurons, in which it co-localizes with Rac. Furthermore, ALS2 stimulates Rac but not Rho or Cdc42 activities, and this induces a corresponding increase in PAK1 activity. Finally, we demonstrate that ALS2 promotes neurite outgrowth. Defects in these functions may therefore contribute to motor neuron demise in ALS.	Kings Coll London, Inst Psychiat, Dept Neurosci, London SE5 8AF, England; Kings Coll London, Dept Neurol, Inst Psychiat, London SE5 8AF, England; Kings Coll London, Old Age Psychiat Sect, Inst Psychiat, London SE5 8AF, England; UCL, MRC, Mol Cell Biol Lab, London WC1E 6BT, England; Proteome Sci Plc, Inst Psychiat, London SE5 8AF, England	University of London; King's College London; University of London; King's College London; University of London; King's College London; University of London; University College London; University of London; King's College London	Miller, CCJ (corresponding author), Kings Coll London, Inst Psychiat, Dept Neurosci, POB P037,De Crespigny Pk,Denmark Hill, London SE5 8AF, England.	chris.miller@iop.kcl.ac.uk	Leigh, Peter/AAD-5638-2019; Miller, Christopher/H-5733-2012	Miller, Christopher/0000-0002-5130-1845; Ward, Malcolm/0000-0003-2164-6938; McLoughlin, Declan/0000-0003-4574-2799; Shaw, Christopher/0000-0003-0251-0146	MRC [G0000749] Funding Source: UKRI; Medical Research Council [G0000749] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Ackerley S, 2004, MOL CELL NEUROSCI, V26, P354, DOI 10.1016/j.mcn.2004.02.009; Arakawa Y, 2003, J CELL BIOL, V161, P381, DOI 10.1083/jcb.200210149; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Brownlees J, 2002, HUM MOL GENET, V11, P2837, DOI 10.1093/hmg/11.23.2837; Brownlees J, 2000, J CELL SCI, V113, P401; Bruijn LI, 2004, ANNU REV NEUROSCI, V27, P723, DOI 10.1146/annurev.neuro.27.070203.144244; Bryan B, 2004, J BIOL CHEM, V279, P45824, DOI 10.1074/jbc.M406216200; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; Devon RS, 2003, CLIN GENET, V64, P210, DOI 10.1034/j.1399-0004.2003.00138.x; Devon RS, 2005, NEUROBIOL DIS, V18, P243, DOI 10.1016/j.nbd.2004.10.002; Dickson BJ, 2001, CURR OPIN NEUROBIOL, V11, P103, DOI 10.1016/S0959-4388(00)00180-X; Estrach S, 2002, CURR BIOL, V12, P307, DOI 10.1016/S0960-9822(02)00658-9; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Eymard-Pierre E, 2002, AM J HUM GENET, V71, P518, DOI 10.1086/342359; Figlewicz DA, 2003, AMYOTROPH LATERAL SC, V4, P225, DOI 10.1080/14660820310011287; Gros-Louis F, 2003, ANN NEUROL, V53, P144, DOI 10.1002/ana.10422; Guidato S, 1998, J NEUROCHEM, V70, P335; Hadano S, 2001, NAT GENET, V29, P166, DOI 10.1038/ng1001-166; Hu JH, 2003, J NEUROCHEM, V85, P422, DOI 10.1046/j.1471-4159.2003.01669.x; Hu JH, 2003, J NEUROCHEM, V85, P432, DOI 10.1046/j.1471-4159.2003.01670.x; Jin Z, 1997, J NEUROSCI, V17, P6256; Kanekura K, 2005, J BIOL CHEM, V280, P4532, DOI 10.1074/jbc.M410508200; KANEKURA K, 2004, J BIOL CHEM; Kuhn TB, 1999, J NEUROSCI, V19, P1965; Kunita R, 2004, J BIOL CHEM, V279, P38626, DOI 10.1074/jbc.M406120200; Lee JH, 2004, J BIOL CHEM, V279, P49099, DOI 10.1074/jbc.M405602200; Li Z, 2000, NAT NEUROSCI, V3, P217, DOI 10.1038/72920; Lundquist EA, 2003, CURR OPIN NEUROBIOL, V13, P384, DOI 10.1016/s0959-4388(03)00071-0; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; May V, 2002, J NEUROSCI, V22, P6980; Mourelatos Z, 1996, P NATL ACAD SCI USA, V93, P5472, DOI 10.1073/pnas.93.11.5472; Nguyen MD, 2001, NEURON, V30, P135, DOI 10.1016/S0896-6273(01)00268-9; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Nikolic M, 2002, INT J BIOCHEM CELL B, V34, P731, DOI 10.1016/S1357-2725(01)00167-4; Nishimura AL, 2004, AM J HUM GENET, V75, P822, DOI 10.1086/425287; Otomo A, 2003, HUM MOL GENET, V12, P1671, DOI 10.1093/hmg/ddg184; Penzes P, 2001, J NEUROSCI, V21, P8426, DOI 10.1523/JNEUROSCI.21-21-08426.2001; Perkinton MS, 2004, J BIOL CHEM, V279, P22084, DOI 10.1074/jbc.M311479200; Raoul C, 2002, NEURON, V35, P1067, DOI 10.1016/S0896-6273(02)00905-4; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Ruchhoeft ML, 1999, J NEUROSCI, V19, P8454; Sahin M, 2005, NEURON, V46, P191, DOI 10.1016/j.neuron.2005.01.030; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Standen CL, 2003, MOL CELL NEUROSCI, V24, P851, DOI 10.1016/j.mcn.2003.07.002; Threadgill R, 1997, NEURON, V19, P625, DOI 10.1016/S0896-6273(00)80376-1; TOPP JD, 2004, J BIOL CHEM; Tortarolo M, 2003, MOL CELL NEUROSCI, V23, P180, DOI 10.1016/S1044-7431(03)00022-8; Tybulewicz VL, 2005, CURR OPIN IMMUNOL, V17, P267, DOI 10.1016/j.coi.2005.04.003; vanLeeuwen FN, 1997, J CELL BIOL, V139, P797, DOI 10.1083/jcb.139.3.797; Yamanaka K, 2003, P NATL ACAD SCI USA, V100, P16041, DOI 10.1073/pnas.2635267100; Yang Y, 2001, NAT GENET, V29, P160, DOI 10.1038/ng1001-160; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a	53	67	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34735	34740		10.1074/jbc.M506216200	http://dx.doi.org/10.1074/jbc.M506216200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16049005	hybrid, Green Published			2022-12-25	WOS:000232403900044
J	Galkin, A; Lu, XF; Dunaway-Mariano, D; Herzberg, O				Galkin, A; Lu, XF; Dunaway-Mariano, D; Herzberg, O			Crystal structures representing the Michaelis complex and the thiouronium reaction intermediate of Pseudomonas aeruginosa arginine deiminase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIMETHYLARGININE DIMETHYLAMINOHYDROLASE; ENZYME; AMIDINOTRANSFERASE; BIOSYNTHESIS; HYDROLYSIS; CATALYSIS; MECHANISM; SOFTWARE	L-Arginine deiminase (ADI) catalyzes the irreversible hydrolysis of L-arginine to citrulline and ammonia. In a previous report of the structure of apoADI from Pseudomonas aeruginosa, the four residues that form the catalytic motif were identified as Cys(406), His(278), Asp(280), and Asp(166). The function of Cys(406) in nucleophilic catalysis has been demonstrated by transient kinetic studies. In this study, the structure of the C406A mutant in complex with L-arginine is reported to provide a snapshot of the enzyme center dot substrate complex. Through the comparison of the structures of apoenzyme and substrate-bound enzyme, a substrate-induced conformational transition, which might play an important role in activity regulation, was discovered. Furthermore, the position of the guanidinium group of the bound substrate relative to the side chains of His(278), Asp(280), and Asp(166) indicated that these residues mediate multiple proton transfers. His(278) and Asp(280), which are positioned to activate the water nucleophile in the hydrolysis of the S-alkylthiouronium intermediate, were replaced with alanine to stabilize the intermediate for structure determination. The structures determined for the H278A and D280A mutants co-crystallized with L-arginine provide a snapshot of the S-alkylthiouronium adduct formed by attack of Cys406 on the guanidinium carbon of L-arginine followed by the elimination of ammonia. Asp280 and Asp166 engage in ionic interactions with the guanidinium group in the C406A ADI center dot L-arginine structure and might orient the reaction center and participate in proton transfer. Structure determination of D166A revealed the apoD166A ADI. The collection of structures is interpreted in the context of recent biochemical data to propose a model for ADI substrate recognition and catalysis.	Univ Maryland, Maryland Biotechnol Inst, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA; Univ New Mexico, Dept Chem, Albuquerque, NM 87131 USA	University of New Mexico	Herzberg, O (corresponding author), Univ Maryland, Maryland Biotechnol Inst, Ctr Adv Res Biotechnol, 9600 Gudelsky Dr, Rockville, MD 20850 USA.	osnat@carb.nist.gov		Herzberg, Osnat/0000-0003-2823-7627	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI059733] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028688, P01GM057890] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI59733] Funding Source: Medline; NIGMS NIH HHS [P01 GM57890, R01 GM28688] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arita K, 2004, NAT STRUCT MOL BIOL, V11, P777, DOI 10.1038/nsmb799; Beloussow K, 2002, CANCER LETT, V183, P155, DOI 10.1016/S0304-3835(01)00793-5; Bhattacharyya R, 2003, J PROTEOME RES, V2, P255, DOI 10.1021/pr025584d; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Das K, 2004, STRUCTURE, V12, P657, DOI 10.1016/j.str.2004.02.017; DeLano WL, 2002, PYMOL USERS MANUAL; Fritsche E, 1998, BIOCHEMISTRY-US, V37, P17664, DOI 10.1021/bi981949p; Galkin A, 2004, J BIOL CHEM, V279, P14001, DOI 10.1074/jbc.M313410200; Humm A, 1997, EMBO J, V16, P3373, DOI 10.1093/emboj/16.12.3373; Kleywegt GJ, 1999, ACTA CRYSTALLOGR D, V55, P941, DOI 10.1107/S0907444999001031; Knodler LA, 1998, J BIOL CHEM, V273, P4470, DOI 10.1074/jbc.273.8.4470; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leiper JM, 1999, BIOCHEM J, V343, P209, DOI 10.1042/0264-6021:3430209; Lu XF, 2004, J AM CHEM SOC, V126, P5374, DOI 10.1021/ja049543p; Murray-Rust J, 2001, NAT STRUCT BIOL, V8, P679, DOI 10.1038/90387; Nakayama-Hamada M, 2005, BIOCHEM BIOPH RES CO, V327, P192, DOI 10.1016/j.bbrc.2004.11.152; Stone EA, 2005, BIOCHEMISTRY-US, V44, P7069, DOI 10.1021/bi047407r; WEICKMANN JL, 1977, J BIOL CHEM, V252, P2615; Wheatley Denys N., 2002, Pathology and Oncology Research, V8, P18; Zuniga M, 2002, MOL PHYLOGENET EVOL, V25, P429, DOI 10.1016/S1055-7903(02)00277-4	20	63	65	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34080	34087		10.1074/jbc.M505471200	http://dx.doi.org/10.1074/jbc.M505471200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16091358	hybrid			2022-12-25	WOS:000232229700048
J	Kruse, O; Rupprecht, J; Bader, KP; Thomas-Hall, S; Schenk, PM; Finazzi, G; Hankamer, B				Kruse, O; Rupprecht, J; Bader, KP; Thomas-Hall, S; Schenk, PM; Finazzi, G; Hankamer, B			Improved photobiological H-2 production in engineered green algal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLAMYDOMONAS-REINHARDTII; NUCLEAR TRANSFORMATION; STATE TRANSITIONS; OXYGEN EVOLUTION; CLIMATE-CHANGE; LIGHT; FLUORESCENCE; HYDROGENASE; GENE; IRON	Oxygenic photosynthetic organisms use solar energy to split water (H2O) into protons (H+), electrons (e(-)), and oxygen. A select group of photosynthetic microorganisms, including the green alga Chlamydomonas reinhardtii, has evolved the additional ability to redirect the derived H+ and e(-) to drive hydrogen (H-2) production via the chloroplast hydrogenases HydA1 and A2 (H(2)ase). This process occurs under anaerobic conditions and provides a biological basis for solar-driven H-2 production. However, its relatively poor yield is a major limitation for the economic viability of this process. To improve H-2 production in Chlamydomonas, we have developed a new approach to increase H+ and e(-) supply to the hydrogenases. In a first step, mutants blocked in the state 1 transition were selected. These mutants are inhibited in cyclic e(-) transfer around photosystem I, eliminating possible competition for e(-) with H(2)ase. Selected strains were further screened for increased H-2 production rates, leading to the isolation of Stm6. This strain has a modified respiratory metabolism, providing it with two additional important properties as follows: large starch reserves ( i.e. enhanced substrate availability), and a low dissolved O-2 concentration (40% of the wild type (WT)), resulting in reduced inhibition of H2ase activation. The H-2 production rates of Stm6 were 5 - 13 times that of the control WT strain over a range of conditions ( light intensity, culture time, +/- uncoupler). Typically, similar to 540 ml of H-2 liter(-1) culture ( up to 98% pure) were produced over a 10-14-day period at a maximal rate of 4 ml h(-1) ( efficiency = similar to 5 times the WT). Stm6 therefore represents an important step toward the development of future solar-powered H-2 production systems.	Univ Bielefeld, Dept Biol 8, D-33501 Bielefeld, Germany; Inst Biol Physicochim, CNRS, UPR 1261, F-75005 Paris, France; Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia; Univ Queensland, Fac Biol & Chem Sci, St Lucia, Qld 4072, Australia	University of Bielefeld; Centre National de la Recherche Scientifique (CNRS); University of Queensland; University of Queensland	Kruse, O (corresponding author), Univ Bielefeld, Dept Biol 8, D-33501 Bielefeld, Germany.	olaf.kruse@uni-bielefeld.de	Schenk, Peer/B-7879-2016; Hankamer, Ben D/C-9688-2015; Kruse, Olaf/O-1127-2015	Schenk, Peer/0000-0003-4878-3799; Hankamer, Ben D/0000-0001-9284-4929; Thomas-Hall, Skye/0000-0002-4208-5992; Kruse, Olaf/0000-0001-9874-382X				ABRAHAM S, 2002, NATL HYDROGEN ENERGY; ADAMS MWW, 1990, BIOCHIM BIOPHYS ACTA, V1020, P115, DOI 10.1016/0005-2728(90)90044-5; ALLEN JF, 1981, NATURE, V291, P25, DOI 10.1038/291025a0; Antal TK, 2003, BBA-BIOENERGETICS, V1607, P153, DOI 10.1016/j.bbabio.2003.09.008; BARBER J, 1992, TRENDS BIOCHEM SCI, V17, P61, DOI 10.1016/0968-0004(92)90503-2; BENDALL DS, 1982, BIOCHIM BIOPHYS ACTA, V683, P119, DOI 10.1016/0304-4173(82)90008-8; BENNOUN P, 1970, BIOCHIM BIOPHYS ACTA, V216, P357, DOI 10.1016/0005-2728(70)90227-6; BONAVENTURA C, 1969, BIOCHIM BIOPHYS ACTA, V189, P366, DOI 10.1016/0005-2728(69)90168-6; BULTE L, 1990, BIOCHIM BIOPHYS ACTA, V1020, P72, DOI 10.1016/0005-2728(90)90095-L; BUTLER WL, 1978, ANNU REV PLANT PHYS, V29, P345, DOI 10.1146/annurev.pp.29.060178.002021; Cournac L, 2004, J BACTERIOL, V186, P1737, DOI 10.1128/JB.186.6.1737-1746.2003; DEBUCHY R, 1989, EMBO J, V8, P2803, DOI 10.1002/j.1460-2075.1989.tb08426.x; DEFFEYES KS, 2001, HUBBERTS PEAK IMPEND, P5; Depege N, 2003, SCIENCE, V299, P1572, DOI 10.1126/science.1081397; Engels A, 1997, BBA-PROTEIN STRUCT M, V1340, P33, DOI 10.1016/S0167-4838(97)00025-3; Finazzi G, 2003, EMBO J, V22, P807, DOI 10.1093/emboj/cdg081; Finazzi G, 2002, EMBO REP, V3, P280, DOI 10.1093/embo-reports/kvf047; Florin L, 2001, J BIOL CHEM, V276, P6125, DOI 10.1074/jbc.M008470200; Forestier M, 2003, EUR J BIOCHEM, V270, P2750, DOI 10.1046/j.1432-1033.2003.03656; FRANK K, 1995, PHOTOCHEM PHOTOBIOL, V61, P2, DOI 10.1111/j.1751-1097.1995.tb09237.x; Ghirardi ML, 2000, TRENDS BIOTECHNOL, V18, P506, DOI 10.1016/S0167-7799(00)01511-0; Gumpel Nicola J., 1994, Trends in Cell Biology, V4, P299, DOI 10.1016/0962-8924(94)90222-4; HANKAMER B, 2005, Patent No. 2005003024; HAPPE T, 1993, EUR J BIOCHEM, V214, P475, DOI 10.1111/j.1432-1033.1993.tb17944.x; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; HELDT HW, 1973, BIOCHIM BIOPHYS ACTA, V314, P224, DOI 10.1016/0005-2728(73)90137-0; KINDLE KL, 1989, J CELL BIOL, V109, P2589, DOI 10.1083/jcb.109.6.2589; Kosourov S, 2003, PLANT CELL PHYSIOL, V44, P146, DOI 10.1093/pcp/pcg020; Kruse O, 1999, PHOTOSYNTH RES, V61, P43, DOI 10.1023/A:1006229308606; Lyon EJ, 2004, EUR J BIOCHEM, V271, P195, DOI 10.1046/j.1432-1033.2003.03920.x; Melis A, 2001, PLANT PHYSIOL, V127, P740, DOI 10.1104/pp.127.3.740; Melis A, 2000, PLANT PHYSIOL, V122, P127, DOI 10.1104/pp.122.1.127; MELIS A, 1999, P 1999 US DOE HYDR P, P1; MURATA N, 1969, BIOCHIM BIOPHYS ACTA, V172, P242, DOI 10.1016/0005-2728(69)90067-X; O'Neill BC, 2002, SCIENCE, V296, P1971, DOI 10.1126/science.1071238; Peters JW, 1999, CURR OPIN STRUC BIOL, V9, P670, DOI 10.1016/S0959-440X(99)00028-7; Peters JW, 1998, SCIENCE, V282, P1853, DOI 10.1126/science.282.5395.1853; Petit JR, 1999, NATURE, V399, P429, DOI 10.1038/20859; Posewitz MC, 2004, PLANT CELL, V16, P2151, DOI 10.1105/tpc.104.021972; PURTON S, 1995, EUR J PHYCOL, V30, P141, DOI 10.1080/09670269500650901; RIFKIN J, 2002, HYDROGEN EC, P64; Schonfeld C, 2004, J BIOL CHEM, V279, P50366, DOI 10.1074/jbc.M408477200; Thomas CD, 2004, NATURE, V427, P145, DOI 10.1038/nature02121; Wollman FA, 2001, EMBO J, V20, P3623, DOI 10.1093/emboj/20.14.3623; Zhang LP, 2002, PLANTA, V214, P552, DOI 10.1007/s004250100660	45	246	260	4	66	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34170	34177		10.1074/jbc.M503840200	http://dx.doi.org/10.1074/jbc.M503840200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16100118	hybrid			2022-12-25	WOS:000232229700058
J	Parri, M; Buricchi, F; Taddei, ML; Giannoni, E; Raugei, G; Ramponi, G; Chiarugi, P				Parri, M; Buricchi, F; Taddei, ML; Giannoni, E; Raugei, G; Ramponi, G; Chiarugi, P			EphrinA1 repulsive response is regulated by an EphA2 tyrosine phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE; OVEREXPRESSION; ACTIVATION; RECEPTORS; FAMILY; ADHESION; PTP; PHOSPHORYLATION; TUMORIGENICITY; PROTEINS	Ephrin kinases and their ephrin ligands transduce repulsion of cells in axon guidance, migration, invasiveness, and tumor growth, exerting a negative signaling on cell proliferation and adhesion. A key role of their kinase activity has been confirmed by mutant kinase inactive receptors that shift the cellular response from repulsion to adhesion. Our present study aimed to investigate the role of low molecular weight protein-tyrosine phosphatase (LMW-PTP) in ephrinA1/EphA2 signaling. LMW-PTP, by means of dephosphorylation of EphA2 kinase, negatively regulates the ephrinA1-mediated repulsive response, cell proliferation, cell adhesion and spreading, and the formation of retraction fibers, thereby confirming the relevance of the net level of tyrosine phosphorylation of Eph receptors. LMW-PTP interferes with ephrin-mediated mitogen-activated protein kinase signaling likely through inhibition of p120RasGAP binding to the activated EphA2 kinase, thereby confirming the key role of mitogen-activated protein kinase inhibition by ephrinA1 repulsive signaling. We conclude that LMW-PTP acts as a terminator of EphA2 signaling causing an efficient negative feedback loop on the biological response mediated by ephrinA1 and pointing on tyrosine phosphorylation as the main event orchestrating the repulsive response.	Univ Florence, Dept Biochem Sci, I-50134 Florence, Italy; Univ Florence, Ctr Res Transfer & High Educ Study Mol & Clin Lev, I-50134 Florence, Italy	University of Florence; University of Florence	Chiarugi, P (corresponding author), Univ Florence, Dept Biochem Sci, Viale Morgagni 50, I-50134 Florence, Italy.	paola.chiarugi@unifi.it	Chiarugi, Paola/CDD-7988-2022; Giannoni, Elisa/AAE-2092-2020	Giannoni, Elisa/0000-0001-7136-1098; Chiarugi, Paola/0000-0001-7655-2969; raugei, giovanni/0000-0003-1294-786X				Baker RK, 2003, DEV DYNAM, V228, P128, DOI 10.1002/dvdy.10354; Bernards A, 2004, TRENDS CELL BIOL, V14, P377, DOI 10.1016/j.tcb.2004.05.003; Binns KL, 2000, MOL CELL BIOL, V20, P4791, DOI 10.1128/MCB.20.13.4791-4805.2000; Chiarugi P, 2004, ONCOGENE, V23, P3905, DOI 10.1038/sj.onc.1207508; Dodelet VC, 2000, ONCOGENE, V19, P5614, DOI 10.1038/sj.onc.1203856; EASTY DJ, 1995, INT J CANCER, V60, P129, DOI 10.1002/ijc.2910600119; Elowe S, 2001, MOL CELL BIOL, V21, P7429, DOI 10.1128/MCB.21.21.7429-7441.2001; Erdmann KS, 2003, EUR J BIOCHEM, V270, P4789, DOI 10.1046/j.1432-1033.2003.03895.x; Fukushima N, 2002, MOL CELL NEUROSCI, V20, P271, DOI 10.1006/mcne.2002.1123; Giannoni E., 2000, Molecular Cell Biology Research Communications, V3, P264, DOI 10.1006/mcbr.2000.0228; Gu C, 2001, MOL CELL BIOL, V21, P4579, DOI 10.1128/MCB.21.14.4579-4597.2001; Harrington RJ, 2002, DEVELOPMENT, V129, P2141; Holder N, 1999, DEVELOPMENT, V126, P2033; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; Holmberg J, 2000, NATURE, V408, P203, DOI 10.1038/35041577; Holmberg J, 2002, TRENDS NEUROSCI, V25, P239, DOI 10.1016/S0166-2236(02)02149-5; Kikawa KD, 2002, J BIOL CHEM, V277, P39274, DOI 10.1074/jbc.M207127200; Kim I, 2002, FASEB J, V16, P1126, DOI 10.1096/fj.01-0805fje; KIYOKAWA E, 1994, CANCER RES, V54, P3645; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Miao H, 2005, J BIOL CHEM, V280, P923, DOI 10.1074/jbc.M411383200; Miao H, 2003, J CELL BIOL, V162, P1281, DOI 10.1083/jcb.200304018; Miao H, 2001, NAT CELL BIOL, V3, P527, DOI 10.1038/35074604; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; MITCHISON TJ, 1992, CELL MOTIL CYTOSKEL, V22, P135, DOI 10.1002/cm.970220207; Nagashima KI, 2002, MOL BIOL CELL, V13, P4231, DOI 10.1091/mbc.E02-04-0181; Nakamoto M, 2002, MICROSC RES TECHNIQ, V59, P58, DOI 10.1002/jemt.10177; Palmer A, 2002, MOL CELL, V9, P725, DOI 10.1016/S1097-2765(02)00488-4; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pratt RL, 2002, ONCOGENE, V21, P7690, DOI 10.1038/sj.onc.1205758; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; Tang XX, 2000, P NATL ACAD SCI USA, V97, P10936, DOI 10.1073/pnas.190123297; Tong JF, 2003, J BIOL CHEM, V278, P6111, DOI 10.1074/jbc.M208972200; Varelias A, 2002, CANCER, V95, P862, DOI 10.1002/cncr.10749; Vindis C, 2003, J CELL BIOL, V162, P661, DOI 10.1083/jcb.200302073; Vogt T, 1998, CLIN CANCER RES, V4, P791; Walker-Daniels J, 2002, MOL CANCER RES, V1, P79; Walker-Daniels J, 1999, PROSTATE, V41, P275, DOI 10.1002/(SICI)1097-0045(19991201)41:4<275::AID-PROS8>3.0.CO;2-T; Wilkinson DG, 2001, NAT REV NEUROSCI, V2, P155, DOI 10.1038/35058515; Wybenga-Groot LE, 2001, CELL, V106, P745, DOI 10.1016/S0092-8674(01)00496-2; Xu Z, 2003, J BIOL CHEM, V278, P24767, DOI 10.1074/jbc.M302454200; Zelinski DP, 2001, CANCER RES, V61, P2301	42	65	68	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34008	34018		10.1074/jbc.M502879200	http://dx.doi.org/10.1074/jbc.M502879200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16051609	hybrid, Green Published			2022-12-25	WOS:000232229700039
J	Chou, YT; Gierasch, LM				Chou, YT; Gierasch, LM			The conformation of a signal peptide bound by Escherichia coli preprotein translocase SecA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATPASE ACTIVITY; PROTEIN EXPORT; PRECURSOR PROTEINS; HYDROPHOBIC REGION; CATALYTIC CYCLE; MODEL MEMBRANES; MATURE REGION; WILD-TYPE; SEQUENCE; BINDING	To understand the structural nature of signal sequence recognition by the preprotein translocase SecA, we have characterized the interactions of a signal peptide corresponding to a LamB signal sequence (modified to enhance aqueous solubility) with SecA by NMR methods. One-dimensional NMR studies showed that the signal peptide binds SecA with a moderately fast exchange rate ( K-d similar to 10(-5) (M)). The line-broadening effects observed from one-dimensional and two-dimensional NMR spectra indicated that the binding mode does not equally immobilize all segments of this peptide. The positively charged arginine residues of the n-region and the hydrophobic residues of the h-region had less mobility than the polar residues of the c-region in the SecA-bound state, suggesting that this peptide has both electrostatic and hydrophobic interactions with the binding pocket of SecA. Transferred nuclear Over-hauser experiments revealed that the h-region and part of the c-region of the signal peptide form an alpha helical conformation upon binding to SecA. One side of the hydrophobic core of the helical h-region appeared to be more strongly bound in the binding pocket, whereas the extreme C terminus of the peptide was not intimately involved. These results argue that the positive charges at the n-region and the hydrophobic helical h-region are the selective features for recognition of signal sequences by SecA and that the signal peptide-binding site on SecA is not fully buried within its structure.	Univ Massachusetts, Dept Biochem & Mol Biol, Amherst, MA 01003 USA; Univ Massachusetts, Dept Chem, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst	Gierasch, LM (corresponding author), Univ Massachusetts, Dept Biochem & Mol Biol, Amherst, MA 01003 USA.	gierasch@biochem.umass.edu	Gierasch, Lila M/D-1494-2009		NIGMS NIH HHS [GM034962] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034962] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baud C, 2005, PROTEIN EXPRES PURIF, V40, P336, DOI 10.1016/j.pep.2004.12.009; Baud C, 2002, J BIOL CHEM, V277, P13724, DOI 10.1074/jbc.M200047200; Benach J, 2003, J BIOL CHEM, V278, P3628, DOI 10.1074/jbc.M205992200; BIEKER KL, 1990, CELL, V61, P833, DOI 10.1016/0092-8674(90)90193-I; BREUKINK E, 1995, J BIOL CHEM, V270, P7902, DOI 10.1074/jbc.270.14.7902; BRIGGS MS, 1986, SCIENCE, V233, P206, DOI 10.1126/science.2941862; BRIGGS MS, 1984, BIOCHEMISTRY-US, V23, P3111, DOI 10.1021/bi00309a001; BRUCH MD, 1990, J BIOL CHEM, V265, P3851; BRUCH MD, 1989, BIOCHEMISTRY-US, V28, P8554, DOI 10.1021/bi00447a043; CAMPBELL AP, 1993, ANNU REV BIOPH BIOM, V22, P99, DOI 10.1146/annurev.bb.22.060193.000531; Cavanagh John, 1996, P95; Chou YT, 2002, J BIOL CHEM, V277, P50985, DOI 10.1074/jbc.M209237200; CLORE GM, 1983, J MAGN RESON, V53, P423, DOI 10.1016/0022-2364(83)90215-9; CLORE GM, 1982, J MAGN RESON, V48, P402, DOI 10.1016/0022-2364(82)90073-7; CUNNINGHAM K, 1989, P NATL ACAD SCI USA, V86, P8630, DOI 10.1073/pnas.86.22.8630; Dalbey RE, 2004, BBA-MOL CELL RES, V1694, P37, DOI 10.1016/j.bbamcr.2004.03.009; DERMAN AI, 1993, EMBO J, V12, P879, DOI 10.1002/j.1460-2075.1993.tb05728.x; Duong F, 1999, EMBO J, V18, P3263, DOI 10.1093/emboj/18.12.3263; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; EMR SD, 1981, CELL, V23, P79, DOI 10.1016/0092-8674(81)90272-5; EMR SD, 1983, P NATL ACAD SCI-BIOL, V80, P4599, DOI 10.1073/pnas.80.15.4599; Fekkes P, 1999, MICROBIOL MOL BIOL R, V63, P161, DOI 10.1128/MMBR.63.1.161-173.1999; FLOWER AM, 1994, J BACTERIOL, V176, P5607, DOI 10.1128/JB.176.18.5607-5614.1994; GENNITY J, 1990, J BIOENERG BIOMEMBR, V22, P233, DOI 10.1007/BF00763167; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; GOLDSTEIN J, 1991, J BIOL CHEM, V266, P14413; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HOYT DW, 1991, J BIOL CHEM, V266, P14406; Hunt JF, 2002, SCIENCE, V297, P2018, DOI 10.1126/science.1074424; Izard JW, 1996, J BIOL CHEM, V271, P21579, DOI 10.1074/jbc.271.35.21579; IZARD JW, 1994, MOL MICROBIOL, V13, P765, DOI 10.1111/j.1365-2958.1994.tb00469.x; KIMURA E, 1991, J BIOL CHEM, V266, P6600; Kourtz L, 2000, MOL MICROBIOL, V37, P1342, DOI 10.1046/j.1365-2958.2000.02078.x; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LIAN LY, 1994, METHOD ENZYMOL, V239, P657; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; MCKNIGHT CJ, 1991, P NATL ACAD SCI USA, V88, P5799, DOI 10.1073/pnas.88.13.5799; MCKNIGHT CJ, 1989, J BIOL CHEM, V264, P17293; Miller A, 1998, J BIOL CHEM, V273, P11409, DOI 10.1074/jbc.273.19.11409; Mori H, 1997, BBA-BIOMEMBRANES, V1326, P23, DOI 10.1016/S0005-2736(97)00004-7; Or E, 2002, EMBO J, V21, P4470, DOI 10.1093/emboj/cdf471; Osborne AR, 2004, P NATL ACAD SCI USA, V101, P10937, DOI 10.1073/pnas.0401742101; RIZO J, 1993, BIOCHEMISTRY-US, V32, P4881, DOI 10.1021/bi00069a025; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; Schmidt M, 2000, J BIOL CHEM, V275, P15440, DOI 10.1074/jbc.M000605200; Sharma V, 2003, P NATL ACAD SCI USA, V100, P2243, DOI 10.1073/pnas.0538077100; Sianidis G, 2001, EMBO J, V20, P961, DOI 10.1093/emboj/20.5.961; STADER J, 1986, J BIOL CHEM, V261, P5075; Triplett TL, 2001, J BIOL CHEM, V276, P19648, DOI 10.1074/jbc.M100098200; ULBRANDT ND, 1992, J BIOL CHEM, V267, P15184; van der Wolk JPW, 1998, EMBO J, V17, P3631, DOI 10.1093/emboj/17.13.3631; van der Wolk JPW, 1997, EMBO J, V16, P7297, DOI 10.1093/emboj/16.24.7297; Veenendaal AKJ, 2004, BBA-MOL CELL RES, V1694, P81, DOI 10.1016/j.bbamcr.2004.02.009; Vrontou E, 2004, BBA-MOL CELL RES, V1694, P67, DOI 10.1016/j.bbamcr.2004.06.003; Wang LG, 2000, J BIOL CHEM, V275, P10154, DOI 10.1074/jbc.275.14.10154; Wang ZL, 1999, BIOCHEMISTRY-US, V38, P12537, DOI 10.1021/bi991070p; WANG ZL, 1993, BIOCHEMISTRY-US, V32, P13991, DOI 10.1021/bi00213a032; Wuthrich K, 1986, NMR PROTEINS NUCL AC, P27	58	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32753	32760		10.1074/jbc.M507532200	http://dx.doi.org/10.1074/jbc.M507532200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16046390	hybrid			2022-12-25	WOS:000231920300026
J	Thomas, M; Massimi, P; Navarro, C; Borg, JP; Banks, L				Thomas, M; Massimi, P; Navarro, C; Borg, JP; Banks, L			The hScrib/Dlg apico-basal control complex is differentially targeted by HPV-16 and HPV-18 E6 proteins	ONCOGENE			English	Article						HPV; PDZ proteins; tumour suppressor; polarity	LARGE TUMOR-SUPPRESSOR; PROTEASOME-MEDIATED DEGRADATION; LETHAL-GIANT-LARVAE; PROLIFERATION CONTROL; DROSOPHILA EPITHELIA; MUTATIONAL ANALYSIS; HUMAN SCRIBBLE; CELL POLARITY; HUMAN HOMOLOG; PDZ DOMAIN	The E6 proteins of the high-risk Human papillomaviruses (HPV) types have a well-documented ability to target certain cellular proteins for ubiquitin-mediated degradation via the proteasome. Previous studies have shown that E6 proteins interact differently with different target proteins, and that the viral proteins, depending upon the target, may recruit diverse cellular ubiquitin-protein ligases. In this study, we have examined the abilities of E6 proteins from HPV-16 and HPV-18 to interact with and induce the degradation of two PDZ domain-containing targets, Dlg and hScrib. We have also mapped the binding site of E6 on hScrib and shown that the interaction of E6 with hScrib is distinct from its interactions with other PDZ domain-containing targets. This is reflected in the efficiency with which the two viral E6 proteins can inhibit hScrib's suppression of cell transformation. Dlg and hScrib have complementary activities in the control of epithelial cell polarity and the fact that both are targeted by high-risk HPV E6 proteins underlines their importance. Our finding that they are each targeted differently by HPV-16 and HPV-18 E6s suggests that the two viruses are subjected to somewhat different constraints and provides a possible explanation for the apparent redundancy in targeting both parts of this important control mechanism.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; Inst J Paoli I Calmettes, INSERM, INst Rech Canc Marseille, UMR 599, F-13009 Marseille, France	International Center for Genetic Engineering & Biotechnology (ICGEB); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC)	Banks, L (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.	banks@icgeb.org	Borg, Jean-Paul/AAX-8096-2020	Borg, Jean-Paul/0000-0001-8418-3382				Albertson R, 2003, NAT CELL BIOL, V5, P166, DOI 10.1038/ncb922; Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; Bilder D, 2003, NAT CELL BIOL, V5, P53, DOI 10.1038/ncb897; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Bryant PJ, 2000, NAT CELL BIOL, V2, pE141, DOI 10.1038/35019616; Cavatorta AL, 2004, INT J CANCER, V111, P373, DOI 10.1002/ijc.20275; Dobrosotskaya IY, 2001, BIOCHEM BIOPH RES CO, V283, P969, DOI 10.1006/bbrc.2001.4880; Dobrosotskaya IY, 2000, BIOCHEM BIOPH RES CO, V270, P903, DOI 10.1006/bbrc.2000.2471; Dow LE, 2003, ONCOGENE, V22, P9225, DOI 10.1038/sj.onc.1207154; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Gardiol D, 2002, J GEN VIROL, V83, P283, DOI 10.1099/0022-1317-83-2-283; Glaunsinger BA, 2000, ONCOGENE, V19, P5270, DOI 10.1038/sj.onc.1203906; Grifoni D, 2004, ONCOGENE, V23, P8688, DOI 10.1038/sj.onc.1208023; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; Humbert P, 2003, BIOESSAYS, V25, P542, DOI 10.1002/bies.10286; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Legouis R, 2003, EMBO REP, V4, P1096, DOI 10.1038/sj.embor.7400006; Massimi P, 2004, ONCOGENE, V23, P8033, DOI 10.1038/sj.onc.1207977; Massimi P, 2003, EXP CELL RES, V290, P265, DOI 10.1016/S0014-4827(03)00317-3; Mathew D, 2002, CURR BIOL, V12, P531, DOI 10.1016/S0960-9822(02)00758-3; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Nakagawa S, 2004, BRIT J CANCER, V90, P194, DOI 10.1038/sj.bjc.6601465; Navarro C, 2005, ONCOGENE, V24, P4330, DOI 10.1038/sj.onc.1208632; Petit MM, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-1; Pim D, 2000, ONCOGENE, V19, P719, DOI 10.1038/sj.onc.1203374; Pim D, 2002, ONCOGENE, V21, P8140, DOI 10.1038/sj.onc.1206026; PIM D, 1994, ONCOGENE, V9, P1869; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; Tanentzapf G, 2003, NAT CELL BIOL, V5, P46, DOI 10.1038/ncb896; Thomas M, 2001, ONCOGENE, V20, P5431, DOI 10.1038/sj.onc.1204719; Thomas M, 1999, MOL CELL BIOL, V19, P1092; Thomas M, 2002, ONCOGENE, V21, P5088, DOI 10.1038/sj.onc.1205668; Thomas U, 1997, MECH DEVELOP, V62, P161, DOI 10.1016/S0925-4773(97)00658-8; Watson RA, 2003, J CELL SCI, V116, P4925, DOI 10.1242/jcs.00809; Watson RA, 2002, CARCINOGENESIS, V23, P1791, DOI 10.1093/carcin/23.11.1791; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; Woods DF, 1997, DEV GENET, V20, P111, DOI 10.1002/(SICI)1520-6408(1997)20:2<111::AID-DVG4>3.3.CO;2-O; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X	40	100	101	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	41					6222	6230		10.1038/sj.onc.1208757	http://dx.doi.org/10.1038/sj.onc.1208757			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964JM	16103886				2022-12-25	WOS:000231877100003
J	Patterson, HM; Brannigan, JA; Cutting, SM; Wilson, KS; Wilkinson, AJ; AB, E; Diercks, T; de Jong, RN; Truffault, V; Folkers, GE; Kaptein, R				Patterson, HM; Brannigan, JA; Cutting, SM; Wilson, KS; Wilkinson, AJ; AB, E; Diercks, T; de Jong, RN; Truffault, V; Folkers, GE; Kaptein, R			The structure of bypass of forespore C, an intercompartmental signaling factor during sporulation in Bacillus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; TORSION ANGLE DYNAMICS; CHEMICAL-SHIFT INDEX; GENE-EXPRESSION; MOTHER-CELL; SPORE FORMATION; SUBTILIS; PRO-SIGMA(K); SPOIVB; ASSIGNMENT	Sporulation in Bacillus subtilis begins with an asymmetric cell division giving rise to smaller forespore and larger mother cell compartments. Different programs of gene expression are subsequently directed by compartment-specific RNA polymerase sigma-factors. In the final stages, spore coat proteins are synthesized in the mother cell under the control of RNA polymerase containing sigma(K), (E sigma(K)). sigma(K) is synthesized as an inactive zymogen, pro-sigma(K), which is activated by proteolytic cleavage. Processing of pro-sigma(K) is performed by SpoIVFB, a metalloprotease that resides in a complex with SpoIVFA and bypass of forespore (Bof) A in the outer forespore membrane. Ensuring coordination of events taking place in the two compartments, pro-sigma(K) processing in the mother cell is delayed until appropriate signals are received from the forespore. Cell-cell signaling is mediated by SpoIVB and BofC, which are expressed in the forespore and secreted to the intercompartmental space where they regulate pro-sigma(K) processing by mechanisms that are not yet fully understood. Here we present the three-dimensional structure of BofC determined by solution state NMR. BofC is a monomer made up of two domains. The N-terminal domain, containing a four-stranded beta-sheet onto one face of which an alpha-helix is packed, closely resembles the third immunoglobulin-binding domain of protein G from Streptococcus. The C-terminal domain contains a three-stranded beta-sheet and three alpha-helices in a novel domain topology. The sequence connecting the domains contains a conserved DISP motif to which mutations that affect BofC activity map. Possible roles for BofC in the sigma(K) checkpoint are discussed in the light of sequence and structure comparisons.	Univ York, Dept Chem, Struct Biol Lab, York YO10 5YW, N Yorkshire, England; Royal Holloway Univ London, Sch Biol Sci, Egham TW20 0EX, Surrey, England; Univ Utrecht, NMR Dept, Bijvoet Ctr, NL-3584 CH Utrecht, Netherlands	University of York - UK; University of London; Royal Holloway University London; Utrecht University	Wilkinson, AJ (corresponding author), Univ York, Dept Chem, Struct Biol Lab, York YO10 5YW, N Yorkshire, England.	ajw@ysbl.york.ac.uk	Diercks, Tammo/AAT-3731-2021; AB, Eiso/H-8177-2012; Diercks, Tammo/G-1167-2011; Folkers, Gert E/C-2863-2009	Diercks, Tammo/0000-0002-5200-0905; Diercks, Tammo/0000-0002-5200-0905; Folkers, Gert E/0000-0003-1070-0505; Wilkinson, Anthony/0000-0003-4577-9479; AB, Eiso/0000-0002-5758-0435; de Jong, Rob N./0000-0002-9300-6633; Wilson, Keith/0000-0002-3581-2194	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BJORCK L, 1990, BACTERIAL IMMUNOGLOB, V1, P113; Boyle, 1990, BACTERIAL IMMUNOGLOB; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; CUTTING S, 1991, J MOL BIOL, V221, P1237; CUTTING S, 1990, CELL, V62, P239, DOI 10.1016/0092-8674(90)90362-I; DERRICK JP, 1994, J MOL BIOL, V243, P906, DOI 10.1006/jmbi.1994.1691; Diercks T, 1999, J BIOMOL NMR, V15, P177, DOI 10.1023/A:1008367912535; Dong TC, 2004, J BIOL CHEM, V279, P43468, DOI 10.1074/jbc.M407048200; Dong TC, 2003, MOL MICROBIOL, V49, P1425, DOI 10.1046/j.1365-2958.2003.03651.x; Furrer J, 2004, J MAGN RESON, V166, P39, DOI 10.1016/j.jmr.2003.09.013; Gomez M, 1997, MICROBIOL-UK, V143, P157, DOI 10.1099/00221287-143-1-157; GOMEZ M, 1995, J BACTERIOL, V177, P4825, DOI 10.1128/jb.177.16.4825-4827.1995; Green DH, 2000, J BACTERIOL, V182, P278, DOI 10.1128/JB.182.2.278-285.2000; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Hilbert DW, 2004, MICROBIOL MOL BIOL R, V68, P234, DOI 10.1128/MMBR.68.2.234-262.2004; Hoa NT, 2002, J BACTERIOL, V184, P191, DOI 10.1128/JB.184.1.191-199.2002; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; KADKHODAIE M, 1991, J MAGN RESON, V91, P437, DOI 10.1016/0022-2364(91)90210-K; Kroos L, 2002, J BACTERIOL, V184, P5393, DOI 10.1128/JB.184.19.5393-5401.2002; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leutner M, 1998, J BIOMOL NMR, V11, P31, DOI 10.1023/A:1008298226961; LOSICK R, 1992, NATURE, V355, P601, DOI 10.1038/355601a0; LU SJ, 1990, P NATL ACAD SCI USA, V87, P9722, DOI 10.1073/pnas.87.24.9722; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; Munoz E, 1998, EUR J IMMUNOL, V28, P2591, DOI 10.1002/(SICI)1521-4141(199808)28:08<2591::AID-IMMU2591>3.0.CO;2-P; Nagarajan Vasantha, 1993, P713; Nederveen AJ, 2005, PROTEINS, V59, P662, DOI 10.1002/prot.20408; Oke V, 1997, MOL MICROBIOL, V23, P223, DOI 10.1046/j.1365-2958.1997.2091573.x; Piggot PJ, 2004, CURR OPIN MICROBIOL, V7, P579, DOI 10.1016/j.mib.2004.10.001; Prehoda KE, 1999, CELL, V97, P471, DOI 10.1016/S0092-8674(00)80757-6; Resnekov O, 1998, P NATL ACAD SCI USA, V95, P3162, DOI 10.1073/pnas.95.6.3162; Rudner DZ, 2002, GENE DEV, V16, P1007, DOI 10.1101/gad.977702; Stragier P, 1996, ANNU REV GENET, V30, P297, DOI 10.1146/annurev.genet.30.1.297; Stragier P., 2002, BACILLUS SUBTILIS IT, P519; Tjalsma H, 2004, MICROBIOL MOL BIOL R, V68, P207, DOI 10.1128/MMBR.68.2.207-233.2004; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wakeley P, 2000, MOL MICROBIOL, V36, P1415, DOI 10.1046/j.1365-2958.2000.01962.x; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Yu YTN, 2000, J BACTERIOL, V182, P3305, DOI 10.1128/JB.182.11.3305-3309.2000; Zhang B, 1998, J BACTERIOL, V180, P2434, DOI 10.1128/JB.180.9.2434-2441.1998; Zhou RB, 2004, P NATL ACAD SCI USA, V101, P6385, DOI 10.1073/pnas.0307709101; Zimmerman DE, 1997, J MOL BIOL, V269, P592, DOI 10.1006/jmbi.1997.1052	45	4	5	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36214	36220		10.1074/jbc.M506910200	http://dx.doi.org/10.1074/jbc.M506910200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16049010	hybrid, Green Published			2022-12-25	WOS:000232726900053
J	Amemiya-Kudo, M; Oka, J; Ide, T; Matsuzaka, T; Sone, H; Yoshikawa, T; Yahagi, N; Ishibashi, S; Osuga, J; Yamada, N; Murase, T; Shimano, H				Amemiya-Kudo, M; Oka, J; Ide, T; Matsuzaka, T; Sone, H; Yoshikawa, T; Yahagi, N; Ishibashi, S; Osuga, J; Yamada, N; Murase, T; Shimano, H			Sterol regulatory element-binding proteins activate insulin gene promoter directly and indirectly through synergy with BETA2/E47	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; BETA-CELLS; PANCREATIC-ISLETS; NUCLEAR SREBP-1C; DNA-BINDING; EXPRESSION; LIVER; MICE; STIMULATION; INDUCTION	Insulin gene expression is regulated by pancreatic beta cell-specific factors, PDX-1 and BETA2/E47. Here we have demonstrated that the insulin promoter is a novel target for SREBPs established as lipid-synthetic transcription factors. Promoter analyses of rat insulin I gene in non-beta cells revealed that nuclear SREBP-1c activates the insulin promoter through three novel SREBP-binding sites (SREs), two of which overlap with E-boxes, binding sites for BETA2/ E47. SREBP-1c activation of the insulin promoter was markedly enhanced by co-expression of BETA2/ E47. This synergistic activation by SREBP-1c/ BETA2/ E47 was not mediated through SREs but through the E-boxes on which BETA2/ E47 physically interacts with SREBP-1c, suggesting a novel function of SREBP as a co-activator. These two cis-DNA regions, E1 and E2, with an appropriate distance separating them, were mandatory for the synergism, which implicates formation of SREBP-1c center dot BETA2 center dot E47 complex in a DNA looping structure for efficient recruitment of CREB- binding protein/ p300. However, in the presence of PDX1, the synergistic action of SREBP-1c with BETA2/E47 was canceled. SREBP-1c-mediated activation of the insulin promoter and expression became overt in beta cell lines and isolated islets when endogenous PDX-1 expression was low. This cryptic SREBP-1c action might play a compensatory role in insulin expression in diabetes with beta cell lipotoxicity.	Toranomon Gen Hosp, Okinaka Mem Inst Med Res, Minato Ku, Tokyo 1058470, Japan; Univ Tokyo, Dept Diabet & Metab Dis, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Internal Med Endocrinol & Metab, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058575, Japan	Toranomon Hospital; University of Tokyo; University of Tsukuba; University of Tsukuba	Shimano, H (corresponding author), Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Internal Med, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.	shimano-tky@umin.ac.jp	Shimano, Hitoshi/V-1761-2019; Sone, Hirohito/ABC-9346-2021; Yahagi, Naoya/D-2360-2014; Shimano, Hitoshi/AAI-5648-2020	Shimano, Hitoshi/0000-0002-5562-5572; Sone, Hirohito/0000-0003-1263-2817; Yahagi, Naoya/0000-0002-1823-1865; 				Amemiya-Kudo M, 2002, J LIPID RES, V43, P1220, DOI 10.1194/jlr.M100417-JLR200; Amemiya-Kudo M, 2000, J BIOL CHEM, V275, P31078, DOI 10.1074/jbc.M005353200; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Andreolas C, 2002, DIABETES, V51, P2536, DOI 10.2337/diabetes.51.8.2536; ARONHEIM A, 1993, P NATL ACAD SCI USA, V90, P8063, DOI 10.1073/pnas.90.17.8063; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Chakrabarti SK, 2002, J BIOL CHEM, V277, P13286, DOI 10.1074/jbc.M111857200; Diraison F, 2004, BIOCHEM J, V378, P769, DOI 10.1042/BJ20031277; Ericsson J, 1996, J BIOL CHEM, V271, P24359, DOI 10.1074/jbc.271.40.24359; Flamez D, 2002, DIABETES, V51, P2018, DOI 10.2337/diabetes.51.7.2018; Glick E, 2000, J BIOL CHEM, V275, P2199, DOI 10.1074/jbc.275.3.2199; Horton JD, 2002, BIOCHEM SOC T, V30, P1091, DOI 10.1042/bst0301091; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; Ide T, 2004, NAT CELL BIOL, V6, P351, DOI 10.1038/ncb1111; ItkinAnsari P, 1996, ENDOCRINOLOGY, V137, P3540, DOI 10.1210/en.137.8.3540; Kajihara M, 2003, BIOCHEM BIOPH RES CO, V312, P831, DOI 10.1016/j.bbrc.2003.10.196; Kakuma T, 2000, P NATL ACAD SCI USA, V97, P8536, DOI 10.1073/pnas.97.15.8536; Kaneto H, 2002, J BIOL CHEM, V277, P12998, DOI 10.1074/jbc.M111148200; Kataoka K, 2002, J BIOL CHEM, V277, P49903, DOI 10.1074/jbc.M206796200; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Marshak S, 1996, P NATL ACAD SCI USA, V93, P15057, DOI 10.1073/pnas.93.26.15057; Matsuoka T, 2003, MOL CELL BIOL, V23, P6049, DOI 10.1128/MCB.23.17.6049-6062.2003; Matsuzaka T, 2004, DIABETES, V53, P560, DOI 10.2337/diabetes.53.3.560; Melloul D, 2002, DIABETOLOGIA, V45, P309, DOI 10.1007/s00125-001-0728-y; MELLOUL D, 1993, P NATL ACAD SCI USA, V90, P3865, DOI 10.1073/pnas.90.9.3865; Najima Y, 2005, J BIOL CHEM, V280, P27523, DOI 10.1074/jbc.M414549200; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; Ohneda K, 2000, MOL CELL BIOL, V20, P900, DOI 10.1128/MCB.20.3.900-911.2000; Olbrot M, 2002, P NATL ACAD SCI USA, V99, P6737, DOI 10.1073/pnas.102168499; Oliner JD, 1996, GENE DEV, V10, P2903, DOI 10.1101/gad.10.22.2903; Olson LK, 1998, MOL ENDOCRINOL, V12, P207, DOI 10.1210/me.12.2.207; PERMUTT MA, 1972, J BIOL CHEM, V247, P1194; PETERSEN HV, 1994, P NATL ACAD SCI USA, V91, P10465, DOI 10.1073/pnas.91.22.10465; Qiu Y, 1998, MOL CELL BIOL, V18, P2957, DOI 10.1128/MCB.18.5.2957; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; Sato R, 1999, J BIOL CHEM, V274, P24714, DOI 10.1074/jbc.274.35.24714; SCHLEIF R, 1992, ANNU REV BIOCHEM, V61, P199, DOI 10.1146/annurev.bi.61.070192.001215; Shapiro AMJ, 1996, CELL TRANSPLANT, V5, P631, DOI 10.1016/S0963-6897(96)00084-X; Sharma A, 1999, MOL CELL BIOL, V19, P704; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shimano H, 2002, VITAM HORM, V65, P167, DOI 10.1016/S0083-6729(02)65064-2; Shimomura I, 1999, J BIOL CHEM, V274, P30028, DOI 10.1074/jbc.274.42.30028; Takahashi A, 2005, DIABETES, V54, P492, DOI 10.2337/diabetes.54.2.492; Wang HY, 2003, J BIOL CHEM, V278, P16622, DOI 10.1074/jbc.M212488200; Wolberger C, 1998, CURR OPIN GENET DEV, V8, P552, DOI 10.1016/S0959-437X(98)80010-5; Yamamoto T, 2004, J BIOL CHEM, V279, P12027, DOI 10.1074/jbc.M310333200; Yoshikawa T, 2001, MOL CELL BIOL, V21, P2991, DOI 10.1128/MCB.21.9.2991-3000.2001	50	24	25	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34577	34589		10.1074/jbc.M506718200	http://dx.doi.org/10.1074/jbc.M506718200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16055439	hybrid			2022-12-25	WOS:000232403900026
J	Hsu, IW; Hsu, M; Li, C; Chuang, TW; Lin, RI; Tarn, WY				Hsu, IW; Hsu, M; Li, C; Chuang, TW; Lin, RI; Tarn, WY			Phosphorylation of Y14 modulates its interaction with proteins involved in mRNA metabolism and influences its methylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXON JUNCTION COMPLEX; NONSENSE-MEDIATED DECAY; ARGININE METHYLATION; MAMMALIAN-CELLS; EXPORT; TRANSLATION; BINDS; ASSOCIATION; EXPRESSION; CYTOPLASM	The multicomponent exon junction complex (EJC) is deposited on the spliced mRNA during pre-mRNA splicing and is implicated in several post-splicing events, including mRNA export, nonsense-mediated mRNA decay (NMD), and translation control. This report is the first to identify potential post-translational modifications of the EJC core component Y14. We demonstrate that Y14 is phosphorylated at its repeated arginine/serine (RS) dipeptides, likely by SR protein-specific kinases. Phosphorylation of Y14 abolished its interaction with EJC components as well as factors that function downstream of the EJC. A non-phosphorylatable Y14 mutant was equivalent to the wild-type protein with respect to its association with spliced mRNA and its ability in NMD activation, but the mutant sequestered EJC and NMD factors on ribosome-containing mRNA ribonucleoproteins (mRNPs). We therefore hypothesize that phosphorylation of Y14 occurs upon completion of mRNA surveillance, leading to dissociation of Y14 from ribosome-containing mRNPs. Moreover, we found that Y14 is possibly methylated at multiple arginine residues in the carboxyl-terminal domain and that methylation of Y14 was antagonized by phosphorylation of RS dipeptides. This study reveals antagonistic post-translational modifications of Y14 that may be involved in the remodeling of Y14-containing mRNPs.	Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan; Natl Yang Ming Univ, Inst Anat & Cell Biol, Taipei 11221, Taiwan	Academia Sinica - Taiwan; National Yang Ming Chiao Tung University	Hsu, IW (corresponding author), Acad Sinica, Inst Biomed Sci, 128 Acad Rd,Sect 2, Taipei 11529, Taiwan.	wtarn@ibms.sinica.edu.tw	Tarn, Woan-Yuh/N-8464-2018					Bedford MT, 2005, MOL CELL, V18, P263, DOI 10.1016/j.molcel.2005.04.003; Bono F, 2004, EMBO REP, V5, P304, DOI 10.1038/sj.embor.7400091; Chan CC, 2004, RNA, V10, P200, DOI 10.1261/rna.5230104; Degot S, 2004, J BIOL CHEM, V279, P33702, DOI 10.1074/jbc.M402754200; Dimaano C, 2004, MOL CELL BIOL, V24, P3069, DOI 10.1128/MCB.24.8.3069-3076.2004; Dostie J, 2002, CURR BIOL, V12, P1060, DOI 10.1016/S0960-9822(02)00902-8; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Fribourg S, 2003, NAT STRUCT BIOL, V10, P433, DOI 10.1038/nsb926; Gatfield D, 2002, J CELL BIOL, V159, P579, DOI 10.1083/jcb.200207128; Gehring NH, 2003, MOL CELL, V11, P939, DOI 10.1016/S1097-2765(03)00142-4; Gilbert W, 2004, MOL CELL, V13, P201, DOI 10.1016/S1097-2765(04)00030-9; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Green DM, 2002, J BIOL CHEM, V277, P7752, DOI 10.1074/jbc.M110053200; Huang YQ, 2005, MOL CELL, V17, P613, DOI 10.1016/j.molcel.2005.02.020; Huang YQ, 2004, P NATL ACAD SCI USA, V101, P9666, DOI 10.1073/pnas.0403533101; Huang YQ, 2003, MOL CELL, V11, P837, DOI 10.1016/S1097-2765(03)00089-3; Kataoka N, 2001, EMBO J, V20, P6424, DOI 10.1093/emboj/20.22.6424; Kim VN, 2001, SCIENCE, V293, P1832, DOI 10.1126/science.1062829; Kim VN, 2001, EMBO J, V20, P2062, DOI 10.1093/emboj/20.8.2062; Lai MC, 2004, J BIOL CHEM, V279, P31745, DOI 10.1074/jbc.C400173200; Lai MC, 2003, BIOCHEM J, V371, P937, DOI 10.1042/BJ20021827; Lau CK, 2003, CURR BIOL, V13, P933, DOI 10.1016/S0960-9822(03)00328-2; Le Hir H, 2003, TRENDS BIOCHEM SCI, V28, P215, DOI 10.1016/S0968-0004(03)00052-5; Le Hir H, 2001, EMBO J, V20, P4987, DOI 10.1093/emboj/20.17.4987; Lejeune F, 2002, EMBO J, V21, P3536, DOI 10.1093/emboj/cdf345; Li C, 2003, MOL CELL BIOL, V23, P7363, DOI 10.1128/MCB.23.20.7363-7376.2003; Lu SH, 2003, RNA, V9, P618, DOI 10.1261/rna.5260303; Lukong KE, 2004, NAT STRUCT MOL BIOL, V11, P914, DOI 10.1038/nsmb1004-914; Lykke-Andersen J, 2000, CELL, V103, P1121, DOI 10.1016/S0092-8674(00)00214-2; Maquat LE, 2004, NAT REV MOL CELL BIO, V5, P89, DOI 10.1038/nrm1310; Mingot JM, 2001, EMBO J, V20, P3685, DOI 10.1093/emboj/20.14.3685; Nott A, 2004, GENE DEV, V18, P210, DOI 10.1101/gad.1163204; Palacios IM, 2004, NATURE, V427, P753, DOI 10.1038/nature02351; Pawlak MR, 2002, J CELL BIOCHEM, V87, P394, DOI 10.1002/jcb.10307; Shibuya T, 2004, NAT STRUCT MOL BIOL, V11, P346, DOI 10.1038/nsmb750; Tam JP, 1997, METHOD ENZYMOL, V289, P612; Wiegand HL, 2003, P NATL ACAD SCI USA, V100, P11327, DOI 10.1073/pnas.1934877100; Xu C, 2004, MOL CELL BIOL, V24, P10742, DOI 10.1128/MCB.24.24.10742-10756.2004; Yu MC, 2004, GENE DEV, V18, P2024, DOI 10.1101/gad.1223204	39	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34507	34512		10.1074/jbc.M507658200	http://dx.doi.org/10.1074/jbc.M507658200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16100109	hybrid			2022-12-25	WOS:000232403900018
J	Romanov, VV; James, CH; Sherrington, PD; Pettitt, AR				Romanov, VV; James, CH; Sherrington, PD; Pettitt, AR			Basic fibroblast growth factor suppresses p53 activation in the neoplastic cells of a proportion of patients with chronic lymphocytic leukaemia	ONCOGENE			English	Article						p53; basic fibroblast growth factor (bFGF); chronic lymphocytic leukaemia (CLL); microenvironment; MDM2; ATM	SYNDECAN-1 CD138 EXPRESSION; PHOSPHORYLATION; MDM2; APOPTOSIS; KINASE; INTERNALIZATION; UBIQUITINATION; ANGIOGENESIS; DYSFUNCTION; RESISTANCE	p53 is the most frequently inactivated gene in human cancers, reflecting its pivotal role in maintaining genomic integrity. The present study was conducted to explore the possibility that tumour cells with no intrinsic defects of the p53 pathway might nevertheless acquire p53 dysfunction through extrinsic suppression of the pathway by microenvironmental factors. Neoplastic cells from patients with chronic lymphocytic leukaemia (CLL) were cultured in the presence or absence of basic fibroblast growth factor ( bFGF) and exposed to ionizing radiation (IR) to induce p53 accumulation. bFGF is greatly increased in the plasma of CLL patients and can suppress p53 activation in some experimental models. IR induced a marked increase in p53 levels in 28 samples from 24 patients. bFGF inhibited IR-induced p53 accumulation to some extent in most of these samples and by more than 50% in seven samples from seven patients. Suppression of p53 activation by bFGF was frequently but not always accompanied by upregulation of the p53-inhibitory protein MDM2 and/or phosphorylation of MDM2 at serine 166, and was associated with impaired transcriptional activation of the p53 target gene p21. These observations provide the first demonstration in human cancer cells that the p53 pathway can be suppressed by factors in the tumour-cell microenvironment.	Royal Liverpool Univ Hosp, Dept Haematol, Liverpool L7 8XP, Merseyside, England	Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool	Pettitt, AR (corresponding author), Royal Liverpool Univ Hosp, Dept Haematol, Level 2 Duncan Bldg,Prescot St, Liverpool L7 8XP, Merseyside, England.	andrew.pettitt@rlbuht.nhs.uk						Aguayo A, 2000, BLOOD, V96, P2240, DOI 10.1182/blood.V96.6.2240.h8002240_2240_2245; Ashcroft M, 2002, ONCOGENE, V21, P1955, DOI 10.1038/sj.onc.1205276; Ashton AW, 2004, CIRC RES, V94, P735, DOI 10.1161/01.RES.0000122043.11286.57; Bairey O, 2001, BRIT J HAEMATOL, V113, P400, DOI 10.1046/j.1365-2141.2001.02731.x; Bourdon JC, 2003, CELL DEATH DIFFER, V10, P397, DOI 10.1038/sj.cdd.4401243; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; Deguchi Y, 2002, J NEUROCHEM, V83, P381, DOI 10.1046/j.1471-4159.2002.01129.x; Dode C, 2003, NAT GENET, V33, P463, DOI 10.1038/ng1122; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Gora-Tybor J, 2003, MEDIAT INFLAMM, V12, P167, DOI 10.1080/0962935031000134888; Gora-Tybor J, 2002, NEOPLASMA, V49, P145; Hosokawa K, 1998, ENDOCRINOLOGY, V139, P4688, DOI 10.1210/en.139.11.4688; Kay NE, 2002, LEUKEMIA, V16, P911, DOI 10.1038/sj.leu.2402467; Krejci P, 2001, LEUKEMIA, V15, P228, DOI 10.1038/sj.leu.2402012; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lin K, 2002, BLOOD, V100, P1404, DOI 10.1182/blood-2001-11-0066; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Menzel T, 1996, BLOOD, V87, P1056, DOI 10.1182/blood.V87.3.1056.bloodjournal8731056; Molica S, 2002, BRIT J CANCER, V86, P31, DOI 10.1038/sj.bjc.6600022; NGUYEN M, 1994, J NATL CANCER I, V86, P356, DOI 10.1093/jnci/86.5.356; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Pardo OE, 2001, ONCOGENE, V20, P7658, DOI 10.1038/sj.onc.1204994; Pettitt AR, 2003, BRIT J HAEMATOL, V121, P692, DOI 10.1046/j.1365-2141.2003.04336.x; Pettitt AR, 2001, BLOOD, V98, P814, DOI 10.1182/blood.V98.3.814; Qiao DH, 2003, J BIOL CHEM, V278, P16045, DOI 10.1074/jbc.M211259200; Sax JK, 2003, CELL DEATH DIFFER, V10, P413, DOI 10.1038/sj.cdd.4401227; Sebestyen A, 1999, BRIT J HAEMATOL, V104, P412, DOI 10.1046/j.1365-2141.1999.01211.x; Sebestyen A, 1997, EUR J CANCER, V33, P2273, DOI 10.1016/S0959-8049(97)00248-7; Shaulian E, 1997, ONCOGENE, V15, P2717, DOI 10.1038/sj.onc.1201453; She QB, 2002, ONCOGENE, V21, P1580, DOI 10.1038/sj.onc.1205239; She QB, 2001, CANCER RES, V61, P1604; Stankovic T, 2002, BLOOD, V99, P300, DOI 10.1182/blood.V99.1.300; Sutcliffe M, 2000, BRIT J HAEMATOL, V110, P239, DOI 10.1046/j.1365-2141.2000.02072-5.x; WATTEL E, 1994, BLOOD, V84, P3148, DOI 10.1182/blood.V84.9.3148.3148; Witzig TE, 1998, LEUKEMIA LYMPHOMA, V31, P167, DOI 10.3109/10428199809057596; Xu Y, 2003, CELL DEATH DIFFER, V10, P1213, DOI 10.1038/sj.cdd.4401292; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Zhu YH, 2002, J BIOL CHEM, V277, P22909, DOI 10.1074/jbc.M200042200	41	9	9	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2005	24	45					6855	6860		10.1038/sj.onc.1208895	http://dx.doi.org/10.1038/sj.onc.1208895			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973MV	16103882				2022-12-25	WOS:000232527800014
J	Abraham, R; Schafer, J; Rothe, M; Bange, J; Knyazev, P; Ullrich, A				Abraham, R; Schafer, J; Rothe, M; Bange, J; Knyazev, P; Ullrich, A			Identification of MMP-15 as an anti-apoptotic factor in cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-TYPE 1; CASPASE RECRUITMENT DOMAIN; PROTEIN-KINASE; TISSUE INHIBITOR; MATRIX METALLOPROTEINASES; FAS LIGAND; PROMOTES ACTIVATION; RNA INTERFERENCE; GENE-EXPRESSION; DECOY RECEPTOR	We have performed an in vitro selection for an anti-apoptotic phenotype that resembles the selection process that pre-malignant cells undergo in the initial phase of carcinogenesis in vivo. Using the cervical carcinoma cell line HeLa S3 as a model system, the selection procedure yielded cell clones that displayed increased resistance to apoptosis induced by Fas, tumor necrosis factor-related apoptosis-inducing ligand, and serum starvation. Gene expression profiling using gene family focused cDNA arrays revealed numerous genes that are differentially expressed in HeLa S3 and the resistant subclones and therefore are potentially involved in the definition of sensitivity to apoptotic stimuli. From the genes identified in this functional genomics approach we validated the anti-apoptotic activity of the membrane-anchored matrix metalloproteinase 15 (MMP-15) by means of small interfering RNA-mediated knockdown and ectopic expression in parental HeLa S3 cells and, to confirm a more general significance of our findings, in other cancer cell lines. The in vivo relevance of these findings is supported by the overexpression of MMP-15 in human lung adenocarcinoma compared with normal lung. Because MMP-15 is known to promote invasion, our results suggest that this protease connects metastasis and apoptosis resistance by an unknown regulatory mechanism. Our findings therefore strongly suggest that cancer characteristics such as metastatic potential, which are thought to evolve late in cancer progression, could be manifested early on by selection for an anti-apoptotic phenotype.	Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany; U3 Pharma AG, D-82152 Martinsried, Germany; Venetian Inst Mol Med, I-35129 Padua, Italy; Univ Munich, Dept Stat, D-80539 Munich, Germany	Max Planck Society; Veneto Institute Molecular Medicine; University of Munich	Abraham, R (corresponding author), Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany.	reimar.abraham@unipd.it						Ahonen M, 2003, ONCOGENE, V22, P2121, DOI 10.1038/sj.onc.1206292; ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Brott BK, 1998, P NATL ACAD SCI USA, V95, P963, DOI 10.1073/pnas.95.3.963; Cheng M, 1996, J BIOL CHEM, V271, P8951, DOI 10.1074/jbc.271.15.8951; Chiarugi P, 2002, J BIOL CHEM, V277, P37331, DOI 10.1074/jbc.M205203200; Chiarugi P, 1997, BIOCHEM BIOPH RES CO, V238, P676, DOI 10.1006/bbrc.1997.7355; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Dumont N, 2003, CANCER CELL, V3, P531, DOI 10.1016/S1535-6108(03)00135-1; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Ellenrieder V, 2000, INT J CANCER, V85, P14, DOI 10.1002/(SICI)1097-0215(20000101)85:1<14::AID-IJC3>3.3.CO;2-F; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Galic S, 2003, MOL CELL BIOL, V23, P2096, DOI 10.1128/MCB.23.6.2096-2108.2003; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Gschwind A, 2004, NAT REV CANCER, V4, P361, DOI 10.1038/nrc1360; GUAN K, 1992, P NATL ACAD SCI USA, V89, P12175, DOI 10.1073/pnas.89.24.12175; Gupta S, 2002, FEBS LETT, V532, P61, DOI 10.1016/S0014-5793(02)03628-1; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Huber Wolfgang, 2002, Bioinformatics, V18 Suppl 1, pS96; HUDZIAK RM, 1990, CELL GROWTH DIFFER, V1, P129; Husain A, 1998, CANCER RES, V58, P1120; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Inohara N, 1998, J BIOL CHEM, V273, P12296, DOI 10.1074/jbc.273.20.12296; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Julien C, 2003, J BIOL CHEM, V278, P42615, DOI 10.1074/jbc.M302724200; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kayagaki N, 1999, J IMMUNOL, V162, P2639; Kayagaki N, 1999, J IMMUNOL, V163, P1906; Khursigara G, 2001, J NEUROSCI, V21, P5854, DOI 10.1523/JNEUROSCI.21-16-05854.2001; Kinoshita T, 1998, J BIOL CHEM, V273, P16098, DOI 10.1074/jbc.273.26.16098; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Klingler-Hoffmann M, 2001, J BIOL CHEM, V276, P46313, DOI 10.1074/jbc.M106571200; Kramer OH, 2001, TRENDS ENDOCRIN MET, V12, P294, DOI 10.1016/S1043-2760(01)00438-6; Kurschat P, 1999, J BIOL CHEM, V274, P21056, DOI 10.1074/jbc.274.30.21056; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; Lim MS, 1999, ANN NY ACAD SCI, V878, P522, DOI 10.1111/j.1749-6632.1999.tb07715.x; Liu XW, 2003, J BIOL CHEM, V278, P40364, DOI 10.1074/jbc.M302999200; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; Maeda T, 1999, J EXP MED, V189, P1063, DOI 10.1084/jem.189.7.1063; Mansouri A, 2003, J BIOL CHEM, V278, P19245, DOI 10.1074/jbc.M208134200; Mariani SM, 1998, EUR J IMMUNOL, V28, P973, DOI 10.1002/(SICI)1521-4141(199803)28:03<973::AID-IMMU973>3.0.CO;2-T; MARIANI SM, 1995, EUR J IMMUNOL, V25, P2303, DOI 10.1002/eji.1830250828; Meneghini MD, 1999, NATURE, V399, P793, DOI 10.1038/21666; Miyamori H, 2001, J BIOL CHEM, V276, P28204, DOI 10.1074/jbc.M103083200; Morrison CJ, 2001, J BIOL CHEM, V276, P47402, DOI 10.1074/jbc.M108643200; Muda M, 1999, J BIOL CHEM, V274, P23991, DOI 10.1074/jbc.274.34.23991; Nakada M, 1999, AM J PATHOL, V154, P417, DOI 10.1016/S0002-9440(10)65288-1; Nakamura H, 1999, CANCER RES, V59, P467; Nayler O, 1998, J BIOL CHEM, V273, P34341, DOI 10.1074/jbc.273.51.34341; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nishihara H, 2004, J BIOL CHEM, V279, P26176, DOI 10.1074/jbc.M313346200; Ojala PM, 2000, NAT CELL BIOL, V2, P819, DOI 10.1038/35041064; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Pitti RM, 1998, NATURE, V396, P699, DOI 10.1038/25387; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Ruckdeschel K, 2002, J IMMUNOL, V168, P4601, DOI 10.4049/jimmunol.168.9.4601; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sanchez-Perez I, 2000, ONCOGENE, V19, P5142, DOI 10.1038/sj.onc.1203887; Sanjo H, 1998, J BIOL CHEM, V273, P29066, DOI 10.1074/jbc.273.44.29066; Sato H, 1997, GENOMICS, V39, P412, DOI 10.1006/geno.1996.4496; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; Shao NS, 1996, ONCOGENE, V13, P1; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shin HJ, 2003, CANCER CELL, V4, P483, DOI 10.1016/S1535-6108(03)00302-7; Shin MS, 2001, CANCER RES, V61, P4942; Soloaga A, 2003, EMBO J, V22, P2788, DOI 10.1093/emboj/cdg273; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Strand S, 2004, ONCOGENE, V23, P3732, DOI 10.1038/sj.onc.1207387; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299; Tiganis T, 1999, J BIOL CHEM, V274, P27768, DOI 10.1074/jbc.274.39.27768; Ueno H, 1997, CANCER RES, V57, P2055; Valente P, 1998, INT J CANCER, V75, P246, DOI 10.1002/(SICI)1097-0215(19980119)75:2<246::AID-IJC13>3.0.CO;2-B; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wang YL, 2004, CANCER BIOL THER, V3, P305, DOI 10.4161/cbt.3.3.697; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Xiong WC, 1997, J CELL BIOL, V139, P529, DOI 10.1083/jcb.139.2.529; Yasuda J, 2003, BIOCHEM BIOPH RES CO, V308, P227, DOI 10.1016/S0006-291X(03)01343-3	97	58	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34123	34132		10.1074/jbc.M508155200	http://dx.doi.org/10.1074/jbc.M508155200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16093241	hybrid			2022-12-25	WOS:000232229700053
J	Ficklin, MB; Zhao, SL; Feng, GP				Ficklin, MB; Zhao, SL; Feng, GP			Ubiquilin-1 regulates nicotine-induced up-regulation of neuronal nicotinic acetylcholine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICE LACKING; RAT-BRAIN; CHOLINERGIC RECEPTOR; CHRONIC EXPOSURE; BINDING-SITES; IN-VIVO; ALPHA 3; PROTEIN; SUBUNIT; TRAFFICKING	Chronic exposure to nicotine, as in tobacco smoking, up-regulates nicotinic acetylcholine receptor surface expression in neurons. This up-regulation has been proposed to play a role in nicotine addiction and withdrawal. The regulatory mechanisms behind nicotine-induced up-regulation of surface nicotinic acetylcholine receptors remain to be determined. It has recently been suggested that nicotine stimulation acts through increased assembly and maturation of receptor subunits into functional pentameric receptors. Studies of muscle nicotinic acetylcholine receptors suggest that the availability of unassembled subunits in the endoplasmic reticulum can be regulated by the ubiquitin-proteosome pathway, resulting in altered surface expression. Here, we describe a role for ubiquilin-1, a ubiquitin-like protein with the capacity to interact with both the proteosome and ubiquitin ligases, in regulating nicotine-induced up-regulation of neuronal nicotinic acetylcholine receptors. Ubiquilin-1 interacts with unassembled alpha 3 and alpha 4 subunits when coexpressed in heterologous cells and interacts with endogenous nicotinic acetylcholine receptors in neurons. Coexpression of ubiquilin-1 and neuronal nicotinic acetylcholine receptors in heterologous cells dramatically reduces the expression of the receptors on the cell surface. In cultured superior cervical ganglion neurons, expression of ubiquilin-1 abolishes nicotine-induced up-regulation of nicotinic acetylcholine receptors but has no effect on the basal level of surface receptors. Coimmunostaining shows that the interaction of ubiquilin-1 with the alpha 3 subunit draws the receptor subunit and proteosome into a complex. These data suggest that ubiquilin-1 limits the availability of unassembled nicotinic acetylcholine receptor subunits in neurons by drawing them to the proteosome, thus regulating nicotine-induced up-regulation.	Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA	Duke University; Duke University	Feng, GP (corresponding author), Duke Univ, Med Ctr, Dept Neurobiol, Box 3209,Res Dr, Durham, NC 27710 USA.	feng@neuro.duke.edu	Feng, Guoping/Y-2827-2019		NINDS NIH HHS [NS042609] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042609] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Albuquerque EX, 1997, J PHARMACOL EXP THER, V280, P1117; Arroyo-Jimenez MD, 1999, J NEUROSCI, V19, P6475; Bedford FK, 2001, NAT NEUROSCI, V4, P908, DOI 10.1038/nn0901-908; Ben-Ami HC, 2005, J BIOL CHEM, V280, P28053, DOI 10.1074/jbc.M504369200; BENCHERIF M, 1995, J PHARMACOL EXP THER, V275, P987; BENWELL MEM, 1988, J NEUROCHEM, V50, P1243, DOI 10.1111/j.1471-4159.1988.tb10600.x; Bertram L, 2005, NEW ENGL J MED, V352, P884, DOI 10.1056/NEJMoa042765; Bredt DS, 2003, NEURON, V40, P361, DOI 10.1016/S0896-6273(03)00640-8; Buisson B, 2001, J NEUROSCI, V21, P1819, DOI 10.1523/JNEUROSCI.21-06-01819.2001; Castillo M, 2005, J BIOL CHEM, V280, P27062, DOI 10.1074/jbc.M503746200; Chang HCJ, 1997, MOL CELL BIOL, V17, P318, DOI 10.1128/MCB.17.1.318; Christianson JC, 2004, EMBO J, V23, P4156, DOI 10.1038/sj.emboj.7600436; Dani JA, 1996, NEURON, V16, P905, DOI 10.1016/S0896-6273(00)80112-9; Darsow T, 2005, J BIOL CHEM, V280, P18311, DOI 10.1074/jbc.M501157200; Del Signore A, 2002, NEUROBIOL DIS, V10, P54, DOI 10.1006/nbdi.2002.0495; Doi H, 2004, FEBS LETT, V571, P171, DOI 10.1016/j.febslet.2004.06.077; Feng GP, 1998, J NEUROSCI, V18, P4166; FENG GP, 1995, GENETICS, V139, P1679; Feng PH, 2004, MOL CELL BIOL, V24, P3938, DOI 10.1128/MCB.24.9.3938-3948.2004; Fenster CP, 1999, J NEUROSCI, V19, P4804; FLORES CM, 1992, MOL PHARMACOL, V41, P31; Gopalakrishnan M, 1997, MOL PHARMACOL, V52, P524, DOI 10.1124/mol.52.3.524; Gotti C, 2004, PROG NEUROBIOL, V74, P363, DOI 10.1016/j.pneurobio.2004.09.006; Halevi S, 2003, J BIOL CHEM, V278, P34411, DOI 10.1074/jbc.M300170200; Halevi S, 2002, EMBO J, V21, P1012, DOI 10.1093/emboj/21.5.1012; Jeanclos EM, 2001, J BIOL CHEM, V276, P28281, DOI 10.1074/jbc.M011549200; Kaye FJ, 2000, FEBS LETT, V467, P348, DOI 10.1016/S0014-5793(00)01135-2; Keller SH, 1996, J BIOL CHEM, V271, P22871, DOI 10.1074/jbc.271.37.22871; Kleijnen MF, 2000, MOL CELL, V6, P409, DOI 10.1016/S1097-2765(00)00040-X; Kleijnen MF, 2003, MOL BIOL CELL, V14, P3868, DOI 10.1091/mbc.E02-11-0766; Lassle M, 1997, J BIOL CHEM, V272, P1876, DOI 10.1074/jbc.272.3.1876; Lindstrom J, 1996, Ion Channels, V4, P377; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; Mah AL, 2000, J CELL BIOL, V151, P847, DOI 10.1083/jcb.151.4.847; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; MANDELZYS A, 1994, J NEUROSCI, V14, P2357; MARKS MJ, 1985, J PHARMACOL EXP THER, V235, P619; MARKS MJ, 1992, J NEUROSCI, V12, P2765; Marubio LM, 1999, NATURE, V398, P805, DOI 10.1038/19756; Massey LK, 2004, J ALZHEIMERS DIS, V6, P79; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; MULLE C, 1991, J NEUROSCI, V11, P2588; Nashmi R, 2003, J NEUROSCI, V23, P11554; Pakkanen JS, 2005, EUR J NEUROSCI, V21, P2681, DOI 10.1111/j.1460-9568.2005.04105.x; Parker MJ, 2004, J NEUROSCI, V24, P378, DOI 10.1523/JNEUROSCI.3865-03.2004; Peng X, 1997, MOL PHARMACOL, V51, P776, DOI 10.1124/mol.51.5.776; PENG X, 1994, MOL PHARMACOL, V46, P523; Perry DC, 1999, J PHARMACOL EXP THER, V289, P1545; PICCIOTTO MR, 1995, NATURE, V374, P65, DOI 10.1038/374065a0; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Role LW, 1996, NEURON, V16, P1077, DOI 10.1016/S0896-6273(00)80134-8; RUST G, 1994, EUR J NEUROSCI, V6, P478, DOI 10.1111/j.1460-9568.1994.tb00290.x; Sallette J, 2004, J BIOL CHEM, V279, P18767, DOI 10.1074/jbc.M308260200; Sallette J, 2005, NEURON, V46, P595, DOI 10.1016/j.neuron.2005.03.029; SCHWARTZ RD, 1983, SCIENCE, V220, P214, DOI 10.1126/science.6828889; SCHWARTZ RD, 1985, J NEUROCHEM, V45, P427, DOI 10.1111/j.1471-4159.1985.tb04005.x; Vallejo YF, 2005, J NEUROSCI, V25, P5563, DOI 10.1523/JNEUROSCI.5240-04.2005; VOJTEK AB, 1993, J CELL SCI, V105, P777; Wang F, 1996, J BIOL CHEM, V271, P17656, DOI 10.1074/jbc.271.30.17656; Wang F, 1998, J BIOL CHEM, V273, P28721, DOI 10.1074/jbc.273.44.28721; Wang JM, 2002, NAT NEUROSCI, V5, P963, DOI 10.1038/nn918; Whiteaker P, 1998, MOL PHARMACOL, V53, P950; Williams BM, 1998, NAT NEUROSCI, V1, P557, DOI 10.1038/2792; WONNACOTT S, 1990, TRENDS PHARMACOL SCI, V11, P216, DOI 10.1016/0165-6147(90)90242-Z; Xu W, 1999, P NATL ACAD SCI USA, V96, P5746, DOI 10.1073/pnas.96.10.5746; Xu W, 1999, J NEUROSCI, V19, P9298; Yeh JJ, 2001, J NEUROCHEM, V77, P336, DOI 10.1046/j.1471-4159.2001.00259.x; ZOLI M, 1995, J NEUROSCI, V15, P1912, DOI 10.1523/JNEUROSCI.15-03-01912.1995	68	48	49	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34088	34095		10.1074/jbc.M506781200	http://dx.doi.org/10.1074/jbc.M506781200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16091357	hybrid			2022-12-25	WOS:000232229700049
J	Lahiri, S; Futerman, AH				Lahiri, S; Futerman, AH			LASS5 is a bona fide dihydroceramide synthase that selectively utilizes palmitoyl-CoA as acyl donor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONGEVITY ASSURANCE GENE-1; CERAMIDE SYNTHASE; SPHINGOLIPID SYNTHESIS; FAMILY-MEMBERS; LAG1; DOMAINS; GROWTH; LAC1P	We demonstrated recently (Riebeling, C., Allegood, J. C., Wang, E., Merrill, A. H. Jr., and Futerman, A. H. ( 2003) J. Biol. Chem. 278, 43452 - 43459) that upon over-expression in human embryonic kidney cells, longevity assurance gene homolog 5 (LASS5, previously named TRH4) elevates the synthesis of ( dihydro) ceramides selectively enriched in palmitic acid. To determine whether LASS5 is a bona fide dihydroceramide synthase or, alternatively, whether it modifies an endogenous dihydroceramide synthase, we over-expressed LASS5 with a hemagglutinin ( HA) tag at the C terminus, solubilized it using digitonin, and purified it by immunoprecipitation. Solubilized LASS5-HA displays the same fatty acid selectivity as the membrane-bound enzyme. After elution from agarose beads, only one band could be detected by SDS-PAGE, and its identity was confirmed to be LASS5 by mass spectrometry. Dihydroceramide synthase activity of the eluted LASS5-HA protein was totally dependent on exogenously added phospholipids. Moreover, eluted LASS5-HA was highly selective toward palmitoyl-CoA as acyl donor and was inhibited by the ( dihydro) ceramide synthase inhibitor, fumonisin B1. This study identifies LASS5 as a genuine dihydroceramide synthase and demonstrates that mammalian dihydroceramide synthases do not require additional subunits for their activity.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Futerman, AH (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	tony.futerman@weizmann.ac.il		Futerman, Anthony/0000-0003-0013-0115				Bodennec J, 2002, FASEB J, V16, P1814, DOI 10.1096/fj.02-0149fje; Futerman AH, 2004, EMBO REP, V5, P777, DOI 10.1038/sj.embor.7400208; Futerman AH, 2005, TRENDS CELL BIOL, V15, P312, DOI 10.1016/j.tcb.2005.04.006; Guillas I, 2001, EMBO J, V20, P2655, DOI 10.1093/emboj/20.11.2655; Gulbins E, 2003, ONCOGENE, V22, P7070, DOI 10.1038/sj.onc.1207146; Hannun YA, 2002, J BIOL CHEM, V277, P25847, DOI 10.1074/jbc.R200008200; HIRSCHBERG K, 1993, BIOCHEM J, V290, P751, DOI 10.1042/bj2900751; Kok JW, 1997, J BIOL CHEM, V272, P21128, DOI 10.1074/jbc.272.34.21128; Koybasi S, 2004, J BIOL CHEM, V279, P44311, DOI 10.1074/jbc.M406920200; Merrill AH, 2002, J BIOL CHEM, V277, P25843, DOI 10.1074/jbc.R200009200; Merrill AH, 1996, TRENDS CELL BIOL, V6, P218, DOI 10.1016/0962-8924(96)10021-0; Mizutani Y, 2005, BIOCHEM J, V390, P263, DOI 10.1042/BJ20050291; Riebeling C, 2003, J BIOL CHEM, V278, P43452, DOI 10.1074/jbc.M307104200; Schorling S, 2001, MOL BIOL CELL, V12, P3417, DOI 10.1091/mbc.12.11.3417; Vallee B, 2005, EMBO J, V24, P730, DOI 10.1038/sj.emboj.7600562; Venkataraman K, 2002, FEBS LETT, V528, P3, DOI 10.1016/S0014-5793(02)03248-9; Venkataraman K, 2002, J BIOL CHEM, V277, P35642, DOI 10.1074/jbc.M205211200; Winter E, 2002, TRENDS BIOCHEM SCI, V27, P381, DOI 10.1016/S0968-0004(02)02154-0; Xu ZW, 2005, J LIPID RES, V46, P1229, DOI 10.1194/jlr.M500001-JLR200	19	92	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33735	33738		10.1074/jbc.M506485200	http://dx.doi.org/10.1074/jbc.M506485200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16100120	hybrid			2022-12-25	WOS:000232229700008
J	Wu, ZLL; Lech, M				Wu, ZLL; Lech, M			Characterizing the non-reducing end structure of heparan sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IDURONATE 2-SULFATE RESIDUES; FIBROBLAST-GROWTH; BINDING-SITES; PROTEOGLYCANS; GLUCOSAMINE; INVOLVEMENT; LOCATION	The reducing end of heparan sulfate has been known for a long time, but information on the non-reducing end has been lacking. Recent studies indicate that the non-reducing end of heparan sulfate might be the place where fibroblast growth factor signaling complex forms. The non-reducing end also changes with heparanase digestion and, thus, might serve as amarker for tumor pathology. Using high performance liquid chromatography-coupled mass spectrometry, we have identified and characterized the non-reducing end of bovine kidney heparan sulfate. We find that the non-reducing end region is highly sulfated and starts with a glucuronic acid ( GlcA) residue. The likely sequence of the non-reducing end hexasaccharides is GlcA-GlcNS6S-UA +/- 2S- GlcNS +/- 6S- Ido2SGlcNS +/- 6S ( where GlcNS is N-sulfate-D-glucosamine, S is sulfate, UA is uronic acid, and Ido is iduronic acid). Our data suggests that the non-reducing end of bovine kidney heparan sulfate is not trimmed by heparanase and is capable of supporting fibroblast growth factor signaling complex formation.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Wu, ZLL (corresponding author), MIT, Dept Biol, 31 Ames St,Bldg 68-247, Cambridge, MA 02139 USA.	zwu@mit.edu		Wu, Zhengliang/0000-0002-0700-0906	NHLBI NIH HHS [P01 HL66105, R501 HL59479] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL066105, R01HL059479] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bame KJ, 2001, GLYCOBIOLOGY, V11, p91R, DOI 10.1093/glycob/11.6.91R; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Gallagher JT, 2001, J CLIN INVEST, V108, P357, DOI 10.1172/JCI13713; Goldshmidt O, 2002, EXP CELL RES, V281, P50, DOI 10.1006/excr.2002.5651; KNECHT J, 1967, J BIOL CHEM, V242, P4652; Kreuger J, 2005, BIOCHEM J, V389, P145, DOI 10.1042/BJ20042129; Kuberan B, 2002, J AM CHEM SOC, V124, P8707, DOI 10.1021/ja0178867; Lander AD, 1998, MATRIX BIOL, V17, P465, DOI 10.1016/S0945-053X(98)90093-2; Lin XH, 2004, DEVELOPMENT, V131, P6009, DOI 10.1242/dev.01522; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; LINKER A, 1984, CARBOHYD RES, V127, P75, DOI 10.1016/0008-6215(84)85107-1; Liu J, 2002, J BIOL CHEM, V277, P33456, DOI 10.1074/jbc.M202034200; LYON M, 1987, BIOCHEM J, V242, P493, DOI 10.1042/bj2420493; LYON M, 1994, J BIOL CHEM, V269, P11208; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; Merry CLR, 1999, J BIOL CHEM, V274, P18455, DOI 10.1074/jbc.274.26.18455; PARTHASARATHY N, 1984, J BIOL CHEM, V259, P2749; Perrimon N, 2004, DEVELOPMENT, V131, P2509, DOI 10.1242/dev.01225; Pikas DS, 1998, J BIOL CHEM, V273, P18770, DOI 10.1074/jbc.273.30.18770; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Sanderson RD, 2004, MATRIX BIOL, V23, P341, DOI 10.1016/j.matbio.2004.08.004; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Stringer SE, 2003, GLYCOBIOLOGY, V13, P97, DOI 10.1093/glycob/cwg006; Thanawiroon C, 2004, J BIOL CHEM, V279, P2608, DOI 10.1074/jbc.M304772200; Turnbull J E, 2001, Methods Mol Biol, V171, P129; TURNBULL JE, 1991, BIOCHEM J, V277, P297, DOI 10.1042/bj2770297; Turnbull JE, 1999, P NATL ACAD SCI USA, V96, P2698, DOI 10.1073/pnas.96.6.2698; TURNBULL JE, 1991, BIOCHEM J, V273, P553, DOI 10.1042/bj2730553; Venkataraman G, 1999, SCIENCE, V286, P537, DOI 10.1126/science.286.5439.537; Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI200113662; Westling C, 2002, J BIOL CHEM, V277, P49247, DOI 10.1074/jbc.M209139200; Wu ZLL, 2004, J BIOL CHEM, V279, P1861, DOI 10.1074/jbc.M311398200; Wu ZLL, 2003, J BIOL CHEM, V278, P17121, DOI 10.1074/jbc.M212590200; Xu D, 2005, BIOCHEM J, V385, P451, DOI 10.1042/BJ20040908; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Zetser A, 2004, J CELL SCI, V117, P2249, DOI 10.1242/jcs.01068; Zhang LJ, 2001, J BIOL CHEM, V276, P42311, DOI 10.1074/jbc.M101441200; Zhang Z, 2001, J BIOL CHEM, V276, P41921, DOI 10.1074/jbc.M106608200	38	26	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33749	33755		10.1074/jbc.M505677200	http://dx.doi.org/10.1074/jbc.M505677200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16079142	hybrid			2022-12-25	WOS:000232229700010
J	Chang, SA; Bralley, P; Jones, GH				Chang, SA; Bralley, P; Jones, GH			The absB gene encodes a double strand-specific endoribonuclease that cleaves the read-through transcript of the rpsO-pnp operon in Streptomyces coelicolor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RIBONUCLEASE-III; POLYNUCLEOTIDE PHOSPHORYLASE; MESSENGER; PURIFICATION; MECHANISM	The absB locus of Streptomyces coelicolor encodes a homolog of bacterial RNase III. We cloned and overexpressed the absB gene product and purified a decahistidine-tagged version of the protein. We show here that AbsB is active against double-stranded RNA transcripts derived from synthetic DNAs but is inactive with single-stranded homopolymers. We thus designate the absB product RNase IIIS. Using T7 RNA polymerase and a cloned template containing the rpsO-pnp intergenic region, we synthesized an RNA substrate representing a portion of the read-through transcript normally produced in S. coelicolor. This transcript contains the sequences that form the putative rpsO terminator and those that form an intergenic stem-loop structure thought to be the site for RNase IIIS processing of the read-through transcript. We show that RNase IIIS does cleave that model transcript, with primary and secondary cleavage sites in an internal loop in the stem-loop structure. We have identified the primary and secondary cleavage sites by primer extension and demonstrate the further processing of the initial cleavage products. Thus, as is the case in Escherichia coli, the read-through transcript from rpsO-pnp is cleaved by RNase IIIS in S. coelicolor. However, the cleavage sites are different in the two systems. The positions of the cleavage sites in the stem-loop of the S. coelicolor transcript are more akin to those identified in the processing of bacteriophage T7 mRNAs. A kinetic assay for RNase IIIS was developed, and kinetic parameters for the reaction utilizing the model transcript from rpsO-pnp were determined.	Emory Univ, Dept Biol, Atlanta, GA 30322 USA	Emory University	Jones, GH (corresponding author), Emory Univ, Dept Biol, Atlanta, GA 30322 USA.	george.h.jones@emory.edu						Aceti DJ, 1998, J BACTERIOL, V180, P3100, DOI 10.1128/JB.180.12.3100-3106.1998; ADAMIDIS T, 1992, J BACTERIOL, V174, P4622, DOI 10.1128/JB.174.14.4622-4628.1992; BABITZKE P, 1993, J BACTERIOL, V175, P229, DOI 10.1128/JB.175.1.229-239.1993; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bralley P, 2004, J BACTERIOL, V186, P3160, DOI 10.1128/JB.186.10.3160-3172.2004; Bralley P, 2003, MICROBIOL-SGM, V149, P2173, DOI 10.1099/mic.0.26334-0; Calin-Jageman I, 2003, NUCLEIC ACIDS RES, V31, P2381, DOI 10.1093/nar/gkg329; Calin-Jageman I, 2003, BIOCHEMISTRY-US, V42, P5025, DOI 10.1021/bi030004r; Campbell FE, 2002, J MOL BIOL, V317, P21, DOI 10.1006/jmbi.2002.5413; DUNN JJ, 1973, P NATL ACAD SCI USA, V70, P3296, DOI 10.1073/pnas.70.12.3296; FRANKLIN RM, 1966, P NATL ACAD SCI USA, V55, P1504, DOI 10.1073/pnas.55.6.1504; He B, 1997, PROTEIN EXPRES PURIF, V9, P142, DOI 10.1006/prep.1996.0663; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI HL, 1993, NUCLEIC ACIDS RES, V21, P1919, DOI 10.1093/nar/21.8.1919; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; PORTIER C, 1987, EMBO J, V6, P2165, DOI 10.1002/j.1460-2075.1987.tb02484.x; Price B, 1999, J BACTERIOL, V181, P6142, DOI 10.1128/JB.181.19.6142-6151.1999; REGNIER P, 1986, J MOL BIOL, V187, P23, DOI 10.1016/0022-2836(86)90403-1; ROBERTLEMEUR M, 1992, EMBO J, V11, P2633, DOI 10.1002/j.1460-2075.1992.tb05329.x; ROBERTLEMEUR M, 1994, NUCLEIC ACIDS RES, V22, P397, DOI 10.1093/nar/22.3.397; ROBERTSON HD, 1968, J BIOL CHEM, V243, P82; Sasaki N, 1998, GENE, V222, P17, DOI 10.1016/S0378-1119(98)00447-8; Sun WM, 2001, BIOCHEMISTRY-US, V40, P5102, DOI 10.1021/bi010022d; Zhang KJ, 1997, P NATL ACAD SCI USA, V94, P13437, DOI 10.1073/pnas.94.25.13437	24	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33213	33219		10.1074/jbc.M503440200	http://dx.doi.org/10.1074/jbc.M503440200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16076842	hybrid			2022-12-25	WOS:000232058100016
J	Drosopoulos, WC; DiRenzo, R; Prasad, VR				Drosopoulos, WC; DiRenzo, R; Prasad, VR			Human telomerase RNA template sequence is a determinant of telomere repeat extension rate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETRAHYMENA-TELOMERASE; ADDITION PROCESSIVITY; REVERSE-TRANSCRIPTASE; MAMMALIAN TELOMERASE; BOUNDARY DEFINITION; MUTANT TELOMERASE; IN-VITRO; EXPRESSION; REQUIREMENT; NUCLEOTIDE	Human telomerase is a specialized reverse transcriptase that utilizes an integral RNA subunit to template the synthesis of telomeres. In the present study, we demonstrate that the human telomerase template sequence not only determines the composition, but also the rate of synthesis, of telomere repeats. Mutagenesis of the template sequence identified variants that reconstitute enzymes with repeat extension rates that were either faster or slower than wild type template. Changes in extension rate could not be attributed solely to altered heteroduplex melting, strongly suggesting that specific interactions between telomerase template, protein, and products contribute significantly in determining repeat extension rate. Furthermore, some substitutions that had no effect on extension rate led to striking increases in repeat processivity, indicating that processivity and extension rates can be regulated independently of each other. Our results suggest that telomerase RNA template sequence is a key determinant of the contribution of telomerase to telomere length regulation.	Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Prasad, VR (corresponding author), Albert Einstein Coll Med, Dept Microbiol & Immunol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	prasad@aecom.yu.edu	Prasad, Vinayaka R./A-1029-2011	Prasad, Vinayaka/0000-0002-9461-0189	NATIONAL CANCER INSTITUTE [K01CA087542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030861] Funding Source: NIH RePORTER; NCI NIH HHS [K01-CACA87542] Funding Source: Medline; NIAID NIH HHS [R01-AI30861] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUTEXIER C, 1994, GENE DEV, V8, P563, DOI 10.1101/gad.8.5.563; Boyer PL, 1996, METHOD ENZYMOL, V275, P538; Bryan TM, 2000, J BIOL CHEM, V275, P24199, DOI 10.1074/jbc.M003246200; Chen JL, 2003, GENE DEV, V17, P2747, DOI 10.1101/gad.1140303; Chen JL, 2003, EMBO J, V22, P304, DOI 10.1093/emboj/cdg024; Collins K, 1999, ANNU REV BIOCHEM, V68, P187, DOI 10.1146/annurev.biochem.68.1.187; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Gavory G, 2002, NUCLEIC ACIDS RES, V30, P4470, DOI 10.1093/nar/gkf575; GILLEY D, 1995, GENE DEV, V9, P2214, DOI 10.1101/gad.9.18.2214; Gilley D, 1996, MOL CELL BIOL, V16, P66; Guiducci C, 2001, ONCOGENE, V20, P714, DOI 10.1038/sj.onc.1204145; Henning KA, 1998, P NATL ACAD SCI USA, V95, P5667, DOI 10.1073/pnas.95.10.5667; Jarstfer MB, 2002, BIOCHEMISTRY-US, V41, P151, DOI 10.1021/bi011649z; Kelleher C, 2002, TRENDS BIOCHEM SCI, V27, P572, DOI 10.1016/S0968-0004(02)02206-5; Kim MM, 2001, P NATL ACAD SCI USA, V98, P7982, DOI 10.1073/pnas.131211098; Kirk KE, 1997, SCIENCE, V275, P1478, DOI 10.1126/science.275.5305.1478; Lai CK, 2003, MOL CELL, V11, P1673, DOI 10.1016/S1097-2765(03)00232-6; Lai CK, 2002, GENE DEV, V16, P415, DOI 10.1101/gad.962602; Maine IP, 1999, BIOCHEMISTRY-US, V38, P15325, DOI 10.1021/bi991596+; Marusic L, 1997, MOL CELL BIOL, V17, P6394, DOI 10.1128/MCB.17.11.6394; McCormickGraham M, 1997, EMBO J, V16, P3233, DOI 10.1093/emboj/16.11.3233; Miller MC, 2002, P NATL ACAD SCI USA, V99, P6585, DOI 10.1073/pnas.102024699; Moriarty TJ, 2004, MOL CELL BIOL, V24, P3720, DOI 10.1128/MCB.24.9.3720-3733.2004; Prescott J, 1997, GENE DEV, V11, P528, DOI 10.1101/gad.11.4.528; Prescott JC, 2000, MOL CELL BIOL, V20, P2941, DOI 10.1128/MCB.20.8.2941-2948.2000; Rivera MA, 2004, J BIOL CHEM, V279, P53770, DOI 10.1074/jbc.M407768200; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SUGIMOTO N, 1995, BIOCHEMISTRY-US, V34, P11211, DOI 10.1021/bi00035a029; Tzfati Y, 2000, SCIENCE, V288, P863, DOI 10.1126/science.288.5467.863; Ware TL, 2000, EMBO J, V19, P3119, DOI 10.1093/emboj/19.12.3119; Wenz C, 2001, EMBO J, V20, P3526, DOI 10.1093/emboj/20.13.3526; Ye AJ, 1999, MOL CELL BIOL, V19, P2887; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0	33	25	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32801	32810		10.1074/jbc.M506319200	http://dx.doi.org/10.1074/jbc.M506319200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16061476	hybrid			2022-12-25	WOS:000231920300032
J	Koh, YH; von Arnim, CAF; Hyman, BT; Tanzi, RE; Tesco, G				Koh, YH; von Arnim, CAF; Hyman, BT; Tanzi, RE; Tesco, G			BACE is degraded via the lysosomal pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; SECRETASE CYTOSOLIC DOMAIN; BETA-SECRETASE; ALZHEIMERS-DISEASE; GGA PROTEINS; HUMAN-BRAIN; A-BETA; PROTEASOME; UBIQUITIN; CLEAVAGE	Amyloid plaques are formed by aggregates of amyloid-beta-peptide, a 37-43-amino acid fragment ( primarily A beta(40) and A beta(42)) generated by proteolytic processing of the amyloid precursor protein (APP) by beta- and gamma-secretases. A type I transmembrane aspartyl protease, BACE (beta-site APP cleaving enzyme), has been identified to be the beta- secretase. BACE is targeted through the secretory pathway to the plasma membrane where it can be internalized to endosomes. The carboxyl terminus of BACE contains a di-leucine-based signal for sorting of transmembrane proteins to endosomes and lysosomes. In this study, we set out to determine whether BACE is degraded by the lysosomal pathway and whether the di-leucine motif is necessary for targeting BACE to the lysosomes. Here we show that lysosomal inhibitors, chloroquine and NH4Cl, lead to accumulation of endogenous and ectopically expressed BACE in a variety of cell types, including primary neurons. Furthermore, the inhibition of lysosomal hydrolases results in the redistribution and accumulation of BACE in the late endosomal/lysosomal compartments (lysosome-associated membrane protein 2 (LAMP2)-positive). In contrast, the BACE-LL/AA mutant, in which Leu(499) and Leu(500) in the COOH-terminal sequence ( DDISLLK) were replaced by alanines, only partially co-localized with LAMP2-positive compartments following inhibition of lysosomal hydrolases. Collectively, our data indicate that BACE is transported to the late endosomal/lysosomal compartments where it is degraded via the lysosomal pathway and that the di-leucine motif plays a role in sorting BACE to lysosomes.	MA Gen Hosp, Genet & Aging Res Unit, Mass Gen Inst Neurodegenerat Dis, Charlestown, MA 02129 USA; MA Gen Hosp, Alzheimer Dis Res Lab, Mass Gen Inst Neurodegenerat Dis, Charlestown, MA 02129 USA		Tanzi, RE (corresponding author), MA Gen Hosp, Genet & Aging Res Unit, Mass Gen Inst Neurodegenerat Dis, 114 16th St,C3009, Charlestown, MA 02129 USA.	tanzi@helix.mgh.harvard.edu; tescog@helix.mgh.harvard.edu	Tanzi, Rudolph/AAE-9622-2019	Tanzi, Rudolph/0000-0002-7032-1454	NATIONAL INSTITUTE OF MENTAL HEALTH [K12MH069281] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012406, P01AG015379] Funding Source: NIH RePORTER; NIA NIH HHS [R01AG12406, 5P01AG15379] Funding Source: Medline; NIMH NIH HHS [1K12MH069281-01] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; Berezovska O, 1999, MOL BRAIN RES, V69, P273, DOI 10.1016/S0169-328X(99)00119-9; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Capell A, 2000, J BIOL CHEM, V275, P30849, DOI 10.1074/jbc.M003202200; Ciechanover A, 2005, NAT REV MOL CELL BIO, V6, P79, DOI 10.1038/nrm1552; Citron M, 2000, MOL MED TODAY, V6, P392, DOI 10.1016/S1357-4310(00)01759-7; Citron M, 2004, NAT REV NEUROSCI, V5, P677, DOI 10.1038/nrn1495; Cuervo AM, 2004, TRENDS CELL BIOL, V14, P70, DOI 10.1016/j.tcb.2003.12.002; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Fujita H, 2001, J INVEST DERM SYMP P, V6, P19, DOI 10.1046/j.0022-202x.2001.00009.x; Fukumoto H, 2002, ARCH NEUROL-CHICAGO, V59, P1381, DOI 10.1001/archneur.59.9.1381; Fukumoto H, 2004, AM J PATHOL, V164, P719, DOI 10.1016/S0002-9440(10)63159-8; Haniu M, 2000, J BIOL CHEM, V275, P21099, DOI 10.1074/jbc.M002095200; He XY, 2005, J BIOL CHEM, V280, P11696, DOI 10.1074/jbc.M411296200; He XY, 2003, BIOCHEMISTRY-US, V42, P12174, DOI 10.1021/bi035199h; He XY, 2002, FEBS LETT, V524, P183, DOI 10.1016/S0014-5793(02)03052-1; Holsinger RMD, 2002, ANN NEUROL, V51, P783, DOI 10.1002/ana.10208; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; Hussain I, 2003, J BIOL CHEM, V278, P36264, DOI 10.1074/jbc.M304186200; KIRSCHKE H, 1987, LYSOSOMES THEIR ROLE; Kisselev AF, 2001, CHEM BIOL, V8, P739, DOI 10.1016/S1074-5521(01)00056-4; Li R, 2004, P NATL ACAD SCI USA, V101, P3632, DOI 10.1073/pnas.0205689101; Marcinkiewicz M, 2000, J NEUROCHEM, V75, P2133, DOI 10.1046/j.1471-4159.2000.0752133.x; Nixon RA, 2000, NEUROCHEM RES, V25, P1161, DOI 10.1023/A:1007675508413; Nixon RA, 2005, J NEUROPATH EXP NEUR, V64, P113, DOI 10.1093/jnen/64.2.113; Nunan J, 2000, FEBS LETT, V483, P6, DOI 10.1016/S0014-5793(00)02076-7; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; Pastorino L, 2002, MOL CELL NEUROSCI, V19, P175, DOI 10.1006/mcne.2001.1065; Pickart CM, 2004, CELL, V116, P181, DOI 10.1016/S0092-8674(03)01074-2; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; POPE A, 1984, NEUROCHEM RES, V9, P291, DOI 10.1007/BF00963980; Puertollano R, 2004, NAT CELL BIOL, V6, P244, DOI 10.1038/ncb1106; Qing H, 2004, FASEB J, V18, P1571, DOI 10.1096/fj.04-1994fje; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; Skovronsky DM, 2000, BIOCHEMISTRY-US, V39, P810, DOI 10.1021/bi991728z; Vassar R, 2005, SUB CELL BIOCHEM, V38, P79; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vassar R, 2001, J MOL NEUROSCI, V17, P157, DOI 10.1385/JMN:17:2:157; von Arnim CAF, 2004, J CELL SCI, V117, P5437, DOI 10.1242/jcs.01422; Wahle T, 2005, MOL CELL NEUROSCI, V29, P453, DOI 10.1016/j.mcn.2005.03.014; Walter J, 2001, J BIOL CHEM, V276, P14634, DOI 10.1074/jbc.M011116200; Yang LB, 2003, NAT MED, V9, P3, DOI 10.1038/nm0103-3; Yu WH, 2004, INT J BIOCHEM CELL B, V36, P2531, DOI 10.1016/j.biocel.2004.05.010	45	136	139	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32499	32504		10.1074/jbc.M506199200	http://dx.doi.org/10.1074/jbc.M506199200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16033761	hybrid			2022-12-25	WOS:000231794800058
J	Xia, WL; Gerard, CM; Liu, LH; Baudson, NM; Ory, TL; Spector, NL				Xia, WL; Gerard, CM; Liu, LH; Baudson, NM; Ory, TL; Spector, NL			Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells	ONCOGENE			English	Article						survivin; vaccine; tyrosine kinase; ErbB2; antibodies; breast cancer	MONOCLONAL-ANTIBODY; ANTITUMOR-ACTIVITY; SINGLE-AGENT; IN-VIVO; RECEPTOR; PROTEIN; GROWTH; HER-2/NEU; SURVIVIN; CHEMOTHERAPY	Antibodies and small molecule tyrosine kinase inhibitors targeting ErbB2 exhibit distinct, noncross resistant mechanisms of action. Here, apoptosis of ErbB2-over-expressing breast cancer cells was enhanced by combining lapatinib, an inhibitor of ErbB1 and ErbB2 tyrosine kinases, with anti-ErbB2 antibodies, including (i) trastuzumab, a humanized monoclonal antibody, and(ii) pAb, rabbit polyclonal antisera generated by vaccination with a human ErbB2 fusion protein. Treating ErbB2-over-expressing breast cancer cell lines with a relatively low concentration of lapatinib alone resulted in a minimal increase in tumor cell apoptosis with an associated decrease in steady-state protein levels of p-ErbB2, p-Akt, p-Erk1/2, and notably survivin, compared to baseline. Exposure to pAb alone reduced total ErbB2 protein, disrupting ErbB3 transactivation, leading to a marked inhibition of p-Akt; however, survivin protein levels remained unchanged and apoptosis only increased slightly. Treatment with trastuzumab alone had relatively little effect on survivin and apoptosis was unaffected. Combining lapatinib with either pAb or trastuzumab markedly downregulated survivin protein and enhanced tumor cell apoptosis. The association between the inhibition of survivin and enhanced apoptosis following the combination of ErbB2-targeted therapies provides a biological effect in order to identify therapeutic strategies that promote tumor cell apoptosis and might improve clinical response.	GlaxoSmithKline Inc, Dept Discovery Med, Res Triangle Pk, NC 27709 USA; GlasoSmithKline Biol, Canc Vaccine Program, Rixensart, Belgium	GlaxoSmithKline	Spector, NL (corresponding author), GlaxoSmithKline Inc, Dept Discovery Med, 5 Moore Dr,POB 13398, Res Triangle Pk, NC 27709 USA.	Neil.L.Spector@gsk.com						Agus DB, 2002, CANCER CELL, V2, P127, DOI 10.1016/S1535-6108(02)00097-1; ALIMANDI M, 1995, ONCOGENE, V10, P1813; Arteaga CL, 2003, EXP CELL RES, V284, P122, DOI 10.1016/S0014-4827(02)00104-0; ARTEAGA CL, 2004, BREAST CANC RES TR S, V88, pA25; BACUS SS, 1994, AM J CLIN PATHOL S1, V102, P13; Baselga J, 1998, CANCER RES, V58, P2825; Brognard J, 2001, CANCER RES, V61, P3986; BURRIS HA, 2004, BREAST CANC RES T S1, V88, pA3043; Carter BZ, 2001, BLOOD, V97, P2784, DOI 10.1182/blood.V97.9.2784; Chen XF, 2001, ONCOGENE, V20, P6073, DOI 10.1038/sj.onc.1204736; Christianson TA, 1998, CANCER RES, V58, P5123; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Cockerill S, 2001, BIOORG MED CHEM LETT, V11, P1401, DOI 10.1016/S0960-894X(01)00219-0; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; Fry DW, 2003, EXP CELL RES, V284, P131, DOI 10.1016/S0014-4827(02)00095-2; GULLICK WJ, 1991, BRIT J CANCER, V63, P434, DOI 10.1038/bjc.1991.100; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HERBST RS, 2004, J CLIN ONCOL, V22, P759; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Huang SM, 2004, CANCER RES, V64, P5355, DOI 10.1158/0008-5472.CAN-04-0562; JOHNSON DH, 2002, ANN ONCOL, V13, P127; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; MAIER LA, 1991, CANCER RES, V51, P5361; Marusawa H, 2003, EMBO J, V22, P2729, DOI 10.1093/emboj/cdg263; Matar P, 2004, CLIN CANCER RES, V10, P6487, DOI 10.1158/1078-0432.CCR-04-0870; Molina MA, 2002, CLIN CANCER RES, V8, P347; Molina MA, 2001, CANCER RES, V61, P4744; Moulder SL, 2001, CANCER RES, V61, P8887; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102; Park J W, 1992, Cancer Treat Res, V61, P193; Pegram M, 1999, ONCOGENE, V18, P2241, DOI 10.1038/sj.onc.1202526; PIETRAS RJ, 1994, ONCOGENE, V9, P1829; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; RODRIGUEZ GC, 1993, AM J OBSTET GYNECOL, V168, P228, DOI 10.1016/S0002-9378(12)90918-7; Rusnak DW, 2001, CANCER RES, V61, P7196; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1999, SEMIN ONCOL S12, V26, P14661; Song ZY, 2003, J BIOL CHEM, V278, P23130, DOI 10.1074/jbc.M300957200; Tamm I, 1998, CANCER RES, V58, P5315; Tenzer A, 2001, CANCER RES, V61, P8203; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; Wood ER, 2004, CANCER RES, V64, P6652, DOI 10.1158/0008-5472.CAN-04-1168; Xia WL, 2004, ONCOGENE, V23, P646, DOI 10.1038/sj.onc.1207166; Xia WL, 2002, ONCOGENE, V21, P6255, DOI 10.1038/sj.onc.1205794; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	51	225	238	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2005	24	41					6213	6221		10.1038/sj.onc.1208774	http://dx.doi.org/10.1038/sj.onc.1208774			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964JM	16091755				2022-12-25	WOS:000231877100002
J	de Roos, B; Rucklidge, G; Reid, M; Ross, K; Duncan, G; Navarro, MA; Arbones-Mainar, JM; Guzman-Garcia, MA; Osada, J; Browne, J; Loscher, CE; Roche, HM				de Roos, B; Rucklidge, G; Reid, M; Ross, K; Duncan, G; Navarro, MA; Arbones-Mainar, JM; Guzman-Garcia, MA; Osada, J; Browne, J; Loscher, CE; Roche, HM			Divergent mechanisms of cis9, trans11-and trans10, cis12-conjugated linoleic acid affecting insulin resistance and inflammation in apolipoprotein E knockout mice: a proteomics approach	FASEB JOURNAL			English	Article						dietary fatty acids; atherosclerosis; glucose metabolism; systems biology	EARLY AORTIC ATHEROSCLEROSIS; MIGRATION INHIBITORY FACTOR; HEAT-SHOCK-PROTEIN; FATTY-ACID; LIPID-PEROXIDATION; BODY-COMPOSITION; CELL-FUNCTION; LIVER; SUPPLEMENTATION; CIS-9,TRANS-11	Conjugated linoleic acids (CLA) affect atherogenesis, but mechanisms are not well understood. We explored how two isomers of CLA, cis9, trans11- CLA and trans10, cis12-CLA, affected lipid and glucose metabolism, as well as hepatic protein expression, in apolipoprotein E knockout mice. After 12 wk of intervention, plasma triglyceride, NEFA, and glucose concentrations were significantly higher in the trans10, cis12-CLA group, whereas plasma triglyceride, NEFA, glucose, and insulin concentrations were significantly lower in the cis9, trans11- CLA group, compared with control mice consuming linoleic acid. Proteomics identified significant up- or down-regulation of 113 liver cytosolic proteins by either CLA isomer. Principal component analysis revealed that the treatment effect of cis9, trans11- CLA was mainly explained by the up- regulation of different posttranslational forms of heat shock protein 70 kD. In contrast, the treatment effect of trans10, cis12-CLA was mainly explained by up- regulation of key enzymes in the gluconeogenic, beta-oxidation, and ketogenesic pathways. Correlation analysis again emphasized the divergent effects of both CLA isomers on different pathways, but also revealed a linkage between insulin resistance and increased levels of hepatic serotransferrin. Thus, our systems biology approach provided novel insights into the mechanisms by which individual CLA isomers differentially affect pathways related to atherogenesis, such as insulin resistance and inflammation.	Rowett Res Inst, Aberdeen AB21 9SB, Scotland; Univ Zaragoza, Sch Vet, Dept Biochem, Zaragoza, Spain; St James Hosp, Inst Mol Med, Dept Clin Med, Nutrigenom Res Grp, Dublin 8, Ireland	University of Aberdeen; University of Zaragoza; Trinity College Dublin	de Roos, B (corresponding author), Rowett Res Inst, Greenburn Rd, Aberdeen AB21 9SB, Scotland.	b.deroos@rowett.ac.uk	Arbones-Mainar, Jose M/AGL-8624-2022; Navarro, Ángeles/AAG-6089-2019; Roche, Helen M/AAF-4164-2019	Arbones-Mainar, Jose M/0000-0002-8982-3737; Roche, Helen M/0000-0002-0628-3318; Loscher, Christine/0000-0002-5276-7321	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Albers R, 2003, EUR J CLIN NUTR, V57, P595, DOI 10.1038/sj.ejcn.1601585; Azain MJ, 2000, J NUTR, V130, P1548; Basu S, 2000, CLIN SCI, V99, P511, DOI 10.1042/cs0990511; Brodie AE, 1999, J NUTR, V129, P602; Chen ZP, 2004, ARTERIOSCL THROM VAS, V24, P709, DOI 10.1161/01.ATV.0000119356.35748.9e; Clement L, 2002, J LIPID RES, V43, P1400, DOI 10.1194/jlr.M20008-JLR200; de Roos B, 2005, FASEB J, V19, P813, DOI 10.1096/fj.04-2974fje; Degrace P, 2003, FEBS LETT, V546, P335, DOI 10.1016/S0014-5793(03)00610-0; Ethridge RT, 1998, GASTROENTEROLOGY, V115, P1454, DOI 10.1016/S0016-5085(98)70024-1; Ferrannini E, 2000, LANCET, V355, P2181, DOI 10.1016/S0140-6736(00)02397-7; Hunt MC, 2002, J BIOL CHEM, V277, P1128, DOI 10.1074/jbc.M106458200; Kritchevsky D, 2004, LIPIDS, V39, P611, DOI 10.1007/s11745-004-1273-8; Kritchevsky D, 2000, J AM COLL NUTR, V19, p472S, DOI 10.1080/07315724.2000.10718950; Latchman DS, 2001, CARDIOVASC RES, V51, P637, DOI 10.1016/S0008-6363(01)00354-6; LEE KN, 1994, ATHEROSCLEROSIS, V108, P19, DOI 10.1016/0021-9150(94)90034-5; Lee KN, 1998, BIOCHEM BIOPH RES CO, V248, P817, DOI 10.1006/bbrc.1998.8994; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; McLeod RS, 2004, AM J CLIN NUTR, V79, p1169S, DOI 10.1093/ajcn/79.6.1169S; Moirand R, 1997, LANCET, V349, P95, DOI 10.1016/S0140-6736(96)06034-5; Moloney F, 2004, AM J CLIN NUTR, V80, P887; Nicolosi RJ, 1997, ARTERY, V22, P266; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; Pan JH, 2004, CIRCULATION, V109, P3149, DOI 10.1161/01.CIR.0000134704.84454.D2; Park Y, 2000, BBA-MOL CELL BIOL L, V1486, P285, DOI 10.1016/S1388-1981(00)00074-3; Park Y, 1997, LIPIDS, V32, P853, DOI 10.1007/s11745-997-0109-x; Parker R, 1999, NETW COMPUT, V10, P12; Perseghin G, 2001, J CLIN ENDOCR METAB, V86, P4776, DOI 10.1210/jc.86.10.4776; Radford NB, 1996, P NATL ACAD SCI USA, V93, P2339, DOI 10.1073/pnas.93.6.2339; Rahman SM, 2001, NUTRITION, V17, P385, DOI 10.1016/S0899-9007(00)00584-0; Riserus U, 2004, AM J CLIN NUTR, V79, p1146S; Riserus U, 2004, AM J CLIN NUTR, V80, P279; Riserus U, 2002, DIABETES CARE, V25, P1516, DOI 10.2337/diacare.25.9.1516; Riserus U, 2002, CIRCULATION, V106, P1925, DOI 10.1161/01.CIR.0000033589.15413.48; Roche HM, 2002, DIABETES, V51, P2037, DOI 10.2337/diabetes.51.7.2037; Roche HM, 2001, NUTR RES REV, V14, P173, DOI [10.1079/095442201108729187, 10.1079/NRR200122]; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Shimizu M, 2002, J THORAC CARDIOV SUR, V124, P933, DOI 10.1067/mtc.2002.122305; Smedman A, 2004, CLIN SCI, V106, P67, DOI 10.1042/CS20030105; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Takahashi Y, 2003, BBA-MOL CELL BIOL L, V1631, P265, DOI 10.1016/S1388-1981(03)00038-6; Terpstra AH, 2004, AM J CLIN NUTR, V79, P352; Toomey S, 2003, BIOCHEM SOC T, V31, P1075, DOI 10.1042/BST0311075; Tricon S, 2004, AM J CLIN NUTR, V80, P1626, DOI 10.1093/ajcn/80.6.1626; Tricon S, 2004, AM J CLIN NUTR, V80, P614; Wallace TM, 2004, DIABETES CARE, V27, P1487, DOI 10.2337/diacare.27.6.1487; West DB, 1998, AM J PHYSIOL-REG I, V275, pR667; Wilson TA, 2000, NUTR RES, V20, P1795, DOI 10.1016/S0271-5317(00)00268-2; Yotsumoto H, 1998, FOOD RES INT, V31, P403, DOI 10.1016/S0963-9969(98)00103-3; Zhu JH, 2003, ARTERIOSCL THROM VAS, V23, P1055, DOI 10.1161/01.ATV.0000074899.60898.FD	49	68	69	1	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1746	+		10.1096/fj.05-3953fje	http://dx.doi.org/10.1096/fj.05-3953fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16055499				2022-12-25	WOS:000230923000001
J	Hou, ZJ; Stapels, SE; Haska, CL; Matherly, LH				Hou, ZJ; Stapels, SE; Haska, CL; Matherly, LH			Localization of a substrate binding domain of the human reduced folate carrier to transmembrane domain 11 by radioaffinity labeling and cysteine-substituted accessibility methods	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCANNING MUTAGENESIS; MEMBRANE TOPOLOGY; METHOTREXATE SENSITIVITY; CELLULAR PHARMACOLOGY; TRANSPORT-DEFICIENT; LACTOSE PERMEASE; FUNCTIONAL-ROLE; FOLIC-ACID; CELLS; IDENTIFICATION	The human reduced folate carrier (hRFC) mediates the membrane transport of reduced folates and classical anti-folates into mammalian cells. RFC is characterized by 12 transmembrane domains (TMDs), internally oriented N and C termini, and a large central linker connecting TMDs 1 - 6 and 7 - 12. By co-expression and N-hydroxysuccinimide methotrexate (Mtx) radioaffinity labeling of hRFC TMD 1 - 6 and TMD 7 - 12 half-molecules, combined with endoproteinase GluC digestion, a substrate binding domain was previously localized to within TMDs 8 - 12 (Witt, T. L., Stapels, S. E., and Matherly, L. H. ( 2004) J. Biol. Chem. 279, 46755 - 46763). In this report, this region was further refined to TMDs 11 - 12 by digestion with 2-nitro-5-thiocyanatobenzoic acid. A transport-competent cysteine-less hRFC was used as a template to prepare single cysteine-replacement mutant constructs in which each residue from Glu-394 to Asp-420 of TMD11 and Tyr-435 to His-457 of TMD 12 was replaced individually by a cysteine. The mutant constructs were transfected into hRFC-null HeLa cells. Most of the 50 single cysteine-substituted constructs were expressed at high levels on Western blots. With the exception of G401C hRFC, all mutants were active for Mtx transport. Treatment with sodium (2-sulfonatoethyl) methanethiosulfonate ( MTSES) had no effect on hRFC activity for all of the cysteine mutants within TMD 12 and for the majority of the cysteine mutants within TMD 11. However, MTSES inhibited Mtx uptake by the T404C, A407C, T408C, T412C, F416C, I417C, V418C, and S419C mutants by 25 - 65%. Losses of activity by MTSES treatment for T404C, A407C, T412C, and I417C hRFCs were appreciably reversed in the presence of excess leucovorin, a hRFC substrate. Our results strongly suggest that residues within TMD11 are likely critical structural and/or functional components of the putative hRFC transmembrane channel for anionic folate and anti-folate substrates.	Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Dev Therapeut Program, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Canc Biol Program, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Wayne State University; Wayne State University	Matherly, LH (corresponding author), Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Dev Therapeut Program, 110 E Warren Ave, Detroit, MI 48201 USA.	matherly@kci.wayne.edu			NCI NIH HHS [CA53535] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Abramson J, 2004, CURR OPIN STRUC BIOL, V14, P413, DOI 10.1016/j.sbi.2004.07.005; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; Bailey LB, 2003, J NUTR, V133, p1961S, DOI 10.1093/jn/133.6.1961S; BRIGLE KE, 1995, J BIOL CHEM, V270, P22974, DOI 10.1074/jbc.270.39.22974; Cao W, 2004, BIOCHEM J, V378, P201, DOI 10.1042/BJ20031288; Cao W, 2003, BIOCHEM J, V374, P27, DOI 10.1042/BJ20030301; DIXON KH, 1994, J BIOL CHEM, V269, P17; Ferguson PL, 1999, J BIOL CHEM, V274, P16269, DOI 10.1074/jbc.274.23.16269; Flintoff WF, 2003, J BIOL CHEM, V278, P40867, DOI 10.1074/jbc.M302102200; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; FRY DW, 1982, J BIOL CHEM, V257, P1890; GOLDMAN ID, 1985, PHARMACOL THERAPEUT, V28, P77, DOI 10.1016/0163-7258(85)90083-X; Goldman ID, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.37461; HENDERSON GB, 1984, J BIOL CHEM, V259, P4558; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; Karlin A, 1998, METHOD ENZYMOL, V293, P123; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu XY, 2001, BIOCHEM J, V358, P511, DOI 10.1042/0264-6021:3580511; Liu XY, 2002, BBA-BIOMEMBRANES, V1564, P333, DOI 10.1016/S0005-2736(02)00467-4; Loo TW, 1999, BBA-BIOMEMBRANES, V1461, P315, DOI 10.1016/S0005-2736(99)00165-0; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lucock M, 2000, MOL GENET METAB, V71, P121, DOI 10.1006/mgme.2000.3027; MATHERLY LH, 1991, CANCER RES, V51, P3420; Matherly LH, 2003, VITAM HORM, V66, P403, DOI 10.1016/S0083-6729(03)01012-4; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOSCOW JA, 1995, CANCER RES, V55, P3790; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; PRASAD PD, 1995, BIOCHEM BIOPH RES CO, V206, P681, DOI 10.1006/bbrc.1995.1096; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Sadlish H, 2002, J BIOL CHEM, V277, P42105, DOI 10.1074/jbc.M206459200; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Sharina IG, 2001, MOL PHARMACOL, V59, P1022, DOI 10.1124/mol.59.5.1022; Stokstad ELR, 1990, FOLIC ACID METABOLIS, P1; Tse A, 1998, J BIOL CHEM, V273, P25953, DOI 10.1074/jbc.273.40.25953; Vardy E, 2004, PROTEIN SCI, V13, P1832, DOI 10.1110/ps.04657704; Whetstine JR, 2002, BIOCHEM J, V367, P629, DOI 10.1042/BJ20020512; WILLIAMS FMR, 1994, J BIOL CHEM, V269, P5810; WILLIAMS FMR, 1995, J BIOL CHEM, V270, P2987, DOI 10.1074/jbc.270.7.2987; Wilson GG, 1998, NEURON, V20, P1269, DOI 10.1016/S0896-6273(00)80506-1; Witt TL, 2004, J BIOL CHEM, V279, P46755, DOI 10.1074/jbc.M408696200; Witt TL, 2002, BBA-BIOMEMBRANES, V1567, P56, DOI 10.1016/S0005-2736(02)00583-7; Wong SC, 1999, J BIOL CHEM, V274, P10388, DOI 10.1074/jbc.274.15.10388; WONG SC, 1995, J BIOL CHEM, V270, P17468, DOI 10.1074/jbc.270.29.17468; Xu M, 1996, J GEN PHYSIOL, V107, P195, DOI 10.1085/jgp.107.2.195; Zhao R, 2000, CLIN CANCER RES, V6, P3304; Zhao R, 1998, J BIOL CHEM, V273, P19065, DOI 10.1074/jbc.273.30.19065; ZHAO R, 1999, MOL PHARM, V56, P1832; Zhao RB, 1999, BIOCHEM PHARMACOL, V58, P1615, DOI 10.1016/S0006-2952(99)00257-9; Zhao RB, 2004, CLIN CANCER RES, V10, P8735, DOI 10.1158/1078-0432.CCR-04-0932; Zhao RB, 1998, J BIOL CHEM, V273, P7873, DOI 10.1074/jbc.273.14.7873	53	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36206	36213		10.1074/jbc.M507295200	http://dx.doi.org/10.1074/jbc.M507295200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16115875	hybrid			2022-12-25	WOS:000232726900052
J	Netea, MG; Ferwerda, G; de Jong, DJ; Werts, C; Boneca, IG; Jehanno, M; Van der Meer, JWM; Mengin-Lecreulx, D; Sansonetti, PJ; Philpott, DJ; Dharancy, S; Girardin, SE				Netea, MG; Ferwerda, G; de Jong, DJ; Werts, C; Boneca, IG; Jehanno, M; Van der Meer, JWM; Mengin-Lecreulx, D; Sansonetti, PJ; Philpott, DJ; Dharancy, S; Girardin, SE			The frameshift mutation in Nod2 results in unresponsiveness not only to Nod2-but also Nod1-activating peptidoglycan agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; REQUIREMENTS ALLOWING DETECTION; INFLAMMATORY-BOWEL-DISEASE; CROHNS-DISEASE; MURAMYL DIPEPTIDE; INNATE IMMUNITY; BACTERIAL PEPTIDOGLYCAN; RECOGNITION PROTEINS; ESCHERICHIA-COLI; HOST RECOGNITION	NOD2/CARD15 is the first characterized susceptibility gene in Crohn disease. The Nod2 1007fs (Nod2fs) frameshift mutation is the most prevalent in Crohn disease patients. Muramyl dipeptide from bacterial peptidoglycan is the minimal motif detected by Nod2 but not by Nod2fs. Here we investigated the response of human peripheral blood mononuclear cells (PBMCs) from Crohn disease patients not only to muramyl dipeptide but also to several other muramyl peptides. Most unexpectedly, we observed that patients homozygous for the Nod2fs mutation were totally unresponsive to MurNAc-L-Ala-D-Glu-meso-diaminopimelic acid (DAP) (M-Tri(DAP)), the specific agonist of Nod1, and to Gram-negative bacterial peptidoglycan. In contrast, PBMCs from a patient homozygous for the Nod2 R702W mutation, also associated with Crohn disease, displayed normal response to Gram-negative bacterial peptidoglycan. In addition, the blockage of the Nod1/M-Tri(DAP) pathway could be partially overcome by co-stimulation with the Toll-like receptors agonists lipoteichoic acid or lipopolysaccharide. Investigation into the mechanism of this finding revealed that Nod2fs did not act as a dominant-negative molecule for the Nod1/M-Tri(DAP) pathway, implying that the blockage is dependent upon the expression or activity of other factors. We demonstrated that PBMCs from Nod2fs patients express high levels of the peptidoglycan recognition protein S, a secreted protein known to interact with muramyl peptides. We proposed that through a scavenger function, peptidoglycan recognition protein S may dampen M-Tri(DAP)-dependent responses in Nod2fs patients. Together, our results identified a cross-talk between the Nod1 and Nod2 pathways and suggested that down-regulation of Nod1/M-Tri(DAP) pathway may be associated with Crohn disease.	Inst Pasteur, Grp Inserm Avenir Peptidoglycan & Innate Immun, F-75724 Paris, France; Radboud Univ Nijmegen Med Ctr, Dept Gastroenterol, NL-6500 HB Nijmegen, Netherlands; Radboud Univ Nijmegen Med Ctr, Univ Nijmegen, Ctr Infect Dis, NL-6500 HB Nijmegen, Netherlands; Radboud Univ Nijmegen Med Ctr, Dept Internal Med, NL-6500 HB Nijmegen, Netherlands; Univ Paris 11, CNRS, UMR 8619, Inst Biochim & Biophys Mol & Cellulaire, F-91400 Orsay, France; CHRU, Hop Swynghedauw, INSERM, EPI 114, F-59000 Lille, France; Inst Pasteur, Unite Pathogenie Bacterienne Muqueuses, F-75724 Paris, France; Inst Pasteur, Unite Pathogenie Microbienne Mol, INSERM, U389, F-75724 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Girardin, SE (corresponding author), Inst Pasteur, 28 Rue Dr Roux, F-75724 Paris, France.	girardin@pasteur.fr	van der Meer, Jos W.M./C-8521-2013; de Jong, D.J./L-4417-2015; WERTS, Catherine/AAD-5447-2020; Boneca, Ivo G/H-1677-2014; Netea, Mihai/N-5155-2014; Ferwerda, J.G./L-4305-2015	van der Meer, Jos W.M./0000-0001-5120-3690; WERTS, Catherine/0000-0003-3079-5476; Boneca, Ivo G/0000-0001-8122-509X; MENGIN-LECREULX, Dominique/0000-0003-3205-0275				Bertin J, 1999, J BIOL CHEM, V274, P12955, DOI 10.1074/jbc.274.19.12955; Bonen DK, 2003, GASTROENTEROLOGY, V124, P140, DOI 10.1053/gast.2003.50019; Chamaillard M, 2003, P NATL ACAD SCI USA, V100, P3455, DOI 10.1073/pnas.0530276100; Chamaillard M, 2003, NAT IMMUNOL, V4, P702, DOI 10.1038/ni945; Chin AI, 2002, NATURE, V416, P190, DOI 10.1038/416190a; FLOURET B, 1981, ANAL BIOCHEM, V114, P59, DOI 10.1016/0003-2697(81)90451-6; Fritz JH, 2005, EUR J IMMUNOL, V35, P2459, DOI 10.1002/eji.200526286; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; Girardin SE, 2003, J BIOL CHEM, V278, P41702, DOI 10.1074/jbc.M307198200; Girardin SE, 2004, EUR J IMMUNOL, V34, P1777, DOI 10.1002/eji.200425095; Girardin SE, 2001, EMBO REP, V2, P736, DOI 10.1093/embo-reports/kve155; Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677; Girardin SE, 2003, TRENDS IMMUNOL, V24, P652, DOI 10.1016/j.it.2003.10.007; Hisamatsu T, 2003, GASTROENTEROLOGY, V124, P993, DOI 10.1053/gast.2003.50153; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Inohara N, 2003, J BIOL CHEM, V278, P5509, DOI 10.1074/jbc.C200673200; Inohara N, 2005, ANNU REV BIOCHEM, V74, P355, DOI 10.1146/annurev.biochem.74.082803.133347; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Inohara N, 2001, J BIOL CHEM, V276, P2551, DOI 10.1074/jbc.M009728200; Kang DW, 1998, P NATL ACAD SCI USA, V95, P10078, DOI 10.1073/pnas.95.17.10078; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; Kobayashi KS, 2005, SCIENCE, V307, P731, DOI 10.1126/science.1104911; Li J, 2004, HUM MOL GENET, V13, P1715, DOI 10.1093/hmg/ddh182; Liu C, 2000, J BIOL CHEM, V275, P24490, DOI 10.1074/jbc.M001239200; Liu C, 2001, J BIOL CHEM, V276, P34686, DOI 10.1074/jbc.M105566200; Maeda S, 2005, SCIENCE, V307, P734, DOI 10.1126/science.1103685; McGovern DPB, 2005, HUM MOL GENET, V14, P1245, DOI 10.1093/hmg/ddi135; Mellroth P, 2005, P NATL ACAD SCI USA, V102, P6455, DOI 10.1073/pnas.0407559102; Mengin-Lecreulx D, 1999, J BACTERIOL, V181, P5909, DOI 10.1128/JB.181.19.5909-5914.1999; MENGINLECREULX D, 1985, J BACTERIOL, V163, P208, DOI 10.1128/JB.163.1.208-212.1985; Netea MG, 2004, EUR J IMMUNOL, V34, P2052, DOI 10.1002/eji.200425229; Netea MG, 2005, J IMMUNOL, V174, P6518, DOI 10.4049/jimmunol.174.10.6518; Ogura Y, 2003, GUT, V52, P1591, DOI 10.1136/gut.52.11.1591; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Philpott DJ, 2001, CURR OPIN IMMUNOL, V13, P410; Rogler G, 2004, CURR OPIN GASTROEN, V20, P311, DOI 10.1097/00001574-200407000-00003; Stenbak CR, 2004, J IMMUNOL, V173, P7339, DOI 10.4049/jimmunol.173.12.7339; Traub S, 2004, J BIOL CHEM, V279, P8694, DOI 10.1074/jbc.M310556200; Travassos LH, 2004, EMBO REP, V5, P1000, DOI 10.1038/sj.embor.7400248; van Heel DA, 2005, EUR J IMMUNOL, V35, P2471, DOI 10.1002/eji.200526296; Vavricka SR, 2004, GASTROENTEROLOGY, V127, P1401, DOI 10.1053/j.gastro.2004.07.024; Watanabe T, 2004, NAT IMMUNOL, V5, P800, DOI 10.1038/ni1092; Wehkamp J, 2004, GUT, V53, P1658, DOI 10.1136/gut.2003.032805	44	66	68	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35859	35867		10.1074/jbc.M504924200	http://dx.doi.org/10.1074/jbc.M504924200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16115863	Green Published, hybrid			2022-12-25	WOS:000232726900012
J	Kang, SG; Dimitrova, MN; Ortega, JQ; Ginsburg, A; Maurizi, MR				Kang, SG; Dimitrova, MN; Ortega, JQ; Ginsburg, A; Maurizi, MR			Human mitochondrial ClpP is a stable heptamer that assembles into a tetradecamer in the presence of ClpX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-DEPENDENT PROTEASES; ESCHERICHIA-COLI; MOLECULAR CHAPERONE; REGULATORY SUBUNITS; DEGRADATION MACHINE; PROTEIN-BINDING; BACTERIAL CLPX; AMINO-ACID; PROTEOLYSIS; SPECIFICITY	The functional form of ClpP, the proteolytic component of ATP-dependent Clp proteases, is a hollow- cored particle composed of two heptameric rings joined face- to- face forming an aqueous chamber containing the proteolytic active sites. We have found that isolated human mitochondrial ClpP ( hClpP) is stable as a heptamer and remains a monodisperse species ( s(20,w) 7.0 S; M-app 169, 200) at concentrations >= 3 mg/ ml. Heptameric hClpP has no proteolytic activity and very low peptidase activity. In the presence of ATP, hClpX interacts with hClpP forming a complex, which by equilibrium sedimentation measurements has a M-app of 1 x 10(6). Electron microscopy confirmed that the complex consisted of a double ring of hClpP with an hClpX ring axially aligned on each end. The hClpXP complex has protease activity and greatly increased peptidase activity, indicating that interaction with hClpX affects the conformation of the hClpP catalytic active site. A mutant of hClpP, in which a cysteine residue was introduced into the handle region at the interface between the two rings formed stable tetradecamers under oxidizing conditions but spontaneously dissociated into two heptamers upon reduction. Thus, hClpP rings interact transiently but very weakly in solution, and hClpX must exert an allosteric effect on hClpP to promote a conformation that stabilizes the tetradecamer. These data suggest that hClpX can regulate the appearance of hClpP peptidase activity in mitochondria and might affect the nature of the degradation products released during ATP- dependent proteolytic cycles.	NCI, Cell Biol Lab, Bethesda, MD 20892 USA; NHLBI, Biochem Lab, NIH, Bethesda, MD 20892 USA; NIAMS, Struct Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Maurizi, MR (corresponding author), NCI, Cell Biol Lab, Bldg 37 Rm 2128,37 Convent Dr, Bethesda, MD 20892 USA.	mmaurizi@helix.nih.gov			Intramural NIH HHS Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000310] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adam Z, 2002, TRENDS PLANT SCI, V7, P451, DOI 10.1016/S1360-1385(02)02326-9; Becker G, 1999, P NATL ACAD SCI USA, V96, P6439, DOI 10.1073/pnas.96.11.6439; Bross P, 1995, FEBS LETT, V377, P249, DOI 10.1016/0014-5793(95)01353-9; Corydon TJ, 2000, MAMM GENOME, V11, P899, DOI 10.1007/s003350010173; Flynn JM, 2003, MOL CELL, V11, P671, DOI 10.1016/S1097-2765(03)00060-1; Gottesman S, 2003, ANNU REV CELL DEV BI, V19, P565, DOI 10.1146/annurev.cellbio.19.110701.153228; Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815; Gribun A, 2005, J BIOL CHEM, V280, P16185, DOI 10.1074/jbc.M414124200; Grimaud R, 1998, J BIOL CHEM, V273, P12476, DOI 10.1074/jbc.273.20.12476; Groll M, 2000, NAT STRUCT BIOL, V7, P1062, DOI 10.1038/80992; Halperin T, 2001, PLANT MOL BIOL, V45, P461, DOI 10.1023/A:1010677220323; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hoskins JR, 2000, P NATL ACAD SCI USA, V97, P8892, DOI 10.1073/pnas.97.16.8892; Kang SG, 2004, J STRUCT BIOL, V148, P338, DOI 10.1016/j.jsb.2004.07.004; Kang SG, 2002, J BIOL CHEM, V277, P21095, DOI 10.1074/jbc.M201642200; Kenniston JA, 2003, CELL, V114, P511, DOI 10.1016/S0092-8674(03)00612-3; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; Kim DY, 2003, J BIOL CHEM, V278, P50664, DOI 10.1074/jbc.M305882200; Levchenko I, 2000, SCIENCE, V289, P2354, DOI 10.1126/science.289.5488.2354; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; Levchenko I, 1997, CELL, V91, P939, DOI 10.1016/S0092-8674(00)80485-7; Lupas A, 1997, TRENDS BIOCHEM SCI, V22, P399, DOI 10.1016/S0968-0004(97)01117-1; Maurizi MR, 1998, BIOCHEMISTRY-US, V37, P7778, DOI 10.1021/bi973093e; Maurizi MR, 2004, STRUCTURE, V12, P175, DOI 10.1016/j.str.2004.01.021; Neuwald AF, 1999, GENOME RES, V9, P27; Nosworthy NJ, 1998, BIOCHEMISTRY-US, V37, P6718, DOI 10.1021/bi980126x; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; Ortega J, 2002, EMBO J, V21, P4938, DOI 10.1093/emboj/cdf483; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; Santagata S, 1999, J BIOL CHEM, V274, P16311, DOI 10.1074/jbc.274.23.16311; SCHACHMAN HK, 1959, ULTRACENTRIFUGATION, P116; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Schweder T, 1996, J BACTERIOL, V178, P470, DOI 10.1128/jb.178.2.470-476.1996; SHAPIRO BM, 1968, BIOCHEMISTRY-US, V7, P2153, DOI 10.1021/bi00846a018; Singh SK, 2000, P NATL ACAD SCI USA, V97, P8898, DOI 10.1073/pnas.97.16.8898; Singh SK, 2001, J BIOL CHEM, V276, P29420, DOI 10.1074/jbc.M103489200; Stafford WF, 1997, CURR OPIN BIOTECH, V8, P14, DOI 10.1016/S0958-1669(97)80152-8; THOMPSON MW, 1994, J BIOL CHEM, V269, P18201; Weber-Ban EU, 1999, NATURE, V401, P90, DOI 10.1038/43481; Whitby FG, 2000, NATURE, V408, P115, DOI 10.1038/35040607; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; ZAMYATNIN AA, 1984, ANNU REV BIOPHYS BIO, V13, P145, DOI 10.1146/annurev.bb.13.060184.001045; Zhou YN, 2001, GENE DEV, V15, P627, DOI 10.1101/gad.864401; Zolkiewski M, 1997, BIOCHEMISTRY-US, V36, P7876, DOI 10.1021/bi962947c	45	86	94	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35424	35432		10.1074/jbc.M507240200	http://dx.doi.org/10.1074/jbc.M507240200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16115876	hybrid			2022-12-25	WOS:000232561200042
J	Wei, X; Ni, S; Correll, PH				Wei, X; Ni, S; Correll, PH			Uncoupling ligand-dependent and -independent mechanisms for mitogen-activated protein kinase activation by the murine ron receptor tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE-STIMULATING PROTEIN; CELL-TRANSFORMATION; STRUCTURAL BASIS; TRUNCATED FORM; IFN-GAMMA; GROWTH; GRB2; MET; BINDING; PATHWAYS	Receptor tyrosine kinases (RTKs) activate downstream signaling through cognate growth factor receptor-induced dimerization and autophosphorylation. Overexpression of RTKs can lead to constitutive activation due to increased dimerization in the absence of ligand, and downstream signals are presumed to be the same as the ligand-induced signals. We have shown that the murine Ron (mRon) receptor tyrosine kinase exhibits constitutive activation of the MAP kinase pathway that is independent of the two docking site tyrosines, whereas activation of this pathway in response to ligand (macrophage-stimulating protein) is abolished in the absence of these tyrosines. Furthermore, we identified three tyrosines (Tyr-1175, Tyr-1265, and Tyr-1294) within the kinase domain that play critical but overlapping roles in controlling constitutive Erk activation by mRon. Phenylalanine mutations at these three tyrosines results in a receptor that fails to constitutively activate the Erk pathway but retains the ability to induce Erk phosphorylation in response to ligand stimulation. The ability of mRon to activate the MAP kinase pathway is dependent on c-Src activity, and we have shown that c-Src co-immunoprecipitates with mRon. c-Src fails to interact with mRon when the three tyrosines required for MAP kinase activation are mutated, whereas the presence of any one of these tyrosines alone restores Erk phosphorylation and recruitment of c-Src. Thus, the ligand-dependent and -independent activity of mRon can be uncoupled through the alteration of selective sets of tyrosines.	Penn State Univ, Grad Program Biochem & Mol Biol, University Pk, PA 16802 USA; Penn State Univ, Integrat Biosci Grad Program, University Pk, PA 16802 USA; Penn State Univ, Dept Vet Sci, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Correll, PH (corresponding author), Penn State Univ, Grad Program Biochem & Mol Biol, 115 Henning Bldg, University Pk, PA 16802 USA.	phc7@psu.edu	wei, xin/C-1395-2011		NHLBI NIH HHS [R01-HL66471] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066471] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arevalo JC, 2000, MOL CELL BIOL, V20, P5908, DOI 10.1128/MCB.20.16.5908-5916.2000; Bezerra JA, 1998, J CLIN INVEST, V101, P1175, DOI 10.1172/JCI1744; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Carlomagno F, 1997, CANCER RES, V57, P391; Chan EL, 2005, ONCOGENE, V24, P479, DOI 10.1038/sj.onc.1208231; Correll Pamela H., 1997, Genes and Function, V1, P69; Cross NCP, 2002, LEUKEMIA, V16, P1207, DOI 10.1038/sj.leu.2402556; Encinas M, 2004, J BIOL CHEM, V279, P18262, DOI 10.1074/jbc.M400505200; Finkelstein LD, 2002, ONCOGENE, V21, P3562, DOI 10.1038/sj.onc.1205442; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; Griffith J, 2004, MOL CELL, V13, P169, DOI 10.1016/S1097-2765(03)00505-7; Hirota S, 2001, J PATHOL, V193, P505, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH818>3.0.CO;2-E; Hong L, 2004, MOL CELL BIOL, V24, P1401, DOI 10.1128/MCB.24.3.1401-1410.2004; Ischenko I, 2003, ONCOGENE, V22, P6311, DOI 10.1038/sj.onc.1206742; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Kiyoi H, 2002, ONCOGENE, V21, P2555, DOI 10.1038/sj.onc.1205332; Lewitzky M, 2001, ONCOGENE, V20, P1052, DOI 10.1038/sj.onc.1204202; Liu QP, 1999, J IMMUNOL, V163, P6606; Maina F, 2001, MOL CELL, V7, P1293, DOI 10.1016/S1097-2765(01)00261-1; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; Morrison AC, 2004, J IMMUNOL, V172, P1825, DOI 10.4049/jimmunol.172.3.1825; Morrison AC, 2002, J IMMUNOL, V168, P853, DOI 10.4049/jimmunol.168.2.853; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; NIEMANN C, 1996, NATURE, V384, P173; Nishigaki K, 2001, J VIROL, V75, P7893, DOI 10.1128/JVI.75.17.7893-7903.2001; Park CY, 1999, J BIOL CHEM, V274, P7583, DOI 10.1074/jbc.274.11.7583; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; Peace BE, 2005, CANCER RES, V65, P1285, DOI 10.1158/0008-5472.CAN-03-3580; Persons DA, 1999, NAT GENET, V23, P159, DOI 10.1038/13787; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Piao XH, 1996, P NATL ACAD SCI USA, V93, P14665, DOI 10.1073/pnas.93.25.14665; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Rosario M, 2003, TRENDS CELL BIOL, V13, P328, DOI 10.1016/S0962-8924(03)00104-1; Sakkab D, 2000, J BIOL CHEM, V275, P10772, DOI 10.1074/jbc.275.15.10772; Santoro MM, 2000, ONCOGENE, V19, P5208, DOI 10.1038/sj.onc.1203819; Santoro MM, 2003, DEV CELL, V5, P257, DOI 10.1016/S1534-5807(03)00201-6; Sasaki A, 2003, NAT CELL BIOL, V5, P427, DOI 10.1038/ncb978; Saucier C, 2002, ONCOGENE, V21, P1800, DOI 10.1038/sj.onc.1205261; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; Schiering N, 2003, P NATL ACAD SCI USA, V100, P12654, DOI 10.1073/pnas.1734128100; SMITH DR, 1989, P NATL ACAD SCI USA, V86, P5291, DOI 10.1073/pnas.86.14.5291; van den Akker E, 2004, BLOOD, V103, P4457, DOI 10.1182/blood-2003-08-2713; Wybenga-Groot LE, 2001, CELL, V106, P745, DOI 10.1016/S0092-8674(01)00496-2; Zhou YQ, 2003, ONCOGENE, V22, P186, DOI 10.1038/sj.onc.1206075	45	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35098	35107		10.1074/jbc.M505737200	http://dx.doi.org/10.1074/jbc.M505737200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16103119	hybrid			2022-12-25	WOS:000232561200006
J	Brodin, P; de Jonge, MI; Majlessi, L; Leclerc, C; Nilges, M; Cole, ST; Brosch, R				Brodin, P; de Jonge, MI; Majlessi, L; Leclerc, C; Nilges, M; Cole, ST; Brosch, R			Functional analysis of early secreted antigenic target-6, the dominant T-cell antigen of Mycobacterium tuberculosis, reveals key residues involved in secretion, complex formation, virulence, and immunogenicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCED PROTECTION; CALMETTE-GUERIN; BOVIS BCG; ESAT-6; RD1; PROTEINS; PATHOGENESIS; ATTENUATION; DELETION; MICROTI	Proteins of the 6-kDa early secreted antigenic target (ESAT-6) secretion system-1 of Mycobacterium tuberculosis are not only strongly involved in the anti-mycobacterial Th1-host immune response but are also key players for virulence. In this study, protein engineering together with bioinformatic, immunological, and virulence analyses allowed us to pinpoint regions of the ESAT-6 molecule that are critical for its biological activity in M. tuberculosis. Mutation of the Trp-Xaa-Gly motif, conserved in a wide variety of ESAT-6-like proteins, abolished complex formation with the partner protein CFP-10, induction of specific T-cell responses, and virulence. Replacement of conserved Leu residues interfered with secretion, coiled-coil formation, and virulence, whereas certain mutations at the extreme C terminus did not affect secretion but caused attenuation, possibly because of altered ESAT-6 targeting or trafficking. In contrast, the mutation of several residues on the outer surface of the four-helical bundle structure of the ESAT-6 center dot CFP-10 complex showed much less effect. Construction of recombinant BCG expressing ESAT-6 with a C-terminal hexahistidine tag allowed us to co-purify ESAT-6 and CFP-10, experimentally confirming their strong interaction both in and outside of the mycobacterial cell. The strain induced potent, antigen-specific T-cell responses and intermediate in vivo growth in mice, suggesting that it remained immunogenic and biologically active despite the tag. Together with previous NMR data, the results of this study have allowed a biologically relevant model of the ESAT-6 center dot CFP-10 complex to be constructed that is critical for understanding the structure-function relationship in tuberculosis pathogenesis.	Inst Pasteur, Unite Genet Mol Bacterienne, F-75724 Paris, France; Inst Pasteur, INSERM, E352, Unite Biol Regulat Immunitaires, F-75724 Paris, France; Inst Pasteur, Unite Bioinformat Struct, F-75724 Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Brosch, R (corresponding author), Inst Pasteur, Unite Genet Mol Bacterienne, 28 Rue Dr Roux, F-75724 Paris, France.	rbrosch@pasteur.fr	Brosch, Roland/ABB-4108-2021; Brodin, Priscille/N-6979-2019; Nilges, Michael/E-4803-2011; Brosch, Roland/AAZ-3850-2021; Brodin, Priscille/E-5802-2014; de Jonge, Marien I./P-5869-2015	Brodin, Priscille/0000-0003-0991-7344; Nilges, Michael/0000-0002-1451-8092; Brosch, Roland/0000-0003-2587-3863; Brodin, Priscille/0000-0003-0991-7344; de Jonge, Marien I./0000-0003-2812-5895; deboosere, Nathalie/0000-0002-2873-5485				Agou F, 2002, J BIOL CHEM, V277, P17464, DOI 10.1074/jbc.M201964200; Brodin P, 2004, J INFECT DIS, V190, P115, DOI 10.1086/421468; Brodin P, 2002, INFECT IMMUN, V70, P5568, DOI 10.1128/IAI.70.10.5568-5578.2002; Brosch R, 2002, P NATL ACAD SCI USA, V99, P3684, DOI 10.1073/pnas.052548299; Brosch R, 1998, INFECT IMMUN, V66, P2221, DOI 10.1128/IAI.66.5.2221-2229.1998; Burts ML, 2005, P NATL ACAD SCI USA, V102, P1169, DOI 10.1073/pnas.0405620102; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Guinn KM, 2004, MOL MICROBIOL, V51, P359, DOI 10.1046/j.1365-2958.2003.03844.x; Horn C, 1999, J BIOL CHEM, V274, P32023, DOI 10.1074/jbc.274.45.32023; Hsu T, 2003, P NATL ACAD SCI USA, V100, P12420, DOI 10.1073/pnas.1635213100; Kim KK, 1999, NATURE, V400, P787, DOI 10.1038/23512; Kwok SC, 2004, J BIOL CHEM, V279, P21576, DOI 10.1074/jbc.M401074200; Lewis KN, 2003, J INFECT DIS, V187, P117, DOI 10.1086/345862; Lightbody KL, 2004, FEMS MICROBIOL LETT, V238, P255, DOI 10.1016/j.femsle.2004.07.043; Mahairas GG, 1996, J BACTERIOL, V178, P1274, DOI 10.1128/jb.178.5.1274-1282.1996; Majlessi L, 2005, J IMMUNOL, V174, P3570, DOI 10.4049/jimmunol.174.6.3570; Mostowy S, 2004, J BACTERIOL, V186, P104, DOI 10.1128/JB.186.1.104-109.2003; NILGES M, 1991, PROTEIN ENG, V4, P649, DOI 10.1093/protein/4.6.649; Okkels LM, 2004, PROTEOMICS, V4, P2954, DOI 10.1002/pmic.200400906; Okkels LM, 2004, J BACTERIOL, V186, P2487, DOI 10.1128/JB.186.8.2487-2491.2004; Pallen MJ, 1997, MOL MICROBIOL, V25, P423, DOI 10.1046/j.1365-2958.1997.4901850.x; Pallen MJ, 2002, TRENDS MICROBIOL, V10, P209, DOI 10.1016/S0966-842X(02)02345-4; Polevoda B, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-5-reviews0006; Pym AS, 2003, NAT MED, V9, P533, DOI 10.1038/nm859; Pym AS, 2002, MOL MICROBIOL, V46, P709, DOI 10.1046/j.1365-2958.2002.03237.x; Renshaw PS, 2004, J BIOMOL NMR, V30, P225, DOI 10.1023/B:JNMR.0000048852.40853.5c; Renshaw PS, 2002, J BIOL CHEM, V277, P21598, DOI 10.1074/jbc.M201625200; Sassetti CM, 2003, P NATL ACAD SCI USA, V100, P12989, DOI 10.1073/pnas.2134250100; Stanley SA, 2003, P NATL ACAD SCI USA, V100, P13001, DOI 10.1073/pnas.2235593100; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606	30	115	139	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33953	33959		10.1074/jbc.M503515200	http://dx.doi.org/10.1074/jbc.M503515200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16048998	hybrid			2022-12-25	WOS:000232229700032
J	Champagne, KS; Sissler, M; Larrabee, Y; Doublie, S; Francklyn, SS				Champagne, KS; Sissler, M; Larrabee, Y; Doublie, S; Francklyn, SS			Activation of the hetero-octameric ATP phosphoribosyl transferase through subunit interface rearrangement by a tRNA synthetase paralog	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; TRIPHOSPHATE SYNTHETASE; ADENOSINE-TRIPHOSPHATE; HISTIDINE BIOSYNTHESIS; 1ST ENZYME; SPECIFICITY; INHIBITION; TRANSITION; PURINE; PHOSPHATE	ATP phosphoribosyl transferase (ATP-PRT) joins ATP and 5-phosphoribosyl-1- pyrophosphate ( PRPP) in a highly regulated reaction that initiates histidine biosynthesis. The unusual hetero-octameric version of ATP-PRT includes four HisG(S) catalytic subunits based on the periplasmic binding protein fold and four HisZ regulatory subunits that resemble histidyl-tRNA synthetases. Here, we present the first structure of a PRPP-bound ATP-PRT at 2.9 angstrom and provide a structural model for allosteric activation based on comparisons with other inhibited and activated ATP-PRTs from both the hetero-octameric and hexameric families. The activated state of the octameric enzyme is characterized by an interstitial phosphate ion in the HisZ-HisG interface and new contacts between the HisZ motif 2 loop and the HisGS dimer interface. These contacts restructure the interface to recruit conserved residues to the active site, where they activate pyrophosphate to promote catalysis. Additionally, mutational analysis identifies the histidine binding sites within a region highly conserved between HisZ and the functional HisRS. Through the oligomerization and functional re-assignment of protein domains associated with aminoacylation and phosphate binding, the HisZ-HisG octameric ATP-PRT acquired the ability to initiate the synthesis of a key metabolic intermediate in an allosterically regulated fashion.	Univ Vermont, Markey Ctr Mol Genet, Dept Microbiol & Mol Genet, Burlington, VT 05405 USA; Univ Vermont, Dept Biochem, Burlington, VT 05405 USA	University of Vermont; University of Vermont	Doublie, S (corresponding author), Univ Vermont, Markey Ctr Mol Genet, Dept Microbiol & Mol Genet, Stafford Hall,95 Carrigan Dr, Burlington, VT 05405 USA.	sdoublie@uvm.edu	Glass, Karen C./AAV-1076-2021	Glass, Karen C./0000-0002-2761-733X; Doublie, Sylvie/0000-0002-6294-5304; SISSLER, Marie/0000-0001-8594-5238	NIGMS NIH HHS [GM62239, R01 GM054899-10, GM54899] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062239, R01GM054899] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arnez JG, 1997, P NATL ACAD SCI USA, V94, P7144, DOI 10.1073/pnas.94.14.7144; ARNEZ JG, 1995, EMBO J, V14, P4143, DOI 10.1002/j.1460-2075.1995.tb00088.x; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BELL RM, 1974, J BIOL CHEM, V249, P4110; Bond JP, 2000, J MOL EVOL, V50, P339, DOI 10.1007/s002399910037; Bovee ML, 2002, BIOCHEMISTRY-US, V41, P11838, DOI 10.1021/bi020243z; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carrodeguas JA, 2001, MOL CELL, V7, P43, DOI 10.1016/S1097-2765(01)00153-8; Cho Y, 2003, J BIOL CHEM, V278, P8333, DOI 10.1074/jbc.M212124200; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; DELORME C, 1992, J BACTERIOL, V174, P6571, DOI 10.1128/JB.174.20.6571-6579.1992; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Eads JC, 1997, STRUCTURE, V5, P47, DOI 10.1016/S0969-2126(97)00165-2; Eriksen TA, 2000, NAT STRUCT BIOL, V7, P303; Fedorov A, 2001, BIOCHEMISTRY-US, V40, P853, DOI 10.1021/bi002499f; Francklyn C, 2003, P NATL ACAD SCI USA, V100, P9650, DOI 10.1073/pnas.1934245100; Francklyn C, 2005, AMINOACYL TRNA SYNTH, P135; GOITEIN RK, 1978, J BIOL CHEM, V253, P2963; Hawko SA, 2001, BIOCHEMISTRY-US, V40, P1930, DOI 10.1021/bi0025316; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLUNGSOYR L, 1971, BIOCHIM BIOPHYS ACTA, V227, P327, DOI 10.1016/0005-2744(71)90064-7; Lohkamp B, 2004, J MOL BIOL, V336, P131, DOI 10.1016/j.jmb.2003.12.020; MARTIN RG, 1963, J BIOL CHEM, V238, P257; Mayans O, 2002, EMBO J, V21, P3245, DOI 10.1093/emboj/cdf298; MORTON DP, 1976, ARCH BIOCHEM BIOPHYS, V175, P677, DOI 10.1016/0003-9861(76)90559-2; MORTON DP, 1977, ARCH BIOCHEM BIOPHYS, V181, P643, DOI 10.1016/0003-9861(77)90270-3; MUSICK WDL, 1981, CRC CR REV BIOCH MOL, V11, P1, DOI 10.3109/10409238109108698; Nakatsu T, 1998, NAT STRUCT BIOL, V5, P15, DOI 10.1038/nsb0198-15; O'Brien PJ, 1999, CHEM BIOL, V6, pR91, DOI 10.1016/S1074-5521(99)80033-7; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARSONS SM, 1974, J BIOL CHEM, V249, P4119; Qiu XY, 1999, BIOCHEMISTRY-US, V38, P12296, DOI 10.1021/bi990482v; Quiocho FA, 1996, KIDNEY INT, V49, P943, DOI 10.1038/ki.1996.132; Quiocho FA, 1996, MOL MICROBIOL, V20, P17, DOI 10.1111/j.1365-2958.1996.tb02484.x; Schramm VL, 2004, PROG NUCLEIC ACID RE, V78, P261, DOI 10.1016/S0079-6603(04)78007-1; Schramm VL, 2003, ACCOUNTS CHEM RES, V36, P588, DOI 10.1021/ar0200495; Sinha SC, 2001, CURR OPIN STRUC BIOL, V11, P733, DOI 10.1016/S0959-440X(01)00274-3; Sissler M, 1999, P NATL ACAD SCI USA, V96, P8985, DOI 10.1073/pnas.96.16.8985; SMITH JL, 1994, SCIENCE, V264, P1427, DOI 10.1126/science.8197456; Smith JL, 1999, NAT STRUCT BIOL, V6, P502, DOI 10.1038/9266; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Uson I, 1999, CURR OPIN STRUC BIOL, V9, P643, DOI 10.1016/S0959-440X(99)00020-2; Vega MC, 2005, MOL MICROBIOL, V55, P675, DOI 10.1111/j.1365-2958.2004.04422.x; Vogel H.J., 1971, METABOLIC REGULATION, V5, P349; VOLL MJ, 1967, J BIOL CHEM, V242, P1760; Wang ZM, 1997, NAT STRUCT BIOL, V4, P519, DOI 10.1038/nsb0797-519; Willemoes M, 2000, J BIOL CHEM, V275, P35408, DOI 10.1074/jbc.M006346200; Winkler M.E., 1987, ESCHERICHIA COLI SAL, P395; Yaremchuk A, 2001, J MOL BIOL, V309, P989, DOI 10.1006/jmbi.2001.4712	50	21	21	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34096	34104		10.1074/jbc.M505041200	http://dx.doi.org/10.1074/jbc.M505041200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16051603	hybrid			2022-12-25	WOS:000232229700050
J	Nakagawa, M; Oliva, JL; Kothapalli, D; Fournier, A; Assoian, RK; Kazanietz, MG				Nakagawa, M; Oliva, JL; Kothapalli, D; Fournier, A; Assoian, RK; Kazanietz, MG			Phorbol ester-induced G(1) phase arrest selectively mediated by protein kinase C delta-dependent induction of p21	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUNG-CANCER CELLS; INTESTINAL EPITHELIAL-CELLS; VASCULAR ENDOTHELIAL-CELLS; PROSTATE-CANCER; PKC-DELTA; COLON CARCINOGENESIS; CLINICAL DEVELOPMENT; TUMOR PROMOTION; DNA-SYNTHESIS; MUSCLE-CELLS	Although protein kinase C (PKC) has been widely implicated in the positive and negative control of proliferation, the underlying cell cycle mechanisms regulated by individual PKC isozymes are only partially understood. In this report, we show that PKC delta mediates phorbol ester-induced G(1) arrest in lung adenocarcinoma cells and establish an essential role for this novel PKC in controlling the expression of the cell cycle inhibitor p21. Activation of PKC with phorbol 12-myristate 13-acetate (PMA) in early G(1) phase impaired progression of lung adenocarcinoma cells into S phase, an effect that was completely abolished by specific depletion of PKC delta, but not PKC alpha. Although the PKC effect was unrelated to the inhibition of cyclin D1 expression, PKC activation significantly up-regulated p21 and down-regulated Rb hyperphosphorylation and cyclin A expression. Elevations in p21 mRNA and protein by PMA were mediated by PKC delta but not PKC alpha. Studies using luciferase reporters also revealed an essential role for PKC delta in the PMA-induced inhibition of Rb-dependent cyclin A promoter activity. Finally, we showed that the cell cycle inhibitory effect of PKC delta is greatly attenuated by RNA interference-mediated knock-down of p21. Our results identify a novel link between PKC delta and G(1) arrest via p21 up-regulation and highlight the complexities in the downstream effectors of PKC isozymes in the context of cell cycle progression and proliferation.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania	Kazanietz, MG (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, 816 Biomed Res Bldg 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	marcelo@spirit.gcrc.upenn.edu			NCI NIH HHS [R25-CA101871, CA-89202, CA-95237] Funding Source: Medline; NIGMS NIH HHS [GM-51878] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R25CA101871, R01CA089202] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051878] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akashi M, 1999, BIOCHEM J, V337, P607, DOI 10.1042/0264-6021:3370607; Alisi A, 2004, J CELL PHYSIOL, V201, P259, DOI 10.1002/jcp.20060; Ashton AW, 1999, J BIOL CHEM, V274, P20805, DOI 10.1074/jbc.274.30.20805; Barry OP, 2001, CURR PHARM DESIGN, V7, P1725, DOI 10.2174/1381612013397041; BORNER C, 1995, J BIOL CHEM, V270, P78, DOI 10.1074/jbc.270.1.78; Buitrago CG, 2003, J BIOL CHEM, V278, P2199, DOI 10.1074/jbc.M205732200; Clamp A, 2002, ANTI-CANCER DRUG, V13, P673, DOI 10.1097/00001813-200208000-00001; Clark AS, 2003, CANCER RES, V63, P780; Clark JA, 2004, J BIOL CHEM, V279, P9233, DOI 10.1074/jbc.M312268200; DeVries TA, 2004, J BIOL CHEM, V279, P45603, DOI 10.1074/jbc.M407448200; Ding L, 2002, J BIOL CHEM, V277, P35305, DOI 10.1074/jbc.M201460200; Fima E, 2001, ONCOGENE, V20, P6794, DOI 10.1038/sj.onc.1204885; Frey MR, 2000, J CELL BIOL, V151, P763, DOI 10.1083/jcb.151.4.763; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; Gavrielides MV, 2004, CURR DRUG TARGETS, V5, P431, DOI 10.2174/1389450043345380; Han ZT, 1998, P NATL ACAD SCI USA, V95, P5357, DOI 10.1073/pnas.95.9.5357; Han ZT, 1998, P NATL ACAD SCI USA, V95, P5362, DOI 10.1073/pnas.95.9.5362; Hemstrom TH, 2005, EXP CELL RES, V305, P200, DOI 10.1016/j.yexcr.2004.12.017; Heusch WL, 1998, CARCINOGENESIS, V19, P551, DOI 10.1093/carcin/19.4.551; Kothapalli D, 2003, MOL PHARMACOL, V64, P249, DOI 10.1124/mol.64.2.249; Lahn M, 2004, ONCOLOGY-BASEL, V67, P1, DOI 10.1159/000080279; Lahn Michael, 2004, Clin Lung Cancer, V6, P184, DOI 10.3816/CLC.2004.n.032; Leontieva OV, 2004, J BIOL CHEM, V279, P5788, DOI 10.1074/jbc.M308375200; Livneh E, 1996, ONCOGENE, V12, P1545; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; Mandil R, 2001, CANCER RES, V61, P4612; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Murray NR, 2004, J CELL BIOL, V164, P797, DOI 10.1083/jcb.200311011; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Reddig PJ, 1999, CANCER RES, V59, P5710; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Strair RK, 2002, CLIN CANCER RES, V8, P2512; Tanaka Y, 2003, J BIOL CHEM, V278, P33753, DOI 10.1074/jbc.M303313200; Tortora G, 2003, SEMIN ONCOL, V30, P26, DOI 10.1016/S0093-7754(03)00282-3; Vrana JA, 1999, BIOCHEM PHARMACOL, V58, P121, DOI 10.1016/S0006-2952(99)00077-5; Wu DQ, 2002, CANCER RES, V62, P2423; Yang CF, 2003, TRENDS PHARMACOL SCI, V24, P602, DOI 10.1016/j.tips.2003.09.003; Yu DS, 2002, BIOCHEMISTRY-US, V41, P11888, DOI 10.1021/bi020270p; Yu WS, 2003, J BIOL CHEM, V278, P11167, DOI 10.1074/jbc.M211424200; Zeng YX, 1996, ONCOGENE, V12, P1557; Zhao X, 1997, J BIOL CHEM, V272, P22751, DOI 10.1074/jbc.272.36.22751; Zhong MH, 2002, ONCOGENE, V21, P1071, DOI 10.1038/sj/onc/1205165; ZHOU W, 1993, J BIOL CHEM, V268, P23041; ZHOU W, 1994, BIOCHEM BIOPH RES CO, V199, P191, DOI 10.1006/bbrc.1994.1213; Zou YY, 1998, J NATL CANCER I, V90, P1130, DOI 10.1093/jnci/90.15.1130	46	64	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33926	33934		10.1074/jbc.M505748200	http://dx.doi.org/10.1074/jbc.M505748200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16055435	hybrid			2022-12-25	WOS:000232229700029
J	Song, YT; Masison, DC				Song, YT; Masison, DC			Independent regulation of Hsp70 and Hsp90 chaperones by Hsp70/Hsp90-organizing protein Sti1 (Hop1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; STEROID-RECEPTOR ACTION; HEAT-SHOCK PROTEINS; PROGESTERONE-RECEPTOR; SIGNAL-TRANSDUCTION; IN-VIVO; BINDING; PROPAGATION; STRESS; PRION	Hsp70 and Hsp90 protein chaperones cooperate in a protein-folding pathway required by many "client" proteins. The co-chaperone Sti1p coordinates functions of Hsp70 and Hsp90 in this pathway. Sti1p has three tetratricopeptide repeat (TPR) domains. TPR1 binds Hsp70, TPR2a binds Hsp90, and the ligand for TPR2b is unknown. Although Sti1p is thought to be dedicated to the client folding pathway, we earlier showed that Sti1p regulated Hsp70, independently of Hsp90, in a way that impairs yeast [PSI+] prion propagation. Using this prion system to monitor Sti1p regulation of Hsp70 and an Hsp90-inhibiting compound to monitor Hsp90 regulation, we identified Sti1p mutations that separately affect Hsp70 and Hsp90. TPR1 mutations impaired Sti1p regulation of Hsp70, but deletion of TPR2a and TPR2b did not. Conversely, TPR2a and TPR2b mutations impaired Sti1p regulation of Hsp90, but deletion of TPR1 did not. All Sti1p mutations variously impaired the client folding pathway, which requires both Hsp70 and Hsp90. Thus, Sti1p regulated Hsp70 and Hsp90 separately, Hsp90 is implicated as a TPR2b ligand, and mutations separately affecting regulation of either chaperone impair a pathway that is dependent upon both. We further demonstrate that client folding depended upon bridging of Hsp70 and Hsp90 by Sti1p and find conservation of the independent regulation of Hsp70 and Hsp90 by human Hop1.	NIDDK, Lab Biochem & Genet, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Masison, DC (corresponding author), NIDDK, Lab Biochem & Genet, NIH, Bldg 8,Rm 407,8 Ctr Dr, Bethesda, MD 20892 USA.	masisond@helix.nih.gov			NIDDK NIH HHS [Z01 DK024946-08] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK024946, Z01DK024946] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abbas-Terki T, 2001, MOL CELL BIOL, V21, P7569, DOI 10.1128/MCB.21.22.7569-7575.2001; Carrigan PE, 2005, J BIOL CHEM, V280, P8906, DOI 10.1074/jbc.M414245200; Carrigan PE, 2004, J BIOL CHEM, V279, P16185, DOI 10.1074/jbc.M314130200; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; Chen SY, 1998, J BIOL CHEM, V273, P35194, DOI 10.1074/jbc.273.52.35194; COX BS, 1965, HEREDITY, V20, P505, DOI 10.1038/hdy.1965.65; Duina AA, 1996, SCIENCE, V274, P1713, DOI 10.1126/science.274.5293.1713; Harger JW, 2003, RNA, V9, P1019, DOI 10.1261/rna.5930803; Hentze MW, 1999, CELL, V96, P307, DOI 10.1016/S0092-8674(00)80542-5; Hernandez MP, 2002, J BIOL CHEM, V277, P38294, DOI 10.1074/jbc.M206566200; Hernandez MP, 2002, J BIOL CHEM, V277, P11873, DOI 10.1074/jbc.M111445200; Johnson BD, 1998, J BIOL CHEM, V273, P3679, DOI 10.1074/jbc.273.6.3679; Jones G, 2004, MOL CELL BIOL, V24, P3928, DOI 10.1128/MCB.24.9.3928-3937.2004; Jones GW, 2003, GENETICS, V163, P495; Jung G, 2000, GENETICS, V156, P559; Lassle M, 1997, J BIOL CHEM, V272, P1876, DOI 10.1074/jbc.272.3.1876; Lee J, 2004, BIOTECHNIQUES, V36, P398, DOI 10.2144/04363BM04; Louvion JF, 1996, P NATL ACAD SCI USA, V93, P13937, DOI 10.1073/pnas.93.24.13937; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; Odunuga OO, 2003, J BIOL CHEM, V278, P6896, DOI 10.1074/jbc.M206867200; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; Pratt WB, 2004, ESSAYS BIOCHEM, V40, P41, DOI 10.1042/bse0400041; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Richter K, 2003, J BIOL CHEM, V278, P10328, DOI 10.1074/jbc.M213094200; Riggs DL, 2003, EMBO J, V22, P1158, DOI 10.1093/emboj/cdg108; SCHATZ PJ, 1988, GENETICS, V120, P681; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; SCHENA M, 1991, METHOD ENZYMOL, V194, P389; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; SHERMAN F, 1994, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; Song YT, 2002, FEBS LETT, V512, P213, DOI 10.1016/S0014-5793(02)02258-5; STANSFIELD I, 1995, EMBO J, V14, P4365, DOI 10.1002/j.1460-2075.1995.tb00111.x; Wegele H, 2003, J BIOL CHEM, V278, P25970, DOI 10.1074/jbc.M301548200; Wickner RB, 2000, J STRUCT BIOL, V130, P310, DOI 10.1006/jsbi.2000.4250; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; ZHOURAVLEVA G, 1995, EMBO J, V14, P4065, DOI 10.1002/j.1460-2075.1995.tb00078.x	38	83	83	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34178	34185		10.1074/jbc.M505420200	http://dx.doi.org/10.1074/jbc.M505420200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16100115	hybrid, Green Accepted			2022-12-25	WOS:000232229700059
J	Meurer, S; Pioch, S; Gross, S; Muller-Esterl, W				Meurer, S; Pioch, S; Gross, S; Muller-Esterl, W			Reactive oxygen species induce tyrosine phosphorylation of and src kinase recruitment to NO-sensitive guanylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; NITRIC-OXIDE; GROWTH-FACTOR; C-SRC; ACTIVATION; MECHANISM; BINDING; PHOSPHATASES; INVOLVEMENT; INHIBITION	Soluble guanylyl cyclase (sGC) is the major cytosolic receptor for nitric oxide (NO) that converts GTP into the second messenger cGMP in a NO-dependent manner. Other factors controlling this key enzyme are intracellular proteins such as Hsp90 and PSD95, which bind to sGC and modulate its activity, stability, and localization. To date little is known about the effects of posttranslational modifications of sGC, although circumstantial evidence suggests that reversible phosphorylation may contribute to sGC regulation. Here we demonstrate that inhibitors of protein-tyrosine phosphatases such as pervanadate and bisperoxo(1,10-phenanthroline) oxovanadate( V) as well as reactive oxygen species such as H2O2 induce specific tyrosine phosphorylation of the beta(1) but not of the alpha(1) subunit of sGC. Tyrosine phosphorylation of sGC beta(1) is also inducible by pervanadate and H2O2 in intact PC12 cells, rat aortic smooth muscle cells, and in rat aortic tissues, indicating that tyrosine phosphorylation of sGC may also occur in vivo. We have mapped the major tyrosine phosphorylation site to position 192 of beta(1), where it forms part of a highly acidic phospho-acceptor site for Src-like kinases. In the phosphorylated state Tyr(P)-192 exposes a docking site for SH2 domains and efficiently recruits Src and Fyn to sGC beta(1), thereby promoting multiple phosphorylation of the enzyme. Our results demonstrate that sGC is subject to tyrosine phosphorylation and interaction with Src-like kinases, revealing an unexpected cross-talk between the NO/cGMP and tyrosine kinase signaling pathways at the level of sGC.	Goethe Univ Frankfurt, Sch Med, Inst Biochem 2, D-60590 Frankfurt, Germany	Goethe University Frankfurt	Muller-Esterl, W (corresponding author), Goethe Univ Frankfurt, Sch Med, Inst Biochem 2, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	office@biochem2.de						Abe J, 1997, J BIOL CHEM, V272, P20389, DOI 10.1074/jbc.272.33.20389; Andreopoulos S, 2000, GEN PHARMACOL-VASC S, V34, P147, DOI 10.1016/S0306-3623(00)00062-8; Balashova N, 2005, J BIOL CHEM, V280, P2186, DOI 10.1074/jbc.M411545200; Bellamy TC, 2002, P NATL ACAD SCI USA, V99, P507, DOI 10.1073/pnas.012368499; Berry CE, 2004, J PHYSIOL-LONDON, V555, P589, DOI 10.1113/jphysiol.2003.055913; BRUNATI AM, 1995, FEBS LETT, V367, P149, DOI 10.1016/0014-5793(95)00555-N; BUECHLER WA, 1994, ANN NY ACAD SCI, V714, P151; Chen ZJ, 2001, J STEROID BIOCHEM, V78, P451, DOI 10.1016/S0960-0760(01)00122-4; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Ferrero R, 2000, J NEUROCHEM, V75, P2029, DOI 10.1046/j.1471-4159.2000.0752029.x; Filippov G, 1997, J CLIN INVEST, V100, P942, DOI 10.1172/JCI119610; Gross S, 1999, J BIOL CHEM, V274, P26378, DOI 10.1074/jbc.274.37.26378; HARTENECK C, 1990, FEBS LETT, V272, P221, DOI 10.1016/0014-5793(90)80489-6; Herrlich P, 2000, BIOCHEM PHARMACOL, V59, P35, DOI 10.1016/S0006-2952(99)00298-1; Houston M, 1999, J BIOL CHEM, V274, P4985, DOI 10.1074/jbc.274.8.4985; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Ivankovic-Dikic I, 2000, NAT CELL BIOL, V2, P574, DOI 10.1038/35023515; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Koesling D, 1999, METHODS, V19, P485, DOI 10.1006/meth.1999.0891; Koesling D, 1999, Rev Physiol Biochem Pharmacol, V135, P41, DOI 10.1007/BFb0033669; Kostic TS, 2004, MOL ENDOCRINOL, V18, P458, DOI 10.1210/me.2003-0015; Kyprianou N, 1997, PROSTATE, V32, P266; LOUIS JC, 1993, BIOCHIM BIOPHYS ACTA, V1177, P299, DOI 10.1016/0167-4889(93)90126-A; Lucas KA, 2000, PHARMACOL REV, V52, P375; Martin E, 2003, P NATL ACAD SCI USA, V100, P9208, DOI 10.1073/pnas.1633590100; Matsuoka H, 2004, J BIOL CHEM, V279, P5975, DOI 10.1074/jbc.M311278200; McPhee I, 1999, J BIOL CHEM, V274, P11796, DOI 10.1074/jbc.274.17.11796; Meurer S, 2004, J BIOL CHEM, V279, P49346, DOI 10.1074/jbc.M410565200; Mulsch A, 2001, CIRCULATION, V103, P2188; Murthy KS, 2001, BIOCHEM J, V360, P199, DOI 10.1042/0264-6021:3600199; Nedvetsky PI, 2002, P NATL ACAD SCI USA, V99, P16510, DOI 10.1073/pnas.262701999; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Rosado JA, 2004, J BIOL CHEM, V279, P1665, DOI 10.1074/jbc.M307963200; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Roskoski R, 2004, BIOCHEM BIOPH RES CO, V324, P1155, DOI 10.1016/j.bbrc.2004.09.171; Russwurm M, 2001, J BIOL CHEM, V276, P44647, DOI 10.1074/jbc.M105587200; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; STONE JR, 1994, BIOCHEMISTRY-US, V33, P5636, DOI 10.1021/bi00184a036; Suzaki Y, 2002, J BIOL CHEM, V277, P9614, DOI 10.1074/jbc.M111790200; Venema RC, 2003, AM J PHYSIOL-HEART C, V285, pH669, DOI 10.1152/ajpheart.01025.2002; WEDEL B, 1994, P NATL ACAD SCI USA, V91, P2592, DOI 10.1073/pnas.91.7.2592; Yoshizumi M, 2000, J BIOL CHEM, V275, P11706, DOI 10.1074/jbc.275.16.11706; Yu XM, 1999, P NATL ACAD SCI USA, V96, P7697, DOI 10.1073/pnas.96.14.7697; Zabel U, 1999, J BIOL CHEM, V274, P18149, DOI 10.1074/jbc.274.26.18149; Zhou ZM, 2004, J BIOL CHEM, V279, P24935, DOI 10.1074/jbc.M402105200; ZHUANG S, 2004, AM J PHYSIOL-RENAL, V286, P858; ZWILLER J, 1985, J BIOL CHEM, V260, P1350; ZWILLER J, 1981, BIOCHEM BIOPH RES CO, V101, P1381, DOI 10.1016/0006-291X(81)91600-4	49	41	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33149	33156		10.1074/jbc.M507565200	http://dx.doi.org/10.1074/jbc.M507565200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16079134	hybrid			2022-12-25	WOS:000232058100009
J	Oka, T; Vasile, E; Penman, M; Novina, CD; Dykxhoorn, DM; Ungar, D; Hughson, FM; Krieger, M				Oka, T; Vasile, E; Penman, M; Novina, CD; Dykxhoorn, DM; Ungar, D; Hughson, FM; Krieger, M			Genetic analysis of the subunit organization and function of the conserved oligomeric golgi (COG) complex - Studies of Cog5- and Cog7-deficient mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; HAMSTER-CELL MUTANTS; ENDOPLASMIC-RETICULUM; PROTEIN COMPLEX; TRANSPORT; RETROGRADE; SEC34P; IDENTIFICATION; GLYCOSYLATION; LOCALIZATION	The conserved oligomeric Golgi (COG) complex is an eight-subunit (Cog1-8) peripheral Golgi protein involved in Golgi-associated membrane trafficking and glycoconjugate synthesis. We have analyzed the structure and function of COG using Cog1 or Cog2 null Chinese hamster ovary cell mutants, fibroblasts from a patient with Cog7-deficient congenital disorders of glycosylation, and stable Cog5-deficient HeLa cells generated by RNA interference. Although the dilation of some Golgi cisternae in Cog5-deficient cells resembled that observed in Cog1- or Cog2-deficient cells, their global glycosylation defects (less severe) and intracellular processing and function of low density lipoprotein receptors (essentially normal) differed from Cog1- and Cog2-deficient cells. Immunoblotting, gel filtration, and immunofluorescence microscopy analyses of the COG-deficient cells and cell extracts indicated that 1) Cog2-4 and Cog5-7 form stable subcomplexes, 2) Cog1 mediates Golgi association of a Cog2-4 plus Cog8 subcomplex, 3) Cog8 associates stably with both Cog5-7 and Cog1-4 subcomplexes, and thus 4) Cog8 helps assemble the Cog1-4 and Cog5-7 subcomplexes into the complete COG complex. This model of the subunit organization of COG is in excellent agreement with in vitro data presented in an accompanying paper (Ungar, D., Oka, T., Vasile, E., Krieger, M., and Hughson, F. M. (2005) J. Biol. Chem. 280, 32729-32735). Only one or two of the seven Cog1- or Cog2-dependent Golgi membrane proteins called GEARs are also sensitive to Cog5 or Cog7 deficiency, indicating that the COG subunits play distinctive roles in controlling Golgi structure and function.	MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Ctr Canc Res, Cambridge, MA 02139 USA; Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Fukuoka 8128582, Japan; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Harvard Univ, Sch Med, Canc Immunol & AIDS, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, CBR Inst Biomed Res, Boston, MA 02115 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Kyushu University; Princeton University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	Krieger, M (corresponding author), MIT, Dept Biol, Cambridge, MA 02139 USA.	krieger@mit.edu	Dykxhoorn, Derek M/D-1357-2015; Ungar, Daniel/A-5302-2012	Ungar, Daniel/0000-0002-9852-6160	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059115] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM59115] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Axelsson MAB, 2001, GLYCOBIOLOGY, V11, P633, DOI 10.1093/glycob/11.8.633; Barlowe C, 2002, CURR OPIN CELL BIOL, V14, P417, DOI 10.1016/S0955-0674(02)00348-4; Barr FA, 2003, CURR OPIN CELL BIOL, V15, P405, DOI 10.1016/S0955-0674(03)00054-1; Berger EG, 2002, GLYCOBIOLOGY, V12, p29R, DOI 10.1093/glycob/12.2.29R; Bidlingmaier Scott, 2002, Functional and Integrative Genomics, V1, P345, DOI 10.1007/s10142-001-0043-1; Bruinsma P, 2004, J BIOL CHEM, V279, P39814, DOI 10.1074/jbc.M405500200; Chatterton JE, 1999, P NATL ACAD SCI USA, V96, P915, DOI 10.1073/pnas.96.3.915; Conde R, 2003, YEAST, V20, P1189, DOI 10.1002/yea.1032; Conibear E, 2003, MOL BIOL CELL, V14, P1610, DOI 10.1091/mbc.E02-10-0654; Corbacho I, 2004, FEMS YEAST RES, V4, P437, DOI 10.1016/S1567-1356(03)00162-4; CUMMINGS RD, 1983, J BIOL CHEM, V258, P5261; Farkas RM, 2003, MOL BIOL CELL, V14, P190, DOI 10.1091/mbc.E02-06-0343; Fotso P, 2005, J BIOL CHEM, V280, P27613, DOI 10.1074/jbc.M504597200; Harris SL, 1996, J CELL BIOL, V132, P985, DOI 10.1083/jcb.132.6.985; Kim DW, 1999, MOL BIOL CELL, V10, P3317, DOI 10.1091/mbc.10.10.3317; Kim DW, 2001, TRAFFIC, V2, P820, DOI 10.1034/j.1600-0854.2001.21111.x; KINGSLEY DM, 1986, J CELL BIOL, V102, P1576, DOI 10.1083/jcb.102.5.1576; KOZARSKY KF, 1986, J CELL BIOL, V102, P1567, DOI 10.1083/jcb.102.5.1567; KRIEGER M, 1983, CELL, V33, P413, DOI 10.1016/0092-8674(83)90423-3; KRIEGER M, 1981, J MOL BIOL, V150, P167, DOI 10.1016/0022-2836(81)90447-2; Loh E, 2004, J BIOL CHEM, V279, P24640, DOI 10.1074/jbc.M400662200; Loh E, 2002, J BIOL CHEM, V277, P21955, DOI 10.1074/jbc.M202326200; Martinez-Menarguez JA, 2001, J CELL BIOL, V155, P1213, DOI 10.1083/jcb.200108029; Mironov AA, 2001, J CELL BIOL, V155, P1225, DOI 10.1083/jcb.200108073; Novina CD, 2004, NATURE, V430, P161, DOI 10.1038/430161a; Oka T, 2005, J BIOCHEM, V137, P109, DOI 10.1093/jb/mvi024; Oka T, 2004, MOL BIOL CELL, V15, P2423, DOI 10.1091/mbc.E03-09-0699; Opat AS, 2001, BIOCHIMIE, V83, P763, DOI 10.1016/S0300-9084(01)01312-8; Pelham HRB, 2001, J CELL BIOL, V155, P1099, DOI 10.1083/jcb.200110160; PODOS SD, 1994, J CELL BIOL, V127, P679, DOI 10.1083/jcb.127.3.679; Puri S, 2002, TRAFFIC, V3, P641, DOI 10.1034/j.1600-0854.2002.30906.x; Ram RJ, 2002, MOL BIOL CELL, V13, P1484, DOI 10.1091/mbc.01-10-0495; REDDY P, 1989, MOL CELL BIOL, V9, P4799, DOI 10.1128/MCB.9.11.4799; Roth J, 2002, CHEM REV, V102, P285, DOI 10.1021/cr000423j; Sacher M, 2001, MOL CELL, V7, P433, DOI 10.1016/S1097-2765(01)00190-3; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Shorter J, 2002, ANNU REV CELL DEV BI, V18, P379, DOI 10.1146/annurev.cellbio.18.030602.133733; Siniossoglou S, 2001, EMBO J, V20, P5991, DOI 10.1093/emboj/20.21.5991; Skrincosky D, 1997, J BIOL CHEM, V272, P22695, DOI 10.1074/jbc.272.36.22695; Sollner TH, 2004, CURR OPIN CELL BIOL, V16, P429, DOI 10.1016/j.ceb.2004.06.015; Spelbrink RG, 1999, MOL BIOL CELL, V10, P4263, DOI 10.1091/mbc.10.12.4263; Storrie B, 2002, TRAFFIC, V3, P521, DOI 10.1034/j.1600-0854.2002.30802.x; Suvorova ES, 2002, J CELL BIOL, V157, P631, DOI 10.1083/jcb.200111081; Suvorova ES, 2001, J BIOL CHEM, V276, P22810, DOI 10.1074/jbc.M011624200; Ungar D, 2005, J BIOL CHEM, V280, P32729, DOI 10.1074/jbc.M504590200; Ungar D, 2003, ANNU REV CELL DEV BI, V19, P493, DOI 10.1146/annurev.cellbio.19.110701.155609; Ungar D, 2002, J CELL BIOL, V157, P405, DOI 10.1083/jcb.200202016; VanRheenen SM, 1999, J CELL BIOL, V147, P729, DOI 10.1083/jcb.147.4.729; VanRheenen SM, 1998, J CELL BIOL, V141, P1107, DOI 10.1083/jcb.141.5.1107; Walter DM, 1998, J BIOL CHEM, V273, P29565, DOI 10.1074/jbc.273.45.29565; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; Whyte JRC, 2002, J CELL SCI, V115, P2627; Whyte JRC, 2001, DEV CELL, V1, P527, DOI 10.1016/S1534-5807(01)00063-6; Wu XH, 2004, NAT MED, V10, P518, DOI 10.1038/nm1041; Wuestehube LJ, 1996, GENETICS, V142, P393; Zerfaoui M, 2002, GLYCOBIOLOGY, V12, P15, DOI 10.1093/glycob/12.1.15; Zhang T, 1997, J CELL BIOL, V139, P1157, DOI 10.1083/jcb.139.5.1157; Zolov SN, 2005, J CELL BIOL, V168, P747, DOI 10.1083/jcb.200412003	58	73	76	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32736	32745		10.1074/jbc.M505558200	http://dx.doi.org/10.1074/jbc.M505558200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16051600	hybrid			2022-12-25	WOS:000231920300024
J	Brown, AK; Sridharan, S; Kremer, L; Lindenberg, S; Dover, LG; Sacchettini, JC; Besra, GS				Brown, AK; Sridharan, S; Kremer, L; Lindenberg, S; Dover, LG; Sacchettini, JC; Besra, GS			Probing the mechanism of the Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein synthase III mtFabH - Factors influencing catalysis and substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYCOLIC ACID BIOSYNTHESIS; FATTY-ACID; CRYSTAL-STRUCTURE; ACP SYNTHASE; BIOCHEMICAL-CHARACTERIZATION; CONDENSING ENZYME; ESCHERICHIA-COLI; FABH; IDENTIFICATION; CONDENSATION	Mycolic acids are the dominant feature of the Mycobacterium tuberculosis cell wall. These alpha-alkyl, beta-hydroxy fatty acids are formed by the condensation of two fatty acids, a long meromycolic acid and a shorter C-24-C-26 fatty acid. The component fatty acids are produced via a combination of type I and II fatty acid synthases (FAS) with FAS-I products being elongated by FAS-II toward meromycolic acids. The beta-ketoacyl-acyl carrier protein (ACP) synthase III encoded by mtfabH (mtFabH) links FAS-I and FAS-II, catalyzing the condensation of FAS-I-derived acyl-CoAs with malonyl-acyl carrier protein ( ACP). The acyl-CoA chain length specificity of mtFabH was assessed in vitro; the enzyme extended longer, physiologically relevant acyl-CoA primers when paired with AcpM, its natural partner, than with Escherichia coli ACP. The ability of the enzyme to use E. coli ACP suggests that a similar mode of binding is likely with both ACPs, yet it is clear that unique factors inherent to AcpM modulate the substrate specificity of mtFabH. Mutation of proposed key mtFabH residues was used to define their catalytic roles. Substitution of supposed acyl-CoA binding residues reduced transacylation, with double substitutions totally abrogating activity. Mutation of Arg(46) revealed its more critical role in malonyl-AcpM decarboxylation than in the acyl-CoA binding role. Interestingly, this effect was suppressed intragenically by Arg(161) -> Ala substitution. Our structural studies suggested that His(258), previously implicated in malonyl-ACP decarboxylation, also acts as an anchor point for a network of water molecules that we propose promotes deprotonation and transacylation of Cys(122).	Newcastle Univ, Sch Cellular & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Univ Montpellier 2, CNRS, UMR 5539, Lab Dynam Interact Membranaires, F-34095 Montpellier, France	Newcastle University - UK; University of Birmingham; Texas A&M University System; Texas A&M University College Station; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Besra, GS (corresponding author), Newcastle Univ, Sch Cellular & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	g.besra@bham.ac.uk	Dover, Lynn G/F-3021-2010; Dover, Lynn George/Q-6778-2019; Kremer, Laurent/M-4935-2017	Dover, Lynn G/0000-0002-4776-2665; Dover, Lynn George/0000-0002-4776-2665; Kremer, Laurent/0000-0002-6604-4458; Brown, Alistair/0000-0003-0479-8294; Besra, Gurdyal/0000-0002-5605-0395	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bloch K, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P1; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Choi KH, 2000, J BIOL CHEM, V275, P28201; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Davies C, 2000, STRUCTURE, V8, P185, DOI 10.1016/S0969-2126(00)00094-0; Dover LG, 2004, FEMS MICROBIOL REV, V28, P225, DOI 10.1016/j.femsre.2003.10.001; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; He X, 2002, ANTIMICROB AGENTS CH, V46, P1310, DOI 10.1128/AAC.46.5.1310-1318.2002; He X, 2000, ANAL BIOCHEM, V282, P107, DOI 10.1006/abio.2000.4594; Heath RJ, 1996, J BIOL CHEM, V271, P10996, DOI 10.1074/jbc.271.18.10996; Heath RJ, 2002, NAT PROD REP, V19, P581, DOI 10.1039/b110221b; Hong X, 2004, BIOMACROMOLECULES, V5, P1066, DOI 10.1021/bm0345155; Jez JM, 2000, J BIOL CHEM, V275, P39640, DOI 10.1074/jbc.M008569200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; Kaye K, 1996, EPIDEMIOL REV, V18, P52, DOI 10.1093/oxfordjournals.epirev.a017916; Kremer L, 2000, J BIOL CHEM, V275, P16857, DOI 10.1074/jbc.M000569200; Kremer L, 2002, BIOCHEM J, V364, P423, DOI 10.1042/BJ20011628; Kremer L, 2001, J BIOL CHEM, V276, P27967, DOI 10.1074/jbc.M103687200; Kremer L, 2000, MOLECULAR GENETICS OF MYCOBACTERIA, P173; Lu YJ, 2004, BIOCHEM CELL BIOL, V82, P145, DOI 10.1139/o03-076; McGuire KA, 2001, BIOCHEMISTRY-US, V40, P9836, DOI 10.1021/bi0105577; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Mdluli K, 1998, SCIENCE, V280, P1607, DOI 10.1126/science.280.5369.1607; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Musayev F, 2005, J MOL BIOL, V346, P1313, DOI 10.1016/j.jmb.2004.12.044; Nachega JB, 2003, CLIN INFECT DIS, V36, pS24, DOI 10.1086/344657; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paolo WF, 2004, LANCET INFECT DIS, V4, P287, DOI 10.1016/S1473-3099(04)01004-7; PETERSON DO, 1977, J BIOL CHEM, V252, P5735; Portevin D, 2004, P NATL ACAD SCI USA, V101, P314, DOI 10.1073/pnas.0305439101; Qiu XY, 1999, J BIOL CHEM, V274, P36465, DOI 10.1074/jbc.274.51.36465; Reddy V, 2003, ACTA CRYSTALLOGR D, V59, P2200, DOI 10.1107/S0907444903020316; Scarsdale JN, 2001, J BIOL CHEM, V276, P20516, DOI 10.1074/jbc.M010762200; Schaeffer ML, 2001, J BIOL CHEM, V276, P47029, DOI 10.1074/jbc.M108903200; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Slayden RA, 1996, ANTIMICROB AGENTS CH, V40, P2813, DOI 10.1128/AAC.40.12.2813; Smith S, 2003, PROG LIPID RES, V42, P289, DOI 10.1016/S0163-7827(02)00067-X; Toossi Z, 2001, CLIN EXP IMMUNOL, V123, P233, DOI 10.1046/j.1365-2249.2001.01401.x; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; WALLIS RS, 1992, RES MICROBIOL, V143, P398, DOI 10.1016/0923-2508(92)90053-Q; Wong HC, 2002, J BIOL CHEM, V277, P15874, DOI 10.1074/jbc.M112300200; Yuan Y, 1998, J BIOL CHEM, V273, P21282, DOI 10.1074/jbc.273.33.21282; Zhang YM, 2001, J BIOL CHEM, V276, P8231, DOI 10.1074/jbc.M008042200	46	50	56	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32539	32547		10.1074/jbc.M413216200	http://dx.doi.org/10.1074/jbc.M413216200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16040614	hybrid			2022-12-25	WOS:000231794800063
J	Hausmann, S; Shuman, S				Hausmann, S; Shuman, S			Giardia lamblia RNA cap guanine-N2 methyltransferase (Tgs2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; IN-VITRO; SACCHAROMYCES-CEREVISIAE; TRANSLATION; HYPERMETHYLATION; PROTEIN; GENE; POSITION-10; EFFICIENCY; MECHANISM	Tgs1 is the enzyme responsible for converting 7-methyl-guanosine RNA caps to the 2,2,7-trimethylguanosine cap structures of small nuclear and small nucleolar RNAs. Whereas budding yeast Saccharomyces cerevisiae and fission yeast Schizosaccharomyces pombe encode a single Tgs1 protein, the primitive eukaryote Giardia lamblia encodes two paralogs, Tgs1 and Tgs2. Here we show that purified Tgs2 is a monomeric enzyme that catalyzes methyl transfer from AdoMet ( Km of 6 mu M) to m(7)GDP (K-m of 65 mu M; k(cat) of 14 min(-1)) to form m(2,7)GDP. Tgs2 also methylates m(7)GTP (K-m of 30 mu M; kcat of 13 min(-1)) and m(7)GpppA (K-m of 7 mu M;k(cat) of 14 min(-1)) but is unreactive with GDP, GTP, GpppA, ATP, CTP, or UTP. We find that the conserved residues Asp-68, Glu-91, and Trp-143 are essential for Tgs2 methyltransferase activity in vitro. The m2,7GDP product formed by Tgs2 can be converted tom2,2,7GDP by S. pombe Tgs1 in the presence of excess AdoMet. However, Giardia Tgs2 itself is apparently unable to add a second methyl group at guanine-N2. This result implies that 2,2,7-trimethylguanosine caps in Giardia are either synthesized by Tgs1 alone or by the sequential action of Tgs2 and Tgs1. The specificity of Tgs2 raises the prospect that some Giardia mRNAs might contain dimethylguanosine caps.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Shuman, S (corresponding author), Amer Canc Soc, Atlanta, GA 30329 USA.	s-shuman@ski.mskcc.org			NIGMS NIH HHS [GM52470] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052470] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Armengaud J, 2004, J BIOL CHEM, V279, P37142, DOI 10.1074/jbc.M403845200; BUSCH H, 1982, ANNU REV BIOCHEM, V51, P617, DOI 10.1146/annurev.bi.51.070182.003153; Cai A, 1999, BIOCHEMISTRY-US, V38, P8538, DOI 10.1021/bi9830213; Constantinesco F, 1999, J MOL BIOL, V291, P375, DOI 10.1006/jmbi.1999.2976; DARZYNKIEWICZ E, 1988, NUCLEIC ACIDS RES, V16, P8953, DOI 10.1093/nar/16.18.8953; ELLIS SR, 1986, J BIOL CHEM, V261, P9703; Fabrega C, 2004, MOL CELL, V13, P77, DOI 10.1016/S1097-2765(03)00522-7; Grudzien E, 2004, RNA, V10, P1479, DOI 10.1261/rna.7380904; Hausmann S, 2005, J BIOL CHEM, V280, P20404, DOI 10.1074/jbc.M501073200; Hausmann S, 2005, J BIOL CHEM, V280, P12077, DOI 10.1074/jbc.M412063200; Hausmann S, 2005, J BIOL CHEM, V280, P4021, DOI 10.1074/jbc.C400554200; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HSUCHEN CC, 1976, NATURE, V264, P190, DOI 10.1038/264190a0; Knodler LA, 1999, MOL MICROBIOL, V34, P327, DOI 10.1046/j.1365-2958.1999.01602.x; Komonyi O, 2005, J BIOL CHEM, V280, P12397, DOI 10.1074/jbc.M409251200; Li L, 2005, EUKARYOT CELL, V4, P948, DOI 10.1128/EC.4.5.948-959.2005; Li L, 2004, J BIOL CHEM, V279, P14656, DOI 10.1074/jbc.M309879200; LIOU RF, 1990, MOL CELL BIOL, V10, P1764, DOI 10.1128/MCB.10.4.1764; Liu JM, 2000, NUCLEIC ACIDS RES, V28, P3445, DOI 10.1093/nar/28.18.3445; MATTAJ IW, 1986, CELL, V46, P905, DOI 10.1016/0092-8674(86)90072-3; Mouaikel J, 2003, NUCLEIC ACIDS RES, V31, P4899, DOI 10.1093/nar/gkg656; Mouaikel J, 2002, MOL CELL, V9, P891, DOI 10.1016/S1097-2765(02)00484-7; NIU XH, 1994, MOL BIOCHEM PARASIT, V66, P49, DOI 10.1016/0166-6851(94)90035-3; Nixon JEJ, 2002, P NATL ACAD SCI USA, V99, P3701, DOI 10.1073/pnas.042700299; PLESSEL G, 1994, MOL CELL BIOL, V14, P4160, DOI 10.1128/MCB.14.6.4160; Purushothaman SK, 2005, MOL CELL BIOL, V25, P4359, DOI 10.1128/MCB.25.11.4359-4370.2005; Seto AG, 1999, NATURE, V401, P177, DOI 10.1038/43694; Speckmann WA, 2000, NUCLEIC ACIDS RES, V28, P4467, DOI 10.1093/nar/28.22.4467; TERNS MP, 1995, EMBO J, V14, P4860, DOI 10.1002/j.1460-2075.1995.tb00167.x; Tscherne JS, 1999, J BIOL CHEM, V274, P924, DOI 10.1074/jbc.274.2.924; VANDUIJN LP, 1986, VIRUS RES, V5, P61, DOI 10.1016/0168-1702(86)90065-1; Yu DC, 1998, MOL BIOCHEM PARASIT, V96, P151, DOI 10.1016/S0166-6851(98)00126-1	32	32	34	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32101	32106		10.1074/jbc.M506438200	http://dx.doi.org/10.1074/jbc.M506438200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16046409	hybrid			2022-12-25	WOS:000231794800009
J	Dudek, EJ; Shang, F; Liu, Q; Valverde, P; Hobbs, M; Taylor, A				Dudek, EJ; Shang, F; Liu, Q; Valverde, P; Hobbs, M; Taylor, A			Selectivity of the ubiquitin pathway for oxidatively modified proteins: relevance to protein precipitation diseases	FASEB JOURNAL			English	Article						cataracts; proteolytic pathways; cellular stress; ubiquitin proteasome pathway	IRON REGULATORY PROTEIN-2; LENS EPITHELIAL-CELLS; PROTEASOME PATHWAY; CONJUGATING ENZYMES; OXIDIZED PROTEINS; HYDROGEN-PEROXIDE; EYE LENS; DEGRADATION; STRESS; SYSTEM	There is now consensus that the accumulation of oxidatively modified proteins is cytotoxic and causally related to several age-related diseases, including the amyloid diseases and age-related cataracts. There is also general agreement that proteolytic pathways provide a quality control mechanism to limit accumulation of damaged proteins. Although many researchers assume that the ubiquitin pathway is involved in recognition and proteolytic removal of oxidatively modified proteins, which are produced upon cellular stress, there has been no direct evidence to support this hypothesis. In this work, we used a novel proteolysis-resistant ubiquitin variant to demonstrate that ubiquitin conjugates isolated from oxidatively stressed mammalian cells are enriched 3.3 - 15-fold for oxidatively modified proteins and that failure to execute ubiquitin-dependent proteolysis renders various cell types more susceptible to oxidative stress-related cytotoxicity. These results were corroborated using several inhibitors of the ubiquitin proteasome pathway, including PS-341, an anticancer drug in clinical use. Taken together the data indicate that the ubiquitin proteolytic pathway recognizes and removes oxidatively modified proteins, and that failure of this system, as occurs upon aging or stress, may be involved in and exacerbate cytotoxicity and age-related syndromes in which accumulation of ubiquitinated and oxidatively modified proteins has an etiologic role.	Tufts Univ, Human Nutr Res Ctr Aging, Lab Nutr & Vis Res, Boston, MA 02111 USA; Tufts Univ, Human Nutr Res Ctr Aging, Vis Res USDA, Boston, MA 02111 USA	Tufts University; United States Department of Agriculture (USDA); Tufts University; United States Department of Agriculture (USDA)	Taylor, A (corresponding author), Tufts Univ, Human Nutr Res Ctr Aging, Lab Nutr & Vis Res, 711 Washington St, Boston, MA 02111 USA.	allen.taylor@tufts.edu	Valverde, Paloma/A-9897-2008		NATIONAL EYE INSTITUTE [R01EY011717, R01EY013250, P30EY013078, R03EY014183, R29EY011717] Funding Source: NIH RePORTER; NEI NIH HHS [EY13078, EY13250, EY14183, EY11717] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADAMO AM, 1994, J NEUROSCI RES, V38, P358, DOI 10.1002/jnr.490380314; Adamo AM, 1999, J NEUROSCI RES, V55, P523, DOI 10.1002/(SICI)1097-4547(19990215)55:4<523::AID-JNR12>3.0.CO;2-Q; ALLIS CD, 1980, CELL, V20, P55; Beal MF, 2002, FREE RADICAL BIO MED, V32, P797, DOI 10.1016/S0891-5849(02)00780-3; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Berlett BS, 1996, J BIOL CHEM, V271, P4177, DOI 10.1074/jbc.271.8.4177; Bleau G, 1998, ANAL BIOCHEM, V263, P13, DOI 10.1006/abio.1998.2801; BLONDIN J, 1986, Journal of Free Radicals in Biology and Medicine, V2, P275; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; Ciechanover A, 1998, P NATL ACAD SCI USA, V95, P2727, DOI 10.1073/pnas.95.6.2727; DICE JF, 1993, PHYSIOL REV, V73, P149, DOI 10.1152/physrev.1993.73.1.149; Dringen R, 1999, J NEUROCHEM, V72, P2523, DOI 10.1046/j.1471-4159.1999.0722523.x; DUNTEN RL, 1989, J BIOL CHEM, V264, P16739; EISENHAUER DA, 1988, EXP EYE RES, V46, P579, DOI 10.1016/S0014-4835(88)80014-9; El-Agnaf OMA, 2002, BIOCHEM SOC T, V30, P559; Elofsson M, 1999, CHEM BIOL, V6, P811, DOI 10.1016/S1074-5521(99)80128-8; FigueiredoPereira ME, 1997, MOL BIOL REP, V24, P35, DOI 10.1023/A:1006848405975; FINCH JS, 1990, NUCLEIC ACIDS RES, V18, P1907, DOI 10.1093/nar/18.7.1907; Floyd RA, 2002, NEUROBIOL AGING, V23, P795, DOI 10.1016/S0197-4580(02)00019-2; Forman HJ, 2002, AM J RESP CRIT CARE, V166, pS4, DOI 10.1164/rccm.2206007; Frederikse PH, 1996, J BIOL CHEM, V271, P10169, DOI 10.1074/jbc.271.17.10169; Gelman MS, 2002, J BIOL CHEM, V277, P11709, DOI 10.1074/jbc.M111958200; Goellner GM, 2003, INT J BIOCHEM CELL B, V35, P562, DOI 10.1016/S1357-2725(02)00388-6; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; Gomes-Marcondes MCC, 2002, CANCER LETT, V180, P69, DOI 10.1016/S0304-3835(02)00006-X; GRAY DA, 2003, SCI AGING KNOWLEDGE, V6, P1; Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076; Guo WM, 2004, INVEST OPHTH VIS SCI, V45, P1194, DOI 10.1167/iovs.03-0830; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HERSHKO A, 1986, J BIOL CHEM, V261, P1992; Hershko A, 2000, NAT MED, V6, P1073, DOI 10.1038/80384; HERSHKO A, 1980, P NATL ACAD SCI-BIOL, V77, P1783, DOI 10.1073/pnas.77.4.1783; Hitchcock AL, 2003, P NATL ACAD SCI USA, V100, P12735, DOI 10.1073/pnas.2135500100; HUANG LL, 1993, BIOCHIM BIOPHYS ACTA, V1175, P181, DOI 10.1016/0167-4889(93)90021-G; HUANG LL, 1995, EXP EYE RES, V61, P45, DOI 10.1016/S0014-4835(95)80057-3; Hyun DH, 2002, J BIOL CHEM, V277, P28572, DOI 10.1074/jbc.M200666200; Iwai K, 1998, P NATL ACAD SCI USA, V95, P4924, DOI 10.1073/pnas.95.9.4924; JAHNGEN JH, 1986, J BIOL CHEM, V261, P3760; JAHNGEN JH, 1990, ARCH BIOCHEM BIOPHYS, V276, P32, DOI 10.1016/0003-9861(90)90006-K; JAHNGENHODGE J, 1992, EXP EYE RES, V55, P897, DOI 10.1016/0014-4835(92)90016-L; JahngenHodge J, 1997, J BIOL CHEM, V272, P28218, DOI 10.1074/jbc.272.45.28218; Jellinger KA, 2003, J NEURAL TRANSM-SUPP, P101; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573; Kim BY, 2001, FREE RADICAL BIO MED, V30, P686, DOI 10.1016/S0891-5849(00)00514-1; KOPITO RR, 1999, PHYSIOL REV, V79, P167; LaVaute T, 2001, NAT GENET, V27, P209, DOI 10.1038/84859; MAYER RJ, 1991, J PATHOL, V163, P279, DOI 10.1002/path.1711630402; McBride WH, 2003, ONCOGENE, V22, P5755, DOI 10.1038/sj.onc.1206676; Obin M, 1998, FASEB J, V12, P561, DOI 10.1096/fasebj.12.7.561; Obin M, 1999, J BIOL CHEM, V274, P11789, DOI 10.1074/jbc.274.17.11789; OLIVER CN, 1987, J BIOL CHEM, V262, P5488; Ramanathan M, 1999, NEUROREPORT, V10, P3797, DOI 10.1097/00001756-199912160-00014; RECHSTEINER M, 1987, ANNU REV CELL BIOL, V3, P1, DOI 10.1146/annurev.cb.03.110187.000245; Reinheckel T, 1998, BIOCHEM J, V335, P637, DOI 10.1042/bj3350637; RUBINSZTEIN DC, 2003, SCI AGING KNOWLEDGE, V17, pPE26; Selkoe DJ, 2003, NATURE, V426, P900, DOI 10.1038/nature02264; SHANG F, 1995, BIOCHEM J, V307, P297, DOI 10.1042/bj3070297; Shang F, 2004, EXP EYE RES, V78, P1, DOI 10.1016/j.exer.2003.10.003; Shang F, 1997, EXP EYE RES, V64, P21, DOI 10.1006/exer.1996.0176; Shang F, 2001, EXP EYE RES, V73, P229, DOI 10.1006/exer.2001.1029; Shang F, 1997, J BIOL CHEM, V272, P23086, DOI 10.1074/jbc.272.37.23086; Shang F, 2005, J BIOL CHEM, V280, P20365, DOI 10.1074/jbc.M414356200; SHANG F, 1994, CURR EYE RES, V13, P423, DOI 10.3109/02713689408999870; Shringarpure R, 2003, J BIOL CHEM, V278, P311, DOI 10.1074/jbc.M206279200; SHRINGARPURE R, 2002, PROTEIN TURNOVER PRO; Sitte N, 2000, FASEB J, V14, P2503, DOI 10.1096/fj.00-0210com; Spector A, 1998, INVEST OPHTH VIS SCI, V39, P1188; SPECTOR A, 1981, EXP EYE RES, V33, P673, DOI 10.1016/S0014-4835(81)80107-8; SPECTOR A, 1995, FASEB J, V9, P1173, DOI 10.1096/fasebj.9.12.7672510; Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142; Taylor A, 2001, NUTRITION, V17, P845, DOI 10.1016/S0899-9007(01)00655-4; Taylor A, 2002, ONCOGENE, V21, P4363, DOI 10.1038/sj.onc.1205557; Taylor A, 1997, MOL ASPECTS MED, V18, P307, DOI 10.1016/S0098-2997(95)00049-6; TAYLOR A, 1999, CRC MOD NUT, P1; Taylor A., 1999, CRC MOD NUT, V1st, P53; Tessier F, 1999, J BIOL CHEM, V274, P20796, DOI 10.1074/jbc.274.30.20796; Vieira O, 2000, FASEB J, V14, P532, DOI 10.1096/fasebj.14.3.532; Wojcik C, 2004, STROKE, V35, P1506, DOI 10.1161/01.STR.0000126891.93919.4e; Wojcik C, 2002, J CELL MOL MED, V6, P25, DOI 10.1111/j.1582-4934.2002.tb00309.x; Zanetti M, 2002, AM J PHYSIOL-HEART C, V283, pH2620, DOI 10.1152/ajpheart.00358.2001; Zhang Y, 2003, GENE DEV, V17, P2733, DOI 10.1101/gad.1156403	83	80	80	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1707	+		10.1096/fj.05-4049fje	http://dx.doi.org/10.1096/fj.05-4049fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16099947				2022-12-25	WOS:000231843700014
J	Bethony, J; Loukas, A; Smout, M; Brooker, S; Mendez, S; Plieskatt, J; Goud, G; Bottazzi, ME; Zhan, B; Wang, Y; Williamson, A; Lustigman, S; Correa-Oliveira, R; Xiao, SH; Hotez, PJ				Bethony, J; Loukas, A; Smout, M; Brooker, S; Mendez, S; Plieskatt, J; Goud, G; Bottazzi, ME; Zhan, B; Wang, Y; Williamson, A; Lustigman, S; Correa-Oliveira, R; Xiao, SH; Hotez, PJ			Antibodies against a secreted protein from hookworm larvae reduce the intensity of hookworm infection in humans and vaccinated laboratory animals	FASEB JOURNAL			English	Article						ancylostoma secreted proteins; morbidity reduction; vaccine	TRANSMITTED HELMINTH INFECTIONS; NECATOR-AMERICANUS; PATHOGENESIS-RELATED-1 PROTEIN; MOLECULAR-CLONING; ENDEMIC AREA; FAMILY; MEBENDAZOLE; EXPRESSION; INHIBITOR; NEMATODES	The development of a vaccine would provide an important new tool for the control of human hookworm infection. On the basis of successful vaccination of laboratory animals with living irradiated, third-stage hookworm larvae (L3), we examined the antibody responses of individuals from hookworm endemic areas of Brazil and China against the most abundant L3 secreted antigens, the ancylostoma secreted proteins, ASP-1 and ASP-2. Logistic regression was used to investigate the effects of antibody isotype responses to ASPs on the risk of an individual harboring heavy hookworm infection. A significant protective association was observed between increasing anti-ASP-2 IgE levels and the risk of heavy hookworm infection. To confirm that ASP-2 is a protective antigen, laboratory dogs were immunized with recombinant ASP-2 formulated with the GlaxoSmithKline Adjuvant, AS03. Sera obtained from the immunized dogs exhibited high geometric mean antibody titers, immunoprecipitated native ASP-2 from L3 extracts and localized the site of ASP-2 expression to the glandular esophagus and body channels exiting to the cuticle. The sera also exhibited an increased ability to inhibit migration of L3 through tissue in vitro relative to sera from AS03-injected controls. Upon L3 challenge, the ASP-2 vaccinated dogs exhibited significant reductions in fecal egg counts and intestinal hookworm burden. These findings provide strong support for the development of an effective recombinant vaccine against hookworm infection in humans.	George Washington Univ, Dept Microbiol & Trop Med, Washington, DC 20037 USA; Queensland Inst Med Res, Div Infect Dis & Immunol, Brisbane, Qld 4006, Australia; Univ Queensland, Australian Ctr Int Trop Hlth & Nutr, Brisbane, Qld 4006, Australia; London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England; New York Blood Ctr, Lindsley F Kimball Res Inst, New York, NY 10021 USA; Fiocruz MS, Ctr Pesquisas Rene Rachou, BR-30190 Belo Horizonte, MG, Brazil; Chinese Ctr Dis Control & Prevenet, Inst Parasit Dis, Shanghai, Peoples R China	George Washington University; QIMR Berghofer Medical Research Institute; University of Queensland; University of London; London School of Hygiene & Tropical Medicine; New York Blood Center; Fundacao Oswaldo Cruz; Chinese Center for Disease Control & Prevention; National Institute of Parasitic Diseases, Chinese Center for Disease Control & Prevention	Bethony, J (corresponding author), George Washington Univ, Dept Microbiol & Trop Med, Ross Hall,Room 736,2300 Eye St NW, Washington, DC 20037 USA.	jeff@cpqrr.fiocruz.br; PHotez@gwu.edu	Loukas, Alex/B-7355-2014	Loukas, Alex/0000-0002-0896-8441; Smout, Michael/0000-0001-6937-0112; Plieskatt, Jordan/0000-0002-2333-7234; Hotez, Peter/0000-0001-8770-1042; Bottazzi, Maria Elena/0000-0002-8429-0476; Wolf, Nathaniel/0000-0001-6567-2447	FIC NIH HHS [1K01 TW00009] Funding Source: Medline; Wellcome Trust [073656] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [K01TW000009] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); Wellcome Trust(Wellcome TrustEuropean Commission); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Albonico M, 2003, B WORLD HEALTH ORGAN, V81, P343; ALBONICO M, 1995, T ROY SOC TROP MED H, V89, P538, DOI 10.1016/0035-9203(95)90101-9; Asojo OA, 2005, ACTA CRYSTALLOGR F, V61, P391, DOI 10.1107/S1744309105007748; Asojo OA, 2005, J MOL BIOL, V346, P801, DOI 10.1016/j.jmb.2004.12.023; Bethony J, 2002, CLIN INFECT DIS, V35, P1336, DOI 10.1086/344268; Bethony J, 1999, J INFECT DIS, V180, P1665, DOI 10.1086/315069; Brooker S, 2005, EXPERT REV VACCINES, V4, P35, DOI 10.1586/14760584.4.1.35; Brooker S, 2004, ADV PARASIT, V58, P197, DOI 10.1016/S0065-308X(04)58004-1; Bungiro R, 2004, CURR OPIN INFECT DIS, V17, P421, DOI 10.1097/00001432-200410000-00006; CAPRON M, 1994, SCIENCE, V264, P1876, DOI 10.1126/science.8009216; de Silva NR, 2003, TRENDS PARASITOL, V19, P547, DOI 10.1016/j.pt.2003.10.002; Del Valle A, 2003, MOL BIOCHEM PARASIT, V129, P167, DOI 10.1016/S0166-6851(03)00121-X; Dombrowicz D, 2000, J IMMUNOL, V165, P1266, DOI 10.4049/jimmunol.165.3.1266; Geiger SM, 2004, CLIN EXP IMMUNOL, V136, P334, DOI 10.1111/j.1365-2249.2004.02449.x; Goud GN, 2004, J INFECT DIS, V189, P919, DOI 10.1086/381901; Hawdon JM, 1996, J PARASITOL, V82, P642, DOI 10.2307/3283794; Hawdon JM, 1996, J BIOL CHEM, V271, P6672, DOI 10.1074/jbc.271.12.6672; Hawdon JM, 1999, MOL BIOCHEM PARASIT, V99, P149, DOI 10.1016/S0166-6851(99)00011-0; Hawdon JM, 1996, CURR OPIN GENET DEV, V6, P618, DOI 10.1016/S0959-437X(96)80092-X; Hotez PJ, 2005, PLOS MED, V2, P187, DOI 10.1371/journal.pmed.0020067; Hotez PJ, 2002, COMP PARASITOL, V69, P72, DOI 10.1654/1525-2647(2002)069[0072:NHOPCH]2.0.CO;2; Hotez PJ, 2002, J PARASITOL, V88, P684, DOI 10.1645/0022-3395(2002)088[0684:EOVWRF]2.0.CO;2; Hotez PJ, 2004, NEW ENGL J MED, V351, P799, DOI 10.1056/NEJMra032492; Jian X, 2003, EXP PARASITOL, V104, P62, DOI 10.1016/S0014-4894(03)00094-8; Katz N, 1972, Rev Inst Med Trop Sao Paulo, V14, P397; Kooyman FNJ, 2000, PARASITE IMMUNOL, V22, P13; Ledizet Michel, 2005, Current Medicinal Chemistry - Cardiovascular & Hematological Agents, V3, P1, DOI 10.2174/1568016052773315; Loukas A, 2004, J INFECT DIS, V189, P1952, DOI 10.1086/386346; LUSTIGMAN S, 1992, J BIOL CHEM, V267, P17339; MacDonald AJ, 2004, PARASITE IMMUNOL, V26, P53, DOI 10.1111/j.0141-9838.2004.00685.x; McKerrow JH, 1999, PARASITOL TODAY, V15, P123, DOI 10.1016/S0169-4758(99)01411-8; Mendelson S, 2002, J MACH LEARN RES, V2, P1, DOI 10.1162/153244302760185225; Miller T A, 1978, Adv Parasitol, V16, P333, DOI 10.1016/S0065-308X(08)60577-1; MOYLE M, 1994, J BIOL CHEM, V269, P10008; Savioli L, 2002, T ROY SOC TROP MED H, V96, P577, DOI 10.1016/S0035-9203(02)90316-0; Stoltzfus RJ, 1997, NUTR REV, V55, P223, DOI 10.1111/j.1753-4887.1997.tb01609.x; *WHO, 2002, WHO TRAD MED STRAT 2; Williamson AL, 2003, PARASITOLOGY, V126, P179, DOI 10.1017/S0031182002002706; Zhan B, 2003, INT J PARASITOL, V33, P897, DOI 10.1016/S0020-7519(03)00111-5; Zhan B, 2002, MOL BIOCHEM PARASIT, V120, P291, DOI 10.1016/S0166-6851(01)00453-4; Zhan B, 1999, MOL BIOCHEM PARASIT, V98, P143, DOI 10.1016/S0166-6851(98)00157-1	41	130	143	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1743	+		10.1096/fj.05-3936fje	http://dx.doi.org/10.1096/fj.05-3936fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16037096				2022-12-25	WOS:000230923000014
J	Claus, RA; Bunck, AC; Bockmeyer, CL; Brunkhorst, FM; Losche, W; Kinscherf, R; Deigner, HP				Claus, RA; Bunck, AC; Bockmeyer, CL; Brunkhorst, FM; Losche, W; Kinscherf, R; Deigner, HP			Role of increased sphingomyelinase activity in apoptosis and organ failure of patients with severe sepsis	FASEB JOURNAL			English	Article						inflammation; ceramide; endotoxin; oxidative stress; desipramine	ACID SPHINGOMYELINASE; SECRETORY SPHINGOMYELINASE; GLUCOSE-TRANSPORT; GENE-EXPRESSION; CELL-DEATH; CERAMIDE; ACTIVATION; ENDOTHELIUM; DYSFUNCTION; LDL	Numerous studies support the notion that an activation of sphingomyelinases and a subsequent increase of the concentration of the bioactive lipid mediator ceramide are critical in the concert of inflammatory stimuli and to the induction of apoptosis during inflammation. Here we show that patients with severe sepsis exhibit an enhanced sphingolytic activity in comparison with controls [ 262 pmol/(mlxh) vs. 123.6 pmol/( mlxh), P < 0.005]. During the clinical course, a further increase was paralleled by the severity of illness and by fatal outcome. Moreover, we show that oxidative stress may partially account for the increased activity through posttranslational modification of the enzyme. In a murine endotoxic shock model, administration of a low molecular weight inhibitor diminished the rise in enzymatic activity and improved the survival rate. In liver specimen, inhibition of activity correlated with a reduced rate of hepato-cellular apoptosis. Our data support the concept that activation of the plasmatic isoform of sphingomyelinase may play a critical role in the development of apoptosis and organ failure in sepsis. An inhibition of the secreted isoform of sphingomyelinase should be explored further as a potential target in the complicated puzzle of sepsis.	Univ Jena, Div Expt Anesthesiol, Dept Anesthesiol & Intens Care Med, D-07747 Jena, Germany; Heidelberg Univ, Dept Anat & Cell Biol, D-69120 Heidelberg, Germany; Univ E Anglia, Sch Chem Sci & Pharm, Norwich NR4 7TJ, Norfolk, England	Friedrich Schiller University of Jena; Ruprecht Karls University Heidelberg; University of East Anglia	Claus, RA (corresponding author), Univ Jena, Div Expt Anesthesiol, Dept Anesthesiol & Intens Care Med, Erlanger Allee 101, D-07747 Jena, Germany.	ralf.claus@med.uni-jena.de; h-p.deigner@uea.ac.uk	Bunck, Alexander C/M-6389-2014; Kinscherf, Ralf/AAV-7164-2021; Claus, Ralf A./Q-4035-2016	Bunck, Alexander C/0000-0003-0986-0042; Brunkhorst, Frank Martin/0000-0002-8132-8651; Claus, Ralf A./0000-0001-7232-4088				Aird WC, 2003, BLOOD, V101, P3765, DOI 10.1182/blood-2002-06-1887; Ayala A, 2003, SCAND J INFECT DIS, V35, P593, DOI 10.1080/00365540310015656; Baumruker T, 2002, SEMIN IMMUNOL, V14, P57, DOI 10.1006/smim.2001.0342; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bochud PY, 2003, BMJ-BRIT MED J, V326, P262, DOI 10.1136/bmj.326.7383.262; Cobb JP, 2002, CRIT CARE MED, V30, P2711, DOI 10.1097/00003246-200212000-00016; Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326; Deigner HP, 2001, FASEB J, V15, P807, DOI 10.1096/fj.15.3.807; Drobnik W, 2003, J LIPID RES, V44, P754, DOI 10.1194/jlr.M200401-JLR200; Favory R, 2004, CRIT CARE MED, V32, P495, DOI 10.1097/01.CCM.0000109452.36271.FA; Garcia-Ruiz C, 2003, J CLIN INVEST, V111, P197, DOI 10.1172/JCI200316010; Goggel R, 2004, NAT MED, V10, P155, DOI 10.1038/nm977; Goni FM, 2002, FEBS LETT, V531, P38, DOI 10.1016/S0014-5793(02)03482-8; Gorski Andrzej, 2003, Med Immunol, V2, P2, DOI 10.1186/1476-9433-2-2; Haberkorn U, 2001, EUR J NUCL MED, V28, P1690, DOI 10.1007/s002590100644; Haberkorn U, 2001, EUR J NUCL MED, V28, P418, DOI 10.1007/s002590100489; HaimovitzFriedman A, 1997, J EXP MED, V186, P1831, DOI 10.1084/jem.186.11.1831; Hotchkiss RS, 1999, P NATL ACAD SCI USA, V96, P14541, DOI 10.1073/pnas.96.25.14541; Hotchkiss RS, 2003, SCAND J INFECT DIS, V35, P585, DOI 10.1080/00365540310015692; Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333; Jones BE, 1999, HEPATOLOGY, V30, P215, DOI 10.1002/hep.510300146; Kinscherf R, 1998, FASEB J, V12, P461, DOI 10.1096/fasebj.12.6.461; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kolzer M, 2004, FEBS LETT, V559, P96, DOI 10.1016/S0014-5793(04)00033-X; Kontush A, 1999, METHOD ENZYMOL, V299, P35; Langmann T, 1999, J LIPID RES, V40, P870; Lightle S, 2003, ARCH BIOCHEM BIOPHYS, V419, P120, DOI 10.1016/j.abb.2003.08.031; Loidl A, 2004, BBA-MOL BASIS DIS, V1690, P150, DOI 10.1016/j.bbadis.2004.06.003; Loidl A, 2003, J BIOL CHEM, V278, P32921, DOI 10.1074/jbc.M306088200; Loidl A, 2002, J LIPID RES, V43, P815; Mahidhara R, 2000, CRIT CARE MED, V28, pN105, DOI 10.1097/00003246-200004001-00013; Marathe S, 1998, J BIOL CHEM, V273, P4081, DOI 10.1074/jbc.273.7.4081; *MEMB AM COLL CHES, 1992, CHEST, V11, P1644; Nakashima I, 2002, ANTIOXID REDOX SIGN, V4, P517, DOI 10.1089/15230860260196326; Oberholzer C, 2001, FASEB J, V15, P879, DOI 10.1096/fj.00-058rev; Papathanassoglou EDE, 2000, CRIT CARE MED, V28, P537, DOI 10.1097/00003246-200002000-00042; Pettus BJ, 2002, BBA-MOL CELL BIOL L, V1585, P114, DOI 10.1016/S1388-1981(02)00331-1; Qiu HW, 2003, J BIOL CHEM, V278, P32744, DOI 10.1074/jbc.M303022200; Riedemann NC, 2003, NAT MED, V9, P517, DOI 10.1038/nm0503-517; Schissel SL, 1998, J BIOL CHEM, V273, P18250, DOI 10.1074/jbc.273.29.18250; Takahashi T, 2002, J PEDIAT HEMATOL ONC, V24, P401, DOI 10.1097/00043426-200206000-00016; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Wong ML, 2000, P NATL ACAD SCI USA, V97, P8681, DOI 10.1073/pnas.150098097; Yu SL, 2004, AM J RESP CRIT CARE, V169, P1135, DOI 10.1164/rccm.200211-1278OC; Zhang DX, 2002, AM J PHYSIOL-HEART C, V283, pH1785, DOI 10.1152/ajpheart.00318.2002	45	87	91	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1719	+		10.1096/fj.04-2842fje	http://dx.doi.org/10.1096/fj.04-2842fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16051685				2022-12-25	WOS:000230923000002
J	Primo, L; Ferrandi, C; Roca, C; Marchio, S; di Blasio, L; Alessio, M; Bussolino, F				Primo, L; Ferrandi, C; Roca, C; Marchio, S; di Blasio, L; Alessio, M; Bussolino, F			Identification of CD36 molecular features required for its in vitro angiostatic activity	FASEB JOURNAL			English	Article						thrombospondin-1; endothelial cells; VEGF	ENDOTHELIAL GROWTH-FACTOR; PROTEIN-TYROSINE KINASES; TERMINAL DOMAIN; CELL RESPONSES; ANGIOGENESIS; THROMBOSPONDIN-1; INTEGRIN; ACTIVATION; INHIBITION; RECEPTOR	Thrombospondin-1 (TSP-1), a natural inhibitor of angiogenesis, acts directly on endothelial cells (EC) via CD36 to inhibit their migration and morphogenesis induced by basic fibroblast growth factor. Here we show that CD36 triggered by TSP-1 inhibits in vitro angiogenesis stimulated by vascular endothelial growth factor-A ( VEGF-A). To demonstrate that the TSP- 1 inhibitory signal was mediated by CD36, we transduced CD36 in CD36-deficient endothelial cells. Both TSP- 1 and the agonist anti-CD36 mAb SMO, which mimics TSP- 1 activity, reduced the VEGF-A165 induced migration and sprouting of CD36-ECs. To address the mechanisms by which CD36 may exert its angiostatic function, we investigated the functional components of the C-terminal cytoplasmic tail by site-directed mutagenesis. Our results indicate that C464, R467, and K469 of CD36 are required for the inhibitory activity of TSP-1. In contrast, point mutation of C466 did not alter TSP- 1 ability to inhibit EC migration and sprouting. Moreover, we show that activation of CD36 by TSP- 1 down-modulates the VEGF receptor-2 (VEGFR-2) and p38 mitogen-associated protein kinase phosphorylation induced by VEGF-A165, and this effect was specifically abolished by point mutation at C464. These results identify specific amino acids of the C-terminal cytoplasmic tail of CD36 crucial for the in vitro angiostatic activity of TSP- 1 and extend our knowledge of regulation of VEGFR-2-mediated biological activities on ECs.	IRCC, Inst Canc Res & Treatment, I-10060 Candiolo, Italy; Univ Turin, Sch Med, Turin, Italy; Ist Sci San Raffaele, DIBIT, Proteom Lab, I-20132 Milan, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Primo, L (corresponding author), IRCC, Inst Canc Res & Treatment, SP 142,KM 3-95, I-10060 Candiolo, Italy.	luca.primo@ircc.it	Marchiò, Serena/G-9054-2017; Bussolino, Federico/AES-3951-2022; Alessio, Massimo/L-4518-2019; di Blasio, Laura/J-7352-2018; Bussolino, Federico/K-2500-2016; Alessio, Massimo/K-7028-2014	Marchiò, Serena/0000-0001-8214-0776; di Blasio, Laura/0000-0002-1337-7654; PRIMO, Luca/0000-0002-1294-0441; Bussolino, Federico/0000-0002-5348-1341; Alessio, Massimo/0000-0002-4133-3472				Armstrong LC, 2003, MATRIX BIOL, V22, P63, DOI 10.1016/S0945-053X(03)00005-2; Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Borges E, 2000, J BIOL CHEM, V275, P39867, DOI 10.1074/jbc.M007040200; BULL HA, 1994, FEBS LETT, V351, P41, DOI 10.1016/0014-5793(94)00814-0; Bussolino F, 1997, TRENDS BIOCHEM SCI, V22, P251, DOI 10.1016/S0968-0004(97)01074-8; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Byzova TV, 2000, MOL CELL, V6, P851, DOI 10.1016/S1097-2765(05)00076-6; Calzada MJ, 2004, CIRC RES, V94, P462, DOI 10.1161/01.RES.0000115555.05668.93; Calzada MJ, 2003, J BIOL CHEM, V278, P40679, DOI 10.1074/jbc.M302014200; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Chandrasekaran L, 2000, MOL BIOL CELL, V11, P2885, DOI 10.1091/mbc.11.9.2885; Chandrasekaran S, 1999, J BIOL CHEM, V274, P11408, DOI 10.1074/jbc.274.16.11408; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DANGELO G, 1995, P NATL ACAD SCI USA, V92, P6374, DOI 10.1073/pnas.92.14.6374; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI200114006; Feitsma K, 2000, J BIOL CHEM, V275, P9396, DOI 10.1074/jbc.275.13.9396; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FRAZIER WA, 1998, TUMOR ANGIOGENESIS M; Gao AG, 1996, J BIOL CHEM, V271, P21, DOI 10.1074/jbc.271.1.21; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; GODYNA S, 1995, J CELL BIOL, V129, P1403, DOI 10.1083/jcb.129.5.1403; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; Grignani F, 1998, CANCER RES, V58, P14; Gruarin P, 2000, BIOCHEM BIOPH RES CO, V275, P446, DOI 10.1006/bbrc.2000.3333; Gruarin P, 1997, BIOCHEM J, V328, P635, DOI 10.1042/bj3280635; Gruarin P, 2000, PARASITE IMMUNOL, V22, P349, DOI 10.1046/j.1365-3024.2000.00313.x; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 1998, NAT MED, V4, P13, DOI 10.1038/nm0198-013; Hemler ME, 2001, J CELL BIOL, V155, P1103, DOI 10.1083/jcb.200108061; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; Iruela-Arispe ML, 1999, CIRCULATION, V100, P1423, DOI 10.1161/01.CIR.100.13.1423; IruelaArispe ML, 1997, THROMB HAEMOSTASIS, V78, P672; IRUELAARISPE ML, 1991, P NATL ACAD SCI USA, V88, P5026, DOI 10.1073/pnas.88.11.5026; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Jimenez B, 2001, ONCOGENE, V20, P3443, DOI 10.1038/sj.onc.1204464; Korff T, 1998, J CELL BIOL, V143, P1341, DOI 10.1083/jcb.143.5.1341; Lamalice L, 2004, ONCOGENE, V23, P434, DOI 10.1038/sj.onc.1207034; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; Leong KG, 2002, MOL CELL BIOL, V22, P2830, DOI 10.1128/MCB.22.8.2830-2841.2002; Locati M, 1999, ANNU REV MED, V50, P425, DOI 10.1146/annurev.med.50.1.425; Malaud E, 2002, BIOCHEM J, V364, P507, DOI 10.1042/BJ20011373; Marchio S, 1999, J BIOL CHEM, V274, P27617, DOI 10.1074/jbc.274.39.27617; Miao WM, 2001, CANCER RES, V61, P7830; Miao WM, 2001, BLOOD, V97, P1689, DOI 10.1182/blood.V97.6.1689; MOSHER DF, 1982, J CELL BIOL, V93, P343, DOI 10.1083/jcb.93.2.343; O'Reilly MS, 1999, SCIENCE, V285, P1926, DOI 10.1126/science.285.5435.1926; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PEARCE SFA, 1994, BLOOD, V84, P384; Rousseau S, 2000, J BIOL CHEM, V275, P10661, DOI 10.1074/jbc.275.14.10661; Ruhrberg C, 2001, J CELL SCI, V114, P3215; Seo DW, 2003, CELL, V114, P171, DOI 10.1016/S0092-8674(03)00551-8; Serini G, 2003, NATURE, V424, P391, DOI 10.1038/nature01784; Shattil SJ, 1991, CURR OPIN CELL BIOL, V3, P869, DOI 10.1016/0955-0674(91)90062-4; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; SWERLICK RA, 1992, J IMMUNOL, V148, P78; TARABOLETTI G, 1990, J CELL BIOL, V111, P765, DOI 10.1083/jcb.111.2.765; Thorne RF, 2000, J BIOL CHEM, V275, P35264, DOI 10.1074/jbc.M003969200; Tolsma SS, 1997, MICROVASC RES, V54, P13, DOI 10.1006/mvre.1997.2015; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; Volpert OV, 2002, NAT MED, V8, P349, DOI 10.1038/nm0402-349; VOLPERT OV, 1995, BIOCHEM BIOPH RES CO, V217, P326, DOI 10.1006/bbrc.1995.2780; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yauch RL, 1998, MOL BIOL CELL, V9, P2751, DOI 10.1091/mbc.9.10.2751; Yauch RL, 2000, BIOCHEM J, V351, P629, DOI 10.1042/0264-6021:3510629; Zhang XA, 2002, MOL BIOL CELL, V13, P1, DOI 10.1091/mbc.01-10-0481	71	61	66	3	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1713	+		10.1096/fj.05-3697fje	http://dx.doi.org/10.1096/fj.05-3697fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16037098				2022-12-25	WOS:000230923000010
J	Debacq, C; Heraud, JM; Asquith, B; Bangham, C; Merien, F; Moules, V; Mortreux, F; Wattel, E; Burny, AN; Kettmann, R; Kazanji, M; Willems, L				Debacq, C; Heraud, JM; Asquith, B; Bangham, C; Merien, F; Moules, V; Mortreux, F; Wattel, E; Burny, AN; Kettmann, R; Kazanji, M; Willems, L			Reduced cell turnover in lymphocytic monkeys infected by human T-lymphotropic virus type 1	ONCOGENE			English	Article						HTLV-1; leukemia; BrdU; turnover	I-ASSOCIATED MYELOPATHY; LEUKEMIA-VIRUS; HTLV-I; ANIMAL-MODEL; SAIMIRI-SCIUREUS; HIV-1 INFECTION; TRANSGENIC RATS; VACCINIA VIRUS; TAX; DNA	Understanding cell dynamics in animal models have implications for therapeutic strategies elaborated against leukemia in human. Quanti. cation of the cell turnover in closely related primate systems is particularly important for rare and aggressive forms of human cancers, such as adult T-cell leukemia. For this purpose, we have measured the death and proliferation rates of the CD4(+) T lymphocyte population in squirrel monkeys (Saimiri sciureus) infected by human T-lymphotropic virus type 1 (HTLV-1). The kinetics of in vivo bromodeoxyuridine labeling revealed no modulation of the cell turnover in HTLV-1-infected monkeys with normal CD4 cell counts. In contrast, a substantial decrease in the proliferation rate of the CD4(+) T population was observed in lymphocytic monkeys (e.g. characterized by excessive proportions of CD4(+) T lymphocytes and by the presence of abnormal flower-like cells). Unexpectedly, onset of HTLV-associated leukemia thus occurs in the absence of increased CD4(+) T-cell proliferation. This dynamics significantly differs from the generalized activation of the T-cell turnover induced by other primate lymphotropic viruses like HIV and SIV.	FUSAG, Ctr Basic Biol, B-5030 Gembloux, Belgium; Inst Pasteur, Lab Retrovirol, Cayenne, French Guiana; Imperial Coll Sch Med, Dept Immunol, London, England; Ctr Leon Berard, CNRS UMR 5537, Unite Oncogenese Virale, F-69373 Lyon, France	Imperial College London; UNICANCER; Centre Leon Berard	Willems, L (corresponding author), FUSAG, Ctr Basic Biol, 13 Ave Marechal Juin, B-5030 Gembloux, Belgium.	willems.l@fsagx.ac.be	Heraud, Jean-Michel/O-1464-2013; mortreux, franck/T-4564-2019; mortreux, franck/M-5944-2014	Heraud, Jean-Michel/0000-0003-1107-0859; mortreux, franck/0000-0002-4840-021X; mortreux, franck/0000-0002-4840-021X; Asquith, Becca/0000-0002-5911-3160; Bangham, Charles/0000-0003-2624-3599; Willems, Luc/0000-0002-0563-2213				Akari H, 1998, AIDS RES HUM RETROV, V14, P367, DOI 10.1089/aid.1998.14.367; Asquith B, 2002, TRENDS IMMUNOL, V23, P596, DOI 10.1016/S1471-4906(02)02337-2; Bartoe JT, 2000, J VIROL, V74, P1094, DOI 10.1128/JVI.74.3.1094-1100.2000; BENVENISTY N, 1992, ONCOGENE, V7, P2399; Bomford R, 1996, AIDS RES HUM RETROV, V12, P403, DOI 10.1089/aid.1996.12.403; Collins ND, 1998, BLOOD, V91, P4701, DOI 10.1182/blood.V91.12.4701.412k23_4701_4707; Debacq C, 2003, J VIROL, V77, P13073, DOI 10.1128/JVI.77.24.13073-13083.2003; Debacq C, 2002, P NATL ACAD SCI USA, V99, P10048, DOI 10.1073/pnas.142100999; Delebecque F, 2002, J VIROL, V76, P7883, DOI 10.1128/JVI.76.15.7883-7889.2002; deThe G, 1996, J ACQ IMMUN DEF SYND, V13, pS191, DOI 10.1097/00042560-199600001-00029; Fang JH, 1998, J VIROL, V72, P3952, DOI 10.1128/JVI.72.5.3952-3957.1998; GESSAIN A, 1985, LANCET, V2, P407; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Hanabuchi S, 2001, J NATL CANCER I, V93, P1775, DOI 10.1093/jnci/93.23.1775; Hasegawa A, 2003, J VIROL, V77, P2956, DOI 10.1128/JVI.77.5.2956-2963.2003; Ibuki K, 1997, J GEN VIROL, V78, P147, DOI 10.1099/0022-1317-78-1-147; ICHIMARU M, 1991, CANCER DETECT PREV, V15, P177; ISHIGURO N, 1992, J EXP MED, V176, P981, DOI 10.1084/jem.176.4.981; Jeang KT, 2004, J BIOL CHEM, V279, P31991, DOI 10.1074/jbc.R400009200; Kazanji M, 1997, VIROLOGY, V231, P258, DOI 10.1006/viro.1997.8528; Kazanji M, 2001, J VIROL, V75, P5939, DOI 10.1128/JVI.75.13.5939-5948.2001; Kazanji M, 2000, AIDS RES HUM RETROV, V16, P1741, DOI 10.1089/08892220050193245; Kazanji M, 1997, INT J CANCER, V71, P300, DOI 10.1002/(SICI)1097-0215(19970410)71:2&lt;300::AID-IJC27&gt;3.0.CO;2-J; Kikuchi K, 2002, INT J EXP PATHOL, V83, P247, DOI 10.1046/j.1365-2613.2003.00233.x; Kovacs JA, 2001, J EXP MED, V194, P1731, DOI 10.1084/jem.194.12.1731; LAIRMORE MD, 1992, INT J CANCER, V50, P124, DOI 10.1002/ijc.2910500125; LENO M, 1995, J EXP MED, V181, P1575, DOI 10.1084/jem.181.4.1575; MOCHIZUKI M, 1992, LANCET, V339, P1110, DOI 10.1016/0140-6736(92)90699-4; Mohri H, 2001, J EXP MED, V194, P1277, DOI 10.1084/jem.194.9.1277; Mohri H, 1998, SCIENCE, V279, P1223, DOI 10.1126/science.279.5354.1223; Mortreux F, 2001, J NATL CANCER I, V93, P367, DOI 10.1093/jnci/93.5.367; Mortreux F, 2001, J VIROL, V75, P1083, DOI 10.1128/JVI.75.2.1083-1089.2001; Nakamaru Y, 2001, PATHOBIOLOGY, V69, P11, DOI 10.1159/000048752; Ohashi T, 2002, J VIROL, V76, P7010, DOI 10.1128/JVI.76.14.7010-7019.2002; Ohashi T, 2000, J VIROL, V74, P9610, DOI 10.1128/JVI.74.20.9610-9616.2000; OSAME M, 1986, LANCET, V1, P1031; PAGLIUCA A, 1988, BRIT MED J, V297, P1456, DOI 10.1136/bmj.297.6661.1456; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Portis T, 2001, J VIROL, V75, P2185, DOI 10.1128/JVI.75.5.2185-2193.2001; Ribeiro RM, 2002, P NATL ACAD SCI USA, V99, P15572, DOI 10.1073/pnas.242358099; Rosenzweig M, 1998, P NATL ACAD SCI USA, V95, P6388, DOI 10.1073/pnas.95.11.6388; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SHIMOYAMA M, 1991, BRIT J HAEMATOL, V79, P428, DOI 10.1111/j.1365-2141.1991.tb08051.x; Silic-Benussi M, 2004, P NATL ACAD SCI USA, V101, P6629, DOI 10.1073/pnas.0305502101; Simpson RM, 1998, AIDS RES HUM RETROV, V14, P711, DOI 10.1089/aid.1998.14.711; Sugaya T, 2002, EXP MOL PATHOL, V72, P56, DOI 10.1006/exmp.2001.2415; Willems L, 2000, AIDS RES HUM RETROV, V16, P1787, DOI 10.1089/08892220050193326; Yamaguchi K, 1992, Nihon Kyobu Shikkan Gakkai Zasshi, V30, P770; YAMAGUCHI K, 1988, BRIT J HAEMATOL, V68, P169, DOI 10.1111/j.1365-2141.1988.tb06185.x; YAMANOUCHI K, 1985, JPN J CANCER RES, V76, P481; Yasunaga J, 2001, BLOOD, V97, P3177, DOI 10.1182/blood.V97.10.3177; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475	53	9	9	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2005	24	51					7514	7523		10.1038/sj.onc.1208896	http://dx.doi.org/10.1038/sj.onc.1208896			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	984VQ	16091751				2022-12-25	WOS:000233333800002
J	Ravia, JJ; Stephen, RM; Ghishan, FK; Collins, JF				Ravia, JJ; Stephen, RM; Ghishan, FK; Collins, JF			Menkes copper ATPase (Atp7a) is a novel metal-responsive gene in rat duodenum, and immunoreactive protein is present on brush-border and basolateral membrane domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIMICROBIAL PEPTIDE HEPCIDIN; NA+-H+ EXCHANGE; PHOSPHATE-TRANSPORT; IRON-DEFICIENCY; MICROVILLUS MEMBRANE; PLASMA-MEMBRANES; EXPRESSION; VESICLES; LIVER; CERULOPLASMIN	We previously noted strong induction of genes related to intestinal copper homeostasis ( Menkes Copper ATPase (Atp7a) and metallothionein) in the duodenal epithelium of iron-deficient rats across several stages of postnatal development ( Collins, J. F., Franck, C. A., Kowdley, K. V., and Ghishan, F. K. ( 2005) Am. J. Physiol., 288, G964 - G971). We now report significant copper loading in the livers and intestines of iron-deficient rats. These findings are consistent with the hypothesis that there is increased intestinal copper transport during iron deficiency. We additionally found that hepatic Atp7b gene expression does not change with iron deficiency, suggesting that liver copper excretion is not altered. We have developed polyclonal antibodies against rat ATP7A, and we demonstrate the specificity of the immunogenic reaction. We show that the ATP7A protein is present on apical domains of duodenal enterocytes in control rats and on brush-border and basolateral membrane domains in iron-deprived rats. This localization is surprising, as previous in vitro studies have suggested that ATP7A traffics between the trans-Golgi network and the basolateral membrane. We further demonstrate that ATP7A protein levels are dramatically increased in brush-border and basolateral membrane vesicles isolated from iron-deficient rats. Other experiments show that iron refeeding partially corrects the hematological abnormalities seen in iron-deficient rats but that it does not ameliorate ATP7A protein induction, suggesting that Atp7a does not respond to intracellular iron levels. We conclude that ATP7A is involved in copper loading observed during iron deficiency and that increased intestinal copper transport is of physiological relevance, as copper plays important roles in overall body iron homeostasis.	Univ Arizona, Hlth Sci Ctr, Steele Childrens Res Ctr, Dept Pediat, Tucson, AZ 85724 USA; Univ Arizona, Hlth Sci Ctr, Steele Childrens Res Ctr, Dept Nutr Sci, Tucson, AZ 85724 USA	University of Arizona; University of Arizona Health Sciences; University of Arizona; University of Arizona Health Sciences	Collins, JF (corresponding author), SUNY Buffalo, Dept Exercise & Nutr Sci, 15 Farber Hall, Buffalo, NY 14214 USA.	jfc8@buffalo.edu			NIDDK NIH HHS [R21 DK068349, 5 R21 DK068349] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK068349] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abboud S, 2000, J BIOL CHEM, V275, P19906, DOI 10.1074/jbc.M000713200; ACRA S, 1993, AM J PHYSIOL, V264, pG45, DOI 10.1152/ajpgi.1993.264.1.G45; ACRA S, 1991, GASTROENTEROLOGY, V101, P430, DOI 10.1016/0016-5085(91)90022-D; Arredondo M, 2003, AM J PHYSIOL-CELL PH, V284, pC1525, DOI 10.1152/ajpcell.00480.2002; Baltussen R, 2004, J NUTR, V134, P2678, DOI 10.1093/jn/134.10.2678; BARNARD JA, 1985, J CLIN INVEST, V75, P869, DOI 10.1172/JCI111785; BJORKMAN DJ, 1990, BIOCHEM BIOPH RES CO, V170, P433, DOI 10.1016/0006-291X(90)92110-L; BOROWITZ SM, 1985, PEDIATR RES, V19, P1308, DOI 10.1203/00006450-198512000-00021; BULL PC, 1994, TRENDS GENET, V10, P246, DOI 10.1016/0168-9525(94)90172-4; CHERUKURI S, 2005, 1 C INT BIOIR SOC PR, P35; Collins JF, 1998, BBA-BIOMEMBRANES, V1369, P247, DOI 10.1016/S0005-2736(97)00226-5; COLLINS JF, 1995, AM J PHYSIOL-GASTR L, V268, pG917, DOI 10.1152/ajpgi.1995.268.6.G917; Collins JF, 2005, AM J PHYSIOL-GASTR L, V288, pG964, DOI 10.1152/ajpgi.00489.2004; Collins JF, 1997, AM J PHYSIOL-CELL PH, V273, pC1937, DOI 10.1152/ajpcell.1997.273.6.C1937; DAHER M, 1992, P SOC EXP BIOL MED, V201, P254; Dameron CT, 1998, AM J CLIN NUTR, V67, p1091S, DOI 10.1093/ajcn/67.5.1091S; Dudeja PK, 2003, DIGEST DIS SCI, V48, P109, DOI 10.1023/A:1021794600864; FAELLI A, 1983, ARCH INT PHYSIOL BIO, V91, P423, DOI 10.3109/13813458309067990; Fox PL, 2003, BIOMETALS, V16, P9, DOI 10.1023/A:1020799512190; Frazer DM, 2002, GASTROENTEROLOGY, V123, P835, DOI 10.1053/gast.2002.35353; GHISHAN FK, 1985, DIABETES, V34, P723, DOI 10.2337/diabetes.34.8.723; GHISHAN FK, 1985, AM J PHYSIOL, V248, pG87, DOI 10.1152/ajpgi.1985.248.1.G87; GHISHAN FK, 1987, BIOCHEM J, V243, P641, DOI 10.1042/bj2430641; GHISHAN FK, 1989, BIOCHIM BIOPHYS ACTA, V979, P77, DOI 10.1016/0005-2736(89)90525-7; Greenough M, 2004, AM J PHYSIOL-CELL PH, V287, pC1463, DOI 10.1152/ajpcell.00179.2004; Griffiths WJH, 1999, MOL MED TODAY, V5, P431, DOI 10.1016/S1357-4310(99)01541-5; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Harris ED, 2000, ANNU REV NUTR, V20, P291, DOI 10.1146/annurev.nutr.20.1.291; Harris ZL, 1998, AM J CLIN NUTR, V67, p972S, DOI 10.1093/ajcn/67.5.972S; Harris ZL, 1999, P NATL ACAD SCI USA, V96, P10812, DOI 10.1073/pnas.96.19.10812; HAUSER H, 1980, BIOCHIM BIOPHYS ACTA, V602, P567, DOI 10.1016/0005-2736(80)90335-1; Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5; Kelly EJ, 1996, NAT GENET, V13, P219, DOI 10.1038/ng0696-219; KIKUCHI K, 1988, GASTROENTEROLOGY, V95, P388, DOI 10.1016/0016-5085(88)90495-7; KIKUCHI K, 1987, GASTROENTEROLOGY, V93, P106, DOI 10.1016/0016-5085(87)90321-0; Knopfel M, 2005, BIOCHEM BIOPH RES CO, V330, P645, DOI 10.1016/j.bbrc.2005.03.023; Ludwiczek S, 2004, J MOL MED, V82, P373, DOI 10.1007/s00109-004-0542-3; McKie AT, 2000, MOL CELL, V5, P299, DOI 10.1016/S1097-2765(00)80425-6; McKie AT, 2001, SCIENCE, V291, P1755, DOI 10.1126/science.1057206; Mercer JFB, 2003, BIOMETALS, V16, P175, DOI 10.1023/A:1020719016675; MOE AJ, 1985, J NUTR, V115, P1173, DOI 10.1093/jn/115.9.1173; Muckenthaler M, 2003, NAT GENET, V34, P102, DOI 10.1038/ng1152; Mukhopadhyay CK, 1998, SCIENCE, V279, P714, DOI 10.1126/science.279.5351.714; Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742; Nicolas G, 2002, P NATL ACAD SCI USA, V99, P4596, DOI 10.1073/pnas.072632499; Nicolas G, 2002, J CLIN INVEST, V110, P1037, DOI 10.1172/JCI200215686; Nicolas G, 2001, P NATL ACAD SCI USA, V98, P8780, DOI 10.1073/pnas.151179498; Park CH, 2001, J BIOL CHEM, V276, P7806, DOI 10.1074/jbc.M008922200; Pase L, 2004, BIOCHEM J, V378, P1031, DOI 10.1042/BJ20031181; Petris MJ, 2002, J BIOL CHEM, V277, P46736, DOI 10.1074/jbc.M208864200; Pigeon C, 2001, J BIOL CHEM, V276, P7811, DOI 10.1074/jbc.M008923200; Roetto A, 2003, NAT GENET, V33, P21, DOI 10.1038/ng1053; SAID HM, 1987, AM J PHYSIOL, V252, pG229, DOI 10.1152/ajpgi.1987.252.2.G229; STIEGER B, 1983, EUR J BIOCHEM, V135, P95; Tapiero H, 2001, BIOMED PHARMACOTHER, V55, P324, DOI 10.1016/S0753-3322(01)00067-1; Trinder D, 2000, GUT, V46, P270, DOI 10.1136/gut.46.2.270; Tyagi S, 2000, DIGEST DIS SCI, V45, P2282, DOI 10.1023/A:1005670404456; Vulpe CD, 1999, NAT GENET, V21, P195, DOI 10.1038/5979; VULPE CD, 1995, ANNU REV NUTR, V15, P293, DOI 10.1146/annurev.nu.15.070195.001453; Weinstein DA, 2002, BLOOD, V100, P3776, DOI 10.1182/blood-2002-04-1260; WILLIAMS LM, 1989, TOXICOLOGY, V55, P307, DOI 10.1016/0300-483X(89)90020-6; Wollenberg P, 1990, Biol Met, V3, P1, DOI 10.1007/BF01141169; Xu H, 2003, AM J PHYSIOL-GASTR L, V285, pG1317, DOI 10.1152/ajpgi.00172.2003; Xu H, 2001, AM J PHYSIOL-CELL PH, V280, pC628, DOI 10.1152/ajpcell.2001.280.3.C628; Yeh KY, 2000, AM J PHYSIOL-GASTR L, V279, pG1070, DOI 10.1152/ajpgi.2000.279.5.G1070; Young SP, 1997, FEBS LETT, V411, P93, DOI 10.1016/S0014-5793(97)00478-X; Zhou B, 1997, P NATL ACAD SCI USA, V94, P7481, DOI 10.1073/pnas.94.14.7481; Zoller H, 2001, GASTROENTEROLOGY, V120, P1412, DOI 10.1053/gast.2001.24033	68	68	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36221	36227		10.1074/jbc.M506727200	http://dx.doi.org/10.1074/jbc.M506727200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16081413	Green Accepted, hybrid			2022-12-25	WOS:000232726900054
J	Kamrava, M; Simpkins, F; Alejandro, E; Michener, C; Meltzer, E; Kohn, EC				Kamrava, M; Simpkins, F; Alejandro, E; Michener, C; Meltzer, E; Kohn, EC			Lysophosphatidic acid and endothelin-induced proliferation of ovarian cancer cell lines is mitigated by neutralization of granulin-epithelin precursor (GEP), a prosurvival factor for ovarian cancer	ONCOGENE			English	Article						ovarian cancer; progranulin; apoptosis; EPAC; signaling	DEPENDENT PROTEIN-KINASE; GROWTH-FACTOR RECEPTOR; CARCINOMA CELLS; COUPLED RECEPTORS; CYCLIC-AMP; SIGNALING PATHWAYS; ALPHA SUBUNIT; FACTOR PCDGF; ACTIVATION; EPAC	Granulin-epithelin precursor (GEP/progranulin) is an autocrine growth factor for ovarian cancer. We examined the production and function of GEP and report that: (1) GEP production is regulated by endothelin (ET-1), lysophosphatidic acid (LPA), and cAMP; (2) cAMP signals GEP production through exchange protein activated by cAMP (EPAC); (3) ET-1 and cAMP/EPAC induce GEP through ERK1/2; and (4) neutralization of GEP results in apoptosis. Exposure of HEY-A8 and OVCAR3 ovarian cancer cells to LPA and ET-1 yielded GEP production and secretion in a dose- and time-dependent fashion; neither stimulated significant concentrations of cAMP directly. Stimulation of cAMP production with pertussis and cholera toxin, or forskolin induced GEP in a PKA-independent fashion. EPAC, an intracellular cAMP receptor, is activated specifically by the cAMP analog, 8-CPT-2'-O-Me-cAMP (8-CPT); 8-CPT treatment stimulated GEP production and secretion. The MEK inhibitor, U0126, abrogated GEP production in response to ET-1 and 8-CPT, confirming involvement of MAPK. A partial inhibition of basal and stimulated GEP production was observed when cells were treated with a internal calcium chelator, BAPTA. Neutralizing anti-GEP antibody reversed basal as well as LPA, ET-1 and 8CPT-induced ovarian cancer cell growth and induced apoptosis as demonstrated by caspase-3 and PARP cleavage, DNA fragmentation, and nuclear condensation. These results indicate that GEP is a growth and survival factor for ovarian cancer, induced by LPA and ET-1 and cAMP/EPAC through ERK1/2.	NCI, Pathol Lab, Mol Signaling Sect, Canc Res Ctr, Bethesda, MD 20892 USA; NIH, Howard Hughes Med Inst, Res Scholars Program, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA	Kohn, EC (corresponding author), NCI, Pathol Lab, Mol Signaling Sect, Canc Res Ctr, 10 Ctr Dr MSC 1500, Bethesda, MD 20892 USA.	ek1b@nih.gov		Alejandro, Emilyn/0000-0002-7941-8439	NATIONAL CANCER INSTITUTE [Z01SC009163, ZIASC009163] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alper O, 1999, ONCOGENE, V18, P4999, DOI 10.1038/sj.onc.1202830; Amsterdam A, 1999, TRENDS ENDOCRIN MET, V10, P255, DOI 10.1016/S1043-2760(99)00164-2; Bagnato A, 1999, CANCER RES, V59, P720; Bagnato A, 1995, CLIN CANCER RES, V1, P1059; Bagnato A, 1997, CANCER RES, V57, P1306; BATEMAN A, 1990, BIOCHEM BIOPH RES CO, V173, P1161, DOI 10.1016/S0006-291X(05)80908-8; Bateman A, 1998, J ENDOCRINOL, V158, P145, DOI 10.1677/joe.0.1580145; Bos JL, 2003, NAT REV MOL CELL BIO, V4, P733, DOI 10.1038/nrm1197; Cho YS, 2001, P NATL ACAD SCI USA, V98, P9819, DOI 10.1073/pnas.171314398; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Davidson B, 2004, CANCER-AM CANCER SOC, V100, P2139, DOI 10.1002/cncr.20219; Del Bufalo D, 2002, CLIN SCI, V103, p302S, DOI 10.1042/CS103S302S; Del Bufalo D, 2002, MOL PHARMACOL, V61, P524, DOI 10.1124/mol.61.3.524; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; Fang XJ, 2002, BBA-MOL CELL BIOL L, V1582, P257, DOI 10.1016/S1388-1981(02)00179-8; Goetzl EJ, 1999, CANCER RES, V59, P4732; Guirland C, 2003, J NEUROSCI, V23, P2274; He ZH, 2003, J MOL MED-JMM, V81, P600, DOI 10.1007/s00109-003-0474-3; He ZH, 2003, NAT MED, V9, P225, DOI 10.1038/nm816; Herrlich A, 1998, P NATL ACAD SCI USA, V95, P8985, DOI 10.1073/pnas.95.15.8985; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Jones MB, 2003, CLIN CANCER RES, V9, P44; Kang GX, 2003, J BIOL CHEM, V278, P8279, DOI 10.1074/jbc.M211682200; Keiper M, 2004, J BIOL CHEM, V279, P46497, DOI 10.1074/jbc.M403604200; Kim S, 2001, J BIOL CHEM, V276, P12864, DOI 10.1074/jbc.M001492200; Kopperud R, 2003, FEBS LETT, V546, P121, DOI 10.1016/S0014-5793(03)00563-5; Liotta LA, 2003, CANCER CELL, V3, P317, DOI 10.1016/S1535-6108(03)00086-2; Lu RQ, 1999, BIOCHEM BIOPH RES CO, V256, P204, DOI 10.1006/bbrc.1999.0253; Lu RQ, 2000, P NATL ACAD SCI USA, V97, P3993, DOI 10.1073/pnas.97.8.3993; Lu RQ, 2001, P NATL ACAD SCI USA, V98, P142, DOI 10.1073/pnas.011525198; McDaid HM, 1999, BRIT J CANCER, V79, P933, DOI 10.1038/sj.bjc.6690149; Mei FC, 2002, J BIOL CHEM, V277, P11497, DOI 10.1074/jbc.M110856200; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Nicosia SV, 2003, HEMATOL ONCOL CLIN N, V17, P927, DOI 10.1016/S0889-8588(03)00056-X; Rangarajan S, 2003, J CELL BIOL, V160, P487, DOI 10.1083/jcb.200209105; Rosano L, 2003, CANCER RES, V63, P2447; Rosano L, 2001, CANCER RES, V61, P8340; Salani D, 2000, AM J PATHOL, V157, P1537, DOI 10.1016/S0002-9440(10)64791-8; Salani D, 2002, CLIN SCI, V103, p318S, DOI 10.1042/CS103S318S; SHABB JB, 1990, J BIOL CHEM, V265, P5267; Vacca F, 2000, CANCER RES, V60, P5310; XU Y, 1995, BIOCHEM J, V309, P933, DOI 10.1042/bj3090933; Zanassi P, 2001, J BIOL CHEM, V276, P11487, DOI 10.1074/jbc.M007631200; Zanocco-Marani T, 1999, CANCER RES, V59, P5331; Zhang HD, 1998, P NATL ACAD SCI USA, V95, P14202, DOI 10.1073/pnas.95.24.14202; ZHOU J, 1993, J BIOL CHEM, V268, P10863; Zhu J, 2002, CELL, V111, P867, DOI 10.1016/S0092-8674(02)01141-8	47	55	61	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2005	24	47					7084	7093		10.1038/sj.onc.1208857	http://dx.doi.org/10.1038/sj.onc.1208857			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	977WC	16044162				2022-12-25	WOS:000232833200010
J	Bera, AK; Akabas, MH				Bera, AK; Akabas, MH			Spontaneous thermal motion of the GABA(A) receptor M2 channel-lining segments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-AMINOBUTYRIC-ACID; NICOTINIC ACETYLCHOLINE-RECEPTOR; CYSTEINE-SUBSTITUTION; PROTEIN MOBILITY; GENERAL-METHOD; ALPHA-HELIX; SUBUNIT; PACKING; BINDING; SITE	The gamma- aminobutyric acid type A ( GABA(A)) receptor channel opening involves translational and rotational motions of the five channel- lining, M2 transmembrane segments. The M2 segment's extracellular half is loosely packed and undergoes significant thermal motion. To characterize the extent of the M2 segment's motion, we used disulfide trapping experiments between pairs of engineered cysteines. In alpha(1)beta(1)gamma(2S) receptors the single gamma subunit is flanked by an alpha and beta subunit. The gamma(2)M2 - 14' position is located in the alpha-gamma subunit interface. gamma(2) 13' faces the channel lumen. We expressed either the gamma(2)14' or the gamma(2)13' cysteine substitution mutants with alpha(1) cysteine substitution mutants between 12' and 16' and wild- type beta(1). Disulfide bonds formed spontaneously between gamma(2)14'C and both alpha(1)15'C and alpha(1)16'C and also between gamma(2)13'C and alpha(1)13'C. Oxidation by copper phenanthroline induced disulfide bond formation between gamma(2)14'C and alpha(1)13' C. Disulfide bond formation rates with gamma(2)14'C were similar in the presence and absence of GABA, although the rate with alpha(1)13' C was slower than with the other two positions. In a homology model based on the acetylcholine receptor structure, alpha M2 would need to rotate in opposite directions by similar to 80 degrees to bring alpha(1)13' and alpha(1)15' into close proximity with gamma(2)14'. Alternatively, translational motion of alpha M2 would reduce the extent of rotational motion necessary to bring these two alpha subunit residues into close proximity with the gamma(2)14' position. These experiments demonstrate that in the closed state the M2 segments undergo continuous spontaneous motion in the region near the extracellular end of the channel gate. Opening the gate may involve similar but concerted motions of the M2 segments.	Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Akabas, MH (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	makabas@aecom.yu.edu		Bera, Amal Kanti/0000-0003-0362-5578; Akabas, Myles/0000-0001-8781-7846	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM061925] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030808] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM61925] Funding Source: Medline; NINDS NIH HHS [NS30808] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; Baumann SW, 2001, J BIOL CHEM, V276, P36275, DOI 10.1074/jbc.M105240200; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; CAREAGA CL, 1992, J MOL BIOL, V226, P1219, DOI 10.1016/0022-2836(92)91063-U; Cha A, 1999, NATURE, V402, P809, DOI 10.1038/45552; Chakrapani S, 2005, P NATL ACAD SCI USA, V102, P87, DOI 10.1073/pnas.0406777102; Chang YC, 1996, J NEUROSCI, V16, P5415; Cromer BA, 2002, TRENDS BIOCHEM SCI, V27, P280, DOI 10.1016/S0968-0004(02)02092-3; Dahan DS, 2004, P NATL ACAD SCI USA, V101, P10195, DOI 10.1073/pnas.0301885101; Goren EN, 2004, J BIOL CHEM, V279, P11198, DOI 10.1074/jbc.M314050200; Halle B, 2002, P NATL ACAD SCI USA, V99, P1274, DOI 10.1073/pnas.032522499; Hastrup H, 2001, P NATL ACAD SCI USA, V98, P10055, DOI 10.1073/pnas.181344298; Horenstein J, 2005, J BIOL CHEM, V280, P1573, DOI 10.1074/jbc.M410881200; Horenstein J, 2001, NAT NEUROSCI, V4, P477, DOI 10.1038/87425; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Johnson JP, 2001, NATURE, V412, P917, DOI 10.1038/35091089; Karlin A, 2002, NAT REV NEUROSCI, V3, P102, DOI 10.1038/nrn731; Kihira Y, 2004, BIOCHEMISTRY-US, V43, P15204, DOI 10.1021/bi0494222; KOBASHI K, 1968, BIOCHIM BIOPHYS ACTA, V158, P239, DOI 10.1016/0304-4165(68)90136-0; Lester HA, 2004, TRENDS NEUROSCI, V27, P329, DOI 10.1016/j.tins.2004.04.002; MILLER C, 1989, NEURON, V2, P1195, DOI 10.1016/0896-6273(89)90304-8; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Olsen RW, 2004, BIOCHEM PHARMACOL, V68, P1675, DOI 10.1016/j.bcp.2004.07.026; Panicker S, 2004, J BIOL CHEM, V279, P28149, DOI 10.1074/jbc.M403545200; RABOW LE, 1995, SYNAPSE, V21, P189, DOI 10.1002/syn.890210302; Reeves DC, 2002, MOL MEMBR BIOL, V19, P11, DOI 10.1080/09687680110110048; REGAN L, 1994, PROTEIN SCI, V3, P2419, DOI 10.1002/pro.5560031225; SOWDHAMINI R, 1989, PROTEIN ENG, V3, P95, DOI 10.1093/protein/3.2.95; Teissere JA, 2001, J NEUROSCI, V21, P4977, DOI 10.1523/JNEUROSCI.21-14-04977.2001; Tretter V, 1997, J NEUROSCI, V17, P2728; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; Unwin N, 2005, J MOL BIOL, V346, P967, DOI 10.1016/j.jmb.2004.12.031; Wu JH, 1996, P NATL ACAD SCI USA, V93, P14498, DOI 10.1073/pnas.93.25.14498; Xiao WZ, 2000, J MOL BIOL, V304, P715, DOI 10.1006/jmbi.2000.4255; XU M, 1993, J BIOL CHEM, V268, P21505; Xu M, 1996, J GEN PHYSIOL, V107, P195, DOI 10.1085/jgp.107.2.195; YU HB, 1995, BIOCHEMISTRY-US, V34, P14963, DOI 10.1021/bi00046a002	37	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35506	35512		10.1074/jbc.M504645200	http://dx.doi.org/10.1074/jbc.M504645200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16091360	hybrid			2022-12-25	WOS:000232561200051
J	Kwon, H; Ogle, L; Benitez, B; Bohuslav, J; Montano, M; Felsher, DW; Greene, WC				Kwon, H; Ogle, L; Benitez, B; Bohuslav, J; Montano, M; Felsher, DW; Greene, WC			Lethal cutaneous disease in transgenic mice conditionally expressing type I human T cell leukemia virus tax	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INTERLEUKIN-10 GENE-EXPRESSION; RECEPTOR BETA-GENE; HTLV-I; INFECTIVE DERMATITIS; RAT FIBROBLASTS; SKIN-DISEASE; PROVIRAL DNA; GAMMA-GENE; LYMPHOMA	Type I human T cell leukemia virus ( HTLV- I) is etiologically linked with adult T cell leukemia, an aggressive and usually fatal expansion of activated CD4(+) T lymphocytes that frequently traffic to skin. T cell transformation induced by HTLV- I involves the action of the 40- kDa viral Tax transactivator protein. Tax both stimulates the HTLV- I long terminal repeat and deregulates the expression of select cellular genes by altering the activity of specific host transcription factors, including cyclic AMP- responsive element-binding protein ( CREB)/ activating transcription factor, NF-kappa B/ Rel, and serum response factor. To study initiating events involved in HTLV- I Tax- induced T cell transformation, we generated " Tet- off" transgenic mice conditionally expressing in a lymphocyte- restricted manner ( E mu SR alpha promoter- enhancer) either wild- type Tax or mutant forms of Tax that selectively compromise the NF-kappa B ( M22) or CREB/ activating transcription factor ( M47) activation pathways. Wild- type Tax and M47 Tax- expressing mice, but not M22- Tax expressing mice, developed progressive alopecia, hyperkeratosis, and skin lesions containing profuse activated CD4 T cell infiltrates with evidence of deregulated inflammatory cytokine production. In addition, these animals displayed systemic lymphadenopathy and splenomegaly. These findings suggest that Tax- mediated activation of NF-kappa B plays a key role in the development of this aggressive skin disease that shares several features in common with the skin disease occurring during the preleukemic stage in HTLV-I-infected patients. Of note, this skin disease completely resolved when Tax transgene expression was suppressed by administration of doxycycline, emphasizing the key role played by this viral oncoprotein in the observed pathology.	Gladstone Inst Virol & Immunol, San Francisco, CA 94158 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Stanford Univ, Dept Med, Div Oncol, Stanford, CA 94305 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Stanford University	Greene, WC (corresponding author), Gladstone Inst Virol & Immunol, 1650 Owens St, San Francisco, CA 94158 USA.	wgreene@gladstone.ucsf.edu			NCI NIH HHS [R01CA89001] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089001] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akagi T, 1997, ONCOGENE, V14, P2071, DOI 10.1038/sj.onc.1201045; Azran Inbal, 2004, Retrovirology, V1, P20; Baker M, 2000, EMBO J, V19, P4644, DOI 10.1093/emboj/19.17.4644; Barton D, 2000, EUR J IMMUNOL, V30, P2323, DOI 10.1002/1521-4141(2000)30:8<2323::AID-IMMU2323>3.0.CO;2-H; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BLANK A, 1995, LANCET, V346, P710, DOI 10.1016/S0140-6736(95)92326-8; Boland CR, 1999, P NATL ACAD SCI USA, V96, P14675, DOI 10.1073/pnas.96.26.14675; Bouvier G, 1996, P NATL ACAD SCI USA, V93, P7877, DOI 10.1073/pnas.93.15.7877; BROWN DA, 1991, EUR J IMMUNOL, V21, P1879, DOI 10.1002/eji.1830210815; BUNKER CB, 1990, LANCET, V335, P426, DOI 10.1016/0140-6736(90)90274-9; Carroll JM, 1997, J INVEST DERMATOL, V108, P412, DOI 10.1111/1523-1747.ep12289702; CHENG J, 1992, GENE DEV, V6, P1444, DOI 10.1101/gad.6.8.1444; Coscoy L, 1998, VIROLOGY, V248, P332, DOI 10.1006/viro.1998.9298; Daniel D, 2003, J EXP MED, V197, P1017, DOI 10.1084/jem.20021047; DOSAKA N, 1991, J INVEST DERMATOL, V96, P196, DOI 10.1111/1523-1747.ep12461033; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; FURUKAWA Y, 1994, CANCER RES, V54, P6533; FURUTA Y, 1989, J VIROL, V63, P3185, DOI 10.1128/JVI.63.7.3185-3189.1989; Gartner F, 1999, IMMUNITY, V10, P537, DOI 10.1016/S1074-7613(00)80053-9; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; Germain M, 2000, INT J DERMATOL, V39, P815, DOI 10.1046/j.1365-4362.2000.00937.x; GESSAIN A, 1990, J AM ACAD DERMATOL, V23, P994, DOI 10.1016/0190-9622(90)70321-8; GESSAIN A, 1985, LANCET, V2, P407; Goncalves DU, 2003, AM J TROP MED HYG, V68, P562, DOI 10.4269/ajtmh.2003.68.562; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; GROVES RW, 1995, P NATL ACAD SCI USA, V92, P11874, DOI 10.1073/pnas.92.25.11874; Hall AP, 1998, J PATHOL, V186, P209; HALL WW, 1994, J EXP MED, V180, P1581, DOI 10.1084/jem.180.5.1581; HANCHARD B, 1991, LANCET, V338, P1593, DOI 10.1016/0140-6736(91)92413-V; Hasegawa H, 2000, BLOOD, V95, P30; Higaki Y, 2003, DERMATOLOGY, V206, P157, DOI 10.1159/000068460; HINRICHS SH, 1987, SCIENCE, V237, P1340, DOI 10.1126/science.2888191; Ishida Y, 1989, Int Immunol, V1, P113, DOI 10.1093/intimm/1.2.113; Kato N, 2001, BRIT J DERMATOL, V144, P1244, DOI 10.1046/j.1365-2133.2001.04242.x; KIM SJ, 1991, MOL CELL BIOL, V11, P5222, DOI 10.1128/MCB.11.10.5222; Kindt TJ, 2000, MICROBES INFECT, V2, P1139, DOI 10.1016/S1286-4579(00)01268-5; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; Klement JF, 1996, MOL CELL BIOL, V16, P2341; Kohler S, 1997, J CUTAN PATHOL, V24, P292, DOI 10.1111/j.1600-0560.1997.tb00794.x; La Grenade L, 1998, ARCH DERMATOL, V134, P439, DOI 10.1001/archderm.134.4.439; LAGRENADE L, 1990, LANCET, V336, P1345; LaGrenade L, 1996, AM J MED GENET, V61, P37, DOI 10.1002/(SICI)1096-8628(19960102)61:1<37::AID-AJMG7>3.0.CO;2-U; Lenzi MER, 2003, CLIN INFECT DIS, V36, P507, DOI 10.1086/367572; Mahe A, 1999, LANCET, V354, P1386, DOI 10.1016/S0140-6736(05)76239-5; Mori N, 1998, LEUKEMIA LYMPHOMA, V29, P239, DOI 10.3109/10428199809068561; Mori N, 1996, BLOOD, V88, P1035; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; PAGLIUCA A, 1990, LANCET, V335, P733, DOI 10.1016/0140-6736(90)90854-X; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; RICH BE, 1993, J EXP MED, V177, P305, DOI 10.1084/jem.177.2.305; Robek MD, 1999, J VIROL, V73, P4856, DOI 10.1128/JVI.73.6.4856-4865.1999; Rosin O, 1998, J BIOL CHEM, V273, P6698, DOI 10.1074/jbc.273.12.6698; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; SEMMES OJ, 1992, J VIROL, V66, P7183, DOI 10.1128/JVI.66.12.7183-7192.1992; SHIMOYAMA M, 1991, BRIT J HAEMATOL, V79, P428, DOI 10.1111/j.1365-2141.1991.tb08051.x; Simpson RM, 1996, J INFECT DIS, V173, P722, DOI 10.1093/infdis/173.3.722; SMITH MR, 1991, J CLIN INVEST, V88, P1038, DOI 10.1172/JCI115364; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Steele KE, 2001, VET PATHOL, V38, P203, DOI 10.1354/vp.38-2-203; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; TAJIMA K, 1988, INT J CANCER, V41, P505; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; TANAKA T, 1989, J AM ACAD DERMATOL, V21, P218, DOI 10.1016/S0190-9622(89)70164-X; TENDLER CL, 1991, J CELL BIOCHEM, V46, P302, DOI 10.1002/jcb.240460405; Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15; UEHIRA M, 1993, INT IMMUNOL, V5, P1619, DOI 10.1093/intimm/5.12.1619; WANO Y, 1987, J CLIN INVEST, V80, P911, DOI 10.1172/JCI113152; Williams IR, 1997, J IMMUNOL, V159, P3044; Yajima A, 2001, DERMATOLOGY, V203, P53, DOI 10.1159/000051704; YAMADA M, 1989, INT J DERMATOL, V28, P107, DOI 10.1111/j.1365-4362.1989.tb01329.x; Yamada Y, 1996, LEUKEMIA LYMPHOMA, V21, P443, DOI 10.3109/10428199609093442; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yoshie O, 2002, BLOOD, V99, P1505, DOI 10.1182/blood.V99.5.1505	75	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35713	35722		10.1074/jbc.M504848200	http://dx.doi.org/10.1074/jbc.M504848200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16105841	hybrid			2022-12-25	WOS:000232561200074
J	Lee, MH; Kim, YJ; Yoon, WJ; Kim, JI; Kim, BG; Hwang, YS; Wozney, JM; Chi, XZ; Bae, SC; Choi, KY; Cho, JY; Choi, JY; Ryoo, HM				Lee, MH; Kim, YJ; Yoon, WJ; Kim, JI; Kim, BG; Hwang, YS; Wozney, JM; Chi, XZ; Bae, SC; Choi, KY; Cho, JY; Choi, JY; Ryoo, HM			Dlx5 specifically regulates Runx2 type II expression by binding to homeodomain-response elements in the Runx2 distal promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-2; CRANIAL SUTURE MORPHOGENESIS; OSTEOCALCIN GENE-EXPRESSION; GROWTH-FACTOR BETA-1; OSTEOBLAST DIFFERENTIATION; MSX2; TRANSCRIPTION; CBFA1; ISOFORMS; PATTERNS	Two major isoforms of the Runx2 gene are expressed by alternative promoter usage: Runx2 type I (Runx2-I) is derived from the proximal promoter (P2), and Runx2 type II (Runx2-II) is produced by the distal promoter (P1). Our previous results indicate that Dlx5 mediates BMP-2-induced Runx2 expression and osteoblast differentiation (Lee, M.-H., Kim, Y-J., Kim, H-J., Park, H-D., Kang, A-R., Kyung, H.-M., Sung, J-H., Wozney, J. M., Kim, H-J., and Ryoo, H-M. (2003) J. Biol. Chem. 278, 34387-34394). However, little is known of the molecular mechanisms by which Dlx5 up-regulates Runx2 expression in BMP-2 signaling. Here, Runx2-II expression was found to be specifically stimulated by BMP-2 treatment or by Dlx5 overexpression. In addition, BMP-2, Dlx5, and Runx2-II were found to be expressed in osteogenic fronts and parietal bones of the developing cranial vault and Runx2-I and Msx2 in the sutural mesenchyme. Furthermore, Runx2 P1 promoter activity was strongly stimulated by Dlx5 overexpression, whereas Runx2 P2 promoter activity was not. Runx2 P1 promoter deletion analysis indicated that the Dlx5-specific response is due to sequences between -756 and -342 bp of the P1 promoter, where three Dlx5-response elements are located. Dlx5 responsiveness to these elements was confirmed by gel mobility shift assay and site-directed mutagenesis. Moreover, Msx2 specifically suppressed the Runx2 P1 promoter, and the responsible region overlaps with that recognized by Dlx5. In summary, Dlx5 specifically transactivates the Runx2 P1 promoter, and its action on the P1 promoter is antagonized by Msx2.	Kyungpook Natl Univ, Sch Dent, Dept Biochem, Taegu 700422, South Korea; Kyungpook Natl Univ, Skeletal Dis Genome Res Ctr, Taegu 700422, South Korea; Kyungpook Natl Univ, Sch Med, Dept Anat, Taegu 700422, South Korea; Kyungpook Natl Univ, Sch Med, Dept Biochem, Taegu 700422, South Korea; Wyeth Pharmaceut, Cambridge, MA 02140 USA; Chungbuk Natl Univ, Sch Med, Dept Biochem, Cheongju 361763, South Korea	Kyungpook National University; Kyungpook National University; Kyungpook National University; Kyungpook National University; Pfizer; Chungbuk National University	Ryoo, HM (corresponding author), Seoul Natl Univ, Coll Dent, Dept Cell & Dev Biol, 28 Yeongeon Dong, Seoul 110749, South Korea.	hmryoo@snu.ac.kr	Ryoo, Hyun-Mo/D-5839-2012	Ryoo, Hyun-Mo/0000-0001-6769-8341; Lee, Mi-Hye/0000-0002-5484-3383				Banerjee C, 2001, ENDOCRINOLOGY, V142, P4026, DOI 10.1210/en.142.9.4026; Bangsow C, 2001, GENE, V279, P221, DOI 10.1016/S0378-1119(01)00760-0; Barnes GL, 2003, CANCER RES, V63, P2631; Benson MD, 2000, J BIOL CHEM, V275, P13907, DOI 10.1074/jbc.275.18.13907; Bidder M, 1998, J BONE MINER RES, V13, P609, DOI 10.1359/jbmr.1998.13.4.609; Cheng SL, 2003, J BIOL CHEM, V278, P45969, DOI 10.1074/jbc.M306972200; Choi KY, 2005, DEV DYNAM, V233, P115, DOI 10.1002/dvdy.20323; Choi KY, 2002, EXP MOL MED, V34, P426, DOI 10.1038/emm.2002.60; Dodig M, 1996, J BIOL CHEM, V271, P16422, DOI 10.1074/jbc.271.27.16422; Drissi H, 2000, J CELL PHYSIOL, V184, P341, DOI 10.1002/1097-4652(200009)184:3<341::AID-JCP8>3.0.CO;2-Z; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Geoffroy V, 1998, MAMM GENOME, V9, P54, DOI 10.1007/s003359900679; Ghozi MC, 1996, P NATL ACAD SCI USA, V93, P1935, DOI 10.1073/pnas.93.5.1935; Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660; Hassan MQ, 2004, MOL CELL BIOL, V24, P9248, DOI 10.1128/MCB.24.20.9248-9261.2004; HOFFMANN HM, 1994, P NATL ACAD SCI USA, V91, P12887, DOI 10.1073/pnas.91.26.12887; Ichida F, 2004, J BIOL CHEM, V279, P34015, DOI 10.1074/jbc.M403621200; JABS EW, 1993, CELL, V75, P443, DOI 10.1016/0092-8674(93)90379-5; Kim HJ, 2003, J BIOL CHEM, V278, P319, DOI 10.1074/jbc.M203750200; Kim HJ, 1998, DEVELOPMENT, V125, P1241; Kim YJ, 2004, J BIOL CHEM, V279, P50773, DOI 10.1074/jbc.M404145200; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Lee MH, 1999, J CELL BIOCHEM, V73, P114, DOI 10.1002/(SICI)1097-4644(19990401)73:1<114::AID-JCB13>3.3.CO;2-D; Lee MH, 2003, BIOCHEM BIOPH RES CO, V309, P689, DOI 10.1016/j.bbrc.2003.08.058; Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200; Lengner CJ, 2002, MECH DEVELOP, V114, P167, DOI 10.1016/S0925-4773(02)00050-3; Ma L, 1996, HUM MOL GENET, V5, P1915, DOI 10.1093/hmg/5.12.1915; Miyama K, 1999, DEV BIOL, V208, P123, DOI 10.1006/dbio.1998.9197; Newberry EP, 1998, BIOCHEMISTRY-US, V37, P16360, DOI 10.1021/bi981878u; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; Park MH, 2001, J BONE MINER RES, V16, P885, DOI 10.1359/jbmr.2001.16.5.885; Ryoo HM, 1997, MOL ENDOCRINOL, V11, P1681, DOI 10.1210/me.11.11.1681; Shen J, 2003, MOL ENDOCRINOL, V17, P743, DOI 10.1210/me.2002-0122; Shen JL, 2002, J BIOL CHEM, V277, P20284, DOI 10.1074/jbc.M112440200; Shirakabe K, 2001, GENES CELLS, V6, P851, DOI 10.1046/j.1365-2443.2001.00466.x; Stewart M, 1997, P NATL ACAD SCI USA, V94, P8646, DOI 10.1073/pnas.94.16.8646; Tadic T, 2002, J BONE MINER RES, V17, P1008, DOI 10.1359/jbmr.2002.17.6.1008; Thirunavukkarasu K, 1998, MOL CELL BIOL, V18, P4197, DOI 10.1128/MCB.18.7.4197; TOWLER DA, 1994, MOL ENDOCRINOL, V8, P1484, DOI 10.1210/me.8.11.1484; Ueta C, 2001, J CELL BIOL, V153, P87, DOI 10.1083/jcb.153.1.87; Xiao ZS, 2001, J CELL BIOCHEM, V82, P647, DOI 10.1002/jcb.1192; Xiao ZS, 2005, DEV BIOL, V283, P345, DOI 10.1016/j.ydbio.2005.04.028; Xiao ZS, 2004, J BIOL CHEM, V279, P20307, DOI 10.1074/jbc.M401109200; Zhang HL, 1997, MOL CELL BIOL, V17, P2920, DOI 10.1128/MCB.17.5.2920	45	160	168	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35579	35587		10.1074/jbc.M502267200	http://dx.doi.org/10.1074/jbc.M502267200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16115867	hybrid, Green Published			2022-12-25	WOS:000232561200060
J	Long, JY; Zuo, DM; Park, M				Long, JY; Zuo, DM; Park, M			Pc2-mediated sumoylation of Smad-interacting protein 1 attenuates transcriptional repression of E-cadherin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-MESENCHYMAL TRANSITIONS; TERMINAL BINDING-PROTEIN; SUMO-1 MODIFICATION; GENE-EXPRESSION; TGF-BETA; TUMOR PROGRESSION; COREPRESSOR CTBP; BREAST-CANCER; ZEB PROTEINS; FACTOR SNAIL	Epithelial- mesenchymal transition ( EMT) is important in embryonic development and tumorigenesis. Smad- interacting protein 1 ( SIP1) can induce EMT by repressing the transcription of E- cadherin through recruitment of the corepressor C- terminal- binding protein ( CtBP). How the activity of SIP1 is regulated still remains unclear. Here we show in vivo and in vitro that SIP1 is covalently modified by sumoylation at two conserved sites, Lys(391) and Lys(866). The polycomb protein Pc2, but not the PIAS ( protein inhibitor of activated STAT) family proteins, acts as a Small ubiquitin- like modifier E3 ligase for SIP1. Sumoylation of SIP1 does not affect its subcellular localization, but regulates its transcriptional activity. Compared with the wild- type, a SIP1 sumoylation null mutant shows more potent repression on E- cadherin transcription but similar repression on two transforming growth factor-beta- responsive reporter genes and comparable activation on vitamin D3 receptor transcription. Coexpression of SIP1 with Pc2 can partially relieve E- cadherin repression by SIP1. We further show that SIP1 sumoylation disrupts the recruitment of CtBP. Thus SIP1 sumoylation regulates its transcriptional activity in a promoter context- dependent manner and may represent an important intervention target to modulate EMT in tumorigenesis.	McGill Univ, Ctr Hlth, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3A 1A1, Canada	McGill University; McGill University; McGill University; McGill University	Park, M (corresponding author), McGill Univ, Ctr Hlth, Mol Oncol Grp, 687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	morag.park@mcgill.ca	Long, Jianyin/H-8261-2013					Andrews EA, 2005, MOL CELL BIOL, V25, P185, DOI 10.1128/MCB.25.1.185-196.2005; Arco PGD, 2005, MOL CELL BIOL, V25, P2688, DOI 10.1128/MCB.25.7.2688-2697.2005; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Cavallaro U, 2002, CANCER LETT, V176, P123, DOI 10.1016/S0304-3835(01)00759-5; Chang CC, 2005, J BIOL CHEM, V280, P10164, DOI 10.1074/jbc.M409161200; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Costantino ME, 2002, BIOCHEM BIOPH RES CO, V296, P368, DOI 10.1016/S0006-291X(02)00880-X; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Dillner NB, 2002, MOL CELL ENDOCRINOL, V192, P85, DOI 10.1016/S0303-7207(02)00088-6; Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429; FUNAHASHI J, 1993, DEVELOPMENT, V119, P433; Furusawa T, 1999, MOL CELL BIOL, V19, P8581; Gill G, 2004, GENE DEV, V18, P2046, DOI 10.1101/gad.1214604; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Gregoire S, 2005, MOL CELL BIOL, V25, P2273, DOI 10.1128/MCB.25.6.2273-2287.2005; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; Hajra KM, 2002, CANCER RES, V62, P1613; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kagey MH, 2005, EMBO J, V24, P108, DOI 10.1038/sj.emboj.7600506; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; Lazarova DL, 2001, CELL GROWTH DIFFER, V12, P319; Lee PSW, 2003, J BIOL CHEM, V278, P27853, DOI 10.1074/jbc.M301755200; Lemercier C, 2000, J BIOL CHEM, V275, P15594, DOI 10.1074/jbc.M908437199; Lin X, 2003, J BIOL CHEM, V278, P18714, DOI 10.1074/jbc.M302243200; Lin X, 2003, MOL CELL, V11, P1389, DOI 10.1016/S1097-2765(03)00175-8; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Long JY, 2004, BIOCHEM J, V379, P23, DOI 10.1042/BJ20031867; Long JY, 2004, P NATL ACAD SCI USA, V101, P99, DOI 10.1073/pnas.0307598100; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; Melchior F, 2003, TRENDS BIOCHEM SCI, V28, P612, DOI 10.1016/j.tibs.2003.09.002; Mowat DR, 2003, J MED GENET, V40, P305, DOI 10.1136/jmg.40.5.305; Muller S, 2004, ONCOGENE, V23, P1998, DOI 10.1038/sj.onc.1207415; Peinado HC, 2004, INT J DEV BIOL, V48, P365, DOI 10.1387/ijdb.041794hp; Perdomo J, 2005, MOL CELL BIOL, V25, P1549, DOI 10.1128/MCB.25.4.1549-1559.2005; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Postigo AA, 2003, EMBO J, V22, P2453, DOI 10.1093/emboj/cdg226; Postigo AA, 2003, EMBO J, V22, P2443, DOI 10.1093/emboj/cdg225; Postigo AA, 1999, P NATL ACAD SCI USA, V96, P6683, DOI 10.1073/pnas.96.12.6683; Postigo AA, 2000, P NATL ACAD SCI USA, V97, P6391, DOI 10.1073/pnas.97.12.6391; Remacle JE, 1999, EMBO J, V18, P5073, DOI 10.1093/emboj/18.18.5073; Ross S, 2002, MOL CELL, V10, P831, DOI 10.1016/S1097-2765(02)00682-2; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Sewalt RGAB, 1999, MOL CELL BIOL, V19, P777; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Shilo Y, 2003, P NATL ACAD SCI USA, V100, P13225, DOI 10.1073/pnas.1735528100; Shook D, 2003, MECH DEVELOP, V120, P1351, DOI 10.1016/j.mod.2003.06.005; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tsai CN, 2002, P NATL ACAD SCI USA, V99, P10084, DOI 10.1073/pnas.152059399; van Grunsven LA, 2003, J BIOL CHEM, V278, P26135, DOI 10.1074/jbc.M300597200; Verger A, 2003, EMBO REP, V4, P137, DOI 10.1038/sj.embor.embor738; Verschueren K, 1999, J BIOL CHEM, V274, P20489, DOI 10.1074/jbc.274.29.20489; Wang AH, 2000, MOL CELL BIOL, V20, P6904, DOI 10.1128/MCB.20.18.6904-6912.2000; Weger S, 2003, EXP CELL RES, V290, P13, DOI 10.1016/S0014-4827(03)00292-1; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang SH, 2004, MOL CELL, V13, P611, DOI 10.1016/S1097-2765(04)00060-7; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	70	118	129	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35477	35489		10.1074/jbc.M504477200	http://dx.doi.org/10.1074/jbc.M504477200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16061479	Green Published, hybrid			2022-12-25	WOS:000232561200048
J	Niederhoff, K; Meindl-Beinker, NM; Kerssen, D; Perband, U; Schafer, A; Schliebs, W; Kunau, WH				Niederhoff, K; Meindl-Beinker, NM; Kerssen, D; Perband, U; Schafer, A; Schliebs, W; Kunau, WH			Yeast Pex14p possesses two functionally distinct Pex5p and one Pex7p binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXISOMAL TARGETING SIGNAL; SACCHAROMYCES-CEREVISIAE; HANSENULA-POLYMORPHA; MEMBRANE-PROTEIN; DIHYDROXYACETONE SYNTHASE; ESCHERICHIA-COLI; IMPORT; RECEPTOR; BIOGENESIS; GENE	Current evidence favors a cycling receptor model for the import of peroxisomal matrix proteins. The yeast Pex14 protein together with Pex13p and Pex17p form the docking subcomplex at the peroxisomal membrane and interact in this cycle with both soluble import receptors Pex5p and Pex7p. In a first step of a structure-function analysis of Saccharomyces cerevisiae Pex14p, we mapped its binding sites with both receptors. Using the yeast two-hybrid system and pull-down assays, we showed that Pex5p directly interacts with two separate regions of ScPex14p, amino acid residues 1-58 and 235-308. The latter binding site at the C terminus of ScPex14p overlaps with a binding site of Pex7p at amino acid residues 235-325. The functional assessment of these two binding sites of ScPex14p with the peroxisomal targeting signal receptors indicates that they have distinct roles. Deletion of the N-terminal 58 amino acids caused a partial defect of matrix protein import in pex14 Delta cells expressing the Pex14-(59-341)-p fragment; however, it did not lead to a pex phenotype. In contrast, truncation of the C-terminal 106 amino acids of ScPex14p completely blocked this process. On the basis of these and other published data, we propose that the C terminus of Pex14p contains the actual docking site and discuss the possibility that the N terminus could be involved in a Pex5p-Pex14p association inside the peroxisomal membrane.	Ruhr Univ Bochum, Fak Med, Abt Syst Biochem, Inst Physiol Chem, D-44780 Bochum, Germany	Ruhr University Bochum	Kunau, WH (corresponding author), Ruhr Univ Bochum, Fak Med, Abt Syst Biochem, Inst Physiol Chem, D-44780 Bochum, Germany.	wolf-h.kunau@ruhr-uni-bochum.de		Schliebs, Wolfgang/0000-0003-2762-3403				Albertini M, 1997, CELL, V89, P83, DOI 10.1016/S0092-8674(00)80185-3; Ausubel FM, 1992, CURRENT PROTOCOLS MO; Baudhuin P, 1974, Methods Enzymol, V31, P356; BERGMEYER HU, 1974, METHODEN ENZYMATISCH, V1, P479; BIGL M, 1994, BIOL CHEM H-S, V375, P153, DOI 10.1515/bchm3.1994.375.3.153; Blobel F, 1996, EUR J BIOCHEM, V240, P468, DOI 10.1111/j.1432-1033.1996.0468h.x; Brocard C, 1997, EMBO J, V16, P5491, DOI 10.1093/emboj/16.18.5491; Brown LA, 2003, J CELL MOL MED, V7, P388, DOI 10.1111/j.1582-4934.2003.tb00241.x; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; Dammai V, 2001, CELL, V105, P187, DOI 10.1016/S0092-8674(01)00310-5; DOUMA AC, 1985, ARCH MICROBIOL, V143, P237, DOI 10.1007/BF00411242; Eckert JH, 2003, REV PHYSIOL BIOCH P, V147, P75, DOI 10.1007/s10254-003-0007-z; ERDMANN R, 1994, YEAST, V10, P935, DOI 10.1002/yea.320100708; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; ERDMANN R, 1989, P NATL ACAD SCI USA, V86, P5419, DOI 10.1073/pnas.86.14.5419; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Girzalsky W, 1999, J CELL BIOL, V144, P1151, DOI 10.1083/jcb.144.6.1151; Gouveia AM, 2003, J BIOL CHEM, V278, P226, DOI 10.1074/jbc.M209498200; Gouveia AMM, 2000, J BIOL CHEM, V275, P32444, DOI 10.1074/jbc.M004366200; Graham J M, 1993, Methods Mol Biol, V19, P29; Johnson MA, 2001, YEAST, V18, P621, DOI 10.1002/yea.711; Klein ATJ, 2002, J BIOL CHEM, V277, P25011, DOI 10.1074/jbc.M203254200; Komori M, 1997, EMBO J, V16, P44, DOI 10.1093/emboj/16.1.44; Kunau WH, 2001, CURR BIOL, V11, pR659, DOI 10.1016/S0960-9822(01)00386-4; Lloyd MD, 1996, ANAL BIOCHEM, V241, P139, DOI 10.1006/abio.1996.0389; Nair DM, 2004, J CELL BIOL, V167, P599, DOI 10.1083/jcb.200407119; Oliveira MEM, 2002, BBA-BIOMEMBRANES, V1567, P13, DOI 10.1016/S0005-2736(02)00635-1; Rehling P, 1996, EMBO J, V15, P2901, DOI 10.1002/j.1460-2075.1996.tb00653.x; Salomons FA, 2000, J BIOL CHEM, V275, P12603, DOI 10.1074/jbc.275.17.12603; Schafer A, 2004, MOL CELL BIOL, V24, P8895, DOI 10.1128/MCB.24.20.8895-8906.2004; Schliebs W, 1999, J BIOL CHEM, V274, P5666, DOI 10.1074/jbc.274.9.5666; Shimizu N, 1999, J BIOL CHEM, V274, P12593, DOI 10.1074/jbc.274.18.12593; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Will GK, 1999, MOL CELL BIOL, V19, P2265	35	35	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35571	35578		10.1074/jbc.M502460200	http://dx.doi.org/10.1074/jbc.M502460200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16107331	hybrid			2022-12-25	WOS:000232561200059
J	Tomomura, M; Furuichi, T				Tomomura, M; Furuichi, T			Apoptosis-associated tyrosine kinase (AATYK) has differential Ca2+-dependent phosphorylation states in response to survival and apoptotic conditions in cerebellar granule cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TROPHIC-FACTOR DEPRIVATION; NERVE GROWTH-FACTOR; C-JUN; NEURONAL APOPTOSIS; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; PKC-DELTA; PROTEIN; LITHIUM; DEATH	In dissociated cultures of cerebellar granule cells, extracellular high potassium (HK) and low potassium (LK) concentrations control cell survival and apoptosis, respectively. Apoptosis-associated tyrosine kinase (AATYK) is up-regulated during the LK-induced apoptosis. Overexpression of wild-type AATYK, but not its kinase-deficient mutant, stimulates apoptosis in LK. In this study, we analyzed the relationship between the phosphorylation states of AATYK and the survival of granule cells. AATYK was hypophosphorylated in HK, whereas it was hyperphosphorylated in apoptotic LK. HK-dependent hypophosphorylation of AATYK was controlled by L-type voltage-dependent calcium channel-mediated Ca2+ influx followed by Ca2+-dependent protein phosphatase activity. However, LK-induced hyperphosphorylation of AATYK at multiple sites was blocked by kainate, lithium, and protein kinase C-delta inhibitor. AATYK phosphorylation was concurrent with c-Jun phosphorylation. In addition, mutations of AATYK on either the kinase domain or Ser-480, Ser-558, and Ser-566 residues suppressed the LK-induced hyperphosphorylation and apoptosis, suggesting the involvement of self-kinase activity and these Ser residues in this process. Our data therefore indicate that the phosphorylation states of AATYK are closely related to the HK-induced survival and LK-induced apoptosis of cerebellar granule cells.	RIKEN, Brain Sci Inst, Lab Mol Neurogenesis, Wako, Saitama 3510198, Japan	RIKEN	Tomomura, M (corresponding author), RIKEN, Brain Sci Inst, Lab Mol Neurogenesis, Wako, Saitama 3510198, Japan.	mtomomura@brain.riken.go.jp	Furuichi, Teiichi/B-5086-2014	Furuichi, Teiichi/0000-0002-9676-1888				Basu A, 2003, J CELL MOL MED, V7, P341, DOI 10.1111/j.1582-4934.2003.tb00237.x; Blass M, 2002, MOL CELL BIOL, V22, P182, DOI 10.1128/MCB.22.1.182-195.2002; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Chiang LW, 2001, P NATL ACAD SCI USA, V98, P2814, DOI 10.1073/pnas.051630598; Ciani E, 1997, DEV BRAIN RES, V99, P112, DOI 10.1016/S0165-3806(96)00187-3; Coffey ET, 2002, J NEUROSCI, V22, P4335, DOI 10.1523/JNEUROSCI.22-11-04335.2002; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; D'MELLO SR, 1994, EXP CELL RES, V211, P332, DOI 10.1006/excr.1994.1095; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; GALLI C, 1995, J NEUROSCI, V15, P1172; GALLO V, 1987, J NEUROSCI, V7, P2203; Gaozza E, 1997, ONCOGENE, V15, P3127, DOI 10.1038/sj.onc.1201575; Grignon S, 1996, EUR J PHARMACOL, V315, P111, DOI 10.1016/S0014-2999(96)00591-2; Gutcher I, 2003, CELL MOL LIFE SCI, V60, P1061, DOI 10.1007/s00018-003-2281-y; HACK N, 1993, NEUROSCIENCE, V57, P9, DOI 10.1016/0306-4522(93)90108-R; HALLCHER LM, 1980, J BIOL CHEM, V255, P896; Ham J, 2000, BIOCHEM PHARMACOL, V60, P1015, DOI 10.1016/S0006-2952(00)00372-5; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HIRAI S, 1994, EMBO J, V13, P2331, DOI 10.1002/j.1460-2075.1994.tb06517.x; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Jin N, 2005, NEUROPHARMACOLOGY, V48, P576, DOI 10.1016/j.neuropharm.2004.11.010; Kawa S, 2004, GENES CELLS, V9, P219, DOI 10.1111/j.1356-9597.2004.00714.x; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; KOIKE T, 1989, P NATL ACAD SCI USA, V86, P6421, DOI 10.1073/pnas.86.16.6421; Koponen S, 2000, J CEREBR BLOOD F MET, V20, P93, DOI 10.1097/00004647-200001000-00013; Kurschner C, 1999, J NEUROSCI, V19, P7770; LASHER RS, 1972, BRAIN RES, V41, P482, DOI 10.1016/0006-8993(72)90521-5; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; Linseman DA, 2003, J NEUROCHEM, V85, P1488, DOI 10.1046/j.1471-4159.2003.09799.x; Miettinen S, 1996, J NEUROSCI, V16, P6236; Miller TM, 1996, J NEUROSCI, V16, P7487; Mora A, 2001, J NEUROCHEM, V78, P199, DOI 10.1046/j.1471-4159.2001.00410.x; NAHORSKI SR, 1991, TRENDS PHARMACOL SCI, V12, P297, DOI 10.1016/0165-6147(91)90581-C; Nijhawan D, 2000, ANNU REV NEUROSCI, V23, P73, DOI 10.1146/annurev.neuro.23.1.73; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Tomomura M, 2003, MOL BRAIN RES, V112, P103, DOI 10.1016/S0169-328X(03)00054-8; Tomomura M, 2001, ONCOGENE, V20, P1022, DOI 10.1038/sj.onc.1204210; Villalba M, 1998, NEUROREPORT, V9, P2381, DOI 10.1097/00001756-199807130-00042; Wang H, 2002, J BIOL CHEM, V277, P49605, DOI 10.1074/jbc.M209335200; Watson A, 1998, J NEUROSCI, V18, P751; WOOD KA, 1993, NEURON, V11, P621, DOI 10.1016/0896-6273(93)90074-2; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zhao LZ, 2003, ACTA PHARMACOL SIN, V24, P539	46	19	19	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35157	35163		10.1074/jbc.M500353200	http://dx.doi.org/10.1074/jbc.M500353200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16100393	hybrid			2022-12-25	WOS:000232561200012
J	Azzouz, TN; Pillai, RS; Dapp, C; Chari, A; Meister, G; Kambach, C; Fischer, U; Schumperli, D				Azzouz, TN; Pillai, RS; Dapp, C; Chari, A; Meister, G; Kambach, C; Fischer, U; Schumperli, D			Toward an assembly line for U7 snRNPs - Interactions of U7-specific Lsm proteins with PRMT5 and SMN complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINAL MUSCULAR-ATROPHY; ARGININE METHYLTRANSFERASE PRMT5; TUDOR DOMAIN; SYMMETRIC DIMETHYLARGININE; CRYSTAL-STRUCTURE; BINDING-SITE; 20S COMPLEX; X-RAY; RNA; METHYLATION	The survival of motor neurons (SMN) complex mediates the assembly of small nuclear ribonucleoproteins (snRNPs) involved in splicing and histone RNA processing. A crucial step in this process is the binding of Sm proteins onto the SMN protein. For Sm B/B', D1, and D3, efficient binding to SMN depends on symmetrical dimethyl arginine (sDMA) modifications of their RG-rich tails. This methylation is achieved by another entity, the PRMT5 complex. Its pICln subunit binds Sm proteins whereas the PRMT5 subunit catalyzes the methylation reaction. Here, we provide evidence that Lsm10 and Lsm11, which replace the Sm proteins D1 and D2 in the histone RNA processing U7 snRNPs, associate with pICln in vitro and in vivo without receiving sDMA modifications. This implies that the PRMT5 complex is involved in an early stage of U7 snRNP assembly and hence may have a second snRNP assembly function unrelated to sDMA modification. We also show that the binding of Lsm10 and Lsm11 to SMN is independent of any methylation activity. Furthermore, we present evidence for two separate binding sites in SMN for Sm/Lsm proteins. One recognizes Sm domains and the second one, the sDMA-modified RG-tails, which are present only in a subset of these proteins.	Univ Bern, Inst Cell Biol, CH-3012 Bern, Switzerland; Univ Wurzburg, Bioctr, Inst Biochem, D-97074 Wurzburg, Germany; Paul Scherrer Inst, CH-5232 Villigen, Switzerland	University of Bern; University of Wurzburg; Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute	Schumperli, D (corresponding author), Univ Bern, Inst Cell Biol, Baltzerstr 4, CH-3012 Bern, Switzerland.	daniel.schuemperli@izb.unibe.ch	Fischer, Utz/A-4090-2016; Fischer, Utz/AAT-8422-2020; Chari, Ashwin/ABC-5304-2020	Fischer, Utz/0000-0002-1465-6591; Fischer, Utz/0000-0002-1465-6591; Chari, Ashwin/0000-0001-6220-9828; Schumperli, Daniel/0000-0002-9644-134X				Amente S, 2005, FEBS LETT, V579, P683, DOI 10.1016/j.febslet.2004.12.045; Azzouz TN, 2005, NUCLEIC ACIDS RES, V33, P2106, DOI 10.1093/nar/gki516; BALDWIN GS, 1991, BIOCHEM J, V123, P69; Brahms H, 2000, J BIOL CHEM, V275, P17122, DOI 10.1074/jbc.M000300200; Brahms H, 2001, RNA, V7, P1531, DOI 10.1017/S135583820101442X; Branscombe TL, 2001, J BIOL CHEM, V276, P32971, DOI 10.1074/jbc.M105412200; Buhler D, 1999, HUM MOL GENET, V8, P2351, DOI 10.1093/hmg/8.13.2351; Collins BM, 2001, J MOL BIOL, V309, P915, DOI 10.1006/jmbi.2001.4693; Fabbrizio E, 2002, EMBO REP, V3, P641, DOI 10.1093/embo-reports/kvf136; Friesen MJ, 2000, J BIOL CHEM, V275, P26370, DOI 10.1074/jbc.M003299200; Friesen WJ, 2001, MOL CELL BIOL, V21, P8289, DOI 10.1128/MCB.21.24.8289-8300.2001; Friesen WJ, 2001, MOL CELL, V7, P1111, DOI 10.1016/S1097-2765(01)00244-1; GRIMM C, 1993, EMBO J, V12, P1229, DOI 10.1002/j.1460-2075.1993.tb05764.x; Grimmler M, 2005, EMBO REP, V6, P70, DOI 10.1038/sj.embor.7400301; Kambach C, 1999, CURR OPIN STRUC BIOL, V9, P222, DOI 10.1016/S0959-440X(99)80032-3; Kambach C, 1999, CELL, V96, P375, DOI 10.1016/S0092-8674(00)80550-4; Kwak YT, 2003, MOL CELL, V11, P1055, DOI 10.1016/S1097-2765(03)00101-1; Lee JH, 2005, J BIOL CHEM, V280, P3656, DOI 10.1074/jbc.M405295200; LERNER EA, 1981, P NATL ACAD SCI-BIOL, V78, P2737, DOI 10.1073/pnas.78.5.2737; Meister G, 2000, HUM MOL GENET, V9, P1977, DOI 10.1093/hmg/9.13.1977; Meister G, 2001, CURR BIOL, V11, P1990, DOI 10.1016/S0960-9822(01)00592-9; Meister G, 2002, EMBO J, V21, P5853, DOI 10.1093/emboj/cdf585; Meister G, 2002, TRENDS CELL BIOL, V12, P472, DOI 10.1016/S0962-8924(02)02371-1; Miranda TB, 2004, J BIOL CHEM, V279, P22902, DOI 10.1074/jbc.M312904200; Moore M., 1993, RNA WORLD, P303; Muller B, 1997, SEMIN CELL DEV BIOL, V8, P567, DOI 10.1006/scdb.1997.0182; Mura C, 2001, P NATL ACAD SCI USA, V98, P5532, DOI 10.1073/pnas.091102298; Pal S, 2004, MOL CELL BIOL, V24, P9630, DOI 10.1128/MCB.24.21.9630-9645.2004; Pal S, 2003, MOL CELL BIOL, V23, P7475, DOI 10.1128/MCB.23.21.7475-7487.2003; Paushkin S, 2002, CURR OPIN CELL BIOL, V14, P305, DOI 10.1016/S0955-0674(02)00332-0; Pellizzoni L, 1999, P NATL ACAD SCI USA, V96, P11167, DOI 10.1073/pnas.96.20.11167; Pillai RS, 2003, GENE DEV, V17, P2321, DOI 10.1101/gad.274403; Pillai RS, 2001, EMBO J, V20, P5470, DOI 10.1093/emboj/20.19.5470; Raker VA, 1996, EMBO J, V15, P2256, DOI 10.1002/j.1460-2075.1996.tb00579.x; Richard S, 2005, BIOCHEM J, V388, P379, DOI 10.1042/BJ20040373; Selenko P, 2001, NAT STRUCT BIOL, V8, P27; Sprangers R, 2003, J MOL BIOL, V327, P507, DOI 10.1016/S0022-2836(03)00148-7; STEFANOVIC B, 1995, NUCLEIC ACIDS RES, V23, P3141, DOI 10.1093/nar/23.16.3141; Toro I, 2001, EMBO J, V20, P2293, DOI 10.1093/emboj/20.9.2293; Will CL, 2001, CURR OPIN CELL BIOL, V13, P290, DOI 10.1016/S0955-0674(00)00211-8; WILL CL, 1994, RNA PROCESSING PRACT, V1, P141	41	32	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34435	34440		10.1074/jbc.M505077200	http://dx.doi.org/10.1074/jbc.M505077200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16087681	Green Published, hybrid			2022-12-25	WOS:000232403900009
J	Barth, S; Hury, A; Liang, XH; Michaeli, S				Barth, S; Hury, A; Liang, XH; Michaeli, S			Elucidating the role of H/ACA-like RNAs in trans-splicing and rRNA processing via RNA interference silencing of the Trypanosoma brucei CBF5 pseudouridine synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEOLAR RNAS; LEADER-ASSOCIATED RNA; SMALL NUCLEAR-RNA; 5' SPLICE-SITE; SACCHAROMYCES-CEREVISIAE; U2 SNRNA; LEPTOMONAS-COLLOSOMA; U3 SNORNA; SEQUENCE CONSERVATION; MODIFIED NUCLEOTIDES	Most pseudouridinylation in eukaryotic rRNA and small nuclear RNAs is guided by H/ACA small nucleolar RNAs. In this study, the Trypanosoma brucei pseudouridine synthase, Cbf5p, a snoRNP protein, was identified and silenced by RNAi. Depletion of this protein destabilized all small nucleolar RNAs of the H/ACA-like family. Following silencing, defects in rRNA processing, such as accumulation of precursors and inhibition of cleavages to generate the mature rRNA, were observed. snR30, an H/ACA RNA involved in rRNA maturation, was identified based on prototypical conserved domains characteristic of this RNA in other eukaryotes. The silencing of CBF5 also eliminated the spliced leader-associated (SLA1) RNA that directs pseudouridylation on the spliced leader RNA (SL RNA), which is the substrate for the trans-splicing reaction. Surprisingly, the depletion of Cbf5p not only eliminated the pseudouridine on the SL RNA but also abolished capping at the fourth cap-4 nucleotide. As a result of defects in the SL RNA and decreased modification on the U small nuclear RNA, trans-splicing was inhibited at the first step of the reaction, providing evidence for the essential role of H/ACA RNAs and the modifications they guide on trans-splicing.	Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel	Bar Ilan University	Michaeli, S (corresponding author), Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel.	michaes@mail.biu.ac.il	Michaeli, Shulamit/AAC-8255-2022					Atzorn V, 2004, MOL CELL BIOL, V24, P1769, DOI 10.1128/MCB.24.4.1769-1778.2004; Bachellerie JP, 2002, BIOCHIMIE, V84, P775, DOI 10.1016/S0300-9084(02)01402-5; Bakin AV, 1998, METH MOL B, V77, P297; BALLY M, 1988, NUCLEIC ACIDS RES, V16, P5291, DOI 10.1093/nar/16.12.5291; Behm-Ansmant I, 2003, RNA, V9, P1371, DOI 10.1261/rna.5520403; Bell M, 1999, NUCLEIC ACIDS RES, V27, P3986, DOI 10.1093/nar/27.20.3986; CAMPBELL DA, 1987, J MOL BIOL, V196, P113, DOI 10.1016/0022-2836(87)90514-6; Donmez G, 2004, RNA, V10, P1925, DOI 10.1261/rna.7186504; Dunbar DA, 2000, J BIOL CHEM, V275, P14767, DOI 10.1074/jbc.M001180200; Dungan JM, 1996, EMBO J, V15, P4016, DOI 10.1002/j.1460-2075.1996.tb00775.x; Filipowicz W, 2002, CURR OPIN CELL BIOL, V14, P319, DOI 10.1016/S0955-0674(02)00334-4; Ganot P, 1997, CELL, V89, P799, DOI 10.1016/S0092-8674(00)80263-9; Gu J, 1996, RNA, V2, P909; Hartshorne T, 1999, NUCLEIC ACIDS RES, V27, P3300, DOI 10.1093/nar/27.16.3300; Hartshorne T, 1998, NUCLEIC ACIDS RES, V26, P2541, DOI 10.1093/nar/26.11.2541; HARTSHORNE T, 1993, MOL CELL BIOL, V13, P144, DOI 10.1128/MCB.13.1.144; Hartshorne T, 2001, J MOL BIOL, V313, P733, DOI 10.1006/jmbi.2001.5078; JIANG WD, 1993, MOL CELL BIOL, V13, P4884, DOI 10.1128/MCB.13.8.4884; Kiss T, 2002, CELL, V109, P145, DOI 10.1016/S0092-8674(02)00718-3; KissLaszlo Z, 1996, CELL, V85, P1077, DOI 10.1016/S0092-8674(00)81308-2; Lafontaine DLJ, 1998, GENE DEV, V12, P527, DOI 10.1101/gad.12.4.527; Liang XH, 2005, RNA, V11, P619, DOI 10.1261/rna.7174805; Liang XH, 2004, J BIOL CHEM, V279, P5100, DOI 10.1074/jbc.M308264200; Liang XH, 2002, RNA, V8, P237, DOI 10.1017/S1355838202018290; Lin YR, 2003, GENETICS, V165, P543; Liu Q, 2004, J BIOL CHEM, V279, P18210, DOI 10.1074/jbc.M400678200; Ma XJ, 2003, EMBO J, V22, P1889, DOI 10.1093/emboj/cdg191; Mandelboim M, 2003, J BIOL CHEM, V278, P51469, DOI 10.1074/jbc.M308997200; Mandelboim M, 2002, J BIOL CHEM, V277, P35210, DOI 10.1074/jbc.M201910200; Mitchell JR, 1999, MOL CELL BIOL, V19, P567; MORRISSEY JP, 1993, MOL CELL BIOL, V13, P2469, DOI 10.1128/MCB.13.4.2469; Newby MI, 2001, RNA, V7, P833, DOI 10.1017/S1355838201002308; Ni JW, 1997, CELL, V89, P565, DOI 10.1016/S0092-8674(00)80238-X; PALFI Z, 1994, J BIOL CHEM, V269, P30620; Phillips B, 1998, MOL GEN GENET, V260, P20, DOI 10.1007/s004380050866; Roberts TG, 1998, MOL CELL BIOL, V18, P4409, DOI 10.1128/MCB.18.8.4409; Ruggero D, 2003, SCIENCE, V299, P259, DOI 10.1126/science.1079447; Russell AG, 2004, RNA, V10, P1034, DOI 10.1261/rna.7300804; Schnaufer A, 2003, MOL CELL, V12, P307, DOI 10.1016/S1097-2765(03)00286-7; Sturm NR, 1998, J BIOL CHEM, V273, P18689, DOI 10.1074/jbc.273.30.18689; TOLLERVEY D, 1987, EMBO J, V6, P4169, DOI 10.1002/j.1460-2075.1987.tb02763.x; Tollervey D, 1997, CURR OPIN CELL BIOL, V9, P337, DOI 10.1016/S0955-0674(97)80005-1; UDEM SA, 1972, J MOL BIOL, V65, P227, DOI 10.1016/0022-2836(72)90279-3; Uliel S, 2004, INT J PARASITOL, V34, P445, DOI 10.1016/j.ijpara.2003.10.014; Venema J, 1999, ANNU REV GENET, V33, P261, DOI 10.1146/annurev.genet.33.1.261; Wang ZF, 2001, EMBO J, V20, P4674, DOI 10.1093/emboj/20.17.4674; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; WATKINS KP, 1994, CELL, V76, P171, DOI 10.1016/0092-8674(94)90181-3; Watkins NJ, 1998, RNA, V4, P1549, DOI 10.1017/S1355838298980761; WHITE TC, 1986, NUCLEIC ACIDS RES, V14, P9471, DOI 10.1093/nar/14.23.9471; Xu YX, 1997, P NATL ACAD SCI USA, V94, P8473, DOI 10.1073/pnas.94.16.8473; Xu YX, 2000, J BIOL CHEM, V275, P27883; Yu YT, 1998, EMBO J, V17, P5783, DOI 10.1093/emboj/17.19.5783	53	39	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34558	34568		10.1074/jbc.M503465200	http://dx.doi.org/10.1074/jbc.M503465200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16107339	hybrid			2022-12-25	WOS:000232403900024
J	Osanai, T; Sato, S; Tabata, S; Tanaka, K				Osanai, T; Sato, S; Tabata, S; Tanaka, K			Identification of PamA as a PII-binding membrane protein important in nitrogen-related and sugar-catabolic gene expression in Synechocystis sp PCC 6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PROTEIN; PHOSPHOPROTEIN P-II; CYANOBACTERIUM SYNECHOCOCCUS; SIGMA-FACTOR; NTCA; PCC-7942; PRODUCT; ASSIMILATION; DEGRADATION; ACTIVATION	The PII signaling protein plays a pivotal role in the coordination of carbon and nitrogen metabolism in a wide variety of bacteria, Archaea, and plant chloroplasts. By using a yeast two-hybrid screening system, we identified a transmembrane protein, designated PamA ( encoded by sll0985), as a PII-binding protein in Synechocystis sp. PCC 6803. The interaction between PII and PamA was confirmed in vitro, and the interaction was inhibited in the presence of ATP and 2-oxoglutarate, whereas the interaction was not influenced by the phosphorylation status of PII. Northern blot analyses revealed that the transcripts of a set of nitrogen-related genes, including nblA, nrtABCD, and ureG, were decreased in a pamA deletion mutant. The mRNA and protein levels of a group 2 sigma factor SigE were also reduced by the pamA mutation, and transcripts for sugar catabolic genes, such as gap1, zwf, and gnd that are under the control of SigE, were consequently decreased in the pamA mutant. In addition, the pamA mutant was found to be unable to grow in glucose-containing media. These results indicate that PamA has a role in the transcript control of genes for nitrogen and sugar metabolism in Synechocystis sp. PCC 6803.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Kazusa DNA Res Inst, Chiba 2920818, Japan	University of Tokyo; Kazusa DNA Research Institute	Tanaka, K (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	kntanaka@iam.u-tokyo.ac.jp	Sato, Shusei/A-3616-2015; Tanaka, Kan/E-3724-2015	Sato, Shusei/0000-0002-0293-5366; Tanaka, Kan/0000-0001-7560-7884				Aichi M, 2001, J BACTERIOL, V183, P5840, DOI 10.1128/JB.183.20.5840-5847.2001; Aldehni MF, 2003, J BACTERIOL, V185, P2582, DOI 10.1128/JB.185.8.2582-2591.2003; Arcondeguy T, 2001, MICROBIOL MOL BIOL R, V65, P80, DOI 10.1128/MMBR.65.1.80-105.2001; Burillo S, 2004, J BACTERIOL, V186, P3346, DOI 10.1128/JB.186.11.3346-3354.2004; COLLIER JL, 1994, EMBO J, V13, P1039, DOI 10.1002/j.1460-2075.1994.tb06352.x; Forchhammer K, 2004, FEMS MICROBIOL REV, V28, P319, DOI 10.1016/j.femsre.2003.11.001; Forchhammer K, 1997, EUR J BIOCHEM, V244, P869, DOI 10.1111/j.1432-1033.1997.00869.x; FORCHHAMMER K, 1995, J BACTERIOL, V177, P2033, DOI 10.1128/jb.177.8.2033-2040.1995; FORCHHAMMER K, 1994, J BACTERIOL, V176, P84, DOI 10.1128/JB.176.1.84-91.1994; Heinrich A, 2004, MOL MICROBIOL, V52, P1303, DOI 10.1111/j.1365-2958.2004.04058.x; Herrero A, 2001, J BACTERIOL, V183, P411, DOI 10.1128/JB.183.2.411-425.2001; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Hisbergues M, 1999, FEBS LETT, V463, P216, DOI 10.1016/S0014-5793(99)01624-5; Irmler A, 2001, P NATL ACAD SCI USA, V98, P12978, DOI 10.1073/pnas.231254998; Irmler A, 1997, MOL MICROBIOL, V26, P81, DOI 10.1046/j.1365-2958.1997.5521918.x; Kanamaru K, 2001, PLANT CELL PHYSIOL, V42, P1034, DOI 10.1093/pcp/pce155; Koksharova O, 1998, PLANT MOL BIOL, V36, P183, DOI 10.1023/A:1005925732743; Lee HM, 1998, FEBS LETT, V427, P291, DOI 10.1016/S0014-5793(98)00451-7; Los DA, 1997, MOL MICROBIOL, V25, P1167, DOI 10.1046/j.1365-2958.1997.5641912.x; Magasanik B, 2000, TRENDS MICROBIOL, V8, P447, DOI 10.1016/S0966-842X(00)01849-7; Muro-Pastor AM, 2001, J BACTERIOL, V183, P1090, DOI 10.1128/JB.183.3.1090-1095.2001; Muro-Pastor MI, 2001, J BIOL CHEM, V276, P38320; Ninfa AJ, 2000, TRENDS MICROBIOL, V8, P172, DOI 10.1016/S0966-842X(00)01709-1; OMATA T, 1989, P NATL ACAD SCI USA, V86, P6612, DOI 10.1073/pnas.86.17.6612; Osanai T, 2005, J BIOL CHEM, V280, P30653, DOI 10.1074/jbc.M505043200; Palinska KA, 2000, MICROBIOL-SGM, V146, P3099, DOI 10.1099/00221287-146-12-3099; Paz-Yepes J, 2003, FEBS LETT, V543, P42, DOI 10.1016/S0014-5793(03)00384-3; Pivetti CD, 2003, MICROBIOL MOL BIOL R, V67, P66, DOI 10.1128/MMBR.67.1.66-85.2003; REECE KS, 1995, GENE, V165, P141, DOI 10.1016/0378-1119(95)00529-F; Richaud C, 2001, J BACTERIOL, V183, P2989, DOI 10.1128/JB.183.10.2989-2994.2001; RIPPKA R, 1988, METHOD ENZYMOL, V167, P3; SHESTOPALOV VI, 1994, GENETIKA+, V30, P452; STANIER RY, 1977, ANNU REV MICROBIOL, V31, P225, DOI 10.1146/annurev.mi.31.100177.001301; TANAKA K, 1993, P NATL ACAD SCI USA, V90, P3511, DOI 10.1073/pnas.90.8.3511; Tanigawa R, 2002, P NATL ACAD SCI USA, V99, P4251, DOI 10.1073/pnas.072587199; Vazquez-Bermudez MF, 2002, FEBS LETT, V512, P71, DOI 10.1016/S0014-5793(02)02219-6; VEGAPALAS MA, 1992, MOL MICROBIOL, V6, P1853, DOI 10.1111/j.1365-2958.1992.tb01357.x; VEGAPALAS MA, 1990, J BACTERIOL, V172, P643, DOI 10.1128/jb.172.2.643-647.1990; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; Zinchenko VV, 1999, RUSS J GENET+, V35, P228	40	46	47	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34684	34690		10.1074/jbc.M507489200	http://dx.doi.org/10.1074/jbc.M507489200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16109709	hybrid			2022-12-25	WOS:000232403900038
J	Yang, CH; Szeliga, J; Jordan, J; Faske, S; Sever-Chroneos, Z; Dorsett, B; Christian, RE; Settlage, RE; Shabanowitz, J; Hunt, DF; Whitsett, JA; Chroneos, ZC				Yang, CH; Szeliga, J; Jordan, J; Faske, S; Sever-Chroneos, Z; Dorsett, B; Christian, RE; Settlage, RE; Shabanowitz, J; Hunt, DF; Whitsett, JA; Chroneos, ZC			Identification of the surfactant protein A receptor 210 as the unconventional myosin 18A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACTANT PROTEIN-A; RAT ALVEOLAR MACROPHAGES; NITRIC-OXIDE PRODUCTION; PDZ-CONTAINING MYOSIN; DEFICIENT MICE; MYCOBACTERIUM-TUBERCULOSIS; LYMPHOCYTE-PROLIFERATION; SUBCELLULAR-LOCALIZATION; MARROW TRANSPLANTATION; LUNG SURFACTANT	Mass spectrometric characterization of the surfactant protein A (SP-A) receptor 210 (SP-R210) led to the identification of myosin (Myo) XVIIIA and nonmuscle myosin IIA. Antibodies generated against the unique C-terminal tail of MyoXVIIIA revealed that MyoXVIIIA, MyoIIA, and SP-R210 have overlapping tissue distribution, all being highly expressed in myeloid cells, bone marrow, spleen, lymph nodes, and lung. Western blot analysis of COS-1 cells stably transfected with either MyoXVIIIA or MyoIIA indicated that SP-R210 antibodies recognize MyoXVIIIA. Furthermore, MyoXVIIIA but not MyoIIA localized to the surface of COS-1 cells, and most importantly, expression of MyoXVIIIA in COS-1 cells conferred SP-A binding. Western analysis of recombinant MyoXVIIIA domains expressed in bacteria mapped the epitopes of previously derived SP-R210 antibodies to the neck region of MyoXVIIIA. Antibodies raised against the neck domain of MyoXVIIIA blocked the binding of SP-A to macrophages. Together, these findings indicate that MyoXVIIIA constitutes a novel receptor for SP-A.	Univ Texas Hlth Ctr, Ctr Biomed Res, Tyler, TX 75708 USA; Cincinnati Childrens Hosp Med Ctr, Sect Neonatol Perinatal & Pulm Biol, Cincinnati, OH 45229 USA; Univ Virginia, Dept Chem, Charlottesville, VA 22904 USA; Univ Virginia, Dept Chem, Charlottesville, VA 22904 USA; Univ Virginia, Dept Pathol, Charlottesville, VA 22904 USA	Cincinnati Children's Hospital Medical Center; University of Virginia; University of Virginia; University of Virginia	Chroneos, ZC (corresponding author), Univ Texas Hlth Ctr, Ctr Biomed Res, 11937 US Highway 271, Tyler, TX 75708 USA.	zissis.chroneos@uthct.edu	Hunt, Donald F/I-6936-2012	Hunt, Donald F/0000-0003-2815-6368; , Zissis/0000-0002-9841-7917	NHLBI NIH HHS [HL56387, P50 HL056387, R01 HL068127, HL068127] Funding Source: Medline; NIGMS NIH HHS [R01 GM037537, GM37537] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068127, P01HL056387, P50HL056387] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037537] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alcorn JF, 2004, AM J PHYSIOL-LUNG C, V286, pL129, DOI 10.1152/ajplung.00427.2002; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; Beharka AA, 2002, J IMMUNOL, V169, P3565, DOI 10.4049/jimmunol.169.7.3565; Berg JS, 2001, MOL BIOL CELL, V12, P780, DOI 10.1091/mbc.12.4.780; Borron P, 2000, AM J PHYSIOL-LUNG C, V278, pL840, DOI 10.1152/ajplung.2000.278.4.L840; Borron P, 1996, AM J RESP CELL MOL, V15, P115, DOI 10.1165/ajrcmb.15.1.8679215; Borron P, 1998, AM J PHYSIOL-LUNG C, V275, pL679, DOI 10.1152/ajplung.1998.275.4.L679; Borron PJ, 2002, J IMMUNOL, V169, P5844, DOI 10.4049/jimmunol.169.10.5844; Brinker KG, 2003, AM J PHYSIOL-LUNG C, V284, pL232, DOI 10.1152/ajplung.00187.2002; Brown SD, 1998, BIOCHEM BIOPH RES CO, V248, P879, DOI 10.1006/bbrc.1998.9061; Chabot S, 2003, J IMMUNOL, V171, P995, DOI 10.4049/jimmunol.171.2.995; Chroneos ZC, 1996, J BIOL CHEM, V271, P16375, DOI 10.1074/jbc.271.27.16375; Cox D, 2002, NAT CELL BIOL, V4, P469, DOI 10.1038/ncb805; Cross M, 2004, BIOCHEM J, V380, P243, DOI 10.1042/BJ20031978; Di Cunto F, 1998, J BIOL CHEM, V273, P29706, DOI 10.1074/jbc.273.45.29706; Furmanek A, 2000, ACTA BIOCHIM POL, V47, P781, DOI 10.18388/abp.2000_3996; Furusawa T, 2000, BIOCHEM BIOPH RES CO, V270, P67, DOI 10.1006/bbrc.2000.2377; Gardai SJ, 2003, CELL, V115, P13, DOI 10.1016/S0092-8674(03)00758-X; GAYNOR CD, 1995, J IMMUNOL, V155, P5343; Ghosh S, 2004, BLOOD, V103, P2369, DOI 10.1182/blood-2003-09-3050; Golomb E, 2004, J BIOL CHEM, V279, P2800, DOI 10.1074/jbc.M309981200; Guillot L, 2002, J IMMUNOL, V168, P5989, DOI 10.4049/jimmunol.168.12.5989; HAAGSMAN HP, 1990, BIOCHEMISTRY-US, V29, P8894, DOI 10.1021/bi00490a003; Haddad IY, 2003, AM J PHYSIOL-LUNG C, V285, pL602, DOI 10.1152/ajplung.00088.2003; Hawgood S, 2002, AM J PHYSIOL-LUNG C, V283, pL1002, DOI 10.1152/ajplung.00118.2002; Hey PJ, 1998, GENE, V216, P103, DOI 10.1016/S0378-1119(98)00311-4; Hickman-Davis JM, 2004, AM J RESP CELL MOL, V30, P319, DOI 10.1165/rcmb.2003-0246OC; Hickman-Davis JM, 2001, AM J PHYSIOL-LUNG C, V281, pL517, DOI 10.1152/ajplung.2001.281.3.L517; Hohlfeld JM, 2002, PATHOBIOLOGY, V70, P287, DOI 10.1159/000070744; Ikemoto M, 2000, P NATL ACAD SCI USA, V97, P6538, DOI 10.1073/pnas.100114397; Isogawa Y, 2005, BIOCHEMISTRY-US, V44, P6190, DOI 10.1021/bi0475931; JENSEN ON, 1999, 2 D PROTEOME ANAL PR, V112, P487; Kato M, 2005, J BIOCHEM, V137, P157, DOI 10.1093/jb/mvi015; Kim KY, 2005, J BIOL CHEM, V280, P22769, DOI 10.1074/jbc.M503488200; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; Kramer BW, 2001, AM J RESP CRIT CARE, V163, P158, DOI 10.1164/ajrccm.163.1.2005084; Kuronuma K, 2004, J BIOL CHEM, V279, P21421, DOI 10.1074/jbc.M312490200; LeVine AM, 2002, AM J PHYSIOL-LUNG C, V282, pL563, DOI 10.1152/ajplung.00280.2001; LeVine AM, 1999, AM J RESP CELL MOL, V20, P279, DOI 10.1165/ajrcmb.20.2.3303; LeVine AM, 1998, AM J RESP CELL MOL, V19, P700, DOI 10.1165/ajrcmb.19.4.3254; LeVine AM, 2000, J IMMUNOL, V165, P3934, DOI 10.4049/jimmunol.165.7.3934; Li G, 2002, AM J RESP CELL MOL, V26, P277, DOI 10.1165/ajrcmb.26.3.4584; Linke MJ, 2001, J INFECT DIS, V183, P943, DOI 10.1086/319252; Lopez JP, 2003, J LEUKOCYTE BIOL, V74, P523, DOI 10.1189/jlb.0103027; Madan T, 1997, INFECT IMMUN, V65, P3171, DOI 10.1128/IAI.65.8.3171-3179.1997; McCormack FX, 2002, J CLIN INVEST, V109, P707, DOI 10.1172/JCI200215293; MICHELIS D, 1994, AM J RESP CELL MOL, V11, P692, DOI 10.1165/ajrcmb.11.6.7946398; Mor-Vaknin N, 2003, NAT CELL BIOL, V5, P59, DOI 10.1038/ncb898; Mori K, 2005, BIOCHEM BIOPH RES CO, V326, P491, DOI 10.1016/j.bbrc.2004.11.058; Mori K, 2003, J BIOCHEM, V133, P405, DOI 10.1093/jb/mvg053; Murakami S, 2002, J BIOL CHEM, V277, P6830, DOI 10.1074/jbc.M106671200; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Oberley RE, 2004, AM J PHYSIOL-LUNG C, V287, pL296, DOI 10.1152/ajplung.00440.2003; OLDEN K, 1976, CELL, V8, P383, DOI 10.1016/0092-8674(76)90150-1; PASTERNAK C, 1989, NATURE, V341, P549, DOI 10.1038/341549a0; Pasula R, 1999, J CLIN INVEST, V103, P483, DOI 10.1172/JCI2991; Puntervoll P, 2003, NUCLEIC ACIDS RES, V31, P3625, DOI 10.1093/nar/gkg545; Rey M, 2002, J IMMUNOL, V169, P5410, DOI 10.4049/jimmunol.169.10.5410; Rezniczek GA, 2003, HUM MOL GENET, V12, P3181, DOI 10.1093/hmg/ddg345; Sanchez JC, 1999, METH MOL B, V112, P221; Sano H, 2000, J BIOL CHEM, V275, P22442, DOI 10.1074/jbc.M001107200; Sato M, 2003, J IMMUNOL, V171, P417, DOI 10.4049/jimmunol.171.1.417; Schagat TL, 2003, AM J PHYSIOL-LUNG C, V284, pL140, DOI 10.1152/ajplung.00125.2002; Schagat TL, 2001, J IMMUNOL, V166, P2727, DOI 10.4049/jimmunol.166.4.2727; Shabanowitz J, 2000, MASS SPECTROMETRY IN BIOLOGY & MEDICINE, P163; Shibata Y, 2001, IMMUNITY, V15, P557, DOI 10.1016/S1074-7613(01)00218-7; Song MC, 2000, INFECT IMMUN, V68, P6611, DOI 10.1128/IAI.68.12.6611-6617.2000; Stamme C, 2000, AM J RESP CELL MOL, V23, P772, DOI 10.1165/ajrcmb.23.6.4083; Swanson JA, 1999, J CELL SCI, V112, P307; SZELIGA J, 2003, IN PRESS ANAL BIOCH; TINO MJ, 1996, AM J PHYSIOL, V270, P677; Togo T, 2004, MOL BIOL CELL, V15, P688, DOI 10.1091/mbc.E03-06-0430; van de Wetering JK, 2004, EUR J BIOCHEM, V271, P1229, DOI 10.1111/j.1432-1033.2004.04040.x; Vandivier RW, 2002, J IMMUNOL, V169, P3978, DOI 10.4049/jimmunol.169.7.3978; VANIWAARDEN F, 1990, AM J RESP CELL MOL, V2, P91, DOI 10.1165/ajrcmb/2.1.91; Wang JY, 1998, AM J RESP CRIT CARE, V158, P510, DOI 10.1164/ajrccm.158.2.9709111; Weikert LF, 2000, AM J PHYSIOL-LUNG C, V279, pL216, DOI 10.1152/ajplung.2000.279.2.L216; Weikert LF, 1997, AM J PHYSIOL-LUNG C, V272, pL989, DOI 10.1152/ajplung.1997.272.5.L989; Wilkins MR, 1997, J THEOR BIOL, V186, P7, DOI 10.1006/jtbi.1996.0346; WRIGHT JR, 1993, AM J PHYSIOL, V264, pL338, DOI 10.1152/ajplung.1993.264.4.L338; Wulfing C, 1998, SCIENCE, V282, P2266, DOI 10.1126/science.282.5397.2266; Xu B, 2004, MOL CELL BIOL, V24, P9198, DOI 10.1128/MCB.24.20.9198-9206.2004; Xu XXS, 2001, DEV BIOL, V232, P255, DOI 10.1006/dbio.2000.0132; Yang SX, 2002, AM J RESP CELL MOL, V27, P297, DOI 10.1165/rcmb.2002-0035OC; YATES JR, 1995, ANAL CHEM, V67, P3202, DOI 10.1021/ac00114a016; Zhu Q, 1997, BIOCHEM BIOPH RES CO, V232, P354, DOI 10.1006/bbrc.1997.6195; [No title captured]	88	44	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34447	34457		10.1074/jbc.M505229200	http://dx.doi.org/10.1074/jbc.M505229200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16087679	Green Accepted, hybrid			2022-12-25	WOS:000232403900011
J	Ma, YM; Pannicke, U; Lu, HH; Niewolik, D; Schwarz, K; Lieber, MR				Ma, YM; Pannicke, U; Lu, HH; Niewolik, D; Schwarz, K; Lieber, MR			The DNA-dependent protein kinase catalytic subunit phosphorylation sites in human artemis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							V(D)J RECOMBINATION; RAG PROTEINS; REPAIR; AUTOPHOSPHORYLATION; COMPLEX; IDENTIFICATION; DEFICIENCY; PATHWAY; DOMAIN; DAMAGE	Artemis protein has irreplaceable functions in V( D) J recombination and nonhomologous end joining (NHEJ) as a hairpin and 5' and 3' overhang endonuclease. The kinase activity of the DNA-dependent protein kinase catalytic subunit (DNA-PKcs) is necessary in activating Artemis as an endonuclease. Here we report that three basal phosphorylation sites and 11 DNA-PKcs phosphorylation sites within the mammalian Artemis are all located in the C-terminal domain. All but one of these phosphorylation sites deviate from the SQ or TQ motif of DNA-PKcs that was predicted previously from in vitro phosphorylation studies. Phosphatase- treated mammalian Artemis and Artemis that is mutated at the three basal phosphorylation sites still retain DNA- PKcs-dependent endonucleolytic activities, indicating that basal phosphorylation is not required for the activation. In vivo studies of Artemis lacking the C-terminal domain have been reported to be sufficient to complement V( D) J recombination in Artemis null cells. Therefore, the C-terminal domain may have a negative regulatory effect on the Artemis endonucleolytic activities, and phosphorylation by DNA- PKcs in the C-terminal domain may relieve this inhibition.	Univ Ulm, Dept Transfus Med, Inst Clin Transfus Med & Immunogenet, D-89081 Ulm, Germany; Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Dept Pathol, Los Angeles, CA 90089 USA; Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA; Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Dept Biol Sci, Los Angeles, CA 90089 USA; Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Dept Mol Microbiol & Immunol, Los Angeles, CA 90089 USA	Ulm University; University of Southern California; University of Southern California; University of Southern California; University of Southern California	Schwarz, K (corresponding author), Univ Ulm, Dept Transfus Med, Inst Clin Transfus Med & Immunogenet, D-89081 Ulm, Germany.	klaus.schwarz@medizin.uni-ulm.de; lieber@usc.edu	Pannicke, Ulrich/D-7348-2014	Lieber, Michael/0000-0003-3700-6345; Lieber, Michael/0000-0001-8809-0909				Anderson CW, 1996, CURR TOP MICROBIOL, V217, P91; Bassing CH, 2002, CELL, V109, pS45, DOI 10.1016/S0092-8674(02)00675-X; Callebaut I, 2002, NUCLEIC ACIDS RES, V30, P3592, DOI 10.1093/nar/gkf470; Chan DW, 1999, BIOCHEMISTRY-US, V38, P1819, DOI 10.1021/bi982584b; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; Chen L, 2005, CANCER SCI, V96, P134, DOI 10.1111/j.1349-7006.2005.00019.x; de Villartay JP, 2002, CURR OPIN ALLERGY CL, V2, P473, DOI 10.1097/00130832-200212000-00001; Ding Q, 2003, MOL CELL BIOL, V23, P5836, DOI 10.1128/MCB.23.16.5836-5848.2003; Douglas P, 2002, BIOCHEM J, V368, P243, DOI 10.1042/BJ20020973; Fugmann SD, 2000, ANNU REV IMMUNOL, V18, P495, DOI 10.1146/annurev.immunol.18.1.495; Gellert M, 2002, ANNU REV BIOCHEM, V71, P101, DOI 10.1146/annurev.biochem.71.090501.150203; Jung D, 2004, CELL, V116, P299, DOI 10.1016/S0092-8674(04)00039-X; KULESZA P, 1999, THESIS WASHINGTON U; Lee KJ, 2004, DNA REPAIR, V3, P267, DOI 10.1016/j.dnarep.2003.11.005; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Lieber MR, 2004, DNA REPAIR, V3, P817, DOI 10.1016/j.dnarep.2004.03.015; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; Meek K, 2004, IMMUNOL REV, V200, P132, DOI 10.1111/j.0105-2896.2004.00162.x; Merkle D, 2002, BIOCHEMISTRY-US, V41, P12706, DOI 10.1021/bi0263558; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Pannicke U, 2004, EMBO J, V23, P1987, DOI 10.1038/sj.emboj.7600206; Poinsignon C, 2004, EUR J IMMUNOL, V34, P3146, DOI 10.1002/eji.200425455; Poinsignon C, 2004, J EXP MED, V199, P315, DOI 10.1084/jem.20031142; Reddy YVR, 2004, J BIOL CHEM, V279, P39408, DOI 10.1074/jbc.M406432200; Riballo E, 2004, MOL CELL, V16, P715, DOI 10.1016/j.molcel.2004.10.029; Rooney S, 2004, IMMUNOL REV, V200, P115, DOI 10.1111/j.0105-2896.2004.00165.x; Rooney S, 2003, J EXP MED, V197, P553, DOI 10.1084/jem.20021891; Rooney S, 2002, MOL CELL, V10, P1379, DOI 10.1016/S1097-2765(02)00755-4; Schwarz K, 2003, BIOESSAYS, V25, P1061, DOI 10.1002/bies.10344; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Wang JH, 2005, DNA REPAIR, V4, P556, DOI 10.1016/j.dnarep.2005.02.001; Yu YP, 2003, DNA REPAIR, V2, P1239, DOI 10.1016/S1568-7864(03)00143-5; Zhang XS, 2004, MOL CELL BIOL, V24, P9207, DOI 10.1128/MCB.24.20.9207-9220.2004	33	103	112	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33839	33846		10.1074/jbc.M507113200	http://dx.doi.org/10.1074/jbc.M507113200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16093244	hybrid			2022-12-25	WOS:000232229700020
J	Nair, D; Kim, Y; Myers, LC				Nair, D; Kim, Y; Myers, LC			Mediator and TFIIH govern carboxyl-terminal domain-dependent transcription in yeast extracts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TATA-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; REPEAT DOMAIN; FUNCTIONAL INTERACTION; GENERAL TRANSCRIPTION; PREINITIATION COMPLEX; DNA-REPAIR; REQUIREMENT; HOLOENZYME	In Saccharomyces cerevisiae, the RNA polymerase II (RNA Pol II) carboxyl-terminal domain (CTD) is required for viability, and truncation of the CTD results in promoter dependent transcriptional defects. ACTD-lessRNAPol II is unable to support transcription in yeast extracts, but basal transcription reactions reconstituted from highly purified general transcription factors are CTD-independent. To reconcile these two findings, we have taken a biochemical approach using yeast extracts and asked whether there is a factor in the cell that confers CTD-dependence upon transcription. By placing a cleavage site for the tobacco etch virus protease prior to the CTD, we have created a highly specific method for removing the CTD from RNA Pol II in yeast whole cell extracts. Using derivatives of this strain, we have analyzed the role of the Srb8-11 complex, Mediator, and TFIIH, in CTD-dependent basal transcription by either mutation or immunodepletion of their function. We have found that Mediator is a direct intermediary of CTD-dependent basal transcription in extracts and that the requirement for Mediator and the CTD in basal transcription originates from their ability to compensate for a limiting amount of TFIIH activity in extracts.	Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Myers, LC (corresponding author), Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA.	larry.myers@dartmouth.edu			NIGMS NIH HHS [GM62483, R01 GM062483] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062483] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akoulitchev S, 2000, NATURE, V407, P102, DOI 10.1038/35024111; ALLISON LA, 1989, P NATL ACAD SCI USA, V86, P2794, DOI 10.1073/pnas.86.8.2794; Bjorklund S, 2004, ADV PROTEIN CHEM, V67, P43; Borggrefe T, 2002, J BIOL CHEM, V277, P44202, DOI 10.1074/jbc.M207195200; Brachmann CB, 1998, YEAST, V14, P115; BUERMEYER AB, 1992, MOL CELL BIOL, V12, P2250, DOI 10.1128/MCB.12.5.2250; BUERMEYER AB, 1995, J BIOL CHEM, V270, P6798, DOI 10.1074/jbc.270.12.6798; Bushnell DA, 1996, J BIOL CHEM, V271, P20170, DOI 10.1074/jbc.271.33.20170; Cang Y, 1999, EMBO J, V18, P6662, DOI 10.1093/emboj/18.23.6662; Carlson M, 1997, ANNU REV CELL DEV BI, V13, P1, DOI 10.1146/annurev.cellbio.13.1.1; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; DAHMUS ME, 1995, BBA-GENE STRUCT EXPR, V1261, P171, DOI 10.1016/0167-4781(94)00233-S; Gadbois EL, 1997, P NATL ACAD SCI USA, V94, P3145, DOI 10.1073/pnas.94.7.3145; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Gilfillan S, 2005, J BIOL CHEM, V280, P6222, DOI 10.1074/jbc.M406343200; Goppelt A, 1996, NUCLEIC ACIDS RES, V24, P4450, DOI 10.1093/nar/24.22.4450; Guidi BW, 2004, J BIOL CHEM, V279, P29114, DOI 10.1074/jbc.M404426200; Hengartner CJ, 1998, MOL CELL, V2, P43, DOI 10.1016/S1097-2765(00)80112-4; HENGARTNER CJ, 1995, GENE DEV, V9, P897, DOI 10.1101/gad.9.8.897; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; KANG ME, 1993, J BIOL CHEM, V268, P25033; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; Kong SE, 2002, DNA REPAIR, V1, P731, DOI 10.1016/S1568-7864(02)00080-0; KUCHIN S, 1995, P NATL ACAD SCI USA, V92, P4006, DOI 10.1073/pnas.92.9.4006; Lee YC, 1998, MOL CELL BIOL, V18, P5364, DOI 10.1128/MCB.18.9.5364; Lewis BA, 2003, J CELL SCI, V116, P3667, DOI 10.1242/jcs.00734; LI Y, 1994, P NATL ACAD SCI USA, V91, P2362, DOI 10.1073/pnas.91.6.2362; LIAO SM, 1991, GENE DEV, V5, P2431, DOI 10.1101/gad.5.12b.2431; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; Liu Y, 2004, MOL CELL BIOL, V24, P1721, DOI 10.1128/MCB.24.4.1721-1735.2004; Myers LC, 1997, METHODS, V12, P212, DOI 10.1006/meth.1997.0473; Myers LC, 2002, MOL CELL, V10, P883, DOI 10.1016/S1097-2765(02)00644-5; Myers LC, 1998, GENE DEV, V12, P45, DOI 10.1101/gad.12.1.45; Myers LC, 2000, ANNU REV BIOCHEM, V69, P729, DOI 10.1146/annurev.biochem.69.1.729; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; NONET ML, 1989, GENETICS, V123, P715; PARKS TD, 1994, ANAL BIOCHEM, V216, P413, DOI 10.1006/abio.1994.1060; PETERSON CL, 1991, CELL, V64, P1135, DOI 10.1016/0092-8674(91)90268-4; Prelich G, 2002, EUKARYOT CELL, V1, P153, DOI 10.1128/EC.1.2.153-162.2002; Rani PG, 2004, MOL CELL BIOL, V24, P1709, DOI 10.1128/MCB.24.4.1709-1720.2004; Ranish JA, 2004, NAT GENET, V36, P707, DOI 10.1038/ng1385; Ranish JA, 1999, GENE DEV, V13, P49, DOI 10.1101/gad.13.1.49; Reeves WM, 2003, MOL CELL BIOL, V23, P349, DOI 10.1128/MCB.23.1.349-358.2003; Sakurai H, 2000, J BIOL CHEM, V275, P37251, DOI 10.1074/jbc.M004364200; Samuelsen CO, 2003, P NATL ACAD SCI USA, V100, P6422, DOI 10.1073/pnas.1030497100; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; Shilatifard A, 2003, ANNU REV BIOCHEM, V72, P693, DOI 10.1146/annurev.biochem.72.121801.161551; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T	52	12	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33739	33748		10.1074/jbc.M506067200	http://dx.doi.org/10.1074/jbc.M506067200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16076843	hybrid			2022-12-25	WOS:000232229700009
J	Ren, Y; Liu, WH; Jiang, HB; Jiang, Q; Feng, J				Ren, Y; Liu, WH; Jiang, HB; Jiang, Q; Feng, J			Selective vulnerability of dopaminergic neurons to microtubule depolymerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARKINSONS-DISEASE; TUBULIN POLYMERIZATION; ROTENONE INHIBITION; SUBSTANTIA-NIGRA; IN-VITRO; CELLS; MECHANISM; PROTEINS; MODELS; SYSTEM	Parkinson disease (PD) is characterized by the specific degeneration of dopaminergic (DA) neurons in substantia nigra and has been linked to a variety of environmental and genetic factors. Rotenone, an environmental PD toxin, exhibited much greater toxicity to DA neurons in midbrain neuronal cultures than to non-DA neurons. The effect was significantly decreased by the microtubule-stabilizing drug taxol and mimicked by microtubule-depolymerizing agents such as colchicine or nocodazole. Microtubule depolymerization disrupted vesicular transport along microtubules and caused the accumulation of dopamine vesicles in the soma. This led to increased oxidative stress due to oxidation of cytosolic dopamine leaked from vesicles. Inhibition of dopamine metabolism significantly reduced rotenone toxicity. Thus, our results suggest that microtubule depolymerization induced by PD toxins such as rotenone plays a key role in the selective death of dopaminergic neurons.	SUNY Buffalo, Dept Physiol & Biophys, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Feng, J (corresponding author), SUNY Buffalo, Dept Physiol & Biophys, 124 Sherman Hall, Buffalo, NY 14214 USA.	jianfeng@buffalo.edu		Liu, Wenhua/0000-0003-0903-8497	NINDS NIH HHS [NS41722] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041722] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barrientos A, 1999, J BIOL CHEM, V274, P16188, DOI 10.1074/jbc.274.23.16188; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; BORISY GG, 1972, ANAL BIOCHEM, V50, P373, DOI 10.1016/0003-2697(72)90046-2; BRINKLEY BR, 1974, EXP CELL RES, V85, P41, DOI 10.1016/0014-4827(74)90210-9; Cappelletti G, 1999, J NEUROSCI RES, V56, P28, DOI 10.1002/(SICI)1097-4547(19990401)56:1<28::AID-JNR4>3.0.CO;2-2; Cappelletti G, 2001, CELL BIOL INT, V25, P981, DOI 10.1006/cbir.2001.0772; CHANCE B, 1963, J BIOL CHEM, V238, P418; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Di Monte DA, 2003, LANCET NEUROL, V2, P531, DOI 10.1016/S1474-4422(03)00501-5; Eisenhofer G, 2004, ANN NY ACAD SCI, V1018, P224, DOI 10.1196/annals.1296.027; Feng J, 2000, P NATL ACAD SCI USA, V97, P9287, DOI 10.1073/pnas.97.16.9287; FLOOR E, 1995, J NEUROCHEM, V64, P689; Goldstein LSB, 2003, NEURON, V40, P415, DOI 10.1016/S0896-6273(03)00630-5; Hastings TG, 1996, P NATL ACAD SCI USA, V93, P1956, DOI 10.1073/pnas.93.5.1956; HIMES RH, 1976, P NATL ACAD SCI USA, V73, P4397, DOI 10.1073/pnas.73.12.4397; Jiang HB, 2004, HUM MOL GENET, V13, P1745, DOI 10.1093/hmg/ddh180; JOSHI HC, 1989, J CELL BIOL, V109, P663, DOI 10.1083/jcb.109.2.663; Langston JW, 2002, NEUROTOXICOLOGY, V23, P443, DOI 10.1016/S0161-813X(02)00098-0; Liu YJ, 1997, ANNU REV NEUROSCI, V20, P125; MARSHALL LE, 1978, BIOCHIM BIOPHYS ACTA, V543, P590, DOI 10.1016/0304-4165(78)90315-X; Miller GW, 1999, TRENDS PHARMACOL SCI, V20, P424, DOI 10.1016/S0165-6147(99)01379-6; Ren Y, 2003, J NEUROSCI, V23, P3316; Seo BB, 2002, MOL THER, V6, P336, DOI 10.1006/mthe.2002.0674; Sherer TB, 2003, J NEUROSCI, V23, P10756, DOI 10.1523/jneurosci.23-34-10756.2003; Shih JC, 1999, ANNU REV NEUROSCI, V22, P197, DOI 10.1146/annurev.neuro.22.1.197; SOFIC E, 1991, J NEUROCHEM, V56, P978, DOI 10.1111/j.1471-4159.1991.tb02017.x; Thiruchelvam M, 2000, J NEUROSCI, V20, P9207; TSE C, 1980, J NEUROCHEM, V35, P767, DOI 10.1111/j.1471-4159.1980.tb07072.x; Zecca L, 2003, TRENDS NEUROSCI, V26, P578, DOI 10.1016/j.tins.2003.08.009; Zhao JH, 2003, J CELL SCI, V116, P4011, DOI 10.1242/jcs.00700	31	145	149	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34105	34112		10.1074/jbc.M503483200	http://dx.doi.org/10.1074/jbc.M503483200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16091364	hybrid			2022-12-25	WOS:000232229700051
J	Vreys, V; Delande, N; Zhang, Z; Coomans, C; Roebroek, A; Durr, J; David, G				Vreys, V; Delande, N; Zhang, Z; Coomans, C; Roebroek, A; Durr, J; David, G			Cellular uptake of mammalian heparanase precursor involves low density lipoprotein receptor-related proteins, mannose 6-phosphate receptors, and heparan sulfate Proteoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; CLONING; ACTIVATION; SECRETION; ENZYME	Mammalian heparanase, strongly implicated in the regulation of cell growth, migration, and differentiation, plays a crucial role in inflammation, angiogenesis, and metastasis. There is thus a clear need for understanding how heparanase activity is regulated. Cells can generate an active form of the enzyme from a larger inactive precursor protein by a process of secretion-recapture, internalization, and proteolytic processing in late endosomes/lysosomes. Cell surface heparan sulfate proteoglycans are the sole known components with a role in this trafficking of the heparanase precursor. Here, we provide evidence that heparan sulfate proteoglycans are not strictly required for this process. More importantly, by heparanase transfection, binding, and uptake experiments and by using a combination of specific inhibitors and receptor-defective cells, we have identified low density lipoprotein receptor-related proteins and mannose 6-phosphate receptors as key elements of the receptor system that mediates the capture of secreted heparanase precursor and its trafficking to the intracellular site of processing/activation.	Univ Leuven, Ctr Human Genet, Dept Human Genet, Lab Glycobiol & Dev Genet, B-3000 Leuven, Belgium; Univ Leuven, Dept Human Genet, Lab Mouse Genet, B-3000 Leuven, Belgium; Flanders Interuniv Inst Biotechnol, B-3000 Leuven, Belgium	KU Leuven; KU Leuven	David, G (corresponding author), Univ Leuven, Ctr Human Genet, Dept Human Genet, Lab Glycobiol & Dev Genet, Campus Gasthuisberg Onderwijs & Navorsing,Herestr, B-3000 Leuven, Belgium.	guido.david@med.kuleuven.ac.be						Bame KJ, 2001, GLYCOBIOLOGY, V11, p91R, DOI 10.1093/glycob/11.6.91R; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961; Fairbanks MB, 1999, J BIOL CHEM, V274, P29587, DOI 10.1074/jbc.274.42.29587; FITZGERALD DJ, 1995, J CELL BIOL, V129, P1533, DOI 10.1083/jcb.129.6.1533; Ghosh P, 2003, NAT REV MOL CELL BIO, V4, P202, DOI 10.1038/nrm1050; Gingis-Velitski S, 2004, J BIOL CHEM, V279, P44084, DOI 10.1074/jbc.M402131200; Gingis-Velitski S, 2004, J BIOL CHEM, V279, P23536, DOI 10.1074/jbc.M400554200; Goldshmidt O, 2002, P NATL ACAD SCI USA, V99, P10031, DOI 10.1073/pnas.152070599; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; JI ZS, 1994, ARTERIOSCLER THROMB, V14, P2025, DOI 10.1161/01.ATV.14.12.2025; Kussie PH, 1999, BIOCHEM BIOPH RES CO, V261, P183, DOI 10.1006/bbrc.1999.0962; Levy-Adam F, 2003, BIOCHEM BIOPH RES CO, V308, P885, DOI 10.1016/S0006-291X(03)01478-5; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; LORIES V, 1989, J BIOL CHEM, V264, P7009; McKenzie E, 2003, BIOCHEM J, V373, P423, DOI 10.1042/BJ20030318; Nadav L, 2002, J CELL SCI, V115, P2179; Nardella C, 2004, BIOCHEMISTRY-US, V43, P1862, DOI 10.1021/bi030203a; Parish CR, 2001, BIOCHIM BIOPHYS ACTA, V1471, P99, DOI DOI 10.1016/S0304-419X(01)00017-8; POHLMANN R, 1995, J BIOL CHEM, V270, P27311, DOI 10.1074/jbc.270.45.27311; Simizu S, 2004, J BIOL CHEM, V279, P2697, DOI 10.1074/jbc.M300541200; Strickland DK, 2003, J THROMB HAEMOST, V1, P1663, DOI 10.1046/j.1538-7836.2003.00330.x; Toyoshima M, 1999, J BIOL CHEM, V274, P24153, DOI 10.1074/jbc.274.34.24153; VASSILIOU G, 1994, J BIOL CHEM, V269, P15172; Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI200113662; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; WILLNOW TE, 1994, J CELL SCI, V107, P719; Zetser A, 2004, J CELL SCI, V117, P2249, DOI 10.1242/jcs.01068	29	71	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33141	33148		10.1074/jbc.M503007200	http://dx.doi.org/10.1074/jbc.M503007200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16046412	hybrid			2022-12-25	WOS:000232058100008
J	Zhao, WM; Fang, GW				Zhao, WM; Fang, GW			Anillin is a substrate of anaphase-promoting complex/cyclosome (APC/C) that controls spatial contractility of myosin during late cytokinesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY LIGHT-CHAIN; SHORT-INTERFERING RNAS; KINESIN-LIKE PROTEIN; MAMMALIAN-CELLS; CULTURED-CELLS; MITOTIC SPINDLE; CLEAVAGE FURROW; HAIRPIN RNAS; MITOSIS; COMPLEX	Anillin, an actin-binding protein localized at the cleavage furrow, is required for cytokinesis. Through an in vitro expression screen, we identified anillin as a substrate of the anaphase-promoting complex/ cyclosome (APC/C), a ubiquitin ligase that controls mitotic progression. We found that the levels of anillin fluctuate in the cell cycle, peaking in mitosis and dropping drastically during mitotic exit. Ubiquitination of anillin required a destruction-box and was mediated by Cdh1, an activator of APC/C. Overexpression of Cdh1 reduced the levels of anillin, whereas inactivation of APC/CCdh1 increased the half-life of anillin. Functionally, anillin was required for the completion of cytokinesis. In anillin knockdown cells, the cleavage furrow ingressed but failed to complete the ingression. At late cytokinesis, the cytosol and DNA in knockdown cells underwent rapid myosin-based oscillatory movement across the furrow. During this movement, RhoA and active myosin were absent from the cleavage furrow, and myosin was redistributed to cortical patches, which powers the random oscillatory movement. We concluded that anillin functions to maintain the localization of active myosin, thereby ensuring the spatial control of concerted contraction during cytokinesis.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	Stanford University	Fang, GW (corresponding author), Stanford Univ, Dept Biol Sci, 337 Campus Dr,MC-5020,Lokey Chem Biol Bldg,Rm 137, Stanford, CA 94305 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062852] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM062852] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bettinger BT, 2004, NAT REV MOL CELL BIO, V5, P410, DOI 10.1038/nrm1370; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Charles JF, 1998, CURR BIOL, V8, P497, DOI 10.1016/S0960-9822(98)70201-5; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; Echard A, 2004, CURR BIOL, V14, P1685, DOI 10.1016/j.cub.2004.08.063; Echard A, 2003, CURR BIOL, V13, P373, DOI 10.1016/S0960-9822(03)00127-1; Eda M, 2001, J CELL SCI, V114, P3273; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; FIELD CM, 1995, J CELL BIOL, V131, P165, DOI 10.1083/jcb.131.1.165; Gadde S, 2004, CURR BIOL, V14, pR797, DOI 10.1016/j.cub.2004.09.021; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Glotzer M, 2001, ANNU REV CELL DEV BI, V17, P351, DOI 10.1146/annurev.cellbio.17.1.351; Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102; Hayashi K, 1999, J CELL SCI, V112, P1149; Hirose K, 2001, J BIOL CHEM, V276, P5821, DOI 10.1074/jbc.M007252200; Komatsu S, 2000, J BIOL CHEM, V275, P34512, DOI 10.1074/jbc.M003019200; Kosako H, 2000, ONCOGENE, V19, P6059, DOI 10.1038/sj.onc.1203987; Kramer ER, 1998, CURR BIOL, V8, P1207, DOI 10.1016/S0960-9822(07)00510-6; LEE KS, 1995, MOL CELL BIOL, V15, P7143; Li A, 2005, EMBO J, V24, P395, DOI 10.1038/sj.emboj.7600520; Liu XQ, 2004, J CELL SCI, V117, P3233, DOI 10.1242/jcs.01173; Lustig KD, 1997, METHOD ENZYMOL, V283, P83; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Oegema K, 2000, J CELL BIOL, V150, P539, DOI 10.1083/jcb.150.3.539; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Petersen BO, 2000, GENE DEV, V14, P2330, DOI 10.1101/gad.832500; Pfleger CM, 2000, GENE DEV, V14, P655; Pfleger CM, 2001, GENE DEV, V15, P2396, DOI 10.1101/gad.918201; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Somma MP, 2002, MOL BIOL CELL, V13, P2448, DOI 10.1091/mbc.01-12-0589; Straight AF, 2005, MOL BIOL CELL, V16, P193, DOI 10.1091/mbc.E04-08-0758; Straight AF, 2003, SCIENCE, V299, P1743, DOI 10.1126/science.1081412; Tasto JJ, 2003, J CELL BIOL, V160, P1093, DOI 10.1083/jcb.200211126; Tatsumoto T, 1999, J CELL BIOL, V147, P921, DOI 10.1083/jcb.147.5.921; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; YAMAKITA Y, 1994, J CELL BIOL, V124, P129, DOI 10.1083/jcb.124.1.129; Yoshizaki H, 2003, J CELL BIOL, V162, P223, DOI 10.1083/jcb.200212049; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499	39	103	106	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33516	33524		10.1074/jbc.M504657200	http://dx.doi.org/10.1074/jbc.M504657200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16040610	hybrid			2022-12-25	WOS:000232058100051
J	Kaiser, RA; Liang, QR; Bueno, O; Huang, Y; Lackey, T; Klevitsky, R; Hewett, TE; Molkentin, JD				Kaiser, RA; Liang, QR; Bueno, O; Huang, Y; Lackey, T; Klevitsky, R; Hewett, TE; Molkentin, JD			Genetic inhibition or activation of JNK1/2 protects the myocardium from ischemia-reperfusion-induced cell death in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUN NH2-TERMINAL KINASE; N-TERMINAL KINASE; CARDIAC MYOCYTE APOPTOSIS; SIGNAL-TRANSDUCTION; MAP KINASES; SUPPRESSES APOPTOSIS; DEPENDENT ACTIVATION; OXIDATIVE STRESS; CROSS-TALK; PATHWAY	The c- Jun NH2- terminal kinase ( JNK) branch of the mitogen- activated protein kinase signaling cascade has been implicated in the regulation of apoptosis in a variety of mammalian cell types. In the heart, disagreement persists concerning the role that JNKs may play in regulating apoptosis, since both pro- and antiapoptotic regulatory functions have been reported in cultured cardiomyocytes. Here we report the first analysis of cardiomyocyte cell death due to JNK inhibition or activation in vivo using genetically modified mice. Three separate mouse models with selective JNK inhibition were assessed for ventricular damage and apoptosis levels following ischemia- reperfusion injury. jnk1 -/-, jnk2 -/-, and transgenic mice expressing dominant negative JNK1/2 within the heart were each shown to have less JNK activity in the heart and less injury and cellular apoptosis in vivo following ischemia- reperfusion injury. To potentially address the reciprocal gain- of- function phenotype associated with sustained JNK activation, transgenic mice were generated that express MKK7 in the heart. These transgenic mice displayed elevated cardiac c- Jun kinase activity but, ironically, were also significantly protected from ischemia- reperfusion. Mechanistically, JNK- inhibited mice showed increased phosphorylation of the proapoptotic factor Bad at position 112, whereas MKK7 transgenic mice showed decreased phosphorylation of this site. Collectively, these results underscore the complexity associated with JNK signaling in regulating apoptosis, such that sustained inhibition or activation both elicit cellular protection in vivo, although probably through different mechanisms.	Univ Cincinnati, Div Mol Cardiovasc Biol, Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA; Univ S Dakota, Sch Med, Cardiovasc Res Inst, Sioux Falls, SD 57105 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University of South Dakota	Molkentin, JD (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Mol Cardiovasc Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	jeff.molkentin@cchmc.org	Hewett, Timothy/G-1023-2011; Hewett, Timothy Edwin/GLT-1556-2022; Hewett, Timothy E/E-3241-2011	Molkentin, Jeffery/0000-0002-3558-6529	NHLBI NIH HHS [HL073550] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL073550] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andreka P, 2001, CIRC RES, V88, P305, DOI 10.1161/01.RES.88.3.305; Aoki H, 2002, J BIOL CHEM, V277, P10244, DOI 10.1074/jbc.M112355200; Baines CP, 2002, CIRC RES, V90, P390, DOI 10.1161/01.RES.0000012702.90501.8D; Baines CP, 2005, J MOL CELL CARDIOL, V38, P47, DOI 10.1016/j.yjmcc.2004.11.004; Bueno OF, 2000, EMBO J, V19, P6341, DOI 10.1093/emboj/19.23.6341; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; De Windt LJ, 2000, J BIOL CHEM, V275, P13571, DOI 10.1074/jbc.275.18.13571; De Windt LJ, 2000, CIRC RES, V86, P255, DOI 10.1161/01.RES.86.3.255; Deng YB, 2003, CELL, V115, P61, DOI 10.1016/S0092-8674(03)00757-8; Donovan N, 2002, J BIOL CHEM, V277, P40944, DOI 10.1074/jbc.M206113200; Dougherty CJ, 2002, BIOCHEM J, V362, P561, DOI 10.1042/0264-6021:3620561; Fan MY, 2000, J BIOL CHEM, V275, P29980, DOI 10.1074/jbc.M003776200; Ferrandi C, 2004, BRIT J PHARMACOL, V142, P953, DOI 10.1038/sj.bjp.0705873; Gabai VL, 2000, J BIOL CHEM, V275, P38088, DOI 10.1074/jbc.M006632200; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Gulick J, 1997, CIRC RES, V80, P655, DOI 10.1161/01.RES.80.5.655; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hess P, 2002, NAT GENET, V32, P201, DOI 10.1038/ng946; Hreniuk D, 2001, MOL PHARMACOL, V59, P867, DOI 10.1124/mol.59.4.867; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; Kaiser RA, 2004, J BIOL CHEM, V279, P15524, DOI 10.1074/jbc.M313717200; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Kwon SH, 2003, J MOL CELL CARDIOL, V35, P615, DOI 10.1016/S0022-2828(03)00084-1; Lei K, 2002, MOL CELL BIOL, V22, P4929, DOI 10.1128/MCB.22.13.4929-4942.2002; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Liang QR, 2003, EMBO J, V22, P5079, DOI 10.1093/emboj/cdg474; Lips DJ, 2004, CIRCULATION, V109, P1938, DOI 10.1161/01.CIR.0000127126.73759.23; Martindale JJ, 2005, J BIOL CHEM, V280, P669, DOI 10.1074/jbc.M406690200; Minamino T, 1999, P NATL ACAD SCI USA, V96, P15127, DOI 10.1073/pnas.96.26.15127; Nishitai G, 2004, J BIOL CHEM, V279, P1621, DOI 10.1074/jbc.M310335200; Petrich BG, 2003, FASEB J, V17, P749, DOI 10.1096/fj.02-0438fje; Petrich BG, 2002, CIRC RES, V91, P640, DOI 10.1161/01.RES.0000035854.11082.01; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; Remondino A, 2003, CIRC RES, V92, P136, DOI 10.1161/01.RES.0000054624.03539.B4; Sabapathy K, 1999, MECH DEVELOP, V89, P115, DOI 10.1016/S0925-4773(99)00213-0; Sabapathy K, 2001, J EXP MED, V193, P317, DOI 10.1084/jem.193.3.317; Sabapathy K, 1999, CURR BIOL, V9, P116, DOI 10.1016/S0960-9822(99)80065-7; Sadoshima J, 2002, J CLIN INVEST, V110, P271, DOI 10.1172/JCI200214938; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Tan Y, 1999, J BIOL CHEM, V274, P34859, DOI 10.1074/jbc.274.49.34859; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Weston CR, 2002, CURR OPIN GENET DEV, V12, P14, DOI 10.1016/S0959-437X(01)00258-1; Whitmarsh AJ, 2001, METHOD ENZYMOL, V332, P319; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yan B, 2003, J BIOL CHEM, V278, P45358, DOI 10.1074/jbc.M307933200; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yu CF, 2004, MOL CELL, V13, P329, DOI 10.1016/S1097-2765(04)00028-0; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911	50	101	111	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32602	32608		10.1074/jbc.M500684200	http://dx.doi.org/10.1074/jbc.M500684200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16043490	hybrid			2022-12-25	WOS:000231920300007
J	Shiflett, AM; Bishop, JR; Pahwa, A; Hajduk, SL				Shiflett, AM; Bishop, JR; Pahwa, A; Hajduk, SL			Human high density lipoproteins are platforms for the assembly of multi-component innate immune complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPANOSOME LYTIC FACTOR; HAPTOGLOBIN-RELATED PROTEIN; APOLIPOPROTEIN-L GENE; NORMAL HUMAN-SERUM; BRUCEI-BRUCEI; AFRICAN TRYPANOSOMES; TRYPANOCIDAL FACTOR; PRIMATE SERA; L-I; LYSIS	Human innate immunity to non- pathogenic species of African trypanosomes is provided by human high density lipoprotein ( HDL) particles. Here we show that native human HDLs containing hapto- globin- related protein ( Hpr), apolipoprotein L- I ( apoL- I) and apolipoprotein A- I ( apoA- I) are the principle antimicrobial molecules providing protection from trypanosome infection. Other HDL subclasses containing either apoA- I and apoL- I or apoA- I and Hpr have reduced trypanolytic activity, whereas HDL subclasses lacking apoL- I and Hpr are non- toxic to trypanosomes. Highly purified, lipid- free Hpr and apoL- I were both toxic to Trypanosoma brucei brucei but with specific activities at least 500- fold less than those of native HDLs, suggesting that association of these apolipoproteins within the HDL particle was necessary for optimal cytotoxicity. These studies show that HDLs can serve as platforms for the assembly of multiple synergistic proteins and that these assemblies may play a critical role in the evolution of primate- specific innate immunity to trypanosome infection.	Josephine Bay Paul Ctr, Global Infect Dis Program, Marine Biol Lab, Woods Hole, MA 02543 USA; Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Alabama, Sch Med, Birmingham, AL 35294 USA	Marine Biological Laboratory - Woods Hole; University of California System; University of California San Diego; University of Alabama System; University of Alabama Birmingham	Hajduk, SL (corresponding author), Josephine Bay Paul Ctr, Global Infect Dis Program, Marine Biol Lab, 7 MBL St,M-S 127, Woods Hole, MA 02543 USA.	shajduk@mbl.edu			NCI NIH HHS [P30 CA 1314] Funding Source: Medline; NIAID NIH HHS [AI054496, AI39033] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K11CA001314] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039033, R03AI054496, R21AI039033] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bishop JR, 2001, MOL BIOCHEM PARASIT, V118, P33, DOI 10.1016/S0166-6851(01)00361-9; Bowman, 1993, HEPATIC PLASMA PROTE, P159; Drain J, 2001, J BIOL CHEM, V276, P30254, DOI 10.1074/jbc.M010198200; Duchateau PN, 2001, J LIPID RES, V42, P620; Duchateau PN, 1997, J BIOL CHEM, V272, P25576, DOI 10.1074/jbc.272.41.25576; Green HP, 2003, J BIOL CHEM, V278, P422, DOI 10.1074/jbc.M207215200; HAGER KM, 1994, J CELL BIOL, V126, P155, DOI 10.1083/jcb.126.1.155; HAJDUK SL, 1989, J BIOL CHEM, V264, P5210; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; JONA A, 1986, METHOD ENZYMOL, P553; LORENZ P, 1994, T ROY SOC TROP MED H, V88, P487, DOI 10.1016/0035-9203(94)90443-X; Lugli EB, 2004, MOL BIOCHEM PARASIT, V138, P9, DOI 10.1016/j.molbiopara.2004.07.004; MAEDA N, 1985, J BIOL CHEM, V260, P6698; Monajemi H, 2002, GENOMICS, V79, P539, DOI 10.1006/geno.2002.6729; Muranjan M, 1998, J BIOL CHEM, V273, P3884, DOI 10.1074/jbc.273.7.3884; Page NM, 2001, GENOMICS, V74, P71, DOI 10.1006/geno.2001.6534; Perez-Morga D, 2005, SCIENCE, V309, P469, DOI 10.1126/science.1114566; Poelvoorde P, 2004, MOL BIOCHEM PARASIT, V134, P155, DOI 10.1016/j.molbiopara.2003.11.006; Portela MPM, 2000, MOL BIOCHEM PARASIT, V110, P273, DOI 10.1016/S0166-6851(00)00277-2; Raper J, 1996, J EXP MED, V183, P1023, DOI 10.1084/jem.183.3.1023; RAPER J, 2002, T R SOC TROP MED HYG, V96, P145; RIFKIN MR, 1978, P NATL ACAD SCI USA, V75, P3450, DOI 10.1073/pnas.75.7.3450; RIFKIN MR, 1991, EXP PARASITOL, V72, P216, DOI 10.1016/0014-4894(91)90139-N; SEED JR, 1990, J PROTOZOOL, V37, P393, DOI 10.1111/j.1550-7408.1990.tb01163.x; Shimamura M, 2001, MOL BIOCHEM PARASIT, V115, P227, DOI 10.1016/S0166-6851(01)00292-4; SMITH AB, 1995, SCIENCE, V268, P284, DOI 10.1126/science.7716520; Tomlinson S, 1997, MOL BIOCHEM PARASIT, V86, P117, DOI 10.1016/S0166-6851(97)90013-X; TYTLER EM, 1995, MOL BIOCHEM PARASIT, V69, P9, DOI 10.1016/0166-6851(94)00172-J; Vanhamme L, 2004, INT J PARASITOL, V34, P887, DOI 10.1016/j.ijpara.2004.04.008; Vanhamme L, 2001, TRENDS PARASITOL, V17, P338, DOI 10.1016/S1471-4922(01)01922-5; Vanhamme L, 2003, NATURE, V422, P83, DOI 10.1038/nature01461	31	129	133	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32578	32585		10.1074/jbc.M503510200	http://dx.doi.org/10.1074/jbc.M503510200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16046400	Green Published, hybrid			2022-12-25	WOS:000231920300004
J	Qiu, LY; Krieger, E; Schaftenaar, G; Swarts, HGP; Willems, PHGM; De Pont, JJHHM; Koenderink, JB				Qiu, LY; Krieger, E; Schaftenaar, G; Swarts, HGP; Willems, PHGM; De Pont, JJHHM; Koenderink, JB			Reconstruction of the complete ouabain-binding pocket of Na,K-ATPase in gastric H,K-ATPase by substitution of only seven amino acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							4TH TRANSMEMBRANE SEGMENT; SITE-DIRECTED MUTAGENESIS; ALPHA-SUBUNIT; CARDIAC-GLYCOSIDES; EXTRACELLULAR DOMAIN; MONOCLONAL-ANTIBODY; CRYSTAL-STRUCTURES; RESISTANT ENZYME; FORCE-FIELD; RESIDUES	Although cardiac glycosides have been used as drugs for more than 2 centuries and their primary target, the sodium pump (Na, K-ATPase), has already been known for 4 decades, their exact binding site is still elusive. In our efforts to define the molecular basis of digitalis glycosides binding we started from the fact that a closely related enzyme, the gastric H, K-ATPase, does not bind glycosides like ouabain. Previously, we showed that a chimera of these two enzymes, in which only the M3-M4 and M5-M6 hairpins were of Na, K- ATPase, bound ouabain with high affinity (Koenderink, J. B., Hermsen, H. P. H., Swarts, H. G. P., Willems, P. H. G. M., and De Pont, J. J. H. H. M. ( 2000) Proc. Natl. Acad. Sci. U. S. A. 97, 11209 11214). We also demonstrated that only three amino acids (Phe(783), Thr(797), and Asp(804)) present in the M5-M6 hairpin of Na,K-ATPase were sufficient to confer high affinity ouabain binding to a chimera which contained in addition the M3-M4 hairpin of Na, K-ATPase (Qiu, L. Y., Koenderink, J. B., Swarts, H. G., Willems, P. H., and De Pont, J. J. H. H. M. ( 2003) J. Biol. Chem. 278, 47240 - 47244). To further pinpoint the ouabain-binding site here we used a chimerabased loss-of-function strategy and identified four amino acids (Glu(312), Val(314), Ile(315), Gly(319)), all present in M4, as being important for ouabain binding. In a final gain-of-function study we showed that a gastric H, K- ATPase that contained Glu312, Val314, Ile315, Gly319, Phe783, Thr797, and Asp804 of Na, K- ATPase bound ouabain with the same affinity as the native enzyme. Based on the E2P crystal structure of Ca2+ -ATPase we constructed a homology model for the ouabain-binding site of Na, K- ATPase involving all seven amino acids as well as several earlier postulated amino acids.	Radboud Univ Nijmegen, Med Ctr, Dept Biochem 160, Nijmegen Ctr Mol Life Sci, NL-6500 HB Nijmegen, Netherlands; Radboud Univ Nijmegen, Med Ctr, Dept Pharmacol Toxicol 233, Nijmegen Ctr Mol Life Sci, NL-6500 HB Nijmegen, Netherlands; Radboud Univ Nijmegen, Ctr Mol & Biomol Informat, NL-6500 GL Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen	De Pont, JJHHM (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Biochem 160, Nijmegen Ctr Mol Life Sci, POB 9101, NL-6500 HB Nijmegen, Netherlands.	J.DePont@ncmls.ru.nl	Schaftenaar, Gijs/Q-8665-2018; Willems, P.H.G.M./L-4759-2015; Koenderink, Jan/N-3578-2014	Willems, P.H.G.M./0000-0002-0915-1599; 				Allen FH, 2002, ACTA CRYSTALLOGR B, V58, P380, DOI 10.1107/S0108768102003890; ANTOLOVIC R, 1995, FEBS LETT, V368, P169, DOI 10.1016/0014-5793(95)00637-O; ASKEW GR, 1994, J BIOL CHEM, V269, P24120; BURNS EL, 1993, J BIOL CHEM, V268, P25632; Burns EL, 1996, J BIOL CHEM, V271, P15879, DOI 10.1074/jbc.271.27.15879; CANESSA CM, 1993, J BIOL CHEM, V268, P17722; CANESSA CM, 1992, EMBO J, V11, P1681, DOI 10.1002/j.1460-2075.1992.tb05218.x; Canutescu AA, 2003, PROTEIN SCI, V12, P2001, DOI 10.1110/ps.03154503; Crambert G, 2004, MOL PHARMACOL, V65, P335, DOI 10.1124/mol.65.2.335; Croyle ML, 1997, EUR J BIOCHEM, V248, P488, DOI 10.1111/j.1432-1033.1997.00488.x; FENG JN, 1994, BIOCHEMISTRY-US, V33, P4218, DOI 10.1021/bi00180a015; FORTES PAG, 1977, BIOCHEMISTRY-US, V16, P531, DOI 10.1021/bi00622a030; GOTTARDI CJ, 1993, J BIOL CHEM, V268, P14342; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Horisberger JD, 2004, J BIOL CHEM, V279, P29542, DOI 10.1074/jbc.M400585200; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; KANO I, 1990, BIOCHEM CELL BIOL, V68, P1262, DOI 10.1139/o90-187; Koenderink JB, 2000, P NATL ACAD SCI USA, V97, P11209, DOI 10.1073/pnas.200109597; Koenderink JB, 1999, J BIOL CHEM, V274, P11604, DOI 10.1074/jbc.274.17.11604; Koenderink JB, 2004, J BIOL CHEM, V279, P16417, DOI 10.1074/jbc.M400020200; Kramer B, 1999, PROTEINS, V37, P228, DOI 10.1002/(SICI)1097-0134(19991101)37:2<228::AID-PROT8>3.0.CO;2-8; Krieger E, 2002, PROTEINS, V47, P393, DOI 10.1002/prot.10104; Krieger E, 2004, PROTEINS, V57, P678, DOI 10.1002/prot.20251; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; Lorenz L, 1996, P NATL ACAD SCI USA, V93, P13362, DOI 10.1073/pnas.93.23.13362; MCPARLAND RA, 1991, SODIUM PUMP RECENT D, P297; Mense M, 2000, J BIOL CHEM, V275, P1749, DOI 10.1074/jbc.275.3.1749; OBRIEN WJ, 1993, J BIOL CHEM, V268, P7707; Palasis M, 1996, J BIOL CHEM, V271, P14176, DOI 10.1074/jbc.271.24.14176; Paula S, 2005, BIOCHEMISTRY-US, V44, P498, DOI 10.1021/bi048680w; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; PRICE EM, 1990, J BIOL CHEM, V265, P6638; Qiu LY, 2003, J BIOL CHEM, V278, P47240, DOI 10.1074/jbc.M308833200; ROSSI B, 1988, METHOD ENZYMOL, V156, P323; SATOH K, 1989, BIOCHIM BIOPHYS ACTA, V994, P104, DOI 10.1016/0167-4838(89)90149-0; Schaftenaar G, 2000, J COMPUT AID MOL DES, V14, P123, DOI 10.1023/A:1008193805436; SCHATZMANN HJ, 1953, HELV PHYSIOL PHARM A, V11, P346; SCHULTHEIS PJ, 1993, J BIOL CHEM, V268, P22686; SCHULTHEIS PJ, 1993, BIOCHEMISTRY-US, V32, P544, DOI 10.1021/bi00053a020; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SKOU JC, 1957, BIOCHIM BIOPHYS ACTA, V23, P394, DOI 10.1016/0006-3002(57)90343-8; Sweadner KJ, 2001, BIOCHEM J, V356, P685, DOI 10.1042/0264-6021:3560685; Toyoshima C, 2004, NATURE, V432, P361, DOI 10.1038/nature02981; VILSEN B, 1995, FEBS LETT, V363, P179, DOI 10.1016/0014-5793(95)00313-X; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; VRIEND G, 1992, J MOL GRAPHICS, V8, P29	47	57	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32349	32355		10.1074/jbc.M505168200	http://dx.doi.org/10.1074/jbc.M505168200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16051601	hybrid, Green Published			2022-12-25	WOS:000231794800039
J	Yu, YH; Sweeney, MD; Saad, OM; Crown, SE; Handel, TM; Leary, JA				Yu, YH; Sweeney, MD; Saad, OM; Crown, SE; Handel, TM; Leary, JA			Chemokine-glycosaminoglycan binding - Specificity for CCR2 ligand binding to highly sulfated oligosaccharides using FTICR mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTION IN-VIVO; HEPARAN-SULFATE; PROTEIN COMPLEXES; CRYSTAL-STRUCTURE; SMALL-MOLECULE; RECEPTOR; OLIGOMERIZATION; GROWTH; IDENTIFICATION; MICROARRAYS	Glycosaminoglycans (GAGs) have recently been demonstrated to be required for the in vivo activity of several chemokines. Minimally, the interaction is thought to provide a mechanism for retention at the site of secretion and the formation of chemokine gradients that provide directional cues for receptor bearing cells, particularly in the presence of shear forces. Thus, a key issue will be to determine the sequence and structure of the GAGs that bind to specific chemokines. Herein, we describe amass spectrometry assay that was developed to detect protein-oligosaccharide noncovalent complexes, in this case chemokine-GAG interactions, and to select for high affinity GAGs. The process is facilitated by the ability of electrospray ionization to transfer the intact noncovalent complexes from solution into the gas phase. The elemental composition as well as the binding stoichiometry can be calculated from the mass of the complex. Ligands of the chemokine receptor, CCR2 (MCP-1/CCL2, MCP-2/CCL8, MCP-3/CCL7, MCP-4/CCL13, and Eotaxin/CCL11), and the CCR10 ligand CTACK/CCL27 were screened against a small, highly sulfated, heparin oligosaccharide library with limited structural variation. The results revealed heparin octasaccharides with 11 and 12 sulfates as binders. Oligomerization of some chemokines was observed upon GAG binding, whereas in other instances only the monomeric noncovalent complex was identified. The results indicate that, in contrast to the apparent redundancy in the chemokine system, where several chemokines bind and activate the same receptor, these chemokines could be differentiated into two groups based on the stoichiometry of their complexes with the heparin oligosaccharides.	Univ Calif Davis, Genome Ctr, Dept Chem, Davis, CA 95616 USA; Univ Calif Davis, Genome Ctr, Dept Mol Cell Biol, Davis, CA 95616 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Leary, JA (corresponding author), Univ Calif Davis, Genome Ctr, Dept Chem, Davis, CA 95616 USA.	jaleary@ucdavis.edu			NIAID NIH HHS [AI37113-09] Funding Source: Medline; NIGMS NIH HHS [GM63581] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037113] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063581] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Blaszczyk J, 2000, BIOCHEMISTRY-US, V39, P14075, DOI 10.1021/bi0009340; Blixt O, 2004, P NATL ACAD SCI USA, V101, P17033, DOI 10.1073/pnas.0407902101; BOURIN MC, 1993, BIOCHEM J, V289, P313, DOI 10.1042/bj2890313; Cao L, UNPUB; Crump MP, 1998, J BIOL CHEM, V273, P22471, DOI 10.1074/jbc.273.35.22471; Delehedde M, 2002, BIOCHEM J, V366, P235, DOI 10.1042/BJ20011718; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Feizi T, 2004, NAT REV MOL CELL BIO, V5, P582, DOI 10.1038/nrm1428; Fukui S, 2002, NAT BIOTECHNOL, V20, P1011, DOI 10.1038/nbt735; Handel TM, 2005, ANNU REV BIOCHEM, V74, P385, DOI 10.1146/annurev.biochem.72.121801.161747; Harmer NJ, 2004, J MOL BIOL, V339, P821, DOI 10.1016/j.jmb.2004.04.031; Hemmerich S, 1999, BIOCHEMISTRY-US, V38, P13013, DOI 10.1021/bi991029m; Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s; Ji QC, 2003, RAPID COMMUN MASS SP, V17, P794, DOI 10.1002/rcm.981; Johnson Z, 2004, J IMMUNOL, V173, P5776, DOI 10.4049/jimmunol.173.9.5776; KANE JF, 1995, CURR OPIN BIOTECH, V6, P494, DOI 10.1016/0958-1669(95)80082-4; KATO M, 1994, J BIOL CHEM, V269, P18881; Keiser N, 2001, NAT MED, V7, P123, DOI 10.1038/83263; Kim KS, 1996, FEBS LETT, V395, P277, DOI 10.1016/0014-5793(96)01024-1; Kuschert GSV, 1999, BIOCHEMISTRY-US, V38, P12959, DOI 10.1021/bi990711d; Lau EK, 2004, J BIOL CHEM, V279, P22294, DOI 10.1074/jbc.M311224200; Lever R, 2002, NAT REV DRUG DISCOV, V1, P140, DOI 10.1038/nrd724; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; Linhardt RJ, 2004, ACCOUNTS CHEM RES, V37, P431, DOI 10.1021/ar030138x; Loo JA, 1997, MASS SPECTROM REV, V16, P1; Lu DS, 1999, J MOL BIOL, V292, P361, DOI 10.1006/jmbi.1999.3089; PAOLINI JF, 1994, J IMMUNOL, V153, P2704; Powell AK, 2004, GLYCOBIOLOGY, V14, p17R, DOI 10.1093/glycob/cwh051; Power CA, 2003, J IMMUNOL METHODS, V273, P73, DOI 10.1016/S0022-1759(02)00419-2; Proudfoot AEI, 2003, P NATL ACAD SCI USA, V100, P1885, DOI 10.1073/pnas.0334864100; Proudfoot AEI, 2003, SEMIN IMMUNOL, V15, P57, DOI 10.1016/S1044-5323(02)00128-8; Proudfoot AEI, 2002, NAT REV IMMUNOL, V2, P106, DOI 10.1038/nri722; ROT A, 1993, EUR J IMMUNOL, V23, P303, DOI 10.1002/eji.1830230150; Saad OM, 2004, J AM SOC MASS SPECTR, V15, P1274, DOI 10.1016/j.jasms.2004.05.008; Smith AW, 1997, SCAND AUDIOL, V26, P11; Sobott F, 2002, CURR OPIN STRUC BIOL, V12, P729, DOI 10.1016/S0959-440X(02)00400-1; Tully SE, 2004, J AM CHEM SOC, V126, P7736, DOI 10.1021/ja0484045; Wieboldt R, 1997, ANAL CHEM, V69, P1683, DOI 10.1021/ac9610265; Yu YH, 2004, J AM SOC MASS SPECTR, V15, P1400, DOI 10.1016/j.jasms.2004.06.002; ZUBAREV RA, 1995, ANAL CHEM, V67, P3793, DOI 10.1021/ac00116a028	41	79	79	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32200	32208		10.1074/jbc.M505738200	http://dx.doi.org/10.1074/jbc.M505738200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16033763	hybrid			2022-12-25	WOS:000231794800021
J	Gapuzan, MER; Schmah, O; Pollock, AD; Hoffmann, A; Gilmore, TD				Gapuzan, MER; Schmah, O; Pollock, AD; Hoffmann, A; Gilmore, TD			Immortalized fibroblasts from NF-kappa B RelA knockout mice show phenotypic heterogeneity and maintain increased sensitivity to tumor necrosis factor alpha after transformation by v-Ras	ONCOGENE			English	Article						RelA; NF-kappa B; Ras; malignant transformation; mouse knockout cells; tumor necrosis factor	CELLULAR-TRANSFORMATION; MEDIATED TRANSFORMATION; EMBRYONIC LETHALITY; INCREASED APOPTOSIS; ONCOGENIC RAS; C-MYC; ACTIVATION; P53; MOUSE; SUPPRESSOR	Activation of the NF-kappa B pathway can either promote or block apoptosis and oncogenesis in different cell types and circumstances. In this report, we show that independently derived immortalized mouse embryonic fibroblast cell lines prepared from RelA knockout mice have different phenotypes, based on their sensitivity to tumor necrosis factor alpha (TNF alpha)-induced apoptosis, morphology, ability to form colonies in soft agar, and the presence of distinct kappa B site-binding complexes. In addition, these RelA-deficient cell lines appear to have distinct alterations in the p53 pathway, which correlate with the normal vs transformed status of individual cell lines. We have also infected mouse embryonic fibroblasts lacking RelA, c-Rel or p50 with a retrovirus for the expression of v-Ha-Ras to determine whether individual NF-kappa B family members are required for Ras-mediated transformation. All three NF-kappa B-deficient cell types could be transformed by v-Ha-Ras. However, v-Ras-infected RelA-deficient cells formed colonies in soft agar at an approximately fourfold reduced efficiency compared to v-Ras-transformed control mouse 3T3 and p50-deficient cells. Ras transformation did not alter the sensitivity of RelA-deficient cells to TNF alpha-induced apoptosis, and Ras transformation did not affect the general resistance of 3T3, c-Rel-deficient, and p50-deficient cells to TNF alpha-induced apoptosis. However, TNF alpha specifically and dose-dependently decreased the ability of v-Ras-transformed RelA-deficient cells to form colonies in soft agar. These results suggest that RelA is a potential protein target for human tumors driven by oncogenic Ras mutations, but caution that inhibition of RelA may promote tumorigenesis in some circumstances.	Boston Univ, Dept Biol, Boston, MA 02215 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	Boston University; University of California System; University of California San Diego	Gilmore, TD (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.	gilmore@bu.edu			NATIONAL CANCER INSTITUTE [R29CA047763, R01CA047763] Funding Source: NIH RePORTER; NCI NIH HHS [CA47763] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1968, J CELL PHYSIOL, V72, P141, DOI 10.1002/jcp.1040720208; Aguilera C, 2004, P NATL ACAD SCI USA, V101, P16537, DOI 10.1073/pnas.0404429101; Alarcon-Vargas D, 2002, CARCINOGENESIS, V23, P541, DOI 10.1093/carcin/23.4.541; Alcamo E, 2001, J IMMUNOL, V167, P1592, DOI 10.4049/jimmunol.167.3.1592; Ayrault O, 2004, ONCOGENE, V23, P8097, DOI 10.1038/sj.onc.1207968; Baldwin AS, 2003, NUCLEAR FACTOR KB: REGULATION AND ROLE IN DISEASE, P393; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chang NS, 2002, J BIOL CHEM, V277, P10323, DOI 10.1074/jbc.M106607200; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; Deng JO, 2002, CANCER CELL, V2, P323, DOI 10.1016/S1535-6108(02)00154-X; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; Doi TS, 1999, P NATL ACAD SCI USA, V96, P2994, DOI 10.1073/pnas.96.6.2994; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; FERNANDEZ A, 1994, ONCOGENE, V9, P2009; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; FINCO TS, 1993, J BIOL CHEM, V268, P17676; Gapuzan MER, 2002, ONCOGENE, V21, P2484, DOI 10.1038/sj.onc.1205333; Gilmore TD, 2004, ONCOGENE, V23, P2275, DOI 10.1038/sj.onc.1207410; Hanson JL, 2004, CANCER RES, V64, P7248, DOI 10.1158/0008-5472.CAN-03-3898; Hanson JL, 2003, J BIOL CHEM, V278, P34910, DOI 10.1074/jbc.M304189200; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hoffmann A, 2003, EMBO J, V22, P5530, DOI 10.1093/emboj/cdg534; Jeay S, 2003, MOL CELL BIOL, V23, P2251, DOI 10.1128/MCB.23.7.2251-2263.2003; Jol H, 2000, ONCOGENE, V19, P841, DOI 10.1038/sj.onc.1203392; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; Li JN, 2003, BIOCHEMISTRY-US, V42, P13476, DOI 10.1021/bi035390r; Loop T, 2003, NUCLEAR FACTOR KB: REGULATION AND ROLE IN DISEASE, P1; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Lundberg AS, 2000, CURR OPIN CELL BIOL, V12, P705, DOI 10.1016/S0955-0674(00)00155-1; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Mayo MW, 2001, METHOD ENZYMOL, V333, P73; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Pando MP, 2000, J BIOL CHEM, V275, P21278, DOI 10.1074/jbc.M002532200; Qi Y, 2004, NATURE, V431, P712, DOI 10.1038/nature02958; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Rocha S, 2003, MOL CELL, V12, P15, DOI 10.1016/S1097-2765(03)00223-5; Rocha S, 2005, EMBO J, V24, P1157, DOI 10.1038/sj.emboj.7600608; Rosenfeld ME, 2000, AM J PATHOL, V156, P997, DOI 10.1016/S0002-9440(10)64967-X; Sigal A, 2000, CANCER RES, V60, P6788; Suzuki J, 2004, ONCOGENE, V23, P8527, DOI 10.1038/sj.onc.1207894; Tergaonkar V, 2002, CANCER CELL, V1, P493, DOI 10.1016/S1535-6108(02)00068-5; VAN AD, 1996, SCIENCE, V274, P787; van Hogerlinden M, 1999, CANCER RES, V59, P3299; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Zhang JY, 2004, GENE DEV, V18, P17, DOI 10.1101/gad.1160904; Zhou MX, 2003, ONCOGENE, V22, P8137, DOI 10.1038/sj.onc.1206911; Zong WX, 1998, CELL DEATH DIFFER, V5, P963, DOI 10.1038/sj.cdd.4400441	51	37	37	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	43					6574	6583		10.1038/sj.onc.1208809	http://dx.doi.org/10.1038/sj.onc.1208809			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	968ZV	16027734				2022-12-25	WOS:000232204100011
J	Smakman, N; Veenendaal, LM; van Diest, P; Bos, R; Offringa, R; Rinkes, IHMB; Kranenburg, O				Smakman, N; Veenendaal, LM; van Diest, P; Bos, R; Offringa, R; Rinkes, IHMB; Kranenburg, O			Dual effect of Kras(D12) knockdown on tumorigenesis: increased immune-mediated tumor clearance and abrogation of tumor malignancy	ONCOGENE			English	Article						Ras; interleukin-18; colorectal; immune-evasion; malignancy	KIRSTEN RAS MUTATIONS; COLORECTAL-CANCER; RNA INTERFERENCE; KI-RAS; COLON; GENE; INTERLEUKIN-18; CELLS; EXPRESSION; INDUCTION	Activating mutations in the human KRAS proto-oncogene are acquired during the earliest stages of colorectal cancer development. If mutant KRAS is to be used as a target for therapy in colorectal cancer, tumor growth should depend on its continued presence. Here, we report that stable knockdown of Kras(D12) in murine C26 colorectal cancer cells by RN A interference resulted in loss of transformed properties in vitro. The incidence of subcutaneous tumor formation was reduced by 60% and the lag time was increased sevenfold. Kras(D12)-knockdown tumors grew noninvasively and did not cause morbidity. Remarkably, some of the Kras(D12)-knockdown tumors regressed spontaneously, which rendered these mice resistant to parental C26 tumor growth. In immune-deficient hosts, the incidence of tumor formation by Kras(D12)-knockdown cells was 100%. None of these tumors regressed spontaneously. We conclude that the reduced incidence of tumor formation by Kras(D12)-knockdown cells is due to tumor cell clearance by the host immune system, but not to an intrinsic inability of these cells to grow out as tumors. Interestingly, Kras(D12) knockdown resulted in increased production of interleukin 18 (Il-18), an immune-stimulatory cytokine that has been implicated in limiting colorectal tumor formation. Thus, mutant Kras(D12) suppresses Il-18 production in colorectal tumor cells, which may contribute to evasion of the local immune system during tumor development.	Univ Utrecht, Med Ctr, Dept Surg, NL-3508 GA Utrecht, Netherlands; Univ Utrecht, Med Ctr, Dept Pathol, NL-3508 GA Utrecht, Netherlands; Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, Tumor Immunol Grp, NL-2333 ZA Leiden, Netherlands	Utrecht University; Utrecht University; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Kranenburg, O (corresponding author), Univ Utrecht, Med Ctr, Dept Surg, POB 85500, NL-3508 GA Utrecht, Netherlands.	o.kranenburg@azu.nl	Kranenburg, Onno/K-4115-2015	Kranenburg, Onno/0000-0002-2112-4390				Andreyev HJN, 2001, BRIT J CANCER, V85, P692, DOI 10.1054/bjoc.2001.1964; Andreyev HJN, 1998, J NATL CANCER I, V90, P675, DOI 10.1093/jnci/90.9.675; BROWN K, 1990, P NATL ACAD SCI USA, V87, P538, DOI 10.1073/pnas.87.2.538; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Campbell I, 2000, CANCER GENE THER, V7, P37, DOI 10.1038/sj.cgt.7700116; Carlotti F, 2004, MOL THER, V9, P209, DOI 10.1016/j.ymthe.2003.11.021; CORBETT TH, 1975, CANCER RES, V35, P2434; FEARON ER, 1988, CANCER RES, V48, P2975; FEARON ER, 1990, CELL, V60, P397, DOI 10.1016/0092-8674(90)90591-2; GRISWOLD DP, 1975, CANCER, V36, P2441, DOI 10.1002/1097-0142(197512)36:6<2441::AID-CNCR2820360627>3.0.CO;2-P; Kranenburg O, 2001, CURR BIOL, V11, P1880, DOI 10.1016/S0960-9822(01)00582-6; Leng JH, 2003, CHINESE MED J-PEKING, V116, P1475; Pages F, 1999, INT J CANCER, V84, P326, DOI 10.1002/(SICI)1097-0215(19990621)84:3<326::AID-IJC22>3.0.CO;2-K; Pages F, 2000, IMMUNOL LETT, V75, P9, DOI 10.1016/S0165-2478(00)00285-6; Plattner R, 1996, P NATL ACAD SCI USA, V93, P6665, DOI 10.1073/pnas.93.13.6665; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Samowitz WS, 2000, CANCER EPIDEM BIOMAR, V9, P1193; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Velde EAT, 2002, BRIT J SURG, V89, P1302, DOI 10.1046/j.1365-2168.2002.02183.x; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	20	30	37	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2005	24	56					8338	8342		10.1038/sj.onc.1208995	http://dx.doi.org/10.1038/sj.onc.1208995			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	993LV	16091732				2022-12-25	WOS:000233956500012
J	An, S; Musier-Forsyth, K				An, S; Musier-Forsyth, K			Cys-tRNA(Pro) editing by Haemophilus influenzae YbaK via a novel synthetase center dot YbaK center dot tRNA ternary complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOACYL-TRANSFER-RNA; ELONGATION-FACTOR-TU; ESCHERICHIA-COLI; PROTEIN-SYNTHESIS; CROSS-LINKING; INSERTION DOMAIN; IN-VITRO; BINDING; RECOGNITION; ISOLEUCINE	Aminoacyl-tRNA synthetases are multidomain enzymes that often possess two activities to ensure translational accuracy. A synthetic active site catalyzes tRNA aminoacylation, while an editing active site hydrolyzes mischarged tRNAs. Prolyl-tRNA synthetases (ProRS) have been shown to misacylate Cys onto tRNA(Pro), but lack a Cys-specific editing function. The synthetase-like Haemophilus influenzae YbaK protein was recently shown to hydrolyze misacylated Cys-tRNA(Pro) in trans. However, the mechanism of specific substrate selection by this single domain hydrolase is unknown. Here, we demonstrate that YbaK alone appears to lack specific tRNA recognition capabilities. Moreover, YbaK cannot compete for aminoacyl-tRNAs in the presence of elongation factor Tu, suggesting that YbaK acts before release of the aminoacyl-tRNA from the synthetase. In support of this idea, cross-linking studies reveal the formation of binary ( ProRS center dot YbaK) and ternary ( ProRS center dot YbaK center dot tRNA) complexes. The binding constants for the interaction between ProRS and YbaK are 550 nM and 45 nM in the absence and presence of tRNA(Pro), respectively. These results suggest that the specificity of trans-editing by YbaK is ensured through formation of a novel ProRS center dot YbaK center dot tRNA complex.	Univ Minnesota, Dept Chem, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Musier-Forsyth, K (corresponding author), Univ Minnesota, Dept Chem, 207 Pleasant St SE, Minneapolis, MN 55455 USA.	musier@chem.umn.edu	An, Songon/A-6714-2009	An, Songon/0000-0003-2189-7374	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049928, R29GM049928, R55GM049928] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49928] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahel I, 2003, P NATL ACAD SCI USA, V100, P15422, DOI 10.1073/pnas.2136934100; Ahel I, 2002, J BIOL CHEM, V277, P34743, DOI 10.1074/jbc.M206928200; Ambrogelly A, 2002, J BIOL CHEM, V277, P34749, DOI 10.1074/jbc.M206929200; Amini F, 2003, CHEM BIOL, V10, P1115, DOI 10.1016/j.chembiol.2003.11.001; ARAI KI, 1972, J BIOL CHEM, V247, P7029; BALDWIN AN, 1966, J BIOL CHEM, V241, P839; Beebe K, 2004, P NATL ACAD SCI USA, V101, P5958, DOI 10.1073/pnas.0401530101; Beebe K, 2003, EMBO J, V22, P668, DOI 10.1093/emboj/cdg065; Beuning PJ, 2000, P NATL ACAD SCI USA, V97, P8916, DOI 10.1073/pnas.97.16.8916; Beuning PJ, 2001, J BIOL CHEM, V276, P30779, DOI 10.1074/jbc.M104761200; Beuning PJ, 1997, J AM CHEM SOC, V119, P8397, DOI 10.1021/ja971020c; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Campanacci V, 2004, J MOL BIOL, V337, P273, DOI 10.1016/j.jmb.2004.01.027; Chen JF, 2000, BIOCHEMISTRY-US, V39, P6726, DOI 10.1021/bi000108r; Christian T, 2000, J MOL BIOL, V303, P503, DOI 10.1006/jmbi.2000.4169; DELARUE M, 1993, BIOESSAYS, V15, P675, DOI 10.1002/bies.950151007; Dock-Bregeon AC, 2000, CELL, V103, P877, DOI 10.1016/S0092-8674(00)00191-4; ELDRED EW, 1972, J BIOL CHEM, V247, P2961; ENGLISCH S, 1986, NUCLEIC ACIDS RES, V14, P7529, DOI 10.1093/nar/14.19.7529; Fancy DA, 1999, P NATL ACAD SCI USA, V96, P6020, DOI 10.1073/pnas.96.11.6020; Fersht AR, 1998, SCIENCE, V280, P541, DOI 10.1126/science.280.5363.541; FERSHT AR, 1975, BIOCHEMISTRY-US, V14, P1, DOI 10.1021/bi00672a001; FERSHT AR, 1979, BIOCHEMISTRY-US, V18, P2627, DOI 10.1021/bi00579a030; GANOZA MC, 1995, J BIOL CHEM, V270, P26377, DOI 10.1074/jbc.270.44.26377; Geslain R, 2004, TRENDS GENET, V20, P604, DOI 10.1016/j.tig.2004.09.012; Gruic-Sovulj I, 2005, J BIOL CHEM, V280, P23978, DOI 10.1074/jbc.M414260200; Heacock D, 1996, BIOORG CHEM, V24, P273, DOI 10.1006/bioo.1996.0025; Hendrickson TL, 2003, MOL B INT U, P34; HOPFIELD JJ, 1976, P NATL ACAD SCI USA, V73, P1164, DOI 10.1073/pnas.73.4.1164; HOU YM, 1993, P NATL ACAD SCI USA, V90, P6776, DOI 10.1073/pnas.90.14.6776; JAKUBOWSKI H, 1994, NUCLEIC ACIDS RES, V22, P1155, DOI 10.1093/nar/22.7.1155; JASIN M, 1983, NATURE, V306, P441, DOI 10.1038/306441a0; Korencic D, 2004, P NATL ACAD SCI USA, V101, P10260, DOI 10.1073/pnas.0403926101; Kurbanyan K, 2003, BIOCHEMISTRY-US, V42, P10269, DOI 10.1021/bi020713p; LaRiviere FJ, 2001, SCIENCE, V294, P165, DOI 10.1126/science.1064242; Lin L, 1996, NATURE, V384, P33, DOI 10.1038/384033b0; Lipman RSA, 2002, J MOL BIOL, V315, P943, DOI 10.1006/jmbi.2001.5297; Lipman RSA, 2002, J MOL BIOL, V316, P421, DOI 10.1006/jmbi.2001.5373; LIU HJ, 1995, NUCLEIC ACIDS RES, V23, P165, DOI 10.1093/nar/23.1.165; LIU HJ, 1994, BIOCHEMISTRY-US, V33, P12708, DOI 10.1021/bi00208a023; Lundblad JR, 1996, MOL ENDOCRINOL, V10, P607, DOI 10.1210/me.10.6.607; MCCLAIN WH, 1994, NUCLEIC ACIDS RES, V22, P522, DOI 10.1093/nar/22.3.522; MULLER B, 1991, BIOCHEMISTRY-US, V30, P3709, DOI 10.1021/bi00229a017; Mursinna RS, 2001, BIOCHEMISTRY-US, V40, P5376, DOI 10.1021/bi002915w; MUSIERFORSYTH K, 1991, P NATL ACAD SCI USA, V88, P209, DOI 10.1073/pnas.88.1.209; NAZARENKO IA, 1995, BIOCHEMISTRY-US, V34, P2545, DOI 10.1021/bi00008a019; NEGRUTSKII BS, 1991, P NATL ACAD SCI USA, V88, P4991, DOI 10.1073/pnas.88.11.4991; PARMEGGIANI A, 1981, MOL CELL BIOCHEM, V35, P129, DOI 10.1007/BF02357085; Petrushenko ZM, 2002, EUR J BIOCHEM, V269, P4811, DOI 10.1046/j.1432-1033.2002.03178.x; Pleiss JA, 2001, J MOL BIOL, V308, P895, DOI 10.1006/jmbi.2001.4612; Reid SL, 2001, BIOCHEMISTRY-US, V40, P2484, DOI 10.1021/bi001956p; Roy H, 2004, EMBO J, V23, P4639, DOI 10.1038/sj.emboj.7600474; Ruan BF, 2005, J BIOL CHEM, V280, P25887, DOI 10.1074/jbc.M502174200; Sankaranarayanan R, 2000, NAT STRUCT BIOL, V7, P461; Schimmel P, 2000, TRENDS BIOCHEM SCI, V25, P207, DOI 10.1016/S0968-0004(00)01553-X; SCHIMMEL P, 1995, CELL, V81, P983, DOI 10.1016/S0092-8674(05)80002-9; SCHMIDT E, 1995, BIOCHEMISTRY-US, V34, P11204, DOI 10.1021/bi00035a028; STARZYK RM, 1987, SCIENCE, V237, P1614, DOI 10.1126/science.3306924; STEINBERG S, 1993, NUCLEIC ACIDS RES, V21, P3011, DOI 10.1093/nar/21.13.3011; TSUI WC, 1981, NUCLEIC ACIDS RES, V9, P4627, DOI 10.1093/nar/9.18.4627; Wong FC, 2003, J BIOL CHEM, V278, P52857, DOI 10.1074/jbc.M309627200; Wong FC, 2002, BIOCHEMISTRY-US, V41, P7108, DOI 10.1021/bi012178j; Zhang H, 2000, PROTEINS, V40, P86, DOI 10.1002/(SICI)1097-0134(20000701)40:1<86::AID-PROT100>3.0.CO;2-Y; Zuurmond AM, 2000, J MOL BIOL, V304, P995, DOI 10.1006/jmbi.2000.4260	64	60	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34465	34472		10.1074/jbc.M507550200	http://dx.doi.org/10.1074/jbc.M507550200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16087664	hybrid			2022-12-25	WOS:000232403900013
J	Baldini, G; Martelli, AM; Tabellini, G; Horn, C; Machaca, K; Narducci, P; Baldini, G				Baldini, G; Martelli, AM; Tabellini, G; Horn, C; Machaca, K; Narducci, P; Baldini, G			Rabphilin localizes with the cell actin cytoskeleton and stimulates association of granules with F-actin cross-linked by alpha-actinin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PC12 NEUROENDOCRINE CELLS; INSULIN-SECRETING CELLS; SMALL SYNAPTIC VESICLES; RAB3 EFFECTOR PROTEIN; DENSE-CORE VESICLES; REGULATED EXOCYTOSIS; CHROMAFFIN CELLS; PLASMA-MEMBRANE; BINDING-PROTEIN; NEUROTRANSMITTER RELEASE	In endocrine cell, granules accumulate within an F-actin-rich region below the plasma membrane. The mechanisms involved in this process are largely unknown. Rabphilin is a cytosolic protein that is expressed in neurons and neuroendocrine cells and binds with high affinity to members of the Rab3 family of GTPases localized to synaptic vesicles and dense core granules. Rabphilin also interacts with alpha-actinin, a protein that cross-links F-actin into bundles and networks and associates with the granule membrane. Here we asked whether rabphilin, in addition to its granule localization, also interacts with the cell actin cytoskeleton. Immunofluorescence and immunoelectron microscopy show that rabphilin localizes to the sub-plasmalemmal actin cytoskeleton both in neuroendocrine and unspecialized cells. By using purified components, it is found that association of rabphilin with F-actin is dependent on added alpha-actinin. In an in vitro assay, granules, unlike endosomes or mitochondria, associate with F-actin cross-linked by alpha-actinin. Rabphilin is shown to stimulate this process. Rabphilin enhances by similar to 8-fold the granule ability to localize within regions of elevated concentration of cross-linked F-actin. These results suggest that rabphilin, by interacting with alpha-actinin, organizes the cell cytoskeleton to facilitate granule localization within F-actin-rich regions.	Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Physiol & Biophys, Little Rock, AR 72205 USA; Univ Trieste, Dipartimento Morfol Umana Normale, I-34138 Trieste, Italy; Univ Bologna, Dipartimento Sci Anat Umane & Fisiopatol Apparato, Sez Anat, Cell Signaling Lab, I-40126 Bologna, Italy; IOR, Ist Trapianti Organo & Immunocitol, CNR, Sez Bologna, I-40136 Bologna, Italy; Univ Brescia, Dipartimento Sci Biomed & Biotecnol, Sez Citol & Istol, I-25123 Brescia, Italy	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Trieste; University of Bologna; Consiglio Nazionale delle Ricerche (CNR); University of Brescia	Baldini, G (corresponding author), Univ Arkansas Med Sci, Dept Biochem & Mol Biol, 4301 W Markham St,Slot 516, Little Rock, AR 72205 USA.	gbaldini@uams.edu	Machaca, Khaled/AAF-3579-2019	Machaca, Khaled/0000-0001-6215-2411	NIDDK NIH HHS [R01-DK53293] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053293] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arribas M, 1997, EUR J CELL BIOL, V74, P209; Bader MF, 2004, BBA-MOL CELL RES, V1742, P37, DOI 10.1016/j.bbamcr.2004.09.028; BADER MF, 1983, NEUROSCIENCE, V8, P165, DOI 10.1016/0306-4522(83)90036-2; Baldini G, 1998, J CELL BIOL, V140, P305, DOI 10.1083/jcb.140.2.305; BENFENATI F, 1992, NEURON, V8, P377, DOI 10.1016/0896-6273(92)90303-U; Cheviet S, 2004, TRENDS CELL BIOL, V14, P525, DOI 10.1016/j.tcb.2004.08.001; Chung SH, 1999, J BIOL CHEM, V274, P18113, DOI 10.1074/jbc.274.25.18113; CHUNG SH, 1995, J BIOL CHEM, V270, P16714, DOI 10.1074/jbc.270.28.16714; Coghill ID, 2003, J BIOL CHEM, V278, P24139, DOI 10.1074/jbc.M213259200; Coppola T, 2001, J CELL SCI, V114, P1757; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; DARCHEN F, 1995, J CELL SCI, V108, P1639; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; Djinovic-Carugo K, 1999, CELL, V98, P537, DOI 10.1016/S0092-8674(00)81981-9; Fukuda M, 2004, J BIOL CHEM, V279, P13065, DOI 10.1074/jbc.M306812200; Fukuda M, 2005, J BIOCHEM, V137, P9, DOI 10.1093/jb/mvi002; Gasman S, 2004, MOL BIOL CELL, V15, P520, DOI 10.1091/mbc.E03-06-0402; GEPPERT M, 1994, NATURE, V369, P493, DOI 10.1038/369493a0; Giovedi S, 2004, J BIOL CHEM, V279, P43769, DOI 10.1074/jbc.M404168200; Giovedi S, 2004, J BIOL CHEM, V279, P43760, DOI 10.1074/jbc.M403293200; Gonzalez L, 1999, CELL, V96, P755, DOI 10.1016/S0092-8674(00)80585-1; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; Haynes LP, 2001, J BIOL CHEM, V276, P9726, DOI 10.1074/jbc.M006959200; Iezzi M, 1999, MOL ENDOCRINOL, V13, P202, DOI 10.1210/me.13.2.202; Joberty G, 1999, J CELL SCI, V112, P3579; JOCKUSH BM, 1977, NATURE, V270, P628, DOI 10.1038/270628a0; Johns LM, 2001, J CELL BIOL, V153, P177, DOI 10.1083/jcb.153.1.177; Kato M, 1996, J BIOL CHEM, V271, P31775, DOI 10.1074/jbc.271.50.31775; Koticha DK, 2002, J CELL SCI, V115, P3341; Lang T, 2000, BIOPHYS J, V78, P2863, DOI 10.1016/S0006-3495(00)76828-7; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; Manabe S, 2004, BIOCHEM BIOPH RES CO, V316, P218, DOI 10.1016/j.bbrc.2004.02.026; Martelli AM, 2000, TRAFFIC, V1, P976, DOI 10.1034/j.1600-0854.2000.011207.x; MARTYS JL, 1995, J BIOL CHEM, V270, P25976, DOI 10.1074/jbc.270.43.25976; McKiernan CJ, 1996, MOL CELL BIOL, V16, P4985; MIZOGUCHI A, 1994, BIOCHEM BIOPH RES CO, V202, P1235, DOI 10.1006/bbrc.1994.2063; Nakano K, 2002, J CELL SCI, V115, P4629, DOI 10.1242/jcs.00150; NAKATA T, 1992, J NEUROSCI, V12, P2186; NOEL G, 1989, J NEUROCHEM, V52, P1050, DOI 10.1111/j.1471-4159.1989.tb01846.x; Nonet ML, 1997, J NEUROSCI, V17, P8061; Ostermeier C, 1999, CELL, V96, P363, DOI 10.1016/S0092-8674(00)80549-8; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; Otey CA, 2004, CELL MOTIL CYTOSKEL, V58, P104, DOI 10.1002/cm.20007; Pelletier O, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.148102; RIBONI L, 1995, J BIOL CHEM, V270, P26868, DOI 10.1074/jbc.270.45.26868; Rudolf R, 2001, MOL BIOL CELL, V12, P1353, DOI 10.1091/mbc.12.5.1353; Schluter OM, 1999, J NEUROSCI, V19, P5834, DOI 10.1523/JNEUROSCI.19-14-05834.1999; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; Stahl B, 1996, EMBO J, V15, P1799, DOI 10.1002/j.1460-2075.1996.tb00529.x; Staunton J, 2001, J NEUROSCI, V21, P9255, DOI 10.1523/JNEUROSCI.21-23-09255.2001; Sunshine C, 2000, EXP CELL RES, V257, P1, DOI 10.1006/excr.2000.4855; Ubach J, 1999, NAT CELL BIOL, V1, P106, DOI 10.1038/10076; WACHSSTOCK DH, 1987, BIOCHEM BIOPH RES CO, V146, P554, DOI 10.1016/0006-291X(87)90564-X; Waselle L, 2003, MOL BIOL CELL, V14, P4103, DOI 10.1091/mbc.E03-01-0022; Weber E, 1996, J BIOL CHEM, V271, P6963, DOI 10.1074/jbc.271.12.6963; Wyszynski M, 1997, NATURE, V385, P439, DOI 10.1038/385439a0; YAMAGUCHI T, 1993, J BIOL CHEM, V268, P27164; Zhao SL, 2002, ENDOCRINOLOGY, V143, P1817, DOI 10.1210/en.143.5.1817	59	15	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34974	34984		10.1074/jbc.M502695200	http://dx.doi.org/10.1074/jbc.M502695200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16043482	hybrid			2022-12-25	WOS:000232403900071
J	Ling, C; Yao, YN; Zheng, YG; Wei, H; Wang, L; Wu, XF; Wang, ED				Ling, C; Yao, YN; Zheng, YG; Wei, H; Wang, L; Wu, XF; Wang, ED			The C-terminal appended domain of human cytosolic leucyl-tRNA synthetase is indispensable in its interaction with arginyl-tRNA synthetase in the multi-tRNA synthetase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOACYL-TRANSFER-RNA; PROTEIN-PROTEIN INTERACTIONS; ESCHERICHIA-COLI; RAT-LIVER; MACROMOLECULAR ASSEMBLAGE; ACCELERATED PUBLICATION; STRUCTURAL-ANALYSIS; BINDING DOMAIN; COILED-COIL; IN-VITRO	Human cytosolic leucyl-tRNA synthetase is one component of a macromolecular aminoacyl-tRNA synthetase complex. This is unlike prokaryotic and lower eukaryotic LeuRSs that exist as free soluble enzymes. There is little known about it, since the purified enzyme has been unavailable. Herein, human cytosolic leucyl-tRNA synthetase was heterologously expressed in a baculovirus system and purified to homogeneity. The molecular mass ( 135 kDa) of the enzyme is close to the theoretical value derived from its cDNA. The kinetic constants of the enzyme for ATP, leucine, and tRNALeu in the ATP-PPi exchange and tRNA leucylation reactions were determined, and the results showed that it is quite active as a free enzyme. Humancytosolic leucyl-tRNA synthetase expressed in human 293 T cells localizes predominantly to the cytosol. Additionally, it is found to have a long C-terminal extension that is absent from bacterial and yeast LeuRSs. A C-terminal 89-amino acid truncated human cytosolic leucyl-tRNA synthetase was constructed and purified, and the catalytic activities, thermal stability, and subcellular location were found to be almost identical to native enzyme. In vivo and in vitro experiments, however, show that the C-terminal extension of human cytosolic leucyl-tRNA synthetase is indispensable for its interaction with the N-terminal of human cytosolic arginyl-tRNA synthetase in the macromolecular complex. Our results also indicate that the two molecules interact with each other only through their appended domains.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, State Key Lab Mol Biol, Shanghai 200031, Peoples R China; Chinese Acad Sci, Grad Sch, Shanghai 200031, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences	Wang, ED (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, State Key Lab Mol Biol, Shanghai 200031, Peoples R China.	edwang@sibs.ac.cn	Zheng, Yonggang/B-5009-2011					Agou F, 1996, J BIOL CHEM, V271, P29295, DOI 10.1074/jbc.271.46.29295; Ahn HC, 2003, FEBS LETT, V542, P119, DOI 10.1016/S0014-5793(03)00362-4; CIRAKOGLU B, 1985, EUR J BIOCHEM, V151, P101, DOI 10.1111/j.1432-1033.1985.tb09074.x; DANG CV, 1979, J BIOL CHEM, V254, P5350; DEUTSCHER MP, 1982, J BIOL CHEM, V257, P6003; DEUTSCHER MP, 1984, J CELL BIOL, V99, P373, DOI 10.1083/jcb.99.2.373; DIETRICH A, 1983, J BIOL CHEM, V258, P2386; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; ESCALANTE C, 1994, MOL CELL BIOCHEM, V140, P55, DOI 10.1007/BF00928366; ESCALANTE C, 1993, J BIOL CHEM, V268, P6014; FILONENKO VV, 1994, J BIOL CHEM, V269, P17375; Francin M, 2003, J BIOL CHEM, V278, P1472, DOI 10.1074/jbc.M208802200; Francin M, 2002, J BIOL CHEM, V277, P1762, DOI 10.1074/jbc.M109759200; Gill SK, 2003, J BIOL CHEM, V278, P20217, DOI 10.1074/jbc.M213153200; Graindorge JS, 2005, BIOCHEMISTRY-US, V44, P1344, DOI 10.1021/bi049024z; Guigou L, 2004, BIOCHEMISTRY-US, V43, P4592, DOI 10.1021/bi036150e; Han JM, 2003, BIOCHEM BIOPH RES CO, V303, P985, DOI 10.1016/S0006-291X(03)00485-6; Ibba M, 2000, ANNU REV BIOCHEM, V69, P617, DOI 10.1146/annurev.biochem.69.1.617; JOHNSON DL, 1980, J BIOL CHEM, V255, P4362; Jorgensen R, 2000, J BIOL CHEM, V275, P16820, DOI 10.1074/jbc.275.22.16820; Kaminska M, 2001, BIOCHEMISTRY-US, V40, P14309, DOI 10.1021/bi015670b; KERN D, 1981, BIOCHIM BIOPHYS ACTA, V653, P83, DOI 10.1016/0005-2787(81)90106-4; Kim T, 2000, J BIOL CHEM, V275, P21768, DOI 10.1074/jbc.M002404200; Ko YG, 2000, J CELL BIOL, V149, P567, DOI 10.1083/jcb.149.3.567; Kost TA, 2002, TRENDS BIOTECHNOL, V20, P173, DOI 10.1016/S0167-7799(01)01911-4; Li T, 1999, BIOCHEMISTRY-US, V38, P13063, DOI 10.1021/bi990384+; Li Y, 1998, SCI CHINA SER C, V41, P225, DOI 10.1007/BF02895095; MURAMATSU T, 1992, NUCLEOS NUCLEOT NUCL, V11, P719, DOI 10.1080/07328319208021736; Nagase T, 2000, DNA RES, V7, P65, DOI 10.1093/dnares/7.1.65; Nathanson L, 2000, J BIOL CHEM, V275, P31559, DOI 10.1074/jbc.C000385200; Negrutskii BS, 1999, J BIOL CHEM, V274, P4545, DOI 10.1074/jbc.274.8.4545; NORCUM MT, 1989, J BIOL CHEM, V264, P15043; Norcum MT, 1998, PROTEIN SCI, V7, P79, DOI 10.1002/pro.5560070108; NORCUM MT, 1991, J BIOL CHEM, V266, P15398; Norcum MT, 2000, J BIOL CHEM, V275, P17921, DOI 10.1074/jbc.C000266200; Pallotti F, 2001, METHOD CELL BIOL, V65, P1, DOI 10.1016/S0091-679X(01)65002-7; Park SG, 1999, J BIOL CHEM, V274, P16673, DOI 10.1074/jbc.274.24.16673; Quevillon S, 1999, J MOL BIOL, V285, P183, DOI 10.1006/jmbi.1998.2316; RABEN N, 1994, J BIOL CHEM, V269, P24277; REED VS, 1994, J BIOL CHEM, V269, P32937; Rho SB, 1996, P NATL ACAD SCI USA, V93, P10128, DOI 10.1073/pnas.93.19.10128; Rho SB, 1999, P NATL ACAD SCI USA, V96, P4488, DOI 10.1073/pnas.96.8.4488; Rho SB, 1998, J BIOL CHEM, V273, P11267, DOI 10.1074/jbc.273.18.11267; Robinson JC, 2000, J MOL BIOL, V304, P983, DOI 10.1006/jmbi.2000.4242; SHIBA K, 1994, J BIOL CHEM, V269, P30049; Shiba K, 1998, NUCLEIC ACIDS RES, V26, P5045, DOI 10.1093/nar/26.22.5045; SHIBA K, 1994, P NATL ACAD SCI USA, V91, P7435, DOI 10.1073/pnas.91.16.7435; SIHAG RK, 1983, J BIOL CHEM, V258, P1846; SYLVERS LA, 1993, BIOCHEMISTRY-US, V32, P3836, DOI 10.1021/bi00066a002; Taanman JW, 1999, BBA-BIOENERGETICS, V1410, P103, DOI 10.1016/S0005-2728(98)00161-3; TAMURA K, 1992, NUCLEIC ACIDS RES, V20, P2335, DOI 10.1093/nar/20.9.2335; Valgardsdottir R, 2001, J BIOL CHEM, V276, P32056, DOI 10.1074/jbc.M011629200; VELLEKAMP G, 1987, J BIOL CHEM, V262, P9927; Wakasugi K, 1999, SCIENCE, V284, P147, DOI 10.1126/science.284.5411.147; Wu H, 1995, BIOCHEMISTRY-US, V34, P16327, DOI 10.1021/bi00050a013; Xu MG, 2002, J BIOL CHEM, V277, P41590, DOI 10.1074/jbc.M205126200; Yang DCH, 1996, CURR TOP CELL REGUL, V34, P101, DOI 10.1016/S0070-2137(96)80004-5; Yao YN, 2003, FEBS LETT, V534, P139, DOI 10.1016/S0014-5793(02)03833-4	58	39	48	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34755	34763		10.1074/jbc.M413511200	http://dx.doi.org/10.1074/jbc.M413511200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16055448	hybrid			2022-12-25	WOS:000232403900047
J	Borucki, B; von Stetten, D; Seibeck, S; Lamparter, T; Michael, N; Mroginski, MA; Otto, H; Murgida, DH; Heyn, MP; Hildebrandt, P				Borucki, B; von Stetten, D; Seibeck, S; Lamparter, T; Michael, N; Mroginski, MA; Otto, H; Murgida, DH; Heyn, MP; Hildebrandt, P			Light-induced proton release of phytochrome is coupled to the transient deprotonation of the tetrapyrrole chromophore	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAMAN; PHOTOTRANSFORMATION; CYANOBACTERIAL; ABSORPTION; KINETICS; SPECTRA; PROTEIN	The P-r-->P-fr phototransformation of the bacteriophytochrome Agp1 from Agrobacterium tumefaciens and the structures of the biliverdin chromophore in the parent states and the cryogenically trapped intermediate Meta-R-C were investigated with resonance Raman spectroscopy and flash photolysis. Strong similarities with the resonance Raman spectra of plant phytochrome A indicate that in Agp1 the methine bridge isomerization state of the chromophore is ZZZasa in P-r and ZZEssa in P-fr, with all pyrrole nitrogens being protonated. Photoexcitation of P-r is followed by ( at least) three thermal relaxation components in the formation of Pfr with time constants of 230 mu s and 3.1 and 260 ms. H2O/D2O exchange reveals kinetic isotope effects of 1.9, 2.6, and 1.3 for the respective transitions that are accompanied by changes of the amplitudes. The second and the third relaxation correspond to the formation and decay of Meta-R-C, respectively. Resonance Raman measurements of Meta-R-C indicate that the chromophore adopts a deprotonated ZZE configuration. Measurements with a pH indicator dye show that formation and decay of Meta-R-C are associated with proton release and uptake, respectively. The stoichiometry of the proton release corresponds to one proton per photoconverted molecule. The coupling of transient chromophore deprotonation and proton release, which is likely to be an essential element in the P-r-->P-fr photoconversion mechanism of phytochromes in general, may play a crucial role for the structural changes in the final step of the Pfr formation that switch between the active and the inactive state of the photoreceptor.	Tech Univ Berlin, Inst Chem, Max Volmer Lab, D-10623 Berlin, Germany; Free Univ Berlin, Fachbereich Phys, Inst Expt Phys, D-14195 Berlin, Germany; Free Univ Berlin, Inst Biol Pflanzenphysiol, D-14195 Berlin, Germany	Technical University of Berlin; Free University of Berlin; Free University of Berlin	Hildebrandt, P (corresponding author), Tech Univ Berlin, Inst Chem, Max Volmer Lab, Sekretariat PC14,Str 17,Juni 135, D-10623 Berlin, Germany.	Hildebrandt@chem.tu-berlin.de	Hildebrandt, Peter/J-5658-2014; Lamparter, Tilman/E-4421-2013; Murgida, Daniel H./F-2350-2018	Hildebrandt, Peter/0000-0003-1030-5900; Lamparter, Tilman/0000-0003-4327-9737; Murgida, Daniel H./0000-0001-5173-0183; von Stetten, David/0000-0001-7906-9788				Andel F, 1996, BIOCHEMISTRY-US, V35, P15997, DOI 10.1021/bi962175k; ARAMENDIA PF, 1987, BIOCHEMISTRY-US, V26, P1418, DOI 10.1021/bi00379a031; Bhoo SH, 2001, NATURE, V414, P776, DOI 10.1038/414776a; Borucki B, 2003, BIOCHEMISTRY-US, V42, P13684, DOI 10.1021/bi035511n; Borucki B, 2002, BIOCHEMISTRY-US, V41, P10026, DOI 10.1021/bi0256227; Borucki B, 1999, J PHYS CHEM B, V103, P6371, DOI 10.1021/jp990679x; EILFELD P, 1985, Z NATURFORSCH C, V40, P109; Foerstendorf H, 2001, BIOCHEMISTRY-US, V40, P14952, DOI 10.1021/bi0156916; HENRY ER, 1992, METHOD ENZYMOL, V210, P129; Heyne K, 2002, BIOPHYS J, V82, P1004, DOI 10.1016/S0006-3495(02)75460-X; Hughes J, 1997, NATURE, V386, P663, DOI 10.1038/386663a0; KENDRICK RE, 1994, PHOTOMORPOGENESIS PL; Kneip C, 1999, BIOCHEMISTRY-US, V38, P15185, DOI 10.1021/bi990688w; Lamparter T, 2004, FEBS LETT, V573, P1, DOI 10.1016/j.febslet.2004.07.050; Lamparter T, 2004, BIOCHEMISTRY-US, V43, P3659, DOI 10.1021/bi035693l; Lamparter T, 2002, P NATL ACAD SCI USA, V99, P11628, DOI 10.1073/pnas.152263999; Matysik J, 1997, J PHARMACEUT BIOMED, V15, P1319, DOI 10.1016/S0731-7085(96)01964-4; MIZUTANI Y, 1994, BIOCHEMISTRY-US, V33, P153, DOI 10.1021/bi00167a020; Mroginski MA, 2004, J AM CHEM SOC, V126, P16734, DOI 10.1021/ja043959l; Quail PH, 2002, NAT REV MOL CELL BIO, V3, P85, DOI 10.1038/nrm728; Remberg A, 1997, BIOCHEMISTRY-US, V36, P13389, DOI 10.1021/bi971563z; RUDIGER W, 1983, P NATL ACAD SCI-BIOL, V80, P6244, DOI 10.1073/pnas.80.20.6244; Schmidt P, 1998, PHOTOCHEM PHOTOBIOL, V68, P754, DOI 10.1111/j.1751-1097.1998.tb02541.x; Song PS, 1999, J BIOCHEM MOL BIOL, V32, P215; van Thor JJ, 2001, BIOCHEMISTRY-US, V40, P11460, DOI 10.1021/bi002651d; Vierstra RD, 2000, SEMIN CELL DEV BIOL, V11, P511, DOI 10.1006/scdb.2000.0206; ZHANG CF, 1992, J AM CHEM SOC, V114, P4569, DOI 10.1021/ja00038a019	27	129	136	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34358	34364		10.1074/jbc.M505493200	http://dx.doi.org/10.1074/jbc.M505493200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16061486	hybrid			2022-12-25	WOS:000232229700079
J	den Hengst, CD; van Hijum, SAFT; Geurts, JMW; Nauta, A; Kok, J; Kuipers, OP				den Hengst, CD; van Hijum, SAFT; Geurts, JMW; Nauta, A; Kok, J; Kuipers, OP			The Lactococcus lactis CodY regulon - Identification of a conserved cis-regulatory element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-ACETOLACTATE DECARBOXYLASE; COMPLETE GENOME SEQUENCE; AMINO-ACID BIOSYNTHESIS; BACILLUS-SUBTILIS; STREPTOCOCCUS-PNEUMONIAE; TRANSCRIPTION INITIATION; NUTRITIONAL REPRESSION; ARGININE METABOLISM; INTRACELLULAR POOL; GENE INACTIVATION	CodY of Lactococcus lactis MG1363 is a transcriptional regulator that represses the expression of several genes encoding proteins of the proteolytic system. DNA microarray analysis, comparing the expression profiles of L. lactis MG1363 and an isogenic strain in which codY was mutated, was used to determine the CodY regulon. In peptide-rich medium and exponentially growing cells, where CodY exerts strong repressing activity, the expression of over 30 genes was significantly increased upon removal of codY. The differentially expressed genes included those predominantly involved in amino acid transport and metabolism. In addition, several genes belonging to other functional categories were derepressed, stressing the pleiotropic role of CodY. Scrutinizing the transcriptome data with bioinformatics tools revealed the presence of a novel overrepresented motif in the upstream regions of several of the genes derepressed in L. lactis MG1363 Delta codY. Evidence is presented that this 15-bp cis-sequence, AATTTTCWGAAAATT, serves as a high affinity binding site for CodY, as shown by electrophoretic mobility shift assays and DNase I footprinting analyses. The presence of this CodY-box is sufficient to evoke CodY-mediated regulation in vivo. A copy of this motif is also present in the upstream region of codY itself. It is shown that CodY regulates its own synthesis and requires the CodY-box and branched-chain amino acids to interact with its promoter.	Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Dept Genet, NL-9751 NN Haren, Netherlands; Friesland Foods Corp Res, NL-7400 AB Deventer, Netherlands	University of Groningen	Kuipers, OP (corresponding author), Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Dept Genet, Kerklaan 30, NL-9751 NN Haren, Netherlands.	O.P.Kuipers@rug.nl	Kok, Jan/C-9972-2012; Kuipers, Oscar/B-6752-2009; van Hijum, Sacha/F-6445-2014	Kuipers, Oscar/0000-0001-5596-7735; van Hijum, Sacha/0000-0003-0741-2991				Baerends RJS, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-5-r37; BAILEY TL, 1994, P 2 INT C INT SYST M, P28; Baldi P, 2001, BIOINFORMATICS, V17, P509, DOI 10.1093/bioinformatics/17.6.509; Bergara F, 2003, J BACTERIOL, V185, P3118, DOI 10.1128/JB.185.10.3118-3126.2003; Bolotin A, 2001, GENOME RES, V11, P731, DOI 10.1101/gr.GR-1697R; Chambellon E, 2003, APPL ENVIRON MICROB, V69, P3061, DOI 10.1128/AEM.69.6.3061-3068.2003; Chaussee MA, 2004, J BACTERIOL, V186, P7091, DOI 10.1128/JB.186.21.7091-7099.2004; CHOPIN A, 1993, FEMS MICROBIOL REV, V12, P21, DOI [10.1111/j.1574-6976.1993.tb00011.x, 10.1016/0168-6445(93)90056-F]; CROW VL, 1982, J BACTERIOL, V150, P1024, DOI 10.1128/JB.150.3.1024-1032.1982; Debarbouille M, 1999, J BACTERIOL, V181, P2059, DOI 10.1128/JB.181.7.2059-2066.1999; DELORME C, 1993, J BACTERIOL, V175, P4391, DOI 10.1128/JB.175.14.4391-4399.1993; den Hengst CD, 2005, J BACTERIOL, V187, P512, DOI 10.1128/JB.187.2.512-521.2005; Eda S, 2000, BIOSCI BIOTECH BIOCH, V64, P484, DOI 10.1271/bbb.64.484; Fisher SH, 1996, J BACTERIOL, V178, P3779, DOI 10.1128/jb.178.13.3779-3784.1996; Fisher SH, 1999, MOL MICROBIOL, V32, P223, DOI 10.1046/j.1365-2958.1999.01333.x; FOUCAUD C, 1995, J BACTERIOL, V177, P4652, DOI 10.1128/jb.177.16.4652-4657.1995; GAJIC O, 2003, THESIS U GRONINGEN G; GASSON MJ, 1983, J BACTERIOL, V154, P1; GODON JJ, 1992, J BACTERIOL, V174, P6580, DOI 10.1128/JB.174.20.6580-6589.1992; GODON JJ, 1993, J BACTERIOL, V175, P4383, DOI 10.1128/JB.175.14.4383-4390.1993; Goupil-Feuillerat N, 2000, J BACTERIOL, V182, P5399, DOI 10.1128/JB.182.19.5399-5408.2000; GoupilFeuillerat N, 1997, J BACTERIOL, V179, P6285, DOI 10.1128/JB.179.20.6285-6293.1997; Guedon E, 2001, MOL MICROBIOL, V40, P1227, DOI 10.1046/j.1365-2958.2001.02470.x; Guedon E, 2001, J BACTERIOL, V183, P3614, DOI 10.1128/JB.183.12.3614-3622.2001; HAGTING A, 1994, J BIOL CHEM, V269, P11391; Holo H, 1995, Methods Mol Biol, V47, P195; Hoskins J, 2001, J BACTERIOL, V183, P5709, DOI 10.1128/JB.183.19.5709-5717.2001; Inaoka T, 2003, J BIOL CHEM, V278, P2169, DOI 10.1074/jbc.M208722200; ISRAELSEN H, 1995, APPL ENVIRON MICROB, V61, P2540, DOI 10.1128/AEM.61.7.2540-2547.1995; Joseph P, 2005, J BACTERIOL, V187, P4127, DOI 10.1128/JB.187.12.4127-4139.2005; Kanehisa M, 2002, NUCLEIC ACIDS RES, V30, P42, DOI 10.1093/nar/30.1.42; Kim HJ, 2003, J BACTERIOL, V185, P1672, DOI 10.1128/JB.185.5.1672-1680.2003; Kok J, 2003, LACTIC ACID BACTERIA, V3, P189; Kuipers OP, 2002, ANTON LEEUW INT J G, V82, P113, DOI 10.1023/A:1020691801251; Kunji ERS, 1996, ANTON LEEUW INT J G, V70, P187, DOI 10.1007/BF00395933; Kunji ERS, 1996, MOL MICROBIOL, V21, P123, DOI 10.1046/j.1365-2958.1996.6231339.x; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; Lamarque M, 2004, J BACTERIOL, V186, P6492, DOI 10.1128/JB.186.19.6492-6500.2004; Lapujade P, 1998, APPL ENVIRON MICROB, V64, P2485; Larsen R, 2004, J BACTERIOL, V186, P1147, DOI 10.1128/JB.186.4.1147-1157.2004; Leenhouts K, 1998, APPL MICROBIOL BIOT, V49, P417, DOI 10.1007/s002530051192; LEENHOUTS KJ, 1991, J BACTERIOL, V173, P4794, DOI 10.1128/jb.173.15.4794-4798.1991; MAGUIN E, 1992, J BACTERIOL, V174, P5633, DOI 10.1128/JB.174.17.5633-5638.1992; Marugg JD, 1996, J BACTERIOL, V178, P1525, DOI 10.1128/jb.178.6.1525-1531.1996; MARUGG JD, 1995, J BACTERIOL, V177, P2982, DOI 10.1128/jb.177.11.2982-2989.1995; Molle V, 2003, J BACTERIOL, V185, P1911, DOI 10.1128/JB.185.6.1911-1922.2003; MORISHITA T, 1995, BIOSCI BIOTECH BIOCH, V59, P251, DOI 10.1271/bbb.59.251; Overweg K, 2000, INFECT IMMUN, V68, P4180, DOI 10.1128/IAI.68.7.4180-4188.2000; Petranovic D, 2004, MOL MICROBIOL, V53, P613, DOI 10.1111/j.1365-2958.2004.04136.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sanders JW, 1998, MOL GEN GENET, V257, P681, DOI 10.1007/s004380050697; Sanz Y, 2003, FEMS MICROBIOL LETT, V227, P33, DOI 10.1016/S0378-1097(03)00662-1; Sanz Y, 2001, ARCH MICROBIOL, V175, P334, DOI 10.1007/s002030100270; Serror P, 1996, MOL MICROBIOL, V20, P843, DOI 10.1111/j.1365-2958.1996.tb02522.x; Serror P, 1996, J BACTERIOL, V178, P5910, DOI 10.1128/jb.178.20.5910-5915.1996; Shivers RP, 2005, MOL MICROBIOL, V56, P1549, DOI 10.1111/j.1365-2958.2005.04634.x; Shivers RP, 2004, MOL MICROBIOL, V53, P599, DOI 10.1111/j.1365-2958.2004.04135.x; SLACK FJ, 1995, MOL MICROBIOL, V15, P689, DOI 10.1111/j.1365-2958.1995.tb02378.x; TERZAGHI BE, 1975, APPL MICROBIOL, V29, P807, DOI 10.1128/AEM.29.6.807-813.1975; Tojo S, 2005, MOL MICROBIOL, V56, P1560, DOI 10.1111/j.1365-2958.2005.04635.x; TYNKKYNEN S, 1993, J BACTERIOL, V175, P7523, DOI 10.1128/JB.175.23.7523-7532.1993; van Hijum Sacha A F T, 2003, Appl Bioinformatics, V2, P241; van Hijum SAFT, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-77; Wang H, 2000, J DAIRY SCI, V83, P1912, DOI 10.3168/jds.S0022-0302(00)75066-1; Wray LV, 1997, J BACTERIOL, V179, P5494, DOI 10.1128/jb.179.17.5494-5501.1997; WRAY LV, 1994, J BACTERIOL, V176, P5466, DOI 10.1128/JB.176.17.5466-5473.1994; Yue HB, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.8.e41; Yvon M, 2000, APPL ENVIRON MICROB, V66, P571, DOI 10.1128/AEM.66.2.571-577.2000	68	160	161	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34332	34342		10.1074/jbc.M502349200	http://dx.doi.org/10.1074/jbc.M502349200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16040604	Green Submitted, Green Published, hybrid			2022-12-25	WOS:000232229700076
J	Rajashankar, KR; Bryk, R; Kniewel, R; Buglino, JA; Nathan, CF; Lima, CD				Rajashankar, KR; Bryk, R; Kniewel, R; Buglino, JA; Nathan, CF; Lima, CD			Crystal structure and functional analysis of lipoamide dehydrogenase from Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROLIPOAMIDE DEHYDROGENASE; AZOTOBACTER-VINELANDII; PYRUVATE-DEHYDROGENASE; ANTIOXIDANT DEFENSE; SUBSTRATE-BINDING; CATALYTIC DOMAIN; REDUCTASE; DISULFIDE; ENZYMES; SEQUENCE	We report the 2.4 angstrom crystal structure for lipoamide dehydrogenase encoded by lpdC from Mycobacterium tuberculosis. Based on the Lpd structure and sequence alignment between bacterial and eukaryotic Lpd sequences, we generated single point mutations in Lpd and assayed the resulting proteins for their ability to catalyze lipoamide reduction/ oxidation alone and in complex with other proteins that participate in pyruvate dehydrogenase and peroxidase activities. The results suggest that amino acid residues conserved in mycobacterial species but not conserved in eukaryotic Lpd family members modulate either or both activities and include Arg-93, His-98, Lys-103, and His-386. In addition, Arg-93 and His- 386 are involved in forming both "open" and "closed" active site conformations, suggesting that these residues play a role in dynamically regulating Lpd function. Taken together, these data suggest protein surfaces that should be considered while developing strategies for inhibiting this enzyme.	Cloan Kettering Inst, Struct Biol Program, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University	Lima, CD (corresponding author), Cloan Kettering Inst, Struct Biol Program, New York, NY 10021 USA.	limac@mskcc.org		Kniewel, Ryan/0000-0003-3462-6450; Lima, Christopher/0000-0002-9163-6092	NHLBI NIH HHS [HL072718] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072718] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Argyrou A, 2004, PROG NUCLEIC ACID RE, V78, P89, DOI 10.1016/S0079-6603(04)78003-4; Argyrou A, 2004, J BIOL CHEM, V279, P52694, DOI 10.1074/jbc.M410704200; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BENEN J, 1992, EUR J BIOCHEM, V207, P487, DOI 10.1111/j.1432-1033.1992.tb17075.x; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; Brautigam CA, 2005, J MOL BIOL, V350, P543, DOI 10.1016/j.jmb.2005.05.014; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bryk R, 2000, NATURE, V407, P211, DOI 10.1038/35025109; Bryk R, 2002, SCIENCE, V295, P1073, DOI 10.1126/science.1067798; Chang CF, 2002, J BIOL CHEM, V277, P15865, DOI 10.1074/jbc.M110952200; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; DELANO WL, 2002, PYMOL USERS MANUAL D; Gouet P, 2003, NUCLEIC ACIDS RES, V31, P3320, DOI 10.1093/nar/gkg556; Guimaraes BG, 2005, J BIOL CHEM, V280, P25735, DOI 10.1074/jbc.M503076200; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HOPKINS N, 1995, BIOCHEMISTRY-US, V34, P11757, DOI 10.1021/bi00037a013; Igamberdiev AU, 2004, FEBS LETT, V568, P146, DOI 10.1016/j.febslet.2004.05.024; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARPLUS PA, 1989, J MOL BIOL, V210, P163, DOI 10.1016/0022-2836(89)90298-2; Kato M, 2005, EMBO J, V24, P1763, DOI 10.1038/sj.emboj.7600663; Knapp JE, 1998, J MOL BIOL, V280, P655, DOI 10.1006/jmbi.1998.1924; Knapp JE, 2000, PROTEIN SCI, V9, P37; Koshkin A, 2004, ARCH BIOCHEM BIOPHYS, V427, P41, DOI 10.1016/j.abb.2004.04.017; MATTEVI A, 1993, BIOCHEMISTRY-US, V32, P3887, DOI 10.1021/bi00066a007; MATTEVI A, 1992, PROTEINS, V13, P336, DOI 10.1002/prot.340130406; MATTEVI A, 1993, J MOL BIOL, V230, P1183, DOI 10.1006/jmbi.1993.1235; Mossessova E, 2000, MOL CELL, V5, P865, DOI 10.1016/S1097-2765(00)80326-3; Nathan C, 2000, P NATL ACAD SCI USA, V97, P8841, DOI 10.1073/pnas.97.16.8841; Nunn CM, 2002, J BIOL CHEM, V277, P20033, DOI 10.1074/jbc.M200864200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perham RN, 2000, ANNU REV BIOCHEM, V69, P961, DOI 10.1146/annurev.biochem.69.1.961; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Tian J, 2005, MOL MICROBIOL, V57, P859, DOI 10.1111/j.1365-2958.2005.04741.x; Zhang YH, 1996, PROTEIN SCI, V5, P52	35	26	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33977	33983		10.1074/jbc.M507466200	http://dx.doi.org/10.1074/jbc.M507466200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16093239	hybrid			2022-12-25	WOS:000232229700035
J	Zvonic, S; Baugh, JE; Arbour-Reily, P; Mynatt, RL; Stephens, JM				Zvonic, S; Baugh, JE; Arbour-Reily, P; Mynatt, RL; Stephens, JM			Cross-talk among gp130 cytokines in adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; SIGNAL TRANSDUCER GP130; CILIARY NEUROTROPHIC FACTOR; ONCOSTATIN-M RECEPTOR; MOLECULAR-CLONING; INTERLEUKIN-6 RECEPTOR; REGULATED EXPRESSION; 3T3-L1 ADIPOCYTES; HEXAMERIC COMPLEX; IL-11 RECEPTOR	The interleukin-6 (IL-6) family of cytokines is a family of structurally and functionally related proteins, including IL-6, IL-11, leukemia inhibitory factor (LIF), oncostatin M (OSM), ciliary neurotrophic factor ( CNTF), and cardiotrophin-1 (CT-1). These proteins are also known as gp130 cytokines because they all share gp130 as a common transducer protein within their functional receptor complexes. Several of these cytokines ( LIF, OSM, CNTF, and CT-1) also utilize the LIF receptor (LIFR) as a component of their receptor complex. We have shown that all of these cytokines are capable of activating both the JAK/STAT and p42/44 mitogen-activated protein kinase signaling pathways in 3T3-L1 adipocytes. By performing a variety of preincubation studies and examining the ability of these cytokines to activate STATs, ERKs, and induce transcription of SOCS-3 mRNA, we have also examined the ability of gp130 cytokines to modulate the action of their family members. Our results indicate that a subset of gp130 cytokines, in particular CT-1, LIF, and OSM, has the ability to impair subsequent signaling activity initiated by gp130 cytokines. However, IL-6 and CNTF do not exhibit this cross-talk ability. Moreover, our results indicate that the cross-talk among gp130 cytokines is mediated by the ability of these cytokines to induce ligand-dependent degradation of the LIFR, in a proteasome-independent manner, which coincides with decreased levels of LIFR at the plasma membrane. In summary, our results demonstrate that an inhibitory cross-talk among specific gp130 cytokines in 3T3-L1 adipocytes occurs as a result of specific degradation of LIFR via a lysosome-mediated pathway.	Louisiana State Univ, Dept Biol Sci, Baton Rouge, LA 70803 USA; Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA	Louisiana State University System; Louisiana State University; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center	Stephens, JM (corresponding author), Louisiana State Univ, Dept Biol Sci, 202 Life Sci Bldg, Baton Rouge, LA 70803 USA.	jsteph1@lsu.edu	Mynatt, Randall L/N-1980-2017; Stephens, Jacqueline M/R-5217-2018	Mynatt, Randall L/0000-0003-4399-0019; 				AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; Aubert J, 1999, J BIOL CHEM, V274, P24965, DOI 10.1074/jbc.274.35.24965; Balhoff JP, 1998, BIOCHEM BIOPH RES CO, V247, P894, DOI 10.1006/bbrc.1998.8890; Baumann H, 1996, J IMMUNOL, V157, P284; Blanchard F, 2001, J BIOL CHEM, V276, P47038, DOI 10.1074/jbc.M107971200; Blanchard F, 2000, J BIOL CHEM, V275, P28793, DOI 10.1074/jbc.M003986200; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DESERIO A, 1995, J MOL BIOL, V254, P795, DOI 10.1006/jmbi.1995.0655; Dinerstein-Cali H, 2000, MOL CELL ENDOCRINOL, V166, P89, DOI 10.1016/S0303-7207(00)00277-X; GEARING DP, 1993, ADV IMMUNOL, V53, P31, DOI 10.1016/S0065-2776(08)60497-6; GEARING DP, 1987, EMBO J, V6, P3995, DOI 10.1002/j.1460-2075.1987.tb02742.x; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GIMBLE JM, 1994, J CELL BIOCHEM, V54, P122, DOI 10.1002/jcb.240540113; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILTON DJ, 1992, TRENDS BIOCHEM SCI, V17, P72, DOI 10.1016/0968-0004(92)90505-4; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; HIRANO T, 1992, CHEM IMMUNOL, V51, P153; Hirano T, 1998, Int Rev Immunol, V16, P249; HIRANO T, 1994, STEM CELLS, V12, P262, DOI 10.1002/stem.5530120303; Hirota H, 1996, J EXP MED, V183, P2627, DOI 10.1084/jem.183.6.2627; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Ip NY, 1996, ANNU REV NEUROSCI, V19, P491; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; Kamimura D, 2004, REV PHYSIOL BIOCH P, V149, P1, DOI 10.1007/s10254-003-0012-2; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN LFH, 1989, SCIENCE, V246, P1023, DOI 10.1126/science.2587985; LIU JW, 1992, J BIOL CHEM, V267, P16763; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Mackiewicz A, 1995, ANN NY ACAD SCI, V762, P361; Mahboubi K, 2003, J BIOL CHEM, V278, P25014, DOI 10.1074/jbc.M211867200; METCALF D, 1991, INT J CELL CLONING, V9, P95, DOI 10.1002/stem.5530090201; Metcalf D, 2003, STEM CELLS, V21, P5, DOI 10.1634/stemcells.21-1-5; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; MURAKAMIMORI K, 1995, J CLIN INVEST, V96, P1319, DOI 10.1172/JCI118167; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; Path G, 2001, J CLIN ENDOCR METAB, V86, P2281, DOI 10.1210/jc.86.5.2281; PATTERSON PH, 1993, CELL, V72, P123, DOI 10.1016/S0092-8674(05)80032-7; PAUL SR, 1990, P NATL ACAD SCI USA, V87, P7512, DOI 10.1073/pnas.87.19.7512; PAUL WE, 1989, CELL, V57, P521, DOI 10.1016/0092-8674(89)90121-9; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; Pennica Diane, 1996, Cytokine and Growth Factor Reviews, V7, P81, DOI 10.1016/1359-6101(96)00007-X; SAITO M, 1992, J IMMUNOL, V148, P4066; SATOH T, 1992, J BIOL CHEM, V267, P24149; SAVINO R, 1994, EMBO J, V13, P1357, DOI 10.1002/j.1460-2075.1994.tb06389.x; SEHGAL PB, 1988, J EXP MED, V167, P1951, DOI 10.1084/jem.167.6.1951; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STEPHENS JM, 1991, J BIOL CHEM, V266, P21839; Stephens JM, 1998, J BIOL CHEM, V273, P31408, DOI 10.1074/jbc.273.47.31408; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAGA T, 1992, P NATL ACAD SCI USA, V89, P10998, DOI 10.1073/pnas.89.22.10998; Taga T, 1996, J NEUROCHEM, V67, P1; THOMA B, 1994, J BIOL CHEM, V269, P6215; WARD LD, 1994, J BIOL CHEM, V269, P23286; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Wollert KC, 1996, J BIOL CHEM, V271, P9535, DOI 10.1074/jbc.271.16.9535; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; YANG YC, 1993, STEM CELLS, V11, P474, DOI 10.1002/stem.5530110617; YIN TG, 1993, J IMMUNOL, V151, P2555; ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zvonic S, 2004, J BIOL CHEM, V279, P47572, DOI 10.1074/jbc.M403998200; Zvonic S, 2003, J BIOL CHEM, V278, P2228, DOI 10.1074/jbc.M205871200	71	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33856	33863		10.1074/jbc.M508020200	http://dx.doi.org/10.1074/jbc.M508020200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16096272	Green Published, hybrid			2022-12-25	WOS:000232229700022
J	Grujic, M; Braga, T; Lukinius, A; Eloranta, ML; Knight, SD; Pejler, G; Abrink, M				Grujic, M; Braga, T; Lukinius, A; Eloranta, ML; Knight, SD; Pejler, G; Abrink, M			Serglycin-deficient cytotoxic T lymphocytes display defective secretory granule maturation and granzyme B storage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATURAL-KILLER-CELLS; MEDIATED APOPTOSIS; CHONDROITIN SULFATE; DNA FRAGMENTATION; CORE PROTEIN; TARGET-CELLS; MAST-CELLS; PROTEOGLYCAN; INDUCTION; HEPARIN	Cytotoxic T lymphocytes eliminate infected and tumor cells mainly by perforin/granzyme-induced apoptosis. Earlier studies suggested that serglycin-proteoglycans form macromolecular complexes with granzymes and perforin in the cytotoxic granule. Serglycin-proteoglycans may also be involved in the delivery of the cytolytic machinery into target cells. We have developed a serglycin-deficient mouse strain, and here we studied the importance of serglycin-proteoglycans for various aspects of cytotoxic T lymphocyte function. (SO42-)-S-35 radiolabeling of serglycin-deficient cells demonstrated a dramatic reduction of incorporated label as compared with wild type cells, indicating that serglycin is by far the dominating proteoglycan species produced by the cytotoxic T lymphocyte. Moreover, lack of serglycin resulted in impaired ability of cytotoxic T lymphocytes to produce secretory granule of high electron density, although granule of lower electron density were produced both in wild type and serglycin-deficient cells. The serglycin deficiency did not affect the mRNA expression for granzyme A, granzyme B, or perforin. However, the storage of granzyme B, but not granzyme A, Fas ligand, or perforin, was severely defective in serglycin-deficient cells. Serglycin-deficient cells did not display defects in late cytotoxicity toward target cell lines. Taken together, these results point to a key role for serglycin in the storage of granzyme B and for secretory granule maturation but argue against a major role for serglycin in the apoptosis mediated by cytotoxic T lymphocytes.	Swedish Univ Agr Sci, Ctr Biomed, Dept Mol Biosci, S-75123 Uppsala, Sweden; Uppsala Univ, Rudbeck Lab, Dept Genet & Pathol, S-75185 Uppsala, Sweden; Swedish Univ Agr Sci, Uppsala Biomed Ctr, SE-75324 Uppsala, Sweden	Swedish University of Agricultural Sciences; Uppsala University; Swedish University of Agricultural Sciences	Abrink, M (corresponding author), Swedish Univ Agr Sci, Ctr Biomed, Dept Mol Biosci, Box 575, S-75123 Uppsala, Sweden.	magnus.abrink@bmc.uu.se	Knight, Stefan/D-4315-2015; Åbrink, Magnus/AAK-8346-2020	Abrink, Magnus/0000-0002-1335-3927; Knight, Stefan/0000-0002-7180-8758				Abrink M, 2004, J BIOL CHEM, V279, P40897, DOI 10.1074/jbc.M405856200; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Beresford PJ, 2001, J BIOL CHEM, V276, P43285, DOI 10.1074/jbc.M108137200; Darmon AJ, 1996, J BIOL CHEM, V271, P21709, DOI 10.1074/jbc.271.36.21709; ELLIOTT JF, 1993, MOL IMMUNOL, V30, P749, DOI 10.1016/0161-5890(93)90146-3; Ewen C, 2003, J IMMUNOL METHODS, V276, P89, DOI 10.1016/S0022-1759(03)00073-5; Faurschou M, 2003, MICROBES INFECT, V5, P1317, DOI 10.1016/j.micinf.2003.09.008; Forsberg E, 1999, NATURE, V400, P773, DOI 10.1038/23488; Forsberg E, 2001, J CLIN INVEST, V108, P175, DOI 10.1172/JCI13561; Froelich CJ, 1996, J BIOL CHEM, V271, P29073, DOI 10.1074/jbc.271.46.29073; Galvin JP, 1999, J IMMUNOL, V162, P5345; Grossman WJ, 2003, CURR OPIN IMMUNOL, V15, P544, DOI 10.1016/S0952-7915(03)00099-2; Henningsson F, 2002, BIOL CHEM, V383, P793, DOI 10.1515/BC.2002.083; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; Hink-Schauer C, 2003, NAT STRUCT BIOL, V10, P535, DOI 10.1038/nsb945; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kagi D, 1996, ANNU REV IMMUNOL, V14, P207, DOI 10.1146/annurev.immunol.14.1.207; Kelso A, 2002, INT IMMUNOL, V14, P605, DOI 10.1093/intimm/dxf028; KJELLEN L, 1989, BIOCHEM J, V263, P105, DOI 10.1042/bj2630105; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P829, DOI 10.1107/S0907444996001783; Kolset SO, 2004, BIOCHEM J, V379, P217, DOI 10.1042/BJ20031230; Lieberman J, 2003, NAT REV IMMUNOL, V3, P361, DOI 10.1038/nri1083; LUKINIUS A, 1995, AM J PATHOL, V146, P429; MACDERMOTT RP, 1985, J EXP MED, V162, P1771, DOI 10.1084/jem.162.6.1771; Manakil JF, 2001, J DENT RES, V80, P1704, DOI 10.1177/00220345010800080501; MASSON D, 1990, BIOCHEMISTRY-US, V29, P11229, DOI 10.1021/bi00503a011; MATZINGER P, 1991, J IMMUNOL METHODS, V145, P185, DOI 10.1016/0022-1759(91)90325-A; Metkar SS, 2002, IMMUNITY, V16, P417, DOI 10.1016/S1074-7613(02)00286-8; Motyka B, 2000, CELL, V103, P491, DOI 10.1016/S0092-8674(00)00140-9; Oynebraten I, 2000, J LEUKOCYTE BIOL, V67, P183, DOI 10.1002/jlb.67.2.183; PEJLER G, 1995, EUR J BIOCHEM, V233, P192, DOI 10.1111/j.1432-1033.1995.192_1.x; Pham CTN, 1999, P NATL ACAD SCI USA, V96, P8627, DOI 10.1073/pnas.96.15.8627; Raja SM, 2003, CURR OPIN IMMUNOL, V15, P528, DOI 10.1016/S0952-7915(03)00111-0; Raja SM, 2002, J BIOL CHEM, V277, P49523, DOI 10.1074/jbc.M209607200; Russell JH, 2002, ANNU REV IMMUNOL, V20, P323, DOI 10.1146/annurev.immunol.20.100201.131730; SCHMIDT RE, 1985, NATURE, V318, P289, DOI 10.1038/318289a0; STEVENS RL, 1985, J BIOL CHEM, V260, P4194; STEVENS RL, 1988, J BIOL CHEM, V263, P7287; Tchougounova E, 2001, FASEB J, V15, P2763, DOI 10.1096/fj.01-0486fje; Trapani JA, 2003, J CELL BIOL, V160, P223, DOI 10.1083/jcb.200210150; Trapani JA, 2001, GENOME BIOL, V2; Waugh SM, 2000, NAT STRUCT BIOL, V7, P762, DOI 10.1038/78992; Zhang D, 2001, P NATL ACAD SCI USA, V98, P5746, DOI 10.1073/pnas.101329598; Zhang D, 2001, J BIOL CHEM, V276, P3683, DOI 10.1074/jbc.M005390200	44	79	81	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33411	33418		10.1074/jbc.M501708200	http://dx.doi.org/10.1074/jbc.M501708200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16046402	hybrid			2022-12-25	WOS:000232058100039
J	Sauter, K; Grampp, T; Fritschy, JM; Kaupmann, K; Bettler, B; Mohler, H; Benke, D				Sauter, K; Grampp, T; Fritschy, JM; Kaupmann, K; Bettler, B; Mohler, H; Benke, D			Subtype-selective interaction with the transcription factor CCAAT/enhancer-binding protein (C/EBP) homologous protein (CHOP) regulates cell surface expression of GABA(B) receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; ENDOPLASMIC-RETICULUM; GADD153; TRAFFICKING; APOPTOSIS; ISCHEMIA; DEATH	The metabotropic gamma-aminobutyric acid, type B (GABA(B)) receptors mediate the slow component of GABAergic transmission in the brain. Functional GABA(B) receptors are heterodimers of the two subunits GABA(B1) and GABA(B2), of which GABA(B1) exists in two main isoforms, GABA(B1a) and GABA(B1b). The significance of the structural heterogeneity of GABAB receptors, the mechanism leading to their differential targeting in neurons as well as the regulation of cell surface numbers of GABAB receptors, is poorly understood. To gain insights into these processes, we searched for proteins interacting with the C-terminal domain of GABA(B2). Here, we showed that the transcription factor CCAAT/enhancer-binding protein (C/EBP) homologous protein ( CHOP) directly interacts with GABA(B) receptors in a subtype-selective manner to regulate cell surface expression of GABA(B1a)/GABA(B2) receptors upon co-expression in HEK293 cells. The interaction of CHOP with GABA(B1a)/ GABA(B2) receptors resulted in their intracellular accumulation and in a reduced number of cell surface receptors. This regulation required the interaction of CHOP via two distinct domains with the heterodimeric receptor; its C-terminal leucine zipper associates with the leucine zipper present in the C-terminal domain of GABA(B2), and its N-terminal domain associates with an as yet unidentified site on GABA(B1a). In conclusion, the data indicated a subtype-selective regulation of cell surface receptors by interaction with the transcription factor CHOP.	Univ Zurich, Inst Pharmacol & Toxicol, CH-8057 Zurich, Switzerland; ETH, Fed Inst Technol, Dept Chem & Appl Biosci, CH-8093 Zurich, Switzerland; Novartis Pharma AG, Novartis Inst Biomed Res, Neurosci Res, CH-4002 Basel, Switzerland; Univ Basel, Pharmazentrum, Dept Clin Biol Sci, Inst Physiol, CH-4056 Basel, Switzerland	University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; Novartis; University of Basel	Benke, D (corresponding author), Univ Zurich, Inst Pharmacol & Toxicol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	benke@pharma.unizh.ch	bettler, bernhard/AAO-8018-2020	Bettler, Bernhard/0000-0003-0842-8207; Fritschy, Jean-Marc/0000-0002-8552-3702; Kaupmann, Klemens/0000-0001-8903-2508				Benke D, 1999, J BIOL CHEM, V274, P27323, DOI 10.1074/jbc.274.38.27323; Benke D, 2002, J RECEPT SIGNAL TR R, V22, P253, DOI 10.1081/RRS-120014600; Bettler B, 2004, PHYSIOL REV, V84, P835, DOI 10.1152/physrev.00036.2003; Blein S, 2004, J BIOL CHEM, V279, P48292, DOI 10.1074/jbc.M406540200; Bowery NG, 2002, PHARMACOL REV, V54, P247, DOI 10.1124/pr.54.2.247; Calver AR, 2002, NEUROSIGNALS, V11, P299, DOI 10.1159/000068257; Couve A, 2004, J BIOL CHEM, V279, P13934, DOI 10.1074/jbc.M311737200; Couve A, 2004, BIOCHEM PHARMACOL, V68, P1527, DOI 10.1016/j.bcp.2004.06.036; Couve A, 1998, J BIOL CHEM, V273, P26361, DOI 10.1074/jbc.273.41.26361; Couve A, 2001, MOL CELL NEUROSCI, V17, P317, DOI 10.1006/mcne.2000.0938; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; Milhavet O, 2002, J NEUROCHEM, V83, P673, DOI 10.1046/j.1471-4159.2002.01165.x; Nehring RB, 2000, J BIOL CHEM, V275, P35185, DOI 10.1074/jbc.M002727200; Oyadomari S, 2002, APOPTOSIS, V7, P335, DOI 10.1023/A:1016175429877; Oyadomari S, 2002, J CLIN INVEST, V109, P525, DOI 10.1172/JCI200214550; Oyadomari S, 2001, P NATL ACAD SCI USA, V98, P10845, DOI 10.1073/pnas.191207498; Pagano A, 2001, J NEUROSCI, V21, P1189; Paschen W, 1998, MOL BRAIN RES, V60, P115, DOI 10.1016/S0169-328X(98)00180-6; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; Steiger JL, 2004, J NEUROSCI, V24, P6115, DOI 10.1523/JNEUROSCI.1200-04.2004; Stokes AH, 2002, NEUROTOXICOLOGY, V23, P675, DOI 10.1016/S0161-813X(02)00093-1; Tajiri S, 2004, CELL DEATH DIFFER, V11, P403, DOI 10.1038/sj.cdd.4401365; Vernon E, 2001, MOL CELL NEUROSCI, V17, P637, DOI 10.1006/mcne.2000.0960; White JH, 2000, P NATL ACAD SCI USA, V97, P13967, DOI 10.1073/pnas.240452197; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	27	26	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33566	33572		10.1074/jbc.M503482200	http://dx.doi.org/10.1074/jbc.M503482200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16081421	hybrid			2022-12-25	WOS:000232058100057
J	Calautti, E; Li, J; Saoncella, S; Brissette, JL; Goetinck, PF				Calautti, E; Li, J; Saoncella, S; Brissette, JL; Goetinck, PF			Phosphoinositide 3-kinase signaling to Akt promotes keratinocyte differentiation versus death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL ADHESION; NF-KAPPA-B; GROWTH-FACTOR RECEPTOR; PROTEIN-KINASE-C; E-CADHERIN; TERMINAL DIFFERENTIATION; PATHWAY; EPIDERMIS; ACTIVATION; SURVIVAL	Signaling pathways regulating the differentiation program of epidermal cells overlap widely with those activated during apoptosis. How differentiating cells remain protected from premature death, however, is still poorly defined. We show here that the phosphoinositide 3-kinase ( PI3K)/ Akt pathway is activated at early stages of mouse keratinocyte differentiation both in culture and in the intact epidermis in vivo. Expression of active Akt in keratinocytes promotes growth arrest and differentiation, whereas pharmacological blockade of PI3K inhibits the expression of "late" differentiation markers and leads to death of cells that would otherwise differentiate. Mechanistically, the activation of the PI3K/Akt pathway in keratinocyte differentiation depends on the activity of the epidermal growth factor receptor and Src families of tyrosine kinases and the engagement of E- cadherin- mediated adhesion. During this process, PI3K associates increasingly with cadherin- catenin protein complexes bearing tyrosine phosphorylated YXXM motifs. Thus, the PI3K signaling pathway regulates the choice between epidermal cell differentiation and death at the cross-talk between tyrosine kinases and cadherin- associated catenins.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital	Calautti, E (corresponding author), Osped Civile Venezia, Epithelial Stem Cell Res Ctr, Veneto Eye Bank Fdn, Castello 6777, I-30122 Venice, Italy.	enzo.calautti@cbrc2.mgh.harvard.edu	Calautti, Enzo/M-8283-2018	Calautti, Enzo/0000-0002-4439-9709	NIAMS NIH HHS [AR454284] Funding Source: Medline; NICHD NIH HHS [HD-37490] Funding Source: Medline; Telethon [TCP06001] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD037490] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Telethon(Fondazione Telethon); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Anderson KE, 2003, INT J BIOCHEM CELL B, V35, P1028, DOI 10.1016/S1357-2725(02)00270-4; Calautti E, 2002, J CELL BIOL, V156, P137, DOI 10.1083/jcb.200105140; Calautti E, 1998, J CELL BIOL, V141, P1449, DOI 10.1083/jcb.141.6.1449; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; DLUGOSZ AA, 1993, J CELL BIOL, V120, P217, DOI 10.1083/jcb.120.1.217; Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002; Foster FM, 2003, J CELL SCI, V116, P3037, DOI 10.1242/jcs.00609; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Fuchs E, 2002, NAT REV GENET, V3, P199, DOI 10.1038/nrg758; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; Fujio Y, 1999, MOL CELL BIOL, V19, P5073; Gandarillas A, 2000, EXP GERONTOL, V35, P53, DOI 10.1016/S0531-5565(99)00088-1; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; Janes SM, 2004, J CELL SCI, V117, P4157, DOI 10.1242/jcs.01302; Laprise P, 2004, J CELL PHYSIOL, V199, P32, DOI 10.1002/jcp.10432; Li Y, 2003, MOL CELL BIOL, V23, P6255, DOI 10.1128/MCB.23.17.6255-6266.2003; Maruoka Y, 1997, BIOCHEM BIOPH RES CO, V238, P886, DOI 10.1006/bbrc.1997.7405; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; Miyauchi H, 2004, EMBO J, V23, P212, DOI 10.1038/sj.emboj.7600045; Nolte RT, 1996, NAT STRUCT BIOL, V3, P364, DOI 10.1038/nsb0496-364; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Ohba M, 1998, MOL CELL BIOL, V18, P5199, DOI 10.1128/MCB.18.9.5199; Okuyama R, 2004, DEV CELL, V6, P551, DOI 10.1016/S1534-5807(04)00098-X; Pece S, 1999, J BIOL CHEM, V274, P19347, DOI 10.1074/jbc.274.27.19347; Pece S, 2000, J BIOL CHEM, V275, P41227, DOI 10.1074/jbc.M006578200; Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403; Rendl M, 2002, J INVEST DERMATOL, V119, P1150, DOI 10.1046/j.1523-1747.2002.19532.x; Saoncella S, 2004, J BIOL CHEM, V279, P47172, DOI 10.1074/jbc.C400299200; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Seitz CS, 2000, J CLIN INVEST, V105, P253, DOI 10.1172/JCI7630; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; Tinkle CL, 2004, P NATL ACAD SCI USA, V101, P552, DOI 10.1073/pnas.0307437100; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Watt FM, 1989, CURR OPIN CELL BIOL, V1, P1107, DOI 10.1016/S0955-0674(89)80058-4; Wymann MP, 2003, TRENDS PHARMACOL SCI, V24, P366, DOI 10.1016/S0165-6147(03)00163-9; Young P, 2003, EMBO J, V22, P5723, DOI 10.1093/emboj/cdg560	41	169	169	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32856	32865		10.1074/jbc.M506119200	http://dx.doi.org/10.1074/jbc.M506119200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16036919	hybrid			2022-12-25	WOS:000231920300039
J	McAlinden, A; Havlioglu, N; Liang, L; Davies, SR; Sandell, LJ				McAlinden, A; Havlioglu, N; Liang, L; Davies, SR; Sandell, LJ			Alternative splicing of type II procollagen Exon 2 is regulated by the combination of a weak 5 ' splice site and an adjacent intronic stem-loop Cis element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; RICH AMINO-PROPEPTIDE; SECONDARY STRUCTURE; SR-PROTEINS; HNRNP A1; DIFFERENTIAL EXPRESSION; U1 SNRNP; SEQUENCES; BINDING; TISSUE	Alternative splicing of the type II procollagen gene (COL2A1) is developmentally regulated during chondrogenesis. Chondroprogenitor cells produce the type IIA procollagen isoform by splicing (including) exon 2 during pre-mRNA processing, whereas differentiated chondrocytes synthesize the type IIB procollagen isoform by exon 2 skipping (exclusion). Using a COL2A1 mini-gene and chondrocytes at various stages of differentiation, we identified a non-classical consensus splicing sequence in intron 2 adjacent to the 5 ' splice site, which is essential in regulating exon 2 splicing. RNA mapping confirmed this region contains secondary structure in the form of a stem-loop. Mutational analysis identified three cis elements within the conserved double-stranded stem region that are functional only in the context of the natural weak 5 ' splice site of exon 2; they are 1) a uridine-rich enhancer element in all cell types tested except differentiated chondrocytes; 2) an adenine-rich silencer element, and 3) an enhancer cis element functional in the context of secondary structure. This is the first report identifying key cis elements in the COL2A1 gene that modulate the cell type-specific alternative splicing switch of exon 2 during cartilage development.	Washington Univ, Dept Orthopaed Surg, Sch Med, St Louis, MO 63110 USA; Washington Univ, Dept Cell Biol, Sch Med, St Louis, MO 63110 USA; St Louis Univ, Dept Pathol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Saint Louis University	McAlinden, A (corresponding author), Washington Univ, Dept Orthopaed Surg, Sch Med, 660 S Euclid Ave,Box 8233, St Louis, MO 63110 USA.	amcalind@msnotes.wustl.edu		McAlinden, Audrey/0000-0001-8433-4224; Davies, Sherri/0000-0002-7141-8354	NIAMS NIH HHS [AR48250, AR036994] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR036994, R03AR048250] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abreu JG, 2002, GENE, V287, P39, DOI 10.1016/S0378-1119(01)00827-7; Aigner T, 1999, ARTHRITIS RHEUM, V42, P1443, DOI 10.1002/1529-0131(199907)42:7<1443::AID-ANR18>3.0.CO;2-A; ALAKOKKO L, 1995, BIOCHEM J, V308, P923, DOI 10.1042/bj3080923; Atkinson BL, 1997, J CELL BIOCHEM, V65, P325, DOI 10.1002/(SICI)1097-4644(19970601)65:3<325::AID-JCB3>3.0.CO;2-U; BALVAY L, 1993, BIOESSAYS, V15, P165, DOI 10.1002/bies.950150304; BALVAY L, 1992, NUCLEIC ACIDS RES, V20, P3987, DOI 10.1093/nar/20.15.3987; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; Blanchette M, 2004, GENOME RES, V14, P708, DOI 10.1101/gr.1933104; Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; Burge CB, 1999, RNA WORLD, P525; CAPUTI M, 1994, NUCLEIC ACIDS RES, V22, P1018, DOI 10.1093/nar/22.6.1018; Carstens RP, 2000, MOL CELL BIOL, V20, P7388, DOI 10.1128/MCB.20.19.7388-7400.2000; Charlet-B N, 2002, MOL CELL, V9, P649, DOI 10.1016/S1097-2765(02)00479-3; Chen YW, 2001, MATRIX BIOL, V20, P589, DOI 10.1016/S0945-053X(01)00169-X; Coleman TP, 1998, BIOCHEMISTRY-US, V37, P15941, DOI 10.1021/bi9808058; COOPER TA, 1985, J BIOL CHEM, V260, P1140; COOPER TA, 2001, SCI STKE; D'Souza I, 2002, J BIOL CHEM, V277, P26587, DOI 10.1074/jbc.M203794200; Del Gato-Konczak F, 2000, MOL CELL BIOL, V20, P6287, DOI 10.1128/MCB.20.17.6287-6299.2000; Delagoutte E, 2003, Q REV BIOPHYS, V36, P1, DOI 10.1017/S0033583502003864; DELGATTO F, 1995, MOL CELL BIOL, V15, P4825; DELGATTO F, 1997, MOL CELL BIOL, V18, P2205; Denker AE, 1999, DIFFERENTIATION, V64, P67, DOI 10.1046/j.1432-0436.1999.6420067.x; Dirksen WP, 2003, J BIOL CHEM, V278, P9722, DOI 10.1074/jbc.M207969200; Dirksen WP, 2000, AM J PHYSIOL-CELL PH, V278, pC589, DOI 10.1152/ajpcell.2000.278.3.C589; DORVAL BC, 1991, SCIENCE, V252, P1823, DOI 10.1126/science.2063195; ESTES PA, 1992, J BIOL CHEM, V267, P14902; Expert-Bezancon A, 2004, J BIOL CHEM, V279, P38249, DOI 10.1074/jbc.M405377200; Fairbrother WG, 2002, SCIENCE, V297, P1007, DOI 10.1126/science.1073774; Fernandes RJ, 1997, EUR J BIOCHEM, V247, P620, DOI 10.1111/j.1432-1033.1997.00620.x; FISZMAN MY, 1992, SYM SOC EXP BIOL, V46, P355; Forch P, 2002, EMBO J, V21, P6882, DOI 10.1093/emboj/cdf668; FUJITA H, 1991, BIOCHEM BIOPH RES CO, V174, P946, DOI 10.1016/0006-291X(91)91510-J; Gallego ME, 1996, BIOCHIMIE, V78, P457, DOI 10.1016/0300-9084(96)84752-3; Gallego ME, 1997, EMBO J, V16, P1772, DOI 10.1093/emboj/16.7.1772; Goldstrohm AC, 2001, GENE, V277, P31, DOI 10.1016/S0378-1119(01)00695-3; GOODING C, 1994, EMBO J, V13, P3861, DOI 10.1002/j.1460-2075.1994.tb06697.x; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Grover A, 1999, J BIOL CHEM, V274, P15134, DOI 10.1074/jbc.274.21.15134; Guil S, 2003, MOL CELL BIOL, V23, P2927, DOI 10.1128/MCB.23.8.2927-2941.2003; Hatano H, 2002, J ORTHOPAED RES, V20, P516, DOI 10.1016/S0736-0266(01)00123-1; Hertel KJ, 1997, CURR OPIN CELL BIOL, V9, P350, DOI 10.1016/S0955-0674(97)80007-5; Hou VC, 2001, CURR OPIN HEMATOL, V8, P74, DOI 10.1097/00062752-200103000-00003; Ihanamaki T, 2002, CURR EYE RES, V24, P439, DOI 10.1076/ceyr.24.6.439.8594; Ismaili N, 2001, RNA, V7, P182, DOI 10.1017/S1355838201001807; Khatri JJ, 2001, J BIOL CHEM, V276, P37250, DOI 10.1074/jbc.M105275200; Kornblihtt AR, 2004, RNA, V10, P1489, DOI 10.1261/rna.7100104; Larrain J, 2000, DEVELOPMENT, V127, P821; LAVIGUEUR A, 1993, GENE DEV, V7, P2405, DOI 10.1101/gad.7.12a.2405; LIBRI D, 1990, MOL CELL BIOL, V10, P5036, DOI 10.1128/MCB.10.10.5036; Liu ZR, 2002, MOL CELL BIOL, V22, P5443, DOI 10.1128/MCB.22.15.5443-5450.2002; LUI VCH, 1995, DEV DYNAM, V203, P198, DOI 10.1002/aja.1002030208; Mackie EJ, 1998, MICROSC RES TECHNIQ, V43, P102; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; McAlinden Audrey, 2004, Birth Defects Res C Embryo Today, V72, P51, DOI 10.1002/bdrc.20004; Muro AF, 1999, MOL CELL BIOL, V19, P2657; NG LJ, 1993, DEV BIOL, V159, P403, DOI 10.1006/dbio.1993.1251; Nishiyama T, 2003, J BONE MINER RES, V18, P1716, DOI 10.1359/jbmr.2003.18.9.1716; Ohe K, 2002, P NATL ACAD SCI USA, V99, P1146, DOI 10.1073/pnas.022645899; Puig O, 1999, GENE DEV, V13, P569, DOI 10.1101/gad.13.5.569; Reardon A, 2000, MATRIX BIOL, V19, P169, DOI 10.1016/S0945-053X(00)00058-5; ROESSER JR, 1993, J BIOL CHEM, V268, P8366; RYAN MC, 1990, J BIOL CHEM, V265, P10334; SANDELL LJ, 1994, DEV DYNAM, V199, P129, DOI 10.1002/aja.1001990206; Schaal TD, 1999, MOL CELL BIOL, V19, P261; Schwartz S, 2003, GENOME RES, V13, P103, DOI 10.1101/gr.809403; Shukla S, 2004, J BIOL CHEM, V279, P13668, DOI 10.1074/jbc.M314138200; Siepel A, 2004, J COMPUT BIOL, V11, P413, DOI 10.1089/1066527041410472; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; SOLNICK D, 1985, CELL, V43, P667, DOI 10.1016/0092-8674(85)90239-9; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; Tange TO, 2001, EMBO J, V20, P5748; Uporova TM, 2000, J CELL BIOCHEM, V76, P341; Valcarcel J, 1996, TRENDS BIOCHEM SCI, V21, P296, DOI 10.1016/0968-0004(96)10039-6; Zahler AM, 2004, J BIOL CHEM, V279, P10077, DOI 10.1074/jbc.M312743200; Zhang D, 1999, GENE DEV, V13, P581, DOI 10.1101/gad.13.5.581; Zhu Y, 1999, J CELL BIOL, V144, P1069, DOI 10.1083/jcb.144.5.1069; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	78	36	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32700	32711		10.1074/jbc.M505940200	http://dx.doi.org/10.1074/jbc.M505940200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16076844	hybrid			2022-12-25	WOS:000231920300020
J	Robert, X; Haser, R; Mori, H; Svensson, B; Aghajari, N				Robert, X; Haser, R; Mori, H; Svensson, B; Aghajari, N			Oligosaccharide binding to barley alpha-amylase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC ALPHA-AMYLASE; X-RAY-STRUCTURE; 2.1 ANGSTROM RESOLUTION; SUBSTRATE-BINDING; CRYSTAL-STRUCTURE; STARCH-BINDING; CYCLODEXTRIN GLYCOSYLTRANSFERASE; STRUCTURAL-ANALYSIS; CATALYTIC (BETA/ALPHA)(8)-BARREL; COMPLEX STRUCTURES	Enzymatic subsite mapping earlier predicted 10 binding subsites in the active site substrate binding cleft of barley alpha-amylase isozymes. The three-dimensional structures of the oligosaccharide complexes with barley alpha-amylase isozyme 1 (AMY1) described here give for the first time a thorough insight into the substrate binding by describing residues defining 9 subsites, namely -7 through +2. These structures support that the pseudotetrasaccharide inhibitor acarbose is hydrolyzed by the active enzymes. Moreover, sugar binding was observed to the starch granule-binding site previously determined in barley alpha-amylase isozyme 2 (AMY2), and the sugar binding modes are compared between the two isozymes. The "sugar tongs" surface binding site discovered in the AMY1-thio-DP4 complex is confirmed in the present work. A site that putatively serves as an entrance for the substrate to the active site was proposed at the glycone part of the binding cleft, and the crystal structures of the catalytic nucleophile mutant (AMY1(D180A)) complexed with acarbose and maltoheptaose, respectively, suggest an additional role for the nucleophile in the stabilization of the Michaelis complex. Furthermore, probable roles are outlined for the surface binding sites. Our data support a model in which the two surface sites in AMY1 can interact with amylose chains in their naturally folded form. Because of the specificities of these two sites, they may locate/orient the enzyme in order to facilitate access to the active site for polysaccharide chains. Moreover, the sugar tongs surface site could also perform the unraveling of amylose chains, with the aid of Tyr-380 acting as "molecular tweezers."	UCBL 1, UMR 5086, CNRS,IFR 128 BioSci Lyon Gerland, Inst Biol & Chim Prot,Lab BioCristallog, F-69367 Lyon, France; Carlsberg Lab, Dept Chem, DK-2500 Copenhagen, Denmark; Tech Univ Denmark, Bioctr, Biochem & Nutr Grp, DK-2800 Lyngby, Denmark	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Technical University of Denmark	Aghajari, N (corresponding author), UCBL 1, UMR 5086, CNRS,IFR 128 BioSci Lyon Gerland, Inst Biol & Chim Prot,Lab BioCristallog, 7 Passage Vercors, F-69367 Lyon, France.	n.aghajari@ibcp.fr	ROBERT, Xavier/C-3879-2015; Aghajari, Nushin B.H./P-1906-2016	ROBERT, Xavier/0000-0002-6174-8595; Aghajari, Nushin B.H./0000-0002-2245-2679; Svensson, Birte/0000-0002-2993-8196				Abe A, 2004, J MOL BIOL, V335, P811, DOI 10.1016/j.jmb.2003.10.078; Aghajari N, 2002, BIOCHEMISTRY-US, V41, P4273, DOI 10.1021/bi0160516; AJANDOUZ EH, 1992, BIOCHIM BIOPHYS ACTA, V1159, P193, DOI 10.1016/0167-4838(92)90025-9; Andre G, 1999, BIOPOLYMERS, V50, P751, DOI 10.1002/(SICI)1097-0282(199912)50:7<751::AID-BIP8>3.3.CO;2-X; Bak-Jensen KS, 2004, J BIOL CHEM, V279, P10093, DOI 10.1074/jbc.M312825200; BOZONNET S, 2005, IN PRESS BIOL BRATIS, V60; Brayer GD, 2000, BIOCHEMISTRY-US, V39, P4778, DOI 10.1021/bi9921182; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Brzozowski AM, 1997, BIOCHEMISTRY-US, V36, P10837, DOI 10.1021/bi970539i; Brzozowski AM, 2000, BIOCHEMISTRY-US, V39, P9099, DOI 10.1021/bi0000317; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; Coutinho PM, 1999, ROY SOC CH, P3; DATTA AK, 1995, NUCLEIC ACIDS RES, V23, P4530, DOI 10.1093/nar/23.21.4530; Dauter Z, 1999, BIOCHEMISTRY-US, V38, P8385, DOI 10.1021/bi990256l; Davies GJ, 2005, ACTA CRYSTALLOGR D, V61, P190, DOI 10.1107/S0907444904027118; delRio G, 1997, FEBS LETT, V416, P221, DOI 10.1016/S0014-5793(97)01192-7; Fujimoto Z, 1998, J MOL BIOL, V277, P393, DOI 10.1006/jmbi.1997.1599; Gessler K, 1999, P NATL ACAD SCI USA, V96, P4246, DOI 10.1073/pnas.96.8.4246; GIBSON RM, 1987, CARLSBERG RES COMMUN, V52, P373, DOI 10.1007/BF02907525; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; IMBERTY A, 1988, J MOL BIOL, V201, P365, DOI 10.1016/0022-2836(88)90144-1; IMBERTY A, 1989, INT J BIOL MACROMOL, V11, P177, DOI 10.1016/0141-8130(89)90065-2; Jensen MT, 2003, J CEREAL SCI, V38, P289, DOI 10.1016/S0733-5210(03)00032-8; Juge N, 1996, PROTEIN EXPRES PURIF, V8, P204, DOI 10.1006/prep.1996.0093; Kadziola A, 1998, J MOL BIOL, V278, P205, DOI 10.1006/jmbi.1998.1683; Kagawa M, 2003, J BACTERIOL, V185, P6981, DOI 10.1128/JB.185.23.6981-6984.2003; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; KNEGTEL RMK, 1995, J BIOL CHEM, V270, P29256, DOI 10.1074/jbc.270.49.29256; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1991, CRYSTALLOGRAPHIC COM, P50; Li CM, 2005, BIOCHEMISTRY-US, V44, P3347, DOI 10.1021/bi048334e; Linden A, 2003, J BIOL CHEM, V278, P9875, DOI 10.1074/jbc.M211339200; MacGregor EA, 2001, BBA-PROTEIN STRUCT M, V1546, P1, DOI 10.1016/S0167-4838(00)00302-2; MACGREGOR EA, 1994, CARBOHYD RES, V257, P249, DOI 10.1016/0008-6215(94)80039-1; Machius M, 1996, J MOL BIOL, V260, P409, DOI 10.1006/jmbi.1996.0410; Matsui I, 1997, J BIOL CHEM, V272, P22456, DOI 10.1074/jbc.272.36.22456; MCFEETERS RF, 1980, ANAL BIOCHEM, V103, P302, DOI 10.1016/0003-2697(80)90614-4; Mori H, 2002, EUR J BIOCHEM, V269, P5377, DOI 10.1046/j.1432-1033.2002.03185.x; Mori H, 2001, EUR J BIOCHEM, V268, P6545, DOI 10.1046/j.0014-2956.2001.02609.x; MUNDY J, 1983, CARLSBERG RES COMMUN, V48, P81, DOI 10.1007/BF02906171; Ohtaki A, 2004, J BIOL CHEM, V279, P31033, DOI 10.1074/jbc.M404311200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Payan F, 2003, J PROTEIN CHEM, V22, P275, DOI 10.1023/A:1025072520607; Przylas I, 2000, J MOL BIOL, V296, P873, DOI 10.1006/jmbi.1999.3503; QIAN MX, 1995, PROTEIN SCI, V4, P747; QIAN MX, 1994, BIOCHEMISTRY-US, V33, P6284, DOI 10.1021/bi00186a031; Qian MX, 2001, BIOCHEMISTRY-US, V40, P7700, DOI 10.1021/bi0102050; Ramasubbu N, 2003, J MOL BIOL, V325, P1061, DOI 10.1016/S0022-2836(02)01326-8; Robert X, 2003, STRUCTURE, V11, P973, DOI 10.1016/S0969-2126(03)00151-5; Robert X, 2002, BIOLOGIA, V57, P59; Robert X, 2002, ACTA CRYSTALLOGR D, V58, P683, DOI 10.1107/S090744490200166X; Rodenburg KW, 2000, EUR J BIOCHEM, V267, P1019, DOI 10.1046/j.1432-1327.2000.01094.x; ROUSSEL A, 1992, BIOGRAPHICS; Sambrook J., 1989, MOL CLONING, pA1; Skov LK, 2002, J BIOL CHEM, V277, P47741, DOI 10.1074/jbc.M207860200; SOGAARD M, 1990, GENE, V94, P173, DOI 10.1016/0378-1119(90)90384-4; SOGAARD M, 1993, J BIOL CHEM, V268, P22480; Uitdehaag JCM, 1999, J BIOL CHEM, V274, P34868, DOI 10.1074/jbc.274.49.34868; Uitdehaag JCM, 1999, NAT STRUCT BIOL, V6, P432, DOI 10.1038/8235; VILLETTE JR, 1992, BIOTECHNOL APPL BIOC, V16, P57; WESELAKE RJ, 1983, CEREAL CHEM, V60, P98	62	60	61	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32968	32978		10.1074/jbc.M505515200	http://dx.doi.org/10.1074/jbc.M505515200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16030022	hybrid			2022-12-25	WOS:000231920300051
J	Park, IH; Chen, J				Park, IH; Chen, J			Mammalian target of rapamycin (mTOR) signaling is required for a late-stage fusion process during skeletal myotube maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR BINDING PROTEIN-5; P70 S6 KINASE; SATELLITE CELL-ACTIVITY; EXTRACELLULAR-MATRIX; SENSITIVE PATHWAY; MUSCLE GROWTH; DIFFERENTIATION; PHOSPHORYLATION; ACTIVATION; RAPTOR	Skeletal myogenesis is a well orchestrated cascade of events regulated by multiple signaling pathways, one of which is recently characterized by its sensitivity to the bacterial macrolide rapamycin. Previously we reported that the mammalian target of rapamycin (mTOR) regulates the initiation of the differentiation program in mouse C2C12 myoblasts by controlling the expression of insulin-like growth factor-II in a kinase-independent manner. Here we provide experimental evidence suggesting that a different mode of mTOR signaling regulates skeletal myogenesis at a later stage. In the absence of endogenous mTOR function in C2C12 cells treated with rapamycin, a kinase-inactive mTOR fully supports myogenin expression, but causes a delay in contractile protein expression. Myoblasts fuse to form nascent myotubes in the absence of kinase-active mTOR, whereas the formation of mature myotubes by further fusion requires the catalytic activity of mTOR. Therefore, the two stages of myocyte fusion are molecularly separable at the level of mTOR signaling. In addition, our data suggest that a factor secreted into the culture medium is responsible for mediating the function of mTOR in regulating the late-stage fusion leading to mature myotubes. Furthermore, taking advantage of the unique features of cells stably expressing a mutant mTOR, we have performed cDNA microarray analysis to compare global gene expression profiles between mature and nascent myotubes, the results of which have implicated classes of genes and revealed candidate regulators in myotube maturation or functions of mature myotubes.	Univ Illinois, Dept Cell & Dev Biol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Chen, J (corresponding author), 601 S Goodwin Ave,B107, Urbana, IL 61801 USA.	jiechen@uiuc.edu		Chen, Jie/0000-0002-7887-3747	NIAMS NIH HHS [AR48914] Funding Source: Medline; NIGMS NIH HHS [GM58064] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048914] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM058064, R01GM058064] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Clemmons David R., 1997, Cytokine and Growth Factor Reviews, V8, P45, DOI 10.1016/S1359-6101(96)00053-6; Conejo R, 2001, J CELL PHYSIOL, V186, P82, DOI 10.1002/1097-4652(200101)186:1<82::AID-JCP1001>3.0.CO;2-R; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; Cuenda A, 1999, J BIOL CHEM, V274, P4341, DOI 10.1074/jbc.274.7.4341; DARR KC, 1989, J APPL PHYSIOL, V67, P1827, DOI 10.1152/jappl.1989.67.5.1827; Erbay E, 2003, J CELL BIOL, V163, P931, DOI 10.1083/jcb.200307158; Erbay E, 2001, J BIOL CHEM, V276, P36079, DOI 10.1074/jbc.C100406200; Fang YM, 2003, CURR BIOL, V13, P2037, DOI 10.1016/j.cub.2003.11.021; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Gangloff YG, 2004, MOL CELL BIOL, V24, P9508, DOI 10.1128/MCB.24.21.9508-9516.2004; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 2001, GENE DEV, V15, P2852; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Horsley V, 2003, CELL, V113, P483, DOI 10.1016/S0092-8674(03)00319-2; Horsley V, 2001, J CELL BIOL, V153, P329, DOI 10.1083/jcb.153.2.329; Horsley V, 2003, J CELL BIOL, V161, P111, DOI 10.1083/jcb.200208085; James PL, 1996, J CELL BIOL, V133, P683, DOI 10.1083/jcb.133.3.683; JAMES PL, 1993, J BIOL CHEM, V268, P22305; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kuno K, 1998, J BIOL CHEM, V273, P13912, DOI 10.1074/jbc.273.22.13912; MCINNES A, 1988, J EXP MED, V167, P598, DOI 10.1084/jem.167.2.598; Mitchell PO, 2001, AM J PHYSIOL-CELL PH, V281, pC1706, DOI 10.1152/ajpcell.2001.281.5.C1706; Moran JL, 2002, PHYSIOL GENOMICS, V10, P103, DOI 10.1152/physiolgenomics.00011.2002; Murakami M, 2004, MOL CELL BIOL, V24, P6710, DOI 10.1128/mcb.24.15.6710-6718.2004; Nojima H, 2003, J BIOL CHEM, V278, P15461, DOI 10.1074/jbc.C200665200; Phelan JN, 1997, ANAT REC, V247, P179, DOI 10.1002/(SICI)1097-0185(199702)247:2<179::AID-AR4>3.0.CO;2-T; ROSENBLATT JD, 1994, MUSCLE NERVE, V17, P608, DOI 10.1002/mus.880170607; ROTWEIN P, 1995, MOL ENDOCRINOL, V9, P913, DOI 10.1210/me.9.7.913; Rousse S, 1998, ENDOCRINOLOGY, V139, P1487, DOI 10.1210/en.139.4.1487; Shu LL, 2002, J BIOL CHEM, V277, P16726, DOI 10.1074/jbc.M112285200; Tanaka TS, 2000, P NATL ACAD SCI USA, V97, P9127, DOI 10.1073/pnas.97.16.9127; Tang BL, 2001, INT J BIOCHEM CELL B, V33, P33, DOI 10.1016/S1357-2725(00)00061-3; Wilson EM, 2004, MOL BIOL CELL, V15, P497, DOI 10.1091/mbc.E03-05-0351; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0	45	68	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 9	2005	280	36					32009	32017		10.1074/jbc.M506120200	http://dx.doi.org/10.1074/jbc.M506120200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	961LZ	16043480	hybrid			2022-12-25	WOS:000231665200081
J	Mikami, F; Gu, H; Jono, H; Andalibi, A; Kai, H; Li, JD				Mikami, F; Gu, H; Jono, H; Andalibi, A; Kai, H; Li, JD			Epidermal growth factor receptor acts as a negative regulator for bacterium nontypeable Haemophilus influenzae-induced toll-like receptor 2 expression via an Src-dependent p38 mitogen-activated protein kinase signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TOLL-LIKE RECEPTORS; MUC5AC MUCIN TRANSCRIPTION; EPITHELIAL-CELLS; HUMAN CYTOMEGALOVIRUS; STAPHYLOCOCCUS-AUREUS; FAMILY KINASES; PAF RECEPTOR; MAP KINASE; INDUCTION	Epidermal growth factor receptor ( EGFR) has been shown to play important roles in regulating diverse biological processes, including cell growth, differentiation, apoptosis, adhesion, and migration. Its role in regulating human Toll-like receptors (TLRs), key host defense receptors that recognize invading bacterial pathogens, however, remains unknown. Here we show for the first time that EGFR acts as a negative regulator for TLR2 induction by the bacterium nontypeable Haemophilus influenzae (NTHi) in vitro and in vivo. The negative regulation of TLR2 induction by EGFR is mediated via an Src-MKK3/6-p38 alpha/beta MAP kinase-dependent mechanism. Moreover, direct activation of EGFR signaling by the bacterium NTHi-derived EGF-like factor appears to be responsible for triggering the downstream Src-MKK3/6-p38 MAPK signaling, which in turn leads to the negative regulation of TLR2 induction. Finally, exogenous EGF increases NTHi invasion of host epithelial cells, thereby demonstrating the biological significance of TLR2 regulation by EGFR signaling. The evidence we provided in the present study may suggest a novel strategy utilized by bacteria to attenuate host defensive and immune response by negatively regulating the expression of host defense receptor TLR2. These studies may bring new insight for fully understanding the important role of EGFR signaling in regulating host defense and immune response by tightly controlling TLR2 induction during bacterial infections.	Univ So Calif, House Ear Inst, Gonda Dept Cell & Mol Biol, Los Angeles, CA 90057 USA; Univ So Calif, Dept Otolaryngol, Los Angeles, CA 90057 USA; Kumamoto Univ, Dept Mol Med, Kumamoto 8620973, Japan	House Research Institute; University of Southern California; University of Southern California; Kumamoto University	Li, JD (corresponding author), Univ So Calif, House Ear Inst, Gonda Dept Cell & Mol Biol, 2100 W 3rd St, Los Angeles, CA 90057 USA.	jdli@hei.org		Li, Jian-Dong/0000-0002-5593-050X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070293] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC005843, R01DC004562] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL070293] Funding Source: Medline; NIDCD NIH HHS [DC005843, DC004562] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548; Boyer L, 2004, NAT REV MICROBIOL, V2, P779, DOI 10.1038/nrmicro1005; Bromann PA, 2004, ONCOGENE, V23, P7957, DOI 10.1038/sj.onc.1208079; Chen R, 2004, BIOCHEM BIOPH RES CO, V324, P1087, DOI 10.1016/j.bbrc.2004.09.157; Compton T, 2004, TRENDS CELL BIOL, V14, P5, DOI 10.1016/j.tcb.2003.10.009; Frey MR, 2004, J BIOL CHEM, V279, P44513, DOI 10.1074/jbc.M406253200; Holbro T, 2004, ANNU REV PHARMACOL, V44, P195, DOI 10.1146/annurev.pharmtox.44.101802.121440; Imasato A, 2002, J BIOL CHEM, V277, P47444, DOI 10.1074/jbc.M208140200; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Jono H, 2003, J BIOL CHEM, V278, P27811, DOI 10.1074/jbc.M301773200; Jono H, 2002, J BIOL CHEM, V277, P45547, DOI 10.1074/jbc.M206883200; Jono H, 2004, J BIOL CHEM, V279, P36171, DOI 10.1074/jbc.M406638200; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Keates S, 2001, J BIOL CHEM, V276, P48127, DOI 10.1074/jbc.M107630200; KELLY SJ, 2003, AM J PHYSIOL, V284, pC339; Kopp E, 2003, CURR OPIN IMMUNOL, V15, P396, DOI 10.1016/S0952-7915(03)00080-3; Lemjabbar H, 2002, NAT MED, V8, P41, DOI 10.1038/nm0102-41; Li JD, 2003, J PHARMACOL SCI, V91, P1, DOI 10.1254/jphs.91.1; Li JD, 1998, P NATL ACAD SCI USA, V95, P5718, DOI 10.1073/pnas.95.10.5718; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; Medzhitov R, 2000, TRENDS MICROBIOL, V8, P452, DOI 10.1016/S0966-842X(00)01845-X; Miller WE, 1999, TRENDS MICROBIOL, V7, P453, DOI 10.1016/S0966-842X(99)01605-4; Monick MM, 2005, J BIOL CHEM, V280, P2147, DOI 10.1074/jbc.M408745200; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Orth K, 2000, SCIENCE, V290, P1594, DOI 10.1126/science.290.5496.1594; Ouwens DM, 2002, EMBO J, V21, P3782, DOI 10.1093/emboj/cdf361; Shuto T, 2002, J BIOL CHEM, V277, P17263, DOI 10.1074/jbc.M112190200; Shuto T, 2001, P NATL ACAD SCI USA, V98, P8774, DOI 10.1073/pnas.151236098; Swords WE, 2000, MOL MICROBIOL, V37, P13, DOI 10.1046/j.1365-2958.2000.01952.x; Swords WE, 2001, CELL MICROBIOL, V3, P525, DOI 10.1046/j.1462-5822.2001.00132.x; Takeuchi O, 2000, J IMMUNOL, V165, P5392, DOI 10.4049/jimmunol.165.10.5392; Thoma-Uszynski S, 2001, SCIENCE, V291, P1544, DOI 10.1126/science.291.5508.1544; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tschumperlin DJ, 2004, NATURE, V429, P83, DOI 10.1038/nature02543; Visintin A, 2001, J IMMUNOL, V166, P249, DOI 10.4049/jimmunol.166.1.249; Wang BN, 2002, J BIOL CHEM, V277, P949, DOI 10.1074/jbc.M107484200; Wang X, 2005, NAT MED, V11, P515, DOI 10.1038/nm1236; Wang X, 2003, NATURE, V424, P456, DOI 10.1038/nature01818; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhang DK, 2004, SCIENCE, V303, P1522, DOI 10.1126/science.1094351	42	50	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36185	36194		10.1074/jbc.M503941200	http://dx.doi.org/10.1074/jbc.M503941200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16115866	hybrid			2022-12-25	WOS:000232726900050
J	Holm, MM; Naur, P; Vestergaard, B; Geballe, MT; Gajhede, M; Kastrup, JS; Traynelis, SF; Egebjerg, J				Holm, MM; Naur, P; Vestergaard, B; Geballe, MT; Gajhede, M; Kastrup, JS; Traynelis, SF; Egebjerg, J			A binding site tyrosine shapes desensitization kinetics and agonist potency at GluR2 - A mutagenic, kinetic, and crystallographic study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTAMATE-RECEPTOR DESENSITIZATION; AMPA RECEPTORS; CRYSTAL-STRUCTURES; KAINATE RECEPTORS; STRUCTURAL BASIS; NMDA RECEPTOR; ION CHANNELS; ACTIVATION; CORE; MECHANISMS	Binding of an agonist to the 2- amino- 3-( 3- hydroxy- 5- methyl- 4-isoxazolyl)- propionic acid ( AMPA) receptor family of the glutamate receptors ( GluRs) results in rapid activation of an ion channel. Continuous application results in a non- desensitizing response for agonists like kainate, whereas most other agonists, such as the endogenous agonist ( S)- glutamate, induce desensitization. We demonstrate that a highly conserved tyrosine, forming a wedge between the agonist and the N- terminal part of the bi- lobed ligand- binding site, plays a key role in the receptor kinetics as well as agonist potency and selectivity. The AMPA receptor GluR2, with mutations in Tyr450, were expressed in Xenopus laevis oocytes and characterized in a two- electrode voltage clamp setup. The mutation GluR2( Y450A) renders the receptor highly kainate selective, and rapid application of kainate to outside- out patches induced strongly desensitizing currents. When Tyr- 450 was substituted with the larger tryptophan, the ( S)- glutamate desensitization is attenuated with a 10- fold increase in steady- state/ peak currents ( 19% compared with 1.9% at the wild type). Furthermore, the tryptophan mutant was introduced into the GluR2- S1S2J ligand binding core construct and co- crystallized with kainate, and the 2.1- angstrom x- ray structure revealed a slightly more closed ligand binding core as compared with the wild- type complex. Through genetic manipulations combined with structural and electrophysiological analysis, we report that mutations in position 450 invert the potency of two central agonists while concurrently strongly shaping the agonist efficacy and the desensitization kinetics of the AMPA receptor GluR2.	Univ Aarhus, Inst Physiol & Biophys, Dept Mol Biol, DK-8000 Aarhus, Denmark; Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; Danish Univ Pharmaceut Sci, Dept Med Chem, DK-2100 Copenhagen, Denmark; Emory Univ, Dept Chem, Atlanta, GA 30322 USA	Aarhus University; Emory University; University of Copenhagen; Emory University	Holm, MM (corresponding author), Univ Aarhus, Inst Physiol & Biophys, Dept Mol Biol, Bldg 16,, DK-8000 Aarhus, Denmark.	mmh@fi.au.dk		Kastrup, Jette Sandholm/0000-0003-2654-1510; Holm, Mai/0000-0001-7347-8724; Vestergaard, Bente/0000-0001-8011-6414; Gajhede, Michael/0000-0001-9864-2287				Anson LC, 1998, J NEUROSCI, V18, P581; Armstrong N, 2003, P NATL ACAD SCI USA, V100, P5736, DOI 10.1073/pnas.1037393100; Armstrong N, 2000, NEURON, V28, P165, DOI 10.1016/S0896-6273(00)00094-5; Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; Ayalon G, 2001, NEURON, V31, P103, DOI 10.1016/S0896-6273(01)00333-6; Bowie D, 2002, J PHYSIOL-LONDON, V539, P725, DOI 10.1113/jphysiol.2001.013407; Bowie D, 2002, J NEUROSCI, V22, P3392; Brauner-Osborne H, 2000, J MED CHEM, V43, P2609, DOI 10.1021/jm000007r; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen GQ, 1999, NATURE, V402, P817, DOI 10.1038/45568; Chen GQ, 1997, P NATL ACAD SCI USA, V94, P13431, DOI 10.1073/pnas.94.25.13431; Dingledine R, 1999, PHARMACOL REV, V51, P7; Furukawa H, 2003, EMBO J, V22, P2873, DOI 10.1093/emboj/cdg303; Gouaux E, 2004, J PHYSIOL-LONDON, V554, P249, DOI 10.1113/jphysiol.2003.054320; Hogner A, 2003, J MED CHEM, V46, P214, DOI 10.1021/jm020989v; Hogner A, 2002, J MOL BIOL, V322, P93, DOI 10.1016/S0022-2836(02)00650-2; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Holm MM, 2005, P NATL ACAD SCI USA, V102, P12053, DOI 10.1073/pnas.0505522102; Jin RS, 2003, NAT NEUROSCI, V6, P803, DOI 10.1038/nn1091; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Koike M, 2000, J NEUROSCI, V20, P2166; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KURYATOV A, 1994, NEURON, V12, P1291, DOI 10.1016/0896-6273(94)90445-6; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Madden DR, 2004, BIOCHEMISTRY-US, V43, P15838, DOI 10.1021/bi048447y; Mansour M, 2001, NEURON, V32, P841, DOI 10.1016/S0896-6273(01)00520-7; Mayer ML, 2004, ANNU REV PHYSIOL, V66, P161, DOI 10.1146/annurev.physiol.66.050802.084104; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Nielsen MM, 2003, MOL PHARMACOL, V63, P19, DOI 10.1124/mol.63.1.19; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pentikainen OT, 2003, BIOCHEM PHARMACOL, V66, P2413, DOI 10.1016/j.bcp.2003.08.013; Robert A, 2001, J NEUROSCI, V21, P5574, DOI 10.1523/JNEUROSCI.21-15-05574.2001; Rosenmund C, 1998, SCIENCE, V280, P1596, DOI 10.1126/science.280.5369.1596; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; Stern-Bach Y, 1998, NEURON, V21, P907, DOI 10.1016/S0896-6273(00)80605-4; Sun Y, 2002, NATURE, V417, P245, DOI 10.1038/417245a	37	22	23	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35469	35476		10.1074/jbc.M507800200	http://dx.doi.org/10.1074/jbc.M507800200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16103115	hybrid			2022-12-25	WOS:000232561200047
J	Verma, SK; Mani, P; Sharma, NR; Krishnan, A; Kumar, VV; Reddy, BS; Chaudhuri, A; Roy, RP; Sarkar, DP				Verma, SK; Mani, P; Sharma, NR; Krishnan, A; Kumar, VV; Reddy, BS; Chaudhuri, A; Roy, RP; Sarkar, DP			Histidylated lipid-modified Sendai viral envelopes mediate enhanced membrane fusion and potentiate targeted gene delivery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS ENVELOPES; F-PROTEIN; HEMAGGLUTININ-NEURAMINIDASE; CATIONIC LIPIDS; HEPG2 CELLS; LIVER-CELLS; THERAPY; NANOPARTICLES; HEPATOCYTES; ACTIVATION	Recent studies have demonstrated that covalent grafting of a single histidine residue into a twin- chain aliphatic hydrocarbon compound enhances its endosome- disrupting properties and thereby generates an excellent DNA transfection system. Significant increase in gene delivery efficiencies has thus been obtained by using endosome- disrupting multiple histidine functionalities in the molecular architecture of various cationic polymers. To take advantage of this unique feature, we have incorporated L- histidine ( N, N-di-n- hexadecylamine) ethylamide ( L-H) in the membrane of hepatocyte-specific Sendai virosomes containing only the fusion protein ( F- virosomes ( Process for Producing a Targeted Gene ( Sarkar, D. P., Ramani, K., Bora, R. S., Kumar, M., and Tyagi, S. K. ( November 4, 1997) U. S. Patent 5,683,866))). Such L-H- modified virosomal envelopes were four times more ( p< 0.001) active in terms of fusion with its target cell membrane. On the other hand, the presence of L-H in reconstituted influenza and vesicular stomatitis virus envelopes failed to enhance spike glycoprotein- induced membrane fusion with host cell membrane. Circular dichroism and limited proteolysis experiments with F- virosomes indicated that the presence of L-H leads to conformational changes in the F protein. The molecular mechanism associated with the increased membrane fusion induced by L-H has been addressed in the light of fusion- competent conformational change in F protein. Such enhancement of fusion resulted in a highly efficient gene delivery system specific for liver cells in culture and in whole animals.	Univ Delhi, Dept Biochem, New Delhi 110021, India; Indian Inst Chem Technol, Div Lipid Sci & Technol, Hyderabad 500007, Andhra Pradesh, India; Natl Inst Immunol, New Delhi 110067, India	University of Delhi; Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Technology (IICT); Department of Biotechnology (DBT) India; National Institute of Immunology (NII)	Sarkar, DP (corresponding author), Univ Delhi, Dept Biochem, S Campus,Benito Juarez Rd, New Delhi 110021, India.	dpsarkar59@rediffmail.com	krishnan, anuja/AAS-3567-2021; Verma, Santosh/AAQ-8952-2020	Verma, Santosh/0000-0001-6058-6494; Sarkar, Debi P/0000-0002-8886-8415; , Anuja/0000-0001-6538-2044				BAGAI S, 1993, J VIROL, V67, P3312, DOI 10.1128/JVI.67.6.3312-3318.1993; BAGAI S, 1993, BIOCHIM BIOPHYS ACTA, V1152, P15, DOI 10.1016/0005-2736(93)90226-P; BAGAI S, 1994, J BIOL CHEM, V269, P1966; BAGAI S, 1993, FEBS LETT, V326, P183, DOI 10.1016/0014-5793(93)81787-Z; Branca MA, 2005, NAT BIOTECHNOL, V23, P519, DOI 10.1038/nbt0505-519; Cavazzana-Calvo M, 2004, NATURE, V427, P779, DOI 10.1038/427779a; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; Dandekar DH, 2005, ANAL BIOCHEM, V342, P341, DOI 10.1016/j.ab.2005.02.006; Fasbender A, 1997, J BIOL CHEM, V272, P6479, DOI 10.1074/jbc.272.10.6479; Fontana A, 2004, ACTA BIOCHIM POL, V51, P299; HSU MC, 1981, J BIOL CHEM, V256, P3557; Jana SS, 2002, FEBS LETT, V515, P184, DOI 10.1016/S0014-5793(02)02467-5; Kichler A, 2003, P NATL ACAD SCI USA, V100, P1564, DOI 10.1073/pnas.0337677100; Koshiba T, 2004, SCIENCE, V305, P858, DOI 10.1126/science.1099793; KREN BT, 2003, GENE THER MOL BIOL, V7, P229; Kumar M, 1997, J VIROL, V71, P6398, DOI 10.1128/JVI.71.9.6398-6406.1997; Kumar VV, 2003, GENE THER, V10, P1206, DOI 10.1038/sj.gt.3301979; Lamb R.A., 2001, FIELDS VIROLOGY; Ludwig K, 2003, EMBO J, V22, P3761, DOI 10.1093/emboj/cdg385; Luo D, 2004, TRENDS BIOTECHNOL, V22, P101, DOI 10.1016/j.tibtech.2004.01.002; Niidome T, 2002, GENE THER, V9, P1647, DOI 10.1038/sj.gt.3301923; Nijhara R, 2001, J VIROL, V75, P10348, DOI 10.1128/JVI.75.21.10348-10358.2001; Okada Y., 1988, TRANSPORT-VILNIUS, P297, DOI [10.1016/S0070-2161(08)60138-0, DOI 10.1016/S0070-2161(08)60138-0]; PATERNOSTRE MT, 1989, FEBS LETT, V243, P251, DOI 10.1016/0014-5793(89)80139-5; Ramani K, 1997, FEBS LETT, V404, P164, DOI 10.1016/S0014-5793(97)00120-8; Ramanj K, 1998, P NATL ACAD SCI USA, V95, P11886, DOI 10.1073/pnas.95.20.11886; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SARKAR DI, 1997, Patent No. 5683866; SCHEID A, 1977, VIROLOGY, V80, P54, DOI 10.1016/0042-6822(77)90380-4; Torchilin VP, 2005, NAT REV DRUG DISCOV, V4, P145, DOI 10.1038/nrd1632; Tsuboniwa N, 2001, HUM GENE THER, V12, P469, DOI 10.1089/104303401300042366; Yamada T, 2003, NAT BIOTECHNOL, V21, P885, DOI 10.1038/nbt843; Zhao X, 2000, P NATL ACAD SCI USA, V97, P14172, DOI 10.1073/pnas.260499197	33	19	21	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35399	35409		10.1074/jbc.M506615200	http://dx.doi.org/10.1074/jbc.M506615200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16085643	hybrid			2022-12-25	WOS:000232561200039
J	Bickel, T; Lehle, L; Schwarz, M; Aebi, M; Jakob, CA				Bickel, T; Lehle, L; Schwarz, M; Aebi, M; Jakob, CA			Biosynthesis of lipid-linked oligosaccharides in Saccharomyces cerevisiae - Alg13p AND Alg14p form a complex required for the formation of GlcNAc(2)-PP-dolichol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; STREPTOCOCCUS-PNEUMONIAE SEROTYPE-14; YEAST MUTANTS DEFICIENT; OLIGOSACCHARYLTRANSFERASE COMPLEX; ENDOPLASMIC-RETICULUM; N-ACETYLGLUCOSAMINE; GLYCOSYLATION PATHWAY; SUBSTRATE-SPECIFICITY; GLUCOSYLATION STEPS; FUNCTIONAL-ANALYSIS	N-Glycosylation in the endoplasmic reticulum is an essential protein modification and highly conserved in evolution from yeast to man. Here we identify and characterize two essential yeast proteins having homology to bacterial glycosyltransferases, designated Alg13p and Alg14p, as being required for the formation of Glc-NAc2-PP-dolichol ( Dol), the second step in the biosynthesis of the unique lipid-linked core oligosaccharide. Down-regulation of each gene led to a defect in protein N-glycosylation and an accumulation of GlcNAc(1)-PP-Dol in vivo as revealed by metabolic labeling with [H-3] glucosamine. Microsomal membranes from cells repressed for ALG13 or ALG14, as well as detergent-solubilized extracts thereof, were unable to catalyze the transfer of N-acetylglucosamine from UDP-GlcNAc to [C-14] GlcNAc(1)-PP-Dol, but did not impair the formation of GlcNAc(1)-PP-Dol or GlcNAc-GPI. Immunoprecipitating Alg13p from solubilized extracts resulted in the formation of Glc-NAc2-PP-Dol but required Alg14p for activity, because an Alg13p immunoprecipitate obtained from cells in which ALG14 was downregulated lacked this activity. In Western blot analysis it was demonstrated that Alg13p, for which no well defined transmembrane segment has been predicted, localizes both to the membrane and cytosol; the latter form, however, is enzymatically inactive. In contrast, Alg14p is exclusively membrane-bound. Repression of the ALG14 gene causes a depletion of Alg13p from the membrane. By affinity chromatography on IgG-Sepharose using Alg14-ZZ as bait, we demonstrate that Alg13-myc co-fractionates with Alg14-ZZ. The data suggest that Alg13p associates with Alg14p to a complex forming the active transferase catalyzing the biosynthesis of GlcNAc(2)-PP-Dol.	Univ Regensburg, Lehrstuhl Zellbiol & Pflanzenphysiol, D-93053 Regensburg, Germany; Swiss Fed Inst Technol, Inst Mikrobiol, CH-8093 Zurich, Switzerland	University of Regensburg; Swiss Federal Institutes of Technology Domain; ETH Zurich	Lehle, L (corresponding author), Univ Regensburg, Lehrstuhl Zellbiol & Pflanzenphysiol, Univ Str 31, D-93053 Regensburg, Germany.	ludwig.lehle@biologie.uni-regensburg.de						ABEIJON C, 1992, TRENDS BIOCHEM SCI, V17, P32, DOI 10.1016/0968-0004(92)90424-8; BECK PJ, 1990, SOMAT CELL MOLEC GEN, V16, P539, DOI 10.1007/BF01233094; Belli G, 1998, YEAST, V14, P1127, DOI 10.1002/(SICI)1097-0061(19980915)14:12<1127::AID-YEA300>3.0.CO;2-#; Burda P, 1999, BBA-GEN SUBJECTS, V1426, P239, DOI 10.1016/S0304-4165(98)00127-5; Burda P, 1998, GLYCOBIOLOGY, V8, P455, DOI 10.1093/glycob/8.5.455; Burda P, 1999, GLYCOBIOLOGY, V9, P617, DOI 10.1093/glycob/9.6.617; Chantret I, 2005, J BIOL CHEM, V280, P9236, DOI 10.1074/jbc.M413941200; CHAPMAN A, 1980, J BIOL CHEM, V255, P4441; DSOUZA C, 1992, ANAL BIOCHEM, V203, P211, DOI 10.1016/0003-2697(92)90305-Q; FOLCH J, 1957, J BIOL CHEM, V226, P497; Ha S, 2000, PROTEIN SCI, V9, P1045, DOI 10.1110/ps.9.6.1045; Hall CW, 1997, J CELL BIOCHEM, V67, P201, DOI 10.1002/(SICI)1097-4644(19971101)67:2<201::AID-JCB5>3.3.CO;2-Q; HANOVER JA, 1981, ARCH BIOCHEM BIOPHYS, V211, P1, DOI 10.1016/0003-9861(81)90423-9; HEIFETZ A, 1977, J BIOL CHEM, V252, P3057; Helenius J, 2002, NATURE, V415, P447, DOI 10.1038/415447a; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; HUFFAKER TC, 1982, J BIOL CHEM, V257, P3203; HUFFAKER TC, 1983, P NATL ACAD SCI-BIOL, V80, P7466, DOI 10.1073/pnas.80.24.7466; KEAN EL, 1983, BIOCHIM BIOPHYS ACTA, V750, P268, DOI 10.1016/0005-2760(83)90028-0; KEAN EL, 1991, J BIOL CHEM, V266, P942; Knauer R, 1999, BBA-GEN SUBJECTS, V1426, P259, DOI 10.1016/S0304-4165(98)00128-7; KNAUER R, 1994, FEBS LETT, V344, P83, DOI 10.1016/0014-5793(94)00356-4; Knauer R, 1999, J BIOL CHEM, V274, P17249, DOI 10.1074/jbc.274.24.17249; Kolkman MAB, 1997, MOL MICROBIOL, V26, P197, DOI 10.1046/j.1365-2958.1997.5791940.x; Kolkman MAB, 1997, J BIOL CHEM, V272, P19502, DOI 10.1074/jbc.272.31.19502; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LEHLE L, 1976, FEBS LETT, V71, P167, DOI 10.1016/0014-5793(76)80922-2; Lehle L., 1995, GLYCOPROTEINS A, V29a, P475; MCLACHLAN KR, 1994, J LIPID RES, V35, P1861; MCLACHLAN KR, 1992, GLYCOBIOLOGY, V2, P313, DOI 10.1093/glycob/2.4.313; MENGINLECREULX D, 1991, J BACTERIOL, V173, P4625, DOI 10.1128/jb.173.15.4625-4636.1991; PALAMARCZYK G, 1980, EUR J BIOCHEM, V105, P517, DOI 10.1111/j.1432-1033.1980.tb04527.x; REARICK JI, 1981, J BIOL CHEM, V256, P3762; RUNGE KW, 1984, J BIOL CHEM, V259, P412; RUNGE KW, 1986, J BIOL CHEM, V261, P5582; SHAILUBHAI K, 1988, J BIOL CHEM, V263, P15964; SHARMA CB, 1990, BIOCHEMISTRY-US, V29, P8901, DOI 10.1021/bi00490a004; SHARMA CB, 1982, EUR J BIOCHEM, V126, P319; Sharma CB, 2001, BIOL CHEM, V382, P321, DOI 10.1515/BC.2001.039; Silberstein S, 1996, FASEB J, V10, P849, DOI 10.1096/fasebj.10.8.8666161; Videira P, 2001, BIOCHEM J, V358, P457, DOI 10.1042/0264-6021:3580457; ZENG Y, 1991, ANAL BIOCHEM, V193, P266, DOI 10.1016/0003-2697(91)90020-T; Zhang Z, 1998, NUCLEIC ACIDS RES, V26, P3986, DOI 10.1093/nar/26.17.3986; ZHU XY, 1992, J BIOL CHEM, V267, P8895	44	49	52	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34500	34506		10.1074/jbc.M506358200	http://dx.doi.org/10.1074/jbc.M506358200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16100113	hybrid			2022-12-25	WOS:000232403900017
J	Openshaw, AEA; Race, PR; Monzo, HJ; Vazquez-Boland, JA; Banfield, MJ				Openshaw, AEA; Race, PR; Monzo, HJ; Vazquez-Boland, JA; Banfield, MJ			Crystal structure of SmcL, a bacterial neutral sphingomyelinase C from Listeria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-CEREUS SPHINGOMYELINASE; PHOSPHOLIPASE-C; NUCLEOTIDE-SEQUENCE; CATALYTIC RESIDUES; COMPLEX; GENE; EXPRESSION; ALIGNMENT; ENZYMES; TOXINS	Sphingomyelinases C are enzymes that catalyze the hydrolysis of sphingomyelin in biological membranes to ceramide and phosphorylcholine. Various pathogenic bacteria produce secreted neutral sphingomyelinases C that act as membrane-damaging virulence factors. Mammalian neutral sphingomyelinases C, which display sequence homology to the bacterial enzymes, are involved in sphingolipid metabolism and signaling. This article describes the first structure to be determined for a member of the neutral sphingomyelinase C family, SmcL, from the intracellular bacterial pathogen Listeria ivanovii. The structure has been refined to 1.9-angstrom resolution with phases derived by single isomorphous replacement with anomalous scattering techniques from a single iridium derivative. SmcL adopts a DNase I-like fold, and is the first member of this protein superfamily to have its structure determined that acts as a phospholipase. The structure reveals several unique features that adapt the protein to its phospholipid substrate. These include large hydrophobic beta-hairpin and hydrophobic loops surrounding the active site that may bind and penetrate the lipid bilayer to position sphingomyelin in a catalytically competent position. The structure also provides insight into the proposed general base/acid catalytic mechanism, in which His-325 and His-185 play key roles.	Newcastle Univ, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Bristol, Bacterial Mol Pathogenesis Grp, Fac Med & Vet Sci, Bristol BS40 5DU, Avon, England; Univ Leon, E-24071 Leon, Spain	Newcastle University - UK; University of Bristol; Universidad de Leon	Banfield, MJ (corresponding author), Newcastle Univ, Inst Cell & Mol Biosci, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	M.J.Banfield@ncl.ac.uk	Banfield, Mark/C-7453-2013	Banfield, Mark/0000-0001-8921-3835				Andrieu-Abadie N, 2002, BBA-MOL CELL BIOL L, V1585, P126, DOI 10.1016/S1388-1981(02)00332-3; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Cho WH, 2005, ANNU REV BIOPH BIOM, V34, P119, DOI 10.1146/annurev.biophys.33.110502.133337; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; DUAN RD, 1995, BBA-LIPID LIPID MET, V1259, P49, DOI 10.1016/0005-2760(95)00137-2; Dziewanowska K, 1996, ARCH BIOCHEM BIOPHYS, V335, P102, DOI 10.1006/abbi.1996.0486; Futerman AH, 2004, EMBO REP, V5, P777, DOI 10.1038/sj.embor.7400208; GEOFFROY C, 1991, INFECT IMMUN, V59, P2382, DOI 10.1128/IAI.59.7.2382-2388.1991; Goni FM, 2002, FEBS LETT, V531, P38, DOI 10.1016/S0014-5793(02)03482-8; Gonzalez-Zorn B, 1999, MOL MICROBIOL, V33, P510, DOI 10.1046/j.1365-2958.1999.01486.x; Hakogi T, 2002, J ORG CHEM, V67, P4839, DOI 10.1021/jo025529o; Hanada K, 2002, J EXP MED, V195, P23, DOI 10.1084/jem.20010724; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; Heinz DW, 1996, BIOCHEMISTRY-US, V35, P9496, DOI 10.1021/bi9606105; HEINZ DW, 1995, EMBO J, V14, P3855, DOI 10.1002/j.1460-2075.1995.tb00057.x; Hofmann K, 2000, P NATL ACAD SCI USA, V97, P5895, DOI 10.1073/pnas.97.11.5895; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Jones SJ, 1996, J MOL BIOL, V264, P1154, DOI 10.1006/jmbi.1996.0703; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1996, STRUCTURE, V4, P1395, DOI 10.1016/S0969-2126(96)00147-5; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; Leslie A. G. W., 1992, JOINT CCP4 ESF EAMCB; Luberto C, 2002, J BIOL CHEM, V277, P41128, DOI 10.1074/jbc.M206747200; Mahfoud R, 2002, J BIOL CHEM, V277, P11292, DOI 10.1074/jbc.M111679200; Matsuo Y, 1996, PROTEIN SCI, V5, P2459, DOI 10.1002/pro.5560051208; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; Murakami MT, 2005, J BIOL CHEM, V280, P13658, DOI 10.1074/jbc.M412437200; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Nesic D, 2004, NATURE, V429, P429, DOI 10.1038/nature02532; Obama T, 2003, BIOL PHARM BULL, V26, P920; Obama T, 2003, J BIOCHEM, V133, P279, DOI 10.1093/jb/mvg038; Page R, 2003, ACTA CRYSTALLOGR D, V59, P1028, DOI 10.1107/S0907444903007790; Parker MW, 2005, PROG BIOPHYS MOL BIO, V88, P91, DOI 10.1016/j.pbiomolbio.2004.01.009; Pettus BJ, 2002, BBA-MOL CELL BIOL L, V1585, P114, DOI 10.1016/S1388-1981(02)00331-1; PROJAN SJ, 1989, NUCLEIC ACIDS RES, V17, P3305, DOI 10.1093/nar/17.8.3305; Rodrigues-Lima F, 2000, J BIOL CHEM, V275, P28316; SCHUCHMAN EH, 1991, J BIOL CHEM, V266, P8531; SEGERS RPAM, 1990, INFECT IMMUN, V58, P2177, DOI 10.1128/IAI.58.7.2177-2185.1990; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2002, ACTA CRYSTALLOGR D, V58, P1937, DOI 10.1107/S0907444902016438; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; TITBALL RW, 1993, FEMS MICROBIOL LETT, V110, P45, DOI 10.1016/0378-1097(93)90240-3; Tomiuk S, 1998, P NATL ACAD SCI USA, V95, P3638, DOI 10.1073/pnas.95.7.3638; Tsujishita Y, 2001, CELL, V105, P379, DOI 10.1016/S0092-8674(01)00326-9; Vargas-Villarreal Javier, 2003, Med Sci Monit, V9, pBR225; Weichenrieder O, 2004, STRUCTURE, V12, P975, DOI 10.1016/j.str.2004.04.011; Weichsel A, 2005, P NATL ACAD SCI USA, V102, P594, DOI 10.1073/pnas.0406549102; WESTON SA, 1992, J MOL BIOL, V226, P1237, DOI 10.1016/0022-2836(92)91064-V; YAMADA A, 1988, EUR J BIOCHEM, V175, P213, DOI 10.1111/j.1432-1033.1988.tb14186.x; Yu BZ, 2002, BBA-MOL CELL BIOL L, V1583, P122, DOI 10.1016/S1388-1981(02)00192-0	51	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					35011	35017		10.1074/jbc.M506800200	http://dx.doi.org/10.1074/jbc.M506800200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16093240	hybrid			2022-12-25	WOS:000232403900074
J	Raychowdhury, MK; McLaughlin, M; Ramos, AJ; Montalbetti, N; Bouley, R; Ausiello, DA; Cantiello, HF				Raychowdhury, MK; McLaughlin, M; Ramos, AJ; Montalbetti, N; Bouley, R; Ausiello, DA; Cantiello, HF			Characterization of single channel currents from primary cilia of renal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ION CHANNELS; CATION CHANNELS; SENSORY CILIA; POLYCYSTIN-2; MEMBRANE; K+; PROTEIN; CYSTIN; FLOW; NA+	The primary cilium is a ubiquitous, non-motile microtubular organelle lacking the central pair of microtubules found in motile cilia. Primary cilia are surrounded by a membrane, which has a unique complement of membrane proteins, and may thus be functionally different from the plasma membrane. The function of the primary cilium remains largely unknown. However, primary cilia have important sensory transducer properties, including the response of renal epithelial cells to fluid flow or mechanical stimulation. Recently, renal cystic diseases have been associated with dysfunctional ciliary proteins. Although the sensory properties of renal epithelial primary cilia may be associated with functional channel activity in the organelle, information in this regard is still lacking. This may be related to the inherent difficulties in assessing electrical activity in this rather small and narrow organelle. In the present study, we provide the first direct electrophysiological evidence for the presence of single channel currents from isolated primary cilia of LLC-PK1 renal epithelial cells. Several channel phenotypes were observed, and addition of vasopressin increased cation channel activity, which suggests the regulation, by the cAMP pathway of ciliary conductance. Ion channel reconstitution of ciliary versus plasma membranes indicated a much higher channel density in cilia. At least three channel proteins, polycystin-2, TRPC1, and interestingly, the alpha-epithelial sodium channel, were immunodetected in this organelle. Ion channel activity in the primary cilium of renal cells may be an important component of its role as a sensory transducer.	MA Gen Hosp E, Renal Unit, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Buenos Aires, Fac Farm & Bioquim, Dept Fisicoquim & Quim Analit, Lab Canales Ion, RA-1113 Buenos Aires, DF, Argentina	Harvard University; Harvard Medical School; University of Buenos Aires	Cantiello, HF (corresponding author), MA Gen Hosp E, Renal Unit, 149 13th St, Charlestown, MA 02129 USA.	cantiello@helix.mgh.harvard.edu	Montalbetti, Nicolas/T-4212-2019	Montalbetti, Nicolas/0000-0003-2897-9540				Afzelius BA, 2004, J PATHOL, V204, P470, DOI 10.1002/path.1652; Brailov I, 2000, BRAIN RES, V872, P271, DOI 10.1016/S0006-8993(00)02519-1; BRAY D, 1992, CELL MOVEMENTS, P265; Delgado R, 2003, J NEUROPHYSIOL, V90, P2022, DOI 10.1152/jn.01167.2002; EHRLICH BE, 1984, SCIENCE, V225, P427, DOI 10.1126/science.6330895; FRINGS S, 1991, J GEN PHYSIOL, V97, P1, DOI 10.1085/jgp.97.1.1; FRINGS S, 1990, BIOPHYS J, V57, P1091, DOI 10.1016/S0006-3495(90)82627-8; FRINGS S, 1991, J GEN PHYSIOL, V97, P725, DOI 10.1085/jgp.97.4.725; FUJIWARA C, 1988, J BIOCHEM, V104, P344, DOI 10.1093/oxfordjournals.jbchem.a122471; FujiwaraHirashima C, 1996, BBA-BIOMEMBRANES, V1280, P207, DOI 10.1016/0005-2736(95)00292-8; Gonzalez-Perrett S, 2001, P NATL ACAD SCI USA, V98, P1182, DOI 10.1073/pnas.021456598; Handel M, 1999, NEUROSCIENCE, V89, P909, DOI 10.1016/S0306-4522(98)00354-6; Honda E, 1995, BRAIN RES, V703, P79, DOI 10.1016/0006-8993(95)01072-6; Hou XY, 2002, J CLIN INVEST, V109, P533, DOI 10.1172/JC1200214099; JORQUERA O, 1995, AM J PHYSIOL-CELL PH, V269, pC1235, DOI 10.1152/ajpcell.1995.269.5.C1235; LABARCA P, 1988, J BIOENERG BIOMEMBR, V20, P551, DOI 10.1007/BF00768919; LABARCA P, 1988, P NATL ACAD SCI USA, V85, P944, DOI 10.1073/pnas.85.3.944; Larsson HP, 1997, BIOPHYS J, V72, P1193, DOI 10.1016/S0006-3495(97)78767-8; Mitchell KAP, 2004, CELL MOTIL CYTOSKEL, V59, P62, DOI 10.1002/cm.20025; Morgan D, 1998, NAT GENET, V20, P149, DOI 10.1038/2450; Murphy GJ, 2003, NEURON, V37, P639, DOI 10.1016/S0896-6273(03)00057-6; Nakamura T, 1996, BIOPHYS J, V70, P813, DOI 10.1016/S0006-3495(96)79625-X; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; Nonaka S, 1998, CELL, V95, P829, DOI 10.1016/S0092-8674(00)81705-5; OOSAWA Y, 1988, CELL STRUCT FUNCT, V13, P51, DOI 10.1247/csf.13.51; Pazour GJ, 2003, CURR OPIN CELL BIOL, V15, P105, DOI 10.1016/S0955-0674(02)00012-1; Pazour GJ, 2002, CURR BIOL, V12, pR378, DOI 10.1016/S0960-9822(02)00877-1; Praetorius HA, 2001, J MEMBRANE BIOL, V184, P71, DOI 10.1007/s00232-001-0075-4; Praetorius HA, 2005, ANNU REV PHYSIOL, V67, P515, DOI 10.1146/annurev.physiol.67.040403.101353; Praetorius HA, 2003, J MEMBRANE BIOL, V191, P69, DOI 10.1007/s00232-002-1042-4; Raychowdhury MK, 2004, J BIOL CHEM, V279, P20137, DOI 10.1074/jbc.M311946200; RIEDER CL, 1979, J ULTRA MOL STRUCT R, V68, P173, DOI 10.1016/S0022-5320(79)90152-7; ROBERTS WM, 1992, METHOD ENZYMOL, V207, P155; Schwartz EA, 1997, AM J PHYSIOL-RENAL, V272, pF132, DOI 10.1152/ajprenal.1997.272.1.F132; Stuhmer W., 1983, SINGLE CHANNEL RECOR, P123; Wheatley DN, 2000, BIOL CELL, V92, P573, DOI 10.1016/S0248-4900(00)01108-4; Yoder BK, 2002, J AM SOC NEPHROL, V13, P2508, DOI 10.1097/01.ASN.0000029587.47950.25; Yoder BK, 2002, AM J PHYSIOL-RENAL, V282, pF541, DOI 10.1152/ajprenal.00273.2001	38	54	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34718	34722		10.1074/jbc.M507793200	http://dx.doi.org/10.1074/jbc.M507793200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16079132	hybrid			2022-12-25	WOS:000232403900042
J	Stenberg, F; Chovanec, P; Maslen, SL; Robinson, CV; Ilag, LL; von Heijne, G; Daley, DO				Stenberg, F; Chovanec, P; Maslen, SL; Robinson, CV; Ilag, LL; von Heijne, G; Daley, DO			Protein complexes of the Escherichia coli cell envelope	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE NATIVE ELECTROPHORESIS; INTEGRAL MEMBRANE-PROTEINS; UBIQUINONE-BINDING-SITE; OUTER-MEMBRANE; CRYSTAL-STRUCTURE; MULTIDRUG EFFLUX; SACCHAROMYCES-CEREVISIAE; PROTEOMIC APPROACH; MASS-SPECTROMETRY; INTERACTION MAP	Protein complexes are an intrinsic aspect of life in the membrane. Knowing which proteins are assembled in these complexes is therefore essential to understanding protein function(s). Unfortunately, recent high throughput protein interaction studies have failed to deliver any significant information on proteins embedded in the membrane, and many membrane protein complexes remain ill defined. In this study, we have optimized the blue native-PAGE technique for the study of membrane protein complexes in the inner and outer membranes of Escherichia coli. In combination with second dimension SDS-PAGE and mass spectrometry, we have been able to identify 43 distinct protein complexes. In addition to a number of well characterized complexes, we have identified known and orphan proteins in novel oligomeric states. For two orphan proteins, YhcB and YjdB, our findings enable a tentative functional assignment. We propose that YhcB is a hitherto unidentified additional subunit of the cytochrome bd oxidase and that YjdB, which co-localizes with the ZipA protein, is involved in cell division. Our reference two-dimensional blue native-SDS-polyacrylamide gels will facilitate future studies of the assembly and composition of E. coli membrane protein complexes during different growth conditions and in different mutant backgrounds.	Stockholm Univ, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden; Stockholm Univ, Prote Facil, Dept Analyt Chem, SE-10691 Stockholm, Sweden; Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England	Stockholm University; Stockholm University; University of Cambridge	Daley, DO (corresponding author), Stockholm Univ, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden.	ddaley@dbb.su.se	von Heijne, Gunnar/F-5576-2011; von Heijne, Gunnar/AAH-9389-2019	von Heijne, Gunnar/0000-0002-4490-8569; Ilag, Leopold/0000-0003-3678-7100; Chovanec, Peter/0000-0002-7063-2658; Daley, Daniel/0000-0002-6425-5059; robinson, carol/0000-0001-7829-5505				Abramson J, 2000, NAT STRUCT BIOL, V7, P910; Agne B, 2003, MOL CELL, V11, P635, DOI 10.1016/S1097-2765(03)00062-5; Alberts B, 1998, CELL, V92, P291, DOI 10.1016/S0092-8674(00)80922-8; Bass RB, 2002, SCIENCE, V298, P1582, DOI 10.1126/science.1077945; Braun M, 2002, MOL MICROBIOL, V45, P1289, DOI 10.1046/j.1365-2958.2002.03091.x; Butland G, 2005, NATURE, V433, P531, DOI 10.1038/nature03239; Capaldi RA, 2002, TRENDS BIOCHEM SCI, V27, P154, DOI 10.1016/S0968-0004(01)02051-5; Casadio R, 2003, PROTEIN SCI, V12, P1158, DOI 10.1110/ps.0223603; CHOI DS, 1986, J BIOL CHEM, V261, P8953; Ciambella C, 2005, PROTEOMICS, V5, P746, DOI 10.1002/pmic.200401129; Cruciat CM, 2000, J BIOL CHEM, V275, P18093, DOI 10.1074/jbc.M001901200; Dalbey RE, 2004, BBA-MOL CELL RES, V1694, P37, DOI 10.1016/j.bbamcr.2004.03.009; Daley DO, 2005, SCIENCE, V308, P1321, DOI 10.1126/science.1109730; Daniels C, 1999, MOL MICROBIOL, V34, P181, DOI 10.1046/j.1365-2958.1999.01591.x; Dartigalongue C, 1998, EMBO J, V17, P3968, DOI 10.1093/emboj/17.14.3968; DEVRIJE T, 1987, BIOCHIM BIOPHYS ACTA, V900, P63, DOI 10.1016/0005-2736(87)90278-1; Doyle SM, 2004, J MOL BIOL, V341, P199, DOI 10.1016/j.jmb.2004.06.021; DRIESSEN AJM, 1993, BIOCHEMISTRY-US, V32, P13190, DOI 10.1021/bi00211a030; Eubel H, 2004, PLANT PHYSIOL, V134, P1450, DOI 10.1104/pp.103.038018; Fountoulakis M, 2003, AMINO ACIDS, V24, P19, DOI 10.1007/s00726-002-0339-z; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Giot L, 2003, SCIENCE, V302, P1727, DOI 10.1126/science.1090289; Hale CA, 1997, CELL, V88, P175, DOI 10.1016/S0092-8674(00)81838-3; Hartinger J, 1996, ANAL BIOCHEM, V240, P126, DOI 10.1006/abio.1996.0339; Heazlewood JL, 2003, PLANT PHYSIOL, V132, P230, DOI 10.1104/pp.102.018986; Herranen M, 2004, PLANT PHYSIOL, V134, P470, DOI 10.1104/pp.103.032326; Heuberger EHML, 2002, J MOL BIOL, V317, P591, DOI 10.1006/jmbi.2002.5416; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Jansch L, 1996, PLANT J, V9, P357, DOI 10.1046/j.1365-313X.1996.09030357.x; Jilaveanu LB, 2005, P NATL ACAD SCI USA, V102, P7511, DOI 10.1073/pnas.0502774102; Kennedy KA, 2004, J BIOL CHEM, V279, P33290, DOI 10.1074/jbc.M403796200; Keseler IM, 2005, NUCLEIC ACIDS RES, V33, pD334, DOI 10.1093/nar/gki108; Koronakis V, 2000, NATURE, V405, P914, DOI 10.1038/35016007; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; LEIF H, 1995, EUR J BIOCHEM, V230, P538, DOI 10.1111/j.1432-1033.1995.tb20594.x; Lowe J, 2004, ANNU REV BIOPH BIOM, V33, P177, DOI 10.1146/annurev.biophys.33.110502.132647; MASTERS PS, 1981, J BACTERIOL, V147, P805, DOI 10.1128/JB.147.3.805-819.1981; MILLER MJ, 1988, J BIOL CHEM, V263, P5235; Molloy MP, 2000, EUR J BIOCHEM, V267, P2871, DOI 10.1046/j.1432-1327.2000.01296.x; Murakami S, 2002, NATURE, V419, P587, DOI 10.1038/nature01050; Nishino K, 2001, J BACTERIOL, V183, P5803, DOI 10.1128/JB.183.20.5803-5812.2001; Nouwen N, 2002, MOL MICROBIOL, V44, P1397, DOI 10.1046/j.1365-2958.2002.02972.x; Obrdlik P, 2004, P NATL ACAD SCI USA, V101, P12242, DOI 10.1073/pnas.0404467101; Or E, 2005, J BIOL CHEM, V280, P9097, DOI 10.1074/jbc.M413947200; Paetzel M, 2000, PHARMACOL THERAPEUT, V87, P27, DOI 10.1016/S0163-7258(00)00064-4; Pautsch A, 1998, NAT STRUCT BIOL, V5, P1013, DOI 10.1038/2983; Pichoff S, 2002, EMBO J, V21, P685, DOI 10.1093/emboj/21.4.685; Price GP, 2000, FEMS MICROBIOL LETT, V193, P51, DOI 10.1016/S0378-1097(00)00453-5; Rain JC, 2001, NATURE, V409, P211, DOI 10.1038/35051615; Rais I, 2004, PROTEOMICS, V4, P2567, DOI 10.1002/pmic.200400829; Reynolds CM, 2005, J BIOL CHEM, V280, P21202, DOI 10.1074/jbc.M500964200; Robillard GT, 1999, BBA-REV BIOMEMBRANES, V1422, P73, DOI 10.1016/S0304-4157(99)00002-7; Ruiz N, 2005, CELL, V121, P307, DOI 10.1016/j.cell.2005.02.014; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; Schagger H, 2001, J BIOL CHEM, V276, P37861; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; Schneider D, 2003, J BIOL CHEM, V278, P3105, DOI 10.1074/jbc.M206287200; SCHRODER I, 1994, MICROBIOL-UK, V140, P731, DOI 10.1099/00221287-140-4-731; Shevchenko A, 2000, METH MOL B, V146, P1, DOI 10.1385/1-59259-045-4:1; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SPELBRINK REJ, 2005, J BIOL CHEM; Stagljar I, 2002, TRENDS BIOCHEM SCI, V27, P559, DOI 10.1016/S0968-0004(02)02197-7; Stroh A, 2004, J BIOL CHEM, V279, P5000, DOI 10.1074/jbc.M309505200; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Uetz P, 2005, FEBS LETT, V579, P1821, DOI 10.1016/j.febslet.2005.02.001; Unden G, 1997, BBA-BIOENERGETICS, V1320, P217, DOI 10.1016/S0005-2728(97)00034-0; van den Berg B, 2004, SCIENCE, V304, P1506, DOI 10.1126/science.1097524; van Lis R, 2003, PLANT PHYSIOL, V132, P318, DOI 10.1104/pp.102.018325; Veenendaal AKJ, 2004, BBA-MOL CELL RES, V1694, P81, DOI 10.1016/j.bbamcr.2004.02.009; Wang Y, 1999, INFECT IMMUN, V67, P4751, DOI 10.1128/IAI.67.9.4751-4756.1999; Wimley WC, 2003, CURR OPIN STRUC BIOL, V13, P404, DOI 10.1016/S0959-440X(03)00099-X; Wimley WC, 2002, PROTEIN SCI, V11, P301, DOI 10.1110/ps.29402; Wu T, 2005, CELL, V121, P235, DOI 10.1016/j.cell.2005.02.015; YAMADA M, 1993, J BIOL CHEM, V268, P12812; Yankovskaya V, 2003, SCIENCE, V299, P700, DOI 10.1126/science.1079605; Zgurskaya HI, 2000, J BACTERIOL, V182, P4264, DOI 10.1128/JB.182.15.4264-4267.2000; Zhai YF, 2002, PROTEIN SCI, V11, P2196, DOI 10.1110/ps.0209002; Zhu H, 2001, SCIENCE, V293, P2101, DOI 10.1126/science.1062191	80	167	225	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34409	34419		10.1074/jbc.M506479200	http://dx.doi.org/10.1074/jbc.M506479200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16079137	hybrid			2022-12-25	WOS:000232403900006
J	Stray, JE; Crisona, NJ; Belotserkovskii, BP; Lindsley, JE; Cozzarelli, NR				Stray, JE; Crisona, NJ; Belotserkovskii, BP; Lindsley, JE; Cozzarelli, NR			The Saccharomyces cerevisiae Smc2/4 condensin compacts DNA into (plus) chiral structures without net supercoiling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOTIC CHROMOSOME ARCHITECTURE; STRAND BREAK REPAIR; 13S CONDENSIN; COMPLEX; PROTEINS; COHESIN; ATP; SUBUNITS; MUKB; PHOSPHORYLATION	Smc2/4 forms the core of the Saccharomyces cerevisiae condensin, which promotes metaphase chromosome compaction. To understand how condensin manipulates DNA, we used two in vitro assays to study the role of SMC ( structural maintenance of chromosome) proteins and ATP in reconfiguring the path of DNA. The first assay evaluated the topology of knots formed in the presence of topoisomerase II. Unexpectedly, both wild-type Smc2/4 and an ATPase mutant promoted (+) chiral knotting of nicked plasmids, revealing that ATP hydrolysis and the non-SMC condensins are not required to compact DNA chirally. The second assay measured Smc2/4-dependent changes in linking number (Lk). Smc2/4 did not induce (+) supercoiling, but instead induced broadening of topoisomer distributions in a cooperative manner without altering Lk(0). To explain chiral knotting in substrates devoid of chiral supercoiling, we propose that Smc2/4 directs chiral DNA compaction by constraining the duplex to retrace its own path. In this highly cooperative process, both (+) and (-) loops are sequestered ( about one per kb), leaving net writhe and twist unchanged while broadening Lk. We have developed a quantitative theory to account for these results. Additionally, we have shown at higher molar stoichiometries that Smc2/4 prevents relaxation by topoisomerase I and nick closure by DNA ligase, indicating that Smc2/4 can saturate DNA. By electron microscopy of Smc2/4-DNA complexes, we observed primarily two protein-laden bound species: long flexible filaments and uniform rings or "doughnuts." Close packing of Smc2/4 on DNA explains the substrate protection we observed. Our results support the hypothesis that SMC proteins bind multiple DNA duplexes.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Utah, Dept Biochem, Salt Lake City, UT 84132 USA	University of California System; University of California Berkeley; Utah System of Higher Education; University of Utah	Cozzarelli, NR (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 16 Barker Hall, Berkeley, CA 94720 USA.	ncozzare@berkeley.edu		Belotserkovskii, Boris/0000-0002-1570-9923	NIGMS NIH HHS [GM31657, GM31655, GM072366-01, GM51194, 5T32GM07464-24] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007464, R01GM031655, F32GM072366, R01GM051194, R37GM031657, R01GM031657] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson DE, 2002, J CELL BIOL, V156, P419, DOI 10.1083/jcb.200111002; BAUER WR, 1980, SCI AM, V243, P118; Bazett-Jones DP, 2002, MOL CELL, V9, P1183, DOI 10.1016/S1097-2765(02)00546-4; Chuang PT, 1996, SCIENCE, V274, P1736, DOI 10.1126/science.274.5293.1736; Cobbe N, 2000, J STRUCT BIOL, V129, P123, DOI 10.1006/jsbi.2000.4255; Cozzarelli N. R., 1990, DNA TOPOLOGY ITS BIO, P139; CRISONA NJ, 1994, J MOL BIOL, V243, P437, DOI 10.1006/jmbi.1994.1671; Dazey I. D., 1997, KNOTS 96, P267; DYNAN WS, 1981, J BIOL CHEM, V256, P5860; Fennell-Fezzie R, 2005, EMBO J, V24, P1921, DOI 10.1038/sj.emboj.7600680; Freeman L, 2000, J CELL BIOL, V149, P811, DOI 10.1083/jcb.149.4.811; Gassmann R, 2004, EXP CELL RES, V296, P35, DOI 10.1016/j.yexcr.2004.03.006; Haering CH, 2003, BIOESSAYS, V25, P1178, DOI 10.1002/bies.10361; Haering CH, 2002, MOL CELL, V9, P773, DOI 10.1016/S1097-2765(02)00515-4; Hagstrom KA, 2003, NAT REV GENET, V4, P520, DOI 10.1038/nrg1110; Hagstrom KA, 2002, GENE DEV, V16, P729, DOI 10.1101/gad.968302; Harvey SH, 2002, GENOME BIOL, V3; Hazbun TR, 2003, MOL CELL, V12, P1353, DOI 10.1016/S1097-2765(03)00476-3; Hirano M, 2004, EMBO J, V23, P2664, DOI 10.1038/sj.emboj.7600264; Hirano M, 2002, EMBO J, V21, P5733, DOI 10.1093/emboj/cdf575; Hirano M, 2001, EMBO J, V20, P3238, DOI 10.1093/emboj/20.12.3238; Hirano M, 1998, EMBO J, V17, P7139, DOI 10.1093/emboj/17.23.7139; Hirano T, 2005, CURR BIOL, V15, pR265, DOI 10.1016/j.cub.2005.03.037; Hirano T, 2002, GENE DEV, V16, P399, DOI 10.1101/gad.955102; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; Hopfner KP, 2000, J BACTERIOL, V182, P6036, DOI 10.1128/JB.182.21.6036-6041.2000; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hopfner KP, 2001, CELL, V105, P473, DOI 10.1016/S0092-8674(01)00335-X; Jessberger R, 1996, EMBO J, V15, P4061, DOI 10.1002/j.1460-2075.1996.tb00779.x; Kagansky A, 2004, J BIOL CHEM, V279, P3382, DOI 10.1074/jbc.M306078200; Kimura K, 1999, CELL, V98, P239, DOI 10.1016/S0092-8674(00)81018-1; Kimura K, 1997, CELL, V90, P625, DOI 10.1016/S0092-8674(00)80524-3; Kimura K, 2001, J BIOL CHEM, V276, P5417, DOI 10.1074/jbc.C000873200; Kimura K, 1998, SCIENCE, V282, P487, DOI 10.1126/science.282.5388.487; Kimura K, 2000, P NATL ACAD SCI USA, V97, P11972, DOI 10.1073/pnas.220326097; KLENIN KV, 1989, J BIOMOL STRUCT DYN, V6, P707, DOI 10.1080/07391102.1989.10507731; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; Koshland DE, 2000, CURR OPIN CELL BIOL, V12, P297, DOI 10.1016/S0955-0674(00)00092-2; Lavoie BD, 2004, GENE DEV, V18, P76, DOI 10.1101/gad.1150404; Lavoie BD, 2000, MOL BIOL CELL, V11, P1293, DOI 10.1091/mbc.11.4.1293; LEVINGER L, 1980, P NATL ACAD SCI-BIOL, V77, P3244, DOI 10.1073/pnas.77.6.3244; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Losada A, 2001, BIOESSAYS, V23, P924, DOI 10.1002/bies.1133; Losada A, 2001, CURR BIOL, V11, P268, DOI 10.1016/S0960-9822(01)00066-5; LOSADA A, 1954, GENE DEV, V19, P1269; Mascarenhas J, 2002, EMBO J, V21, P3108, DOI 10.1093/emboj/cdf314; Melby TE, 1998, J CELL BIOL, V142, P1595, DOI 10.1083/jcb.142.6.1595; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; NIKI H, 1991, EMBO J, V10, P183, DOI 10.1002/j.1460-2075.1991.tb07935.x; Ono T, 2003, CELL, V115, P109, DOI 10.1016/S0092-8674(03)00724-4; Rybenkov VV, 1997, SCIENCE, V277, P690, DOI 10.1126/science.277.5326.690; Sakai A, 2003, EMBO J, V22, P2764, DOI 10.1093/emboj/cdg247; Schleiffer A, 2003, MOL CELL, V11, P571, DOI 10.1016/S1097-2765(03)00108-4; Stray JE, 2003, J BIOL CHEM, V278, P26238, DOI 10.1074/jbc.M302699200; Strunnikov AV, 1999, EUR J BIOCHEM, V263, P6, DOI 10.1046/j.1432-1327.1999.00509.x; Sutani T, 1997, NATURE, V388, P798, DOI 10.1038/42062; Sutani T, 1999, GENE DEV, V13, P2271, DOI 10.1101/gad.13.17.2271; Uhlmann F, 2004, EXP CELL RES, V296, P80, DOI 10.1016/j.yexcr.2004.03.005; Volkov A, 2003, MOL CELL BIOL, V23, P5638, DOI 10.1128/MCB.23.16.5638-5650.2003; Vologodskii AV., 1992, TOPOLOGY PHYS CIRCUL; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WASSERMAN SA, 1991, J BIOL CHEM, V266, P20567; Yamanaka K, 1996, MOL GEN GENET, V250, P241; Yamazoe M, 1999, EMBO J, V18, P5873, DOI 10.1093/emboj/18.21.5873; Yoshimura SH, 2002, CURR BIOL, V12, P508, DOI 10.1016/S0960-9822(02)00719-4; Zhao XL, 2005, P NATL ACAD SCI USA, V102, P4777, DOI 10.1073/pnas.0500537102	67	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34723	34734		10.1074/jbc.M506589200	http://dx.doi.org/10.1074/jbc.M506589200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16100111	hybrid			2022-12-25	WOS:000232403900043
J	Fitter, S; James, R				Fitter, S; James, R			Deconvolution of a complex target using DNA aptamers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO SELECTION; NUCLEIC-ACID APTAMERS; AFFINITY RNA LIGANDS; SYSTEMATIC EVOLUTION; COMBINATORIAL SELECTION; PROTEIN MICROARRAYS; BINDING; CELLS; TRANSCRIPTOME; RECEPTORS	In vitro selection of single-stranded nucleic acid aptamers from large random sequence libraries is now a straightforward process particularly when screening with a single target molecule. These libraries contain considerable shape diversity as evident by the successful isolation of aptamers that bind with high affinity and specificity to chemically diverse targets. We propose that aptamer libraries contain sufficient shape diversity to allow deconvolution of a complex mixture of targets. Using unfractionated human plasma as our experimental model, we aim to develop methods to obtain aptamers against as many proteins as possible. To begin, it is critical that we understand how aptamer populations change with increasing rounds of in vitro selection when using complex mixtures. Our results show that sequence representation in the selected population changes dramatically with increasing rounds of selection. Certain aptamer families were apparent after only three selection rounds. Two additional cycles saw a decline in the relative abundance of these families and the emergence of yet another family that accounted for more than 60% of sequences in the pool. To overcome this population convergence, an aptamer-based target depletion method was developed, and the library screen was repeated. The previous dominant family effectively disappeared from the selected populations but was replaced by other aptamer families. Insights gained from these initial experiments are now being applied in the creation of second generation plasma protein screens and also to the analysis of other complex biological targets.	Flinders Med Ctr, Dept Gastroenterol & Hepatol, Adelaide, SA 5042, Australia	Flinders Medical Centre	James, R (corresponding author), Flinders Med Ctr, Dept Gastroenterol & Hepatol, Bedford Pk, SA 5042, Australia.	rob.james@flinders.edu.au		Fitter, Stephen/0000-0003-1663-6807				Anderson NL, 2002, MOL CELL PROTEOMICS, V1, P845, DOI 10.1074/mcp.R200007-MCP200; Baliga NS, 2002, P NATL ACAD SCI USA, V99, P14913, DOI 10.1073/pnas.192558999; Batey RT, 1999, ANGEW CHEM INT EDIT, V38, P2327; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Blank M, 2001, J BIOL CHEM, V276, P16464, DOI 10.1074/jbc.M100347200; Brandenberger R, 2004, NAT BIOTECHNOL, V22, P707, DOI 10.1038/nbt971; Califano A, 2000, BIOINFORMATICS, V16, P341, DOI 10.1093/bioinformatics/16.4.341; Carothers JM, 2004, J AM CHEM SOC, V126, P5130, DOI 10.1021/ja031504a; Charlton J, 1997, CHEM BIOL, V4, P809, DOI 10.1016/S1074-5521(97)90114-9; Clark SL, 2002, ELECTROPHORESIS, V23, P1335, DOI 10.1002/1522-2683(200205)23:9<1335::AID-ELPS1335>3.0.CO;2-E; Conrad RC, 1996, METHOD ENZYMOL, V267, P336; Daniels DA, 2003, P NATL ACAD SCI USA, V100, P15416, DOI 10.1073/pnas.2136683100; Davidson EH, 2002, SCIENCE, V295, P1669, DOI 10.1126/science.1069883; de Wildt RMT, 2000, NAT BIOTECHNOL, V18, P989, DOI 10.1038/79494; Farokhzad OC, 2004, CANCER RES, V64, P7668, DOI 10.1158/0008-5472.CAN-04-2550; Harbison CT, 2004, NATURE, V431, P99, DOI 10.1038/nature02800; Hicke BJ, 2001, J BIOL CHEM, V276, P48644, DOI 10.1074/jbc.M104651200; Homann M, 1999, NUCLEIC ACIDS RES, V27, P2006, DOI 10.1093/nar/27.9.2006; Hoogenboom HR, 1999, EUR J BIOCHEM, V260, P774, DOI 10.1046/j.1432-1327.1999.00214.x; IRVINE D, 1991, J MOL BIOL, V222, P739, DOI 10.1016/0022-2836(91)90509-5; Kampa D, 2004, GENOME RES, V14, P331, DOI 10.1101/gr.2094104; Kodadek T, 2001, CHEM BIOL, V8, P105, DOI 10.1016/S1074-5521(00)90067-X; Lin BY, 2005, CANCER RES, V65, P3081, DOI 10.1158/0008-5472.CAN-04-3218; Liotta LA, 2003, CANCER CELL, V3, P317, DOI 10.1016/S1535-6108(03)00086-2; Lorger M, 2003, EUKARYOT CELL, V2, P84, DOI 10.1128/EC.2.1.84-94.2003; MANDECKI W, 1995, J THEOR BIOL, V176, P523, DOI 10.1006/jtbi.1995.0218; Masayesva BG, 2004, P NATL ACAD SCI USA, V101, P8715, DOI 10.1073/pnas.0400027101; Messmer BT, 2000, J MOL BIOL, V296, P821, DOI 10.1006/jmbi.1999.3487; Morris KN, 1998, P NATL ACAD SCI USA, V95, P2902, DOI 10.1073/pnas.95.6.2902; Mutuberria R, 1999, J IMMUNOL METHODS, V231, P65, DOI 10.1016/S0022-1759(99)00141-6; Nimjee SM, 2005, ANNU REV MED, V56, P555, DOI 10.1146/annurev.med.56.062904.144915; Noronha EJ, 1998, J IMMUNOL, V161, P2968; Osborne SE, 1997, CHEM REV, V97, P349, DOI 10.1021/cr960009c; PAN WH, 1995, P NATL ACAD SCI USA, V92, P11509, DOI 10.1073/pnas.92.25.11509; Pieper R, 2003, PROTEOMICS, V3, P422, DOI 10.1002/pmic.200390057; Rimmele M, 2003, CHEMBIOCHEM, V4, P963, DOI 10.1002/cbic.200300648; RINGQUIST S, 1995, BIOCHEMISTRY-US, V34, P3640, DOI 10.1021/bi00011a019; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shi H, 2002, RNA, V8, P1461, DOI 10.1017/S1355838202029941; Soukup JK, 2004, CURR OPIN STRUC BIOL, V14, P344, DOI 10.1016/j.sbi.2004.04.007; Sperger JM, 2003, P NATL ACAD SCI USA, V100, P13350, DOI 10.1073/pnas.2235735100; Thomas M, 1997, J BIOL CHEM, V272, P27980, DOI 10.1074/jbc.272.44.27980; Tian HC, 2002, MOL CELL PROTEOMICS, V1, P99, DOI 10.1074/mcp.T100002-MCP200; Tirumalai RS, 2003, MOL CELL PROTEOMICS, V2, P1096, DOI 10.1074/mcp.M300031-MCP200; Ulrich H, 2002, J BIOL CHEM, V277, P20756, DOI 10.1074/jbc.M111859200; Vant-Hull B, 1998, J MOL BIOL, V278, P579, DOI 10.1006/jmbi.1998.1727; Wang J, 2000, RNA, V6, P571, DOI 10.1017/S1355838200992215; Wilson DS, 1999, ANNU REV BIOCHEM, V68, P611, DOI 10.1146/annurev.biochem.68.1.611; Wlotzka B, 2002, P NATL ACAD SCI USA, V99, P8898, DOI 10.1073/pnas.132067399	49	26	30	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34193	34201		10.1074/jbc.M504772200	http://dx.doi.org/10.1074/jbc.M504772200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16081419	hybrid			2022-12-25	WOS:000232229700061
J	Heeb, MJ; Cabral, KM; Ruan, LJ				Heeb, MJ; Cabral, KM; Ruan, LJ			Down-regulation of factor IXa in the factor Xase complex by protein Z-dependent protease inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; Z PLASMA-LEVELS; ISCHEMIC-STROKE; Z-DEFICIENCY; ANTIPHOSPHOLIPID ANTIBODIES; Z GENE; RISK; THROMBOSIS; FREQUENCY; COMMON	Protein Z-dependent protease inhibitor (ZPI) is a serpin inhibitor of coagulation factor ( F) Xa dependent on protein Z, Ca2+, and phospholipids. In new studies, ZPI inhibited FIXa in the FXase complex. Since this observation could merely represent inhibition of the FXa product whose activity was measured, inhibition of FIXa was investigated five ways. 1) FXase incubation mixtures with/without ZPI/ protein Z were diluted in EDTA; FXa activity was measured after reversal of its inhibition. 2) FXase incubation mixtures were immunoblotted for FXa product. 3) FX activation peptide region was H-3-labeled; release of H-3 was used to measure FXase activity. 4) Activity was monitored in a FIXa-based clotting assay. 5) FIXa amidolytic activity was measured. In all cases, FIXa was inhibited by subphysiologic levels of ZPI. Unlike inhibition of FXa, inhibition of FIXa did not strictly require protein Z. Low concentrations of FVIIIa increased the efficiency of ZPI inhibition of FIXa; FVIIIa in molar excess was not protective of FIXa unless FIXa/FVIIIa interacted prior to ZPI exposure. Unusual time courses were observed for inhibition of both FIXa in the FXase complex and FXa in the prothrombinase complex. Activity loss stabilized in <100 s at a level dependent on ZPI concentration, suggesting equilibrium interactions rather than typical covalent serpin-protease interactions. Surface plasmon resonance binding experiments revealed binding and dissociation of ZPI/ FIXa with K-d(app) of 9-12 nM, similar to the concentration of ZPI needed for 50% inhibition. ZPI may be an unusual physiologic regulator of both the intrinsic FXase and the prothrombinase complexes.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Heeb, MJ (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, MEM 180,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	heeb@scripps.edu						Al-Shanqeeti A, 2005, THROMB HAEMOSTASIS, V93, P411, DOI 10.1160/TH04-11-0715; Ayoub N, 2004, STROKE, V35, P1329, DOI 10.1161/01.STR.0000127534.54538.15; BROZE GJ, 1984, J CLIN INVEST, V73, P933, DOI 10.1172/JCI111317; Broze GJ, 2001, LANCET, V357, P900, DOI 10.1016/S0140-6736(00)04229-X; Forastiero RR, 2003, J THROMB HAEMOST, V1, P1764, DOI 10.1046/j.1538-7836.2003.00303.x; Gris JC, 2002, BLOOD, V99, P2606, DOI 10.1182/blood.V99.7.2606; Han X, 1999, BIOCHEMISTRY-US, V38, P11073, DOI 10.1021/bi990641a; Han X, 2000, BLOOD, V96, P3049; Han X, 1998, P NATL ACAD SCI USA, V95, P9250, DOI 10.1073/pnas.95.16.9250; Heeb MJ, 2002, BLOOD CELL MOL DIS, V29, P139, DOI 10.1006/bcmd.2002.0549; HEEB MJ, 1993, J BIOL CHEM, V268, P2872; HOGG PJ, 1991, J BIOL CHEM, V266, P10953; Kemkes-Matthes B, 2001, SEMIN THROMB HEMOST, V27, P551, DOI 10.1055/s-2001-17966; Kobelt K, 2001, BRIT J HAEMATOL, V114, P169, DOI 10.1046/j.1365-2141.2001.02913.x; Konstantinides S, 2001, CIRCULATION, V103, P576, DOI 10.1161/01.CIR.103.4.576; LAMPHEAR BJ, 1992, J BIOL CHEM, V267, P3725; Lichy C, 2004, STROKE, V35, P40, DOI 10.1161/01.STR.0000106909.75418.E4; Lopaciuk S, 2002, THROMB HAEMOSTASIS, V88, P536; McColl MD, 2003, BRIT J HAEMATOL, V120, P913, DOI 10.1046/j.1365-2141.2003.04151_5.x; McQuillan AM, 2003, STROKE, V34, P2415, DOI 10.1161/01.STR.0000092124.52084.4B; Mikolajczyk SD, 1999, INT J CANCER, V81, P438, DOI 10.1002/(SICI)1097-0215(19990505)81:3<438::AID-IJC18>3.3.CO;2-L; MILETICH JP, 1987, BLOOD, V69, P1580; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; New L, 1996, BIOCHEM BIOPH RES CO, V223, P404, DOI 10.1006/bbrc.1996.0906; Santacroce R, 2004, J THROMB HAEMOST, V2, P1197, DOI 10.1111/j.1538-7836.2004.00808.x; Tabatabai A, 2001, THROMB HAEMOSTASIS, V85, P655, DOI 10.1055/s-0037-1615649; TANS G, 1991, BLOOD, V77, P2641; Vasse M, 2001, LANCET, V357, P933, DOI 10.1016/S0140-6736(00)04218-5; WATER N, 2004, BRIT J HAEMATOL, V127, P190; Yin ZF, 2000, P NATL ACAD SCI USA, V97, P6734, DOI 10.1073/pnas.120081897; ZUR M, 1980, J BIOL CHEM, V255, P5703	31	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33819	33825		10.1074/jbc.M506502200	http://dx.doi.org/10.1074/jbc.M506502200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16093243	hybrid			2022-12-25	WOS:000232229700018
J	Kepert, JF; Mazurkiewicz, J; Heuvelman, GL; Toth, KF; Rippe, K				Kepert, JF; Mazurkiewicz, J; Heuvelman, GL; Toth, KF; Rippe, K			NAP1 modulates binding of linker histone H1 to chromatin and induces an extended chromatin fiber conformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSOME ASSEMBLY PROTEIN-1; SCANNING FORCE MICROSCOPY; TRANSCRIPTION FACTOR-BINDING; RNA-POLYMERASE; ANALYTICAL ULTRACENTRIFUGATION; GENE-EXPRESSION; H2A-H2B DIMERS; NONRANDOM BEHAVIOR; PAF1 COMPLEX; IN-VITRO	NAP1 ( nucleosome assembly protein 1) is a histone chaperone that has been described to bind predominantly to the histone H2A center dot H2B dimer in the cell during shuttling of histones into the nucleus, nucleosome assembly/ remodeling, and transcription. Here it was examined how NAP1 interacts with chromatin fibers isolated from HeLa cells. NAP1 induced a reversible change toward an extended fiber conformation as demonstrated by sedimentation velocity ultracentrifugation experiments. This transition was due to the removal of the linker histone H1. The H2A center dot H2B dimer remained stably bound to the native fiber fragments and to fibers devoid of linker histone H1. This was in contrast to mononucleosome substrates, which displayed a NAP1-induced removal of a single H2A center dot H2B dimer from the core particle. The effect of NAP1 on the chromatin fiber structure was examined by scanning/ atomic force microscopy. A quantitative image analysis of similar to 36,000 nucleosomes revealed an increase of the average internucleosomal distance from 22.3 +/- 0.4 to 27.6 +/- 0.6 nm, whereas the overall fiber structure was preserved. This change reflects the disintegration of the chromatosome due to binding of H1 to NAP1 as chromatin fibers stripped from H1 showed an average nucleosome distance of 27.4 +/- 0.8 nm. The findings suggest a possible role of NAP1 in chromatin remodeling processes involved in transcription and replication by modulating the local linker histone content.	Heidelberg Univ, Kirchhoff Inst Phys, Mol Biophys Grp, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Rippe, K (corresponding author), Heidelberg Univ, Kirchhoff Inst Phys, Mol Biophys Grp, Neuenheimer Feld 227, D-69120 Heidelberg, Germany.	Karsten.Rippe@kip.uni-heidelberg.de	Rippe, Karsten/A-3562-2012	Rippe, Karsten/0000-0001-9951-9395				Adams CR, 1999, CURR OPIN GENET DEV, V9, P185, DOI 10.1016/S0959-437X(99)80028-8; AUSIO J, 1984, J MOL BIOL, V177, P373, DOI 10.1016/0022-2836(84)90291-2; Ausio J, 2000, BIOPHYS CHEM, V86, P141, DOI 10.1016/S0301-4622(00)00144-7; Bash R, 2003, BIOCHEMISTRY-US, V42, P4681, DOI 10.1021/bi026887o; Bash RC, 2001, J BIOL CHEM, V276, P48362, DOI 10.1074/jbc.M104916200; Bednar J, 1998, P NATL ACAD SCI USA, V95, P14173, DOI 10.1073/pnas.95.24.14173; BELLARD M, 1980, NUCLEIC ACIDS RES, V8, P2737, DOI 10.1093/nar/8.12.2737; BELMONT AS, 1994, J CELL BIOL, V127, P287, DOI 10.1083/jcb.127.2.287; Belotserkovskaya R, 2004, BBA-GENE STRUCT EXPR, V1677, P87, DOI 10.1016/j.bbaexp.2003.09.017; Belotserkovskaya R, 2003, SCIENCE, V301, P1090, DOI 10.1126/science.1085703; Bruno M, 2003, MOL CELL, V12, P1599, DOI 10.1016/S1097-2765(03)00499-4; Carruthers LM, 1998, BIOCHEMISTRY-US, V37, P14776, DOI 10.1021/bi981684e; Carruthers LM, 2000, J BIOL CHEM, V275, P37285, DOI 10.1074/jbc.M006801200; Carruthers LM, 2000, METHOD ENZYMOL, V321, P66; CHEN H, 1994, EMBO J, V13, P380, DOI 10.1002/j.1460-2075.1994.tb06272.x; Crane-Robinson C, 1999, BIOESSAYS, V21, P367, DOI 10.1002/(SICI)1521-1878(199905)21:5<367::AID-BIES2>3.0.CO;2-4; d'Erme M, 2001, BIOCHEMISTRY-US, V40, P10947, DOI 10.1021/bi002742a; Dillon N, 2004, BIOL CELL, V96, P631, DOI 10.1016/j.biolcel.2004.06.003; Dorigo B, 2003, J MOL BIOL, V327, P85, DOI 10.1016/S0022-2836(03)00025-1; Fan JY, 2002, NAT STRUCT BIOL, V9, P172, DOI 10.1038/nsb767; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; GARCIARAMIREZ M, 1992, J BIOL CHEM, V267, P19587; GARCIARAMIREZ M, 1995, J BIOL CHEM, V270, P17923, DOI 10.1074/jbc.270.30.17923; GIANNASCA PJ, 1993, J CELL SCI, V105, P551; Gilbert N, 2004, CELL, V118, P555, DOI 10.1016/j.cell.2004.08.011; Grummt I, 2003, NAT REV MOL CELL BIO, V4, P641, DOI 10.1038/nrm1171; HANSEN JC, 1989, BIOCHEMISTRY-US, V28, P9129, DOI 10.1021/bi00449a026; Hansen JC, 1999, METH MOL B, V119, P127; Hartzog GA, 2002, BBA-GENE STRUCT EXPR, V1577, P276, DOI 10.1016/S0167-4781(02)00458-X; Haushalter KA, 2003, NAT REV MOL CELL BIO, V4, P613, DOI 10.1038/nrm1177; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; ISHIMI Y, 1984, EUR J BIOCHEM, V142, P431, DOI 10.1111/j.1432-1033.1984.tb08305.x; Ito T, 2000, GENE DEV, V14, P1899; Karymov MA, 2001, FASEB J, V15, P2631, DOI 10.1096/fj.01-0345com; KELLOGG DR, 1995, J CELL BIOL, V130, P675, DOI 10.1083/jcb.130.3.675; Kepert JF, 2003, BIOPHYS J, V85, P4012, DOI 10.1016/S0006-3495(03)74815-2; Krogan NJ, 2003, MOL CELL, V11, P721, DOI 10.1016/S1097-2765(03)00091-1; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Lee KM, 1997, P NATL ACAD SCI USA, V94, P8959, DOI 10.1073/pnas.94.17.8959; LEUBA SH, 1994, P NATL ACAD SCI USA, V91, P11621, DOI 10.1073/pnas.91.24.11621; Leuba SH, 1998, BIOPHYS J, V74, P2823, DOI 10.1016/S0006-3495(98)77989-5; Levchenko V, 2005, BIOCHEMISTRY-US, V44, P5357, DOI 10.1021/bi047786o; Levchenko V, 2004, BIOCHEMISTRY-US, V43, P2359, DOI 10.1021/bi035737q; Loyola A, 2004, BBA-GENE STRUCT EXPR, V1677, P3, DOI 10.1016/j.bbaexp.2003.09.012; Martic G, 2005, J BIOL CHEM, V280, P16143, DOI 10.1074/jbc.M410175200; McBryant SJ, 2003, J BIOL CHEM, V278, P44574, DOI 10.1074/jbc.M305636200; McKittrick E, 2004, P NATL ACAD SCI USA, V101, P1525, DOI 10.1073/pnas.0308092100; McQuibban GA, 1998, J BIOL CHEM, V273, P6582, DOI 10.1074/jbc.273.11.6582; Misteli T, 2001, SCIENCE, V291, P843, DOI 10.1126/science.291.5505.843; Mizuguchi G, 2004, SCIENCE, V303, P343, DOI 10.1126/science.1090701; NACHEVA GA, 1989, CELL, V58, P27, DOI 10.1016/0092-8674(89)90399-1; Neben K, 2004, ONCOGENE, V23, P2379, DOI 10.1038/sj.onc.1207401; Ohkuni K, 2003, BIOCHEM BIOPH RES CO, V306, P5, DOI 10.1016/S0006-291X(03)00907-0; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; Orphanides G, 1999, NATURE, V400, P284, DOI 10.1038/22350; Orphanides G, 2000, NATURE, V407, P471, DOI 10.1038/35035000; Park YJ, 2005, J BIOL CHEM, V280, P1817, DOI 10.1074/jbc.M411347200; Peng HF, 1997, BIOCHEMISTRY-US, V36, P12371, DOI 10.1021/bi971046g; Philo JS, 2000, ANAL BIOCHEM, V279, P151, DOI 10.1006/abio.2000.4480; Rabbani A, 1999, J BIOL CHEM, V274, P18401, DOI 10.1074/jbc.274.26.18401; Ramos I, 2005, BIOCHEMISTRY-US, V44, P8274, DOI 10.1021/bi050386w; Redon C, 2002, CURR OPIN GENET DEV, V12, P162, DOI 10.1016/S0959-437X(02)00282-4; Rivetti C, 1996, J MOL BIOL, V264, P919, DOI 10.1006/jmbi.1996.0687; Rivetti C, 2001, ULTRAMICROSCOPY, V87, P55, DOI 10.1016/S0304-3991(00)00064-4; Schuck P, 2003, ANAL BIOCHEM, V320, P104, DOI 10.1016/S0003-2697(03)00289-6; SCHWARZ PM, 1994, J BIOL CHEM, V269, P16284; SEDAT J, 1977, COLD SPRING HARB SYM, V42, P331, DOI 10.1101/SQB.1978.042.01.035; Shintomi K, 2005, P NATL ACAD SCI USA, V102, P8210, DOI 10.1073/pnas.0500822102; Sims RJ, 2004, CURR OPIN CELL BIOL, V16, P263, DOI 10.1016/j.ceb.2004.04.004; Squazzo SL, 2002, EMBO J, V21, P1764, DOI 10.1093/emboj/21.7.1764; Studitsky VM, 1997, SCIENCE, V278, P1960, DOI 10.1126/science.278.5345.1960; Studitsky VM, 2004, TRENDS BIOCHEM SCI, V29, P127, DOI 10.1016/j.tibs.2004.01.003; Toth KF, 2005, J BIOL CHEM, V280, P15690, DOI 10.1074/jbc.M413329200; Tumbar T, 1999, J CELL BIOL, V145, P1341, DOI 10.1083/jcb.145.7.1341; Tyler JK, 2002, EUR J BIOCHEM, V269, P2268, DOI 10.1046/j.1432-1033.2002.02890.x; van Holde KE., 1989, SPRINGER SERIES MOL; Vermaak D, 2003, CURR OPIN CELL BIOL, V15, P266, DOI 10.1016/S0955-0674(03)00043-7; WALTER PP, 1995, MOL CELL BIOL, V15, P6178; Wang HD, 2002, BIOPHYS J, V83, P3619, DOI 10.1016/S0006-3495(02)75362-9; Wang XY, 2001, J BIOL CHEM, V276, P12764, DOI 10.1074/jbc.M100501200; WEINTRAUB H, 1976, SCIENCE, V193, P848, DOI 10.1126/science.948749; WU C, 1979, CELL, V16, P807, DOI 10.1016/0092-8674(79)90096-5; Yodh JG, 2002, BIOCHEMISTRY-US, V41, P3565, DOI 10.1021/bi011612e; Yodh JG, 1999, BIOCHEMISTRY-US, V38, P15756, DOI 10.1021/bi991034q; Zlatanova J, 2000, FASEB J, V14, P1697, DOI 10.1096/fj.99-0869rev; Zlatanova J, 1996, PROG NUCLEIC ACID RE, V52, P217, DOI 10.1016/S0079-6603(08)60968-X; Zlatanova J, 1998, BIOPHYS J, V74, P2554, DOI 10.1016/S0006-3495(98)77963-9; ZLATANOVA J, 1990, TRENDS BIOCHEM SCI, V15, P273, DOI 10.1016/0968-0004(90)90053-E	90	61	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34063	34072		10.1074/jbc.M507322200	http://dx.doi.org/10.1074/jbc.M507322200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16105835	Green Accepted, hybrid, Green Published			2022-12-25	WOS:000232229700046
J	Kim, HP; Kim, BG; Letterio, J; Leonard, WJ				Kim, HP; Kim, BG; Letterio, J; Leonard, WJ			Smad-dependent cooperative regulation of interleukin 2 receptor alpha chain gene expression by T cell receptor and transforming growth factor-beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; IL-2 RECEPTOR; TARGETED DISRUPTION; MOLECULAR-CLONING; PROMOTER REGION; POTENTIAL ROLE; LYMPHOCYTES-T; ACTIVATION; MICE; GROWTH-FACTOR-BETA-1	The interleukin 2 receptor alpha chain (IL-2R alpha) is a component of high affinity IL-2 receptors and thus critically regulates T cell growth and other lymphoid functions. Five positive regulatory regions together control lineage-restricted and activation-dependent IL-2R alpha induction in response to antigen and IL-2. We now show that TGF-beta cooperates with T cell receptor (TCR) signaling to increase IL-2R alpha gene expression. Moreover, we identify a sixth positive regulatory region that regulates IL-2R alpha expression in cells treated with anti-CD3 + anti-CD28 as well as TGF-beta and show that this region contains binding sites for Smad3, AP-1, and cAMP-responsive element-binding protein/ ATF proteins. The importance of Smad complexes is indicated by impaired IL-2R alpha induction by TGF-beta in CD4(+) T cells from both Smad3(-/-) and Smad4(-/-) mice. Thus, we have identified a novel positive regulatory region in the IL-2R alpha gene that mediates TGF-beta-dependent induction of the gene. These findings have implications related to IL-2R alpha expression on activated T cells and regulatory T cells.	NHLBI, Lab Mol Immunol, NIH, Bethesda, MD 20892 USA; NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Leonard, WJ (corresponding author), NHLBI, Lab Mol Immunol, NIH, Bldg 10,Rm 7N252, Bethesda, MD 20892 USA.	wjl@helix.nih.gov	Leonard, Warren/AAA-1397-2022	Kim, Hyoung-Pyo/0000-0003-1441-8822	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000711] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000711] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL005402, Z01HL005402] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agarwal S, 1998, IMMUNITY, V9, P765, DOI 10.1016/S1074-7613(00)80642-1; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; BROWN PH, 1994, ONCOGENE, V9, P791; Cerwenka A, 1996, J IMMUNOL, V156, P459; CERWENKA A, 1994, J IMMUNOL, V153, P4367; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; CROSS SL, 1989, SCIENCE, V244, P466, DOI 10.1126/science.2497520; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; Datto MB, 1999, MOL CELL BIOL, V19, P2495; DEJONG R, 1994, INT IMMUNOL, V6, P631, DOI 10.1093/intimm/6.4.631; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dubchak I, 2000, GENOME RES, V10, P1304, DOI 10.1101/gr.142200; Gorelik L, 2000, IMMUNITY, V12, P171, DOI 10.1016/S1074-7613(00)80170-3; Gorelik L, 2002, NAT REV IMMUNOL, V2, P46, DOI 10.1038/nri704; Gray JD, 1998, J IMMUNOL, V160, P2248; GRAY JD, 1994, J EXP MED, V180, P1937, DOI 10.1084/jem.180.5.1937; Guo LY, 2004, IMMUNITY, V20, P193, DOI 10.1016/S1074-7613(04)00025-1; JOHN S, 1995, MOL CELL BIOL, V15, P1786; John S, 1996, EMBO J, V15, P5627, DOI 10.1002/j.1460-2075.1996.tb00947.x; KAARTINEN V, 1995, NAT GENET, V11, P415, DOI 10.1038/ng1295-415; KEHRL JH, 1986, J EXP MED, V163, P1037, DOI 10.1084/jem.163.5.1037; Kim HP, 2002, EMBO J, V21, P3051, DOI 10.1093/emboj/cdf321; Kim HP, 2001, IMMUNITY, V15, P159, DOI 10.1016/S1074-7613(01)00167-4; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Lecine P, 1996, MOL CELL BIOL, V16, P6829; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; Leonard WJ, 2001, NAT REV IMMUNOL, V1, P200, DOI 10.1038/35105066; LEONARD WJ, 1985, P NATL ACAD SCI USA, V82, P6281, DOI 10.1073/pnas.82.18.6281; LEONARD WJ, 1985, SCIENCE, V230, P633, DOI 10.1126/science.2996141; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LEONARD WJ, 1982, NATURE, V300, P267, DOI 10.1038/300267a0; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LIN BB, 1990, MOL CELL BIOL, V10, P850, DOI 10.1128/MCB.10.2.850; Lin Jian-Xin, 1997, Cytokine and Growth Factor Reviews, V8, P313; LIN JX, 2003, SIGNAL TRANSDUCERS A, P435; Liu H, 2002, MOL CELL BIOL, V22, P6471, DOI 10.1128/MCB.22.18.6471-6479.2002; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Lucas PJ, 2000, J EXP MED, V191, P1187, DOI 10.1084/jem.191.7.1187; Malek TR, 2002, IMMUNITY, V17, P167, DOI 10.1016/S1074-7613(02)00367-9; Mayor C, 2000, BIOINFORMATICS, V16, P1046, DOI 10.1093/bioinformatics/16.11.1046; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; PROETZEL G, 1995, NAT GENET, V11, P409, DOI 10.1038/ng1295-409; Rao SH, 2001, J IMMUNOL, V167, P4494, DOI 10.4049/jimmunol.167.8.4494; Reeves R, 2000, MOL CELL BIOL, V20, P4666, DOI 10.1128/MCB.20.13.4666-4679.2000; ROMAN D, 1990, New Biologist, V2, P642; Sanford LP, 1997, DEVELOPMENT, V124, P2659; SCHLUESENER H, 1990, J NEUROIMMUNOL, V28, P271, DOI 10.1016/0165-5728(90)90020-N; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; SIEBENLIST U, 1986, MOL CELL BIOL, V6, P3042, DOI 10.1128/MCB.6.9.3042; SOLDAINI E, 1995, J BIOL CHEM, V270, P10733, DOI 10.1074/jbc.270.18.10733; SOMPAYRAC LM, 1981, P NATL ACAD SCI-BIOL, V78, P7575, DOI 10.1073/pnas.78.12.7575; SPERISEN P, 1995, J BIOL CHEM, V270, P10743, DOI 10.1074/jbc.270.18.10743; STOECK M, 1989, J IMMUNOL, V143, P3258; TOLEDANO MB, 1990, P NATL ACAD SCI USA, V87, P1830, DOI 10.1073/pnas.87.5.1830; VanParijs L, 1997, J IMMUNOL, V158, P3738; Yamagiwa S, 2001, J IMMUNOL, V166, P7282, DOI 10.4049/jimmunol.166.12.7282; Yang X, 2002, GENESIS, V32, P80, DOI 10.1002/gene.10029; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Yeh JH, 2001, MOL CELL BIOL, V21, P4515, DOI 10.1128/MCB.21.14.4515-4527.2001; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; ZHANG XH, 1995, J EXP MED, V182, P699, DOI 10.1084/jem.182.3.699; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	66	33	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34042	34047		10.1074/jbc.M505833200	http://dx.doi.org/10.1074/jbc.M505833200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16087671	hybrid			2022-12-25	WOS:000232229700043
J	Lai, WS; Carrick, DM; Blackshear, PJ				Lai, WS; Carrick, DM; Blackshear, PJ			Influence of nonameric AU-rich tristetraprolin-binding sites on mRNA deadenylation and turnover	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEINS; ELEMENT; DEGRADATION; DOMAIN; HUR; DESTABILIZATION; STABILITY; MARCKS	Tristetraprolin (TTP), a member of the tandem CCCH zinc finger protein family, promotes deadenylation of tumor necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor mRNAs after binding to the AU-rich elements ( ARE) in their 3'-untranslated regions. The high affinity TTP-ARE binding occurs between the tandem zinc finger domain and the preferred nonamer UUAUUUAUU. By mutating a well defined core sequence of 24 bases from the tumor necrosis factor-alpha ARE, we compared the influence of four possible nonameric TTP-binding sites in the wildtype ARE with that of a single binding site in the mutated probe on the binding of TTP to the RNA and the subsequent deadenylation of the poly( A) tail. By inserting this 24-base ARE into an otherwise stable transcript, we also attempted to determine the extent of the instability conferred by the presence of one or two TTP-binding sites. These sites were created or modified by mutating the As in the UUAUUUAUU nonamer or by changing the central U in the nonamer, in both cases to C residues. The results suggest that even a single nonamer TTP-binding site can confer at least partial sensitivity to the TTP-mediated mRNA turnover on an otherwise stable mRNA, but that two binding sites make the transcript much more unstable. Even though the central U of the nonamer binding site was predicted by structural studies possibly to permit base substitution, mutation of this U to C greatly inhibited the binding of TTP to the ARE, thus reducing the ability of the TTP to promote deadenylation and instability of the mRNA.	NIEHS, Neurobiol Lab, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Off Clin Res, NIH, Res Triangle Pk, NC 27709 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Duke University; Duke University	Blackshear, PJ (corresponding author), NIEHS, Neurobiol Lab, NIH, A2-05,111 Alexander Dr, Res Triangle Pk, NC 27709 USA.	Black009@niehs.nih.gov	Blackshear, Perry J./C-6206-2019	Blackshear, Perry J./0000-0002-9561-8529	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES090080, Z01ES090080] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Blackshear PJ, 2002, BIOCHEM SOC T, V30, P945, DOI 10.1042/BST0300945; BLACKSHEAR PJ, 1992, J BIOL CHEM, V267, P13540; Blackshear PJ, 2003, J BIOL CHEM, V278, P19947, DOI 10.1074/jbc.M301290200; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; Brewer BY, 2004, J BIOL CHEM, V279, P27870, DOI 10.1074/jbc.M402551200; Carballo E, 2000, BLOOD, V95, P1891, DOI 10.1182/blood.V95.6.1891; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Carrick DM, 2004, ARTHRITIS RES THER, V6, P248, DOI 10.1186/ar1441; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Hudson BP, 2004, NAT STRUCT MOL BIOL, V11, P257, DOI 10.1038/nsmb738; Lai WS, 2001, J BIOL CHEM, V276, P23144, DOI 10.1074/jbc.M100680200; Lai WS, 2003, MOL CELL BIOL, V23, P3798, DOI 10.1128/MCB.23.11.3798-3812.2003; Lai WS, 2000, J BIOL CHEM, V275, P17827, DOI 10.1074/jbc.M001696200; Lai WS, 1999, MOL CELL BIOL, V19, P4311; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; UMEKAGE T, 1991, FEBS LETT, V286, P147, DOI 10.1016/0014-5793(91)80961-2; Worthington MT, 2002, J BIOL CHEM, V277, P48558, DOI 10.1074/jbc.M206505200; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	21	44	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34365	34377		10.1074/jbc.M506757200	http://dx.doi.org/10.1074/jbc.M506757200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16061475	hybrid			2022-12-25	WOS:000232229700080
J	Zheng, CY; Lu, X; Hansen, JC; Jeffrey, JH				Zheng, CY; Lu, X; Hansen, JC; Jeffrey, JH			Salt-dependent intra- and internucleosomal interactions of the H3 tail domain in a model oligonucleosomal array	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSOME CORE PARTICLE; CHROMATIN FIBER; LINKER DNA; HISTONE ACETYLATION; BINDING; TRANSCRIPTION; COMPACTION; REVEAL	The core histone tail domains are known to be key regulators of chromatin structure and function. The tails are required for condensation of nucleosome arrays into secondary and tertiary chromatin structures, yet little is known regarding tail structures or sites of tail interactions in chromatin. We have developed a system to test the hypothesis that the tails participate in internucleosomal interactions during salt-dependent chromatin condensation, and here we used it to examine interactions of the H3 tail domain. We found that the H3 tail participates primarily in intranucleosome interactions when the nucleosome array exists in an extended "beads-onastring" conformation and that tail interactions reorganize to engage in primarily internucleosome interactions as the array successively undergoes salt-dependent folding and oligomerization. These results indicated that the location and interactions of the H3 tail domain are dependent upon the degree of condensation of the nucleosomal array, suggesting amechanism by which alterations in tail interactions may elaborate different structural and functional states of chromatin.	Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA; Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA	University of Rochester; Colorado State University	Jeffrey, JH (corresponding author), Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA.	jjhs@mail.rochester.edu			NIGMS NIH HHS [GM45916, GM52426] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045916, R29GM045916, R01GM052426] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAN J, 1982, J CELL BIOL, V93, P285, DOI 10.1083/jcb.93.2.285; Becker PB, 2002, ANNU REV BIOCHEM, V71, P247, DOI 10.1146/annurev.biochem.71.110601.135400; Bednar J, 1998, P NATL ACAD SCI USA, V95, P14173, DOI 10.1073/pnas.95.24.14173; BELMONT AS, 1994, J CELL BIOL, V127, P287, DOI 10.1083/jcb.127.2.287; Butler PJG, 1998, J MOL BIOL, V281, P401, DOI 10.1006/jmbi.1998.1954; Carruthers LM, 1998, BIOCHEMISTRY-US, V37, P14776, DOI 10.1021/bi981684e; Dorigo B, 2004, SCIENCE, V306, P1571, DOI 10.1126/science.1103124; Dorigo B, 2003, J MOL BIOL, V327, P85, DOI 10.1016/S0022-2836(03)00025-1; GARCIARAMIREZ M, 1992, J BIOL CHEM, V267, P19587; GEORGEL P, 1993, J BIOL CHEM, V268, P1947; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hansen JC, 2002, ANNU REV BIOPH BIOM, V31, P361, DOI 10.1146/annurev.biophys.31.101101.140858; HANSEN JC, 1989, BIOCHEMISTRY-US, V28, P9129, DOI 10.1021/bi00449a026; Harp JM, 2000, ACTA CRYSTALLOGR D, V56, P1513, DOI 10.1107/S0907444900011847; Hayes JJ, 1997, METHODS, V12, P2, DOI 10.1006/meth.1997.0441; HONG L, 1993, J BIOL CHEM, V268, P305; Luger K, 2005, CURR OPIN STRUC BIOL, V15, P188, DOI 10.1016/j.sbi.2005.03.006; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; NACHEVA GA, 1989, CELL, V58, P27, DOI 10.1016/0092-8674(89)90399-1; Schwarz PM, 1996, BIOCHEMISTRY-US, V35, P4009, DOI 10.1021/bi9525684; Scrittori L, 2001, J BIOL CHEM, V276, P30002, DOI 10.1074/jbc.M102701200; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; STEFANOVSKY VY, 1989, NUCLEIC ACIDS RES, V17, P10069, DOI 10.1093/nar/17.23.10069; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; WIDOM J, 1989, ANNU REV BIOPHYS BIO, V18, P365, DOI 10.1146/annurev.biophys.18.1.365; Woodcock CL, 2001, CURR OPIN GENET DEV, V11, P130, DOI 10.1016/S0959-437X(00)00169-6; YAO J, 1991, BIOCHEMISTRY-US, V30, P8408, DOI 10.1021/bi00098a019; YAO J, 1990, P NATL ACAD SCI USA, V87, P7603, DOI 10.1073/pnas.87.19.7603; Zheng CY, 2004, METHOD ENZYMOL, V375, P179; Zheng CY, 2003, J BIOL CHEM, V278, P24217, DOI 10.1074/jbc.M302817200	30	79	80	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33552	33557		10.1074/jbc.M507241200	http://dx.doi.org/10.1074/jbc.M507241200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16079127	hybrid			2022-12-25	WOS:000232058100055
J	Zhang, Y; Wang, DX; Johnson, AD; Papp, AC; Sadee, W				Zhang, Y; Wang, DX; Johnson, AD; Papp, AC; Sadee, W			Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DECAY; GENE POLYMORPHISMS; FUNCTIONAL POLYMORPHISM; SUBSTANCE DEPENDENCE; ASSOCIATION; ADDICTION; ALCOHOL; BRAIN; LOCUS; SUSCEPTIBILITY	As a primary target for opioid drugs and peptides, the mu opioid receptor ( OPRM1) plays a key role in pain perception and addiction. Genetic variants of OPRM1 have been implicated in predisposition to drug addiction, in particular the single nucleotide polymorphism A118G, leading to an N40D substitution, with an allele frequency of 10 - 32%, and uncertain functions. We have measured allele- specific mRNA expression of OPRM1 in human autopsy brain tissues, using A118G as a marker. In 8 heterozygous samples measured, the A118 mRNA allele was 1.5 - 2.5- fold more abundant than the G118 allele. Transfection into Chinese hamster ovary cells of a cDNA representing only the coding region of OPRM1, carrying adenosine, guanosine, cytidine, and thymidine in position 118, resulted in 1.5- fold lower mRNA levels only for OPRM1- G118, and more than 10- fold lower OPRM1 protein levels, measured by Western blotting and receptor binding assay. After transfection and inhibition of transcription with actinomycin D, analysis of mRNA turnover failed to reveal differences in mRNA stability between A118 and G118 alleles, indicating a defect in transcription or mRNA maturation. These results indicate that OPRM1- G118 is a functional variant with deleterious effects on both mRNA and protein yield. Clarifying the functional relevance of polymorphisms associated with susceptibility to a complex disorder such as drug addiction provides a foundation for clinical association studies.	Ohio State Univ, Dept Pharmacol, Coll Med & Publ Hlth, Program Pharmacogenom, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Sadee, W (corresponding author), Ohio State Univ, Dept Pharmacol, Coll Med & Publ Hlth, Program Pharmacogenom, 5072 Graves Hall,333 W 10th Ave, Columbus, OH 43210 USA.	sadee-1@medctr.osu.edu	Johnson, Andrew D/G-6520-2013; Wang, Danxin/I-5810-2019	Johnson, Andrew D/0000-0001-6369-5178; Wang, Danxin/0000-0002-7134-3065	NATIONAL INSTITUTE ON DRUG ABUSE [R21DA018744] Funding Source: NIH RePORTER; NIDA NIH HHS [DA018744] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Arraiano Cecilia Maria, 2003, Molecular Microbiology, V49, P267, DOI 10.1046/j.1365-2958.2003.03545.x; Bart G, 2004, MOL PSYCHIATR, V9, P547, DOI 10.1038/sj.mp.4001504; BASBAUM AI, 1984, ANNU REV NEUROSCI, V7, P309, DOI 10.1146/annurev.ne.07.030184.001521; Befort K, 2001, J BIOL CHEM, V276, P3130, DOI 10.1074/jbc.M006352200; Beyer A, 2004, J NEUROCHEM, V89, P553, DOI 10.1111/j.1471-4159.2004.02340.x; Bond C, 1998, P NATL ACAD SCI USA, V95, P9608, DOI 10.1073/pnas.95.16.9608; Bray NJ, 2004, MOL PSYCHIATR, V9, P109, DOI 10.1038/sj.mp.4001366; Bray NJ, 2003, AM J HUM GENET, V73, P152, DOI 10.1086/376578; Byers PH, 2002, J CLIN INVEST, V109, P3, DOI 10.1172/JCI14841; Crowley JJ, 2003, PSYCHIAT GENET, V13, P169, DOI 10.1097/00041444-200309000-00006; Duan JB, 2003, HUM MOL GENET, V12, P205, DOI 10.1093/hmg/ddg055; Gscheidel N, 2000, POL J PHARMACOL, V52, P27; Hernandez-Avila CA, 2003, AM J MED GENET B, V118B, P60, DOI 10.1002/ajmg.b.10054; Herz A, 1997, PSYCHOPHARMACOLOGY, V129, P99, DOI 10.1007/s002130050169; Hirota T, 2004, HUM MOL GENET, V13, P2959, DOI 10.1093/hmg/ddh313; Hoehe MR, 2000, HUM MOL GENET, V9, P2895, DOI 10.1093/hmg/9.19.2895; Johnson AD, 2005, PHARMACOL THERAPEUT, V106, P19, DOI 10.1016/j.pharmthera.2004.11.001; Kreek MJ, 1996, NEUROCHEM RES, V21, P1469, DOI 10.1007/BF02532387; Kreek MJ, 1996, J ADDICT DIS, V15, P73, DOI 10.1300/J069v15n04_05; Kreek MJ, 2004, NEUROMOL MED, V5, P85, DOI 10.1385/NMM:5:1:085; Kreek MJ, 1996, MOL PSYCHIATR, V1, P232; KROSLAK T, 2003, INT NARC RES C PERP; LaForge KS, 2000, EUR J PHARMACOL, V410, P249, DOI 10.1016/S0014-2999(00)00819-0; Le Hellard S, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf070; Lo HS, 2003, GENOME RES, V13, P1855, DOI 10.1101/gr.1006603; Luo XG, 2003, AM J MED GENET B, V120B, P97, DOI 10.1002/ajmg.b.20034; Maquat LE, 2004, NAT REV MOL CELL BIO, V5, P89, DOI 10.1038/nrm1310; Oslin DW, 2003, NEUROPSYCHOPHARMACOL, V28, P1546, DOI 10.1038/sj.npp.1300219; Peckys D, 1999, NEUROSCIENCE, V88, P1093, DOI 10.1016/S0306-4522(98)00251-6; Pinsonneault J, 2004, J PHARMACOL EXP THER, V311, P1088, DOI 10.1124/jpet.104.073098; Schinka JA, 2002, MOL PSYCHIATR, V7, P224, DOI 10.1038/sj.mp.4000951; Stamatoyannopoulos JA, 2004, GENOMICS, V84, P449, DOI 10.1016/j.ygeno.2004.05.002; Szeto CYK, 2001, NEUROREPORT, V12, P1103, DOI 10.1097/00001756-200105080-00011; Tan EC, 2003, NEUROREPORT, V14, P569, DOI 10.1097/00001756-200303240-00008; Wand GS, 2002, NEUROPSYCHOPHARMACOL, V26, P106, DOI 10.1016/S0893-133X(01)00294-9; Wang DX, 2005, MOL PHARMACOL, V67, P2173, DOI 10.1124/mol.104.010272; Wittkopp PJ, 2004, NATURE, V430, P85, DOI 10.1038/nature02698; Yan H, 2004, CURR OPIN ONCOL, V16, P39, DOI 10.1097/00001622-200401000-00008; Zhang YH, 2004, GENE, V341, P93, DOI 10.1016/j.gene.2004.07.017; Zuker M, 1998, RNA, V4, P669, DOI 10.1017/S1355838298980116; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	41	449	462	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32618	32624		10.1074/jbc.M504942200	http://dx.doi.org/10.1074/jbc.M504942200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16046395	hybrid			2022-12-25	WOS:000231920300009
J	Fikaris, AJ; Kao, GD; Brown, EJ; Kazanietz, MG; Meinkoth, JL				Fikaris, AJ; Kao, GD; Brown, EJ; Kazanietz, MG; Meinkoth, JL			Protein kinase C delta stimulates apoptosis by initiating G(1) phase cell cycle progression and S phase arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-CANCER CELLS; RAT-THYROID CELLS; ABL TYROSINE KINASE; GLAND ACINAR-CELLS; PKC-DELTA; PHORBOL ESTER; SUBSTRATE-SPECIFICITY; IONIZING-RADIATION; DNA-SYNTHESIS; LATE G1	Overexpression of protein kinase C delta(PKC delta) stimulates apoptosis in a wide variety of cell types through a mechanism that is incompletely understood. PKC delta-deficient cells are impaired in their response to DNA damage-induced apoptosis, suggesting that PKC delta is required to mount an appropriate apoptotic response under conditions of stress. The mechanism through which it does so remains elusive. In addition to effects on cell survival, PKC delta elicits pleiotropic effects on cellular proliferation. We now provide the first evidence that the ability of PKC delta to stimulate apoptosis is intimately linked to its ability to stimulate G(1) phase cell cycle progression. Using an adenoviral-based expression system to express PKC alpha, -delta, and -epsilon in epithelial cells, we demonstrate that a modest increase in PKC delta activity selectively stimulates quiescent cells to initiate G1 phase cell cycle progression. Rather than completing the cell cycle, PKC delta-infected cells arrest in S phase, an event that triggers caspase-dependent apoptotic cell death. Apoptosis was preceded by the activation of cell cycle checkpoints, culminating in the phosphorylation of Chk-1 and p53. Strikingly, blockade of S phase entry using the phosphatidylinositol 3-kinase inhibitor LY294002 prevented checkpoint activation and apoptosis. In contrast, inhibitors of mitogen-activated protein kinase cascades failed to prevent apoptosis. These findings demonstrate that the biological effects of PKC delta can be extended to include positive regulation of G1 phase cell cycle progression. Importantly, they reveal the existence of a novel, cell cycle-dependent mechanism through which PKC delta stimulates cell death.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Meinkoth, JL (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, Rm 1251 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	meinkoth@pharm.med.upenn.edu	Meinkoth, Judy L/G-2900-2010		NCI NIH HHS [CA-109543, CA-92537, CA-89202] Funding Source: Medline; NIDDK NIH HHS [DK-45696] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA092537, R01CA089202, R01CA109543] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045696] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Cass LA, 1999, MOL CELL BIOL, V19, P5882; Castellone MD, 2003, ONCOGENE, V22, P246, DOI 10.1038/sj.onc.1206112; Cheng GJ, 2003, MOL ENDOCRINOL, V17, P450, DOI 10.1210/me.2002-0344; Cheng GJ, 2001, ONCOGENE, V20, P7334, DOI 10.1038/sj.onc.1204928; Clark AS, 2003, CANCER RES, V63, P780; Cross T, 2000, ONCOGENE, V19, P2331, DOI 10.1038/sj.onc.1203555; DeVries TA, 2002, EMBO J, V21, P6050, DOI 10.1093/emboj/cdf606; Dimitrova DS, 2000, NAT CELL BIOL, V2, P686, DOI 10.1038/35036309; Ettinger SL, 1996, J BIOL CHEM, V271, P14514, DOI 10.1074/jbc.271.24.14514; Fernandez N, 2000, ENDOCRINOLOGY, V141, P146, DOI 10.1210/en.141.1.146; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; Garcia-Bermejo ML, 2002, J BIOL CHEM, V277, P645, DOI 10.1074/jbc.M107639200; Goerke A, 2002, J BIOL CHEM, V277, P32054, DOI 10.1074/jbc.M203734200; Goodarzi AA, 2004, DNA REPAIR, V3, P753, DOI 10.1016/j.dnarep.2004.03.041; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; Harrington EO, 1997, J BIOL CHEM, V272, P7390, DOI 10.1074/jbc.272.11.7390; HATADA T, 1992, CANCER, V70, P2918, DOI 10.1002/1097-0142(19921215)70:12<2918::AID-CNCR2820701231>3.0.CO;2-5; Inari A, 2004, J BIOL CHEM, V279, P30830, DOI 10.1074/jbc.M402403200; Izzard RA, 1999, CANCER RES, V59, P2581; Kazanietz MG, 2000, BIOCHEM PHARMACOL, V60, P1417, DOI 10.1016/S0006-2952(00)00470-6; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; Kikkawa U, 2002, J BIOCHEM, V132, P831, DOI 10.1093/oxfordjournals.jbchem.a003294; Kilpatrick LE, 2002, AM J PHYSIOL-CELL PH, V283, pC48, DOI 10.1152/ajpcell.00385.2001; Kitamura K, 2003, GENES CELLS, V8, P311, DOI 10.1046/j.1365-2443.2003.00635.x; Knauf JA, 1999, J BIOL CHEM, V274, P23414, DOI 10.1074/jbc.274.33.23414; Knauf JA, 2002, J CLIN ENDOCR METAB, V87, P2150, DOI 10.1210/jc.87.5.2150; KOBAYASHI K, 1993, THYROID, V3, P25, DOI 10.1089/thy.1993.3.25; Kumar V, 2000, EMBO J, V19, P1087, DOI 10.1093/emboj/19.5.1087; Kupperman E, 1996, ENDOCRINOLOGY, V137, P96, DOI 10.1210/en.137.1.96; Lee YJ, 2002, CELL GROWTH DIFFER, V13, P237; Lewis AE, 2004, MOL ENDOCRINOL, V18, P2321, DOI 10.1210/me.2004-0104; Li LW, 1999, MOL CELL BIOL, V19, P8547; Liu JH, 2003, CANCER RES, V63, P1153; Mitsutake N, 2001, ONCOGENE, V20, P989, DOI 10.1038/sj.onc.1204179; Nakaigawa N, 1996, BIOCHEM BIOPH RES CO, V222, P95, DOI 10.1006/bbrc.1996.0703; PREVOSTEL C, 1995, ONCOGENE, V11, P669; Ren J, 2002, J BIOL CHEM, V277, P33758, DOI 10.1074/jbc.M110667200; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Reyland ME, 2000, CELL DEATH DIFFER, V7, P1200, DOI 10.1038/sj.cdd.4400744; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rosenzweig KE, 1997, CLIN CANCER RES, V3, P1149; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Sengupta S, 2003, EMBO J, V22, P1210, DOI 10.1093/emboj/cdg114; Sherman SI, 2003, LANCET, V361, P501, DOI 10.1016/S0140-6736(03)12488-9; Shirokawa JM, 2000, MOL ENDOCRINOL, V14, P1725, DOI 10.1210/me.14.11.1725; Sun XG, 2000, J BIOL CHEM, V275, P7470, DOI 10.1074/jbc.275.11.7470; Tanaka Y, 2003, J BIOL CHEM, V278, P33753, DOI 10.1074/jbc.M303313200; Tsygankova OM, 2001, MOL CELL BIOL, V21, P1921, DOI 10.1128/MCB.21.6.1921-1929.2001; Wang JW, 2003, MOL ENDOCRINOL, V17, P1425, DOI 10.1210/me.2003-0041; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	54	44	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32107	32114		10.1074/jbc.M504432200	http://dx.doi.org/10.1074/jbc.M504432200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16051606	hybrid			2022-12-25	WOS:000231794800010
J	Pittman, MS; Robinson, HC; Poole, RK				Pittman, MS; Robinson, HC; Poole, RK			A bacterial glutathione transporter (Escherichia coli CydDC) exports reductant to the periplasm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE-BOND FORMATION; BD QUINOL OXIDASE; CYTOCHROME-BD; RESPIRATORY-CHAIN; REDOX STATE; STREPTOCOCCUS-MUTANS; N-ETHYLMALEIMIDE; GENE-PRODUCT; AMINO-ACIDS; PROTEIN	Glutathione (GSH), a major biological antioxidant, maintains redox balance in prokaryotes and eukaryotic cells and forms exportable conjugates with compounds of pharmacological and agronomic importance. However, no GSH transporter has been characterized in a prokaryote. We show here that a heterodimeric ATP-binding cassette-type transporter, CydDC, mediates GSH transport across the Escherichia coli cytoplasmic membrane. In everted membrane vesicles, GSH is imported via an ATP-driven, protonophore-insensitive, orthovanadate-sensitive mechanism, equating with export to the periplasm in intact cells. GSH transport and cytochrome bd quinol oxidase assembly are abolished in the cydD1 mutant. Glutathione disulfide ( GSSG) was not transported in either Cyd(+) or Cyd(-) strains. Exogenous GSH restores defective swarming motility and benzylpenicillin sensitivity in a cydD mutant and also benzylpenicillin sensitivity in a gshA mutant defective in GSH synthesis. Overexpression of the cydDC operon in dsbD mutants defective in disulfide bond formation restores dithiothreitol tolerance and periplasmic cytochrome b assembly, revealing redundant pathways for reductant export to the periplasm. These results identify the first prokaryotic GSH transporter and indicate a key role for GSH in periplasmic redox homeostasis.	Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England	University of Sheffield	Poole, RK (corresponding author), Univ Sheffield, Dept Mol Biol & Biotechnol, Firth Court, Sheffield S10 2TN, S Yorkshire, England.	r.poole@sheffield.ac.uk			Biotechnology and Biological Sciences Research Council [BB/C514174/1] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		AMBUDKAR SV, 1984, J BIOL CHEM, V259, P6142; ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BEBBINGTON KJ, 1993, FEMS MICROBIOL LETT, V112, P19; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; BUTLER J, 1976, ANAL BIOCHEM, V75, P674, DOI 10.1016/0003-2697(76)90129-9; Carelli S, 1997, MOL BIOL CELL, V8, P564; Cook GM, 2000, MICROBIOL-SGM, V146, P527, DOI 10.1099/00221287-146-2-527; CROOKE H, 1995, MOL MICROBIOL, V15, P1139, DOI 10.1111/j.1365-2958.1995.tb02287.x; Cruz-Ramos H, 2004, MICROBIOL-SGM, V150, P3415, DOI 10.1099/mic.0.27191-0; Cuozzo JW, 1999, NAT CELL BIOL, V1, P130, DOI 10.1038/11047; DAILEY FE, 1993, P NATL ACAD SCI USA, V90, P1043, DOI 10.1073/pnas.90.3.1043; Dartigalongue C, 2000, EMBO J, V19, P5980, DOI 10.1093/emboj/19.22.5980; Davidson AL, 2002, J BACTERIOL, V184, P1225, DOI 10.1128/JB.184.5.1225-1233.2002; de Crouy-Chanel A, 2001, RES MICROBIOL, V152, P663, DOI 10.1016/S0923-2508(01)01245-1; Dickinson DA, 2002, BIOCHEM PHARMACOL, V64, P1019, DOI 10.1016/S0006-2952(02)01172-3; Dmello R, 1996, MICROBIOL-UK, V142, P755, DOI 10.1099/00221287-142-4-755; Fabianek RA, 2000, FEMS MICROBIOL REV, V24, P303, DOI 10.1111/j.1574-6976.2000.tb00544.x; FAHEY RC, 1978, J BACTERIOL, V133, P1126, DOI 10.1128/JB.133.3.1126-1129.1978; Ferguson GP, 1997, J BACTERIOL, V179, P1007, DOI 10.1128/jb.179.4.1007-1012.1997; GEORGIOU CD, 1987, J BACTERIOL, V169, P2107, DOI 10.1128/jb.169.5.2107-2112.1987; Goldman BS, 1996, J BACTERIOL, V178, P6348, DOI 10.1128/jb.178.21.6348-6351.1996; Goldman BS, 1996, J BACTERIOL, V178, P6338, DOI 10.1128/jb.178.21.6338-6347.1996; Gralnick J, 2000, J BACTERIOL, V182, P5180, DOI 10.1128/JB.182.18.5180-5187.2000; GREENBERG JT, 1986, J BACTERIOL, V168, P1026, DOI 10.1128/jb.168.2.1026-1029.1986; Hoober KL, 1996, J BIOL CHEM, V271, P30510, DOI 10.1074/jbc.271.48.30510; Hosie AHF, 2001, RES MICROBIOL, V152, P259, DOI 10.1016/S0923-2508(01)01197-4; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; INOUE M, 1985, J BIOL CHEM, V260, P326; Jamai A, 1996, PLANT PHYSIOL, V111, P1145, DOI 10.1104/pp.111.4.1145; Kalnenieks U, 1998, FEMS MICROBIOL LETT, V168, P91; Kobayashi T, 1997, P NATL ACAD SCI USA, V94, P11857, DOI 10.1073/pnas.94.22.11857; Kobayashi T, 1999, EMBO J, V18, P1192, DOI 10.1093/emboj/18.5.1192; Kogan I, 2003, EMBO J, V22, P1981, DOI 10.1093/emboj/cdg194; Konings WN, 2002, IUBMB LIFE, V53, P213, DOI 10.1080/15216540212646; Krebs H A, 1967, Adv Enzyme Regul, V5, P409, DOI 10.1016/0065-2571(67)90029-5; Krupp R, 2001, J BIOL CHEM, V276, P3696, DOI 10.1074/jbc.M009500200; Li ZS, 1996, J BIOL CHEM, V271, P6509, DOI 10.1074/jbc.271.11.6509; Li ZS, 1997, P NATL ACAD SCI USA, V94, P42, DOI 10.1073/pnas.94.1.42; Linton KJ, 1998, MOL MICROBIOL, V28, P5, DOI 10.1046/j.1365-2958.1998.00764.x; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MARTENSSON J, 1990, P NATL ACAD SCI USA, V87, P7185, DOI 10.1073/pnas.87.18.7185; McLaggan D, 2000, APPL ENVIRON MICROB, V66, P1393, DOI 10.1128/AEM.66.4.1393-1399.2000; MEISTER A, 1988, J BIOL CHEM, V263, P17205; MISSIAKAS D, 1995, EMBO J, V14, P3415, DOI 10.1002/j.1460-2075.1995.tb07347.x; OBRIAN MR, 2002, ADV MICROBIAL PHYSL, P257; Parry J, 2002, FEMS MICROBIOL LETT, V209, P81, DOI 10.1111/j.1574-6968.2002.tb11113.x; Pittman MS, 2002, J BIOL CHEM, V277, P49841, DOI 10.1074/jbc.M205615200; POOLE RK, 1989, J GEN MICROBIOL, V135, P1865; POOLE RK, 1993, MOL MICROBIOL, V10, P421, DOI 10.1111/j.1365-2958.1993.tb02673.x; POOLE RK, 1994, FEMS MICROBIOL LETT, V117, P217, DOI 10.1111/j.1574-6968.1994.tb06768.x; POOLE RK, 1986, J GEN MICROBIOL, V132, P1525; Raina S, 1997, ANNU REV MICROBIOL, V51, P179, DOI 10.1146/annurev.micro.51.1.179; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Sherrill C, 1998, J BACTERIOL, V180, P1454, DOI 10.1128/JB.180.6.1454-1459.1998; Siegele DA, 1996, J BACTERIOL, V178, P6091, DOI 10.1128/jb.178.21.6091-6096.1996; STEWART V, 1988, J BACTERIOL, V170, P1589, DOI 10.1128/jb.170.4.1589-1597.1988; THOMAS EL, 1984, J BACTERIOL, V157, P240, DOI 10.1128/JB.157.1.240-246.1984; THONYMEYER L, 1995, J BACTERIOL, V177, P4321; TROWER MK, 1993, BIOCHIM BIOPHYS ACTA, V1143, P109, DOI 10.1016/0005-2728(93)90223-3; TUGGLE CK, 1985, J BACTERIOL, V162, P448, DOI 10.1128/JB.162.1.448-450.1985; Vergauwen B, 2003, J BACTERIOL, V185, P5555, DOI 10.1128/JB.185.18.5555-5562.2003; WILLIS RC, 1974, ARCH BIOCHEM BIOPHYS, V161, P64, DOI 10.1016/0003-9861(74)90235-5; WUNDERLICH M, 1993, PROTEIN SCI, V2, P717, DOI 10.1002/pro.5560020503; Zhang J, 2004, FEBS LETT, V561, P58, DOI 10.1016/S0014-5793(04)00125-5	65	123	131	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32254	32261		10.1074/jbc.M503075200	http://dx.doi.org/10.1074/jbc.M503075200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16040611	hybrid			2022-12-25	WOS:000231794800027
J	Najima, Y; Yahagi, N; Takeuchi, Y; Matsuzaka, T; Sekiya, M; Nakagawa, Y; Amemiya-Kudo, M; Okazaki, H; Okazaki, S; Tamura, Y; Iizuka, Y; Ohashi, K; Harada, K; Gotoda, T; Nagai, R; Kadowaki, T; Ishibashi, S; Yamada, N; Osuga, J; Shimano, H				Najima, Y; Yahagi, N; Takeuchi, Y; Matsuzaka, T; Sekiya, M; Nakagawa, Y; Amemiya-Kudo, M; Okazaki, H; Okazaki, S; Tamura, Y; Iizuka, Y; Ohashi, K; Harada, K; Gotoda, T; Nagai, R; Kadowaki, T; Ishibashi, S; Yamada, N; Osuga, J; Shimano, H			High mobility group protein-B1 interacts with sterol regulatory element-binding proteins to enhance their DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPROTEIN RECEPTOR GENE; FATTY-ACID SYNTHASE; HELIX-LOOP-HELIX; TRANSGENIC MICE; TRANSCRIPTIONAL ACTIVATION; CHOLESTEROL-SYNTHESIS; PROMOTER; HMG1; EXPRESSION; LIVERS	Sterol regulatory element-binding proteins (SREBPs) are transcription factors that are predominately involved in the regulation of lipogenic and cholesterogenic enzyme gene expression. To identify unknown proteins that interact with SREBP, we screened nuclear extract proteins with S-35-labeled SREBP-1 bait in Far Western blotting analysis. Using this approach, high mobility group protein-B1 (HMGB1), a chromosomal protein, was identified as a novel SREBP interacting protein. In vitro glutathione S-transferase pull-down and in vivo coimmunoprecipitation studies confirmed an interaction between HMGB1 and both SREBP-1 and -2. The protein-protein interaction was mediated through the helix-loop-helix domain of SREBP-1, residues 309-344, and the A box of HMGB1. Furthermore, an electrophoretic mobility shift assay demonstrated that HMGB1 enhances SREBPs binding to their cognate DNA sequences. Moreover, luciferase reporter analyses, including RNA interference technique showed that HMGB1 potentiates the transcriptional activities of SREBP in cultured cells. These findings raise the intriguing possibility that HMGB1 is potentially involved in the regulation of lipogenic and cholesterogenic gene transcription.	Univ Tsukuba, Inst Clin Med, Dept Internal Med, Tsukuba, Ibaraki 3058575, Japan; Univ Tokyo, Grad Sch Med, Dept Internal Med, Tokyo 1138655, Japan	University of Tsukuba; University of Tokyo	Shimano, H (corresponding author), Univ Tsukuba, Inst Clin Med, Dept Internal Med, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.	shimano-tky@umin.ac.jp	Shimano, Hitoshi/V-1761-2019; Shimano, Hitoshi/AAI-5648-2020; Najima, Yuho/W-3858-2019; Yahagi, Naoya/D-2360-2014	Shimano, Hitoshi/0000-0002-5562-5572; Najima, Yuho/0000-0001-8910-0021; Yahagi, Naoya/0000-0002-1823-1865				Amemiya-Kudo M, 2002, J LIPID RES, V43, P1220, DOI 10.1194/jlr.M100417-JLR200; Amemiya-Kudo M, 2000, J BIOL CHEM, V275, P31078, DOI 10.1074/jbc.M005353200; Bennett MK, 1999, J BIOL CHEM, V274, P13025, DOI 10.1074/jbc.274.19.13025; BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; Bianchi ME, 2000, EMBO REP, V1, P109, DOI 10.1093/embo-reports/kvd030; Boonyaratanakornkit V, 1998, MOL CELL BIOL, V18, P4471, DOI 10.1128/MCB.18.8.4471; Brickman JM, 1999, P NATL ACAD SCI USA, V96, P10679, DOI 10.1073/pnas.96.19.10679; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; BUSTIN M, 2002, SCI STKE, pE39; Calogero S, 1999, NAT GENET, V22, P276, DOI 10.1038/10338; Ericsson J, 1999, J BIOL CHEM, V274, P14508, DOI 10.1074/jbc.274.20.14508; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; Ericsson J, 1996, J BIOL CHEM, V271, P24359, DOI 10.1074/jbc.271.40.24359; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; Fragiadakis GS, 2004, EMBO J, V23, P333, DOI 10.1038/sj.emboj.7600043; GE H, 1994, J BIOL CHEM, V269, P17136; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; Lloyd DJ, 2002, HUM MOL GENET, V11, P769, DOI 10.1093/hmg/11.7.769; Magana MM, 2000, J BIOL CHEM, V275, P4726, DOI 10.1074/jbc.275.7.4726; Misawa K, 2003, J BIOL CHEM, V278, P36176, DOI 10.1074/jbc.M302387200; Moreira JMA, 2000, EMBO J, V19, P6804, DOI 10.1093/emboj/19.24.6804; Oliner JD, 1996, GENE DEV, V10, P2903, DOI 10.1101/gad.10.22.2903; Parraga A, 1998, STRUCT FOLD DES, V6, P661, DOI 10.1016/S0969-2126(98)00067-7; Rae FK, 2004, ONCOGENE, V23, P3067, DOI 10.1038/sj.onc.1207360; Rishi V, 2004, J BIOL CHEM, V279, P11863, DOI 10.1074/jbc.M308000200; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; Sato R, 2000, J BIOL CHEM, V275, P12497, DOI 10.1074/jbc.275.17.12497; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimano H, 1997, J CLIN INVEST, V100, P2115, DOI 10.1172/JCI119746; Thomas JO, 2001, TRENDS BIOCHEM SCI, V26, P167, DOI 10.1016/S0968-0004(01)01801-1; Yamamoto T, 2004, J BIOL CHEM, V279, P12027, DOI 10.1074/jbc.M310333200; Zappavigna V, 1996, EMBO J, V15, P4981, DOI 10.1002/j.1460-2075.1996.tb00878.x; Zeng LF, 2004, EMBO J, V23, P950, DOI 10.1038/sj.emboj.7600106	42	34	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2005	280	30					27523	27532		10.1074/jbc.M414549200	http://dx.doi.org/10.1074/jbc.M414549200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	947WS	16040616	hybrid			2022-12-25	WOS:000230678600008
J	Yang, XH; Liu, DH; Murray, TJ; Mitchell, GC; Hesterman, EV; Karchner, SI; Merson, RR; Hahn, ME; Sherr, DH				Yang, XH; Liu, DH; Murray, TJ; Mitchell, GC; Hesterman, EV; Karchner, SI; Merson, RR; Hahn, ME; Sherr, DH			The aryl hydrocarbon receptor constitutively represses c-myc transcription in human mammary tumor cell	ONCOGENE			English	Review						aryl hydrocarbon receptor; c-Myc; mammary tumorigenesis	NF-KAPPA-B; BREAST-CANCER CELLS; AH RECEPTOR; AROMATIC-HYDROCARBON; ESTROGEN-RECEPTOR; GENE-EXPRESSION; RECEPTOR/TRANSCRIPTION FACTOR; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN TCDD; RETINOBLASTOMA PROTEIN; TRANSIENT EXPRESSION	The aryl hydrocarbon receptor (AhR) is an environmental carcinogen-activated transcription factor associated with tumorigenesis. High levels of apparently active AhR characterize a variety of tumors, even in the absence of environmental ligands. Despite this association between transformation and AhR upregulation, little is known of the transcriptional consequences of constitutive AhR activation. Here, the effects of constitutively active and environmental ligand-induced AhR on c-myc, an oncogene whose promoter contains six AhR-binding sites (AhREs (aryl hydrocarbon response elements)), were investigated. A reporter containing the human c-myc promoter, with its six AhREs and two NF-kappa B-binding sites, was constructed. This vector, and variants with deletions in the NF-kappa B and/or AhR-binding sites, was transfected into a human breast cancer cell line, Hs578T, which expresses high levels of apparently active, nuclear AhR. Results indicate that: (1) the AhR constitutively binds the c-myc promoter; (2) there is a low but significant baseline level of c-myc promoter activity, which is not regulated by NF-kappa B and is not affected by an environmental AhR ligand; (3) deletion of any one of the AhREs has no effect on constitutive reporter activity, while deletion of all six increases reporter activity approximately fivefold; (4) a similar increase in reporter activity occurs when constitutively active AhR is suppressed by transfection with an AhR repressor plasmid (AhRR); (5) AhRR transfection significantly increases background levels of endogenous c-myc mRNA and c-Myc protein. These results suggest that the AhR influences the expression of c-Myc, a protein critical to malignant transformation.	Boston Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02118 USA; Furman Univ, Dept Biol, Greenville, SC 29613 USA; Woods Hole Oceanog Inst, Dept Biol, Woods Hole, MA 02543 USA	Boston University; Woods Hole Oceanographic Institution	Sherr, DH (corresponding author), Boston Univ, Sch Publ Hlth, Dept Environm Hlth, 715 Albany St,R-408, Boston, MA 02118 USA.	dsherr@bu.edu	Hahn, Mark/AAV-7516-2020	Hahn, Mark/0000-0003-4358-2082; Sherr, David/0000-0003-3353-0553	NIEHS NIH HHS [P01-ES11624, P42-ES07381, R01-ES06086] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES011624, R01ES006086, P42ES007381] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abdelrahim M, 2003, MOL PHARMACOL, V63, P1373, DOI 10.1124/mol.63.6.1373; Allan LL, 2005, MOL PHARMACOL, V67, P1740, DOI 10.1124/mol.104.009100; Baba T, 2001, J BIOL CHEM, V276, P33101, DOI 10.1074/jbc.M011497200; Beischlag TV, 2005, J BIOL CHEM, V280, P21607, DOI 10.1074/jbc.C500090200; Beischlag TV, 2002, MOL CELL BIOL, V22, P4319, DOI 10.1128/MCB.22.12.4319-4333.2002; Bellas RE, 1999, CELL GROWTH DIFFER, V10, P287; Blaustein JD, 2004, ENDOCRINOLOGY, V145, P1075, DOI 10.1210/en.2003-1485; BORG A, 1992, INT J CANCER, V51, P687, DOI 10.1002/ijc.2910510504; Buters JTM, 1999, P NATL ACAD SCI USA, V96, P1977, DOI 10.1073/pnas.96.5.1977; CALAF G, 1993, CARCINOGENESIS, V14, P483, DOI 10.1093/carcin/14.3.483; Cao YX, 2003, J MAMMARY GLAND BIOL, V8, P215, DOI 10.1023/A:1025905008934; CARRIER F, 1992, MOL CELL BIOL, V12, P1856, DOI 10.1128/MCB.12.4.1856; Caruso JA, 2004, MOL PHARMACOL, V65, P1016, DOI 10.1124/mol.65.4.1016; Carver LA, 1998, J BIOL CHEM, V273, P33580, DOI 10.1074/jbc.273.50.33580; Chan WK, 1999, J BIOL CHEM, V274, P12115, DOI 10.1074/jbc.274.17.12115; Chang CY, 1998, MOL CELL BIOL, V18, P525, DOI 10.1128/MCB.18.1.525; Channavajhala P, 2002, ONCOGENE, V21, P5280, DOI 10.1038/sj.onc.1205640; CHEN HS, 1994, J BIOL CHEM, V269, P27554; Chen ZP, 1998, CANCER LETT, V129, P173, DOI 10.1016/S0304-3835(98)00108-6; Chesire DR, 2004, CANCER RES, V64, P2523, DOI 10.1158/0008-5472.CAN-03-3309; CHRISTOU M, 1987, CARCINOGENESIS, V8, P73, DOI 10.1093/carcin/8.1.73; Corton JC, 1996, TOXICOL LETT, V85, P67, DOI 10.1016/0378-4274(96)03636-3; DANIEL FB, 1984, CARCINOGENESIS, V5, P1021, DOI 10.1093/carcin/5.8.1021; DAS SK, 1989, CANCER RES, V49, P920; Davarinos NA, 1999, J BIOL CHEM, V274, P28708, DOI 10.1074/jbc.274.40.28708; DEAN M, 1988, CURR TOP MICROBIOL, V141, P216; Dertinger SD, 2001, CARCINOGENESIS, V22, P171, DOI 10.1093/carcin/22.1.171; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; Fallone F, 2004, BIOCHEM BIOPH RES CO, V322, P551, DOI 10.1016/j.bbrc.2004.07.153; Fowler AM, 2004, FASEB J, V18, P81, DOI 10.1096/fj.03-0038com; Garrison PM, 1996, FUND APPL TOXICOL, V30, P194, DOI 10.1006/faat.1996.0056; Ge NL, 1998, J BIOL CHEM, V273, P22708, DOI 10.1074/jbc.273.35.22708; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; HACKETT AJ, 1977, J NATL CANCER I, V58, P1795, DOI 10.1093/jnci/58.6.1795; Han D, 2004, BIOFACTORS, V20, P11, DOI 10.1002/biof.5520200102; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; Hayashibara T, 2003, BIOCHEM BIOPH RES CO, V300, P128, DOI 10.1016/S0006-291X(02)02793-6; Helbig G, 2003, J BIOL CHEM, V278, P21631, DOI 10.1074/jbc.M300609200; Hestermann EV, 2003, MOL CELL BIOL, V23, P7920, DOI 10.1128/MCB.23.21.7920-7925.2003; Ishibe N, 1998, CANCER RES, V58, P667; JERRY DJ, 1994, MOL CARCINOGEN, V9, P175, DOI 10.1002/mc.2940090309; Karchner SI, 2002, J BIOL CHEM, V277, P6949, DOI 10.1074/jbc.M110779200; KESSLER DJ, 1992, ONCOGENE, V7, P2447; Kikuchi Y, 2003, J BIOCHEM, V134, P83, DOI 10.1093/jb/mvg115; Kim DW, 2000, ONCOGENE, V19, P5498, DOI 10.1038/sj.onc.1203945; Kim DW, 2000, CARCINOGENESIS, V21, P871, DOI 10.1093/carcin/21.5.871; Koliopanos A, 2002, ONCOGENE, V21, P6059, DOI 10.1038/sj.onc.1205633; Korkalainen M, 2004, BIOCHEM BIOPH RES CO, V315, P123, DOI 10.1016/j.bbrc.2004.01.028; Kumar MB, 1999, GENE EXPRESSION, V8, P273; Kumar MB, 1999, J BIOL CHEM, V274, P22155, DOI 10.1074/jbc.274.32.22155; Lai ZW, 1996, CHEM-BIOL INTERACT, V100, P97, DOI 10.1016/0009-2797(96)03691-5; LaPres JJ, 2000, J BIOL CHEM, V275, P6153, DOI 10.1074/jbc.275.9.6153; LARSEN M, 1997, FUND APPL TOXICOL, V36, P24; Latil A, 2000, INT J CANCER, V89, P172; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; Levine-Fridman A, 2004, MOL PHARMACOL, V65, P461, DOI 10.1124/mol.65.2.461; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Liao DJ, 2003, LAB INVEST, V83, P1437, DOI 10.1097/01.LAB.0000090153.13977.AE; Liu CQ, 2003, J BIOL CHEM, V278, P44857, DOI 10.1074/jbc.M304489200; Ma Q, 1996, MOL CELL BIOL, V16, P2144; Maecker B, 2003, BLOOD, V102, P3287, DOI 10.1182/blood-2003-05-1374; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; Marcus RS, 1998, J PHARMACOL EXP THER, V287, P1113; Matikainen T, 2001, NAT GENET, V28, P355, DOI 10.1038/ng575; Matikainen TM, 2002, ENDOCRINOLOGY, V143, P615, DOI 10.1210/en.143.2.615; McDougal A, 1997, CANCER LETT, V120, P53, DOI 10.1016/S0304-3835(97)00299-1; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; Meyer BK, 1999, BIOCHEMISTRY-US, V38, P8907, DOI 10.1021/bi982223w; Mimura J, 1999, GENE DEV, V13, P20, DOI 10.1101/gad.13.1.20; Miyoshi K, 2002, ONCOGENE, V21, P5548, DOI 10.1038/sj.onc.1205686; Nazarenko I, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e37; NEBERT DW, 1991, PHARMACOGENETICS, V1, P68, DOI 10.1097/00008571-199111000-00003; Negri E, 2003, EUR J CANCER PREV, V12, P509, DOI 10.1097/00008469-200312000-00010; Nguyen TA, 1999, ARCH BIOCHEM BIOPHYS, V367, P250, DOI 10.1006/abbi.1999.1282; Ohtake F, 2003, NATURE, V423, P545, DOI 10.1038/nature01606; OKEY AB, 1994, TOXICOL LETT, V70, P1, DOI 10.1016/0378-4274(94)90139-2; Pelengaris S, 2003, ARCH BIOCHEM BIOPHYS, V416, P129, DOI 10.1016/S0003-9861(03)00294-7; POLAND A, 1991, MOL PHARMACOL, V39, P20; POLAND AP, 1974, J BIOL CHEM, V249, P5599; Porter W, 2001, J MOL ENDOCRINOL, V26, P31, DOI 10.1677/jme.0.0260031; Puga A, 2002, CHEM-BIOL INTERACT, V141, P117, DOI 10.1016/S0009-2797(02)00069-8; Puga A, 2000, J BIOL CHEM, V275, P2943, DOI 10.1074/jbc.275.4.2943; PUGA A, 1992, DNA CELL BIOL, V11, P269, DOI 10.1089/dna.1992.11.269; Ruggero D, 2004, NAT MED, V10, P484, DOI 10.1038/nm1042; Rushing SR, 2002, ARCH BIOCHEM BIOPHYS, V403, P189, DOI 10.1016/S0003-9861(02)00233-3; RUSSO J, 1987, LAB INVEST, V57, P112; Ryu HY, 2003, J IMMUNOL, V170, P4897, DOI 10.4049/jimmunol.170.10.4897; SADEK CM, 1994, J BIOL CHEM, V269, P31505; Saez AI, 2003, LAB INVEST, V83, P143, DOI 10.1097/01.LAB.0000057000.41585.FD; Safe S, 1998, TOXICOL LETT, V103, P343; Safe S, 2001, TOXICOL LETT, V120, P1, DOI 10.1016/S0378-4274(01)00301-0; Singh SS, 1996, ARCH BIOCHEM BIOPHYS, V329, P47, DOI 10.1006/abbi.1996.0190; Sulentic CEW, 2000, J PHARMACOL EXP THER, V295, P705; Sulentic CEW, 1998, MOL PHARMACOL, V53, P623, DOI 10.1124/mol.53.4.623; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; THOMSEN JS, 1994, CARCINOGENESIS, V15, P933, DOI 10.1093/carcin/15.5.933; Thomsen JS, 2004, MOL PHARMACOL, V65, P165, DOI 10.1124/mol.65.1.165; Tian Y, 1999, J BIOL CHEM, V274, P510, DOI 10.1074/jbc.274.1.510; Tohkin M, 2000, MOL PHARMACOL, V58, P845, DOI 10.1124/mol.58.4.845; Trombino AF, 2000, BREAST CANCER RES TR, V63, P117, DOI 10.1023/A:1006443104670; Vaziri C, 1996, J BIOL CHEM, V271, P25921, DOI 10.1074/jbc.271.42.25921; Wang F, 1999, BIOCHEMISTRY-US, V38, P11490, DOI 10.1021/bi982578f; Wang F, 2001, MOL CELL ENDOCRINOL, V172, P91, DOI 10.1016/S0303-7207(00)00379-8; Wang S, 2004, J BIOL CHEM, V279, P13593, DOI 10.1074/jbc.M312274200; Wang WL, 1996, BRIT J CANCER, V73, P316, DOI 10.1038/bjc.1996.55; WANG XH, 1995, EUR J PHARM-ENVIRON, V293, P191, DOI 10.1016/S0922-4106(05)80044-6; Wang Y, 2004, CANCER CELL, V5, P501, DOI 10.1016/S1535-6108(04)00113-8; Watanabe T, 2001, J HUM GENET, V46, P342, DOI 10.1007/s100380170070; WEIGEL NL, 1995, J STEROID BIOCHEM, V53, P509, DOI 10.1016/0960-0760(95)00098-K; Weiss C, 1996, EXP CELL RES, V226, P154, DOI 10.1006/excr.1996.0214; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251; Wormke M, 2003, MOL CELL BIOL, V23, P1843, DOI 10.1128/MCB.23.6.1843-1855.2003; Wu M, 1996, MOL CELL BIOL, V16, P5015; Yamaguchi K, 1997, J IMMUNOL, V158, P2165; Zhang S, 2003, ENVIRON HEALTH PERSP, V111, P1877, DOI 10.1289/ehp.6322; Ziccardi MH, 2000, TOXICOL SCI, V54, P183, DOI 10.1093/toxsci/54.1.183; [No title captured]	119	63	72	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2005	24	53					7869	7881		10.1038/sj.onc.1208938	http://dx.doi.org/10.1038/sj.onc.1208938			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	986PU	16091746				2022-12-25	WOS:000233463000006
J	Jin, WJ; Fuki, IV; Seidah, NG; Benjannet, S; Glick, JM; Rader, DJ				Jin, WJ; Fuki, IV; Seidah, NG; Benjannet, S; Glick, JM; Rader, DJ			Proprotein covertases are responsible for proteolysis and inactivation of endothelial lipase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DERIVED LIPASE; GENE-EXPRESSION; PROHORMONE CONVERTASES; TRIGLYCERIDE LIPASE; PRECURSOR PROTEINS; HDL METABOLISM; IN-VITRO; FURIN; FAMILY; ACTIVATION	Plasma lipoprotein metabolism is tightly regulated by several members of the triglyceride lipase family, including endothelial lipase (EL) and lipoprotein lipase (LPL). Our previous work suggested that EL is proteolytically processed. In this report, we have used a combination of epitope tagging, mutagenesis, and N-terminal sequencing to determine the precise location of the cleavage site within EL. The cleavage occurs immediately after the sequence RNKR, a known recognition sequence for the proprotein convertase ( PC) family. We demonstrate that some PCs, but not all, can proteolytically cleave EL at this site and thereby directly regulate EL enzymatic activity through modulating EL cleavage. Furthermore, specific knockdown of individual PCs proves that PCs are the proteases that cleave EL in human endothelial cells. Interestingly, a homologous site in LPL is also cleaved by PCs. This action is unusual for PCs, which are traditionally known as activators of pro-proteins, and highlights a potential role of PCs in lipid metabolism through their proteolytic processing of lipases.	Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Expt Therapeut, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA; Clin Res Inst Montreal, Labs Biochem Neuroendocrinol, Montreal, PQ H2W 1R7, Canada	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Jin, WJ (corresponding author), BRB 2-3,Rm 646,421 Curie Blvd, Philadelphia, PA 19104 USA.	weijun@mail.med.upenn.edu	Seidah, Nabil/I-3596-2013	Seidah, Nabil/0000-0001-6503-9342	NHLBI NIH HHS [HL55323] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL055323, R01HL055323] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abifadel M, 2003, NAT GENET, V34, P154, DOI 10.1038/ng1161; Azumi H, 2003, CARDIOVASC RES, V58, P647, DOI 10.1016/S0008-6363(03)00287-6; Bazan JF, 1996, NATURE, V380, P21, DOI 10.1038/380021a0; BEAUBIEN G, 1995, CELL TISSUE RES, V279, P539; Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; Broedl UC, 2004, CIRC RES, V94, P1554, DOI 10.1161/01.RES.0000130657.00222.39; BURKHARDT JK, 1989, J CELL SCI, V92, P643; Bush G, 2001, DEV BIOL, V229, P494, DOI 10.1006/dbio.2000.9992; Campan M, 1996, BIOCHEMISTRY-US, V35, P3797, DOI 10.1021/bi952552d; Cheng M, 1997, INT J CANCER, V71, P966, DOI 10.1002/(SICI)1097-0215(19970611)71:6<966::AID-IJC10>3.3.CO;2-A; Choi SY, 2002, J LIPID RES, V43, P1763, DOI 10.1194/jlr.R200011-JLR200; Cohen J, 2005, NAT GENET, V37, P328, DOI 10.1038/ng0305-328c; ENERBACK S, 1993, BIOCHIM BIOPHYS ACTA, V1169, P107, DOI 10.1016/0005-2760(93)90196-G; Fuki IV, 2003, J BIOL CHEM, V278, P34331, DOI 10.1074/jbc.M302181200; GARTEN W, 1989, VIROLOGY, V172, P25, DOI 10.1016/0042-6822(89)90103-7; Gauster M, 2005, J LIPID RES, V46, P1517, DOI 10.1194/jlr.M500054-JLR200; Hirata K, 2000, BIOCHEM BIOPH RES CO, V272, P90, DOI 10.1006/bbrc.2000.2747; Horton JD, 2002, COLD SPRING HARB SYM, V67, P491, DOI 10.1101/sqb.2002.67.491; Ishida T, 2004, J BIOL CHEM, V279, P45085, DOI 10.1074/jbc.M406360200; Ishida T, 2003, J CLIN INVEST, V111, P347, DOI [10.1172/JCI200316306, 10.1172/JCI16306]; Jaye M, 2004, CURR OPIN LIPIDOL, V15, P183, DOI 10.1097/00041433-200404000-00011; Jaye M, 1999, NAT GENET, V21, P424, DOI 10.1038/7766; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; Jin WJ, 2003, CIRC RES, V92, P644, DOI 10.1161/01.RES.0000064502.47539.6D; Jin WJ, 2003, J CLIN INVEST, V111, P357, DOI [10.1172/JCI16146, 10.1172/JCI200316146]; Kageyama T, 2002, CELL MOL LIFE SCI, V59, P288, DOI 10.1007/s00018-002-8423-9; Kalus I, 2003, J BIOL CHEM, V278, P10381, DOI 10.1074/jbc.M208351200; KERN PA, 1988, J CLIN INVEST, V81, P398, DOI 10.1172/JCI113332; Ko KWS, 1998, J BIOL CHEM, V273, P27779, DOI 10.1074/jbc.273.43.27779; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; Ma K, 2003, P NATL ACAD SCI USA, V100, P2748, DOI 10.1073/pnas.0438039100; Maugeais C, 2003, CIRCULATION, V108, P2121, DOI 10.1161/01.CIR.0000092889.24713.DC; Mayer G, 2003, J CELL SCI, V116, P1763, DOI 10.1242/jcs.00394; McCoy MG, 2002, J LIPID RES, V43, P921; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Nour N, 2003, J BIOL CHEM, V278, P2886, DOI 10.1074/jbc.M208009200; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; Rader DJ, 2000, CURR OPIN LIPIDOL, V11, P141, DOI 10.1097/00041433-200004000-00006; REDMAN CM, 1975, J CELL BIOL, V66, P42, DOI 10.1083/jcb.66.1.42; Salvesen GS, 2004, ONCOGENE, V23, P2774, DOI 10.1038/sj.onc.1207522; Seidah NG, 2002, ESSAYS BIOCHEM, V38, P79, DOI 10.1042/bse0380079; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; Seidah NG, 2003, P NATL ACAD SCI USA, V100, P928, DOI 10.1073/pnas.0335507100; Seidah NG, 1997, CURR OPIN BIOTECH, V8, P602, DOI 10.1016/S0958-1669(97)80036-5; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; Tikhonov I, 2004, FEBS LETT, V565, P89, DOI 10.1016/j.febslet.2004.03.079; Tsuji A, 2003, BBA-PROTEINS PROTEOM, V1645, P95, DOI 10.1016/S1570-9639(02)00532-0; Willnow TE, 1996, BIOCHEM J, V313, P71, DOI 10.1042/bj3130071; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; Wong H, 2002, J LIPID RES, V43, P993, DOI 10.1194/jlr.R200007-JLR200; Zhong M, 1999, J BIOL CHEM, V274, P33913, DOI 10.1074/jbc.274.48.33913	51	82	83	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36551	36559		10.1074/jbc.M502264200	http://dx.doi.org/10.1074/jbc.M502264200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16109723	hybrid			2022-12-25	WOS:000232901800004
J	Balabanian, K; Lagane, B; Infantino, S; Chow, KYC; Harriague, J; Moepps, B; Arenzana-Seisdedos, F; Thelen, M; Bachelerie, F				Balabanian, K; Lagane, B; Infantino, S; Chow, KYC; Harriague, J; Moepps, B; Arenzana-Seisdedos, F; Thelen, M; Bachelerie, F			The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; IMMUNODEFICIENCY-VIRUS CORECEPTOR; VIP RECEPTOR; BONE-MARROW; FACTOR-I; CXCR4; SDF-1; EXPRESSION; CLONING; GENE	Combined phylogenetic and chromosomal location studies suggest that the orphan receptor RDC1 is related to CXC chemokine receptors. RDC1 provides a co- receptor function for a restricted number of human immunodeficiency virus ( HIV) isolates, in particular for the CXCR4- using HIV- 2 ROD strain. Here we show that CXCL12, the only known natural ligand for CXCR4, binds to and signals through RDC1. We demonstrate that RDC1 is expressed in T lymphocytes and that CXCL12- promoted chemotaxis is inhibited by an anti- RDC1 monoclonal antibody. Concomitant blockade of RDC1 and CXCR4 produced additive inhibitory effects in CXCL12-induced T cell migration. Furthermore, we provide evidence that interaction of CXCL12 with RDC1 is specific, saturable, and of high affinity ( apparent K-D = 0.4 nM). In CXCR4- negative cells expressing RDC1, CXCL12 promotes internalization of the receptor and chemotactic signals through RDC1. Collectively, our data indicate that RDC1, which we propose to rename as CXCR7, is a receptor for CXCL12.	Inst Pasteur, Unite Immunol Virale, F-75015 Paris, France; Inst Biomed Res, CH-6500 Bellinzona, Switzerland; Univ Ulm, Dept Pharmacol & Toxicol, D-89081 Ulm, Germany	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Universita della Svizzera Italiana; Ulm University	Bachelerie, F (corresponding author), Inst Pasteur, Unite Immunol Virale, 28 Rue Dr Roux, F-75015 Paris, France.	fbachele@pasteur.fr	Lagane, Bernard/AAA-2205-2019; Balabanian, Karl/I-2990-2016; BACHELERIE, FRANCOISE/F-8823-2013; Balabanian, Karl/S-6250-2019; Lagane, Bernard/K-8446-2016; Arenzana-Seisdedos, Fernando/E-5835-2016	Lagane, Bernard/0000-0002-3459-7867; Balabanian, Karl/0000-0002-0534-3198; BACHELERIE, FRANCOISE/0000-0002-0399-3277; Balabanian, Karl/0000-0002-0534-3198; Harriague, Julie/0000-0001-6824-9169				AHUJA SK, 1992, NAT GENET, V2, P31, DOI 10.1038/ng0992-31; Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; Balabanian K, 2005, BLOOD, V105, P2449, DOI 10.1182/blood-2004-06-2289; Balabanian K, 2004, J IMMUNOL, V173, P7150, DOI 10.4049/jimmunol.173.12.7150; Brelot A, 2000, J BIOL CHEM, V275, P23736, DOI 10.1074/jbc.M000776200; Brelot A, 1999, J VIROL, V73, P2576, DOI 10.1128/JVI.73.4.2576-2586.1999; Brelot A, 1997, J VIROL, V71, P4744, DOI 10.1128/JVI.71.6.4744-4751.1997; Buckley CD, 2000, J IMMUNOL, V165, P3423, DOI 10.4049/jimmunol.165.6.3423; Campbell DJ, 2003, IMMUNOL REV, V195, P58, DOI 10.1034/j.1600-065X.2003.00067.x; COOK JS, 1992, FEBS LETT, V300, P149, DOI 10.1016/0014-5793(92)80184-I; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; Epstein RJ, 2004, NAT REV CANCER, V4, P901, DOI 10.1038/nrc1473; EVA C, 1993, DNA CELL BIOL, V12, P393, DOI 10.1089/dna.1993.12.393; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; Fredriksson R, 2003, MOL PHARMACOL, V63, P1256, DOI 10.1124/mol.63.6.1256; Haribabu B, 1997, J BIOL CHEM, V272, P28726, DOI 10.1074/jbc.272.45.28726; Heesen M, 1998, IMMUNOGENETICS, V47, P364, DOI 10.1007/s002510050371; Joost P, 2002, GENOME BIOL, V3; Lagane B, 2005, MOL PHARMACOL, V67, P1966, DOI 10.1124/mol.104.009779; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; LIBERT F, 1990, NUCLEIC ACIDS RES, V18, P1917, DOI 10.1093/nar/18.7.1917; LIBERT F, 1991, GENOMICS, V11, P225, DOI 10.1016/0888-7543(91)90125-X; LIBERT F, 1989, SCIENCE, V244, P569, DOI 10.1126/science.2541503; Loetscher P, 2001, J LEUKOCYTE BIOL, V69, P881; Lukacs NW, 2002, AM J PATHOL, V160, P1353, DOI 10.1016/S0002-9440(10)62562-X; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; Madden SL, 2004, AM J PATHOL, V165, P601, DOI 10.1016/S0002-9440(10)63324-X; Martin C, 2003, IMMUNITY, V19, P583, DOI 10.1016/S1074-7613(03)00263-2; MOEPPS B, 2005, IN PRESS MOL IMMUNOL; Moser B, 2004, TRENDS IMMUNOL, V25, P75, DOI 10.1016/j.it.2003.12.005; Murphy PM, 2000, PHARMACOL REV, V52, P145; NAGATA S, 1992, TRENDS PHARMACOL SCI, V13, P102; Nelson PJ, 2001, IMMUNITY, V14, P377, DOI 10.1016/S1074-7613(01)00118-2; Okada T, 2002, J EXP MED, V196, P65, DOI 10.1084/jem.20020201; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; Petit I, 2002, NAT IMMUNOL, V3, P687, DOI 10.1038/ni813; Raggo C, 2005, CANCER RES, V65, P5084, DOI 10.1158/0008-5472.CAN-04-2822; Shimizu N, 2000, J VIROL, V74, P619, DOI 10.1128/JVI.74.2.619-626.2000; Shimizu N, 2000, GENE, V259, P199, DOI 10.1016/S0378-1119(00)00432-7; Signoret N, 1997, J CELL BIOL, V139, P651, DOI 10.1083/jcb.139.3.651; SREEDHARAN SP, 1991, P NATL ACAD SCI USA, V88, P4986, DOI 10.1073/pnas.88.11.4986; Thelen M, 2001, NAT IMMUNOL, V2, P129, DOI 10.1038/84224; Valenzuela-Fernandez A, 2002, J BIOL CHEM, V277, P15677, DOI 10.1074/jbc.M111388200; Venkatesan S, 2001, J BIOL CHEM, V276, P40133, DOI 10.1074/jbc.M105722200; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	48	808	881	0	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35760	35766		10.1074/jbc.M508234200	http://dx.doi.org/10.1074/jbc.M508234200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16107333	hybrid			2022-12-25	WOS:000232561200079
J	Folgueira, C; Quijada, L; Soto, M; Abanades, DR; Alonso, C; Requena, JM				Folgueira, C; Quijada, L; Soto, M; Abanades, DR; Alonso, C; Requena, JM			The translational efficiencies of the two Leishmania infantum HSP70 mRNAs, differing in their 3 '-untranslated regions, are affected by shifts in the temperature of growth through different mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; MAJOR FRIEDLIN CHROMOSOME-1; 3 UNTRANSLATED REGION; POSTTRANSCRIPTIONAL REGULATION; DEVELOPMENTAL REGULATION; GENOMIC ORGANIZATION; TRYPANOSOMA-BRUCEI; EXPRESSION; GENES; TRANSCRIPTION	Exposure of Leishmania promastigotes to the temperature of their mammalian hosts induces a typical heat-shock response. In Leishmania infantum, HSP70 is encoded by two types of genes that differ in their 3'-untranslated regions (3'-UTRs). Previously, we have shown that specific transcripts for each gene are present in promastigotes growing at normal temperature (26 degrees C), but only transcripts with 3'-UTR-type I (3'-UTRI) accumulate in a temperature-dependent manner. Here, we have investigated the translational efficiencies of both types of HSP70 transcripts at the different temperatures that the parasite encounters in the insect (26 degrees C, normal temperature) or in the mammalian host (heat-shock temperatures). Interestingly, 3'-UTRI-bearing transcripts (HSP70-I) were found associated with ribosomes in promastigotes at normal and heat-shock temperatures, whereas the HSP70-II transcripts appear to be preferentially translated at heat-shock temperatures but not at 26 C. We have analyzed the function of these UTRs in the translational control by use of plasmid constructs in which the CAT reporter gene was flanked by UTRs of the HSP70 genes. Unexpectedly, it was found that CAT transcripts with 3'-UTRII bind to ribosomes at 26 C, and, indeed, the CAT protein is synthesized. A valid conclusion of these experiments was that both types of 3'-UTRs are essential for translation of HSP70 mRNAs at heat shock temperatures, although the 3'-UTRII is more efficient during severe heat shock (39 degrees C). In addition, these results suggest that sequence region other than the 3'-UTR of HSP70-II gene is involved in the translational silent state of HSP70-II transcripts at 26 degrees C. Finally, a null mutant has been created by targeted disruption of both HSP70-II alleles. Remarkably, the Delta HSP70 mutant synthesizes HSP70 at a lower rate than the wild-type parasites. Overall, our data suggest that the biological function of the HSP70-II gene is to top up HSP70 levels under conditions of stress.	Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Requena, JM (corresponding author), Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.	jmrequena@cbm.uam.es	Álvarez, Manuel Soto/Q-5234-2018; Requena, Jose M/I-2022-2019	Álvarez, Manuel Soto/0000-0001-6825-841X; Requena, Jose M/0000-0001-7550-0198				AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; Angel SO, 1996, ACTA TROP, V62, P45, DOI 10.1016/S0001-706X(96)00020-4; Arava Y, 2005, NUCLEIC ACIDS RES, V33, P2421, DOI 10.1093/nar/gki331; Boucher N, 2002, J BIOL CHEM, V277, P19511, DOI 10.1074/jbc.M200500200; BRANDAU S, 1995, BIOCHEM J, V310, P225, DOI 10.1042/bj3100225; Campbell DA, 2003, MICROBES INFECT, V5, P1231, DOI 10.1016/j.micinf.2003.09.005; Clayton C, 1998, MOL BIOCHEM PARASIT, V97, P221, DOI 10.1016/S0166-6851(98)00115-7; Clayton CE, 2002, EMBO J, V21, P1881, DOI 10.1093/emboj/21.8.1881; Clos J, 1999, AM ZOOL, V39, P848; De Bor VV, 2004, CURR OPIN CELL BIOL, V16, P300, DOI 10.1016/j.ceb.2004.03.008; Desjeux P, 2004, COMP IMMUNOL MICROB, V27, P305, DOI 10.1016/j.cimid.2004.03.004; Feder ME, 1999, ANNU REV PHYSIOL, V61, P243, DOI 10.1146/annurev.physiol.61.1.243; Furger A, 1997, MOL CELL BIOL, V17, P4372, DOI 10.1128/MCB.17.8.4372; GENSKE JE, 1991, MOL CELL BIOL, V11, P240, DOI 10.1128/MCB.11.1.240; Gong WJ, 2004, GENETICS, V168, P1467, DOI 10.1534/genetics.104.030874; Hotz HR, 1997, NUCLEIC ACIDS RES, V25, P3017, DOI 10.1093/nar/25.15.3017; Ivens AC, 2005, SCIENCE, V309, P436, DOI 10.1126/science.1112680; Kloc M, 2002, CELL, V108, P533, DOI 10.1016/S0092-8674(02)00651-7; Larreta R, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-3; LEBOWITZ JH, 1991, GENE, V103, P119, DOI 10.1016/0378-1119(91)90402-W; Mahmood R, 1999, MOL CELL BIOL, V19, P6174; Martinez-Calvillo S, 2003, MOL CELL, V11, P1291, DOI 10.1016/S1097-2765(03)00143-6; Martinez-Calvillo S, 2004, EUKARYOT CELL, V3, P506, DOI 10.1128/EC.3.2.506-517.2004; McKoy G, 1997, MOL BIOCHEM PARASIT, V90, P169, DOI 10.1016/S0166-6851(97)00172-2; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; Myler PJ, 1999, P NATL ACAD SCI USA, V96, P2902, DOI 10.1073/pnas.96.6.2902; Myung KS, 2002, J BIOL CHEM, V277, P16489, DOI 10.1074/jbc.M200174200; Quijada L, 2003, MOL BIOCHEM PARASIT, V130, P139, DOI 10.1016/S0166-6851(03)00159-2; Quijada L, 1997, J BIOL CHEM, V272, P4493, DOI 10.1074/jbc.272.7.4493; Quijada L, 2000, MOL BIOCHEM PARASIT, V110, P79, DOI 10.1016/S0166-6851(00)00258-9; Requena JM, 1997, MEM I OSWALDO CRUZ, V92, P853, DOI 10.1590/S0074-02761997000600022; Rico AI, 1999, MOL IMMUNOL, V36, P1131, DOI 10.1016/S0161-5890(99)00136-4; Robinson KA, 2003, MOL BIOCHEM PARASIT, V128, P217, DOI 10.1016/S0166-6851(03)00079-3; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schurch N, 1997, MOL BIOCHEM PARASIT, V89, P109, DOI 10.1016/S0166-6851(97)00107-2; SOARES CMA, 1989, FEBS LETT, V250, P497, DOI 10.1016/0014-5793(89)80784-7; SOTO M, 1993, J BIOL CHEM, V268, P21835; SOTO M, 1993, MOL BIOCHEM PARASIT, V61, P265, DOI 10.1016/0166-6851(93)90072-6; Soto M, 2004, BIOCHEM J, V379, P617, DOI 10.1042/BJ20031522; Soto M, 2003, PARASITOLOGY, V127, P95, DOI 10.1017/S0031182003003445; Stiles JK, 1999, ANN TROP MED PARASIT, V93, P781, DOI 10.1080/00034989957781; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; Weston D, 1999, MOL BIOCHEM PARASIT, V102, P53, DOI 10.1016/S0166-6851(99)00079-1; Worthey EA, 2003, NUCLEIC ACIDS RES, V31, P4201, DOI 10.1093/nar/gkg469; Yao CQ, 2003, MOL BIOCHEM PARASIT, V132, P1, DOI 10.1016/S0166-6851(03)00211-1; ZILBERSTEIN D, 1994, ANNU REV MICROBIOL, V48, P449, DOI 10.1146/annurev.mi.48.100194.002313; Zilka A, 2001, J BIOL CHEM, V276, P47922, DOI 10.1074/jbc.M108271200	47	46	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35172	35183		10.1074/jbc.M505559200	http://dx.doi.org/10.1074/jbc.M505559200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16105831	hybrid			2022-12-25	WOS:000232561200014
J	Heidemann, AC; Schipke, CG; Kettenmann, H				Heidemann, AC; Schipke, CG; Kettenmann, H			Extracellular application of nicotinic acid adenine dinucleotide phosphate induces Ca2+ signaling in astrocytes in situ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; SEA-URCHIN EGGS; GLIAL-CELLS; CALCIUM; NAADP; RELEASE; CD38; BRAIN; 2ND-MESSENGER; MECHANISMS	Nicotinic acid adenine dinucleotide phosphate (NAADP(+)) has been identified as a novel second messenger triggering Ca2+ release from intracellular stores. Here we report that murine cortical astrocytes in culture and in acute slices respond with transient intracellular Ca2+ increases to extracellularly applied NAADP(+) and express the NAADP(+)-producing enzyme CD38. The Ca2+ transients triggered by NAADP(+) occurred with an average delay of 35 s as compared with ATP-triggered Ca2+ signaling, suggesting that NAADP(+) may have to enter the cell to act. Blockage of connexin hemichannels (a possible entry route for NAADP(+) into the cell) reduced the number of astrocytes responding to NAADP(+). Disruption of lysosomes as the suggested site of NAADP(+) receptors reduced the number of astrocytes responding to NAADP(+) strongly. The NAADP(+)-triggeredCa(2+) signal also depended on intact endoplasmic reticulum Ca2+ stores linked to activation of inositol 1,4,5-risphosphate receptors and on the activity of voltage-gated Ca2+ channels. Adenosine receptor-mediated signaling contributes to the NAADP+evoked signal, since it is strongly reduced by the adenosine receptor blocker CGS-15943. Moreover, NAADP(+) triggered responses in all other cell types (cultured cerebellar neurons, microglia, and oligodendrocytes) of the central nervous system.	Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine	Kettenmann, H (corresponding author), Max Delbruck Ctr Mol Med, 10 Robert Rossle Str, D-13092 Berlin, Germany.	kettenmann@mdc-berlin.de	Kettenmann, Helmut/AAJ-5142-2021	Kettenmann, Helmut/0000-0001-8208-0291				Aarhus R, 1996, J BIOL CHEM, V271, P8513, DOI 10.1074/jbc.271.15.8513; Aarhus R, 1995, J BIOL CHEM, V270, P30327, DOI 10.1074/jbc.270.51.30327; Bak J, 1999, CURR BIOL, V9, P751, DOI 10.1016/S0960-9822(99)80335-2; Berg I, 2000, J CELL BIOL, V150, P581, DOI 10.1083/jcb.150.3.581; Brailoiu E, 2001, MOL PHARMACOL, V60, P718; Bruzzone S, 2001, FASEB J, V15, P10; Cancela JM, 2003, PFLUG ARCH EUR J PHY, V446, P322, DOI 10.1007/s00424-003-1035-x; Cancela JM, 1999, NATURE, V398, P74, DOI 10.1038/18032; Ceni C, 2003, BIOCHEM J, V370, P175, DOI 10.1042/BJ20020604; Chini EN, 2002, BIOCHEM J, V362, P125, DOI 10.1042/0264-6021:3620125; CHINI EN, 1995, BIOCHEM BIOPH RES CO, V209, P167, DOI 10.1006/bbrc.1995.1485; Churamani D, 2004, BIOCHEM J, V380, P449, DOI 10.1042/BJ20031754; Churchill GC, 2003, CURR BIOL, V13, P125, DOI 10.1016/S0960-9822(03)00002-2; Churchill GC, 2002, CELL, V111, P703, DOI 10.1016/S0092-8674(02)01082-6; Diaz-Hernandez M, 2002, J PHARMACOL EXP THER, V301, P441, DOI 10.1124/jpet.301.2.441; Esguerra M, 2002, GLIA, V39, P314, DOI 10.1002/glia.10115; Franco L, 1998, FASEB J, V12, P1507; Genazzani AA, 1996, J BIOL CHEM, V271, P11599, DOI 10.1074/jbc.271.20.11599; Gerasimenko J, 2003, BIOCHEM SOC T, V31, P76, DOI 10.1042/bst0310076; Guida L, 2002, J BIOL CHEM, V277, P47097, DOI 10.1074/jbc.M207793200; Guse AH, 2004, CURR MOL MED, V4, P239, DOI 10.2174/1566524043360771; HAAS B, 2005, IN PRESS CEREB CORTE; Hotta T, 2000, J NEUROCHEM, V74, P669, DOI 10.1046/j.1471-4159.2000.740669.x; Johnson JD, 2002, P NATL ACAD SCI USA, V99, P14566, DOI 10.1073/pnas.222099799; Kang J, 1998, NAT NEUROSCI, V1, P683, DOI 10.1038/3684; LEE HC, 1995, J BIOL CHEM, V270, P2152, DOI 10.1074/jbc.270.5.2152; Lee HC, 1997, PHYSIOL REV, V77, P1133, DOI 10.1152/physrev.1997.77.4.1133; Lee HC, 1997, J BIOL CHEM, V272, P4172, DOI 10.1074/jbc.272.7.4172; Lyons SA, 1998, J CEREBR BLOOD F MET, V18, P521, DOI 10.1097/00004647-199805000-00007; Matyash V, 2001, MOL CELL NEUROSCI, V18, P664, DOI 10.1006/mcne.2001.1047; MEYER HD, 2002, BIOCHIM BIOPHYS ACTA, V1582, P178; Moccia F, 2003, FASEB J, V17, P1907, DOI 10.1096/fj.03-0178fje; Newman EA, 2005, J NEUROSCI, V25, P5502, DOI 10.1523/JNEUROSCI.1354-05.2005; Patel S, 2000, J BIOL CHEM, V275, P36495, DOI 10.1074/jbc.C000458200; Patel S, 2004, BIOL CELL, V96, P19, DOI 10.1016/j.biolcel.2003.12.001; Peters O, 2003, J NEUROSCI, V23, P9888; Santella L, 2000, J BIOL CHEM, V275, P8301, DOI 10.1074/jbc.275.12.8301; SCHNITZER J, 1981, J NEUROIMMUNOL, V1, P471, DOI 10.1016/0165-5728(81)90024-2; SHEN SS, 1993, DEV BIOL, V157, P157, DOI 10.1006/dbio.1993.1120; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Venkatachalam K, 2002, NAT CELL BIOL, V4, pE263, DOI 10.1038/ncb1102-e263; Verderio C, 2001, J NEUROCHEM, V78, P646, DOI 10.1046/j.1471-4159.2001.00455.x; Verkhratsky A, 1998, PHYSIOL REV, V78, P99, DOI 10.1152/physrev.1998.78.1.99; Yamada M, 1997, BRAIN RES, V756, P52, DOI 10.1016/S0006-8993(97)00117-0; Ye ZC, 2003, J NEUROSCI, V23, P3588, DOI 10.1523/jneurosci.23-09-03588.2003; Zocchi E, 1999, FASEB J, V13, P273, DOI 10.1096/fasebj.13.2.273	46	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35630	35640		10.1074/jbc.M507338200	http://dx.doi.org/10.1074/jbc.M507338200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16061474	hybrid			2022-12-25	WOS:000232561200066
J	Yuste, VJ; Sanchez-Lopez, I; Sole, C; Moubarak, RS; Bayascas, JR; Dolcet, X; Encinas, M; Susin, SA; Comella, JX				Yuste, VJ; Sanchez-Lopez, I; Sole, C; Moubarak, RS; Bayascas, JR; Dolcet, X; Encinas, M; Susin, SA; Comella, JX			The contribution of apoptosis-inducing factor, caspase-activated DNase, and inhibitor of caspase-activated DNase to the nuclear phenotype and DNA degradation during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRAGMENTATION FACTOR; CHROMATIN CONDENSATION; CHROMOSOMAL DNA; CYCLOPHILIN-A; CLEAVAGE; DEATH; INVOLVEMENT; THYMOCYTES; ABSENCE; MOUSE	We have assessed the contribution of apoptosis- inducing factor ( AIF) and inhibitor of caspase- activated DNase ( ICAD) to the nuclear morphology and DNA degradation pattern in staurosporine-induced apoptosis. Expression of D117E ICAD, a mutant that is resistant to caspase cleavage at residue 117, prevented low molecular weight ( LMW) DNA fragmentation, stage II nuclear morphology, and detection of terminal deoxynucleotidyl transferase staining. However, high molecular weight ( HMW) DNA fragmentation and stage I nuclear morphology remained unaffected. On the other hand, expression of either D224E or wild type ICAD had no effect on DNA fragmentation or nuclear morphology. In addition, both HMW and LMW DNA degradation required functional executor caspases. Interestingly, silencing of endogenous AIF abolished type I nuclear morphology without any effect on HMW or LMW DNA fragmentation. Together, these results demonstrate that AIF is responsible for stage I nuclear morphology and suggest that HMW DNA degradation is a caspase- activated DNase and AIF independent process.	Univ Lleida, Fac Med, Dept Ciencies Med Basiques, Cell Signalling & Apoptosis Grp, E-25008 Lleida, Spain; Hosp Univ Arnau Vilanova, Lab Rec, E-25198 Lleida, Spain; Inst Pasteur, CNRS, URA 1961, Apoptose & Syst Immunitaire Grp,Dept Immunol, F-75015 Paris, France	Universitat de Lleida; University Hospital Arnau de Vilanova; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Comella, JX (corresponding author), Univ Lleida, Fac Med, Dept Ciencies Med Basiques, Cell Signalling & Apoptosis Grp, Montserrat Roig 2, E-25008 Lleida, Spain.	joan.comella@cmb.udl.es	Susin, Santos A/Q-6754-2017; Comella, Joan/GQA-4279-2022; Dolcet, Xavi/B-5665-2009; Encinas, Mario/B-5600-2009; Sole Serra, Carme/A-4470-2008; Comella, Joan X/D-7333-2012; Bayascas, Jose R/C-9450-2011; Yuste, Victor J./C-7071-2008	Susin, Santos A/0000-0002-3366-1628; Dolcet, Xavi/0000-0003-1921-0449; Encinas, Mario/0000-0003-3509-7431; Sole Serra, Carme/0000-0003-4543-7401; Comella, Joan X/0000-0002-6218-0786; Bayascas, Jose R/0000-0002-6096-2151; Yuste, Victor J./0000-0001-5322-9261; Sanchez Lopez, Isabel/0000-0003-1218-3636; Moubarak, Rana/0000-0003-2096-1258				Boix J, 1997, NEUROPHARMACOLOGY, V36, P811, DOI 10.1016/S0028-3908(97)00030-0; Cande C, 2004, ONCOGENE, V23, P1514, DOI 10.1038/sj.onc.1207279; Creagh EM, 2001, BIOCHEM SOC T, V29, P696, DOI 10.1042/0300-5127:0290696; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Halenbeck R, 1998, CURR BIOL, V8, P537, DOI 10.1016/S0960-9822(98)79298-X; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kawane K, 2003, NAT IMMUNOL, V4, P138, DOI 10.1038/ni881; Lecoeur H, 2002, EXP CELL RES, V277, P1, DOI 10.1006/excr.2002.5537; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Lu ZG, 2004, CELL RES, V14, P134, DOI 10.1038/sj.cr.7290212; McIlroy D, 1999, ONCOGENE, V18, P4401, DOI 10.1038/sj.onc.1202868; Montague JW, 1997, J BIOL CHEM, V272, P6677, DOI 10.1074/jbc.272.10.6677; Mukae N, 1998, P NATL ACAD SCI USA, V95, P9123, DOI 10.1073/pnas.95.16.9123; Nagata S, 2003, CELL DEATH DIFFER, V10, P108, DOI 10.1038/sj.cdd.4401161; Nagata T, 2000, J IMMUNOL, V165, P4281, DOI 10.4049/jimmunol.165.8.4281; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; Parrish JZ, 2003, MOL CELL, V11, P987, DOI 10.1016/S1097-2765(03)00095-9; Ricci JE, 2004, CELL, V117, P773, DOI 10.1016/j.cell.2004.05.008; Sakahira H, 1999, J BIOL CHEM, V274, P15740, DOI 10.1074/jbc.274.22.15740; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Sakahira H, 1999, CURR BIOL, V9, P543, DOI 10.1016/S0960-9822(99)80240-1; Samejima K, 2001, J BIOL CHEM, V276, P45427, DOI 10.1074/jbc.M108844200; Samejima K, 1998, J CELL BIOL, V143, P225, DOI 10.1083/jcb.143.1.225; Sotolongo B, 2005, J ANDROL, V26, P272; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; UCKER DS, 1992, MOL CELL BIOL, V12, P3060, DOI 10.1128/MCB.12.7.3060; Walker PR, 1999, ANN NY ACAD SCI, V887, P48, DOI 10.1111/j.1749-6632.1999.tb07921.x; Wolf BB, 1999, J BIOL CHEM, V274, P30651, DOI 10.1074/jbc.274.43.30651; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yuste VJ, 2001, J BIOL CHEM, V276, P22323, DOI 10.1074/jbc.M100072200; Zhang JH, 1998, P NATL ACAD SCI USA, V95, P12480, DOI 10.1073/pnas.95.21.12480; Zhang JH, 2000, BIOCHEM BIOPH RES CO, V274, P225, DOI 10.1006/bbrc.2000.3122	36	77	84	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35670	35683		10.1074/jbc.M504015200	http://dx.doi.org/10.1074/jbc.M504015200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16049016	hybrid			2022-12-25	WOS:000232561200070
J	Gianni, S; Engstrom, A; Larsson, M; Calosci, N; Malatesta, F; Eklund, L; Ngang, CC; Travaglini-Allocatelli, C; Jemth, P				Gianni, S; Engstrom, A; Larsson, M; Calosci, N; Malatesta, F; Eklund, L; Ngang, CC; Travaglini-Allocatelli, C; Jemth, P			The kinetics of PDZ domain-ligand interactions and implications for the binding mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PTP-BL; POSTSYNAPTIC PROTEIN; RECOGNITION; PEPTIDES; DETERMINANTS; SPECIFICITY; DYNAMICS; AFFINITY; PSD-95; TARGET	PDZ domains are protein adapter modules present in a few hundred human proteins. They play important roles in scaffolding and signal transduction. PDZ domains usually bind to the C termini of their target proteins. To assess the binding mechanism of this interaction we have performed the first in-solution kinetic study for PDZ domains and peptides corresponding to target ligands. Both PDZ3 from postsynaptic density protein 95 and PDZ2 from protein tyrosine phosphatase L1 bind their respective target peptides through an apparent A + B --> A center dot B mechanism without rate-limiting conformational changes. But a mutant with a fluorescent probe (Trp) outside of the binding pocket suggests that slight changes in the structure take place upon binding in protein tyrosine phosphatase-L1 PDZ2. For PDZ3 from postsynaptic density protein 95 the pH dependence of the binding reaction is consistent with a one-step mechanism with one titratable group. The salt dependence of the interaction shows that the formation of electrostatic interactions is rate-limiting for the association reaction but not for dissociation of the complex.	Uppsala Univ, Dept Med Biochem & Microbiol, SE-75123 Uppsala, Sweden; Univ Roma La Sapienza, Dipartimento Sci Biochim A Rossi SFanelli, I-00185 Rome, Italy; Univ Roma La Sapienza, CNR, Ist Biol & Patol Mol, I-00185 Rome, Italy; Univ Aquila, Dept Pure & Appl Biol, I-67010 Coppito, Italy	Uppsala University; Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome; University of L'Aquila	Jemth, P (corresponding author), Uppsala Univ, Dept Med Biochem & Microbiol, BMC Box 582, SE-75123 Uppsala, Sweden.	Per.Jemth@imbim.uu.se	Larsson, Marten/A-5992-2012; gianni, stefano/C-8536-2009; Malatesta, Francesco/AAT-4757-2020	Gianni, Stefano/0000-0003-1653-1925; Travaglini-Allocatelli, Carlo/0000-0001-8735-1126; Eklund, Lars/0000-0002-0572-9410; Larsson, Marten/0000-0002-7855-9539				Bronsted JN, 1924, J AM CHEM SOC, V46, P555, DOI 10.1021/ja01668a006; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; DeLano WL, 2002, PYMOL USERS MANUAL; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Erdmann KS, 2000, ONCOGENE, V19, P3894, DOI 10.1038/sj.onc.1203725; Feng HQ, 2005, J MOL BIOL, V346, P345, DOI 10.1016/j.jmb.2004.11.040; Ferrer M, 2005, PROTEIN ENG DES SEL, V18, P165, DOI 10.1093/protein/gzi018; Fersht A, 1999, STRUCTURE MECH PROTE, P132; Fuentes EJ, 2004, J MOL BIOL, V335, P1105, DOI 10.1016/j.jmb.2003.11.010; Fuh G, 2000, J BIOL CHEM, V275, P21486, DOI 10.1074/jbc.275.28.21486; Fujii N, 2003, J AM CHEM SOC, V125, P12074, DOI 10.1021/ja035540l; Gao XL, 2001, J BIOL CHEM, V276, P42219, DOI 10.1074/jbc.M105760200; Gee SH, 1998, J BIOL CHEM, V273, P21980, DOI 10.1074/jbc.273.34.21980; GEIGER T, 1987, J BIOL CHEM, V262, P785; Gianni S, 2005, PROTEIN ENG DES SEL, V18, P389, DOI 10.1093/protein/gzi047; Harris BZ, 2003, BIOCHEMISTRY-US, V42, P2797, DOI 10.1021/bi027061p; Harris BZ, 2001, BIOCHEMISTRY-US, V40, P5921, DOI 10.1021/bi010142l; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Kim E, 1998, J BIOL CHEM, V273, P1591, DOI 10.1074/jbc.273.3.1591; Kim EJ, 2004, NAT REV NEUROSCI, V5, P771, DOI 10.1038/nrn1517; Kozlov G, 2002, J MOL BIOL, V320, P813, DOI 10.1016/S0022-2836(02)00544-2; Li T, 2004, BIOORG MED CHEM LETT, V14, P1385, DOI 10.1016/j.bmcl.2003.09.103; Lim IA, 2002, J BIOL CHEM, V277, P21697, DOI 10.1074/jbc.M112339200; Lockless SW, 1999, SCIENCE, V286, P295, DOI 10.1126/science.286.5438.295; Long JF, 2003, J MOL BIOL, V327, P203, DOI 10.1016/S0022-2836(03)00113-X; Madsen KL, 2005, J BIOL CHEM, V280, P20539, DOI 10.1074/jbc.M500577200; Malatesta F, 2005, BIOPHYS CHEM, V116, P251, DOI 10.1016/j.bpc.2005.04.006; MOORE WJ, 1983, BASIC PHYS CHEM, P370; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; Piserchio A, 2002, J BIOL CHEM, V277, P6967, DOI 10.1074/jbc.M109453200; Saro D, 2004, ORG LETT, V6, P3429, DOI 10.1021/ol049181q; Schreiber G, 2002, CURR OPIN STRUC BIOL, V12, P41, DOI 10.1016/S0959-440X(02)00287-7; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Udugamasooriya G, 2005, ORG LETT, V7, P1203, DOI 10.1021/ol0475966; Walma T, 2002, J MOL BIOL, V316, P1101, DOI 10.1006/jmbi.2002.5402; Wang L, 2005, J BIOL CHEM, V280, P26992, DOI 10.1074/jbc.M503555200; Wiedemann U, 2004, J MOL BIOL, V343, P703, DOI 10.1016/j.jmb.2004.08.064	38	76	77	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34805	34812		10.1074/jbc.M506017200	http://dx.doi.org/10.1074/jbc.M506017200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16049001	hybrid			2022-12-25	WOS:000232403900052
J	Cismasiu, VB; Adamo, K; Gecewicz, J; Duque, J; Lin, QS; Avram, D				Cismasiu, VB; Adamo, K; Gecewicz, J; Duque, J; Lin, QS; Avram, D			BCL11B functionally associates with the NuRD complex in T lymphocytes to repress targeted promoter	ONCOGENE			English	Article						BCL11B; NuRD; transcriptional repression	METASTASIS-ASSOCIATED PROTEIN-1; ZINC-FINGER PROTEINS; TRANSCRIPTIONAL REPRESSION; SIR2-ALPHA PROTEIN; CELL-FATE; P53; SUBUNIT; FAMILY; SIR2; GENE	BCL11 genes play crucial roles in lymphopoiesis and have been associated with hematopoietic malignancies. Specifically, disruption of the BCL11B (B-cell chronic lymphocytic leukemia/lymphoma 11B) locus is linked to T-cell acute lymphoblastic leukemia, and the loss of heterozygosity in mice results in T-cell lymphoma. BCL11 proteins are related C2H2 zinc-finger transcription factors that act as transcriptional repressors. Here, we demonstrate the association of the endogenous BCL11B with the nucleosome remodeling and histone deacetylase (NuRD) complex, one of the major transcriptional corepressor complexes in mammalian cells. BCL11B complexes from T lymphocytes possess trichostatin A-sensitive histone deacetylase activity, confirming the functionality of the complexes. Analysis of the BCL11B-NuRD association demonstrated that BCL11B directly interacted with the metastasis-associated proteins MTA1 and MTA2 through the amino-terminal region. We provide evidence for the functional requirement of MTA1 in transcriptional repression mediated by BCL11B through the following: (1) overexpression of MTA1 enhanced the transcriptional repression mediated by BCL11B, (2) knockdown of MTA1 expression by small interfering RNA inhibited BCL11B transcriptional repression activity and (3) MTA1 was specifically recruited to a BCL11B targeted promoter. Taken together, these data support the hypothesis that the NuRD complex mediates transcriptional repression function of BCL11B.	Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA; SUNY Albany, Ctr Funct Genom, Rensselaer, NY 12144 USA	Albany Medical College; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Avram, D (corresponding author), Albany Med Coll, Ctr Cell Biol & Canc Res, 47 New Scotland Ave MC 165, Albany, NY 12208 USA.	avramd@mail.amc.edu	Cismasiu, Valeriu Bogdan/F-1512-2011	Lin, Qishan/0000-0002-1756-1432	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K01AR002194] Funding Source: NIH RePORTER; NIAMS NIH HHS [K01-AR02194] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Arlotta P, 2005, NEURON, V45, P207, DOI 10.1016/j.neuron.2004.12.036; Avram D, 2000, J BIOL CHEM, V275, P10315, DOI 10.1074/jbc.275.14.10315; Avram D, 2002, BIOCHEM J, V368, P555, DOI 10.1042/BJ20020496; Bowen NJ, 2004, BBA-GENE STRUCT EXPR, V1677, P52, DOI 10.1016/j.bbaexp.2003.10.010; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Cheng HL, 2003, P NATL ACAD SCI USA, V100, P10794, DOI 10.1073/pnas.1934713100; Douagi I, 2002, SEMIN IMMUNOL, V14, P361, DOI 10.1016/S1044532302000702; Durum SK, 2003, NAT IMMUNOL, V4, P512, DOI 10.1038/ni0603-512; Engel I, 2001, NAT REV IMMUNOL, V1, P193, DOI 10.1038/35105060; Fischer A, 1998, SCIENCE, V280, P237, DOI 10.1126/science.280.5361.237; Fujita N, 2004, CELL, V119, P75, DOI 10.1016/j.cell.2004.09.014; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; Gartenberg MR, 2000, CURR OPIN MICROBIOL, V3, P132, DOI 10.1016/S1369-5274(00)00064-3; Georgopoulos K, 2002, NAT REV IMMUNOL, V2, P162, DOI 10.1038/nri747; Guarente L, 2000, GENE DEV, V14, P1021; Guarente L, 1999, NAT GENET, V23, P281, DOI 10.1038/15458; Gururaja T, 2002, J PROTEOME RES, V1, P253, DOI 10.1021/pr0255147; HONG W, 2005, IN PRESS EMBO J; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Kehle J, 1998, SCIENCE, V282, P1897, DOI 10.1126/science.282.5395.1897; Kiefer SM, 2002, J BIOL CHEM, V277, P14869, DOI 10.1074/jbc.M200052200; Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5; KLAVER B, 1994, J VIROL, V68, P3830, DOI 10.1128/JVI.68.6.3830-3840.1994; Kowalski K, 2002, J BIOL CHEM, V277, P35720, DOI 10.1074/jbc.M204663200; Kumar R, 2003, SEMIN ONCOL, V30, P30, DOI 10.1053/j.seminoncol.2003.08.005; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Li YC, 2001, SCIENCE, V291, P650, DOI 10.1126/science.291.5504.650; Liberg D, 1999, CRIT REV IMMUNOL, V19, P127; Lin AC, 2004, J BIOL CHEM, V279, P55017, DOI 10.1074/jbc.M411240200; Liu PT, 2003, NAT IMMUNOL, V4, P525, DOI 10.1038/ni925; Liu XF, 2004, J BIOL CHEM, V279, P15050, DOI 10.1074/jbc.M311932200; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; McBurney MW, 2003, MOL CANCER RES, V1, P402; McBurney MW, 2003, MOL CELL BIOL, V23, P38, DOI 10.1128/MCB.23.1.38-54.2003; Medina KL, 2005, CURR OPIN HEMATOL, V12, P203, DOI 10.1097/01.moh.0000160735.67596.a0; Miyazawa T, 2002, JPN J CANCER RES, V93, P994, DOI 10.1111/j.1349-7006.2002.tb02475.x; Murawsky CM, 2001, EMBO REP, V2, P1089, DOI 10.1093/embo-reports/kve252; Nakamura T, 2000, MOL CELL BIOL, V20, P3178, DOI 10.1128/MCB.20.9.3178-3186.2000; Przybylski GK, 2005, LEUKEMIA, V19, P201, DOI 10.1038/sj.leu.2403619; Quong MW, 2002, ANNU REV IMMUNOL, V20, P301, DOI 10.1146/annurev.immunol.20.092501.162048; Saito M, 2002, J BIOL CHEM, V277, P35434, DOI 10.1074/jbc.M203455200; Satterwhite E, 2001, BLOOD, V98, P3413, DOI 10.1182/blood.V98.12.3413; Schultz DC, 2001, GENE DEV, V15, P428, DOI 10.1101/gad.869501; Senawong T, 2005, ARCH BIOCHEM BIOPHYS, V434, P316, DOI 10.1016/j.abb.2004.10.028; Senawong T, 2003, J BIOL CHEM, V278, P43041, DOI 10.1074/jbc.M307477200; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Thiagalingam S, 2003, ANN NY ACAD SCI, V983, P84, DOI 10.1111/j.1749-6632.2003.tb05964.x; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Verreault A, 1998, CURR BIOL, V8, P96, DOI 10.1016/S0960-9822(98)70040-5; Wakabayashi Y, 2003, NAT IMMUNOL, V4, P533, DOI 10.1038/ni927; Wakabayashi Y, 2003, BIOCHEM BIOPH RES CO, V301, P598, DOI 10.1016/S0006-291X(02)03069-3; Warren LA, 2003, CURR OPIN IMMUNOL, V15, P166, DOI 10.1016/S0952-7915(03)00011-6; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yao YL, 2003, J BIOL CHEM, V278, P42560, DOI 10.1074/jbc.M302955200; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924	58	127	133	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2005	24	45					6753	6764		10.1038/sj.onc.1208904	http://dx.doi.org/10.1038/sj.onc.1208904			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973MV	16091750				2022-12-25	WOS:000232527800003
J	Jiang, PH; Cui, M; Zhao, BH; Snyder, LA; Benard, LMJ; Osman, R; Max, M; Margolskee, RF				Jiang, PH; Cui, M; Zhao, BH; Snyder, LA; Benard, LMJ; Osman, R; Max, M; Margolskee, RF			Identification of the cyclamate interaction site within the transmembrane domain of the human sweet taste receptor subunit T1R3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UMAMI TASTE; CONFORMATIONAL-CHANGES; CA2+-SENSING RECEPTOR; ALLOSTERIC MODULATOR; MAMMALIAN SWEET; BINDING-SITE; TRANSDUCTION; ACTIVATION; PREFERENCE; LACTISOLE	The artificial sweetener cyclamate tastes sweet to humans, but not to mice. When expressed in vitro, the human sweet receptor ( a heterodimer of two taste receptor subunits: hT1R2 + hT1R3) responds to cyclamate, but the mouse receptor (mT1R2 + mT1R3) does not. Using mixed-species pairings of human and mouse sweet receptor subunits, we determined that responsiveness to cyclamate requires the human form of T1R3. Using chimeras, we determined that it is the transmembrane domain of hT1R3 that is required for the sweet receptor to respond to cyclamate. Using directed mutagenesis, we identified several amino acid residues within the transmembrane domain of T1R3 that determine differential responsiveness to cyclamate of the human versus mouse sweet receptors. Alanine-scanning mutagenesis of residues predicted to line a transmembrane domain binding pocket in hT1R3 identified six residues specifically involved in responsiveness to cyclamate. Using molecular modeling, we docked cyclamate within the transmembrane domain of T1R3. Our model predicts substantial overlap in the hT1R3 binding pockets for the agonist cyclamate and the inverse agonist lactisole. The transmembrane domain of T1R3 is likely to play a critical role in the interconversion of the sweet receptor from the ground state to the active state.	CUNY Mt Sinai Sch Med, Howard Hughes Med Inst, Dept Neurosci, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA	City University of New York (CUNY) System; Howard Hughes Medical Institute; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Margolskee, RF (corresponding author), CUNY Mt Sinai Sch Med, Howard Hughes Med Inst, Dept Neurosci, POB 1065,1425 Madison Ave, New York, NY 10029 USA.	bob@inka.mssm.edu		Margolskee, Robert/0000-0002-9572-2887	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R03DC007721, R01DC003055, F32DC007021, R01DC003155] Funding Source: NIH RePORTER; NIDCD NIH HHS [DC003055, 1F32 DC007021-01, 1R03 DC007721-01, DC003155] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Bachmanov AA, 2001, CHEM SENSES, V26, P905, DOI 10.1093/chemse/26.7.905; Bachmanov AA, 2001, CHEM SENSES, V26, P925, DOI 10.1093/chemse/26.7.925; Binet V, 2004, J BIOL CHEM, V279, P29085, DOI 10.1074/jbc.M400930200; BRENEMAN CM, 1990, J COMPUT CHEM, V11, P361, DOI 10.1002/jcc.540110311; Damak S, 2003, SCIENCE, V301, P850, DOI 10.1126/science.1087155; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Frisch G.W., 2016, GAUSSIAN 16 REVISION; Ghanouni P, 2001, P NATL ACAD SCI USA, V98, P5997, DOI 10.1073/pnas.101126198; Gilbertson TA, 2000, CURR OPIN NEUROBIOL, V10, P519, DOI 10.1016/S0959-4388(00)00118-5; Gilbertson TA, 2003, NEUROREPORT, V14, P905, DOI 10.1097/01.wnr.0000074346.81633.76; Hoon MA, 1999, CELL, V96, P541, DOI 10.1016/S0092-8674(00)80658-3; Jiang P, 2005, CHEM SENSES, V30, pI17, DOI 10.1093/chemse/bjh091; Jiang PH, 2005, J BIOL CHEM, V280, P15238, DOI 10.1074/jbc.M414287200; Jiang PH, 2004, J BIOL CHEM, V279, P45068, DOI 10.1074/jbc.M406779200; Kitagawa M, 2001, BIOCHEM BIOPH RES CO, V283, P236, DOI 10.1006/bbrc.2001.4760; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Li XD, 2002, P NATL ACAD SCI USA, V99, P4692, DOI 10.1073/pnas.072090199; Lindemann B, 2001, NATURE, V413, P219, DOI 10.1038/35093032; Malherbe P, 2003, J BIOL CHEM, V278, P8340, DOI 10.1074/jbc.M211759200; Max M, 2001, NAT GENET, V28, P58, DOI 10.1038/88270; Montmayeur JP, 2001, NAT NEUROSCI, V4, P492, DOI 10.1038/87440; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Nelson G, 2001, CELL, V106, P381, DOI 10.1016/S0092-8674(01)00451-2; Pagano A, 2000, J BIOL CHEM, V275, P33750, DOI 10.1074/jbc.M006230200; Petrel C, 2004, J BIOL CHEM, V279, P18990, DOI 10.1074/jbc.M400724200; Petrel C, 2003, J BIOL CHEM, V278, P49487, DOI 10.1074/jbc.M308010200; Pin JP, 2003, PHARMACOL THERAPEUT, V98, P325, DOI 10.1016/S0163-7258(03)00038-X; RICHARDS RK, 1951, J AM PHARM ASSOC SCI, V40, P1; Sainz E, 2001, J NEUROCHEM, V77, P896, DOI 10.1046/j.1471-4159.2001.00292.x; Ward SDC, 2002, J BIOL CHEM, V277, P2247, DOI 10.1074/jbc.M107647200; Winnig M, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-22; Xu H, 2004, P NATL ACAD SCI USA, V101, P14258, DOI 10.1073/pnas.0404384101; Zhao GQ, 2003, CELL, V115, P255, DOI 10.1016/S0092-8674(03)00844-4	33	167	174	4	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34296	34305		10.1074/jbc.M505255200	http://dx.doi.org/10.1074/jbc.M505255200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16076846	hybrid			2022-12-25	WOS:000232229700072
J	Xue, X; Piao, JH; Nakajima, A; Sakon-Komazawa, S; Kojima, Y; Mori, K; Yagita, H; Okumura, K; Harding, H; Nakano, H				Xue, X; Piao, JH; Nakajima, A; Sakon-Komazawa, S; Kojima, Y; Mori, K; Yagita, H; Okumura, K; Harding, H; Nakano, H			Tumor necrosis factor alpha (TNF alpha) induces the unfolded protein response (UPR) in a reactive oxygen species (ROS)-dependent fashion, and the UPR counteracts ROS accumulation by TNF alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETICULUM STRESS-RESPONSE; NF-KAPPA-B; ENDOPLASMIC-RETICULUM; ER STRESS; TRANSLATIONAL CONTROL; MESSENGER-RNA; ATF6; ACTIVATION; KINASE; INITIATION	Accumulation of unfolded proteins in the endoplasmic reticulum ( ER) causes ER overload, resulting in ER stress. To cope with ER stress, mammalian cells trigger a specific response known as the unfolded protein response (UPR). Although recent studies have indicated cross-talk between ER stress and oxidative stress, the mechanistic link is not fully understood. By using murine fibrosarcoma ;L929 cells, in which tumor necrosis factor (TNF) alpha induces accumulation of reactive oxygen species (ROS) and cell death, we show that TNF alpha induces the UPR in a ROS-dependent fashion. In contrast to TNF alpha, oxidative stresses by H2O2 or arsenite only induce eukaroytic initiation factor 2 alpha phosphorylation, but not activation of PERK- or IRE1-dependent pathways, indicating the specificity of downstream signaling induced by various oxidative stresses. Conversely, the UPR induced by tunicamycin substantially suppresses TNF alpha-induced ROS accumulation and cell death by inhibiting reduction of cellular glutathione levels. Collectively, some, but not all, oxidative stresses induce the UPR, and pre-emptive UPR counteracts TNF alpha-induced ROS accumulation.	Juntendo Univ, Sch Med, Dept Immunol, Bunkyo Ku, Tokyo 1138421, Japan; Kyoto Univ, Grad Sch Sci, Dept Biophys, Sakyo Ku, Kyoto 6068502, Japan; NYU, Sch Med, Skirball Inst, Dept Pharmacol, New York, NY 10016 USA	Juntendo University; Kyoto University; New York University	Nakano, H (corresponding author), Juntendo Univ, Sch Med, Dept Immunol, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	hnakano@med.juntendo.ac.jp	Mori, Kazutoshi/K-6106-2015; Longo, Kenneth A/A-5631-2010	Nakano, Hiroyasu/0000-0003-4843-1427; Harding, Heather P/0000-0002-7359-7974				Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Brostrom CO, 1998, PROG NUCLEIC ACID RE, V58, P79; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; Liu CY, 2000, J BIOL CHEM, V275, P24881, DOI 10.1074/jbc.M004454200; Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Nakano H, 2004, TRENDS IMMUNOL, V25, P402, DOI 10.1016/j.it.2004.05.007; Pham CG, 2004, CELL, V119, P529, DOI 10.1016/j.cell.2004.10.017; PIA JH, 2004, GENE THER MOL BIOL, V8, P163; Ron D, 2002, J CLIN INVEST, V110, P1383, DOI 10.1172/JCI200216784; Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001; Sakon S, 2003, EMBO J, V22, P3898, DOI 10.1093/emboj/cdg379; Sasazuki T, 2004, MOL IMMUNOL, V41, P547, DOI 10.1016/j.molimm.2004.03.030; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Shen XH, 2001, CELL, V107, P893, DOI 10.1016/S0092-8674(01)00612-2; Shindo M, 1998, BIOCHEM BIOPH RES CO, V244, P285, DOI 10.1006/bbrc.1998.8250; Srivastava SP, 1998, J BIOL CHEM, V273, P2416, DOI 10.1074/jbc.273.4.2416; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Wang Y, 2000, J BIOL CHEM, V275, P27013; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741	31	315	332	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33917	33925		10.1074/jbc.M505818200	http://dx.doi.org/10.1074/jbc.M505818200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16107336	hybrid			2022-12-25	WOS:000232229700028
J	Umeda, S; Suzuki, MT; Okamoto, H; Ono, F; Mizota, A; Terao, K; Yoshikawa, Y; Tanaka, Y; Iwata, T				Umeda, S; Suzuki, MT; Okamoto, H; Ono, F; Mizota, A; Terao, K; Yoshikawa, Y; Tanaka, Y; Iwata, T			Molecular composition of drusen and possible involvement of anti-retinal autoimmunity in two different forms of macular degeneration in cynomolgus monkey (Macaca fascicularis)	FASEB JOURNAL			English	Article						liquid chromatography tandem mass spectroscopy	HIGH-FAT DIET; BRUCHS MEMBRANE; ANIMAL-MODEL; ANNEXIN-V; ANTIBODIES; PROTEINS; AUTOANTIBODIES; PATHOGENESIS; MACULOPATHY; EXPRESSION	We have previously reported a cynomolgus monkey (Macaca fascicularis) pedigree with early onset macular degeneration that develops drusen at 2 yr after birth (1). In this study, the molecular composition of drusen in monkeys affected with late onset and early onset macular degeneration was both characterized. Involvement of anti-retinalautoimmunity in the deposition of drusen and the pathogenesis of the disease was also evaluated. Funduscopic and histological examinations were performed on 278 adult monkeys (mean age = 16.94 yr) for late onset macular degeneration. The molecular composition of drusen was analyzed by immunohistochemistry and/or direct proteome analysis using liquid chromatography tandem mass spectroscopy (LC-MS/ MS). Anti-retinal autoantibodies in sera were screened in 20 affected and 10 age-matched control monkeys by Western blot techniques. Immunogenic molecules were identified by 2D electrophoresis and LC-MS/ MS. Relative antibody titer against each antigen was determined by ELISA in sera from 42 affected (late onset) and 41 normal monkeys. Yellowish-white spots in the macular region were observed in 90 (32%) of the late onset monkeys that were examined. Histological examination demonstrated that drusen or degenerative retinal pigment epithelium (RPE) cells were associated with the pigmentary abnormalities. Drusen in both late and early onset monkeys showed immunoreactivities for apolipoprotein E, amyloid P component, complement component C5, the terminal C5b-9 complement complex, vitronectin, and membrane cofactor protein. LC-MS/MS analyses identified 60 proteins as constituents of drusen, including a number of common components in drusen of human age-related macular degeneration (AMD), such as annexins, crystallins, immunoglobulins, and complement components. Half of the affected monkeys had single or multiple autoantibodies against 38, 40, 50, and 60 kDa retinal proteins. The reacting antigens of 38 and 40 kDa were identified as annexin II and mu-crystallin, respectively. Relative antibody titer against annexin II in affected monkeys was significantly higher than control animals (P<0.01). Significant difference was not observed in antibody titer against mu-crystallin; however, several affected monkeys showed considerably elevated titer (360-610%) compared with the mean for unaffected animals. Monkey drusen both in late and early onset forms of macular degeneration had common components with drusen in human AMD patients, indicating that chronic inflammation mediated by complement activation might also be involved in the formation of drusen in these affected monkeys. The high prevalence of anti-retinalautoantibodies in sera from affected monkeys demonstrated an autoimmune aspect of the pathogenesis of the disease. Although further analyses are required to determine whether and how autoantibodies against annexin II or mu-crystallin relate to the pathogenesis of the disease, it could be hypothesized that immune responses directed against these antigens might trigger chronic activation of the complement cascade at the site of drusen formation.	Natl Hosp Org, Tokyo Med Ctr, Natl Inst Sensory Organs, Meguro Ku, Tokyo 1528902, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biomed Sci, Tokyo 1138657, Japan; Corp Prod & Res Lab Primates, Tsukuba 3050843, Japan; Juntendo Univ, Urayasu Hosp, Dept Ophthalmol, Chiba 2790021, Japan; Natl Inst Biomed Innovat, Tsukuba Primate Res Ctr, Tsukuba 3050843, Japan	University of Tokyo; Juntendo University; National Institute of Health Sciences - Japan	Iwata, T (corresponding author), Natl Hosp Org, Tokyo Med Ctr, Natl Inst Sensory Organs, Meguro Ku, 2-5-1 Higashikgaoka, Tokyo 1528902, Japan.	iwatatakeshi@kankakuki.go.jp						Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950; BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X; BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032; Chen L, 2003, MOL VIS, V9, P151; CIRINO G, 1989, P NATL ACAD SCI USA, V86, P3428, DOI 10.1073/pnas.86.9.3428; COMERA C, 1995, BRIT J PHARMACOL, V115, P1043, DOI 10.1111/j.1476-5381.1995.tb15916.x; Cousins SW, 2002, EXP EYE RES, V75, P543, DOI 10.1006/exer.2002.2047; Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899; Dithmar S, 2001, ARCH OPHTHALMOL-CHIC, V119, P1643, DOI 10.1001/archopht.119.11.1643; Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035; DUBOIS T, 1995, J RHEUMATOL, V22, P1230; DUMONDE DC, 1982, LANCET, V2, P787; GALBRAITH GMP, 1986, J CLIN INVEST, V78, P865, DOI 10.1172/JCI112672; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; GREGORY CY, 1992, EXP EYE RES, V54, P843, DOI 10.1016/0014-4835(92)90147-K; GURNE DH, 1991, OPHTHALMOLOGY, V98, P602; Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477; Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6; HOPE GM, 1992, BRIT J OPHTHALMOL, V76, P11, DOI 10.1136/bjo.76.1.11; ISHIBASHI T, 1986, INVEST OPHTH VIS SCI, V27, P184; Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798; Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417; Kaufman M, 1996, BIOCHEM J, V316, P35, DOI 10.1042/bj3160035; KIM RY, 1992, P NATL ACAD SCI USA, V89, P9292, DOI 10.1073/pnas.89.19.9292; Liu H, 1998, J BIOL CHEM, V273, P12858, DOI 10.1074/jbc.273.21.12858; Liu H, 1997, J BIOL CHEM, V272, P21751, DOI 10.1074/jbc.272.35.21751; Majji AB, 2000, INVEST OPHTH VIS SCI, V41, P3936; MONACO WA, 1990, OPTOMETRY VISION SCI, V67, P532, DOI 10.1097/00006324-199007000-00011; Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142; Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835; NEWSOME DA, 1986, INVEST OPHTH VIS SCI, V27, P1675; Nicolas MG, 1996, EXP EYE RES, V62, P399, DOI 10.1006/exer.1996.0045; Nicolas MG, 1996, EXP EYE RES, V62, P211, DOI 10.1006/exer.1996.0026; PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033; Rakoczy PE, 2002, AM J PATHOL, V161, P1515, DOI 10.1016/S0002-9440(10)64427-6; RodriguezGarcia MI, 1996, ANN RHEUM DIS, V55, P895, DOI 10.1136/ard.55.12.895; Stafford T J, 1974, Mod Probl Ophthalmol, V12, P214; STAFFORD TJ, 1984, OPHTHALMOLOGY, V91, P513; Suzuki MT, 2003, PRIMATES, V44, P291, DOI 10.1007/s10329-002-0016-6; SUZUKI MT, 1985, EXP ANIM TOKYO, V34, P131, DOI 10.1538/expanim1978.34.2_131; Thirkill CE, 2000, OCUL IMMUNOL INFLAMM, V8, P25, DOI 10.1076/0927-3948(200003)8:1;1-S;FT025; Umeda S, 2005, INVEST OPHTH VIS SCI, V46, P683, DOI 10.1167/iovs.04-1031; Vingerling JR, 1995, EPIDEMIOL REV, V17, P347, DOI 10.1093/oxfordjournals.epirev.a036198; Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9; WISTOW G, 1991, J MOL EVOL, V32, P262, DOI 10.1007/BF02342749; Yang YH, 1997, INFLAMMATION, V21, P583, DOI 10.1023/A:1027330021479	46	125	133	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1683	+		10.1096/fj.04-3525fje	http://dx.doi.org/10.1096/fj.04-3525fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16099945				2022-12-25	WOS:000231843700018
J	Yamashita, JK; Takano, M; Hiraoka-Kanie, M; Shimazu, C; Peishi, Y; Yanagi, K; Nakano, A; Inoue, E; Kita, F; Nishikawa, SI				Yamashita, JK; Takano, M; Hiraoka-Kanie, M; Shimazu, C; Peishi, Y; Yanagi, K; Nakano, A; Inoue, E; Kita, F; Nishikawa, SI			Prospective identification of cardiac progenitors by a novel single cell-based cardiomyocyte induction	FASEB JOURNAL			English	Article						embryonic stem cells; stroma cells; Flk1; CXCR4; regenerative medicine	EMBRYONIC STEM-CELLS; IN-VITRO DIFFERENTIATION; CHEMOKINE RECEPTOR CXCR4; C-KIT RECEPTOR; STROMAL CELLS; MYOCARDIAL REGENERATION; ENDOTHELIAL-CELLS; ES CELLS; HEART; EXPRESSION	Dissection of cardiomyocyte differentiation process at the cellular level is indispensable in the research for cardiac development and regeneration. Previously, we have established an embryonic stem cell differentiation system that reproduces early vascular development from progenitor cells that express Flk1, a vascular endothelial growth factor receptor, by the combinatory application of 2-dimensional culture and flowcytometry. Here we show that cardiomyocytes can be successfully induced from a single Flk1(+) cell on 2-dimensional culture, enabling the direct observation of differentiating cardiomyocytes and the prospective identification of cardiac progenitor potentials. Flk1+ cells could give rise to cardiomyocytes, as well as endothelial cells, from a single cell by the co-culture on OP9 stroma cells in a fusion-independent manner. Among the cell populations in intermediate stages from Flk1+ cells to cardiomyocytes, Flk1(+)/CXCR4(+)/ vascular endothelial cadherin(-) cells were cardiac-specific progenitors at the single cell level. Noggin, a bone morphogenetic protein inhibitor, abolished cardiomyocyte differentiation by inhibiting the cardiac progenitor induction. However, wnt inhibitors Dkk-1 or Frizzled-8/Fc chimeric protein augmented, but wnt3a inhibited, cardiomyocyte differentiation. In vitro reproduction of cardiomyocyte differentiation process should be a potent tool for the cellular and molecular elucidation of cardiac development, which would provide various targets for cardiac regeneration.	Kyoto Univ, Inst Frontier Med Sci, Stem Cell Res Ctr, Lab Stem Cell Differentiat,Sakyo Ku, Kyoto 6068507, Japan; Jichi Med Sch, Dept Physiol, Minami Kawachi, Tochigi, Japan; Fdn Biomed Res & Innovat, Dept Tissue Engn & Cell Therapy, Kobe, Hyogo, Japan; RIKEN, Lab Stem Cell Biol, Ctr Dev Biol, Kobe, Hyogo, Japan	Kyoto University; Jichi Medical University; Institute for Biomedical Research & Innovation (IBRI); RIKEN	Yamashita, JK (corresponding author), Kyoto Univ, Inst Frontier Med Sci, Stem Cell Res Ctr, Lab Stem Cell Differentiat,Sakyo Ku, 53 Shogoin Kawahara Cho, Kyoto 6068507, Japan.	juny@frontier.kyoto-u.ac.jp						Ara T, 2003, P NATL ACAD SCI USA, V100, P5319, DOI 10.1073/pnas.0730719100; Beltrami AP, 2003, CELL, V114, P763, DOI 10.1016/S0092-8674(03)00687-1; Boheler KR, 2002, CIRC RES, V91, P189, DOI 10.1161/01.RES.0000027865.61704.32; Caplice NM, 2003, CIRC RES, V92, P6, DOI 10.1161/01.RES.0000052826.35667.40; Caspi O, 2004, ANN NY ACAD SCI, V1015, P285, DOI 10.1196/annals.1302.024; Chien KR, 2004, NATURE, V428, P607, DOI 10.1038/nature02500; Conley BJ, 2004, INT J BIOCHEM CELL B, V36, P555, DOI 10.1016/j.biocel.2003.07.003; Foley A, 2004, TRENDS CARDIOVAS MED, V14, P121, DOI 10.1016/j.tcm.2004.01.003; Fraser ST, 2003, METHOD ENZYMOL, V365, P59; Goodell MA, 2001, ANN NY ACAD SCI, V938, P208; Gros D, 2004, CARDIOVASC RES, V62, P299, DOI 10.1016/j.cardiores.2004.02.010; GULICK J, 1991, J BIOL CHEM, V266, P9180; Hescheler J, 1997, CARDIOVASC RES, V36, P149, DOI 10.1016/S0008-6363(97)00193-4; Hidaka K, 2003, FASEB J, V17, P740, DOI 10.1096/fj.02-0104fje; Hirai H, 2003, BLOOD, V101, P886, DOI 10.1182/blood-2002-02-0655; Hirashima M, 1999, BLOOD, V93, P1253, DOI 10.1182/blood.V93.4.1253.404k31_1253_1263; Kasahara H, 1998, CIRC RES, V82, P936, DOI 10.1161/01.RES.82.9.936; Kataoka H, 1997, DEV GROWTH DIFFER, V39, P729; Kawasaki H, 2000, NEURON, V28, P31, DOI 10.1016/S0896-6273(00)00083-0; KODAMA H, 1994, EXP HEMATOL, V22, P979; KODAMA H, 1992, J EXP MED, V176, P351, DOI 10.1084/jem.176.2.351; Lin TX, 2005, NAT CELL BIOL, V7, P165, DOI 10.1038/ncb1211; Makino S, 1999, J CLIN INVEST, V103, P697, DOI 10.1172/JCI5298; Matsuyoshi N, 1997, P ASSOC AM PHYSICIAN, V109, P362; McGrath KE, 1999, DEV BIOL, V213, P442, DOI 10.1006/dbio.1999.9405; Mummery C, 2003, CIRCULATION, V107, P2733, DOI 10.1161/01.CIR.0000068356.38592.68; Nadal-Ginard B, 2003, CIRC RES, V92, P139, DOI 10.1161/01.RES.0000053618.86362.DF; Nishikawa S, 1998, DEVELOPMENT, V125, P1747; NISHIKAWA SI, 1988, EUR J IMMUNOL, V18, P1767, DOI 10.1002/eji.1830181117; Oh H, 2003, P NATL ACAD SCI USA, V100, P12313, DOI 10.1073/pnas.2132126100; Oh H, 2004, ANN NY ACAD SCI, V1015, P182, DOI 10.1196/annals.1302.015; Olson EN, 2001, SCIENCE, V291, P2327, DOI 10.1126/science.1060063; Orlic D, 2002, CIRC RES, V91, P1092, DOI 10.1161/01.RES.0000046045.00846.B0; Oswald J, 2004, STEM CELLS, V22, P377, DOI 10.1634/stemcells.22-3-377; Sachinidis A, 2003, CARDIOVASC RES, V58, P278, DOI 10.1016/S0008-6363(03)00248-7; Schroeder T, 2003, P NATL ACAD SCI USA, V100, P4018, DOI 10.1073/pnas.0438008100; Srivastava D, 2000, NATURE, V407, P221, DOI 10.1038/35025190; Stieber J, 2004, TRENDS CARDIOVAS MED, V14, P23, DOI 10.1016/j.tcm.2003.09.006; Sussman MA, 2004, ANNU REV PHYSIOL, V66, P29, DOI 10.1146/annurev.physiol.66.032102.140723; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Tamamura H, 1998, BIOCHEM BIOPH RES CO, V253, P877, DOI 10.1006/bbrc.1998.9871; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Tsuneto M, 2003, METHOD ENZYMOL, V365, P98; Wurmser AE, 2004, NATURE, V430, P350, DOI 10.1038/nature02604; Wurmser AE, 2002, NATURE, V416, P485, DOI 10.1038/416485a; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489; Yamashita J, 2000, NATURE, V408, P92, DOI 10.1038/35040568; Yamashita JK, 2004, INT J HEMATOL, V80, P1, DOI 10.1532/ijh97.04043; Zaffran S, 2002, CIRC RES, V91, P457, DOI 10.1161/01.RES.0000034152.74523.A8	49	117	138	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1534	+		10.1096/fj.04-3540fje	http://dx.doi.org/10.1096/fj.04-3540fje			29	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16033809				2022-12-25	WOS:000230923000015
J	Christmann, M; Tomicic, MT; Origer, J; Kaina, B				Christmann, M; Tomicic, MT; Origer, J; Kaina, B			Fen1 is induced p53 dependently and involved in the recovery from UV- light-induced replication inhibition	ONCOGENE			English	Article						DNA repair; inducible response; UV sensitivity	REPAIR PROTEINS MSH2; BASE EXCISION-REPAIR; DNA-DAMAGE; FLAP ENDONUCLEASE-1; C-FOS; MOUSE CELLS; S-PHASE; PHOSPHORYLATION; RADIATION; FIBROBLASTS	Mouse embryonic fibroblasts (MEFs) that lack p53 are hypersensitive to the cytotoxic and genotoxic effect of ultraviolet (UV-C) light. They also display a defect in the recovery from UV-C-induced DNA replication inhibition. An enzyme involved in processing stalled DNA replication forks is flap endonuclease 1 (Fen1). Gene expression pro. ling of UV-C-irradiated MEFs revealed fen1 to be upregulated, which was confirmed by RT-PCR and Western blot experiments. Increased Fen1 levels upon UV-C exposure are due to transcriptional activation, as revealed by inhibitor studies. Fen1 induction was dose- and time-dependent; it occurred on protein level already 3 h after irradiation. Induction of Fen1 by UV-C requires p53 since it was observed in p53 wild-type (wt) but not in p53 null (p53-/-) fibroblasts. Fen1 upregulation paralleled the increase in p53 protein level in replicating wt cells, whereas in nonreplicating cells both Fen1 and p53 were not induced by UV-C. The mouse fen1 promoter was cloned and shown to harbor a p53 consensus sequence to which p53 binds. In cotransfection experiments, p53 stimulated the expression of a fen1 promoter-reporter construct. Transgenic expression of Fen1 in p53 null cells attenuated UV-C light-induced DNA replication inhibition, supporting the hypothesis that Fen1 induction is involved in the recovery of cells from DNA damage.	Univ Mainz, Dept Toxicol, D-55131 Mainz, Germany	Johannes Gutenberg University of Mainz	Kaina, B (corresponding author), Univ Mainz, Dept Toxicol, Obere Zahlbacher Str 67, D-55131 Mainz, Germany.	kaina@uni-mainz.de	Kaina, Bernd/AAE-4692-2020; Tomicic, Maja/S-1377-2019	Tomicic, Maja/0000-0001-9289-4168				Bae SH, 2001, NATURE, V412, P456, DOI 10.1038/35086609; Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; CHAN GL, 1985, BIOCHEMISTRY-US, V24, P5723, DOI 10.1021/bi00342a006; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Christmann M, 2002, NUCLEIC ACIDS RES, V30, P1959, DOI 10.1093/nar/30.9.1959; Christmann M, 2000, J BIOL CHEM, V275, P36256, DOI 10.1074/jbc.M005377200; Christmann M, 2003, TOXICOLOGY, V193, P3, DOI 10.1016/S0300-483X(03)00287-7; Cistulli CA, 1998, CANCER RES, V58, P1993; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; Grombacher T, 1998, ONCOGENE, V17, P845, DOI 10.1038/sj.onc.1202000; HAAS S, 1995, CARCINOGENESIS, V16, P985, DOI 10.1093/carcin/16.5.985; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Hawkins DS, 1996, CANCER RES, V56, P892; Henneke G, 2003, ONCOGENE, V22, P4301, DOI 10.1038/sj.onc.1206606; Janus F, 1999, CELL MOL LIFE SCI, V55, P12, DOI 10.1007/s000180050266; KASTAN MB, 1991, CANCER RES, V51, P6304; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Kim IS, 1998, EXP MOL MED, V30, P252, DOI 10.1038/emm.1998.37; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Lackinger D, 2001, MUTAGENESIS, V16, P233, DOI 10.1093/mutage/16.3.233; Lackinger D, 2000, MUTAT RES-FUND MOL M, V457, P113, DOI 10.1016/S0027-5107(00)00133-0; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Larsen E, 2003, MOL CELL BIOL, V23, P5346, DOI 10.1128/MCB.23.15.5346-5353.2003; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Prasad R, 2000, J BIOL CHEM, V275, P4460, DOI 10.1074/jbc.275.6.4460; Prost S, 1998, J BIOL CHEM, V273, P33327, DOI 10.1074/jbc.273.50.33327; Ruggiero BL, 2004, J BIOL CHEM, V279, P23088, DOI 10.1074/jbc.M313170200; Rumbaugh JA, 1999, J BIOL CHEM, V274, P14602, DOI 10.1074/jbc.274.21.14602; Sharma S, 2004, MOL BIOL CELL, V15, P734, DOI 10.1091/mbc.E03-08-0567; Shi BS, 2001, ACTA BIOCH BIOPH SIN, V33, P309; Shibata Y, 2002, J BIOL CHEM, V277, P746, DOI 10.1074/jbc.M109461200; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Tomicic MT, 2003, MOL PHARMACOL, V63, P439, DOI 10.1124/mol.63.2.439; Warbrick E, 1998, J PATHOL, V186, P319; Zheng L, 2005, EMBO REP, V6, P83, DOI 10.1038/sj.embor.7400313	36	31	33	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2005	24	56					8304	8313		10.1038/sj.onc.1208994	http://dx.doi.org/10.1038/sj.onc.1208994			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	993LV	16103874				2022-12-25	WOS:000233956500009
J	Beiter, K; Hiendlmeyer, E; Brabletz, T; Hlubek, F; Haynl, A; Knoll, C; Kirchner, T; Jung, A				Beiter, K; Hiendlmeyer, E; Brabletz, T; Hlubek, F; Haynl, A; Knoll, C; Kirchner, T; Jung, A			beta-Catenin regulates the expression of tenascin-C in human colorectal tumors	ONCOGENE			English	Article						beta-catenin; tenascin-C; Wnt signalling; colorectal cancer	INVASION FRONT; CANCER; CELLS; TRANSCRIPTION; GASTRULATION; TARGET	Tenascin-C (TN-C) is a component of the extracellular matrix (ECM). It is expressed during development and re-expressed in many types of cancers, where it is involved in the modulation of adhesion and proliferation. TN-C expression is especially high at sites of epithelial mesenchymal transition (EMT), which are found frequently at the invasion front of well-differentiated human colorectal adenocarcinomas. Tumor cells in this compartment are characterized by a strong nuclear expression of the oncogenic transcription factor beta-catenin. Here, we demonstrate that TN-C is a beta-catenin target gene in human colorectal tumors. Thus, by far the most common mutations in colorectal tumors, found in the Wnt-signaling pathway and leading to the stabilizing of beta-catenin, might influence invasion by altering adhesive properties and EMT of tumor cells.	Univ Erlangen Nurnberg, Inst Pathol Anat, D-91054 Erlangen, Germany	University of Erlangen Nuremberg	Jung, A (corresponding author), Univ Erlangen Nurnberg, Inst Pathol Anat, Krankenhausstr 8-10, D-91054 Erlangen, Germany.	andreas.jung@patho.imed.uni-erlangen.de						Barker N, 1999, AM J PATHOL, V154, P29, DOI 10.1016/S0002-9440(10)65247-9; Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Brabletz T, 1998, PATHOL RES PRACT, V194, P701, DOI 10.1016/S0344-0338(98)80129-5; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Brabletz T, 2002, VIRCHOWS ARCH, V441, P1, DOI 10.1007/s00428-002-0642-9; Brembeck FH, 2004, GENE DEV, V18, P2225, DOI 10.1101/gad.317604; Chiquet-Ehrismann R, 2003, J PATHOL, V200, P488, DOI 10.1002/path.1415; Conacci-Sorrell M, 2003, J CELL BIOL, V163, P847, DOI 10.1083/jcb.200308162; Hanamura N, 1997, INT J CANCER, V73, P10, DOI 10.1002/(SICI)1097-0215(19970926)73:1<10::AID-IJC2>3.0.CO;2-4; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hiendlmeyer E, 2004, CANCER RES, V64, P1209, DOI 10.1158/0008-5472.CAN-3627-2; Jones PL, 2000, MATRIX BIOL, V19, P581, DOI 10.1016/S0945-053X(00)00106-2; Jung A, 2001, AM J PATHOL, V159, P1613, DOI 10.1016/S0002-9440(10)63007-6; Kirchner T, 2000, AM J PATHOL, V157, P1113, DOI 10.1016/S0002-9440(10)64626-3; Kodjabachian L, 1999, DEV BIOL, V213, P231, DOI 10.1006/dbio.1999.9392; Rosin-Arbesfeld R, 2003, EMBO J, V22, P1101, DOI 10.1093/emboj/cdg105; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Shirasaki F, 1999, ONCOGENE, V18, P7755, DOI 10.1038/sj.onc.1203360; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Verma UN, 2003, CLIN CANCER RES, V9, P1291	22	63	67	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2005	24	55					8200	8204		10.1038/sj.onc.1208960	http://dx.doi.org/10.1038/sj.onc.1208960			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	991JL	16091738				2022-12-25	WOS:000233809400011
J	Wei, H; Ruthenburg, AJ; Bechis, SK; Verdine, GL				Wei, H; Ruthenburg, AJ; Bechis, SK; Verdine, GL			Nucleotide-dependent domain movement in the ATPase domain of a human type IIA DNA topoisomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND-PASSAGE REACTION; STEADY-STATE ANALYSIS; CRYSTAL-STRUCTURE; OPERATED CLAMP; DOUBLE HELIX; GYRASE-B; ALPHA; MECHANISM; TRANSPORT; YEAST	Type IIA DNA topoisomerases play multiple essential roles in the management of higher-order DNA structure, including modulation of topological state, chromosome segregation, and chromatin condensation. These diverse physiologic functions are all accomplished through a common molecular mechanism, wherein the protein catalyzes transient cleavage of a DNA duplex ( the G-segment) to yield a double-stranded gap through which another duplex ( the T-segment) is passed. The overall process is orchestrated by the opening and closing of molecular "gates" in the topoisomerase structure, which is regulated by ATP binding, hydrolysis, and release of ADP and inorganic phosphate. Here we present two crystal structures of the ATPase domain of human DNA topoisomerase II alpha in different nucleotide-bound states. Comparison of these structures revealed rigid-body movement of the structural modules within the ATPase domain, suggestive of the motions of a molecular gate.	Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Dana Farber Canc Inst, Program Canc Chem Biol, Boston, MA 02115 USA	Harvard University; Harvard University; Harvard University; Dana-Farber Cancer Institute	Verdine, GL (corresponding author), Harvard Univ, Dept Chem & Biol Chem, 12 Oxford St,Rm 194, Cambridge, MA 02138 USA.	Gregory_verdine@harvard.edu	Ruthenburg, Alexander/F-3992-2015; Ruthenburg, Alexander/C-3941-2008	Ruthenburg, Alexander/0000-0003-2709-4564; 	NCRR NIH HHS [RR-15301] Funding Source: Medline; NIGMS NIH HHS [GM044853, R01 GM044853] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR015301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044853] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baird CL, 1999, P NATL ACAD SCI USA, V96, P13685, DOI 10.1073/pnas.96.24.13685; Baird CL, 2001, J BIOL CHEM, V276, P27893, DOI 10.1074/jbc.M102544200; Bellon S, 2004, ANTIMICROB AGENTS CH, V48, P1856, DOI 10.1128/AAC.48.5.1856-1864.2004; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Bjergbaek L, 2000, J BIOL CHEM, V275, P13041, DOI 10.1074/jbc.275.17.13041; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cabral JHM, 1997, NATURE, V388, P903, DOI 10.1038/42294; Campbell S, 2002, J MOL BIOL, V320, P171, DOI 10.1016/S0022-2836(02)00461-8; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Classen S, 2003, P NATL ACAD SCI USA, V100, P10629, DOI 10.1073/pnas.1832879100; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; CORBETT AH, 1992, J BIOL CHEM, V267, P683; Corbett KD, 2005, STRUCTURE, V13, P873, DOI 10.1016/j.str.2005.03.013; Corbett KD, 2004, ANNU REV BIOPH BIOM, V33, P95, DOI 10.1146/annurev.biophys.33.110502.140357; Corbett KD, 2003, EMBO J, V22, P151, DOI 10.1093/emboj/cdg008; Dutta R, 2000, TRENDS BIOCHEM SCI, V25, P24, DOI 10.1016/S0968-0004(99)01503-0; Fass D, 1999, NAT STRUCT BIOL, V6, P322; Gardiner LP, 1998, BIOCHEMISTRY-US, V37, P16997, DOI 10.1021/bi9818321; Hammonds TR, 1997, J BIOL CHEM, V272, P32696, DOI 10.1074/jbc.272.51.32696; Harkins TT, 1998, BIOCHEMISTRY-US, V37, P7299, DOI 10.1021/bi9729108; Harkins TT, 1998, BIOCHEMISTRY-US, V37, P7292, DOI 10.1021/bi9729099; Hu T, 2002, J BIOL CHEM, V277, P5944, DOI 10.1074/jbc.M111394200; Hu T, 1998, J BIOL CHEM, V273, P9586, DOI 10.1074/jbc.273.16.9586; JACKSON AP, 1993, P NATL ACAD SCI USA, V90, P11232, DOI 10.1073/pnas.90.23.11232; Lamour V, 2002, ACTA CRYSTALLOGR D, V58, P1376, DOI 10.1107/S0907444902010429; Lindsley JE, 1996, P NATL ACAD SCI USA, V93, P2975, DOI 10.1073/pnas.93.7.2975; LINDSLEY JE, 1993, NATURE, V361, P749, DOI 10.1038/361749a0; LINDSLEY JE, 1993, J BIOL CHEM, V268, P8096; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; Maxwell A, 1996, NAT STRUCT BIOL, V3, P109, DOI 10.1038/nsb0296-109; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Oestergaard VH, 2004, J BIOL CHEM, V279, P28093, DOI 10.1074/jbc.M402120200; Oestergaard VH, 2004, J BIOL CHEM, V279, P1684, DOI 10.1074/jbc.M309624200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Roca J, 1996, P NATL ACAD SCI USA, V93, P4057, DOI 10.1073/pnas.93.9.4057; Roca J, 2004, J BIOL CHEM, V279, P25783, DOI 10.1074/jbc.M402555200; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; Skouboe C, 2003, J BIOL CHEM, V278, P5768, DOI 10.1074/jbc.M210332200; Smith CV, 1998, BIOCHEMISTRY-US, V37, P9658, DOI 10.1021/bi9801309; Tingey AP, 1996, NUCLEIC ACIDS RES, V24, P4868, DOI 10.1093/nar/24.24.4868; Topcu Z, 2001, J CLIN PHARM THER, V26, P405, DOI 10.1046/j.1365-2710.2001.00368.x; Walker JV, 2004, J BIOL CHEM, V279, P25947, DOI 10.1074/jbc.M312314200; Wang JC, 1998, Q REV BIOPHYS, V31, P107, DOI 10.1017/S0033583598003424; WASSERMAN RA, 1993, CANCER RES, V53, P3591; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0	46	178	182	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					37041	37047		10.1074/jbc.M506520200	http://dx.doi.org/10.1074/jbc.M506520200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16100112	Green Published, hybrid			2022-12-25	WOS:000232901800062
J	Elward, K; Griffiths, M; Mizuno, M; Harris, CL; Neal, JW; Morgan, BP; Gasque, P				Elward, K; Griffiths, M; Mizuno, M; Harris, CL; Neal, JW; Morgan, BP; Gasque, P			CD46 plays a key role in tailoring innate immune recognition of apoptotic and necrotic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE-BINDING LECTIN; COFACTOR PROTEIN MCP; COMPLEMENT ACTIVATION; ENDOTHELIAL-CELLS; CLASSICAL PATHWAY; MEMBRANE-PROTEIN; DOWN-REGULATION; MYELOID CELLS; C1Q; CLEARANCE	Complement is the canonical innate immune system involved in host defense and tissue repair with the clearance of cell debris. In contrast to the robust armory mounted against microbial nonself-pathogens, complement is selectively activated on altered self (i.e. apoptotic and necrotic cells) to instruct the safe demise by poorly characterized mechanisms. Our data shed new light on the role of complement C1q in sensing nucleic acids (NA) rapidly exposed on apoptotic Jurkat T cell membranes and in driving C3 opsonization but without the lytic membrane attack complex. DNA/RNase-treated apoptotic cells failed to activate complement. We found that several other apoptotic cell models, including senescent keratinocytes, ionophore-treated sperm cells, and CMK-derived platelets, stained for cleaved caspase 3 were rapidly losing the key complement regulator CD46. CD46 from nuclear and membrane stores was found to cluster into blebs and shed into microparticles together with NA, phosphatidylserine, C1q, and factor H. Classical and alternative pathways of complement were involved in the recognition of H2O2-treated necrotic cells. Membrane attack complex was detected on necrotic cells possibly as a result of CD46 and CD59 shedding into soluble forms. Our data highlight a novel and universal paradigm whereby the complement innate immune system is using two synergistic strategies with the recognition of altered self-NA and missing self-CD46 signals to instruct and tailor the efficient removal of apoptotic and necrotic cells in immunoprivileged sites.	Cardiff Univ, Sch Med, Dept Med Biochem & Immunol, Brain Inflammat & Immun Grp, Cardiff CF14 4XN, Wales; Cardiff Univ, Sch Med, Dept Med Biochem & Immunol, Complement Biol Grp, Cardiff CF14 4XN, Wales; Cardiff Univ, Sch Med, Dept Pathol, Neuropathol Lab, Cardiff CF14 4XN, Wales	Cardiff University; Cardiff University; Cardiff University	Gasque, P (corresponding author), Cardiff Univ, Sch Med, Dept Med Biochem & Immunol, Brain Inflammat & Immun Grp, Heath Pk Campus, Cardiff CF14 4XN, Wales.	gasque@cardiff.ac.uk		Morgan, Paul/0000-0003-4075-7676	Multiple Sclerosis Society [714] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Multiple Sclerosis Society(National Multiple Sclerosis Society); Wellcome Trust(Wellcome TrustEuropean Commission)		Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Anderson HA, 2003, NAT IMMUNOL, V4, P87, DOI 10.1038/ni871; Arama E, 2003, DEV CELL, V4, P687, DOI 10.1016/S1534-5807(03)00120-5; Arur S, 2003, DEV CELL, V4, P587, DOI 10.1016/S1534-5807(03)00090-X; Barclay AN, 2002, TRENDS IMMUNOL, V23, P285, DOI 10.1016/S1471-4906(02)02223-8; Botto M, 1998, NAT GENET, V19, P56, DOI 10.1038/ng0598-56; Caragine TA, 2002, BLOOD, V100, P3304, DOI 10.1182/blood.V100.9.3304; CASCIOLAROSEN LA, 1994, J EXP MED, V179, P1317, DOI 10.1084/jem.179.4.1317; Ciurana CLF, 2004, EUR J IMMUNOL, V34, P2609, DOI 10.1002/eji.200425045; Clarke MCH, 2003, J CELL BIOL, V160, P577, DOI 10.1083/jcb.200210111; Crocker PR, 2001, TRENDS IMMUNOL, V22, P337, DOI 10.1016/S1471-4906(01)01930-5; Eda S, 2004, J BIOL CHEM, V279, P5967, DOI 10.1074/jbc.M310805200; Elward K, 2003, MOL IMMUNOL, V40, P85, DOI 10.1016/S0161-5890(03)00109-3; Fishelson Z, 2001, MOL IMMUNOL, V38, P207, DOI 10.1016/S0161-5890(01)00055-4; Franc NC, 1999, CURR OPIN IMMUNOL, V11, P47, DOI 10.1016/S0952-7915(99)80009-0; GASQUE P, 1995, J IMMUNOL, V154, P4726; Gasque P, 1998, J IMMUNOL, V160, P3543; Gasque P, 2004, MOL IMMUNOL, V41, P1089, DOI 10.1016/j.molimm.2004.06.011; Gasque P, 2000, IMMUNOPHARMACOLOGY, V49, P171, DOI 10.1016/S0162-3109(00)80302-1; Ghiran I, 2000, J EXP MED, V192, P1797, DOI 10.1084/jem.192.12.1797; Gorczynski R, 2004, J IMMUNOL, V172, P7744, DOI 10.4049/jimmunol.172.12.7744; Gordon S, 2002, CELL, V111, P927, DOI 10.1016/S0092-8674(02)01201-1; Gregory CD, 2004, IMMUNOLOGY, V113, P1, DOI 10.1111/j.1365-2567.2004.01959.x; Gregory CD, 2000, CURR OPIN IMMUNOL, V12, P27, DOI 10.1016/S0952-7915(99)00047-3; Hara T, 1997, IMMUNOBIOLOGY, V196, P491, DOI 10.1016/S0171-2985(97)80066-6; Hart SP, 2004, CLIN EXP IMMUNOL, V135, P181, DOI 10.1111/j.1365-2249.2003.02330.x; Hoek RM, 2000, SCIENCE, V290, P1768, DOI 10.1126/science.290.5497.1768; Hoffmann PR, 2001, J CELL BIOL, V155, P649, DOI 10.1083/jcb.200108080; JIANG HX, 1992, J BIOL CHEM, V267, P25597; Jones J, 1995, IMMUNOLOGY, V86, P651; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; KAUL M, 1995, J IMMUNOL, V155, P5795; Kim SJ, 2002, J EXP MED, V196, P655, DOI 10.1084/jem.20020542; Kishore U, 2004, TRENDS IMMUNOL, V25, P551, DOI 10.1016/j.it.2004.08.006; Kishore U, 2003, J IMMUNOL, V171, P812, DOI 10.4049/jimmunol.171.2.812; Kishore U, 2002, IMMUNOBIOLOGY, V205, P355, DOI 10.1078/0171-2985-00138; Korb LC, 1997, J IMMUNOL, V158, P4525; Kovacs GG, 2004, NEUROBIOL DIS, V15, P21, DOI 10.1016/j.nbd.2003.09.010; Lauber K, 2003, CELL, V113, P717, DOI 10.1016/S0092-8674(03)00422-7; Lozahic S, 2000, EUR J IMMUNOL, V30, P900, DOI 10.1002/1521-4141(200003)30:3<900::AID-IMMU900>3.0.CO;2-X; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; Mevorach D, 1998, J EXP MED, V188, P2313, DOI 10.1084/jem.188.12.2313; Mevorach D, 1998, J EXP MED, V188, P387, DOI 10.1084/jem.188.2.387; Morgan BP, 1999, CRIT REV IMMUNOL, V19, P173; Morgan BP, 1997, CLIN EXP IMMUNOL, V107, P1, DOI 10.1046/j.1365-2249.1997.d01-890.x; Nauta AJ, 2002, EUR J IMMUNOL, V32, P1726, DOI 10.1002/1521-4141(200206)32:6<1726::AID-IMMU1726>3.0.CO;2-R; Navratil JS, 2001, J IMMUNOL, V166, P3231, DOI 10.4049/jimmunol.166.5.3231; NICHOLSONWELLER A, 1992, CURR TOP MICROBIOL, V178, P7; Nusbaum P, 2005, J BIOL CHEM, V280, P5843, DOI 10.1074/jbc.M413405200; Ogden CA, 2001, J EXP MED, V194, P781, DOI 10.1084/jem.194.6.781; Oldenborg PA, 2000, SCIENCE, V288, P2051, DOI 10.1126/science.288.5473.2051; Palaniyar N, 2004, J BIOL CHEM, V279, P32728, DOI 10.1074/jbc.M403763200; PEITSCH MC, 1988, BIOCHEM J, V249, P495, DOI 10.1042/bj2490495; Quartier P, 2005, EUR J IMMUNOL, V35, P252, DOI 10.1002/eji.200425497; Richards A, 2003, P NATL ACAD SCI USA, V100, P12966, DOI 10.1073/pnas.2135497100; Riley RC, 2002, MOL REPROD DEV, V62, P534, DOI 10.1002/mrd.10144; Riley-Vargas RC, 2004, TRENDS IMMUNOL, V25, P496, DOI 10.1016/j.it.2004.07.004; Roos A, 2004, EUR J IMMUNOL, V34, P921, DOI 10.1002/eji.200424904; Sohn JH, 2003, NAT MED, V9, P206, DOI 10.1038/nm814; Taylor PR, 2000, J EXP MED, V192, P359, DOI 10.1084/jem.192.3.359; Tenner AJ, 1999, CURR OPIN IMMUNOL, V11, P34, DOI 10.1016/S0952-7915(99)80007-7; Trouw LA, 2004, J CLIN INVEST, V114, P679, DOI 10.1172/JCI200421075; TSUJI S, 1994, J BIOCHEM-TOKYO, V116, P794, DOI 10.1093/oxfordjournals.jbchem.a124598; Valazquez P, 1997, NAT MED, V3, P77, DOI 10.1038/nm0197-77; Verbovetski I, 2002, J EXP MED, V196, P1553, DOI 10.1084/jem.20020263; Wang GX, 2000, J IMMUNOL, V164, P1839, DOI 10.4049/jimmunol.164.4.1839; Wright GJ, 2000, IMMUNITY, V13, P233, DOI 10.1016/S1074-7613(00)00023-6; Xu CG, 2000, SCIENCE, V287, P498, DOI 10.1126/science.287.5452.498	68	115	121	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36342	36354		10.1074/jbc.M506579200	http://dx.doi.org/10.1074/jbc.M506579200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16087667	hybrid			2022-12-25	WOS:000232726900068
J	Yu, QY; Ciemerych, MA; Sicinski, P				Yu, QY; Ciemerych, MA; Sicinski, P			Ras and Myc can drive oncogenic cell proliferation through individual D-cyclins	ONCOGENE			English	Article						D-cyclins; oncogenic transformation; Ras; Myc	TRANSCRIPTIONAL INDUCTION; EXPRESSION; GENE; TRANSFORMATION; KINASE; PATHWAYS; PROTEIN; PHOSPHORYLATION; OVEREXPRESSION; SEQUESTRATION	D-type cyclins serve as cell cycle recipients of several oncogenic pathways. The specific sequences of the promoters of the cyclin D genes are thought to render particular D-cyclins responsive to specific oncogenic pathways. For instance, the Ras oncogene was postulated to signal through cyclin D1, while Myc can impact the cell cycle machinery by transcriptionally upregulating cyclin D2. In the current study we engineered mouse fibroblasts to express only cyclin D1, only D2, or only D3. These 'single-cyclin' cells allowed us to rigorously test the ability of cyclin D1, D2, or D3, when expressed on their own, to serve as recipients of the Ras- and Myc-driven oncogenic pathways. We found that each of the D-cyclins was sufficient to drive oncogenic proliferation of mouse fibroblasts. This, together with our recent observations that cells lacking all three D-cyclins show greatly reduced susceptibility to the oncogenic action of Ras and Myc, reveals that the Ras and Myc oncogenes can impact the core cell cycle machinery through all three D-cyclins.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Peking Univ, Sch Oncol, Beijing Canc Hosp, Dept Cell Biol, Beijing 100034, Peoples R China; Univ Warsaw, Inst Zool, Dept Embryol, PL-02089 Warsaw, Poland	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Peking University; University of Warsaw	Sicinski, P (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.	peter_sicinski@dfci.harvard.edu		Ciemerych, Maria A./0000-0003-0387-4179	NATIONAL CANCER INSTITUTE [R01CA083688] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA83688] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albanese C, 2003, MOL BIOL CELL, V14, P585, DOI 10.1091/mbc.02-06-0101; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Amanatullah DF, 2001, METHOD ENZYMOL, V333, P116; Balasenthil S, 2004, J BIOL CHEM, V279, P1422, DOI 10.1074/jbc.M309937200; Bartkova J, 1998, ONCOGENE, V17, P1027, DOI 10.1038/sj.onc.1202016; Bouchard C, 2004, EMBO J, V23, P2830, DOI 10.1038/sj.emboj.7600279; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Ciemerych MA, 2002, GENE DEV, V16, P3277, DOI 10.1101/gad.1023602; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Dey A, 2000, MOL BIOL CELL, V11, P3835, DOI 10.1091/mbc.11.11.3835; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dufourny B, 2000, J ENDOCRINOL, V166, P329, DOI 10.1677/joe.0.1660329; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; FILMUS J, 1994, ONCOGENE, V9, P3627; Friedrichsen BN, 2003, MOL ENDOCRINOL, V17, P945, DOI 10.1210/me.2002-0356; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; Hsia CY, 2002, INT IMMUNOL, V14, P905, DOI 10.1093/intimm/dxf055; Huang YP, 2001, ONCOGENE, V20, P1094, DOI 10.1038/sj.onc.1204198; Hurt EM, 2004, CANCER CELL, V5, P191, DOI 10.1016/S1535-6108(04)00019-4; Kozar K, 2004, CELL, V118, P477, DOI 10.1016/j.cell.2004.07.025; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Malstrom S, 2001, P NATL ACAD SCI USA, V98, P14967, DOI 10.1073/pnas.231467698; Marshall C, 1999, CURR OPIN CELL BIOL, V11, P732, DOI 10.1016/S0955-0674(99)00044-7; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Sicinska E, 2003, CANCER CELL, V4, P451, DOI 10.1016/S1535-6108(03)00301-5; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Soh JW, 2003, J BIOL CHEM, V278, P34709, DOI 10.1074/jbc.M302016200; Terada Y, 2003, J AM SOC NEPHROL, V14, P1223, DOI 10.1097/01.ASN.0000060577.94532.06; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Virolle T, 2003, J BIOL CHEM, V278, P11802, DOI 10.1074/jbc.M210279200; Yang M, 1998, BIOCHEM MOL BIOL INT, V44, P51; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zou XH, 2002, GENE DEV, V16, P2923, DOI 10.1101/gad.1033002	43	51	52	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2005	24	47					7114	7119		10.1038/sj.onc.1208853	http://dx.doi.org/10.1038/sj.onc.1208853			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	977WC	16103884				2022-12-25	WOS:000232833200013
J	de Keyzer, J; van der Sluis, EO; Spelbrink, REJ; Nijstad, N; de Kruijff, B; Nouwen, N; van der Does, C; Driessen, AJM				de Keyzer, J; van der Sluis, EO; Spelbrink, REJ; Nijstad, N; de Kruijff, B; Nouwen, N; van der Does, C; Driessen, AJM			Covalently dimerized SecA is functional in protein translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI MEMBRANE-VESICLES; ESCHERICHIA-COLI; SIGNAL SEQUENCE; PREPROTEIN TRANSLOCASE; ESSENTIAL COMPONENT; TERMINAL REGION; ATPASE SECA; BINDING; SECYEG; DISSOCIATION	The ATPase SecA provides the driving force for the transport of secretory proteins across the cytoplasmic membrane of Escherichia coli. SecA exists as a dimer in solution, but the exact oligomeric state of SecA during membrane binding and preprotein translocation is a topic of debate. To study the requirements of oligomeric changes in SecA during protein translocation, a non-dissociable SecA dimer was formed by oxidation of the carboxyl-terminal cysteines. The cross-linked SecA dimer interacts with the SecYEG complex with a similar stoichiometry as non-cross-linked SecA. Cross-linking reversibly disrupts the SecB binding site on SecA. However, in the absence of SecB, the activity of the disulfide-bonded SecA dimer is indistinguishable from wild-type SecA. Moreover, SecYEG binding stabilizes a cold sodium dodecylsulfate-resistant dimeric state of SecA. The results demonstrate that dissociation of the SecA dimer is not an essential feature of the protein translocation reaction.	Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Dept Mol Microbiol, NL-9751 NN Haren, Netherlands; Univ Groningen, Mat & Sci Ctr Plus, NL-9751 NN Haren, Netherlands; Univ Utrecht, Dept Biochem & Membranes, Inst Biomembranes, NL-3584 CH Utrecht, Netherlands; Univ Utrecht, Bijvoet Ctr Biomol Res, NL-3584 CH Utrecht, Netherlands; Goethe Univ Frankfurt, Biozentrum Frankfurt, Inst Biochem, D-60439 Frankfurt, Germany	University of Groningen; University of Groningen; Utrecht University; Utrecht University; Goethe University Frankfurt	Driessen, AJM (corresponding author), Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Dept Mol Microbiol, Kerklaan 30, NL-9751 NN Haren, Netherlands.	a.j.m.driessen@rug.nl	Driessen, Arnold J.M./D-1876-2012	Driessen, Arnold J.M./0000-0001-9258-9104				AKITA M, 1991, BIOCHEM BIOPH RES CO, V174, P211, DOI 10.1016/0006-291X(91)90507-4; Benach J, 2003, J BIOL CHEM, V278, P3628, DOI 10.1074/jbc.M205992200; BREUKINK E, 1995, J BIOL CHEM, V270, P7902, DOI 10.1074/jbc.270.14.7902; Bu ZM, 2003, J MOL BIOL, V332, P23, DOI 10.1016/S0022-2836(03)00840-4; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; de Keyzer J, 2003, J BIOL CHEM, V278, P29581, DOI 10.1074/jbc.M303490200; de Keyzer J, 2002, J BIOL CHEM, V277, P46059, DOI 10.1074/jbc.M208449200; de Keyzer J, 2002, FEBS LETT, V510, P17, DOI 10.1016/S0014-5793(01)03213-6; DRIESSEN AJM, 1993, BIOCHEMISTRY-US, V32, P13190, DOI 10.1021/bi00211a030; Duong F, 2003, EMBO J, V22, P4375, DOI 10.1093/emboj/cdg418; Fekkes P, 1999, BIOCHEMISTRY-US, V38, P5111, DOI 10.1021/bi982818r; Fekkes P, 1998, MOL MICROBIOL, V29, P1179, DOI 10.1046/j.1365-2958.1998.00997.x; Fekkes P, 1997, EMBO J, V16, P6105, DOI 10.1093/emboj/16.20.6105; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; Hunt JF, 2002, SCIENCE, V297, P2018, DOI 10.1126/science.1074424; Jilaveanu LB, 2005, P NATL ACAD SCI USA, V102, P7511, DOI 10.1073/pnas.0502774102; Karamanou S, 2005, FEBS LETT, V579, P1267, DOI 10.1016/j.febslet.2005.01.025; Kaufmann A, 1999, BIOCHEMISTRY-US, V38, P9115, DOI 10.1021/bi990539d; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; MATSUYAMA S, 1990, J BIOL CHEM, V265, P8760; Or E, 2005, J BIOL CHEM, V280, P9097, DOI 10.1074/jbc.M413947200; Or E, 2002, EMBO J, V21, P4470, DOI 10.1093/emboj/cdf471; Osborne AR, 2004, P NATL ACAD SCI USA, V101, P10937, DOI 10.1073/pnas.0401742101; RAJAPANDI T, 1994, BIOCHEM BIOPH RES CO, V200, P1477, DOI 10.1006/bbrc.1994.1617; Randall LL, 2005, J MOL BIOL, V348, P479, DOI 10.1016/j.jmb.2005.02.036; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; Spelbrink REJ, 2005, J BIOL CHEM, V280, P28742, DOI 10.1074/jbc.M501617200; Tziatzios C, 2004, J MOL BIOL, V340, P513, DOI 10.1016/j.jmb.2004.04.076; van der Does C, 2003, METHOD ENZYMOL, V372, P86; van der Wolk JPW, 1998, EMBO J, V17, P3631, DOI 10.1093/emboj/17.13.3631; Veenendaal AKJ, 2004, BBA-MOL CELL RES, V1694, P81, DOI 10.1016/j.bbamcr.2004.02.009; Woodbury RL, 2002, PROTEIN SCI, V11, P875, DOI 10.1110/ps.4090102; Zhou JH, 2003, NAT STRUCT BIOL, V10, P942, DOI 10.1038/nsb980	33	71	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35255	35260		10.1074/jbc.M506157200	http://dx.doi.org/10.1074/jbc.M506157200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16115882	hybrid, Green Published			2022-12-25	WOS:000232561200023
J	Pirok, EW; Domowicz, MS; Henry, J; Wang, YL; Santore, M; Mueller, MM; Schwartz, NB				Pirok, EW; Domowicz, MS; Henry, J; Wang, YL; Santore, M; Mueller, MM; Schwartz, NB			APBP-1, a DNA/RNA-binding protein, interacts with the chick aggrecan regulatory region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-2(I) COLLAGEN GENE; TRANSCRIPTION FACTOR; TRANSLATIONAL REGULATION; RNA; RICH; PROTEOGLYCAN; CHONDROCYTES; RECOGNITION; EXPRESSION; PROMOTER	Expression of the extracellular proteoglycan aggrecan is both cell-specific and developmentally regulated. Previous studies identified six functionally defined cis elements in the aggrecan promoter region which were shown to repress aggrecan gene expression (1). Using competition electrophoretic mobility shift assays (EMSAs) we have now identified in nuclear extracts a functional repressor cis element, (T/C)TCCCCT(A/C)RRC, which occurs at multiple locations within the chick aggrecan regulatory region. We purified the factor that binds to this cis element and established that it, APBP-1 (aggrecan promoter-binding protein-1), is a 19-kDa protein that has significant homology to CIRP (cold inducible RNA-binding protein). Recombinantly expressed APBP-1 mimics the native cis element-trans factor interaction in EMSAs. In situ hybridization demonstrates that aggrecan and APBP-1 RNA expression are restricted to complementary tissues in the developing limb, and Northern blot analysis of chick limb bud mRNA shows that APBP-1 mRNA expression is inversely correlated with aggrecan mRNA expression. Functional analyses by transient transfections and Northern blot analyses suggest APBP-1 has the capacity to repress aggrecan expression, indicating that this factor may be important regulator of aggrecan gene expression.	Univ Chicago, Dept Pediat, Chicago, IL 60637 USA; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago	Schwartz, NB (corresponding author), Univ Chicago, Dept Pediat, 5841 S Maryland Ave,MC 5058, Chicago, IL 60637 USA.	n-schwartz@uchicago.edu	Domowicz, Miriam/AFL-7930-2022; Domowicz, Miriam/AAG-7886-2022	Domowicz, Miriam/0000-0001-7860-4427; Domowicz, Miriam/0000-0001-7860-4427	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD017332, P01HD009402] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-07237] Funding Source: Medline; NICHD NIH HHS [HD-09402, HD-17332, HD-007009] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aoki K, 2002, NUCLEIC ACIDS RES, V30, P5182, DOI 10.1093/nar/gkf638; Auboeuf D, 2004, MOL CELL BIOL, V24, P442, DOI 10.1128/MCB.24.1.442-453.2004; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CLEMENS KR, 1993, SCIENCE, V260, P530, DOI 10.1126/science.8475383; Day JM, 2004, J BIOL CHEM, V279, P12511, DOI 10.1074/jbc.M400242200; Deyrup AT, 1998, J BIOL CHEM, V273, P9450, DOI 10.1074/jbc.273.16.9450; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; Dubnau J, 1996, NATURE, V379, P694, DOI 10.1038/379694a0; Ghayor C, 2001, J BIOL CHEM, V276, P36881, DOI 10.1074/jbc.M105083200; Grove EA, 1998, DEVELOPMENT, V125, P2315; Ihn H, 1996, J BIOL CHEM, V271, P26717, DOI 10.1074/jbc.271.43.26717; Ihn H, 1997, J BIOL CHEM, V272, P24666, DOI 10.1074/jbc.272.39.24666; Maruyama K, 1999, NUCLEIC ACIDS RES, V27, P2029, DOI 10.1093/nar/27.9.2029; Mayfield S, 1996, CHEM BIOL, V3, P415, DOI 10.1016/S1074-5521(96)90088-5; MCBRYANT SJ, 1995, J MOL BIOL, V248, P44, DOI 10.1006/jmbi.1995.0201; Murray D, 2000, J BIOL CHEM, V275, P3610, DOI 10.1074/jbc.275.5.3610; Nishiyama H, 1997, GENE, V204, P115, DOI 10.1016/S0378-1119(97)00530-1; Nishiyama H, 1997, J CELL BIOL, V137, P899, DOI 10.1083/jcb.137.4.899; Pirok EW, 1997, J BIOL CHEM, V272, P11566, DOI 10.1074/jbc.272.17.11566; Pirok EW, 2001, J BIOL CHEM, V276, P16894, DOI 10.1074/jbc.M009944200; Saito T, 2000, COMP BIOCHEM PHYS B, V125, P237, DOI 10.1016/S0305-0491(99)00174-1; SCHWARTZ NB, 1993, PROG CLIN BIOL RES, V383, P505; Tanaka KJ, 2000, DEV GENES EVOL, V210, P464, DOI 10.1007/s004270000080; Xue JH, 1999, FREE RADICAL BIO MED, V27, P1238, DOI 10.1016/S0891-5849(99)00158-6	24	3	4	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35606	35616		10.1074/jbc.M505380200	http://dx.doi.org/10.1074/jbc.M505380200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16100116	hybrid			2022-12-25	WOS:000232561200063
J	Suzuki, A; Iida, S; Kato-Uranishi, M; Tajima, E; Zhan, FH; Hanamura, I; Huang, YS; Ogura, T; Takahashi, S; Ueda, R; Barlogie, B; Shaughnessy, J; Esumi, H				Suzuki, A; Iida, S; Kato-Uranishi, M; Tajima, E; Zhan, FH; Hanamura, I; Huang, YS; Ogura, T; Takahashi, S; Ueda, R; Barlogie, B; Shaughnessy, J; Esumi, H			ARK5 is transcriptionally regulated by the Large-MAF family and mediates IGF-1-induced cell invasion in multiple myeloma: ARK5 as a new molecular determinant of malignant multiple myeloma	ONCOGENE			English	Article						ARK5; multiple myeloma; Large-MAF family; invasion; IGF-1	ACTIVATED PROTEIN-KINASE; INTEGRIN-LINKED KINASE; GROWTH-FACTOR; BONE-MARROW; CHROMOSOMAL TRANSLOCATIONS; TUMOR INVASION; PLASMA-CELLS; INSULIN; PROLIFERATION; EXPRESSION	ARK5, AMP-activated protein kinase (AMPK)-related protein kinase mediating Akt signals, is closely involved in tumor progression, and its stage-associated expression was observed in colorectal cancer. In this study, we found ARK5 expression in multiple myeloma cell lines expressing c-MAF and MAFB. In addition, gene expression profiling of 351 clinical specimens revealed ARK5 expression in primary myelomas expressing c-MAF and MAFB, suggesting that ARK5 may be a transcriptional target of the Large-MAF family. Sequence analysis of the ARK5 gene promoter revealed that it contains two putative MAF-recognition element (MARE) sequences. In support of this hypothesis, ARK5 was induced when an MAFB or c-MAF expression vector was introduced into non-ARK5-expressing colon cancer cells. Furthermore, ARK5 promoter activity was dramatically decreased by mutation or deletion of MARE sequences. Chromatin immunoprecipitation assays revealed an interaction between the Large-MAF family proteins and MARE sequences in the ARK5 promoter. Moreover, in ARK5 mRNA- expressing multiple myeloma lines, but not in ARK5-negative lines, insulin-like growth factor (IGF)-1 increased invasion activity. IGF-1-induced invasion was reproduced when ARK5 was overexpressed in Burkitt's lymphoma and plasmacytoma lines. Based on results, we conclude that ARK5 is a transcriptional target of the Large-MAF family through MARE sequence and that ARK5 may in part mediate the aggressive phenotype associated with c-MAF- and MAFB-expressing myelomas.	Natl Canc Ctr, Res Inst E, Canc Physiol Project, Kashiwa, Chiba 2778577, Japan; Nagoya City Univ, Grad Sch Med Sci, Dept Internal Med & Mol Sci, Nagoya, Aichi 4678601, Japan; Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Donna D & Donald M Lambert Lab Myeloma Genet, Little Rock, AR 72205 USA; Univ Tsukuba, Dept Basic Med Sci, Tsukuba, Ibaraki 3058575, Japan	National Cancer Center - Japan; Nagoya City University; University of Arkansas System; University of Arkansas Medical Sciences; University of Tsukuba	Esumi, H (corresponding author), Natl Canc Ctr, Res Inst E, Canc Physiol Project, 6-5-1 Kashiwanoha, Kashiwa, Chiba 2778577, Japan.	hesumi@east.ncc.go.jp			NCI NIH HHS [CA55819, CA97513] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA055819, R33CA097513] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Asosingh K, 2003, Verh K Acad Geneeskd Belg, V65, P127; Bergsagel PL, 2005, BLOOD, V106, P296, DOI 10.1182/blood-2005-01-0034; Bergsagel PL, 2001, ONCOGENE, V20, P5611, DOI 10.1038/sj.onc.1204641; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Di Raimondo F, 2000, HAEMATOLOGICA, V85, P800; Drevs J, 2003, ANTICANCER RES, V23, P1159; Ferlin M, 2000, BRIT J HAEMATOL, V111, P626, DOI 10.1046/j.1365-2141.2000.02364.x; Hanamura I, 2001, JPN J CANCER RES, V92, P638, DOI 10.1111/j.1349-7006.2001.tb01142.x; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Hayman S R, 2001, Curr Treat Options Oncol, V2, P205, DOI 10.1007/s11864-001-0034-4; Hegde SP, 1998, MOL CELL BIOL, V18, P2729, DOI 10.1128/MCB.18.5.2729; Hideshima T, 2002, NAT REV CANCER, V2, P927, DOI 10.1038/nrc952; Huang K, 2000, GENE, V242, P419, DOI 10.1016/S0378-1119(99)00500-4; Hurt EM, 2004, CANCER CELL, V5, P191, DOI 10.1016/S1535-6108(04)00019-4; Iida S, 2000, INT J HEMATOL, V72, P85; Iida S, 1997, NAT GENET, V17, P226, DOI 10.1038/ng1097-226; Ishikawa H, 2003, LEUKEMIA LYMPHOMA, V44, P1477, DOI 10.1080/1042819031000097339; Kajihara M, 2003, BIOCHEM BIOPH RES CO, V312, P831, DOI 10.1016/j.bbrc.2003.10.196; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; Kemp BE, 2003, BIOCHEM SOC T, V31, P162; Kemp BE, 1999, TRENDS BIOCHEM SCI, V24, P22, DOI 10.1016/S0968-0004(98)01340-1; Klein B, 2003, INT J HEMATOL, V78, P106, DOI 10.1007/BF02983377; Kusakai G, 2004, J EXP CLIN CANC RES, V23, P263; Kusakai G, 2004, AM J PATHOL, V164, P987, DOI 10.1016/S0002-9440(10)63186-0; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Persad S, 2003, CANCER METAST REV, V22, P375, DOI 10.1023/A:1023777013659; Qiang YW, 2004, BLOOD, V103, P301, DOI 10.1182/blood-2003-06-2066; Ria R, 2003, LEUKEMIA, V17, P1961, DOI 10.1038/sj.leu.2403076; Seidl S, 2003, LANCET ONCOL, V4, P557, DOI 10.1016/S1470-2045(03)01195-1; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Suzuki A, 2004, ONCOGENE, V23, P7067, DOI 10.1038/sj.onc.1207963; Suzuki A, 2004, MOL CELL BIOL, V24, P3526, DOI 10.1128/MCB.24.8.3526-3535.2004; Suzuki A, 2003, ONCOGENE, V22, P6177, DOI 10.1038/sj.onc.1206899; Suzuki A, 2003, J BIOL CHEM, V278, P48, DOI 10.1074/jbc.M206025200; Tai YT, 2003, CANCER RES, V63, P5850; Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847; Yoshida S, 1999, LEUKEMIA, V13, P1812, DOI 10.1038/sj.leu.2401563; ZHAN F, 2004, BLOOD, V104, P26; Zhan FH, 2003, BLOOD, V101, P1128, DOI 10.1182/blood-2002-06-1737; Zhan FH, 2002, BLOOD, V99, P1745, DOI 10.1182/blood.V99.5.1745	45	56	61	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2005	24	46					6936	6944		10.1038/sj.onc.1208844	http://dx.doi.org/10.1038/sj.onc.1208844			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	975ZD	16044163				2022-12-25	WOS:000232701700008
J	Cape, JL; Strahan, JR; Lenaeus, MJ; Yuknis, BA; Le, TT; Shepherd, JN; Bowman, MK; Kramer, DM				Cape, JL; Strahan, JR; Lenaeus, MJ; Yuknis, BA; Le, TT; Shepherd, JN; Bowman, MK; Kramer, DM			The respiratory substrate rhodoquinol induces Q-cycle bypass reactions in the yeast cytochrome bc(1) complex - Mechanistic and physiological implications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-TRANSPORT CHAIN; IRON-SULFUR PROTEIN; ANAEROBICALLY FUNCTIONING EUKARYOTES; FUMARATE REDUCTASE-ACTIVITY; THERMOPHILIC BACTERIUM PS3; LUMBRICOIDES VAR SUIS; Q(O) SITE; UBIQUINOL OXIDATION; RHODOBACTER-SPHAEROIDES; RHODOSPIRILLUM-RUBRUM	The mitochondrial cytochrome bc(1) complex catalyzes the transfer of electrons from ubiquinol to cyt c while generating a proton motive force for ATP synthesis via the "Q-cycle" mechanism. Under certain conditions electron flow through the Q-cycle is blocked at the level of a reactive intermediate in the quinol oxidase site of the enzyme, resulting in "bypass reactions," some of which lead to superoxide production. Using analogs of the respiratory substrates ubiquinol-3 and rhodoquinol-3, we show that the relative rates of Q-cycle bypass reactions in the Saccharomyces cerevisiae cyt bc1 complex are highly dependent by a factor of up to 100-fold on the properties of the substrate quinol. Our results suggest that the rate of Q-cycle bypass reactions is dependent on the steady state concentration of reactive intermediates produced at the quinol oxidase site of the enzyme. We conclude that normal operation of the Q-cycle requires a fairly narrow window of redox potentials with respect to the quinol substrate to allow normal turnover of the complex while preventing potentially damaging bypass reactions.	Gonzaga Univ, Dept Chem, Spokane, WA 99258 USA; Washington State Univ, Inst Biol Chem, Pullman, WA 99164 USA; Battelle NW Lab, Struct Biol & Microimaging, Richland, WA 99352 USA	Gonzaga University; Washington State University; United States Department of Energy (DOE); Pacific Northwest National Laboratory	Shepherd, JN (corresponding author), Gonzaga Univ, Dept Chem, 502 E Boone Ave, Spokane, WA 99258 USA.	shepherd@gonzaga.edu	Bowman, Michael/F-4265-2011; Kramer, David/B-9588-2016	Bowman, Michael/0000-0003-3464-9409; Kramer, David/0000-0003-2181-6888	NIGMS NIH HHS [GM61904] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061904] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN PC, 1973, EXP PARASITOL, V34, P211, DOI 10.1016/0014-4894(73)90080-5; BAUSCHER M, 1992, J PHYS CHEM-US, V96, P11101, DOI 10.1021/j100205a087; BEACH DH, 1980, MOL BIOCHEM PARASIT, V1, P269, DOI 10.1016/0166-6851(80)90060-2; BEROZA P, 1995, BIOPHYS J, V68, P2233, DOI 10.1016/S0006-3495(95)80406-6; Berry EA, 2000, ANNU REV BIOCHEM, V69, P1005, DOI 10.1146/annurev.biochem.69.1.1005; Brasseur G, 2004, J BIOL CHEM, V279, P24203, DOI 10.1074/jbc.M311576200; Brasseur G, 2002, BBA-BIOENERGETICS, V1555, P37, DOI 10.1016/S0005-2728(02)00251-7; Brasseur G, 2001, BBA-BIOENERGETICS, V1506, P89, DOI 10.1016/S0005-2728(01)00186-4; Cape JL, 2005, J AM CHEM SOC, V127, P4208, DOI 10.1021/ja043955g; Covian R, 2004, J BIOL CHEM, V279, P15040, DOI 10.1074/jbc.M400193200; Crofts AR, 2004, BBA-BIOENERGETICS, V1655, P77, DOI 10.1016/j.bbabio.2003.10.012; Crofts AR, 2004, ANNU REV PHYSIOL, V66, P689, DOI 10.1146/annurev.physiol.66.032102.150251; Crofts AR, 2003, J BIOL CHEM, V278, P36191, DOI 10.1074/jbc.M305461200; Crofts AR, 2002, BBA-BIOENERGETICS, V1555, P48, DOI 10.1016/S0005-2728(02)00253-0; CROFTS AR, 1989, PHOTOSYNTH RES, V22, P69, DOI 10.1007/BF00114768; Crofts AR, 2000, BBA-BIOENERGETICS, V1459, P456, DOI 10.1016/S0005-2728(00)00184-5; ERABI T, 1975, J BIOCHEM-TOKYO, V78, P795, DOI 10.1093/oxfordjournals.jbchem.a130968; FIORAVANTI CF, 1988, MOL BIOCHEM PARASIT, V28, P129, DOI 10.1016/0166-6851(88)90060-6; Fisher N, 2001, EUR J BIOCHEM, V268, P1155, DOI 10.1046/j.1432-1327.2001.02010.x; FORQUER I, 2005, PHOTOSYNTHESIS FUNDA, V1, P430; GIBSON F, 1973, Biochemical Society Transactions, V1, P317; GIMENEZGALLEGO G, 1982, EUR J BIOCHEM, V121, P343, DOI 10.1111/j.1432-1033.1982.tb05792.x; GLERUM DM, 1995, J BIOL CHEM, V270, P15585, DOI 10.1074/jbc.270.26.15585; Gong X, 2005, J BIOL CHEM, V280, P9251, DOI 10.1074/jbc.M409994200; GU LQ, 1990, BIOCHIM BIOPHYS ACTA, V1015, P482, DOI 10.1016/0005-2728(90)90082-F; GU LQ, 1989, J BIOL CHEM, V264, P4506; Gutierrez-Cirlos EB, 2002, J BIOL CHEM, V277, P1195, DOI 10.1074/jbc.M109097200; HENDLER RW, 1985, J BIOENERG BIOMEMBR, V17, P51, DOI 10.1007/BF00744988; Hoffmeister M, 2004, J BIOL CHEM, V279, P22422, DOI 10.1074/jbc.M400913200; Hong SJ, 1999, J BIOL CHEM, V274, P33931, DOI 10.1074/jbc.274.48.33931; KANTILAL PB, 1973, J CHEM SOC F1, P814; KITA K, 1988, BIOCHIM BIOPHYS ACTA, V935, P130, DOI 10.1016/0005-2728(88)90210-1; Knox PP, 2004, BIOCHEMISTRY-MOSCOW+, V69, P890, DOI 10.1023/B:BIRY.0000040221.43531.00; Kolling DRJ, 2003, J BIOL CHEM, V278, P39747, DOI 10.1074/jbc.M305913200; Kramer D, 2004, METHOD ENZYMOL, V382, P21; Kramer DM, 1997, BIOCHEMISTRY-US, V36, P4203, DOI 10.1021/bi962241i; Kramer DM, 2005, PHOTOSYNTHESIS FUNDA, P424; KUTOH E, 1988, J BIOL CHEM, V263, P9020; Link TA, 1997, FEBS LETT, V412, P257, DOI 10.1016/S0014-5793(97)00772-2; LJUNGDAHL O, 1987, BIOCHIM BIOPHYS ACTA, V891, P227; Lundbaek JA, 2003, BIOPHYS J, V84, P2080, DOI 10.1016/S0006-3495(03)75015-2; Marbois B, 2005, J BIOL CHEM, V280, P20231, DOI 10.1074/jbc.M501315200; Miyadera H, 2003, EUR J BIOCHEM, V270, P1863, DOI 10.1046/j.1432-1033.2003.03553.x; MOORE HW, 1965, J AM CHEM SOC, V87, P1409, DOI 10.1021/ja01084a065; MOORE HW, 1966, J AM CHEM SOC, V88, P567, DOI 10.1021/ja00955a032; Muller F, 2002, BIOCHEMISTRY-US, V41, P7866, DOI 10.1021/bi025581e; Muller F, 2000, J AM AGING ASSOC, V23, P227, DOI 10.1007/s11357-000-0022-9; Muller FL, 2003, BIOCHEMISTRY-US, V42, P6493, DOI 10.1021/bi0342160; NAGARAJAN S, 1987, J ORG CHEM, V52, P5044, DOI 10.1021/jo00231a044; NARUTA Y, 1980, J ORG CHEM, V45, P4097, DOI 10.1021/jo01309a006; OHNISHI T, 1980, J BIOL CHEM, V255, P3278; OKAYAMA S, 1968, J BIOL CHEM, V243, P2995; OLSON RE, 1983, VITAM HORM, V40, P1, DOI 10.1016/S0083-6729(08)60431-8; Osyczka A, 2005, TRENDS BIOCHEM SCI, V30, P176, DOI 10.1016/j.tibs.2005.02.001; Osyczka A, 2004, NATURE, V427, P607, DOI 10.1038/nature02242; OZAWA H, 1969, EXPERIENTIA, V25, P484, DOI 10.1007/BF01900769; Palsdottir H, 2003, J BIOL CHEM, V278, P31303, DOI 10.1074/jbc.M302195200; Poon WW, 1999, J BIOL CHEM, V274, P21665, DOI 10.1074/jbc.274.31.21665; Roginsky VA, 1999, J CHEM SOC PERK T 2, P871, DOI 10.1039/a807650b; Sakamoto K, 2002, J PESTIC SCI, V27, P147; SATO M, 1969, J BIOCHEM-TOKYO, V65, P861, DOI 10.1093/oxfordjournals.jbchem.a129090; Shim YB, 1997, J ELECTROANAL CHEM, V425, P201, DOI 10.1016/S0022-0728(96)04956-X; Shinkarev VP, 2001, BIOCHEMISTRY-US, V40, P12584, DOI 10.1021/bi011334j; Snyder CH, 1999, J BIOL CHEM, V274, P31209, DOI 10.1074/jbc.274.44.31209; Snyder CH, 2000, J BIOL CHEM, V275, P13535, DOI 10.1074/jbc.275.18.13535; SONE N, 1987, J BIOL CHEM, V262, P15386; Sun H, 2003, ARCH BIOCHEM BIOPHYS, V419, P198, DOI 10.1016/j.abb.2003.08.028; TAKAHASHI E, 1992, BIOCHEMISTRY-US, V31, P855, DOI 10.1021/bi00118a031; Takamiya S, 1999, ARCH BIOCHEM BIOPHYS, V371, P284, DOI 10.1006/abbi.1999.1465; Tielens AGM, 1998, BBA-BIOENERGETICS, V1365, P71, DOI 10.1016/S0005-2728(98)00045-0; TRUMPOWER BL, 1981, J BIOENERG BIOMEMBR, V13, P1, DOI 10.1007/BF00744743; Trumpower BL, 2002, BBA-BIOENERGETICS, V1555, P166, DOI 10.1016/S0005-2728(02)00273-6; van Hellemond JJ, 2003, PHILOS T ROY SOC B, V358, P205, DOI 10.1098/rstb.2002.1182; VanHellemond JJ, 1995, J BIOL CHEM, V270, P31065, DOI 10.1074/jbc.270.52.31065; VanHellemond JJ, 1996, MOL BIOCHEM PARASIT, V82, P217, DOI 10.1016/0166-6851(96)02738-7; VAULTIER M, 1983, TETRAHEDRON LETT, V24, P763, DOI 10.1016/S0040-4039(00)81520-8; Wang TY, 2000, BIOPHYS J, V79, P1478, DOI 10.1016/S0006-3495(00)76399-5; Yamashita T, 2004, BBA-BIOENERGETICS, V1608, P97, DOI 10.1016/j.bbabio.2003.10.006; Zhang L, 2002, BBA-BIOENERGETICS, V1556, P226, DOI 10.1016/S0005-2728(02)00368-7; Zhang L, 1998, J BIOL CHEM, V273, P33972, DOI 10.1074/jbc.273.51.33972	80	22	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34654	34660		10.1074/jbc.M507616200	http://dx.doi.org/10.1074/jbc.M507616200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16087663	hybrid			2022-12-25	WOS:000232403900034
J	Colige, A; Ruggiero, F; Vandenberghe, I; Dubail, J; Kesteloot, F; Van Beeumen, J; Beschin, A; Brys, L; Lapiere, CM; Nusgens, B				Colige, A; Ruggiero, F; Vandenberghe, I; Dubail, J; Kesteloot, F; Van Beeumen, J; Beschin, A; Brys, L; Lapiere, CM; Nusgens, B			Domains and maturation processes that regulate the activity of ADAMTS-2, a metalloproteinase cleaving the aminopropeptide of fibrillar procollagens types I-III and V	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-1; BOVINE DERMATOSPARAXIS; N-PROTEINASE; COLLAGEN-V; AGGRECANASE-1; ACTIVATION; CLEAVAGE; PROPEPTIDE; BINDING; MATRIX	Processing of fibrillar collagens is required to generate collagen monomers able to self-assemble into elongated and cylindrical collagen fibrils. ADAMTS-2 belongs to the "A disintegrin and metalloproteinase with thrombospondin type 1 motifs" ( ADAMTS) family. It is responsible for most of the processing of the aminopropeptide of type I procollagen in the skin, and it also cleaves type II and type III procollagens. ADAMTS are complex secreted enzymes that are implicated in various physiological and pathological processes. Despite accumulating evidence indicating that their activity is regulated by ancillary domains, additional information is required for a better understanding of the specific function of each domain. We have generated 17 different recombinant forms of bovine ADAMTS-2 and characterized their processing, activity, and cleavage specificity. The results indicated the following: (i) activation of the ADAMTS-2 zymogen involves several cleavages, by proprotein convertases and C-terminal processing, and generates at least seven distinct processed forms; (ii) the C-terminal domain negatively regulates enzyme activity, whereas two thrombospondin type 1 repeats are enhancer regulators; (iii) the 104-kDa form displays the highest aminoprocollagen peptidase activity on procollagen type I; (iv) ADAMTS-2 processes the aminopropeptide of alpha 1 type V procollagen homotrimer at the end of the variable domain; and ( v) the cleaved sequence (PA) is different from the previously described sites (( P/A) Q) for ADAMTS-2, redefining its cleavage specificity. This finding and the existence of multiple processed forms of ADAMTS-2 strongly suggest that ADAMTS-2 may be involved in function(s) other than processing of fibrillar procollagen types I - III.	Univ Liege, Lab Connect Tissues Biol, Ctr Biomed Integrat Genoprote, B-4000 Sart Tilman Par Liege, Belgium; Univ Ghent, Lab Eiwitbiochem & Eiwitengn, B-9000 Ghent, Belgium; Vrije Univ Brussels VIB, Dept Cellular & Mol Interact, Lab Cellulaire & Mol Immunol, B-1050 Brussels, Belgium; CNRS, UMR 5086, IFR Biosci 128, Inst Biol & Chim Prot, F-69367 Lyon, France	University of Liege; Ghent University; Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB)	Colige, A (corresponding author), Univ Liege, Lab Connect Tissues Biol, Ctr Biomed Integrat Genoprote, Tour Pathol,B23-3, B-4000 Sart Tilman Par Liege, Belgium.	acolige@ulg.ac.be	Dubail, Johanne/AAB-1980-2021; Beschin, Alain/L-2154-2014	Dubail, Johanne/0000-0001-9124-9765; Beschin, Alain/0000-0001-8478-6941; RUGGIERO, Florence/0000-0003-2915-5359				Apte SS, 2004, INT J BIOCHEM CELL B, V36, P981, DOI 10.1016/j.biocel.2004.01.014; Birk DE, 2001, MICRON, V32, P223, DOI 10.1016/S0968-4328(00)00043-3; Bissonnette L, 2004, BIOCHEM J, V379, P757, DOI 10.1042/BJ20031902; Blelloch R, 1999, NATURE, V399, P586, DOI 10.1038/21196; BROEK DL, 1985, J BIOL CHEM, V260, P555; Cabral WA, 2003, J BIOL CHEM, V278, P10006, DOI 10.1074/jbc.M212523200; COLIGE A, 1995, J BIOL CHEM, V270, P16724, DOI 10.1074/jbc.270.28.16724; Colige A, 2004, J INVEST DERMATOL, V123, P656, DOI 10.1111/j.0022-202X.2004.23406.x; Colige A, 1997, P NATL ACAD SCI USA, V94, P2374, DOI 10.1073/pnas.94.6.2374; Colige A, 1999, AM J HUM GENET, V65, P308, DOI 10.1086/302504; Colige A, 2002, J BIOL CHEM, V277, P5756, DOI 10.1074/jbc.M105601200; Fernandes RJ, 2001, J BIOL CHEM, V276, P31502, DOI 10.1074/jbc.M103466200; Fichard A, 1997, J BIOL CHEM, V272, P30083, DOI 10.1074/jbc.272.48.30083; FICHARD A, 1995, MATRIX BIOL, V14, P515, DOI 10.1016/S0945-053X(05)80001-0; Gao G, 2004, J BIOL CHEM, V279, P10042, DOI 10.1074/jbc.M312100200; Gao G, 2002, J BIOL CHEM, V277, P11034, DOI 10.1074/jbc.M107443200; Gopalakrishnan B, 2004, J BIOL CHEM, V279, P30904, DOI 10.1074/jbc.M402252200; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; Imamura Y, 1998, J BIOL CHEM, V273, P27511, DOI 10.1074/jbc.273.42.27511; Kashiwagi M, 2004, J BIOL CHEM, V279, P10109, DOI 10.1074/jbc.M312123200; Kessler E, 2001, J BIOL CHEM, V276, P27051, DOI 10.1074/jbc.M102921200; LINSENMAYER TF, 1993, J CELL BIOL, V121, P1181, DOI 10.1083/jcb.121.5.1181; Loechel F, 2001, FEBS LETT, V506, P65, DOI 10.1016/S0014-5793(01)02873-3; Longpre JM, 2004, J BIOL CHEM, V279, P33237, DOI 10.1074/jbc.M313151200; Majerus EM, 2003, J BIOL CHEM, V278, P46643, DOI 10.1074/jbc.M309872200; MORADIAMELI M, 1994, EUR J BIOCHEM, V221, P987, DOI 10.1111/j.1432-1033.1994.tb18815.x; NIYIBIZI C, 1993, BIOCHIM BIOPHYS ACTA, V1203, P304, DOI 10.1016/0167-4838(93)90099-D; NUSGENS BV, 1992, NAT GENET, V1, P214, DOI 10.1038/ng0692-214; Rodriguez-Manzaneque JC, 2000, J BIOL CHEM, V275, P33471, DOI 10.1074/jbc.M002599200; RUGGIERO F, 1994, EXP CELL RES, V210, P215, DOI 10.1006/excr.1994.1032; Tortorella M, 2000, J BIOL CHEM, V275, P25791, DOI 10.1074/jbc.M001065200; Tortorella MD, 2004, J BIOL CHEM, V279, P17554, DOI 10.1074/jbc.M313041200; Unsold C, 2002, J BIOL CHEM, V277, P5596, DOI 10.1074/jbc.M110003200; Wang P, 2004, J BIOL CHEM, V279, P15434, DOI 10.1074/jbc.M312797200; Wang WM, 2003, J BIOL CHEM, V278, P19549, DOI 10.1074/jbc.M300767200; Zheng XL, 2003, J BIOL CHEM, V278, P30136, DOI 10.1074/jbc.M305331200	36	83	86	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34397	34408		10.1074/jbc.M506458200	http://dx.doi.org/10.1074/jbc.M506458200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16046392	hybrid, Green Submitted			2022-12-25	WOS:000232403900005
J	Knight, PJ; Thirumurugan, K; Xu, YH; Wang, F; Kalverda, AP; Stafford, WF; Sellers, JR; Peckham, M				Knight, PJ; Thirumurugan, K; Xu, YH; Wang, F; Kalverda, AP; Stafford, WF; Sellers, JR; Peckham, M			The predicted coiled-coil domain of myosin 10 forms a novel elongated domain that lengthens the head	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; LARGE STEP-SIZE; UNCONVENTIONAL MYOSINS; ION-PAIRS; STABILITY; HELIX; VI; PROCESSIVITY; COEFFICIENTS; SEQUENCES	Myosin 10 contains a region of predicted coiled coil 120 residues long. However, the highly charged nature and pattern of charges in the proximal 36 residues appear incompatible with coiled-coil formation. Circular dichroism, NMR, and analytical ultracentrifugation show that a synthesized peptide containing this region forms a stable single alpha-helix (SAH) domain in solution and does not dimerize to form a coiled coil even at millimolar concentrations. Additionally, electron microscopy of a recombinant myosin 10 containing the motor, the three calmodulin binding domains, and the full-length predicted coiled coil showed that it was mostly monomeric at physiological protein concentration. In dimers the molecules were joined only at their extreme distal ends, and no coiled-coil tail was visible. Furthermore, the neck lengths of both monomers and dimers were much longer than expected from the number of calmodulin binding domains. In contrast, micrographs of myosin 5 heavy meromyosin obtained under the same conditions clearly showed a coiled-coil tail, and the necks were the predicted length. Thus the predicted coiled coil of myosin 10 forms a novel elongated structure in which the proximal region is a SAH domain and the distal region is a SAH domain ( or has an unknown extended structure) that dimerizes only at its end. Sequence comparisons show that similar structures may exist in the predicted coiled-coil domains of myosins 6 and 7a and MyoM and could function to increase the size of the working stroke.	Univ Leeds, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England; Univ Leeds, Astbury Ctr Struct Mol Biol, Leeds LS2 9JT, W Yorkshire, England; Univ Leeds, Sch Biochem & Microbiol, Leeds LS2 9JT, W Yorkshire, England; Boston Biomed Res Inst, Analyt Ultracentrifugat Res Lab, Boston, MA 02472 USA; NHLBI, Lab Mol Physiol, NIH, Bethesda, MD 20892 USA	University of Leeds; University of Leeds; University of Leeds; Boston Biomedical Research Institute; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Peckham, M (corresponding author), Univ Leeds, Sch Biomed Sci, Worsley Bldg, Leeds LS2 9JT, W Yorkshire, England.	m.peckham@leeds.ac.uk	Peckham, Michelle/J-4991-2015; Thirumurugan, Kavitha/B-3282-2010; Stafford, Walter/ABC-6553-2020	Peckham, Michelle/0000-0002-3754-2028; Thirumurugan, Kavitha/0000-0002-4673-4099; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL004231, ZIAHL004231] Funding Source: NIH RePORTER; Biotechnology and Biological Sciences Research Council [BB/C004906/1] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission)		Berg JS, 2000, J CELL SCI, V113, P3439; Berg JS, 2001, MOL BIOL CELL, V12, P780, DOI 10.1091/mbc.12.4.780; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; Burgess SA, 2004, J STRUCT BIOL, V147, P247, DOI 10.1016/j.jsb.2004.04.004; Burkhard P, 2002, J MOL BIOL, V318, P901, DOI 10.1016/S0022-2836(02)00114-6; ELLIOTT A, 1978, J MOL BIOL, V123, P505, DOI 10.1016/0022-2836(78)90204-8; Hodge T, 2000, J CELL SCI, V113, P3353; Houdusse A, 1996, STRUCTURE, V4, P1475, DOI 10.1016/S0969-2126(96)00154-2; Kammerer RA, 1998, P NATL ACAD SCI USA, V95, P13419, DOI 10.1073/pnas.95.23.13419; Kuhlman B, 1997, J MOL BIOL, V270, P640, DOI 10.1006/jmbi.1997.1146; Letunic I, 2004, NUCLEIC ACIDS RES, V32, pD142, DOI 10.1093/nar/gkh088; Lister I, 2004, EMBO J, V23, P1729, DOI 10.1038/sj.emboj.7600180; Litowski JR, 2001, J PEPT RES, V58, P477, DOI 10.1034/j.1399-3011.2001.10972.x; Lobley A, 2002, BIOINFORMATICS, V18, P211, DOI 10.1093/bioinformatics/18.1.211; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; LYU PCC, 1992, J MOL BIOL, V223, P343, DOI 10.1016/0022-2836(92)90735-3; MARQUSEE S, 1987, P NATL ACAD SCI USA, V84, P8898, DOI 10.1073/pnas.84.24.8898; Mermall V, 1998, SCIENCE, V279, P527, DOI 10.1126/science.279.5350.527; OFFER G, 1995, J MOL BIOL, V249, P967, DOI 10.1006/jmbi.1995.0352; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; Rock RS, 2005, MOL CELL, V17, P603, DOI 10.1016/j.molcel.2005.01.015; Rock RS, 2001, P NATL ACAD SCI USA, V98, P13655, DOI 10.1073/pnas.191512398; Sakamoto T, 2003, J BIOL CHEM, V278, P29201, DOI 10.1074/jbc.M303662200; Schwarzinger S, 2001, J AM CHEM SOC, V123, P2970, DOI 10.1021/ja003760i; Stafford WF, 2004, BIOPHYS CHEM, V108, P231, DOI 10.1016/j.bpc.2003.10.028; Turbedsky K, 2005, J MOL BIOL, V345, P351, DOI 10.1016/j.jmb.2004.10.049; Wang EZ, 1996, ARCH BIOCHEM BIOPHYS, V329, P156, DOI 10.1006/abbi.1996.0204; Wang F, 2000, J BIOL CHEM, V275, P4329, DOI 10.1074/jbc.275.6.4329; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; Wuthrich K., 1986, NMR PROTEINS NUCL AC, P162	30	124	126	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34702	34708		10.1074/jbc.M504887200	http://dx.doi.org/10.1074/jbc.M504887200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16030012	hybrid			2022-12-25	WOS:000232403900040
J	Nordahl, EA; Rydengard, V; Morgelin, M; Schmidtchen, A				Nordahl, EA; Rydengard, V; Morgelin, M; Schmidtchen, A			Domain 5 of high molecular weight kininogen is antibacterial	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIMICROBIAL PEPTIDE LL-37; VASCULAR-PERMEABILITY ENHANCEMENT; INHIBITS ANGIOGENESIS; NEUTROPHIL ELASTASE; CYSTEINE PROTEINASE; ENDOTHELIAL-CELLS; INNATE IMMUNITY; LIGHT-CHAIN; ACTIVATION; BINDING	Antimicrobial peptides are important effectors of the innate immune system. These peptides belong to a multifunctional group of molecules that apart from their antibacterial activities also interact with mammalian cells and glycosaminoglycans and control chemotaxis, apoptosis, and angiogenesis. Here we demonstrate a novel antimicrobial activity of the heparin-binding and cell-binding domain 5 of high molecular weight kininogen. Antimicrobial epitopes of domain 5 were characterized by analysis of overlapping peptides. A peptide, HKH20 (His(479) - His(498)), efficiently killed the Gram-negative bacteria Escherichia coli and Pseudomonas aeruginosa and the Gram-positive Enterococcus faecalis. Fluorescence microscopy and electron microscopy demonstrated that HKH20 binds to and induces breaks in bacterial membranes. Furthermore, no discernible hemolysis or membrane-permeabilizing effects on eukaryotic cells were noted. Proteolytic degradation of high molecular weight kininogen by neutrophil-derived proteases as well as the metalloproteinase elastase from P. aeruginosa yielded fragments comprising HKH20 epitopes, indicating that kininogen-derived antibacterial peptides are released during proteolysis.	Lund Univ, Biomed Ctr, Dept Clin Sci, Sect Dermatol & Venereol, SE-22184 Lund, Sweden; Lund Univ, Biomed Ctr, Dept Clin Sci, Sect Clin & Expt Infect Med, SE-22184 Lund, Sweden	Lund University; Lund University	Nordahl, EA (corresponding author), Biomed Ctr B14, Dept Clin Sci, Tornavagen 10, SE-22184 Lund, Sweden.	emma.nordahl@med.lu.se	Schmidtchen, Artur/F-9507-2015					Agerberth B, 2000, BLOOD, V96, P3086, DOI 10.1182/blood.V96.9.3086.h8003086_3086_3093; Andersson E, 2004, EUR J BIOCHEM, V271, P1219, DOI 10.1111/j.1432-1033.2004.04035.x; Blondelle SE, 2000, BIOPOLYMERS, V55, P74, DOI 10.1002/1097-0282(2000)55:1&lt;74::AID-BIP70&gt;3.0.CO;2-S; Brogden KA, 2005, NAT IMMUNOL, V6, P558, DOI 10.1038/ni1209; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Ciornei CD, 2003, ACTA ANAESTH SCAND, V47, P213, DOI 10.1034/j.1399-6576.2003.00045.x; Cole AM, 2001, J IMMUNOL, V167, P623, DOI 10.4049/jimmunol.167.2.623; Colman RW, 1997, J CLIN INVEST, V100, P1481, DOI 10.1172/JCI119669; Colman RW, 1997, BLOOD, V90, P3819, DOI 10.1182/blood.V90.10.3819; Colman RW, 2000, BLOOD, V95, P543, DOI 10.1182/blood.V95.2.543; de Kreij A, 2000, J BIOL CHEM, V275, P31115, DOI 10.1074/jbc.M003889200; DELACADENA RA, 1992, PROTEIN SCI, V1, P151; Elsbach P, 2003, J CLIN INVEST, V111, P1643, DOI 10.1172/JCI200318761; Ganz T, 2001, Semin Respir Infect, V16, P4; Goumon Y, 1998, J BIOL CHEM, V273, P29847, DOI 10.1074/jbc.273.45.29847; HABAZETTL J, 1992, NATURE, V359, P855, DOI 10.1038/359855a0; HASAN AAK, 1995, J BIOL CHEM, V270, P19256, DOI 10.1074/jbc.270.33.19256; Herwald H, 1996, J EXP MED, V184, P665, DOI 10.1084/jem.184.2.665; Herwald H, 1996, J BIOL CHEM, V271, P13040, DOI 10.1074/jbc.271.22.13040; Herwald H, 2001, EUR J BIOCHEM, V268, P396, DOI 10.1046/j.1432-1327.2001.01888.x; Imamura T, 2004, BIOL CHEM, V385, P989, DOI 10.1515/BC.2004.129; IMAMURA T, 1994, J CLIN INVEST, V94, P361, DOI 10.1172/JCI117330; Imamura T, 1996, LAB INVEST, V74, P861; Imamura T, 2002, BIOCHEM BIOPH RES CO, V294, P423, DOI 10.1016/S0006-291X(02)00490-4; Jacobson MP, 2004, PROTEINS, V55, P351, DOI 10.1002/prot.10613; Kaplan AP, 2002, J ALLERGY CLIN IMMUN, V109, P195, DOI 10.1067/mai.2002.121316; Koczulla R, 2003, J CLIN INVEST, V111, P1665, DOI 10.1172/JCI200317545; Kowalska K, 2002, LIFE SCI, V71, P747, DOI 10.1016/S0024-3205(02)01740-X; Kozik A, 1998, J BIOL CHEM, V273, P33224, DOI 10.1074/jbc.273.50.33224; LEHRER RI, 1991, J IMMUNOL METHODS, V137, P167, DOI 10.1016/0022-1759(91)90021-7; Li J, 2000, NAT MED, V6, P49, DOI 10.1038/71527; MOR A, 1994, BIOCHEMISTRY-US, V33, P6642, DOI 10.1021/bi00187a034; Murakami M, 2004, J IMMUNOL, V172, P3070, DOI 10.4049/jimmunol.172.5.3070; Nordahl EA, 2004, P NATL ACAD SCI USA, V101, P16879, DOI 10.1073/pnas.0406678101; OHKUBO I, 1984, BIOCHEMISTRY-US, V23, P5691, DOI 10.1021/bi00319a005; Okumura K, 2004, CANCER LETT, V212, P185, DOI 10.1016/j.canlet.2004.04.006; Oren Z, 1999, BIOCHEM J, V341, P501, DOI 10.1042/0264-6021:3410501; Park PW, 2001, NATURE, V411, P98, DOI 10.1038/35075100; Pixley RA, 2003, J THROMB HAEMOST, V1, P1791, DOI 10.1046/j.1538-7836.2003.00291.x; Rozalski A, 1997, MICROBIOL MOL BIOL R, V61, P65; SCHMAIER AH, 1983, J CLIN INVEST, V71, P1477, DOI 10.1172/JCI110901; Schmidtchen A, 2002, MOL MICROBIOL, V46, P157, DOI 10.1046/j.1365-2958.2002.03146.x; Shimizu M, 1998, ANTIMICROB AGENTS CH, V42, P2745, DOI 10.1128/AAC.42.10.2745; Sieprawska-Lupa M, 2004, ANTIMICROB AGENTS CH, V48, P4673, DOI 10.1128/AAC.48.12.4673-4679.2004; STEINER H, 1981, NATURE, V292, P246, DOI 10.1038/292246a0; TERRITO MC, 1989, J CLIN INVEST, V84, P2017, DOI 10.1172/JCI114394; Tossi A, 2000, BIOPOLYMERS, V55, P4; Vouldoukis I, 1996, FEBS LETT, V380, P237, DOI 10.1016/0014-5793(96)00050-6; WACHTFOGEL YT, 1994, J BIOL CHEM, V269, P19307; Yang D, 2000, J EXP MED, V192, P1069, DOI 10.1084/jem.192.7.1069; Yoo YC, 1997, BIOCHEM BIOPH RES CO, V237, P624, DOI 10.1006/bbrc.1997.7199; Zanetti M, 2004, J LEUKOCYTE BIOL, V75, P39, DOI 10.1189/jlb.0403147; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449; ZEYA HI, 1963, SCIENCE, V142, P1085, DOI 10.1126/science.142.3595.1085; Zhang JC, 2000, FASEB J, V14, P2589, DOI 10.1096/fj.99-1025com	55	88	99	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34832	34839		10.1074/jbc.M507249200	http://dx.doi.org/10.1074/jbc.M507249200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16091369	Green Submitted, hybrid			2022-12-25	WOS:000232403900055
J	Stieber, J; Stockl, G; Herrmann, S; Hassfurth, B; Hofmann, F				Stieber, J; Stockl, G; Herrmann, S; Hassfurth, B; Hofmann, F			Functional expression of the human HCN3 channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED CATION CHANNEL; PACEMAKER CHANNELS; MODULATION; KINETICS; LINKER; DOMAIN; HEART	Hyperpolarization-activated, cyclic nucleotide-gated cation (HCN) channels underlie the inward pacemaker current, termed I-f/I-h, in a variety of tissues. Many details are known for the HCN subtypes 1, 2, and 4. We now successfully cloned the cDNA for HCN3 from human brain and compared the electrophysiological properties of hHCN3 to the other three HCN subtypes. Overexpression of human HCN3 channels in HEK293 cells resulted in a functional channel protein. Similar to hHCN2 channels, hHCN3 channels are activated with a rather slow time constant of 1244 +/- 526 ms at - 100 mV, which is a greater time constant than that of HCN1 but a smaller one than that of HCN4 channels. The membrane potential for half-maximal activation V-1/2 was - 77 +/- 5.4 mV, and the reversal potential E-rev was - 20.5 +/- 4 mV, resulting in a permeability ratio P-Na/ P-K of 0.3. Like all other HCNs, hHCN3 was inhibited rapidly and reversibly by extracellular cesium and slowly and irreversibly by extracellular applied ZD7288. Surprisingly, the human HCN3 channel was not modulated by intracellular cAMP, a hallmark of the other known HCN channels. Sequence comparison revealed > 80% homology of the transmembrane segments, the pore region, and the cyclic nucleotide binding domain of hHCN3 with the other HCN channels. The missing response to cAMP distinguishes human HCN3 from both the well cAMP responding HCN subtypes 2 and 4 and the weak responding subtype 1.	Tech Univ Munich, Inst Pharmakol & Toxikol, D-80802 Munich, Germany	Technical University of Munich	Stieber, J (corresponding author), Tech Univ Munich, Inst Pharmakol & Toxikol, Biedersteiner Str 29, D-80802 Munich, Germany.	stieber@ipt.med.tu-muenchen.de						Berman HM, 2005, P NATL ACAD SCI USA, V102, P45, DOI 10.1073/pnas.0408579102; BOSMITH R, 1993, BRIT J PHARMACOL, V353, P64; Chiavegatto S, 2001, P NATL ACAD SCI USA, V98, P1277, DOI 10.1073/pnas.031487198; DIFRANCESCO D, 1986, J PHYSIOL-LONDON, V377, P61, DOI 10.1113/jphysiol.1986.sp016177; Ishii TM, 1999, J BIOL CHEM, V274, P12835, DOI 10.1074/jbc.274.18.12835; Ludwig A, 1998, NATURE, V393, P587, DOI 10.1038/31255; Ludwig A, 2003, EMBO J, V22, P216, DOI 10.1093/emboj/cdg032; Ludwig A, 1999, EMBO J, V18, P2323, DOI 10.1093/emboj/18.9.2323; Ludwig A, 1999, CELL PHYSIOL BIOCHEM, V9, P179, DOI 10.1159/000016315; Luthi A, 1998, NEURON, V21, P9, DOI 10.1016/S0896-6273(00)80509-7; Macri V, 2004, J BIOL CHEM, V279, P16832, DOI 10.1074/jbc.M400518200; Mistrik P, 2005, J BIOL CHEM, V280, P27056, DOI 10.1074/jbc.M502696200; Moosmang S, 2001, EUR J BIOCHEM, V268, P1646, DOI 10.1046/j.1432-1327.2001.02036.x; Moroni A, 2001, J BIOL CHEM, V276, P29233, DOI 10.1074/jbc.M100830200; Pape HC, 1996, ANNU REV PHYSIOL, V58, P299, DOI 10.1146/annurev.ph.58.030196.001503; Qu JH, 2002, PFLUG ARCH EUR J PHY, V444, P597, DOI 10.1007/s00424-002-0860-7; Robinson RB, 2003, ANNU REV PHYSIOL, V65, P453, DOI 10.1146/annurev.physiol.65.092101.142734; Santoro B, 1998, CELL, V93, P717, DOI 10.1016/S0092-8674(00)81434-8; Shi WM, 1999, CIRC RES, V85, pE1; Shin KS, 2001, J GEN PHYSIOL, V117, P91, DOI 10.1085/jgp.117.2.91; Stieber J, 2003, P NATL ACAD SCI USA, V100, P15235, DOI 10.1073/pnas.2434235100; Stieber J, 2003, J BIOL CHEM, V278, P33672, DOI 10.1074/jbc.M305318200; Tran N, 2002, J BIOL CHEM, V277, P43588, DOI 10.1074/jbc.M208477200; Tsang SY, 2004, J BIOL CHEM, V279, P43752, DOI 10.1074/jbc.M408747200; Wainger BJ, 2001, NATURE, V411, P805, DOI 10.1038/35081088; Wang J, 2002, NEURON, V36, P451, DOI 10.1016/S0896-6273(02)00968-6; Zagotta WN, 2003, NATURE, V425, P200, DOI 10.1038/nature01922; Zong XG, 2001, J BIOL CHEM, V276, P6313, DOI 10.1074/jbc.M010326200	28	109	114	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34635	34643		10.1074/jbc.M502508200	http://dx.doi.org/10.1074/jbc.M502508200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16043489	hybrid			2022-12-25	WOS:000232403900032
J	Zhang, XH; Shirahatti, NV; Mahadevan, D; Wright, SH				Zhang, XH; Shirahatti, NV; Mahadevan, D; Wright, SH			A conserved glutamate residue in transmembrane helix 10 influences substrate specificity of rabbit OCT2 (SLC22A2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORGANIC CATION TRANSPORTERS; FUNCTIONAL EXPRESSION; ANION TRANSPORTER; AMINO-ACIDS; 3-DIMENSIONAL STRUCTURE; GLUCOSE-TRANSPORTER; RENAL SECRETION; BINDING; CLONING; MECHANISM	OCT1 and OCT2 are involved in renal secretion of cationic drugs. Although they have similar selectivity for some substrates ( e. g. tetraethylammonium ( TEA)), they have distinct selectivities for others ( e. g. cimetidine). We postulated that "homolog-specific residues," i.e. the 24 residues that are conserved in OCT1 orthologs as one amino acid and in OCT2 as a different one, influence homolog-specific selectivity and examined the influence on substrate binding of three of these conserved residues that are found in the C-terminal half of the rabbit orthologs of OCT1/2. The N353L and R403I substitutions ( OCT2 to OCT1) did not significantly change the properties of OCT2. However, the E447Q replacement shifted substrate selectivity toward an OCT1-like phenotype. Substitution of glutamate with cationic amino acids (E447K and E447R) abolished transport activity, and the E447L mutant displayed markedly reduced transport of TEA and cimetidine while retaining transport of 1-methyl-4-phenylpyridinium. In a novel homology model of the three-dimensional structure of OCT2, Glu(447) was found in a putative docking region within a hydrophilic cleft of the protein. In addition, six residues identified in separate studies as exerting significant effects on OCT binding were also found within the putative cleft region. There was a significant correlation (r(2) = 0.82) between the IC50 values for inhibition of TEA transport by 14 different compounds and their calculated K-D values for binding to the model of rabbit OCT2. The results suggest that homology modeling offers an opportunity to direct future site-directed studies of OCT/substrate interaction.	Univ Arizona, Coll Med, Dept Physiol, Tucson, AZ 85724 USA; Univ Arizona, Dept Med, Tucson, AZ 85724 USA	University of Arizona; University of Arizona	Wright, SH (corresponding author), Univ Arizona, Coll Med, Dept Physiol, Tucson, AZ 85724 USA.	shwright@u.arziona.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058251, R56DK058251] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006694] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07249] Funding Source: Medline; NIDDK NIH HHS [DK58251] Funding Source: Medline; NIEHS NIH HHS [ES06694] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Arndt P, 2001, AM J PHYSIOL-RENAL, V281, pF454, DOI 10.1152/ajprenal.2001.281.3.F454; Bednarczyk D, 2000, PFLUG ARCH EUR J PHY, V440, P184, DOI 10.1007/s004240051038; DANTZLER WH, 1997, COMPREHENSIVE TOXICO, V7, P61; Eraly SA, 2004, PHYSIOL GENOMICS, V18, P12, DOI 10.1152/physiolgenomics.00014.2004; Feng B, 2002, BIOCHEMISTRY-US, V41, P8941, DOI 10.1021/bi0200615; Feng B, 2001, BIOCHEMISTRY-US, V40, P5511, DOI 10.1021/bi002841o; Gorboulev V, 1999, MOL PHARMACOL, V56, P1254, DOI 10.1124/mol.56.6.1254; Gorboulev V, 2005, MOL PHARMACOL, V67, P1612, DOI 10.1124/mol.104.008821; Gorboulev V, 1997, DNA CELL BIOL, V16, P871, DOI 10.1089/dna.1997.16.871; Green RM, 1999, HEPATOLOGY, V29, P1556, DOI 10.1002/hep.510290530; GRUNDEMANN D, 1994, NATURE, V372, P549, DOI 10.1038/372549a0; Hayer-Zillgen M, 2002, BRIT J PHARMACOL, V136, P829, DOI 10.1038/sj.bjp.0704785; Hirai T, 2002, NAT STRUCT BIOL, V9, P597, DOI 10.1038/nsb821; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; Jonker JW, 2004, J PHARMACOL EXP THER, V308, P2, DOI 10.1124/jpet.103.053298; Jonker JW, 2003, MOL CELL BIOL, V23, P7902, DOI 10.1128/MCB.23.21.7902-7908.2003; Kaewmokul S, 2003, AM J PHYSIOL-RENAL, V285, pF1149, DOI 10.1152/ajprenal.00112.2003; Karbach U, 2000, AM J PHYSIOL-RENAL, V279, pF679, DOI 10.1152/ajprenal.2000.279.4.F679; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leabman MK, 2002, PHARMACOGENETICS, V12, P395, DOI 10.1097/00008571-200207000-00007; Mooslehner KA, 1999, MAMM GENOME, V10, P218, DOI 10.1007/s003359900976; Motohashi H, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V134866; Mueckler M, 2004, J BIOL CHEM, V279, P46876, DOI 10.1074/jbc.M408632200; Okuda M, 1996, BIOCHEM BIOPH RES CO, V224, P500, DOI 10.1006/bbrc.1996.1056; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; Pontius J, 1996, J MOL BIOL, V264, P121, DOI 10.1006/jmbi.1996.0628; Popp C, 2005, MOL PHARMACOL, V67, P1600, DOI 10.1124/mol.104.008839; POWELL MJD, 1977, MATH PROGRAM, V12, P241, DOI 10.1007/BF01593790; PRITCHARD JB, 1993, PHYSIOL REV, V73, P765, DOI 10.1152/physrev.1993.73.4.765; Robbins MJ, 1999, J NEUROCHEM, V72, P2539, DOI 10.1046/j.1471-4159.1999.0722539.x; Roch-Ramel F., 1992, HDB PHYSL 8, P2189; Salas-Burgos A, 2004, BIOPHYS J, V87, P2990, DOI 10.1529/biophysj.104.047886; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Suhre WM, 2005, MOL PHARMACOL, V67, P1067, DOI 10.1124/mol.104.004713; Tanaka K, 2004, J BIOL CHEM, V279, P14961, DOI 10.1074/jbc.M400197200; Terashita S, 1998, BBA-BIOMEMBRANES, V1369, P1, DOI 10.1016/S0005-2736(97)00207-1; Towbin H, 1992, Biotechnology, V24, P145; Vardy E, 2004, PROTEIN SCI, V13, P1832, DOI 10.1110/ps.04657704; Volk C, 2003, MOL PHARMACOL, V64, P1037, DOI 10.1124/mol.64.5.1037; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wolff NA, 2001, J AM SOC NEPHROL, V12, P2012, DOI 10.1681/ASN.V12102012; Wright SH, 2004, AM J PHYSIOL-RENAL, V287, pF442, DOI 10.1152/ajprenal.00115.2004; Wright SH, 2004, PHYSIOL REV, V84, P987, DOI 10.1152/physrev.00040.2003; Xing L, 2004, J COMPUT AID MOL DES, V18, P333, DOI 10.1023/B:JCAM.0000047812.39758.ab; Zhang C, 2005, J MED CHEM, V48, P2325, DOI 10.1021/jm049314d; Zhang L, 1997, MOL PHARMACOL, V51, P913, DOI 10.1124/mol.51.6.913; Zhang XH, 2002, AM J PHYSIOL-RENAL, V283, pF124, DOI 10.1152/ajprenal.00367.2001	49	58	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34813	34822		10.1074/jbc.M506342200	http://dx.doi.org/10.1074/jbc.M506342200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16087669	hybrid			2022-12-25	WOS:000232403900053
J	Placido, A; Gagliardi, D; Gallerani, R; Grienenberger, JM; Marechal-Drouard, L				Placido, A; Gagliardi, D; Gallerani, R; Grienenberger, JM; Marechal-Drouard, L			Fate of a larch unedited tRNA precursor expressed in potato mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANT-MITOCHONDRIA; MESSENGER-RNA; RIBOSOMAL-RNA; POLYADENYLATION; GENES; DEGRADATION; PREREQUISITE; RECOGNITION; ELEMENTS; IMPORT	In higher plant mitochondria, post-transcriptional C to U conversion known as editing mostly affects mRNAs. However, three tRNAs were also shown to be edited. Among them, three editing sites were identified in larch mitochondrial tRNAHis. We have previously shown that only the edited version can undergo maturation in vitro. In this paper, we introduced via direct DNA uptake the edited or unedited version of larch mitochondrial trnH into isolated potato mitochondria and expressed them under the control of potato mitochondrial 18 S rRNA promoter. As expected, the edited form of larch mitochondrial tRNAHis precursor was processed in the isolated organelles. By contrast, no mature tRNAHis was detected when using the unedited version of trnH. However, precursor molecules could be characterized by reverse transcription-PCR. These data demonstrate that the potato mitochondrial editing machinery is not able to recognize these "foreign" editing sites and confirm that these unedited tRNA precursor molecules are not correctly processed in organello. As a consequence, the fate of these RNA precursor molecules is likely to be degradation. Indeed, we detected by PCR two 3'-end truncated precursor RNAs. Interestingly, both RNA species exhibit poly( A) tails, a hallmark of degradation in plant mitochondria. Taken together, these data suggest that, in plant mitochondria, a defective unedited RNA precursor that cannot be processed to give a mature stable tRNA, is degraded through a polyadenylation-dependent pathway.	CNRS, UPR 2357, Inst Biol Mol Plantes, F-67084 Strasbourg, France; Univ Bari, CNR, Dipartimento Biochim & Biol Mol, I-70126 Bari, Italy	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biomembrane e Bioenergetica (IBBE-CNR); Universita degli Studi di Bari Aldo Moro	Marechal-Drouard, L (corresponding author), CNRS, UPR 2357, Inst Biol Mol Plantes, 12 Rue Gen Zimmer, F-67084 Strasbourg, France.	laurence.drouard@ibmp-ulp.u-strabg.fr	Gagliardi, Dominique/AAS-1783-2021; Drouard, Laurence/D-2385-2010; Gagliardi, Dominique/P-2834-2016	Gagliardi, Dominique/0000-0002-5871-7544; Drouard, Laurence/0000-0001-6537-524X; Gagliardi, Dominique/0000-0002-5871-7544				BURKARD U, 1988, J BIOL CHEM, V263, P9578; Choury D, 2004, NUCLEIC ACIDS RES, V32, P6397, DOI 10.1093/nar/gkh969; COOLEY L, 1982, P NATL ACAD SCI-BIOL, V79, P6475, DOI 10.1073/pnas.79.21.6475; Farre JC, 2002, PLANT J, V29, P203, DOI 10.1046/j.1365-313x.2002.01207.x; Farre JC, 2001, MOL CELL BIOL, V21, P6731, DOI 10.1128/MCB.21.20.6731-6737.2001; Farre JC, 2001, NUCLEIC ACIDS RES, V29, P2484, DOI 10.1093/nar/29.12.2484; Fey J, 1999, FEBS LETT, V458, P124, DOI 10.1016/S0014-5793(99)01140-0; Fey J, 2000, RNA, V6, P470, DOI 10.1017/S1355838200992380; Gagliardi D, 2004, TRENDS GENET, V20, P260, DOI 10.1016/j.tig.2004.04.006; Gagliardi D, 1999, EMBO J, V18, P3757, DOI 10.1093/emboj/18.13.3757; Gagliardi D, 2004, ADV PHOTO RESPIRAT, V17, P55; Gagliardi D, 2001, J BIOL CHEM, V276, P43541, DOI 10.1074/jbc.M106601200; Giese A, 1996, MOL GEN GENET, V252, P429, DOI 10.1007/BF02173008; HIMENO H, 1989, NUCLEIC ACIDS RES, V17, P7855, DOI 10.1093/nar/17.19.7855; Koulintchenko M, 2003, EMBO J, V22, P1245, DOI 10.1093/emboj/cdg128; Kuai L, 2004, P NATL ACAD SCI USA, V101, P8581, DOI 10.1073/pnas.0402888101; Kuhn J, 2001, MOL CELL BIOL, V21, P731, DOI 10.1128/MCB.21.3.731-742.2001; Kuhn K, 2005, NUCLEIC ACIDS RES, V33, P337, DOI 10.1093/nar/gki179; Kunzmann A, 1998, P NATL ACAD SCI USA, V95, P108, DOI 10.1073/pnas.95.1.108; Li ZW, 2002, EMBO J, V21, P1132, DOI 10.1093/emboj/21.5.1132; Li ZW, 1998, P NATL ACAD SCI USA, V95, P12158, DOI 10.1073/pnas.95.21.12158; Lupold DS, 1999, PLANT CELL, V11, P1565, DOI 10.1105/tpc.11.8.1565; Marchfelder A, 1996, J BIOL CHEM, V271, P1898, DOI 10.1074/jbc.271.4.1898; Marchfelder A, 1996, MOL BIOL REP, V22, P151, DOI 10.1007/BF00988721; Marck C, 2002, RNA, V8, P1189, DOI 10.1017/S1355838202022021; MARECHAL L, 1986, PLANT MOL BIOL, V7, P245, DOI 10.1007/BF00752898; MarechalDrouard L, 1996, MOL CELL BIOL, V16, P3504; MarechalDrouard L, 1996, NUCLEIC ACIDS RES, V24, P3229, DOI 10.1093/nar/24.16.3229; Perrin R, 2004, NUCLEIC ACIDS RES, V32, P5174, DOI 10.1093/nar/gkh852; Perrin R, 2004, J BIOL CHEM, V279, P25440, DOI 10.1074/jbc.M401182200; SMALL I, 1992, EMBO J, V11, P1291, DOI 10.1002/j.1460-2075.1992.tb05172.x; Staudinger M, 2005, MOL GENET GENOMICS, V273, P130, DOI 10.1007/s00438-005-1117-x; SUTTON CA, 1995, MOL CELL BIOL, V15, P1377; Vanacova S, 2005, PLOS BIOL, V3, P986, DOI 10.1371/journal.pbio.0030189; WEBER F, 1990, NUCLEIC ACIDS RES, V18, P5027, DOI 10.1093/nar/18.17.5027	35	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33573	33579		10.1074/jbc.M505269200	http://dx.doi.org/10.1074/jbc.M505269200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16061472	hybrid			2022-12-25	WOS:000232058100058
J	Oltean, S; Banerjee, R				Oltean, S; Banerjee, R			A B-12-responsive internal ribosome entry site (IRES) element in human methionine synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERCUTANEOUS CORONARY INTERVENTION; HOMOCYSTEINE-LOWERING THERAPY; CONTROLS GENE-EXPRESSION; MESSENGER-RNA STRUCTURE; X-LINKED INHIBITOR; MEDIATED TRANSLATION; PLASMA HOMOCYSTEINE; MYXOCOCCUS-XANTHUS; HEPATITIS-C; FOLIC-ACID	Regulation of homocysteine, a sulfur- containing amino acid that is a risk factor for cardiovascular diseases, is poorly understood. Methionine synthase ( MS) is a key enzyme that clears intracellular homocysteine, and its activity is induced by its cofactor, vitamin B-12, at a translational level. In this study, we demonstrate that translation of MS, which has a long and highly structured 5'- untranslated region, is initiated from an internal ribosome entry site ( IRES), which is modulated by B-12. The minimal IRES element spans 71 bases immediately upstream of the initiation codon. Electrophoretic mobility shift analysis reveals the presence of a B-12- dependent protein- RNA complex and suggests the possibility that B-12- dependent increase of IRES efficiency is mediated via a protein. Modulation of the IRES- dependent translation of an essential gene by the cofactor of the encoded enzyme represents a novel example of a gene- nutrient interaction.	Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln	Banerjee, R (corresponding author), Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA.	rbanerjee1@unl.edu		Oltean, Sebastian/0000-0001-7890-8439	NIDDK NIH HHS [DK64959] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064959] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; Cervantes M, 2002, J BACTERIOL, V184, P2215, DOI 10.1128/JB.184.8.2215-2224.2002; Clarke R, 1998, ARCH NEUROL-CHICAGO, V55, P1449, DOI 10.1001/archneur.55.11.1449; Fernandez J, 2001, J BIOL CHEM, V276, P12285, DOI 10.1074/jbc.M009714200; FINKELSTEIN JD, 1990, J NUTR BIOCHEM, V1, P228, DOI 10.1016/0955-2863(90)90070-2; Friso S, 2002, J NUTR, V132, p2382S, DOI 10.1093/jn/132.8.2382S; HELLEN CUT, 1993, P NATL ACAD SCI USA, V90, P7642, DOI 10.1073/pnas.90.16.7642; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; HERSHEY J, 2000, INITIATION PROTEIN S, P33; Holcik M, 2003, MOL CELL BIOL, V23, P280, DOI 10.1128/MCB.23.1.280-288.2003; Holcik M, 2000, ONCOGENE, V19, P4174, DOI 10.1038/sj.onc.1203765; Holcik M, 2000, MOL CELL BIOL, V20, P4648, DOI 10.1128/MCB.20.13.4648-4657.2000; Holcik M, 1999, NAT CELL BIOL, V1, P190, DOI 10.1038/11109; Jan E, 2002, J MOL BIOL, V324, P889, DOI 10.1016/S0022-2836(02)01099-9; KOLHOUSE JF, 1977, P NATL ACAD SCI USA, V74, P921, DOI 10.1073/pnas.74.3.921; KOZICH V, 1995, HUM MOL GENET, V4, P623, DOI 10.1093/hmg/4.4.623; Lopez-Rubio JJ, 2002, J BIOL CHEM, V277, P7262, DOI 10.1074/jbc.M110351200; Lott WB, 2001, P NATL ACAD SCI USA, V98, P4916, DOI 10.1073/pnas.081072798; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MANGUM JH, 1969, BIOCHEMISTRY-US, V8, P3496, DOI 10.1021/bi00837a002; MELLMAN IS, 1977, P NATL ACAD SCI USA, V74, P916, DOI 10.1073/pnas.74.3.916; MILLS JL, 1995, LANCET, V345, P149, DOI 10.1016/S0140-6736(95)90165-5; Nahvi A, 2002, CHEM BIOL, V9, P1043, DOI 10.1016/S1074-5521(02)00224-7; Nahvi A, 2004, NUCLEIC ACIDS RES, V32, P143, DOI 10.1093/nar/gkh167; Nevins TA, 2003, J BIOL CHEM, V278, P3572, DOI 10.1074/jbc.M206781200; Oltean S, 2003, J BIOL CHEM, V278, P20778, DOI 10.1074/jbc.M300845200; Olteanu H, 2001, J BIOL CHEM, V276, P35558, DOI 10.1074/jbc.M103707200; Paoloni-Giacobino A, 2003, CLIN NUTR, V22, P429, DOI 10.1016/S0261-5614(03)00064-5; Refsum H, 1998, ANNU REV MED, V49, P31, DOI 10.1146/annurev.med.49.1.31; Schnyder G, 2003, AM J CARDIOL, V91, P1265, DOI 10.1016/S0002-9149(03)00281-9; Schnyder G, 2002, JAMA-J AM MED ASSOC, V288, P973, DOI 10.1001/jama.288.8.973; Schnyder G, 2001, NEW ENGL J MED, V345, P1593, DOI 10.1056/NEJMoa011364; Soukup GA, 1999, RNA, V5, P1308, DOI 10.1017/S1355838299990891; Stoneley M, 2004, ONCOGENE, V23, P3200, DOI 10.1038/sj.onc.1207551; Sudarsan N, 2003, RNA, V9, P644, DOI 10.1261/rna.5090103; Swanson DA, 2001, MOL CELL BIOL, V21, P1058, DOI 10.1128/MCB.21.4.1058-1065.2001; Takyar SS, 2002, J MOL BIOL, V319, P1, DOI 10.1016/S0022-2836(02)00300-5; Watkins D, 2002, AM J HUM GENET, V71, P143, DOI 10.1086/341354; Winkler W, 2002, NATURE, V419, P952, DOI 10.1038/nature01145; Winkler WC, 2003, CHEMBIOCHEM, V4, P1024, DOI 10.1002/cbic.200300685; Winkler WC, 2002, P NATL ACAD SCI USA, V99, P15908, DOI 10.1073/pnas.212628899; Winkler WC, 2003, NAT STRUCT BIOL, V10, P701, DOI 10.1038/nsb967; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	44	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32662	32668		10.1074/jbc.M501964200	http://dx.doi.org/10.1074/jbc.M501964200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16051610	hybrid			2022-12-25	WOS:000231920300015
J	Hinz, B; Rosch, S; Ramer, R; Tamm, ER; Brune, K				Hinz, B; Rosch, S; Ramer, R; Tamm, ER; Brune, K			Latanoprost induces matrix metalloproteinase-1 expression in human nonpigmented ciliary epithelial cells through a cyclooxygenase-2-dependent mechanism	FASEB JOURNAL			English	Article						COX; MMP; intraocular pressure	PROSTAGLANDIN F-2 ALPHA; UP-REGULATION; CYCLIC-AMP; E-2; RELEASE; IRIS; TRANSCRIPTION; LOCALIZATION; MUSCLES; TIMP-1	Prostaglandins ( PGs) have been implicated in the regulation of intraocular pressure ( IOP) by facilitating the remodeling of tissues involved in aqueous humor outflow. A contribution of cyclooxygenase- 2 ( COX- 2)- dependent PGs to this process was emphasized by a recent study showing an impaired COX- 2 expression in the nonpigmented ciliary epithelium ( NPE) of patients with primary open- angle glaucoma. With the use of human NPE cells ( ODM- 2), the present study therefore investigated the effect of the antiglaucomatous drug latanoprost ( PGF(2 alpha) analog) on the expression of COX- 2 and its association with the induction of matrix metalloproteinases ( MMPs). In NPE cells, latanoprost led to a concentration- and time- dependent increase of COX- 2 mRNA levels. Up- regulation of COX- 2 expression was accompanied by phosphorylations of p38 mitogen- activated protein kinase ( MAPK) and p42/ 44 MAPK and was abrogated by specific inhibitors of both pathways. PGE(2) formation by latanoprost was abolished by the selective COX- 2 inhibitor NS- 398 and by the F- prostaglandin receptor antagonist AL- 8810. Moreover, latanoprost led to a delayed up- regulation of MMP- 1 mRNA, whereas the expression of MMP- 2, MMP- 9, TIMP- 1, and TIMP- 2 remained unchanged. Latanoprost- induced MMP- 1 mRNA and protein expression was abolished by NS- 398 and by COX- 2- silencing small- interfering RNA. In line with this finding, MMP- 1 expression was also induced by PGE2, a major COX- 2 product. As a whole, our results show that MMP- 1 expression by latanoprost requires prior up- regulation of COX- 2. Induction of COX- 2- and subsequent MMP- 1 expression in the NPE may represent a potential mechanism underlying the IOP- lowering and antiglaucomatous action of latanoprost.	Univ Erlangen Nurnberg, Dept Expt & Clin Pharmacol & Toxicol, D-91054 Erlangen, Germany; Univ Regensburg, Inst Human Anat & Embryol, D-8400 Regensburg, Germany	University of Erlangen Nuremberg; University of Regensburg	Hinz, B (corresponding author), Univ Erlangen Nurnberg, Dept Expt & Clin Pharmacol & Toxicol, Fahrstr 17, D-91054 Erlangen, Germany.	hinz@pharmakologie.uni-erlangen.de	Tamm, Ernst/AAB-9772-2019	Tamm, Ernst/0000-0002-6679-8743				ABRAMOVITZ M, 1994, J BIOL CHEM, V269, P2632; Anthony TL, 2002, INVEST OPHTH VIS SCI, V43, P3705; Bazan NG, 2001, NAT MED, V7, P414, DOI 10.1038/86477; Bito LZ, 1997, SURV OPHTHALMOL, V41, pS1, DOI 10.1016/S0039-6257(97)80002-1; Callejas NA, 2001, HEPATOLOGY, V33, P860, DOI 10.1053/jhep.2001.23002; CLOHISY JC, 1994, ENDOCRINOLOGY, V135, P1447, DOI 10.1210/en.135.4.1447; DAVIS P, 1987, J RHEUMATOL, V14, P94; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Gaton DD, 1999, INVEST OPHTH VIS SCI, V40, P363; Hinz B, 2000, BIOCHEM BIOPH RES CO, V278, P790, DOI 10.1006/bbrc.2000.3885; Hinz B, 2000, BIOCHEM BIOPH RES CO, V272, P744, DOI 10.1006/bbrc.2000.2859; Hinz B, 2002, J PHARMACOL EXP THER, V300, P367, DOI 10.1124/jpet.300.2.367; Hinz B, 2004, MOL PHARMACOL, V66, P1643, DOI 10.1124/mol.104.002618; Husain S, 2001, EXP EYE RES, V72, P581, DOI 10.1006/exer.2001.0991; Jeffrey JJ, 1998, BIOL EXTRAC, P15; Kashiwagi K, 2003, BRIT J OPHTHALMOL, V87, P297, DOI 10.1136/bjo.87.3.297; Kashiwagi K, 2002, EXP EYE RES, V74, P41, DOI 10.1006/exer.2001.1104; Kim JW, 2001, INVEST OPHTH VIS SCI, V42, P1514; Lindsey JD, 1996, CURR EYE RES, V15, P869, DOI 10.3109/02713689609017628; Maihofner C, 2001, INVEST OPHTH VIS SCI, V42, P2616; Maldve RE, 2000, J LIPID RES, V41, P873; Minghetti L, 1997, EUR J NEUROSCI, V9, P934, DOI 10.1111/j.1460-9568.1997.tb01444.x; Ottino P, 2001, CURR EYE RES, V23, P77, DOI 10.1076/ceyr.23.2.77.5471; POYER JF, 1995, INVEST OPHTH VIS SCI, V36, P2461; Ramer R, 2003, MOL PHARMACOL, V64, P1189, DOI 10.1124/mol.64.5.1189; Ramer R, 2001, BIOCHEM BIOPH RES CO, V286, P1144, DOI 10.1006/bbrc.2001.5518; RITTIG M, 1990, CELL TISSUE RES, V259, P305, DOI 10.1007/BF00318453; Schlotzer-Schrehardt U, 2002, INVEST OPHTH VIS SCI, V43, P1475; STJERNSCHANTZ J, 1992, Drugs of the Future, V17, P691; Toris CB, 1997, SURV OPHTHALMOL, V41, pS69, DOI 10.1016/S0039-6257(97)80010-0; Tsai SJ, 1997, BIOL REPROD, V57, P1016, DOI 10.1095/biolreprod57.5.1016; VANALPHEN GWHM, 1977, DOC OPHTHALMOL, V42, P397, DOI 10.1007/BF02742255; Wang N, 2001, CURR EYE RES, V22, P198, DOI 10.1076/ceyr.22.3.198.5515; Weinreb R N, 1994, J Glaucoma, V3, P70; Weinreb RN, 2002, INVEST OPHTH VIS SCI, V43, P716; Weinreb RN, 2002, SURV OPHTHALMOL, V47, pS53, DOI 10.1016/S0039-6257(02)00306-5; Weinreb RN, 1997, INVEST OPHTH VIS SCI, V38, P2772; Wu YL, 2001, BIOL REPROD, V65, P1565, DOI 10.1095/biolreprod65.5.1565; Yousufzai SYK, 1996, EXP EYE RES, V63, P305, DOI 10.1006/exer.1996.0119; Zhang YH, 1998, J IMMUNOL, V161, P3071	41	43	45	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1929	+		10.1096/fj.04-3626fje	http://dx.doi.org/10.1096/fj.04-3626fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16076963				2022-12-25	WOS:000231843700025
J	Meaney, S				Meaney, S			Is C-26 hydroxylation an evolutionarily conserved steroid inactivation mechanism?	FASEB JOURNAL			English	Article						brassinolide; ecdysone; 27-hydroxycholesterol; 26-hydroxylase	BILE-ACID SYNTHESIS; DROSOPHILA-MELANOGASTER; SIGNAL-TRANSDUCTION; P450 ENZYMES; CHOLESTEROL; BIOSYNTHESIS; 7-KETOCHOLESTEROL; METABOLISM; ECDYSONE; 27-HYDROXYLASE	Sterols are essential components of virtually all higher eukaryotic organisms, though the exact identity of the dominating sterol varies between species, from the C- 27 of cholesterol in vertebrates to the C- 28 and C- 29 sterols of plants and invertebrates. In addition to their role as structural components of cell membranes these sterols are also converted into a variety of biologically active hormones. This conversion generally involves modifications of the basic structure of the sterol by dealkylation, hydroxylation and/ or isomerization. Recent studies have demonstrated that irreversible inactivation of both plant and insect hormones is achieved by a specific C- 26 hydroxylation. The concept of sterol deactivation by 26- hydroxylation appears to be an example of an evolutionarily conserved mechanism that has persisted despite the widely varying requirements for sterols in the species where it has been detected.	Karolinska Univ Hosp Huddinge, Karolinska Inst, Dept Lab Med, Div Clin Chem C174, S-14186 Huddinge, Sweden	Karolinska Institutet; Karolinska University Hospital	Meaney, S (corresponding author), Karolinska Univ Hosp Huddinge, Karolinska Inst, Dept Lab Med, Div Clin Chem C174, S-14186 Huddinge, Sweden.	steve.meaney@labmed.ki.se	Meaney, Steve/X-9289-2019	Meaney, Steve/0000-0002-7789-516X				Barenholz Y, 2002, PROG LIPID RES, V41, P1, DOI 10.1016/S0163-7827(01)00016-9; Benveniste P, 2004, ANNU REV PLANT BIOL, V55, P429, DOI 10.1146/annurev.arplant.55.031903.141616; BERGMANN W, 1958, CHOLESTEROL, P435; BJORKHEM I, 1992, J LIPID RES, V33, P455; CLAYTON RB, 1964, J LIPID RES, V5, P3; Clouse SD, 2003, J PLANT GROWTH REGUL, V22, P273, DOI 10.1007/s00344-003-0067-y; Diczfalusy U, 1996, SCAND J CLIN LAB INV, V56, P9; Fu X, 2001, J BIOL CHEM, V276, P38378, DOI 10.1074/jbc.M105805200; Gilbert LI, 2004, MOL CELL ENDOCRINOL, V215, P1, DOI 10.1016/j.mce.2003.11.003; GUSTAFSSON J, 1978, J BIOL CHEM, V253, P199; HASLEWOOD GA, 1967, J LIPID RES, V8, P535; Javitt NB, 2002, J LIPID RES, V43, P665; Kanazawa A, 2001, FISHERIES SCI, V67, P997, DOI 10.1046/j.1444-2906.2001.00354.x; KOOLMAN J, 1979, H-S Z PHYSIOL CHEM, V360, P1351; Kurzchalia TV, 2003, NAT CELL BIOL, V5, P684, DOI 10.1038/ncb0803-684; Lee EY, 2005, BIOCHEM BIOPH RES CO, V328, P929, DOI 10.1016/j.bbrc.2005.01.050; Lyons MA, 2001, LIPIDS, V36, P701, DOI 10.1007/s11745-001-0775-8; Lyons MA, 2001, BBA-MOL CELL BIOL L, V1530, P209, DOI 10.1016/S1388-1981(01)00083-X; Lyons MA, 1999, J LIPID RES, V40, P1846; Matyash V, 2004, PLOS BIOL, V2, P1561, DOI 10.1371/journal.pbio.0020280; Mussig C, 2001, TRENDS ENDOCRIN MET, V12, P398, DOI 10.1016/S1043-2760(01)00477-5; Nakamura M, 2005, J EXP BOT, V56, P833, DOI 10.1093/jxb/eri073; Neff MM, 1999, P NATL ACAD SCI USA, V96, P15316, DOI 10.1073/pnas.96.26.15316; Niwa R, 2004, J BIOL CHEM, V279, P35942, DOI 10.1074/jbc.M404514200; Petryk A, 2003, P NATL ACAD SCI USA, V100, P13773, DOI 10.1073/pnas.2336088100; Pharis RP, 2001, PHYTOCHEMISTRY, V58, P1043, DOI 10.1016/S0031-9422(01)00381-8; POPJAK G, 1977, J AM CHEM SOC, V99, P931, DOI 10.1021/ja00445a041; Rosen H, 1998, J BIOL CHEM, V273, P14805, DOI 10.1074/jbc.273.24.14805; Russell DW, 2003, ANNU REV BIOCHEM, V72, P137, DOI 10.1146/annurev.biochem.72.121801.161712; Seto H, 1999, TETRAHEDRON, V55, P8341, DOI 10.1016/S0040-4020(99)00427-5; Soriano IR, 2004, J CHEM ECOL, V30, P1885, DOI 10.1023/B:JOEC.0000045584.56515.11; Thummel CS, 2002, GENE DEV, V16, P3113, DOI 10.1101/gad.1042102; Turk EM, 2003, PLANT PHYSIOL, V133, P1643, DOI 10.1104/pp.103.030882; Une M, 1997, STEROIDS, V62, P458, DOI 10.1016/S0039-128X(97)00012-3; Walters MR, 2004, CELL MOL LIFE SCI, V61, P2309, DOI 10.1007/s00018-004-4065-4; Wang ZY, 2004, TRENDS PLANT SCI, V9, P91, DOI 10.1016/j.tplants.2003.12.009; Warren JT, 2004, INSECT BIOCHEM MOLEC, V34, P991, DOI 10.1016/j.ibmb.2004.06.009; Warren JT, 2002, P NATL ACAD SCI USA, V99, P11043, DOI 10.1073/pnas.162375799; You L, 2004, CHEM-BIOL INTERACT, V147, P233, DOI 10.1016/j.cbi.2004.01.006	39	6	7	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1220	1224		10.1096/fj.04-3304hyp	http://dx.doi.org/10.1096/fj.04-3304hyp			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16051688				2022-12-25	WOS:000231843700028
J	Bouleau, S; Grimal, H; Rincheval, V; Godefroy, N; Mignotte, B; Vayssiere, JL; Renaud, F				Bouleau, S; Grimal, H; Rincheval, V; Godefroy, N; Mignotte, B; Vayssiere, JL; Renaud, F			FGF1 inhibits p53-dependent apoptosis and cell cycle arrest via an intracrine pathway	ONCOGENE			English	Article						FGF1; p53; apoptosis	FIBROBLAST-GROWTH-FACTOR; P53-MEDIATED TRANSCRIPTIONAL REPRESSION; WILD-TYPE P53; MESSENGER-RNA; EXPRESSION; SURVIVAL; GENE; BCL-2; FIBROBLAST-GROWTH-FACTOR-1; PROTEIN	We analysed the relationships between p53-induced apoptosis and the acidic fibroblast growth factor 1 (FGF1) survival pathway. We found that p53 activation in rat embryonic fibroblasts induced the downregulation of FGF1 expression. These data suggest that the fgf1 gene is a repressed target of p53. Unlike extracellular FGF1, which has no effect on p53-dependent pathways, intracellular FGF1 inhibits both p53-dependent apoptosis and cell growth arrest via an intracrine pathway. FGF1 increases MDM2 expression at both mRNA and protein levels. This increase is associated with an acceleration of p53 degradation, which may partly account for the ability of endogenous FGF1 to counteract p53 pathways. In the presence of FGF1, p53 was unable to transactivate bax, but no modi. cation of p21 gene transactivation was observed. As Bax is an essential component of the p53-dependent apoptosis pathway, this suggests that intracellular FGF1 inhibits p53 pathways not only by decreasing the stability of p53, but also by modifying some of its transactivation properties. In conclusion, we showed that p53 and FGF1 pathways may interact in the cell to determine cell fate. Deregulation of one of these pathways modifies the balance between cell proliferation and cell death and may lead to tumor progression.	Univ Versailles, Lab Genet & Biol Cellulaire, CNRS, FRE 2445, F-78035 Versailles, France; Ecole Prat Hautes Etud, Lab Genet Mol & Physiol, F-78035 Versailles, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Renaud, F (corresponding author), Univ Versailles, Lab Genet & Biol Cellulaire, CNRS, FRE 2445, 45 Ave Etats Unis, F-78035 Versailles, France.	frenaud@genetique.uvsq.fr	Godefroy, Nelly/AAG-2052-2020; Mignotte, Bernard/A-3499-2009	Mignotte, Bernard/0000-0002-8512-8518				Ashe PC, 2003, PROG NEURO-PSYCHOPH, V27, P199, DOI 10.1016/S0278-5846(03)00016-2; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Chiu IM, 2001, PROG NUCLEIC ACID RE, V70, P155, DOI 10.1016/S0079-6603(01)70016-5; CRUMLEY GR, 1989, GENE, V85, P489, DOI 10.1016/0378-1119(89)90443-5; D'Souza S, 2001, J BIOL CHEM, V276, P298, DOI 10.1074/jbc.M007155200; Desire L, 1998, EXP CELL RES, V241, P210, DOI 10.1006/excr.1998.4048; Galy B, 2001, ONCOGENE, V20, P4613, DOI 10.1038/sj.onc.1204630; Galy B, 2001, ONCOGENE, V20, P1669, DOI 10.1038/sj.onc.1204271; Godefroy N, 2004, NUCLEIC ACIDS RES, V32, P4480, DOI 10.1093/nar/gkh773; Guenal I, 1997, ONCOGENE, V15, P347, DOI 10.1038/sj.onc.1201182; Hashimoto M, 2002, J BIOL CHEM, V277, P32985, DOI 10.1074/jbc.M202803200; Haupt Ygal, 1997, Leukemia (Basingstoke), V11, P337; Heron-Milhavet L, 2002, J BIOL CHEM, V277, P15600, DOI 10.1074/jbc.M111142200; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; JAYE M, 1988, EMBO J, V7, P963, DOI 10.1002/j.1460-2075.1988.tb02902.x; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Kaufmann SH, 2001, TRENDS CELL BIOL, V11, P526, DOI 10.1016/S0962-8924(01)02173-0; Lin YZ, 1996, J BIOL CHEM, V271, P5305, DOI 10.1074/jbc.271.10.5305; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Murray SA, 2003, ONCOGENE, V22, P1703, DOI 10.1038/sj.onc.1206327; Ong SH, 2001, P NATL ACAD SCI USA, V98, P6074, DOI 10.1073/pnas.111114298; Ornitz DM, 2001, GENOME BIOL, V2; PETIT CA, 1983, VIROLOGY, V127, P74, DOI 10.1016/0042-6822(83)90372-0; PHILIPPE JM, 1992, BIOCHEM BIOPH RES CO, V188, P843, DOI 10.1016/0006-291X(92)91133-B; Philippe JM, 1996, DNA CELL BIOL, V15, P703, DOI 10.1089/dna.1996.15.703; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Prudovsky I, 2002, J CELL BIOL, V158, P201, DOI 10.1083/jcb.200203084; Raguenez G, 1999, BIOCHEM BIOPH RES CO, V258, P745, DOI 10.1006/bbrc.1999.0613; RENAUD F, 1992, BIOCHEM BIOPH RES CO, V184, P945, DOI 10.1016/0006-291X(92)90682-B; Renaud F, 1996, BIOCHEM BIOPH RES CO, V219, P679, DOI 10.1006/bbrc.1996.0294; Renaud F, 1996, J BIOL CHEM, V271, P2801, DOI 10.1074/jbc.271.5.2801; RENAUD F, 1994, J CELL PHYSIOL, V158, P435, DOI 10.1002/jcp.1041580307; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Rincheval V, 2002, BIOCHEM BIOPH RES CO, V298, P282, DOI 10.1016/S0006-291X(02)02454-3; Rincheval V, 1999, FEBS LETT, V460, P203, DOI 10.1016/S0014-5793(99)01345-9; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Shaulian E, 1997, ONCOGENE, V15, P2717, DOI 10.1038/sj.onc.1201453; Singh B, 2002, GENE DEV, V16, P984, DOI 10.1101/gad.973602; TAMM I, 1991, P NATL ACAD SCI USA, V88, P3372, DOI 10.1073/pnas.88.8.3372; UEBA T, 1994, P NATL ACAD SCI USA, V91, P9009, DOI 10.1073/pnas.91.19.9009; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WALICKE P, 1986, P NATL ACAD SCI USA, V83, P3012, DOI 10.1073/pnas.83.9.3012; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; Wu YL, 2001, ONCOGENE, V20, P240, DOI 10.1038/sj.onc.1204067	48	36	37	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2005	24	53					7839	7849		10.1038/sj.onc.1208932	http://dx.doi.org/10.1038/sj.onc.1208932			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	986PU	16091747				2022-12-25	WOS:000233463000003
J	Cusson-Hermance, N; Khurana, S; Lee, TH; Fitzgerald, KA; Kelliher, MA				Cusson-Hermance, N; Khurana, S; Lee, TH; Fitzgerald, KA; Kelliher, MA			Rip1 mediates the Trif-dependent Toll-like receptor 3- and 4-induced NF-kappa B activation but does not contribute to interferon regulatory factor 3 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN-CONTAINING ADAPTER; CUTTING EDGE; TRANSCRIPTION FACTORS; TNF RECEPTOR-1; MAP KINASE; A20; PATHWAY; RECRUITMENT; IKK; UBIQUITINATION	Rip1 is required for I kappa B kinase activation in response to tumor necrosis factor alpha (TNF-alpha) and has been implicated in the Toll-like receptor 3 (TLR3) response to double-stranded RNA. Cytokine production is impaired when rip1-/- cells are treated with TNF-alpha, poly(I-C), or lipopolysaccharide, implicating Rip1 in the Trif-dependent TLR3 and TLR4 pathways. To examine the role of Rip1 in the Trif-dependent TLR4 pathway, we generated rip1(-/-) MyD88(-/-) cells. Lipopolysaccharide failed to stimulate NF-kappa B activation in rip1-/- MyD88-/- cells, revealing that Rip1 is also required for the Trif-dependent TLR4-induced NF-kappa B pathway. In addition to activating NF-kappa B, TLR3/4 pathways also stimulate interferon regulatory factor 3 activation. However, we find that Rip1 expression stimulates NF-kappa B but not interferon regulatory factor 3 activity. In the TNF-alpha pathway, Rip1 interacts with the E3 ubiquitin ligase Traf2 and is modified by polyubiquitin chains. Upon TLR3 activation, Rip1 is also modified by polyubiquitin chains and is recruited to TLR3 along with Traf6 and the ubiquitin-activated kinase Tak1. These studies suggest that Rip1 uses a similar, ubiquitin-dependent mechanism to activate I kappa B kinase-beta in response to TNF-alpha and TLR3 ligands.	Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Kelliher, MA (corresponding author), Univ Massachusetts, Sch Med, Dept Canc Biol, Lazare Res Bldg,364 Plantat St, Worcester, MA 01605 USA.	michelle.kelliher@umassmed.edu	Fitzgerald, Katherine/ABE-6317-2020	Fitzgerald, Kate/0000-0003-3175-609X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061298] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM061298, GM061298] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		Balachandran S, 2004, NATURE, V432, P401, DOI 10.1038/nature03124; Boone DL, 2004, NAT IMMUNOL, V5, P1052, DOI 10.1038/ni1110; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Gohda J, 2004, J IMMUNOL, V173, P2913, DOI 10.4049/jimmunol.173.5.2913; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Janssens S, 2003, MOL CELL, V11, P293, DOI 10.1016/S1097-2765(03)00053-4; Jiang ZF, 2003, J BIOL CHEM, V278, P16713, DOI 10.1074/jbc.M300562200; Kanayama A, 2004, MOL CELL, V15, P535, DOI 10.1016/j.molcel.2004.08.008; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Lee TH, 2004, J BIOL CHEM, V279, P33185, DOI 10.1074/jbc.M404206200; Lee TH, 2003, MOL CELL BIOL, V23, P8377, DOI 10.1128/MCB.23.22.8377-8385.2003; Legler DF, 2003, IMMUNITY, V18, P655, DOI 10.1016/S1074-7613(03)00092-X; Li K, 2005, J BIOL CHEM, V280, P16739, DOI 10.1074/jbc.M414139200; Meylan E, 2004, NAT IMMUNOL, V5, P503, DOI 10.1038/ni1061; Saitoh T, 2005, J IMMUNOL, V174, P1507, DOI 10.4049/jimmunol.174.3.1507; Sato S, 2003, J IMMUNOL, V171, P4304, DOI 10.4049/jimmunol.171.8.4304; Silverman N, 2000, GENE DEV, V14, P2461, DOI 10.1101/gad.817800; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Wang YY, 2004, FEBS LETT, V576, P86, DOI 10.1016/j.febslet.2004.08.071; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	30	245	254	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36560	36566		10.1074/jbc.M506831200	http://dx.doi.org/10.1074/jbc.M506831200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16115877	hybrid			2022-12-25	WOS:000232901800005
J	Xia, M; Hou, MJ; Zhu, HL; Ma, J; Tang, ZH; Wang, Q; Li, Y; Chi, DS; Yu, XP; Zhao, T; Han, PH; Xia, XD; Ling, WH				Xia, M; Hou, MJ; Zhu, HL; Ma, J; Tang, ZH; Wang, Q; Li, Y; Chi, DS; Yu, XP; Zhao, T; Han, PH; Xia, XD; Ling, WH			Anthocyanins induce cholesterol efflux from mouse peritoneal macrophages - The role of the peroxisome proliferator-activated receptor gamma-liver X receptor alpha-ABCA1 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; PPAR-GAMMA; CELLULAR CHOLESTEROL; ABCA1; CELLS; ATHEROSCLEROSIS; EXPRESSION; DIFFERENTIATION; METABOLISM; MECHANISMS	It is widely accepted that stimulation of reverse cholesterol transport, the efflux of excess cholesterol from peripheral tissues and transferring it to the liver for biliary excretion, is becoming an important component in reducing excess cholesterol deposition in atherosclerotic plaques. The ATP-binding cassette transporter has been identified as a key regulator of macrophage cholesterol efflux and apoAI-mediated reverse cholesterol transport. In vivo studies have documented anthocyanins, a large group of naturally phenolic compounds rich in plants, possess substantial capacities in improving plasma cholesterol levels. In this study, we investigated the potential role of anthocyanins in modulating cholesterol efflux from mouse peritoneal macrophages and macrophage-derived foam cells and the possible molecular mechanism linking ABCA1 to cholesterol efflux. Incubation of the mouse peritoneal macrophages and macrophage-derived foam cells with cyanidin-3-O-beta-glucoside and peonidin-3-O-beta-glucoside led to dose-dependent ( 1 - 100 mu M) induction in cholesterol efflux and ABCA1 mRNA expression, and this effect could be blocked by the ABCA1 inhibitor 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid, disodium salt, and a general inhibitor of gene transcription actinomycin D. Treatment of the macrophages with anthocyanins also activated peroxisome proliferator-activated receptor gamma, liver X receptor alpha mRNA expression, and their mediated gene expression. Addition of geranylgeranyl pyrophosphate ammonium salt or GW9662 markedly inhibited the anthocyanin-induced increase of ABCA1 gene expression and apoAI-mediated cholesterol efflux. These data demonstrated that anthocyanin induces cholesterol efflux from mouse peritoneal macrophages and macrophage-derived foam cells and that stimulation of cholesterol efflux by anthocyanin is mediated, at least in part, by peroxisome proliferator-activated receptor gamma-liver X receptor alpha-ABCA1 signaling pathway activation.	Sun Yat Sen Univ, Sch Publ Hlth, Dept Nutr, Guangzhou 510080, Guangdong, Peoples R China	Sun Yat Sen University	Ling, WH (corresponding author), Sun Yat Sen Univ, Sch Publ Hlth, Dept Nutr, No Campus,Zhongshan Rd 2, Guangzhou 510080, Guangdong, Peoples R China.	whling@gzsums.edu.cn						Acquaviva R, 2003, CELL BIOL TOXICOL, V19, P243, DOI 10.1023/B:CBTO.0000003974.27349.4e; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BERLINER JA, 1995, CIRCULATION, V91, P2488, DOI 10.1161/01.CIR.91.9.2488; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; Chinetti G, 2003, CIRC RES, V92, P212, DOI 10.1161/01.RES.0000053386.46813.E9; Chinetti G, 2001, NAT MED, V7, P53, DOI 10.1038/83348; Costet P, 2000, J BIOL CHEM, V275, P28240; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; FALK E, 1992, CIRCULATION, V86, P30; Favari E, 2004, ARTERIOSCL THROM VAS, V24, P2345, DOI 10.1161/01.ATV.0000148706.15947.8a; Field FJ, 2004, J LIPID RES, V45, P905, DOI 10.1194/jlr.M300473-JLR200; HARBORNE JB, 1988, FLAVONOIDS ADV RES 1, P1, DOI DOI 10.1007/978-1-4899-2913-6_1; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Kritharides L, 1998, ARTERIOSCL THROM VAS, V18, P1589, DOI 10.1161/01.ATV.18.10.1589; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Le Goff W, 2004, ARTERIOSCL THROM VAS, V24, P2155, DOI 10.1161/01.ATV.0000144811.94581.52; Le Lay S, 2003, J LIPID RES, V44, P1499, DOI 10.1194/jlr.M200466-JLR200; Liuzzo G, 2001, Rays, V26, P221; Lougheed M, 1999, ARTERIOSCL THROM VAS, V19, P1881, DOI 10.1161/01.ATV.19.8.1881; LOWRY OH, 1951, J BIOL CHEM, V193, P275; Marx N, 1999, ARTERIOSCL THROM VAS, V19, P546, DOI 10.1161/01.ATV.19.3.546; Marx N, 1998, AM J PATHOL, V153, P17, DOI 10.1016/S0002-9440(10)65540-X; Moller P, 2004, MUTAT RES-FUND MOL M, V551, P119, DOI 10.1016/j.mrfmmm.2004.02.020; Oram JF, 2000, CURR OPIN LIPIDOL, V11, P253, DOI 10.1097/00041433-200006000-00005; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; OTTNAD E, 1995, P NATL ACAD SCI USA, V92, P1391, DOI 10.1073/pnas.92.5.1391; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Ruan XZ, 2003, J AM SOC NEPHROL, V14, P593, DOI 10.1097/01.ASN.0000050414.52908.DA; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Strohm C, 2002, CARDIOVASC RES, V55, P602, DOI 10.1016/S0008-6363(02)00453-4; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; Wang YT, 2002, J BIOL CHEM, V277, P5692, DOI 10.1074/jbc.M109977200; Williams CA, 2004, NAT PROD REP, V21, P539, DOI 10.1039/b311404j; Witting SR, 2003, J BIOL CHEM, V278, P40121, DOI 10.1074/jbc.M305193200; Xia M, 2003, J NUTR, V133, P744, DOI 10.1093/jn/133.3.744; Zaman AG, 2000, ATHEROSCLEROSIS, V149, P251, DOI 10.1016/S0021-9150(99)00479-7; Zhang YY, 2002, MOL GENET METAB, V77, P150, DOI 10.1016/S1096-7192(02)00111-7	40	117	135	0	34	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36792	36801		10.1074/jbc.M505047200	http://dx.doi.org/10.1074/jbc.M505047200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16107338	hybrid			2022-12-25	WOS:000232901800033
J	Liu, Y; Soto, I; Tong, Q; Chin, A; Buhring, HJ; Wu, T; Zen, K; Parkos, CA				Liu, Y; Soto, I; Tong, Q; Chin, A; Buhring, HJ; Wu, T; Zen, K; Parkos, CA			SIRP beta 1 is expressed as a disulfide-linked homodimer in leukocytes and positively regulates neutrophil transepithelial migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATURAL-KILLER-CELLS; INTEGRIN-ASSOCIATED PROTEIN; T-CELL; MYELOID CELLS; SIRP-ALPHA; NEGATIVE REGULATION; ADHESION MOLECULE; ACTIVATION MOTIF; DENDRITIC CELLS; CUTTING EDGE	Signal regulatory proteins (SIRPs) comprise a family of cell surface signaling receptors differentially expressed in leukocytes and the central nervous system. Although the extracellular domains of SIRPs are highly similar, classical motifs in the cytoplasmic or transmembrane domains distinguish them as either activating (beta) or inhibitory (alpha) isoforms. We reported previously that human neutrophils ( polymorphonuclear leukocytes (PMN)) express multiple SIRP isoforms and that SIRP alpha binding to its ligand CD47 regulates PMN transmigration. Here we further characterized the expression of PMN SIRPs, and we reported that the major SIRP alpha and SIRP beta isoforms expressed in PMN include Bit/PTPNS-1 and SIRP beta 1, respectively. Furthermore, although SIRP alpha (Bit/PTPNS-1) is expressed as a monomer, we showed that SIRP beta 1 is expressed on the cell surface as a disulfide-linked homodimer with bond formation mediated by Cys-320 in the membrane-proximal Ig loop. Subcellular fractionation studies revealed a major pool of SIRP beta 1 within the plasma membrane fractions of PMN. In contrast, the majority of SIRP alpha(Bit/PTPNS-1) is present in fractions enriched in secondary granules and is translocated to the cell surface after chemoattractant (formylmethionylleucylphenylalanine) stimulation. Functional studies revealed that antibody-mediated ligation of SIRP beta 1 enhanced formylmethionylleucylphenylalanine-driven PMN transepithelial migration. Co-immunoprecipitation experiments to identify associated adaptor proteins revealed a 10-12-kDa protein associated with SIRP beta 1 that was tyrosine-phosphorylated after PMN stimulation and is not DAP10/12 or Fc receptor gamma chain. These results provide new insights into the structure and function of SIRPs in leukocytes and their potential role(s) in fine-tuning responses to inflammatory stimuli.	Georgia State Univ, Dept Biol, Atlanta, GA 30302 USA; Emory Univ, Dept Pathol & Lab Med, Epithelial Pathobiol Res Unit, Atlanta, GA 30322 USA; Univ Tubingen, Dept Internal Med 2, Div Hematol Immunol & Oncol, Tubingen, Germany	University System of Georgia; Georgia State University; Emory University; Eberhard Karls University of Tubingen	Liu, Y (corresponding author), Georgia State Univ, Dept Biol, POB 4010, Atlanta, GA 30303 USA.	yliu@gsu.edu; cparkos@emory.edu	Parkos, Charles a/B-3896-2009	Mauldin, Ileana/0000-0002-9318-8342	NIDDK NIH HHS [DK61379, DK62894, DK72564, DK064399] Funding Source: Medline; PHS HHS [DL72124] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK062894, R01DK072564, R01DK061379, R24DK064399] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams S, 1998, J IMMUNOL, V161, P1853; Brooke G, 2004, J IMMUNOL, V173, P2562, DOI 10.4049/jimmunol.173.4.2562; Chen TT, 2004, CANCER RES, V64, P117, DOI 10.1158/0008-5472.CAN-3455-2; Chiesa S, 2005, MOL IMMUNOL, V42, P477, DOI 10.1016/j.molimm.2004.07.030; de Vries HE, 2002, J IMMUNOL, V168, P5832, DOI 10.4049/jimmunol.168.11.5832; Dietrich J, 2000, J IMMUNOL, V164, P9, DOI 10.4049/jimmunol.164.1.9; Florian S, 2005, J LEUKOCYTE BIOL, V77, P984, DOI 10.1189/jlb.0604349; Han X, 2000, J BIOL CHEM, V275, P37984, DOI 10.1074/jbc.M002334200; Hope JC, 2001, J LEUKOCYTE BIOL, V69, P271; Jiang PH, 1999, J BIOL CHEM, V274, P559, DOI 10.1074/jbc.274.2.559; Kapoor GS, 2004, CANCER RES, V64, P6444, DOI 10.1158/0008-5472.CAN-04-0256; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; LANIER LL, 1991, J IMMUNOL, V146, P1571; Lanier LL, 2003, CURR OPIN IMMUNOL, V15, P308, DOI 10.1016/S0952-7915(03)00039-6; Lanier LL, 2001, NAT IMMUNOL, V2, P23, DOI 10.1038/83130; Lanier LL, 1998, IMMUNITY, V8, P693, DOI 10.1016/S1074-7613(00)80574-9; Lanier LL, 1998, NATURE, V391, P703, DOI 10.1038/35642; Latour S, 2001, J IMMUNOL, V167, P2547, DOI 10.4049/jimmunol.167.5.2547; Litman GW, 2001, IMMUNOL REV, V181, P250, DOI 10.1034/j.1600-065X.2001.1810121.x; Liu Y, 2004, J IMMUNOL, V172, P2578, DOI 10.4049/jimmunol.172.4.2578; Liu Y, 2002, J BIOL CHEM, V277, P10028, DOI 10.1074/jbc.M109720200; Liu Y, 2000, J CELL SCI, V113, P2363; Liu Y, 2001, J BIOL CHEM, V276, P40156, DOI 10.1074/jbc.M104138200; Mi ZP, 2000, J COMP NEUROL, V416, P335; Nakajima H, 1999, J IMMUNOL, V162, P5; Ohnishi H, 1996, J BIOL CHEM, V271, P25569, DOI 10.1074/jbc.271.41.25569; Olcese L, 1997, J IMMUNOL, V158, P5083; Oldenborg PA, 2000, SCIENCE, V288, P2051, DOI 10.1126/science.288.5473.2051; Parkos CA, 1996, J CELL BIOL, V132, P437, DOI 10.1083/jcb.132.3.437; Piccio L, 2005, BLOOD, V105, P2421, DOI 10.1182/blood-2004-07-2823; REINHOLD MI, 1995, J CELL SCI, V108, P3419; Saginario C, 1998, MOL CELL BIOL, V18, P6213, DOI 10.1128/MCB.18.11.6213; Seiffert M, 1999, BLOOD, V94, P3633, DOI 10.1182/blood.V94.11.3633.423k01_3633_3643; Seiffert M, 2001, BLOOD, V97, P2741, DOI 10.1182/blood.V97.9.2741; Taniguchi H, 2004, BIOCHEM BIOPH RES CO, V319, P178, DOI 10.1016/j.bbrc.2004.04.173; Tomasello E, 2000, EUR J IMMUNOL, V30, P2147, DOI 10.1002/1521-4141(2000)30:8<2147::AID-IMMU2147>3.0.CO;2-1; Veillette A, 1998, J BIOL CHEM, V273, P22719, DOI 10.1074/jbc.273.35.22719; Vernon-Wilson EF, 2000, EUR J IMMUNOL, V30, P2130; Voehringer D, 2004, J BIOL CHEM, V279, P54117, DOI 10.1074/jbc.M406997200; Wu J, 2000, J EXP MED, V192, P1059, DOI 10.1084/jem.192.7.1059; Yan HX, 2004, HEPATOLOGY, V40, P618, DOI 10.1002/hep.20360	41	38	39	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36132	36140		10.1074/jbc.M506419200	http://dx.doi.org/10.1074/jbc.M506419200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16081415	hybrid			2022-12-25	WOS:000232726900044
J	de Mestre, AM; Rao, S; Hornby, JR; Soe-Htwe, T; Khachigian, LM; Hulett, MD				de Mestre, AM; Rao, S; Hornby, JR; Soe-Htwe, T; Khachigian, LM; Hulett, MD			Early growth response gene 1 (EGR1) regulates heparanase gene transcription in tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROSTATE-CANCER; A-CHAIN PROMOTER; MAMMALIAN HEPARANASE; ENDOTHELIAL-CELLS; BREAST-CANCER; IN-VITRO; SULFATE PROTEOGLYCANS; EXPRESSION; METASTASIS; ACTIVATION	Heparanase is an endoglycosidase that degrades heparan sulfate chains of heparan sulfate proteoglycans, a key component of extracellular matrix and basement membranes. Studies using heparanase inhibitors and gene silencing have provided evidence to support an important role for heparanase in tumor metastasis and angiogenesis. The expression of heparanase is normally very tightly controlled, however, it is commonly deregulated in tumor cells, which express elevated heparanase activity that correlates with high levels of heparanase mRNA. We recently identified the transcription factor early growth response gene 1, EGR1, as a key regulator of inducible heparanase transcription in T cells. In this study using chromatin immunoprecipitation, we demonstrate for the first time that EGR1 binds to the heparanase gene promoter in vivo. The important question of the role of EGR1 in regulating heparanase transcription in tumor cells was then assessed. Studies were carried out in four epithelial tumor lines of different tissue origin. Functional dissection of the heparanase promoter identified a 280-bp region that was critical for transcription of the heparanase gene. Transactivation studies using an EGR1 expression vector co-transfected with a reporter construct containing the 280-bp region showed EGR1-activated heparanase promoter activity in a dose-dependent manner in prostate or breast adenocarcinoma and colon carcinoma cell lines. In contrast, overexpression of EGR1 resulted in a dose-dependent repression of promoter activity in melanoma cells. Using site-directed mutagenesis the 280-bp region was found to contain two functional EGR1 sites and electrophoretic mobility shift assays showed binding of EGR1 to both of these sites upon activation of tumor cells. Furthermore, the heparanase promoter region containing the EGR1 sites was also inducible in tumor cells and induction corresponded to HPSE expression levels. These studies show that EGR1 regulates heparanase transcription in tumor cells and importantly, can have a repressive or activating role depending on the tumor type.	Australian Natl Univ, John Curtin Sch Med Res, Div Immunol & Genet, Canc & Vasc Biol Grp, Acton, ACT 2601, Australia; Univ New S Wales, Ctr Vasc Res, Sydney, NSW 2052, Australia	Australian National University; John Curtin School of Medical Research; University of New South Wales Sydney	Hulett, MD (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Div Immunol & Genet, Canc & Vasc Biol Grp, Acton, ACT 2601, Australia.	mark.hulett@anu.edu.au	Hulett, Mark D/C-4160-2012; Rao, Sudha/AAW-5192-2020; Khachigian, Levon/AAZ-7458-2020; de Mestre, Amanda/H-7455-2018	Rao, Sudha/0000-0001-9547-947X; Khachigian, Levon/0000-0003-3446-0323; Hulett, Mark/0000-0003-2072-5968; de Mestre, Amanda/0000-0002-9422-2370				Abboud-Jarrous G, 2005, J BIOL CHEM, V280, P13568, DOI 10.1074/jbc.M413370200; Abdulkadir SA, 2001, NAT MED, V7, P101, DOI 10.1038/83231; Aucoin R, 2004, J CELL BIOCHEM, V93, P215, DOI 10.1002/jcb.20231; Baron V, 2003, ANN NY ACAD SCI, V1002, P197, DOI 10.1196/annals.1281.024; Bernard D, 2001, J INVEST DERMATOL, V117, P1266, DOI 10.1046/j.1523-1747.2001.15401.x; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Castellanos MD, 2002, EUR J IMMUNOL, V32, P3108; Chen GP, 2004, BIOCHEMISTRY-US, V43, P4971, DOI 10.1021/bi0356552; Chen XX, 2005, MOL CELL BIOL, V25, P3209, DOI 10.1128/MCB.25.8.3209-3219.2005; Day FL, 1999, J BIOL CHEM, V274, P23726, DOI 10.1074/jbc.274.34.23726; de Mestre AM, 2003, J BIOL CHEM, V278, P50377, DOI 10.1074/jbc.M310154200; Dempsey LA, 2000, GLYCOBIOLOGY, V10, P467, DOI 10.1093/glycob/10.5.467; Dong J, 2000, GENE, V253, P171, DOI 10.1016/S0378-1119(00)00251-1; Edovitsky E, 2004, JNCI-J NATL CANCER I, V96, P1219, DOI 10.1093/jnci/djh230; Eid MA, 1998, CANCER RES, V58, P2461; Elkin M, 2003, CANCER RES, V63, P8821; Fahmy RG, 2003, NAT MED, V9, P1026, DOI 10.1038/nm905; Fairbanks MB, 1999, J BIOL CHEM, V274, P29587, DOI 10.1074/jbc.274.42.29587; Friedmann Y, 2000, AM J PATHOL, V157, P1167, DOI 10.1016/S0002-9440(10)64632-9; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GODDER K, 1991, J CELL PHYSIOL, V148, P274, DOI 10.1002/jcp.1041480213; Gohji K, 2001, J UROLOGY, V166, P1286, DOI 10.1016/S0022-5347(05)65754-0; Goshen R, 1996, MOL HUM REPROD, V2, P679, DOI 10.1093/molehr/2.9.679; HAN J, 2004, CARDIOVASC PATHOL, V13, P85; Huang RP, 1997, INT J CANCER, V72, P102, DOI 10.1002/(SICI)1097-0215(19970703)72:1<102::AID-IJC15>3.0.CO;2-L; Hulett MD, 2000, BIOCHEMISTRY-US, V39, P15659, DOI 10.1021/bi002080p; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; Ihrcke NS, 1998, J CELL PHYSIOL, V175, P255, DOI 10.1002/(SICI)1097-4652(199806)175:3<255::AID-JCP3>3.0.CO;2-N; Jiang P, 2002, J BIOL CHEM, V277, P8989, DOI 10.1074/jbc.M105682200; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Khachigian LM, 1998, J MOL MED-JMM, V76, P613, DOI 10.1007/s001090050258; Khachigian LM, 1997, ARTERIOSCL THROM VAS, V17, P2280, DOI 10.1161/01.ATV.17.10.2280; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Kobayashi D, 2002, ANTICANCER RES, V22, P3963; Koliopanos A, 2001, CANCER RES, V61, P4655; Levkovitz Y, 2002, J NEUROSCI, V22, P3845, DOI 10.1523/JNEUROSCI.22-10-03845.2002; Levy-Adam F, 2003, BIOCHEM BIOPH RES CO, V308, P885, DOI 10.1016/S0006-291X(03)01478-5; Litt MD, 2001, EMBO J, V20, P2224, DOI 10.1093/emboj/20.9.2224; Lowe HC, 2001, CIRC RES, V89, P670, DOI 10.1161/hh2001.097867; Lu WC, 2003, ONCOGENE, V22, P919, DOI 10.1038/sj.onc.1206201; Maxhimer JB, 2002, SURGERY, V132, P326, DOI 10.1067/msy.2002.125719; McKenzie E, 2003, BIOCHEM J, V373, P423, DOI 10.1042/BJ20030318; Mitchell A, 2004, NUCLEIC ACIDS RES, V32, P3065, DOI 10.1093/nar/gkh626; Murry BP, 2005, INT J ONCOL, V26, P345; Nadav L, 2002, J CELL SCI, V115, P2179; Ogishima T, 2005, CLIN CANCER RES, V11, P1028; Parish CR, 1999, CANCER RES, V59, P3433; Parish CR, 2001, BIOCHIM BIOPHYS ACTA, V1471, P99, DOI DOI 10.1016/S0304-419X(01)00017-8; Pratt MAC, 2003, MOL CELL BIOL, V23, P6887, DOI 10.1128/MCB.23.19.6887-6900.2003; RATNER S, 1992, INVAS METAST, V12, P82; Robinson L, 1997, P NATL ACAD SCI USA, V94, P7170, DOI 10.1073/pnas.94.14.7170; Sasaki M, 2001, MEDIAT INFLAMM, V10, P259, DOI 10.1080/09629350120093731; Sato T, 2004, J SURG ONCOL, V87, P174, DOI 10.1002/jso.20097; Shteper PJ, 2003, ONCOGENE, V22, P7737, DOI 10.1038/sj.onc.1207056; Simizu S, 2003, CANCER LETT, V193, P83, DOI 10.1016/S0304-3835(02)00719-X; Toyoshima M, 1999, J BIOL CHEM, V274, P24153, DOI 10.1074/jbc.274.34.24153; Uno F, 2001, CANCER RES, V61, P7855; Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI200113662; VLODAVSKY I, 1994, INVAS METAST, V14, P290; Vlodavsky I, 2000, ISRAEL MED ASSOC J, V2, P37; VLODAVSKY I, 1992, INVAS METAST, V12, P112; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; Walch ET, 1999, CLIN EXP METASTAS, V17, P307, DOI 10.1023/A:1006652605568; Yan SF, 1999, J BIOL CHEM, V274, P15030, DOI 10.1074/jbc.274.21.15030; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; Zetser A, 2004, J CELL SCI, V117, P2249, DOI 10.1242/jcs.01068; Zhang R, 2003, APPL PHYS LETT, V83, P204, DOI 10.1063/1.1592624	67	70	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35136	35147		10.1074/jbc.M503414200	http://dx.doi.org/10.1074/jbc.M503414200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16093249	Green Published, hybrid			2022-12-25	WOS:000232561200010
J	Liu, YN; Motyka, SA; Englund, PT				Liu, YN; Motyka, SA; Englund, PT			Effects of RNA interference of Trypanosoma brucei structure-specific endonuclease-I on kinetoplast DNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRITHIDIA-FASCICULATA; CELL-CYCLE; TOPOISOMERASE-II; POLYMERASE-BETA; 2 SITES; MINICIRCLES; LOCALIZATION; NETWORKS; ORGANIZATION; SEGREGATION	Kinetoplast DNA, the mitochondrial DNA of trypanosomatid protozoa, is a network containing several thousand topologically interlocked DNA minicircles. Kinetoplast DNA synthesis involves release of minicircles from the network, replication of the free minicircles, and reattachment of the progeny back onto the network. One enzyme involved in this process is structure- specific endonuclease- I. This enzyme, originally purified from Crithidia fasciculata, has been proposed to remove minicircle replication primers ( Engel, M. L., and Ray, D. S. ( 1998) Nucleic Acids Res. 26, 4773 - 4778). We have studied the structure- specific endonuclease-I homolog from Trypanosoma brucei, showing it to be localized in the antipodal sites flanking the kinetoplast DNA disk, as previously shown in C. fasciculata. RNA interference of structure- specific endonuclease- I caused persistence of a single ribonucleotide at the 5 ' end of both the leading strand and at least the first Okazaki fragment in network minicircles, demonstrating that this enzyme in fact functions in primer removal. Probably because of the persistence of primers, RNA interference also impeded the reattachment of newly replicated free minicircles to the network and caused a delay in kinetoplast DNA segregation. These effects ultimately led to shrinkage and loss of the kinetoplast DNA network and cessation of growth of the cell.	Johns Hopkins Med Sch, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine	Englund, PT (corresponding author), Johns Hopkins Med Sch, Dept Biol Chem, Baltimore, MD 21205 USA.	penglund@jhmi.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI058613] Funding Source: NIH RePORTER; NIAID NIH HHS [AI058613] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abu-Elneel K, 2001, J CELL BIOL, V153, P725, DOI 10.1083/jcb.153.4.725; BIRKENMEYER L, 1987, J BIOL CHEM, V262, P2384; COSGROVE WB, 1970, J PROTOZOOL, V17, P172, DOI 10.1111/j.1550-7408.1970.tb02350.x; DOWNEY N, 2002, EUKARYOT CELL, V4, P765; Drew ME, 2001, J CELL BIOL, V153, P735, DOI 10.1083/jcb.153.4.735; Engel ML, 2001, NUCLEIC ACIDS RES, V29, P725, DOI 10.1093/nar/29.3.725; Engel ML, 1998, NUCLEIC ACIDS RES, V26, P4733, DOI 10.1093/nar/26.20.4733; Engel ML, 1999, P NATL ACAD SCI USA, V96, P8455, DOI 10.1073/pnas.96.15.8455; ENGLUND PT, 1979, J BIOL CHEM, V254, P4895; FERGUSON M, 1992, CELL, V70, P621, DOI 10.1016/0092-8674(92)90431-B; FERGUSON ML, 1994, J CELL BIOL, V126, P631, DOI 10.1083/jcb.126.3.631; Guilbride DL, 1998, J CELL SCI, V111, P675; Hesslein DGT, 1997, MOL BIOCHEM PARASIT, V86, P121, DOI 10.1016/S0166-6851(97)90014-1; Hines JC, 2001, MOL BIOCHEM PARASIT, V115, P63, DOI 10.1016/S0166-6851(01)00272-9; HOEIJMAKERS JHJ, 1980, PLASMID, V4, P97, DOI 10.1016/0147-619X(80)90086-4; Hong M, 2003, PROTIST, V154, P265, DOI 10.1078/143446103322166554; Johnson CE, 1998, J CELL BIOL, V143, P911, DOI 10.1083/jcb.143.4.911; Kao HI, 2003, CRIT REV BIOCHEM MOL, V38, P433, DOI 10.1080/10409230390259382; Klingbeil MM, 2002, MOL CELL, V10, P175, DOI 10.1016/S1097-2765(02)00571-3; Klingbeil MM, 2001, PROTIST, V152, P255, DOI 10.1078/1434-4610-00066; Kobil JH, 2000, BIOCHEM BIOPH RES CO, V270, P336, DOI 10.1006/bbrc.2000.2397; Li CJ, 1997, J BIOL CHEM, V272, P20787, DOI 10.1074/jbc.272.33.20787; Liu BY, 2005, TRENDS PARASITOL, V21, P363, DOI 10.1016/j.pt.2005.06.008; Liu Y, 2004, ANNU REV BIOCHEM, V73, P589, DOI 10.1146/annurev.biochem.73.012803.092453; Lukes J, 2002, EUKARYOT CELL, V1, P495, DOI 10.1128/EC.1.4.495-502.2002; Madison-Antenucci S, 2002, CELL, V108, P435, DOI 10.1016/S0092-8674(02)00653-0; Marchetti MA, 2000, J CELL SCI, V113, P899; MELENDY T, 1988, CELL, V55, P1083, DOI 10.1016/0092-8674(88)90252-8; NTAMBI JM, 1986, J BIOL CHEM, V261, P1890; Ogbadoyi EO, 2003, MOL BIOL CELL, V14, P1769, DOI 10.1091/mbc.E02-08-0525; PEREZMORGA DL, 1993, CELL, V74, P703, DOI 10.1016/0092-8674(93)90517-T; ROBINSON DR, 1991, NATURE, V352, P731, DOI 10.1038/352731a0; ROBINSON DR, 1994, J CELL BIOL, V126, P641, DOI 10.1083/jcb.126.3.641; RYAN KA, 1989, J BIOL CHEM, V264, P823; RYAN KA, 1989, MOL CELL BIOL, V9, P3212, DOI 10.1128/MCB.9.8.3212; Shen SY, 2001, MOL BIOCHEM PARASIT, V113, P171, DOI 10.1016/S0166-6851(00)00383-2; SHERWIN T, 1987, J CELL BIOL, V104, P439, DOI 10.1083/jcb.104.3.439; Shlomai J, 2004, CURR MOL MED, V4, P623, DOI 10.2174/1566524043360096; SIMPSON AM, 1976, J PROTOZOOL, V23, P583, DOI 10.1111/j.1550-7408.1976.tb03846.x; Simpson L, 2003, RNA, V9, P265, DOI 10.1261/rna.2178403; Sinha KM, 2004, P NATL ACAD SCI USA, V101, P4361, DOI 10.1073/pnas.0305705101; TORRI AF, 1995, J BIOL CHEM, V270, P3495, DOI 10.1074/jbc.270.8.3495; Wang ZF, 2002, EMBO J, V21, P4998, DOI 10.1093/emboj/cdf482; Wang ZF, 2001, EMBO J, V20, P4674, DOI 10.1093/emboj/20.17.4674; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; WOODWARD R, 1990, J CELL SCI, V95, P49; Yang MY, 2002, CELL, V111, P495, DOI 10.1016/S0092-8674(02)01075-9	47	19	20	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35513	35520		10.1074/jbc.M507296200	http://dx.doi.org/10.1074/jbc.M507296200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16096280	hybrid			2022-12-25	WOS:000232561200052
J	Vetrano, AM; Heck, DE; Mariano, TM; Mishin, V; Laskin, DL; Laskin, JD				Vetrano, AM; Heck, DE; Mariano, TM; Mishin, V; Laskin, DL; Laskin, JD			Characterization of the oxidase activity in mammalian catalase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; OXIDATIVE STRESS; HORSERADISH-PEROXIDASE; FLUORIDE INHIBITION; COMPOUND-I; MECHANISM; NADPH; KINETICS; PURIFICATION; BENZIDINE	Catalase is a highly conserved heme- containing antioxidant enzyme known for its ability to degrade hydrogen peroxide into water and oxygen. In low concentrations of hydrogen peroxide, the enzyme also exhibits peroxidase activity. We report that mammalian catalase also possesses oxidase activity. This activity, which is detected in purified catalases, cell lysates, and intact cells, requires oxygen and utilizes electron donor substrates in the absence of hydrogen peroxide or any added cofactors. Using purified bovine catalase and 10- acetyl- 3,7- dihydroxyphenoxazine as the substrate, the oxidase activity was found to be temperature- dependent and displays a pH optimum of 7 - 9. The K-m for the substrate is 2.4 x 10(-4) M, and V-max is 4.7 x 10(-5) M/ s. Endogenous substrates, including the tryptophan precursor indole, the neurotransmitter precursor beta- phenylethylamine, and a variety of peroxidase and laccase substrates, as well as carcinogenic benzidines, were found to be oxidized by catalase or to inhibit this activity. Several dietary plant micronutrients that inhibit carcinogenesis, including indole- 3- carbinol, indole- 3- carboxaldehyde, ferulic acid, vanillic acid, and epigallocatechin-3- gallate, were effective inhibitors of the activity of catalase oxidase. Difference spectroscopy revealed that catalase oxidase/ substrate interactions involve the heme- iron; the resulting spectra show time- dependent decreases in the ferric heme of the enzyme with corresponding increases in the formation of an oxyferryl intermediate, potentially reflecting a compound II- like intermediate. These data suggest a mechanism of oxidase activity involving the formation of an oxygen- bound, substrate- facilitated reductive intermediate. Our results describe a novel function for catalase potentially important in metabolism of endogenous substrates and in the action of carcinogens and chemopreventative agents.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Environm & Occupat Med, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Pharmacol & Toxicol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick	Laskin, JD (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Environm & Occupat Med, 170 Frelinghuysen Rd, Piscataway, NJ 08854 USA.	jlaskin@eohsi.rutgers.edu		Laskin, Debra/0000-0003-1832-7311	NATIONAL CANCER INSTITUTE [R01CA100994] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004738, P01ES006897, R01ES003647] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034310] Funding Source: NIH RePORTER; NCI NIH HHS [CA100994] Funding Source: Medline; NIEHS NIH HHS [ES06897, ES03647, ES004738, ES05022] Funding Source: Medline; NIGMS NIH HHS [GM034310] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASSON CT, 1985, MOL CELL BIOCHEM, V67, P151, DOI 10.1007/BF02370174; Brignall M S, 2001, Altern Med Rev, V6, P580; Campos R, 2001, J BIOTECHNOL, V89, P131, DOI 10.1016/S0168-1656(01)00303-0; CHANCE B, 1950, BIOCHEM J, V46, P387, DOI 10.1042/bj0460387; CHANCE B, 1952, ARCH BIOCHEM BIOPHYS, V37, P301, DOI 10.1016/0003-9861(52)90194-X; CHANCE B, 1971, BIOCHEM J, V122, P225, DOI 10.1042/bj1220225; Chelikani P, 2004, CELL MOL LIFE SCI, V61, P192, DOI 10.1007/s00018-003-3206-5; DEISSEROTH A, 1970, PHYSIOL REV, V50, P319, DOI 10.1152/physrev.1970.50.3.319; Gazaryan IG, 1996, BIOCHEM J, V313, P841, DOI 10.1042/bj3130841; Guengerich FP, 2004, DRUG METAB REV, V36, P159, DOI 10.1081/DMR-120033996; HALEY TJ, 1975, CLIN TOXICOL, V8, P13, DOI 10.3109/15563657508988044; Heck DE, 2003, J BIOL CHEM, V278, P22432, DOI 10.1074/jbc.C300048200; Hunt CR, 1998, CANCER RES, V58, P3986; Ivancich A, 1997, BIOCHEMISTRY-US, V36, P9356, DOI 10.1021/bi970886s; Johannes C, 2000, J BIOTECHNOL, V78, P193, DOI 10.1016/S0168-1656(00)00208-X; JONES P, 1977, J THEOR BIOL, V69, P457, DOI 10.1016/0022-5193(77)90152-7; JOSEPHY PD, 1985, ENVIRON HEALTH PERSP, V64, P171, DOI 10.2307/3430007; KEHRER JP, 1993, CRIT REV TOXICOL, V23, P21, DOI 10.3109/10408449309104073; KEILIN D, 1955, BIOCHEM J, V60, P310, DOI 10.1042/bj0600310; KEILIN D, 1951, BIOCHEM J, V49, P88, DOI 10.1042/bj0490088; Kirkman HN, 1999, J BIOL CHEM, V274, P13908, DOI 10.1074/jbc.274.20.13908; KIRKMAN HN, 1987, J BIOL CHEM, V262, P660; KREMER ML, 1970, BIOCHIM BIOPHYS ACTA, V198, P199, DOI 10.1016/0005-2744(70)90052-5; Loewen PC, 2004, BIOCHEMISTRY-US, V43, P3089, DOI 10.1021/bi035663i; MIYAHARA T, 1982, J BIOCHEM-TOKYO, V91, P525, DOI 10.1093/oxfordjournals.jbchem.a133725; Nagai M, 2003, MICROBIOL-SGM, V149, P2455, DOI 10.1099/mic.0.26414-0; Nicholls P, 2001, ADV INORG CHEM, V51, P51; Ozdemir H, 2001, PREP BIOCHEM BIOTECH, V31, P125, DOI 10.1081/PB-100103378; PerezGilabert M, 1997, FREE RADICAL BIO MED, V23, P548, DOI 10.1016/S0891-5849(97)00118-4; Phan TN, 2001, ORAL MICROBIOL IMMUN, V16, P28, DOI 10.1034/j.1399-302x.2001.160105.x; Putnam CD, 2000, J MOL BIOL, V296, P295, DOI 10.1006/jmbi.1999.3458; Rhee SG, 2003, J AM SOC NEPHROL, V14, pS211, DOI 10.1097/01.ASN.0000077404.45564.7E; Rota C, 1999, FREE RADICAL BIO MED, V27, P873, DOI 10.1016/S0891-5849(99)00137-9; SILKAITIS RP, 1976, BRAIN RES, V114, P105, DOI 10.1016/0006-8993(76)91010-6; Singh R, 2004, J BIOL CHEM, V279, P43098, DOI 10.1074/jbc.M406374200; SPITZ DR, 1993, J CELL PHYSIOL, V156, P72, DOI 10.1002/jcp.1041560111; TESTA B, 1995, METABOLISM DRUGS OTH, P363; TESTA B, 1995, METABOLISM DRUGS OTH, P357; THIBODEAU EA, 1990, ORAL MICROBIOL IMMUN, V5, P328, DOI 10.1111/j.1399-302X.1990.tb00435.x; Veitch NC, 2004, PHYTOCHEMISTRY, V65, P249, DOI 10.1016/j.phytochem.2003.10.022; Wargovich MJ, 2000, CARCINOGENESIS, V21, P1149, DOI 10.1093/carcin/21.6.1149; Xu F, 1996, BIOCHEMISTRY-US, V35, P7608, DOI 10.1021/bi952971a; Yang CS, 2001, ANNU REV NUTR, V21, P381, DOI 10.1146/annurev.nutr.21.1.381; Zamocky M, 1999, PROG BIOPHYS MOL BIO, V72, P19, DOI 10.1016/S0079-6107(98)00058-3; Zhou MJ, 1997, ANAL BIOCHEM, V253, P162, DOI 10.1006/abio.1997.2391	45	108	110	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35372	35381		10.1074/jbc.M503991200	http://dx.doi.org/10.1074/jbc.M503991200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16079130	hybrid			2022-12-25	WOS:000232561200036
J	Lay, D; Grosshans, BL; Heid, H; Gorgas, K; Just, WW				Lay, D; Grosshans, BL; Heid, H; Gorgas, K; Just, WW			Binding and functions of ADP-ribosylation factor on mammalian and yeast peroxisomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DILYSINE RETRIEVAL MOTIFS; ENDOPLASMIC-RETICULUM; PHOSPHOLIPASE-D; COATED VESICLES; SACCHAROMYCES-CEREVISIAE/; NUCLEOTIDE-EXCHANGE; GOLGI MEMBRANES; RAT-LIVER; ARF; COATOMER	We have analyzed in vitro the binding characteristics of members of the ADP-ribosylation factor (ARF) family of proteins to a highly purified rat liver peroxisome preparation void of Golgi membranes and studied in vivo a role these proteins play in the proliferation of yeast peroxisomes. Although both ARF1 and ARF6 were found on peroxisomes, coatomer recruitment only depended on ARF1-GTP. Recruitment of ARF1 and coatomer to peroxisomes was significantly affected both by pretreating the animals with peroxisome proliferators and by ATP and a cytosolic fraction designated the intermediate pool fraction depleted of ARF and coatomer. In the presence of ATP, the concentrations of ARF1 and coatomer on peroxisomes were reduced, whereas intermediate pool fraction led to a concentration-dependent decrease in ARF and increase in coatomer. Brefeldin A, a fungal toxin that is known to reduce ARF1 binding to Golgi membranes, did not affect ARF1 binding to peroxisomes. In Saccharomyces cerevisiae, both ScARF1 and ScARF3, the yeast orthologs of mammalian ARF1 and ARF6, were implicated in the control of peroxisome proliferation. ScARF1 regulated this process in a positive manner, and ScARF3 regulated it in a negative manner.	Heidelberg Univ, Zentrum Biochem, D-69120 Heidelberg, Germany; Yale Univ, Dept Cell Biol, New Haven, CT 06520 USA; Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany; Heidelberg Univ, Inst Anat & Zellbiol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg; Yale University; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg	Just, WW (corresponding author), Heidelberg Univ, Zentrum Biochem, Neuenheimer Feld 328, D-69120 Heidelberg, Germany.	wilhelm.just@urz.uni-heidelberg.de						AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; Anton M, 2000, CELL BIOCHEM BIOPHYS, V32, P27, DOI 10.1385/CBB:32:1-3:27; Asp L, 2000, J BIOL CHEM, V275, P26285, DOI 10.1074/jbc.M003520200; Brugger B, 2000, J CELL BIOL, V151, P507, DOI 10.1083/jcb.151.3.507; Donaldson JG, 2000, P NATL ACAD SCI USA, V97, P3792, DOI 10.1073/pnas.97.8.3792; Donaldson JG, 2000, CURR OPIN CELL BIOL, V12, P475, DOI 10.1016/S0955-0674(00)00119-8; Exton JH, 2002, FEBS LETT, V531, P58, DOI 10.1016/S0014-5793(02)03405-1; FRANCO M, 1995, J BIOL CHEM, V270, P1337, DOI 10.1074/jbc.270.3.1337; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Funato K, 2001, J CELL BIOL, V155, P949, DOI 10.1083/jcb.200105033; Geuze HJ, 2003, MOL BIOL CELL, V14, P2900, DOI 10.1091/mbc.E02-11-0734; Godi A, 1999, NAT CELL BIOL, V1, P280, DOI 10.1038/12993; Gommel DU, 2001, EMBO J, V20, P6751, DOI 10.1093/emboj/20.23.6751; Harter C, 1996, P NATL ACAD SCI USA, V93, P1902, DOI 10.1073/pnas.93.5.1902; Harter C, 1998, P NATL ACAD SCI USA, V95, P11649, DOI 10.1073/pnas.95.20.11649; HARTL FU, 1985, ARCH BIOCHEM BIOPHYS, V237, P124, DOI 10.1016/0003-9861(85)90261-9; Heid HW, 1998, CELL TISSUE RES, V294, P309, DOI 10.1007/s004410051181; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HELMS JB, 1993, J CELL BIOL, V121, P751, DOI 10.1083/jcb.121.4.751; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; Hoepfner D, 2005, CELL, V122, P85, DOI 10.1016/j.cell.2005.04.025; Hoepfner D, 2001, J CELL BIOL, V155, P979, DOI 10.1083/jcb.200107028; Hosaka M, 1996, J BIOCHEM-TOKYO, V120, P813; Huber CN, 1999, EMBO J, V18, P5476, DOI 10.1093/emboj/18.20.5476; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jackson CL, 2000, TRENDS CELL BIOL, V10, P60, DOI 10.1016/S0962-8924(99)01699-2; JUST WW, 1989, HEPATOLOGY, V9, P570, DOI 10.1002/hep.1840090411; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; Koch A, 2003, J BIOL CHEM, V278, P8597, DOI 10.1074/jbc.M211761200; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; LEE FJS, 1994, J BIOL CHEM, V269, P20931; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Li XL, 2003, J BIOL CHEM, V278, P17012, DOI 10.1074/jbc.M212031200; Li XL, 2002, MOL CELL BIOL, V22, P4358, DOI 10.1128/MCB.22.12.4358-4365.2002; Li XL, 2002, J CELL BIOL, V156, P643, DOI 10.1083/jcb.200112028; Li YW, 2004, FASEB J, V18, P1834, DOI 10.1096/fj.04-2273com; Marelli M, 2004, J CELL BIOL, V167, P1099, DOI 10.1083/jcb.200404119; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; Nakamura N, 2004, BIOCHEM BIOPH RES CO, V322, P957, DOI 10.1016/j.bbrc.2004.08.010; Passreiter M, 1998, J CELL BIOL, V141, P373, DOI 10.1083/jcb.141.2.373; Powner DJ, 2002, FEBS LETT, V531, P62, DOI 10.1016/S0014-5793(02)03410-5; Purdue PE, 2001, ANNU REV CELL DEV BI, V17, P701, DOI 10.1146/annurev.cellbio.17.1.701; Randazzo PA, 1997, J BIOL CHEM, V272, P7688; Robinson MS, 2001, CURR OPIN CELL BIOL, V13, P444, DOI 10.1016/S0955-0674(00)00235-0; Roth MG, 1999, CELL, V97, P149, DOI 10.1016/S0092-8674(00)80723-0; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Rottensteiner H, 2003, MOL BIOL CELL, V14, P4316, DOI 10.1091/mbc.E03-03-0153; Sacksteder KA, 2000, ANNU REV GENET, V34, P623, DOI 10.1146/annurev.genet.34.1.623; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Schrader M, 1998, J BIOL CHEM, V273, P29607, DOI 10.1074/jbc.273.45.29607; Seidel RD, 2004, BIOCHEMISTRY-US, V43, P15393, DOI 10.1021/bi0490385; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Short B, 2003, CURR BIOL, V13, pR311, DOI 10.1016/S0960-9822(03)00234-3; SMIDSROD O, 1990, TRENDS BIOTECHNOL, V8, P71, DOI 10.1016/0167-7799(90)90139-O; Smith KD, 1999, NEUROCHEM RES, V24, P521, DOI 10.1023/A:1022535930009; Spang A, 2002, CURR OPIN CELL BIOL, V14, P423, DOI 10.1016/S0955-0674(02)00346-0; Springer S, 1999, CELL, V97, P145, DOI 10.1016/S0092-8674(00)80722-9; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tam YYC, 2003, MOL BIOL CELL, V14, P4089, DOI 10.1091/mbc.E03-03-0150; Tanaka A, 2003, BIOCHEM BIOPH RES CO, V300, P819, DOI 10.1016/S0006-291X(02)02936-4; Titorenko VI, 1998, TRENDS BIOCHEM SCI, V23, P231, DOI 10.1016/S0968-0004(98)01226-2; Titorenko VI, 2000, CELL BIOCHEM BIOPHYS, V32, P21, DOI 10.1385/CBB:32:1-3:21; Trotter PJ, 2001, ANNU REV NUTR, V21, P97, DOI 10.1146/annurev.nutr.21.1.97; Yu S, 2002, MOL BIOL CELL, V13, P2559, DOI 10.1091/mbc.E02-04-0189; Yu ST, 2003, CURR MOL MED, V3, P561, DOI 10.2174/1566524033479537; Zhao LY, 1999, J BIOL CHEM, V274, P14198, DOI 10.1074/jbc.274.20.14198; Zhao LY, 1997, P NATL ACAD SCI USA, V94, P4418, DOI 10.1073/pnas.94.9.4418	69	26	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34489	34499		10.1074/jbc.M503497200	http://dx.doi.org/10.1074/jbc.M503497200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16100119	hybrid			2022-12-25	WOS:000232403900016
J	Padayatti, PS; Helfand, MS; Totir, MA; Carey, MP; Carey, PR; Bonomo, RA; van den Akker, F				Padayatti, PS; Helfand, MS; Totir, MA; Carey, MP; Carey, PR; Bonomo, RA; van den Akker, F			High resolution crystal structures of the trans-enamine intermediates formed by sulbactam and clavulanic acid and E166A SHV-1 beta-lactamase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MECHANISM-BASED INHIBITORS; ACYL-ENZYME INTERMEDIATE; ESCHERICHIA-COLI; INACTIVATION; RESISTANCE; TAZOBACTAM; MUTANT; SULFONES	Antibiotic resistance mediated by constantly evolving beta-lactamases is a serious threat to human health. The mechanism of inhibition of these enzymes by therapeutic beta-lactamase inhibitors is probed using a novel approach involving Raman microscopy and x-ray crystallography. We have presented here the high resolution crystal structures of the beta-lactamase inhibitors sulbactam and clavulanic acid bound to the deacylation-deficient E166A variant of SHV-1 beta-lactamase. Our previous Raman measurements have identified the trans-enamine species for both inhibitors and were used to guide the soaking time and concentration to achieve full occupancy of the active sites. The two inhibitor-bound x-ray structures revealed a linear trans-enamine intermediate covalently attached to the active site Ser-70 residue. This intermediate was thought to play a key role in the transient inhibition of class A beta-lactamases. Both the Raman and x-ray data indicated that the clavulanic acid intermediate is decarboxylated. When compared with our previously determined tazobactam-bound inhibitor structure, our new inhibitor-bound structures revealed an increased disorder in the tail region of the inhibitors as well as in the enamine skeleton. The x-ray crystallographic observations correlated with the broadening of the O-C=C-N (enamine) symmetric stretch Raman band near 1595 cm(-1). Band broadening in the sulbactam and clavulanic acid intermediates reflected a heterogeneous conformational population that results from variations of torsional angles in the O-(C=O)-C=C=NH-C skeleton. These observations led us to conclude that the conformational stability of the trans-enamine form is critical for their transient inhibitory efficacy.	Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA; Louis Stokes Cleveland Vet Affairs Med Ctr, Div Res, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center	van den Akker, F (corresponding author), Case Western Reserve Univ, Sch Med, Dept Biochem RT500, 10900 Euclid Ave, Cleveland, OH 44106 USA.	focco.vandenakker@case.edu		Padayatti, Pius/0000-0002-1384-3774				Bonomo R.A., 1999, FRONT BIOSCI, V4, P34; Bonomo RA, 2001, BBA-PROTEIN STRUCT M, V1547, P196, DOI 10.1016/S0167-4838(01)00175-3; BONOMO RA, 1995, BBA-PROTEIN STRUCT M, V1247, P121, DOI 10.1016/0167-4838(94)00188-M; Bradford PA, 2001, CLIN MICROBIOL REV, V14, P933, DOI 10.1128/CMR.14.4.933-951.2001; BRENNER DG, 1984, BIOCHEMISTRY-US, V23, P5839, DOI 10.1021/bi00319a025; BRENNER DG, 1981, BIOCHEMISTRY-US, V20, P3680, DOI 10.1021/bi00516a003; BRENNER DG, 1984, BIOCHEMISTRY-US, V23, P5833, DOI 10.1021/bi00319a024; Brown RPA, 1996, BIOCHEMISTRY-US, V35, P12421, DOI 10.1021/bi961044g; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bush Karen, 2002, Curr Opin Investig Drugs, V3, P1284; CAREY PR, 1973, BIOCHEMISTRY-US, V12, P2198, DOI 10.1021/bi00736a004; CHARNAS RL, 1981, BIOCHEMISTRY-US, V20, P3214, DOI 10.1021/bi00514a035; CHARNAS RL, 1978, BIOCHEMISTRY-US, V17, P2185, DOI 10.1021/bi00604a025; CHEN CCH, 1992, J MOL BIOL, V224, P1103, DOI 10.1016/0022-2836(92)90472-V; Chen CCH, 2001, BIOCHEMISTRY-US, V40, P2351, DOI 10.1021/bi002277h; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V55, P760; FISHER J, 1978, BIOCHEMISTRY-US, V17, P2180, DOI 10.1021/bi00604a024; FISHER J, 1980, BIOCHEMISTRY-US, V19, P2895, DOI 10.1021/bi00554a012; FISHER J, 1981, BIOCHEMISTRY-US, V20, P2726, DOI 10.1021/bi00513a004; FISHER J, 1980, PHILOS T ROY SOC B, V289, P309, DOI 10.1098/rstb.1980.0048; Georgopapadakou NH, 2004, EXPERT OPIN INV DRUG, V13, P1307, DOI 10.1517/13543784.13.10.1307; Giakkoupi P, 1998, FEMS MICROBIOL LETT, V160, P49, DOI 10.1016/S0378-1097(98)00009-3; Helfand Marion S., 2003, Current Drug Targets - Infectious Disorders, V3, P9, DOI 10.2174/1568005033342181; Helfand MS, 2003, BIOCHEMISTRY-US, V42, P13386, DOI 10.1021/bi035716w; Hokenson MJ, 2000, BIOCHEMISTRY-US, V39, P6538, DOI 10.1021/bi9928041; Ibuka A, 1999, J MOL BIOL, V285, P2079, DOI 10.1006/jmbi.1998.2432; IMTIAZ U, 1994, BIOCHEMISTRY-US, V33, P5728, DOI 10.1021/bi00185a009; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kuzin AP, 1999, BIOCHEMISTRY-US, V38, P5720, DOI 10.1021/bi990136d; Kuzin AP, 2001, BIOCHEMISTRY-US, V40, P1861, DOI 10.1021/bi0022745; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee N, 2003, DRUGS, V63, P1511, DOI 10.2165/00003495-200363140-00006; Lin S, 1999, BBA-PROTEIN STRUCT M, V1432, P125, DOI 10.1016/S0167-4838(99)00025-4; Nathan C, 2004, NATURE, V431, P899, DOI 10.1038/431899a; Nukaga M, 2003, J MOL BIOL, V328, P289, DOI 10.1016/S0022-2836(03)00210-9; Padayatti PS, 2004, BIOCHEMISTRY-US, V43, P843, DOI 10.1021/bi035985m; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; Sulton D, 2005, J BIOL CHEM, V280, P35528, DOI 10.1074/jbc.M501251200; Sun T, 2004, BIOCHEMISTRY-US, V43, P14111, DOI 10.1021/bi0487903; Therrien C, 2000, FEMS MICROBIOL REV, V24, P251, DOI 10.1111/j.1574-6976.2000.tb00541.x; Williams JD, 1997, CLIN INFECT DIS, V24, P494, DOI 10.1093/clinids/24.3.494; ZAFARALLA G, 1992, BIOCHEMISTRY-US, V31, P3847, DOI 10.1021/bi00130a016	43	58	58	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34900	34907		10.1074/jbc.M505333200	http://dx.doi.org/10.1074/jbc.M505333200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16055923	hybrid			2022-12-25	WOS:000232403900062
J	Cordle, A; Koenigsknecht-Talboo, J; Wilkinson, B; Limpert, A; Landreth, G				Cordle, A; Koenigsknecht-Talboo, J; Wilkinson, B; Limpert, A; Landreth, G			Mechanisms of statin-mediated inhibition of small G-protein function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COA REDUCTASE INHIBITOR; TRANSGENIC MOUSE MODEL; CENTRAL-NERVOUS-SYSTEM; NITRIC-OXIDE SYNTHASE; AMYLOID-BETA-PEPTIDE; ALZHEIMERS-DISEASE; ALPHA-SECRETASE; SIMVASTATIN; CHOLESTEROL; EXPRESSION	3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have been reported to reduce the risk of Alzheimer disease. We have shown previously that statins inhibit a beta-amyloid (A beta)mediated inflammatory response through mechanisms independent of cholesterol reduction. Specifically, statins exert anti-inflammatory actions through their ability to prevent the isoprenylation of members of the Rho family of small G-proteins, resulting in the functional inactivation of these G-proteins. We report that statin treatment of microglia results in perturbation of the cytoskeleton and morphological changes due to alteration in Rho family function. Statins also block A beta-stimulated phagocytosis through inhibition of Rac action. Paradoxically, the statin-mediated inactivation of G-protein function was associated with increased GTP loading of Rac and RhoA, and this effect was observed in myeloid lineage cells and other cell types. Statin treatment disrupted the interaction of Rac with its negative regulator the Rho guanine nucleotide dissociation inhibitor ( RhoGDI), an interaction that is dependent on protein isoprenylation. We propose that lack of negative regulation accounts for the increased GTP loading. Isoprenylation of Rac is also required for efficient interaction with the plasma membrane, and we report that statin treatment dramatically reduces the capacity of Rac to interact with membranes. These results suggest amechanism by which statins inhibit the actions of Rho GTPases and attenuate A beta-stimulated inflammation.	Case Western Reserve Univ, Sch Med, Dept Neurosci, Cleveland, OH 44106 USA	Case Western Reserve University	Landreth, G (corresponding author), Case Western Reserve Univ, Sch Med, Dept Neurosci, Cleveland, OH 44106 USA.	gel2@cwru.edu			NIA NIH HHS [AG20202, AG16740] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG016740, R01AG020202] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Bi XN, 2004, J BIOL CHEM, V279, P48238, DOI 10.1074/jbc.M405442200; Blanco-Colio LM, 2002, ATHEROSCLEROSIS, V161, P17, DOI 10.1016/S0021-9150(01)00613-X; Bodovitz S, 1996, J BIOL CHEM, V271, P4436; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURDICK D, 1992, J BIOL CHEM, V267, P546; Burns M, 2002, ANN NY ACAD SCI, V977, P367, DOI 10.1111/j.1749-6632.2002.tb04839.x; Buxbaum JD, 2002, FRONT BIOSCI, V7, pA50, DOI 10.2741/buxbaum; Caballero J, 2004, J CLIN PHARM THER, V29, P209, DOI 10.1111/j.1365-2710.2004.00560.x; Cole SL, 2005, J BIOL CHEM, V280, P18755, DOI 10.1074/jbc.M413895200; Combs CK, 2001, J NEUROSCI, V21, P1179; Cordle A, 2005, J NEUROSCI, V25, P299, DOI 10.1523/JNEUROSCI.2544-04.2005; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; del Real G, 2004, J EXP MED, V200, P541, DOI 10.1084/jem.20040061; Di-Poi N, 2001, BIOCHEMISTRY-US, V40, P10014, DOI 10.1021/bi010289c; Engel ME, 1998, J BIOL CHEM, V273, P9921, DOI 10.1074/jbc.273.16.9921; Fassbender K, 2001, P NATL ACAD SCI USA, V98, P5856, DOI 10.1073/pnas.081620098; Gorzalczany Y, 2000, J BIOL CHEM, V275, P40073, DOI 10.1074/jbc.M006013200; Hernandez-Perera O, 2000, CIRC RES, V87, P616, DOI 10.1161/01.RES.87.7.616; Ishibashi T, 2002, BBA-MOL CELL RES, V1590, P123, DOI 10.1016/S0167-4889(02)00201-X; Ito T, 2002, CARDIOVASC DRUG THER, V16, P121, DOI 10.1023/A:1015701415588; Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140-6736(00)03155-X; Klegeris A, 2004, J NEUROIMMUNOL, V152, P73, DOI 10.1016/j.jneuroim.2004.04.001; Koenigsknecht J, 2004, J NEUROSCI, V24, P9838, DOI 10.1523/JNEUROSCI.2557-04.2004; Kunieda Y, 2003, THROMB RES, V110, P227, DOI 10.1016/S0049-3848(03)00346-3; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Laufs U, 1998, J BIOL CHEM, V273, P24266, DOI 10.1074/jbc.273.37.24266; Laufs U, 2002, CARDIOVASC RES, V53, P911, DOI 10.1016/S0008-6363(01)00540-5; LEONARD S, 1990, J BIOL CHEM, V265, P5157; Lian LY, 2000, STRUCT FOLD DES, V8, P47, DOI 10.1016/S0969-2126(00)00080-0; Liao JK, 2005, ANNU REV PHARMACOL, V45, P89, DOI 10.1146/annurev.pharmtox.45.120403.095748; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Matos P, 2003, J BIOL CHEM, V278, P50442, DOI 10.1074/jbc.M308215200; Miida Takashi, 2004, J Atheroscler Thromb, V11, P253; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; Nath N, 2004, J IMMUNOL, V172, P1273, DOI 10.4049/jimmunol.172.2.1273; Parvathy S, 2004, J NEUROCHEM, V90, P1005, DOI 10.1111/j.1471-4159.2004.02521.x; Patel NS, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-9; Patel TR, 2004, J SURG RES, V116, P116, DOI 10.1016/j.jss.2003.07.006; Pedrini S, 2005, PLOS MED, V2, P69, DOI 10.1371/journal.pmed.0020018; Petanceska SS, 2002, J MOL NEUROSCI, V19, P155, DOI 10.1007/s12031-002-0026-2; Refolo LM, 2001, NEUROBIOL DIS, V8, P890, DOI 10.1006/nbdi.2001.0422; Rockwood K, 2002, ARCH NEUROL-CHICAGO, V59, P223, DOI 10.1001/archneur.59.2.223; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Simons M, 2002, ANN NEUROL, V52, P346, DOI 10.1002/ana.10292; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; Sjogren M, 2003, DEMENT GERIATR COGN, V16, P25, DOI 10.1159/000069989; Sparks DL, 2005, ARCH NEUROL-CHICAGO, V62, P753, DOI 10.1001/archneur.62.5.753; Stamatakis K, 2002, J BIOL CHEM, V277, P49389, DOI 10.1074/jbc.M204049200; Stuve O, 2003, CURR OPIN NEUROL, V16, P393, DOI 10.1097/01.wco.0000073942.19076.d1; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; TERZI E, 1994, BIOCHEMISTRY-US, V33, P7434, DOI 10.1021/bi00189a051; Tobert JA, 2003, NAT REV DRUG DISCOV, V2, P517, DOI 10.1038/nrd1112; VAN AL, 1997, GENE DEV, V11, P2295; Vecchione C, 2002, CIRC RES, V91, P173, DOI 10.1161/01.RES.0000028004.76218.B8; Wahrle S, 2002, NEUROBIOL DIS, V9, P11, DOI 10.1006/nbdi.2001.0470; Wilcock DM, 2004, J NEUROSCI, V24, P6144, DOI 10.1523/JNEUROSCI.1090-04.2004; Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P1439, DOI 10.1001/archneur.57.10.1439; Yates SL, 2000, J NEUROCHEM, V74, P1017, DOI 10.1046/j.1471-4159.2000.0741017.x; Yoshida Masayuki, 2003, J Atheroscler Thromb, V10, P140; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zhao XX, 2002, J BIOL CHEM, V277, P25385, DOI 10.1074/jbc.M203630200	65	189	200	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34202	34209		10.1074/jbc.M505268200	http://dx.doi.org/10.1074/jbc.M505268200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16085653	hybrid			2022-12-25	WOS:000232229700062
J	Petit, A; Kawarai, T; Paitel, E; Sanjo, N; Maj, M; Scheid, M; Chen, FS; Gu, YJ; Hasegawa, H; Salehi-Rad, S; Wang, L; Rogaeva, E; Fraser, P; Robinson, B; St George-Hyslop, P; Tandon, A				Petit, A; Kawarai, T; Paitel, E; Sanjo, N; Maj, M; Scheid, M; Chen, FS; Gu, YJ; Hasegawa, H; Salehi-Rad, S; Wang, L; Rogaeva, E; Fraser, P; Robinson, B; St George-Hyslop, P; Tandon, A			Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson disease-related mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTANT ALPHA-SYNUCLEIN; 2 PARTS; PTEN; GENE; PATHWAY; DJ-1; STIMULI	Mutations in the PTEN-induced kinase 1 (PINK1) gene have recently been implicated in autosomal recessive early onset Parkinson Disease ( 1, 2). To investigate the role of PINK1 in neurodegeneration, we designed human and murine neuronal cell lines expressing either wild-type PINK1 or PINK1 bearing a mutation associated with Parkinson Disease. We show that under basal and staurosporine-induced conditions, the number of terminal deoxynucleotidyl-transferase-mediated dUTP nick end labeling (TUNEL)-positive cells was lower in wild-type PINK1 expressing SH-SY5Y cells than in mock-transfected cells. This phenotype was due to a PINK1-mediated reduction in cytochrome c release from mitochondria, which prevents subsequent caspase-3 activation. We show that overexpression of wild-type PINK1 strongly reduced both basal and staurosporine-induced caspase 3 activity. Overexpression of wild-type PINK1 also reduced the levels of cleaved caspase-9, caspase-3, caspase-7, and activated poly(ADP-ribose) polymerase under both basal and staurosporine-induced conditions. In contrast, Parkinson disease-related mutations and a kinase-inactive mutation in PINK1 abrogated the protective effect of PINK1. Together, these results suggest that PINK1 reduces the basal neuronal pro-apoptotic activity and protects neurons from staurosporine-induced apoptosis. Loss of this protective function may therefore underlie the degeneration of nigral dopaminergic neurons in patients with PINK1 mutations.	Univ Toronto, Ctr Res Neurodegenerat Dis, Dept Med Neurol, Toronto, ON M5S 3H2, Canada; Hosp Sick Children, Res Inst, Metab res Programme, Toronto, ON M5G 1X8, Canada; York Univ, Dept Biol, N York, ON M3J 1P3, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); York University - Canada	St George-Hyslop, P (corresponding author), Univ Toronto, Ctr Res Neurodegenerat Dis, Dept Med Neurol, 6 Queens Pk Crescent W, Toronto, ON M5S 3H2, Canada.	p.hyslop@utoronto.ca	Maj, Mary/R-6969-2019; Kawarai, Toshitaka/C-2822-2013	Kawarai, Toshitaka/0000-0003-4547-8131; Petit-Paitel, Agnes/0000-0003-1138-9966; St George-Hyslop, Peter/0000-0003-0796-7209; Sanjo, Nobuo/0000-0002-1226-2425; Maj, Mary/0000-0002-9258-2823				Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; da Costa CA, 2000, J BIOL CHEM, V275, P24065, DOI 10.1074/jbc.M002413200; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; Gary DS, 2002, NEUROMOL MED, V2, P261, DOI 10.1385/NMM:2:3:261; Hague S, 2003, ANN NEUROL, V54, P271, DOI 10.1002/ana.10663; Kim RH, 2005, CANCER CELL, V7, P263, DOI 10.1016/j.ccr.2005.02.010; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Lang AE, 1998, NEW ENGL J MED, V339, P1130, DOI 10.1056/NEJM199810153391607; Lang AE, 1998, NEW ENGL J MED, V339, P1044, DOI 10.1056/NEJM199810083391506; Lee M, 2001, J NEUROCHEM, V76, P998, DOI 10.1046/j.1471-4159.2001.00149.x; Paitel E, 2003, J BIOL CHEM, V278, P10061, DOI 10.1074/jbc.M211580200; Parsons R, 2004, SEMIN CELL DEV BIOL, V15, P171, DOI 10.1016/j.semcdb.2003.12.021; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Rogaeva E, 2004, ARCH NEUROL-CHICAGO, V61, P1898, DOI 10.1001/archneur.61.12.1898; Sansal I, 2004, J CLIN ONCOL, V22, P2954, DOI 10.1200/jco.2004.02.141; Unoki M, 2001, ONCOGENE, V20, P4457, DOI 10.1038/sj.onc.1204608; Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284; Yang DS, 2002, J BIOL CHEM, V277, P28135, DOI 10.1074/jbc.M110871200	18	257	321	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					34025	34032		10.1074/jbc.M505143200	http://dx.doi.org/10.1074/jbc.M505143200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16079129	hybrid			2022-12-25	WOS:000232229700041
J	Gaur, T; Lengner, CJ; Hovhannisyan, H; Bhat, RA; Bodine, PVN; Komm, BS; Javed, A; van Wijnen, AJ; Stein, JL; Stein, GS; Lian, JB				Gaur, T; Lengner, CJ; Hovhannisyan, H; Bhat, RA; Bodine, PVN; Komm, BS; Javed, A; van Wijnen, AJ; Stein, JL; Stein, GS; Lian, JB			Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN-5; HIGH BONE-DENSITY; OSTEOBLAST DIFFERENTIATION; WNT/BETA-CATENIN; BETA-CATENIN; CLEIDOCRANIAL DYSPLASIA; RUNX/CBFA/AML FACTORS; TRANSCRIPTION FACTORS; LIMB DEVELOPMENT; MUTANT MICE	Both activating and null mutations of proteins required for canonical WNT signaling have revealed the importance of this pathway for normal skeletal development. However, tissue-specific transcriptional mechanisms through which WNT signaling promotes the differentiation of bone-forming cells have yet to be identified. Here, we address the hypothesis that canonical WNT signaling and the bone-related transcription factor RUNX2/CBFA1/ AML3 are functionally linked components of a pathway required for the onset of osteoblast differentiation. Our findings show that, in bone of the SFRP1 ( secreted frizzled-related protein-1)-null mouse, which exhibits activated WNT signaling and a high bone mass phenotype, there is a significant increase in expression of T-cell factor (TCF)-1, Runx2, and the RUNX2 target gene osteocalcin. We demonstrate by mutational analysis that a functional TCF regulatory element responsive to canonical WNT signaling resides in the promoter of the Runx2 gene ( - 97 to - 93). By chromatin immunoprecipitation, recruitment of beta-catenin and TCF1 to the endogenous Runx2 gene is shown. Coexpression of TCF1 with canonical WNT proteins resulted in a 2-5-fold activation of Runx2 promoter activity and a 7-8-fold induction of endogenous mRNA in mouse pluripotent mesenchymal and osteoprogenitor cells. This enhancement was abrogated by SFRP1. Taken together, our results provide evidence for direct regulation of Runx2 by canonical WNT signaling and suggest that Runx2 is a target of beta-catenin/TCF1 for the stimulation of bone formation. We propose that WNT/TCF1 signaling, like bone morphogenetic protein/transforming growth factor-beta signaling, activates Runx2 gene expression in mesenchymal cells for the control of osteoblast differentiation and skeletal development.	Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Ctr Canc, Worcester, MA 01655 USA; Wyeth Res, Womens Hlth Res Inst, Collegeville, PA 19426 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Pfizer	Lian, JB (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, 55 Lake Ave N, Worcester, MA 01655 USA.	jane.lian@umassmed.edu	van Wijnen, Andre J./AAG-3578-2019	van Wijnen, Andre J./0000-0002-4458-0946; Javed, Amjad/0000-0002-0847-8266; Lengner, Christopher/0000-0002-0574-5189	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049069, P01AR048818, R01AR039588] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK032520] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39588, P01 AR48818, R01 AR049069] Funding Source: Medline; NIDDK NIH HHS [P30 DK32520] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adamska M, 2004, DEV BIOL, V272, P134, DOI 10.1016/j.ydbio.2004.04.026; Afzal F, 2005, J CELL PHYSIOL, V204, P63, DOI 10.1002/jcp.20258; Akhter MP, 2004, BONE, V35, P162, DOI 10.1016/j.bone.2004.02.018; AUGUSTINE K, 1993, DEV GENET, V14, P500, DOI 10.1002/dvg.1020140611; Aulehla A, 2003, DEV CELL, V4, P395, DOI 10.1016/S1534-5807(03)00055-8; Babij P, 2003, J BONE MINER RES, V18, P960, DOI 10.1359/jbmr.2003.18.6.960; Banerjee C, 1997, J CELL BIOCHEM, V66, P1, DOI 10.1002/(SICI)1097-4644(19970701)66:1<1::AID-JCB1>3.0.CO;2-V; Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102; Bodine PVN, 2004, MOL ENDOCRINOL, V18, P1222, DOI 10.1210/me.2003-0498; Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444; Brault V, 2001, DEVELOPMENT, V128, P1253; Choi JY, 2001, P NATL ACAD SCI USA, V98, P8650, DOI 10.1073/pnas.151236498; Church VL, 2002, INT J DEV BIOL, V46, P927; Clevers H, 1997, TRENDS GENET, V13, P485, DOI 10.1016/S0168-9525(97)01305-X; Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016; Derfoul A, 2004, DIFFERENTIATION, V72, P209, DOI 10.1111/j.1432-0436.2004.07205003.x; Drissi H, 2000, J CELL PHYSIOL, V184, P341, DOI 10.1002/1097-4652(200009)184:3<341::AID-JCP8>3.0.CO;2-Z; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Filali M, 2002, J BIOL CHEM, V277, P33398, DOI 10.1074/jbc.M107977200; Gazzerro E, 2005, ENDOCRINOLOGY, V146, P655, DOI 10.1210/en.2004-0766; Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; HAEGEL H, 1995, DEVELOPMENT, V121, P3529; Hartmann C, 2001, CELL, V104, P341, DOI 10.1016/S0092-8674(01)00222-7; Hartmann C, 2000, DEVELOPMENT, V127, P3141; Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013; Hoang BH, 1998, DEV DYNAM, V212, P364, DOI 10.1002/(SICI)1097-0177(199807)212:3<364::AID-AJA4>3.0.CO;2-F; Holmen SL, 2004, J BONE MINER RES, V19, P2033, DOI 10.1359/JBMR.040907; Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200; Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/88264; Hovhannisyan H, 2003, MOL CELL BIOL, V23, P1460, DOI 10.1128/MCB.23.4.1460-1469.2003; Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564; Ikeya M, 2001, MECH DEVELOP, V103, P27, DOI 10.1016/S0925-4773(01)00338-0; Javed A, 2001, MOL CELL BIOL, V21, P2891, DOI 10.1128/MCB.21.8.2891-2905.2001; KARAPLIS A, 2002, PRINCIPLES BONE BIOL, P3; Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; Kobayashi T, 2005, ENDOCRINOLOGY, V146, P1012, DOI 10.1210/en.2004-1343; KOCKX M, 1994, J CELL BIOCHEM, V54, P47, DOI 10.1002/jcb.240540106; Kokubu C, 2004, DEVELOPMENT, V131, P5469, DOI 10.1242/dev.01405; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Komori T, 2005, J CELL BIOCHEM, V95, P445, DOI 10.1002/jcb.20420; Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200; Lengner CJ, 2004, J CELL PHYSIOL, V200, P327, DOI 10.1002/jcp.20118; Lengner CJ, 2002, MECH DEVELOP, V114, P167, DOI 10.1016/S0925-4773(02)00050-3; Lengner CJ, 2005, J BIOL CHEM, V280, P15872, DOI 10.1074/jbc.M411144200; Lian JB, 2004, CRIT REV EUKAR GENE, V14, P1; LIAN JB, 2003, PRIMER METABOLIC BON, P13; Little RD, 2002, NEW ENGL J MED, V347, P943; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Niemann S, 2004, AM J HUM GENET, V74, P558, DOI 10.1086/382196; Otto F, 2002, HUM MUTAT, V19, P209, DOI 10.1002/humu.10043; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Pandur P, 2002, BIOESSAYS, V24, P881, DOI 10.1002/bies.10164; Paredes R, 2004, MOL CELL BIOL, V24, P8847, DOI 10.1128/MCB.24.20.8847-8861.2004; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Soshnikova N, 2003, GENE DEV, V17, P1963, DOI 10.1101/gad.263003; Tamamura Y, 2005, J BIOL CHEM, V280, P19185, DOI 10.1074/jbc.M414275200; Vaes BLT, 2005, BONE, V36, P803, DOI 10.1016/j.bone.2005.02.001; Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044; Yamaguchi TP, 1999, DEVELOPMENT, V126, P1211; Yoshida T, 2003, BLOOD CELL MOL DIS, V30, P184, DOI 10.1016/S1079-9796(03)00020-2; Yu HMI, 2005, DEVELOPMENT, V132, P1995, DOI 10.1242/dev.01786; Zaidi SK, 2004, EMBO J, V23, P790, DOI 10.1038/sj.emboj.7600073; Zaidi SK, 2002, P NATL ACAD SCI USA, V99, P8048, DOI 10.1073/pnas.112664499; ZAKANY J, 1993, NATURE, V362, P546, DOI 10.1038/362546a0; Zambotti A, 2002, J BIOL CHEM, V277, P41497, DOI 10.1074/jbc.M204271200; Zhang YW, 2000, P NATL ACAD SCI USA, V97, P10549, DOI 10.1073/pnas.180309597; Zhou SH, 2004, J BONE MINER RES, V19, P463, DOI 10.1359/JBMR.0301239	69	860	918	5	92	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33132	33140		10.1074/jbc.M500608200	http://dx.doi.org/10.1074/jbc.M500608200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16043491	hybrid			2022-12-25	WOS:000232058100007
J	Sharoni, M; Steiner-Mordoch, S; Schuldiner, S				Sharoni, M; Steiner-Mordoch, S; Schuldiner, S			Exploring the binding domain of EmrE, the smallest multidrug transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SUBSTRATE-BINDING; LACTOSE PERMEASE; MEMBRANE-PROTEIN; SITE; ANTIPORTER; CHANNEL; H+; RESISTANCE; RESIDUES	EmrE is a small multidrug transporter in Escherichia coli that extrudes various positively charged drugs across the plasma membrane in exchange with protons, thereby rendering cells resistant to these compounds. Biochemical experiments indicate that the basic functional unit of EmrE is a dimer where the common binding site for protons and substrate is formed by the interaction of an essential charged residue (Glu(14)) from both EmrE monomers. Previous studies implied that other residues in the vicinity of Glu14 are part of the binding domain. Alkylation of Cys replacements in the same transmembrane domain inhibits the activity of the protein and this inhibition is fully prevented by substrates of EmrE. To monitor directly the reaction we tested also the extent of modification using fluorescein-5-maleimide. While most residues are not accessible or only partially accessible, four, Y4C, 15C, L7C, and A10C, were modified at least 80%. Furthermore, preincubation with tetraphenylphosphonium reduces the reaction of two of these residues by up to 80%. To study other essential residues we generated functional hetero-oligomers and challenged them with various methane thiosulfonates. Taken together the findings imply the existence of a binding cavity accessible to alkylating reagents where at least three residues from TM1, Tyr(40) from TM2, and Trp(63) in TM3 are involved in substrate binding.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Schuldiner, S (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel.	Shimon.Schuldiner@huji.ac.il	Schuldiner, Shimon/F-7628-2012	Schuldiner, Shimon/0000-0002-4874-6237	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS016708, R01NS016708] Funding Source: NIH RePORTER; NINDS NIH HHS [NS16708] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AKABAS MH, 1994, J BIOL CHEM, V269, P14865; Butler PJG, 2004, J MOL BIOL, V340, P797, DOI 10.1016/j.jmb.2004.05.014; Elbaz Y, 2005, BIOCHEMISTRY-US, V44, P7369, DOI 10.1021/bi050356t; Elbaz Y, 2004, P NATL ACAD SCI USA, V101, P1519, DOI 10.1073/pnas.0306533101; GOLDBERG EB, 1987, P NATL ACAD SCI USA, V84, P2615, DOI 10.1073/pnas.84.9.2615; GRINIUS LL, 1994, J BIOL CHEM, V269, P29998; Gutman N, 2003, J BIOL CHEM, V278, P16082, DOI 10.1074/jbc.M213120200; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Koteiche HA, 2003, BIOCHEMISTRY-US, V42, P6099, DOI 10.1021/bi0342867; Ma C, 2004, P NATL ACAD SCI USA, V101, P2852, DOI 10.1073/pnas.0400137101; Mordoch SS, 1999, J BIOL CHEM, V274, P19480, DOI 10.1074/jbc.274.27.19480; Muth TR, 2000, EMBO J, V19, P234, DOI 10.1093/emboj/19.2.234; Ninio S, 2003, J BIOL CHEM, V278, P12000, DOI 10.1074/jbc.M213119200; Ninio S, 2001, J BIOL CHEM, V276, P48250, DOI 10.1074/jbc.M108231200; Rotem D, 2001, J BIOL CHEM, V276, P48243, DOI 10.1074/jbc.M108229200; SCHNEIDER TD, 1990, NUCLEIC ACIDS RES, V18, P6097, DOI 10.1093/nar/18.20.6097; Schuldiner S, 2001, J MOL MICROB BIOTECH, V3, P155; Schuldiner S, 2001, NEWS PHYSIOL SCI, V16, P130; Schumacher MA, 2001, SCIENCE, V294, P2158, DOI 10.1126/science.1066020; Schwaiger M, 1998, EUR J BIOCHEM, V254, P610, DOI 10.1046/j.1432-1327.1998.2540610.x; Soskine M, 2004, J BIOL CHEM, V279, P9951, DOI 10.1074/jbc.M312853200; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Tate CG, 2001, EMBO J, V20, P77, DOI 10.1093/emboj/20.1.77; Ubarretxena-Belandia I, 2003, EMBO J, V22, P6175, DOI 10.1093/emboj/cdg611; Vardy E, 2004, PROTEIN SCI, V13, P1832, DOI 10.1110/ps.04657704; Weinglass AB, 2005, J BIOL CHEM, V280, P7487, DOI 10.1074/jbc.M413555200; Weinglass AB, 2001, BIOCHEMISTRY-US, V40, P769, DOI 10.1021/bi002171m; XU M, 1993, J BIOL CHEM, V268, P21505; Ye LW, 2001, J BACTERIOL, V183, P2490, DOI 10.1128/JB.183.8.2490-2496.2001; Yerushalmi H, 2000, BIOCHEMISTRY-US, V39, P14711, DOI 10.1021/bi001892i; Yerushalmi H, 2000, FEBS LETT, V476, P93, DOI 10.1016/S0014-5793(00)01677-X; Yerushalmi H, 2000, J BIOL CHEM, V275, P5264, DOI 10.1074/jbc.275.8.5264; YERUSHALMI H, 1995, J BIOL CHEM, V270, P6856, DOI 10.1074/jbc.270.12.6856; Yerushalmi H, 2001, J BIOL CHEM, V276, P12744, DOI 10.1074/jbc.M010979200; Yerushalmi H, 1996, J BIOL CHEM, V271, P31044, DOI 10.1074/jbc.271.49.31044; Zheleznova EE, 1999, CELL, V96, P353, DOI 10.1016/S0092-8674(00)80548-6	38	32	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32849	32855		10.1074/jbc.M504910200	http://dx.doi.org/10.1074/jbc.M504910200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16049002	hybrid			2022-12-25	WOS:000231920300038
J	Arai, N; Ito, D; Inoue, T; Shibata, T; Takahashi, H				Arai, N; Ito, D; Inoue, T; Shibata, T; Takahashi, H			Heteroduplex joint formation by a stoichiometric complex of Rad51 and Rad52 of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION PROTEIN-A; ESCHERICHIA-COLI RECA; DNA STRAND EXCHANGE; CLOSED CIRCULAR DNA; YEAST RAD51; GENETIC-RECOMBINATION; SUPERHELICAL DNA; BRANCH MIGRATION; DUPLEX DNA; MULTIPLE PATHWAYS	Both Rad51 and Rad52 are required for homologous genetic recombination in Saccharomyces cerevisiae. Rad51 promotes heteroduplex joint formation, a general step in homologous recombination. Rad52 facilitates the binding of Rad51 to replication protein A (RPA)-coated single-stranded DNA. The requirement of RPA can be avoided in vitro, if the single-stranded DNA is short. Using short single-stranded DNA and homologous double-stranded DNA, in the absence of RPA, we found that Rad52 ( optimal at three per Rad51) was still required for Rad51-promoted heteroduplex joint formation in vitro, as assayed by the formation of D-loops, suggesting another role for Rad52. Rad51 has to bind to the single-stranded DNA before the addition of double-stranded DNA for efficient D-loop formation. Immunoprecipitation and single-stranded DNA-bead precipitation analyses revealed the presence of the free and DNA-bound complexes of Rad51 and Rad52 at a 1 to 2 stoichiometry. In the presence of single-stranded DNA, in addition to Rad51, Rad52 was required for extensive untwisting that is an intermediate step toward D-loop formation. Thus, these results suggest that the formation of the stoichiometric complex of Rad52 with Rad51 on single-stranded DNA is required for the functional binding of the protein-single-stranded DNA complex to the double-stranded DNA to form D-loops.	Nihon Univ, Coll Bioresource Sci, Dept Appl Biol Sci, Fujisawa, Kanagawa 2528510, Japan; RIKEN, Discovert Res Inst, Wako, Saitama 3510198, Japan	Nihon University; RIKEN	Arai, N (corresponding author), Nihon Univ, Coll Bioresource Sci, Dept Appl Biol Sci, Fujisawa, Kanagawa 2528510, Japan.	narai@brs.nihon-u.ac.jp						ABOUSSEKHRA A, 1992, MOL CELL BIOL, V12, P3224, DOI 10.1128/MCB.12.7.3224; ALANI E, 1992, J MOL BIOL, V227, P54, DOI 10.1016/0022-2836(92)90681-9; ARAI N, 1992, J BIOL CHEM, V267, P3514; BENSON FE, 1994, EMBO J, V13, P5764, DOI 10.1002/j.1460-2075.1994.tb06914.x; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P6018, DOI 10.1073/pnas.78.10.6018; CUNNINGHAM RP, 1979, NATURE, V281, P191, DOI 10.1038/281191a0; CUNNINGHAM RP, 1980, CELL, V20, P223, DOI 10.1016/0092-8674(80)90250-0; DICAPUA E, 1982, J MOL BIOL, V157, P87, DOI 10.1016/0022-2836(82)90514-9; DONOVAN JW, 1994, GENE DEV, V8, P2552, DOI 10.1101/gad.8.21.2552; FLORY J, 1984, P NATL ACAD SCI-BIOL, V81, P7026, DOI 10.1073/pnas.81.22.7026; Kagawa W, 2001, J BIOL CHEM, V276, P35201, DOI 10.1074/jbc.M104938200; KAGAWA W, 2003, THESIS U TOKYO; Krejci L, 2002, J BIOL CHEM, V277, P40132, DOI 10.1074/jbc.M206511200; Kurumizaka H, 1999, J MOL BIOL, V291, P537, DOI 10.1006/jmbi.1999.2950; LIU JH, 1995, EMBO J, V14, P4599, DOI 10.1002/j.1460-2075.1995.tb00139.x; Mazin AV, 2000, EMBO J, V19, P1148, DOI 10.1093/emboj/19.5.1148; MCENTEE K, 1979, P NATL ACAD SCI USA, V76, P2615, DOI 10.1073/pnas.76.6.2615; MILNE GT, 1993, GENE DEV, V7, P1755, DOI 10.1101/gad.7.9.1755; Mortensen UH, 1996, P NATL ACAD SCI USA, V93, P10729, DOI 10.1073/pnas.93.20.10729; Namsaraev E, 1997, MOL CELL BIOL, V17, P5359, DOI 10.1128/MCB.17.9.5359; New JH, 2002, J BIOL CHEM, V277, P26171, DOI 10.1074/jbc.M203670200; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; Nishinaka T, 1998, P NATL ACAD SCI USA, V95, P11071, DOI 10.1073/pnas.95.19.11071; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; OHTANI T, 1982, NATURE, V299, P86, DOI 10.1038/299086a0; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; Petukhova G, 2000, GENE DEV, V14, P2206, DOI 10.1101/gad.826100; RADDING CM, 1977, J MOL BIOL, V116, P825, DOI 10.1016/0022-2836(77)90273-X; RATTRAY AJ, 1995, GENETICS, V139, P45; RATTRAY AJ, 1994, GENETICS, V138, P587; Rice KP, 2001, J BIOL CHEM, V276, P38570, DOI 10.1074/jbc.M105678200; Shen ZY, 1996, J BIOL CHEM, V271, P148, DOI 10.1074/jbc.271.1.148; SHIBATA T, 1979, P NATL ACAD SCI USA, V76, P5100, DOI 10.1073/pnas.76.10.5100; SHIBATA T, 1979, P NATL ACAD SCI USA, V76, P1638, DOI 10.1073/pnas.76.4.1638; SHIBATA T, 1983, METHOD ENZYMOL, V100, P197; SHIBATA T, 1982, J BIOL CHEM, V257, P3981; SHIBATA T, 1981, J BIOL CHEM, V256, P7565; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Shinohara A, 1998, NATURE, V391, P404, DOI 10.1038/34943; Shinohara A, 1998, GENES CELLS, V3, P145, DOI 10.1046/j.1365-2443.1998.00176.x; Song BW, 2000, J BIOL CHEM, V275, P15895, DOI 10.1074/jbc.M910244199; SUGAWARA N, 1995, NATURE, V373, P84, DOI 10.1038/373084a0; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; Sugiyama T, 2002, J BIOL CHEM, V277, P31663, DOI 10.1074/jbc.M203494200; Sugiyama T, 1998, P NATL ACAD SCI USA, V95, P6049, DOI 10.1073/pnas.95.11.6049; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Sung P, 2000, MUTAT RES-FUND MOL M, V451, P257, DOI 10.1016/S0027-5107(00)00054-3; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194; Symington LS, 2002, MICROBIOL MOL BIOL R, V66, P630, DOI 10.1128/MMBR.66.4.630-670.2002; Tracy RB, 1997, GENE DEV, V11, P3423, DOI 10.1101/gad.11.24.3423; TSANG SS, 1985, J MOL BIOL, V185, P295, DOI 10.1016/0022-2836(85)90405-X; WIEGAND RC, 1977, J MOL BIOL, V116, P805, DOI 10.1016/0022-2836(77)90272-8; WU TC, 1994, SCIENCE, V263, P515, DOI 10.1126/science.8290959	55	8	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32218	32229		10.1074/jbc.M507521200	http://dx.doi.org/10.1074/jbc.M507521200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16033757	hybrid			2022-12-25	WOS:000231794800023
J	Lee, MS; Edwards, RA; Thede, GL; Glover, JNM				Lee, MS; Edwards, RA; Thede, GL; Glover, JNM			Structure of the BRCT repeat domain of MDC1 and its specificity for the free COOH-terminal end of the gamma-H2AX histone tail	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; CRYSTAL-STRUCTURE; ELECTRON-DENSITY; PHOSPHOPEPTIDE; CANCER; RECOGNITION; BREAST; REGION; BACH1; P53	MDC1 ( mediator of DNA damage checkpoint protein 1) regulates the recognition and repair of DNA double strand breaks in mammalian cells through its interactions with nuclear foci containing the COOH-terminally phosphorylated form of the histone variant, H2AX. Here we demonstrate that the tandem BRCT repeats of MDC1 directly bind to the phosphorylated tail of H2AX-Ser(P)-Gln-Glu-Tyr, in a manner that is critically dependent on the free carboxylate group of the COOH-terminal Tyr residue. We have determined the x-ray crystal structure of the MDC1 BRCT repeats at 1.45 angstrom resolution. By a comparison with the structure of the BRCA1 BRCT bound to a phosphopeptide, we suggest that two arginine residues in MDC1, Arg(1932) and Arg(1933) may recognize the COOH terminus of the peptide as well as the penultimate Glu of H2AX, while Gln(2013) may provide additional specificity for the COOH-terminal Tyr.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada	University of Alberta	Glover, JNM (corresponding author), Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada.	mark.glover@ualberta.ca						Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Clapperton JA, 2004, NAT STRUCT MOL BIOL, V11, P512, DOI 10.1038/nsmb775; Derbyshire DJ, 2002, EMBO J, V21, P3863, DOI 10.1093/emboj/cdf383; Glover JNM, 2004, TRENDS BIOCHEM SCI, V29, P579, DOI 10.1016/j.tibs.2004.09.010; Goldberg M, 2003, NATURE, V421, P952, DOI 10.1038/nature01445; Joo WS, 2002, GENE DEV, V16, P583, DOI 10.1101/gad.959202; Manke IA, 2003, SCIENCE, V302, P636, DOI 10.1126/science.1088877; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Morris RJ, 2003, METHOD ENZYMOL, V374, P229, DOI 10.1016/S0076-6879(03)74011-7; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pilch DR, 2003, BIOCHEM CELL BIOL, V81, P123, DOI 10.1139/o03-042; Rodriguez M, 2003, J BIOL CHEM, V278, P52914, DOI 10.1074/jbc.C300407200; Shiozaki EN, 2004, MOL CELL, V14, P405, DOI 10.1016/S1097-2765(04)00238-2; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Terwilliger T, 2004, J SYNCHROTRON RADIAT, V11, P49, DOI 10.1107/S0909049503023938; Williams RS, 2004, NAT STRUCT MOL BIOL, V11, P519, DOI 10.1038/nsmb776; Williams RS, 2003, J BIOL CHEM, V278, P2630, DOI 10.1074/jbc.M210019200; Williams RS, 2001, NAT STRUCT BIOL, V8, P838, DOI 10.1038/nsb1001-838; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Yu XC, 2004, MOL CELL BIOL, V24, P9478, DOI 10.1128/MCB.24.21.9478-9486.2004	23	98	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32053	32056		10.1074/jbc.C500273200	http://dx.doi.org/10.1074/jbc.C500273200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16049003	hybrid			2022-12-25	WOS:000231794800003
J	Sun, Y; Buki, KG; Ettala, O; Vaaraniemi, JP; Vaananen, HK				Sun, Y; Buki, KG; Ettala, O; Vaaraniemi, JP; Vaananen, HK			Possible role of direct Rac1-Rab7 interaction in ruffled border formation of osteoclasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL GTPASE RAB7; ENDOCYTIC PATHWAY; BONE-RESORPTION; PROTEIN RILP; RHO GTPASES; MEMBRANE; ACTIN; RAC1; TRANSPORT; CDC42	Rab7 has been shown to regulate the late steps of the endocytic pathway. In bone-resorbing osteoclasts, it is involved in formation of the ruffled border, which is a late endosomal-like compartment in the plasma membrane. Here we report a new Rab7-interacting protein, Rac1, another small GTPase protein that binds to the GTP-form of Rab7 as found with a two-hybrid system. We demonstrate further that Rab7 colocalizes with Rac1 at the fusion zone of the ruffled border in bone-resorbing osteoclasts. In other cell types, such as fibroblast-like cells, partial colocalization is perinuclear. Because Rac1 is known to control the actin cytoskeleton through its effectors, the Rab7-Rac1 interaction may mediate late endosomal transport between microtubules and microfilaments enabling endosomal vesicles to switch tracks and may thus also regulate ruffled border formation in osteoclasts.	Turku Univ, Inst Biomed, Dept Anat, FI-20700 Turku, Finland	University of Turku	Vaananen, HK (corresponding author), Turku Univ, Inst Biomed, Dept Anat, Kiinamyllynkatu 10, FI-20700 Turku, Finland.	kalervo.vaananen@utu.fi		Ettala, Otto/0000-0003-1011-4602				BARON R, 1985, J CELL BIOL, V101, P2210, DOI 10.1083/jcb.101.6.2210; Cantalupo G, 2001, EMBO J, V20, P683, DOI 10.1093/emboj/20.4.683; CAVIER P, 1999, CURR OPIN CELL BIOL, V11, P466; Dong JB, 2004, J BIOL CHEM, V279, P21334, DOI 10.1074/jbc.M401022200; Dove SL, 1997, NATURE, V386, P627, DOI 10.1038/386627a0; Echard A, 1998, SCIENCE, V279, P580, DOI 10.1126/science.279.5350.580; Erickson JW, 1997, J BIOL CHEM, V272, P24443, DOI 10.1074/jbc.272.39.24443; FENG Y, 1995, J CELL BIOL, V131, P1435, DOI 10.1083/jcb.131.6.1435; Fukata M, 2002, CELL, V109, P873, DOI 10.1016/S0092-8674(02)00800-0; Fukata M, 1997, J BIOL CHEM, V272, P29579, DOI 10.1074/jbc.272.47.29579; Glogauer M, 2003, J IMMUNOL, V170, P5652, DOI 10.4049/jimmunol.170.11.5652; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Jordens I, 2001, CURR BIOL, V11, P1680, DOI 10.1016/S0960-9822(01)00531-0; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Knaus UG, 1998, J BIOL CHEM, V273, P21512, DOI 10.1074/jbc.273.34.21512; Mattson NP, 1997, J BONE MINER RES, V12, P753, DOI 10.1359/jbmr.1997.12.5.753; MERESSE S, 1995, J CELL SCI, V108, P3349; Mizuno K, 2003, MOL BIOL CELL, V14, P3741, DOI 10.1091/mbc.E02-08-0495; MOLL J, 1991, ONCOGENE, V6, P863; Mulari MTK, 2003, TRAFFIC, V4, P113, DOI 10.1034/j.1600-0854.2003.40206.x; Nomura N, 1994, DNA Res, V1, P223, DOI 10.1093/dnares/1.5.223; Olkkonen VM, 1997, INT REV CYTOL, V176, P1, DOI 10.1016/S0074-7696(08)61608-3; Palokangas H, 1997, J CELL SCI, V110, P1767; Peranen J, 1996, J CELL BIOL, V135, P153, DOI 10.1083/jcb.135.1.153; Perez F, 1999, CELL, V96, P517, DOI 10.1016/S0092-8674(00)80656-X; Pfeffer SR, 2001, TRENDS CELL BIOL, V11, P487, DOI 10.1016/S0962-8924(01)02147-X; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; Salo J, 1997, SCIENCE, V276, P270, DOI 10.1126/science.276.5310.270; SALO J, 1996, J CELL SCI, V106, P301; Salo J., 1994, MOL BIOL CELL S, V5, P431; Seabra MC, 2004, TRAFFIC, V5, P393, DOI 10.1111/j.1398-9219.2004.00190.x; SHIRSAT NV, 1990, ONCOGENE, V5, P769; Stein MP, 2003, TRAFFIC, V4, P754, DOI 10.1034/j.1600-0854.2003.00133.x; SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66; Sugihara K, 1998, ONCOGENE, V17, P3427, DOI 10.1038/sj.onc.1202595; Vaananen HK, 2000, J CELL SCI, V113, P377; VAANANEN HK, 1990, J CELL BIOL, V111, P1305, DOI 10.1083/jcb.111.3.1305; VAANANEN HK, 1995, J CELL SCI, V108, P2729; Vitelli R, 1997, J BIOL CHEM, V272, P4391, DOI 10.1074/jbc.272.7.4391; WANG T, 2000, MOL BIOL CELL, V13, P4317; Waters MG, 1999, CURR OPIN CELL BIOL, V11, P453, DOI 10.1016/S0955-0674(99)80065-9; Weernink PAO, 2004, J BIOL CHEM, V279, P7840, DOI 10.1074/jbc.M312737200; WEISSBACH L, 1994, J BIOL CHEM, V269, P20517; Wells CM, 2004, J CELL SCI, V117, P1259, DOI 10.1242/jcs.00997; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I; Zhang X, 2005, ARTHRITIS RHEUM-US, V52, P1297, DOI 10.1002/art.20984; Zhao H., 2000, CALCIFIED TISSUE INT, V52, pS63; Zhao HB, 2001, J BIOL CHEM, V276, P39295, DOI 10.1074/jbc.M010999200	49	57	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32356	32361		10.1074/jbc.M414213200	http://dx.doi.org/10.1074/jbc.M414213200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16040606	hybrid			2022-12-25	WOS:000231794800040
J	Aziz, MA; Sikriwal, D; Singh, S; Jarugula, S; Kumar, PA; Bhatnagar, R				Aziz, MA; Sikriwal, D; Singh, S; Jarugula, S; Kumar, PA; Bhatnagar, R			Transformation of an edible crop with the pagA gene of Bacillus anthracis	FASEB JOURNAL			English	Article						anthrax; protective antigen; chloroplast; biolistics; vaccine	TOXIN B-SUBUNIT; PROTECTIVE ANTIGEN; TRANSGENIC PLANTS; EXPRESSION; VACCINE; IMMUNIZATION; ANTIBODIES; PROMOTERS; INDUCTION; STABILITY	Vaccination against anthrax is the most important strategy to combat the disease. This study describes a generation of edible transgenic crop expressing, functional protective antigen (PA). In vitro studies showed that the plant-expressed antigen is qualitatively similar to recombinant PA. Immunization studies in mouse animal models indicated the generation of PA-specific neutralizing antibodies and stressed the need for improving expression levels to generate higher antibody titers. Genetic engineering of a plant organelle offers immense scope for increasing levels of antigen expression. An AT-rich PA gene (pagA) coding for the 83-kDa PA molecule was thus cloned and expressed in tobacco chloroplasts. Biolistics was used for the transformation of a chloroplast genome under a set of optimized conditions. The expression of the pagA gene with 69% AT content was highly favored by an AT-rich chloroplast genome. A multifold expression level of functional PA was obtained as compared with the nuclear transgenic tobacco plants. This report describes for the first time a comprehensive study on generating transgenic plants expressing PA, which may serve as a source of an edible vaccine against anthrax. Two important achievements of expressing PA in an edible crop and use of chloroplast technology to enhance the expression levels are discussed here.	Jawaharlal Nehru Univ, Ctr Biotechnol, New Delhi 110067, India; Indian Agr Res Inst, Natl Res Ctr Plant Biotechnol, New Delhi 110012, India	Jawaharlal Nehru University, New Delhi; Indian Council of Agricultural Research (ICAR); ICAR - Indian Agricultural Research Institute; ICAR - National Institute For Plant Biotechnology (NIPB)	Bhatnagar, R (corresponding author), Jawaharlal Nehru Univ, Ctr Biotechnol, New Delhi 110067, India.	rakeshbhatnagar@mail.jnu.ac.in	Aziz, Mohammad Azhar/F-7486-2013; Singh, Samer/H-8468-2013; Jarugula, Sridhar/L-9588-2019; P, Anantakumar/D-3605-2009	Aziz, Mohammad Azhar/0000-0002-0798-5063; Singh, Samer/0000-0002-0921-1686; 				Aziz MA, 2002, BIOCHEM BIOPH RES CO, V299, P345, DOI 10.1016/S0006-291X(02)02625-6; Bhatnagar R, 2001, CRIT REV MICROBIOL, V27, P167, DOI 10.1080/20014091096738; Biemelt S, 2003, J VIROL, V77, P9211, DOI 10.1128/JVI.77.17.9211-9220.2003; Bock R, 2004, TRENDS BIOTECHNOL, V22, P311, DOI 10.1016/j.tibtech.2004.03.005; Bock R, 2001, J MOL BIOL, V312, P425, DOI 10.1006/jmbi.2001.4960; Dale PJ, 2002, NAT BIOTECHNOL, V20, P567, DOI 10.1038/nbt0602-567; Daniell H, 2001, J MOL BIOL, V311, P1001, DOI 10.1006/jmbi.2001.4921; Daniell H, 2002, TRENDS PLANT SCI, V7, P84, DOI 10.1016/S1360-1385(01)02193-8; Daniell H, 2001, TRENDS PLANT SCI, V6, P219, DOI 10.1016/S1360-1385(01)01922-7; Fei SZ, 2000, PLANT CELL TISS ORG, V60, P197, DOI 10.1023/A:1006468324616; FRIEDLANDER AM, 1986, J BIOL CHEM, V261, P7123; Giddings G, 2000, NAT BIOTECHNOL, V18, P1151, DOI 10.1038/81132; Gu ML, 1999, VACCINE, V17, P340, DOI 10.1016/S0264-410X(98)00210-2; Gupta P, 1999, PROTEIN EXPRES PURIF, V16, P369, DOI 10.1006/prep.1999.1066; HAQ TA, 1995, SCIENCE, V268, P714, DOI 10.1126/science.7732379; HOEKEMA A, 1983, NATURE, V303, P179, DOI 10.1038/303179a0; IACONOCONNORS LC, 1991, INFECT IMMUN, V59, P1961, DOI 10.1128/IAI.59.6.1961-1965.1991; IVINS BE, 1992, INFECT IMMUN, V60, P662, DOI 10.1128/IAI.60.2.662-668.1992; Jani D, 2002, TRANSGENIC RES, V11, P447, DOI 10.1023/A:1020336332392; Komine Y, 2002, P NATL ACAD SCI USA, V99, P4085, DOI 10.1073/pnas.052327599; LEPPLA SH, 1985, MICROBIOLOGY, P62; Losey JE, 1999, NATURE, V399, P214, DOI 10.1038/20338; Maliga P, 2002, CURR OPIN PLANT BIOL, V5, P164, DOI 10.1016/S1369-5266(02)00248-0; Mason HS, 2002, TRENDS MOL MED, V8, P324, DOI 10.1016/S1471-4914(02)02360-2; Muellenhoff M, 2004, J AM ACAD DERMATOL, V50, P136, DOI 10.1016/S0190-9622(03)00407-9; Muniz AE, 2003, J EMERG MED, V25, P271, DOI 10.1016/S0736-4679(03)00201-4; PEZARD C, 1995, INFECT IMMUN, V63, P1369, DOI 10.1128/IAI.63.4.1369-1372.1995; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANFORD JC, 1993, METHOD ENZYMOL, V217, P483; Santos MJD, 2002, VACCINE, V20, P1141, DOI 10.1016/S0264-410X(01)00434-0; SHIMADA H, 1991, NUCLEIC ACIDS RES, V19, P983, DOI 10.1093/nar/19.5.983; Sojikul P, 2003, P NATL ACAD SCI USA, V100, P2209, DOI 10.1073/pnas.0438037100; Staub JM, 2000, NAT BIOTECHNOL, V18, P333, DOI 10.1038/73796; Streatfield SJ, 2003, INT J PARASITOL, V33, P479, DOI 10.1016/S0020-7519(03)00052-3; Streatfield Stephen J, 2003, Expert Rev Vaccines, V2, P763, DOI 10.1586/14760584.2.6.763; Sussman HE, 2003, DRUG DISCOV TODAY, V8, P428, DOI 10.1016/S1359-6446(03)02706-5; VERA A, 1995, CURR GENET, V27, P280, DOI 10.1007/BF00326161; Walmsley AM, 2000, CURR OPIN BIOTECH, V11, P126, DOI 10.1016/S0958-1669(00)00070-7; Wasserman GM, 2003, J OCCUP ENVIRON MED, V45, P222, DOI 10.1097/01.jom.0000058345.05741.6b; Watson J, 2004, VACCINE, V22, P4374, DOI 10.1016/j.vaccine.2004.01.069; Webster DE, 2002, MED J AUSTRALIA, V176, P434; Wein LM, 2003, P NATL ACAD SCI USA, V100, P4346, DOI 10.1073/pnas.0636861100; Welkos S, 2001, MICROBIOL-SGM, V147, P1677, DOI 10.1099/00221287-147-6-1677; Yuki Y, 2003, REV MED VIROL, V13, P293, DOI 10.1002/rmv.398	45	25	29	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1501	+		10.1096/fj.04-3215fje	http://dx.doi.org/10.1096/fj.04-3215fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16030177				2022-12-25	WOS:000230923000018
J	Nguyen, QD; De Wever, O; Bruyneel, E; Hendrix, A; Xie, WZ; Lombet, A; Leibl, M; Mareel, M; Gieseler, F; Bracke, M; Gespach, C				Nguyen, QD; De Wever, O; Bruyneel, E; Hendrix, A; Xie, WZ; Lombet, A; Leibl, M; Mareel, M; Gieseler, F; Bracke, M; Gespach, C			Commutators of PAR-1 signaling in cancer cell invasion reveal an essential role of the Rho-Rho kinase axis and tumor microenvironment	ONCOGENE			English	Article						PKG; hypoxia; SPARC/BM-40; tenascin-C; peritoneal and pleural effusions; metastasis and thrombosis	PROTEASE-ACTIVATED RECEPTOR-1; VASCULAR SMOOTH-MUSCLE; GROWTH-FACTOR RECEPTOR; THROMBIN RECEPTOR; EPITHELIAL-CELLS; NEOPLASTIC PROGRESSION; TREFOIL PEPTIDES; FOCAL ADHESIONS; STRESS FIBERS; EXPRESSION	We recently reported that proteinase-activated receptors type I (PAR-1) are coupled to both negative and positive invasion pathways in colonic and kidney cancer cells cultured on collagen type I gels. Here, we found that treatments with the cell-permeant analog 8-Br-cGMP and the soluble guanylate cyclase activator BAY41-2272, and Rho kinase (ROK) inhibit ion by Y27632 or a dominant negative form of ROK lead to PAR-1-mediated invasion through differential Rac1 and Cdc42 signaling. Hypoxia or the counteradhesive matricellular protein SPARC/BM-40 ( SPARC: secreted protein acidic rich in cysteine) overexpressed during cancer progression also commutated PAR-1 to cellular invasion through the cGMP/protein kinase G (PKG) cascade, RhoA inactivation, and Rac1-dependent or -independent signaling. Cultured primary cancer cells isolated from peritoneal and pleural effusions from patients with colon cancer or other malignant tumors harbored PAR-1, as shown by RT-PCR and FACS analyses. These malignant effusions also contained high levels of activated thrombin and fibrin, and induced a proinvasive response in HCT8/S11 human colorectal cancer cells. Our data underline the essential role of the tumor microenvironment and of several commutators targeting cGMP/PKG signaling and the RhoA-ROK axis in the control of PAR-1 proinvasive activity and metastatic potential of cancer cells in distant organs and peritoneal or pleural cavities. We also add new insights into the mechanisms linking the coagulation mediators thrombin and PAR-1 in the context of blood coagulation disorders and venous thrombosis often observed in cancer patients, as described in 1865 by Armand Trousseau.	Hop St Antoine, INSERM, U673, F-75571 Paris, France; Ghent Univ Hosp, Expt Cancerol Lab, B-9000 Ghent, Belgium; Univ Kiel, Dept Internal Med, D-24105 Kiel, Germany; Zhejiang Univ, Affiliated Hosp 1, Coll Med, Zhejiang, Peoples R China; Hop Marie Lannelongue, CNRS, UMR8078, F-92350 Le Plessis Robinson, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Ghent University; Ghent University Hospital; University of Kiel; Zhejiang University; Centre National de la Recherche Scientifique (CNRS); Hopital Marie Lannelongue	Gespach, C (corresponding author), Hop St Antoine, INSERM, U673, 184 Rue Faubourg St Antoine, F-75571 Paris, France.	gespach@st-antoine.inserm.fr	Gieseler, Frank/L-4668-2013; Hendrix, An/L-5918-2019; de wever, olivier/J-3094-2013; Gieseler, Frank/E-8386-2012	de wever, olivier/0000-0002-5453-760X; Gieseler, Frank/0000-0001-6409-3822				Ahn B, 2001, CANCER RES, V61, P8357; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Andre T, 2000, INT J CANCER, V86, P174, DOI 10.1002/(SICI)1097-0215(20000415)86:2<174::AID-IJC5>3.3.CO;2-5; Begum N, 2002, J BIOL CHEM, V277, P6214, DOI 10.1074/jbc.M110508200; Bellanger JM, 2000, NAT CELL BIOL, V2, P888, DOI 10.1038/35046533; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Boccaccio C, 2005, NATURE, V434, P396, DOI 10.1038/nature03357; Boire A, 2005, CELL, V120, P303, DOI 10.1016/j.cell.2004.12.018; Booden MA, 2002, MOL CELL BIOL, V22, P4053, DOI 10.1128/MCB.22.12.4053-4061.2002; BRACKE ME, 2000, COLLAGEN INVASION AS, V58, P81; Bradshaw AD, 2001, J CLIN INVEST, V107, P1049, DOI 10.1172/JCI12939; Cerione RA, 2004, TRENDS CELL BIOL, V14, P127, DOI 10.1016/j.tcb.2004.01.008; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Darmoul D, 2004, MOL CANCER RES, V2, P514; Darmoul D, 2003, AM J PATHOL, V162, P1503, DOI 10.1016/S0002-9440(10)64283-6; De Wever O, 2004, FASEB J, V18, P1016, DOI 10.1096/fj.03-1110fje; EMAMI S, 1984, BIOCHIM BIOPHYS ACTA, V804, P77, DOI 10.1016/0167-4889(84)90101-0; Even-Ram S, 1998, NAT MED, V4, P909, DOI 10.1038/nm0898-909; Even-Ram SC, 2001, J BIOL CHEM, V276, P10952, DOI 10.1074/jbc.M007027200; Faivre S, 2001, MOL PHARMACOL, V60, P363, DOI 10.1124/mol.60.2.363; Hansen SH, 2000, MOL CELL BIOL, V20, P9364, DOI 10.1128/MCB.20.24.9364-9375.2000; Hou YL, 2004, CELL SIGNAL, V16, P1061, DOI 10.1016/j.cellsig.2004.03.002; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Kamath L, 2001, CANCER RES, V61, P5933; Kawasaki K, 2003, MOL CELL BIOL, V23, P5726, DOI 10.1128/MCB.23.16.5726-5737.2003; Kisley LR, 2002, CANCER RES, V62, P6850; Kotelevets L, 1998, J BIOL CHEM, V273, P14138, DOI 10.1074/jbc.273.23.14138; Kureishi Y, 1997, J BIOL CHEM, V272, P12257, DOI 10.1074/jbc.272.19.12257; Le Floch N, 2004, FASEB J, V18, P144, DOI 10.1096/fj.04-2373fje; Ledda MF, 1997, NAT MED, V3, P171, DOI 10.1038/nm0297-171; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Marinissen MJ, 2004, MOL CELL, V14, P29, DOI 10.1016/S1097-2765(04)00153-4; Maschler S, 2004, ONCOGENE, V23, P3622, DOI 10.1038/sj.onc.1207403; McHardy LM, 2004, CANCER RES, V64, P1468, DOI 10.1158/0008-5472.CAN-03-2733; MURPHYULLRICH JE, 1995, J CELL BIOCHEM, V57, P341, DOI 10.1002/jcb.240570218; Nguyen QD, 2002, FASEB J, V16, P565, DOI 10.1096/fj.01-0525com; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Poola I, 2005, NAT MED, V11, P481, DOI 10.1038/nm1243; PORTE H, 1995, INT J CANCER, V64, P70, DOI 10.1002/ijc.2910640114; Ricort JM, 2002, FEBS LETT, V527, P293, DOI 10.1016/S0014-5793(02)03250-7; Ridley AJ, 2001, J CELL SCI, V114, P2713; Rivat C, 2003, FASEB J, V17, P1721, DOI 10.1096/fj.03-0132fje; Rodrigues S, 2003, ONCOGENE, V22, P4488, DOI 10.1038/sj.onc.1206685; Rodrigues S, 2001, FASEB J, V15, P1517, DOI 10.1096/fj.00-0802com; Sandu OA, 2001, J APPL PHYSIOL, V91, P1475, DOI 10.1152/jappl.2001.91.3.1475; Sauzeau V, 2000, J BIOL CHEM, V275, P21722, DOI 10.1074/jbc.M000753200; Sawada N, 2001, BIOCHEM BIOPH RES CO, V280, P798, DOI 10.1006/bbrc.2000.4194; Schafer B, 2004, ONCOGENE, V23, P991, DOI 10.1038/sj.onc.1207278; Stasch JP, 2001, NATURE, V410, P212, DOI 10.1038/35065611; Thomas R, 2000, CLIN CANCER RES, V6, P1140; VanObberghenSchilling E, 1995, ANN NY ACAD SCI, V766, P431, DOI 10.1111/j.1749-6632.1995.tb26692.x; WOJTUKIEWICZ MZ, 1995, CANCER RES, V55, P698; Xie WZ, 2005, BIOMED PHARMACOTHER, V59, P70, DOI 10.1016/j.biopha.2005.01.001; Zhao DZ, 2004, J BIOL CHEM, V279, P43547, DOI 10.1074/jbc.M401453200	55	42	46	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2005	24	56					8240	8251		10.1038/sj.onc.1208990	http://dx.doi.org/10.1038/sj.onc.1208990			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	993LV	16091733				2022-12-25	WOS:000233956500003
J	Fischer, C; Sanchez-Ruderisch, H; Welzel, M; Wiedenmann, B; Sakai, T; Andre, S; Gabius, HJ; Khachigian, L; Detjen, KM; Rosewicz, S				Fischer, C; Sanchez-Ruderisch, H; Welzel, M; Wiedenmann, B; Sakai, T; Andre, S; Gabius, HJ; Khachigian, L; Detjen, KM; Rosewicz, S			Galectin-1 interacts with the alpha 5 beta 1 fibronectin receptor to restrict carcinoma cell growth via induction of p21 and p27	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUROBLASTOMA-CELLS; FACTOR GENE-TRANSCRIPTION; DNA-BINDING ACTIVITY; GANGLIOSIDE GM(1); CYCLE PROGRESSION; PROTEIN-KINASE; MAMMALIAN GALECTINS; SP1 PHOSPHORYLATION; INTEGRIN RECEPTORS; INTERFERON-ALPHA	Surface binding of galectin family members has the potential to link distinct glycan structures to growth regulation. Therefore, we addressed the antiproliferative potential of galectin-1 (Gal-1) in a panel of carcinoma cell lines. We discovered growth inhibition by Gal-1 in epithelial tumor cell lines from different origins and provide evidence that this effect requires functional interaction with the alpha 5 beta 1 integrin. Antiproliferative effects result from inhibition of the Ras-MEK-ERK pathway and consecutive transcriptional induction of p27. We have further identified two Sp1-binding sites in the p27 promoter as crucial for Gal-1 responsiveness. Inhibition of the Ras-MEK-ERK cascade by Gal-1 increased Sp1 transactivation and DNA binding due to reduced threonine phosphorylation of Sp1. Furthermore, Gal-1 induced p21 transcription and selectively increased p27 protein stability. Gal-1-mediated accumulation of p27 and p21 inhibited cyclin-dependent kinase 2 activity and ultimately resulted in G(1) cell cycle arrest and growth inhibition. These data define a novel mechanism whereby Gal-1 regulates epithelial tumor cell homeostasis via carbohydrate-dependent interaction with the alpha 5 beta 1 integrin.	Charite Univ Med Berlin, Med Klin Schwerpunkt Hepatol & Gastroenterol, D-13353 Berlin, Germany; Kyoto Prefectural Univ Med, Dept Prevent Med, Kamigyo Ku, Kyoto 6028566, Japan; Univ Munich, Tierarztliche Fak, Inst Physiol Chem, D-80539 Munich, Germany; Univ New S Wales, Prince Wales Hosp, Ctr Vasc Res, Sydney, NSW 2052, Australia	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Kyoto Prefectural University of Medicine; University of Munich; University of New South Wales Sydney	Fischer, C (corresponding author), Charite Univ Med Berlin, Med Klin Schwerpunkt Hepatol & Gastroenterol, Campus Virchow Klinikum,Augustenburger Pl 1, D-13353 Berlin, Germany.	katharina.detjen@charite.de	Khachigian, Levon/AAZ-7458-2020	Gabius, Hans-Joachim/0000-0003-3467-3900; Wiedenmann, Bertram/0000-0002-7890-2552; Khachigian, Levon/0000-0003-3446-0323; Sanchez Ruderisch, Hugo/0000-0001-9315-4508; Andre, Sabine/0000-0003-0850-0432				Adams L, 1996, BBA-MOL CELL RES, V1312, P137, DOI 10.1016/0167-4889(96)00031-6; Ahmad N, 2004, J BIOL CHEM, V279, P10841, DOI 10.1074/jbc.M312834200; Andre S, 1999, J CANCER RES CLIN, V125, P461, DOI 10.1007/s004320050303; Andre S, 2005, INT J CANCER, V114, P46, DOI 10.1002/ijc.20699; Andre S, 2004, EUR J BIOCHEM, V271, P118, DOI 10.1046/j.1432-1033.2003.03910.x; Andre S, 2001, CHEMBIOCHEM, V2, P822, DOI 10.1002/1439-7633(20011105)2:11<822::AID-CBIC822>3.0.CO;2-W; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; Assoian RK, 2001, CURR OPIN GENET DEV, V11, P48, DOI 10.1016/S0959-437X(00)00155-6; Berberat PO, 2001, J HISTOCHEM CYTOCHEM, V49, P539, DOI 10.1177/002215540104900414; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Bonello MR, 2004, J BIOL CHEM, V279, P2377, DOI 10.1074/jbc.M308254200; Brewer CF, 2002, BBA-GEN SUBJECTS, V1572, P255, DOI 10.1016/S0304-4165(02)00312-4; Cooper DNW, 2002, BBA-GEN SUBJECTS, V1572, P209, DOI 10.1016/S0304-4165(02)00310-0; Detjen KM, 2000, GASTROENTEROLOGY, V118, P735, DOI 10.1016/S0016-5085(00)70143-0; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Gabius HJ, 2004, CHEMBIOCHEM, V5, P740, DOI 10.1002/cbic.200300753; Gabius HJ, 1997, EUR J BIOCHEM, V243, P543, DOI 10.1111/j.1432-1033.1997.t01-1-00543.x; GABIUS HJ, 1984, J NATL CANCER I, V73, P1349; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; Giancotti FG, 2003, ANNU REV CELL DEV BI, V19, P173, DOI 10.1146/annurev.cellbio.19.031103.133334; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GU MJ, 1994, J CELL SCI, V107, P175; Hadari YR, 2000, J CELL SCI, V113, P2385; Haidweger E, 2001, J MOL BIOL, V306, P201, DOI 10.1006/jmbi.2000.4406; Hata Y, 1998, J BIOL CHEM, V273, P19294, DOI 10.1074/jbc.273.30.19294; Hughes RC, 2001, BIOCHIMIE, V83, P667; Inoue T, 1999, J BIOL CHEM, V274, P32309, DOI 10.1074/jbc.274.45.32309; Klein S, 2002, MOL CELL BIOL, V22, P5912, DOI 10.1128/MCB.22.16.5912-5922.2002; Kopitz J, 1998, J BIOL CHEM, V273, P11205, DOI 10.1074/jbc.273.18.11205; Kopitz J, 2003, ONCOGENE, V22, P6277, DOI 10.1038/sj.onc.1206631; Kopitz J, 2001, J BIOL CHEM, V276, P35917, DOI 10.1074/jbc.M105135200; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; Levy Y, 2003, J BIOL CHEM, V278, P14533, DOI 10.1074/jbc.M207380200; Lopez-Lucendo MF, 2004, J MOL BIOL, V343, P957, DOI 10.1016/j.jmb.2004.08.078; Maeda N, 2003, J BIOL CHEM, V278, P18938, DOI 10.1074/jbc.M209673200; Milanini-Mongiat J, 2002, J BIOL CHEM, V277, P20631, DOI 10.1074/jbc.M201753200; Minami S, 1997, FEBS LETT, V411, P1, DOI 10.1016/S0014-5793(97)00660-1; MIRANTI CK, 2002, NATURE CELL BIOL, V4, P83; Moiseeva EP, 1999, J VASC RES, V36, P47, DOI 10.1159/000025625; Moiseeva EP, 2003, BIOCHEM BIOPH RES CO, V310, P1010, DOI 10.1016/j.bbrc.2003.09.112; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; Plath T, 2000, J CELL BIOL, V150, P1467, DOI 10.1083/jcb.150.6.1467; Qiang YW, 2000, EXP HEMATOL, V28, P1147, DOI 10.1016/S0301-472X(00)00521-X; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Ruoslahti E, 1999, ADV CANCER RES, V76, P1, DOI 10.1016/S0065-230X(08)60772-1; Schuppan D, 2003, HEPATOLOGY, V38, P289, DOI 10.1053/jhep.2003.50338; Siebert HC, 2003, BIOCHEMISTRY-US, V42, P14762, DOI 10.1021/bi035477c; Sturm A, 2004, J IMMUNOL, V173, P3825, DOI 10.4049/jimmunol.173.6.3825; TOWNSEND CM, 1993, ACTA ONCOL, V32, P125, DOI 10.3109/02841869309083900; van den Brule F, 2003, LAB INVEST, V83, P377, DOI 10.1097/01.LAB.0000059949.01480.40; Vespa GNR, 1999, J IMMUNOL, V162, P799; von Marschall Z, 2003, J NATL CANCER I, V95, P437, DOI 10.1093/jnci/95.6.437; Vrasidas I, 2003, ORG BIOMOL CHEM, V1, P803, DOI 10.1039/b210923a; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Yang RY, 2003, CELL MOL LIFE SCI, V60, P267, DOI 10.1007/s000180300022; Ye XB, 2002, J BIOL CHEM, V277, P31863, DOI 10.1074/jbc.M205544200; Zhang H, 2003, HEPATOLOGY, V38, P305, DOI 10.1053/jhep.2003.50345; Zhang Y, 1997, BBA-GENE STRUCT EXPR, V1353, P307, DOI 10.1016/S0167-4781(97)00063-8; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161	61	153	158	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					37266	37277		10.1074/jbc.M411580200	http://dx.doi.org/10.1074/jbc.M411580200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16105842	hybrid			2022-12-25	WOS:000232901800085
J	Henriksen, U; Fog, JU; Litman, T; Gether, U				Henriksen, U; Fog, JU; Litman, T; Gether, U			Identification of intra- and intermolecular disulfide bridges in the multidrug resistance transporter ABCG2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER RESISTANCE; HALF-TRANSPORTER; MONOCLONAL-ANTIBODY; PROTEIN; CELLS; MITOXANTRONE; OVEREXPRESSION; EXPRESSION; MXR; HETERODIMERIZATION	ABCG2 is an ATP binding cassette (ABC) half-transporter that plays a key role in multidrug resistance to chemotherapy. ABCG2 is believed to be a functional homodimer that has been proposed to be linked by disulfide bridges. We have investigated the structural and functional role of the only three cysteines predicted to be on the extracellular face of ABCG2. Upon mutation of Cys-592 or Cys-608 to alanine (C592A and C608A), ABCG2 migrated as a dimer in SDS-PAGE under non-reducing conditions; however, mutation of Cys-603 to Ala (C603A) caused the transporter to migrate as a single monomeric band. Despite this change, C603A displayed efficient membrane targeting and preserved transport function. Because the transporter migrated as a dimer in SDS-PAGE, when only Cys-603 was present (C592A-C608A), the data suggest that Cys-603 forms a symmetrical intermolecular disulfide bridge in the ABCG2 homodimer that is not essential for protein expression and function. In contrast to C603A, both C592A and C608A displayed impaired membrane targeting and function. Moreover, when only Cys-592 or Cys-608 were present ( C592A/C603A and C603A/ C608A), the transporter displayed impaired plasma membrane expression and function. The combined mutation (C592A/C608A) partially restored plasma membrane expression; however, although transport of mitoxantrone was almost normal, we observed impairment of BODIPY-prazosin transport. This supports the conclusion that Cys-592 and Cys-608 form an intramolecular disulfide bridge in ABCG2 that is critical for substrate specificity. Finally, mutation of all three cysteines simultaneously resulted in low expression and no measurable function. Altogether, our data are consistent with a scenario in which an inter- and an intramolecular disulfide bridge together are of fundamental importance for the structural and functional integrity of ABCG2.	Univ Copenhagen, Panum Inst, Dept Pharmacol, Mol Neuropharmacol Grp, DK-2200 Copenhagen, Denmark; Univ Copenhagen, Bioinformat Ctr, DK-2100 Copenhagen, Denmark	University of Copenhagen; University of Copenhagen	Gether, U (corresponding author), Univ Copenhagen, Panum Inst, Dept Pharmacol, Mol Neuropharmacol Grp, Bldg 18-6,Blegdamsvej 3, DK-2200 Copenhagen, Denmark.	gether@neuropharm.ku.dk		Gether, Ulrik/0000-0002-0020-3807; Litman, Thomas/0000-0002-6068-901X				Allikmets R, 1998, CANCER RES, V58, P5337; Brangi M, 1999, CANCER RES, V59, P5938; Cao W, 2004, BIOCHEM J, V378, P201, DOI 10.1042/BJ20031288; Davidson AL, 1997, J BACTERIOL, V179, P5458, DOI 10.1128/jb.179.17.5458-5464.1997; Diah SK, 2001, CANCER RES, V61, P5461; Diestra JE, 2002, J PATHOL, V198, P213, DOI 10.1002/path.1203; Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665; Getz EB, 1999, ANAL BIOCHEM, V273, P73, DOI 10.1006/abio.1999.4203; Graf GA, 2004, J BIOL CHEM, V279, P24881, DOI 10.1074/jbc.M402634200; Graf GA, 2003, J BIOL CHEM, V278, P48275, DOI 10.1074/jbc.M310223200; Graf GA, 2002, J CLIN INVEST, V110, P659, DOI 10.1172/JCI200216000; Henriksen U, 2005, J CELL SCI, V118, P1417, DOI 10.1242/jcs.01729; Janvilisri T, 2003, J BIOL CHEM, V278, P20645, DOI 10.1074/jbc.M301358200; Kage K, 2002, INT J CANCER, V97, P626, DOI 10.1002/ijc.10100; Kim M, 2002, CLIN CANCER RES, V8, P22; Langosch D, 1996, J MOL BIOL, V263, P525, DOI 10.1006/jmbi.1996.0595; LEE JS, 1994, MOL PHARMACOL, V46, P627; LEMMON MA, 1994, NAT STRUCT BIOL, V1, P157, DOI 10.1038/nsb0394-157; Litman T, 2001, CELL MOL LIFE SCI, V58, P931, DOI 10.1007/PL00000912; Litman T, 2002, BBA-BIOMEMBRANES, V1565, P6, DOI 10.1016/S0005-2736(02)00492-3; Litman T, 2000, J CELL SCI, V113, P2011; Liu LX, 1999, J BIOL CHEM, V274, P32738, DOI 10.1074/jbc.274.46.32738; Maliepaard M, 2001, CANCER RES, V61, P3458; Miyake K, 1999, CANCER RES, V59, P8; Ozvegy C, 2002, J BIOL CHEM, V277, P47980, DOI 10.1074/jbc.M207857200; Ozvegy-Laczka C, 2005, J BIOL CHEM, V280, P4219, DOI 10.1074/jbc.M411338200; Polgar O, 2004, BIOCHEMISTRY-US, V43, P9448, DOI 10.1021/bi0497953; Rees S, 1996, BIOTECHNIQUES, V20, P102; Robey RW, 2001, CLIN CANCER RES, V7, P145; Rocchi E, 2000, BIOCHEM BIOPH RES CO, V271, P42, DOI 10.1006/bbrc.2000.2590; Ross DD, 2000, BLOOD, V96, P365, DOI 10.1182/blood.V96.1.365.013k46_365_368; Sauerbrey A, 2002, BRIT J HAEMATOL, V118, P147, DOI 10.1046/j.1365-2141.2002.03550.x; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; van Veen HW, 2000, EMBO J, V19, P2503, DOI 10.1093/emboj/19.11.2503; Volk EL, 2002, CANCER RES, V62, P5035; Xu JK, 2004, J BIOL CHEM, V279, P19781, DOI 10.1074/jbc.M310785200; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028	37	102	108	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36926	36934		10.1074/jbc.M502937200	http://dx.doi.org/10.1074/jbc.M502937200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16107343	hybrid			2022-12-25	WOS:000232901800049
J	Narita, N; Fujieda, S; Tokuriki, M; Takahashi, N; Tsuzuki, H; Ohtsubo, T; Matsumoto, H				Narita, N; Fujieda, S; Tokuriki, M; Takahashi, N; Tsuzuki, H; Ohtsubo, T; Matsumoto, H			Inhibition of histone deacetylase 3 stimulates apoptosis induced by heat shock under acidic conditions in human maxillary cancer	ONCOGENE			English	Article						cDNA array; hyperthermia; low pH; HDAC3; head and neck cancer	HISTONE DEACETYLASE INHIBITOR; EPIDERMAL-GROWTH-FACTOR; IN-VITRO; SIGNAL-TRANSDUCTION; RANDOMIZED-TRIAL; NITRIC-OXIDE; TUMOR-GROWTH; EXPRESSION; CELLS; P53	To elucidate the molecular mechanisms for the enhancement of heat-induced apoptosis on exposure to acidic conditions, human maxillary carcinoma IMC-3 cells were heat-shocked at 44 degrees C for 30 min at either pH 7.4 or 6.7. Analyses with cDNA arrays, the reverse transcription polymerase chain reaction (RT-PCR), and Western blotting were performed. We found that histone deacetylase 3 (HDAC3) was specifically induced after hyperthermia at 44 degrees C for 30 min at pH 6.7. Although the cytotoxicity of heating at 44 degrees C for 30 min was enhanced by decreasing the pH from 7.4 to 6.7, it was enhanced even more by antisense RNA oligonucleotides for HDAC3. The induction of G(2)/M arrest after heating occurred earlier at pH 6.7 than at pH 7.4. The inhibition of HDAC3 by the antisense RNA oligonucleotides suppressed partially the induction of G2/M arrest, resulting in an enhancement of the apoptosis caused by the heating under acidic conditions. Antisense RNA oligonucleotides for HDAC3 enhanced apoptosis 48 h after hyperthermia at 43 degrees C for 30 min in vivo. Analyses of p65 activity suggested that NF-KB is involved in this enhancement of hyperthermia. HDAC3 may be a novel target enhancing hyperthermia and combined treatment with hyperthermia and HDAC inhibitors is a possible modality for cancer therapy.	Univ Fukui, Dept Otorhinolaryngol, Matsuoka, Fukui 9101193, Japan; Univ Fukui, Fac Med Sci, Dept Expt Radiol & Hlth Phys, Matsuoka, Fukui 9101193, Japan	University of Fukui; University of Fukui	Narita, N (corresponding author), Univ Fukui, Dept Otorhinolaryngol, Matsuoka, Fukui 9101193, Japan.	norihiko@fmsrsa.fukui-med.ac.jp	Narita, Norihiko/AAA-4801-2022	Narita, Norihiko/0000-0001-9765-9669				AKIN RE, 2004, J BIOL CHEM, V297, P51218; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; Dahl O, 2002, INT J HYPERTHER, V18, P25, DOI 10.1080/02656730110083756; ENGIN K, 1995, CLIN CANCER RES, V1, P139; FUJIEDA S, 1995, J IMMUNOL, V155, P2318; Gan YH, 2005, J BIOL CHEM, V280, P16467, DOI 10.1074/jbc.M412960200; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Glaser KB, 2003, BIOCHEM BIOPH RES CO, V310, P529, DOI 10.1016/j.bbrc.2003.09.043; HARMON BV, 1990, INT J RADIAT BIOL, V58, P845, DOI 10.1080/09553009014552221; Huang YH, 2002, CANCER RES, V62, P2913; Jin ZH, 2004, INT J RADIAT ONCOL, V59, P852, DOI 10.1016/j.ijrobp.2004.01.033; Khochbin S, 2001, CURR OPIN GENET DEV, V11, P162, DOI 10.1016/S0959-437X(00)00174-X; Kiernan R, 2003, J BIOL CHEM, V278, P2758, DOI 10.1074/jbc.M209572200; Levenson VV, 2000, CANCER RES, V60, P5027; Liu F, 2004, J BIOL CHEM, V279, P34537, DOI 10.1074/jbc.M402475200; Marshall John L, 2002, J Exp Ther Oncol, V2, P325, DOI 10.1046/j.1359-4117.2002.01039.x; Matsumoto H, 1997, INT J RADIAT ONCOL, V38, P1089, DOI 10.1016/S0360-3016(97)00300-3; Matsumoto H, 1998, INT J ONCOL, V13, P741; Matsumoto H, 1998, INT J RADIAT ONCOL, V41, P915, DOI 10.1016/S0360-3016(98)00121-7; Matsumoto H, 1999, CANCER RES, V59, P3239; MIZOGUCHI H, 1991, INT J CANCER, V49, P738, DOI 10.1002/ijc.2910490518; MORONI MC, 1992, J BIOL CHEM, V267, P2714; Mukhopadhyay T, 1996, CRIT REV ONCOGENESIS, V7, P151, DOI 10.1615/CritRevOncog.v7.i3-4.20; Murata M, 2000, JPN J CANCER RES, V91, P1154, DOI 10.1111/j.1349-7006.2000.tb00899.x; Narita N, 2002, INT J RADIAT ONCOL, V53, P190, DOI 10.1016/S0360-3016(02)02727-X; Ohnishi K, 2001, INT J HYPERTHER, V17, P415, DOI 10.1080/02656730110063604; Ohtsubo T, 2001, INT J RADIAT ONCOL, V49, P1391, DOI 10.1016/S0360-3016(00)01590-X; Ohtsubo T, 2000, INT J HYPERTHER, V16, P481, DOI 10.1080/02656730050199331; OVERGAARD J, 1995, LANCET, V345, P540, DOI 10.1016/S0140-6736(95)90463-8; Park HJ, 1999, BRIT J CANCER, V80, P1892, DOI 10.1038/sj.bjc.6690617; Pena LA, 1997, BIOCHEM PHARMACOL, V53, P615, DOI 10.1016/S0006-2952(96)00834-9; RHEE JG, 1984, INT J RADIAT ONCOL, V10, P393, DOI 10.1016/0360-3016(84)90060-9; Ru K, 1999, ONCOL RES, V11, P505; Sasakawa Y, 2002, BIOCHEM PHARMACOL, V64, P1079, DOI 10.1016/S0006-2952(02)01261-3; Sneed PK, 1998, INT J RADIAT ONCOL, V40, P287, DOI 10.1016/S0360-3016(97)00731-1; Sugimoto C, 1999, INT J CANCER, V82, P860, DOI 10.1002/(SICI)1097-0215(19990909)82:6<860::AID-IJC15>3.0.CO;2-6; Takahashi A, 2003, INT J HYPERTHER, V19, P145, DOI 10.1080/02656730210166131; Takahashi I, 2002, SURGERY, V131, pS78, DOI 10.1067/msy.2002.119308; Takasu T, 1998, CANCER RES, V58, P2504; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Yu XD, 2002, J NATL CANCER I, V94, P504	43	23	25	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2005	24	49					7346	7354		10.1038/sj.onc.1208879	http://dx.doi.org/10.1038/sj.onc.1208879			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982FA	16044157				2022-12-25	WOS:000233142100011
J	Gohil, VM; Thompson, MN; Greenberg, ML				Gohil, VM; Thompson, MN; Greenberg, ML			Synthetic lethal interaction of the mitochondrial phosphatidylethanolamine and cardiolipin biosynthetic pathways in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMORPHIC PHASE-BEHAVIOR; TEMPERATURE SENSITIVITY; SUBCELLULAR MEMBRANES; LIPID-COMPOSITION; ESCHERICHIA-COLI; CARBON-SOURCES; NULL ALLELE; WILD-TYPE; SYNTHASE; GENE	Saccharomyces cerevisiae mitochondria contain enzymes required for synthesis of the phospholipids cardiolipin ( CL) and phosphatidylethanolamine ( PE), which are enriched in mitochondrial membranes. Previous studies indicated that PE may compensate for the lack of CL, and vice versa. These data suggest that PE and CL have overlapping functions and that the absence of both lipids may be lethal. To address this hypothesis, we determined whether the crd1 Delta mutant, which lacks CL, was viable in genetic backgrounds in which PE synthesis was genetically blocked. Deletion of the mitochondrial PE pathway gene PSD1 was synthetically lethal with the crd1 Delta mutant, whereas deletion of the Golgi and endoplasmic reticulum pathway genes PSD2 and DPL1 did not result in synthetic lethality. A 20- fold reduction in phosphatidylcholine did not affect the growth of crd1 Delta cells. Supplementation with ethanolamine, which led to increased PE synthesis, or with propanolamine, which led to synthesis of the novel phospholipid phosphatidylpropanolamine, failed to rescue the synthetic lethality of the crd1 Delta psd1 Delta cells. These results suggest that mitochondrial biosynthesis of PE is essential for the viability of yeast mutants lacking CL.	Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA	Wayne State University	Greenberg, ML (corresponding author), Wayne State Univ, Dept Biol Sci, 5047 Gullen Mall,Biol Sci Bldg, Detroit, MI 48202 USA.	MLGREEN@sun.science.wayne.edu		Gohil, Vishal/0000-0002-9920-2563	NHLBI NIH HHS [HL62263] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062263] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Birner R, 2001, MOL BIOL CELL, V12, P997, DOI 10.1091/mbc.12.4.997; Brink-van der Laan EV, 2004, BBA-BIOMEMBRANES, V1666, P275, DOI 10.1016/j.bbamem.2004.06.010; Burgermeister M, 2004, BBA-MOL CELL BIOL L, V1686, P161, DOI 10.1016/j.bbalip.2004.09.007; Chang SC, 1998, J BIOL CHEM, V273, P9829, DOI 10.1074/jbc.273.16.9829; Chang SC, 1998, J BIOL CHEM, V273, P14933, DOI 10.1074/jbc.273.24.14933; Choi JY, 2004, J BIOL CHEM, V279, P42321, DOI 10.1074/jbc.M405074200; CULLIS PR, 1978, BIOCHIM BIOPHYS ACTA, V513, P31, DOI 10.1016/0005-2736(78)90109-8; DAUM G, 1982, J BIOL CHEM, V257, P3028; de Kruijff B, 1997, CURR OPIN CHEM BIOL, V1, P564, DOI 10.1016/S1367-5931(97)80053-1; Dzugasova V, 1998, CURR GENET, V34, P297, DOI 10.1007/s002940050399; FOLCH J, 1957, J BIOL CHEM, V226, P497; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Gohil VM, 2004, J BIOL CHEM, V279, P42612, DOI 10.1074/jbc.M402545200; JAKOVCIC S, 1971, J CELL BIOL, V48, P490, DOI 10.1083/jcb.48.3.490; Janitor M, 1996, FEMS MICROBIOL LETT, V140, P43; Jiang F, 1997, MOL MICROBIOL, V26, P481, DOI 10.1046/j.1365-2958.1997.5841950.x; Jiang F, 1999, MOL MICROBIOL, V31, P373, DOI 10.1046/j.1365-2958.1999.01181.x; Jiang F, 2000, J BIOL CHEM, V275, P22387, DOI 10.1074/jbc.M909868199; Mandala SM, 1998, P NATL ACAD SCI USA, V95, P150, DOI 10.1073/pnas.95.1.150; MENON AK, 1992, J BIOL CHEM, V267, P15277; RIETVELD AG, 1993, J BIOL CHEM, V268, P12427; Saba JD, 1997, J BIOL CHEM, V272, P26087, DOI 10.1074/jbc.272.42.26087; Schlame M, 2000, PROG LIPID RES, V39, P257, DOI 10.1016/S0163-7827(00)00005-9; SCHLAME M, 1991, J BIOL CHEM, V266, P22398; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Storey MK, 2001, J BIOL CHEM, V276, P48539, DOI 10.1074/jbc.M109043200; TAMAI KT, 1990, BIOCHIM BIOPHYS ACTA, V1046, P214, DOI 10.1016/0005-2760(90)90192-Z; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; TROTTER PJ, 1995, J BIOL CHEM, V270, P6071, DOI 10.1074/jbc.270.11.6071; TROTTER PJ, 1993, J BIOL CHEM, V268, P21416; Tuller G, 1999, YEAST, V15, P1555, DOI 10.1002/(SICI)1097-0061(199910)15:14<1555::AID-YEA479>3.0.CO;2-Z; Tuller G, 1998, FEBS LETT, V421, P15, DOI 10.1016/S0014-5793(97)01525-1; Vaden DL, 2005, ANAL BIOCHEM, V338, P162, DOI 10.1016/j.ab.2004.11.020; VASILENKO I, 1982, BIOCHIM BIOPHYS ACTA, V684, P282, DOI 10.1016/0005-2736(82)90018-9; Wikstrom M, 2004, J BIOL CHEM, V279, P10484, DOI 10.1074/jbc.M310183200; Zhong Q, 2005, MOL BIOL CELL, V16, P665, DOI 10.1091/mbc.E04-09-0808; Zhong Q, 2004, J BIOL CHEM, V279, P32294, DOI 10.1074/jbc.M403275200; ZINSER E, 1991, J BACTERIOL, V173, P2026, DOI 10.1128/jb.173.6.2026-2034.1991	38	108	108	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35410	35416		10.1074/jbc.M505478200	http://dx.doi.org/10.1074/jbc.M505478200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16036913	hybrid			2022-12-25	WOS:000232561200040
J	Hekmat, O; Kim, YW; Williams, SJ; He, SM; Withers, SG				Hekmat, O; Kim, YW; Williams, SJ; He, SM; Withers, SG			Active-site peptide "fingerprinting" of glycosidases in complex mixtures by mass spectrometry - Discovery of a novel retaining beta-1,4-glycanase in Cellulomonas fimi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVITY-BASED PROBES; MODULAR XYLANASE; MECHANISMS; NUCLEOPHILE; IDENTIFICATION; BINDING; FAMILY; GLUCOSIDASE; SPECIFICITY; CELLULASES	New proteomics methods are required for targeting and identification of subsets of a proteome in an activity-based fashion. Here, we report the first gel-free, mass spectrometry-based strategy for mechanism-based profiling of retaining beta-endoglycosidases in complex proteomes. Using a biotinylated, cleavable 2-deoxy-2-fluoroxylobioside inactivator, we have isolated and identified the active-site peptides of target retaining beta-1,4-glycanases in systems of increasing complexity: pure enzymes, artificial proteomes, and the secreted proteome of the aerobic mesophilic soil bacterium Cellulomonas fimi. The active-site peptide of a new C. fimi beta-1,4-glycanase was identified in this manner, and the peptide sequence, which includes the catalytic nucleophile, is highly conserved among glycosidase family 10 members. The glycanase gene (GenBank(TM) accession number DQ146941) was cloned using inverse PCR techniques, and the protein was found to comprise a catalytic domain that shares similar to 70% sequence identity with those of xylanases from Streptomyces sp. and a family 2b carbohydrate-binding module. The new glycanase hydrolyzes natural and artificial xylo-configured substrates more efficiently than their cello-configured counterparts. It has a pH dependence very similar to that of known C. fimi retaining glycanases.	Univ British Columbia, Dept Chem, Prot Engn Network Ctr Excellence Canada, Vancouver, BC V6T 1Z1, Canada	University of British Columbia	Withers, SG (corresponding author), Univ British Columbia, Dept Chem, Prot Engn Network Ctr Excellence Canada, 2036 Main Mall, Vancouver, BC V6T 1Z1, Canada.	withers@chem.ubc.ca	Hekmat, Omid/AAU-4182-2021; Williams, Spencer/C-3545-2009	Williams, Spencer/0000-0001-6341-4364				Adam GC, 2004, J AM CHEM SOC, V126, P1363, DOI 10.1021/ja038441g; Adam GC, 2002, NAT BIOTECHNOL, V20, P805, DOI 10.1038/nbt714; Birsan C, 1998, BIOCHEM SOC T, V26, P156, DOI 10.1042/bst0260156; BLACK GW, 1995, BIOCHEM J, V307, P191, DOI 10.1042/bj3070191; Bogyo M, 2000, CHEM BIOL, V7, P27, DOI 10.1016/S1074-5521(00)00061-2; Bogyo M, 1997, P NATL ACAD SCI USA, V94, P6629, DOI 10.1073/pnas.94.13.6629; Bray MR, 1996, ACS SYM SER, V655, P64; BUCHERT J, 1994, BIORESOURCE TECHNOL, V50, P65, DOI 10.1016/0960-8524(94)90222-4; Clarke JH, 1996, FEMS MICROBIOL LETT, V139, P27, DOI 10.1016/0378-1097(96)00101-2; CLARKE JH, 1991, FEMS MICROBIOL LETT, V83, P305, DOI [10.1016/0378-1097(91)90493-T, 10.1111/j.1574-6968.1991.tb04481.x]; CLELAND WW, 1964, BIOCHEMISTRY-US, V3, P480, DOI 10.1021/bi00892a002; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; Ducros V, 2000, J BIOL CHEM, V275, P23020, DOI 10.1074/jbc.275.30.23020; Godl K, 2003, P NATL ACAD SCI USA, V100, P15434, DOI 10.1073/pnas.2535024100; Greenbaum D, 2000, CHEM BIOL, V7, P569, DOI 10.1016/S1074-5521(00)00014-4; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; HAN JC, 1994, ANAL BIOCHEM, V220, P5, DOI 10.1006/abio.1994.1290; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; Ichikawa M, 2001, BIOORG MED CHEM LETT, V11, P1769, DOI 10.1016/S0960-894X(01)00300-6; KEMPTON JB, 1992, BIOCHEMISTRY-US, V31, P9961, DOI 10.1021/bi00156a015; Kidd D, 2001, BIOCHEMISTRY-US, V40, P4005, DOI 10.1021/bi002579j; Kobe B, 1999, NATURE, V402, P373, DOI 10.1038/46478; Kumar S, 2004, P NATL ACAD SCI USA, V101, P7943, DOI 10.1073/pnas.0402323101; Kurogochi M, 2004, J BIOL CHEM, V279, P44704, DOI 10.1074/jbc.M401718200; Lawson SL, 1996, BIOCHEMISTRY-US, V35, P10110, DOI 10.1021/bi960586v; LEVER M, 1984, ANAL BIOCHEM, V139, P205, DOI 10.1016/0003-2697(84)90406-8; Lichtenthaler Hartmut K., METHODS ENZYMOLOGY, P350, DOI [10.1016/0076-6879(87)48036-1, DOI 10.1016/0076-6879(90)84256-G, DOI 10.1016/0076-6879(87)48036-1]; Liu YS, 1999, P NATL ACAD SCI USA, V96, P14694, DOI 10.1073/pnas.96.26.14694; Mackenzie LF, 1997, BIOCHEMISTRY-US, V36, P5893, DOI 10.1021/bi962962h; MEINKE A, 1993, J BACTERIOL, V175, P1910, DOI 10.1128/JB.175.7.1910-1918.1993; MIAO SC, 1994, BIOCHEMISTRY-US, V33, P7027, DOI 10.1021/bi00189a002; Notenboom V, 1998, BIOCHEMISTRY-US, V37, P4751, DOI 10.1021/bi9729211; OCHMAN H, 1988, GENETICS, V120, P621; Saghatelian A, 2004, P NATL ACAD SCI USA, V101, P10000, DOI 10.1073/pnas.0402784101; Speers AE, 2004, CHEMBIOCHEM, V5, P41, DOI 10.1002/cbic.200300721; Thompson J, 1998, J BIOL CHEM, V273, P27347, DOI 10.1074/jbc.273.42.27347; Tsai CS, 2002, ORG LETT, V4, P3607, DOI 10.1021/ol0265315; TULL D, 1991, J BIOL CHEM, V266, P15621; TULL D, 1994, BIOCHEMISTRY-US, V33, P6363, DOI 10.1021/bi00186a041; Vocadlo DJ, 2004, ANGEW CHEM INT EDIT, V43, P5338, DOI 10.1002/anie.200454235; Vocadlo DJ, 2003, P NATL ACAD SCI USA, V100, P9116, DOI 10.1073/pnas.1632821100; WAKARCHUK WW, 1994, PROTEIN SCI, V3, P467; Wakarchuk WW, 1998, PROTEIN ENG, V11, P295, DOI 10.1093/protein/11.4.295; WEICKERT MJ, 1989, J BACTERIOL, V171, P3656, DOI 10.1128/jb.171.7.3656-3666.1989; WHITE A, 1994, BIOCHEMISTRY-US, V33, P12546, DOI 10.1021/bi00208a003; Wicki J, 2002, METHOD ENZYMOL, V354, P84; WITHERS SG, 1987, J AM CHEM SOC, V109, P7530, DOI 10.1021/ja00258a047; Woodward J, 2000, NATURE, V405, P1014, DOI 10.1038/35016633; Zechel DL, 2000, ACCOUNTS CHEM RES, V33, P11, DOI 10.1021/ar970172+; Zhang H, 2003, NAT BIOTECHNOL, V21, P660, DOI 10.1038/nbt827; Zhou HL, 2001, NAT BIOTECHNOL, V19, P375, DOI 10.1038/86777; ZISER L, 1995, CARBOHYD RES, V274, P137, DOI 10.1016/0008-6215(95)00080-D	52	68	70	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35126	35135		10.1074/jbc.M508434200	http://dx.doi.org/10.1074/jbc.M508434200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16085650	hybrid			2022-12-25	WOS:000232561200009
J	Rosenfeld, SS; Xing, J; Jefferson, GM; King, PH				Rosenfeld, SS; Xing, J; Jefferson, GM; King, PH			Docking and rolling, a model of how the mitotic motor Eg5 works	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORIENTATIONAL FREEDOM; CRYSTAL-STRUCTURE; NECK LINKER; KINESIN; PROTEIN; STRAIN; MICROTUBULES; INHIBITION; MECHANISM; BINDING	Whereas kinesin I is designed to transport cargoes long distances in isolation, a closely related kinesin motor, Eg5, is designed to generate a sustained opposing force necessary for proper mitotic spindle formation. Do the very different roles for these evolutionarily related motors translate into differences in how they generate movement? We have addressed this question by examining when in the ATPase cycle the Eg5 motor domain and neck linker move through the use of a series of novel spectroscopic probes utilizing fluorescence resonance energy transfer, and we have compared our results to kinesin I. Our results are consistent with a model in which movement in Eg5 occurs in two sequential steps, an ATP- dependent docking of the neck linker, followed by a rotation or " rolling" of the entire motor domain on the microtubule surface that occurs with ATP hydrolysis. These two forms of movement are consistent with the functions of a motor designed to generate sustained opposing force, and hence, our findings support the argument that the mechanochemical features of a molecular motor are shaped more by the demands placed on it than by its particular family of origin.	Columbia Univ, Neurol Inst, Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA; Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL USA; Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35294 USA; Biurmingham Vet Affairs Med Ctr, Neurol Serv, Cambridge, MA 02138 USA	Columbia University; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Rosenfeld, SS (corresponding author), Columbia Univ, Neurol Inst, Coll Phys & Surg, Dept Neurol, Rm 204,710 W 168th St, New York, NY 10032 USA.	sr2327@columbia.edu		King, Peter/0000-0001-9391-7464	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048565] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR048565] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Blangy A, 1997, J BIOL CHEM, V272, P19418, DOI 10.1074/jbc.272.31.19418; Block SM, 2003, P NATL ACAD SCI USA, V100, P2351, DOI 10.1073/pnas.0436709100; Case RB, 2000, CURR BIOL, V10, P157, DOI 10.1016/S0960-9822(00)00316-X; Cheung H.C., 1991, TOPICS FLUORESCENCE, P127; Cochran JC, 2004, J BIOL CHEM, V279, P38861, DOI 10.1074/jbc.M404203200; COLE DG, 1994, J BIOL CHEM, V269, P22913; Cooke R, 2004, J GEN PHYSIOL, V123, P643, DOI 10.1085/jgp.200409089; Cremo CR, 1998, BIOCHEMISTRY-US, V37, P1969, DOI 10.1021/bi9722406; DALE RE, 1979, BIOPHYS J, V26, P161, DOI 10.1016/S0006-3495(79)85243-1; DALE RE, 1974, BIOPOLYMERS, V13, P1573, DOI 10.1002/bip.1974.360130807; De la Cruz EM, 2000, BIOPHYS J, V79, P1524, DOI 10.1016/S0006-3495(00)76403-4; Endow SA, 2003, BIOESSAYS, V25, P1212, DOI 10.1002/bies.10358; HEIDECKER M, 1995, BIOCHEMISTRY-US, V37, P14428; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; Hirose K, 2000, EMBO J, V19, P5308, DOI 10.1093/emboj/19.20.5308; Hoenger A, 2000, J MOL BIOL, V297, P1087, DOI 10.1006/jmbi.2000.3627; Holmes KC, 2000, PHILOS T R SOC B, V355, P419, DOI 10.1098/rstb.2000.0583; Kapitein LC, 2005, NATURE, V435, P114, DOI 10.1038/nature03503; Kashina AS, 1996, NATURE, V379, P270, DOI 10.1038/379270a0; Kikkawa M, 2001, NATURE, V411, P439, DOI 10.1038/35078000; Kozielski F, 1997, CELL, V91, P985, DOI 10.1016/S0092-8674(00)80489-4; Kull FJ, 2002, J CELL SCI, V115, P15; Lang MJ, 2002, BIOPHYS J, V83, P491, DOI 10.1016/S0006-3495(02)75185-0; Ma YZ, 1997, J BIOL CHEM, V272, P717, DOI 10.1074/jbc.272.2.717; Maliga Z, 2002, CHEM BIOL, V9, P989, DOI 10.1016/S1074-5521(02)00212-0; Marcus AI, 2005, J BIOL CHEM, V280, P11569, DOI 10.1074/jbc.M413471200; Moyer ML, 1998, BIOCHEMISTRY-US, V37, P800, DOI 10.1021/bi9711184; Rice S, 1999, NATURE, V402, P778, DOI 10.1038/45483; Rice S, 2003, BIOPHYS J, V84, P1844, DOI 10.1016/S0006-3495(03)74992-3; Rosenfeld SS, 2003, J BIOL CHEM, V278, P18550, DOI 10.1074/jbc.M300849200; Rosenfeld SS, 2002, J BIOL CHEM, V277, P36731, DOI 10.1074/jbc.M205261200; Rosenfeld SS, 2001, J BIOL CHEM, V276, P40167, DOI 10.1074/jbc.M103899200; Schnitzer MJ, 2000, NAT CELL BIOL, V2, P718, DOI 10.1038/35036345; Sharp DJ, 1999, J CELL BIOL, V144, P125, DOI 10.1083/jcb.144.1.125; Sindelar CV, 2002, NAT STRUCT BIOL, V9, P844, DOI 10.1038/nsb852; Turner J, 2001, J BIOL CHEM, V276, P25496, DOI 10.1074/jbc.M100395200; Vale RD, 2000, SCIENCE, V288, P88, DOI 10.1126/science.288.5463.88; Vale RD, 2003, CELL, V112, P467, DOI 10.1016/S0092-8674(03)00111-9; Visscher K, 1999, NATURE, V400, P184, DOI 10.1038/22146; Xing J, 2000, J BIOL CHEM, V275, P35413, DOI 10.1074/jbc.M004232200; Yan YW, 2004, J MOL BIOL, V335, P547, DOI 10.1016/j.jmb.2003.10.074	41	57	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35684	35695		10.1074/jbc.M506561200	http://dx.doi.org/10.1074/jbc.M506561200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16115880	hybrid			2022-12-25	WOS:000232561200071
J	Miller, MS; Palmer, BM; Ruch, S; Martin, LA; Farman, GP; Wang, Y; Robbins, J; Irving, TC; Maughan, DW				Miller, MS; Palmer, BM; Ruch, S; Martin, LA; Farman, GP; Wang, Y; Robbins, J; Irving, TC; Maughan, DW			The essential light chain N-terminal extension alters force and fiber kinetics in mouse cardiac muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONMUSCLE MYOSIN-II; CONTRACTILE ACTIVATION; PHOSPHATE RELEASE; SARCOMERE-LENGTH; MOLECULAR MOTORS; ISOMETRIC FORCE; TRANSGENIC MICE; STRIATED-MUSCLE; BINDING-SITES; SMOOTH-MUSCLE	The functional significance of the actin-binding region at the N terminus of the cardiac myosin essential light chain (ELC) remains elusive. In a previous experiment, the endogenous ventricular ELC was replaced with a protein containing a 10-amino acid deletion at positions 5 - 14 (ELC1v Delta 5 - 14, referred to as 1v Delta 5 - 14), a region that interacts with actin (Sanbe, A., Gulick, J., Fewell, J., and Robbins, J. ( 2001) J. Biol. Chem. 276, 32682 - 32686). 1v Delta 5 - 14 mice showed no discernable mutant phenotype in skinned ventricular strips. However, because the myofilament lattice swells upon skinning, the mutant phenotype may have been concealed by the inability of the ELC to reach the actin- binding site. Using the same mouse model, we repeated earlier measurements and performed additional experiments on skinned strips osmotically compressed to the intact lattice spacing as determined by x-ray diffraction. 1v Delta 5 - 14 mice exhibited decreased maximum isometric tension without a change in calcium sensitivity. The decreased force was most evident in 5 - 6-month-old mice compared with 13 - 15-month-old mice and may account for the greater ventricular wall thickness in young 1v Delta 5 - 14 mice compared with age-matched controls. No differences were observed in unloaded shortening velocity at maximum calcium activation. However, 1v Delta 5 - 14 mice exhibited a significant difference in the frequency at which minimum complex modulus amplitude occurred, indicating a change in cross-bridge kinetics. We hypothesize that the ELC N-terminal extension interaction with actin inhibits the reversal of the power stroke, thereby increasing isometric force. Our results strongly suggest that an interaction between residues 5 - 14 of the ELC N terminus and the C-terminal residues of actin enhances cardiac performance.	Univ Vermont, Dept Mol Physiol & Biophys, Burlington, VT 05405 USA; IIT, Biophys Collaborat Access Team, Chicago, IL 60616 USA; IIT, Ctr Synchrotron Radiat Res & Instrumentat, Dept Biol Chem & Phys Sci, Chicago, IL 60616 USA; Childrens Hosp Res Fdn, Div Mol Cardiovasc Biol, Cincinnati, OH 45229 USA; Univ Cincinnati, Dept Pediat, Cincinnati, OH 45229 USA	University of Vermont; Illinois Institute of Technology; United States Department of Energy (DOE); Argonne National Laboratory; Illinois Institute of Technology; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati	Miller, MS (corresponding author), Univ Vermont, Dept Mol Physiol & Biophys, 127 HSRF Bldg,149 Beaumont Ave, Burlington, VT 05405 USA.	mmiller@cems.uvm.edu	Miller, Mark/B-6523-2008		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068034, P01HL069779] Funding Source: NIH RePORTER; NCRR NIH HHS [RR08630] Funding Source: Medline; NHLBI NIH HHS [R01 HL68034, R01 HL068034, P01 HL69779] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andreev OA, 1999, BIOCHEMISTRY-US, V38, P2480, DOI 10.1021/bi981706x; Blanchard E, 1999, CIRC RES, V84, P475, DOI 10.1161/01.RES.84.4.475; Bresnick AR, 1999, CURR OPIN CELL BIOL, V11, P26, DOI 10.1016/S0955-0674(99)80004-0; Davis JS, 2001, CELL, V107, P631, DOI 10.1016/S0092-8674(01)00586-4; EDMAN KAP, 1979, J PHYSIOL-LONDON, V291, P143, DOI 10.1113/jphysiol.1979.sp012804; Fewell JG, 1997, AM J PHYSIOL-HEART C, V273, pH1595, DOI 10.1152/ajpheart.1997.273.3.H1595; Fewell JG, 1998, J CLIN INVEST, V101, P2630, DOI 10.1172/JCI2825; Gao WD, 1998, J PHYSIOL-LONDON, V507, P175, DOI 10.1111/j.1469-7793.1998.175bu.x; GODT RE, 1982, J GEN PHYSIOL, V80, P279, DOI 10.1085/jgp.80.2.279; HAYASHIBARA T, 1994, BIOCHEMISTRY-US, V33, P12821, DOI 10.1021/bi00209a013; HUXLEY HE, 1990, J BIOL CHEM, V265, P8347; Irving T, 2001, J MUSCLE RES CELL M, V22, P675, DOI 10.1023/A:1016336024366; Irving TC, 2000, NUCL INSTRUM METH A, V448, P250, DOI 10.1016/S0168-9002(99)00732-9; Irving TC, 2000, AM J PHYSIOL-HEART C, V279, pH2568, DOI 10.1152/ajpheart.2000.279.5.H2568; Jones WK, 1996, J CLIN INVEST, V98, P1906, DOI 10.1172/JCI118992; KAWAI M, 1991, BIOPHYS J, V59, P329, DOI 10.1016/S0006-3495(91)82227-5; Kawai M, 1980, J Muscle Res Cell Motil, V1, P279, DOI 10.1007/BF00711932; KAWAI M, 1993, CIRC RES, V73, P35, DOI 10.1161/01.RES.73.1.35; Krenz M, 2003, J BIOL CHEM, V278, P17466, DOI 10.1074/jbc.M210804200; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; Millman BM, 1998, PHYSIOL REV, V78, P359, DOI 10.1152/physrev.1998.78.2.359; Moore JR, 2000, BIOPHYS J, V78, P1431, DOI 10.1016/S0006-3495(00)76696-3; Morano I, 1999, J MOL MED-JMM, V77, P544, DOI 10.1007/s001099900031; MORANO I, 1995, CIRC RES, V76, P720, DOI 10.1161/01.RES.76.5.720; MULIERI LA, 1989, CIRC RES, V65, P1441, DOI 10.1161/01.RES.65.5.1441; Nieznanska H, 2002, ACTA BIOCHIM POL, V49, P709; Rarick HM, 1996, J BIOL CHEM, V271, P27039, DOI 10.1074/jbc.271.43.27039; Sanbe A, 2001, J BIOL CHEM, V276, P32682, DOI 10.1074/jbc.M009975200; Sanbe A, 1999, J BIOL CHEM, V274, P21085, DOI 10.1074/jbc.274.30.21085; SANCHEZ A, 1991, J BIOL CHEM, V266, P22419; Schaub MC, 1998, CARDIOVASC RES, V37, P381, DOI 10.1016/S0008-6363(97)00258-7; Somlyo AP, 2000, J PHYSIOL-LONDON, V522, P177, DOI 10.1111/j.1469-7793.2000.t01-2-00177.x; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; STEPKOWSKI D, 1995, FEBS LETT, V374, P6, DOI 10.1016/0014-5793(95)01049-K; SUTOH K, 1982, BIOCHEMISTRY-US, V21, P3654, DOI 10.1021/bi00258a020; SWEENEY HL, 1995, BIOPHYS J, V68, pS112; Sweeney HL, 1998, AM J RESP CRIT CARE, V158, pS95, DOI 10.1164/ajrccm.158.supplement_2.13tac400; SWEENEY HL, 1993, AM J PHYSIOL, V264, pC1085, DOI 10.1152/ajpcell.1993.264.5.C1085; Timson DJ, 1999, J BIOL CHEM, V274, P18271, DOI 10.1074/jbc.274.26.18271; Timson DJ, 2003, BIOCHIMIE, V85, P639, DOI 10.1016/S0300-9084(03)00131-7; TOHTONG R, 1995, NATURE, V374, P650, DOI 10.1038/374650a0; Wang G, 1997, BIOPHYS J, V73, P878, DOI 10.1016/S0006-3495(97)78121-9; Yang B, 1999, AM J PHYSIOL-HEART C, V277, pH1906, DOI 10.1152/ajpheart.1999.277.5.H1906	43	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34427	34434		10.1074/jbc.M508430200	http://dx.doi.org/10.1074/jbc.M508430200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16085933	hybrid			2022-12-25	WOS:000232403900008
J	Buchholz, M; Braun, M; Heidenblut, A; Kestler, HA; Kloppel, G; Schmiegel, W; Hahn, SA; Luttges, J; Gress, TM				Buchholz, M; Braun, M; Heidenblut, A; Kestler, HA; Kloppel, G; Schmiegel, W; Hahn, SA; Luttges, J; Gress, TM		German Pancreatic Cancer Net Deuts	Transcriptome analysis of microdissected pancreatic intraepithelial neoplastic lesions	ONCOGENE			English	Article						PanIN progression; gene expression; early diagnosis; target genes	K-RAS MUTATIONS; DUCTAL ADENOCARCINOMA; EXTRACELLULAR-MATRIX; CANCER; EXPRESSION; INACTIVATION; RESECTION; TUMORS; MODEL; CLASSIFICATION	Pancreatic ductal adenocarcinoma (PDAC) carries the most dismal prognosis of all solid tumours. Both the late clinical presentation of patients, due to lack of early symptoms, as well as the rapid and aggressive course of the disease contribute to the extremely high mortality of this malignancy. Recently, a multistep progression model for PDAC integrating morphological, clinical and molecular evidence has been proposed. Putative precursor lesions, termed pancreatic intraepithelial neoplasia (PanIN), are classified into three different grades (PanIN-1 through -3) based on the degree of cellular atypia they display. We have conducted large-scale expression pro. ling analyses of microdissected cells from normal pancreatic ducts, PanINs of different grades and PDACs using whole-genome oligonucleotide microarrays. Veri. cation of hybridisation results for selected genes was performed using quantitative real-time PCR and immunohistochemical analyses on PanIN tissue microarrays. Comparison of the expression profiles demonstrated that the greatest changes in gene expression occur between PanIN stages 1B and 2, suggesting that PanIN-2 may represent the first truly preneoplastic stage in PDAC progression. Our results identify a large number of potential target genes for the development of novel molecular diagnostic and therapeutic tools for the prevention and early diagnosis of PDAC and provide novel insights into the pathophysiological mechanisms involved in tumour progression in the pancreas.	Univ Hosp Ulm, Dept Internal Med 1, D-89081 Ulm, Germany; Ruhr Univ Bochum, Dept Internal Med, D-4630 Bochum, Germany; Univ Kiel, Dept Pathol, D-2300 Kiel, Germany	Ulm University; Ruhr University Bochum; University of Kiel	Gress, TM (corresponding author), Univ Hosp Ulm, Dept Internal Med 1, Robert Koch Str 8, D-89081 Ulm, Germany.	thomas.gress@medizin.uni-ulm.de	Kestler, Hans A./D-5799-2012; Hahn, Stephan/E-3880-2010; Hahn, Stephan A./AAV-6062-2021	Kestler, Hans A./0000-0002-4759-5254; Hahn, Stephan/0000-0003-0855-9741; Hahn, Stephan A./0000-0003-0855-9741; Gress, Thomas/0000-0002-9333-5461				Bramhall SR, 1997, J PATHOL, V182, P347, DOI 10.1002/(SICI)1096-9896(199707)182:3<347::AID-PATH848>3.0.CO;2-J; Brentnall TA, 1999, ANN INTERN MED, V131, P247, DOI 10.7326/0003-4819-131-4-199908170-00003; Bubendorf L, 2001, J PATHOL, V195, P72, DOI 10.1002/path.893; Buchholz M, 2003, CANCER RES, V63, P4945; Canto MI, 2004, CLIN GASTROENTEROL H, V2, P606, DOI 10.1016/S1542-3565(04)00244-7; Conlon KC, 1996, ANN SURG, V223, P273, DOI 10.1097/00000658-199603000-00007; Crnogorac-Jurcevic T, 2003, J PATHOL, V201, P63, DOI 10.1002/path.1418; Ellenrieder V, 2000, INT J CANCER, V85, P14, DOI 10.1002/(SICI)1097-0215(20000101)85:1<14::AID-IJC3>3.3.CO;2-F; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Goggins M, 2000, AM J PATHOL, V156, P1767, DOI 10.1016/S0002-9440(10)65047-X; Gronborg M, 2004, J PROTEOME RES, V3, P1042, DOI 10.1021/pr0499085; Heinmoller E, 2000, AM J PATHOL, V157, P83, DOI 10.1016/S0002-9440(10)64520-8; Hruban RH, 2001, AM J SURG PATHOL, V25, P579, DOI 10.1097/00000478-200105000-00003; Hruban RH, 2000, AM J PATHOL, V156, P1821, DOI 10.1016/S0002-9440(10)65054-7; Hruban RH, 2004, AM J SURG PATHOL, V28, P977, DOI 10.1097/01.pas.0000126675.59108.80; Hruban RH, 2001, DIGEST DIS, V19, P76, DOI 10.1159/000050656; Huflejt ME, 2003, GLYCOCONJUGATE J, V20, P247, DOI 10.1023/B:GLYC.0000025819.54723.a0; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kawakami K, 2001, CANCER RES, V61, P6194; Kloppel Gunter, 2004, Curr Gastroenterol Rep, V6, P111, DOI 10.1007/s11894-004-0037-y; Kos J, 2000, INT J BIOL MARKER, V15, P84, DOI 10.1177/172460080001500116; Kristiansen G, 2005, J PATHOL, V205, P359, DOI 10.1002/path.1676; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Luttges J, 2004, CANCER-AM CANCER SOC, V100, P173, DOI 10.1002/cncr.11860; Luttges J, 2000, CANCER, V88, P2495, DOI 10.1002/1097-0142(20000601)88:11<2495::AID-CNCR10>3.0.CO;2-B; Luttges J, 2001, AM J PATHOL, V158, P1677, DOI 10.1016/S0002-9440(10)64123-5; Luttges J, 1999, VIRCHOWS ARCH, V435, P461, DOI 10.1007/s004280050428; LYNCH HT, 1994, ARCH SURG-CHICAGO, V129, P266; LYNCH HT, 1990, AM J GASTROENTEROL, V85, P54; Lynch HT, 1996, SEMIN ONCOL, V23, P251; Maitra A, 2003, MODERN PATHOL, V16, P902, DOI 10.1097/01.MP.0000086072.56290.FB; Neoptolemos JP, 2004, NEW ENGL J MED, V350, P1200, DOI 10.1056/NEJMoa032295; Pupa SM, 2002, J CELL PHYSIOL, V192, P259, DOI 10.1002/jcp.10142; Smyth G.K., 2004, STAT APPL GENET MOL, V3, DOI DOI 10.2202/1544-6115.1027; Sperti C, 1997, WORLD J SURG, V21, P195, DOI 10.1007/s002689900215; Stepanova L, 2000, ONCOGENE, V19, P2186, DOI 10.1038/sj.onc.1203561; Strojan P, 2004, CLIN CHIM ACTA, V344, P155, DOI 10.1016/j.cccn.2004.02.011; Sturn A, 2002, BIOINFORMATICS, V18, P207, DOI 10.1093/bioinformatics/18.1.207; Suomela S, 2004, J INVEST DERMATOL, V122, P717, DOI 10.1111/j.0022-202X.2004.22322.x; Terris B, 2002, AM J PATHOL, V160, P1745, DOI 10.1016/S0002-9440(10)61121-2; Trede M, 2001, SURG CLIN N AM, V81, P595, DOI 10.1016/S0039-6109(05)70146-8; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vimalachandran Dale, 2004, Cancer Control, V11, P6; Wilentz RE, 1998, CANCER RES, V58, P4740; Wilentz RE, 2000, CANCER RES, V60, P2002; Yamakawa T, 1998, BBA-GENE STRUCT EXPR, V1395, P202, DOI 10.1016/S0167-4781(97)00149-8; Yeo CJ, 1998, LANGENBECK ARCH SURG, V383, P129, DOI 10.1007/s004230050104; Zeeberg BR, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-4-r28	48	155	161	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2005	24	44					6626	6636		10.1038/sj.onc.1208804	http://dx.doi.org/10.1038/sj.onc.1208804			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	971FL	16103885				2022-12-25	WOS:000232367800004
J	Sakoh, M; Ito, K; Akiyama, Y				Sakoh, M; Ito, K; Akiyama, Y			Proteolytic activity of HtpX, a membrane-bound and stress-controlled protease from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FTSH-MEDIATED PROTEOLYSIS; SIGMA-FACTOR; GENE; SECY; PROTEINS; EXPRESSION; SUBSTRATE; SUBUNIT; PRODUCT; COMPLEX	Escherichia coli HtpX is a putative membrane-bound zinc metalloprotease that has been suggested to participate in the proteolytic quality control of membrane proteins in conjunction with FtsH, a membrane-bound and ATP-dependent protease. Here, we biochemically characterized HtpX and confirmed its proteolytic activities against membrane and soluble proteins. HtpX underwent self-degradation upon cell disruption or membrane solubilization. Consequently, we purified HtpX under denaturing conditions and then refolded it in the presence of a zinc chelator. When supplemented with Zn2+, the purified enzyme exhibited self-cleavage activity. In the presence of zinc, it also degraded casein and cleaved a solubilized membrane protein, SecY. We verified its ability to cleave SecY in vivo by overproducing both HtpX and SecY. These results showed that HtpX is a zinc-dependent endoprotease member of the membrane-localized proteolytic system in E. coli.	Kyoto Univ, Inst Virus Res, Kyoto 6068507, Japan	Kyoto University	Akiyama, Y (corresponding author), Kyoto Univ, Inst Virus Res, Kyoto 6068507, Japan.	yakiyama@virus.kyoto-u.ac.jp						Ades SE, 2004, CURR OPIN MICROBIOL, V7, P157, DOI 10.1016/j.mib.2004.02.010; AKIYAMA Y, 1990, BIOCHEM BIOPH RES CO, V167, P711, DOI 10.1016/0006-291X(90)92083-C; Akiyama Y, 1998, MOL MICROBIOL, V28, P803, DOI 10.1046/j.1365-2958.1998.00843.x; Akiyama Y, 2004, EMBO J, V23, P4434, DOI 10.1038/sj.emboj.7600449; AKIYAMA Y, 1995, J BIOL CHEM, V270, P23485, DOI 10.1074/jbc.270.40.23485; Akiyama Y, 2003, J BIOL CHEM, V278, P18146, DOI 10.1074/jbc.M302152200; Akiyama Y, 1996, FEBS LETT, V399, P26, DOI 10.1016/S0014-5793(96)01283-5; AKIYAMA Y, 1985, EMBO J, V4, P3351, DOI 10.1002/j.1460-2075.1985.tb04088.x; Akiyama Y, 2000, EMBO J, V19, P3888, DOI 10.1093/emboj/19.15.3888; AKIYAMA Y, 2004, HDB PROTEOLYTIC ENZY, P794; Chiba S, 2002, J BACTERIOL, V184, P4775, DOI 10.1128/JB.184.17.4775-4782.2002; Chiba S, 2000, EMBO REP, V1, P47, DOI 10.1093/embo-reports/kvd005; Coltri PP, 2004, CURR MICROBIOL, V48, P391, DOI 10.1007/s00284-003-4179-1; Davis R., 1980, ADV BACTERIAL GENETI; Duguay AR, 2004, BBA-MOL CELL RES, V1694, P121, DOI 10.1016/j.bbamcr.2004.04.012; Grigorova IL, 2004, GENE DEV, V18, P2686, DOI 10.1101/gad.1238604; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Ito K, 2005, ANNU REV MICROBIOL, V59, P211, DOI 10.1146/annurev.micro.59.030804.121316; ITO K, 1984, MOL GEN GENET, V197, P204, DOI 10.1007/BF00330964; Kaser M, 2003, J BIOL CHEM, V278, P46414, DOI 10.1074/jbc.M305584200; KIHARA A, 1995, P NATL ACAD SCI USA, V92, P4532, DOI 10.1073/pnas.92.10.4532; Kihara A, 1998, J MOL BIOL, V279, P175, DOI 10.1006/jmbi.1998.1781; Kihara A, 1999, EMBO J, V18, P2970, DOI 10.1093/emboj/18.11.2970; KORNITZER D, 1991, J BACTERIOL, V173, P2944, DOI 10.1128/JB.173.9.2944-2953.1991; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Murphy KC, 1998, J BACTERIOL, V180, P2063, DOI 10.1128/JB.180.8.2063-2071.1998; Paetzel M, 2002, CHEM REV, V102, P4549, DOI 10.1021/cr010166y; SAWANO A, 2000, NUCLEIC ACIDS RES, V28, P78, DOI DOI 10.1093/NAR/28.16.E78; Shimohata N, 2002, GENES CELLS, V7, P653, DOI 10.1046/j.1365-2443.2002.00554.x; SHIMOIKE T, 1995, J BIOL CHEM, V270, P5519, DOI 10.1074/jbc.270.10.5519; TAM A, 1998, HDB PROTEOLYTIC ENZY, P1094; Vickerman MM, 2002, ORAL MICROBIOL IMMUN, V17, P22, DOI 10.1046/j.0902-0055.2001.00000.x	32	87	93	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33305	33310		10.1074/jbc.M506180200	http://dx.doi.org/10.1074/jbc.M506180200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16076848	hybrid			2022-12-25	WOS:000232058100026
J	Smith, GB; Umbach, JA; Hirano, A; Gundersen, CB				Smith, GB; Umbach, JA; Hirano, A; Gundersen, CB			Interaction between constitutively expressed heat shock protein, Hsc 70, and cysteine string protein is important for cortical granule exocytosis in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAEVIS OOCYTES; NEUROTRANSMITTER EXOCYTOSIS; NEUROMUSCULAR-JUNCTIONS; REGULATED EXOCYTOSIS; COGNATE PROTEIN; CALCIUM-CHANNEL; MEMBRANE-FUSION; MESSENGER-RNA; C-TERMINUS; J-DOMAIN	In many species, binding of sperm to the egg initiates cortical granule exocytosis, an event that contributes to a sustained block of polyspermy. Interestingly, cortical granule exocytosis can be elicited in immature Xenopus oocytes by the protein kinase C activator, phorbol- 12- myristate- 13- acetate. In this study, we investigated the role of cysteine string protein ( csp) in phorbol- 12- myristate- 13- acetate- evoked cortical granule exocytosis. Prior work indicated that csp is associated with cortical granules of Xenopus oocytes. In oocytes exhibiting > 20- fold overexpression of full- length Xenopus csp, cortical granule exocytosis was reduced by similar to 80%. However, csp overexpression did not affect constitutive exocytosis. Subcellular fractionation and confocal fluorescence microscopy revealed that little or none of the overexpressed csp was associated with cortical granules. This accumulation of csp at sites other than cortical granules suggested that mislocalized csp might sequester a protein that is important for regulated exocytosis. Because the NH2- terminal region of csp includes a J- domain, which interacts with constitutively expressed 70- kDa heat shock proteins ( Hsc 70), we evaluated the effect of overexpressing the J- domain of csp. Although the native J- domain of csp inhibited cortical granule exocytosis, point mutations that interfere with J- domain binding to Hsc 70 eliminated this inhibition. These data indicate that csp interaction with Hsc 70 molecular chaperones is vital for regulated secretion in Xenopus oocytes.	Univ Calif Los Angeles, David P Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David P Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David P Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Gundersen, CB (corresponding author), Univ Calif Los Angeles, David P Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA.	cgundersen@mednet.ucla.edu		Gundersen, Cameron/0000-0002-1552-6086	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031934] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS031934] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ali A, 1996, COMP BIOCHEM PHYS B, V113, P681, DOI 10.1016/0305-0491(95)02081-0; Ali A, 1996, BBA-GENE STRUCT EXPR, V1309, P174, DOI 10.1016/S0167-4781(96)00156-X; Arnold C, 2004, J EXP BIOL, V207, P1323, DOI 10.1242/jeb.00898; Augustine GJ, 1996, ANNU REV PHARMACOL, V36, P659, DOI 10.1146/annurev.pa.36.040196.003303; BALINSKY B. I., 1963, ACTA EMBRYOL ET MORPHOL EXPTL, V6, P55; BEMENT WM, 1989, J CELL BIOL, V108, P885, DOI 10.1083/jcb.108.3.885; BEMENT WM, 1990, CELL REGUL, V1, P315, DOI 10.1091/mbc.1.3.315; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; Boal F, 2004, BIOCHEMISTRY-US, V43, P16212, DOI 10.1021/bi048612+; Braun JEA, 1996, J BIOL CHEM, V271, P25989, DOI 10.1074/jbc.271.42.25989; Brown H, 1998, EMBO J, V17, P5048, DOI 10.1093/emboj/17.17.5048; Buchner E, 1997, TRENDS NEUROSCI, V20, P223, DOI 10.1016/S0166-2236(96)10082-5; BURGOYNE RD, 1993, BIOCHEM J, V293, P305, DOI 10.1042/bj2930305; Chamberlain LH, 1998, MOL BIOL CELL, V9, P2259, DOI 10.1091/mbc.9.8.2259; Chamberlain LH, 1997, BIOCHEM J, V322, P853, DOI 10.1042/bj3220853; Chamberlain LH, 2000, J NEUROCHEM, V74, P1781, DOI 10.1046/j.1471-4159.2000.0741781.x; Chamberlain LH, 1997, J BIOL CHEM, V272, P31420, DOI 10.1074/jbc.272.50.31420; CHARBONNEAU M, 1984, DEV BIOL, V102, P90, DOI 10.1016/0012-1606(84)90177-5; Chen S, 2002, J PHYSIOL-LONDON, V538, P383, DOI 10.1113/jphysiol.2001.013397; Cordeiro ML, 2004, NEUROPSYCHOPHARMACOL, V29, P39, DOI 10.1038/sj.npp.1300288; Dawson-Scully K, 2000, J NEUROSCI, V20, P6039, DOI 10.1523/JNEUROSCI.20-16-06039.2000; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; Graham ME, 2000, J NEUROSCI, V20, P1281; GUNDERSEN CB, 1992, NEURON, V9, P527, DOI 10.1016/0896-6273(92)90190-O; Gundersen CB, 2002, J CELL SCI, V115, P1313; Gundersen CB, 2001, CELL TISSUE RES, V303, P211, DOI 10.1007/s004410000314; GUNDERSEN CB, 1984, NATURE, V308, P421, DOI 10.1038/308421a0; GUNDERSEN CB, 1995, J THEOR BIOL, V172, P269, DOI 10.1006/jtbi.1995.0023; GUNDERSEN CB, 1994, J BIOL CHEM, V269, P19197; GURDON JB, 1971, NATURE, V233, P177, DOI 10.1038/233177a0; HERBERTS C, 1993, INT J DEV BIOL, V37, P397; Kelley WL, 1998, TRENDS BIOCHEM SCI, V23, P222, DOI 10.1016/S0968-0004(98)01215-8; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Kohan SA, 2003, J EXP ZOOL PART A, V300A, P113, DOI 10.1002/jez.a.10317; LANE CD, 1980, EUR J BIOCHEM, V111, P225; Leveque C, 1998, J BIOL CHEM, V273, P13488, DOI 10.1074/jbc.273.22.13488; MANDELL RB, 1990, J CELL BIOL, V111, P1775, DOI 10.1083/jcb.111.5.1775; Mastrogiacomo A, 1998, BBA-MOL CELL RES, V1401, P239, DOI 10.1016/S0167-4889(97)00160-2; Poage RE, 1999, J NEUROPHYSIOL, V82, P50, DOI 10.1152/jn.1999.82.1.50; SCHUEL H, 1978, GAMETE RES, V1, P299, DOI 10.1002/mrd.1120010311; Stahl B, 1999, EUR J CELL BIOL, V78, P375, DOI 10.1016/S0171-9335(99)80079-X; Tobaben S, 2001, NEURON, V31, P987, DOI 10.1016/S0896-6273(01)00427-5; Umbach JA, 1998, J NEUROSCI, V18, P3233; UMBACH JA, 1994, NEURON, V13, P899, DOI 10.1016/0896-6273(94)90255-0; Umbach JA, 1997, J NEUROSCI, V17, P7203; Zampighi GA, 1999, J GEN PHYSIOL, V113, P507, DOI 10.1085/jgp.113.4.507; Zhang H, 1998, FEBS LETT, V437, P267, DOI 10.1016/S0014-5793(98)01233-2; Zhang H, 1999, J CELL SCI, V112, P1345; Zinsmaier KE, 2001, BIOCHEM PHARMACOL, V62, P1, DOI 10.1016/S0006-2952(01)00648-7; ZINSMAIER KE, 1990, J NEUROGENET, V7, P15, DOI 10.3109/01677069009084150	50	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32669	32675		10.1074/jbc.M501806200	http://dx.doi.org/10.1074/jbc.M501806200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16055447	Green Accepted, hybrid			2022-12-25	WOS:000231920300016
J	Kim, JK; Xu, Y; Xu, XJ; Keene, DR; Gurusiddappa, S; Liang, XW; Wary, KK; Hook, M				Kim, JK; Xu, Y; Xu, XJ; Keene, DR; Gurusiddappa, S; Liang, XW; Wary, KK; Hook, M			A novel binding site in collagen type III for integrins alpha(1)beta(1) and alpha(2)beta(1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRINS ALPHA(1)BETA(1); I-DOMAIN; RECOGNITION; SEQUENCE; IDENTIFICATION; RECEPTORS; DISEASES; CLONING; GFOGER	Previously identified high affinity integrin-binding motifs in collagens, GFOGER and GLOGER, are not present in type III collagen. Here, we first characterized the binding of recombinant I domains from integrins alpha(1) and alpha(2) (alpha(1)I and alpha(2)I) to fibrillar collagen types I-III and showed that each I domain bound to the three types of collagens with similar affinities. Using rotary shadowing followed by electron microscopy, we identified a high affinity binding region in human type III collagen recognized by alpha(1)I and alpha(2)I. Examination of the region revealed the presence of two sequences that contain the critical GERmotif, GROGER and GAOGER. Collagen-like peptides containing these two motifs were synthesized, and their triple helical nature was confirmed by circular dichroism spectroscopy. Experiments show that the GROGER-containing peptide was able to bind both alpha(1)I and alpha(2)I with high affinity and effectively inhibit the binding of alpha(1)I and alpha(2)I to type III and I collagens, whereas the GAOGER-containing peptide was considerably less effective. Furthermore, the GROGER-containing peptide supported adhesion of human lung fibroblast cells when coated on a culture dish. Thus, we have identified a novel high affinity binding sequence for the collagen-binding integrin I domains.	Texas A&M Univ, Syst Hlth Sci Ctr, Ctr Extracellular Matrix Biol, Inst Biosci & Technol, Houston, TX 77030 USA; Shriners Hosp Children, Portland, OR 97201 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Hook, M (corresponding author), Texas A&M Univ, Syst Hlth Sci Ctr, Ctr Extracellular Matrix Biol, Inst Biosci & Technol, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	mhook@ibt.tamhsc.edu		Wary, Kishore/0000-0001-8851-8565; Liang, Xiaowen/0000-0002-6174-2951	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044415] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR44415] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; Camper L, 1998, J BIOL CHEM, V273, P20383, DOI 10.1074/jbc.273.32.20383; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Gelse K, 2003, ADV DRUG DELIVER REV, V55, P1531, DOI 10.1016/j.addr.2003.08.002; Gullberg DE, 2002, PROG HISTOCHEM CYTO, V37, P9; Hulmes DJS, 1992, ESSAYS BIOCHEM, V27, P49; Humtsoe JO, 2005, J BIOL CHEM, V280, P13848, DOI 10.1074/jbc.M410605200; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Knight CG, 2000, J BIOL CHEM, V275, P35, DOI 10.1074/jbc.275.1.35; Knight CG, 1998, J BIOL CHEM, V273, P33287, DOI 10.1074/jbc.273.50.33287; KRAMER RH, 1989, J BIOL CHEM, V264, P4684; Kuivaniemi H, 1997, HUM MUTAT, V9, P300, DOI 10.1002/(SICI)1098-1004(1997)9:4<300::AID-HUMU2>3.0.CO;2-9; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; Liu X, 1997, P NATL ACAD SCI USA, V94, P1852, DOI 10.1073/pnas.94.5.1852; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; Nykvist P, 2000, J BIOL CHEM, V275, P8255, DOI 10.1074/jbc.275.11.8255; PATTI JM, 1992, J BIOL CHEM, V267, P4766; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; RAMACHANDRAN GN, 1988, INT J PEPT PROT RES, V31, P1; Rich RL, 1999, J BIOL CHEM, V274, P24906, DOI 10.1074/jbc.274.35.24906; Siljander PRM, 2004, J BIOL CHEM, V279, P47763, DOI 10.1074/jbc.M404685200; Velling T, 1999, J BIOL CHEM, V274, P25735, DOI 10.1074/jbc.274.36.25735; Xu Y, 2000, J BIOL CHEM, V275, P38981, DOI 10.1074/jbc.M007668200; Zhang WM, 2003, J BIOL CHEM, V278, P7270, DOI 10.1074/jbc.M210313200	24	84	94	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32512	32520		10.1074/jbc.M502431200	http://dx.doi.org/10.1074/jbc.M502431200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16043429	hybrid			2022-12-25	WOS:000231794800060
J	Nakamura, F; Hartwig, JH; Stossel, TP; Szymanski, PT				Nakamura, F; Hartwig, JH; Stossel, TP; Szymanski, PT			Ca2+ and calmodulin regulate the binding of filamin A to actin filaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; ALPHA-ACTININ; CH DOMAINS; PROTEINS; SMOOTH; SEQUENCE; SUPERFAMILY; SENSITIVITY; DYSTROPHIN; MECHANICS	Filamin A (FLNa) cross-links actin filaments (F-actin) into three-dimensional gels in cells, attaches F-actin to membrane proteins, and is a scaffold that collects numerous and diverse proteins. We report that Ca2+-calmodulin binds the actin-binding domain (ABD) of FLNa and dissociates FLNa from F- actin, thereby dissolving (FLNaF)-F-.-actin gels. The FLNa ABD has two calponin homology domains (CH1 and CH2) separated by a linker. Recombinant CH1 but neither FLNa nor its ABD binds Ca2+-calmodulin in the absence of F- actin. Extending recombinant CH1 to include the negatively charged region linker domain makes it, like full-length FLNa, unable to bind Ca2+-calmodulin. Ca2+-calmodulin does, however, dissociate the FLNa ABD from F- actin provided that the CH2 domain is present. These findings identify the first evidence for direct regulation of FLNa, implicating amechanism whereby Ca2+-calmodulin selectively targets the (FLNaF)-F-.-actin complex.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Nakamura, F (corresponding author), Brigham & Womens Hosp, Div Hematol, Karp Family Res Labs 6F, 1 Blackfan Circle, Boston, MA 02115 USA.	fnakamura@rics.bwh.harvard.edu	Nakamura, Fumihiko/N-5476-2016	Nakamura, Fumihiko/0000-0002-6872-4246	NHLBI NIH HHS [HL19429, HL56252] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056252, R37HL019429, R01HL019429] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Banuelos S, 1998, STRUCTURE, V6, P1419, DOI 10.1016/S0969-2126(98)00141-5; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BERS DM, 1982, AM J PHYSIOL, V242, pC404, DOI 10.1152/ajpcell.1982.242.5.C404; BRESNICK AR, 1991, J BIOL CHEM, V266, P12989; DesMarais V, 2005, J CELL SCI, V118, P19, DOI 10.1242/jcs.01631; Feng YY, 2004, NAT CELL BIOL, V6, P1034, DOI 10.1038/ncb1104-1034; Gimona M, 2002, FEBS LETT, V513, P98, DOI 10.1016/S0014-5793(01)03240-9; Gimona M, 1998, CURR BIOL, V8, pR674; HARTWIG JH, 1995, PROTEIN PROFILE, V2, P703; HARTWIG JH, 1986, J CELL BIOL, V103, P1007, DOI 10.1083/jcb.103.3.1007; HARTWIG JH, 1981, J MOL BIOL, V145, P563, DOI 10.1016/0022-2836(81)90545-3; Hayashi N, 1998, PROTEIN EXPRES PURIF, V12, P25, DOI 10.1006/prep.1997.0807; JARRETT HW, 1995, J BIOL CHEM, V270, P5578, DOI 10.1074/jbc.270.10.5578; KINOSIAN HJ, 1991, BIOCHIM BIOPHYS ACTA, V1077, P151, DOI 10.1016/0167-4838(91)90052-2; LEVINE BA, 1992, FEBS LETT, V298, P44, DOI 10.1016/0014-5793(92)80019-D; Mori MX, 2004, SCIENCE, V304, P432, DOI 10.1126/science.1093490; Nakamura F, 2002, J BIOL CHEM, V277, P9148, DOI 10.1074/jbc.M111297200; PACAUD M, 1993, BIOCHEMISTRY-US, V32, P363, DOI 10.1021/bi00052a045; RADDING W, 1994, J CELL PHYSIOL, V160, P17, DOI 10.1002/jcp.1041600104; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Silacci P, 2004, CELL MOL LIFE SCI, V61, P2614, DOI 10.1007/s00018-004-4225-6; SOBEL JS, 1988, DEV BIOL, V126, P47, DOI 10.1016/0012-1606(88)90237-0; Stossel TP, 2001, NAT REV MOL CELL BIO, V2, P138, DOI 10.1038/35052082; Stradal T, 1998, FEBS LETT, V431, P134, DOI 10.1016/S0014-5793(98)00751-0; Szymanska G, 1997, ANAL BIOCHEM, V252, P96, DOI 10.1006/abio.1997.2319; Szymanski PT, 2002, AM J PHYSIOL-CELL PH, V282, pC94, DOI 10.1152/ajpcell.00257.2001; Tang JH, 2001, J MOL BIOL, V310, P845, DOI 10.1006/jmbi.2001.4789; TANSEY MG, 1994, J BIOL CHEM, V269, P9912; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WAY M, 1992, J CELL BIOL, V119, P835, DOI 10.1083/jcb.119.4.835; WINDER SJ, 1995, FEBS LETT, V357, P125, DOI 10.1016/0014-5793(94)01347-4; WINDER SJ, 1995, J CELL SCI, V108, P63; WINDER SJ, 1993, BIOCHEMISTRY-US, V32, P13327, DOI 10.1021/bi00211a046; Yap Kyoko L., 2000, Journal of Structural and Functional Genomics, V1, P8, DOI 10.1023/A:1011320027914; YASUTAKA O, 1995, BIOCHEMISTRY-US, V34, P6745, DOI 10.1021/bi00020a020	35	61	62	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32426	32433		10.1074/jbc.M502203200	http://dx.doi.org/10.1074/jbc.M502203200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16030015	hybrid			2022-12-25	WOS:000231794800049
J	Blumenthal, SB; Kiemer, AK; Tiegs, G; Seyfried, S; Holtje, M; Brandt, B; Holtje, HD; Zahler, S; Vollmar, AM				Blumenthal, SB; Kiemer, AK; Tiegs, G; Seyfried, S; Holtje, M; Brandt, B; Holtje, HD; Zahler, S; Vollmar, AM			Metalloporphyrins inactivate caspase-3 and-8	FASEB JOURNAL			English	Article						porphyrin ring; HO-1 expression; heme-iron	HEME OXYGENASE-1; NITRIC-OXIDE; ZINC-PROTOPORPHYRIN; CELL-DEATH; APOPTOSIS; INHIBITION; INDUCTION; MACROPHAGES; EXPRESSION; REDUCTION	Activation of caspases represents one of the earliest biochemical indicators for apoptotic cell death. Therefore, measurement of caspase activity is a widely used and generally accepted method to determine apoptosis in a wide range of in vivo and in vitro settings. Numerous publications characterize the role of the heme-catabolizing enzyme heme oxygenase-1 (HO-1) in regulating apoptotic processes. Different metalloporphyrins representing inducers and inhibitors of this enzyme are often used, followed by assessment of apoptotic cell death. In the present work, we found that caspase-3-like activity, as well as activity of caspase-8 measured in either Fas (CD95) ligand-treated Jurkat T-lymphocytes or by the use of recombinant caspase-3 or -8, was inhibited by different metalloporphyrins (cobalt(III) protoporphyrin IX, tin and zinc(II) protoporphyrin- IX). Moreover, employing the mouse model of Fas-induced liver apoptosis these properties of porphyrins could also be demonstrated in vivo. The metalloporphyrins were shown to inhibit caspase-3-mediated PARP cleavage. Molecular modeling studies demonstrated that porphyrins can occupy the active site of caspase-3 in an energetically favorable manner and in a binding mode similar to that of known inhibitors. The data shown here introduce metalloporphyrins as direct inhibitors of caspase activity. This finding points to the need for careful employment of metalloporphyrins as modulators of HO.	Univ Munich, Dept Pharm, Ctr Drug Res, D-81377 Munich, Germany; Univ Saarland, Inst Pharmaceut Biol, D-6600 Saarbrucken, Germany; Univ Erlangen Nurnberg, Dept Expt & Clin Pharmacol & Toxicol, D-8520 Erlangen, Germany; Univ Dusseldorf, Inst Pharmaceut Chem, D-4000 Dusseldorf, Germany	University of Munich; Saarland University; University of Erlangen Nuremberg; Heinrich Heine University Dusseldorf	Vollmar, AM (corresponding author), Univ Munich, Dept Pharm, Ctr Drug Res, Butenandtstr 5-13, D-81377 Munich, Germany.	Angelika.Vollmar@cup.uni-muenchen.de	Kiemer, Alexandra K./I-9300-2012	Kiemer, Alexandra K./0000-0002-7224-9900				Akamatsu Y, 2004, FASEB J, V18, P771, DOI 10.1096/fj.03-0921fje; BONNETT R, 2003, COMPR COORDINATION C, V2; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Denault JB, 2002, CHEM REV, V102, P4489, DOI 10.1021/cr010183n; Dirsch VM, 2003, CANCER RES, V63, P8869; Dorman Robert B, 2004, Comp Hepatol, V3 Suppl 1, pS42, DOI 10.1186/1476-5926-2-S1-S42; Erlanson DA, 2003, NAT BIOTECHNOL, V21, P308, DOI 10.1038/nbt786; Fauconneau B, 2002, J NEUROCHEM, V83, P1338, DOI 10.1046/j.1471-4159.2002.01230.x; Gurtu V, 1997, ANAL BIOCHEM, V251, P98, DOI 10.1006/abio.1997.2220; Ito K, 2000, HEPATOLOGY, V31, P416, DOI 10.1002/hep.510310222; Jozkowicz A, 2003, ACTA BIOCHIM POL, V50, P69, DOI 10.18388/abp.2003_3715; Kampfer H, 2001, MOL MED, V7, P488, DOI 10.1007/BF03401854; Kiemer AK, 1998, J BIOL CHEM, V273, P13444, DOI 10.1074/jbc.273.22.13444; Kown MH, 2000, CIRCULATION, V102, P228; Labbe RF, 1999, CLIN CHEM, V45, P2060; Lee D, 2000, J BIOL CHEM, V275, P16007, DOI 10.1074/jbc.275.21.16007; Leist M, 1997, BIOCHEM BIOPH RES CO, V236, P1, DOI 10.1006/bbrc.1997.6890; Liu ZM, 2004, ONCOGENE, V23, P503, DOI 10.1038/sj.onc.1207173; LUO DS, 1994, EUR J PHARM-MOLEC PH, V267, P263, DOI 10.1016/0922-4106(94)90149-X; MAINES MD, 1992, BIOCHIM BIOPHYS ACTA, V1131, P166, DOI 10.1016/0167-4781(92)90072-8; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; MAINES MD, 1981, BIOCHIM BIOPHYS ACTA, V673, P339, DOI 10.1016/0304-4165(81)90465-7; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicotera P, 2004, ONCOGENE, V23, P2757, DOI 10.1038/sj.onc.1207559; Pae HO, 2004, MOL PHARMACOL, V66, P122, DOI 10.1124/mol.66.1.122; Perry DK, 1997, J BIOL CHEM, V272, P18530, DOI 10.1074/jbc.272.30.18530; Petrache I, 2000, AM J PHYSIOL-LUNG C, V278, pL312, DOI 10.1152/ajplung.2000.278.2.L312; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(02)02036-6; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; Ryter SW, 2002, MOL CELL BIOCHEM, V234, P249, DOI 10.1023/A:1015957026924; SARDANA MK, 1987, P NATL ACAD SCI USA, V84, P2464, DOI 10.1073/pnas.84.8.2464; Sass G, 2003, HEPATOLOGY, V38, P909, DOI 10.1053/jhep.2003.50386; Serfas L, 1998, ARCH BIOCHEM BIOPHYS, V359, P8, DOI 10.1006/abbi.1998.0887; Shan Y, 2002, ARCH BIOCHEM BIOPHYS, V399, P159, DOI 10.1006/abbi.2001.2742; Shan Y, 2000, ARCH BIOCHEM BIOPHYS, V380, P219, DOI 10.1006/abbi.2000.1921; SMITHKM, 1975, PORPHYRINS METALLOPO; Stennicke HR, 2002, TRENDS BIOCHEM SCI, V27, P94, DOI 10.1016/S0968-0004(01)02045-X; Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719; STEVENSON DK, 1989, AM J DIS CHILD, V143, P353, DOI 10.1001/archpedi.1989.02150150111027; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; Yang G, 2001, BLOOD, V97, P1306, DOI 10.1182/blood.V97.5.1306; Zbinden P, 1998, QUANT STRUCT-ACT REL, V17, P122, DOI 10.1002/(SICI)1521-3838(199804)17:02<122::AID-QSAR122>3.3.CO;2-C; Zhang XC, 2004, J BIOL CHEM, V279, P10677, DOI 10.1074/jbc.M312941200	44	29	30	1	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1272	1279		10.1096/fj.04-3259com	http://dx.doi.org/10.1096/fj.04-3259com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16051694	Green Submitted			2022-12-25	WOS:000231843700034
J	Fernando, P; Brunette, S; Megeney, LA				Fernando, P; Brunette, S; Megeney, LA			Neural stem cell differentiation is dependent upon endogenous caspase-3 activity	FASEB JOURNAL			English	Article						apoptosis; kinase; neurogenesis	ACTIVATED PROTEIN-KINASE; NEURONAL DIFFERENTIATION; KERATINOCYTE DIFFERENTIATION; MEDIATED ACTIVATION; INDUCED APOPTOSIS; PC12 CELLS; IN-VIVO; ROCK-I; 1 ASK1; CLEAVAGE	Caspase proteases have become the focal point for the development and application of antiapoptotic therapies in a variety of central nervous system diseases. However, this approach is based on the premise that caspase function is limited to invoking cell death signals. Here, we show that caspase-3 activity is elevated in nonapoptotic differentiating neuronal cell populations. Moreover, peptide inhibition of protease activity effectively inhibits the differentiation process in a cultured neurosphere model. These results implicate caspase-3 activation as a conserved feature of neuronal differentiation and suggest that targeted inhibition of this protease in neural cell populations may have unintended consequences.	Ottawa Hlth Res Inst, Mol Med Program, Ottawa, ON, Canada; StemPath Inc, Ottawa, ON K1Y 4E9, Canada; Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa	Megeney, LA (corresponding author), Ottawa Hlth Res Inst, Mol Med Program, 501 Smyth Rd, Ottawa, ON, Canada.	lmegeney@ohri.ca		Fernando, Pasan/0000-0001-8792-9637; Megeney, Lynn/0000-0002-6824-8569				Abraham MC, 2004, TRENDS CELL BIOL, V14, P184, DOI 10.1016/j.tcb.2004.03.002; Bez A, 2003, BRAIN RES, V993, P18, DOI 10.1016/j.brainres.2003.08.061; Bokoch GM, 1998, CELL DEATH DIFFER, V5, P637, DOI 10.1038/sj.cdd.4400405; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chan YM, 2003, EXP NEUROL, V181, P190, DOI 10.1016/S0014-4886(03)00023-2; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; Cregan SP, 1999, J NEUROSCI, V19, P7860; Crocker SJ, 2001, EUR J NEUROSCI, V14, P391, DOI 10.1046/j.0953-816x.2001.01653.x; Faigle R, 2004, MOL CELL BIOL, V24, P280, DOI 10.1128/MCB.24.1.280-293.2004; Fernando P, 2002, P NATL ACAD SCI USA, V99, P11025, DOI 10.1073/pnas.162172899; Fiskum G, 2003, ANN NY ACAD SCI, V991, P111; Flygare J, 2000, EUR J BIOCHEM, V267, P5977, DOI 10.1046/j.1432-1327.2000.01675.x; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gao SY, 2004, NEPHRON EXP NEPHROL, V97, pE49, DOI 10.1159/000078406; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Hansson O, 2000, EXP NEUROL, V164, P102, DOI 10.1006/exnr.2000.7406; Hurelbrink CB, 2001, EXP NEUROL, V171, P46, DOI 10.1006/exnr.2001.7749; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Katz LM, 2001, NEUROREPORT, V12, P3751, DOI 10.1097/00001756-200112040-00029; Kipp M, 2000, J BIOL CHEM, V275, P5031, DOI 10.1074/jbc.275.7.5031; Kraus WL, 2003, CELL, V113, P677, DOI 10.1016/S0092-8674(03)00433-1; Kugler S, 2000, CELL DEATH DIFFER, V7, P815, DOI 10.1038/sj.cdd.4400712; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Laplante I, 2004, J NEUROBIOL, V60, P289, DOI 10.1002/neu.20036; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Li H, 2000, STROKE, V31, P176, DOI 10.1161/01.STR.31.1.176; LYONS GE, 1995, J NEUROSCI, V15, P5727, DOI 10.1523/jneurosci.15-08-05727.1995; McMullan R, 2003, CURR BIOL, V13, P2185, DOI 10.1016/S0960-9822(03)00906-0; Melendez-Vasquez CV, 2004, J NEUROSCI, V24, P3953, DOI 10.1523/JNEUROSCI.4920-03.2004; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Nijhawan D, 2000, ANNU REV NEUROSCI, V23, P73, DOI 10.1146/annurev.neuro.23.1.73; Okamoto S, 2000, P NATL ACAD SCI USA, V97, P7561, DOI 10.1073/pnas.130502697; Okuyama R, 2004, DEV CELL, V6, P551, DOI 10.1016/S1534-5807(04)00098-X; Oomman S, 2004, J COMP NEUROL, V476, P154, DOI 10.1002/cne.20223; Perrelet D, 2000, EUR J NEUROSCI, V12, P2059, DOI 10.1046/j.1460-9568.2000.00098.x; Petrache I, 2003, FASEB J, V17, P407, DOI 10.1096/fj.02-0672com; Reynolds BA, 1996, DEV BIOL, V175, P1, DOI 10.1006/dbio.1996.0090; Rohn TT, 2004, EXP CELL RES, V295, P215, DOI 10.1016/j.yexcr.2003.12.029; Sayama K, 2001, J BIOL CHEM, V276, P999, DOI 10.1074/jbc.M003425200; Schierle GS, 1999, NAT MED, V5, P97, DOI 10.1038/4785; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; Skerjanc IS, 2000, FEBS LETT, V472, P53, DOI 10.1016/S0014-5793(00)01438-1; Takeda K, 2000, J BIOL CHEM, V275, P9805, DOI 10.1074/jbc.275.13.9805; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Xu DG, 1997, NAT MED, V3, P997, DOI 10.1038/nm0997-997; Yanazume T, 2002, J BIOL CHEM, V277, P8618, DOI 10.1074/jbc.M107924200; Zhang BL, 2003, MOL CELL BIOL, V23, P5716, DOI 10.1128/MCB.23.16.5716-5725.2003	50	163	166	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1671	+		10.1096/fj.04-2981fje	http://dx.doi.org/10.1096/fj.04-2981fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16103108				2022-12-25	WOS:000231843700013
J	Hopfer, U; Fukai, N; Hopfer, H; Wolf, G; Joyce, N; Li, E; Olsen, BR				Hopfer, U; Fukai, N; Hopfer, H; Wolf, G; Joyce, N; Li, E; Olsen, BR			Targeted disruption of Col8a1 and Col8a2 genes in mice leads to anterior segment abnormalities in the eye	FASEB JOURNAL			English	Article						type VIII collagen; corneal endothelial cells; proliferation	POSTERIOR POLYMORPHOUS DYSTROPHY; SHORT-CHAIN COLLAGEN; ENDOTHELIAL-CELL-PROLIFERATION; EPIDERMAL GROWTH-FACTOR; TRIPLE-HELICAL DOMAINS; SMOOTH-MUSCLE-CELLS; VIII COLLAGEN; CORNEAL ENDOTHELIUM; DESCEMETS-MEMBRANE; DIFFERENTIAL EXPRESSION	Collagen VIII is localized in subendothelial and subepithelial extracellular matrices. It is a major component of Descemet's membrane, a thick basement membrane under the corneal endothelium, where it forms a hexagonal lattice structure; a similar structure, albeit less extensive, may be formed in other basement membranes. We have examined the function of collagen VIII in mice by targeted inactivation of the genes encoding the two polypeptide subunits, Co18a1 and Co18a2. Analysis of these mice reveals no major structural defects in most organs, but demonstrates that type VIII collagen is required for normal anterior eye development, particularly the formation of a corneal stroma with the appropriate number of fibroblastic cell layers and Descemet's membrane of appropriate thickness. Complete lack of type VIII collagen leads to dysgenesis of the anterior segment of the eye: a globoid, keratoglobus- like protrusion of the anterior chamber with a thin corneal stroma. Descemet's membrane is markedly thinned. The corneal endothelial cells are enlarged and reduced in number, and show a decreased ability to proliferate in response to different growth factors in vitro. An important function of collagen VIII may therefore be to generate a peri- or subcellular matrix environment that permits or stimulates cell proliferation.	Harvard Univ, Sch Dent Med, Dept Oral & Dev Biol, Boston, MA 02115 USA; Univ Hamburg, Dept Pathol, Hamburg, Germany; Univ Hamburg, Dept Med, Hamburg, Germany; Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA; Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA USA; Massachusetts Gen Hosp, Cardiovasc Res Div, Boston, MA 02114 USA	Harvard University; Harvard School of Dental Medicine; University of Hamburg; University of Hamburg; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Schepens Eye Research Institute; Harvard University; Massachusetts General Hospital	Olsen, BR (corresponding author), Harvard Univ, Sch Dent Med, Dept Oral & Dev Biol, 188 Longwood Ave, Boston, MA 02115 USA.	bjorn_olsen@hms.harvard.edu	Hopfer, Helmut/T-5954-2019	Hopfer, Helmut/0000-0003-1755-2170	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR036820, R37AR036820, R37AR036819, R01AR036819] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR36819, AR36820] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALITALO K, 1983, J BIOL CHEM, V258, P2653; Aszodi A, 1998, J MOL MED-JMM, V76, P238, DOI 10.1007/s001090050214; BARD JBL, 1988, DEVELOPMENT, V103, P195; Bendeck MP, 1996, CIRC RES, V79, P524, DOI 10.1161/01.RES.79.3.524; BENYA P D, 1980, Renal Physiology, V3, P30; Biswas S, 2001, HUM MOL GENET, V10, P2415, DOI 10.1093/hmg/10.21.2415; Chakravarti S, 1998, J CELL BIOL, V141, P1277, DOI 10.1083/jcb.141.5.1277; Chakravarti S, 2001, EXP EYE RES, V73, P411, DOI 10.1006/exer.2001.1055; Chen KH, 2001, CORNEA, V20, P731, DOI 10.1097/00003226-200110000-00012; Chen KH, 1999, INVEST OPHTH VIS SCI, V40, P2513; FABRICANT RN, 1981, ARCH OPHTHALMOL-CHIC, V99, P305; Flugel-Koch C, 2002, DEV DYNAM, V225, P111, DOI 10.1002/dvdy.10144; Forsberg E, 1996, P NATL ACAD SCI USA, V93, P6594, DOI 10.1073/pnas.93.13.6594; GOSPODAROWICZ D, 1977, EXP EYE RES, V25, P75, DOI 10.1016/0014-4835(77)90248-2; Gottsch JD, 2003, INVEST OPHTH VIS SCI, V44, P594, DOI 10.1167/iovs.02-0300; Greenhill NS, 2000, MATRIX BIOL, V19, P19, DOI 10.1016/S0945-053X(99)00053-0; Grupcheva CN, 2001, CLIN EXP OPHTHALMOL, V29, P256, DOI 10.1046/j.1442-9071.2001.00432.x; Hay E.D., 1980, International Review of Cytology, V63, P263, DOI 10.1016/S0074-7696(08)61760-X; HENRIQUEZ AS, 1984, SURV OPHTHALMOL, V29, P139, DOI 10.1016/0039-6257(84)90171-1; HEON E, 1995, HUM MOL GENET, V4, P485, DOI 10.1093/hmg/4.3.485; Heon E, 2002, HUM MOL GENET, V11, P1029, DOI 10.1093/hmg/11.9.1029; Hirano S, 2004, BIOCHEM BIOPH RES CO, V317, P437, DOI 10.1016/j.bbrc.2004.03.049; Hou GP, 2000, AM J PATHOL, V156, P467, DOI 10.1016/S0002-9440(10)64751-7; Illidge C, 1998, J BIOL CHEM, V273, P22091, DOI 10.1074/jbc.273.34.22091; IRUELAARISPE ML, 1991, LAB INVEST, V64, P174; IRUELAARISPE ML, 1991, DEV BIOL, V144, P107, DOI 10.1016/0012-1606(91)90483-J; JAKUS MARIE A., 1956, JOUR BIOPHYS AND BIOCHEM CYTOL, V2, P243, DOI 10.1083/jcb.2.4.243; JOHNSON DH, 1982, ARCH OPHTHALMOL-CHIC, V100, P1942, DOI 10.1001/archopht.1982.01030040922011; Jones PL, 2000, MATRIX BIOL, V19, P581, DOI 10.1016/S0945-053X(00)00106-2; KENNEY MC, 1984, EXP EYE RES, V39, P267, DOI 10.1016/0014-4835(84)90015-0; KITTELBERGER R, 1990, CONNECT TISSUE RES, V24, P303, DOI 10.3109/03008209009152157; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LEVY SG, 1995, EXP EYE RES, V61, P323, DOI 10.1016/S0014-4835(05)80127-7; Levy SG, 1996, ARCH OPHTHALMOL-CHIC, V114, P1265, DOI 10.1001/archopht.1996.01100140465021; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Li QJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P1597; LIU CY, 2003, J BIOL CHEM, V28, P28; MacBeath JRE, 1996, BIOCHEM J, V319, P993, DOI 10.1042/bj3190993; MURAGAKI Y, 1991, J BIOL CHEM, V266, P7721; MURAGAKI Y, 1991, EUR J BIOCHEM, V197, P615, DOI 10.1111/j.1432-1033.1991.tb15951.x; MURAGAKI Y, 1992, EUR J BIOCHEM, V207, P895, DOI 10.1111/j.1432-1033.1992.tb17122.x; MURPHY C, 1984, INVEST OPHTH VIS SCI, V25, P1402; PAULUS W, 1991, BRIT J CANCER, V63, P367, DOI 10.1038/bjc.1991.87; PAULUS W, 1992, ACTA HISTOCHEM, P195; PEARCE WG, 1969, BRIT J OPHTHALMOL, V53, P577, DOI 10.1136/bjo.53.9.577; Pellegata NS, 2000, NAT GENET, V25, P91, DOI 10.1038/75664; RAO GN, 1982, INVEST OPHTH VIS SCI, V22, P271; Reneker LW, 2000, DEVELOPMENT, V127, P533; SAGE H, 1982, COLLAGEN REL RES, V2, P465; Saika S, 2001, DEV BIOL, V240, P419, DOI 10.1006/dbio.2001.0480; SAVION N, 1981, J BIOL CHEM, V256, P1149; SAWADA H, 1990, J CELL BIOL, V110, P219, DOI 10.1083/jcb.110.1.219; Semina EV, 2000, GENOMICS, V63, P289, DOI 10.1006/geno.1999.6093; Sibinga NES, 1997, CIRC RES, V80, P532, DOI 10.1161/01.RES.80.4.532; Sinha S, 2001, INT J EXP PATHOL, V82, P295, DOI 10.1046/j.1365-2613.2001.00201.x; Tan ST, 2004, PLAST RECONSTR SURG, V113, P999, DOI 10.1097/01.PRS.0000105683.10752.A6; Tan ST, 2000, PLAST RECONSTR SURG, V106, P529, DOI 10.1097/00006534-200009030-00001; WARING GO, 1982, OPHTHALMOLOGY, V89, P531; Weitkamp B, 1999, FASEB J, V13, P1445, DOI 10.1096/fasebj.13.11.1445; Xu R, 2001, BIOCHEM BIOPH RES CO, V289, P264, DOI 10.1006/bbrc.2001.5970; YAMAGUCHI N, 1991, J BIOL CHEM, V266, P4508; YAMAGUCHI N, 1989, J BIOL CHEM, V264, P16022	62	85	86	2	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1232	1244		10.1096/fj.04-3019com	http://dx.doi.org/10.1096/fj.04-3019com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16051690				2022-12-25	WOS:000231843700030
J	Jarvis, MC; Gray, TJB; Palmer, CNA				Jarvis, MC; Gray, TJB; Palmer, CNA			Both PPAR gamma and PPAR delta influence sulindac sulfide-mediated p21(WAF1/CIP1) upregulation in a human prostate epithelial cell line	ONCOGENE			English	Article						PPAR gamma; PPAR delta; p21; prostate cancer; NSAIDs	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ACTIVATED RECEPTOR-GAMMA; COLON-CANCER CELLS; COLORECTAL-CANCER; CARCINOGENESIS; PROLIFERATION; EXPRESSION; PROTEINS; TARGET; ALPHA	Nonsteroidal anti-inflammatory drugs (NSAIDs) including sulindac sulfide are known to exert cancer chemo-preventative activity in a range of cell lines. This activity has been shown to involve the upregulation of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1). It is also known that NSAIDs can act as peroxisome proliferator-activated receptor (PPAR) agonists and antagonists. In this study, we show that sulindac sulfide acts both as a PPARc agonist and a PPAR delta antagonist in an immortalized prostatic epithelial cell line (PNT1A). We utilized siRNA technology to show that PPAR gamma is required for both growth inhibition and p21(WAF1/CIP1) upregulation in response to sulindac sulfide treatment in PNT1A cells. In addition, the overexpression of PPARd partially rescued these cells from growth inhibition and also dramatically inhibited sulindac sulfide-mediated p21(WAF1/CIP1) upregulation. Together these data identify a novel link between PPAR gamma/PPAR delta/p21(WAF1/CIP1) and the cancer chemo-preventative properties of NSAIDs.	Univ Dundee, Ninewells Hosp & Med Sch, Ctr Biomed Res, Dundee DD1 9SY, Scotland; Sanofi Aventis, Dept Toxicol, Alnwick, England	University of Dundee; Sanofi-Aventis	Palmer, CNA (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Ctr Biomed Res, Dundee DD1 9SY, Scotland.	colin.palmer@cancer.org.uk	Palmer, Colin NA/C-7053-2008	Palmer, Colin NA/0000-0002-6415-6560				Adamson DJA, 2002, MOL PHARMACOL, V61, P7, DOI 10.1124/mol.61.1.7; CUSSENOT O, 1991, J UROLOGY, V146, P881, DOI 10.1016/S0022-5347(17)37953-3; Fredersdorf S, 1996, AM J PATHOL, V148, P825; Goldberg Y, 1996, ONCOGENE, V12, P893; Gupta RA, 2000, P NATL ACAD SCI USA, V97, P13275, DOI 10.1073/pnas.97.24.13275; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hong J, 2004, ENDOCRINOLOGY, V145, P5774, DOI 10.1210/en.2004-0686; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; LUPULESCU A, 1978, NATURE, V272, P634, DOI 10.1038/272634a0; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Morrison RF, 1999, J CELL BIOCHEM, P59; Mueller E, 2000, P NATL ACAD SCI USA, V97, P10990, DOI 10.1073/pnas.180329197; Nelson JE, 2000, ONCOL REP, V7, P169; Park BH, 2001, P NATL ACAD SCI USA, V98, P2598, DOI 10.1073/pnas.051630998; Piazza GA, 1997, CANCER RES, V57, P2909; Smalley W E, 1997, Adv Pharmacol, V39, P1, DOI 10.1016/S1054-3589(08)60067-8; Stephen RL, 2004, CANCER RES, V64, P3162, DOI 10.1158/0008-5472.CAN-03-2760; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Vosper H, 2001, J BIOL CHEM, V276, P44258, DOI 10.1074/jbc.M108482200; Wick M, 2002, MOL PHARMACOL, V62, P1207, DOI 10.1124/mol.62.5.1207; Yang WC, 2001, CANCER RES, V61, P6297; Young V, 2002, RHEUMATOLOGY, V41, P869, DOI 10.1093/rheumatology/41.8.869	23	26	31	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2005	24	55					8211	8215		10.1038/sj.onc.1208983	http://dx.doi.org/10.1038/sj.onc.1208983			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	991JL	16091736				2022-12-25	WOS:000233809400013
J	Pim, D; Massimi, P; Dilworth, SM; Banks, L				Pim, D; Massimi, P; Dilworth, SM; Banks, L			Activation of the protein kinase B pathway by the HPV-16 E7 oncoprotein occurs through a mechanism involving interaction with PP2A	ONCOGENE			English	Article						PKB/Akt; PI3 kinase; human papillomavirus; E7; PP2A	HUMAN-PAPILLOMAVIRUS TYPE-16; PLECKSTRIN HOMOLOGY DOMAIN; MIDDLE-T-ANTIGEN; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSFORMING ACTIVITY; BINDING-PROTEIN; PHOSPHATASE 2A; CELL-SURVIVAL; IN-VITRO; AKT	Protein kinase B (PKB) or Akt is one of several second messenger kinases that are activated by cell attachment and growth factor signaling, and that transmit signals to the cell nucleus to inhibit apoptosis and thereby increase cell survival during proliferation. Other viral proteins target this pathway by increasing PKB/Akt phosphorylation, and this pathway has been implicated in the transformation of human keratinocytes by HPV E6 and E7, together with activated notch 1. Here, we examine how HPV E7 expression affects the phosphorylation of PKB. We show that HPV-16 E7 increases the level of phosphorylation of PKB in response to serum stimulation, by a mechanism independent of downregulation of PTEN phosphatase, a known inhibitor of the PI3K (PI3 kinase) pathway. The use of specific antibodies shows that some proportion of PKB/Akt that is phosphorylated both on threonine 308 and serine 473 is maintained in the presence of E7 in a PI3 kinase-independent manner, and is activated for phosphorylation of BAD, a known downstream target of PKB/Akt. Use of E7 mutants has ruled out both an inhibition of IGFBP-3, a known E7 target and PKB/Akt modulator, and the interaction of E7 with cellular pocket proteins, as being the mechanism for the PKB/Akt stimulation. PKB binds PP2A and is a known substrate of PP2A. Here, we show that HPV E7 also binds to both the 35 kDa catalytic and 65 kDa structural subunits of PP2A, an interaction that sequesters these subunits and inhibits their interaction with PKB, thereby maintaining PKB/Akt signaling by inhibiting its dephosphorylation.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; Univ London Imperial Coll Sci & Technol, Dept Metab Med, London W12 0NN, England	International Center for Genetic Engineering & Biotechnology (ICGEB); Imperial College London	Pim, D (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99,Area Sci Pk, I-34012 Trieste, Italy.	pim@icgeb.org			Biotechnology and Biological Sciences Research Council [C19979, BBS/B/06962] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; BANKS L, 1990, ONCOGENE, V5, P1383; Borgatti P, 1997, EUR J IMMUNOL, V27, P2805, DOI 10.1002/eji.1830271110; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Crusius K, 1997, ONCOGENE, V15, P1437, DOI 10.1038/sj.onc.1201312; Dajee M, 2002, ONCOGENE, V21, P1527, DOI 10.1038/sj.onc.1205287; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; DILWORTH SM, 1993, J VIROL, V67, P2235, DOI 10.1128/JVI.67.4.2235-2244.1993; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Frese KK, 2003, ONCOGENE, V22, P710, DOI 10.1038/sj.onc.1206151; Fujisaki H, 2002, EXP CELL RES, V280, P255, DOI 10.1006/excr.2002.5639; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GU ZM, 1995, J VIROL, V69, P8051, DOI 10.1128/JVI.69.12.8051-8056.1995; Hanada M, 2004, BBA-PROTEINS PROTEOM, V1697, P3, DOI 10.1016/j.bbapap.2003.11.009; Harlow E., 1988, ANTIBODIES LAB MANUA; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; He YP, 2002, J VIROL, V76, P9207, DOI 10.1128/JVI.76.18.9207-9217.2002; Huynh H, 2002, CELL GROWTH DIFFER, V13, P115; ISHIWATARI H, 1994, J MED VIROL, V44, P243, DOI 10.1002/jmv.1890440306; Johnston D, 1999, CANCER RES, V59, P968; Mannhardt B, 2000, MOL CELL BIOL, V20, P6483, DOI 10.1128/MCB.20.17.6483-6495.2000; Massimi P, 1997, J GEN VIROL, V78, P2607, DOI 10.1099/0022-1317-78-10-2607; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; Meili R, 1998, ONCOGENE, V16, P903, DOI 10.1038/sj.onc.1201605; Milburn CC, 2003, BIOCHEM J, V375, P531, DOI 10.1042/BJ20031229; MUNGER K, 1989, J VIROL, V63, P4417; PALLAS DC, 1992, J VIROL, V66, P886, DOI 10.1128/JVI.66.2.886-893.1992; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Pankov R, 2003, J BIOL CHEM, V278, P18671, DOI 10.1074/jbc.M300879200; PIM D, 1992, ONCOGENE, V7, P27; PIM D, 1994, ONCOGENE, V9, P1869; Pim D, 1997, ONCOGENE, V15, P257, DOI 10.1038/sj.onc.1201202; Pouliot N, 2002, EXP DERMATOL, V11, P387, DOI 10.1034/j.1600-0625.2002.110501.x; Rangarajan A, 2001, VIROLOGY, V286, P23, DOI 10.1006/viro.2001.0867; Resjo S, 2002, CELL SIGNAL, V14, P231, DOI 10.1016/S0898-6568(01)00238-8; Sayama K, 2002, J BIOL CHEM, V277, P40390, DOI 10.1074/jbc.M112423200; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Stambolic V, 1999, ONCOGENE, V18, P6094, DOI 10.1038/sj.onc.1203126; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; Summers SA, 1998, BIOCHEM BIOPH RES CO, V246, P76, DOI 10.1006/bbrc.1998.8575; Sun P, 2002, J INVEST DERMATOL, V119, P107, DOI 10.1046/j.1523-1747.2002.01802.x; Troussard AA, 2003, J BIOL CHEM, V278, P22374, DOI 10.1074/jbc.M303083200; Velling T, 2004, EMBO REP, V5, P901, DOI 10.1038/sj.embor.7400234; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Westbrook TF, 2002, MOL CELL BIOL, V22, P7041, DOI 10.1128/MCB.22.20.7041-7052.2002; Xu WP, 2003, CANCER RES, V63, P7777; zur Hausen H, 1999, SEMIN CANCER BIOL, V9, P405, DOI 10.1006/scbi.1999.0144	50	127	138	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2005	24	53					7830	7838		10.1038/sj.onc.1208935	http://dx.doi.org/10.1038/sj.onc.1208935			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	986PU	16044149				2022-12-25	WOS:000233463000002
J	Kalvodova, L; Kahya, N; Schwille, P; Ehehalt, R; Verkade, P; Drechsel, D; Simons, K				Kalvodova, L; Kahya, N; Schwille, P; Ehehalt, R; Verkade, P; Drechsel, D; Simons, K			Lipids as modulators of proteolytic activity of BACE - Involvement of cholesterol, glycosphingolipids, and anionic phospholipids in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; BETA-SECRETASE; ALZHEIMERS-DISEASE; ASYMMETRIC VESICLES; CYTOSOLIC DOMAIN; RAFTS; MEMBRANES; GENERATION; RECEPTOR; NEURONS	The beta-secretase, BACE, is a membrane spanning aspartic protease, which cleaves the amyloid precursor protein (APP) in the first step of proteolytic processing leading to the formation of the neurotoxic beta-amyloid peptide (A beta). Previous results have suggested that the regulation of beta-secretase and BACE access to APP is lipid dependent, and involves lipid rafts. Using the baculovirus expression system, we have expressed recombinant human full-length BACE in insect cells and purified milligram amounts to homogeneity. We have studied partitioning of fluorophor-conjugated BACE between the liquid ordered and disordered phases in giant ( 10 - 150 mu m) unilamellar vesicles, and found similar to 20% to associate with the raft-like, liquid-ordered phase; the fraction associated with liquid-ordered phase increased upon cross-linking of raft lipids. To examine involvement of individual lipid species in modulating BACE activity, we have reconstituted the purified BACE in large ( similar to 100 nm) unilamellar vesicles, and determined its specific activity in vesicles of various lipid compositions. We have identified 3 groups of lipids that stimulate proteolytic activity of BACE: 1) neutral glycosphingolipids (cerebrosides), 2) anionic glycerophospholipids, and 3) sterols ( cholesterol).	Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany; Bioinnovat Ctr, D-01307 Dresden, Germany; Heidelberg Univ, Dept Internal Med 4, D-69120 Heidelberg, Germany	Max Planck Society; Ruprecht Karls University Heidelberg	Simons, K (corresponding author), Max Planck Inst Mol Cell Biol & Genet, Pfotenhauerstr 108, D-01307 Dresden, Germany.	simons@mpi-cbg.de	Schwille, Petra/A-4983-2010; Verkade, Paul/N-7240-2014; Kalvodova, Lucie/A-1546-2013	Verkade, Paul/0000-0002-2497-1026; Simons, Kai/0000-0002-9231-9996; , Lucie/0000-0003-3270-9463; Ehehalt, Robert/0000-0003-4252-5801				Bodovitz S, 1996, J BIOL CHEM, V271, P4436; Bogdanov M, 1996, J BIOL CHEM, V271, P11615, DOI 10.1074/jbc.271.20.11615; Bouillot C, 1996, J BIOL CHEM, V271, P7640, DOI 10.1074/jbc.271.13.7640; Brink-van der Laan EV, 2004, BBA-BIOMEMBRANES, V1666, P275, DOI 10.1016/j.bbamem.2004.06.010; Buckland AG, 2000, BBA-MOL CELL BIOL L, V1483, P199, DOI 10.1016/S1388-1981(99)00188-2; Cordy JM, 2003, P NATL ACAD SCI USA, V100, P11735, DOI 10.1073/pnas.1635130100; de Almeida RFM, 2003, BIOPHYS J, V85, P2406, DOI 10.1016/S0006-3495(03)74664-5; De Strooper B, 2000, J CELL SCI, V113, P1857; DENKINS YM, 1986, BIOCHIM BIOPHYS ACTA, V862, P343, DOI 10.1016/0005-2736(86)90237-3; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; He XY, 2002, FEBS LETT, V524, P183, DOI 10.1016/S0014-5793(02)03052-1; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Kahya N, 2005, BIOCHEMISTRY-US, V44, P7479, DOI 10.1021/bi047429d; Kakio A, 2002, BIOCHEMISTRY-US, V41, P7385, DOI 10.1021/bi0255874; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Lang T, 2001, EMBO J, V20, P2202, DOI 10.1093/emboj/20.9.2202; MCLAUGHLIN S, 1977, CURR TOP MEMBR TRANS, V9, P71; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; Pautot S, 2003, P NATL ACAD SCI USA, V100, P10718, DOI 10.1073/pnas.1931005100; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; Poveda JA, 2002, BIOCHEMISTRY-US, V41, P12253, DOI 10.1021/bi0200099; Puglielli L, 2003, J BIOL CHEM, V278, P19777, DOI 10.1074/jbc.M300466200; Riddell DR, 2001, CURR BIOL, V11, P1288, DOI 10.1016/S0960-9822(01)00394-3; Rigaud JL, 2002, BRAZ J MED BIOL RES, V35, P753, DOI 10.1590/S0100-879X2002000700001; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; Rouvinski A, 2003, BIOCHEM BIOPH RES CO, V308, P750, DOI 10.1016/S0006-291X(03)01470-0; Russo T, 1998, FEBS LETT, V434, P1, DOI 10.1016/S0014-5793(98)00941-7; Selkoe Dennis J., 1994, Current Opinion in Neurobiology, V4, P708, DOI 10.1016/0959-4388(94)90014-0; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shogomori H, 2005, J BIOL CHEM, V280, P18931, DOI 10.1074/jbc.M500247200; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; Subtil A, 1999, P NATL ACAD SCI USA, V96, P6775, DOI 10.1073/pnas.96.12.6775; Westmeyer GG, 2004, J BIOL CHEM, V279, P53205, DOI 10.1074/jbc.M410378200; Zha Q, 2004, MOL PSYCHIATR, V9, P946, DOI 10.1038/sj.mp.4001509	36	240	247	1	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 4	2005	280	44					36815	36823		10.1074/jbc.M504484200	http://dx.doi.org/10.1074/jbc.M504484200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	978VT	16115865	hybrid			2022-12-25	WOS:000232901800036
J	Santama, N; Ogg, SC; Malekkou, A; Zographos, SE; Weis, K; Lamond, AI				Santama, N; Ogg, SC; Malekkou, A; Zographos, SE; Weis, K; Lamond, AI			Characterization of hCINAP, a novel coilin-interacting protein encoded by a transcript from the transcription factor TAFIID(32) locus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAJAL BODIES; GENE-EXPRESSION; ASSOCIATION; SNRNA; SMN; IDENTIFICATION; TRANSPORT; REVEALS; CLONING; LINK	Coilin is a marker protein for the Cajal body, a subnuclear domain acting as a site for assembly and maturation of nuclear RNA-protein complexes. Using a yeast two-hybrid screen to identify coilin-interacting proteins, we have identified hCINAP ( human coilin interacting nuclear ATPase protein), a nuclear factor of 172 amino acids with a P-loop nucleotide binding motif and ATPase activity. The hCINAP protein sequence is highly conserved across its full-length from human to plants and yeast and is ubiquitously expressed in all human tissues and cell lines tested. The yeast orthologue of CINAP is a single copy, essential gene. Tagged hCINAP is present in complexes containing coilin in mammalian cells and recombinant, Escherichia coli expressed hCINAP binds directly to coilin in vitro. The 214 carboxyl-terminal residues of coilin appear essential for the interaction with hCINAP. Both immunofluorescence and fluorescent protein tagging show that hCINAP is specifically nuclear and distributed in a widespread, diffuse nucleoplasmic pattern, excluding nucleoli, with some concentration also in Cajal bodies. Overexpression of hCINAP in HeLa cells results in a decrease in the average number of Cajal bodies per nucleus, consistent with it affecting either the stability of Cajal bodies and/or their rate of assembly. The hCINAP mRNA is an alternatively spliced transcript from the TAF9 locus, which encodes the basal transcription factor subunit TAFIID(32). However, hCINAP and TAFIID(32) mRNAs are translated from different ATG codons and use distinct reading frames, resulting in them having no identity in their respective protein sequences.	Univ Cyprus, Dept Biol Sci, CY-1678 Nicosia, Cyprus; Cyprus Inst Neurol & Genet, CY-1678 Nicosia, Cyprus; Univ Dundee, Div Gene Regulat & Express, Dundee DD1 5EH, Scotland; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of Cyprus; University of Dundee; University of California System; University of California Berkeley	Santama, N (corresponding author), Univ Cyprus, Dept Biol Sci, POB 20537, CY-1678 Nicosia, Cyprus.	santama@ucy.ac.cy; a.i.lamond@lifesci.dundee.ac.uk	Zographos, Spyros/H-9058-2013; Weis, Karsten/F-5719-2011; Santama, Niovi/GLR-7648-2022	Zographos, Spyros/0000-0001-8455-2352; Weis, Karsten/0000-0001-7224-925X; Santama, Niovi/0000-0002-8370-8674; Ogg, Stephen/0000-0003-4157-1654; Malekkou, Anna/0000-0001-5918-9213	Wellcome Trust [073980] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bellini M, 1998, MOL BIOL CELL, V9, P2987, DOI 10.1091/mbc.9.10.2987; BOHMANN K, 1995, J CELL BIOL, V131, P817, DOI 10.1083/jcb.131.4.817; Carvalho T, 1999, J CELL BIOL, V147, P715, DOI 10.1083/jcb.147.4.715; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Frey MR, 1999, CURR BIOL, V9, P126, DOI 10.1016/S0960-9822(99)80066-9; Frey MR, 2001, J CELL BIOL, V154, P499, DOI 10.1083/jcb.200105084; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hebert MD, 2002, DEV CELL, V3, P329, DOI 10.1016/S1534-5807(02)00222-8; Hebert MD, 2001, GENE DEV, V15, P2720, DOI 10.1101/gad.908401; Hebert MD, 2000, MOL BIOL CELL, V11, P4159, DOI 10.1091/mbc.11.12.4159; Hu RM, 2000, P NATL ACAD SCI USA, V97, P9543, DOI 10.1073/pnas.160270997; Isaac C, 1998, J CELL BIOL, V142, P319, DOI 10.1083/jcb.142.2.319; Juhnke H, 2000, MOL MICROBIOL, V35, P936, DOI 10.1046/j.1365-2958.2000.01768.x; KAMBACH C, 1992, J CELL BIOL, V118, P11, DOI 10.1083/jcb.118.1.11; KANDELSLEWIS S, 1993, SCIENCE, V262, P2035, DOI 10.1126/science.8266100; KLEMM RD, 1995, P NATL ACAD SCI USA, V92, P5788, DOI 10.1073/pnas.92.13.5788; Ladomery M, 1997, BIOESSAYS, V19, P903, DOI 10.1002/bies.950191010; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai CH, 2000, GENOME RES, V10, P703, DOI 10.1101/gr.10.5.703; Muller F, 2004, EMBO J, V23, P2, DOI 10.1038/sj.emboj.7600027; Nachury MV, 1998, P NATL ACAD SCI USA, V95, P582, DOI 10.1073/pnas.95.2.582; Ogg SC, 2002, J CELL BIOL, V159, P17, DOI 10.1083/jcb.200206111; Ren H, 2005, P NATL ACAD SCI USA, V102, P303, DOI 10.1073/pnas.0407459102; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Santama N, 1998, EMBO J, V17, P5855, DOI 10.1093/emboj/17.20.5855; Shopland LS, 2001, MOL BIOL CELL, V12, P565, DOI 10.1091/mbc.12.3.565; Shpargel KB, 2003, J CELL SCI, V116, P303, DOI 10.1242/jcs.00211; Skamnaki VT, 1999, BIOCHEMISTRY-US, V38, P14718, DOI 10.1021/bi991454f; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Stelzer E H, 1991, Semin Cell Biol, V2, P145; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Tucker KE, 2001, J CELL BIOL, V154, P293, DOI 10.1083/jcb.200104083; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385	33	29	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36429	36441		10.1074/jbc.M501982200	http://dx.doi.org/10.1074/jbc.M501982200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16079131	hybrid			2022-12-25	WOS:000232726900077
J	Verriere, VA; Hynes, D; Faherty, S; Devaney, J; Bousquet, J; Harvey, BJ; Urbach, V				Verriere, VA; Hynes, D; Faherty, S; Devaney, J; Bousquet, J; Harvey, BJ; Urbach, V			Rapid effects of dexamethasone on intracellular pH and Na+/H+ exchanger activity in human bronchial epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; 17 BETA-ESTRADIOL; H+ ANTIPORT; GLUCOCORTICOID-RECEPTOR; NONGENOMIC ACTIONS; NA/H-EXCHANGE; ALDOSTERONE; MEMBRANE; ACTIVATION; TRANSPORT	Glucocorticoids have been shown to produce rapid nongenomic responses in airway epithelia. By using an intracellular pH (pH(i)) spectrofluorescence imaging system and the NH4Cl acid-loading technique, we have shown that the synthetic glucocorticoid, dexamethasone, accelerated intracellular pH recovery after an acid load in a human bronchial epithelial cell line (16HBE14o(-) cells). Exposure to NH4Cl ( 20 mM) elicited an intracellular acidification, followed by a pH(i) recovery. Inhibition of the Na+/H+ exchanger decreased the steady-state pH(i) and antagonized the dexamethasone stimulation of pH(i) regulation. The rapid effect of dexamethasone on pH(i) was neither affected by the inhibitor of transcription, cycloheximide, nor by the classical glucocorticoid and mineralocorticoid receptors antagonists, RU486 and spironolactone, respectively. The dexamethasone effect on pH(i) regulation was reduced by inhibitors of adenylate cyclase, cAMP-dependent protein kinase and mitogen-activated protein kinase (ERK1/2). By using a PepTag assay system and Western blotting, we have shown that dexamethasone stimulated cAMP-dependent protein kinase and mitogen-activated protein kinase activities. Taken together our results provide evidence for the rapid stimulation of Na+/H+ exchange activity by glucocorticoids in bronchial epithelial cells via a nongenomic mechanism involving cAMP-dependent protein kinase and mitogen-activated protein kinase ERK1/2 pathways.	CHU A Villeneuve, INSERM, U454, F-34295 Montpellier, France; Beaumont Hosp, Royal Coll Surg Ireland, Mol Med Labs, Dublin 9, Ireland	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; Royal College of Surgeons - Ireland	Urbach, V (corresponding author), CHU A Villeneuve, INSERM, U454, F-34295 Montpellier, France.	urbach@montp.inserm.fr	Harvey, Brian J/A-5120-2010; Urbach, Valerie/C-3615-2012; Harvey, Brian/AAJ-4085-2020	Harvey, Brian J/0000-0002-7388-8034; Urbach, Valerie/0000-0001-7437-9365; Harvey, Brian/0000-0002-7388-8034; Faherty, Sheila/0000-0002-7317-7136; Faherty, Sheila/0000-0001-9618-0912; Devaney, James/0000-0002-7489-5463				Al-Bazzaz F J, 2001, JOP, V2, P285; Alvaro D, 2002, GASTROENTEROLOGY, V122, P1058, DOI 10.1053/gast.2002.32374; Ambuhl PM, 1999, J CLIN INVEST, V103, P429, DOI 10.1172/JCI2913; Andres M, 1997, CELL MOL LIFE SCI, V53, P673, DOI 10.1007/s000180050087; BAUM M, 1994, AM J PHYSIOL, V267, pF437, DOI 10.1152/ajprenal.1994.267.3.F437; BONANNO JA, 1991, OPTOMETRY VISION SCI, V68, P682, DOI 10.1097/00006324-199109000-00002; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; Bousquet J, 2000, CLIN EXP ALLERGY, V30, P2; COOPER GJ, 1994, J PHYSIOL-LONDON, V479, P423, DOI 10.1113/jphysiol.1994.sp020306; COZENS AL, 1994, AM J RESP CELL MOL, V10, P38, DOI 10.1165/ajrcmb.10.1.7507342; Croxtall JD, 2002, BRIT J PHARMACOL, V135, P511, DOI 10.1038/sj.bjp.0704474; Daufeldt S, 2003, J STEROID BIOCHEM, V85, P9, DOI 10.1016/S0960-0760(03)00141-9; DECOURSEY TE, 1994, J GEN PHYSIOL, V103, P755, DOI 10.1085/jgp.103.5.755; Doolan CM, 2000, BRIT J PHARMACOL, V129, P1375, DOI 10.1038/sj.bjp.0703193; Ebata S, 1999, KIDNEY INT, V56, P1400, DOI 10.1046/j.1523-1755.1999.00674.x; Fan Y, 2002, BIOCHEM BIOPH RES CO, V293, P979, DOI 10.1016/S0006-291X(02)00339-X; Gekle M, 2002, STEROIDS, V67, P499, DOI 10.1016/S0039-128X(01)00183-0; GRINSTEIN S, 1985, P NATL ACAD SCI USA, V82, P1429, DOI 10.1073/pnas.82.5.1429; Gu Q, 1996, J NEUROSCI, V16, P3620; GUERRA L, 1993, J MEMBRANE BIOL, V135, P209; Gupta N, 2001, KIDNEY INT, V60, P173, DOI 10.1046/j.1523-1755.2001.00784.x; Hamann S, 2000, PFLUG ARCH EUR J PHY, V440, P84, DOI 10.1007/s004240051025; Harvey BJ, 2002, BBA-BIOMEMBRANES, V1566, P116, DOI 10.1016/S0005-2736(02)00589-8; Harvey BJ, 2001, NEWS PHYSIOL SCI, V16, P174; Harvey BJ, 2000, KIDNEY INT, V57, P1395, DOI 10.1046/j.1523-1755.2000.00981.x; IBARROLA I, 1992, J MEMBRANE BIOL, V125, P185; JENTSCH TJ, 1986, J BIOL CHEM, V261, P2120; KINSELLA JL, 1990, SEMIN NEPHROL, V10, P330; Koukouritaki SB, 1996, J CELL BIOCHEM, V62, P251, DOI 10.1002/(SICI)1097-4644(199608)62:2<251::AID-JCB13>3.0.CO;2-O; Larsson B, 2003, ENDOCRINOLOGY, V144, P1726, DOI 10.1210/en.2002-221060; Limbourg FP, 2002, J CLIN INVEST, V110, P1729, DOI 10.1172/JCI200215481; LIN H, 1992, INVEST OPHTH VIS SCI, V33, P3528; LUBMAN RL, 1995, AM J RESP CELL MOL, V12, P211, DOI 10.1165/ajrcmb.12.2.7865219; LUBMAN RL, 1989, AM J PHYSIOL, V257, pL438, DOI 10.1152/ajplung.1989.257.6.L438; LUBMAN RL, 1994, AM J PHYSIOL, V266, pL138, DOI 10.1152/ajplung.1994.266.2.L138; Maguire D, 1999, STEROIDS, V64, P51, DOI 10.1016/S0039-128X(98)00096-8; Marchetti MC, 2003, TOXICOL LETT, V139, P175, DOI 10.1016/S0378-4274(02)00431-9; Muto S, 2000, KIDNEY INT, V57, P2319, DOI 10.1046/j.1523-1755.2000.00092.x; NOEL J, 1995, AM J PHYSIOL-CELL PH, V268, pC283, DOI 10.1152/ajpcell.1995.268.2.C283; NORD EP, 1987, AM J PHYSIOL, V252, pC490, DOI 10.1152/ajpcell.1987.252.5.C490; NORD EP, 1988, J BIOL CHEM, V263, P5599; PARADISO AM, 1992, AM J PHYSIOL, V262, pL757, DOI 10.1152/ajplung.1992.262.6.L757; Picotto G, 1996, MOL CELL ENDOCRINOL, V119, P129, DOI 10.1016/0303-7207(96)03799-9; ROSENBERG SO, 1991, AM J PHYSIOL, V260, pC868, DOI 10.1152/ajpcell.1991.260.4.C868; SELVAGGIO AM, 1986, AM J PHYSIOL, V251, pC558, DOI 10.1152/ajpcell.1986.251.4.C558; Solito E, 2003, ENDOCRINOLOGY, V144, P1164, DOI 10.1210/en.2002-220592; STEINER A, 1989, J HYPERTENS, V7, pS140, DOI 10.1097/00004872-198900076-00066; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; Thwaites DT, 2002, GASTROENTEROLOGY, V122, P1322, DOI 10.1053/gast.2002.32992; TOBEY NA, 1992, GASTROENTEROLOGY, V103, P830, DOI 10.1016/0016-5085(92)90014-P; Urbach V, 2002, J PHYSIOL-LONDON, V545, P869, DOI 10.1113/jphysiol.2002.028183; Urbach V, 2002, J PHYSIOL-LONDON, V543, P13, DOI 10.1113/jphysiol.2001.015180; Urbach V, 2001, J PHYSIOL-LONDON, V537, P267, DOI 10.1111/j.1469-7793.2001.0267k.x; Wehling M, 1996, BIOCHEM BIOPH RES CO, V223, P181, DOI 10.1006/bbrc.1996.0866; Wehling M, 1997, ANNU REV PHYSIOL, V59, P365, DOI 10.1146/annurev.physiol.59.1.365; WILLUMSEN NJ, 1992, J PHYSIOL-LONDON, V455, P247, DOI 10.1113/jphysiol.1992.sp019300; WINTER DC, 1999, J PHYSIOL-LONDON, V1, P17; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010; YUN CHC, 1993, J BIOL CHEM, V268, P206; ZADUNAISKY JA, 1989, INVEST OPHTH VIS SCI, V30, P2332; ZALLOCCHI M, 2003, MED SCI MONITOR, V9, P85; Zhou J, 2003, J ENDOCRINOL, V177, pR1, DOI 10.1677/joe.0.177R001	62	30	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					35807	35814		10.1074/jbc.M506584200	http://dx.doi.org/10.1074/jbc.M506584200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16040608	hybrid			2022-12-25	WOS:000232726900006
J	Veldhuis, G; Gabellieri, E; Vos, EPP; Poolman, B; Strambini, GB; Broos, J				Veldhuis, G; Gabellieri, E; Vos, EPP; Poolman, B; Strambini, GB; Broos, J			Substrate-induced conformational changes in the membrane-embedded IICmtl-domain of the mannitol permease from Escherichia coli, EnzymeII(mtl), probed by tryptophan phosphorescence spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PHOSPHOTRANSFERASE SYSTEM; PROTEIN-LIGAND INTERACTIONS; TRIPLET-STATE LIFETIME; ENZYME-II; SUBUNIT INTERACTIONS; TRANSPORT PROTEIN; PHOSPHORYLATION; DIMER; IIMTL; RESONANCE	Membrane-bound transport proteins are expected to proceed via different conformational states during the translocation of a solute across the membrane. Tryptophan phosphorescence spectroscopy is one of the most sensitive methods used for detecting conformational changes in proteins. We employed this technique to study substrate-induced conformational changes in the mannitol permease, EnzymeII(mtl), of the phosphoenolpyruvate-dependent phosphotransferase system from Escherichia coli. Ten mutants containing a single tryptophan were engineered in the membrane embedded IICmtl-domain, harboring the mannitol translocation pathway. The mutants were characterized with respect to steady-state and time-resolved phosphorescence, yielding detailed, site-specific information of the Trp microenvironment and protein conformational homogeneity. The study revealed that the Trp environments vary from apolar, unstructured, and flexible sites to buried, highly homogeneous, rigid peptide cores. The most remarkable example of the latter was observed for position 97, because its long sub-second phosphorescence lifetime and highly structured spectra in both glassy and fluid media imply a well defined and rigid core around the probe that is typical of beta-sheet-rich structural motifs. The addition of mannitol had a large impact on most of the Trp positions studied. In the case of position 97, mannitol binding induced partial unfolding of the rigid protein core. On the contrary, for residue positions 126, 133, and 147, both steady-state and time-resolved data showed that mannitol binding induces a more ordered and homogeneous structure around these residues. The observations are discussed in context of the current mechanistic and structural model of EIImtl.	CNR, Ist Biofis, Area Ric, I-56124 Pisa, Italy; Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Dept Biophys & Biophys Chem, NL-9747 AG Groningen, Netherlands	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biofisica (IBF-CNR); University of Groningen	Broos, J (corresponding author), CNR, Ist Biofis, Area Ric, Via Moruzzi 1, I-56124 Pisa, Italy.	j.broos@rug.nl	Poolman, Bert/D-1882-2012	Gabellieri, Edi/0000-0003-0750-4095				[Anonymous], 1967, FLUORESCENCE PHOSPHO; BOER H, 1994, J BIOL CHEM, V269, P17863; Broos J, 2003, J BIOL CHEM, V278, P47578, DOI 10.1074/jbc.M309287200; Broos J, 2002, J AM CHEM SOC, V124, P6812, DOI 10.1021/ja017812v; Broos J, 2004, J AM CHEM SOC, V126, P22, DOI 10.1021/ja0385585; Broos J, 1999, BIOCHEMISTRY-US, V38, P9798, DOI 10.1021/bi991157a; Broos J, 2000, BIOCHEMISTRY-US, V39, P10877, DOI 10.1021/bi000803z; Cioni P, 2004, BIOPHYS J, V86, P1149, DOI 10.1016/S0006-3495(04)74189-2; ELFERINK MGL, 1990, J BACTERIOL, V172, P7119, DOI 10.1128/jb.172.12.7119-7125.1990; Galley W. C., 1976, CONCEPTS BIOCH FLUOR, V2, P409; Gonnelli M, 2005, PHOTOCHEM PHOTOBIOL, V81, P614, DOI 10.1562/2004-11-09-RA-367.1; GONNELLI M, 1995, BIOCHEMISTRY-US, V34, P13847, DOI 10.1021/bi00042a017; GRISAFI PL, 1989, J BACTERIOL, V171, P2719, DOI 10.1128/jb.171.5.2719-2727.1989; HERSHBERGER MV, 1980, BIOCHEMISTRY-US, V19, P2204, DOI 10.1021/bi00551a032; KHANDEKAR SS, 1989, J CELL BIOCHEM, V39, P207, DOI 10.1002/jcb.240390212; Koning RI, 1999, J MOL BIOL, V287, P845, DOI 10.1006/jmbi.1999.2650; LENGELER JW, 1994, BBA-BIOENERGETICS, V1188, P1, DOI 10.1016/0005-2728(94)90017-5; LOLKEMA JS, 1993, BIOCHEMISTRY-US, V32, P1396, DOI 10.1021/bi00057a002; LOLKEMA JS, 1990, BIOCHEMISTRY-US, V29, P10659, DOI 10.1021/bi00499a012; LOLKEMA JS, 1991, BIOCHEMISTRY-US, V30, P6716, DOI 10.1021/bi00241a012; Meijberg W, 1998, J BIOL CHEM, V273, P20785, DOI 10.1074/jbc.273.33.20785; Meijberg W, 1998, J BIOL CHEM, V273, P7949, DOI 10.1074/jbc.273.14.7949; PAS HH, 1987, BIOCHEMISTRY-US, V26, P6689, DOI 10.1021/bi00395a019; ROBILLARD GT, 1987, BIOCHEMISTRY-US, V26, P5796, DOI 10.1021/bi00392a032; Robillard GT, 1999, BBA-REV BIOMEMBRANES, V1422, P73, DOI 10.1016/S0304-4157(99)00002-7; ROBILLARD GT, 1996, HDB BIOL PHYS, V2, P549; ROOSSIEN FF, 1984, BIOCHEMISTRY-US, V23, P5682, DOI 10.1021/bi00319a003; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; STEPHAN MM, 1986, BIOCHEMISTRY-US, V25, P4046, DOI 10.1021/bi00362a009; STRAMBINI GB, 1995, J AM CHEM SOC, V117, P7646, DOI 10.1021/ja00134a008; Strambini GB, 2004, PHOTOCHEM PHOTOBIOL, V80, P462, DOI 10.1562/2004-06-22-RA-21.1; STRAMBINI GB, 1985, CHEM PHYS LETT, V115, P196, DOI 10.1016/0009-2614(85)80678-3; SUGIYAMA JE, 1991, P NATL ACAD SCI USA, V88, P9603, DOI 10.1073/pnas.88.21.9603; SWAVINGDIJKSTRA D, 1997, BIOCHEMISTRY-US, V36, P4860; SWAVINGDIJKSTRA D, 1996, BIOCHEMISTRY-US, V35, P6628; SWAVINGDIJKSTRA D, 1996, ANAL BIOCHEM, V240, P142; van Montfort BA, 2001, J BIOL CHEM, V276, P12756, DOI 10.1074/jbc.M010728200; Veldhuis G, 2005, BIOPHYS J, V89, P201, DOI 10.1529/biophysj.105.062877; Veldhuis G, 2004, BIOPHYS J, V86, P1959, DOI 10.1016/S0006-3495(04)74259-9; Vervoort EB, 2005, J MOL BIOL, V346, P733, DOI 10.1016/j.jmb.2004.12.011	40	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35148	35156		10.1074/jbc.M507061200	http://dx.doi.org/10.1074/jbc.M507061200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16093245	hybrid, Green Published			2022-12-25	WOS:000232561200011
J	Alzayady, KJ; Panning, MM; Kelley, GG; Wojcikiewicz, RJH				Alzayady, KJ; Panning, MM; Kelley, GG; Wojcikiewicz, RJH			Involvement of the p97-Ufd1-Npl4 complex in the regulated endoplasmic reticulum-associated degradation of inositol 1,4,5-trisphosphate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; PROTEIN-QUALITY CONTROL; INDUCED DOWN-REGULATION; SMOOTH-MUSCLE-CELLS; MEMBRANE-PROTEIN; RNA INTERFERENCE; TRISPHOSPHATE RECEPTORS; CONJUGATING ENZYMES; MAMMALIAN-CELLS; IN-VIVO	Inositol 1,4,5-trisphosphate (IP3) receptors form tetrameric, IP3-gated channels in endoplasmic reticulum membranes that govern the release of Ca2+ from this organelle. In response to activation of certain G protein-coupled receptors that persistently elevate IP3 concentration, IP3 receptors are ubiquitinated and degraded by the ubiquitin-proteasome pathway. IP3 receptor ubiquitination is mediated by the ubiquitin-conjugating enzyme, (mam)Ubc7, a component of the endoplasmic reticulum-associated degradation pathway. However, the mechanism by which ubiquitinated IP3 receptors are transferred to the proteasome is not known. Here, we examine this process and show in several mammalian cell types that the ATPase p97 associates with IP3 receptors in response to hormonal stimuli that induce IP3 receptor ubiquitination. To examine the functional relevance of the p97 interaction with IP3 receptors, we stably and specifically reduced p97 protein levels by 62 +/- 3% in Rat-1 fibroblasts using RNA interference. In these cells, endothelin-1- induced IP3 receptor degradation was markedly retarded and the accumulation of ubiquitinated IP3 receptors was markedly enhanced. These effects were reversed by expression of exogenous p97. In addition, Ufd1 and Npl4, which complex with p97, also associated with IP3 receptors upon hormonal stimulation. We conclude that the p97-Ufd1-Npl4 complex couples ubiquitinated IP3 receptors to proteasomal degradation and, thus, plays a key role in IP3 receptor processing. These data also establish that the p97-Ufd1-Npl4 complex mediates endoplasmic reticulum-associated degradation in mammalian cells.	SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA; SUNY Upstate Med Univ, Dept Med, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Wojcikiewicz, RJH (corresponding author), SUNY Upstate Med Univ, Dept Pharmacol, 750 E Adams St, Syracuse, NY 13210 USA.	wojcikir@upstate.edu		Panning Pearce, Margaret/0000-0002-5846-9632	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK049194, R01DK056294, R01DK049194] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK56294, R01 DK049194, R29 DK049194, DK49194, R01 DK056294] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bays NW, 2001, MOL BIOL CELL, V12, P4114, DOI 10.1091/mbc.12.12.4114; Bays NW, 2002, CURR BIOL, V12, pR366, DOI 10.1016/S0960-9822(02)00862-X; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bokkala S, 1997, J BIOL CHEM, V272, P12454, DOI 10.1074/jbc.272.19.12454; Bosanac I, 2004, BBA-MOL CELL RES, V1742, P89, DOI 10.1016/j.bbamcr.2004.09.016; Braun S, 2002, EMBO J, V21, P615, DOI 10.1093/emboj/21.4.615; Bruderer RM, 2004, J BIOL CHEM, V279, P49609, DOI 10.1074/jbc.M408695200; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Dreveny I, 2004, BIOCHEM SOC T, V32, P715, DOI 10.1042/BST0320715; Elkabetz Y, 2004, J BIOL CHEM, V279, P3980, DOI 10.1074/jbc.M309938200; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; Hatakeyama S, 2003, J BIOCHEM, V134, P1, DOI 10.1093/jb/mvg106; HIRSCH C, 2004, BIOCHIM BIOPHYS ACTA, V1695, P208; Jarosch E, 2003, INT REV CYTOL, V223, P39; Jellerette T, 2000, DEV BIOL, V223, P238, DOI 10.1006/dbio.2000.9675; Kaneko C, 2003, BIOCHEM BIOPH RES CO, V300, P297, DOI 10.1016/S0006-291X(02)02834-6; Kobayashi T, 2002, J BIOL CHEM, V277, P47358, DOI 10.1074/jbc.M207783200; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; Kostova Z, 2003, EMBO J, V22, P2309, DOI 10.1093/emboj/cdg227; Lilley BN, 2004, NATURE, V429, P834, DOI 10.1038/nature02592; Maki CG, 1996, CANCER RES, V56, P2649; McCracken AA, 2003, BIOESSAYS, V25, P868, DOI 10.1002/bies.10320; Medema RH, 2004, BIOCHEM J, V380, P593, DOI 10.1042/BJ20040260; Meyer HH, 2002, EMBO J, V21, P5645, DOI 10.1093/emboj/cdf579; MULDOON LL, 1989, J BIOL CHEM, V264, P8529; Oberdorf J, 1999, BIOCHEM J, V339, P453, DOI 10.1042/0264-6021:3390453; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Patterson RL, 2004, ANNU REV BIOCHEM, V73, P437, DOI 10.1146/annurev.biochem.73.071403.161303; Rabinovich E, 2002, MOL CELL BIOL, V22, P626, DOI 10.1128/MCB.22.2.626-634.2002; Ravid T, 2000, J BIOL CHEM, V275, P35840, DOI 10.1074/jbc.M004793200; Saliba RS, 2002, J CELL SCI, V115, P2907; Sambrook J, 2001, MOL CLONING LAB MANU; Sgambato A, 2000, J CELL PHYSIOL, V183, P18, DOI 10.1002/(SICI)1097-4652(200004)183:1<18::AID-JCP3>3.0.CO;2-S; Sipma H, 1998, CELL CALCIUM, V23, P11, DOI 10.1016/S0143-4160(98)90070-7; Sutcliffe JE, 2004, FEBS LETT, V567, P86, DOI 10.1016/j.febslet.2004.03.122; Taylor CW, 1999, CELL CALCIUM, V26, P237, DOI 10.1054/ceca.1999.0090; Taylor CW, 2004, TRENDS BIOCHEM SCI, V29, P210, DOI 10.1016/j.tibs.2004.02.010; Tiwari S, 2001, J BIOL CHEM, V276, P16193, DOI 10.1074/jbc.M007640200; Tovey SC, 2001, J CELL SCI, V114, P3979; Uchiyama K, 2002, J CELL BIOL, V159, P855, DOI 10.1083/jcb.200208112; Vermassen E, 2004, BIOL CELL, V96, P3, DOI 10.1016/j.biolcel.2003.11.004; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Wang Q, 2004, J STRUCT BIOL, V146, P44, DOI 10.1016/j.jsb.2003.11.014; Wang YZ, 2004, J CELL BIOL, V164, P973, DOI 10.1083/jcb.200401010; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Webster JM, 2003, J BIOL CHEM, V278, P38238, DOI 10.1074/jbc.M305600200; Wojcik C, 2004, J CELL SCI, V117, P281, DOI 10.1242/jcs.00841; Wojcikiewicz RJH, 1999, GASTROENTEROLOGY, V116, P1194, DOI 10.1016/S0016-5085(99)70023-5; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; Wojcikiewicz RJH, 2004, TRENDS PHARMACOL SCI, V25, P35, DOI 10.1016/j.tips.2003.11.008; Wojcikiewicz RJH, 2003, J BIOL CHEM, V278, P940, DOI 10.1074/jbc.M206607200; WOJCIKIEWICZ RJH, 1994, J BIOL CHEM, V269, P7963; WOJCIKIEWICZ RJH, 1991, J BIOL CHEM, V266, P22234; Woodman PG, 2003, J CELL SCI, V116, P4283, DOI 10.1242/jcs.00817; Xu Q, 2004, MOL CANCER THER, V3, P1263; Yang M, 1998, J EXP MED, V187, P835, DOI 10.1084/jem.187.6.835; Ye YH, 2003, J CELL BIOL, V162, P71, DOI 10.1083/jcb.200302169; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Ye YH, 2004, NATURE, V429, P841, DOI 10.1038/nature02656; Zhu CC, 1999, J BIOL CHEM, V274, P3476, DOI 10.1074/jbc.274.6.3476; Zhu CC, 2000, BIOCHEM J, V348, P551, DOI 10.1042/0264-6021:3480551	66	41	43	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34530	34537		10.1074/jbc.M508890200	http://dx.doi.org/10.1074/jbc.M508890200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16103111	Green Accepted, hybrid			2022-12-25	WOS:000232403900021
J	Porras-Yakushi, TR; Whitelegge, JP; Miranda, TB; Clarke, S				Porras-Yakushi, TR; Whitelegge, JP; Miranda, TB; Clarke, S			A novel SET domain methyltransferase modifies ribosomal protein Rpl23ab in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRINSIC MEMBRANE-PROTEINS; IN-GEL DIGESTION; SACCHAROMYCES-CEREVISIAE; MASS-SPECTROMETRY; AFFINITY PURIFICATION; S-ADENOSYLMETHIONINE; COMPLEX INCLUDES; METHYLATION; IDENTIFICATION; GENERATION	In vivo studies have shown that the ribosomal large subunit protein L23a (Rpl23ab) in Saccharomyces cerevisiae is methylated at lysine residues. However, the gene encoding the methyltransferase responsible for the modification has not been identified. We show here that the yeast YPL208w gene product, a member of the SET domain family of methyltransferases, catalyzes the reaction, and we have now designated it Rkm1 ( ribosomal lysine ( K) methyltransferase 1). Yeast strains with deletion mutations in candidate SET domain-containing genes were in vivo labeled with S-adenosyl-L[ methyl-H-3] methionine. [H-3]] Methyl radioactivity was determined after lysates were fractionated by SDS gel electrophoresis. When compared with the parent strain or other candidate deletion strains, a loss of a radiolabeled 15-kDa species was observed in the rkm1 (Delta ypl208w) knock-out strain. Treatment of wild-type cell extracts with RNase or proteinase K demonstrated that the methyl-accepting substrate is a protein. Cellular lysates from parent and knockout strains were fractionated using high salt sucrose gradients. Analysis of the gradient fractions by SDS gel electrophoresis demonstrated that the 15-kDa methyl-accepting substrate elutes with the large ribosomal subunit. In vitro methylation experiments using purified ribosomes confirmed that the methyl-accepting substrate is a ribosomal protein. Amino acid analysis of the in vivo labeled 15 kDa polypeptide showed that it contains epsilon- [H-3] dimethyllysine residues. Mass spectrometry of tryptic peptides of the 15 kDa polypeptide identified it as Rpl23ab. Analysis of the intact masses of the large ribosomal subunit proteins by electrospray mass spectrometry confirmed that the substrate is Rpl23ab and that it is specifically dimethylated at two distinct sites by Rkm1. These results show that SET domain methyltransferases can be involved in translational roles as well as in the previously described transcriptional roles.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Psychiat & Behav Sci, Pasarow Mass Spectrometry Lab, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Clarke, S (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, 611 Charles E Young Dr E,Paul Boyer Hall 639, Los Angeles, CA 90095 USA.	clarke@mbi.ucla.edu			NIGMS NIH HHS [GM26020, GM07185] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026020, R37GM026020] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aravind L, 2003, CELL CYCLE, V2, P369, DOI 10.4161/cc.2.4.419; Audhya A, 2003, EMBO J, V22, P4223, DOI 10.1093/emboj/cdg397; Ausubel F. M., 1999, SHORT PROTOCOLS MOL; Bachand F, 2004, EMBO J, V23, P2641, DOI 10.1038/sj.emboj.7600265; Boa S, 2003, YEAST, V20, P827, DOI 10.1002/yea.995; Branscombe TL, 2001, J BIOL CHEM, V276, P32971, DOI 10.1074/jbc.M105412200; Chern MK, 2002, J BIOL CHEM, V277, P15345, DOI 10.1074/jbc.M111379200; COLLART M, 1993, CURRENT PROTOCOLS MI; DELANGE RJ, 1970, J BIOL CHEM, V245, P3325; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; HARDY SJS, 1969, BIOCHEMISTRY-US, V8, P2897, DOI 10.1021/bi00835a031; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; HOUTZ RL, 1992, PLANT PHYSIOL, V98, P1170, DOI 10.1104/pp.98.3.1170; HRYCYNA CA, 1994, BIOCHEMISTRY-US, V33, P9806, DOI 10.1021/bi00198a053; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Inada T, 2002, RNA, V8, P948, DOI 10.1017/S1355838202026018; Jenuwein T, 1998, CELL MOL LIFE SCI, V54, P80, DOI 10.1007/s000180050127; JONES RS, 1993, MOL CELL BIOL, V13, P6357, DOI 10.1128/MCB.13.10.6357; Kluck RM, 2000, J BIOL CHEM, V275, P16127, DOI 10.1074/jbc.275.21.16127; Krogan NJ, 2004, MOL CELL, V13, P225, DOI 10.1016/S1097-2765(04)00003-6; KRUISWIJK T, 1978, BIOCHEM J, V175, P221, DOI 10.1042/bj1750221; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee SW, 2002, P NATL ACAD SCI USA, V99, P5942, DOI 10.1073/pnas.082119899; LHOEST J, 1984, EUR J BIOCHEM, V141, P585, DOI 10.1111/j.1432-1033.1984.tb08233.x; LOBET Y, 1989, BIOCHIM BIOPHYS ACTA, V997, P224, DOI 10.1016/0167-4838(89)90191-X; Mueller EG, 1998, NUCLEIC ACIDS RES, V26, P2606, DOI 10.1093/nar/26.11.2606; MURPHY JT, 1972, J BACTERIOL, V109, P499, DOI 10.1128/JB.109.2.499-504.1972; Pijnappel WWMP, 2001, GENE DEV, V15, P2991, DOI 10.1101/gad.207401; Polevoda B, 2000, J BIOL CHEM, V275, P20508, DOI 10.1074/jbc.M001891200; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Roguev A, 2001, EMBO J, V20, P7137, DOI 10.1093/emboj/20.24.7137; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; Rouillon A, 1999, J BIOL CHEM, V274, P28096, DOI 10.1074/jbc.274.40.28096; Schubert HL, 2003, TRENDS BIOCHEM SCI, V28, P329, DOI 10.1016/S0968-0004(03)00090-2; SHRAHL BD, 2002, MOL CELL BIOL, V22, P1298; STASSEN MJ, 1995, MECH DEVELOP, V52, P209, DOI 10.1016/0925-4773(95)00402-M; Swiercz R, 2005, BIOCHEM J, V386, P85, DOI 10.1042/BJ20041466; TOLEDO H, 1988, ARCH BIOL MED EXP, V21, P219; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; Whitelegge JP, 1998, PROTEIN SCI, V7, P1423, DOI 10.1002/pro.5560070619; Whitelegge Julian P, 2004, Methods Mol Biol, V251, P323	45	43	48	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2005	280	41					34590	34598		10.1074/jbc.M507672200	http://dx.doi.org/10.1074/jbc.M507672200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	971SD	16096273	hybrid			2022-12-25	WOS:000232403900027
J	Zhang, AS; West, AP; Wyman, AE; Bjorkman, PJ; Enns, CA				Zhang, AS; West, AP; Wyman, AE; Bjorkman, PJ; Enns, CA			Interaction of hemojuvelin with neogenin results in iron accumulation in human embryonic kidney 293 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPULSIVE GUIDANCE MOLECULE; HEREDITARY HEMOCHROMATOSIS PROTEIN; JUVENILE HEMOCHROMATOSIS; EXPRESSION PATTERN; RECEPTOR NEOGENIN; GENE-MUTATIONS; CHROMOSOME 1Q; LOCUS MAPS; HFE; MOUSE	Type 2 hereditary hemochromatosis (HH) or juvenile hemochromatosis is an early onset, genetically heterogeneous, autosomal recessive disorder of iron overload. Type 2A HH is caused by mutations in the recently cloned hemojuvelin gene (HJV; also called HFE2) ( Papanikolaou, G., Samuels, M. E., Ludwig, E. H., MacDonald, M. L., Franchini, P. L., Dube, M. P., Andres, L., MacFarlane, J., Sakellaropoulos, N., Politou, M., Nemeth, E., Thompson, J., Risler, J. K., Zaborowska, C., Babakaiff, R., Radomski, C. C., Pape, T. D., Davidas, O., Christakis, J., Brissot, P., Lockitch, G., Ganz, T., Hayden, M. R., and Goldberg, Y. P. ( 2004) Nat. Genet. 36, 77 - 82), whereas Type 2B HH is caused by mutations in hepcidin. HJV is highly expressed in both skeletal muscle and liver. Mutations in HJV are implicated in the majority of diagnosed juvenile hemochromatosis patients. In this study, we stably transfected HJV cDNA into human embryonic kidney 293 cells and characterized the processing of HJV and its effect on iron homeostasis. Our results indicate that HJV is a glycosylphosphatidylinositol-linked protein and undergoes a partial autocatalytic cleavage during its intracellular processing. HJV co-immunoprecipitated with neogenin, a receptor involved in a variety of cellular signaling processes. It did not interact with the closely related receptor DCC( deleted in Colon Cancer). In addition, the HJV G320V mutant implicated in Type 2A HH did not co-immunoprecipitate with neogenin. Immunoblot analysis of ferritin levels and transferrin-Fe-55 accumulation studies indicated that the HJV-induced increase in intracellular iron levels in human embryonic kidney 293 cells is dependent on the presence of neogenin in the cells, thus linking these two proteins to intracellular iron homeostasis.	Oregon Hlth & Sci Univ, Dept Cell & Dev Biol, Portland, OR 97239 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA; CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA	Oregon Health & Science University; California Institute of Technology; California Institute of Technology; Howard Hughes Medical Institute	Zhang, AS (corresponding author), Oregon Hlth & Sci Univ, Dept Cell & Dev Biol, L215,3181 SW Sam Jackson Pk Blvd, Portland, OR 97239 USA.	zhanga@ohsu.edu			NIDDK NIH HHS [DK54488, R01 DK60770] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060770, R01DK054488, R37DK054488] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arakawa H, 2004, NAT REV CANCER, V4, P978, DOI 10.1038/nrc1504; Barallobre MJ, 2000, DEVELOPMENT, V127, P4797; BARTON JC, 2004, BMC MED GENETICS; Brinks H, 2004, J NEUROSCI, V24, P3862, DOI 10.1523/JNEUROSCI.5296-03.2004; Camaschella C, 2002, SEMIN HEMATOL, V39, P242, DOI 10.1053/shem.2002.35635; Carlson H, 2005, BLOOD, V105, P2564, DOI 10.1182/blood-2004-03-1204; Davies PS, 2004, J BIOL CHEM, V279, P25085, DOI 10.1074/jbc.M400537200; De Gobbi M, 2002, BRIT J HAEMATOL, V117, P973, DOI 10.1046/j.1365-2141.2002.03509.x; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Gehrke SG, 2005, CLIN GENET, V67, P425, DOI 10.1111/j.1399-0004.2005.00413.x; Gross CN, 1998, J BIOL CHEM, V273, P22068, DOI 10.1074/jbc.273.34.22068; Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Huang FW, 2004, BLOOD, V104, P2176, DOI 10.1182/blood-2004-01-0400; Janosi A, 2005, BLOOD, V105, P432, DOI 10.1182/blood-2004-09-3508; Kang JS, 2004, J CELL BIOL, V167, P493, DOI 10.1083/jcb.200405039; Keeling SL, 1997, ONCOGENE, V15, P691, DOI 10.1038/sj.onc.1201225; Krause A, 2000, FEBS LETT, V480, P147, DOI 10.1016/S0014-5793(00)01920-7; Krijt J, 2004, BLOOD, V104, P4308, DOI 10.1182/blood-2004-06-2422; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lanzara C, 2004, BLOOD, V103, P4317, DOI 10.1182/blood-2004-01-0192; Lebron JA, 1998, CELL, V93, P111, DOI 10.1016/S0092-8674(00)81151-4; Lee PL, 2004, BLOOD, V103, P4669, DOI 10.1182/blood-2004-01-0072; Levine SJ, 2004, J IMMUNOL, V173, P5343, DOI 10.4049/jimmunol.173.9.5343; Lidell ME, 2003, J BIOL CHEM, V278, P13944, DOI 10.1074/jbc.M210069200; Martinez AR, 2004, HAEMATOLOGICA, V89, P1441; Matsunaga E, 2004, NAT CELL BIOL, V6, P749, DOI 10.1038/ncb1157; Matsunaga E, 2004, DEV GROWTH DIFFER, V46, P481; Mawdsley DJ, 2004, DEV BIOL, V269, P302, DOI 10.1016/j.ydbio.2004.02.001; MENON AK, 1994, METHOD ENZYMOL, V230, P418; Meyerhardt JA, 1997, ONCOGENE, V14, P1129, DOI 10.1038/sj.onc.1200935; Monnier PP, 2002, NATURE, V419, P392, DOI 10.1038/nature01041; Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742; Nicolas G, 2002, J CLIN INVEST, V110, P1037, DOI 10.1172/JCI200215686; Niederkofler V, 2004, J NEUROSCI, V24, P808, DOI 10.1523/JNEUROSCI.4610-03.2004; Nikolopoulos SN, 2005, CELL CYCLE, V4, P429, DOI 10.4161/cc.4.3.1547; Oldekamp J, 2004, GENE EXPR PATTERNS, V4, P283, DOI 10.1016/j.modgep.2003.11.008; Ordway GA, 2004, J EXP BIOL, V207, P3441, DOI 10.1242/jeb.01172; Papanikolaou G, 2004, NAT GENET, V36, P77, DOI 10.1038/ng1274; Papanikolaou G, 2002, BLOOD CELL MOL DIS, V29, P168, DOI 10.1006/bcmd.2002.0553; Papanikolaou G, 2001, BLOOD CELL MOL DIS, V27, P744, DOI 10.1006/bcmd.2001.0444; Park CH, 2001, J BIOL CHEM, V276, P7806, DOI 10.1074/jbc.M008922200; Parkin ET, 2004, J BIOL CHEM, V279, P11170, DOI 10.1074/jbc.M312105200; Pietrangelo A, 2004, NEW ENGL J MED, V350, P2383, DOI 10.1056/NEJMra031573; Rajagopalan S, 2004, NAT CELL BIOL, V6, P756, DOI 10.1038/ncb1156; Rivard SR, 2003, EUR J HUM GENET, V11, P585, DOI 10.1038/sj.ejhg.5201009; Roetto A, 1999, AM J HUM GENET, V64, P1388, DOI 10.1086/302379; Schmidtmer J, 2004, GENE EXPR PATTERNS, V4, P105, DOI 10.1016/S1567-133X(03)00144-3; Srinivasan K, 2003, DEV CELL, V4, P371, DOI 10.1016/S1534-5807(03)00054-6; Velcich A, 1999, ONCOGENE, V18, P2599, DOI 10.1038/sj.onc.1202610; VIELMETTER J, 1994, J CELL BIOL, V127, P2009, DOI 10.1083/jcb.127.6.2009; Zhang AS, 2004, BLOOD, V103, P1509, DOI 10.1182/blood-2003-07-2378; Zhang AS, 2003, P NATL ACAD SCI USA, V100, P9500, DOI 10.1073/pnas.1233675100	53	117	123	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33885	33894		10.1074/jbc.M506207200	http://dx.doi.org/10.1074/jbc.M506207200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16103117	hybrid, Green Accepted			2022-12-25	WOS:000232229700025
J	Chen, SH; Lin, F; Hamm, HE				Chen, SH; Lin, F; Hamm, HE			RACK1 binds to a signal transfer region of G beta gamma and inhibits phospholipase C beta 2 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-PROTEIN; CRYSTAL-STRUCTURE; REPEAT PROTEINS; AMINO-TERMINUS; SWISS-MODEL; SUBUNIT; STIMULATION; RESOLUTION; COMPLEX; DOMAIN	Receptor for Activated C Kinase 1 (RACK1), a novel G beta gamma-interacting protein, selectively inhibits the activation of a subclass of G beta gamma effectors such as phospholipase C beta 2 (PLC beta 2) and adenylyl cyclase II by direct binding to G beta gamma (Chen, S., Dell, E. J., Lin, F., Sai, J., and Hamm, H. E. (2004) J. Biol. Chem. 279, 17861 - 17868). Here we have mapped the RACK1 binding sites on G beta gamma. We found that RACK1 interacts with several different G beta gamma isoforms, including G beta(1)gamma(1), G beta(1)gamma(2), and G beta(5)gamma(2), with similar affinities, suggesting that the conserved residues between G beta(1) and G beta(5) may be involved in their binding to RACK1. We have confirmed this hypothesis and shown that several synthetic peptides corresponding to the conserved residues can inhibit the RACK1/G beta gamma interaction as monitored by fluorescence spectroscopy. Interestingly, these peptides are located at one side of G beta(1) and have little overlap with the G alpha subunit binding interface. Additional experiments indicate that the G beta gamma contact residues for RACK1, in particular the positively charged amino acids within residues 44 - 54 of G beta(1), are also involved in the interaction with PLC beta 2 and play a critical role in G beta gamma-mediated PLC beta 2 activation. These data thus demonstrate that RACK1 can regulate the activity of a G beta gamma effector by competing for its binding to the signal transfer region of G beta gamma.	Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA	Vanderbilt University	Hamm, HE (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, Rm 442,Robinson Res Bldg, Nashville, TN 37232 USA.	Heidi.Hamm@Vanderbilt.edu	Hamm, Heidi E/G-2374-2014	chen, songhai/0000-0001-7316-7125; Lin, Fang/0000-0003-2179-7031				Bonacci TM, 2005, J BIOL CHEM, V280, P10174, DOI 10.1074/jbc.M412514200; Buck E, 2002, J BIOL CHEM, V277, P49707, DOI 10.1074/jbc.M205553200; Buck E, 1999, SCIENCE, V283, P1332, DOI 10.1126/science.283.5406.1332; Buck E, 2001, J BIOL CHEM, V276, P36014, DOI 10.1074/jbc.M103228200; Cabrera-Vera TM, 2004, P NATL ACAD SCI USA, V101, P16339, DOI 10.1073/pnas.0407416101; Chen SH, 2004, J MOL CELL CARDIOL, V37, P399, DOI 10.1016/j.yjmcc.2004.04.019; Chen SH, 2004, J BIOL CHEM, V279, P17861, DOI 10.1074/jbc.M313727200; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Dell EJ, 2002, J BIOL CHEM, V277, P49888, DOI 10.1074/jbc.M202755200; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; INGLESE J, 1994, P NATL ACAD SCI USA, V91, P3637, DOI 10.1073/pnas.91.9.3637; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Lodowski DT, 2003, SCIENCE, V300, P1256, DOI 10.1126/science.1082348; MAZZONI MR, 1991, J BIOL CHEM, V266, P14072; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; Myung CS, 2000, P NATL ACAD SCI USA, V97, P9311, DOI 10.1073/pnas.97.16.9311; Panchenko MP, 1998, J BIOL CHEM, V273, P28298, DOI 10.1074/jbc.273.43.28298; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17032; Preininger AM, 2003, BIOCHEMISTRY-US, V42, P7931, DOI 10.1021/bi0345438; Schulz R, 2001, PHARMACOL RES, V43, P1, DOI 10.1006/phrs.2000.0757; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Yan K, 1997, J BIOL CHEM, V272, P2056; Yoshikawa DM, 2001, J BIOL CHEM, V276, P11246, DOI 10.1074/jbc.M006073200; Zhang SY, 1996, J BIOL CHEM, V271, P20208, DOI 10.1074/jbc.271.33.20208	30	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33445	33452		10.1074/jbc.M505422200	http://dx.doi.org/10.1074/jbc.M505422200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16051595	hybrid			2022-12-25	WOS:000232058100043
J	Tamayo, R; Tischler, AD; Camilli, A				Tamayo, R; Tischler, AD; Camilli, A			The EAL domain protein VieA is a cyclic diguanylate phosphodiesterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O1 EL-TOR; VIBRIO-CHOLERAE; ACETOBACTER-XYLINUM; BIOFILM FORMATION; DI-GMP; NUCLEOTIDE PHOSPHODIESTERASE; GENETIC ORGANIZATION; CELLULOSE SYNTHESIS; ESCHERICHIA-COLI; GGDEF DOMAIN	The newly recognized bacterial second messenger 3', 5'-cyclic diguanylic acid ( cyclic diguanylate (c-di-GMP)) has been shown to regulate a wide variety of bacterial behaviors and traits. Biosynthesis and degradation of c-di-GMP have been attributed to the GGDEF and EAL protein domains, respectively, based primarily on genetic evidence. Whereas the GGDEF domain was demonstrated to possess diguanylate cyclase activity in vitro, the EAL domain has not been tested directly for c-di-GMP phosphodiesterase activity. This study describes the analysis of c-di-GMP hydrolysis by an EAL domain protein in a purified system. The Vibrio cholerae EAL domain protein VieA has been shown to inversely regulate biofilm-specific genes (vps) and virulence genes (ctxA), presumably by decreasing the cellular pool of c-di-GMP. VieA was maximally active at neutral pH, physiological ionic strength, and ambient temperatures and demonstrated c-di-GMP hydrolytic activity with a K-m of 0.06 mu M. VieA was unable to hydrolyze cGMP. The putative metal coordination site of the EAL domain, Glu(170), was demonstrated to be necessary for VieA activity. Furthermore, the divalent cations Mg2+ and Mn2+ were necessary for VieA activity; conversely, Ca2+ and Zn2+ were potent inhibitors of the VieA phosphodiesterase. Calcium inhibition of the VieA EAL domain provides a potential mechanism for regulation of c-di-GMP degradation.	Tufts Univ, Dept Mol Biol & Microbiol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Boston, MA 02111 USA; Howard Hughes Med Inst, Boston, MA 02111 USA	Tufts University; Tufts University; Howard Hughes Medical Institute	Camilli, A (corresponding author), Tufts Univ, Dept Mol Biol & Microbiol, 136 Harrison Ave, Boston, MA 02111 USA.	Andrew.camilli@tufts.edu		Tischler, Anna/0000-0001-8404-0250	Howard Hughes Medical Institute Funding Source: Medline; NIAID NIH HHS [AI45746, R01 AI045746, R01 AI045746-03] Funding Source: Medline; NIDDK NIH HHS [P30DK34928, P30 DK034928] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045746] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausmees N, 2001, FEMS MICROBIOL LETT, V204, P163, DOI 10.1111/j.1574-6968.2001.tb10880.x; BOBROV AG, 2005, FEMS MICROBIOL LETT; CALLAHAN SM, 1995, J BIOL CHEM, V270, P17627, DOI 10.1074/jbc.270.29.17627; Camilli A, 1995, MOL MICROBIOL, V18, P671, DOI 10.1111/j.1365-2958.1995.mmi_18040671.x; Chan C, 2004, P NATL ACAD SCI USA, V101, P17084, DOI 10.1073/pnas.0406134101; DZIEJMAN M, 1994, MOL MICROBIOL, V13, P485, DOI 10.1111/j.1365-2958.1994.tb00443.x; Galperin MY, 2001, FEMS MICROBIOL LETT, V203, P11, DOI 10.1111/j.1574-6968.2001.tb10814.x; Garcia B, 2004, MOL MICROBIOL, V54, P264, DOI 10.1111/j.1365-2958.2004.04269.x; HERRINGTON DA, 1988, J EXP MED, V168, P1487, DOI 10.1084/jem.168.4.1487; Hidaka Y, 1997, FEBS LETT, V400, P238, DOI 10.1016/S0014-5793(96)01396-8; Hisert KB, 2005, MOL MICROBIOL, V56, P1234, DOI 10.1111/j.1365-2958.2005.04632.x; HUQ A, 1983, APPL ENVIRON MICROB, V45, P275, DOI 10.1128/AEM.45.1.275-283.1983; Imamura R, 1996, J BIOL CHEM, V271, P25423, DOI 10.1074/jbc.271.41.25423; Karaolis DKR, 2005, ANTIMICROB AGENTS CH, V49, P1029, DOI 10.1128/AAC.49.3.1029-1038.2005; KEIRNS JJ, 1974, ANAL BIOCHEM, V61, P336, DOI 10.1016/0003-2697(74)90400-X; Kierek K, 2003, P NATL ACAD SCI USA, V100, P14357, DOI 10.1073/pnas.2334614100; Kierek K, 2003, APPL ENVIRON MICROB, V69, P5079, DOI 10.1128/AEM.69.9.5079-5088.2003; Lee SH, 1998, J BACTERIOL, V180, P2298, DOI 10.1128/JB.180.9.2298-2305.1998; Lee SH, 1999, CELL, V99, P625, DOI 10.1016/S0092-8674(00)81551-2; Lee SH, 2001, P NATL ACAD SCI USA, V98, P6889, DOI 10.1073/pnas.111581598; MILLER VL, 1985, J BACTERIOL, V163, P580, DOI 10.1128/JB.163.2.580-585.1985; Pei JM, 2001, PROTEINS, V42, P210, DOI 10.1002/1097-0134(20010201)42:2<210::AID-PROT80>3.0.CO;2-8; ROSS P, 1986, CARBOHYD RES, V149, P101, DOI 10.1016/S0008-6215(00)90372-0; ROSS P, 1990, J BIOL CHEM, V265, P18933; Ryjenkov DA, 2005, J BACTERIOL, V187, P1792, DOI 10.1128/JB.187.5.1792-1798.2005; SCARLATO V, 1991, J BACTERIOL, V173, P7401, DOI 10.1128/jb.173.22.7401-7404.1991; Schoolnik GK, 2001, METHOD ENZYMOL, V336, P3, DOI 10.1016/S0076-6879(01)36573-4; Simm R, 2004, MOL MICROBIOL, V53, P1123, DOI 10.1111/j.1365-2958.2004.04206.x; Tal R, 1998, J BACTERIOL, V180, P4416, DOI 10.1128/JB.180.17.4416-4425.1998; TAMPLIN ML, 1990, APPL ENVIRON MICROB, V56, P1977, DOI 10.1128/AEM.56.6.1977-1980.1990; TAYLOR RK, 1987, P NATL ACAD SCI USA, V84, P2833, DOI 10.1073/pnas.84.9.2833; Tischler AD, 2004, MOL MICROBIOL, V53, P857, DOI 10.1111/j.1365-2958.2004.04155.x; Tischler AD, 2002, J BACTERIOL, V184, P4104, DOI 10.1128/JB.184.15.4104-4113.2002; TISCHLER ADA, 2005, IN PRESS INFECT IMMU; Watnick PI, 1999, MOL MICROBIOL, V34, P586, DOI 10.1046/j.1365-2958.1999.01624.x; WONG HC, 1990, P NATL ACAD SCI USA, V87, P8130, DOI 10.1073/pnas.87.20.8130; Yildiz FH, 1999, P NATL ACAD SCI USA, V96, P4028, DOI 10.1073/pnas.96.7.4028; Yildiz FH, 1998, J BACTERIOL, V180, P773, DOI 10.1128/JB.180.4.773-784.1998	38	211	223	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33324	33330		10.1074/jbc.M506500200	http://dx.doi.org/10.1074/jbc.M506500200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16081414	Green Accepted, Green Published, hybrid			2022-12-25	WOS:000232058100029
J	Profirovic, J; Gorovoy, M; Niu, JX; Pavlovic, S; Voyno-Yasenetskaya, T				Profirovic, J; Gorovoy, M; Niu, JX; Pavlovic, S; Voyno-Yasenetskaya, T			A novel mechanism of g protein-dependent phosphorylation of vasodilator-stimulated phosphoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ACTIN-BASED MOTILITY; AMP-INDEPENDENT ACTIVATION; HUMAN ENDOTHELIAL-CELLS; HUMAN-PLATELETS; ENA/VASP PROTEINS; FOCAL ADHESION; NITRIC-OXIDE; SERINE/THREONINE KINASE; LISTERIA-MONOCYTOGENES	Vasodilator-stimulated phosphoprotein (VASP) is a major substrate of protein kinaseA (PKA). Here we described the novel mechanism of VASP phosphorylation via cAMP-independent PKA activation. We showed that in human umbilical vein endothelial cells (HUVECs) alpha-thrombin induced phosphorylation of VASP. Specific inhibition of G alpha(13) protein by the RGS domain of a guanine nucleotide exchange factor, p115RhoGEF, inhibited thrombin-dependent phosphorylation of VASP. More importantly, G alpha(13)-induced VASP phosphorylation was dependent on activation of RhoA and mitogen-activated protein kinase kinase kinase, MEKK1, leading to the stimulation of the NF-B-kappa signaling pathway. alpha-Thrombin-dependent VASP phosphorylation was inhibited by small interfering RNA-mediated knockdown of RhoA, whereas G alpha(13)-dependent VASP phosphorylation was inhibited by a specific RhoA inhibitor botulinum toxin C3 and by a dominant negative mutant of MEKK1. We determined that G alpha(13)-dependent VASP phosphorylation was also inhibited by specific PKA inhibitors, PKI and H-89. In addition, the expression of phosphorylation-deficient I kappa B and pretreatment with the proteasome inhibitor MG-132 abolished G alpha(13)- and alpha-thrombin-induced VASP phosphorylation. In summary, we have described a novel pathway of G alpha 13-induced VASP phosphorylation that involves activation of RhoA and MEKK1, phosphorylation and degradation of I kappa B, release of PKA catalytic subunit from the complex with I kappa B and NF-kappa B, and subsequent phosphorylation of VASP.	Univ Illinois, Dept Pharmacol, Coll Med, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Voyno-Yasenetskaya, T (corresponding author), Univ Illinois, Dept Pharmacol, Coll Med, MC 868,835 S Wolcott Ave, Chicago, IL 60612 USA.	tvy@uic.edu	voyno-yasenetskaya, tatyana/A-3171-2008		NHLBI NIH HHS [HL06078] Funding Source: Medline; NIGMS NIH HHS [GM65160, GM56159] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM056159, R01GM065160, R01GM056159] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bear JE, 2000, CELL, V101, P717, DOI 10.1016/S0092-8674(00)80884-3; Bear JE, 2001, CURR OPIN CELL BIOL, V13, P158, DOI 10.1016/S0955-0674(00)00193-9; Berestetskaya YV, 1998, J BIOL CHEM, V273, P27816, DOI 10.1074/jbc.273.43.27816; BOURNE HR, 1993, NEURON S, V10, P65; Browning DD, 2001, J BIOL CHEM, V276, P13039, DOI 10.1074/jbc.M009187200; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; BUTT E, 1994, J BIOL CHEM, V269, P14509; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Comerford KM, 2002, FASEB J, V16, P583, DOI 10.1096/fj.01-0739fje; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Dan C, 2001, J BIOL CHEM, V276, P32115, DOI 10.1074/jbc.M100871200; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DRAIJER R, 1995, CIRC RES, V77, P897, DOI 10.1161/01.RES.77.5.897; Dulin NO, 2001, J BIOL CHEM, V276, P20827, DOI 10.1074/jbc.C100195200; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; Fradelizi J, 2001, NAT CELL BIOL, V3, P699, DOI 10.1038/35087009; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; GARCIA JGN, 1995, J CELL PHYSIOL, V163, P510, DOI 10.1002/jcp.1041630311; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; GERTLER FB, 1995, GENE DEV, V9, P521, DOI 10.1101/gad.9.5.521; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAFFNER C, 1995, EMBO J, V14, P19, DOI 10.1002/j.1460-2075.1995.tb06971.x; HALBRUGGE M, 1989, EUR J BIOCHEM, V185, P41, DOI 10.1111/j.1432-1033.1989.tb15079.x; HALBRUGGE M, 1990, J CHROMATOGR, V521, P335, DOI 10.1016/0021-9673(90)85057-3; Han YH, 2002, J BIOL CHEM, V277, P49877, DOI 10.1074/jbc.M209107200; Harbeck B, 2000, J BIOL CHEM, V275, P30817, DOI 10.1074/jbc.M005066200; Harris TE, 1997, BIOCHEM BIOPH RES CO, V232, P648, DOI 10.1006/bbrc.1997.6344; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Lambrechts A, 2000, J BIOL CHEM, V275, P36143, DOI 10.1074/jbc.M006274200; Laurent V, 1999, J CELL BIOL, V144, P1245, DOI 10.1083/jcb.144.6.1245; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; Louvet-Vallee S, 2000, BIOL CELL, V92, P305, DOI 10.1016/S0248-4900(00)01078-9; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Massberg S, 2004, BLOOD, V103, P136, DOI 10.1182/blood-2002-11-3417; McDonald LJ, 1996, P SOC EXP BIOL MED, V211, P1; Meyer CF, 1996, J BIOL CHEM, V271, P8971, DOI 10.1074/jbc.271.15.8971; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3; Niu JX, 2001, CURR BIOL, V11, P1686, DOI 10.1016/S0960-9822(01)00530-9; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; Pando MP, 2000, J BIOL CHEM, V275, P21278, DOI 10.1074/jbc.M002532200; Patterson CE, 2000, ENDOTHELIUM-NEW YORK, V7, P287, DOI 10.3109/10623320009072215; REES DD, 1990, BRIT J PHARMACOL, V101, P746, DOI 10.1111/j.1476-5381.1990.tb14151.x; REINHARD M, 1992, EMBO J, V11, P2063, DOI 10.1002/j.1460-2075.1992.tb05264.x; Reinhard M, 2001, TRENDS BIOCHEM SCI, V26, P243, DOI 10.1016/S0968-0004(00)01785-0; Rottner K, 1999, NAT CELL BIOL, V1, P321, DOI 10.1038/13040; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Scheschonka A, 2000, MOL PHARMACOL, V58, P719, DOI 10.1124/mol.58.4.719; Sechi AS, 2004, FRONT BIOSCI, V9, P1294, DOI 10.2741/1324; Skoble J, 2001, J CELL BIOL, V155, P89, DOI 10.1083/jcb.200106061; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; Vaiskunaite R, 2000, J BIOL CHEM, V275, P26206, DOI 10.1074/jbc.M001863200; Venema RC, 1996, J BIOL CHEM, V271, P6435, DOI 10.1074/jbc.271.11.6435; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Walders-Harbeck B, 2002, FEBS LETT, V529, P275, DOI 10.1016/S0014-5793(02)03356-2; Wojciak-Stothard B, 1998, J CELL PHYSIOL, V176, P150, DOI 10.1002/(SICI)1097-4652(199807)176:1<150::AID-JCP17>3.0.CO;2-B; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744; YAN MH, 1994, NATURE, V372, P798; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HL, 2001, J PHARMACOL EXP THER, V297, P837; Zieger M, 2001, BIOCHEM BIOPH RES CO, V282, P952, DOI 10.1006/bbrc.2001.4683	73	36	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32866	32876		10.1074/jbc.M501361200	http://dx.doi.org/10.1074/jbc.M501361200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16046415	hybrid			2022-12-25	WOS:000231920300040
J	Adamson, TE; Shutt, DC; Price, DH				Adamson, TE; Shutt, DC; Price, DH			Functional coupling of cleavage and polyadenylation with transcription of mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II ELONGATION COMPLEXES; CELL-FREE SYSTEM; POLYMERASE-II; IN-VITRO; P-TEFB; POLY(A) POLYMERASE; PROCESSING FACTORS; 3'-END FORMATION; TERMINATION; KINASE	Cleavage and polyadenylation define the 3' ends of almost all eukaryotic mRNAs and are thought to occur during transcription. We describe a human in vitro system utilizing an immobilized template, in which transcripts in RNA polymerase II elongation complexes are efficiently cleaved and polyadenylated. Because the cleavage rate of free RNA is much slower, we conclude that cleavage is functionally coupled to transcription. Inhibition of positive transcription elongation factor b(P-TEFb) had only a modest negative effect on cleavage, as long as transcripts were long enough to contain the polyadenylation signal. In contrast, removal of the carboxyl-terminal domain of the large subunit of RNA polymerase II had a dramatic negative effect on cleavage. Unexpectedly, the 5' portion of transcript after cleavage remained associated with the template in a functional, polyadenylation-competent complex. Efficient cleavage required 5' capping by the human capping enzyme, but the reduction of cleavage seen of transcripts in COOH-terminal domain-less polymerase elongation complexes, was not because of lack of capping.	Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA	University of Iowa	Price, DH (corresponding author), Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA.	david-price@uiowa.edu	Price, David H/F-6173-2010	Price, David/0000-0002-5597-385X	NIGMS NIH HHS [GM35500] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035500] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adamson TE, 2003, METHOD ENZYMOL, V371, P264; Adamson TE, 2003, MOL CELL BIOL, V23, P4046, DOI 10.1128/MCB.23.12.4046-4055.2003; Ahn SH, 2004, MOL CELL, V13, P67, DOI 10.1016/S1097-2765(03)00492-1; Bird G, 2004, MOL CELL BIOL, V24, P8963, DOI 10.1128/MCB.24.20.8963-8969.2004; Calvo O, 2003, GENE DEV, V17, P1321, DOI 10.1101/gad.1093603; Chao SH, 2000, J BIOL CHEM, V275, P28345, DOI 10.1074/jbc.C000446200; Chao SH, 2001, J BIOL CHEM, V276, P31793, DOI 10.1074/jbc.M102306200; CHENKIANG S, 1982, CELL, V28, P575, DOI 10.1016/0092-8674(82)90212-4; Colgan DF, 1997, GENE DEV, V11, P2755, DOI 10.1101/gad.11.21.2755; COOPER DL, 1978, J BIOL CHEM, V253, P8375; Cramer P, 2001, FEBS LETT, V498, P179, DOI 10.1016/S0014-5793(01)02485-1; Flaherty SM, 1997, P NATL ACAD SCI USA, V94, P11893, DOI 10.1073/pnas.94.22.11893; Hirose Y, 1998, NATURE, V395, P93, DOI 10.1038/25786; Hirose Y, 2000, GENE DEV, V14, P1415; Howe KJ, 2002, BBA-GENE STRUCT EXPR, V1577, P308, DOI 10.1016/S0167-4781(02)00460-8; Jiang Y, 2004, MOL CELL, V14, P375, DOI 10.1016/S1097-2765(04)00234-5; Kaufmann I, 2004, EMBO J, V23, P616, DOI 10.1038/sj.emboj.7600070; Kim M, 2004, EMBO J, V23, P354, DOI 10.1038/sj.emboj.7600053; Kim M, 2004, NATURE, V432, P517, DOI 10.1038/nature03041; Kim SJ, 2003, J BIOL CHEM, V278, P41691, DOI 10.1074/jbc.M306304200; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Kuhn U, 2004, BBA-GENE STRUCT EXPR, V1678, P67, DOI 10.1016/j.bbaexp.2004.03.008; Licatalosi DD, 2002, MOL CELL, V9, P1101, DOI 10.1016/S1097-2765(02)00518-X; Liu MY, 1998, J BIOL CHEM, V273, P25541, DOI 10.1074/jbc.273.40.25541; MANLEY JL, 1983, CELL, V33, P595, DOI 10.1016/0092-8674(83)90440-3; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; Martin G, 2004, J MOL BIOL, V341, P911, DOI 10.1016/j.jmb.2004.06.047; MIFFLIN RC, 1991, J BIOL CHEM, V266, P19593; MOORE CL, 1985, CELL, V41, P845, DOI 10.1016/S0092-8674(85)80065-9; Moteki S, 2002, MOL CELL, V10, P599, DOI 10.1016/S1097-2765(02)00660-3; MURTHY KGK, 1995, GENE DEV, V9, P2672, DOI 10.1101/gad.9.21.2672; Ni ZY, 2004, MOL CELL, V13, P55, DOI 10.1016/S1097-2765(03)00526-4; Park NJ, 2004, MOL CELL BIOL, V24, P4092, DOI 10.1128/MCB.24.10.4092-4103.2004; PRESCOTT JC, 1992, J BIOL CHEM, V267, P8175; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Proudfoot N, 2004, CURR OPIN CELL BIOL, V16, P272, DOI 10.1016/j.ceb.2004.03.007; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; Renner DB, 2001, J BIOL CHEM, V276, P42601, DOI 10.1074/jbc.M104967200; Shatkin AJ, 2000, NAT STRUCT BIOL, V7, P838, DOI 10.1038/79583; Skaar DA, 2002, MOL CELL, V10, P1429, DOI 10.1016/S1097-2765(02)00731-1; West S, 2004, NATURE, V432, P522, DOI 10.1038/nature03035; Xie Z, 1996, J BIOL CHEM, V271, P11043, DOI 10.1074/jbc.271.19.11043; Yonaha M, 2000, EMBO J, V19, P3770, DOI 10.1093/emboj/19.14.3770; Yonaha M, 1999, MOL CELL, V3, P593, DOI 10.1016/S1097-2765(00)80352-4; Zhao J, 1999, MICROBIOL MOL BIOL R, V63, P405, DOI 10.1128/MMBR.63.2.405-445.1999; Zorio DAR, 2004, EXP CELL RES, V296, P91, DOI 10.1016/j.yexcr.2004.03.019	47	33	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32262	32271		10.1074/jbc.M505532200	http://dx.doi.org/10.1074/jbc.M505532200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16041059	hybrid			2022-12-25	WOS:000231794800028
J	Johnson, NP; Baase, WA; von Hippel, PH				Johnson, NP; Baase, WA; von Hippel, PH			Low energy CD of RNA hairpin unveils a loop conformation required for lambda N antitermination activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T4 DNA-POLYMERASE; 2-AMINOPURINE FLUORESCENCE; NUCLEOTIDE INCORPORATION; CIRCULAR-DICHROISM; PHAGE-LAMBDA; TRANSCRIPTIONAL ANTITERMINATION; KLENOW FRAGMENT; PROTEIN; COMPLEX; BINDING	N protein coded by phage lambda is a transcription factor that stimulates the antitermination activity of Escherichia coli RNA polymerase by binding specifically to the nascent RNA transcript at a stem-loop structure called boxB. We use a new biophysical technique, involving the monitoring of the low energy circular dichroism spectra of 2-aminopurine residues site-specifically placed in the boxB RNA loop, to investigate this binding interaction. The low energy CDspectra of these 2-aminopurine probes reflect specific asymmetric interactions with adjacent nucleotide bases. Consequently, these CD spectra provide detailed and specific conformational information about the RNA chain at these chromophores that cannot be obtained from changes in the related fluorescence signals of these probes. CD changes were observed on binding the N peptide to boxB RNA that correspond to structural changes that had been previously seen by NMR, thus validating our experimental approach. The low energy CD method was then used to quantify the ordered and disordered states of the free hairpin loop and to show that a significant fraction of the boxB loop assumes a product-like structure in the absence of protein. A boxB derivative with an intact stem and a reduced concentration of ordered loop was identified and used to show that the extent of the reaction between protein and boxB depends on the concentration of structured loop in the RNA reactant population. This result has general implications for the conformational specificity of RNA- protein interactions.	CNRS, Inst Pharmacol & Biol Struct, UMR 5089, F-31077 Toulouse, France; Univ Oregon, Dept Chem, Eugene, OR 97403 USA; Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; University of Oregon; University of Oregon	von Hippel, PH (corresponding author), CNRS, Inst Pharmacol & Biol Struct, UMR 5089, 205 Route Narbonne, F-31077 Toulouse, France.	petevh@molbio.uoregon.edu		von Hippel, Peter H./0000-0003-2512-8097	NIGMS NIH HHS [GM-15792, GM-29158] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029158, R37GM015792, R01GM015792] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARIK S, 1987, CELL, V50, P885, DOI 10.1016/0092-8674(87)90515-0; CANTOR CR, 1980, BIOPHYSICAL CHEM 2, P409; Cavaluzzi MJ, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh015; CHATTOPADHYAY S, 1995, P NATL ACAD SCI USA, V92, P4061, DOI 10.1073/pnas.92.9.4061; Cilley CD, 1997, RNA, V3, P57; da Silva EF, 2002, J BIOL CHEM, V277, P40640, DOI 10.1074/jbc.M203315200; ERITJA R, 1986, NUCLEIC ACIDS RES, V14, P5869, DOI 10.1093/nar/14.14.5869; FREY MW, 1995, BIOCHEMISTRY-US, V34, P9185, DOI 10.1021/bi00028a031; Friedman DI., 1983, LAMBDA 2, P21; GOODMAN MF, 1977, P NATL ACAD SCI USA, V74, P4806, DOI 10.1073/pnas.74.11.4806; GREENBLATT J, 1993, NATURE, V364, P401, DOI 10.1038/364401a0; GRIEVE SJ, 2005, NAT REV MOL STRUCT B, V6, P221; HEUS HA, 1991, SCIENCE, V253, P191, DOI 10.1126/science.1712983; Jean JM, 2001, P NATL ACAD SCI USA, V98, P37, DOI 10.1073/pnas.011442198; Johnson NP, 2005, P NATL ACAD SCI USA, V102, P7169, DOI 10.1073/pnas.0502359102; Johnson NP, 2004, P NATL ACAD SCI USA, V101, P3426, DOI 10.1073/pnas.0400591101; JOHNSON WC, 1969, BIOPOLYMERS, V8, P715, DOI 10.1002/bip.1969.360080603; JOHNSON WC, 1969, BIOPOLYMERS, V8, P409; Legault P, 1998, CELL, V93, P289, DOI 10.1016/S0092-8674(00)81579-2; Mandal SS, 2002, BIOCHEMISTRY-US, V41, P4399, DOI 10.1021/bi015723p; Mogridge J, 1998, MOL CELL, V1, P265, DOI 10.1016/S1097-2765(00)80027-1; NODWELL JR, 1991, GENE DEV, V5, P2141, DOI 10.1101/gad.5.11.2141; Purohit V, 2003, BIOCHEMISTRY-US, V42, P10200, DOI 10.1021/bi0341206; RIPPE K, 1995, TRENDS BIOCHEM SCI, V20, P500, DOI 10.1016/S0968-0004(00)89117-3; Rist M, 2002, CHEMPHYSCHEM, V3, P704, DOI 10.1002/1439-7641(20020816)3:8<704::AID-CPHC704>3.0.CO;2-F; ROSENBERG M, 1978, NATURE, V272, P414, DOI 10.1038/272414a0; SALSTROM JS, 1978, J MOL BIOL, V124, P195, DOI 10.1016/0022-2836(78)90156-0; Scharpf M, 2000, EUR J BIOCHEM, V267, P2397, DOI 10.1046/j.1432-1327.2000.01251.x; SMAGOWICZ J, 1974, Journal of Luminescence, V8, P210, DOI 10.1016/0022-2313(74)90057-X; SOWERS LC, 1986, P NATL ACAD SCI USA, V83, P5434, DOI 10.1073/pnas.83.15.5434; Su LL, 1997, GENE DEV, V11, P2214, DOI 10.1101/gad.11.17.2214; TAN RY, 1995, P NATL ACAD SCI USA, V92, P5282, DOI 10.1073/pnas.92.12.5282; VanGilst MR, 1997, BIOCHEMISTRY-US, V36, P1514, DOI 10.1021/bi961920q; WANG MLJ, 1981, J BIOL CHEM, V256, P7097; WARD DC, 1969, J BIOL CHEM, V244, P1228; WHALEN W A, 1990, New Biologist, V2, P975	36	20	20	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32177	32183		10.1074/jbc.M504619200	http://dx.doi.org/10.1074/jbc.M504619200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16033760	hybrid			2022-12-25	WOS:000231794800018
J	Barrier, A; Lemoine, A; Boelle, PY; Tse, C; Brault, D; Chiappini, F; Breittschneider, J; Lacaine, F; Houry, S; Huguier, M; Van der Laan, MJ; Speed, T; Debuire, B; Flahault, A; Dudoit, S				Barrier, A; Lemoine, A; Boelle, PY; Tse, C; Brault, D; Chiappini, F; Breittschneider, J; Lacaine, F; Houry, S; Huguier, M; Van der Laan, MJ; Speed, T; Debuire, B; Flahault, A; Dudoit, S			Colon cancer prognosis prediction by gene expression profiling	ONCOGENE			English	Article						functional genomics; colon cancer; prognosis prediction; non-neoplastic mucosa; cross-validation	CDNA MICROARRAYS; COLORECTAL-CANCER; SURVIVAL; TISSUES; TUMOR; ADENOCARCINOMA; CLASSIFICATION; IDENTIFICATION; FLUOROURACIL; CHEMOTHERAPY	This study assessed the possibility to build a prognosis predictor, based on microarray gene expression measures, in stage II and III colon cancer patients. Tumour ( T) and non-neoplastic mucosa ( NM) mRNA samples from 18 patients ( nine with a recurrence, nine with no recurrence) were pro. led using the Affymetrix HGU133A GeneChip. The k-nearest neighbour method was used for prognosis prediction using T and NM gene expression measures. Six-fold cross-validation was applied to select the number of neighbours and the number of informative genes to include in the predictors. Based on this information, one T-based and one NM-based predictor were proposed and their accuracies were estimated by double cross-validation. In six-fold cross-validation, the lowest numbers of informative genes giving the lowest numbers of false predictions ( two out of 18) were 30 and 70 with the T and NM gene expression measures, respectively. A 30-gene T-based predictor and a 70-gene NM-based predictor were then built, with estimated accuracies of 78 and 83%, respectively. This study suggests that one can build an accurate prognosis predictor for stage II and III colon cancer patients, based on gene expression measures, and one can use either tumour or non-neoplastic mucosa for this purpose.	Univ Paris 06, Hop Tenon, Serv Chirurg Digest, Assistance Publ, F-75020 Paris, France; Univ Paris 06, Fac Med St Antoine, INSERM U444, F-75571 Paris, France; Univ Calif Berkeley, Sch Publ Hlth, Div Biostat, Berkeley, CA 94720 USA; Univ Paris 11, Hop Paul Brousse, Serv Biochem, INSERM U602, F-94800 Villejuif, France; Univ Paris 06, Hop Tenon, Serv Biochem, Assistance Publ, F-75020 Paris, France; Univ Calif Berkeley, Dept Stat, Berkeley, CA 94720 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; University of California System; University of California Berkeley; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; University of California System; University of California Berkeley	Barrier, A (corresponding author), Univ Paris 06, Hop Tenon, Serv Chirurg Digest, Assistance Publ, F-75020 Paris, France.	barrier@stat.Berkeley.edu	Speed, Terence P/B-8085-2009; Chiappini, Franck/AAB-9894-2021	Speed, Terence P/0000-0002-5403-7998; Chiappini, Franck/0000-0002-2684-1241				Agrawal D, 2002, J NATL CANCER I, V94, P513; Alon U, 1999, P NATL ACAD SCI USA, V96, P6745, DOI 10.1073/pnas.96.12.6745; Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709; Backert S, 1999, INT J CANCER, V82, P868, DOI 10.1002/(SICI)1097-0215(19990909)82:6<868::AID-IJC16>3.0.CO;2-W; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Benson AB, 2004, J CLIN ONCOL, V22, P3408, DOI 10.1200/JCO.2004.05.063; Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; Bertucci F, 2004, ONCOGENE, V23, P1377, DOI 10.1038/sj.onc.1207262; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Birkenkamp-Demtroder K, 2002, CANCER RES, V62, P4352; Boland CR, 1998, CANCER RES, V58, P5248; Bustin SA, 2002, TUMOR BIOL, V23, P130, DOI 10.1159/000064029; Cersosimo RJ, 2005, ANN PHARMACOTHER, V39, P128, DOI 10.1345/aph.1E319; Chen LC, 2004, CANCER RES, V64, P3694, DOI 10.1158/0008-5472.CAN-03-3264; Dudoit S, 2003, STAT SCI, V18, P71, DOI 10.1214/ss/1056397487; Dudoit S, 2003, INTERDISC STAT, P93; Durai R, 2005, INT J COLORECTAL DIS, V20, P203, DOI 10.1007/s00384-004-0675-4; Erlichman C, 1999, J CLIN ONCOL, V17, P1356, DOI 10.1200/JCO.1999.17.5.1356; Frederiksen CM, 2003, J CANCER RES CLIN, V129, P263, DOI 10.1007/s00432-003-0434-x; Hedge P, 2001, CANCER RES, V61, P7792; Iacopetta B, 2002, INT J CANCER, V101, P403, DOI 10.1002/ijc.10635; Irizarry R. A., 2003, ANAL GENE EXPRESSION, P102; Jiang ZY, 2003, J BIOL CHEM, V278, P31964, DOI 10.1074/jbc.M303314200; Kitahara O, 2001, CANCER RES, V61, P3544; Lin YM, 2002, ONCOGENE, V21, P4120, DOI 10.1038/sj.onc.1205518; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; Notterman DA, 2001, CANCER RES, V61, P3124; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; Tureci O, 2003, FASEB J, V17, P376, DOI 10.1096/fj.02-0478com; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang YX, 2004, J CLIN ONCOL, V22, P1564, DOI 10.1200/JCO.2004.08.186; Williams NS, 2003, CLIN CANCER RES, V9, P931; Zou TT, 2002, ONCOGENE, V21, P4855, DOI 10.1038/sj.onc.1205613	38	79	87	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2005	24	40					6155	6164		10.1038/sj.onc.1208984	http://dx.doi.org/10.1038/sj.onc.1208984			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	962GD	16091735	Green Published			2022-12-25	WOS:000231718100009
J	Caterina, C; Marcella, M; Giordano, A				Caterina, C; Marcella, M; Giordano, A			Tumor-specific exon 1 mutations could be the 'hit event' predisposing Rb2/p130 gene to epigenetic silencing in lung cancer	ONCOGENE			English	Article						methylation; Rb2/p130 silencing; tumor markers; lung tumors; Rb2/p130 mutations	DNA METHYLATION; PROTEIN; FAMILY; TRANSCRIPTION; PROGRESSION; EXPRESSION; COMPLEXES; MEMBER; CELLS; P130	Genetic alterations in Rb2/p130 gene have been reported in several tumors, but till now there are insufficient and conflicting data linking the loss of pRb2/p130 expression with the mutational status of this gene in lung cancer. We recently reported that loss or lowering of pRb2/p130 expression is mainly due to aberrant Rb2/p130 promoter methylation, in retinoblastoma tumors, and indicated that epigenetic silencing of Rb2/p130 can impair its function to negatively regulate cell cycle progression as well as apoptotic response. In order to clarify Rb2/p130 gene inactivation in lung cancer, we investigated whether epigenetic events could impair the expression of this gene in NSLC. Here, we show that specific Rb2-exon 1 homozygous mutations, occurring in an Rb2/p130, region, rich in CpG dinucleotides, could be the 'hit event' that predispose this gene to epigenetic changes, leading to Rb2/p130 gene silencing in lung cancer. Moreover, these homozygous mutations, found in different tumor histotypes, could represent tumor-specific markers.	Temple Univ, Sbarro Inst Canc Res & Mol Med, Ctr Biotechnol, Coll Sci & Technol, Philadelphia, PA 19122 USA; Univ Siena, CNR, Inst Clin Physiol, I-53100 Siena, Italy; Univ Siena, Dept Human Pathol & Oncol, I-53100 Siena, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR); University of Siena; University of Siena	Giordano, A (corresponding author), Temple Univ, Sbarro Inst Canc Res & Mol Med, Ctr Biotechnol, Coll Sci & Technol, Biolife Sci Bldg,1900 N 12th St,Suite 333, Philadelphia, PA 19122 USA.	giordano@temple.edu	Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X; Cinti, Caterina/0000-0001-8049-0369	NATIONAL CANCER INSTITUTE [R01CA066999] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA066999-09A2] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldi A, 1997, CLIN CANCER RES, V3, P1691; Belinsky SA, 2004, NAT REV CANCER, V4, P707, DOI 10.1038/nrc1432; Cinti C, 2000, CANCER RES, V60, P383; Claudio PP, 2000, CANCER RES, V60, P372; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Helin K, 1997, P NATL ACAD SCI USA, V94, P6933, DOI 10.1073/pnas.94.13.6933; Jun HX, 2003, MOL CARCINOGEN, V38, P124, DOI 10.1002/mc.10152; KALEBIC T, 2003, ANN ACAD SCI, V293, P278; La Sala D, 2003, ONCOGENE, V22, P3518, DOI 10.1038/sj.onc.1206487; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; Macaluso M, 2005, ANN ONCOL, V16, P20, DOI 10.1093/annonc/mdi903; Macaluso M, 2004, TUMORI J, V90, P367, DOI 10.1177/030089160409000401; Macaluso M, 2003, ONCOGENE, V22, P6472, DOI 10.1038/sj.onc.1206955; Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578; MACALUSO M, 2005, IN PRESS SEMIN ONCOL; MAYOL X, 1993, ONCOGENE, V8, P2561; Modi S, 2000, ONCOGENE, V19, P4632, DOI 10.1038/sj.onc.1203815; Nephew KP, 2003, CANCER LETT, V190, P125, DOI 10.1016/S0304-3835(02)00511-6; Russo G, 2003, ONCOGENE, V22, P6959, DOI 10.1038/sj.onc.1206866; Scarano MI, 2005, J CELL PHYSIOL, V204, P21, DOI 10.1002/jcp.20280; Suzuki M, 2005, LUNG CANCER, V47, P309, DOI 10.1016/j.lungcan.2004.08.006; TOSI GM, 2005, IN PRESS ONCOGENE; Yokota J, 2004, CANCER SCI, V95, P197, DOI 10.1111/j.1349-7006.2004.tb02203.x; Zochbauer-Muller S, 2002, ONCOLOGIST, V7, P451, DOI 10.1634/theoncologist.7-5-451	24	16	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	38					5821	5826		10.1038/sj.onc.1208880	http://dx.doi.org/10.1038/sj.onc.1208880			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960KW	16044156				2022-12-25	WOS:000231590400004
J	Carvalho, R; Milne, ANA; Polak, M; Corver, WE; Offerhaus, GJA; Weterman, MAJ				Carvalho, R; Milne, ANA; Polak, M; Corver, WE; Offerhaus, GJA; Weterman, MAJ			Exclusion of RUNX3 as a tumour-suppressor gene in early-onset gastric carcinomas	ONCOGENE			English	Article						RUNX3; gastric carcinoma; EOGC; TSG	TRANSCRIPTION FACTOR; CLEIDOCRANIAL DYSPLASIA; REGULATED EXPRESSION; CANCER; CELLS; HYBRIDIZATION; SURVIVAL; NEURONS; PROTEIN; REGION	Recent studies claim a critical role for RUNX3 in gastric epithelial homeostasis. However, conflicting results exist regarding RUNX3 expression in the stomach and its potential role as a tumour-suppressor gene (TSG) in gastric carcinogenesis. Our aim was to evaluate the role of RUNX3 in early-onset gastric carcinomas (EOGCs). We analysed 41 EOGCs for RUNX3 aberrations using loss of heterozygosity (LOH), fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) analyses. LOH of markers flanking RUNX3 was relatively common, indicating that loss of the gene may play a role in gastric carcinogenesis. However, FISH analysis of selected cases and a panel of 14 gastric carcinoma-derived cell lines showed widespread presence of multiple copies of centromere 1. While RUNX3 copy numbers were generally equal to or fewer than those of centromere 1, at least two copies were present in almost all cells analysed. Accordingly, a subpopulation of tumour cells in 12/37 cases showed RUNX3 protein expression. However, expression was not detected in the adjacent nontumorous mucosa of any case. Together, these observations indicate that chromosome 1 aberrations occur frequently in EOGCs and are rejected in the LOH and IHC patterns found. Our findings refute a role for RUNX3 as a TSG in EOGCs.	Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands; Leiden Univ, Med Ctr, Dept Pathol, Leiden, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Carvalho, R (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Pathol, Meibergdreef 9,Room L2-114, NL-1105 AZ Amsterdam, Netherlands.	r.p.carvalho@amc.uva.nl	Corver, Willem/T-6576-2018	Corver, Willem/0000-0001-8313-3658				Bae SC, 2004, ONCOGENE, V23, P4336, DOI 10.1038/sj.onc.1207286; Bangsow C, 2001, GENE, V279, P221, DOI 10.1016/S0378-1119(01)00760-0; Brenner O, 2004, P NATL ACAD SCI USA, V101, P16016, DOI 10.1073/pnas.0407180101; Carvalho R, 2004, J PATHOL, V204, P75, DOI 10.1002/path.1602; Corver WE, 2005, J PATHOL, V206, P233, DOI 10.1002/path.1765; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; Ehlers M, 2003, J IMMUNOL, V171, P3594, DOI 10.4049/jimmunol.171.7.3594; Etoh T, 2004, AM J PATHOL, V164, P689, DOI 10.1016/S0002-9440(10)63156-2; Fainaru O, 2004, EMBO J, V23, P969, DOI 10.1038/sj.emboj.7600085; FernandezSalguero PM, 1997, VET PATHOL, V34, P605, DOI 10.1177/030098589703400609; Fukamachi H, 2004, ONCOGENE, V23, P4330, DOI 10.1038/sj.onc.1207121; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Haralambieva E, 2002, J PATHOL, V198, P163, DOI 10.1002/path.1197; Igarashi J, 2000, JPN J CANCER RES, V91, P797, DOI 10.1111/j.1349-7006.2000.tb01016.x; Inoue K, 2002, NAT NEUROSCI, V5, P946, DOI 10.1038/nn925; Ito Y, 2003, CURR OPIN GENET DEV, V13, P43, DOI 10.1016/S0959-437X(03)00007-8; Jemal A, 2004, CANCER-AM CANCER SOC, V101, P3, DOI 10.1002/cncr.20288; Kokkola A, 1998, CANCER GENET CYTOGEN, V107, P32, DOI 10.1016/S0165-4608(98)00092-2; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Le XF, 1999, J BIOL CHEM, V274, P21651, DOI 10.1074/jbc.274.31.21651; Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797-307; Levanon D, 2003, EMBO REP, V4, P560, DOI 10.1038/sj.embor.embor868; Levanon D, 2001, MECH DEVELOP, V109, P413, DOI 10.1016/S0925-4773(01)00537-8; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; Levanon D, 2004, ONCOGENE, V23, P4211, DOI 10.1038/sj.onc.1207670; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Miki R, 2004, J VET MED SCI, V66, P797, DOI 10.1292/jvms.66.797; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Osaki M, 2004, EUR J CLIN INVEST, V34, P605, DOI 10.1111/j.1365-2362.2004.01401.x; Parkin DM, 1999, INT J CANCER, V80, P827, DOI 10.1002/(SICI)1097-0215(19990315)80:6&lt;827::AID-IJC6&gt;3.0.CO;2-P; Sakakura C, 1999, GENE CHROMOSOME CANC, V24, P299, DOI 10.1002/(SICI)1098-2264(199904)24:4<299::AID-GCC2>3.0.CO;2-U; SANO T, 1991, CANCER RES, V51, P2926; TANAKA K, 1993, ONCOGENE, V8, P2253; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Varis A, 2003, BRIT J CANCER, V88, P1914, DOI 10.1038/sj.bjc.6600969; Woolf E, 2003, P NATL ACAD SCI USA, V100, P7731, DOI 10.1073/pnas.1232420100; Wu CW, 2002, GENE CHROMOSOME CANC, V35, P219, DOI 10.1002/gcc.10106	38	29	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 15	2005	24	56					8252	8258		10.1038/sj.onc.1208963	http://dx.doi.org/10.1038/sj.onc.1208963			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	993LV	16091737				2022-12-25	WOS:000233956500004
J	Jutras, I; Laplante, A; Boulais, J; Brunet, S; Thinakaran, G; Desjardins, M				Jutras, I; Laplante, A; Boulais, J; Brunet, S; Thinakaran, G; Desjardins, M			gamma-secretase is a functional component of phagosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; INTRAMEMBRANE PROTEOLYSIS; MEDIATED PHAGOCYTOSIS; INTERFERON-GAMMA; PRESENILIN; NICASTRIN; COMPLEX; MEMBRANE; BINDING; APH-1	gamma-Secretase is a high molecular mass protein complex that catalyzes the intramembrane cleavage of its protein substrates. Two proteins involved in phagocytosis, CD44 and the low density lipoprotein receptor-related protein, are gamma-secretase substrates, suggesting that this complex might regulate some aspects of phagocytosis. Our results indicate that the four components of gamma-secretase, viz. presenilin, nicastrin, APH-1, and PEN-2, are present and enriched on phagosome membranes from both murine macrophages and Drosophila S2 phagocytes. The gamma-secretase components form high molecular mass complexes in lipid microdomains of the phagosome membrane with the topology expected for the functional enzyme. In contrast to the majority of the phagosome proteins studied so far, which appear to associate transiently with this organelle, gamma-secretase resides on newly formed phagosomes and remains associated throughout their maturation into phagolysosomes. Finally, our results indicate that interferon-gamma stimulates gamma-secretase-dependent cleavages on phagosomes and that gamma-secretase activity may be involved in the phagocytic response of macrophages to inflammatory cytokines.	Univ Montreal, Dept Pathol & Biol Cellulaire, Montreal, PQ H3C 3J7, Canada; Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA; Caprion Pharmaceut Inc, Montreal, PQ H4S 2C8, Canada	Universite de Montreal; University of Chicago	Desjardins, M (corresponding author), Univ Montreal, Dept Pathol & Biol Cellulaire, 2900 Edouard Montpetit, Montreal, PQ H3T 1J4, Canada.	michel.desjardins@umontreal.ca	Boulais, jonathan/Y-4019-2019	Desjardins, Michel/0000-0002-5684-5980; Boulais, Jonathan/0000-0003-1848-0068	NATIONAL INSTITUTE ON AGING [R01AG019070, R01AG021495] Funding Source: NIH RePORTER; NIA NIH HHS [AG019070, AG021495] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bajno L, 2000, J CELL BIOL, V149, P697, DOI 10.1083/jcb.149.3.697; Brunet S, 2003, TRENDS CELL BIOL, V13, P629, DOI 10.1016/j.tcb.2003.10.006; Cao XW, 2004, J BIOL CHEM, V279, P24601, DOI 10.1074/jbc.M402248200; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Crystal AS, 2003, J BIOL CHEM, V278, P20117, DOI 10.1074/jbc.M213107200; Dermine JF, 2001, J BIOL CHEM, V276, P18507, DOI 10.1074/jbc.M101113200; DESJARDINS M, 1994, J CELL BIOL, V124, P677, DOI 10.1083/jcb.124.5.677; Desjardins M, 2003, NAT REV IMMUNOL, V3, P280, DOI 10.1038/nri1053; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Erwig LP, 1999, BLOOD, V93, P1406, DOI 10.1182/blood.V93.4.1406.404k10_1406_1412; Farmery MR, 2003, J BIOL CHEM, V278, P24277, DOI 10.1074/jbc.M211992200; Gagnon E, 2002, CELL, V110, P119, DOI 10.1016/S0092-8674(02)00797-3; Gardai SJ, 2003, CELL, V115, P13, DOI 10.1016/S0092-8674(03)00758-X; Garin J, 2001, J CELL BIOL, V152, P165, DOI 10.1083/jcb.152.1.165; Gu YJ, 2004, J BIOL CHEM, V279, P31329, DOI 10.1074/jbc.M401548200; Gupta-Rossi N, 2004, J CELL BIOL, V166, P73, DOI 10.1083/jcb.200310098; Hansson CA, 2004, J BIOL CHEM, V279, P51654, DOI 10.1074/jbc.M404500200; Houde M, 2003, NATURE, V425, P402, DOI 10.1038/nature01912; Hu Y, 2003, J CELL BIOL, V161, P685, DOI 10.1083/jcb.200304014; Iwatsubo T, 2004, CURR OPIN NEUROBIOL, V14, P379, DOI 10.1016/j.conb.2004.05.010; Kim SH, 2004, J BIOL CHEM, V279, P48615, DOI 10.1074/jbc.C400396200; Kim SH, 2003, J BIOL CHEM, V278, P33992, DOI 10.1074/jbc.M305834200; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Koo EH, 2004, NAT MED, V10, pS26, DOI 10.1038/nm1065; Lammich S, 2002, J BIOL CHEM, V277, P44754, DOI 10.1074/jbc.M206872200; LaVoie MJ, 2003, J BIOL CHEM, V278, P37213, DOI 10.1074/jbc.M303941200; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; Leemans JC, 2003, J CLIN INVEST, V111, P681, DOI 10.1172/JCI200316936; Li XJ, 1998, P NATL ACAD SCI USA, V95, P7109, DOI 10.1073/pnas.95.12.7109; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Liao YF, 2004, J BIOL CHEM, V279, P49523, DOI 10.1074/jbc.M402034200; Luo WJ, 2003, J BIOL CHEM, V278, P7850, DOI 10.1074/jbc.C200648200; May P, 2003, J BIOL CHEM, V278, P37386, DOI 10.1074/jbc.M305858200; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; Nyabi O, 2003, J BIOL CHEM, V278, P43430, DOI 10.1074/jbc.M306957200; Ogden CA, 2001, J EXP MED, V194, P781, DOI 10.1084/jem.194.6.781; Parent AT, 2005, J NEUROSCI, V25, P1540, DOI 10.1523/JNEUROSCI.3850-04.2005; Pasternak SH, 2003, J BIOL CHEM, V278, P26687, DOI 10.1074/jbc.M304009200; Ramet M, 2002, NATURE, V416, P644, DOI 10.1038/nature735; Runz H, 2002, J NEUROSCI, V22, P1679, DOI 10.1523/JNEUROSCI.22-05-01679.2002; Saura CA, 2000, J BIOL CHEM, V275, P17136, DOI 10.1074/jbc.M909624199; Schagger H, 2001, METHOD CELL BIOL, V65, P231, DOI 10.1016/S0091-679X(01)65014-3; Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252; Selkoe D, 2003, ANNU REV NEUROSCI, V26, P565, DOI 10.1146/annurev.neuro.26.041002.131334; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; TARDIEUX I, 1992, CELL, V71, P1117, DOI 10.1016/S0092-8674(05)80061-3; Thinakaran G, 1998, NEUROBIOL DIS, V4, P438, DOI 10.1006/nbdi.1998.0171; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Underhill DM, 2002, ANNU REV IMMUNOL, V20, P825, DOI 10.1146/annurev.immunol.20.103001.114744; Vetrivel KS, 2004, J BIOL CHEM, V279, P44945, DOI 10.1074/jbc.M407986200; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xia WM, 2003, J CELL SCI, V116, P2839, DOI 10.1242/jcs.00651; Xu HX, 1998, NAT MED, V4, P447, DOI 10.1038/nm0498-447; Yang DS, 2002, J BIOL CHEM, V277, P28135, DOI 10.1074/jbc.M110871200; Yu CJ, 2001, J BIOL CHEM, V276, P43756, DOI 10.1074/jbc.C100410200; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhang JM, 1998, J BIOL CHEM, V273, P12436, DOI 10.1074/jbc.273.20.12436	60	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2005	280	43					36310	36317		10.1074/jbc.M504069200	http://dx.doi.org/10.1074/jbc.M504069200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	976IM	16103123	hybrid			2022-12-25	WOS:000232726900064
J	Kugimiya, F; Kawaguchi, H; Kamekura, S; Chikuda, H; Ohba, S; Yano, F; Ogata, N; Katagiri, T; Harada, Y; Azuma, Y; Nakamura, K; Chung, UG				Kugimiya, F; Kawaguchi, H; Kamekura, S; Chikuda, H; Ohba, S; Yano, F; Ogata, N; Katagiri, T; Harada, Y; Azuma, Y; Nakamura, K; Chung, UG			Involvement of endogenous bone morphogenetic protein (BMP)2 and BMP6 in bone formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CBFA1; DIFFERENTIATION; CHONDROCYTES; EXPRESSION	Although accumulated evidence has shown the bone anabolic effects of bone morphogenetic proteins ( BMPs) that were exogenously applied in vitro and in vivo, the roles of endogenous BMPs during bone formation remain to be clarified. This study initially investigated expression patterns of BMPs in the mouse long bone and found that BMP2 and BMP6 were the main subtypes expressed in hypertrophic chondrocytes that induce endochondral bone formation. We then examined the involvement of the combination of these BMPs in bone formation in vivo by generating the compound-deficient mice ( Bmp2 +/-; Bmp6 -/-). Under physiological conditions, these mice exhibited moderate growth retardation compared with the wild- type ( WT) littermates during the observation period up to 52 weeks of age. Both the fetal and adult compound- deficient mice showed a reduction in the trabecular bone volume with suppressed bone formation, but normal bone resorption, whereas the single deficient mice ( Bmp2 +/- or Bmp6 -/-) did not. When a fracture was created at the femoral midshaft and the bone healing was analyzed, the endochondral bone formation, but not intramembranous bone formation, was impaired by the compound deficiency. In the cultures of bone marrow cells, however, there was no difference in osteogenic differentiation between WT and compounddeficient cells in the presence or absence of the exogenous BMP2. We thus concluded that endogenous BMP2 and BMP6 cooperatively play pivotal roles in bone formation under both physiological and pathological conditions.	Univ Tokyo, Fac Med, Div Tissue Engn, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Fac Med, Div Sensory & Motor Syst Med, Bunkyo Ku, Tokyo 1138655, Japan; Saitama Med Sch, Div Pathophysiol, Res Ctr Genom Med, Hidaka, Saitama 3501241, Japan; Teijin Co Ltd, Tokyo 1918512, Japan	University of Tokyo; University of Tokyo; Saitama Medical University; Teijin Limited	Chung, UG (corresponding author), Univ Tokyo, Fac Med, Div Tissue Engn, Bunkyo Ku, Hongo 7-3-1, Tokyo 1138655, Japan.	uichung-tky@umin.ac.jp		Ohba, Shinsuke/0000-0002-6874-8539				Aubin JE, 1998, J CELL BIOCHEM, P73, DOI 10.1002/(SICI)1097-4644(1998)72:30/31+<73::AID-JCB11>3.0.CO;2-L; Chung UI, 2004, ENDOCR J, V51, P19, DOI 10.1507/endocrj.51.19; Chung UI, 2001, J CLIN INVEST, V107, P295, DOI 10.1172/JCI11706; Corral DA, 1998, P NATL ACAD SCI USA, V95, P13835, DOI 10.1073/pnas.95.23.13835; D'Angelo M, 2000, J CELL BIOCHEM, V77, P678, DOI 10.1002/(SICI)1097-4644(20000615)77:4<678::AID-JCB15>3.3.CO;2-G; Israel DI, 1996, GROWTH FACTORS, V13, P291, DOI 10.3109/08977199609003229; Jimenez MJG, 2001, J CELL BIOL, V155, P1333, DOI 10.1083/jcb.200106147; Kamekura S, 2005, OSTEOARTHR CARTILAGE, V13, P632, DOI 10.1016/j.joca.2005.03.004; Karsenty Gerard, 2000, P291; Kawabata Masahiro, 2000, P269; KAWAGUCHI H, 1994, ENDOCRINOLOGY, V135, P774, DOI 10.1210/en.135.2.774; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657; LEE KC, 1995, ENDOCRINOLOGY, V136, P453, DOI 10.1210/en.136.2.453; Long FX, 2004, DEVELOPMENT, V131, P1309, DOI 10.1242/dev.01006; Long FX, 2001, DEVELOPMENT, V128, P5099; Malaval L, 2001, J CELL BIOCHEM, P63; Mishina Y, 2004, J BIOL CHEM, V279, P27560, DOI 10.1074/jbc.M404222200; Nishida S, 2002, BONE, V30, P872, DOI 10.1016/S8756-3282(02)00725-1; Shimoaka T, 2004, J BIOL CHEM, V279, P15314, DOI 10.1074/jbc.M312525200; Solloway MJ, 1998, DEV GENET, V22, P321, DOI 10.1002/(SICI)1520-6408(1998)22:4<321::AID-DVG3>3.3.CO;2-7; Takeda S, 2001, GENE DEV, V15, P467, DOI 10.1101/gad.845101; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Zhang HB, 1996, DEVELOPMENT, V122, P2977; Zhao GQ, 2003, GENESIS, V35, P43, DOI 10.1002/gene.10167; Zhao M, 2002, J CELL BIOL, V157, P1049, DOI 10.1083/jcb.200109012	27	118	125	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 21	2005	280	42					35704	35712		10.1074/jbc.M505166200	http://dx.doi.org/10.1074/jbc.M505166200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	973ZN	16109715	hybrid			2022-12-25	WOS:000232561200073
J	Murphy, PJM; Morishima, Y; Kovacs, JJ; Yao, TP; Pratt, WB				Murphy, PJM; Morishima, Y; Kovacs, JJ; Yao, TP; Pratt, WB			Regulation of the dynamics of hsp90 action on the glucocorticoid receptor by acetylation/deacetylation of the chaperone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							7-AMINO ACID SEQUENCE; SHOCK-PROTEIN 90; ATP-BINDING; HSP90-BINDING IMMUNOPHILINS; DEPENDENT ACTIVATION; TERMINAL DOMAIN; AMINO-TERMINUS; P23; HEAT-SHOCK-PROTEIN-90; HDAC6	It is known that inhibition of histone deacetylases (HDACs) leads to acetylation of the abundant protein chaperone hsp90. In a recent study, we have shown that knockdown of HDAC6 by a specific small interfering RNA leads to hyperacetylation of hsp90 and that the glucocorticoid receptor (GR), an established hsp90 "client" protein, is defective in ligand binding, nuclear translocation, and gene activation in HDAC6-deficient cells ( Kovacs, J. J., Murphy, P. J. M., Gaillard, S., Zhao, X., Wu, J-T., Nicchitta, C. V., Yoshida, M., Toft, D. O., Pratt, W. B., and Yao, T-P. ( 2005) Mol. Cell 18, 601 - 607). Using human embryonic kidney wild-type and HDAC6( small interfering RNA) knockdown cells transiently expressing the mouse GR, we show here that the intrinsic properties of the receptor protein itself are not affected by HDAC6 knockdown, but the knockdown cytosol has a markedly decreased ability to assemble stable GR center dot hsp90 heterocomplexes and generate stable steroid binding activity under cell-free conditions. HDAC6 knockdown cytosol has the same ability to carry out dynamic GR center dot hsp90 heterocomplex assembly as wild-type cytosol. Addition of purified hsp90 to HDAC6 knockdown cytosol restores stable GR center dot hsp90 heterocomplex assembly to the level of wild-type cytosol. hsp90 from HDAC6 knockdown cytosol has decreased ATP-binding affinity, and it does not assemble stable GR center dot hsp90 heterocomplexes when it is a component of a purified five-protein assembly system. Incubation of knockdown cell hsp90 with purified HDAC6 converts the hsp90 to wild-type behavior. Thus, acetylation of hsp90 results in dynamic GR center dot hsp90 heterocomplex assembly/ disassembly, and this is manifest in the cell as a similar to 100-fold shift to the right in the steroid dose response for gene activation.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA; Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	University of Michigan System; University of Michigan; Duke University	Pratt, WB (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, 1301 Med Sci Res Bldg 3, Ann Arbor, MI 48109 USA.	ymo@umich.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001004, Z01HD000711] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA028010] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [Z01EY000311] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL004231] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000898, Z01AI000881] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551, Z01DE000379] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031573, Z01DK032003, Z01DK070004, R37DK031573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES065078, Z01ES090087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS054022] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [Z01AG000726] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [Z01DC000047] Funding Source: NIH RePORTER; NCI NIH HHS [CA28010] Funding Source: Medline; NIDDK NIH HHS [DK31573] Funding Source: Medline; NINDS NIH HHS [R01 NS054022-01, R01 NS054022] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bender AT, 1999, J BIOL CHEM, V274, P1472, DOI 10.1074/jbc.274.3.1472; Billecke SS, 2004, J BIOL CHEM, V279, P30252, DOI 10.1074/jbc.M403864200; Dittmar KD, 1997, J BIOL CHEM, V272, P13047, DOI 10.1074/jbc.272.20.13047; Dittmar KD, 1997, J BIOL CHEM, V272, P21213, DOI 10.1074/jbc.272.34.21213; Felts SJ, 2003, CELL STRESS CHAPERON, V8, P108, DOI 10.1379/1466-1268(2003)008<0108:PASPWC>2.0.CO;2; Galigniana MD, 2004, J BIOL CHEM, V279, P22483, DOI 10.1074/jbc.M402223200; Garnier C, 2002, J BIOL CHEM, V277, P12208, DOI 10.1074/jbc.M111874200; Giannakakou P, 2000, NAT CELL BIOL, V2, P709, DOI 10.1038/35036335; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Grenert JP, 1999, J BIOL CHEM, V274, P17525, DOI 10.1074/jbc.274.25.17525; Harrell JM, 2004, J BIOL CHEM, V279, P54647, DOI 10.1074/jbc.M406863200; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Isaacs JS, 2003, CANCER CELL, V3, P213, DOI 10.1016/S1535-6108(03)00029-1; Kanelakis KC, 2003, METHOD ENZYMOL, V364, P159; Kaul S, 2002, J BIOL CHEM, V277, P36223, DOI 10.1074/jbc.M206748200; Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Kovacs JJ, 2005, MOL CELL, V18, P601, DOI 10.1016/j.molcel.2005.04.021; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; Marcu MG, 2000, J BIOL CHEM, V275, P37181, DOI 10.1074/jbc.M003701200; Marks PA, 2001, CURR OPIN ONCOL, V13, P477, DOI 10.1097/00001622-200111000-00010; Morishima Y, 2000, J BIOL CHEM, V275, P18054, DOI 10.1074/jbc.M000434200; Morishima Y, 2003, J BIOL CHEM, V278, P48754, DOI 10.1074/jbc.M309814200; Pratt WB, 2004, CELL SIGNAL, V16, P857, DOI 10.1016/j.cellsig.2004.02.004; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; Soti C, 2002, J BIOL CHEM, V277, P7066, DOI 10.1074/jbc.M105568200; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; Sullivan WP, 2002, J BIOL CHEM, V277, P45942, DOI 10.1074/jbc.M207754200; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705; Xu M, 1998, J BIOL CHEM, V273, P13918, DOI 10.1074/jbc.273.22.13918; Yoshida M, 2001, CANCER CHEMOTH PHARM, V48, pS20, DOI 10.1007/s002800100300; Yu XD, 2002, J NATL CANCER I, V94, P504	36	133	137	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33792	33799		10.1074/jbc.M506997200	http://dx.doi.org/10.1074/jbc.M506997200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16087666	hybrid			2022-12-25	WOS:000232229700015
J	Wanamaker, CP; Green, WN				Wanamaker, CP; Green, WN			N-linked glycosylation is required for nicotinic receptor assembly but not for subunit associations with calnexin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTOCOMPATIBILITY COMPLEX-MOLECULES; TORPEDO ACETYLCHOLINE-RECEPTOR; ENDOPLASMIC-RETICULUM; CHAPERONE CALNEXIN; QUALITY-CONTROL; IN-VIVO; SURFACE EXPRESSION; BETA-SUBUNIT; PROTEIN; CALRETICULIN	We investigated how asparagine (N)-linked glycosylation affects assembly of acetylcholine receptors (AChRs) in the endoplasmic reticulum (ER). Block of N-linked glycosylation inhibited AChR assembly whereas block of glucose trimming partially blocked assembly at the late stages. Removal of each of seven glycans had a distinct effect on AChR assembly, ranging from no effect to total loss of assembly. Because the chaperone calnexin (CN) associates with N-linked glycans, we examined CN interactions with AChR subunits. CN rapidly associates with 50% or more of newly synthesized AChR subunits, but not with subunits after maturation. Block of N-linked glycosylation or trimming did not alter CN-AChR subunit associations nor did subunit mutations prevent N-linked glycosylation. Additionally, CN associations with subunits lacking N-linked glycans occurred without subunit aggregation or misfolding. Our data indicate that CN associates with AChR subunits without N-linked glycan interactions. Furthermore, CN-subunit associations only occur early in AChR assembly and have no role in events later that require N-linked glycosylation.	Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA; Univ Chicago, Comm Neurobiol, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Green, WN (corresponding author), Univ Chicago, Dept Neurobiol Pharmacol & Physiol, 947 E 58th St, Chicago, IL 60637 USA.	wgreen@midway.uchicago.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032693] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS032693-07, R01 NS032693-05A1, R01 NS032693-06, R01 NS032693-08, R01 NS032693] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON DJ, 1981, P NATL ACAD SCI-BIOL, V78, P5598, DOI 10.1073/pnas.78.9.5598; ARUNACHALAM B, 1995, J BIOL CHEM, V270, P2784, DOI 10.1074/jbc.270.6.2784; Basu S, 1999, J EXP MED, V189, P797, DOI 10.1084/jem.189.5.797; BLOUNT P, 1990, J CELL BIOL, V111, P2601, DOI 10.1083/jcb.111.6.2601; Cannon KS, 1996, J BIOL CHEM, V271, P14280, DOI 10.1074/jbc.271.24.14280; CARRENO BM, 1995, J IMMUNOL, V154, P5173; Chang W, 1997, J BIOL CHEM, V272, P28925, DOI 10.1074/jbc.272.46.28925; Christianson JC, 2004, EMBO J, V23, P4156, DOI 10.1038/sj.emboj.7600436; CLAUDIO T, 1989, J CELL BIOL, V108, P2277, DOI 10.1083/jcb.108.6.2277; CLAUDIO T, 1987, SCIENCE, V238, P1688, DOI 10.1126/science.3686008; Daniels R, 2003, MOL CELL, V11, P79, DOI 10.1016/S1097-2765(02)00821-3; Danilczyk UG, 2001, J BIOL CHEM, V276, P25532, DOI 10.1074/jbc.M100270200; Eertmoed AL, 1998, METHOD ENZYMOL, V293, P564; Ellgaard L, 2003, CELL BIOCHEM BIOPHYS, V39, P223, DOI 10.1385/CBB:39:3:223; Frickel EM, 2002, P NATL ACAD SCI USA, V99, P1954, DOI 10.1073/pnas.042699099; Gehle VM, 1997, MOL BRAIN RES, V45, P219, DOI 10.1016/S0169-328X(96)00256-2; GELMAN MS, 1995, J BIOL CHEM, V270, P15085, DOI 10.1074/jbc.270.25.15085; Green WN, 1998, J NEUROSCI, V18, P5555; GREEN WN, 1993, CELL, V74, P57, DOI 10.1016/0092-8674(93)90294-Z; Green WN, 1997, J BIOL CHEM, V272, P20945, DOI 10.1074/jbc.272.33.20945; GU Y, 1991, J CELL BIOL, V114, P799, DOI 10.1083/jcb.114.4.799; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Ihara Y, 1999, MOL CELL, V4, P331, DOI 10.1016/S1097-2765(00)80335-4; Jannatipour M, 1998, BIOCHEMISTRY-US, V37, P17253, DOI 10.1021/bi981785c; Jorgensen CS, 2000, EUR J BIOCHEM, V267, P2945, DOI 10.1046/j.1432-1033.2000.01309.x; Keller SH, 1996, J BIOL CHEM, V271, P22871, DOI 10.1074/jbc.271.37.22871; Keller SH, 1998, J BIOL CHEM, V273, P17064, DOI 10.1074/jbc.273.27.17064; Kleizen B, 2004, CURR OPIN CELL BIOL, V16, P343, DOI 10.1016/j.ceb.2004.06.012; Leach MR, 2004, J BIOL CHEM, V279, P9072, DOI 10.1074/jbc.M310788200; LEACH MR, 2002, J BIOL CHEM, V6, P6; LEE BS, 1991, J BIOL CHEM, V266, P11448; LOO TW, 1994, J BIOL CHEM, V269, P28683; MARGOLSKEE RF, 1993, BIOTECHNIQUES, V15, P906; MERLIE JP, 1982, J BIOL CHEM, V257, P2694; Molinari M, 2000, SCIENCE, V288, P331, DOI 10.1126/science.288.5464.331; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; Nair S, 1999, J IMMUNOL, V162, P6426; OU WJ, 1995, J BIOL CHEM, V270, P18051, DOI 10.1074/jbc.270.30.18051; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; Parodi AJ, 2000, BIOCHEM J, V348, P1, DOI 10.1042/0264-6021:3480001; PAULSON HL, 1991, J CELL BIOL, V113, P1371, DOI 10.1083/jcb.113.6.1371; Pollock S, 2004, EMBO J, V23, P1020, DOI 10.1038/sj.emboj.7600119; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; ROSS AF, 1991, J CELL BIOL, V113, P623, DOI 10.1083/jcb.113.3.623; SAEDI MS, 1991, J CELL BIOL, V112, P1007, DOI 10.1083/jcb.112.5.1007; Schrag JD, 2001, MOL CELL, V8, P633, DOI 10.1016/S1097-2765(01)00318-5; SMITH MM, 1987, J BIOL CHEM, V262, P4367; SUMIKAWA K, 1992, J BIOL CHEM, V267, P6286; SUMIKAWA K, 1989, MOL BRAIN RES, V5, P183, DOI 10.1016/0169-328X(89)90034-X; Swanton E, 2003, EMBO J, V22, P2948, DOI 10.1093/emboj/cdg300; vanLeeuwen JEM, 1996, J BIOL CHEM, V271, P9660, DOI 10.1074/jbc.271.16.9660; WADA I, 1995, J BIOL CHEM, V270, P20298, DOI 10.1074/jbc.270.35.20298; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; WILLIAMS DB, 1995, BIOCHEM CELL BIOL, V73, P123, DOI 10.1139/o95-015; YONG G, 1989, J CELL BIOL, V109, P729, DOI 10.1083/jcb.109.2.729; Zapun A, 1998, J BIOL CHEM, V273, P6009, DOI 10.1074/jbc.273.11.6009; ZHANG Q, 1995, J BIOL CHEM, V270, P3944, DOI 10.1074/jbc.270.8.3944	57	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 7	2005	280	40					33800	33810		10.1074/jbc.M501813200	http://dx.doi.org/10.1074/jbc.M501813200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	969JF	16091366	Green Accepted, hybrid			2022-12-25	WOS:000232229700016
J	Zhang, ZC; Rehmann, H; Price, LS; Riedl, J; Bos, JL				Zhang, ZC; Rehmann, H; Price, LS; Riedl, J; Bos, JL			AF6 negatively regulates Rap1-induced cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAS-BINDING DOMAIN; GENE-EXPRESSION; AF-6 INTERACTS; RAP1 EFFECTOR; PROTEIN AF-6; GTPASE; ACTIVATION; MOLECULE; LYMPHOCYTE; JUNCTIONS	AF6 is involved in the connection of membrane-associated proteins to the actin cytoskeleton. It binds to Ras-like small GTPases and is suggested to be an effector of both Ras and Rap. Here we show that knockdown of AF6 in T cells by RNA interference enhanced Rap1-induced integrin-mediated cell adhesion, whereas overexpression of AF6 had the opposite effect. Interestingly, AF6-induced inhibition of cell adhesion correlated with an increase in RapGTP levels. Like AF6, protein KIAA1849 contains a Ras association domain and interacted with Rap1. However, KIAA1849 did not inhibit Rap1-induced cell adhesion. We concluded that AF6 is a negative regulator of Rap-induced cell adhesion. We proposed that AF6 inhibits Rap-mediated cell adhesion by sequestering RapGTP in an unproductive complex and thus prevents the interaction of Rap1 not only with effectors that mediate adhesion but also with Rap GTPase-activating proteins. Thus, AF6 may buffer RapGTP in resting T cells and maintain them in a non-adherent state.	Univ Med Ctr, Dept Physiol Chem, NL-3508 AB Utrecht, Netherlands; Univ Med Ctr, Ctr Biomed Genet, NL-3508 AB Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	Bos, JL (corresponding author), Univ Med Ctr Utrecht, Dept Physiol Chem, Univ Weg 100, NL-3584 CG Utrecht, Netherlands.	J.L.Bos@med.uu.nl						Arthur WT, 2004, J CELL BIOL, V167, P111, DOI 10.1083/jcb.200404068; Boettner B, 2003, GENETICS, V165, P159; Boettner B, 2000, P NATL ACAD SCI USA, V97, P9064, DOI 10.1073/pnas.97.16.9064; Bos JL, 2003, NAT REV MOL CELL BIO, V4, P733, DOI 10.1038/nrm1197; Bos JL, 2005, CURR OPIN CELL BIOL, V17, P123, DOI 10.1016/j.ceb.2005.02.009; Buchert M, 1999, J CELL BIOL, V144, P361, DOI 10.1083/jcb.144.2.361; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; Herrmann C, 1996, PROG BIOPHYS MOL BIO, V66, P1, DOI 10.1016/S0079-6107(96)00015-6; Hogan C, 2004, MOL CELL BIOL, V24, P6690, DOI 10.1128/mcb.24.15.6690-6700.2004; Katagiri K, 2002, MOL CELL BIOL, V22, P1001, DOI 10.1128/MCB.22.4.1001-1015.2002; Katagiri K, 2003, NAT IMMUNOL, V4, P741, DOI 10.1038/ni950; Katagiri K, 2004, NAT IMMUNOL, V5, P1045, DOI 10.1038/ni1111; Knox AL, 2002, SCIENCE, V295, P1285, DOI 10.1126/science.1067549; Krugmann S, 2004, CURR BIOL, V14, P1380, DOI 10.1016/j.cub.2004.07.058; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; Lafuente EM, 2004, DEV CELL, V7, P585, DOI 10.1016/j.devcel.2004.07.021; Linnemann T, 1999, J BIOL CHEM, V274, P13556, DOI 10.1074/jbc.274.19.13556; MEDEMA RH, 1992, MOL CELL BIOL, V12, P3425, DOI 10.1128/MCB.12.8.3425; Nagase T, 2001, DNA RES, V8, P85, DOI 10.1093/dnares/8.2.85; PRASAD R, 1993, CANCER RES, V53, P5624; Price LS, 2004, J BIOL CHEM, V279, P35127, DOI 10.1074/jbc.M404917200; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; Sebzda E, 2002, NAT IMMUNOL, V3, P251, DOI 10.1038/ni765; Su L, 2003, J BIOL CHEM, V278, P15232, DOI 10.1074/jbc.M211888200; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; Yamamoto T, 1997, J CELL BIOL, V139, P785, DOI 10.1083/jcb.139.3.785; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	31	38	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2005	280	39					33200	33205		10.1074/jbc.M505057200	http://dx.doi.org/10.1074/jbc.M505057200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	966YG	16051602	hybrid			2022-12-25	WOS:000232058100014
J	Peterfy, M; Phan, J; Reue, K				Peterfy, M; Phan, J; Reue, K			Alternatively spliced lipin isoforms exhibit distinct expression pattern, subcellular localization, and role in adipogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C-BETA; TRANSCRIPTION FACTOR; MESSENGER-RNA; INSULIN; GENE; PROTEIN; LIPODYSTROPHY; MUTATION; OBESITY; CELLS	We recently identified mutations in the Lpin1 ( lipin) gene to be responsible for lipodystrophy in the fatty liver dystrophy (fld) mouse strain. Previous studies revealed that lipin plays a critical role in adipogenesis, explaining the adipose-deficient phenotype of the fld mouse. In the current study, we demonstrate that alternative mRNA splicing generates two lipin isoforms, lipin-alpha and lipin-beta, which are differentially expressed during adipocyte differentiation. Lipin-alpha expression peaks at day 2 of 3T3-L1 cell differentiation, after which its levels gradually decrease. In contrast, lipin-beta expression is transiently elevated at 10 h, followed by a drop to background levels at 20 h and a gradual increase between days 2 and 6 of differentiation. The two lipin isoforms also exhibit differences in subcellular localization. Lipin-alpha is predominantly nuclear, whereas lipin-beta is primarily located in the cytoplasm of 3T3-L1 adipocytes, suggesting distinct cellular functions. Using primary mouse embryonic fibroblasts expressing either lipin-alpha or lipin-alpha, we demonstrate functional differences between the two isoforms. Whereas effect of lipin-beta expression is the induction of lipogenic genes. In vivo, overexpression of lipin-beta specifically in mature adipocytes leads to elevated expression of lipogenic genes and adipocyte hypertrophy, confirming a role of lipin-beta in the regulation of lipogenesis. In conclusion, our data suggest that the two lipin isoforms have distinct, but complementary, functions in adipogenesis, with lipin-alpha playing a primary role in differentiation and lipin-beta being predominantly involved in lipogenesis.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA; Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Reue, K (corresponding author), 11301 Wilshire Blvd,Bldg 113,Rm 312, Los Angeles, CA 90073 USA.	reuek@ucla.edu		Phan, Jack/0000-0001-5977-6004	NHLBI NIH HHS [HL24841] Funding Source: Medline; NIGMS NIH HHS [GM08042] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Caricasole A, 2002, J BIOL CHEM, V277, P4790, DOI 10.1074/jbc.M110249200; Casolari JM, 2004, CELL, V117, P427, DOI 10.1016/S0092-8674(04)00448-9; CHALFANT CE, 1995, J BIOL CHEM, V270, P13326, DOI 10.1074/jbc.270.22.13326; DIAMOND RH, 1993, J BIOL CHEM, V268, P15185; Ganesh S, 2002, BIOCHEM BIOPH RES CO, V291, P1134, DOI 10.1006/bbrc.2002.6590; Garg A, 2000, AM J MED, V108, P143, DOI 10.1016/S0002-9343(99)00414-3; Holmes KD, 2002, J BIOL CHEM, V277, P1457, DOI 10.1074/jbc.M107809200; Huffman TA, 2002, P NATL ACAD SCI USA, V99, P1047, DOI 10.1073/pnas.022634399; Kamai Y, 1996, J BIOL CHEM, V271, P9883, DOI 10.1074/jbc.271.17.9883; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Liu XT, 2003, J CLIN INVEST, V111, P399, DOI 10.1172/JCI200315737; Lopez AJ, 1995, DEV BIOL, V172, P396, DOI 10.1006/dbio.1995.8050; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; Min J, 1999, MOL CELL, V3, P751, DOI 10.1016/S1097-2765(01)80007-1; Ozaita A, 2002, J NEUROPHYSIOL, V88, P394, DOI 10.1152/jn.2002.88.1.394; Pasqualini C, 2001, MOL ENDOCRINOL, V15, P894, DOI 10.1210/me.15.6.894; Patel NA, 2001, J BIOL CHEM, V276, P22648, DOI 10.1074/jbc.M101260200; Peterfy M, 2001, NAT GENET, V27, P121, DOI 10.1038/83685; Phan J, 2005, DRUG NEWS PERSPECT, V18, P5, DOI 10.1358/dnp.2005.18.1.877165; Phan J, 2005, CELL METAB, V1, P73, DOI 10.1016/j.cmet.2004.12.002; Phan J, 2004, J BIOL CHEM, V279, P29558, DOI 10.1074/jbc.M403506200; Reue K, 2000, J LIPID RES, V41, P1067; ROSS SR, 1990, P NATL ACAD SCI USA, V87, P9590, DOI 10.1073/pnas.87.24.9590; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; SELL SM, 1994, J BIOL CHEM, V269, P30769; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; Tange Y, 2002, J CELL SCI, V115, P4375, DOI 10.1242/jcs.00135; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Wang ZH, 1996, RNA, V2, P1241; XU L, 1994, NUCLEIC ACIDS RES, V22, P646, DOI 10.1093/nar/22.4.646	30	174	187	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32883	32889		10.1074/jbc.M503885200	http://dx.doi.org/10.1074/jbc.M503885200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16049017	hybrid			2022-12-25	WOS:000231920300042
J	Takahashi, K; Nakagawa, M; Young, SG; Yamanaka, S				Takahashi, K; Nakagawa, M; Young, SG; Yamanaka, S			Differential membrane localization of ERas and Rheb, two Ras-related proteins involved in the phosphatidylinositol 3-kinase/mTOR pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; TSC2 GAP ACTIVITY; K-RAS; MAMMALIAN TARGET; H-RAS; GENE; GOLGI; CELLS; ASSOCIATION; GROWTH	Two Ras-related proteins, ERas and Rheb, which are involved in the phosphatidylinositol 3-kinase pathway, display high GTP affinity and have atypical CAAX motifs. The factors governing the intracellular localization of ERas and Rheb are incompletely understood. In the current study, we show by confocal microscopy that ERas is localized to the plasma membrane, whereas Rheb is confined to the endomembranes. Membrane localization of the two proteins was abolished by mutation of the cysteine of the CAAX motif. Membrane targeting was also abolished by a farnesyltransferase inhibitor but not by a geranylgeranyltransferase inhibitor. In mouse fibroblasts deficient in either Rce1 ( Ras converting enzyme 1) or Icmt ( isoprenylcysteine carboxyl methyltransferase), ERas was mislocalized mainly to the Golgi apparatus, whereas Rheb showed diffuse localization. Mutation of cysteines in the hypervariable region of ERas prevented the plasma membrane localization of ERas, very strongly suggesting that palmitoylation of the cysteines is essential for membrane targeting. The hypervariable region of Rheb does not contain cysteines or polybasic residues, and when it was replaced with the hypervariable region of H-Ras, Rheb displayed plasma membrane localization. These data indicate that ERas shares the same posttranslational modifications with H-Ras and N-Ras and is localized at the plasmamembrane. Rheb also shares the same membrane-targeting pathway but because of the absence of palmitoylation is located on endomembranes.	Kyoto Univ, Dept Stem Cell Biol, Inst Frontier Med Sci, Sakyo Ku, Kyoto 6068507, Japan; Japan Sci & Technol Agcy, CREST, Kyoto 6068507, Japan; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA	Kyoto University; Japan Science & Technology Agency (JST); University of California System; University of California Los Angeles	Yamanaka, S (corresponding author), Kyoto Univ, Dept Stem Cell Biol, Inst Frontier Med Sci, Sakyo Ku, 53 Kawahara Cho, Kyoto 6068507, Japan.	yamanaka@frontier.kyoto-u.ac.jp	Takahashi, Kazutoshi/ABE-5504-2020	Takahashi, Kazutoshi/0000-0002-5329-8395; Young, Stephen/0000-0001-7270-3176	NCI NIH HHS [CA103999-01, CA099506] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA103999, R01CA099506] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; Aspuria PJ, 2004, CELL SIGNAL, V16, P1105, DOI 10.1016/j.cellsig.2004.03.019; BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; Bergo MO, 2000, J BIOL CHEM, V275, P17605, DOI 10.1074/jbc.C000079200; Bergo MO, 2001, J BIOL CHEM, V276, P5841, DOI 10.1074/jbc.C000831200; Bivona TG, 2003, CURR OPIN CELL BIOL, V15, P136, DOI 10.1016/S0955-0674(03)00016-4; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Clark GJ, 1997, J BIOL CHEM, V272, P10608; COX AD, 1995, METHOD ENZYMOL, V255, P195; Drenan RM, 2004, J BIOL CHEM, V279, P772, DOI 10.1074/jbc.M305912200; Ehrhardt A, 2002, EXP HEMATOL, V30, P1089, DOI 10.1016/S0301-472X(02)00904-9; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Karbowniczek M, 2004, J BIOL CHEM, V279, P29930, DOI 10.1074/jbc.M402591200; Kato M, 1999, MOL REPROD DEV, V54, P43, DOI 10.1002/(SICI)1098-2795(199909)54:1&lt;43::AID-MRD6&gt;3.0.CO;2-N; Kim E, 1999, J BIOL CHEM, V274, P8383, DOI 10.1074/jbc.274.13.8383; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; Lerner EC, 1997, ONCOGENE, V15, P1283, DOI 10.1038/sj.onc.1201296; Li Y, 2004, MOL CELL BIOL, V24, P7965, DOI 10.1128/MCB.24.18.7965-7975.2004; Manning BD, 2003, TRENDS BIOCHEM SCI, V28, P573, DOI 10.1016/j.tibs.2003.09.003; McGuire TF, 1996, J BIOL CHEM, V271, P27402, DOI 10.1074/jbc.271.44.27402; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; Nomura K, 2004, J BIOL CHEM, V279, P22664, DOI 10.1074/jbc.M314169200; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; Seabra MC, 1998, CELL SIGNAL, V10, P167, DOI 10.1016/S0898-6568(97)00120-4; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; Takahashi K, 2003, NATURE, V423, P541, DOI 10.1038/nature01646; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Tokuzawa Y, 2003, MOL CELL BIOL, V23, P2699, DOI 10.1128/MCB.23.8.2699-2708.2003; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; YAMAGATA K, 1994, J BIOL CHEM, V269, P16333	32	78	82	3	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 23	2005	280	38					32768	32774		10.1074/jbc.M506280200	http://dx.doi.org/10.1074/jbc.M506280200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	964ZU	16046393	hybrid			2022-12-25	WOS:000231920300028
J	Alderwick, LJ; Radmacher, E; Seidel, M; Gande, R; Hitchen, PG; Morris, HR; Dell, A; Sahm, H; Eggeling, L; Besra, GS				Alderwick, LJ; Radmacher, E; Seidel, M; Gande, R; Hitchen, PG; Morris, HR; Dell, A; Sahm, H; Eggeling, L; Besra, GS			Deletion of Cg-emb in corynebacterianeae leads to a novel truncated cell wall arabinogalactan, whereas inactivation of Cg-ubiA results in an Arabinan-deficient mutant with a cell wall galactan core	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYCOLIC ACID BIOSYNTHESIS; MYCOBACTERIUM-TUBERCULOSIS; ETHAMBUTOL RESISTANCE; MASS-SPECTROMETRY; GENOME SEQUENCE; IDENTIFICATION; PEPTIDOGLYCAN; SMEGMATIS; ARABINOSYLATION; RECOGNITION	The cell wall of Mycobacterium tuberculosis has a complex ultrastructure that consists of mycolic acids connected to peptidoglycan via arabinogalactan (AG) and abbreviated as the mAGP complex. The mAGP complex is crucial for the survival and pathogenicity of M. tuberculosis and is the target of several anti-tubercular agents. Apart from sharing a similar mAGP and the availability of the complete genome sequence, Corynebacterium glutamicum has proven useful in the study of orthologous M. tuberculosis genes essential for viability. Here we examined the effects of particular genes involved in AG polymerization by gene deletion in C. glutamicum. The anti-tuberculosis drug ethambutol is thought to target a set of arabinofuranosyltransferases (Emb) that are involved in arabinan polymerization. Deletion of emb in C. glutamicum results in a slow growing mutant with profound morphological changes. Chemical analysis revealed a dramatic reduction of arabinose resulting in a novel truncated AG structure possessing only terminal arabinofuranoside (t-Araf) residues with a corresponding loss of cell wall bound mycolic acids. Treatment of wild-type C. glutamicum with ethambutol and subsequent cell wall analyses resulted in an identical phenotype comparable to the C. glutamicum emb deletion mutant. Additionally, disruption of ubiA in C. glutamicum, the first enzyme involved in the biosynthesis of the sugar donor decaprenol phosphoarabinose (DPA), resulted in a complete loss of cell wall arabinan. Herein, we establish for the first time, (i) that in contrast to M. tuberculosis embA and embB mutants, deletion of C. glutamicum emb leads to a highly truncated AG possessing t-Araf residues, (ii) the exact site of attachment of arabinan chains in AG, and (iii) DPA is the only Araf sugar donor in AG biosynthesis suggesting the presence of a novel enzyme responsible for "priming" the galactan domain for further elaboration by Emb, resulting in the final maturation of the native AG polysaccharide.	Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England; Res Ctr Luelich, Inst Biotechnol 1, D-52425 Julich, Germany; Univ London Imperial Coll Sci Technol & Med, Fac Life Sci, Div Mol Biosci, London SW7 2AZ, England; MSCAN, Mass Spectrometry Res & Training Ctr, Ascot SL5 7PZ, Berks, England	University of Birmingham; Imperial College London	Besra, GS (corresponding author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.	g.besra@bham.ac.uk		Besra, Gurdyal/0000-0002-5605-0395; Alderwick, Luke/0000-0002-1257-6053				Belanger AE, 1996, P NATL ACAD SCI USA, V93, P11919, DOI 10.1073/pnas.93.21.11919; Belisle JT, 1997, SCIENCE, V276, P1420, DOI 10.1126/science.276.5317.1420; BESRA GS, 1995, BIOCHEMISTRY-US, V34, P4257, DOI 10.1021/bi00013a015; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; Cerdeno-Tarraga AM, 2003, NUCLEIC ACIDS RES, V31, P6516, DOI 10.1093/nar/gkg874; DAFFE M, 1990, J BIOL CHEM, V265, P6734; De Sousa-D'Auria C, 2003, FEMS MICROBIOL LETT, V224, P35, DOI 10.1016/S0378-1097(03)00396-3; Dover LG, 2004, FEMS MICROBIOL REV, V28, P225, DOI 10.1016/j.femsre.2003.10.001; Eggeling L, 2005, HDB CORYNEBACTERIUM, P535; Escuyer VE, 2001, J BIOL CHEM, V276, P48854, DOI 10.1074/jbc.M102272200; Funke G, 1997, CLIN MICROBIOL REV, V10, P125, DOI 10.1128/CMR.10.1.125; Gande R, 2004, J BIOL CHEM, V279, P44847, DOI 10.1074/jbc.M408648200; Hancock IC, 2002, MICROBIOL-SGM, V148, P3059, DOI 10.1099/00221287-148-10-3059; Huang HR, 2005, J BIOL CHEM, V280, P24539, DOI 10.1074/jbc.M504068200; Kacem R, 2004, MICROBIOL-SGM, V150, P73, DOI 10.1099/mic.0.26583-0; Kalinowski J, 2003, J BIOTECHNOL, V104, P5, DOI 10.1016/S0168-1656(03)00154-8; Klutts JS, 2002, ARCH BIOCHEM BIOPHYS, V398, P229, DOI 10.1006/abbi.2001.2723; Kremer L, 2001, J BIOL CHEM, V276, P26430, DOI 10.1074/jbc.M102022200; LEE RE, 1995, J AM CHEM SOC, V117, P11829, DOI 10.1021/ja00153a002; Lee RE, 1997, GLYCOBIOLOGY, V7, P1121, DOI 10.1093/glycob/7.8.1121; MCNEIL M, 1990, J BIOL CHEM, V265, P18200; MCNEIL M, 1991, J BIOL CHEM, V266, P13217; Mergaert P, 1996, MOL MICROBIOL, V21, P409, DOI 10.1046/j.1365-2958.1996.6451366.x; Mergaert P, 1997, MOL MICROBIOL, V25, P811, DOI 10.1111/j.1365-2958.1997.mmi526.x; Mikusova K, 2000, J BIOL CHEM, V275, P33890, DOI 10.1074/jbc.M006875200; Mikusova K, 1996, J BIOL CHEM, V271, P7820, DOI 10.1074/jbc.271.13.7820; Mills JA, 2004, J BIOL CHEM, V279, P43540, DOI 10.1074/jbc.M407782200; Nakamura Y, 2003, GENE, V317, P149, DOI 10.1016/S0378-1119(03)00653-X; Pan F, 2001, J BACTERIOL, V183, P3991, DOI 10.1128/JB.183.13.3991-3998.2001; Portevin D, 2004, P NATL ACAD SCI USA, V101, P314, DOI 10.1073/pnas.0305439101; Radmacher E, 2005, MICROBIOL-SGM, V151, P1359, DOI 10.1099/mic.0.27804-0; Ramaswamy SV, 2004, J MED MICROBIOL, V53, P107, DOI 10.1099/jmm.0.05343-0; Ramaswamy SV, 2000, ANTIMICROB AGENTS CH, V44, P326, DOI 10.1128/AAC.44.2.326-336.2000; Sahm H, 2000, BIOL CHEM, V381, P899, DOI 10.1515/BC.2000.111; Sanders DAR, 2001, NAT STRUCT BIOL, V8, P858, DOI 10.1038/nsb1001-858; SINGH S, 1994, MICROBIOS, V77, P217; Sreevatsan S, 1997, ANTIMICROB AGENTS CH, V41, P1677, DOI 10.1128/AAC.41.8.1677; TAKAYAMA K, 1979, ANTIMICROB AGENTS CH, V16, P240, DOI 10.1128/AAC.16.2.240; TAKAYAMA K, 1989, ANTIMICROB AGENTS CH, V33, P1493, DOI 10.1128/AAC.33.9.1493; Telenti A, 1997, NAT MED, V3, P567, DOI 10.1038/nm0597-567; Trivedi OA, 2005, MOL CELL, V17, P631, DOI 10.1016/j.molcel.2005.02.009; Vilcheze C, 2000, J BACTERIOL, V182, P4059, DOI 10.1128/JB.182.14.4059-4067.2000; Weston A, 1998, TUBERCLE LUNG DIS, V78, P123, DOI 10.1016/S0962-8479(98)80005-1; WOLUCKA BA, 1994, J BIOL CHEM, V269, P23328; Xin Y, 1997, BBA-GEN SUBJECTS, V1335, P231, DOI 10.1016/S0304-4165(97)00002-0; Yagi T, 2003, J BIOL CHEM, V278, P26497, DOI 10.1074/jbc.M302216200; Zhang N, 2003, MOL MICROBIOL, V50, P69, DOI 10.1046/j.1365-2958.2003.03681.x	47	109	118	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32362	32371		10.1074/jbc.M506339200	http://dx.doi.org/10.1074/jbc.M506339200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16040600	hybrid, Green Published			2022-12-25	WOS:000231794800041
J	Raschle, T; Amrhein, N; Fitzpatrick, TB				Raschle, T; Amrhein, N; Fitzpatrick, TB			On the two components of pyridoxal 5 '-phosphate synthase from Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBAMOYL-PHOSPHATE SYNTHETASE; VITAMIN-B-6 BIOSYNTHESIS; SACCHAROMYCES-CEREVISIAE; INCORPORATION PATTERN; GLUTAMINE HYDROLYSIS; NITROGEN ATOM; YEAST; PATHWAY; HISTIDINE; ORIGIN	Vitamin B6 is an essential nutrient in the human diet. It can act as a co-enzyme for numerous metabolic enzymes and has recently been shown to be a potent antioxidant. Plants and microorganisms have the ability to make the compound. Yet, studies of vitamin B6 biosynthesis have been mainly restricted to Escherichia coli, where the vitamin is synthesized from 1-deoxy-D-xylulose5-phosphate and 4-phosphohydroxy-L-threonine. Recently, a novel pathway for its synthesis has been discovered, involving two genes (PDX1 and PDX2) neither of which is homologous to any of those participating in the E. coli pathway. In Bacillus subtilis, YaaD and YaaE represent the PDX1 and PDX2 homolog, respectively. The two proteins form a complex that functions as a glutamine amidotransferase, with YaaE as the glutaminase domain and YaaD as the acceptor and pyridoxal 5'-phosphate (PLP) synthesis domain. In this report we corroborate a recent report on the identification of the substrates of YaaD and provide unequivocal proof of the identity of the reaction product. We show that both the glutaminase and synthase reactions are dependent on the respective protein partner. The synthase reaction can also utilize an external ammonium source but, in contrast to other glutamine amidotransferases, is dependent on YaaE under certain conditions. Furthermore, we report on the detailed characterization of the inhibition of the glutaminase domain, and thus PLP synthesis, by the glutamine analog acivicin. Employing pull-out assays and native-PAGE, we provide evidence for the dissociation of the bi-enzyme complex under these conditions. The results are discussed in light of the nature of the interaction of the two components of the enzyme complex.	ETH, Inst Pflanzenwissensch, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Fitzpatrick, TB (corresponding author), ETH, Inst Pflanzenwissensch, Univ Str 2, CH-8092 Zurich, Switzerland.	teresa.fitzpatrick@ipw.biol.ethz.ch						Banks J, 2004, BIOORG MED CHEM LETT, V14, P1633, DOI 10.1016/j.bmcl.2004.01.065; Bauer JA, 2004, J BIOL CHEM, V279, P2704, DOI 10.1074/jbc.M310311200; Belitsky BR, 2004, J BACTERIOL, V186, P1191, DOI 10.1128/JB.186.4.1191-1196.2004; Burns KE, 2005, J AM CHEM SOC, V127, P3682, DOI 10.1021/ja042792t; Cane DE, 1998, J AM CHEM SOC, V120, P1936, DOI 10.1021/ja9742085; Cane DE, 1999, J AM CHEM SOC, V121, P7722, DOI 10.1021/ja9914947; Cane DE, 2000, J AM CHEM SOC, V122, P4213, DOI 10.1021/ja000224h; Chittur SV, 2001, BIOCHEMISTRY-US, V40, P876, DOI 10.1021/bi0014047; Dong YX, 2004, EUR J BIOCHEM, V271, P745, DOI 10.1111/j.1432-1033.2003.03973.x; Ehrenshaft M, 1999, P NATL ACAD SCI USA, V96, P9374, DOI 10.1073/pnas.96.16.9374; Ehrenshaft M, 2001, J BACTERIOL, V183, P3383, DOI 10.1128/JB.183.11.3383-3390.2001; Fitzpatrick TB, 2003, J BIOL CHEM, V278, P19891, DOI 10.1074/jbc.M211778200; Galperin MY, 1997, MOL MICROBIOL, V24, P443, DOI 10.1046/j.1365-2958.1997.3671706.x; Gupta RN, 2001, J AM CHEM SOC, V123, P11353, DOI 10.1021/ja0113201; Hill RE, 1996, J BIOL CHEM, V271, P30426, DOI 10.1074/jbc.271.48.30426; Jain SK, 2001, FREE RADICAL BIO MED, V30, P232, DOI 10.1016/S0891-5849(00)00462-7; KLEM TJ, 1993, BIOCHEMISTRY-US, V32, P5177, DOI 10.1021/bi00070a029; Kondo H, 2004, BIOCHEM J, V379, P65, DOI 10.1042/BJ20031268; Laber B, 1999, FEBS LETT, V449, P45, DOI 10.1016/S0014-5793(99)00393-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM HM, 1990, J BACTERIOL, V172, P6518, DOI 10.1128/jb.172.11.6518-6528.1990; Miles BW, 2002, J BIOL CHEM, V277, P4368, DOI 10.1074/jbc.M108582200; Mittenhuber G, 2001, J MOL MICROB BIOTECH, V3, P1; NAKAMURA J, 1995, J BIOL CHEM, V270, P23450, DOI 10.1074/jbc.270.40.23450; Osmani AH, 1999, J BIOL CHEM, V274, P23565, DOI 10.1074/jbc.274.33.23565; Sakai A, 2002, J BIOSCI BIOENG, V93, P309, DOI 10.1263/jbb.93.309; Tanaka K, 2000, J NUTR SCI VITAMINOL, V46, P55; TAZUYA K, 1995, BBA-GEN SUBJECTS, V1244, P113, DOI 10.1016/0304-4165(94)00205-C; Thoden JB, 1999, BIOCHEMISTRY-US, V38, P16158, DOI 10.1021/bi991741j; Thoden JB, 1998, BIOCHEMISTRY-US, V37, P8825, DOI 10.1021/bi9807761; Wrenger C, 2005, J BIOL CHEM, V280, P5242, DOI 10.1074/jbc.M412475200; Zalkin H, 1998, ADV ENZYMOL RAMB, V72, P87; Zeidler J, 2003, J AM CHEM SOC, V125, P13094, DOI 10.1021/ja030261j; Zeidler J, 2003, J ORG CHEM, V68, P3486, DOI 10.1021/jo020730k; Zeidler J, 2002, J AM CHEM SOC, V124, P4542, DOI 10.1021/ja012708z	35	103	107	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32291	32300		10.1074/jbc.M501356200	http://dx.doi.org/10.1074/jbc.M501356200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16030023	hybrid, Green Published			2022-12-25	WOS:000231794800032
J	Yang, Y; Kovacs, M; Xu, Q; Anderson, JB; Sellers, JR				Yang, Y; Kovacs, M; Xu, Q; Anderson, JB; Sellers, JR			Myosin VIIB from Drosophila is a high duty ratio motor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINETIC MECHANISM; UNCONVENTIONAL MYOSINS; FLUORESCENT-PROBE; HEAVY-MEROMYOSIN; V PROCESSIVITY; RELAY LOOP; ACTIN; COMPLEX; BINDING; IDENTIFICATION	Myosin VII is an unconventional myosin widely expressed in organisms ranging from amoebae to mammals that has been shown to play vital roles in cell adhesion and phagocytosis. Here we present the first study of the mechanism of action of a myosin VII isoform. We have expressed a truncated single-headed Drosophila myosin VIIB construct in the baculovirus-Sf9 system that bound calmodulin light chains. By using steady-state and transient kinetic methods, we showed that myosin VIIB exhibits a fast release of phosphate and a slower, rate-limiting ADP release from actomyosin. As a result, myosin VIIB will be predominantly strongly bound to actin during steady-state ATP hydrolysis ( its duty ratio will be at least 80%). This kinetic pattern is in many respects similar to that of the single-molecule vesicle transporters myosin V and VI. The enzymatic properties of myosin VIIB provide a kinetic basis for processivity upon possible dimerization via the C-terminal domains of the heavy chain. Our experiments also revealed conformational heterogeneity of the actomyosin VIIB complex in the absence of nucleotide.	NHLBI, NIH, Lab Mol Physiol, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Sellers, JR (corresponding author), NHLBI, NIH, Lab Mol Physiol, Bldg 10,Rm 8N202, Bethesda, MD 20892 USA.	sellersj@nhlbi.nih.gov	Kovacs, Mihaly/A-6841-2011	Kovacs, Mihaly/0000-0002-1200-4741	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL004232, ZIAHL004232] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baker JE, 2004, P NATL ACAD SCI USA, V101, P5542, DOI 10.1073/pnas.0307247101; Baker JP, 1997, J MOL BIOL, V272, P523, DOI 10.1006/jmbi.1997.1232; BRUNE M, 1994, BIOCHEMISTRY-US, V33, P8262, DOI 10.1021/bi00193a013; CRIDDLE AH, 1985, BIOCHEM J, V232, P343, DOI 10.1042/bj2320343; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; De La Cruz EM, 2004, CURR OPIN CELL BIOL, V16, P61, DOI 10.1016/j.ceb.2003.11.011; De la Cruz EM, 2001, J BIOL CHEM, V276, P32373, DOI 10.1074/jbc.M104136200; El-Amraoui A, 2002, EMBO REP, V3, P463, DOI 10.1093/embo-reports/kvf090; Geeves MA, 2000, J BIOL CHEM, V275, P21624, DOI 10.1074/jbc.M000342200; GIBSON F, 1995, NATURE, V374, P62, DOI 10.1038/374062a0; Hasson T, 1996, GENOMICS, V36, P431, DOI 10.1006/geno.1996.0488; Hasson T, 1999, CURR BIOL, V9, pR838, DOI 10.1016/S0960-9822(00)80040-8; Inoue A, 2003, J BIOL CHEM, V278, P5478, DOI 10.1074/jbc.M210489200; Kiehart DP, 2004, GENETICS, V168, P1337, DOI 10.1534/genetics.104.026369; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; Kovacs M, 2003, J BIOL CHEM, V278, P38132, DOI 10.1074/jbc.M305453200; Kovacs M, 2005, J BIOL CHEM, V280, P15071, DOI 10.1074/jbc.M500616200; Kovacs M, 2004, BIOCHEMISTRY-US, V43, P4219, DOI 10.1021/bi036007l; Kussel-Andermann P, 2000, EMBO J, V19, P6020, DOI 10.1093/emboj/19.22.6020; Malnasi-Csizmadia A, 2001, J BIOL CHEM, V276, P19483, DOI 10.1074/jbc.M010886200; Nyitrai M, 2004, PHILOS T R SOC B, V359, P1867, DOI 10.1098/rstb.2004.1560; Park S, 2000, BIOCHEMISTRY-US, V39, P11732, DOI 10.1021/bi000945t; Petit C, 2001, ANNU REV GENOM HUM G, V2, P271, DOI 10.1146/annurev.genom.2.1.271; Rosenfeld SS, 2004, J BIOL CHEM, V279, P40100, DOI 10.1074/jbc.M402583200; Self T, 1999, DEV BIOL, V214, P331, DOI 10.1006/dbio.1999.9424; Sellers J. R., 1999, MYOSINS; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Titus MA, 1999, CURR BIOL, V9, P1297, DOI 10.1016/S0960-9822(00)80051-2; Todi SV, 2005, CURR BIOL, V15, P862, DOI 10.1016/j.cub.2005.03.050; Toth J, 2005, J BIOL CHEM, V280, P30594, DOI 10.1074/jbc.M505209200; Tuxworth RI, 2001, CURR BIOL, V11, P318, DOI 10.1016/S0960-9822(01)00097-5; Udovichenko IP, 2002, J CELL SCI, V115, P445; Wang F, 2003, J BIOL CHEM, V278, P27439, DOI 10.1074/jbc.M302510200; Wang F, 2000, BIOCHEMISTRY-US, V39, P5555, DOI 10.1021/bi000133x; White HD, 1997, BIOCHEMISTRY-US, V36, P11828, DOI 10.1021/bi970540h; Wu XF, 2002, MOL BIOL CELL, V13, P1735, DOI 10.1091/mbc.01-12-0595; Wu XFS, 2002, NAT CELL BIOL, V4, P271, DOI 10.1038/ncb760; Yamashita RA, 2000, J MUSCLE RES CELL M, V21, P491, DOI 10.1023/A:1026589626422; Yengo CM, 2000, J BIOL CHEM, V275, P25481, DOI 10.1074/jbc.M002910200; Yengo CM, 2004, BIOCHEMISTRY-US, V43, P2605, DOI 10.1021/bi035510v	40	33	36	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 16	2005	280	37					32061	32068		10.1074/jbc.M506765200	http://dx.doi.org/10.1074/jbc.M506765200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	963HM	16055438	hybrid			2022-12-25	WOS:000231794800005
J	Mali, RS; Cheng, M; Chintala, SK				Mali, RS; Cheng, M; Chintala, SK			Plasminogen activators promote excitotoxicity-induced retinal damage	FASEB JOURNAL			English	Article						retina; ganglion cells; excitotoxicity; kainic acid; tissue plasminogen activator; urokinase plasminogen activator and non-NMDA receptors	GANGLION-CELL DEATH; ELEVATED GLUTAMATE LEVELS; VITREOUS BODY; KAINIC ACID; NEURONAL DEGENERATION; GRANULE NEURONS; MESSENGER-RNAS; ALBINO-RATS; IN-VIVO; TISSUE	Increased levels of extracellular L-glutamate have been suggested to play a role in retinal damage in a number of blinding diseases such as glaucoma and diabetic retinopathy. Although glutamate can cause retinal damage in part by hyperstimulating its receptors ("excitotoxicity"), the downstream events that lead to retinal damage are poorly understood. In this study, we injected kainic acid (KA), a glutamate receptor agonist that specifically hyperstimulates non-NMDA- type receptors, into the vitreous humor of CD-1 mice and have investigated the role of plasminogen activators (PAs) [tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA)] in excitotoxicity-induced retinal damage. Injection of KA into the vitreous humor led to an up-regulation in tPA and an induction in uPA activity in the retina and this was associated with activation of zymogen plasminogen to active plasmin. Immunocytochemical analysis indicated that retinal ganglion cells (RGCs), constitutively express tPA and release it into the extracellular space upon KA injection. Immunocytochemical analysis also indicated an increase in uPA in the nerve fiber layer after KA injection that was absent in the control retinas. These events were associated with apoptotic death of cells initially in the ganglion cell layer and subsequently in the inner and outer nuclear layer, associated with loss of RGCs and amacrine cells. These phenomena were inhibited when recombinant plasminogen activator inhibitor (rPAI-1) or tPA-STOP were injected into the vitreous humor with KA, whereas a plasmin inhibitor, alpha-2-antiplasmin, failed to attenuate KA-induced retinal damage. Taken together, these results suggest that inhibition of plasminogen activators might attenuate retinal damage in blinding retinal diseases in which hyperstimulation of glutamate receptors is implicated as a causative factor to retinal damage.	Oakland Univ, Eye Res Inst, Rochester, MI 48309 USA	Oakland University	Chintala, SK (corresponding author), Oakland Univ, Eye Res Inst, 409 Dodge Hall, Rochester, MI 48309 USA.	Chintala@oakland.edu			NATIONAL EYE INSTITUTE [R24EY014803, R01EY013643] Funding Source: NIH RePORTER; NEI NIH HHS [EY13643, R01 EY013643, EY014803, R24 EY014803] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ambati J, 1997, ARCH OPHTHALMOL-CHIC, V115, P1161, DOI 10.1001/archopht.1997.01100160331011; Barber AJ, 2003, PROG NEURO-PSYCHOPH, V27, P283, DOI 10.1016/S0278-5846(03)00023-X; Benchenane K, 2004, TRENDS NEUROSCI, V27, P155, DOI 10.1016/j.tins.2003.12.011; BRANDSTATTER JH, 1994, EUR J NEUROSCI, V6, P1100, DOI 10.1111/j.1460-9568.1994.tb00607.x; Brooks DE, 1997, AM J VET RES, V58, P864; Chen SN, 2001, RETINA-J RET VIT DIS, V21, P460, DOI 10.1097/00006982-200110000-00007; Chen ZL, 1997, CELL, V91, P917, DOI 10.1016/S0092-8674(00)80483-3; Chintala SK, 2002, J BIOL CHEM, V277, P47461, DOI 10.1074/jbc.M204824200; Christow SP, 1999, EUR J BIOCHEM, V265, P264, DOI 10.1046/j.1432-1327.1999.00729.x; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; Das A, 1999, INVEST OPHTH VIS SCI, V40, P809; Dreyer EB, 1996, ARCH OPHTHALMOL-CHIC, V114, P299, DOI 10.1001/archopht.1996.01100130295012; Esser P, 1997, BRIT J OPHTHALMOL, V81, P590, DOI 10.1136/bjo.81.7.590; Fernandez-Monreal M, 2004, MOL CELL NEUROSCI, V25, P594, DOI 10.1016/j.mcn.2003.11.002; Flammer J, 2002, PROG RETIN EYE RES, V21, P359, DOI 10.1016/S1350-9462(02)00008-3; Fletcher EL, 1997, J COMP NEUROL, V380, P449, DOI 10.1002/(SICI)1096-9861(19970421)380:4<449::AID-CNE3>3.0.CO;2-1; FRIEDMAN GC, 1995, J COMP NEUROL, V360, P658; Gualandris A, 1996, J NEUROSCI, V16, P2220; Hesse L, 1999, GRAEF ARCH CLIN EXP, V237, P273, DOI 10.1007/s004170050232; Hesse L, 2000, RETINA-J RET VIT DIS, V20, P500, DOI 10.1097/00006982-200009000-00011; Hrach CJ, 2000, ARCH OPHTHALMOL-CHIC, V118, P659; Huang YY, 1996, P NATL ACAD SCI USA, V93, P8699, DOI 10.1073/pnas.93.16.8699; IRVINE WD, 1991, ARCH OPHTHALMOL-CHIC, V109, P718, DOI 10.1001/archopht.1991.01080050134044; Izumi Y, 1995, NEUROBIOL DIS, V2, P139, DOI 10.1006/nbdi.1995.0015; IZUMI Y, 1995, J NEUROSCI METH, V60, P219, DOI 10.1016/0165-0270(95)00015-M; JOHNSON MW, 1992, OPHTHALMOLOGY, V99, P515; Kim TW, 2000, ARCH OPHTHALMOL-CHIC, V118, P533; KRYSTOSEK A, 1981, P NATL ACAD SCI-BIOL, V78, P7810, DOI 10.1073/pnas.78.12.7810; KRYSTOSEK A, 1981, SCIENCE, V213, P1532, DOI 10.1126/science.7197054; Lewis H, 1997, OPHTHALMOLOGY, V104, P1847, DOI 10.1016/S0161-6420(97)30018-9; LEWIS H, 1991, AM J OPHTHALMOL, V111, P197, DOI 10.1016/S0002-9394(14)72259-7; Lipton SA, 2003, SURV OPHTHALMOL, V48, pS38, DOI 10.1016/S0039-6257(03)00008-0; LUCAS DR, 1957, ARCH OPHTHALMOL-CHIC, V58, P193; LUTTY GA, 1991, INVEST OPHTH VIS SCI, V32, P237; Majka S, 2001, INVEST OPHTH VIS SCI, V42, P210; Manabe S, 2003, INVEST OPHTH VIS SCI, V44, P385, DOI 10.1167/iovs.02-0187; Masos T, 1997, MOL BRAIN RES, V47, P157, DOI 10.1016/S0169-328X(97)00040-5; MOONEN G, 1982, NATURE, V298, P753, DOI 10.1038/298753a0; MORGAN IG, 1981, NEUROSCI LETT, V21, P275, DOI 10.1016/0304-3940(81)90216-0; Nakajima K, 1996, J NEUROCHEM, V66, P2500; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; Nicole O, 2001, NAT MED, V7, P59, DOI 10.1038/83358; OLNEY JW, 1969, J NEUROPATH EXP NEUR, V28, P455, DOI 10.1097/00005072-196907000-00007; Osborne NN, 2004, PROG RETIN EYE RES, V23, P91, DOI 10.1016/j.preteyeres.2003.12.001; Osborne NN, 1996, NEUROCHEM INT, V29, P263, DOI 10.1016/0197-0186(96)00005-8; OSBORNE NN, 1995, INVEST OPHTH VIS SCI, V36, P1692; Osborne NN, 2001, BRIT J OPHTHALMOL, V85, P1252, DOI 10.1136/bjo.85.10.1252; Osborne NN, 1999, SURV OPHTHALMOL, V43, pS102, DOI 10.1016/S0039-6257(99)00044-2; Rogove AD, 1999, J CELL SCI, V112, P4007; Schacke W, 2002, INVEST OPHTH VIS SCI, V43, P2799; SCHWARCZ R, 1977, INVEST OPHTH VIS SCI, V16, P141; SEEDS NW, 1995, SCIENCE, V270, P1992, DOI 10.1126/science.270.5244.1992; SellesNavarro I, 1996, INVEST OPHTH VIS SCI, V37, P2002; Siao CJ, 2002, J NEUROSCI, V22, P3352; SILIPRANDI R, 1992, VISUAL NEUROSCI, V8, P567, DOI 10.1017/S0952523800005666; SISK DR, 1985, GRAEF ARCH CLIN EXP, V223, P250, DOI 10.1007/BF02153655; SISK DR, 1984, INVEST OPHTH VIS SCI, V25, P1124; Sucher NJ, 1997, VISION RES, V37, P3483, DOI 10.1016/S0042-6989(97)00047-3; THANOS S, 1991, EUR J NEUROSCI, V3, P1189, DOI 10.1111/j.1460-9568.1991.tb00054.x; THANOS S, 1993, J NEUROSCI, V13, P455; Thanos S, 2004, EXP EYE RES, V79, P119, DOI 10.1016/j.exer.2004.02.005; Traynelis SF, 2001, NAT MED, V7, P17, DOI 10.1038/83289; TRIPATHI BJ, 1987, OPHTHALMOLOGY, V94, P1434; TRIPATHI RC, 1990, EXP EYE RES, V51, P545, DOI 10.1016/0014-4835(90)90085-9; TRIPATHI RC, 1988, AM J OPHTHALMOL, V106, P719, DOI 10.1016/0002-9394(88)90707-6; Tsirka SE, 1997, J MOL MED, V75, P341, DOI 10.1007/s001090050119; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0; Tsirka SE, 1996, NATURE, V384, P123, DOI 10.1038/384123b0; Tsirka SE, 1997, J NEUROSCI, V17, P543; Tsirka SE, 1997, P NATL ACAD SCI USA, V94, P9779, DOI 10.1073/pnas.94.18.9779; Vorwerk CK, 1999, SURV OPHTHALMOL, V43, pS142, DOI 10.1016/S0039-6257(99)00017-X; Vorwerk CK, 2004, BRAIN RES BULL, V62, P485, DOI 10.1016/S0361-9230(03)00075-3; Vorwerk CK, 1996, INVEST OPHTH VIS SCI, V37, P1618; Wang YMF, 1998, NAT MED, V4, P228, DOI 10.1038/nm0298-228; Yoles E, 1998, ARCH OPHTHALMOL-CHIC, V116, P906, DOI 10.1001/archopht.116.7.906; Zhang X, 2004, INVEST OPHTH VIS SCI, V45, P2374, DOI 10.1167/iovs.03-1239; Zhang X, 2003, MOL VIS, V9, P238	77	41	46	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1280	1289		10.1096/fj.04-3403com	http://dx.doi.org/10.1096/fj.04-3403com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	16051695	Green Accepted			2022-12-25	WOS:000231843700035
J	Harfouche, R; Abdel-Malak, NA; Brandes, RP; Karsan, A; Irani, K; Hussain, SNA				Harfouche, R; Abdel-Malak, NA; Brandes, RP; Karsan, A; Irani, K; Hussain, SNA			Roles of reactive oxygen species in angiopoietin-1/tie-2 receptor signaling	FASEB JOURNAL			English	Article						Rac-1; NADPH oxidase; mitogen-activated protein kinases; endothelial cell migration	ENDOTHELIAL GROWTH-FACTOR; NAD(P)H OXIDASE; TYROSINE KINASES; PROTEIN-KINASE; CELL-SURVIVAL; NADPH OXIDASE; ANGIOTENSIN-II; TIE2 RECEPTOR; ACTIVATION; ALPHA	In this study we identified the involvement of reactive oxygen species (ROS) in signaling and biological effects of the angiopoietin-1 (Ang-1)/tie-2 receptor pathway. Exposure of human umbilical vein endothelial cells to Ang-1 ( 50 ng/ml) induced rapid and transient production of ROS, particularly superoxide anions. ROS production was attenuated by preincubation with a peptide (gp91ds-tat) that inhibits the association of the gp91(phox) subunit with the p47(phox) subunit of NADPH oxidase and by the expression of a dominant-negative form of Rac-1 (Rac1N17). These results suggest that ROS production in response to Ang-1 exposure originates mainly from a Rac-1-dependent NADPH oxidase. Overexpression of antioxidants ( superoxide dismutase and catalase) and Rac1N17, as well as preincubation with selective inhibitors of NADPH oxidase augmented basal p38 phosphorylation, inhibited Ang-1-induced PAK-1 phosphorylation and potentiated Ang-1-induced Erk1/2 phosphorylation but had no influence on AKT and SAPK/JNK phosphorylation by Ang-1. Exposure to Ang-1 ( 100 ng/ml) for 5 h induced a threefold increase in endothelial cell migration, a response that was strongly inhibited by overexpression of antioxidants, Rac1N17, and selective NADPH oxidase inhibitors. We conclude that activation of tie-2 receptors by Ang-1 triggers the production of ROS through activation of NADPH oxidase and that ROS generation by Ang-1 promotes endothelial cell migration while negatively regulating Erk1/2 phosphorylation.	Royal Victoria Hosp, Crit Care Div, Montreal, PQ, Canada; Royal Victoria Hosp, Div Resp, Montreal, PQ, Canada; McGill Univ, Meakins Christie Labs, Montreal, PQ, Canada; Goethe Univ Frankfurt, Inst Kardiovask Physiol, D-6000 Frankfurt, Germany; Johns Hopkins Univ, Sch Med, Dept Med, Div Cardiol, Baltimore, MD 21205 USA; Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada; British Columbia Canc Agcy, Dept Med Biophys, Vancouver, BC V5Z 1M9, Canada; British Columbia Canc Agcy, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; McGill University; Johns Hopkins University; University of British Columbia; British Columbia Cancer Agency; British Columbia Cancer Agency	Hussain, SNA (corresponding author), Royal Victoria Hosp, Crit Care Div, Room L3-05,687 Pine Ave W, Montreal, PQ, Canada.	sabah.hussain@muhc.mcgill.ca	Brandes, Ralf P/L-3058-2017; Hussain, Sabah/ABC-5315-2021; Karsan, Aly/K-2067-2015	Brandes, Ralf P/0000-0002-8035-0048; Irani, Kaikobad/0000-0001-9194-7387				Abid MR, 2000, FEBS LETT, V486, P252, DOI 10.1016/S0014-5793(00)02305-X; Aslan M, 2003, ANTIOXID REDOX SIGN, V5, P781, DOI 10.1089/152308603770380089; Bayraktutan U, 2000, ARTERIOSCL THROM VAS, V20, P1903, DOI 10.1161/01.ATV.20.8.1903; Bokoch GM, 1998, J BIOL CHEM, V273, P8137, DOI 10.1074/jbc.273.14.8137; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Cascone I, 2003, BLOOD, V102, P2482, DOI 10.1182/blood-2003-03-0670; Cho YJ, 1999, BIOCHEM BIOPH RES CO, V262, P708, DOI 10.1006/bbrc.1999.1274; Colavitti R, 2002, J BIOL CHEM, V277, P3101, DOI 10.1074/jbc.M107711200; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DeLeo FR, 1996, J BIOL CHEM, V271, P17013, DOI 10.1074/jbc.271.29.17013; Deshpande SS, 2000, FASEB J, V14, P1705, DOI 10.1096/fj.99-0910com; Donovan D., 2001, Angiogenesis, V4, P113, DOI 10.1023/A:1012218401036; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Frey RS, 2002, CIRC RES, V90, P1012, DOI 10.1161/01.RES.0000017631.28815.8E; Fujikawa K, 1999, EXP CELL RES, V253, P663, DOI 10.1006/excr.1999.4693; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; Gamble JR, 2000, CIRC RES, V87, P603, DOI 10.1161/01.RES.87.7.603; Gatti A, 1999, J BIOL CHEM, V274, P8022, DOI 10.1074/jbc.274.12.8022; Harfouche R, 2003, FASEB J, V17, P1523, DOI 10.1096/fj.02-0698fje; Jones N, 1999, J BIOL CHEM, V274, P30896, DOI 10.1074/jbc.274.43.30896; Jones N, 1998, ONCOGENE, V17, P1097, DOI 10.1038/sj.onc.1202115; Kampfer H, 2001, LAB INVEST, V81, P361, DOI 10.1038/labinvest.3780244; Karsan A, 1996, J BIOL CHEM, V271, P27201, DOI 10.1074/jbc.271.44.27201; Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24; King K, 2000, HENRY JAMES REV, V21, P1; KOLIZEK TI, 1998, CURR BIOL, V8, P529; Kontos CD, 1998, MOL CELL BIOL, V18, P4131, DOI 10.1128/MCB.18.7.4131; Kwak HJ, 1999, FEBS LETT, V448, P249, DOI 10.1016/S0014-5793(99)00378-6; Kwon J, 2004, P NATL ACAD SCI USA, V101, P16419, DOI 10.1073/pnas.0407396101; Lassegue B, 2003, AM J PHYSIOL-REG I, V285, pR277, DOI 10.1152/ajpregu.00758.2002; Lee YJ, 2004, J APPL PHYSIOL, V96, P793, DOI 10.1152/japplphysiol.00797.2003; Mahadev K, 2004, CELL SIGNAL, V16, P323, DOI 10.1016/j.cellsig.2003.08.002; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Master Z, 2001, EMBO J, V20, P5919, DOI 10.1093/emboj/20.21.5919; Moldovan L, 2000, CIRC RES, V86, P549, DOI 10.1161/01.RES.86.5.549; Nakatsu MN, 2003, MICROVASC RES, V66, P102, DOI 10.1016/S0026-2862(03)00045-1; Noguchi K, 1999, J BIOL CHEM, V274, P32580, DOI 10.1074/jbc.274.46.32580; Papadakis CM, 2000, EUR PHYS J E, V1, P275, DOI 10.1007/s101890050029; Papapetropoulos A, 1999, LAB INVEST, V79, P213; Rey FE, 2001, CIRC RES, V89, P408, DOI 10.1161/hh1701.096037; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Seshiah PN, 2002, CIRC RES, V91, P406, DOI 10.1161/01.RES.0000033523.08033.16; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; Usatyuk PV, 2003, ANTIOXID REDOX SIGN, V5, P723, DOI 10.1089/152308603770380025; Ushio-Fukai M, 2002, CIRC RES, V91, P1160, DOI 10.1161/01.RES.0000046227.65158.F8; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022; Weber DS, 2004, CIRC RES, V94, P1219, DOI 10.1161/01.RES.0000126848.54740.4A; Witzenbichler B, 1998, J BIOL CHEM, V273, P18514, DOI 10.1074/jbc.273.29.18514; Wu RF, 2003, J BIOL CHEM, V278, P36830, DOI 10.1074/jbc.M302251200; Yamaoka-Tojo M, 2004, CIRC RES, V95, P276, DOI 10.1161/01.RES.0000136522.58649.60	52	97	97	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2005	19	9					1728	+		10.1096/fj.04-3621fje	http://dx.doi.org/10.1096/fj.04-3621fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	951IO	16049136				2022-12-25	WOS:000230923000003
